PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Newton, M; Fitzgerald, S; Rose, RR; Adams, PW; Tesch, SD; Sessions, J; Atzet, T; Powers, RF; Skinner, C				Newton, M.; Fitzgerald, S.; Rose, R. R.; Adams, P. W.; Tesch, S. D.; Sessions, J.; Atzet, T.; Powers, R. F.; Skinner, C.			Comment on "Post-wildfire logging hinders regeneration and increases fire risk"	SCIENCE			English	Editorial Material							FORESTS	Donato et at. (Brevia, 20 January 2006, p. 352) concluded that logging after wildfire kills natural regeneration and increases fire risk. We argue that their paper tacks adequate context and supporting information to be clearly interpreted by scientists, resource managers, policy-makers, and the public.	Oregon State Univ, Dept Forest Engn, Corvallis, OR 97331 USA; Oregon State Univ, Dept Forest Sci, Corvallis, OR 97331 USA; Oregon State Univ, Dept Forest Resources, Corvallis, OR 97331 USA; Atzet Ecol Consulting, Grants Pass, OR 97528 USA; Pacific SW Res Stn, Redding, CA 96002 USA	Oregon State University; Oregon State University; Oregon State University	Sessions, J (corresponding author), Oregon State Univ, Dept Forest Engn, Corvallis, OR 97331 USA.	john.sessions@oregonstate.edu						Agee, 1993, FIRE ECOLOGY PACIFIC; BROWN K, 2003, RMRSGTR105 USDA FOR; Donato DC, 2006, SCIENCE, V311, P352, DOI 10.1126/science.1122855; Everett R, 1999, INT J WILDLAND FIRE, V9, P223, DOI 10.1071/WF00011; HOBBS S, 1992, REFORESTATION PRACTI; ISAAC L, 1930, J FOREST, V21, P492; McIver James D., 2001, Western Journal of Applied Forestry, V16, P159; Rothermel R.C, 1983, PREDICT SPREAD INTEN, DOI [10.2737/INT-GTR-143, DOI 10.2737/INT-GTR-143]; ROY DF, 1956, 107 USFS CAL FOR RAN; Sessions J, 2004, J FOREST, V102, P38; Shepperd WD, 2006, WEST J APPL FOR, V21, P19, DOI 10.1093/wjaf/21.1.19; STUART JD, 1993, FOREST SCI, V39, P561; *US BUR LAND MAN, 2003, H57051 USDI BLM; *USDA FOR SERV, 2004, BISC FIR FIN ENV IMP	14	18	22	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 4	2006	313	5787								10.1126/science.1126478	http://dx.doi.org/10.1126/science.1126478			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	072IQ	16888122	Green Submitted			2022-12-28	WOS:000239667500020
J	Betzig, E; Patterson, GH; Sougrat, R; Lindwasser, OW; Olenych, S; Bonifacino, JS; Davidson, MW; Lippincott-Schwartz, J; Hess, HF				Betzig, Eric; Patterson, George H.; Sougrat, Rachid; Lindwasser, O. Wolf; Olenych, Scott; Bonifacino, Juan S.; Davidson, Michael W.; Lippincott-Schwartz, Jennifer; Hess, Harald F.			Imaging intracellular fluorescent proteins at nanometer resolution	SCIENCE			English	Article							STRUCTURED-ILLUMINATION MICROSCOPY; DIFFRACTION LIMIT; LIVING CELLS; LOCALIZATION; SPECTROSCOPY; MOLECULES	We introduce a method for optically imaging intracellular proteins at nanometer spatial resolution. Numerous sparse subsets of photoactivatable fluorescent protein molecules were activated, localized ( to similar to 2 to 25 nanometers), and then bleached. The aggregate position information from all subsets was then assembled into a superresolution image. We used this method - termed photoactivated localization microscopy - to image specific target proteins in thin sections of lysosomes and mitochondria; in fixed whole cells, we imaged vinculin at focal adhesions, actin within a lamellipodium, and the distribution of the retroviral protein Gag at the plasma membrane.	Howard Hughes Med Inst, Ashburn, VA USA; New Millennium Res LLC, Okemos, MI 48864 USA; NICHHD, Cell Biol & Metab Branch, Bethesda, MD 20892 USA; Florida State Univ, Natl High Magnet Field Lab, Tallahassee, FL 32310 USA; NuQuest Res LLC, La Jolla, CA 92037 USA	Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); State University System of Florida; Florida State University	Betzig, E (corresponding author), Howard Hughes Med Inst, Janelia Farm Res Campus, Ashburn, VA USA.	betzige@janelia.hhmi.org	Patterson, George/ABI-4751-2020	Bonifacino, Juan S./0000-0002-5673-6370; Sougrat, Rachid/0000-0001-6476-1886	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD008850, ZIAHD001607] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [ZIAHD008834, Z01HD001607, Z01HD008850, Z01HD008834] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ando R, 2002, P NATL ACAD SCI USA, V99, P12651, DOI 10.1073/pnas.202320599; Ando R, 2004, SCIENCE, V306, P1370, DOI 10.1126/science.1102506; AXELROD D, 1989, METHOD CELL BIOL, V30, P245; BETZIG E, 1992, SCIENCE, V257, P189, DOI 10.1126/science.257.5067.189; BETZIG E, 1995, OPT LETT, V20, P237, DOI 10.1364/OL.20.000237; Betzig E, 2005, OPT EXPRESS, V13, P3021, DOI 10.1364/OPEX.13.003021; BETZIG E, 1993, SCIENCE, V262, P1422, DOI 10.1126/science.262.5138.1422; Cheezum MK, 2001, BIOPHYS J, V81, P2378, DOI 10.1016/S0006-3495(01)75884-5; Chen I, 2005, CURR OPIN BIOTECH, V16, P35, DOI 10.1016/j.copbio.2004.12.003; Churchman LS, 2005, P NATL ACAD SCI USA, V102, P1419, DOI 10.1073/pnas.0409487102; Gaietta G, 2002, SCIENCE, V296, P503, DOI 10.1126/science.1068793; Gordon MP, 2004, P NATL ACAD SCI USA, V101, P6462, DOI 10.1073/pnas.0401638101; Gustafsson MGL, 2000, J MICROSC-OXFORD, V198, P82, DOI 10.1046/j.1365-2818.2000.00710.x; Gustafsson MGL, 2005, P NATL ACAD SCI USA, V102, P13081, DOI 10.1073/pnas.0406877102; HESS HF, 1994, SCIENCE, V264, P1740, DOI 10.1126/science.264.5166.1740; Hofmann M, 2005, P NATL ACAD SCI USA, V102, P17565, DOI 10.1073/pnas.0506010102; Lidke KA, 2005, OPT EXPRESS, V13, P7052, DOI 10.1364/OPEX.13.007052; Lippincott-Schwartz J, 2003, SCIENCE, V300, P87, DOI 10.1126/science.1082520; Lukyanov KA, 2005, NAT REV MOL CELL BIO, V6, P885, DOI 10.1038/nrm1741; Moerner WE, 2002, J PHYS CHEM B, V106, P910, DOI 10.1021/jp012992g; Patterson GH, 2002, SCIENCE, V297, P1873, DOI 10.1126/science.1074952; Politz JC, 1999, TRENDS CELL BIOL, V9, P284, DOI 10.1016/S0962-8924(99)01585-8; Qu XH, 2004, P NATL ACAD SCI USA, V101, P11298, DOI 10.1073/pnas.0402155101; Thompson RE, 2002, BIOPHYS J, V82, P2775, DOI 10.1016/S0006-3495(02)75618-X; Tsutsui H, 2005, EMBO REP, V6, P233, DOI 10.1038/sj.embor.7400361; van Oijen AM, 1999, J OPT SOC AM A, V16, P909, DOI 10.1364/JOSAA.16.000909; Wiedenmann J, 2004, P NATL ACAD SCI USA, V101, P15905, DOI 10.1073/pnas.0403668101; Willig KI, 2006, NATURE, V440, P935, DOI 10.1038/nature04592; Yildiz A, 2003, SCIENCE, V300, P2061, DOI 10.1126/science.1084398	29	5759	6033	114	2026	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 15	2006	313	5793					1642	1645		10.1126/science.1127344	http://dx.doi.org/10.1126/science.1127344			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	083YS	16902090	Green Submitted			2022-12-28	WOS:000240498900047
J	Oury, F; Murakami, Y; Renaud, JS; Pasqualetti, M; Charnay, P; Ren, SY; Rijli, FM				Oury, Franck; Murakami, Yasunori; Renaud, Jean-Sebastien; Pasqualetti, Massimo; Charnay, Patrick; Ren, Shu-Yue; Rijli, Filippo M.			Hoxa2- and rhombomere-dependent development of the mouse facial somatosensory map	SCIENCE			English	Article							CRE-MEDIATED RECOMBINATION; PRINCIPAL SENSORY NUCLEUS; STEM TRIGEMINAL COMPLEX; VIBRISSAL INFORMATION; TRANSCRIPTION FACTOR; NEURONAL DEVELOPMENT; NEURAL DEVELOPMENT; ROSTRAL HINDBRAIN; NEONATAL RAT; SYSTEM	In the mouse trigeminal pathway, sensory inputs from distinct facial structures, such as whiskers or lower jaw and lip, are topographically mapped onto the somatosensory cortex through relay stations in the thalamus and hindbrain. In the developing hindbrain, the mechanisms generating such maps remain elusive. We found that in the principal sensory nucleus, the whisker-related map is contributed by rhombomere 3 - derived neurons, whereas the rhombomere 2 - derived progeny supply the lower jaw and lip representation. Moreover, early Hoxa2 expression in neuroepithelium prevents the trigeminal nerve from ectopically projecting to the cerebellum, whereas late expression in the principal sensory nucleus promotes selective arborization of whisker-related afferents and topographic connectivity to the thalamus. Hoxa2 inactivation further results in the absence of whisker-related maps in the postnatal brain. Thus, Hoxa2- and rhombomere 3 - dependent cues determine the whisker area map and are required for the assembly of the whisker-to-barrel somatosensory circuit.	Univ Strasbourg 1, INSERM, CNRS, UMR 7104,Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; Univ Oslo, Inst Basic Med Sci, Dept Physiol, N-0317 Oslo, Norway; Ecole Normale Super, INSERM, U784, F-75230 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Oslo; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Rijli, FM (corresponding author), Univ Strasbourg 1, INSERM, CNRS, UMR 7104,Inst Genet & Biol Mol & Cellulaire, BP 10142, F-67404 Illkirch Graffenstaden, France.	rijli@igbmc.u-strasbg.fr	RIJLI, Filippo/AAP-2516-2020; Pasqualetti, Massimo/F-8682-2012	RIJLI, Filippo/0000-0003-0515-0182; OURY, FRANCK/0000-0003-0562-9900; Pasqualetti, Massimo/0000-0002-0844-8139; Charnay, Patrick/0000-0002-3847-6042				ALGHOUL WM, 1993, J COMP NEUROL, V330, P464, DOI 10.1002/cne.903300403; BELFORD GR, 1980, J COMP NEUROL, V193, P335, DOI 10.1002/cne.901930203; BELFORD GR, 1979, J COMP NEUROL, V183, P305, DOI 10.1002/cne.901830207; Brunet I, 2005, NATURE, V438, P94, DOI 10.1038/nature04110; CHIAIA NL, 1991, J COMP NEUROL, V314, P217, DOI 10.1002/cne.903140203; Dasen JS, 2005, CELL, V123, P477, DOI 10.1016/j.cell.2005.09.009; Davenne M, 1999, NEURON, V22, P677, DOI 10.1016/S0896-6273(00)80728-X; Davies AM, 1997, J ANAT, V191, P483, DOI 10.1046/j.1469-7580.1997.19140483.x; Ding YQ, 2003, J NEUROSCI, V23, P7246; ERZURUMLU RS, 1993, P NATL ACAD SCI USA, V90, P7235, DOI 10.1073/pnas.90.15.7235; ERZURUMLU RS, 1980, NEUROSCIENCE, V5, P1891, DOI 10.1016/0306-4522(80)90037-8; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Gaufo GO, 2004, DEVELOPMENT, V131, P1259, DOI 10.1242/dev.01029; Gavalas A, 1997, DEVELOPMENT, V124, P3693; Genc B, 2005, J NEUROBIOL, V64, P145, DOI 10.1002/neu.20134; Jacquin MF, 1996, EUR J NEUROSCI, V8, P1641, DOI 10.1111/j.1460-9568.1996.tb01308.x; Kiecker C, 2005, NAT REV NEUROSCI, V6, P553, DOI 10.1038/nrn1702; KILLACKEY HP, 1994, J NEUROSCI, V14, P1496, DOI 10.1523/JNEUROSCI.14-03-01496.1994; KILLACKEY HP, 1985, DEV BRAIN RES, V22, P141, DOI 10.1016/0165-3806(85)90077-X; Klein R, 2004, CURR OPIN CELL BIOL, V16, P580, DOI 10.1016/j.ceb.2004.07.002; LI YQ, 1994, CELL, V76, P427, DOI 10.1016/0092-8674(94)90108-2; Lobe CG, 1999, DEV BIOL, V208, P281, DOI 10.1006/dbio.1999.9209; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; MA PM, 1993, J COMP NEUROL, V327, P376, DOI 10.1002/cne.903270306; Maklad A, 2003, BRAIN RES BULL, V60, P497, DOI 10.1016/S0361-9230(03)00054-6; MARIN F, 1995, EUR J NEUROSCI, V7, P1714, DOI 10.1111/j.1460-9568.1995.tb00693.x; McLaughlin T, 2005, ANNU REV NEUROSCI, V28, P327, DOI 10.1146/annurev.neuro.28.061604.135714; O'Leary D D, 1994, Curr Opin Neurobiol, V4, P535, DOI 10.1016/0959-4388(94)90054-X; Ozdinler PH, 2002, J NEUROSCI, V22, P4540, DOI 10.1523/JNEUROSCI.22-11-04540.2002; Pasqualetti M, 2002, GENESIS, V32, P109, DOI 10.1002/gene.10053; Pierret T, 2000, J NEUROSCI, V20, P7455; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; Ren SY, 2002, GENESIS, V32, P105, DOI 10.1002/gene.10052; Santagati F, 2005, DEVELOPMENT, V132, P4927, DOI 10.1242/dev.02078; Ulupinar E, 1999, MOL CELL NEUROSCI, V13, P281, DOI 10.1006/mcne.1999.0747; Vanderhaeghen P, 2000, NAT NEUROSCI, V3, P358, DOI 10.1038/73929; Voiculescu O, 2000, GENESIS, V26, P123, DOI 10.1002/(SICI)1526-968X(200002)26:2<123::AID-GENE7>3.0.CO;2-O; WONGRILEY M, 1979, BRAIN RES, V162, P201, DOI 10.1016/0006-8993(79)90284-1; WOOLSEY TA, 1970, BRAIN RES, V17, P205, DOI 10.1016/0006-8993(70)90079-X	39	103	104	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 8	2006	313	5792					1408	1413		10.1126/science.1130042	http://dx.doi.org/10.1126/science.1130042			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	081WQ	16902088				2022-12-28	WOS:000240348700034
J	af Geijerstam, JL; Oredsson, S; Britton, M				af Geijerstam, Jean-Luc; Oredsson, Sven; Britton, Mona		OCTOPUS Study Investigators	Medical outcome after immediate computed tomography or admission for observation in patients with mild head injury: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TRAUMATIC BRAIN-INJURY; RAY TECHNIQUE FACTORS; EMERGENCY-DEPARTMENT; RADIATION; MANAGEMENT; DISCHARGE; MORTALITY; COHORT; SCALE; SIZE	Objective To compare immediate computed tomography during triage for admission with observation in hospital in patients with mild head injury. Design Multicentre, pragmatic, non-inferiority randomised trial. Setting 39 acute hospitals in Sweden. Participants 2602 patients (aged >= 6) with mild head injury. Interventions Immediate computed tomography or admission for observation. Main outcome measure Dichotomised extended Glasgow outcome scale (1-7 v 8). The non-inferiority margin was 5 percentage points. Results At three months, 275 patients (21.4%) in the computed tomography group had not recovered completely compared with 300 (24.2%) admitted for observation. The difference was - 2.8 percentage points, non-significantly in favour of computed tomography (95% confidence interval - 6.1% to 0.6%). The worst outcomes (mortality and more severe loss of function) were similar between the groups. In the patients admitted for observation, there was a considerable delay in time to treatment in those who required surgery. None of the patients with normal findings on immediate computed tomography had complications later. Patients' satisfaction with the two strategies was similar. Conclusions The use of computed tomography in the management of patients with mild head injury is feasible and leads to similar clinical outcomes compared with observation in hospital.	Karolinska Univ Hosp, Dept Med, Clin Epidemiol Unit, S-17176 Stockholm, Sweden; Helsingborg Hosp, Emergency Dept, Helsingborg, Sweden; Swedish Council Technol Assessement Hlth Care, Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Helsingborgs Hospital	af Geijerstam, JL (corresponding author), Karolinska Univ Hosp, Dept Med, Clin Epidemiol Unit, S-17176 Stockholm, Sweden.	jean-luc.af.geijerstam@ki.se						Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; de Kruijk JR, 2001, BRAIN INJURY, V15, P117, DOI 10.1080/026990501458353; Fabbri A, 2004, J NEUROL NEUROSUR PS, V75, P410, DOI 10.1136/jnnp.2003.016113; Geijerstam JL, 2005, EMERG MED J, V22, P103; Geijerstam JLA, 2003, ACTA NEUROCHIR, V145, P843, DOI 10.1007/s00701-003-0115-1; GEIJERSTAM JLA, 2004, EMERG MED J, V21, P54; Griffiths PD, 2004, BRIT MED J, V329, P930, DOI 10.1136/bmj.329.7472.930; Hall P, 2004, BMJ-BRIT MED J, V328, P19, DOI 10.1136/bmj.328.7430.19; Huda W, 2004, MED PHYS, V31, P595, DOI 10.1118/1.1646233; Huda W, 2004, MED PHYS, V31, P588, DOI 10.1118/1.1646232; Livingston DH, 2000, ANN SURG, V232, P126, DOI 10.1097/00000658-200007000-00018; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; National Institute for Clinical Excellence National Collaborating Centre for Acute Care, 2003, HEAD INJ TRIAG ASS I; Norlund A, 2006, BMJ-BRIT MED J, V333, P469, DOI 10.1136/bmj.38918.659120.4F; Peloso PM, 2004, J REHABIL MED, V36, P106, DOI 10.1080/16501960410023868; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; *SWED COUNC TECHN, 2000, MILD HEAD INJ OBS CT; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2002, J NEUROTRAUM, V19, P999, DOI 10.1089/089771502760341910	25	65	65	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 2	2006	333	7566					465	468		10.1136/bmj.38918.669317.4F	http://dx.doi.org/10.1136/bmj.38918.669317.4F			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	085QP	16895944	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000240618900013
J	Nalley, K; Johnston, SA; Kodadek, T				Nalley, Kip; Johnston, Stephen Albert; Kodadek, Thomas			Proteolytic turnover of the Gal4 transcription factor is not required for function in vivo	NATURE			English	Article							RECEPTOR-REGULATED TRANSCRIPTION; MOLECULAR CHAPERONES; SACCHAROMYCES-CEREVISIAE; GLUCOCORTICOID-RECEPTOR; BINDING DOMAIN; ACTIVATOR; ALPHA; RECRUITMENT; PROMOTER; YEAST	Transactivator - promoter complexes are essential intermediates in the activation of eukaryotic gene expression. Recent studies of these complexes have shown that some are quite dynamic in living cells(1) owing to rapid and reversible disruption of activator promoter complexes by molecular chaperones(2-6), or a slower, ubiquitin - proteasome-pathway-mediated turnover of DNA-bound activator(7-9). These mechanisms may act to ensure continued responsiveness of activators to signalling cascades by limiting the lifetime of the active protein - DNA complex. Furthermore, the potency of some activators is compromised by proteasome inhibition, leading to the suggestion that periodic clearance of activators from a promoter is essential for high-level expression(8,10-12). Here we describe a variant of the chromatin immunoprecipitation assay that has allowed direct observation of the kinetic stability of native Gal4-promoter complexes in yeast. Under non-inducing conditions, the complex is dynamic, but on induction the Gal4 - promoter complexes 'lock in' and exhibit long half-lives. Inhibition of proteasome-mediated proteolysis had little or no effect on Gal4-mediated gene expression. These studies, combined with earlier data, show that the lifetimes of different transactivator - promoter complexes in vivo can vary widely and that proteasome-mediated turnover is not a general requirement for transactivator function.	Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Kodadek, T (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Thomas.Kodadek@utsouthwestern.edu		Kodadek, Thomas/0000-0003-1930-4795				Arndt K, 2005, CELL, V120, P733, DOI 10.1016/j.cell.2005.03.004; Elbi C, 2004, P NATL ACAD SCI USA, V101, P2876, DOI 10.1073/pnas.0400116101; FANKHAUSER CP, 1994, BIOCHEM BIOPH RES CO, V200, P195, DOI 10.1006/bbrc.1994.1433; Fletcher TM, 2002, MOL CELL BIOL, V22, P3255, DOI 10.1128/MCB.22.10.3255-3263.2002; Freeman BC, 2000, GENE DEV, V14, P422; Freeman BC, 2002, SCIENCE, V296, P2232, DOI 10.1126/science.1073051; Freeman BC, 2001, TRENDS BIOCHEM SCI, V26, P285, DOI 10.1016/S0968-0004(01)01834-5; Gonzalez F, 2002, SCIENCE, V296, P548, DOI 10.1126/science.1069490; Lee DH, 1996, J BIOL CHEM, V271, P27280, DOI 10.1074/jbc.271.44.27280; Lipford JR, 2005, NATURE, V438, P113, DOI 10.1038/nature04098; LOHR D, 1995, FASEB J, V9, P777, DOI 10.1096/fasebj.9.9.7601342; LOUVION JF, 1993, GENE, V131, P129, DOI 10.1016/0378-1119(93)90681-R; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Muratani M, 2005, CELL, V120, P887, DOI 10.1016/j.cell.2004.12.025; Nawaz Z, 2004, MOL ENDOCRINOL, V18, P493, DOI 10.1210/me.2003-0388; Picard D, 2000, METHOD ENZYMOL, V327, P385, DOI 10.1016/S0076-6879(00)27291-1; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; SIDDIQUI AH, 1989, MOL CELL BIOL, V9, P4706, DOI 10.1128/MCB.9.11.4706; Sprague BL, 2005, TRENDS CELL BIOL, V15, P84, DOI 10.1016/j.tcb.2004.12.001; Valley CC, 2005, MOL CELL BIOL, V25, P5417, DOI 10.1128/MCB.25.13.5417-5428.2005; Wehrman TS, 2005, NAT METHODS, V2, P521, DOI 10.1038/NMETH771; YAO J, NATURE	24	69	70	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 31	2006	442	7106					1054	1057		10.1038/nature05067	http://dx.doi.org/10.1038/nature05067			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	078YF	16929306				2022-12-28	WOS:000240142000053
J	Murahashi, T; Fujimoto, M; Oka, M; Hashimoto, Y; Uemura, T; Tatsumi, Y; Nakao, Y; Ikeda, A; Sakaki, S; Kurosawa, H				Murahashi, Tetsuro; Fujimoto, Mayu; Oka, Masa-aki; Hashimoto, Yasuhiro; Uemura, Tomohito; Tatsumi, Yasuki; Nakao, Yoshihide; Ikeda, Atsushi; Sakaki, Shigeyoshi; Kurosawa, Hideo			Discrete sandwich compounds of monolayer palladium sheets	SCIENCE			English	Article							RAY CRYSTAL-STRUCTURE; FLUXIONAL BEHAVIOR; COMPLEXES; CLUSTERS; COORDINATION; TRIPHENYLENE; HYDROCARBON; FACE	Despite the abundance of "sandwich'' complexes, in which two cyclic aromatic hydrocarbon ligands flank a metal center, this motif has not been extended to sheets of multiple metal atoms. We prepared and isolated two such compounds. In the first, three palladium centers form a planar triangular array, capped by chlorides, between two cycloheptatrienyl ligands. In the second, a pentapalladium sheet adopts an edge-sharing triangle-trapezoid skeleton between two naphthacene rings. The compounds were characterized by x-ray crystallography and nuclear magnetic resonance spectroscopy. The nature of bonding in the clusters was analyzed by quantum calculations.	Osaka Univ, Grad Sch Engn, Dept Appl Chem, Osaka 5650871, Japan; Japan Sci & Technol Agcy, PRESTO, Osaka 5650871, Japan; Kyoto Univ, Grad Sch Engn, Dept Mol Engn, Nishikyo Ku, Kyoto 6158510, Japan	Osaka University; Japan Science & Technology Agency (JST); Kyoto University	Murahashi, T (corresponding author), Osaka Univ, Grad Sch Engn, Dept Appl Chem, Osaka 5650871, Japan.	tetsu@chem.eng.osaka-u.ac.jp; kurosawa@chem.eng.osaka-u.ac.jp	Ikeda, Atsushi/G-5210-2011	Ikeda, Atsushi/0000-0003-3107-374X; Murahashi, Tetsuro/0000-0002-2288-0681				AIROLDI M, 1993, ORGANOMETALLICS, V12, P3964, DOI 10.1021/om00034a031; ALLEGRA G, 1965, J AM CHEM SOC, V87, P1394, DOI 10.1021/ja01084a051; AYALON A, 1994, SCIENCE, V265, P1065, DOI 10.1126/science.265.5175.1065; BURDETT JK, 1985, ORGANOMETALLICS, V4, P805, DOI 10.1021/om00124a001; COTTON FA, 1975, DYNAMIC NUCLEAR MAGN, pCH10; Diederich F., 1998, METAL CATALYZED CROS; FALLER JW, 1977, ADV ORGANOMET CHEM, V16, P211; FISCHER EO, 1967, CHEM COMMUN, P643, DOI 10.1039/c19670000643; FISCHER EO, 1952, Z NATURFORSCH B, V7, P377; FU WY, 1995, INORG CHIM ACTA, V229, P307, DOI 10.1016/0020-1693(94)04259-X; Gomez-Sal M.D., 1985, CHEM COMMUN, P1682; Gorlov M, 2004, J ORGANOMET CHEM, V689, P489, DOI 10.1016/j.jorganchem.2003.10.033; GREEN MLH, 1995, CHEM REV, V95, P439, DOI 10.1021/cr00034a006; Haneline MR, 2002, J AM CHEM SOC, V124, P3737, DOI 10.1021/ja0166794; Kurikawa T, 1999, ORGANOMETALLICS, V18, P1430, DOI 10.1021/om9807349; LONG NJ, 1998, METALLOCENES; MIYAURA N, 1995, CHEM REV, V95, P2457, DOI 10.1021/cr00039a007; MIYAURA N, 1979, TETRAHEDRON LETT, V20, P3437, DOI 10.1016/S0040-4039(01)95429-2; MUETTERTIES EL, 1979, CHEM REV, V79, P91, DOI 10.1021/cr60318a001; Munakata M, 2000, COORDIN CHEM REV, V198, P171, DOI 10.1016/S0010-8545(99)00162-9; Murahashi T, 2003, J AM CHEM SOC, V125, P8436, DOI 10.1021/ja0358246; Murahashi T, 2002, COORDIN CHEM REV, V231, P207, DOI 10.1016/S0010-8545(02)00121-2; Murahashi T, 1999, J AM CHEM SOC, V121, P10660, DOI 10.1021/ja992387f; Murahashi T, 2000, CHEM COMMUN, P1689, DOI 10.1039/b004726k; NAGASHIMA H, 1993, J AM CHEM SOC, V115, P10430, DOI 10.1021/ja00075a097; Petrukhina MA, 2004, ANGEW CHEM INT EDIT, V43, P5477, DOI 10.1002/anie.200460855; Schneider JJ, 2003, INORG CHIM ACTA, V350, P625, DOI 10.1016/S0020-1693(03)00109-9; Shirai M, 2000, CHEM COMMUN, P623, DOI 10.1039/a906596b; Thiele KH, 1998, ANGEW CHEM INT EDIT, V37, P2886, DOI 10.1002/(SICI)1521-3773(19981102)37:20<2886::AID-ANIE2886>3.0.CO;2-G; Togni A., 2000, METALLOCENES SYNTHES; Tsuji J., 2004, PALLADIUM REAGENTS C; Wadepohl H, 1999, COORDIN CHEM REV, V185-6, P551, DOI 10.1016/S0010-8545(99)00010-7; Walter J, 2000, ADV MATER, V12, P31, DOI 10.1002/(SICI)1521-4095(200001)12:1<31::AID-ADMA31>3.0.CO;2-N; WIBERG KB, 1968, TETRAHEDRON, V24, P1083, DOI 10.1016/0040-4020(68)88057-3; WILKINSON G, 1952, J AM CHEM SOC, V74, P2125, DOI 10.1021/ja01128a527	35	157	159	5	83	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 25	2006	313	5790					1104	1107		10.1126/science.1125245	http://dx.doi.org/10.1126/science.1125245			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	076ZT	16931758				2022-12-28	WOS:000239998200041
J	Rodrigues, ASL				Rodrigues, Ana S. L.			Are global conservation efforts successful?	SCIENCE			English	Editorial Material							EXTINCTIONS		Univ Cambridge, Dept Zool, Cambridge CB4 1AD, England	University of Cambridge	Rodrigues, ASL (corresponding author), Univ Cambridge, Dept Zool, Cambridge CB4 1AD, England.	aslr2@cam.ac.uk	Rodrigues, Ana/GYQ-6273-2022; Rodrigues, Ana S.L./A-5914-2009	Rodrigues, Ana S.L./0000-0003-4775-0127				[Anonymous], 2001, RED LIST CAT CRIT VE; Balmford A, 2005, SCIENCE, V307, P212, DOI 10.1126/science.1106281; *BIRDL INT, 2006, DAT ZON SPEC; Butchart S. H. M., 2006, Bulletin of the British Ornithologists' Club, V126, P7; Butchart SHM, 2006, ORYX, V40, P266, DOI 10.1017/S0030605306000950; Chape S, 2005, PHILOS T R SOC B, V360, P443, DOI 10.1098/rstb.2004.1592; Collar NJ, 1998, ORYX, V32, P239, DOI 10.1046/j.1365-3008.1998.d01-51.x; Gaston K.J, 1996, BIODIVERSITY BIOL NU; *IUCN, 2006, 2006 IUCN RED LIST T; James AN, 1999, NATURE, V401, P323, DOI 10.1038/43774; Ricketts TH, 2005, P NATL ACAD SCI USA, V102, P18497, DOI 10.1073/pnas.0509060102; World Resources Institute, 2005, MILL EC ASS EC HUM W	12	52	55	5	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 25	2006	313	5790					1051	1052		10.1126/science.1131302	http://dx.doi.org/10.1126/science.1131302			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	076ZT	16931741				2022-12-28	WOS:000239998200023
J	Kannel, WB; Vasan, RS				Kannel, William B.; Vasan, Ramachandran S.			Aggressive lowering of blood pressure	LANCET			English	Editorial Material							MYOCARDIAL-INFARCTION; HYPERTENSION; DISEASE		Boston Univ, Sch Med, Framingham Heart Study, Framingham, MA 01702 USA	Boston University; Framingham Heart Study	Kannel, WB (corresponding author), Boston Univ, Sch Med, Framingham Heart Study, Framingham, MA 01702 USA.	billkannel@yahoo.com	Ramachandran, Vasan/Y-2527-2019	Ramachandran, Vasan/0000-0001-7357-5970				[Anonymous], 1991, JAMA, V265, P3255; Chalmers J, 1999, J HYPERTENS, V17, P151; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; CRUICKSHANK JM, 1987, LANCET, V1, P581; DAGOSTINO RB, 1991, BRIT MED J, V303, P385, DOI 10.1136/bmj.303.6799.385; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; KANNEL WB, 1980, AM J CARDIOL, V45, P326, DOI 10.1016/0002-9149(80)90654-2; Kannel WB, 2004, AM J CARDIOL, V94, P380, DOI 10.1016/j.amjcard.2004.04.043; Mancia G, 2003, J HYPERTENS, V21, P1011, DOI 10.1097/01.hjh.0000059051.65882.32; MESSERLI FH, 2004, INCREASED PULSE PRES; Messerli FH, 2006, ANN INTERN MED, V144, P884, DOI 10.7326/0003-4819-144-12-200606200-00005; PERRY HM, 1986, J HYPERTENS, V4, pS21; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; Wang JG, 2005, HYPERTENSION, V45, P907, DOI 10.1161/01.HYP.0000165020.14745.79; Wang JG, 2000, ARCH INTERN MED, V160, P211, DOI 10.1001/archinte.160.2.211	15	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 19	2006	368	9536					627	628		10.1016/S0140-6736(06)69224-6	http://dx.doi.org/10.1016/S0140-6736(06)69224-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	074YT	16920451				2022-12-28	WOS:000239849200008
J	Campen, RB; Duncan, LM; Sang, CN; Harris, NL; Cusack, JC				Campen, Rebecca B.; Duncan, Lyn M.; Sang, Christine N.; Harris, Nancy Lee; Cusack, James C.			Case 25-2006: A 41-year-old woman with painful subcutaneous nodules - Adiposis dolorosa (Dercum's disease)	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							AUTOSOMAL DOMINANT INHERITANCE; INTRAVENOUS LIDOCAINE; SYMMETRICAL LIPOMATOSIS; INTRACTABLE PAIN; HYPERALGESIA; MANAGEMENT; ALLODYNIA; RELIEF; NERVE		Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dermatopathol Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Anesthesiol Perioperat &Pain Med, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Campen, RB (corresponding author), Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA.							ATKINSON RL, 1982, INT J OBESITY, V6, P351; BONATUS TJ, 1986, CLIN ORTHOP RELAT R, P251; Campen R, 2001, J AM ACAD DERMATOL, V44, P132, DOI 10.1067/mjd.2001.110872; CANTU JM, 1973, HUMANGENETIK, V18, P89; CHALK CH, 1990, NEUROLOGY, V40, P1246, DOI 10.1212/WNL.40.8.1246; DEFRANZO AJ, 1990, PLAST RECONSTR SURG, V85, P289, DOI 10.1097/00006534-199002000-00022; DERCUM FX, 1892, AM J MED SCI, V104, P521; DERCUM FX, 1888, U MED MAG PHILA, V1, P140; Devillers ACA, 1999, CLIN EXP DERMATOL, V24, P240; Gamez J, 1998, NEUROLOGY, V51, P258, DOI 10.1212/WNL.51.1.258; Gonciarz Z, 1997, J HEPATOL, V27, P1141, DOI 10.1016/S0168-8278(97)80164-X; GREENBAUM SS, 1991, ARCH DERMATOL, V127, P231, DOI 10.1001/archderm.127.2.231; HELD JL, 1989, J DERMATOL SURG ONC, V15, P1294, DOI 10.1111/j.1524-4725.1989.tb03150.x; HUSON SM, 1988, BRAIN, V111, P1355, DOI 10.1093/brain/111.6.1355; IWANE T, 1976, ANESTH ANALG, V55, P257; JUHLIN L, 1986, J AM ACAD DERMATOL, V15, P383, DOI 10.1016/S0190-9622(86)70184-9; KUMAR R, 1989, CLIN GENET, V35, P202; LEFFELL DJ, 1986, J AM ACAD DERMATOL, V15, P275, DOI 10.1016/S0190-9622(86)70166-7; PETERSEN P, 1987, PAIN, V28, P77, DOI 10.1016/0304-3959(87)91062-1; ROSS CM, 1969, ARCH DERMATOL, V100, P320, DOI 10.1001/archderm.100.3.320; RUZICKA T, 1987, J AM ACAD DERMATOL, V17, P663, DOI 10.1016/S0190-9622(87)70253-9; Sang CN, 1996, ANESTHESIOLOGY, V85, P491, DOI 10.1097/00000542-199609000-00007; Stavropoulos PG, 1997, DERMATOLOGY, V194, P26, DOI 10.1159/000246052; TAL M, 1994, PAIN, V57, P375, DOI 10.1016/0304-3959(94)90013-2; Woolf CJ, 1999, LANCET, V353, P1959, DOI 10.1016/S0140-6736(99)01307-0	25	12	13	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 17	2006	355	7					714	722		10.1056/NEJMcpc069018	http://dx.doi.org/10.1056/NEJMcpc069018			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	074AN	16914708				2022-12-28	WOS:000239784500012
J	Minkler, M; Fuller-Thomson, E; Guralnik, JM				Minkler, Meredith; Fuller-Thomson, Esme; Guralnik, Jack M.			Gradient of disability across the socioeconomic spectrum in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SELF-REPORT; HEALTH; INEQUALITIES; PERFORMANCE; DISPARITIES; DETERMINANTS; AGE	BACKGROUND: Although the relationship between extreme poverty and poor health among older adults has long been recognized, less attention has been devoted to investigating whether a gradient in disability exists in the United States among persons with middle-class and upper-class incomes. We attempted to determine whether a gradient in functional limitation exists across the full spectrum of income among persons 55 years of age or older. METHODS: We obtained data from the Census 2000 Supplementary Survey, which used the methods and questionnaire of the American Community Survey, a nationally representative survey of 890,698 households with a response rate of 95 percent. Our sample included 149,000 men and 186,675 women who were at least 55 years of age, of whom 32,680 men and 48,111 women reported having a functional limitation (a long-lasting condition that substantially limited one or more basic physical activities, such as climbing stairs or lifting). RESULTS: A social-class gradient was observed for both men and women between the ages of 55 and 84, a gradient that held true even at the upper rungs of the socioeconomic ladder. For example, in comparison to persons between the ages of 55 and 64 who lived at 700 percent of the poverty line or above, persons of the same age but below the poverty line had six times the odds of reporting a functional limitation. With increasing income, the odds ratio declined. A significant gradient was present up to, but not beyond, the age of 85 years. CONCLUSIONS: Our findings suggest that functional limitation in Americans between the ages of 55 and 84 years is inversely related to social class across the full spectrum of the socioeconomic gradient.	Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA; Univ Toronto, Dept Family & Community Med, Toronto, ON M5S 1A1, Canada; NIA, Dept Demog & Biometry, Lab Epidmeiol, Bethesda, MD 20892 USA	University of California System; University of California Berkeley; University of Toronto; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Minkler, M (corresponding author), Univ Calif Berkeley, Sch Publ Hlth, 316 Warren Hall, Berkeley, CA 94720 USA.	mink@berkeley.edu			Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Braveman PA, 2005, JAMA-J AM MED ASSOC, V294, P2879, DOI 10.1001/jama.294.22.2879; Breeze E, 2001, AM J PUBLIC HEALTH, V91, P277, DOI 10.2105/AJPH.91.2.277; BULATAO RA, 2004, UNDERSTANDING RACE E; *BUR CENS, 2000, AM COMM SURV US DAT; *BUR CENS, 2002, 63RV BUR CENS; *BUR CENS, 2004, MIDDL INT MIGR SER 1; *BUR CENS, 2002, 2 BUR CENS; Burchard EG, 2003, NEW ENGL J MED, V348, P1170, DOI 10.1056/NEJMsb025007; CRESS ME, 1995, J AM GERIATR SOC, V43, P93, DOI 10.1111/j.1532-5415.1995.tb06372.x; DALAKER J, 2001, CURRENT POPULATION S; Department of Health Human Services Washington DC. Healthy People 2010 (Group) and United States Government Printing Office., 2000, HLTH PEOPL 2010; Eichner J, 2005, HEALTH AFFAIR, V24, P365, DOI 10.1377/hlthaff.24.2.365; FRANK JW, 1994, DAEDALUS, V123, P1; HARRINGTON C, 2004, NURSING FACILITIES S; HOUSE JS, 1994, J HEALTH SOC BEHAV, V35, P213, DOI 10.2307/2137277; House JS, 2002, J HEALTH SOC BEHAV, V43, P125, DOI 10.2307/3090192; Institute of Medicine, 1991, DIS AM NAT AG PREV; Isaacs SL, 2004, NEW ENGL J MED, V351, P1137, DOI 10.1056/NEJMsb040329; Kempen GIJM, 1996, J GERONTOL B-PSYCHOL, V51, pP254, DOI 10.1093/geronb/51B.5.P254; Kington RS, 1997, AM J PUBLIC HEALTH, V87, P805, DOI 10.2105/AJPH.87.5.805; Kitagawa EM, 1973, DIFFERENTIAL MORTALI; Lantz PM, 2001, SOC SCI MED, V53, P29, DOI 10.1016/S0277-9536(00)00319-1; Manton KG, 2001, P NATL ACAD SCI USA, V98, P6354, DOI 10.1073/pnas.111152298; Marmot MG, 2003, PERSPECT BIOL MED, V46, pS9, DOI 10.1353/pbm.2003.0056; McDonough P, 1999, J HEALTH SOC BEHAV, V40, P17, DOI 10.2307/2676376; *NAT CTR HLTH STAT, 1999, 1999 NAT NURS HOM SU; PAPPAS G, 1993, NEW ENGL J MED, V329, P1139; SAGER MA, 1992, J AM GERIATR SOC, V40, P457, DOI 10.1111/j.1532-5415.1992.tb02011.x; SATARIANO WA, 2005, SOCIAL EPIDEMIOLOGY; Schoeni RF, 2005, AM J PUBLIC HEALTH, V95, P2065, DOI 10.2105/AJPH.2004.048744; Siegrist J, 2004, SOC SCI MED, V58, P1463, DOI 10.1016/S0277-9536(03)00349-6	31	191	193	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 17	2006	355	7					695	703		10.1056/NEJMsa044316	http://dx.doi.org/10.1056/NEJMsa044316			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	074AN	16914705				2022-12-28	WOS:000239784500008
J	Greenberger, NJ; Sharma, P				Greenberger, Norton J.; Sharma, Prateek			Update in gastroenterology and hepatology	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Kansas, Sch Med, Kansas City, KS USA; Harvard Univ, Sch Med, Cambridge, MA 02138 USA	University of Kansas; University of Kansas Medical Center; Harvard University	Greenberger, NJ (corresponding author), Brigham & Womens Hosp, Div Gastroenterol, 75 Francis St, Boston, MA 02115 USA.	ngreenberger@partners.org						Morton C, 2004, AM J GASTROENTEROL, V99, P731, DOI 10.1111/j.1572-0241.2004.04143.x; Okhuysen PC, 2004, AM J GASTROENTEROL, V99, P1774, DOI 10.1111/j.1572-0241.2004.30435.x	2	2	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	2006	145	4					294	298		10.7326/0003-4819-145-4-200608150-00009	http://dx.doi.org/10.7326/0003-4819-145-4-200608150-00009			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	075CC	16908920				2022-12-28	WOS:000239858800007
J	Collins, P; Rhodes, J				Collins, Paul; Rhodes, Jonathan			Ulcerative colitis: diagnosis and management	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INFLAMMATORY-BOWEL-DISEASE; MAINTAINING REMISSION; COLORECTAL-CANCER; AZATHIOPRINE; THERAPY; INFLIXIMAB; EFFICACY		Univ Liverpool, Henry Wellcome Lab, Liverpool L69 3GE, Merseyside, England; Univ Liverpool, Liverpool L69 3GA, Merseyside, England	University of Liverpool; University of Liverpool	Collins, P (corresponding author), Univ Liverpool, Henry Wellcome Lab, Nuffield Bldg, Liverpool L69 3GE, Merseyside, England.	paul_d_collins1@yahoo.co.uk						Ardizzone S, 2002, J INTERN MED, V252, P475, DOI 10.1046/j.1365-2796.2002.01067.x; CARTER MJ, 2004, GUT, V53, P16; Cohen RD, 2000, AM J GASTROENTEROL, V95, P1263; Collins PD, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000279.pub3; CONNELL WR, 1993, GUT, V34, P1081, DOI 10.1136/gut.34.8.1081; Eaden J, 2000, ALIMENT PHARM THERAP, V14, P145; Forrest K, 2004, ALIMENT PHARM THER, V20, P1035, DOI 10.1111/j.1365-2036.2004.02270.x; Fraser AG, 2002, GUT, V50, P485, DOI 10.1136/gut.50.4.485; Fraser AG, 2002, ALIMENT PHARM THER, V16, P693, DOI 10.1046/j.1365-2036.2002.01227.x; Hawthorne AB, 2003, EUR J GASTROEN HEPAT, V15, P239, DOI 10.1097/00042737-200303000-00005; Jarnerot G, 2005, GASTROENTEROLOGY, V128, P1805, DOI 10.1053/j.gastro.2005.03.003; Kandiel A, 2005, GUT, V54, P1121, DOI 10.1136/gut.2004.049460; Kruis W, 2004, GUT, V53, P1617, DOI 10.1136/gut.2003.037747; Marteau P, 2005, GUT, V54, P960, DOI 10.1136/gut.2004.060103; Nayar M, 2004, POSTGRAD MED J, V80, P206, DOI 10.1136/pgmj.2003.013722; PRESENT DH, 1989, ANN INTERN MED, V111, P641, DOI 10.7326/0003-4819-111-8-641; RAO SSC, 1987, GASTROENTEROLOGY, V93, P934, DOI 10.1016/0016-5085(87)90554-3; Rubin DT, 2006, GASTROENTEROLOGY, V130, P1350, DOI 10.1053/j.gastro.2006.03.015; Rutgeerts P, 2005, NEW ENGL J MED, V353, P2462, DOI 10.1056/NEJMoa050516; Sutherland L, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000543.pub2; TRUELOVE SC, 1955, BRIT MED J, V2, P1041, DOI 10.1136/bmj.2.4947.1041; Tursi A, 2004, MED SCI MONITOR, V10, pPI126	22	40	44	1	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 12	2006	333	7563					340	343		10.1136/bmj.333.7563.340	http://dx.doi.org/10.1136/bmj.333.7563.340			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	073VI	16902215	Green Published			2022-12-28	WOS:000239770300020
J	Dustin, ML				Dustin, Michael L.			When F-actin becomes too much of a good thing	SCIENCE			English	Editorial Material							PLASMA-MEMBRANE; ARP2/3 COMPLEX; PROTEIN; CYTOSKELETON; APOPTOSIS; CORONIN-1; ASSOCIATION; LYMPHOCYTES; ACTIVATION; DYNAMICS		NYU Med Ctr, Skirball Inst, Program Mol Pathogenesis, New York, NY 10016 USA	New York University	Dustin, ML (corresponding author), NYU Med Ctr, Skirball Inst, Program Mol Pathogenesis, 540 1st Ave, New York, NY 10016 USA.	dustin@saturn.med.nyu.edu	Dustin, Michael/AAM-4611-2020	Dustin, Michael/0000-0003-4983-6389				Appleton BA, 2006, STRUCTURE, V14, P87, DOI 10.1016/j.str.2005.09.013; Boldogh IR, 2003, MOL BIOL CELL, V14, P4618, DOI 10.1091/mbc.E03-04-0225; De Vos KJ, 2005, CURR BIOL, V15, P678, DOI 10.1016/j.cub.2005.02.064; Fehrenbacher KL, 2005, MOL BIOL CELL, V16, P5094, DOI 10.1091/mbc.E05-06-0590; Foger N, 2006, SCIENCE, V313, P839, DOI 10.1126/science.1130563; Gatfield J, 2005, MOL BIOL CELL, V16, P2786, DOI 10.1091/mbc.E05-01-0042; Gomez TS, 2006, IMMUNITY, V24, P741, DOI 10.1016/j.immuni.2006.03.022; Gupton SL, 2005, J CELL BIOL, V168, P619, DOI 10.1083/jcb.200406063; Humphries CL, 2002, J CELL BIOL, V159, P993, DOI 10.1083/jcb.200206113; Koya RC, 2000, J BIOL CHEM, V275, P15343, DOI 10.1074/jbc.275.20.15343; Kusano H, 2000, ONCOGENE, V19, P4807, DOI 10.1038/sj.onc.1203868; Nal B, 2004, INT IMMUNOL, V16, P231, DOI 10.1093/intimm/dxh022; Nolz JC, 2006, CURR BIOL, V16, P24, DOI 10.1016/j.cub.2005.11.036; Raucher D, 2000, CELL, V100, P221, DOI 10.1016/S0092-8674(00)81560-3; Tang HL, 2006, BIOCHEM J, V396, P1, DOI 10.1042/BJ20060241; Verkhovsky AB, 1999, CURR BIOL, V9, P11, DOI 10.1016/S0960-9822(99)80042-6	16	7	12	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 11	2006	313	5788					767	768		10.1126/science.1131714	http://dx.doi.org/10.1126/science.1131714			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	072KC	16902113				2022-12-28	WOS:000239671300031
J	Lee, BJ; Cansizoglu, AE; Suel, KE; Louis, TH; Zhang, ZC; Chook, YM				Lee, Brittany J.; Cansizoglu, Ahmet E.; Suel, Katherine E.; Louis, Thomas H.; Zhang, Zichao; Chook, Yuh Min			Rules for nuclear localization sequence recognition by karyopherin beta 2	CELL			English	Article							NUCLEOCYTOPLASMIC SHUTTLING SEQUENCE; HNRNP A1; STRUCTURAL BASIS; IMPORT; TRANSPORT; RECEPTOR; IDENTIFICATION; DISSOCIATION; DOMAIN; SIGNAL	Karyopherin beta (Kap beta) proteins bind nuclear localization and export signals (NLSs and NESs) to mediate nucleocytoplasmic trafficking, a process regulated by Ran GTPase through its nucleotide cycle. Diversity and complexity of signals recognized by Kapos have prevented prediction of new Kap beta substrates. The structure of Kap beta 2 (also known as Transportin) bound to one of its substrates, the NILS of hnRNP A1, that we report here explains the mechanism of substrate displacement by Ran GTPase. Further analyses reveal three rules for NILS recognition by Kap beta 2: NLSs are structurally disordered in free substrates, have overall basic character, and possess a central hydrophobic or basic motif followed by a C-terminal R/H/KX(2-5)PY consensus sequence. We demonstrate the predictive nature of these rules by identifying NLSs in seven previously known Kap beta 2 substrates and uncovering 81 new candidate substrates, confirming five experimentally. These studies define and validate a new NLS that could not be predicted by primary sequence analysis alone.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chook, YM (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 6001 Forest Pk, Dallas, TX 75235 USA.	yuhmin.chook@utsouthwestern.edu	ZHANG, ZICHAO/C-1764-2014; Chook, Yuh Min/AAA-9549-2019	ZHANG, ZICHAO/0000-0003-3402-7757; Zhang, Zi Chao/0000-0001-5769-948X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069909] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01- GM069909, R01 GM069909] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allemand E, 2005, P NATL ACAD SCI USA, V102, P3605, DOI 10.1073/pnas.0409889102; Apweiler R, 2004, CURR OPIN CHEM BIOL, V8, P76, DOI 10.1016/j.cbpa.2003.12.004; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bairoch A, 2004, BRIEF BIOINFORM, V5, P39, DOI 10.1093/bib/5.1.39; Bogerd HP, 1999, J BIOL CHEM, V274, P9771, DOI 10.1074/jbc.274.14.9771; Bonifaci N, 1997, P NATL ACAD SCI USA, V94, P5055, DOI 10.1073/pnas.94.10.5055; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chook YM, 1999, NATURE, V399, P230, DOI 10.1038/20375; Chook YM, 2002, BIOCHEMISTRY-US, V41, P6955, DOI 10.1021/bi012122p; Chook YM, 2001, CURR OPIN STRUC BIOL, V11, P703, DOI 10.1016/S0959-440X(01)00264-0; Cingolani G, 2002, MOL CELL, V10, P1345, DOI 10.1016/S1097-2765(02)00727-X; Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; Conti E, 2001, CURR OPIN CELL BIOL, V13, P310, DOI 10.1016/S0955-0674(00)00213-1; Cook A, 2005, MOL CELL, V18, P355, DOI 10.1016/j.molcel.2005.03.021; DeLano WL, 2002, PYMOL USERS MANUAL; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Floer M, 1996, J BIOL CHEM, V271, P5313, DOI 10.1074/jbc.271.10.5313; Fridell RA, 1997, J CELL SCI, V110, P1325; Fukuhara N, 2004, J BIOL CHEM, V279, P2176, DOI 10.1074/jbc.M309112200; Gattiker Alexandre, 2002, Appl Bioinformatics, V1, P107; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Guttinger S, 2004, P NATL ACAD SCI USA, V101, P2918, DOI 10.1073/pnas.0400342101; Iijima M, 2006, FEBS LETT, V580, P1365, DOI 10.1016/j.febslet.2006.01.058; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kawamura H, 2002, J BIOL CHEM, V277, P2732, DOI 10.1074/jbc.M108477200; Lee SJ, 2005, NATURE, V435, P693, DOI 10.1038/nature03578; Lee SJ, 2003, SCIENCE, V302, P1571, DOI 10.1126/science.1088372; Linding R, 2003, STRUCTURE, V11, P1453, DOI 10.1016/j.str.2003.10.002; Matsuura Y, 2004, NATURE, V432, P872, DOI 10.1038/nature03144; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Mosammaparast N, 2004, TRENDS CELL BIOL, V14, P547, DOI 10.1016/j.tcb.2004.09.004; Nakielny S, 1996, EXP CELL RES, V229, P261, DOI 10.1006/excr.1996.0369; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Petosa C, 2004, MOL CELL, V16, P761, DOI 10.1016/j.molcel.2004.11.018; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; Rebane A, 2004, RNA, V10, P590, DOI 10.1261/rna.5224304; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Siomi MC, 1997, J CELL BIOL, V138, P1181, DOI 10.1083/jcb.138.6.1181; Suzuki M, 2005, FEBS J, V272, P3975, DOI 10.1111/j.1742-4658.2005.04820.x; Truant R, 1999, J BIOL CHEM, V274, P32167, DOI 10.1074/jbc.274.45.32167; Vetter IR, 1999, CELL, V97, P635, DOI 10.1016/S0092-8674(00)80774-6; WEIGHARDT F, 1995, J CELL SCI, V108, P545; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5	45	414	428	1	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 11	2006	126	3					543	558		10.1016/j.cell.2006.05.049	http://dx.doi.org/10.1016/j.cell.2006.05.049			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	075KI	16901787	Green Accepted, Bronze			2022-12-28	WOS:000239883400014
J	Afraz, SR; Kiani, R; Esteky, H				Afraz, Seyed-Reza; Kiani, Roozbeh; Esteky, Hossein			Microstimulation of inferotemporal cortex influences face categorization	NATURE			English	Article							PYRAMIDAL TRACT CELLS; ELECTRICAL MICROSTIMULATION; SINGLE NEURONS; AREA; RESPONSES; MONKEY; ORGANIZATION; EXCITATION; DIRECTION; PRIMATE	The inferior temporal cortex ( IT) of primates is thought to be the final visual area in the ventral stream of cortical areas responsible for object recognition(1,2). Consistent with this hypothesis, single IT neurons respond selectively to highly complex visual stimuli such as faces(3-6). However, a direct causal link between the activity of face- selective neurons and face perception has not been demonstrated. In the present study of macaque monkeys, we artificially activated small clusters of IT neurons by means of electrical microstimulation while the monkeys performed a categorization task, judging whether noisy visual images belonged to ' face ' or ' non- face' categories. Here we show that microstimulation of face-selective sites, but not other sites, strongly biased the monkeys' decisions towards the face category. The magnitude of the effect depended upon the degree of face selectivity of the stimulation site, the size of the stimulated cluster of face- selective neurons, and the exact timing of microstimulation. Our results establish a causal relationship between the activity of face- selective neurons and face perception.	Inst Studies Theoret Phys & Math, Sch Cognit Sci, Tehran 19395, Iran; Shahid Beheshti Univ Med Sci, Res Ctr Brain & Cognit Sci, Tehran 19385, Iran; Shahid Beheshti Univ Med Sci, Neurosci Res Ctr, Tehran 19385, Iran	Shahid Beheshti University Medical Sciences; Shahid Beheshti University Medical Sciences	Esteky, H (corresponding author), Inst Studies Theoret Phys & Math, Sch Cognit Sci, Tehran 19395, Iran.	esteky@ipm.ir						ASANUMA H, 1976, EXP BRAIN RES, V26, P443; BRUCE C, 1981, J NEUROPHYSIOL, V46, P369, DOI 10.1152/jn.1981.46.2.369; Buffalo EA, 1999, LEARN MEMORY, V6, P572, DOI 10.1101/lm.6.6.572; Cohen MR, 2004, CURR OPIN NEUROBIOL, V14, P169, DOI 10.1016/j.conb.2004.03.016; DeAngelis GC, 2004, PLOS BIOL, V2, P394, DOI 10.1371/journal.pbio.0020077; DESIMONE R, 1984, J NEUROSCI, V4, P2051; Foldiak P, 2003, PROG BRAIN RES, V144, P107, DOI 10.1016/S0079-6123(03)14400-7; Green DM, 1988, SIGNAL DETECTION THE; Gross CG, 2005, AM PSYCHOL, V60, P755, DOI 10.1037/0003-066X.60.8.755; HOREL JA, 1987, BEHAV BRAIN RES, V23, P29, DOI 10.1016/0166-4328(87)90240-3; Keysers C, 2001, J COGNITIVE NEUROSCI, V13, P90, DOI 10.1162/089892901564199; Kiani R, 2005, J NEUROPHYSIOL, V94, P1587, DOI 10.1152/jn.00540.2004; Logothetis NK, 1996, ANNU REV NEUROSCI, V19, P577, DOI 10.1146/annurev.ne.19.030196.003045; MEEKER WQ, 1995, AM STAT, V49, P48, DOI 10.2307/2684811; Moore T, 2003, NATURE, V421, P370, DOI 10.1038/nature01341; Nichols MJ, 2002, J NEUROSCI, V22, P9530; PERRETT DI, 1992, PHILOS T ROY SOC B, V335, P23, DOI 10.1098/rstb.1992.0003; PERRETT DI, 1982, EXP BRAIN RES, V47, P329; ROLLS ET, 1984, HUM NEUROBIOL, V3, P209; Romo R, 1998, NATURE, V392, P387, DOI 10.1038/32891; Romo R, 1999, CURR OPIN NEUROBIOL, V9, P487, DOI 10.1016/S0959-4388(99)80073-7; SALZMAN CD, 1992, J NEUROSCI, V12, P2331; SALZMAN CD, 1990, NATURE, V346, P589, DOI 10.1038/346589b0; STONEY SD, 1968, J NEUROPHYSIOL, V31, P659, DOI 10.1152/jn.1968.31.5.659; Sugase Y, 1999, NATURE, V400, P869, DOI 10.1038/23703; Tanaka K, 1996, ANNU REV NEUROSCI, V19, P109, DOI 10.1146/annurev.ne.19.030196.000545; Tolias AS, 2005, NEURON, V48, P901, DOI 10.1016/j.neuron.2005.11.034; TOVEE MJ, 1993, J NEUROPHYSIOL, V70, P640, DOI 10.1152/jn.1993.70.2.640; Tsao DY, 2003, NAT NEUROSCI, V6, P989, DOI 10.1038/nn1111; Zangenehpour S, 2005, CURR BIOL, V15, P993, DOI 10.1016/j.cub.2005.04.031	30	211	214	3	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 10	2006	442	7103					692	695		10.1038/nature04982	http://dx.doi.org/10.1038/nature04982			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	071UU	16878143				2022-12-28	WOS:000239630200047
J	Braude, P				Braude, Peter			Preimplantation diagnosis for genetic susceptibility	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Kings Coll London, Sch Med, Dept Womens Hlth, London WC2R 2LS, England	University of London; King's College London	Braude, P (corresponding author), Kings Coll London, Sch Med, Dept Womens Hlth, London WC2R 2LS, England.							MEIKLE J, 2005, GUARDIAN        0317; Rechitsky Svetlana, 2002, Reprod Biomed Online, V5, P148; Renwick P, 2006, REPROD BIOMED ONLINE, V13, P110, DOI 10.1016/S1472-6483(10)62024-X	3	24	24	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 10	2006	355	6					541	543		10.1056/NEJMp068139	http://dx.doi.org/10.1056/NEJMp068139			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	071QM	16899771				2022-12-28	WOS:000239616700001
J	Scales, H; Balmford, A; Liu, M; Sadovy, Y; Manica, A				Scales, Helen; Balmford, Andrew; Liu, Min; Sadovy, Yvonne; Manica, Andrea			Keeping bandits at bay?	SCIENCE			English	Letter									Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England; Univ Hong Kong, Dept Ecol & Biodivers, Swire Inst Marine Sci, Hong Kong, Hong Kong, Peoples R China	University of Cambridge; University of Hong Kong	Manica, A (corresponding author), Univ Cambridge, Dept Zool, Downing St, Cambridge CB2 3EJ, England.	am315@cam.ac.uk	Sadovy, Yvonne Jill/D-3121-2009; Manica, Andrea/N-9013-2019; Manica, Andrea/B-5497-2008; Hughes, Terry/L-4721-2013	Manica, Andrea/0000-0003-1895-450X; Manica, Andrea/0000-0003-1895-450X; Balmford, Andrew/0000-0002-0144-3589; Hughes, Terry/0000-0002-5257-5063				Bentley N., 1999, FISHING SOLUTIONS CA; Chan P, 2000, SPC LIVE REEF FISH I, V7, P3; Lee C., 1998, Naga, V21, P38; Riepen, 1995, ENV EC SOCIAL IMPLIC; SADOVY YJ, 2003, STOCKS LAST LIVE FOO; SMITH AJ, 1997, SPC LIVE REEF INF B, V3, P47; Spalding M. D., 2001, WORLD ATLAS CORAL RE; Warren-Rhodes K, 2003, AMBIO, V32, P481, DOI 10.1639/0044-7447(2003)032[0481:MEAITI]2.0.CO;2	8	38	39	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 4	2006	313	5787					612	613		10.1126/science.313.5787.612c	http://dx.doi.org/10.1126/science.313.5787.612c			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	072IQ	16888119				2022-12-28	WOS:000239667500016
J	Weisler, RH; Barbee, JG; Townsend, MH				Weisler, Richard H.; Barbee, James G.; Townsend, Mark H.			Mental health and recovery in the Gulf Coast after Hurricanes Katrina and Rita	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							LIFE EVENTS; NEW-ORLEANS; DEPRESSION; MORTALITY; SYMPTOMS; ANXIETY; RISK		Univ N Carolina, Dept Psychiat, Chapel Hill, NC USA; Duke Univ, Med Ctr, Durham, NC USA; Louisiana State Univ, Hlth Sci Ctr, Dept Psychiat, New Orleans, LA USA	University of North Carolina; University of North Carolina Chapel Hill; Duke University; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Weisler, RH (corresponding author), UNC CH Duke Univ Med Ctr, Dept Psychiat, 700 Spring Forest Rd,Suite 125, Raleigh, NC 27609 USA.	rweisler@aol.com		Townsend, Mark H/0000-0002-9385-4325				ABRAMASON D, EDGE CHILDREN FAMILI; ALLGULANDER C, 1994, ARCH GEN PSYCHIAT, V51, P708; Berggren RE, 2006, NEW ENGL J MED, V354, P1549, DOI 10.1056/NEJMp068039; Bernard B. P., 2006, Morbidity and Mortality Weekly Report, V55, P456; BROWN GW, 1994, ARCH GEN PSYCHIAT, V51, P525; DAVIS R, 2005, USA TODAY       1016; Foa EB, 2006, J CLIN PSYCHIAT, V67, P15; FRANK E, 1994, ARCH GEN PSYCHIAT, V51, P519; Golden SH, 2004, DIABETES CARE, V27, P429, DOI 10.2337/diacare.27.2.429; Hurricane Kat-Federal Emergency Management Agency, 2006, HURR KATR CURR LOC R; Jonas BS, 1997, ARCH FAM MED, V6, P43, DOI 10.1001/archfami.6.1.43; *LA DEP HLTH HOSP, 2006, ORL PAR DECL HLTH PR; *LA DEP HLTH HOSP, REP MISS DEC; *LA PUBL HLTH I, 2006, NOLA DASHB; McGinnis JM, 1999, P ASSOC AM PHYSICIAN, V111, P109, DOI 10.1046/j.1525-1381.1999.09256.x; Musselman DL, 2000, PROG BRAIN RES, V122, P43; PERLSTEIN M, 2006, TIMES PICAYUNE  0625; POPE J, 2006, NEW ORLEANS TIM 0426; SAUNA S, 2006, NY TIMES        0621; 2006, MMWR MORB MORTAL WKL, V55, P38; 2005, SUN HERALD      1214; 2006, NATIONS BUILDIN 0619	22	134	134	1	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 2	2006	296	5					585	588		10.1001/jama.296.5.585	http://dx.doi.org/10.1001/jama.296.5.585			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	069YW	16882968				2022-12-28	WOS:000239486900026
J	MacDonald, R				MacDonald, Rhona			Where next for arms control?	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		MacDonald, R (corresponding author), The Lancet, London NW1 7BY, England.							*CONTR ARMS, 2006, UN WORLD C SMALL ARM; *CONTR ARMS, 2006, ALM ON 3 AFF GUN CRI; *CONTR ARMS AMN IN, 2006, SHATT LIV CAS TOUGH; *UN, 2006, UN SMALL ARMS REV C	4	1	1	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG-SEP	2006	368	9537					713	714		10.1016/S0140-6736(06)69264-7	http://dx.doi.org/10.1016/S0140-6736(06)69264-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	080ID	16935670				2022-12-28	WOS:000240240200008
J	Flood, C; Byford, S; Henderson, C; Leese, M; Thornicroft, G; Sutherby, K; Szmukler, G				Flood, Chris; Byford, Sarah; Henderson, Claire; Leese, Morven; Thornicroft, Graham; Sutherby, Kim; Szmukler, George			Joint crisis plans for people with psychosis: economic evaluation of a randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							EFFECTIVENESS ACCEPTABILITY CURVES; COST-EFFECTIVENESS	Objective To investigate the cost effectiveness of joint crisis plans.. a form of advance agreement for people with severe mental illness. Design Single blind randomised controlled trial. Setting Eight community mental health teams in southern England. Participants 160 people with a diagnosis of psychotic illness or non-psychotic bipolar disorder who had been admitted to hospital at least once within the previous two years. Intervention joint crisis plan formulated by the patient, care coordinator, psychiatrist, and project worker containing contact information, details of illnesses, treatments, relapse indicators, and advance statements of preferences for care for future relapses. Control group was standardised service information. Main outcome measures Admission to hospital; service use over 15 months. Results Use of a joint crisis plan was associated with less service use and lower costs on average than in the standardised service information group, but differences were not significant. Total costs during follow-up were,0264 (E10 616, $13 560) for each participant with a joint crisis plan and;8359 pound (E12 217. $15 609) for each participant with standardised service information (mean difference 1095; pound 95% confidence interval - 2814 to 5004). Cost effectiveness acceptability curves, used to explore uncertainty in estimates of costs and effects, suggest there is a greater than 78% probability that joint crisis plans are more cost effective than standardised service information ill reducing the proportion of patients admitted to hospital. Conclusion joint crisis plans produced a non-significant decrease in admissions mid total costs. Though the cost estimates had wide confidence intervals, the associated uncertainty suggests there is a relatively high probability, of the plans being more cost effective than standardised service information for people with psychotic disorders.	Kings Coll London, Inst Psychiat, Ctr Econ Mental Hlth, London SE5 8AF, England; City Univ London, Dept Mental Hlth & Learning Disabil, London E1 2EA, England; Kings Coll London, Inst Psychiat, Hlth Serv Res Dept, Sect Community Psychiat, London, England; S London & Maudsley NHS Trust, Croydon CR0 1XT, England	University of London; King's College London; City University London; University of London; King's College London	Byford, S (corresponding author), Kings Coll London, Inst Psychiat, Ctr Econ Mental Hlth, London SE5 8AF, England.	s.byford@iop.kcl.ac.uk	Thornicroft, Graham/B-4027-2010; Henderson, Claire/E-4664-2010; Leese, Morven N/E-4195-2010; Byford, Sarah/D-1699-2010	Thornicroft, Graham/0000-0003-0662-0879; Henderson, Claire/0000-0002-6998-5659; Byford, Sarah/0000-0001-7084-1495; Flood, Chris/0000-0001-5170-7792				[Anonymous], 2001, BRIT NAT FORM; [Anonymous], MENT HLTH RES REV; Barber JA, 2000, STAT MED, V19, P3219, DOI 10.1002/1097-0258(20001215)19:23<3219::AID-SIM623>3.0.CO;2-P; Beecham J., 2001, MEASURING MENTAL HLT, V2nd ed, P200; *DEP HLTH, 2001, NHS REF COSTS; Efron B., 1994, MONOGRAPHS STAT APPL; Fenwick E, 2004, HEALTH ECON, V13, P405, DOI 10.1002/hec.903; Fenwick E, 2005, BRIT J PSYCHIAT, V187, P106, DOI 10.1192/bjp.187.2.106; Fenwick E, 2001, HEALTH ECON, V10, P779, DOI 10.1002/hec.635; Henderson C, 2004, BRIT MED J, V329, P136, DOI 10.1136/bmj.38155.585046.63; KNAPP M, 1999, RESOURCE IMPLICATION; McGuire A, 2001, EC EVALUATION HLTH C, P172; Morris S, 1998, CLIN DRUG INVEST, V15, P137, DOI 10.2165/00044011-199815020-00007; MORRIS S, 1998, CLIN PHARMAECONOMICS, V13, P137; Netten A.P., 2000, UNIT COSTS HLTH SOCI; *PRIS SERV, 2000, PRIS SERV ANN REP AC; Rice DP, 1996, HDB MENTAL HLTH EC H; Sutherby K, 1999, ACTA PSYCHIAT SCAND, V100, P56, DOI 10.1111/j.1600-0447.1999.tb10914.x; VANHOUT BA, 1994, HEALTH ECON, V3, P309, DOI 10.1002/hec.4730030505	19	37	38	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	OCT 7	2006	333	7571					729	732A		10.1136/bmj.38929.653704.55	http://dx.doi.org/10.1136/bmj.38929.653704.55			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	094OK	16914458	Green Accepted, Green Submitted, Green Published, Bronze			2022-12-28	WOS:000241248600019
J	Cohen, E; Bieschke, J; Perciavalle, RM; Kelly, JW; Dillin, A				Cohen, Ehud; Bieschke, Jan; Perciavalle, Rhonda M.; Kelly, Jeffery W.; Dillin, Andrew			Opposing activities protect against age-onset proteotoxicity	SCIENCE			English	Article							CAENORHABDITIS-ELEGANS; LIFE-SPAN; A-BETA; LONGEVITY; DAF-16; MUTANT; BRAIN; LONG; NEURODEGENERATION; INSULIN/IGF-1	Aberrant protein aggregation is a common feature of late-onset neurodegenerative diseases, including Alzheimer's disease, which is associated with themisassembly of the A beta(1-42) peptide. Aggregation-mediated A beta(1-42) toxicity was reduced in Caenorhabiditis elegans when aging was slowed by decreased insulin/ insulin growth factor - 1 - like signaling (IIS). The downstream transcription factors, heat shock factor 1, and DAF-16 regulate opposing disaggregation and aggregation activities to promote cellular survival in response to constitutive toxic protein aggregation. Because the IIS pathway is central to the regulation of longevity and youthfulness in worms, flies, and mammals, these results suggest a mechanistic link between the aging process and aggregation-mediated proteotoxicity.	Salk Inst Biol Studies, Mol & Cell Biol Lab, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Salk Institute; Scripps Research Institute; Scripps Research Institute	Dillin, A (corresponding author), Salk Inst Biol Studies, Mol & Cell Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	dillin@salk.edu	Longo, Kenneth A/A-5631-2010; Bieschke, Jan/AAG-2705-2019	Cohen, Ehud/0000-0001-5552-7086; Bieschke, Jan/0000-0002-3485-9767	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK046335, R29DK046335, R01DK046335] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS050636] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 46335] Funding Source: Medline; NINDS NIH HHS [NS 50636] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; Bossy-Wetzel E, 2004, NAT MED, V10, pS2, DOI 10.1038/nm1067; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Dillin A, 2002, SCIENCE, V298, P830, DOI 10.1126/science.1074240; Gidalevitz T, 2006, SCIENCE, V311, P1471, DOI 10.1126/science.1124514; Gong YS, 2003, P NATL ACAD SCI USA, V100, P10417, DOI 10.1073/pnas.1834302100; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Hasegawa K, 1999, BIOCHEMISTRY-US, V38, P15514, DOI 10.1021/bi991161m; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; Hsu AL, 2003, SCIENCE, V300, P1142, DOI 10.1126/science.1083701; Iwata N, 2001, SCIENCE, V292, P1550, DOI 10.1126/science.1059946; Kenyon C, 2005, CELL, V120, P449, DOI 10.1016/j.cell.2005.02.002; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Kopito RR, 2000, NAT CELL BIOL, V2, pE207, DOI 10.1038/35041139; Leissring MA, 2003, NEURON, V40, P1087, DOI 10.1016/S0896-6273(03)00787-6; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; Lin K, 2001, NAT GENET, V28, P139, DOI 10.1038/88850; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; LINK CD, 1995, P NATL ACAD SCI USA, V92, P9368, DOI 10.1073/pnas.92.20.9368; Link CD, 2001, NEUROBIOL AGING, V22, P217, DOI 10.1016/S0197-4580(00)00237-2; Morley JF, 2004, MOL BIOL CELL, V15, P657, DOI 10.1091/mbc.E03-07-0532; Morley JF, 2002, P NATL ACAD SCI USA, V99, P10417, DOI 10.1073/pnas.152161099; Muchowski PJ, 2005, NAT REV NEUROSCI, V6, P11, DOI 10.1038/nrn1587; O'Brien J, 2000, EUR J BIOCHEM, V267, P5421, DOI 10.1046/j.1432-1327.2000.01606.x; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Parker JA, 2005, NAT GENET, V37, P349, DOI 10.1038/ng1534; Ross CA, 2005, NAT REV MOL CELL BIO, V6, P891, DOI 10.1038/nrm1742; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Selkoe DJ, 2003, NATURE, V426, P900, DOI 10.1038/nature02264; Takahashi RH, 2002, AM J PATHOL, V161, P1869, DOI 10.1016/S0002-9440(10)64463-X; TOWNSEND M, 2006, J PHYSL; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a	34	650	679	2	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 15	2006	313	5793					1604	1610		10.1126/science.1124646	http://dx.doi.org/10.1126/science.1124646			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	083YS	16902091				2022-12-28	WOS:000240498900036
J	Jayawardhana, R; Ivanov, VD				Jayawardhana, Ray; Ivanov, Valentin D.			Discovery of a young planetary-mass binary	SCIENCE			English	Article							BROWN DWARF DISKS; L FIELD DWARFS; UPPER-SCORPIUS; MULTIPLICITY; POPULATION; STARS	We have identified a companion to the young planetary-mass brown dwarf Oph 162225-240515. This pair forms a resolved binary consisting of two objects with masses comparable to those of extrasolar giant planets. Several lines of evidence confirm the coevality and youth of the two objects, suggesting that they form a physical binary. Models yield masses of similar to 14 and similar to 7 times the mass of Jupiter for the primary and the secondary object, respectively, at an age of similar to 1 million years. A wide (similar to 240-astronomical unit) binary in the ultra-low-mass regime poses a challenge to some popular models of brown dwarf formation.	Univ Toronto, Dept Astron & Astrophys, Toronto, ON M5S 3H8, Canada; European So Observ, Santiago 19001, Chile	University of Toronto; European Southern Observatory	Jayawardhana, R (corresponding author), Univ Toronto, Dept Astron & Astrophys, Toronto, ON M5S 3H8, Canada.	rayjay@astro.utoronto.ca		Jayawardhana, Ray/0000-0001-5349-6853; Ivanov, Valentin/0000-0002-5963-1283				Allers KN, 2006, ASTROPHYS J, V644, P364, DOI 10.1086/503355; ALLERS KN, 2005, THESIS U TEXAS AUSTI; Baraffe O, 2002, ASTRON ASTROPHYS, V382, P563, DOI 10.1051/0004-6361:20011638; Basri G, 2000, ANNU REV ASTRON ASTR, V38, P485, DOI 10.1146/annurev.astro.38.1.485; Bouy H, 2006, ASTRON ASTROPHYS, V451, P177, DOI 10.1051/0004-6361:20054252; Bouy H, 2003, ASTRON J, V126, P1526, DOI 10.1086/377343; Chabrier G, 2000, ASTROPHYS J, V542, P464, DOI 10.1086/309513; Chauvin G, 2004, ASTRON ASTROPHYS, V425, pL29, DOI 10.1051/0004-6361:200400056; Gizis JE, 2003, ASTRON J, V125, P3302, DOI 10.1086/374991; Jayawardhana R, 2003, ASTRON J, V126, P1515, DOI 10.1086/377144; Jayawardhana R, 2003, ASTROPHYS J, V592, P282, DOI 10.1086/375573; JAYAWARDHANA R, IN PRESS ASTROPHYS J; Kraus AL, 2005, ASTROPHYS J, V633, P452, DOI 10.1086/449303; Leggett SK, 2002, ASTROPHYS J, V564, P452, DOI 10.1086/324037; Lodato G, 2005, MON NOT R ASTRON SOC, V364, pL91, DOI 10.1111/j.1745-3933.2005.00112.x; Lucas PW, 2000, MON NOT R ASTRON SOC, V314, P858, DOI 10.1046/j.1365-8711.2000.03515.x; Luhman KL, 2004, ASTROPHYS J, V614, P398, DOI 10.1086/423666; Martin EL, 1999, ASTRON J, V118, P2466, DOI 10.1086/301107; Martin EL, 2003, ASTROPHYS J, V594, P525, DOI 10.1086/376938; Mohanty S, 2003, ASTROPHYS J, V583, P451, DOI 10.1086/345097; Natta A, 2002, ASTRON ASTROPHYS, V393, P597, DOI 10.1051/0004-6361:20021065; Osorio MRZ, 2000, SCIENCE, V290, P103, DOI 10.1126/science.290.5489.103; Padoan P, 2004, ASTROPHYS J, V617, P559, DOI 10.1086/345413; Reipurth B, 2001, ASTRON J, V122, P432, DOI 10.1086/321121; Testi L., 2002, APJ, V571, P155, DOI 10.1086/341361; [No title captured]	27	49	49	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 1	2006	313	5791					1279	1281		10.1126/science.1132128	http://dx.doi.org/10.1126/science.1132128			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	081JI	16888101				2022-12-28	WOS:000240313500038
J	Cronan, JE				Cronan, John E.			Avant garde fatty acid synthesis by trypanosomes	CELL			English	Editorial Material							AFRICAN TRYPANOSOMES; MYRISTATE; TARGETS; ANCHORS; BRUCEI		Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Cronan, JE (corresponding author), Univ Illinois, Dept Microbiol, 131 Burrill Hall, Urbana, IL 61801 USA.	j-cronan@life.uiuc.edu	Cronan, John/V-6626-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015650] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI015650, R01 AI015650-30] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Campbell JW, 2001, ANNU REV MICROBIOL, V55, P305, DOI 10.1146/annurev.micro.55.1.305; Cronan JE, 2006, NAT CHEM BIOL, V2, P232, DOI 10.1038/nchembio0506-232; Cronan JE, 2005, ADV MICROB PHYSIOL, V50, P103, DOI 10.1016/S0065-2911(05)50003-1; DOERING TL, 1994, P NATL ACAD SCI USA, V91, P9735, DOI 10.1073/pnas.91.21.9735; FERGUSON MAJ, 1985, J BIOL CHEM, V260, P4547; LEE SH, 2006, CELL; Morita YS, 2000, SCIENCE, V288, P140, DOI 10.1126/science.288.5463.140; Morita YS, 2001, MOL BIOCHEM PARASIT, V115, P157, DOI 10.1016/S0166-6851(01)00279-1; Paul KS, 2001, TRENDS PARASITOL, V17, P381, DOI 10.1016/S1471-4922(01)01984-5; Sonda S, 2006, TRENDS PARASITOL, V22, P41, DOI 10.1016/j.pt.2005.11.001	10	6	6	0	4	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 25	2006	126	4					641	643		10.1016/j.cell.2006.08.001	http://dx.doi.org/10.1016/j.cell.2006.08.001			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	080VN	16923380	Green Accepted, Bronze			2022-12-28	WOS:000240276700008
J	Ozcan, U; Yilmaz, E; Ozcan, L; Furuhashi, M; Vaillancourt, E; Smith, RO; Gorgun, CZ; Hotamisligil, GS				Oezcan, Umut; Yilmaz, Erkan; Oezcan, Lale; Furuhashi, Masato; Vaillancourt, Eric; Smith, Ross O.; Goerguen, Cem Z.; Hotamisligil, Goekhan S.			Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes	SCIENCE			English	Article							ENDOPLASMIC-RETICULUM STRESS; PRIMARY BILIARY-CIRRHOSIS; INSULIN-RESISTANCE; DEFICIENCY	Endoplasmic reticulum ( ER) stress is a key link between obesity, insulin resistance, and type 2 diabetes. Here, we provide evidence that this mechanistic link can be exploited for therapeutic purposes with orally active chemical chaperones. 4-Phenyl butyric acid and taurine-conjugated ursodeoxycholic acid alleviated ER stress in cells and whole animals. Treatment of obese and diabetic mice with these compounds resulted in normalization of hyperglycemia, restoration of systemic insulin sensitivity, resolution of fatty liver disease, and enhancement of insulin action in liver, muscle, and adipose tissues. Our results demonstrate that chemical chaperones enhance the adaptive capacity of the ER and act as potent antidiabetic modalities with potential application in the treatment of type 2 diabetes.	Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Hotamisligil, GS (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, 665 Huntington Ave, Boston, MA 02115 USA.	ghotamis@hsph.harvard.edu	Longo, Kenneth A/A-5631-2010; Furuhashi, Masato/AAT-5518-2021; YILMAZ, ERKAN/O-1592-2014; Vaillancourt, Eric/HGD-0666-2022	Furuhashi, Masato/0000-0002-0145-3541; YILMAZ, ERKAN/0000-0001-7355-3878; Vaillancourt, Eric/0000-0002-1810-126X; Ozcan, Lale/0000-0002-2710-7057	NIDDK NIH HHS [R01 DK052539, P30 DK040561, DK52539, P30 DK040561-11] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK040561, R01DK052539] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Burrows JAJ, 2000, P NATL ACAD SCI USA, V97, P1796, DOI 10.1073/pnas.97.4.1796; Chen WY, 1997, P NATL ACAD SCI USA, V94, P5798, DOI 10.1073/pnas.94.11.5798; COLLINS AF, 1995, BLOOD, V85, P43, DOI 10.1182/blood.V85.1.43.bloodjournal85143; Kaplan MM, 2005, NEW ENGL J MED, V353, P1261, DOI 10.1056/NEJMra043898; Maestri NE, 1996, NEW ENGL J MED, V335, P855, DOI 10.1056/NEJM199609193351204; Nakatani Y, 2005, J BIOL CHEM, V280, P847, DOI 10.1074/jbc.M411860200; Ozawa K, 2005, DIABETES, V54, P657, DOI 10.2337/diabetes.54.3.657; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; Permutt MA, 2005, J CLIN INVEST, V115, P1431, DOI 10.1172/JCI24758; Poupon RE, 1999, HEPATOLOGY, V29, P1668, DOI 10.1002/hep.510290603; Shaffer AL, 2004, IMMUNITY, V21, P81, DOI 10.1016/j.immuni.2004.06.010; Welch WJ, 1996, CELL STRESS CHAPERON, V1, P109, DOI 10.1379/1466-1268(1996)001<0109:IOMACC>2.3.CO;2; Wellen KE, 2005, J CLIN INVEST, V115, P1111, DOI 10.1172/JCI200525102; Yie Q, 2002, HEPATOLOGY, V36, P592, DOI 10.1053/jhep.2002.35441	14	1898	2006	8	189	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 25	2006	313	5790					1137	1140		10.1126/science.1128294	http://dx.doi.org/10.1126/science.1128294			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	076ZT	16931765	Green Accepted			2022-12-28	WOS:000239998200051
J	Ristein, J				Ristein, Juergen			Surface transfer doping of semiconductors	SCIENCE			English	Editorial Material							DIAMOND; CONDUCTIVITY		Univ Erlangen Nurnberg, Lehrstuhl Phys, D-91058 Erlangen, Germany	University of Erlangen Nuremberg	Ristein, J (corresponding author), Univ Erlangen Nurnberg, Lehrstuhl Phys, D-91058 Erlangen, Germany.	juergen.ristein@physik.uni-erlangen.de	Ristein, Juergen/E-1742-2013					Collins PG, 2000, SCIENCE, V287, P1801, DOI 10.1126/science.287.5459.1801; Foord JS, 2002, DIAM RELAT MATER, V11, P856, DOI 10.1016/S0925-9635(01)00689-6; Hedberg L, 2004, J PHYS CHEM A, V108, P4731, DOI 10.1021/jp049798p; Kong J, 2000, SCIENCE, V287, P622, DOI 10.1126/science.287.5453.622; LANDSTRASS MI, 1989, APPL PHYS LETT, V55, P1391, DOI 10.1063/1.101604; LANDSTRASS MI, 1989, APPL PHYS LETT, V55, P975, DOI 10.1063/1.101694; Maier F, 2000, PHYS REV LETT, V85, P3472, DOI 10.1103/PhysRevLett.85.3472; Riedel M, 2004, DIAM RELAT MATER, V13, P746, DOI 10.1016/j.diamond.2003.11.094; Ristein J, 2006, J PHYS D APPL PHYS, V39, pR71, DOI 10.1088/0022-3727/39/4/R01; Strobel P, 2005, DIAM RELAT MATER, V14, P451, DOI 10.1016/j.diamond.2004.12.051; Strobel P, 2004, NATURE, V430, P439, DOI 10.1038/nature02751; Zhang PP, 2006, NATURE, V439, P703, DOI 10.1038/nature04501	12	126	127	5	87	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 25	2006	313	5790					1057	1058		10.1126/science.1127589	http://dx.doi.org/10.1126/science.1127589			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	076ZT	16931745				2022-12-28	WOS:000239998200027
J	Greene, AK; Winograd, JM				Greene, Ann K.; Winograd, Jonathan M.			Skin redundancy after massive weight loss	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Greene, AK (corresponding author), Massachusetts Gen Hosp, Boston, MA 02114 USA.								0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 24	2006	355	8					830	830		10.1056/NEJMicm062339	http://dx.doi.org/10.1056/NEJMicm062339			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	076KA	16928998				2022-12-28	WOS:000239955200011
J	Mehdiabadi, NJ; Jack, CN; Farnham, TT; Platt, TG; Kalla, SE; Shaulsky, G; Queller, DC; Strassmann, JE				Mehdiabadi, Natasha J.; Jack, Chandra N.; Farnham, Tiffany Talley; Platt, Thomas G.; Kalla, Sara E.; Shaulsky, Gad; Queller, David C.; Strassmann, Joan E.			Kin preference in a social microbe - Given the right circumstances, even an amoeba chooses to be altruistic towards its relatives.	NATURE			English	Article							EVOLUTION; BEHAVIOR		Rice Univ, Dept Ecol & Evolutionary Biol, Houston, TX 77005 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	Rice University; Baylor College of Medicine	Mehdiabadi, NJ (corresponding author), Rice Univ, Dept Ecol & Evolutionary Biol, Houston, TX 77005 USA.	njum@rice.edu	Jack, Chandra/ABD-8387-2021	Platt, Thomas/0000-0003-0082-1127; Strassmann, Joan/0000-0003-0638-8440; Jack, Chandra/0000-0003-0167-1271; Shaulsky, Gad/0000-0002-0532-0551				BONNER JT, 1958, J EMBRYOL EXP MORPH, V6, P346; BONNER JT, 1967, CELLULAR SLIME MOLDS; Crespi BJ, 2001, TRENDS ECOL EVOL, V16, P178, DOI 10.1016/S0169-5347(01)02115-2; Fletcher DJ., 1987, KIN RECOGNITION ANIM; FOSTER KR, 2004, P ROY SOC LOND B BIO, V269, P2357; Kessin R.H., 2001, DICTYOSTELIUM EVOLUT; REEVE HK, 1989, AM NAT, V133, P407, DOI 10.1086/284926; Strassmann JE, 2000, NATURE, V408, P965, DOI 10.1038/35050087	10	119	121	0	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 24	2006	442	7105					881	882		10.1038/442881a	http://dx.doi.org/10.1038/442881a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	076LT	16929288				2022-12-28	WOS:000239960500025
J	Dohrenwend, BP; Turner, JB; Turse, NA; Adams, BG; Koenen, KC; Marshall, R				Dohrenwend, Bruce P.; Turner, J. Blake; Turse, Nicholas A.; Adams, Ben G.; Koenen, Karestan C.; Marshall, Randall			The psychological risks of Vietnam for US veterans: A revisit with new data and methods	SCIENCE			English	Article							POSTTRAUMATIC-STRESS-DISORDER; WAR; PATTERNS; PTSD	In 1988, the National Vietnam Veterans Readjustment Study (NVVRS) of a representative sample of 1200 veterans estimated that 30.9% had developed posttraumatic stress disorder ( PTSD) during their lifetimes and that 15.2% were currently suffering from PTSD. The study also found a strong dose-response relationship: As retrospective reports of combat exposure increased, PTSD occurrence increased. Skeptics have argued that these results are inflated by recall bias and other flaws. We used military records to construct a new exposure measure and to cross-check exposure reports in diagnoses of 260 NVVRS veterans. We found little evidence of falsification, an even stronger dose-response relationship, and psychological costs that were lower than previously estimated but still substantial. According to our fully adjusted PTSD rates, 18.7% of the veterans had developed war-related PTSD during their lifetimes and 9.1% were currently suffering from PTSD 11 to 12 years after the war; current PTSD was typically associated with moderate impairment.	New York State Psychiat Inst & Hosp, New York, NY 10032 USA; Columbia Univ, Dept Psychiat, New York, NY 10032 USA; Columbia Univ, Mailman Sch Publ Hlth, New York, NY 10032 USA; Columbia Univ, Teachers Coll, New York, NY 10027 USA; Brookdale Univ Hosp & Med Ctr, Brooklyn, NY 11212 USA; Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Boston Univ, Dept Psychiat, Boston, MA 02115 USA	New York State Psychiatry Institute; Columbia University; Columbia University; Columbia University; Columbia University Teachers College; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Boston University	Dohrenwend, BP (corresponding author), New York State Psychiat Inst & Hosp, New York, NY 10032 USA.	dohrenw@pi.cpmc.columbia.edu	Koenen, Karestan/K-5402-2014	Koenen, Karestan/0000-0003-3293-4281; Adams, Ben G./0000-0003-0988-110X	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059309, T32MH013043, K08MH070627] Funding Source: NIH RePORTER; NIMH NIH HHS [R01-MH059309, K08 MH070627, K08 MH070627-01, 5T32MH13043] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		American Psychiatric Association, 1987, DIAGN STAT MAN MENT; [Anonymous], 1988, JAMA, V259, P2701; Baskir Lawrence M., 1978, CHANCE CIRCUMSTANCE, V1st; BURKETT BG, 1998, STOLEN VALOR; Clodefelter M., 1995, VIETNAM MILITARY STA; COFFELT RD, 2002, ELECT DATABASE; Fox Roger P., 1979, AIR BASE DEFENSE REP; Frueh BC, 2005, BRIT J PSYCHIAT, V186, P467, DOI 10.1192/bjp.186.6.467; Gough H. G., 1950, J CONSULT PSYCHOL, V14, P408; GOUGH HG, 1947, J ABNORM SOC PSYCH, V42, P215, DOI 10.1037/h0063295; GOUGH HG, 1957, CALIFORNIA PSYCHOL I; GREENE RL, 1988, MMPI USE SPECIFIC PO; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Jones E, 2001, BRIT J PSYCHIAT, V178, P242, DOI 10.1192/bjp.178.3.242; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Kolko G., 1985, ANATOMY WAR; Kulka R.A., 1988, CONTRACTUAL REPORT F, V1; Kulka R.A., 1990, TRAUMA VIETNAM WAR G; Marlowe DH, 2000, PSYCHOL PSYCHOSOCIAL; Marshall RD, 2006, J NERV MENT DIS, V194, P275, DOI 10.1097/01.nmd.0000207363.25750.56; McNally RJ, 2003, ANNU REV PSYCHOL, V54, P229, DOI 10.1146/annurev.psych.54.101601.145112; ROBERTS L, 1988, SCIENCE, V241, P788, DOI 10.1126/science.2841757; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; SATEL S, 2004, NY TIMES        0305, pA23; SHANE S, 2004, NY TIMES        1216, pA1; Shephard B, 2001, WAR NERVES; Sigler David Burns, 1992, VIETNAM BATTLE CHRON; SOLOMON Z, 1987, AM J PSYCHIAT, V144, P448; Southwick SM, 1997, AM J PSYCHIAT, V154, P173; Spitzer R. L., 1987, STRUCTURED CLIN INTE; Thayer Thomas C, 1985, WAR WITHOUT FRONTS; Thompson WW, 2006, BMC PSYCHIATRY, V6, DOI 10.1186/1471-244X-6-19; *US NAT ARCH REC A, 2006, MIL SERV REC OFF MIL; Wessely S, 2005, BRIT J PSYCHIAT, V186, P459, DOI 10.1192/bjp.186.6.459; Wessely S, 2005, BRIT J PSYCHIAT, V186, P473, DOI 10.1192/bjp.186.6.473; WIENER DN, 1948, J CONSULT PSYCHOL, V12, P164, DOI 10.1037/h0055594; Young Allan, 2004, POSTTRAUMATIC STRESS, P127	38	486	490	0	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 18	2006	313	5789					979	982		10.1126/science.1128944	http://dx.doi.org/10.1126/science.1128944			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	074MR	16917066	Green Accepted			2022-12-28	WOS:000239817000047
J	Beynon, RP; Bahl, VK; Prendergast, BD				Beynon, Rhys P.; Bahl, V. K.; Prendergast, Bernard D.			Infective endocarditis	BMJ-BRITISH MEDICAL JOURNAL			English	Review							INTERNATIONAL COLLABORATION; STREPTOCOCCAL ENDOCARDITIS; MERGED DATABASE; WORKING PARTY; DIAGNOSIS; GUIDELINES; CRITERIA; PROPHYLAXIS; PREVENTION; ADULTS		Wythenshawe Hosp, Dept Cardiol, Manchester M23 9LT, Lancs, England; All India Inst Med Sci, New Delhi, India	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; All India Institute of Medical Sciences (AIIMS) New Delhi	Prendergast, BD (corresponding author), Wythenshawe Hosp, Dept Cardiol, Manchester M23 9LT, Lancs, England.	Bernard.Prendergast@smuht.nwest.nhs.uk						Alexiou C, 2000, ANN THORAC SURG, V69, P1448, DOI 10.1016/S0003-4975(00)01139-5; Anguera I, 2005, AM J CARDIOL, V96, P976, DOI 10.1016/j.amjcard.2005.05.056; Baddour LM, 2005, CIRCULATION, V111, pE394, DOI 10.1161/CIRCULATIONAHA.105.165564; Benjamin DK, 2004, SCAND J INFECT DIS, V36, P453, DOI 10.1080/00365540410020703; BLACKSTONE EH, 1985, CIRCULATION, V72, P753, DOI 10.1161/01.CIR.72.4.753; Bouza E, 2001, MEDICINE, V80, P298, DOI 10.1097/00005792-200109000-00003; Cabell CH, 2002, ARCH INTERN MED, V162, P90, DOI 10.1001/archinte.162.1.90; Cabell Christopher H., 2003, Cardiology Clinics, V21, P147, DOI 10.1016/S0733-8651(03)00033-X; Chatterjee A, 2004, Indian J Pediatr, V71, P184, DOI 10.1007/BF02723109; Chirouze C, 2004, CLIN INFECT DIS, V38, P1323, DOI 10.1086/383035; Chu VH, 2004, CLIN INFECT DIS, V39, P1527, DOI 10.1086/424878; Danchin N, 2005, HEART, V91, P715, DOI 10.1136/hrt.2003.033183; DURACK DT, 1994, AM J MED, V96, P200, DOI 10.1016/0002-9343(94)90143-0; Elliott TSJ, 2004, J ANTIMICROB CHEMOTH, V54, P971, DOI 10.1093/jac/dkh474; Essop MR, 2005, CIRCULATION, V112, P3584, DOI 10.1161/CIRCULATIONAHA.105.539775; Fournier PE, 1996, AM J MED, V100, P629, DOI 10.1016/S0002-9343(96)00040-X; FRANCIOLI P, 1992, JAMA-J AM MED ASSOC, V267, P264, DOI 10.1001/jama.267.2.264; Francioli P, 1995, CLIN INFECT DIS, V21, P1406, DOI 10.1093/clinids/21.6.1406; Garg N, 2005, INT J CARDIOL, V98, P253, DOI 10.1016/j.ijcard.2003.10.043; Gould FK, 2006, J ANTIMICROB CHEMOTH, V57, P1035, DOI 10.1093/jac/dkl121; Greaves K, 2003, HEART, V89, P273, DOI 10.1136/heart.89.3.273; Hoen B, 2005, EUR J CLIN MICROBIOL, V24, P12, DOI 10.1007/s10096-004-1266-6; Hoen B, 2002, JAMA-J AM MED ASSOC, V288, P75, DOI 10.1001/jama.288.1.75; HOEN B, 1995, CLIN INFECT DIS, V20, P501, DOI 10.1093/clinids/20.3.501; Horstkotte D, 2004, EUR HEART J, V25, P267, DOI 10.1016/j.ehj.2003.11.008; Kothari S S, 2005, Indian Heart J, V57, P289; Li JS, 2000, CLIN INFECT DIS, V30, P633, DOI 10.1086/313753; Lisby G, 2002, INFECT DIS CLIN N AM, V16, P393, DOI 10.1016/S0891-5520(01)00002-2; Martin M, 2006, BRIT DENT J, V200, P471, DOI 10.1038/sj.bdj.4813621; MATHEW J, 1995, ARCH INTERN MED, V155, P1641, DOI 10.1001/archinte.155.15.1641; MCKINSEY DS, 1987, AM J MED, V82, P681, DOI 10.1016/0002-9343(87)90001-5; Miro JM, 2005, CLIN INFECT DIS, V41, P507, DOI 10.1086/431979; Miro JM, 2002, INFECT DIS CLIN N AM, V16, P273, DOI 10.1016/S0891-5520(01)00008-3; Moreillon P, 2004, LANCET, V363, P139, DOI 10.1016/S0140-6736(03)15266-X; Mylonakis E, 2001, NEW ENGL J MED, V345, P1318, DOI 10.1056/NEJMra010082; Olaison L, 2002, INFECT DIS CLIN N AM, V16, P453, DOI 10.1016/S0891-5520(01)00006-X; Piper C, 2001, HEART, V85, P590, DOI 10.1136/heart.85.5.590; Prendergast BD, 2006, HEART, V92, P879, DOI 10.1136/hrt.2005.067256; Ramsdale DR, 2004, CLIN MED, V4, P545, DOI 10.7861/clinmedicine.4-6-545; Santoshkumar B, 1996, J NEUROL SCI, V137, P139, DOI 10.1016/0022-510X(95)00346-4; Tornos P, 2005, REV ESP CARDIOL, V58, P1145, DOI 10.1016/S1885-5857(06)60392-7; Tornos P, 2005, HEART, V91, P571, DOI 10.1136/hrt.2003.032128; VONREYN CF, 1981, ANN INTERN MED, V94, P505, DOI 10.7326/0003-4819-94-4-505	43	90	96	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 12	2006	333	7563					334	339		10.1136/bmj.333.7563.334	http://dx.doi.org/10.1136/bmj.333.7563.334			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	073VI	16902214	Green Published			2022-12-28	WOS:000239770300017
J	Girart, JM; Rao, R; Marrone, DP				Girart, Josep M.; Rao, Ramprasad; Marrone, Daniel P.			Magnetic fields in the formation of Sun-like stars	SCIENCE			English	Article							FORMING REGIONS; NGC-1333 IRAS-4; CLOUD CORES; AMBIPOLAR DIFFUSION; MOLECULAR CLOUDS; POLARIZATION; OUTFLOW; FRAGMENTATION; EMISSION; ENVELOPE	We report high-angular-resolution measurements of polarized dust emission toward the low-mass protostellar system NGC 1333 IRAS 4A. We show that in this system the observed magnetic field morphology is in agreement with the standard theoretical models of the formation of Sun-like stars in magnetized molecular clouds at scales of a few hundred astronomical units; gravity has overcome magnetic support, and the magnetic field traces a clear hourglass shape. The magnetic field is substantially more important than turbulence in the evolution of the system, and the initial misalignment of the magnetic and spin axes may have been important in the formation of the binary system.	Fac Ciencies, CSIC, IEEC, Inst Ciencies Espai, Bellaterra 08193, Catalunya, Spain; Harvard Smithsonian Ctr Astrophys, Cambridge, MA 02138 USA; Acad Sinica, Inst Astron & Astrophys, Hilo, HI 96720 USA	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Ciencias del Espacio (ICE); Institut d'Estudis Espacials de Catalunya (IEEC); Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution; Academia Sinica - Taiwan	Girart, JM (corresponding author), Fac Ciencies, CSIC, IEEC, Inst Ciencies Espai, Campus UAB,Torre C5 Parell 2a, Bellaterra 08193, Catalunya, Spain.	girart@ieec.uab.es	Girart, Josep M/P-3931-2019; Girart, Josep/O-1638-2014; Rao, Ramprasad/L-2115-2017	Girart, Josep/0000-0002-3829-5591; Marrone, Daniel/0000-0002-2367-1080; Rao, Ramprasad/0000-0002-1407-7944				Blundell R., 2004, P 15 INT S SPAC TER, P3; CHANDRASEKHAR S, 1953, ASTROPHYS J, V118, P113, DOI 10.1086/145731; Choi MH, 2005, ASTROPHYS J, V630, P976, DOI 10.1086/432113; Crutcher RM, 1999, ASTROPHYS J, V520, P706, DOI 10.1086/307483; Di Francesco J, 2001, ASTROPHYS J, V562, P770, DOI 10.1086/323854; FIEDLER RA, 1993, ASTROPHYS J, V415, P680, DOI 10.1086/173193; GALLI D, 1993, ASTROPHYS J, V417, P243, DOI 10.1086/173306; Girart JM, 1999, ASTROPHYS J, V525, pL109, DOI 10.1086/312345; GOODMAN AA, 1990, ASTROPHYS J, V359, P363, DOI 10.1086/169070; Ho PTP, 2004, ASTROPHYS J, V616, pL1, DOI 10.1086/423245; Houde M, 2004, ASTROPHYS J, V616, pL111, DOI 10.1086/426684; Lai SP, 2002, ASTROPHYS J, V566, P925, DOI 10.1086/338336; Lai SP, 2001, ASTROPHYS J, V561, P864, DOI 10.1086/323372; Looney LW, 2000, ASTROPHYS J, V529, P477, DOI 10.1086/308239; Machida MN, 2006, ASTROPHYS J, V645, P1227, DOI 10.1086/504423; Machida MN, 2005, MON NOT R ASTRON SOC, V362, P369, DOI 10.1111/j.1365-2966.2005.09297.x; Maret S, 2002, ASTRON ASTROPHYS, V395, P573, DOI 10.1051/0004-6361:20021334; Marrone DP, 2006, ASTROPHYS J, V640, P308, DOI 10.1086/500106; McKee C. F, 1993, PROTOSTARS PLANETS, P327; MINCHIN NR, 1995, ASTRON ASTROPHYS, V293, pL61; MOUSCHOVIAS TC, 1991, ASTROPHYS J, V373, P169, DOI 10.1086/170035; Nakamura F, 2003, ASTROPHYS J, V594, P363, DOI 10.1086/376862; OSSENKOPF V, 1994, ASTRON ASTROPHYS, V291, P943; Ostriker EC, 2001, ASTROPHYS J, V546, P980, DOI 10.1086/318290; RIDGE NA, IN PRESS ASTROPHYS J; SANDELL G, 1991, ASTROPHYS J, V376, pL17, DOI 10.1086/186092; Schleuning DA, 1998, ASTROPHYS J, V493, P811, DOI 10.1086/305139; TAMURA M, 1995, ASTROPHYS J, V448, P346, DOI 10.1086/175965; Weintraub D. A., 2000, Protostars and planets 4, P247	29	276	276	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 11	2006	313	5788					812	814		10.1126/science.1129093	http://dx.doi.org/10.1126/science.1129093			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	072KC	16902132	Green Submitted			2022-12-28	WOS:000239671300052
J	Wood, AJJ				Wood, Alastair J. J.			A proposal for radical changes in the drug-approval process	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							LIPID-LOWERING TREATMENT; ATTACK TRIAL ALLHAT; MEDICINES; SAFETY; BOARD		Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA	Vanderbilt University	Wood, AJJ (corresponding author), Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA.							*ALLHAT COLL RES G, 2002, JAMA-J AM MED ASSOC, V288, P2976; Angell M., 2004, TRUTH DRUG CO THEY D; Avorn J, 2005, NEW ENGL J MED, V353, P969, DOI 10.1056/NEJMp058174; Barton JH, 2005, JAMA-J AM MED ASSOC, V294, P2075, DOI 10.1001/jama.294.16.2075; DiMasi JA, 2001, CLIN PHARMACOL THER, V69, P297, DOI 10.1067/mcp.2001.115446; DiMasi JA, 2003, J HEALTH ECON, V22, P151, DOI 10.1016/S0167-6296(02)00126-1; *FOOD DRUG ADM, 2004, CHALL OPP CRIT PATH; Furberg CD, 2000, JAMA-J AM MED ASSOC, V283, P1967; Furberg CD, 2002, JAMA-J AM MED ASSOC, V288, P2981; Griffith JL, 2003, JAMA-J AM MED ASSOC, V289, P178; Jemal A, 2005, JAMA-J AM MED ASSOC, V294, P1255, DOI 10.1001/jama.294.10.1255; Mervis J, 2005, SCIENCE, V309, P726, DOI 10.1126/science.309.5735.726; Nestico PF, 2004, JAMA-J AM MED ASSOC, V291, P2196; Reichert Janice M, 2002, Am J Ther, V9, P543, DOI 10.1097/00045391-200211000-00016; Roberts TG, 2004, NEW ENGL J MED, V351, P501, DOI 10.1056/NEJMsb040064; *THOMS PDR, 2005, PHYS DESK REF; Wood AJJ, 1998, NEW ENGL J MED, V339, P1851, DOI 10.1056/NEJM199812173392512; Wood AJJ, 1999, JAMA-J AM MED ASSOC, V281, P1753, DOI 10.1001/jama.281.18.1753; 2005, FED REG, V70, P8379	19	95	98	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 10	2006	355	6					618	623		10.1056/NEJMsb055203	http://dx.doi.org/10.1056/NEJMsb055203			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	071QM	16899784				2022-12-28	WOS:000239616700015
J	Hicks, CB; Cahn, P; Cooper, DA; Walmsley, SL; Katlama, C; Clotet, B; Lazzarin, A; Johnson, MA; Neubacher, D; Mayers, D; Valdez, H				Hicks, Charles B.; Cahn, Pedro; Cooper, David A.; Walmsley, Sharon L.; Katlama, Christine; Clotet, Bonaventura; Lazzarin, Adriano; Johnson, Margaret A.; Neubacher, Dietmar; Mayers, Douglas; Valdez, Hernan		RESIST investigator grp	Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug resistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials	LANCET			English	Article							PROTEASE INHIBITOR TIPRANAVIR; REDUCED SUSCEPTIBILITY; VIROLOGICAL FAILURE; FUSION INHIBITOR; THERAPY; HIV-1; ENFUVIRTIDE; PNU-140690	Background Treatment options for HIV-1 infected individuals who have received extensive previous antiretroviral therapy are limited. We compared efficacy and safety of the novel non-peptidic protease inhibitor tipranavir co-administered with ritonavir plus an optimised background regimen with that of an investigator-selected ritonavir-boosted comparator protease inhibitor (CPI-ritonavir) in such patients. Methods We did a combined analysis of 48-week data from two ongoing, randomised, open-label, multinational, phase III, RESIST studies. HIV-1-infected adults with 3 months or longer previous triple antiretroviral class experience, two or more previous protease inhibitor regimens, HIV-1 RNA 1000 copies per mL or greater, and genotypically demonstrated primary resistance to protease inhibitor, were eligible. Primary endpoints were proportion of treatment responders (with reduction in viral load of 1 log,, copies per mL or greater below baseline without treatment change) at 48 weeks and time to treatment failure through 48 weeks (intention-to-treat analysis). The RESIST studies are registered with ClinicalTrials.gov, numbers NCT00054717 (RESIST-1) and NCT00144170 (RESIST-2). Findings 3324 patients were screened; 746 received tipranavir-ritonavir and 737 CPI-ritonavir. 486 (65.1%) patients on tipranavir-ritonavir and 192 (26.1%) on CPI-ritonavir remained on assigned treatment until week 48. At week 48, more patients achieved and maintained treatment response in the tipranavir-ritonavir group than in the CPI-ritonavir group (251 [33.6%] vs 113 [15.3%]; p<0.0001). Median time to treatment failure was significantly longer in the tipranavir-ritonavir group than in the CPI-ritonavir group (113 days vs 0 days; p<0.0001). Gastrointestinal system disorders and raised transaminase, cholesterol, and triglycerides were more frequent in the tipranavir-ritonavir group than in the CPI-ritonavir group. Interpretation Compared with CPI-ritonavir, tipranavir-ritonavir with an optimised background regimen provides better virological and immunological responses over 48 weeks in patients who have received extensive previous antiretroviral treatment.	Duke Univ, Med Ctr, Div Infect Dis & Int Hlth, Durham, NC 27710 USA; Fdn Huesped, Buenos Aires, DF, Argentina; Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia; Univ Toronto, Toronto, ON, Canada; Hop La Pitie Salpetriere, Paris, France; Hosp Univ Germans Trias & Pujol, Barcelona, Spain; Vita Salute San Raffaele Univ, Milan, Italy; Royal Free Hosp, London NW3 2QG, England; Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany; Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA	Duke University; University of New South Wales Sydney; Kirby Institute; University of Toronto; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Hospital Germans Trias i Pujol; Vita-Salute San Raffaele University; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Boehringer Ingelheim; Boehringer Ingelheim	Hicks, CB (corresponding author), Duke Univ, Med Ctr, Div Infect Dis & Int Hlth, Durham, NC 27710 USA.	charies.hicks@duke.edu	; LAZZARIN, Adriano/K-3607-2018	Walmsley, Sharon/0000-0002-3959-5692; LAZZARIN, Adriano/0000-0003-2551-7754				*AD AIDS CLIN TRIA, 1992, TABL GRAD SEV AD ADV; Back NKT, 2000, AIDS, V14, P101, DOI 10.1097/00002030-200001070-00019; Cahn P, 2004, 7 INT C DRUG THER HI; Deeks SG, 2000, CLIN INFECT DIS, V30, pS177, DOI 10.1086/313855; *DHHS PAN ANT GUID, 2006, GUID US ANT AG HIV 1; Doyon L, 2005, ANTIVIR RES, V68, P27, DOI 10.1016/j.antiviral.2005.07.003; GATHE J, 2003, 10 C RETR OPP INF; Gulick RM, 2002, J INFECT DIS, V186, P626, DOI 10.1086/342681; Hammer SM, 2002, JAMA-J AM MED ASSOC, V288, P169, DOI 10.1001/jama.288.2.169; Hicks C, 2004, 44 INT C ANT AG CHEM; Johnson Victoria A, 2003, Top HIV Med, V11, P215; KATLAMA C, 2005, 3 IAS C HIV PATH TRE; Lalezari JP, 2003, NEW ENGL J MED, V348, P2175, DOI 10.1056/NEJMoa035026; Lazzarin A, 2003, NEW ENGL J MED, V348, P2186, DOI 10.1056/NEJMoa035211; Ledergerber B, 2004, LANCET, V364, P51, DOI 10.1016/S0140-6736(04)16589-6; MacGregor TR, 2004, HIV CLIN TRIALS, V5, P371, DOI 10.1310/RRX7-49ME-27V7-MWWV; McCallister S, 2004, JAIDS-J ACQ IMM DEF, V35, P376, DOI 10.1097/00126334-200404010-00007; Mocroft A, 2004, J INFECT DIS, V190, P1947, DOI 10.1086/425424; Poppe SM, 1997, ANTIMICROB AGENTS CH, V41, P1058, DOI 10.1128/AAC.41.5.1058; Raffi F, 2006, CLIN INFECT DIS, V42, P870, DOI 10.1086/500206; SABO J, 2006, 7 INT WORKSH CLIN PH; Turner SR, 1998, J MED CHEM, V41, P3467, DOI 10.1021/jm9802158; WILKIN T, 2005, 45 INT C ANT AG CHEM	23	255	261	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 5	2006	368	9534					466	475		10.1016/S0140-6736(06)69154-X	http://dx.doi.org/10.1016/S0140-6736(06)69154-X			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	071AL	16890833				2022-12-28	WOS:000239569000029
J	Okie, S				Okie, Susan			Access before approval - A right to take experimental drugs?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		Begg CB, 2006, CLIN TRIALS, V3, P154, DOI 10.1191/1740774506cn141oa	1	52	53	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 3	2006	355	5					437	440		10.1056/NEJMp068132	http://dx.doi.org/10.1056/NEJMp068132			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	069FT	16885545				2022-12-28	WOS:000239432500001
J	O'Byrne, PM; Parameswaran, K				O'Byrne, Paul M.; Parameswaran, Krishnan			Pharmacological management of mild or moderate persistent asthma	LANCET			English	Review							EXHALED NITRIC-OXIDE; DOSE INHALED BUDESONIDE; SPUTUM CELL COUNTS; SINGLE INHALER; RELIEVER MEDICATION; AIRWAY INFLAMMATION; EARLY INTERVENTION; LUNG-FUNCTION; SALMETEROL; FORMOTEROL	Patients with mild persistent asthma rarely see their doctor with symptoms of the disease. Partly as a result of this situation, mild asthma is generally undertreated. Findings of several large randomised clinical trials have shown benefits for this population of regular treatment with low doses of inhaled corticosteroids. Additional drugs are rarely needed, and although leukotriene modifiers are effective, they are less so than inhaled corticosteroids. People with moderate persistent asthma are not well controlled on low doses of inhaled corticosteroids. A combination of this drug and long-acting inhaled beta 2 agonists provides improved control compared with doubling of the maintenance dose of inhaled corticosteroids. The combination of budesonide and formoterol has been assessed as both maintenance and reliever treatment. This approach further reduces the risk for severe exacerbations. With these strategies, most individuals can achieve good control of their asthma. For patients who do not achieve asthma control despite taking drugs, measurement of the inflammatory response in the airway in induced sputum could provide further information to guide treatment.	McMaster Univ, Med Ctr, Dept Med, Hamilton, ON L9G 4R7, Canada; St Josephs Healthcare, Firestone Inst Resp Hlth, Hamilton, ON, Canada	McMaster University; McMaster University	O'Byrne, PM (corresponding author), McMaster Univ, Med Ctr, Dept Med, 1200 Main St W, Hamilton, ON L9G 4R7, Canada.	obyrnep@mcmaster.ca		O'Byrne, Paul/0000-0003-0979-281X				Agertoft L, 2000, NEW ENGL J MED, V343, P1064, DOI 10.1056/NEJM200010123431502; American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; ANDERSON GP, 1993, LIFE SCI, V52, P2145, DOI 10.1016/0024-3205(93)90729-M; Andersson F, 2001, RESP MED, V95, P505, DOI 10.1053/rmed.2001.1078; Bacharier LB, 2004, PEDIATRICS, V113, P1693, DOI 10.1542/peds.113.6.1693; Barnes PJ, 1998, AM J RESP CRIT CARE, V157, pS1, DOI 10.1164/ajrccm.157.3.157315; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Belda J, 2000, AM J RESP CRIT CARE, V161, P475, DOI 10.1164/ajrccm.161.2.9903097; Belda Jose, 2006, Can Respir J, V13, P129; Berlyne GS, 2000, J ALLERGY CLIN IMMUN, V106, P638, DOI 10.1067/mai.2000.109622; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Bisgaard H, 2003, PEDIATR PULM, V36, P391, DOI 10.1002/ppul.10381; Boushey HA, 2005, NEW ENGL J MED, V352, P1519, DOI 10.1056/NEJMoa042552; Briggs AH, 2006, ALLERGY, V61, P531, DOI 10.1111/j.1398-9995.2006.01038.x; CASTLE W, 1993, BRIT MED J, V306, P1034, DOI 10.1136/bmj.306.6884.1034; Chanez P, 2001, EUR RESPIR J, V17, P856, DOI 10.1183/09031936.01.17508560; Chapman K R, 2001, Can Respir J, V8 Suppl A, p35A; *CHILDH ASTHM MAN, 2000, NEW ENGLAND J MED, V0343; Cockcroft DW, 1996, J ALLERGY CLIN IMMUN, V98, P1016, DOI 10.1016/S0091-6749(96)80185-0; CRANE J, 1989, LANCET, V1, P917; Djukanovic R, 2002, EUR RESPIR J, V20, p1S, DOI 10.1183/09031936.02.00000102; Drazen JM, 1999, NEW ENGL J MED, V340, P197, DOI 10.1056/NEJM199901213400306; Ducharme FM, 2002, BMJ-BRIT MED J, V324, P1545, DOI 10.1136/bmj.324.7353.1545; Evans DJ, 1997, NEW ENGL J MED, V337, P1412, DOI 10.1056/NEJM199711133372002; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082; FitzGerald JM, 2004, THORAX, V59, P550, DOI 10.1136/thx.2003.014936; Garcia MLG, 2005, PEDIATRICS, V116, P360, DOI 10.1542/peds.2004-1172; Garrett J, 1998, ARCH DIS CHILD, V79, P12, DOI 10.1136/adc.79.1.12; *GLOB IN ASTHM, 2004, NIH PUBL; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Green RH, 2002, THORAX, V57, P875, DOI 10.1136/thorax.57.10.875; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Harrison TW, 2004, LANCET, V363, P271, DOI 10.1016/S0140-6736(03)15384-6; Ind PW, 2002, EUR RESPIR J, V20, P859, DOI 10.1183/09031936.02.00278302; Israel E, 2004, LANCET, V364, P1505, DOI 10.1016/S0140-6736(04)17273-5; ISRAEL E, 1993, ANN INTERN MED, V119, P1059, DOI 10.7326/0003-4819-119-11-199312010-00001; Jatakanon A, 2000, AM J RESP CRIT CARE, V161, P64, DOI 10.1164/ajrccm.161.1.9809100; Jayaram L, 2006, EUR RESPIR J, V27, P483, DOI 10.1183/09031936.06.00137704; Jones SL, 2001, AM J RESP CRIT CARE, V164, P738, DOI 10.1164/ajrccm.164.5.2012125; Jonsson B, 2004, RESP MED, V98, P1146, DOI 10.1016/j.rmed.2004.04.005; Kelly MM, 2006, J ALLERGY CLIN IMMUN, V117, P989, DOI 10.1016/j.jaci.2006.01.045; Kwok MY, 2006, PEDIATRICS, V117, pS71, DOI 10.1542/peds.2005-2000D; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Leigh R, 2002, AM J RESP CRIT CARE, V166, P1212, DOI 10.1164/rccm.200206-509OC; Lemiere Catherine, 2004, Can Respir J, V11 Suppl A, p9A; Lim S, 2000, THORAX, V55, P184, DOI 10.1136/thorax.55.3.184; Masoli M, 2005, THORAX, V60, P730, DOI 10.1136/thx.2004.039180; Nelson HS, 2000, J ALLERGY CLIN IMMUN, V106, P1088, DOI 10.1067/mai.2000.110920; Nelson HS, 2006, CHEST, V129, P15, DOI 10.1378/chest.129.1.15; NI CM, 2005, COCHRANE DB SYST REV, V2; O'Byrne PM, 2006, CHEST, V129, P1478, DOI 10.1378/chest.129.6.1478; O'Byrne PM, 2001, AM J RESP CRIT CARE, V164, P1392, DOI 10.1164/ajrccm.164.8.2104102; O'Byrne PM, 2005, AM J RESP CRIT CARE, V171, P129, DOI 10.1164/rccm.200407-884OC; Palmqvist M, 1999, AM J RESP CRIT CARE, V160, P244, DOI 10.1164/ajrccm.160.1.9901063; Parameswaran K, 2004, AM J RESP CRIT CARE, V169, P915, DOI 10.1164/rccm.200312-1645OC; Parameswaran K, 2004, J ALLERGY CLIN IMMUN, V114, P73, DOI 10.1016/j.jaci.2004.03.054; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Pauwels RA, 2003, LANCET, V361, P1071, DOI 10.1016/S0140-6736(03)12891-7; Pearlman DS, 2005, J ALLERGY CLIN IMMUN, V116, P1206, DOI 10.1016/j.jaci.2005.08.037; Pearlman DS, 2004, J ASTHMA, V41, P797, DOI 10.1081/JAS-200038368; Pedersen S, 1997, ALLERGY, V52, P1, DOI 10.1111/j.1398-9995.1997.tb05047.x; Pijnenburg MW, 2005, AM J RESP CRIT CARE, V172, P831, DOI 10.1164/rccm.200503-458OC; Rabe KF, 2004, J ALLERGY CLIN IMMUN, V114, P40, DOI 10.1016/j.jaci.2004.04.042; Rabe KF, 2006, CHEST, V129, P246, DOI 10.1378/chest.129.2.246; Rabe KF, 2000, EUR RESPIR J, V16, P802, DOI 10.1183/09031936.00.16580200; Scicchitano R, 2004, CURR MED RES OPIN, V20, P1403, DOI 10.1185/030079904X2051; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SHEPHERD GL, 1981, BRIT J DIS CHEST, V75, P215, DOI 10.1016/0007-0971(81)90057-7; Simpson JL, 2006, RESPIROLOGY, V11, P54, DOI 10.1111/j.1440-1843.2006.00784.x; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; TURNERWARWICK M, 1989, J ROY COLL GEN PRACT, V39, P239; Vaquerizo MJ, 2003, THORAX, V58, P204, DOI 10.1136/thorax.58.3.204; Walker S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003559.pub3; Woolcock A, 1996, AM J RESP CRIT CARE, V153, P1481, DOI 10.1164/ajrccm.153.5.8630590; Zacharasiewicz A, 2005, AM J RESP CRIT CARE, V171, P1077, DOI 10.1164/rccm.200409-1242OC; Zeiger RS, 2006, J ALLERGY CLIN IMMUN, V117, P45, DOI 10.1016/j.jaci.2005.10.012; Zeiger RS, 2005, AM J MED, V118, P649, DOI 10.1016/j.amjmed.2005.03.003; Zetterstrom O, 2001, EUR RESPIR J, V18, P262, DOI 10.1183/09031936.01.00065801	79	35	35	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG-SEP	2006	368	9537					794	803		10.1016/S0140-6736(06)69289-1	http://dx.doi.org/10.1016/S0140-6736(06)69289-1			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	080ID	16935690				2022-12-28	WOS:000240240200031
J	King, MC; Lusk, CP; Blobel, G				King, Megan C.; Lusk, C. Patrick; Blobel, Guenter			Karyopherin-mediated import of integral inner nuclear membrane proteins	NATURE			English	Article							PORE COMPLEX; SACCHAROMYCES-CEREVISIAE; YEAST NUCLEOPORIN; NUCLEOCYTOPLASMIC TRANSPORT; CELL-CYCLE; ENVELOPE; EXPORT; NUP2P; SIGNALS	Targeting of newly synthesized integral membrane proteins to the appropriate cellular compartment is specified by discrete sequence elements, many of which have been well characterized. An understanding of the signals required to direct integral membrane proteins to the inner nuclear membrane (INM) remains a notable exception. Here we show that integral INM proteins possess basic sequence motifs that resemble 'classical' nuclear localization signals. These sequences can mediate direct binding to karyopherin-alpha and are essential for the passage of integral membrane proteins to the INM. Furthermore, karyopherin-alpha, karyopherin-beta 1 and the Ran GTPase cycle are required for INM targeting, underscoring parallels between mechanisms governing the targeting of integral INM proteins and soluble nuclear transport. We also provide evidence that specific nuclear pore complex proteins contribute to this process, suggesting a role for signal-mediated alterations in the nuclear pore complex to allow for passage of INM proteins along the pore membrane.	Rockefeller Univ, Howard Hughes Med Inst, Cell Biol Lab, New York, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University	King, MC (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, Cell Biol Lab, 1230 York Ave, New York, NY 10021 USA.	mking@rockefeller.edu; plusk@rockefeller.edu		Lusk, C. Patrick/0000-0003-4703-0533				AITCHISON JD, 1995, J CELL BIOL, V131, P1133, DOI 10.1083/jcb.131.5.1133; Beilharz T, 2003, J BIOL CHEM, V278, P8219, DOI 10.1074/jbc.M212725200; Booth JW, 1999, J BIOL CHEM, V274, P32360, DOI 10.1074/jbc.274.45.32360; Chial HJ, 1998, J CELL BIOL, V143, P1789, DOI 10.1083/jcb.143.7.1789; Fried H, 2003, CELL MOL LIFE SCI, V60, P1659, DOI 10.1007/s00018-003-3070-3; Gilchrist D, 2002, J BIOL CHEM, V277, P18161, DOI 10.1074/jbc.M112306200; Gruenbaum Y, 2005, NAT REV MOL CELL BIO, V6, P21, DOI 10.1038/nrm1550; Hood JK, 2000, J CELL SCI, V113, P1471; Horton P, 1997, ISMB-97 - FIFTH INTERNATIONAL CONFERENCE ON INTELLIGENT SYSTEMS FOR MOLECULAR BIOLOGY, PROCEEDINGS, P147; Iovine MK, 1997, J CELL BIOL, V137, P797, DOI 10.1083/jcb.137.4.797; KADOWAKI T, 1994, J CELL BIOL, V126, P649, DOI 10.1083/jcb.126.3.649; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; Leslie DM, 2002, MOL CELL BIOL, V22, P2544, DOI 10.1128/MCB.22.8.2544-2555.2002; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; Makhnevych T, 2003, CELL, V115, P813, DOI 10.1016/S0092-8674(03)00986-3; Mans BJ, 2004, CELL CYCLE, V3, P1612; Miao M, 2006, GENETICS, V172, P1441, DOI 10.1534/genetics.105.052068; Mounkes L, 2003, CURR OPIN GENET DEV, V13, P223, DOI 10.1016/S0959-437X(03)00058-3; Nehrbass U, 1996, J CELL BIOL, V133, P1153, DOI 10.1083/jcb.133.6.1153; Ohba T, 2004, J CELL BIOL, V167, P1051, DOI 10.1083/jcb.200409149; Ostlund C, 2006, BIOCHEMISTRY-US, V45, P1374, DOI 10.1021/bi052156n; Rodriguez-Navarro S, 2002, YEAST, V19, P43, DOI 10.1002/yea.803; Ryan KJ, 2000, CURR OPIN CELL BIOL, V12, P361, DOI 10.1016/S0955-0674(00)00101-0; Saksena S, 2006, NAT STRUCT MOL BIOL, V13, P500, DOI 10.1038/nsmb1098; Shulga N, 2003, MOL CELL BIOL, V23, P534, DOI 10.1128/MCB.23.2.534-542.2003; Solsbacher J, 2000, MOL CELL BIOL, V20, P8468, DOI 10.1128/MCB.20.22.8468-8479.2000; SOULLAM B, 1995, J CELL BIOL, V130, P15, DOI 10.1083/jcb.130.1.15; Suntharalingam M, 2003, DEV CELL, V4, P775, DOI 10.1016/S1534-5807(03)00162-X; Vaughan OA, 2001, J CELL SCI, V114, P2577; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; Wu W, 2002, J CELL SCI, V115, P1361; YANO R, 1994, P NATL ACAD SCI USA, V91, P6880, DOI 10.1073/pnas.91.15.6880	32	210	215	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 31	2006	442	7106					1003	1007		10.1038/nature05075	http://dx.doi.org/10.1038/nature05075			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	078YF	16929305				2022-12-28	WOS:000240142000040
J	Murphy, GE; Leadbetter, JR; Jensen, GJ				Murphy, Gavin E.; Leadbetter, Jared R.; Jensen, Grant J.			In situ structure of the complete Treponema primitia flagellar motor	NATURE			English	Article							FREEZE ELECTRON-MICROSCOPY; SALMONELLA-TYPHIMURIUM; BASAL BODY; MEMBRANE; ROTOR; FLIG; ULTRASTRUCTURE; ARRANGEMENT	The bacterial flagellar motor is an amazing nanomachine: built from approximately 25 different proteins, it uses an electrochemical ion gradient to drive rotation at speeds of up to 300 Hz (refs 1, 2). The flagellar motor consists of a fixed, membrane-embedded, torque-generating stator and a typically bidirectional, spinning rotor that changes direction in response to chemotactic signals. Most structural analyses so far have targeted the purified rotor(3,4), and hence little is known about the stator and its interactions. Here we show, using electron cryotomography of whole cells, the in situ structure of the complete flagellar motor from the spirochaete Treponema primitia at 7 nm resolution. Twenty individual motor particles were computationally extracted from the reconstructions, aligned and then averaged. The stator assembly, revealed for the first time, possessed 16-fold symmetry and was connected directly to the rotor, C ring and a novel P-ring-like structure. The unusually large size of the motor suggested mechanisms for increasing torque and supported models wherein critical interactions occur atop the C ring, where our data suggest that both the carboxy-terminal and middle domains of FliG are found.	CALTECH, Div Biol, Pasadena, CA 91125 USA; CALTECH, Div Environm Sci & Engn, Pasadena, CA 91125 USA	California Institute of Technology; California Institute of Technology	Jensen, GJ (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.	jensen@caltech.edu		Leadbetter, Jared/0000-0002-7033-0844				Berg HC, 2003, ANNU REV BIOCHEM, V72, P19, DOI 10.1146/annurev.biochem.72.121801.161737; Braun TF, 2004, BIOCHEMISTRY-US, V43, P35, DOI 10.1021/bi035406d; Brown PN, 2002, EMBO J, V21, P3225, DOI 10.1093/emboj/cdf332; Charon NW, 2002, ANNU REV GENET, V36, P47, DOI 10.1146/annurev.genet.36.041602.134359; COULTON JW, 1978, J BACTERIOL, V136, P1037, DOI 10.1128/JB.136.3.1037-1049.1978; FRANCIS NR, 1994, J MOL BIOL, V235, P1261, DOI 10.1006/jmbi.1994.1079; JACKSON S, 1971, ARCH MIKROBIOL, V76, P325, DOI 10.1007/BF00408529; Katayama E, 1996, J MOL BIOL, V255, P458, DOI 10.1006/jmbi.1996.0038; KHAN S, 1988, J MOL BIOL, V202, P575, DOI 10.1016/0022-2836(88)90287-2; KHAN S, 1992, J BACTERIOL, V174, P5123, DOI 10.1128/JB.174.15.5123-5126.1992; KHAN S, 1991, J BACTERIOL, V173, P2888, DOI 10.1128/JB.173.9.2888-2896.1991; Kojima S, 2004, INT REV CYTOL, V233, P93, DOI 10.1016/S0074-7696(04)33003-2; Leadbetter JR, 1999, SCIENCE, V283, P686, DOI 10.1126/science.283.5402.686; Limberger RJ, 2004, J MOL MICROB BIOTECH, V7, P30, DOI 10.1159/000077867; Lowder BJ, 2005, J BACTERIOL, V187, P5640, DOI 10.1128/JB.187.16.5640-5647.2005; SOSINSKY GE, 1992, J MOL BIOL, V223, P171, DOI 10.1016/0022-2836(92)90724-X; STALLMEYER MJB, 1989, J MOL BIOL, V205, P511, DOI 10.1016/0022-2836(89)90222-2; Suzuki H, 2004, J MOL BIOL, V337, P105, DOI 10.1016/j.jmb.2004.01.034; Thomas D, 2001, J BACTERIOL, V183, P6404, DOI 10.1128/JB.183.21.6404-6412.2001; Yonekura K, 2006, J MOL BIOL, V357, P73, DOI 10.1016/j.jmb.2005.12.041; Young HS, 2003, BIOPHYS J, V84, P571, DOI [10.1016/s0006-3495(03)74877-2, 10.1016/S0006-3495(03)74877-2]	21	144	144	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 31	2006	442	7106					1062	1064		10.1038/nature05015	http://dx.doi.org/10.1038/nature05015			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	078YF	16885937				2022-12-28	WOS:000240142000055
J	Wilf, P; Labandeira, CC; Johnson, KR; Ellis, B				Wilf, Peter; Labandeira, Conrad C.; Johnson, Kirk R.; Ellis, Beth			Decoupled plant and insect diversity after the end-Cretaceous extinction	SCIENCE			English	Article							TERTIARY BOUNDARY; TROPICAL FORESTS; MASS EXTINCTION; ASSOCIATIONS; RECOVERY; HERBIVORY; RICHNESS; CLIMATE; EVENT	Food web recovery from mass extinction is poorly understood. We analyzed insect-feeding damage on 14,999 angiosperm leaves from 14 latest Cretaceous, Paleocene, and early Eocene sites in the western interior United States. Most Paleocene floras have low richness of plants and of insect damage. However, a low-diversity 64.4-million-year-old flora from southeastern Montana shows extremely high insect damage richness, especially of leaf mining, whereas an anomalously diverse 63.8-million-year-old flora from the Denver Basin shows little damage and virtually no specialized feeding. These findings reveal severely unbalanced food webs 1 to 2 million years after the end-Cretaceous extinction 65.5 million years ago.	Penn State Univ, Dept Geosci, University Pk, PA 16802 USA; Penn State Univ, Inst Environm, University Pk, PA 16802 USA; Smithsonian Inst, Dept Paleobiol, Washington, DC 20560 USA; Univ Maryland, Dept Entomol, College Pk, MD 20742 USA; Denver Museum Nat & Sci, Dept Earth Sci, Denver, CO 80205 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Smithsonian Institution; Smithsonian National Museum of Natural History; University System of Maryland; University of Maryland College Park	Wilf, P (corresponding author), Penn State Univ, Dept Geosci, University Pk, PA 16802 USA.	pwilf@psu.edu		Wilf, Peter/0000-0001-6813-1937				Burnham RJ, 2004, PHILOS T R SOC B, V359, P1595, DOI 10.1098/rstb.2004.1531; Coley PD, 1996, ANNU REV ECOL SYST, V27, P305, DOI 10.1146/annurev.ecolsys.27.1.305; Coxall HK, 2006, GEOLOGY, V34, P297, DOI 10.1130/G21702.1; D'Hondt S, 1998, SCIENCE, V282, P276, DOI 10.1126/science.282.5387.276; ELLIS B, 2004, 20042 DENV MUS NAT S, P1; ELLIS B, 2003, ROCKY MT GEOL, V38, P73, DOI DOI 10.2113/GSR0CKY.38.1.173; Hawkins BA, 2003, AM NAT, V161, P40, DOI 10.1086/345479; JANZEN DH, 1970, AM NAT, V104, P501, DOI 10.1086/282687; Johnson KR, 2002, SCIENCE, V296, P2379, DOI 10.1126/science.1072102; JOHNSON KR, 2002, GEOL S AM S, V361, P329, DOI DOI 10.1130/0-8137-2361-2.329; Johnson KR., 2003, ROCKY MT GEOL, V38, P101; Labandeira CC, 2002, P NATL ACAD SCI USA, V99, P2061, DOI 10.1073/pnas.042492999; Labandeira Conrad C., 2002, Geological Society of America Special Paper, V361, P297; Labandeira Conrad C., 2002, Rocky Mountain Geology, V37, P31, DOI 10.2113/gsrocky.37.1.31; LANG PJ, 1996, THESIS U LONDON; Lopez-Vaamonde C, 2006, J EVOLUTION BIOL, V19, P1314, DOI 10.1111/j.1420-9101.2005.01070.x; POWELL J, 1998, HDB ZOOLOGY, P403; Raman Anantanarayanan, 2005, P1; Sewall JO, 2006, GEOLOGY, V34, P81, DOI 10.1130/G22177.1; Siemann E, 1998, AM NAT, V152, P738, DOI 10.1086/286204; Sole RV, 2002, PHILOS T R SOC B, V357, P697, DOI 10.1098/rstb.2001.0987; Spencer KA., 1990, HOST SPECIALIZATION; TIPPER JC, 1979, PALEOBIOLOGY, V5, P423, DOI 10.1017/S0094837300016924; Wilf P, 2005, P NATL ACAD SCI USA, V102, P8944, DOI 10.1073/pnas.0500516102; Wilf P, 1999, SCIENCE, V284, P2153, DOI 10.1126/science.284.5423.2153; Wills C, 2006, SCIENCE, V311, P527, DOI 10.1126/science.1117715; Wright MG, 1998, OECOLOGIA, V115, P427, DOI 10.1007/s004420050537; ZACHOS JC, 1989, NATURE, V337, P61, DOI 10.1038/337061a0	28	119	121	3	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 25	2006	313	5790					1112	1115		10.1126/science.1129569	http://dx.doi.org/10.1126/science.1129569			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	076ZT	16931760				2022-12-28	WOS:000239998200044
J	Arepally, GM; Ortel, TL				Arepally, Gowthami M.; Ortel, Thomas L.			Heparin-induced thrombocytopenia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MOLECULAR-WEIGHT HEPARIN; HEMODIALYSIS-PATIENTS; RECOMBINANT HIRUDIN; PROSPECTIVE COHORT; RISK-FACTORS; THROMBOSIS; ANTIBODIES; LEPIRUDIN; ANTICOAGULATION; ARGATROBAN		Duke Univ, Med Ctr, Dept Med, Div Hematol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA	Duke University; Duke University	Ortel, TL (corresponding author), Duke Univ Hlth Syst, Ctr Thrombosis & Hemostasis, Box 3422,Stead Bldg,Rm 0563, Durham, NC 27710 USA.	thomas.ortel@duke.edu			CENTERS FOR DISEASE CONTROL AND PREVENTION [U18DD000014] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U54HL077878, R01HL081395, U01HL072289] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL072289, HL081395, HL077878] Funding Source: Medline; NCBDD CDC HHS [U18DD00014] Funding Source: Medline	CENTERS FOR DISEASE CONTROL AND PREVENTION(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCBDD CDC HHS		AMIRAL J, 1992, THROMB HAEMOSTASIS, V68, P95; Amiral J, 1996, BLOOD, V88, P410, DOI 10.1182/blood.V88.2.410.bloodjournal882410; Chong BH, 2001, THROMB HAEMOSTASIS, V86, P1170, DOI 10.1055/s-0037-1616046; Fabris F, 2002, J INTERN MED, V252, P149, DOI 10.1046/j.1365-2796.2002.01021.x; Farner B, 2001, THROMB HAEMOSTASIS, V85, P950, DOI 10.1055/s-0037-1615946; Fausett MB, 2001, AM J OBSTET GYNECOL, V185, P148, DOI 10.1067/mob.2001.114690; Girolami B, 2003, BLOOD, V101, P2955, DOI 10.1182/blood-2002-07-2201; Greer IA, 2005, BLOOD, V106, P401, DOI 10.1182/blood-2005-02-0626; Greinacher A, 2005, THROMB HAEMOSTASIS, V94, P132, DOI 10.1160/TH04-12-0825; Greinacher A, 2003, CIRCULATION, V108, P2062, DOI 10.1161/01.CIR.0000096056.37269.14; Greinacher A, 1999, CIRCULATION, V100, P587, DOI 10.1161/01.CIR.100.6.587; Greinacher A, 1999, CIRCULATION, V99, P73, DOI 10.1161/01.CIR.99.1.73; Greinacher A, 2005, CHEST, V127, P416; Hong AP, 2003, BLOOD, V101, P3049, DOI 10.1182/blood-2002-05-1448; Keeling D, 2006, BRIT J HAEMATOL, V133, P259, DOI 10.1111/j.1365-2141.2006.06018.x; KELTON JG, 2005, CHEST S9S, V127, pS20; Klenner AF, 2004, THROMB HAEMOSTASIS, V91, P719, DOI 10.1160/TH03-09-0571; Lewis BE, 2003, ARCH INTERN MED, V163, P1849, DOI 10.1001/archinte.163.15.1849; Lewis BE, 2001, CIRCULATION, V103, P1838; Lincoff AM, 2003, JAMA-J AM MED ASSOC, V289, P853, DOI 10.1001/jama.289.7.853; LINCOFF AM, 2003, JAMA-J AM MED ASSOC, V289, P1638; Lindhoff-Last E, 2002, BRIT J HAEMATOL, V118, P1137, DOI 10.1046/j.1365-2141.2002.03687.x; Lo GK, 2006, J THROMB HAEMOST, V4, P759, DOI 10.1111/j.1538-7836.2006.01787.x; LOUET AL, 2004, J THROMB HAEMOST, V2, P1882; Lubenow N, 2005, J THROMB HAEMOST, V3, P2428, DOI 10.1111/j.1538-7836.2005.01623.x; Lubenow N, 2004, BLOOD, V104, P3072, DOI 10.1182/blood-2004-02-0621; Magnani HN, 2006, THROMB HAEMOSTASIS, V95, P967, DOI 10.1160/TH05-07-0489; Martel N, 2005, BLOOD, V106, P2710, DOI 10.1182/blood-2005-04-1546; Matsuo T, 2005, THROMB RES, V115, P475, DOI 10.1016/j.thromres.2004.10.009; O'Shea SI, 2002, AM J HEMATOL, V69, P72, DOI 10.1002/ajh.10032; Pohl C, 2005, NEUROLOGY, V64, P1285, DOI 10.1212/01.WNL.0000156947.45112.16; Potzsch B, 2000, NEW ENGL J MED, V343, P515, DOI 10.1056/NEJM200008173430718; Pouplard C, 1999, AM J CLIN PATHOL, V111, P700; Prandoni P, 2005, BLOOD, V106, P3049, DOI 10.1182/blood-2005-03-0912; Rice L, 2002, ANN INTERN MED, V136, P210, DOI 10.7326/0003-4819-136-3-200202050-00009; Sheth SB, 2001, THROMB HAEMOSTASIS, V85, P435; TARDY B, IN PRESS BLOOD; Verma AK, 2003, PHARMACOTHERAPY, V23, P745, DOI 10.1592/phco.23.6.745.32188; Wallis DE, 1999, AM J MED, V106, P629, DOI 10.1016/S0002-9343(99)00124-2; Warkentin TE, 2000, BLOOD, V96, P1703, DOI 10.1182/blood.V96.5.1703.h8001703_1703_1708; Warkentin TE, 2001, ANN INTERN MED, V135, P502, DOI 10.7326/0003-4819-135-7-200110020-00009; Warkentin TE, 2001, NEW ENGL J MED, V344, P1286, DOI 10.1056/NEJM200104263441704; Warkentin TE, 2004, CHEST, V126, p311S, DOI 10.1378/chest.126.3_suppl.311S; Warkentin TE, 2005, J LAB CLIN MED, V146, P341, DOI 10.1016/j.lab.2005.08.003; Warkentin TE, 2005, THROMB HAEMOSTASIS, V94, P958, DOI 10.1160/TH05-03-0154; Warkentin TE, 2005, CHEST, V127, P1857, DOI 10.1378/chest.127.5.1857; Warkentin TE, 2003, ARCH INTERN MED, V163, P2518, DOI 10.1001/archinte.163.20.2518; Warkentin TE, 1997, ANN INTERN MED, V127, P804, DOI 10.7326/0003-4819-127-9-199711010-00005; Warkentin TE, 1996, AM J MED, V101, P502, DOI 10.1016/S0002-9343(96)00258-6; Yamamoto S, 1996, AM J KIDNEY DIS, V28, P82, DOI 10.1016/S0272-6386(96)90134-1	51	346	366	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 24	2006	355	8					809	817		10.1056/NEJMcp052967	http://dx.doi.org/10.1056/NEJMcp052967			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	076KA	16928996				2022-12-28	WOS:000239955200009
J	Weaver, BAA; Silk, AD; Cleveland, DW				Weaver, Beth A. A.; Silk, Alain D.; Cleveland, Don W.			Nondisjunction, aneuploidy and tetraploidy	NATURE			English	Letter							MITOTIC CHECKPOINT; MAMMALIAN-CELLS; CYTOKINESIS; MUTATIONS; FAILURE; BUB1B		Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego	Weaver, BAA (corresponding author), Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA.	dcleveland@ucsd.edu	Cleveland, Don/AAN-9783-2021	Cleveland, Don/0000-0002-1934-3682				Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Babu JR, 2003, J CELL BIOL, V160, P341, DOI 10.1083/jcb.200211048; Hanks S, 2004, NAT GENET, V36, P1159, DOI 10.1038/ng1449; Limwongse C, 1999, AM J MED GENET, V82, P20, DOI 10.1002/(SICI)1096-8628(19990101)82:1<20::AID-AJMG4>3.0.CO;2-5; Matsuura S, 2006, AM J MED GENET A, V140A, P358, DOI 10.1002/ajmg.a.31069; MULLINS JM, 1977, J CELL BIOL, V73, P672, DOI 10.1083/jcb.73.3.672; Shi QH, 2005, NATURE, V437, P1038, DOI 10.1038/nature03958; Uetake Y, 2004, J CELL BIOL, V165, P609, DOI 10.1083/jcb.200403014; Weaver BAA, 2003, J CELL BIOL, V162, P551, DOI 10.1083/jcb.200303167; Wong C, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-6	10	40	40	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 17	2006	442	7104					E9	E10		10.1038/nature05139	http://dx.doi.org/10.1038/nature05139			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	074DK	16915240				2022-12-28	WOS:000239792700033
J	Farooqi, N; Kouyialis, AT; Brodbelt, A				Farooqi, Naeem; Kouyialis, Andreas T.; Brodbelt, Andrew			First things first	LANCET			English	Editorial Material									Walton Ctr Neurol & Neurosurg, Dept Neurosurg, Liverpool, Merseyside, England	Walton Centre	Farooqi, N (corresponding author), Walton Ctr Neurol & Neurosurg, Dept Neurosurg, Liverpool, Merseyside, England.	drnaf@yahoo.com							0	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 12	2006	368	9535					617	617		10.1016/S0140-6736(06)69206-4	http://dx.doi.org/10.1016/S0140-6736(06)69206-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	074OF	16905027				2022-12-28	WOS:000239821000036
J	Holland, RA; Wikelski, M; Wilcove, DS				Holland, Richard A.; Wikelski, Martin; Wilcove, David S.			How and why do insects migrate?	SCIENCE			English	Editorial Material							WIND DRIFT COMPENSATION; REVEALS; COMPASS; CRICKET	Countless numbers of insects migrate within and between continents every year, and yet we know very little about the ultimate reasons and proximate mechanisms that would explain these mass movements. Here we suggest that perhaps the most important reason for insects to migrate is to hedge their reproductive bets. By spreading their breeding efforts in space and time, insects distribute their offspring over a range of environmental conditions. We show how the study of individual long-distance movements of insects may contribute to a better understanding of migration. In the future, advances in tracking methods may enable the global surveillance of large insects such as desert locusts.	Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA; Princeton Univ, Woodrow Wilson Sch, Princeton, NJ 08544 USA; Univ Leeds, Inst Integrat & Comparat Biol, Leeds LS2 9JT, W Yorkshire, England	Princeton University; Princeton University; University of Leeds	Wikelski, M (corresponding author), Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA.	wikelski@princeton.edu	Holland, Richard A/A-6107-2010	Holland, Richard A/0000-0003-4495-8061; Wilcove, David S./0000-0002-1354-0503				[Anonymous], 2020, ECONOMIST 0326; ARIDJIS H, 1996, NY TIMES        0126, pA27; Berthold P, 2001, AUK, V2nd; Bingman VP, 2005, ETHOL ECOL EVOL, V17, P295; Brower L.P., 1988, Animal Kingdom, V91, P42; Brower LP, 1996, J EXP BIOL, V199, P93; Busvine JR, 1993, DIS TRANSMISSION INS; Calvert William H., 2001, Journal of the Lepidopterists' Society, V55, P162; Cochran WW, 2004, SCIENCE, V304, P405, DOI 10.1126/science.1095844; Collett M, 2006, CURR BIOL, V16, pR48, DOI 10.1016/j.cub.2006.01.007; DRAKE VA, 1995, INSECT MIGRATION: TRACKING RESOURCES THROUGH SPACE AND TIME, P427, DOI 10.1017/CBO9780511470875.022; DRAKE VA, 1988, ANNU REV ENTOMOL, V33, P183, DOI 10.1146/annurev.en.33.010188.001151; Farrow R.A., 1990, P227; Gasser RB, 2006, VET PARASITOL, V136, P69, DOI 10.1016/j.vetpar.2005.12.002; GATEHOUSE AG, 1995, INSECT MIGRATION: TRACKING RESOURCES THROUGH SPACE AND TIME, P193; Gatehouse AG, 1997, ANNU REV ENTOMOL, V42, P475, DOI 10.1146/annurev.ento.42.1.475; GREGG PC, 1995, INSECT MIGRATION: TRACKING RESOURCES THROUGH SPACE AND TIME, P151; HARVEY MJ, 1999, BATS US; Johnsgard PA, 1991, CRANE MUSIC NATURAL; Kennedy J.S., 1985, Contributions in Marine Science, V27, P5; Kremen C, 2005, FRONT ECOL ENVIRON, V3, P540, DOI 10.1890/1540-9295(2005)003[0540:ACTEMA]2.0.CO;2; Lorch PD, 2005, ECOL ENTOMOL, V30, P548, DOI 10.1111/j.0307-6946.2005.00725.x; Magor J.I., 2003, DESERT LOCUST POPULA; MAGOR JI, 1995, INSECT MIGRATION: TRACKING RESOURCES THROUGH SPACE AND TIME, P399; Mouritsen H, 2002, P NATL ACAD SCI USA, V99, P10162, DOI 10.1073/pnas.152137299; Naef-Daenzer B, 2005, J EXP BIOL, V208, P4063, DOI 10.1242/jeb.01870; Oliveira EG, 1998, J EXP BIOL, V201, P3317; PERDECK A. C., 1958, ARDEA, V46, P1; Russell RW, 1998, AM MIDL NAT, V140, P325, DOI 10.1674/0003-0031(1998)140[0325:MSMODO]2.0.CO;2; SHAW MJP, 1970, ANN APPL BIOL, V65, P197, DOI 10.1111/j.1744-7348.1970.tb04579.x; SINCLAIR ARE, 1995, SERENGETI, V2; SOUTHWOOD TRE, 1977, J ANIM ECOL, V46, P337; Srygley RB, 2006, ANIM BEHAV, V71, P183, DOI 10.1016/j.anbehav.2005.04.013; Srygley RB, 2001, J NAVIGATION, V54, P405, DOI 10.1017/S0373463301001448; Srygley RB, 1996, P ROY SOC B-BIOL SCI, V263, P1351, DOI 10.1098/rspb.1996.0198; Swenson G.W., 2004, P IEEE INT GEOSC REM; TAYLOR LR, 1974, J ANIM ECOL, V43, P225, DOI 10.2307/3169; URQUHART FA, 1964, P ENTOMOL SOC ONT, V95, P23; WIKELSKI M, IN PRESS BIOL LETT; WILLIAMS CB, 1957, ANNU REV ENTOMOL, V2, P163, DOI 10.1146/annurev.en.02.010157.001115; WILSON K, 1995, INSECT MIGRATION: TRACKING RESOURCES THROUGH SPACE AND TIME, P243; Woiwod I.P., 2001, INSECT MOVEMENT MECH, V1st; Zera AJ, 2005, INTEGR COMP BIOL, V45, P511, DOI 10.1093/icb/45.3.511	43	158	174	3	112	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 11	2006	313	5788					794	796		10.1126/science.1127272	http://dx.doi.org/10.1126/science.1127272			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	072KC	16902129				2022-12-28	WOS:000239671300047
J	Kondo, T; Sawa, S; Kinoshita, A; Mizuno, S; Kakimoto, T; Fukuda, H; Sakagami, Y				Kondo, Tatsuhiko; Sawa, Shinichiro; Kinoshita, Atsuko; Mizuno, Satoko; Kakimoto, Tatsuo; Fukuda, Hiroo; Sakagami, Youji			A plant peptide encoded by CLV3 identified by in situ MALDI-TOF MS analysis	SCIENCE			English	Article							GENE ENCODES; ARABIDOPSIS; MERISTEM; SHOOT; CLAVATA3; KINASES; FAMILY; CLE40	The Arabidopsis CLAVATA3 (CLV3) gene encodes a stem cell - specific protein presumed to be a precursor of a secreted peptide hormone. Matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry (MALDI-TOF MS) applied to in situ Arabidopsis tissues determined the structure of a modified 12 - amino acid peptide (MCLV3), which was derived from a conserved motif in the CLV3 sequence. Synthetic MCLV3 induced shoot and root meristem consumption as cells differentiated into other organs, displaying the typical phenotype of transgenic plants overexpressing CLV3. These results suggest that the functional peptide of CLV3 is MCLV3.	Nagoya Univ, Grad Sch Bioagr Sci, Chikusa Ku, Nagoya, Aichi 4648601, Japan; Univ Tokyo, Grad Sch Sci, Tokyo 1130033, Japan; Osaka Univ, Grad Sch Sci, Toyonaka, Osaka 5600043, Japan	Nagoya University; University of Tokyo; Osaka University	Sawa, S (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Chikusa Ku, Nagoya, Aichi 4648601, Japan.	sawa@biol.s.u-tokyo.ac.jp; ysaka@agr.nagoya-u.ac.jp		Kinoshita, Atsuko/0000-0001-9095-389X; Sawa, Shinichiro/0000-0002-9309-9104				Brand U, 2000, SCIENCE, V289, P617, DOI 10.1126/science.289.5479.617; Clark SE, 1997, CELL, V89, P575, DOI 10.1016/S0092-8674(00)80239-1; Cock JM, 2001, PLANT PHYSIOL, V126, P939, DOI 10.1104/pp.126.3.939; Fiers M, 2005, PLANT CELL, V17, P2542, DOI 10.1105/tpc.105.034009; Fletcher JC, 2000, CURR OPIN PLANT BIOL, V3, P23, DOI 10.1016/S1369-5266(99)00033-3; Fletcher JC, 2002, ANNU REV PLANT BIOL, V53, P45, DOI 10.1146/annurev.arplant.53.092701.143332; Fletcher LC, 1999, SCIENCE, V283, P1911, DOI 10.1126/science.283.5409.1911; Hobe M, 2003, DEV GENES EVOL, V213, P371, DOI 10.1007/s00427-003-0329-5; Ito Y, 2006, SCIENCE, V313, P842, DOI 10.1126/science.1128436; Jeong S, 1999, PLANT CELL, V11, P1925, DOI 10.1105/tpc.11.10.1925; Matsubayashi Y, 2006, ANNU REV PLANT BIOL, V57, P649, DOI 10.1146/annurev.arplant.56.032604.144204; Myllyharju J, 2003, MATRIX BIOL, V22, P15, DOI 10.1016/S0945-053X(03)00006-4; Ni J, 2006, PLANT PHYSIOL, V140, P726, DOI 10.1104/pp.105.072678; Pearce G, 2003, J BIOL CHEM, V278, P30044, DOI 10.1074/jbc.M304159200; Shiu SH, 2001, P NATL ACAD SCI USA, V98, P10763, DOI 10.1073/pnas.181141598; Showalter AM, 2001, CELL MOL LIFE SCI, V58, P1399, DOI 10.1007/PL00000784; Torii KU, 2004, INT REV CYTOL, V234, P1, DOI 10.1016/S0074-7696(04)34001-5; Yasuda A, 2004, GEN COMP ENDOCR, V135, P391, DOI 10.1016/j.ygcen.2003.10.001	18	349	382	3	102	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 11	2006	313	5788					845	848		10.1126/science.1128439	http://dx.doi.org/10.1126/science.1128439			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	072KC	16902141				2022-12-28	WOS:000239671300063
J	Feeley, F				Feeley, Frank			Fight AIDS as well as the brain drain	LANCET			English	Editorial Material									Boston Univ, Sch Publ Hlth, Ctr Int Hlth & Dev, Boston, MA 02118 USA	Boston University	Feeley, F (corresponding author), Boston Univ, Sch Publ Hlth, Ctr Int Hlth & Dev, Boston, MA 02118 USA.	ffeeley@bu.edu		Feeley, Frank/0000-0002-7176-5698				[Anonymous], 2004, HUM RES HLTH OV CRIS; Coetzee D, 2004, AIDS, V18, P887, DOI 10.1097/00002030-200404090-00006; FEELEY R, 2004, COSTS HIV AIDS PROFE; GAUMER G, 2006, FEASIBILITY INSURANC; *MIN HLTH REP ZAMB, 2001, NAT 10 YEAR HUM RES; Narasimhan V, 2004, LANCET, V363, P1469, DOI 10.1016/S0140-6736(04)16108-4; Nullis-Kapp C, 2005, B WORLD HEALTH ORGAN, V83, P84; Thirumurthy H., 2005, EC IMPACT AIDS TREAT; *WHO, 2006, 2006 WORLD HLTH REP	9	8	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 5	2006	368	9534					435	436		10.1016/S0140-6736(06)69133-2	http://dx.doi.org/10.1016/S0140-6736(06)69133-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	071AL	16890815				2022-12-28	WOS:000239569000010
J	Liu, W; Jawerth, LM; Sparks, EA; Falvo, MR; Hantgan, RR; Superfine, R; Lord, ST; Guthold, M				Liu, W.; Jawerth, L. M.; Sparks, E. A.; Falvo, M. R.; Hantgan, R. R.; Superfine, R.; Lord, S. T.; Guthold, M.			Fibrin fibers have extraordinary extensibility and elasticity	SCIENCE			English	Article							CLOT		Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; Wake Forest Univ, Dept Phys, Winston Salem, NC 27109 USA; Harvard Univ, Dept Phys, Cambridge, MA 02138 USA; Univ N Carolina, Curriculum Appl & Mat Sci, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Phys & Astron, Chapel Hill, NC 27599 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, Winston Salem, NC 27157 USA	University of North Carolina; University of North Carolina Chapel Hill; Wake Forest University; Harvard University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Wake Forest University; Wake Forest Baptist Medical Center	Lord, ST (corresponding author), Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA.	stl@med.unc.edu; gutholdm@wfu.edu	Liu, Wenhua/B-8044-2010; Superfine, Richard/A-1968-2012; , Guthold/AAU-9371-2021	Liu, Wenhua/0000-0002-1199-435X; Superfine, Richard/0000-0002-2569-071X; Guthold, Martin/0000-0003-4177-6115	NATIONAL CANCER INSTITUTE [R41CA103120] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031048] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB002025] Funding Source: NIH RePORTER; NCI NIH HHS [R41 CA10312, R41 CA103120-01, R41 CA103120] Funding Source: Medline; NHLBI NIH HHS [R01 HL31048] Funding Source: Medline; NIBIB NIH HHS [P41 EB002025] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Collet JP, 2005, P NATL ACAD SCI USA, V102, P9133, DOI 10.1073/pnas.0504120102; FERRY JD, 1947, J AM CHEM SOC, V69, P388, DOI 10.1021/ja01194a066; Guthold M, 2004, BIOPHYS J, V87, P4226, DOI 10.1529/biophysj.104.042333; MCKEE PA, 1970, P NATL ACAD SCI USA, V66, P738, DOI 10.1073/pnas.66.3.738; Ryan EA, 1999, BIOPHYS J, V77, P2813, DOI 10.1016/S0006-3495(99)77113-4; Weisel JW, 2004, BIOPHYS CHEM, V112, P267, DOI 10.1016/j.bpc.2004.07.029	6	212	214	3	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 4	2006	313	5787					634	634		10.1126/science.1127317	http://dx.doi.org/10.1126/science.1127317			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	072IQ	16888133	Green Accepted, Green Submitted			2022-12-28	WOS:000239667500033
J	Morrison, LJ; Visentin, LM; Kiss, A; Theriault, R; Eby, D; Vermeulen, M; Sherbino, J; Verbeek, PR				Morrison, Laurie J.; Visentin, Laura M.; Kiss, Alex; Theriault, Rob; Eby, Don; Vermeulen, Marian; Sherbino, Jonathan; Verbeek, P. Richard		TOR Investigators	Validation of a rule for termination of resuscitation in out-of-hospital cardiac arrest	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the National-Association-of-Emergency-Medical-Services-Physicians	JAN   20, 2006	Tucson, AZ	Natl Assoc Emergency Med Serv Physicians			AMERICAN-HEART-ASSOCIATION; CLINICAL-PREDICTION RULES; CARDIOPULMONARY-RESUSCITATION; LIFE-SUPPORT; METHODOLOGICAL STANDARDS; EMERGENCY; FUTILITY; CARE; GUIDELINES	BACKGROUND: We prospectively evaluated a clinical prediction rule to be used by emergency medical technicians (EMTs) trained in the use of an automated external defibrillator for the termination of basic life support resuscitative efforts during out-of-hospital cardiac arrest. The rule recommends termination when there is no return of spontaneous circulation, no shocks are administered, and the arrest is not witnessed by emergency medical-services personnel. Otherwise, the rule recommends transportation to the hospital, in accordance with routine practice. METHODS: The study included 24 emergency medical systems in Ontario, Canada. All patients 18 years of age or older who had an arrest of presumed cardiac cause and who were treated by EMTs trained in the use of an automated external defibrillator were included. The patients were treated according to standard guidelines. Characteristics of diagnostic tests for the prediction rule were calculated. These characteristics include sensitivity, specificity, and positive and negative predictive values. RESULTS: Follow-up data were obtained for all 1240 patients. Of 776 patients with cardiac arrest for whom the rule recommended termination, 4 survived (0.5 percent). The rule had a specificity of 90.2 percent for recommending transport of survivors to the emergency department and had a positive predictive value for death of 99.5 percent when termination was recommended. Implementation of this rule would result in a decrease in the rate of transportation from 100 percent of patients to 37.4 percent. The addition of other criteria (a response interval greater than eight minutes or a cardiac arrest not witnessed by a bystander) would further improve both the specificity and positive predictive value of the rule but would result in the transportation of a larger proportion of patients. CONCLUSIONS: The use of a clinical prediction rule for the termination of resuscitation may help clinicians decide whether to terminate basic life support resuscitative efforts in patients having an out-of-hospital cardiac arrest.	Sunnybrook & Womens Coll Hlth Sci Ctr, Prehosp & Transport Med Res Program, Toronto, ON, Canada; Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Res Design & Biostat, Toronto, ON, Canada; Sunnybrook & Womens Coll Hlth Sci Ctr, Sunnybrook Osler Ctr Prehosp Care, Toronto, ON, Canada; Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada; Univ Toronto, Dept Med, Div Emergency Med, Toronto, ON, Canada; Inst Clin & Evaluat Studies, Toronto, ON, Canada; Owen Sound Hosp, Grey Bruce Hlth Serv, Grey Bruce Huron Paramed Base Hosp Program, Owen Sound, ON, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto	Morrison, LJ (corresponding author), Sunnybrook & Womens Coll Hlth Sci Ctr, Prehosp & Transport Med Res Program, Toronto, ON, Canada.		Morrison, Laurie Jean/A-6325-2012	Morrison, Laurie Jean/0000-0001-8369-9774				Ardagh M, 2000, J MED ETHICS, V26, P396, DOI 10.1136/jme.26.5.396; Bailey E D, 2000, Prehosp Emerg Care, V4, P190, DOI 10.1080/10903120090941498; BONNIN MJ, 1993, JAMA-J AM MED ASSOC, V270, P1457, DOI 10.1001/jama.270.12.1457; BONNIN MJ, 1989, ANN EMERG MED, V18, P507, DOI 10.1016/S0196-0644(89)80834-0; Cheung M, 2001, CJEM, V3, P19; Clawson J J, 1997, Prehosp Disaster Med, V12, P274; CUMMINS RO, 1985, JAMA-J AM MED ASSOC, V253, P2408, DOI 10.1001/jama.253.16.2408; Delbridge TR, 1996, ANN EMERG MED, V27, P649, DOI 10.1016/S0196-0644(96)70170-1; Eckstein M, 2005, ACAD EMERG MED, V12, P65, DOI 10.1197/j.aem.2004.07.020; EISENBERG MS, 1990, ANN EMERG MED, V19, P179, DOI 10.1016/S0196-0644(05)81805-0; FINLAY I, 1991, BRIT MED J, V302, P1524, DOI 10.1136/bmj.302.6791.1524; GRAY WA, 1991, NEW ENGL J MED, V325, P1393, DOI 10.1056/NEJM199111143252001; Helft PR, 2000, NEW ENGL J MED, V343, P293, DOI 10.1056/NEJM200007273430411; Hick JL, 1998, ANN EMERG MED, V32, P19, DOI 10.1016/S0196-0644(98)70094-0; Jacobs I, 2004, CIRCULATION, V110, P3385, DOI 10.1161/01.CIR.0000147236.85306.15; JECKER NS, 1993, ARCH INTERN MED, V153, P2195, DOI 10.1001/archinte.153.19.2195; KELEN GD, 1989, JAMA-J AM MED ASSOC, V262, P516, DOI 10.1001/jama.262.4.516; KELLERMANN AL, 1988, ANN EMERG MED, V17, P589, DOI 10.1016/S0196-0644(88)80398-6; KELLERMANN AL, 1993, JAMA-J AM MED ASSOC, V270, P1433, DOI 10.1001/jama.270.12.1433; KELLERMANN AL, 1993, JAMA-J AM MED ASSOC, V270, P1708, DOI 10.1001/jama.270.14.1708; KELSEY SF, 1991, CONTROL CLIN TRIALS, V12, P525; Laupacis A, 1997, JAMA-J AM MED ASSOC, V277, P488, DOI 10.1001/jama.277.6.488; Mayfield T, 1998, JEMS, V23, P50; Morrison Laurie J, 2005, Prehosp Emerg Care, V9, P14, DOI 10.1080/10903120590891679; Morrison LJ, 2003, ACAD EMERG MED, V10, P633, DOI 10.1197/aemj.10.6.633; *NAT ASS EMS DIR, 1994, DO NUT RES DNR PROGR; Pepe P E, 2001, Prehosp Emerg Care, V5, P79, DOI 10.1080/10903120190940399; Petrie D A, 2001, CJEM, V3, P186; Safar PBN, 1988, CARDIOPULMONARY CERE; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; SMITH JP, 1985, ANN EMERG MED, V14, P1093; Stiell IG, 1999, ANN EMERG MED, V34, P256, DOI 10.1016/S0196-0644(99)70241-6; Suchard JR, 1999, J EMERG MED, V17, P801, DOI 10.1016/S0736-4679(99)00086-4; VANDERHOEVEN JG, 1993, ANN EMERG MED, V22, P1659, DOI 10.1016/S0196-0644(05)81303-4; Verbeek PR, 2002, ACAD EMERG MED, V9, P671, DOI 10.1197/aemj.9.7.671; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; 2000, CIRCULATION S1, V102, P12; 2005, CIRCULATION S4, V112, pR1; 2000, CIRCULATION S1, V102, P60	39	223	224	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 3	2006	355	5					478	487		10.1056/NEJMoa052620	http://dx.doi.org/10.1056/NEJMoa052620			10	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	069FT	16885551				2022-12-28	WOS:000239432500007
J	Pearson, ER; Flechtner, I; Njolstad, PR; Malecki, MT; Flanagan, SE; Larkin, B; Ashcroft, FM; Klimes, I; Codner, E; Iotova, V; Slingerland, AS; Shield, J; Robert, J; Holst, JJ; Clark, PM; Ellard, S; Sovik, O; Polak, M; Hattersley, AT				Pearson, Ewan R.; Flechtner, Isabelle; Njolstad, Pal R.; Malecki, Maciej T.; Flanagan, Sarah E.; Larkin, Brian; Ashcroft, Frances M.; Klimes, Iwar; Codner, Ethel; Iotova, Violeta; Slingerland, Annabelle S.; Shield, Julian; Robert, Jean-Jacques; Holst, Jens J.; Clark, Penny M.; Ellard, Sian; Sovik, Oddmund; Polak, Michel; Hattersley, Andrew T.		Neonatal Diabet Int Collaborative	Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACTIVATING MUTATIONS; ENCODES KIR6.2; COMMON-CAUSE; KCNJ11; THERAPY; ATP; MELLITUS; SUBUNIT; CHANNEL; GLUCOSE	BACKGROUND: Heterozygous activating mutations in KCNJ11, encoding the Kir6.2 subunit of the ATP-sensitive potassium (K(sub ATP)) channel, cause 30 to 58 percent of cases of diabetes diagnosed in patients under six months of age. Patients present with ketoacidosis or severe hyperglycemia and are treated with insulin. Diabetes results from impaired insulin secretion caused by a failure of the beta-cell K(sub ATP) channel to close in response to increased intracellular ATP. Sulfonylureas close the K(sub ATP) channel by an ATP-independent route. METHODS: We assessed glycemic control in 49 consecutive patients with Kir6.2 mutations who received appropriate doses of sulfonylureas and, in smaller subgroups, investigated the insulin secretory responses to intravenous and oral glucose, a mixed meal, and glucagon. The response of mutant K(sub ATP) channels to the sulfonylurea tolbutamide was assayed in xenopus oocytes. RESULTS: A total of 44 patients (90 percent) successfully discontinued insulin after receiving sulfonylureas. The extent of the tolbutamide blockade of K(sub ATP) channels in vitro reflected the response seen in patients. Glycated hemoglobin levels improved in all patients who switched to sulfonylurea therapy (from 8.1 percent before treatment to 6.4 percent after 12 weeks of treatment, P<0.001). Improved glycemic control was sustained at one year. Sulfonylurea treatment increased insulin secretion, which was more highly stimulated by oral glucose or a mixed meal than by intravenous glucose. Exogenous glucagon increased insulin secretion only in the presence of sulfonylureas. CONCLUSIONS: Sulfonylurea therapy is safe in the short term for patients with diabetes caused by KCNJ11 mutations and is probably more effective than insulin therapy. This pharmacogenetic response to sulfonylureas may result from the closing of mutant K(sub ATP) channels, thereby increasing insulin secretion in response to incretins and glucose metabolism.	Peninsula Med Sch, Inst Biomed & Clin Sci, Exeter EX2 5DW, Devon, England; Univ Dundee, Div Med & Therapeut, Dundee, Scotland; Univ Lab Physiol, Oxford, England; Univ Bristol, Dept Child Hlth, Bristol, Avon, England; Univ Hosp Birmingham, Birmingham, W Midlands, England; Univ Paris 05, Fac Med, Hop Necker Enfants Malad, Paris, France; Univ Bergen, Dept Clin Med, Bergen, Norway; Haukeland Univ Hosp, Dept Pediat, N-5021 Bergen, Norway; Jagiellonian Univ, Coll Med, Dept Metab Dis, Krakow, Poland; Slovak Acad Sci, Inst Expt Endocrinol, Bratislava, Slovakia; Univ Chile, Sch Med, Inst Maternal & Child Res, Santiago, Chile; Med Univ, Varna, Bulgaria; Leiden Univ, Med Ctr, Dept Cardiol, Leiden, Netherlands; Univ Copenhagen, Panum Inst, Dept Med Physiol, DK-2200 Copenhagen, Denmark	University of Exeter; University of Dundee; University of Oxford; University of Bristol; University of Birmingham; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Bergen; University of Bergen; Haukeland University Hospital; Jagiellonian University; Collegium Medicum Jagiellonian University; Slovak Academy of Sciences; Universidad de Chile; Medical University Varna; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Copenhagen	Hattersley, AT (corresponding author), Peninsula Med Sch, Inst Biomed & Clin Sci, Barrack Rd, Exeter EX2 5DW, Devon, England.	andrew.hattersley@pms.ac.uk	Holst, Jens/AAA-8022-2022; Iotova, Violeta/AAO-2387-2021; Shield, Julian PH/D-6297-2014	Shield, Julian PH/0000-0003-2601-7575; Ellard, Sian/0000-0002-7620-5526; Flanagan, Sarah/0000-0002-8670-6340; Holst, Jens Juul/0000-0001-6853-3805; Pearson, Ewan/0000-0001-9237-8585; Iotova, Violeta/0000-0003-4160-1200; Jaap, Alan/0000-0001-8289-704X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ashcroft F, 2004, HUM MOL GENET, V13, pR21, DOI 10.1093/hmg/ddh066; Babenko AP, 2006, NEW ENGL J MED, V355, P456, DOI 10.1056/NEJMoa055068; Codner E, 2005, DIABETES CARE, V28, P758, DOI 10.2337/diacare.28.3.758; Flanagan SE, 2006, DIABETOLOGIA, V49, P1190, DOI 10.1007/s00125-006-0246-z; Freeman H, 2006, CELL METAB, V3, P35, DOI 10.1016/j.cmet.2005.10.008; Gloyn AL, 2004, NEW ENGL J MED, V351, P1470; Gloyn AL, 2004, J CLIN ENDOCR METAB, V89, P3932, DOI 10.1210/jc.2004-0568; Gloyn AL, 2005, HUM MOL GENET, V14, P925, DOI 10.1093/hmg/ddi086; Gloyn AL, 2004, NEW ENGL J MED, V350, P1838, DOI 10.1056/NEJMoa032922; Hattersley AT, 2005, DIABETES, V54, P2503, DOI 10.2337/diabetes.54.9.2503; HOLST JJ, 1982, BIOCHEM J, V207, P381, DOI 10.1042/bj2070381; Kennedy HJ, 1999, J BIOL CHEM, V274, P13281, DOI 10.1074/jbc.274.19.13281; Klupa T, 2005, DIABETOLOGIA, V48, P1029, DOI 10.1007/s00125-005-1731-5; Koster JC, 2005, DIABETES, V54, P2645, DOI 10.2337/diabetes.54.9.2645; KRARUP T, 1983, J CLIN ENDOCR METAB, V56, P1306, DOI 10.1210/jcem-56-6-1306; Maechler P, 1998, FEBS LETT, V422, P328, DOI 10.1016/S0014-5793(97)01618-9; Massa O, 2005, HUM MUTAT, V25, P22, DOI 10.1002/humu.20124; MUSCELLI E, IN PRESS AM J PHYSL; Nauck MA, 2004, REGUL PEPTIDES, V122, P209, DOI 10.1016/j.regpep.2004.06.020; ORSKOV C, 1994, DIABETES, V43, P535, DOI 10.2337/diabetes.43.4.535; Proks P, 2005, EMBO REP, V6, P470, DOI 10.1038/sj.embor.7400393; Proks P, 2004, P NATL ACAD SCI USA, V101, P17539, DOI 10.1073/pnas.0404756101; Proks P, 2006, HUM MOL GENET, V15, P1793, DOI 10.1093/hmg/ddl101; Rohlfing CL, 2002, DIABETES CARE, V25, P275, DOI 10.2337/diacare.25.2.275; Sagen JV, 2005, DIABETIC MED, V22, P406, DOI 10.1111/j.1464-5491.2005.01439.x; Sagen JV, 2004, DIABETES, V53, P2713, DOI 10.2337/diabetes.53.10.2713; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Slingerland AS, 2005, ANN MED, V37, P186, DOI 10.1080/07853890510007287; Stoffers DA, 1997, NAT GENET, V15, P106, DOI 10.1038/ng0197-106; Vaxillaire M, 2004, DIABETES, V53, P2719, DOI 10.2337/diabetes.53.10.2719; Zung A, 2004, J CLIN ENDOCR METAB, V89, P5504, DOI 10.1210/jc.2004-1241	31	678	723	0	37	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 3	2006	355	5					467	477		10.1056/NEJMoa061759	http://dx.doi.org/10.1056/NEJMoa061759			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	069FT	16885550	Bronze			2022-12-28	WOS:000239432500006
J	Lu, LF; Lind, EF; Gondek, DC; Bennett, KA; Gleeson, MW; Pino-Lagos, K; Scott, ZA; Coyle, AJ; Reed, JL; Van Snick, J; Strom, TB; Zheng, XX; Noelle, RJ				Lu, Li-Fan; Lind, Evan F.; Gondek, David C.; Bennett, Kathy A.; Gleeson, Michael W.; Pino-Lagos, Karina; Scott, Zachary A.; Coyle, Anthony J.; Reed, Jennifer L.; Van Snick, Jacques; Strom, Terry B.; Zheng, Xin Xiao; Noelle, Randolph J.			Mast cells are essential intermediaries in regulatory T-cell tolerance	NATURE			English	Article							GRANZYME-B; MICE; INDUCTION; KIT; INTERLEUKIN-9; ACTIVATION; EXPRESSION; REJECTION; RESPONSES; GROWTH	Contrary to the proinflammatory role of mast cells in allergic disorders, the results obtained in this study establish that mast cells are essential in CD4(+)CD25(+)Foxp3(+) regulatory T (T-Reg)-cell-dependent peripheral tolerance. Here we confirm that tolerant allografts, which are sustained owing to the immunosuppressive effects of T-Reg cells, acquire a unique genetic signature dominated by the expression of mast-cell-gene products. We also show that mast cells are crucial for allograft tolerance, through the inability to induce tolerance in mast-cell-deficient mice. High levels of interleukin (IL)-9 - a mast cell growth and activation factor - are produced by activated T-Reg cells, and IL-9 production seems important in mast cell recruitment to, and activation in, tolerant tissue. Our data indicate that IL-9 represents the functional link through which activated T-Reg cells recruit and activate mast cells to mediate regional immune suppression, because neutralization of IL-9 greatly accelerates allograft rejection in tolerant mice. Finally, immunohistochemical analysis clearly demonstrates the existence of this novel T-Reg - IL-9-mast cell relationship within tolerant allografts.	Dartmouth Med Sch, Dept Microbiol & Immunol, Lebanon, NH 03756 USA; Norris Cotton Canc Ctr, Lebanon, NH 03756 USA; Medimmune Inc, Dept Autoimmun & Inflammat, Gaithersburg, MD 20878 USA; Ludwig Inst Canc Res Brussels Branch, B-1200 Brussels, Belgium; Univ Louvain, Expt Med Unit, Brussels Branch, B-1200 Brussels, Belgium; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA	Dartmouth College; Norris Cotton Cancer Center; AstraZeneca; Medimmune; Universite Catholique Louvain; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Noelle, RJ (corresponding author), Dartmouth Med Sch, Dept Microbiol & Immunol, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	rjn@dartmouth.edu	Pino-Lagos, Karina/H-7581-2013; Pino-Lagos, Karina/C-9583-2017; Strom, Terry B./E-9268-2010	Pino-Lagos, Karina/0000-0002-4070-6169; Pino-Lagos, Karina/0000-0002-4070-6169; Strom, Terry B./0000-0002-7570-0736; Lind, Evan/0000-0001-7026-2012; Lu, Li-Fan/0000-0002-9727-0036				Benoist C, 2002, NATURE, V420, P875, DOI 10.1038/nature01324; Berrozpe G, 1999, BLOOD, V94, P2658, DOI 10.1182/blood.V94.8.2658.420k23_2658_2666; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Corti B, 2005, TRANSPL P, V37, P4467, DOI 10.1016/j.transproceed.2005.11.035; Galli SJ, 2005, ANNU REV IMMUNOL, V23, P749, DOI 10.1146/annurev.immunol.21.120601.141025; Galli SJ, 2005, NAT IMMUNOL, V6, P135, DOI 10.1038/ni1158; Gondek DC, 2005, J IMMUNOL, V174, P1783, DOI 10.4049/jimmunol.174.4.1783; Graca L, 2002, J EXP MED, V195, P1641, DOI 10.1084/jem.20012097; Grimbaldeston MA, 2005, AM J PATHOL, V167, P835, DOI 10.1016/S0002-9440(10)62055-X; Harada Akihisa, 1996, Methods (Orlando), V10, P166, DOI 10.1006/meth.1996.0091; Jarnicki AG, 2003, CURR OPIN PHARMACOL, V3, P449, DOI 10.1016/S1471-4892(03)00077-8; Jarvinen LZ, 2003, TRANSPLANTATION, V76, P1375, DOI 10.1097/01.TP.0000093462.16309.73; Khan WI, 2003, INFECT IMMUN, V71, P2430, DOI 10.1128/IAI.71.5.2430-2438.2003; Lee GK, 2002, IMMUNOLOGY, V107, P452, DOI 10.1046/j.1365-2567.2002.01526.x; Mesples B, 2005, NEUROBIOL DIS, V18, P193, DOI 10.1016/j.nbd.2004.09.018; Quezada SA, 2005, J IMMUNOL, V175, P771, DOI 10.4049/jimmunol.175.2.771; RAZIN E, 1990, METHOD ENZYMOL, V187, P514; Saitoh S, 2000, IMMUNITY, V12, P525, DOI 10.1016/S1074-7613(00)80204-6; Sakaguchi S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178; Shimizu J, 2002, NAT IMMUNOL, V3, P135, DOI 10.1038/ni759; Taylor PA, 2001, J EXP MED, V193, P1311, DOI 10.1084/jem.193.11.1311; Theoharides TC, 2004, TRENDS IMMUNOL, V25, P235, DOI 10.1016/j.it.2004.02.013; Tone M, 2003, P NATL ACAD SCI USA, V100, P15059, DOI 10.1073/pnas.2334901100; Townsend MJ, 2000, IMMUNITY, V13, P573, DOI 10.1016/S1074-7613(00)00056-X; VANSNICK J, 1989, J EXP MED, V169, P363, DOI 10.1084/jem.169.1.363; Wang HW, 1998, J CLIN INVEST, V102, P1617, DOI 10.1172/JCI3704; Wedemeyer J, 2005, LAB INVEST, V85, P388, DOI 10.1038/labinvest.3700232; YAMAZAKI M, 1994, BLOOD, V83, P3509; Zelenika D, 2001, IMMUNOL REV, V182, P164, DOI 10.1034/j.1600-065X.2001.1820113.x; Zhou YH, 2001, RESP RES, V2, P80, DOI 10.1186/rr42	30	601	632	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 31	2006	442	7106					997	1002		10.1038/nature05010	http://dx.doi.org/10.1038/nature05010			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	078YF	16921386				2022-12-28	WOS:000240142000039
J	Thompson, BJ; Cohen, SM				Thompson, Barry J.; Cohen, Stephen M.			The hippo pathway regulates the bantam microRNA to control cell proliferation and apoptosis in Drosophila	CELL			English	Article							PROMOTES APOPTOSIS; TUMOR-SUPPRESSOR; CYCLE EXIT; ENCODES; SALVADOR; GROWTH; EYE; MORPHOGENS; HOMOLOG; PATTERN	The Hippo signaling pathway acts upon the Yorkie transcriptional activator to control tissue growth in Drosophila. Activated Yorkie drives growth by stimulating cell proliferation and inhibiting apoptosis, but how it achieves this is not understood. Yorkie is known to activate Cyclin E (CycE) and the apoptosis inhibitor DIAP1. However, overexpression of these targets is not sufficient to cause tissue overgrowth. Here we show that Yorkie also activates expression of the bantam microRNA, a known regulator of both proliferation and apoptosis. bantam overexpression mimics Yorkie activation while loss of bantam function slows the rate of cell proliferation. bantam is necessary for Yorkie-induced overproliferation and bantam overexpression is sufficient to rescue survival and proliferation of yorkie mutant cells. Finally, we show that bantam levels are regulated during both developmentally programmed proliferation arrest and apoptosis. In summary, the results show that the Hippo pathway regulates expression of bantam to control tissue growth in Drosophila.	European Mol Biol Lab, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Cohen, SM (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.	cohen@embl.de	Cohen, Stephen M/G-9930-2011	Cohen, Stephen M/0000-0003-2858-9163; Thompson, Barry/0000-0002-0103-040X				Brachmann CB, 2003, TRENDS GENET, V19, P91, DOI 10.1016/S0168-9525(02)00041-0; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; Duffy JB, 2002, GENESIS, V34, P1, DOI 10.1002/gene.10150; Edgar BA, 2006, CELL, V124, P267, DOI 10.1016/j.cell.2006.01.005; FREEMAN M, 1992, CELL, V69, P963, DOI 10.1016/0092-8674(92)90615-J; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Hamaratoglu F, 2006, NAT CELL BIOL, V8, P27, DOI 10.1038/ncb1339; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harvey KF, 2003, CELL, V114, P457, DOI 10.1016/S0092-8674(03)00557-9; Hipfner DR, 2002, GENETICS, V161, P1527; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; Kango-Singh M, 2002, DEVELOPMENT, V129, P5719, DOI 10.1242/dev.00168; Lai ZC, 2005, CELL, V120, P675, DOI 10.1016/j.cell.2004.12.036; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; Lee TM, 2001, TRENDS NEUROSCI, V24, P251, DOI 10.1016/S0166-2236(00)01791-4; Lin HV, 2004, DEVELOPMENT, V131, P2409, DOI 10.1242/dev.01104; MORATA G, 1975, DEV BIOL, V42, P211, DOI 10.1016/0012-1606(75)90330-9; Neumann C, 1997, BIOESSAYS, V19, P721, DOI 10.1002/bies.950190813; Pantalacci S, 2003, NAT CELL BIOL, V5, P921, DOI 10.1038/ncb1051; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Udan RS, 2003, NAT CELL BIOL, V5, P914, DOI 10.1038/ncb1050; Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; Wu S, 2003, CELL, V114, P445, DOI 10.1016/S0092-8674(03)00549-X	26	318	327	2	33	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 25	2006	126	4					767	774		10.1016/j.cell.2006.07.013	http://dx.doi.org/10.1016/j.cell.2006.07.013			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	080VN	16923395	Bronze			2022-12-28	WOS:000240276700024
J	Diehm, N; Baumgartner, I				Diehm, Nicolas; Baumgartner, Iris			ACE inhibitors and abdominal aortic aneurysm	LANCET			English	Editorial Material							ANGIOTENSIN-II; ATHEROSCLEROSIS; STATEMENT		Univ Hosp Bern, Swiss Cardiovasc Ctr, CH-3010 Bern, Switzerland	University of Bern; University Hospital of Bern	Baumgartner, I (corresponding author), Univ Hosp Bern, Swiss Cardiovasc Ctr, CH-3010 Bern, Switzerland.	iris.baumgartner@insel.ch						Barba A, 2005, EUR J VASC ENDOVASC, V30, P504, DOI 10.1016/j.ejvs.2005.05.011; Calonge N, 2005, ANN INTERN MED, V142, P198, DOI 10.7326/0003-4819-142-3-200502010-00011; Claridge MW, 2004, EUR J VASC ENDOVASC, V28, P67, DOI 10.1016/j.ejvs.2004.01.021; Cornuz J, 2004, EUR J PUBLIC HEALTH, V14, P343, DOI 10.1093/eurpub/14.4.343; da Cunha V, 2005, ATHEROSCLEROSIS, V178, P9, DOI 10.1016/j.atherosclerosis.2004.08.023; Daugherty A, 2004, CURR HYPERTENS REP, V6, P442, DOI 10.1007/s11906-004-0038-0; Diehm N, 2005, VASA-J VASCULAR DIS, V34, P217, DOI 10.1024/0301-1526.34.4.217; Hackam DG, 2006, LANCET, V368, P659, DOI 10.1016/S0140-6736(06)69250-7; Kent KC, 2004, J VASC SURG, V39, P267, DOI 10.1016/j.jvs.2003.08.019; Klevay LM, 1996, ANN NY ACAD SCI, V800, P239, DOI 10.1111/j.1749-6632.1996.tb33317.x; Lederle FA, 2000, ARCH INTERN MED, V160, P1425, DOI 10.1001/archinte.160.10.1425; Liao SX, 2001, J VASC SURG, V33, P1057, DOI 10.1067/mva.2001.112810; Van Vickle-Chavez SJ, 2006, J VASC SURG, V43, P1010, DOI 10.1016/j.jvs.2006.01.004	13	14	15	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 19	2006	368	9536					622	623		10.1016/S0140-6736(06)69221-0	http://dx.doi.org/10.1016/S0140-6736(06)69221-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	074YT	16920448				2022-12-28	WOS:000239849200005
J	Hackam, DG; Thiruchelvam, D; Redelmeier, DA				Hackam, Daniel G.; Thiruchelvam, Deva; Redelmeier, Donald A.			Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case-control study	LANCET			English	Article							II-INDUCED ATHEROSCLEROSIS; ELDERLY-PATIENTS; COMORBIDITY ADJUSTMENT; ADMINISTRATIVE DATA; ACE-INHIBITORS; HEART-FAILURE; ANEURYSM; DISEASE; RISK; GENOTYPE	Background Angiotensin-converting enzyme (ACE) inhibitors prevent the expansion and rupture of aortic aneurysms in animals. We investigated the association between ACE inhibitors and rupture in patients with abdominal aortic aneurysms. Methods We did a population-based case-control study of linked administrative databases in Ontario, Canada. The sample included consecutive patients older than 65 (n=15326) admitted to hospital with a primary diagnosis of ruptured or intact abdominal aortic aneurysm between April 1, 1992, and April 1, 2002. Findings Patients who received ACE inhibitors before admission were significantly less likely to present with ruptured aneurysm (odds ratio [OR] 0.82, 95% CI 0.74-0.90) than those who did not receive ACE inhibitors. Adjustment for demographic characteristics, risk factors for rupture, comorbidities, contraindications to ACE inhibitors, measures of health-care use, and aneurysm screening yielded similar results (0.83, 0.73-0.95). Consistent findings were noted in subgroups at high risk of rupture, including patients older than 75 years and those with a history of hypertension. Conversely, such protective associations were not observed for beta blockers (1.02, 0.89-1.17), calcium channel blockers (1.01, 0.89-1.14), alpha blockers (1.15, 0.86-1.54), angiotensin receptor blockers (1.24, 0.71-2.18), or thiazide diuretics (0.91, 0.78-1.07). Interpretation ACE inhibitors are associated with a reduced risk of ruptured abdominal aortic aneurysm, unlike other antihypertensive agents. Randomised trials of ACE inhibitors for prevention of aortic rupture might be warranted.	Univ Toronto, Dept Hlth Policy Management & Evaluat, Clin Epidemiol & Hlth Care Res Program, Toronto, ON, Canada; Univ Toronto, Dept Med, Div Gen Internal Med, Toronto, ON, Canada; Inst Clin Evaluat Sci, Toronto, ON, Canada; Toronto Rehabil Inst, Secondary Prevent & Cardiac Rehabil Program, Toronto, ON, Canada; Sunnybrook Hlth Sci Ctr, Patient Safety Serv, Toronto, ON M4N 3M5, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto Rehabilitation Institute; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Hackam, DG (corresponding author), Sunnybrook Hlth Sci Ctr, Patient Safety Serv, Room G-157,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	daniel.hackam@ices.on.ca	Hackam, Dan G/A-1143-2009					Adam DJ, 1999, J VASC SURG, V30, P922, DOI 10.1016/S0741-5214(99)70018-2; Ahimastos AA, 2005, HYPERTENSION, V45, P1194, DOI 10.1161/01.HYP.0000168945.44069.aa; Alter DA, 1999, NEW ENGL J MED, V341, P1359, DOI 10.1056/NEJM199910283411806; Austin PC, 2002, AM HEART J, V144, P290, DOI 10.1067/mhj.2002.123839; BENGTSSON H, 1993, J VASC SURG, V18, P74, DOI 10.1067/mva.1993.42107; Bown MJ, 2002, BRIT J SURG, V89, P714, DOI 10.1046/j.1365-2168.2002.02122.x; Brown LC, 1999, ANN SURG, V230, P289, DOI 10.1097/00000658-199909000-00002; Cassis LA, 2005, BRIT J PHARMACOL, V144, P443, DOI 10.1038/sj.bjp.0706098; Chan B., 1999, SUPPLY PHYS SERVICES; Chen JQ, 2001, CIRCULATION, V104, P2391, DOI 10.1161/hc4501.099729; Claridge MW, 2004, EUR J VASC ENDOVASC, V28, P67, DOI 10.1016/j.ejvs.2004.01.021; CRONENWETT JL, 1985, SURGERY, V98, P472; da Cunha V, 2005, ATHEROSCLEROSIS, V178, P9, DOI 10.1016/j.atherosclerosis.2004.08.023; DARLING RC, 1977, CIRCULATION, V56, P161; Daugherty A, 2004, CURR HYPERTENS REP, V6, P442, DOI 10.1007/s11906-004-0038-0; Fatini C, 2005, EUR J VASC ENDOVASC, V29, P227, DOI 10.1016/j.ejvs.2004.12.018; Greenhalgh RM, 2000, EUR J VASC ENDOVASC, V19, P636; Huang W, 1998, CIRC RES, V82, P879; Huber TS, 2001, J VASC SURG, V33, P304, DOI 10.1067/mva.2001.112703; Ihara M, 1999, HYPERTENSION, V33, P1399, DOI 10.1161/01.HYP.33.6.1399; Jacoby DS, 2003, ARCH INTERN MED, V163, P1155, DOI 10.1001/archinte.163.10.1155; Juurlink DN, 2004, NEW ENGL J MED, V351, P543, DOI 10.1056/NEJMoa040135; Juurlink DN, 2003, JAMA-J AM MED ASSOC, V289, P1652, DOI 10.1001/jama.289.13.1652; Keramatipour M, 2000, J MED GENET, V37, P498, DOI 10.1136/jmg.37.7.498; Laupacis A, 2002, J VASC SURG, V35, P72, DOI 10.1067/mva.2002.121308; Lederle FA, 2000, ARCH INTERN MED, V160, P1425, DOI 10.1001/archinte.160.10.1425; Lederle FA, 2001, J VASC SURG, V34, P122, DOI 10.1067/mva.2001.115275; Levy Adrian R, 2003, Can J Clin Pharmacol, V10, P67; Liao SX, 2001, J VASC SURG, V33, P1057, DOI 10.1067/mva.2001.112810; Lindholt JS, 2005, BMJ-BRIT MED J, V330, P750, DOI 10.1136/bmj.38369.620162.82; Lindholt JS, 1999, INT ANGIOL, V18, P52; Lopez-Sendon J, 2004, EUR HEART J, V25, P1454, DOI 10.1016/j.ehj.2004.06.003; MACSWEENEY STR, 1994, LANCET, V344, P651, DOI 10.1016/S0140-6736(94)92087-7; Mamdani M, 2004, LANCET, V363, P1751, DOI 10.1016/S0140-6736(04)16299-5; Nagashima H, 2002, J VASC SURG, V36, P818, DOI 10.1067/mva.2002.126091; Naylor CD, 1999, CARDIOVASCULAR HLTH; Nishimoto M, 2002, LIFE SCI, V71, P2195, DOI 10.1016/S0024-3205(02)01998-7; OSBORNEPELLEGRIN MJ, 1994, INT J EXP PATHOL, V75, P179; Pola R, 2001, EUR J VASC ENDOVASC, V21, P445, DOI 10.1053/ejvs.2001.1339; Powell JT, 2001, ACTA CHIR BELG, V101, P11; Redelmeier DA, 2005, BRIT MED J, V331, P932, DOI 10.1136/bmj.38603.746944.3A; Rochon PA, 2004, J GEN INTERN MED, V19, P676, DOI 10.1111/j.1525-1497.2004.30328.x; Sakomura Y, 1999, CIRCULATION, V100, P319; Schneeweiss S, 2000, INT J EPIDEMIOL, V29, P891, DOI 10.1093/ije/29.5.891; Schneeweiss S, 2004, J GEN INTERN MED, V19, P444, DOI 10.1111/j.1525-1497.2004.30109.x; Schneeweiss S, 2003, HEALTH SERV RES, V38, P1103, DOI 10.1111/1475-6773.00165; Slowik A, 2004, STROKE, V35, P1594, DOI 10.1161/01.STR.0000131655.45227.f7; Steinmetz Eric F, 2003, Vasc Endovascular Surg, V37, P151, DOI 10.1177/153857440303700301; STERPETTI AV, 1991, SURG GYNECOL OBSTET, V173, P175; STRACHAN DP, 1991, BRIT J SURG, V78, P401, DOI 10.1002/bjs.1800780407; Takeda K, 1997, NEPHROL DIAL TRANSPL, V12, P952, DOI 10.1093/ndt/12.5.952; Takenaka K, 1998, NEUROL RES, V20, P607; Takeuchi K, 1997, EUR J PEDIATR, V156, P266, DOI 10.1007/s004310050597; Tham DM, 2002, AM J PHYSIOL-REG I, V283, pR1442, DOI 10.1152/ajpregu.00295.2002; Tsunemi K, 2002, HYPERTENS RES, V25, P817; Wilmink A.B.M., 2002, BRIT J SURG, V87, P499, DOI [10.1046/j.1365-2168.2000.01420-23.x, DOI 10.1046/J.1365-2168.2000.01420-23.X]; Wilmink ABM, 2003, J VASC SURG, V38, P72, DOI 10.1016/S0741-5214(03)00135-6; WOLF YG, 1994, J VASC SURG, V20, P529, DOI 10.1016/0741-5214(94)90277-1; *WRIT COMM DEV GUI, 2005, CIRCULATION, V113, P463	59	219	233	2	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 19	2006	368	9536					659	665		10.1016/S0140-6736(06)69250-7	http://dx.doi.org/10.1016/S0140-6736(06)69250-7			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	074YT	16920471				2022-12-28	WOS:000239849200033
J	Teo, KK; Ounpuu, S; Hawken, S; Pandey, MR; Valentin, V; Hunt, D; Diaz, R; Rashed, W; Freeman, R; Jiang, LX; Zhang, XF; Yusuf, S				Teo, Koon K.; Ounpuu, Stephanie; Hawken, Steven; Pandey, M. R.; Valentin, Vicent; Hunt, David; Diaz, Rafael; Rashed, Wafa; Freeman, Rosario; Jiang, Lixin; Zhang, Xiaofei; Yusuf, Salim		INTERHEART Study Investigators	Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study	LANCET			English	Article							CORONARY-HEART-DISEASE; MIDDLE-AGED MEN; SMOKELESS TOBACCO; ATTRIBUTABLE RISKS; CIGARETTE-SMOKING; PASSIVE SMOKING; UNITED-STATES; MORTALITY; HEALTH; POPULATION	Background Tobacco use is one of the major avoidable causes of cardiovascular diseases. We aimed to assess the risks associated with tobacco use (both smoking and non-smoking) and second hand tobacco smoke (SHS) worldwide. Methods We did a standardised case-control study of acute myocardial infarction (AMI) with 27089 participants in 52 countries (12461 cases, 14637 controls). We assessed relation between risk of AMI and current or former smoking, type of tobacco, amount smoked, effect of smokeless tobacco, and exposure to SHS. We controlled for confounders such as differences in lifestyles between smokers and non-smokers. Findings Current smoking was associated with a greater risk of non-fatal AMI (odds ratio [OR] 2.95, 95% CI 2.77-3.14, p<0.0001) compared with never smoking; risk increased by 5.6% for every additional cigarette smoked. The OR associated with former smoking fell to 1.87 (95% CI 1.55-2.24) within 3 years of quitting. A residual excess risk remained 20 or more years after quitting (1.22, 1.09-1.37). Exclusion of individuals exposed to SHS in the never smoker reference group raised the risk in former smokers by about 10%. Smoking beedies alone (indigenous to South Asia) was associated with increased risk (2.89, 2.11-3.96) similar to that associated with cigarette smoking. Chewing tobacco alone was associated with OR 2.23 (1.41-3.52), and smokers who also chewed tobacco had the highest increase in risk (4.09, 2.98-5.61). SHS was associated with a graded increase in risk related to exposure; OR was 1.24 (1.17-1.32) in individuals who were least exposed (1-7 h per week) and 1.62 (1.45-1.81) in people who were most exposed (>21 h per week). Young male current smokers had the highest population attributable risk (58.3%; 95% CI 55.0-61.6) and older women the lowest (6.2%, 4.1-9.2). Population attributable risk for exposure to SHS for more than l h per week in never smokers was 15.4% (12.1-19.3). Conclusion Tobacco use is one of the most important causes of AMI globally, especially in men. All forms of tobacco use, including different types of smoking and chewing tobacco and inhalation of SHS, should be discouraged to prevent cardiovascular diseases.	McMaster Univ, Hamilton Hlth Sci, Populat Hlth Res Inst, Hamilton, ON L8L 2X2, Canada; Nepal Hlth Res Council, Kathmandu, Nepal; Hosp Univ Dr Peset, Valencia, Spain; Univ Melbourne, Royal Melbourne Hosp, Melbourne, Vic 3050, Australia; Inst Cardiovasc Rosario, Dept Cardiol, Rosario, Santa Fe, Argentina; Kuwait Univ, Kuwait, Kuwait; Univ Washington, Seattle, WA 98195 USA; Cardiovasc Inst, Beijing, Peoples R China	McMaster University; Population Health Research Institute; Royal Melbourne Hospital; University of Melbourne; Kuwait University; University of Washington; University of Washington Seattle	Yusuf, S (corresponding author), McMaster Univ, Hamilton Hlth Sci, Populat Hlth Res Inst, Hamilton, ON L8L 2X2, Canada.	yusufs@mcmaster.ca		Hawken, Steven/0000-0002-3341-9022; Yusuf, Salim/0000-0003-4776-5601				*AUSTR I HLTH WELF, 2002, DRUG STAT SER, V9; Bolinder G, 1997, ATHEROSCLEROSIS, V132, P95, DOI 10.1016/S0021-9150(97)00075-0; Bolinder G, 1998, AM J HYPERTENS, V11, P1153, DOI 10.1016/S0895-7061(98)00137-X; BOLINDER G, 1994, AM J PUBLIC HEALTH, V84, P399, DOI 10.2105/AJPH.84.3.399; Chen ZM, 1997, JAMA-J AM MED ASSOC, V278, P1500, DOI 10.1001/jama.278.18.1500; Diethelm PA, 2005, LANCET, V366, P86, DOI 10.1016/S0140-6736(05)66474-4; Doll R, 2004, BMJ-BRIT MED J, V328, P1519, DOI 10.1136/bmj.38142.554479.AE; Engel LS, 2003, J NATL CANCER I, V95, P1404, DOI 10.1093/jnci/djg047; Glantz S.A., 1996, CIGARETTE PAPERS; GUINDON GE, 2003, PAST CURRENT FUTURE; Gupta P C, 1996, Tob Control, V5, P114, DOI 10.1136/tc.5.2.114; Gupta PC, 2000, B WORLD HEALTH ORGAN, V78, P877; He J, 1999, NEW ENGL J MED, V340, P920, DOI 10.1056/NEJM199903253401204; Henley SJ, 2005, CANCER CAUSE CONTROL, V16, P347, DOI 10.1007/s10552-004-5519-6; Hergens MP, 2005, EPIDEMIOLOGY, V16, P12, DOI 10.1097/01.ede.0000147108.92895.ba; Huhtasaari F, 1999, J AM COLL CARDIOL, V34, P1784, DOI 10.1016/S0735-1097(99)00409-X; Kataria, 2016, SAUDI J SPORTS MED, V16, P139; KIYOHARA Y, 1990, J HYPERTENS, V8, pS9; Kumra V, 2000, CLIN CHEST MED, V21, P1, DOI 10.1016/S0272-5231(05)70004-6; Lam TH, 1997, JAMA-J AM MED ASSOC, V278, P1505, DOI 10.1001/jama.278.18.1505; Law MR, 2003, PROG CARDIOVASC DIS, V46, P31, DOI 10.1016/S0033-0620(03)00078-1; Lightwood JM, 1997, CIRCULATION, V96, P1089, DOI 10.1161/01.CIR.96.4.1089; Mackay J, 1998, PUBLIC HEALTH REP, V113, P14; Mackay J, 2002, TOBACCO ATLAS; McKee M, 2000, EUR J PUBLIC HEALTH, V10, P161, DOI 10.1093/eurpub/10.3.161; McKee M, 1998, TOB CONTROL, V7, P22, DOI 10.1136/tc.7.1.22; NEGRI E, 1995, PREV MED, V24, P603, DOI 10.1006/pmed.1995.1095; Ounpuu S, 2001, AM HEART J, V141, P711, DOI 10.1067/mhj.2001.114974; PARISH S, 1995, BMJ-BRIT MED J, V311, P471, DOI 10.1136/bmj.311.7003.471; Pechacek TF, 2003, EVIDENCE BASED CARDI, P103; Peto RLA, 2001, CRITICAL ISSUES GLOB; Rani M, 2003, Tob Control, V12, pe4, DOI 10.1136/tc.12.4.e4; *SCOTH, SEC SMOK REV EV 1998; Subramanian SV, 2004, BMJ-BRIT MED J, V328, P801, DOI 10.1136/bmj.328.7443.801; Thun M, 2003, TOBACCO CONTROL COUN; WALTER SD, 1975, BIOMETRIKA, V62, P371, DOI 10.1093/biomet/62.2.371; Whincup PH, 2004, BRIT MED J, V329, P200, DOI 10.1136/bmj.38146.427188.55; *WHO, 1997, SMOK CHIN TIM BOMB 2; WOODWARD M, 1992, EUR HEART J, V13, P160, DOI 10.1093/oxfordjournals.eurheartj.a060140; World Bank, 1999, CURB EP GOV EC TOB C; World Health Organization, 2003, WHO FRAM CONV TOB CO; Yang GH, 1999, JAMA-J AM MED ASSOC, V282, P1247, DOI 10.1001/jama.282.13.1247; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9	43	671	713	3	82	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 19	2006	368	9536					647	658		10.1016/S0140-6736(06)69249-0	http://dx.doi.org/10.1016/S0140-6736(06)69249-0			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	074YT	16920470				2022-12-28	WOS:000239849200032
J	Helms, B; Meijer, EW				Helms, Brett; Meijer, E. W.			Dendrimers at work	SCIENCE			English	Editorial Material							POLYAMIDOAMINE DENDRIMERS; DENDRITIC MACROMOLECULES; IN-VITRO; POLYMERS; TRANSFECTION; MOLECULES; DELIVERY		Eindhoven Univ Technol, Lab Macromol & Organ Chem, NL-5600 MB Eindhoven, Netherlands; Eindhoven Univ Technol, Dept Biomed Engn, NL-5600 MB Eindhoven, Netherlands	Eindhoven University of Technology; Eindhoven University of Technology	Meijer, EW (corresponding author), Eindhoven Univ Technol, Lab Macromol & Organ Chem, NL-5600 MB Eindhoven, Netherlands.	e.w.meijer@tue.nl	Meijer, E.W./K-7632-2013	Meijer, E.W./0000-0003-4126-7492; Helms, Brett/0000-0003-3925-4174				Altinier S, 2000, CLIN CHEM, V46, P991; De Brabander-van den Berg E.M.M., 1993, ANGEW CHEM INT EDIT, V105, P1370; Denkewalter R.G., 1981, US. Patent, Patent No. [4 289 872, 4289872, 4,289,872]; Flory PJ, 1941, J AM CHEM SOC, V63, P3083, DOI 10.1021/ja01856a061; Froehling P, 2004, J POLYM SCI POL CHEM, V42, P3110, DOI 10.1002/pola.20113; GRIES H, 1990, Patent No. 4957939; HAENSLER J, 1993, BIOCONJUGATE CHEM, V4, P372, DOI 10.1021/bc00023a012; HAWKER CJ, 1990, J AM CHEM SOC, V112, P7638, DOI 10.1021/ja00177a027; Hudde T, 1999, GENE THER, V6, P939, DOI 10.1038/sj.gt.3300886; JANSEN JFGA, 1994, SCIENCE, V266, P1226, DOI 10.1126/science.266.5188.1226; Jiang YH, 2005, AIDS RES HUM RETROV, V21, P207, DOI 10.1089/aid.2005.21.207; Ma DG, 2002, APPL PHYS LETT, V81, P2285, DOI 10.1063/1.1507826; Malik N, 2000, J CONTROL RELEASE, V65, P133, DOI 10.1016/S0168-3659(99)00246-1; Mynar JL, 2006, J AM CHEM SOC, V128, P6334, DOI 10.1021/ja061735s; NEWKOME GR, 1985, J ORG CHEM, V50, P2003, DOI 10.1021/jo00211a052; Smith DK, 2006, CHEM COMMUN, P34, DOI 10.1039/b507416a; Tack F, 2006, J DRUG TARGET, V14, P69, DOI 10.1080/10611860600635665; Tang MX, 1996, BIOCONJUGATE CHEM, V7, P703, DOI 10.1021/bc9600630; TOMALIA DA, 1985, POLYM J, V17, P117, DOI 10.1295/polymj.17.117; Tomalia DA, 2006, U.S. Patents, Patent No. 7005124; Yin R., 2001, POLYM MAT SCI ENG, V84, P856; Zhou JH, 2006, CHEM COMMUN, P2362, DOI 10.1039/b601381c	22	180	184	1	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 18	2006	313	5789					929	930		10.1126/science.1130639	http://dx.doi.org/10.1126/science.1130639			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	074MR	16917051				2022-12-28	WOS:000239817000031
J	Musevic, I; Skarabot, M; Tkalec, U; Ravnik, M; Zumer, S				Musevic, Igor; Skarabot, Miha; Tkalec, Uros; Ravnik, Miha; Zumer, Slobodan			Two-dimensional nematic colloidal crystals self-assembled by topological defects	SCIENCE			English	Article								The ability to generate regular spatial arrangements of particles is an important technological and fundamental aspect of colloidal science. We showed that colloidal particles confined to a few-micrometer-thick layer of a nematic liquid crystal form two-dimensional crystal structures that are bound by topological defects. Two basic crystalline structures were observed, depending on the ordering of the liquid crystal around the particle. Colloids inducing quadrupolar order crystallize into weakly bound two-dimensional ordered structure, where the particle interaction is mediated by the sharing of localized topological defects. Colloids inducing dipolar order are strongly bound into antiferroelectric-like two-dimensional crystallites of dipolar colloidal chains. Self-assembly by topological defects could be applied to other systems with similar symmetry.	Jozef Stefan Inst, Ljubljana 1000, Slovenia; Univ Ljubljana, Fac Math & Phys, Ljubljana 1000, Slovenia	Slovenian Academy of Sciences & Arts (SASA); Jozef Stefan Institute; University of Ljubljana	Musevic, I (corresponding author), Jozef Stefan Inst, Jamova 39, Ljubljana 1000, Slovenia.	igor.musevic@ijs.si	Zumer, Slobodan/K-2840-2018; Ravnik, Miha/F-3616-2011; Tkalec, Uroš/C-6386-2011	Zumer, Slobodan/0000-0003-4872-9530; Ravnik, Miha/0000-0001-8883-9318; Tkalec, Uroš/0000-0003-0552-0518				Aoki K, 2003, NAT MATER, V2, P117, DOI 10.1038/nmat802; Araki T, 2006, J PHYS-CONDENS MAT, V18, pL193, DOI 10.1088/0953-8984/18/15/L05; Chiou PY, 2005, NATURE, V436, P370, DOI [10.1038/nature03831, 10.1038/nature0383l]; de Gennes P. G., 1993, PHYS LIQUID CRYSTALS; de Villeneuve VWA, 2005, SCIENCE, V309, P1231, DOI 10.1126/science.1113207; Lavrentovich OD, 1998, LIQ CRYST, V24, P117, DOI 10.1080/026782998207640; Loudet JC, 2000, NATURE, V407, P611, DOI 10.1038/35036539; Loudet JC, 2001, PHYS REV LETT, V87, part. no., DOI 10.1103/PhysRevLett.87.165503; Lubensky TC, 1998, PHYS REV E, V57, P610, DOI 10.1103/PhysRevE.57.610; Meeker SP, 2000, PHYS REV E, V61, pR6083, DOI 10.1103/PhysRevE.61.R6083; Nazarenko VG, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.075504; Noda S., 2003, ROADMAP PHOTONIC CRY; Poulin P, 1997, SCIENCE, V275, P1770, DOI 10.1126/science.275.5307.1770; Poulin P, 1998, PHYS REV E, V57, P626, DOI 10.1103/PhysRevE.57.626; Press W., 1986, NUMERICAL RECIPES; Skarabot M, 2006, PHYS REV E, V73, DOI 10.1103/PhysRevE.73.021705; Smalyukh II, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.157801; Smalyukh II, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.117801; Stark H, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.032701; Stark H, 2001, PHYS REP, V351, P387, DOI 10.1016/S0370-1573(00)00144-7; vanBlaaderen A, 1997, NATURE, V385, P321, DOI 10.1038/385321a0; Yada M, 2002, LANGMUIR, V18, P7436, DOI 10.1021/la025757d; Yada M, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.185501; YUEDONG NG, 2000, PHYS REV LETT, V85, P4719; Zapotocky M, 1999, SCIENCE, V283, P209, DOI 10.1126/science.283.5399.209	25	640	643	11	251	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 18	2006	313	5789					954	958		10.1126/science.1129660	http://dx.doi.org/10.1126/science.1129660			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	074MR	16917058				2022-12-28	WOS:000239817000039
J	Rakic, P				Rakic, Pasko			No more cortical neurons for you	SCIENCE			English	Editorial Material							NEUROGENESIS; NEOCORTEX; CORTEX; CELLS		Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT 06520 USA	Yale University	Rakic, P (corresponding author), Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT 06520 USA.	pasko.rakic@yale.edun						ANGEVINE JB, 1961, NATURE, V192, P766, DOI 10.1038/192766b0; Bhardwaj RD, 2006, P NATL ACAD SCI USA, V103, P12564, DOI 10.1073/pnas.0605177103; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Gould E, 1999, SCIENCE, V286, P548, DOI 10.1126/science.286.5439.548; Kempermann G, 2006, ADULT NEUROGENESIS; Koketsu D, 2003, J NEUROSCI, V23, P937; Kornack DR, 2001, P NATL ACAD SCI USA, V98, P4752, DOI 10.1073/pnas.081074998; Kornack DR, 1999, P NATL ACAD SCI USA, V96, P5768, DOI 10.1073/pnas.96.10.5768; Kornack DR, 2001, SCIENCE, V294, P2127, DOI 10.1126/science.1065467; LUSKIN MB, 1985, J COMP NEUROL, V242, P611, DOI 10.1002/cne.902420409; Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083; Nowakowski R S, 2000, Science, V288, P771; RAKIC P, 1974, SCIENCE, V183, P425, DOI 10.1126/science.183.4123.425; Rakic P, 2002, NAT REV NEUROSCI, V3, P65, DOI 10.1038/nrn700; RAKIC P, 1985, SCIENCE, V227, P1054, DOI 10.1126/science.3975601; Sanai N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301; Shen Q, 2006, NAT NEUROSCI, V9, P743, DOI 10.1038/nn1694; Spalding KL, 2005, CELL, V122, P133, DOI 10.1016/j.cell.2005.04.028	18	47	48	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 18	2006	313	5789					928	929		10.1126/science.1131713	http://dx.doi.org/10.1126/science.1131713			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	074MR	16917050				2022-12-28	WOS:000239817000030
J	Leininger, S; Urich, T; Schloter, M; Schwark, L; Qi, J; Nicol, GW; Prosser, JI; Schuster, SC; Schleper, C				Leininger, S.; Urich, T.; Schloter, M.; Schwark, L.; Qi, J.; Nicol, G. W.; Prosser, J. I.; Schuster, S. C.; Schleper, C.			Archaea predominate among ammonia-oxidizing prokaryotes in soils	NATURE			English	Article							REAL-TIME PCR; 16S RIBOSOMAL-RNA; POPULATION-SIZE; BACTERIA; CRENARCHAEOTA; DIVERSITY; LIPIDS; TERRESTRIAL; QUANTIFICATION; AMOA	Ammonia oxidation is the first step in nitrification, a key process in the global nitrogen cycle that results in the formation of nitrate through microbial activity(1,2). The increase in nitrate availability in soils is important for plant nutrition, but it also has considerable impact on groundwater pollution owing to leaching. Here we show that archaeal ammonia oxidizers are more abundant in soils than their well-known bacterial counterparts. We investigated the abundance of the gene encoding a subunit of the key enzyme ammonia monooxygenase (amoA) in 12 pristine and agricultural soils of three climatic zones. amoA gene copies of Crenarchaeota ( Archaea) were up to 3,000-fold more abundant than bacterial amoA genes. High amounts of crenarchaeota-specific lipids, including crenarchaeol, correlated with the abundance of archaeal amoA gene copies. Furthermore, reverse transcription quantitative PCR studies and complementary DNA analysis using novel cloning-independent pyrosequencing technology demonstrated the activity of the archaea in situ and supported the numerical dominance of archaeal over bacterial ammonia oxidizers. Our results indicate that crenarchaeota may be the most abundant ammonia-oxidizing organisms in soil ecosystems on Earth.	Univ Bergen, Dept Biol, N-5020 Bergen, Norway; GSF Natl Res Ctr Environm & Hlth, Inst Soil Ecol, D-85764 Neuherberg, Germany; Univ Cologne, Inst Geol & Mineral, D-50674 Cologne, Germany; Penn State Univ, Ctr Comparat Genom & Bioinformat, University Pk, PA 16802 USA; Univ Aberdeen, Sch Biol Sci, Aberdeen AB24 3UU, Scotland	University of Bergen; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Cologne; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Aberdeen	Schleper, C (corresponding author), Univ Bergen, Dept Biol, Jahnebakken 5, N-5020 Bergen, Norway.	christa.schleper@bio.uib.no	Nicol, Graeme/E-4902-2011; Schleper, Christa M/C-2567-2013; Prosser, Jim/F-5280-2010; Schloter, 1Michael/H-9151-2013; Nicol, Graeme/AFM-9614-2022; Urich, Tim/C-2887-2013; Schwark, Lorenz/AAF-1902-2021; QI, JI/E-2797-2016; Urich, Tim/J-8241-2016	Nicol, Graeme/0000-0002-3876-022X; Prosser, Jim/0000-0003-1757-5102; Nicol, Graeme/0000-0002-3876-022X; Urich, Tim/0000-0002-5718-1354; Schwark, Lorenz/0000-0003-0683-0817; Schleper, Christa/0000-0002-1918-2735				BOCK E, 2001, PROKARYOTES EVOLVING; Damste JSS, 2002, J LIPID RES, V43, P1641, DOI 10.1194/jlr.M200148-JLR200; DeLong EF, 1998, APPL ENVIRON MICROB, V64, P1133; DEROSA M, 1988, PROG LIPID RES, V27, P153, DOI 10.1016/0163-7827(88)90011-2; Griffiths RI, 2000, APPL ENVIRON MICROB, V66, P5488, DOI 10.1128/AEM.66.12.5488-5491.2000; HALLAM SJ, 2006, PLOS BIOL, V4, P520, DOI ARTN E95; Hermansson A, 2001, APPL ENVIRON MICROB, V67, P972, DOI 10.1128/AEM.67.2.972-976.2001; Hopmans EC, 2004, EARTH PLANET SC LETT, V224, P107, DOI 10.1016/j.epsl.2004.05.012; Konneke M, 2005, NATURE, V437, P543, DOI 10.1038/nature03911; Kowalchuk GA, 2001, ANNU REV MICROBIOL, V55, P485, DOI 10.1146/annurev.micro.55.1.485; Kurola J, 2005, FEMS MICROBIOL LETT, V250, P33, DOI 10.1016/j.femsle.2005.06.057; LANE DJ, 1985, P NATL ACAD SCI USA, V82, P6955, DOI 10.1073/pnas.82.20.6955; Margulies M, 2005, NATURE, V437, P376, DOI 10.1038/nature03959; Mendum TA, 1999, APPL ENVIRON MICROB, V65, P4155; Ochsenreiter T, 2003, ENVIRON MICROBIOL, V5, P787, DOI 10.1046/j.1462-2920.2003.00476.x; Okano Y, 2004, APPL ENVIRON MICROB, V70, P1008, DOI 10.1128/AEM.70.2.1008-1016.2004; Ovreas L, 1998, MICROB ECOL, V36, P303, DOI 10.1007/s002489900117; Phillips CJ, 2000, FEMS MICROBIOL ECOL, V32, P167, DOI 10.1111/j.1574-6941.2000.tb00710.x; Prosser JI, 2002, ANTON LEEUW INT J G, V81, P165, DOI 10.1023/A:1020598114104; Purkhold U, 2000, APPL ENVIRON MICROB, V66, P5368, DOI 10.1128/AEM.66.12.5368-5382.2000; Rotthauwe JH, 1997, APPL ENVIRON MICROB, V63, P4704, DOI 10.1128/AEM.63.12.4704-4712.1997; Schleper C, 2005, NAT REV MICROBIOL, V3, P479, DOI 10.1038/nrmicro1159; Stephen JR, 1998, APPL ENVIRON MICROB, V64, P2958; Treusch AH, 2005, ENVIRON MICROBIOL, V7, P1985, DOI 10.1111/j.1462-2920.2005.00906.x; Venter JC, 2004, SCIENCE, V304, P66, DOI 10.1126/science.1093857; Weigel A, 2000, J PLANT NUTR SOIL SC, V163, P261; Weijers JWH, 2006, ENVIRON MICROBIOL, V8, P648, DOI 10.1111/j.1462-2920.2005.00941.x	27	1743	1958	24	1146	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 17	2006	442	7104					806	809		10.1038/nature04983	http://dx.doi.org/10.1038/nature04983			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	074DK	16915287				2022-12-28	WOS:000239792700044
J	Macilwain, C				Macilwain, Colin			More fizz at Pfizer?	NATURE			English	News Item																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 17	2006	442	7104					734	734		10.1038/442734a	http://dx.doi.org/10.1038/442734a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	074DK	16915258	Bronze			2022-12-28	WOS:000239792700012
J	Rai, R; Regan, L				Rai, Raj; Regan, Lesley			Recurrent miscarriage	LANCET			English	Review							NATURAL-KILLER-CELLS; LOW-DOSE ASPIRIN; CIRCULATING PROCOAGULANT MICROPARTICLES; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CONGENITAL UTERINE ANOMALIES; POLYCYSTIC-OVARY-SYNDROME; LOW-MOLECULAR-WEIGHT; EARLY-PREGNANCY LOSS; FACTOR-V-LEIDEN; ANTIPHOSPHOLIPID ANTIBODY	Many human conceptions are genetically abnormal and end in miscarriage, which is the commonest complication of pregnancy. Recurrent miscarriage, the loss of three or more consecutive pregnancies, affects 1% of couples trying to conceive. It is associated with psychological morbidity and has often proven to be frustrating for both patient and clinician. A third of women attending specialist clinics are clinically depressed, and one in five have levels of anxiety that are similar to those in psychiatric outpatient populations. Many conventional beliefs about the cause and treatment of women with recurrent miscarriage have not withstood scrutiny, but progress has been made. Research has emphasised the importance of recurrent miscarriage in the range of reproductive failure linking subfertility and late pregnancy complications and has allowed us to reject practice based on anecdotal evidence in favour of evidence-based management.	Imperial Coll London, Dept Obstet & Gynaecol, London W2 1PG, England	Imperial College London	Regan, L (corresponding author), Imperial Coll London, Dept Obstet & Gynaecol, St Marys Campus,Mint Wing,S Wharf Rd, London W2 1PG, England.	l.regan@imperial.ac.uk						Althuisius SM, 2000, AM J OBSTET GYNECOL, V183, P823, DOI 10.1067/mob.2000.108874; *AM SOC REPR MED P, 2004, FERTIL STERIL S1, V82, P199; Andersen AMN, 2000, BRIT MED J, V320, P1708, DOI 10.1136/bmj.320.7251.1708; Arck PC, 2001, HUM REPROD, V16, P1505, DOI 10.1093/humrep/16.7.1505; Bose P, 2005, AM J OBSTET GYNECOL, V192, P23, DOI 10.1016/j.ajog.2004.09.029; Bose P, 2004, AM J OBSTET GYNECOL, V191, P2125, DOI 10.1016/j.ajog.2004.05.014; Braude P, 2002, NAT REV GENET, V3, P941, DOI 10.1038/nrg953; Brigham SA, 1999, HUM REPROD, V14, P2868, DOI 10.1093/humrep/14.11.2868; BROCKLEHURST P, 2000, COCHRANE DB SYST REV, V2; CAMP JM, 1996, HUM REPROD, V11, P1575; Carp H, 2004, FERTIL STERIL, V81, P1296, DOI 10.1016/j.fertnstert.2003.09.059; Carp H, 2004, HUM REPROD, V19, P191, DOI 10.1093/humrep/deg512; CHARD T, 1991, BAILLIERE CLIN OB GY, V5, P179, DOI 10.1016/S0950-3552(05)80077-X; Clifford K, 1996, BRIT MED J, V312, P1508, DOI 10.1136/bmj.312.7045.1508; Clifford K, 1999, HUM REPROD, V14, P2727, DOI 10.1093/humrep/14.11.2727; Clifford K, 1997, HUM REPROD, V12, P387, DOI 10.1093/humrep/12.2.387; CLIFFORD K, 1994, HUM REPROD, V9, P1328, DOI 10.1093/oxfordjournals.humrep.a138703; Craig LB, 2002, FERTIL STERIL, V78, P487, DOI 10.1016/S0015-0282(02)03247-8; Craig M, 2002, J PSYCHOSOM OBST GYN, V23, P157, DOI 10.3109/01674820209074668; CREAGH MD, 1991, J CLIN PATHOL, V44, P45, DOI 10.1136/jcp.44.1.45; Dale PO, 1998, HUM REPROD, V13, P567, DOI 10.1093/humrep/13.3.567; DAYA S, 1989, BRIT J OBSTET GYNAEC, V96, P275, DOI 10.1111/j.1471-0528.1989.tb02386.x; DEWOLF F, 1982, AM J OBSTET GYNECOL, V142, P829, DOI 10.1016/S0002-9378(16)32527-3; Di Nisio M, 2005, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD004734.PUB2; Di Simone N, 1999, HUM REPROD, V14, P489, DOI 10.1093/humrep/14.2.489; Di Simone N, 2002, FERTIL STERIL, V77, P805, DOI 10.1016/S0015-0282(01)03258-7; DISIMONE N, 1995, PLACENTA, V16, P75, DOI 10.1016/0143-4004(95)90083-7; DiSimone N, 1997, HUM REPROD, V12, P2061, DOI 10.1093/humrep/12.9.2061; DizonTomson DS, 1997, AM J OBSTET GYNECOL, V177, P402, DOI 10.1016/S0002-9378(97)70205-9; Drakeley AJ, 1998, HUM REPROD, V13, P1975, DOI 10.1093/humrep/13.7.1975; DRAKELEY AJ, 2003, COCHRANE DB SYST REV, V1; Empson M, 2002, OBSTET GYNECOL, V99, P135, DOI 10.1016/S0029-7844(01)01646-5; Esplin MS, 1998, AM J OBSTET GYNECOL, V179, P1583, DOI 10.1016/S0002-9378(98)70029-8; Farquharson RG, 2002, OBSTET GYNECOL, V100, P408, DOI 10.1016/S0029-7844(02)02165-8; Fleischmann Roy M, 2004, Expert Opin Drug Saf, V3, P391, DOI 10.1517/14740338.3.5.391; Freeman SB, 2000, AM J HUM GENET, V66, P1680, DOI 10.1086/302907; Fritz B, 2001, EUR J HUM GENET, V9, P539, DOI 10.1038/sj.ejhg.5200669; Garzia E, 2004, HUM REPROD, V19, P1911, DOI 10.1093/humrep/deh350; Giorlandino C, 1998, FERTIL STERIL, V70, P576, DOI 10.1016/S0015-0282(98)00192-7; Glueck CJ, 2002, HUM REPROD, V17, P2858, DOI 10.1093/humrep/17.11.2858; Glueck CJ, 2000, FERTIL STERIL, V74, P394, DOI 10.1016/S0015-0282(00)00630-0; GOLDSTEIN P, 1989, BRIT J OBSTET GYNAEC, V96, P265, DOI 10.1111/j.1471-0528.1989.tb02385.x; Greenwold N, 2003, FERTIL STERIL, V79, P1373, DOI 10.1016/S0015-0282(03)00364-9; Greenwold N, 2002, HUM REPROD, V17, P452, DOI 10.1093/humrep/17.2.452; Grimbizis GF, 2001, HUM REPROD UPDATE, V7, P161, DOI 10.1093/humupd/7.2.161; HARGER JH, 1989, OBSTET GYNECOL, V73, P419; HARRIS EN, 1987, BRIT J RHEUMATOL, V26, P324; Hart R, 2001, HUM REPROD, V16, P2411, DOI 10.1093/humrep/16.11.2411; HASSOLD T, 1985, HUM GENET, V70, P11, DOI 10.1007/BF00389450; HAY PE, 1994, BRIT MED J, V308, P295, DOI 10.1136/bmj.308.6924.295; Heeps A, 2006, J SOC GYNECOL INVEST, V13, p333A; Hellgren M, 1996, HAEMOSTASIS, V26, P244; Hemels MEH, 2005, ANN PHARMACOTHER, V39, P803, DOI 10.1345/aph.1E547; Hempstock J, 2003, HUM PATHOL, V34, P1265, DOI 10.1016/j.humpath.2003.08.006; Hirahara F, 1998, FERTIL STERIL, V70, P246, DOI 10.1016/S0015-0282(98)00164-2; Hogge WA, 2003, AM J OBSTET GYNECOL, V189, P397, DOI 10.1067/S0002-9378(03)00700-2; HUSTIN J, 1990, PLACENTA, V11, P477, DOI 10.1016/S0143-4004(05)80193-6; Isermann B, 2003, NAT MED, V9, P331, DOI 10.1038/nm825; Jacobs P.A., 1987, HUM GENET, P233; Jakubowicz DJ, 2002, J CLIN ENDOCR METAB, V87, P524, DOI 10.1210/jc.87.2.524; Jauniaux E, 2003, FERTIL STERIL, V79, P100, DOI 10.1016/S0015-0282(02)04568-5; Jenkins C, 2000, ANTIOXID REDOX SIGN, V2, P623, DOI 10.1089/15230860050192369; Jivraj S, 2006, HUM REPROD, V21, P1161, DOI 10.1093/humrep/dei466; Jivraj S, 2001, HUM REPROD, V16, P102, DOI 10.1093/humrep/16.1.102; Kaider AS, 1999, AM J REPROD IMMUNOL, V42, P335; Kalousek D K, 1993, Birth Defects Orig Artic Ser, V29, P53; KAPLAN HB, 1991, SOC SCI MED, V33, P909, DOI 10.1016/0277-9536(91)90262-B; KESMODEL U, 2002, ALCOHOL ALCOHOLISM, V37, P435; Kline J, 2000, AM J HUM GENET, V67, P395, DOI 10.1086/303009; KLINE J, 1989, MONOGRAPHS EPIDEMIOL; KNUDSEN UB, 1991, EUR J OBSTET GYN R B, V39, P31, DOI 10.1016/0028-2243(91)90138-B; Koopman LA, 2003, J EXP MED, V198, P1201, DOI 10.1084/jem.20030305; Kovalevsky G, 2004, ARCH INTERN MED, V164, P558, DOI 10.1001/archinte.164.5.558; Kozer E, 2002, AM J OBSTET GYNECOL, V187, P1623, DOI 10.1067/mob.2002.127376; Kutteh WH, 1999, HUM REPROD, V14, P2886, DOI 10.1093/humrep/14.11.2886; Kutteh WH, 1999, FERTIL STERIL, V71, P843, DOI 10.1016/S0015-0282(99)00091-6; Kutteh WH, 1996, AM J OBSTET GYNECOL, V174, P1584, DOI 10.1016/S0002-9378(96)70610-5; Lachapelle MH, 1996, J IMMUNOL, V156, P4027; Lashen H, 2004, HUM REPROD, V19, P1644, DOI 10.1093/humrep/deh277; Laskin CA, 1997, NEW ENGL J MED, V337, P148, DOI 10.1056/NEJM199707173370302; Laude I, 2001, THROMB HAEMOSTASIS, V85, P18, DOI 10.1055/s-0037-1612657; Li DK, 2003, BRIT MED J, V327, P368, DOI 10.1136/bmj.327.7411.368; LIDDELL HS, 1991, AUST NZ J OBSTET GYN, V31, P320, DOI 10.1111/j.1479-828X.1991.tb02811.x; Lim KJH, 2000, FERTIL STERIL, V73, P136, DOI 10.1016/S0015-0282(99)00457-4; Lindbohm ML, 2002, SCAND J WORK ENV HEA, V28, P84; LYDEN TW, 1992, J REPROD IMMUNOL, V22, P1, DOI 10.1016/0165-0378(92)90002-L; Mak IYH, 2002, J CLIN ENDOCR METAB, V87, P2581, DOI 10.1210/jc.87.6.2581; Malinowski A, 1994, Zentralbl Gynakol, V116, P631; Marcus M, 2000, J Am Med Womens Assoc (1972), V55, P84; McGregor DG, 2000, MAYO CLIN PROC, V75, P273; MILLS JL, 1988, NEW ENGL J MED, V319, P1617, DOI 10.1056/NEJM198812223192501; Moffett A, 2004, BMJ-BRIT MED J, V329, P1283, DOI 10.1136/bmj.329.7477.1283; Moffett-King A, 2002, NAT REV IMMUNOL, V2, P656, DOI 10.1038/nri886; Munne S, 2000, CYTOGENET CELL GENET, V90, P303, DOI 10.1159/000056793; Ness RB, 1999, NEW ENGL J MED, V340, P333, DOI 10.1056/NEJM199902043400501; Nicol CJ, 2000, FASEB J, V14, P111, DOI 10.1096/fasebj.14.1.111; Nielsen GL, 2001, BRIT MED J, V322, P266, DOI 10.1136/bmj.322.7281.266; Oates-Whitehead R M, 2003, Cochrane Database Syst Rev, pCD004000, DOI 10.1002/14651858.CD003511; Ober C, 1999, LANCET, V354, P365, DOI 10.1016/S0140-6736(98)12055-X; OUT HJ, 1991, EUR J OBSTET GYN R B, V41, P179, DOI 10.1016/0028-2243(91)90021-C; Philipp T, 2003, HUM REPROD, V18, P1724, DOI 10.1093/humrep/deg309; Platteau P, 2005, FERTIL STERIL, V83, P393, DOI 10.1016/j.fertnstert.2004.06.071; Preston FE, 1996, LANCET, V348, P913, DOI 10.1016/S0140-6736(96)04125-6; Prummel MF, 2004, EUR J ENDOCRINOL, V150, P751, DOI 10.1530/eje.0.1500751; Quenby S, 2004, OBSTET GYNECOL, V104, P354, DOI 10.1097/01.AOG.0000128902.84876.d4; Quenby S, 1999, HUM REPROD, V14, P2386, DOI 10.1093/humrep/14.9.2386; Rackow BW, 2006, J SOC GYNECOL INVEST, V13, p280A; Raghupathy R, 2000, HUM REPROD, V15, P713, DOI 10.1093/humrep/15.3.713; Ragusa A, 2004, LUPUS, V13, P639, DOI 10.1191/0961203304lu2007oa; Rai R, 2000, HUM REPROD, V15, P2220, DOI 10.1093/humrep/15.10.2220; Rai R, 2000, HUM REPROD, V15, P612, DOI 10.1093/humrep/15.3.612; Rai R, 2002, HUM REPROD, V17, P442, DOI 10.1093/humrep/17.2.442; Rai R, 2001, HUM REPROD, V16, P961, DOI 10.1093/humrep/16.5.961; Rai R, 2003, HUM REPROD, V18, P2540, DOI 10.1093/humrep/deg494; Rai R, 1997, BRIT MED J, V314, P253, DOI 10.1136/bmj.314.7076.253; Rai R, 1996, BRIT J OBSTET GYNAEC, V103, P106, DOI 10.1111/j.1471-0528.1996.tb09658.x; RAI RS, 1995, HUM REPROD, V10, P2001, DOI 10.1093/oxfordjournals.humrep.a136224; Rai RS, 1995, HUM REPROD, V10, P3301, DOI 10.1093/oxfordjournals.humrep.a135907; Ralph SG, 1999, BRIT MED J, V319, P220, DOI 10.1136/bmj.319.7204.220; Rasch V, 2003, ACTA OBSTET GYN SCAN, V82, P182, DOI 10.1034/j.1600-0412.2003.00078.x; Regan L, 2000, BEST PRACT RES CL OB, V14, P839, DOI 10.1053/beog.2000.0123; REGAN L, 1989, BRIT MED J, V299, P541, DOI 10.1136/bmj.299.6698.541; REGAN L, 1991, BMJ-BRIT MED J, V302, P543, DOI 10.1136/bmj.302.6776.543; Regan L, 2005, J SOC GYNECOL INVEST, V12, p91A; REGAN L, 2001, INFECT PREGNANCY, P291; Reinhard G, 1998, BIOCHEM BIOPH RES CO, V245, P933, DOI 10.1006/bbrc.1998.8549; Rey E, 2003, LANCET, V361, P901, DOI 10.1016/S0140-6736(03)12771-7; RISCH HA, 1988, AM J EPIDEMIOL, V128, P420, DOI 10.1093/oxfordjournals.aje.a114982; Robinson WP, 1999, AM J MED GENET, V84, P34, DOI 10.1002/(SICI)1096-8628(19990507)84:1<34::AID-AJMG8>3.3.CO;2-Z; ROSENN B, 1994, OBSTET GYNECOL, V84, P515; Rubio C, 2003, HUM REPROD, V18, P182, DOI 10.1093/humrep/deg015; Rushworth FH, 2000, HUM REPROD, V15, P1637, DOI 10.1093/humrep/15.7.1637; Rust OA, 2000, AM J OBSTET GYNECOL, V183, P830, DOI 10.1067/mob.2000.109040; Salim R, 2003, HUM REPROD, V18, P162, DOI 10.1093/humrep/deg030; Sanson BJ, 1996, THROMB HAEMOSTASIS, V75, P387; SCOTT JR, 2003, COCHRANE DB SYST REV, V1, P112; Sebire NJ, 2002, HUM REPROD, V17, P1067, DOI 10.1093/humrep/17.4.1067; Sebire NJ, 2003, OBSTET GYNECOL, V101, P258, DOI 10.1016/S0029-7844(02)02385-2; Sebire NJ, 2002, BJOG-INT J OBSTET GY, V109, P570, DOI 10.1016/S1470-0328(02)00077-0; Sebire NJ, 2001, INT J OBESITY, V25, P1175, DOI 10.1038/sj.ijo.0801670; Sherer Y, 2001, PHARMACOLOGY, V62, P133, DOI 10.1159/000056085; Smith GCS, 2003, BMJ-BRIT MED J, V326, P423, DOI 10.1136/bmj.326.7386.423; Stephenson MD, 2002, HUM REPROD, V17, P446, DOI 10.1093/humrep/17.2.446; STIRLING Y, 1984, THROMB HAEMOSTASIS, V52, P176; STIRRAT GM, 1990, LANCET, V336, P673, DOI 10.1016/0140-6736(90)92159-F; STRAYPEDERSEN B, 1984, AM J OBSTET GYNECOL, V148, P140, DOI 10.1016/S0002-9378(84)80164-7; STROBINO B, 1986, AM J PUBLIC HEALTH, V76, P986, DOI 10.2105/AJPH.76.8.986; Sugiura-Ogasawara M, 2002, HUM REPROD, V17, P2580, DOI 10.1093/humrep/17.10.2580; Sullivan AE, 2004, OBSTET GYNECOL, V104, P784, DOI 10.1097/01.AOG.0000137832.86727.e2; Tempfer C, 2001, HUM REPROD, V16, P1644, DOI 10.1093/humrep/16.8.1644; Toder V, 2003, J ASSIST REPROD GEN, V20, P73, DOI 10.1023/A:1021740108284; Tulppala M, 1997, HUM REPROD, V12, P1567, DOI 10.1093/humrep/12.7.1567; Ugwumadu A, 2003, LANCET, V361, P983, DOI 10.1016/S0140-6736(03)12823-1; Van Horn JT, 2004, PLACENTA, V25, P642, DOI 10.1016/j.placenta.2003.12.006; Vincent T, 1998, LANCET, V352, P116, DOI 10.1016/S0140-6736(98)85022-8; von Wolff M, 2000, MOL HUM REPROD, V6, P627; Wang JX, 2001, HUM REPROD, V16, P2606, DOI 10.1093/humrep/16.12.2606; Warburton D, 2004, AM J HUM GENET, V75, P376, DOI 10.1086/423331; Warburton D, 1989, Prog Clin Biol Res, V311, P165; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D; Werler MM, 2002, AM J EPIDEMIOL, V155, P26, DOI 10.1093/aje/155.1.26; WILCOX AJ, 1988, NEW ENGL J MED, V319, P189, DOI 10.1056/NEJM198807283190401; Wilson W A, 2001, Lupus, V10, P457, DOI 10.1191/096120301678415999; Woelfer B, 2001, OBSTET GYNECOL, V98, P1099, DOI 10.1016/S0029-7844(01)01599-X; Zaveri V, 2002, AM J OBSTET GYNECOL, V187, P868, DOI 10.1067/mob.2002.126959	165	878	948	7	146	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 12	2006	368	9535					601	611		10.1016/S0140-6736(06)69204-0	http://dx.doi.org/10.1016/S0140-6736(06)69204-0			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	074OF	16905025				2022-12-28	WOS:000239821000034
J	Didelot, G; Molinari, F; Tchenio, P; Comas, D; Milhiet, E; Munnich, A; Colleaux, L; Preat, T				Didelot, Gerard; Molinari, Florence; Tchenio, Paul; Comas, Daniel; Milhiet, Elodie; Munnich, Arnold; Colleaux, Laurence; Preat, Thomas			Tequila, a neurotrypsin ortholog, regulates long-term memory formation in Drosophila	SCIENCE			English	Article							CONSOLIDATED MEMORY; MENTAL-RETARDATION; MUSHROOM BODIES; NERVOUS-SYSTEM; INHIBITORS; EXPRESSION; PROTEASES	Mutations in the human neurotrypsin gene are associated with autosomal recessive mental retardation. To further understand the pathophysiological consequences of the lack of this serine protease, we studied Tequila (Teq), the Drosophila neurotrypsin ortholog, using associative memory as a behavioral readout. We found that teq inactivation resulted in a long-term memory (LTM) specific defect. After LTM conditioning of wild-type flies, teq expression transiently increased in the mushroom bodies. Moreover, specific inhibition of teq expression in adult mushroom bodies resulted in a reversible LTM defect. Hence, the Teq pathway is essential for information processing in Drosophila.	Ecole Super Phys & Chim Ind Ville Paris, CNRS, UMR 7637, F-75005 Paris, France; CNRS, F-91198 Gif Sur Yvette, France; Hop Necker Enfants Malad, INSERM, U781, Unite Rech Handicaps Genet Enfant, F-75743 Paris, France; Hop Necker Enfants Malad, Dept Genet, F-75743 Paris 15, France; CNRS, UPR 3321, Aime Cotton Lab, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Preat, T (corresponding author), Ecole Super Phys & Chim Ind Ville Paris, CNRS, UMR 7637, 10 Rue Vauquelin, F-75005 Paris, France.	thomas.preat@espci.fr	COLLEAUX, Laurence/H-6455-2017; Molinari, Florence/M-7683-2016; COLLEAUX, LAURENCE/AAA-8144-2022	Molinari, Florence/0000-0001-5111-7215; COLLEAUX, LAURENCE/0000-0002-0987-7648; Preat, Thomas/0000-0001-9976-1763				Armstrong JD, 1998, LEARN MEMORY, V5, P102; Comas D, 2004, NATURE, V430, P460, DOI 10.1038/nature02726; Crittenden JR, 1998, LEARN MEMORY, V5, P38; Dubnau J, 2003, CURR BIOL, V13, P286, DOI 10.1016/S0960-9822(03)00064-2; GRENNINGLOH G, 1991, CELL, V67, P45, DOI 10.1016/0092-8674(91)90571-F; Gschwend TP, 1997, MOL CELL NEUROSCI, V9, P207, DOI 10.1006/mcne.1997.0616; Inlow JK, 2004, GENETICS, V166, P835, DOI 10.1534/genetics.166.2.835; Isabel G, 2004, SCIENCE, V304, P1024, DOI 10.1126/science.1094932; Mao ZM, 2004, P NATL ACAD SCI USA, V101, P198, DOI 10.1073/pnas.0306128101; Molinari F, 2003, HUM MOL GENET, V12, pR195, DOI 10.1093/hmg/ddg276; Molinari F, 2002, SCIENCE, V298, P1779, DOI 10.1126/science.1076521; Pascual A, 2001, SCIENCE, V294, P1115, DOI 10.1126/science.1064200; Piccin A, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.12.e55; Shiosaka S, 2000, NEUROSCI RES, V37, P85, DOI 10.1016/S0168-0102(00)00115-2; Shiosaka Sadao, 2004, Anatomical Science International, V79, P137, DOI 10.1111/j.1447-073x.2004.00080.x; SKOULAKIS EMC, 1993, NEURON, V11, P197, DOI 10.1016/0896-6273(93)90178-T; Thibault ST, 2004, NAT GENET, V36, P283, DOI 10.1038/ng1314; TULLY T, 1994, CELL, V79, P35, DOI 10.1016/0092-8674(94)90398-0; Zars T, 2000, LEARN MEMORY, V7, P18, DOI 10.1101/lm.7.1.18	19	67	68	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 11	2006	313	5788					851	853		10.1126/science.1127215	http://dx.doi.org/10.1126/science.1127215			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	072KC	16902143				2022-12-28	WOS:000239671300065
J	Greenleaf, WJ; Block, SM				Greenleaf, William J.; Block, Steven M.			Single-molecule, motion-based DNA sequencing using RNA polymerase	SCIENCE			English	Article							DISCRIMINATION		Stanford Univ, Dept Appl Phys, Stanford, CA 94305 USA; Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	Stanford University; Stanford University	Block, SM (corresponding author), Stanford Univ, Dept Appl Phys, Stanford, CA 94305 USA.	sblock@stanford.edu			NIGMS NIH HHS [R01 GM057035, GM057035] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057035, R37GM057035] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbondanzieri EA, 2005, NATURE, V438, P460, DOI 10.1038/nature04268; Braslavsky I, 2003, P NATL ACAD SCI USA, V100, P3960, DOI 10.1073/pnas.0230489100; Herbert KM, 2006, CELL, V125, P1083, DOI 10.1016/j.cell.2006.04.032; Meller A, 2000, P NATL ACAD SCI USA, V97, P1079, DOI 10.1073/pnas.97.3.1079; Shendure J, 2004, NAT REV GENET, V5, P335, DOI 10.1038/nrg1325; Vercoutere W, 2001, NAT BIOTECHNOL, V19, P248, DOI 10.1038/85696	6	90	103	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 11	2006	313	5788					801	801		10.1126/science.1130105	http://dx.doi.org/10.1126/science.1130105			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	072KC	16902131	Green Accepted			2022-12-28	WOS:000239671300049
J	Taylor, BW; Flecker, AS; Hall, RO				Taylor, Brad W.; Flecker, Alexander S.; Hall, Robert O., Jr.			Loss of a harvested fish species disrupts carbon flow in a diverse tropical river	SCIENCE			English	Article							STREAMS; DYNAMICS	Harvesting threatens many vertebrate species, yet few whole-system manipulations have been conducted to predict the consequences of vertebrate losses on ecosystem function. Here, we show that a harvested migratory detrital-feeding fish (Prochilodontidae: Prochilodus mariae) modulates carbon flow and ecosystem metabolism. Natural declines in and experimental removal of Prochilodus decreased downstream transport of organic carbon and increased primary production and respiration. Thus, besides its economic value, Prochilodus is a critical ecological component of South American rivers. Lack of functional redundancy for this species highlights the importance of individual species and, contrary to theory, suggests that losing one species from lower trophic levels can affect ecosystem functioning even in species-rich ecosystems.	Univ Wyoming, Dept Zool & Physiol, Laramie, WY 82071 USA; Cornell Univ, Dept Ecol & Evolutionary Biol, Ithaca, NY 14853 USA	University of Wyoming; Cornell University	Taylor, BW (corresponding author), Dartmouth Coll, Dept Biol Sci, Hanover, NH 03755 USA.	brad.taylor@dartmouth.edu		Taylor, Brad/0000-0002-7824-2304				Allan JD, 2005, BIOSCIENCE, V55, P1041, DOI 10.1641/0006-3568(2005)055[1041:OOIW]2.0.CO;2; Barbarino A., 1998, ENVIRON BIOL FISH, V53, P33, DOI DOI 10.1023/A:1007447004451; BAYLEY P B, 1989, Canadian Special Publication of Fisheries and Aquatic Sciences, V106, P385; Castillo MM, 2004, FRESHWATER BIOL, V49, P1400, DOI 10.1111/j.1365-2427.2004.01277.x; FIGUEREDO D, COMMUNICATION; Flecker AS, 1997, J N AM BENTHOL SOC, V16, P286, DOI 10.2307/1468258; Flecker AS, 2002, ECOLOGY, V83, P1831, DOI 10.2307/3071768; Flecker AS, 1996, ECOLOGY, V77, P1845, DOI 10.2307/2265788; GELWICK FP, 1992, ECOLOGY, V73, P1630, DOI 10.2307/1940016; Huryn AD, 1998, OECOLOGIA, V115, P173, DOI 10.1007/s004420050505; Jenkins M, 2003, SCIENCE, V302, P1175, DOI 10.1126/science.1088666; Lewis W. M., 1995, RIVER STREAM ECOSYST, P219; Loreau M, 2001, SCIENCE, V294, P804, DOI 10.1126/science.1064088; Millennium Ecosystem Assessment, 2005, EC HUM WELL BEING BI; Moore JC, 2004, ECOL LETT, V7, P584, DOI 10.1111/j.1461-0248.2004.00606.x; NEWBOLD JD, 1982, OIKOS, V38, P266, DOI 10.2307/3544663; NEWBOLD JD, 1982, AM NAT, V120, P628, DOI 10.1086/284017; Power ME, 2003, CATFISHES, VOLS 1-2, P581; Pringle CM, 1999, ECOLOGY, V80, P1860, DOI 10.1890/0012-9658(1999)080[1860:LSAEDB]2.0.CO;2; Schindler DE, 1997, SCIENCE, V277, P248, DOI 10.1126/science.277.5323.248; Simon KS, 2004, ECOSYSTEMS, V7, P777, DOI 10.1007/s10021-004-0024-z; Solan M, 2004, SCIENCE, V306, P1177, DOI 10.1126/science.1103960; VANNOTE RL, 1980, CAN J FISH AQUAT SCI, V37, P130, DOI 10.1139/f80-017; WALLACE JB, 1991, LIMNOL OCEANOGR, V36, P670, DOI 10.4319/lo.1991.36.4.0670; Winemiller Kirk O., 1996, P99, DOI 10.1016/B978-012178075-3/50006-4; WINEMILLER KO, 1990, ECOL MONOGR, V60, P331, DOI 10.2307/1943061; Wright JP, 2004, BIOL CONSERV, V120, P439, DOI 10.1016/j.biocon.2004.02.022	27	226	236	1	66	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 11	2006	313	5788					833	836		10.1126/science.1128223	http://dx.doi.org/10.1126/science.1128223			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	072KC	16902137				2022-12-28	WOS:000239671300059
J	Potti, A; Mukherjee, S; Petersen, R; Dressman, HK; Bild, A; Koontz, J; Kratzke, R; Watson, MA; Kelley, M; Ginsburg, GS; West, M; Harpole, DH; Nevins, JR				Potti, Anil; Mukherjee, Sayan; Petersen, Rebecca; Dressman, Holly K.; Bild, Andrea; Koontz, Jason; Kratzke, Robert; Watson, Mark A.; Kelley, Michael; Ginsburg, Geoffrey S.; West, Mike; Harpole, David H., Jr.; Nevins, Joseph R.			RETRACTED: A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer (Retracted Article. See vol 356, pg 201, 2007)	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Retracted Publication							GENE-EXPRESSION PROFILES; BREAST-CANCER; ADJUVANT CHEMOTHERAPY; ADENOCARCINOMA; SURVIVAL; PREDICTION; OUTCOMES; CLASSIFICATION; IDENTIFICATION; THERAPY	BACKGROUND: Clinical trials have indicated a benefit of adjuvant chemotherapy for patients with stage IB, II, or IIIA -- but not stage IA -- non-small-cell lung cancer (NSCLC). This classification scheme is probably an imprecise predictor of the prognosis of an individual patient. Indeed, approximately 25 percent of patients with stage IA disease have a recurrence after surgery, suggesting the need to identify patients in this subgroup for more effective therapy. METHODS: We identified gene-expression profiles that predicted the risk of recurrence in a cohort of 89 patients with early-stage NSCLC (the lung metagene model). We evaluated the predictor in two independent groups of 25 patients from the American College of Surgeons Oncology Group (ACOSOG) Z0030 study and 84 patients from the Cancer and Leukemia Group B (CALGB) 9761 study. RESULTS: The lung metagene model predicted recurrence for individual patients significantly better than did clinical prognostic factors and was consistent across all early stages of NSCLC. Applied to the cohorts from the ACOSOG Z0030 trial and the CALGB 9761 trial, the lung metagene model had an overall predictive accuracy of 72 percent and 79 percent, respectively. The predictor also identified a subgroup of patients with stage IA disease who were at high risk for recurrence and who might be best treated by adjuvant chemotherapy. CONCLUSIONS: The lung metagene model provides a potential mechanism to refine the estimation of a patient's risk of disease recurrence and, in principle, to alter decisions regarding the use of adjuvant chemotherapy in early-stage NSCLC.	Duke Univ, Duke Inst Genome Sci & Policy, Durham, NC 27708 USA; Duke Univ, Inst Stat & Decis Sci, Durham, NC 27708 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA; Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA	Duke University; Duke University; Duke University; Duke University; Duke University; University of Minnesota System; University of Minnesota Twin Cities; Washington University (WUSTL)	Nevins, JR (corresponding author), Duke Univ, Duke Inst Genome Sci & Policy, 101 Sci Dr,Box 3382, Durham, NC 27708 USA.	nevin001@mc.duke.edu	Kelley, Michael/AAC-8939-2019	Kelley, Michael/0000-0001-9523-6080				Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Berrar D, 2005, J COMPUT BIOL, V12, P534, DOI 10.1089/cmb.2005.12.534; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Breiman L, 2001, STAT SCI, V16, P199, DOI 10.1214/ss/1009213726; Brundage MD, 2002, CHEST, V122, P1037, DOI 10.1378/chest.122.3.1037; Chen GA, 2003, P NATL ACAD SCI USA, V100, P13537, DOI 10.1073/pnas.2233850100; D'Amico TA, 1999, J THORAC CARDIOV SUR, V117, P736, DOI 10.1016/S0022-5223(99)70294-1; Douillard JY, 2005, J CLIN ONCOL, V23, P7013; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Hoffman PC, 2000, LANCET, V355, P1280; Huang E, 2003, LANCET, V361, P1590, DOI 10.1016/S0140-6736(03)13308-9; Ju Z, 2005, MOL GENET GENOMICS, V274, P141, DOI 10.1007/s00438-005-0014-7; Kato H, 2004, NEW ENGL J MED, V350, P1713, DOI 10.1056/NEJMoa032792; Kikuchi T, 2003, ONCOGENE, V22, P2192, DOI 10.1038/sj.onc.1206288; Le Chevalier T, 2004, NEW ENGL J MED, V350, P351, DOI 10.1056/nejmoa031644; Meyerson M, 2005, J CLIN ONCOL, V23, P3219, DOI 10.1200/JCO.2005.15.511; Mountain CF, 1997, CHEST, V111, P1710, DOI 10.1378/chest.111.6.1710; MOUNTAIN CF, 1987, SURG CLIN N AM, V67, P925; NESBITT JC, 1995, ANN THORAC SURG, V60, P466, DOI 10.1016/0003-4975(95)00169-L; Nevins JR, 2003, HUM MOL GENET, V12, pR153, DOI 10.1093/hmg/ddg287; Pittman J, 2004, BIOSTATISTICS, V5, P587, DOI 10.1093/biostatistics/kxh011; Pittman J, 2004, P NATL ACAD SCI USA, V101, P8431, DOI 10.1073/pnas.0401736101; Schneider PM, 2000, BRIT J CANCER, V83, P473, DOI 10.1054/bjoc.2000.1287; Spira A, 2004, NEW ENGL J MED, V350, P379, DOI 10.1056/NEJMra035536; Strauss GM, 2004, J CLIN ONCOL, V22, p621S; Tonon G, 2005, P NATL ACAD SCI USA, V102, P9625, DOI 10.1073/pnas.0504126102; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998; Wigle DA, 2002, CANCER RES, V62, P3005; Winton T, 2005, NEW ENGL J MED, V352, P2589, DOI 10.1056/NEJMoa043623; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025	31	458	489	1	51	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 10	2006	355	6					570	580		10.1056/NEJMoa060467	http://dx.doi.org/10.1056/NEJMoa060467			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	071QM	16899777				2022-12-28	WOS:000239616700007
J	Montaner, JSG; Hogg, R; Wood, E; Kerr, T; Tyndall, M; Levy, AR; Harrigan, PR				Montaner, Julio S. G.; Hogg, Robert; Wood, Evan; Kerr, Thomas; Tyndall, Mark; Levy, Adrian R.; Harrigan, P. Richard			The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic	LANCET			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; VIRAL LOAD; HETEROSEXUAL TRANSMISSION; DRUG-RESISTANCE; INFECTED ADULTS; RISK-FACTORS; ZIDOVUDINE; NEVIRAPINE; LAMIVUDINE; EFAVIRENZ		Univ British Columbia, British Columbia Ctr Excellence HIV AIDS, Prov Hlth Care, Vancouver, BC V5Z 1M9, Canada; Univ British Columbia, Dept Med, Vancouver, BC V5Z 1M9, Canada; Univ British Columbia, Dept Hlth Care & Epidemiol, Vancouver, BC V6T 1W5, Canada	B.C. Centre for Excellence in HIV/AIDS; University of British Columbia; University of British Columbia; University of British Columbia	Montaner, JSG (corresponding author), Univ British Columbia, St Pauls Hosp, AIDS Res Program, Vancouver, BC V6Z 1Y6, Canada.	jmontaner@cfenet.ubc.ca	Harding, Richard/G-9729-2012; Montaner, Julio/K-7621-2012; Hogg, Robert S/B-2783-2012	Hogg, Robert S/0000-0003-3463-5488; Tyndall, Mark/0000-0003-4450-5679				Anema A, 2004, LANCET, V364, P1034, DOI 10.1016/S0140-6736(04)17053-0; Bicego G, 2003, SOC SCI MED, V56, P1235, DOI 10.1016/S0277-9536(02)00125-9; Blower SM, 2000, SCIENCE, V287, P650, DOI 10.1126/science.287.5453.650; Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2; CAMERON DW, 1989, LANCET, V2, P403; Cane P, 2005, BMJ-BRIT MED J, V331, P1368, DOI 10.1136/bmj.38665.534595.55; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; Castilla J, 2005, JAIDS-J ACQ IMM DEF, V40, P96, DOI 10.1097/01.qai.0000157389.78374.45; Cote HCF, 2002, NEW ENGL J MED, V346, P811, DOI 10.1056/NEJMoa012035; Cu-Uvin S, 2000, AIDS, V14, P415, DOI 10.1097/00002030-200003100-00015; Daar ES, 2005, AIDS RES HUM RETROV, V21, P343, DOI 10.1089/aid.2005.21.343; De Cock KM, 2000, JAMA-J AM MED ASSOC, V283, P1175, DOI 10.1001/jama.283.9.1175; *DEP HHS, 2006, GUID US ANT AG HIV 1; Fang CT, 2004, J INFECT DIS, V190, P879, DOI 10.1086/422601; Fang GW, 1995, P NATL ACAD SCI USA, V92, P12100, DOI 10.1073/pnas.92.26.12100; Farmer P, 2001, LANCET, V358, P404, DOI 10.1016/S0140-6736(01)05550-7; Furtado MR, 1999, NEW ENGL J MED, V340, P1614, DOI 10.1056/NEJM199905273402102; Gallant JE, 2006, NEW ENGL J MED, V354, P251, DOI 10.1056/NEJMoa051871; Gayle Helene D, 2006, AIDS Res Ther, V3, P2, DOI 10.1186/1742-6405-3-2; Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7; Guerrero A, 2005, ENFERM INFEC MICR CL, V23, P605, DOI 10.1016/S0213-005X(05)75040-0; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; HAMMER SM, IN PRESS JAMA; HARDY AM, 1985, JAMA-J AM MED ASSOC, V253, P215, DOI 10.1001/jama.253.2.215; Hogg R, 2002, LANCET, V360, P1710, DOI 10.1016/S0140-6736(02)11722-3; Hogg RS, 1997, LANCET, V349, P1294, DOI 10.1016/S0140-6736(05)62505-6; Hogg RS, 1998, JAMA-J AM MED ASSOC, V279, P450, DOI 10.1001/jama.279.6.450; Hogg RS, 1998, AIDS, V12, P279, DOI 10.1097/00002030-199803000-00005; Hosseinipour M, 2002, CLIN INFECT DIS, V34, P1391, DOI 10.1086/340403; Karon JM, 2001, AM J PUBLIC HEALTH, V91, P1060, DOI 10.2105/AJPH.91.7.1060; Kerr T, 2004, LANCET, V364, P11, DOI 10.1016/S0140-6736(04)16610-5; KINGSLEY LA, 1987, LANCET, V1, P345; Kuritzkes D, 2003, NAT MED, V9, P1343, DOI 10.1038/nm1103-1343b; Law MG, 2001, AIDS, V15, P1287, DOI 10.1097/00002030-200107060-00011; Levy AR, 2006, LANCET INFECT DIS, V6, P171, DOI 10.1016/S1473-3099(06)70413-3; Markel H, 2005, NEW ENGL J MED, V353, P753, DOI 10.1056/NEJMp058146; MILLS E, IN PRESS JAMA; Mocroft A, 2003, LANCET, V362, P22, DOI 10.1016/S0140-6736(03)13802-0; Montaner JSG, 1998, AIDS, V12, P1398, DOI 10.1097/00002030-199811000-00028; Montaner JSG, 1998, JAMA-J AM MED ASSOC, V279, P930, DOI 10.1001/jama.279.12.930; MUSICCO M, 1994, ARCH INTERN MED, V154, P1971, DOI 10.1001/archinte.154.17.1971; Pillay D, 2004, ANTIVIR THER, V9, P695; PIOT P, 2005, SPEECH GIV LOND SCH; Pomerantz RJ, 1999, NEW ENGL J MED, V340, P1672, DOI 10.1056/NEJM199905273402110; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Routy JP, 2004, AIDS, V18, P2305, DOI 10.1097/00002030-200411190-00011; SCHECHTER MT, 1993, LANCET, V341, P658, DOI 10.1016/0140-6736(93)90421-C; Staszewski S, 1999, NEW ENGL J MED, V341, P1865, DOI 10.1056/NEJM199912163412501; Strathdee SA, 1998, J ACQ IMMUN DEF SYND, V19, P61, DOI 10.1097/00042560-199809010-00010; Tovanabutra S, 2002, J ACQ IMMUN DEF SYND, V29, P275, DOI 10.1097/00126334-200203010-00008; *UNAIDS, 2005, FIN EXP RESP AIDS HI; UNAIDS, 2006, REP GLOB AIDS EP; *UNAIDS, 2005, RES NEEDS EXP RESP A; *USAID UNAIDS WHO, 2004, COV SEL SERV HIV AID; van Leth F, 2004, LANCET, V363, P1253, DOI 10.1016/S0140-6736(04)15997-7; Velasco-Hernandez JX, 2002, LANCET INFECT DIS, V2, P487, DOI 10.1016/S1473-3099(02)00346-8; Vernazza PL, 1997, AIDS, V11, P1249, DOI 10.1097/00002030-199710000-00008; *WHO, EST PERC PEOPL ANT T; Wood E, 2005, LANCET INFECT DIS, V5, P407, DOI 10.1016/S1473-3099(05)70162-6; Wood E, 2002, AIDS, V16, P941, DOI 10.1097/00002030-200204120-00021; World Health Organization, 2005, PREV CHRON DIS VIT I, V34, P34; Yerly S, 2004, ANTIVIR THER, V9, P375; Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101; 2005, LANCET, V365, P1597; 2003, LANCET, V362, P179	65	381	385	2	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 5	2006	368	9534					531	536		10.1016/S0140-6736(06)69162-9	http://dx.doi.org/10.1016/S0140-6736(06)69162-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	071AL	16890841				2022-12-28	WOS:000239569000037
J	Babenko, AP; Polak, M; Cave, H; Busiah, K; Czernichow, P; Scharfmann, R; Bryan, J; Aguilar-Bryan, L; Vaxillaire, M; Froguel, P				Babenko, Andrey P.; Polak, Michel; Cave, Helene; Busiah, Kanetee; Czernichow, Paul; Scharfmann, Raphael; Bryan, Joseph; Aguilar-Bryan, Lydia; Vaxillaire, Martine; Froguel, Philippe			Activating mutations in the ABCC8 gene in neonatal diabetes mellitus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SULFONYLUREA RECEPTOR; IMMUNE DYSREGULATION; KIR6.2 MUTATIONS; ATP; INSULIN; STOICHIOMETRY; CHANNELS; NUCLEOTIDES; REGULATOR; TRANSIENT	BACKGROUND: The ATP-sensitive potassium (K(sub ATP)) channel, composed of the beta-cell proteins sulfonylurea receptor (SUR1) and inward-rectifying potassium channel subunit Kir6.2, is a key regulator of insulin release. It is inhibited by the binding of adenine nucleotides to subunit Kir6.2, which closes the channel, and activated by nucleotide binding or hydrolysis on SUR1, which opens the channel. The balance of these opposing actions determines the low open-channel probability, P(sub O), which controls the excitability of pancreatic beta cells. We hypothesized that activating mutations in ABCC8, which encodes SUR1, cause neonatal diabetes. METHODS: We screened the 39 exons of ABCC8 in 34 patients with permanent or transient neonatal diabetes of unknown origin. We assayed the electrophysiologic activity of mutant and wild-type K(sub ATP) channels. RESULTS: We identified seven missense mutations in nine patients. Four mutations were familial and showed vertical transmission with neonatal and adult-onset diabetes; the remaining mutations were not transmitted and not found in more than 300 patients without diabetes or with early-onset diabetes of similar genetic background. Mutant channels in intact cells and in physiologic concentrations of magnesium ATP had a markedly higher P(sub O) than did wild-type channels. These overactive channels remained sensitive to sulfonylurea, and treatment with sulfonylureas resulted in euglycemia. CONCLUSIONS: Dominant mutations in ABCC8 accounted for 12 percent of cases of neonatal diabetes in the study group. Diabetes results from a newly discovered mechanism whereby the basal magnesium-nucleotide-dependent stimulatory action of SUR1 on the Kir pore is elevated and blockade by sulfonylureas is preserved.	Hop Necker Enfants Malad, INSERM, U0363, Fac Med, Paris, France; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Hop Robert Debre, Dept Biochem Genet, F-75019 Paris, France; Hop Robert Debre, Dept Pediat Endocrinol, F-75019 Paris, France; Inst Pasteur, CNRS, U8090, Lille, France; Imperial Coll London, Hammersmith Hosp, Dept Genom Med, London, England	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Baylor College of Medicine; Baylor College of Medicine; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Imperial College London	Polak, M (corresponding author), Hop Necker Enfants Malad, INSERM, U0363, Fac Med, Paris, France.	michel.polak@nck.aphp.fr	Kanetee, BUSIAH/AAP-8292-2020; scharfmann, raphael/L-3296-2017; FROGUEL, Philippe/O-6799-2017	Kanetee, BUSIAH/0000-0002-1059-0791; FROGUEL, Philippe/0000-0003-2972-0784; Scharfmann, Raphael/0000-0001-7619-337X; Cave, Helene/0000-0003-2840-1511	Medical Research Council [G0000477] Funding Source: researchfish; MRC [G0000477] Funding Source: UKRI; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044311, R01DK052771] Funding Source: NIH RePORTER	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Babenko ADP, 2005, J MOL CELL CARDIOL, V39, P79, DOI 10.1016/j.yjmcc.2004.12.004; Babenko AP, 2003, J BIOL CHEM, V278, P41577, DOI 10.1074/jbc.C300363200; Babenko AP, 1999, FEBS LETT, V445, P131, DOI 10.1016/S0014-5793(99)00102-7; Babenko AP, 2001, J BIOL CHEM, V276, P49083, DOI 10.1074/jbc.M108763200; Babenko AP, 1999, FEBS LETT, V459, P367, DOI 10.1016/S0014-5793(99)01215-6; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Bryan J, 2004, DIABETES, V53, pS104, DOI 10.2337/diabetes.53.suppl_3.S104; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Delepine M, 2000, NAT GENET, V25, P406, DOI 10.1038/78085; Gardner RJ, 2000, HUM MOL GENET, V9, P589, DOI 10.1093/hmg/9.4.589; Gloyn AL, 2004, NEW ENGL J MED, V350, P1838, DOI 10.1056/NEJMoa032922; Gribble FM, 1997, J PHYSIOL-LONDON, V504, P35, DOI 10.1111/j.1469-7793.1997.00035.x; Gribble FM, 2000, J BIOL CHEM, V275, P30046, DOI 10.1074/jbc.M001010200; Inagaki N, 1997, FEBS LETT, V409, P232, DOI 10.1016/S0014-5793(97)00488-2; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Klupa T, 2005, DIABETOLOGIA, V48, P1029, DOI 10.1007/s00125-005-1731-5; Koster JC, 2000, CELL, V100, P645, DOI 10.1016/S0092-8674(00)80701-1; Metz C, 2002, J PEDIATR-US, V141, P483, DOI 10.1067/mpd.2002.127089; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; Njolstad PR, 2001, NEW ENGL J MED, V344, P1588, DOI 10.1056/NEJM200105243442104; Peake JE, 1996, ARCH DIS CHILD-FETAL, V74, pF195, DOI 10.1136/fn.74.3.F195; Pearson ER, 2006, NEW ENGL J MED, V355, P467, DOI 10.1056/NEJMoa061759; Proks P, 2004, P NATL ACAD SCI USA, V101, P17539, DOI 10.1073/pnas.0404756101; Proks P, 2006, HUM MOL GENET, V15, P1793, DOI 10.1093/hmg/ddl101; Sellick GS, 2004, NAT GENET, V36, P1301, DOI 10.1038/ng1475; Shyng SL, 1998, DIABETES, V47, P1145, DOI 10.2337/diabetes.47.7.1145; Shyng SL, 1997, J GEN PHYSIOL, V110, P655, DOI 10.1085/jgp.110.6.655; Stoffers DA, 1997, NAT GENET, V15, P106, DOI 10.1038/ng0197-106; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Vaxillaire M, 2004, DIABETES, V53, P2719, DOI 10.2337/diabetes.53.10.2719	32	458	489	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 3	2006	355	5					456	466		10.1056/NEJMoa055068	http://dx.doi.org/10.1056/NEJMoa055068			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	069FT	16885549				2022-12-28	WOS:000239432500005
J	Mashchenko, S; Couchman, HMP; Wadsley, J				Mashchenko, Sergey; Couchman, H. M. P.; Wadsley, James			The removal of cusps from galaxy centres by stellar feedback in the early Universe	NATURE			English	Article							DWARF GALAXIES; GLOBULAR-CLUSTERS; STAR-FORMATION; DARK HALO; RESOLUTION; EVOLUTION; PROFILES; HYDROGEN	The standard cosmological model, now strongly constrained by direct observations of the Universe at early epochs, is very successful in describing the evolution of structure on large and intermediate scales(1). Unfortunately, serious contradictions remain on smaller, galactic scales(1,2). Among the main small-scale problems is a significant and persistent discrepancy between observations of nearby galaxies, which imply that galactic dark matter haloes have a density profile with a flat core(3-6), and the cosmological model, which predicts that the haloes should have divergent density ( a cusp) at the centre(7,8). Here we report numerical simulations that show that random bulk motions of gas in small primordial galaxies, of the magnitude expected in these systems, will result in a flattening of the central dark matter cusp on relatively short timescales (similar to 10(8) years). Gas bulk motions in early galaxies are driven by supernova explosions that result from ongoing star formation. Our mechanism is general, and would have operated in all star-forming galaxies at redshifts z >= 10. Once removed, the cusp cannot be reintroduced during the subsequent mergers involved in the build-up of larger galaxies(9,10). As a consequence, in the present Universe both small and large galaxies would have flat dark matter core density profiles, in agreement with observations.	McMaster Univ, Dept Phys & Astron, Hamilton, ON L8S 4M1, Canada	McMaster University	Mashchenko, S (corresponding author), McMaster Univ, Dept Phys & Astron, Hamilton, ON L8S 4M1, Canada.	syam@physics.mcmaster.ca						Begum A, 2003, ASTRON ASTROPHYS, V409, P879, DOI 10.1051/0004-6361:20031163; BRINKS E, 1986, ASTRON ASTROPHYS, V169, P14; Bromm V, 2002, ASTROPHYS J, V566, pL1, DOI 10.1086/339440; BURKERT A, 1995, ASTROPHYS J, V447, pL25, DOI 10.1086/309560; Coles P, 2005, NATURE, V433, P248, DOI 10.1038/nature03282; de Avillez MA, 2005, ASTRON ASTROPHYS, V436, P585, DOI 10.1051/0004-6361:20042146; De Blok WJG, 2005, ASTROPHYS J, V634, P227, DOI 10.1086/496912; de Blok WJG, 2002, ASTRON ASTROPHYS, V385, P816, DOI 10.1051/0004-6361:20020080; Dehnen W, 2005, MON NOT R ASTRON SOC, V360, P892, DOI 10.1111/j.1365-2966.2005.09099.x; DEUL ER, 1987, ASTRON ASTROPHYS SUP, V67, P509; El-Zant A, 2001, ASTROPHYS J, V560, P636, DOI 10.1086/322516; Gentile G, 2005, ASTROPHYS J, V634, pL145, DOI 10.1086/498939; Gnedin OY, 2002, MON NOT R ASTRON SOC, V333, P299, DOI 10.1046/j.1365-8711.2002.05361.x; Kazantzidis S, 2006, ASTROPHYS J, V641, P647, DOI 10.1086/500579; Kim S, 1998, ASTROPHYS J, V503, P674, DOI 10.1086/306030; LYNDENBELL D, 1967, MON NOT R ASTRON SOC, V136, P101, DOI 10.1093/mnras/136.1.101; Mac Low MM, 1999, ASTROPHYS J, V513, P142, DOI 10.1086/306832; Merritt D, 2004, ASTROPHYS J, V607, pL9, DOI 10.1086/421551; Moore B, 1999, ASTROPHYS J, V524, pL19, DOI 10.1086/312287; Navarro JF, 2004, MON NOT R ASTRON SOC, V349, P1039, DOI 10.1111/j.1365-2966.2004.07586.x; Navarro JF, 1997, ASTROPHYS J, V490, P493, DOI 10.1086/304888; Pelupessy FI, 2004, ASTRON ASTROPHYS, V422, P55, DOI 10.1051/0004-6361:20047071; Sanchez-Salcedo FJ, 2005, ASTROPHYS J, V631, P244, DOI 10.1086/432593; Slyz AD, 2005, MON NOT R ASTRON SOC, V356, P737, DOI 10.1111/j.1365-2966.2004.08494.x; Spergel DN, 2003, ASTROPHYS J SUPPL S, V148, P175, DOI 10.1086/377226; Springel V, 2001, NEW ASTRON, V6, P79, DOI 10.1016/S1384-1076(01)00042-2; Tasitsiomi A, 2003, INT J MOD PHYS D, V12, P1157, DOI 10.1142/S0218271803003426; Weinberg MD, 2002, ASTROPHYS J, V580, P627, DOI 10.1086/343847; Young LM, 1997, ASTROPHYS J, V490, P710, DOI 10.1086/304909	30	220	221	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 3	2006	442	7102					539	542		10.1038/nature04944	http://dx.doi.org/10.1038/nature04944			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	069NQ	16885978				2022-12-28	WOS:000239455900037
J	Maxted, PFL; Napiwotzki, R; Dobbie, PD; Burleigh, MR				Maxted, P. F. L.; Napiwotzki, R.; Dobbie, P. D.; Burleigh, M. R.			Survival of a brown dwarf after engulfment by a red giant star	NATURE			English	Article							WHITE-DWARFS; CATACLYSMIC VARIABLES; PLANETS; MASS; COMPANIONS; EVOLUTION; BINARIES; PROGENITORS; PHOTOMETRY; SEARCH	Many sub-stellar companions ( usually planets but also some brown dwarfs) orbit solar-type stars. These stars can engulf their sub-stellar companions when they become red giants. This interaction may explain several outstanding problems in astrophysics(1-5) but it is unclear under what conditions a low mass companion will evaporate, survive the interaction unchanged or gain mass(1,4,5). Observational tests of models for this interaction have been hampered by a lack of positively identified remnants that is, white dwarf stars with close, sub-stellar companions. The companion to the pre-white dwarf AA Doradus may be a brown dwarf, but the uncertain history of this star and the extreme luminosity difference between the components make it difficult to interpret the observations or to put strong constraints on the models(6,7). The magnetic white dwarf SDSS J121209.31+013627.7 may have a close brown dwarf companion(8) but little is known about this binary at present. Here we report the discovery of a brown dwarf in a short period orbit around a white dwarf. The properties of both stars in this binary can be directly observed and show that the brown dwarf was engulfed by a red giant but that this had little effect on it.	Univ Keele, Astrophys Grp, Keele ST5 5BG, Staffs, England; Univ Hertfordshire, Ctr Astrophys Res, Hatfield AL10 9AB, Herts, England; Univ Leicester, Dept Phys & Astron, Leicester LE1 7RH, Leics, England	Keele University; University of Hertfordshire; University of Leicester	Maxted, PFL (corresponding author), Univ Keele, Astrophys Grp, Keele ST5 5BG, Staffs, England.	pflm@astro.keele.ac.uk		Burleigh, Matthew/0000-0003-0684-7803	Science and Technology Facilities Council [PP/D000955/1] Funding Source: researchfish; STFC [PP/D000955/1] Funding Source: UKRI	Science and Technology Facilities Council(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC)); STFC(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC))		BEERS TC, 1992, ASTRON J, V103, P267, DOI 10.1086/116060; Benvenuto OG, 1999, MON NOT R ASTRON SOC, V303, P30, DOI 10.1046/j.1365-8711.1999.02215.x; BERGERON P, 1995, PUBL ASTRON SOC PAC, V107, P1047, DOI 10.1086/133661; Dobbie PD, 2005, MON NOT R ASTRON SOC, V357, P1049, DOI 10.1111/j.1365-2966.2005.08720.x; Driebe T, 1998, ASTRON ASTROPHYS, V339, P123; Endl M, 2004, ASTROPHYS J, V611, P1121, DOI 10.1086/422310; Farihi J, 2005, ASTROPHYS J SUPPL S, V161, P394, DOI 10.1086/444362; Grether D, 2006, ASTROPHYS J, V640, P1051, DOI 10.1086/500161; HARPAZ A, 1994, MON NOT R ASTRON SOC, V270, P734, DOI 10.1093/mnras/270.4.734; Hilditch RW, 2003, MON NOT R ASTRON SOC, V344, P644, DOI 10.1046/j.1365-8711.2003.06860.x; Koester D, 2001, ASTRON ASTROPHYS, V378, P556, DOI 10.1051/0004-6361:20011235; LIEBERT JW, 2002, ENCY ASTRONOMY ASTRO; Littlefair SP, 2005, ASTRON ASTROPHYS, V437, P637, DOI 10.1051/0004-6361:20052780; Littlefair SP, 2003, MON NOT R ASTRON SOC, V340, P264, DOI 10.1046/j.1365-8711.2003.06295.x; LIVIO M, 1983, ASTRON ASTROPHYS, V125, pL12; MARSH TR, 1995, MON NOT R ASTRON SOC, V275, P828, DOI 10.1093/mnras/275.3.828; Maxted PFL, 1998, MON NOT R ASTRON SOC, V300, P1225, DOI 10.1046/j.1365-8711.1998.02036.x; Napiwotzki R, 2001, ASTRON NACHR, V322, P411, DOI 10.1002/1521-3994(200112)322:5/6<411::AID-ASNA411>3.0.CO;2-I; Nelemans G, 2005, MON NOT R ASTRON SOC, V356, P753, DOI 10.1111/j.1365-2966.2004.08496.X; Nelemans G, 1998, ASTRON ASTROPHYS, V335, pL85; Politano M, 2004, ASTROPHYS J, V604, P817, DOI 10.1086/381958; PRESTON GW, 1991, ASTROPHYS J SUPPL S, V76, P1001, DOI 10.1086/191587; Rauch T., 2004, REV MEX ASTRON ASTR, V20, P246; Schmidt GD, 2005, ASTROPHYS J, V630, pL173, DOI 10.1086/491702; Schreiber MR, 2003, ASTRON ASTROPHYS, V406, P305, DOI 10.1051/0004-6361:20030801; Siess L, 1999, MON NOT R ASTRON SOC, V308, P1133, DOI 10.1046/j.1365-8711.1999.02784.x; Soker N, 2000, MON NOT R ASTRON SOC, V317, P861, DOI 10.1046/j.1365-8711.2000.03738.x; Vauclair G, 1997, ASTRON ASTROPHYS, V325, P1055	28	141	142	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 3	2006	442	7102					543	545		10.1038/nature04987	http://dx.doi.org/10.1038/nature04987			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	069NQ	16885979	Green Submitted			2022-12-28	WOS:000239455900038
J	Mulholland, EK				Mulholland, E. Kim			Measles in the United States, 2006	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							OUTBREAK		London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, London WC1, England	University of London; London School of Hygiene & Tropical Medicine	Mulholland, EK (corresponding author), London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, London WC1, England.							EDMONSON MB, 1990, JAMA-J AM MED ASSOC, V263, P2467, DOI 10.1001/jama.263.18.2467; GARENNE M, 1990, J INFECT DIS, V161, P1088, DOI 10.1093/infdis/161.6.1088; Gershman K., 2006, Morbidity and Mortality Weekly Report, V55, P559; Katz SL, 2004, J INFECT DIS, V189, pS43, DOI 10.1086/377696; Whittle HC, 1999, LANCET, V353, P98, DOI 10.1016/S0140-6736(98)02364-2	5	15	17	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 3	2006	355	5					440	443		10.1056/NEJMp068149	http://dx.doi.org/10.1056/NEJMp068149			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	069FT	16885546	Green Published, Bronze			2022-12-28	WOS:000239432500002
J	Calonge, N; Petitti, DB; DeWitt, TG; Gordis, L; Gregory, KD; Harris, R; Kizer, KW; LeFevre, ML; Loveland-Cherry, C; Marion, LN; Moyer, VA; Ockene, JK; Sawaya, GF; Siu, AL; Teutsch, SM; Yawn, BP				Calonge, Ned; Petitti, Diana B.; DeWitt, Thomas G.; Gordis, Leon; Gregory, Kimberly D.; Harris, Russell; Kizer, Kenneth W.; LeFevre, Michael L.; Loveland-Cherry, Carol; Marion, Lucy N.; Moyer, Virginia A.; Ockene, Judith K.; Sawaya, George F.; Siu, Albert L.; Teutsch, Steven M.; Yawn, Barbara P.		US Preventive Serv Task Force	Screening for hemochromatosis: Recommendation statement	ANNALS OF INTERNAL MEDICINE			English	Article							LONG-TERM SURVIVAL; HEREDITARY HEMOCHROMATOSIS; POPULATION; IRON	This statement summarizes the U.S. Preventive Services Task Force (USPSTF) recommendation on screening for hemochromatosis and the supporting scientific evidence. The complete information on which this statement is based, including evidence tables and references, is available in the accompanying article in this issue and on the USPSTF Web site (www.preventiveservices.ahrq.gov). The USPSTF is redesigning its recommendation statement in response to feedback from primary care clinicians. The USPSTF plans to release, later in 2006, a new, updated recommendation statement that is easier to read and incorporates advances in USPSTF methods. The recommendation statement in this paper is an interim version that combines existing language and elements with a new format. Although the definitions of grades remain the same, other elements have been revised.	US Prevent Serv Task Force, Agcy Healthcare Res & Qual, Rockville, MD USA	Agency for Healthcare Research & Quality	Calonge, N (corresponding author), US Prevent Serv Task Force, Agcy Healthcare Res & Qual, Rockville, MD USA.							ADAMS PC, 1991, GASTROENTEROLOGY, V101, P368, DOI 10.1016/0016-5085(91)90013-B; Andersen RV, 2004, BLOOD, V103, P2914, DOI 10.1182/blood-2003-10-3564; Beutler E, 2002, ACTA HAEMATOL-BASEL, V107, P145, DOI 10.1159/000057632; BOMFORD A, 1976, Q J MED, V45, P611; *CDCP, IR OV HEM HOM; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Niederau C, 1996, GASTROENTEROLOGY, V110, P1107, DOI 10.1053/gast.1996.v110.pm8613000; Olynyk JK, 2004, MAYO CLIN PROC, V79, P309, DOI 10.4065/79.3.309; Powell LW, 2006, ARCH INTERN MED, V166, P294, DOI 10.1001/archinte.166.3.294; Qaseem A, 2005, ANN INTERN MED, V143, P517, DOI 10.7326/0003-4819-143-7-200510040-00010; Tavill AS, 2001, HEPATOLOGY, V33, P1321, DOI 10.1053/jhep.2001.24783; Whitlock EP, 2006, ANN INTERN MED, V145, P209, DOI 10.7326/0003-4819-145-3-200608010-00009	12	30	31	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	2006	145	3					204	208		10.7326/0003-4819-145-3-200608010-00008	http://dx.doi.org/10.7326/0003-4819-145-3-200608010-00008			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	070MN	16880462				2022-12-28	WOS:000239526800006
J	Greenwood, RC; Franchi, IA; Jambon, A; Barrat, JA; Burbine, TH				Greenwood, R. C.; Franchi, I. A.; Jambon, A.; Barrat, J. A.; Burbine, T. H.			Oxygen isotope variation in stony-iron meteorites	SCIENCE			English	Article							PARENT BODY; PLANETESIMALS; ORIGIN; MESOSIDERITES; CONSTRAINTS; COLLISIONS; ACCRETION; HISTORY; SYSTEM	Asteroidal material, delivered to Earth as meteorites, preserves a record of the earliest stages of planetary formation. High-precision oxygen isotope analyses for the two major groups of stony-iron meteorites (main-group pallasites and mesosiderites) demonstrate that each group is from a distinct asteroidal source. Mesosiderites are isotopically identical to the howardite-eucrite-diogenite clan and, like them, are probably derived from the asteroid 4 Vesta. Main-group pallasites represent intermixed core-mantle material from a single disrupted asteroid and have no known equivalents among the basaltic meteorites. The stony-iron meteorites demonstrate that intense asteroidal deformation accompanied planetary accretion in the early Solar System.	Open Univ, Planetary & Space Sci Res Inst, Milton Keynes MK7 6AA, Bucks, England; Univ Paris 06, Lab Magmatol & Geochim Inorgan & Expt, CNRS, UMR 7047, F-75252 Paris 05, France; Univ Bretagne Occidentale, Univ Europeen Mer, CNRS, UMR 6538, F-29280 Plouzane, France; Mt Holyoke Coll, Dept Astron, S Hadley, MA 01075 USA	Open University - UK; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); Universite de Bretagne Occidentale; Institut Universitaire Europeen de la Mer (IUEM); Mount Holyoke College	Greenwood, RC (corresponding author), Open Univ, Planetary & Space Sci Res Inst, Walton Hall, Milton Keynes MK7 6AA, Bucks, England.	r.c.greenwood@open.ac.uk	Barrat, Jean-Alix/C-8416-2017; Jean-Alix, BARRAT/F-8035-2012	Barrat, Jean-Alix/0000-0003-3158-3109; Greenwood, Richard/0000-0002-5544-8027				Asphaug E, 2006, NATURE, V439, P155, DOI 10.1038/nature04311; Bizzarro M, 2005, ASTROPHYS J, V632, pL41, DOI 10.1086/497638; Burbine T. H., 2002, ASTEROIDS, VIII, P653, DOI DOI 10.2307/J.CTV1V7ZDN4.50; Burbine TH, 2001, METEORIT PLANET SCI, V36, P761, DOI 10.1111/j.1945-5100.2001.tb01915.x; Clayton RN, 1996, GEOCHIM COSMOCHIM AC, V60, P1999, DOI 10.1016/0016-7037(96)00074-9; Greenwood RC, 2005, NATURE, V435, P916, DOI 10.1038/nature03612; HEWINS RH, 1983, J GEOPHYS RES, V88, pB257, DOI 10.1029/JB088iS01p0B257; Markowski A, 2006, EARTH PLANET SC LETT, V242, P1, DOI 10.1016/j.epsl.2005.11.048; Miller MF, 1999, RAPID COMMUN MASS SP, V13, P1211, DOI 10.1002/(SICI)1097-0231(19990715)13:13<1211::AID-RCM576>3.3.CO;2-D; Miller MF, 2002, GEOCHIM COSMOCHIM AC, V66, P1881, DOI 10.1016/S0016-7037(02)00832-3; MITTLEFEHLDT DW, 1998, MIN SOC AM REV MINER, V36; ROSING MT, 2004, LUNAR PLANET SCI C, V35, P1487; Rubie DC, 2004, NATURE, V429, P58, DOI 10.1038/nature02473; RUBIN AE, 1993, ICARUS, V101, P201, DOI 10.1006/icar.1993.1018; Russell CT, 2004, PLANET SPACE SCI, V52, P465, DOI 10.1016/j.pss.2003.06.013; Scott E.R.D., 1990, 21 LUN PLAN SCI C, P1119; Scott ERD, 2001, METEORIT PLANET SCI, V36, P869, DOI 10.1111/j.1945-5100.2001.tb01927.x; Song IS, 2005, NATURE, V436, P363, DOI 10.1038/nature03853; TOMIYAMA T, 2005, LUNAR PLANET SCI C, V36, P2071; Wadhwa M, 2003, GEOCHIM COSMOCHIM AC, V67, P5047, DOI 10.1016/j.gca.2003.08.005; WASSON JT, 1985, NATURE, V318, P168, DOI 10.1038/318168a0; Wasson JT, 2003, GEOCHIM COSMOCHIM AC, V67, P3079, DOI 10.1016/S0016-7037(03)00306-5; Weidenschilling SJ, 2000, SPACE SCI REV, V92, P295, DOI 10.1023/A:1005259615299; Wiechert UH, 2004, EARTH PLANET SC LETT, V221, P373, DOI 10.1016/S0012-821X(04)00090-1; YAMAGUCHI A, 2006, LUNAR PLANET SCI C, V37, P1678	25	94	94	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 22	2006	313	5794					1763	1765		10.1126/science.1128865	http://dx.doi.org/10.1126/science.1128865			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	086ED	16931721	Bronze			2022-12-28	WOS:000240655700041
J	Sturm, A; Amino, R; van de Sand, C; Regen, T; Retzlaff, S; Rennenberg, A; Krueger, A; Pollok, JM; Menard, R; Heussler, VT				Sturm, Angelika; Amino, Rogerio; van de Sand, Claudia; Regen, Tommy; Retzlaff, Silke; Rennenberg, Annika; Krueger, Andreas; Pollok, Joerg-Matthias; Menard, Robert; Heussler, Volker T.			Manipulation of host hepatocytes by the malaria parasite for delivery into liver sinusoids	SCIENCE			English	Article							PLASMODIUM-BERGHEI; PHOSPHATIDYLSERINE; EXPOSURE; MOSQUITO; CELLS	The merozoite stage of the malaria parasite that infects erythrocytes and causes the symptoms of the disease is initially formed inside host hepatocytes. However, the mechanism by which hepatic merozoites reach blood vessels (sinusoids) in the liver and escape the host immune system before invading erythrocytes remains unknown. Here, we show that parasites induce the death and the detachment of their host hepatocytes, followed by the budding of parasite-filled vesicles (merosomes) into the sinusoid lumen. Parasites simultaneously inhibit the exposure of phosphatidylserine on the outer leaflet of host plasma membranes, which act as "eat me'' signals to phagocytes. Thus, the hepatocyte-derived merosomes appear to ensure both the migration of parasites into the bloodstream and their protection from host immunity.	Bernhard Nocht Inst Trop Med, D-20359 Hamburg, Germany; Inst Pasteur, Dept Parasitol, F-75724 Paris 15, France; Univ Fed Sao Paulo, Dept Biochem, BR-04044020 Sao Paulo, Brazil; Univ Hamburg, Hosp Eppendorf, Dept Hepatobiliary Surg, D-20246 Hamburg, Germany	Bernhard Nocht Institut fur Tropenmedizin; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Universidade Federal de Sao Paulo (UNIFESP); University of Hamburg	Heussler, VT (corresponding author), Bernhard Nocht Inst Trop Med, Bernhard Nocht Str 74, D-20359 Hamburg, Germany.	heussler@bni-hamburg.de	Regen, Tommy/GQH-6929-2022; Heussler, Volker/H-9322-2019	Heussler, Volker/0000-0001-8028-9825; Regen, Tommy/0000-0002-7275-3330				Amino R, 2006, NAT MED, V12, P220, DOI 10.1038/nm1350; Biagini GA, 2003, J BIOL CHEM, V278, P27910, DOI 10.1074/jbc.M304193200; Fadok VA, 2001, J BIOL CHEM, V276, P1071, DOI 10.1074/jbc.M003649200; Franke-Fayard B, 2004, MOL BIOCHEM PARASIT, V137, P23, DOI 10.1016/j.molbiopara.2004.04.007; Frevert U, 2005, PLOS BIOL, V3, P1034, DOI 10.1371/journal.pbio.0030192; Leiriao P, 2005, CELL MICROBIOL, V7, P603, DOI 10.1111/j.1462-5822.2004.00490.x; Li MO, 2003, SCIENCE, V302, P1560, DOI 10.1126/science.1087621; Natarajan R, 2001, CELL MICROBIOL, V3, P371, DOI 10.1046/j.1462-5822.2001.00117.x; TERZAKIS JA, 1979, J PROTOZOOL, V26, P385, DOI 10.1111/j.1550-7408.1979.tb04641.x; van de Sand C, 2005, MOL MICROBIOL, V58, P731, DOI 10.1111/j.1365-2958.2005.04888.x; VERHOVEN B, 1995, J EXP MED, V182, P1597, DOI 10.1084/jem.182.5.1597; WASSERMAN M, 1990, PARASITOL RES, V76, P681, DOI 10.1007/BF00931087	12	339	348	1	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 1	2006	313	5791					1287	1290		10.1126/science.1129720	http://dx.doi.org/10.1126/science.1129720			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	081JI	16888102				2022-12-28	WOS:000240313500041
J	Muzzey, D; van Oudenaarden, A				Muzzey, Dale; van Oudenaarden, Alexander			When it comes to decisions, myeloid progenitors crave positive feedback	CELL			English	Editorial Material							ESCHERICHIA-COLI		MIT, Dept Phys, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Grad Program Biophys, Boston, MA 02115 USA	Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School	van Oudenaarden, A (corresponding author), MIT, Dept Phys, Cambridge, MA 02139 USA.	avano@mit.edu	van Oudenaarden, Alexander/AAA-1705-2019					Acar M, 2005, NATURE, V435, P228, DOI 10.1038/nature03524; Becskei A, 2001, EMBO J, V20, P2528, DOI 10.1093/emboj/20.10.2528; Cantor AB, 2001, CURR OPIN GENET DEV, V11, P513, DOI 10.1016/S0959-437X(00)00226-4; Dahl R, 2003, NAT IMMUNOL, V4, P1029, DOI 10.1038/ni973; Gardner TS, 2000, NATURE, V403, P339, DOI 10.1038/35002131; Isaacs FJ, 2003, P NATL ACAD SCI USA, V100, P7714, DOI 10.1073/pnas.1332628100; LASLO P, 2006, CELL; Miyamoto T, 2005, INT J HEMATOL, V81, P361, DOI 10.1532/IJH97.05003; Orkin SH, 2000, NAT REV GENET, V1, P57, DOI 10.1038/35049577; Ozbudak EM, 2004, NATURE, V427, P737, DOI 10.1038/nature02298	10	9	9	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 25	2006	126	4					650	652		10.1016/j.cell.2006.08.007	http://dx.doi.org/10.1016/j.cell.2006.08.007			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	080VN	16923384	Bronze			2022-12-28	WOS:000240276700012
J	Bunge, J; Epstein, SS; Peterson, DG				Bunge, John; Epstein, Slava S.; Peterson, Daniel G.			Comment on "Computational improvements reveal great bacterial diversity and high metal toxicity in soil"	SCIENCE			English	Editorial Material							DNA-SEQUENCES; KINETICS		Cornell Univ, Dept Stat Sci, Ithaca, NY 14853 USA; Northeastern Univ, Dept Biol, Boston, MA 02115 USA; Northeastern Univ, Ctr Marine Sci, Boston, MA 02115 USA; Mississippi State Univ, Dept Plant & Soil Sci, Mississippi State, MS 39762 USA	Cornell University; Northeastern University; Northeastern University; Mississippi State University	Bunge, J (corresponding author), Cornell Univ, Dept Stat Sci, Ithaca, NY 14853 USA.	jab18@cornell.edu		Peterson, Daniel/0000-0002-0274-5968				BENDICH AJ, 1977, BIOCHEMISTRY-US, V16, P4655, DOI 10.1021/bi00640a020; Bissett A, 2006, FEMS MICROBIOL ECOL, V55, P48, DOI 10.1111/j.1574-6941.2005.00012.x; Bohning D, 2005, J R STAT SOC C-APPL, V54, P721, DOI 10.1111/j.1467-9876.2005.05324.x; Britten R J, 1974, Methods Enzymol, V29, P363; Davidian M, 2003, J AGR BIOL ENVIR ST, V8, P387, DOI 10.1198/1085711032697; ERDI P., 1989, MATH MODELS CHEM REA; Gans J, 2005, SCIENCE, V309, P1387, DOI 10.1126/science.1112665; GRAHAM DE, 1974, CELL, V1, P127, DOI 10.1016/0092-8674(74)90128-7; Hong SH, 2006, P NATL ACAD SCI USA, V103, P117, DOI 10.1073/pnas.0507245102; Kemp PF, 2004, FEMS MICROBIOL ECOL, V47, P161, DOI 10.1016/S0168-6496(03)00257-5; Murugan R, 2002, BIOCHEM BIOPH RES CO, V293, P870, DOI 10.1016/S0006-291X(02)00305-4; Nagy ML, 2005, FEMS MICROBIOL ECOL, V54, P233, DOI 10.1016/j.femsec.2005.03.011; Sandaa RA, 1999, FEMS MICROBIOL ECOL, V30, P237, DOI 10.1111/j.1574-6941.1999.tb00652.x; Seber G., 1989, NONLINEAR REGRESSION; SMITH MJ, 1975, P NATL ACAD SCI USA, V72, P4805, DOI 10.1073/pnas.72.12.4805	15	19	20	3	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 18	2006	313	5789								10.1126/science.1126593	http://dx.doi.org/10.1126/science.1126593			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	074MR	16917045				2022-12-28	WOS:000239817000021
J	Volkov, I; Banavar, JR; Maritan, A				Volkov, Igor; Banavar, Jayanth R.; Maritan, Amos			Comment on "Computational improvements reveal great bacterial diversity and high metal toxicity in soil"	SCIENCE			English	Editorial Material									Penn State Univ, Dept Phys, University Pk, PA 16802 USA; Penn State Univ, Dept Biol, Mueller Lab 208, University Pk, PA 16802 USA; Univ Padua, Dipartimento Fis Galileo Galilei, I-35131 Padua, Italy; Ist Nazl Fis Mat, I-35131 Padua, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Padua; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Padua	Volkov, I (corresponding author), Penn State Univ, Dept Phys, 104 Davey Lab, University Pk, PA 16802 USA.	volkov@psu.edu	Volkov, Igor/GVT-6571-2022	Maritan, Amos/0000-0002-3535-7873				Curtis TP, 2005, SCIENCE, V309, P1331, DOI 10.1126/science.1118176; Gans J, 2005, SCIENCE, V309, P1387, DOI 10.1126/science.1112665; Sandaa RA, 1999, FEMS MICROBIOL ECOL, V30, P237, DOI 10.1111/j.1574-6941.1999.tb00652.x	3	14	16	2	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 18	2006	313	5789								10.1126/science.1121225	http://dx.doi.org/10.1126/science.1121225			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	074MR	16917044				2022-12-28	WOS:000239817000019
J	Gautschi, OP; Zellweger, R				Gautschi, Oliver P.; Zellweger, Rene			Methicillin-resistant Staphylococcus aureus abscess after intramuscular steroid injection	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Royal Perth Hosp, Perth, WA 6000, Australia	Royal Perth Hospital; University of Western Australia	Gautschi, OP (corresponding author), Royal Perth Hosp, Perth, WA 6000, Australia.								0	4	5	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 17	2006	355	7					713	713		10.1056/NEJMicm062498	http://dx.doi.org/10.1056/NEJMicm062498			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	074AN	16914707				2022-12-28	WOS:000239784500010
J	Kim, JY; Farmer, P				Kim, Jim Yong; Farmer, Paul			AIDS in 2006 - Moving toward one world, one hope?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SURVIVAL; HEALTH		Brigham & Womens Hosp, Div Social Med & Hlth Inequal, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Partners Hlth, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Partners Healthcare System	Kim, JY (corresponding author), Brigham & Womens Hosp, Div Social Med & Hlth Inequal, 75 Francis St, Boston, MA 02115 USA.							Behforouz HL, 2004, CLIN INFECT DIS, V38, pS429, DOI 10.1086/421408; Gupta R, 2001, SCIENCE, V293, P1049, DOI 10.1126/science.1061861; Paton NI, 2006, HIV MED, V7, P323, DOI 10.1111/j.1468-1293.2006.00383.x; Walensky RP, 2006, J INFECT DIS, V194, P11, DOI 10.1086/505147; Walton DA, 2004, J PUBLIC HEALTH POL, V25, P137, DOI 10.1057/palgrave.jphp.3190013	5	36	38	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 17	2006	355	7					645	647		10.1056/NEJMp068166	http://dx.doi.org/10.1056/NEJMp068166			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	074AN	16914698				2022-12-28	WOS:000239784500001
J	Shlipak, MG; Katz, R; Sarnak, MJ; Fried, LF; Newman, AB; Stehman-Breen, C; Seliger, SL; Kestenbaum, B; Psaty, B; Tracy, RP; Siscovick, DS				Shlipak, Michael G.; Katz, Ronit; Sarnak, Mark J.; Fried, Linda F.; Newman, Anne B.; Stehman-Breen, Catherine; Seliger, Stephen L.; Kestenbaum, Brian; Psaty, Bruce; Tracy, Russell P.; Siscovick, David S.			Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease	ANNALS OF INTERNAL MEDICINE			English	Article							GLOMERULAR-FILTRATION-RATE; THYROID-DYSFUNCTION; RENAL DYSFUNCTION; HEART-FAILURE; RISK-FACTOR; CREATININE; EVENTS; DEFINITION; MORTALITY; GLUCOSE	Background: Cystatin C is an alternative measure of kidney function that may have prognostic importance among elderly persons who do not meet standard criteria for chronic kidney disease (estimated glomerular filtration rate [GFR] >= 60 mL/min per 1.73 m(2)). Objective: To evaluate cystatin C as a prognostic biomarker for death, cardiovascular disease, and incident chronic kidney disease among elderly persons without chronic kidney disease. Design: Cohort study. Setting: The Cardiovascular Health Study, a population-based cohort recruited from 4 communities in the United States. Participants: 4663 elderly persons Measurements: Measures of kidney function were creatinine-based estimated GFR by using the Modification of Diet in Renal Disease equation and cystatin C concentration. Outcomes were death, cardiovascular death, noncardiovascular death, heart failure, stroke, myocardial infarction, and incident chronic kidney disease during follow-up (median, 9.3 years). Results: At baseline, 78% of participants did not have chronic kidney disease (estimated GFR 60 mL/min per 1.73 m(2)) and mean cystatin C concentration, creatinine concentration, and estimated GFR were 1.0 mg/L, 79.6 mu mol/L (0.9 mg/dL, and 83 mL/min per 1.73 m(2), respectively. Cystatin C concentrations (per SD, 0.18 mg/L) had strong associations with death (hazard ratio, 1.33 [95% CI, 1.25 to 1.40]), cardiovascular death (hazard ratio, 1.42 [CI, 1.30 to 1.54]), noncardiovascular death (hazard ratio, 1.26 [CI, 1.17 to 1.36]), incident heart failure (hazard ratio, 1.28 [CI, 1.17 to 1.401), stroke (hazard ratio, 1.22 [CI, 1.08 to 1.381), and myocardial infarction (hazard ratio, 1.20 [CI, 1.06 to 1.36]) among these participants. Serum creatinine concentrations had much weaker associations with each outcome and only predicted cardiovascular death. Participants without chronic kidney disease who had elevated cystatin C concentrations (>= 1.0 mg/L) had a 4-fold risk for progressing to chronic kidney disease after 4 years of follow-up compared with those with cystatin C concentrations less than 1.0 mg/L. Limitations: Because this study did not directly measure GFR or albuminuria, the extent to which cystatin C may be influenced by nonrenal factors was not determined and participants with albuminuria might have been misclassified as having no kidney disease. Conclusions: Among elderly persons without chronic kidney disease, cystatin C is a prognostic biomarker of risk for death, cardiovascular disease, and chronic kidney disease. In this setting, cystatin C seems to identify a "preclinical" state of kidney dysfunction that is not detected with serum creatinine or estimated GFR.	Vet Adm Med Ctr, Gen Internal Med Sect, San Francisco, CA 94121 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Univ Washington, Seattle, WA 98195 USA; Tufts Univ, New England Med Ctr, Boston, MA 02111 USA; Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA; Univ Pittsburgh, Pittsburgh, PA USA; Amgen Inc, Thousand Oaks, CA 91320 USA; Univ Vermont, Coll Med, Burlington, VT USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of Washington; University of Washington Seattle; Tufts Medical Center; Tufts University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Amgen; University of Vermont	Shlipak, MG (corresponding author), Vet Adm Med Ctr, Gen Internal Med Sect, 111A1,4150 Clement St, San Francisco, CA 94121 USA.	michael.shlipak@ucsf.edu	Katz, Ronit/ABA-1880-2021; Newman, Anne B./C-6408-2013	Newman, Anne B./0000-0002-0106-1150	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC015103, N01HC085081, N01HC085079, N01HC085085, N01HC085082, N01HC085083, N01HC085084, N01HC035129, N01HC085080, N01HC085086] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073208] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK066488] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG027002] Funding Source: NIH RePORTER	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BJARNADOTTIR M, 1995, SCAND J CLIN LAB INV, V55, P617, DOI 10.3109/00365519509110261; Burkhardt H, 2002, GERONTOLOGY, V48, P140, DOI 10.1159/000052832; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; CUSHMAN M, 1995, CLIN CHEM, V41, P264; den Hollander JG, 2005, CLIN ENDOCRINOL, V62, P423, DOI 10.1111/j.1365-2265.2005.02236.x; Dharnidharka VR, 2002, AM J KIDNEY DIS, V40, P221, DOI 10.1053/ajkd.2002.34487; Eilers PHC, 1996, STAT SCI, V11, P89, DOI 10.1214/ss/1038425655; Erlandsen EJ, 1999, SCAND J CLIN LAB INV, V59, P1, DOI 10.1080/00365519950185940; Finney H, 2000, ANN CLIN BIOCHEM, V37, P49, DOI 10.1258/0004563001901524; Fliser D, 2001, AM J KIDNEY DIS, V37, P79, DOI 10.1053/ajkd.2001.20591; Fricker M, 2003, KIDNEY INT, V63, P1944, DOI 10.1046/j.1523-1755.2003.00925.x; Fried LF, 2005, J AM SOC NEPHROL, V16, P3728, DOI 10.1681/ASN.2005040384; Fried Linda P., 1991, Annals of Epidemiology, V1, P263; Garg AX, 2002, KIDNEY INT, V61, P2165, DOI 10.1046/j.1523-1755.2002.00356.x; Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031; Gottdiener JS, 2000, J AM COLL CARDIOL, V35, P1628, DOI 10.1016/S0735-1097(00)00582-9; Hu FB, 2002, DIABETES CARE, V25, P1129, DOI 10.2337/diacare.25.7.1129; Ives Diane G., 1995, Annals of Epidemiology, V5, P278, DOI 10.1016/1047-2797(94)00093-9; Kanaya AM, 2005, ANN INTERN MED, V142, P813, DOI 10.7326/0003-4819-142-10-200505170-00006; Knight EL, 2004, KIDNEY INT, V65, P1416, DOI 10.1111/j.1523-1755.2004.00517.x; Levey AS, 2005, KIDNEY INT, V67, P2089, DOI 10.1111/j.1523-1755.2005.00365.x; Manjunath G, 2003, KIDNEY INT, V63, P1121, DOI 10.1046/j.1523-1755.2003.00838.x; O'Hare AM, 2005, ARCH INTERN MED, V165, P2666, DOI 10.1001/archinte.165.22.2666; O'Riordan SE, 2003, ANN CLIN BIOCHEM, V40, P648, DOI 10.1258/000456303770367243; Perkins BA, 2005, J AM SOC NEPHROL, V16, P1404, DOI 10.1681/ASN.2004100854; Price T R, 1993, Ann Epidemiol, V3, P504; Psaty Bruce M., 1995, Annals of Epidemiology, V5, P270, DOI 10.1016/1047-2797(94)00092-8; Risch L, 2001, CLIN CHEM, V47, P2055; Rule AD, 2004, ANN INTERN MED, V141, P929, DOI 10.7326/0003-4819-141-12-200412210-00009; Rule AD, 2006, KIDNEY INT, V69, P399, DOI 10.1038/sj.ki.5000073; Sarnak MJ, 2005, ANN INTERN MED, V142, P497, DOI 10.7326/0003-4819-142-7-200504050-00008; Shlipak MG, 2005, J AM COLL CARDIOL, V45, P268, DOI 10.1016/j.jacc.2004.09.061; Shlipak MG, 2005, JAMA-J AM MED ASSOC, V293, P1737, DOI 10.1001/jama.293.14.1737; Shlipak MG, 2005, NEW ENGL J MED, V352, P2049, DOI 10.1056/NEJMoa043161; Stevens LA, 2004, ANN INTERN MED, V141, P959, DOI 10.7326/0003-4819-141-12-200412210-00013; Unwin N, 2002, DIABETIC MED, V19, P708, DOI 10.1046/j.1464-5491.2002.00835.x; Van Den Noortgate NJ, 2002, J AM GERIATR SOC, V50, P1278, DOI 10.1046/j.1532-5415.2002.50317.x; Vasan RS, 2001, LANCET, V358, P1682, DOI 10.1016/S0140-6736(01)06710-1; Wasen E, 2004, J INTERN MED, V256, P70, DOI 10.1111/j.1365-2796.2004.01340.x; Wolf G, 2002, AM J KIDNEY DIS, V39, P1, DOI 10.1053/ajkd.2002.29865; 2005, NEPHROLOGY CARLTON, V10, pS157	41	410	439	1	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	2006	145	4					237	246		10.7326/0003-4819-145-4-200608150-00003	http://dx.doi.org/10.7326/0003-4819-145-4-200608150-00003			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	075CC	16908914				2022-12-28	WOS:000239858800001
J	Steinman, MA; Bero, LA; Chren, MM; Landefeld, CS				Steinman, Michael A.; Bero, Lisa A.; Chren, Mary-Margaret; Landefeld, C. Seth			Narrative review: The promotion of gabapentin: An analysis of internal industry documents	ANNALS OF INTERNAL MEDICINE			English	Review							CONFLICTS-OF-INTEREST; PHARMACEUTICAL-INDUSTRY; COMMERCIAL SUPPORT; DOUBLE-BLIND; GUIDELINES; PAIN	Background: Internal documents from the pharmaceutical industry provide a unique window for understanding the structure and methods of pharmaceutical promotion. Such documents have become available through litigation concerning the promotion of gabapentin (Neurontin, Pfizer, Inc., New York, New York) for off-label uses. Purpose: To describe how gabapentin was promoted, focusing on the use of medical education, research, and publication. Data Sources: Court documents available to the public from United States ex. rel David Franklin vs. Pfizer, Inc, and Parke-Davis, Division of Warner-Lambert Company, mostly from 1994-1998. Data Extraction: All documents were reviewed by 1 author, with selected review by coauthors. Marketing strategies and tactics were identified by using an iterative process of review, discussion, and re-review of selected documents. Data Synthesis: The promotion of gabapentin was a comprehensive and multifaceted process. Advisory boards, consultants meetings, and accredited continuing medical education events organized by third-party vendors were used to deliver promotional messages. These tactics were augmented by the recruitment of local champions and engagement of thought leaders, who could be used to communicate favorable messages about gabapentin to their physician colleagues. Research and scholarship were also used for marketing by encouraging "key customers" to participate in research, using a large study to advance promotional themes and build market share, paying medical communication companies to develop and publish articles about gabapentin for the medical literature, and planning to suppress unfavorable study results. Limitations: Most available documents were submitted by the plaintiff and may not represent a complete picture of marketing practices. Conclusion: Activities traditionally considered independent of promotional intent, including continuing medical education and research, were extensively used to promote gabapentin. New strategies are needed to ensure a clear separation between scientific and commercial activity.	Vet Adm Med Ctr, San Francisco, CA 94121 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	Steinman, MA (corresponding author), Vet Adm Med Ctr, 4150 Clement St,Box 181G, San Francisco, CA 94121 USA.	mike.steinman@ucsf.edu		Bero, Lisa/0000-0003-1893-6651	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K02AR002203] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR02203] Funding Source: Medline; NIA NIH HHS [AG00912] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anderson GD, 1998, ANN PHARMACOTHER, V32, P554, DOI 10.1345/aph.17332; Angell M., 2004, TRUTH DRUG CO THEY D; [Anonymous], 2005, COMMUNICATION 0505, P24; ARMSTRONG EP, 1999, J MANAGE CARE PHARM, V5, P351; Bero LA, 1999, BRIT MED J, V319, P653, DOI 10.1136/bmj.319.7211.653; Brennan TA, 2006, JAMA-J AM MED ASSOC, V295, P429, DOI 10.1001/jama.295.4.429; CALFEE JE, 1994, J PUBLIC POLICY MARK, V13, P228, DOI 10.1177/074391569401300204; Chadwick DW, 1998, NEUROLOGY, V51, P1282, DOI 10.1212/WNL.51.5.1282; Chimonas S, 2005, HEALTH AFFAIR, V24, P949, DOI 10.1377/hlthaff.24.4.949; Furberg CD, 2004, CURR CONTR TRIALS C, V5, DOI 10.1186/1468-6708-5-6; GIDAL B, 1998, CONSULTANT PHARM, V1, P62; Gorson KC, 1999, J NEUROL NEUROSUR PS, V66, P251, DOI 10.1136/jnnp.66.2.251; Hansen HC, 1999, SOUTH MED J, V92, P642, DOI 10.1097/00007611-199907000-00001; Hovland CI, 1951, PUBLIC OPIN QUART, V15, P635, DOI 10.1086/266350; Kassirer J, 2005, TAKE AM COMPLICITY B; Knoll J, 1998, J AFFECT DISORDERS, V49, P229, DOI 10.1016/S0165-0327(98)00027-5; KOWALCZYK L, 2002, BOSTON GLOBE    1217, pA1; Krimsky S., 2004, SCI PRIVATE INTEREST; Merren MD, 1998, SOUTHERN MED J, V91, P739, DOI 10.1097/00007611-199808000-00007; Morrell MJ, 2000, SEIZURE-EUR J EPILEP, V9, P241, DOI 10.1053/seiz.2000.0407; Pande AC, 2000, BIPOLAR DISORD, V2, P249, DOI 10.1034/j.1399-5618.2000.20305.x; PETERSEN M, 2002, NY TIMES, pC2; POLLACK MH, 1997, CNS SPECTRUMS, P55; Pope C, 2000, BMJ-BRIT MED J, V320, P114, DOI 10.1136/bmj.320.7227.114; Relman AS, 2003, JAMA-J AM MED ASSOC, V289, P2418, DOI 10.1001/jama.289.18.2418; Relman AS, 2001, JAMA-J AM MED ASSOC, V285, P2009, DOI 10.1001/jama.285.15.2009; Schafer A, 2004, J MED ETHICS, V30, P8, DOI 10.1136/jme.2003.005702; Steinbrook R, 2005, NEW ENGL J MED, V352, P534, DOI 10.1056/NEJMp048322; Studdert DM, 2004, NEW ENGL J MED, V351, P1891, DOI 10.1056/NEJMlim042229	29	237	241	0	17	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	2006	145	4					284	293		10.7326/0003-4819-145-4-200608150-00008	http://dx.doi.org/10.7326/0003-4819-145-4-200608150-00008			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	075CC	16908919				2022-12-28	WOS:000239858800006
J	Nathan, R				Nathan, Ran			Long-distance dispersal of plants	SCIENCE			English	Review							SEED DISPERSAL; COMPETITION; CONSEQUENCES; EVOLUTION; PATTERNS; MODELS; LIFE		Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Evolut Systemat & Ecol, Movement Ecol Lab, IL-91904 Jerusalem, Israel; Smithsonian Trop Res Inst, Balboa, Ancon, Panama	Hebrew University of Jerusalem; Smithsonian Institution; Smithsonian Tropical Research Institute	Nathan, R (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Evolut Systemat & Ecol, Movement Ecol Lab, IL-91904 Jerusalem, Israel.	rnathan@cc.huji.ac.il	Nathan, Ran/A-9380-2008	Nathan, Ran/0000-0002-5733-6715				Bacles CFE, 2006, SCIENCE, V311, P628, DOI 10.1126/science.1121543; Boedeltje G, 2003, J ECOL, V91, P855, DOI 10.1046/j.1365-2745.2003.00820.x; Bolker BM, 1999, AM NAT, V153, P575, DOI 10.1086/303199; Bullock JM, 2002, DISPERSAL ECOLOGY, P279; Cain ML, 2000, AM J BOT, V87, P1217, DOI 10.2307/2656714; CARLQUIST S, 1981, AM SCI, V69, P509; Chave J, 2002, AM NAT, V159, P1, DOI 10.1086/324112; Clark JS, 1999, ECOLOGY, V80, P1475, DOI 10.1890/0012-9658(1999)080[1475:SDNAFP]2.0.CO;2; Clark JS, 2005, ECOL LETT, V8, P2, DOI 10.1111/j.1461-0248.2004.00702.x; Couvreur M, 2005, ECOGRAPHY, V28, P37, DOI 10.1111/j.0906-7590.2005.04159.x; Darwin, 1859, ORIGINS SPECIES MEAN; GIVNISH TJ, 2004, INT J PLANT SCI, V165, P51; Godoy JA, 2001, MOL ECOL, V10, P2275, DOI 10.1046/j.0962-1083.2001.01342.x; Greene DF, 2005, ECOLOGY, V86, P3105, DOI 10.1890/04-1430; Higgins SI, 2003, ECOLOGY, V84, P1945, DOI 10.1890/01-0616; Higgins SI, 2002, J ECOL, V90, P616, DOI 10.1046/j.1365-2745.2002.00694.x; Hubbell Stephen P., 2001, V32, pi; Kot M, 1996, ECOLOGY, V77, P2027, DOI 10.2307/2265698; Levey DJ, 2005, SCIENCE, V309, P146, DOI 10.1126/science.1111479; Levin SA, 2003, ANNU REV ECOL EVOL S, V34, P575, DOI 10.1146/annurev.ecolsys.34.011802.132428; Levine JM, 2003, ANNU REV ECOL EVOL S, V34, P549, DOI 10.1146/annurev.ecolsys.34.011802.132400; Muller-Landau HC, 2003, ECOLOGY, V84, P1957, DOI 10.1890/01-0617; Munoz J, 2004, SCIENCE, V304, P1144, DOI 10.1126/science.1095210; Myers JA, 2004, OECOLOGIA, V139, P35, DOI 10.1007/s00442-003-1474-2; Nathan R, 2002, NATURE, V418, P409, DOI 10.1038/nature00844; Nathan R, 2003, OIKOS, V103, P261, DOI 10.1034/j.1600-0706.2003.12146.x; Nathan R, 2005, DIVERS DISTRIB, V11, P125, DOI 10.1111/j.1366-9516.2005.00159.x; NATHAN R, IN PRESS SEED DISPER; Nichols J., 2001, DISPERSAL; Ridley H., 1930, J ECOL, DOI DOI 10.2307/2255951; TILMAN D, 1994, ECOLOGY, V75, P2, DOI 10.2307/1939377; Visher SS, 1925, AM NAT, V59, P70, DOI 10.1086/280016; WILLSON MF, 1993, VEGETATIO, V108, P261	33	785	861	3	285	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 11	2006	313	5788					786	788		10.1126/science.1124975	http://dx.doi.org/10.1126/science.1124975			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	072KC	16902126				2022-12-28	WOS:000239671300044
J	Parsons, AB; Lopez, A; Givoni, IE; Williams, DE; Gray, CA; Porter, J; Chua, G; Sopko, R; Brost, RL; Ho, CH; Wang, JY; Ketela, T; Brenner, C; Brill, JA; Fernandez, GE; Lorenz, TC; Payne, GS; Ishihara, S; Ohya, Y; Andrews, B; Hughes, TR; Frey, BJ; Graham, TR; Andersen, RJ; Boone, C				Parsons, Ainslie B.; Lopez, Andres; Givoni, Inmar E.; Williams, David E.; Gray, Christopher A.; Porter, Justin; Chua, Gordon; Sopko, Richelle; Brost, Renee L.; Ho, Cheuk-Hei; Wang, Jiyi; Ketela, Troy; Brenner, Charles; Brill, Julie A.; Fernandez, G. Esteban; Lorenz, Todd C.; Payne, Grego S.; Ishihara, Satoru; Ohya, Yoshikazu; Andrews, Brenda; Hughes, Timothy R.; Frey, Brendan J.; Graham, Todd R.; Andersen, Raymond J.; Boone, Charles			Exploring the mode-of-action of bioactive compounds by chemical-genetic profiling in yeast	CELL			English	Article							GENOME-WIDE ANALYSIS; BREAST-CANCER CELLS; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; 1,3-BETA-D-GLUCAN SYNTHASE; INDUCED HAPLOINSUFFICIENCY; THEONELLA-SWINHOEI; DELETION MUTANTS; DRUG; EXPRESSION	Discovering target and off-target effects of specific compounds is critical to drug discovery and development. We generated a compendium of "chemical-genetic interaction" profiles by testing the collection of viable yeast haploid deletion mutants for hypersensitivity to 82 compounds and natural product extracts. To cluster compounds with a similar mode-of-action and to reveal insights into the cellular pathways and proteins affected, we applied both a hierarchical clustering and a factorgram method, which allows a gene or compound to be associated with more than one group. In particular, tamoxifen, a breast cancer therapeutic, was found to disrupt calcium homeostasis and phosphatidylserine (PS) was recognized as a target for papuamide B, a cytotoxic lipopeptide with anti-HIV activity. Further, the profile of crude extracts resembled that of its constituent purified natural product, enabling detailed classification of extract activity prior to purification. This compendium should serve as a valuable key for interpreting cellular effects of novel compounds with similar activities.	Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Univ Toronto, Probabilist & Stat Inference Grp, Dept Elect & Comp Engn, Toronto, ON M5S 3G4, Canada; Univ Toronto, Probabilist & Stat Inference Grp, Dept Comp Sci, Toronto, ON M5S 3G4, Canada; Univ Toronto, Dept Elect & Comp Engn, Toronto, ON M5S 3G4, Canada; Univ British Columbia, Dept Chem Earth & Ocean Sci, Vancouver, BC V6T 1Z1, Canada; Vanderbilt Univ, Dept Biol Sci, Nashville, TN 37235 USA; Infin Pharmaceut Inc, Cambridge, MA 02130 USA; Dartmouth Med Sch, Dept Genet, Lebanon, NH 03756 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Kashiwa, Chiba 2778562, Japan	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of British Columbia; Vanderbilt University; Dartmouth College; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Tokyo	Boone, C (corresponding author), Univ Toronto, Banting & Best Dept Med Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.	charlie.boone@utoronto.ca	Ohya, Yoshikazu/AAW-2200-2021; Brill, Julie A/A-1044-2008; Fernandez, G. Esteban/AAE-4589-2022; Brenner, Charles/D-6339-2014	Ohya, Yoshikazu/0000-0003-0837-1239; Brill, Julie A/0000-0002-5925-9901; Brenner, Charles/0000-0002-4955-3226; Fernandez, G. Esteban/0000-0002-8393-9229	NCI NIH HHS [R01 CA075954, R01 CA075954-10] Funding Source: Medline; NIGMS NIH HHS [GM67911, GM72119] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067911, F31GM072119] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aoun M, 2000, INT J ANTIMICROB AG, V16, P143, DOI 10.1016/S0924-8579(00)00220-X; Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; Baetz K, 2004, P NATL ACAD SCI USA, V101, P4525, DOI 10.1073/pnas.0307122101; Bechinger B, 1997, J MEMBRANE BIOL, V156, P197, DOI 10.1007/s002329900201; Brown JA, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100043; Callahan MK, 2003, J IMMUNOL, V170, P4840, DOI 10.4049/jimmunol.170.9.4840; Chang HT, 2002, BREAST CANCER RES TR, V71, P125, DOI 10.1023/A:1013807731642; Chang HT, 2001, ARCH TOXICOL, V75, P184, DOI 10.1007/s002040100212; Cheng Y., 2000, P 8 INT C INT SYST M, P93; CHEUNG V, 2006, PSI200644 U TOR; Courchesne WE, 2003, MOL MICROBIOL, V47, P223, DOI 10.1046/j.1365-2958.2003.03291.x; Courchesne WE, 2002, J PHARMACOL EXP THER, V300, P195, DOI 10.1124/jpet.300.1.195; Deutschbauer AM, 2005, GENETICS, V169, P1915, DOI 10.1534/genetics.104.036871; DOUGLAS CM, 1994, J BACTERIOL, V176, P5686, DOI 10.1128/JB.176.18.5686-5696.1994; Dueck D, 2005, BIOINFORMATICS, V21, pI144, DOI 10.1093/bioinformatics/bti1041; Flaherty P, 2005, BIOINFORMATICS, V21, P3286, DOI 10.1093/bioinformatics/bti515; Ford PW, 1999, J AM CHEM SOC, V121, P5899, DOI 10.1021/ja990582o; FRIED HM, 1982, NUCLEIC ACIDS RES, V10, P3133, DOI 10.1093/nar/10.10.3133; FROMTILING R A, 1988, Clinical Microbiology Reviews, V1, P187; Giaever G, 1999, NAT GENET, V21, P278, DOI 10.1038/6791; Giaever G, 2004, P NATL ACAD SCI USA, V101, P793, DOI 10.1073/pnas.0307490100; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Grigull J, 2004, MOL CELL BIOL, V24, P5534, DOI 10.1128/MCB.24.12.5534-5547.2004; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HEMANDEZ F, 1982, J ANTIBIOT, V35, P875; Hosono K, 2000, ARCH MICROBIOL, V173, P284, DOI 10.1007/s002030000147; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Jain PT, 1997, ANTICANCER RES, V17, P1167; Jan CR, 2003, ARCH TOXICOL, V77, P160, DOI 10.1007/s00204-002-0420-0; Jan CR, 2000, TOXICOL APPL PHARM, V168, P58, DOI 10.1006/taap.2000.9011; Kafadar KA, 2003, GENE DEV, V17, P2698, DOI 10.1101/gad.1140603; Kartsonis NA, 2003, DRUG RESIST UPDATE, V6, P197, DOI 10.1016/S1368-7646(03)00064-5; KITAGAWA I, 1981, CHEM PHARM BULL, V29, P2387; KIYONO K, 1987, J BIOCHEM-TOKYO, V102, P1089, DOI 10.1093/oxfordjournals.jbchem.a122147; KUNKEL W, 1980, Z ALLG MIKROBIOL, V20, P315, DOI 10.1002/jobm.3630200503; Lee W, 2005, PLOS GENET, V1, P235, DOI 10.1371/journal.pgen.0010024; Lum PY, 2004, CELL, V116, P121, DOI 10.1016/S0092-8674(03)01035-3; Makino A, 2003, J BIOL CHEM, V278, P3204, DOI 10.1074/jbc.M210347200; MARCIREAU C, 1990, ANTIMICROB AGENTS CH, V34, P989, DOI 10.1128/AAC.34.6.989; Marton MJ, 1998, NAT MED, V4, P1293, DOI 10.1038/3282; Matheos DP, 1997, GENE DEV, V11, P3445, DOI 10.1101/gad.11.24.3445; Moebius FF, 1996, BIOCHEMISTRY-US, V35, P16871, DOI 10.1021/bi961996m; Natarajan P, 2004, P NATL ACAD SCI USA, V101, P10614, DOI 10.1073/pnas.0404146101; Pan XW, 2004, MOL CELL, V16, P487, DOI 10.1016/j.molcel.2004.09.035; Parsons AB, 2004, NAT BIOTECHNOL, V22, P62, DOI 10.1038/nbt919; Pomorski T, 2003, MOL BIOL CELL, V14, P1240, DOI 10.1091/mbc.E02-08-0501; Robinson MD, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-35; Roe SM, 1999, J MED CHEM, V42, P260, DOI 10.1021/jm980403y; ROSE M, 1983, J MOL BIOL, V170, P883, DOI 10.1016/S0022-2836(83)80193-4; Schmidt EW, 1998, J ORG CHEM, V63, P1254, DOI 10.1021/jo9718455; Schroeder R, 2000, EMBO J, V19, P1, DOI 10.1093/emboj/19.1.1; Schuldiner M, 2005, CELL, V123, P507, DOI 10.1016/j.cell.2005.08.031; Sen Gupta S, 2003, J BIOL CHEM, V278, P28831, DOI 10.1074/jbc.M303300200; Shoemaker DD, 1996, NAT GENET, V14, P450, DOI 10.1038/ng1296-450; SOBELL HM, 1985, P NATL ACAD SCI USA, V82, P5328, DOI 10.1073/pnas.82.16.5328; Stathopoulos AM, 1997, GENE DEV, V11, P3432, DOI 10.1101/gad.11.24.3432; Stathopoulos-Gerontides A, 1999, GENE DEV, V13, P798, DOI 10.1101/gad.13.7.798; THOMAS JH, 1985, GENETICS, V111, P715; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; Torralba S, 1998, MICROBIOL-SGM, V144, P45, DOI 10.1099/00221287-144-1-45; TRUAN G, 1994, GENE, V142, P123, DOI 10.1016/0378-1119(94)90366-2; van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R; Williams DE, 2005, J NAT PROD, V68, P327, DOI 10.1021/np049711r; YOSHIDA S, 1992, MOL GEN GENET, V231, P337, DOI 10.1007/BF00292700; Yoshimoto H, 2002, J BIOL CHEM, V277, P31079, DOI 10.1074/jbc.M202718200; Zhao RM, 2005, CELL, V120, P715, DOI 10.1016/j.cell.2004.12.024	68	369	382	0	54	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 11	2006	126	3					611	625		10.1016/j.cell.2006.06.040	http://dx.doi.org/10.1016/j.cell.2006.06.040			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	075KI	16901791	Bronze			2022-12-28	WOS:000239883400019
J	Vonholdt, BM; Ostrander, EA				vonHoldt, Bridgett M.; Ostrander, Elaine A.			The singular history of a canine transmissible tumor	CELL			English	Editorial Material							VENEREAL TUMOR; HOST	In this issue of Cell, Murgia et al. (2006) confirm that the infectious agent of canine transmissible venereal tumor is the cancer cell itself and that the tumor is clonal in origin. Their findings have implications for understanding the relationship between genome instability and transmissible cancer and for conservation biology, canine genomics, and companion animal medicine.	Univ Calif Los Angeles, Dept Ecol & Evolutionary Biol, Los Angeles, CA 90095 USA; NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA	University of California System; University of California Los Angeles; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Ostrander, EA (corresponding author), Univ Calif Los Angeles, Dept Ecol & Evolutionary Biol, Los Angeles, CA 90095 USA.	eostrand@mail.nih.gov		Ostrander, Elaine/0000-0001-6075-9738	Intramural NIH HHS Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG200325, ZIAHG200325] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Bentolila S, 1999, MAMM GENOME, V10, P699, DOI 10.1007/s003359901074; Biek R, 2006, SCIENCE, V311, P538, DOI 10.1126/science.1121360; COHEN D, 1985, ADV CANCER RES, V43, P75, DOI 10.1016/S0065-230X(08)60943-4; KATZIR N, 1987, ONCOGENE, V1, P445; Liao KW, 2003, J VET DIAGN INVEST, V15, P399, DOI 10.1177/104063870301500501; Moulton JE, 1978, TUMORS DOMESTIC ANIM; MURGIA C, 2006, CELL; Pearse AM, 2006, NATURE, V439, P549, DOI 10.1038/439549a; Whiteman NK, 2005, ANIM CONSERV, V8, P175, DOI 10.1017/S1367943005001915	9	20	22	1	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 11	2006	126	3					445	447		10.1016/j.cell.2006.07.016	http://dx.doi.org/10.1016/j.cell.2006.07.016			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	075KI	16901777	Bronze			2022-12-28	WOS:000239883400004
J	Liberles, SD; Buck, LB				Liberles, Stephen D.; Buck, Linda B.			A second class of chemosensory receptors in the olfactory epithelium	NATURE			English	Article							PROTEIN-COUPLED RECEPTORS; PUBERTY-ACCELERATING PHEROMONES; TRACE AMINES; ODORANT RECEPTORS; GENE; MOUSE; IDENTIFICATION; FAMILY; EXPRESSION; STRESS	The mammalian olfactory system detects chemicals sensed as odours as well as social cues that stimulate innate responses. Odorants are detected in the nasal olfactory epithelium by the odorant receptor family, whose,1,000 members allow the discrimination of a myriad of odorants. Here we report the discovery of a second family of receptors in the mouse olfactory epithelium. Genes encoding these receptors, called ' trace amine- associated receptors' ( TAARs), are present in human, mouse and fish. Like odorant receptors, individual mouse TAARs are expressed in unique subsets of neurons dispersed in the epithelium. Notably, at least three mouse TAARs recognize volatile amines found in urine: one detects a compound linked to stress, whereas the other two detect compounds enriched in male versus female urine - one of which is reportedly a pheromone. The evolutionary conservation of the TAAR family suggests a chemosensory function distinct from odorant receptors. Ligands identified for TAARs thus far suggest a function associated with the detection of social cues.	Fred Hutchinson Canc Res Ctr, Howard Hughes Med Inst, Div Basic Sci, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; Howard Hughes Medical Institute	Buck, LB (corresponding author), Fred Hutchinson Canc Res Ctr, Howard Hughes Med Inst, Div Basic Sci, 1100 Fairview Ave N, Seattle, WA 98109 USA.	lbuck@fhcrc.org		Liberles, Stephen/0000-0002-2177-9741				Boehm U, 2005, CELL, V123, P683, DOI 10.1016/j.cell.2005.09.027; Borowsky B, 2001, P NATL ACAD SCI USA, V98, P8966, DOI 10.1073/pnas.151105198; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Buck LB, 2000, CELL, V100, P611, DOI 10.1016/S0092-8674(00)80698-4; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; Del Punta K, 2002, NATURE, V419, P70, DOI 10.1038/nature00955; Durocher Y, 2000, ANAL BIOCHEM, V284, P316, DOI 10.1006/abio.2000.4698; FIERING SN, 1991, CYTOMETRY, V12, P291, DOI 10.1002/cyto.990120402; Gloriam DEI, 2005, MOL PHYLOGENET EVOL, V35, P470, DOI 10.1016/j.ympev.2004.12.003; Godfrey PA, 2004, P NATL ACAD SCI USA, V101, P2156, DOI 10.1073/pnas.0308051100; Grimsby J, 1997, NAT GENET, V17, P206, DOI 10.1038/ng1097-206; Halpern M, 2003, PROG NEUROBIOL, V70, P245, DOI 10.1016/S0301-0082(03)00103-5; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; Kajiya K, 2001, J NEUROSCI, V21, P6018, DOI 10.1523/JNEUROSCI.21-16-06018.2001; Kandel E., 2000, PRINCIPLES NEURAL SC; Krautwurst D, 1998, CELL, V95, P917, DOI 10.1016/S0092-8674(00)81716-X; Lee MB, 2006, CLIN CHIM ACTA, V365, P264, DOI 10.1016/j.cca.2005.09.004; Lewin AH, 2006, AAPS J, V8, pE138, DOI 10.1208/aapsj080116; Lindemann L, 2005, TRENDS PHARMACOL SCI, V26, P274, DOI 10.1016/j.tips.2005.03.007; Malnic B, 1999, CELL, V96, P713, DOI 10.1016/S0092-8674(00)80581-4; McKee CLG, 2006, J PROTEOME RES, V5, P378, DOI 10.1021/pr050255h; Meyer MR, 2000, P NATL ACAD SCI USA, V97, P10595, DOI 10.1073/pnas.97.19.10595; Montmayeur JP, 2001, NAT NEUROSCI, V4, P492, DOI 10.1038/87440; NISHIMURA K, 1989, J EXP ZOOL, V251, P300, DOI 10.1002/jez.1402510306; Novotny MV, 2003, BIOCHEM SOC T, V31, P117, DOI 10.1042/BST0310117; PAULOS MA, 1982, SCIENCE, V215, P1127, DOI 10.1126/science.7063846; PRICE MA, 1992, J EXP ZOOL, V264, P42, DOI 10.1002/jez.1402640107; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; Restrepo D, 2004, HORM BEHAV, V46, P247, DOI 10.1016/j.yhbeh.2004.02.009; Serizawa S, 2003, SCIENCE, V302, P2088, DOI 10.1126/science.1089122; Shepherd G.M., 2004, SYNAPTIC ORG BRAIN, DOI [DOI 10.1093/ACPROF:OSO/9780195159561.001.1, 10.1093/acprof:oso/9780195159561.001.1]; SNODDY AM, 1985, PHARMACOL BIOCHEM BE, V22, P497, DOI 10.1016/0091-3057(85)90054-1; Spehr M, 2006, J NEUROSCI, V26, P1961, DOI 10.1523/JNEUROSCI.4939-05.2006; Vanti WB, 2003, GENOMICS, V82, P531, DOI 10.1016/S0888-7543(03)00173-3; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; Vassilatis DK, 2003, P NATL ACAD SCI USA, V100, P4903, DOI 10.1073/pnas.0230374100; Wittwer CT, 1997, BIOTECHNIQUES, V22, P130, DOI 10.2144/97221bi01; Yoon HY, 2005, CELL, V123, P669, DOI 10.1016/j.cell.2005.08.039; Young JM, 2002, HUM MOL GENET, V11, P1153, DOI 10.1093/hmg/11.10.1153; Zhang XM, 2002, NAT NEUROSCI, V5, P124, DOI 10.1038/nn800	40	509	535	3	84	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 10	2006	442	7103					645	650		10.1038/nature05066	http://dx.doi.org/10.1038/nature05066			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	071UU	16878137				2022-12-28	WOS:000239630200036
J	May, MT; Sterne, JAC; Costagliola, D; Sabin, CA; Phillips, AN; Justice, AC; Dabis, F; Gill, J; Lundgren, J; Hogg, RS; de Wolf, F; Fatkenheuer, G; Staszewski, S; Monforte, AD; Egger, M; Sterne, J; Weller, I; May, M; Beckthold, B; Yip, B; Dauer, B; Fusco, J; Lanoy, E; Rickenbach, M; Lavignolle, V; Sighem, A; Pereira, E; Pezzotti, P; Phillips, A; Sabin, C; Schmeisser, N				May, Margaret T.; Sterne, Jonathan A. C.; Costagliola, Dominique; Sabin, Caroline A.; Phillips, Andrew N.; Justice, Amy C.; Dabis, Francois; Gill, John; Lundgren, Jens; Hogg, Robert S.; de Wolf, Frank; Fatkenheuer, Gerd; Staszewski, Schlomo; Monforte, Antonella d'Arminio; Egger, Matthias; Sterne, Jonathan; Weller, Ian; May, Margaret; Beckthold, Brenda; Yip, Benita; Dauer, Brenda; Fusco, Jennifer; Lanoy, Emilie; Rickenbach, Martin; Lavignolle, Valerie; van Sighem, Ard; Pereira, Edwige; Pezzotti, Patrizio; Phillips, Andrew; Sabin, Caroline; Schmeisser, Norbert		ART Cohort Collaboration	HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis	LANCET			English	Article							HIV-1-INFECTED PATIENTS; DISEASE PROGRESSION; INFECTED PATIENTS; TUBERCULOSIS; RISK; AIDS; ERA; TRANSMISSION; RESISTANCE; INITIATION	Background Highly active antiretroviral therapy (HAART) for the treatment of HIV infection was introduced a decade ago. We aimed to examine trends in the characteristics of patients starting HAART in Europe and North America, and their treatment response and short-term prognosis. Methods We analysed data from 22 217 treatment-naive HIV-1-infected adults who had started HAART and were followed up in one of 12 cohort studies. The probability of reaching 500 or less HIV-1 RNA copies per mL by 6 months, and the change in CD4 cell counts, were analysed for patients starting HAART in 1995-96, 1997, 1998, 1999, 2000, 2001, and 2002-03. The primary endpoints were the hazard ratios for AIDS and for death from all causes in the first year of HAART which were estimated using Cox regression. Results The proportion of heterosexually infected patients increased from 20% in 1995-96 to 47% in 2002-03, and the proportion of women from 16% to 32%. The median CD4 cell count when starting HAART increased from 170 cells per mu L in 1995-96 to 269 cells per mu L in 1998 but then decreased to around 200 cells per mu L. In 1995-96, 58% achieved HIV-1 RNA of 500 copies per mL or less by 6 months compared with 83% in 2002-03. Compared with 1998, adjusted hazard ratios for AIDS were 1.07 (95% CI 0.84-1.36) in 1995-96 and 1.35 (1.06-1.71) in 2002-03. Corresponding figures for death were 0.87 (0.56-1.36) and 0.96 (0.61-1.51). Interpretation Virological response after starting HAART improved over calendar years, but such improvement has not translated into a decrease in mortality.	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England	University of Bristol	May, MT (corresponding author), Univ Bristol, Dept Social Med, Canynge Hall,Whiteladies Rd, Bristol BS8 2PR, Avon, England.	m.t.may@bristol.ac.uk	Sterne, Jonathan/Z-3106-2019; Lundgren, Jens/AAE-6876-2019; Phillips, Andrew N/B-4427-2008; Costagliola, Dominique/H-5849-2011; DABIS, FRANCOIS/S-9298-2019; Sabin, Caroline/C-2464-2008; PEZZOTTI, PATRIZIO/C-6480-2016; Dodsley, Maria/G-7083-2016; Hogg, Robert S/B-2783-2012; VALLET, Yannick/F-9979-2011; Lanoy, Emilie/A-8541-2011; May, Margaret/E-8099-2013; Gill, Michael John/G-7083-2016	Sterne, Jonathan/0000-0001-8496-6053; Phillips, Andrew N/0000-0003-2384-4807; Costagliola, Dominique/0000-0003-0765-0869; DABIS, FRANCOIS/0000-0002-1614-8857; Sabin, Caroline/0000-0001-5173-2760; PEZZOTTI, PATRIZIO/0000-0002-0805-2927; Dodsley, Maria/0000-0001-7587-558X; Hogg, Robert S/0000-0003-3463-5488; Lanoy, Emilie/0000-0002-4789-7770; May, Margaret/0000-0002-9733-1003; Gill, Michael John/0000-0002-8546-8790	MRC [G0100221] Funding Source: UKRI; Medical Research Council [G0100221] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		[Anonymous], 1992, MMWR Recomm Rep, V41, P1; Barnes PF, 1999, AM J RESP CRIT CARE, V159, P1081, DOI 10.1164/ajrccm.159.4.9807153; Becker SL, 2001, J ACQ IMMUN DEF SYND, V26, P72, DOI 10.1097/00126334-200101010-00011; Binquet C, 2001, AM J EPIDEMIOL, V153, P386, DOI 10.1093/aje/153.4.386; Brodt HR, 1997, AIDS, V11, P1731, DOI 10.1097/00002030-199714000-00010; Delgado J, 2003, ANTIVIR THER, V8, P471; DeSimone JA, 2000, ANN INTERN MED, V133, P447, DOI 10.7326/0003-4819-133-6-200009190-00013; Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4; Egger M, 1997, BMJ-BRIT MED J, V315, P1194, DOI 10.1136/bmj.315.7117.1194; Fatkenheuer G, 1997, AIDS, V11, pF113, DOI 10.1097/00002030-199714000-00001; Girardi E, 2000, AIDS, V14, P1985, DOI 10.1097/00002030-200009080-00015; Grabar S, 2000, ANN INTERN MED, V133, P401, DOI 10.7326/0003-4819-133-6-200009190-00007; Hogg RS, 1999, CAN MED ASSOC J, V160, P659; Kitahata MM, 1996, NEW ENGL J MED, V334, P701, DOI 10.1056/NEJM199603143341106; Lampe FC, 2006, ARCH INTERN MED, V166, P521, DOI 10.1001/archinte.166.5.521; Landon BE, 2005, ARCH INTERN MED, V165, P1133, DOI 10.1001/archinte.165.10.1133; Lewden C, 2005, INT J EPIDEMIOL, V34, P121, DOI 10.1093/ije/dyh307; Lundgren JD, 1997, J ACQ IMMUN DEF SYND, V16, P153, DOI 10.1097/00042560-199711010-00003; Maggiolo F, 2003, ANTIVIR THER, V8, P339; Masquelier B, 2005, J MED VIROL, V76, P441, DOI 10.1002/jmv.20380; May M, 2005, J CLIN EPIDEMIOL, V58, P1033, DOI 10.1016/j.jclinepi.2005.02.015; May M, 2004, STAT MED, V23, P2375, DOI 10.1002/sim.1825; McLaughlin SI, 2003, INT J TUBERC LUNG D, V7, P665; Mocroft A, 1999, AIDS, V13, P1255, DOI 10.1097/00002030-199907090-00016; Mocroft A, 2003, LANCET, V362, P22, DOI 10.1016/S0140-6736(03)13802-0; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; Mocroft A, 1998, AIDS, V12, P2161, DOI 10.1097/00002030-199816000-00011; Monforte AD, 2000, AIDS, V14, P499, DOI 10.1097/00002030-200003310-00005; Narita M, 1998, AM J RESP CRIT CARE, V158, P157, DOI 10.1164/ajrccm.158.1.9712001; Nieuwkerk PT, 2001, ARCH INTERN MED, V161, P1962, DOI 10.1001/archinte.161.16.1962; Nikolopoulos G, 2005, EUR J PUBLIC HEALTH, V15, P296, DOI 10.1093/eurpub/cki064; Paltiel AD, 2005, NEW ENGL J MED, V352, P586, DOI 10.1056/NEJMsa042088; Sabin CA, 2006, AIDS, V20, P67, DOI 10.1097/01.aids.0000196178.73174.24; Staehelin C, 2003, AIDS, V17, P2237, DOI 10.1097/00002030-200310170-00012; Sterling TR, 2000, INT J TUBERC LUNG D, V4, P1066; Suligoi B, 2003, SCAND J INFECT DIS, V35, P12, DOI 10.1080/03008870310009588; Sullivan AK, 2005, BRIT MED J, V330, P1301, DOI 10.1136/bmj.38398.590602.E0; 2004, WKLY EPIDEMIOL REC, V79, P441	38	187	187	0	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 5	2006	368	9534					451	458						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	071AL	16890831				2022-12-28	WOS:000239569000027
J	Khurana, RN; Sadda, SR				Khurana, Rahul N.; Sadda, Srinivas R.			Salt-and-pepper retinopathy of rubella	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Doheny Eye Inst, Los Angeles, CA 90033 USA	Doheny Eye Institute	Khurana, RN (corresponding author), Doheny Eye Inst, 1355 San Pablo St, Los Angeles, CA 90033 USA.			Khurana, Rahul/0000-0001-5198-1353					0	2	2	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 3	2006	355	5					499	499		10.1056/NEJMicm040780	http://dx.doi.org/10.1056/NEJMicm040780			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	069FT	16885553				2022-12-28	WOS:000239432500009
J	Illi, S; von Mutius, E; Lau, S; Niggemann, B; Gruber, C; Wahn, U				Illi, Sabina; von Mutius, Erika; Lau, Susanne; Niggemann, Bodo; Grueber, Christoph; Wahn, Ulrich		Multictr Allergy Study Grp	Perennial allergen sensitisation early in life and chronic asthma in children: a birth cohort study	LANCET			English	Article							HOUSE-DUST MITE; AGE 3 YEARS; CHILDHOOD ASTHMA; LUNG-FUNCTION; INHALED CORTICOSTEROIDS; PRESCHOOL-CHILDREN; EXPOSURE; PREVALENCE; SYMPTOMS; GERMANY	Background Reduced lung function is a feature of chronic asthma, which becomes apparent at school age. Unknown factors between birth and school age determine the progressive loss of pulmonary function in children with persistent asthma. We investigated the role of allergic sensitisation and allergen exposure early in life. Methods The German Multicentre Allergy Study followed 1314 children from birth to 13 years of age. We regularly interviewed parents about their child's asthma and measured IgE levels. Allergen exposure was assessed at age 6 months, 18 months, and at 3, 4, and 5 years; lung function was assessed at 7, 10, and 13 years; post-bronchodilator response at 10 and 13 years; and a bronchial histamine challenge was done at 7 years. Results 90% of children with wheeze but no atopy lost their symptoms at school age and retained normal lung function at puberty. By contrast, sensitisation to perennial allergens (eg, house dust mite, cat and dog hair) developing in the first 3 years of life was associated with a loss of lung function at school age. Concomitant exposure to high levels of perennial allergens early in life aggravated this process: forced expiratory volume in 1 s (FEV1) to forced vital capacity (FVC) ratio was 87.4 (SD 7.4) for those sensitised and with high exposure compared with 92.6 (6.0) for those not sensitised, p<0.0001; and maximal expiratory flow at 50% (MEF50) 86.4 (25.1) for sensitised and with high exposure compared with 101.5 (23.2; p=0.0031) for those not sensitised. Such exposure also enhanced the development of airway hyper-responsiveness in sensitised children with wheeze. Sensitisation and exposure later in life had much weaker effects and sensitisation to seasonal allergens did not play a part. Interpretation The chronic course of asthma characterised by airway hyper-responsiveness and impairment of lung function at school age is determined by continuing allergic airway inflammation beginning in the first 3 years of life. However, children with a non-atopic wheezing phenotype lose their symptoms over school age and retain normal lung function at puberty.	Charite Univ Med Berlin, Dept Pediat Pneumol & Immunol, Berlin, Germany; Univ Childrens Hosp, Munich, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich	Illi, S (corresponding author), Univ Munich, Dr Von Haunerschen Kinderspital, Lindwurmstr 4, D-80337 Munich, Germany.	sabina.illi@med.uni-muenchen.de		von Mutius, Erika/0000-0002-8893-4515				Bergmann R L, 1994, Pediatr Allergy Immunol, V5, P19, DOI 10.1111/j.1399-3038.1994.tb00343.x; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Bisgaard H, 1997, PEDIATR PULM, P27; Chen YZ, 2006, PEDIAT ALLERG IMM-UK, V17, P7, DOI 10.1111/j.1600-5562.2006.00379.x; *CHILDH ASTHM MAN, 2000, NEW ENGLAND J MED, V0343; Cnaan A, 1997, STAT MED, V16, P2349, DOI 10.1002/(SICI)1097-0258(19971030)16:20<2349::AID-SIM667>3.0.CO;2-E; Fedorov IA, 2005, THORAX, V60, P389, DOI 10.1136/thx.2004.030262; *GLOB IN ASTHM, 2005, GINA GUID WORKSH REP; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Hirsch T, 2000, CLIN EXP ALLERGY, V30, P529, DOI 10.1046/j.1365-2222.2000.00785.x; Holt PG, 2004, NAT IMMUNOL, V5, P695, DOI 10.1038/ni0704-695; Holt PG, 2000, ALLERGY, V55, P688, DOI 10.1034/j.1398-9995.2000.00118.x; Illi S, 2001, BMJ-BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; Koopman LP, 2002, AM J RESP CRIT CARE, V166, P307, DOI 10.1164/rccm.2106026; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Lowe LA, 2004, ARCH PEDIAT ADOL MED, V158, P996, DOI 10.1001/archpedi.158.10.996; Lowe LA, 2005, AM J RESP CRIT CARE, V171, P231, DOI 10.1164/rccm.200406-695OC; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; Niggemann B, 2001, EUR RESPIR J, V17, P246, DOI 10.1183/09031936.01.17202460; Phelan PD, 2002, J ALLERGY CLIN IMMUN, V109, P189, DOI 10.1067/mai.2002.120951; Saglani S, 2005, AM J RESP CRIT CARE, V171, P722, DOI 10.1164/rccm.200410-1404OC; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; van den Akker-van Marle ME, 2005, ALLERGY, V60, P140, DOI 10.1111/j.1398-9995.2005.00692.x; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; Wahn U, 1997, PEDIAT ALLERG IMM-UK, V8, P16; Weiland SK, 1999, EUR RESPIR J, V14, P862, DOI 10.1034/j.1399-3003.1999.14d23.x; WILLIAMS H, 1969, BRIT MED J, V4, P321, DOI 10.1136/bmj.4.5679.321; Woodcock A, 2004, AM J RESP CRIT CARE, V170, P433, DOI 10.1164/rccm.200401-083OC	28	522	537	0	42	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG-SEP	2006	368	9537					763	770		10.1016/S0140-6736(06)69286-6	http://dx.doi.org/10.1016/S0140-6736(06)69286-6			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	080ID	16935687				2022-12-28	WOS:000240240200028
J	Pedersen, S				Pedersen, Soren			Budesonide plus formoterol for reliever therapy in asthma	LANCET			English	Editorial Material							MILD PERSISTENT ASTHMA; EXACERBATIONS; COMBINATION		Kolding Cty Hosp, Paediat Res Unit, Kolding 6000, Denmark	Kolding Hospital	Pedersen, S (corresponding author), Kolding Cty Hosp, Paediat Res Unit, Kolding 6000, Denmark.	spconsult@post1.tele.dk						Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; *GINA, 2002, PUBL GINA; O'Byrne PM, 2001, AM J RESP CRIT CARE, V164, P1392, DOI 10.1164/ajrccm.164.8.2104102; O'Byrne PM, 2005, AM J RESP CRIT CARE, V171, P129, DOI 10.1164/rccm.200407-884OC; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Pauwels RA, 2003, LANCET, V361, P1071, DOI 10.1016/S0140-6736(03)12891-7; Rabe KF, 2006, LANCET, V368, P744, DOI 10.1016/S0140-6736(06)69284-2; TOOGOOD JH, 1982, J ALLERGY CLIN IMMUN, V70, P288, DOI 10.1016/0091-6749(82)90065-3; Wedzicha JA, 2003, THORAX, V58, P1, DOI 10.1136/thorax.58.1.1	9	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG-SEP	2006	368	9537					707	708		10.1016/S0140-6736(06)69260-X	http://dx.doi.org/10.1016/S0140-6736(06)69260-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	080ID	16935666				2022-12-28	WOS:000240240200004
J	Lee, JW; Beebe, K; Nangle, LA; Jang, JS; Longo-Guess, CM; Cook, SA; Davisson, MT; Sundberg, JP; Schimmel, P; Ackerman, SL				Lee, Jeong Woong; Beebe, Kirk; Nangle, Leslie A.; Jang, Jaeseon; Longo-Guess, Chantal M.; Cook, Susan A.; Davisson, Muriel T.; Sundberg, John P.; Schimmel, Paul; Ackerman, Susan L.			Editing-defective tRNA synthetase causes protein misfolding and neurodegeneration	NATURE			English	Article							MARINESCO-SJOGREN-SYNDROME; ENDOPLASMIC-RETICULUM; MOLECULAR CHAPERONES; MAJOR DETERMINANT; ESCHERICHIA-COLI; CELL VIABILITY; DISEASES; SIL1; DISCRIMINATION; AGGREGATION	Misfolded proteins are associated with several pathological conditions including neurodegeneration. Although some of these abnormally folded proteins result from mutations in genes encoding disease-associated proteins (for example, repeat-expansion diseases), more general mechanisms that lead to misfolded proteins in neurons remain largely unknown. Here we demonstrate that low levels of mischarged transfer RNAs (tRNAs) can lead to an intracellular accumulation of misfolded proteins in neurons. These accumulations are accompanied by upregulation of cytoplasmic protein chaperones and by induction of the unfolded protein response. We report that the mouse sticky mutation, which causes cerebellar Purkinje cell loss and ataxia, is a missense mutation in the editing domain of the alanyl-tRNA synthetase gene that compromises the proofreading activity of this enzyme during aminoacylation of tRNAs. These findings demonstrate that disruption of translational fidelity in terminally differentiated neurons leads to the accumulation of misfolded proteins and cell death, and provide a novel mechanism underlying neurodegeneration.	Jackson Lab, Bar Harbor, ME 04609 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Howard Hughes Med Inst, Bar Harbor, ME 04609 USA	Jackson Laboratory; Scripps Research Institute; Howard Hughes Medical Institute	Ackerman, SL (corresponding author), Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA.	susan.ackerman@jax.org			NINDS NIH HHS [R01 NS042613] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042613] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ackerman SL, 1997, NATURE, V386, P838, DOI 10.1038/386838a0; Ahel I, 2003, P NATL ACAD SCI USA, V100, P15422, DOI 10.1073/pnas.2136934100; Anttonen AK, 2005, NAT GENET, V37, P1309, DOI 10.1038/ng1677; Bacher JM, 2005, P NATL ACAD SCI USA, V102, P1697, DOI 10.1073/pnas.0409064102; Barral JM, 2004, SEMIN CELL DEV BIOL, V15, P17, DOI 10.1016/j.semcdb.2003.12.010; Beebe K, 2004, P NATL ACAD SCI USA, V101, P5958, DOI 10.1073/pnas.0401530101; Beebe K, 2003, EMBO J, V22, P668, DOI 10.1093/emboj/cdg065; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Dobson CM, 2004, SEMIN CELL DEV BIOL, V15, P3, DOI 10.1016/j.semcdb.2003.12.008; Dock-Bregeon AC, 2000, CELL, V103, P877, DOI 10.1016/S0092-8674(00)00191-4; Doring V, 2001, SCIENCE, V292, P501, DOI 10.1126/science.1057718; Gatchel JR, 2005, NAT REV GENET, V6, P743, DOI 10.1038/nrg1691; HOGAN B, 1986, MANIPULATING MOUSE E; HOU YM, 1989, BIOCHEMISTRY-US, V28, P6800, DOI 10.1021/bi00443a003; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; JAKUBOWSKI H, 1992, MICROBIOL REV, V56, P412, DOI 10.1128/MMBR.56.3.412-429.1992; LOFTFIELD RB, 1972, BIOCHEM J, V128, P1353, DOI 10.1042/bj1281353; Muchowski PJ, 2005, NAT REV NEUROSCI, V6, P11, DOI 10.1038/nrn1587; Murphy RM, 2002, ANNU REV BIOMED ENG, V4, P155, DOI 10.1146/annurev.bioeng.4.092801.094202; Nangle LA, 2002, J BIOL CHEM, V277, P45729, DOI 10.1074/jbc.M208093200; NANGLE LA, IN PRESS CHEM BIOL; Pezo V, 2004, P NATL ACAD SCI USA, V101, P8593, DOI 10.1073/pnas.0402893101; Pleiss JA, 2001, J MOL BIOL, V308, P895, DOI 10.1006/jmbi.2001.4612; RIPMASTER TL, 1995, P NATL ACAD SCI USA, V92, P4932, DOI 10.1073/pnas.92.11.4932; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; Ross CA, 2004, TRENDS CELL BIOL, V14, P703, DOI 10.1016/j.tcb.2004.10.006; Selkoe DJ, 2003, NATURE, V426, P900, DOI 10.1038/nature02264; Senderek J, 2005, NAT GENET, V37, P1312, DOI 10.1038/ng1678; Sokabe M, 2005, P NATL ACAD SCI USA, V102, P11669, DOI 10.1073/pnas.0502119102; Swairjo MA, 2004, MOL CELL, V13, P829, DOI 10.1016/S1097-2765(04)00126-1; Welch WJ, 2004, SEMIN CELL DEV BIOL, V15, P31, DOI 10.1016/j.semcdb.2003.12.011; Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JCI26373; XUE H, 1993, J CHROMATOGR-BIOMED, V613, P247, DOI 10.1016/0378-4347(93)80139-U; Zhao LH, 2005, NAT GENET, V37, P974, DOI 10.1038/ng1620; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	35	430	454	0	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 7	2006	443	7107					50	55		10.1038/nature05096	http://dx.doi.org/10.1038/nature05096			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	081JM	16906134				2022-12-28	WOS:000240313900036
J	McGinnis, JM; Birt, DF; Brannon, PM; Carroll, RJ; Gibbons, RD; Hazzard, WR; Kamerow, DB; Levin, B; Ntambi, JM; Paneth, N; Rogers, D; Saftlas, AF; Vaughan, W				McGinnis, J. Michael; Birt, Diane F.; Brannon, Patsy M.; Carroll, Raymond J.; Gibbons, Robert D.; Hazzard, William R.; Kamerow, Douglas B.; Levin, Bernard; Ntambi, James M.; Paneth, Nigel; Rogers, Douglas; Saftlas, Audrey F.; Vaughan, William		NIH State of Science	National Institutes of Health state-of-the-science conference statement: Multivitamin/mineral supplements and chronic disease prevention	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							BETA-CAROTENE; ALPHA-TOCOPHEROL; CONTROLLED-TRIAL; CARDIOVASCULAR-DISEASE; VITAMIN-E; INTERVENTION TRIALS; CANCER PREVENTION; PROSTATE-CANCER; LUNG-CANCER; MORTALITY		Natl Acad, Inst Med, Washington, DC USA; Iowa State Univ, Dept Food Sci & Human Nutr, Ctr Res Bot Dietary Supplements, Ames, IA USA; Iowa State Univ, Coll Agr, Ames, IA USA; Iowa State Univ, Coll Human Sci, Ames, IA USA; Cornell Univ, Div Nutrit Sci, Ithaca, NY USA; Texas A&M Univ, Dept Stat, College Stn, TX 77843 USA; Univ Illinois, Ctr Hlth Stat, Chicago, IL USA; Univ Washington, Dept Med, Div Gerontol & Geriatr Med, VA Puget Sound Hlth Care Syst, Seattle, WA USA; Georgetown Univ, Washington, DC USA; RTI Int, Washington, DC USA; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53705 USA; Univ Wisconsin, Dept Nutrit Sci, Madison, WI 53705 USA; Michigan State Univ, Coll Human Med, E Lansing, MI 48824 USA; Cleveland Clin, Sect Pediat & Adolescent Endocrinol, Cleveland, OH 44106 USA; Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA USA; Consumers Union, Washington, DC USA; NIH, Bethesda, MD 20892 USA	National Academies of Sciences, Engineering & Medicine; Iowa State University; Iowa State University; Iowa State University; Cornell University; Texas A&M University System; Texas A&M University College Station; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; Georgetown University; Research Triangle Institute; University of Texas System; UTMD Anderson Cancer Center; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Michigan State University; Michigan State University College of Human Medicine; Cleveland Clinic Foundation; University of Iowa; National Institutes of Health (NIH) - USA	McGinnis, JM (corresponding author), Natl Acad, Inst Med, Washington, DC USA.							Albanes D, 2000, CANCER CAUSE CONTROL, V11, P197, DOI 10.1023/A:1008936214087; Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501; BLOT WJ, 1993, JNCI-J NATL CANCER I, V85, P1483, DOI 10.1093/jnci/85.18.1483; Chylack LT, 2002, OPHTHAL EPIDEMIOL, V9, P49; Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957; Goodman GE, 2004, J NATL CANCER I, V96, P1743, DOI 10.1093/jnci/djh320; Green A, 1999, LANCET, V354, P723, DOI 10.1016/S0140-6736(98)12168-2; Greenberg ER, 1996, JAMA-J AM MED ASSOC, V275, P699, DOI 10.1001/jama.275.9.699; Heinonen OP, 1998, J NATL CANCER I, V90, P440, DOI 10.1093/jnci/90.6.440; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; Hercberg S, 2004, ARCH INTERN MED, V164, P2335, DOI 10.1001/archinte.164.21.2335; Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439; Lee IM, 1999, J NATL CANCER I, V91, P2102, DOI 10.1093/jnci/91.24.2102; Lee IM, 2005, JAMA-J AM MED ASSOC, V294, P56, DOI 10.1001/jama.294.1.56; Leppala JM, 2000, ARTERIOSCL THROM VAS, V20, P230, DOI 10.1161/01.ATV.20.1.230; MALOUF M, 2003, COCHRANE DB SYST REV; MALOUF R, 2003, DATABASE SYST REV; McNeil JJ, 2004, OPHTHALMOLOGY, V111, P75, DOI 10.1016/j.ophtha.2003.04.009; Meyer F, 2005, INT J CANCER, V116, P182, DOI 10.1002/ijc.21058; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; Rapola JM, 1996, JAMA-J AM MED ASSOC, V275, P693, DOI 10.1001/jama.275.9.693; Richer S, 1996, J Am Optom Assoc, V67, P30; SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P1246, DOI 10.1001/archopht.1993.01090090098027; Teikari JM, 1998, ACTA OPHTHALMOL SCAN, V76, P224, DOI 10.1034/j.1600-0420.1998.760220.x; Tognoni G, 2001, LANCET, V357, P89, DOI 10.1016/S0140-6736(00)03539-X; Wactawski-Wende J, 2006, NEW ENGL J MED, V354, P684, DOI 10.1056/NEJMoa055222; YU SY, 1991, BIOL TRACE ELEM RES, V29, P289, DOI 10.1007/BF03032685	27	71	74	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 5	2006	145	5					364	371		10.7326/0003-4819-145-5-200609050-00136	http://dx.doi.org/10.7326/0003-4819-145-5-200609050-00136			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	080NZ	16880454				2022-12-28	WOS:000240255900007
J	Li, H; Tsang, CK; Watkins, M; Bertram, PG; Zheng, XFS				Li, Hong; Tsang, Chi Kwan; Watkins, Marcus; Bertram, Paula G.; Zheng, X. F. Steven			Nutrient regulates Tor1 nuclear localization and association with rDNA promoter	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; SIGNALING PATHWAY; CELL-GROWTH; FKBP12-RAPAMYCIN-ASSOCIATED PROTEIN; GENE-EXPRESSION; RAPAMYCIN; YEAST; RECRUITMENT; INTEGRATION; COMPLEXES	TOR is the target of the immunosuppressant rapamycin and a key regulator of cell growth. It modulates diverse cellular processes in the cytoplasm and nucleus(1-5), including the expression of amino acid transporters, ribosomal RNAs and ribosomal proteins. Despite considerable recent progress, little is known about the spatial and temporal regulation of TOR signalling, particularly that leading into the nucleus. Here we show that Tor1 is dynamically distributed in the cytoplasm and nucleus in yeast. Tor1 nuclear localization is nutrient dependent and rapamycin sensitive: starvation or treatment with rapamycin causes Tor1 to exit from the nucleus. Tor1 nuclear localization is critical for 35S rRNA synthesis, but not for the expression of amino acid transporters and ribosomal protein genes. We show further that Tor1 is associated with 35S ribosomal DNA ( rDNA) promoter chromatin in a rapamycin- and starvation-sensitive manner; this association is necessary for 35S rRNA synthesis and cell growth. These results indicate that the spatial regulation of TOR complex 1 (TORC1) might be involved in differential control of its target genes. TOR is known as a classic cytoplasmic kinase that mediates the cytoplasm-to-nucleus signalling by controlling the localization of transcription factors. Our data indicate that TOR might be more intimately involved in gene regulation than previously thought.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Washington University (WUSTL)	Zheng, XFS (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, 675 Hoes Lane, Piscataway, NJ 08854 USA.	zhengst@umdnj.edu	Watkins, Marcus/V-8817-2019; Tsang, Chi Kwan/AAD-6819-2020	Watkins, Marcus/0000-0002-1224-3478; Tsang, Chi Kwan/0000-0002-0133-1544				Abraham RT, 2005, CURR BIOL, V15, pR139, DOI 10.1016/j.cub.2005.02.015; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Bertram PG, 2002, MOL CELL BIOL, V22, P1246, DOI 10.1128/MCB.22.4.1246-1252.2002; Bertram PG, 2000, J BIOL CHEM, V275, P35727, DOI 10.1074/jbc.M004235200; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; Carvalho J, 2001, J BIOL CHEM, V276, P25359, DOI 10.1074/jbc.M103050200; Chan TF, 2000, P NATL ACAD SCI USA, V97, P13227, DOI 10.1073/pnas.240444197; Claypool JA, 2004, MOL BIOL CELL, V15, P946, DOI 10.1091/mbc.E03-08-0594; Desai BN, 2002, P NATL ACAD SCI USA, V99, P4319, DOI 10.1073/pnas.261702698; Drenan RM, 2004, J BIOL CHEM, V279, P772, DOI 10.1074/jbc.M305912200; Duvel K, 2003, MOL CELL, V11, P1467, DOI 10.1016/S1097-2765(03)00228-4; Harris Thurl E, 2003, Sci STKE, V2003, pre15; Jorgensen P, 2004, GENE DEV, V18, P2491, DOI 10.1101/gad.1228804; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Martin DE, 2004, CELL, V119, P969, DOI 10.1016/j.cell.2004.11.047; Moss T, 2002, CELL, V109, P545, DOI 10.1016/S0092-8674(02)00761-4; Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1; Powers T, 1999, MOL BIOL CELL, V10, P987, DOI 10.1091/mbc.10.4.987; Rout MP, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P120; Rudra D, 2005, EMBO J, V24, P533, DOI 10.1038/sj.emboj.7600553; Schawalder SB, 2004, NATURE, V432, P1058, DOI 10.1038/nature03200; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Schneper L, 2004, CURR OPIN MICROBIOL, V7, P624, DOI 10.1016/j.mib.2004.10.002; Shamji AF, 2003, MOL CELL, V12, P271, DOI 10.1016/j.molcel.2003.08.016; Tsang CK, 2003, EMBO J, V22, P6045, DOI 10.1093/emboj/cdg578; UDEM SA, 1972, J MOL BIOL, V65, P227, DOI 10.1016/0022-2836(72)90279-3; Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7; Wedaman KP, 2003, MOL BIOL CELL, V14, P1204, DOI 10.1091/mbc.E02-09-0609; Zaragoza D, 1998, MOL CELL BIOL, V18, P4463, DOI 10.1128/MCB.18.8.4463; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6	30	173	176	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 31	2006	442	7106					1058	1061		10.1038/nature05020	http://dx.doi.org/10.1038/nature05020			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	078YF	16900101				2022-12-28	WOS:000240142000054
J	Linn, MC; Lee, HS; Tinker, R; Husic, F; Chiu, JL				Linn, Marcia C.; Lee, Hee-Sun; Tinker, Robert; Husic, Freda; Chiu, Jennifer L.			Teaching and assessing knowledge integration in science	SCIENCE			English	Editorial Material							CURRICULA; EDUCATION		Univ Calif Berkeley, Grad Sch Educ, Berkeley, CA 94720 USA; Tufts Univ, Dept Educ, Medford, MA 02155 USA; Concord Consortium, Concord, MA 01742 USA	University of California System; University of California Berkeley; Tufts University	Linn, MC (corresponding author), Univ Calif Berkeley, Grad Sch Educ, Berkeley, CA 94720 USA.	mclinn@berkeley.edu						Ben-Zvi R., 1987, EDUC CHEM, V24, P117; BENZVI R, 1986, J CHEM EDUC, V63, P64, DOI 10.1021/ed063p64; Bhattacharjee Y, 2005, SCIENCE, V310, P224, DOI 10.1126/science.310.5746.224; Bransford JD., 1999, PEOPLE LEARN; Clark D, 2003, J LEARN SCI, V12, P451, DOI 10.1207/S15327809JLS1204_1; Linn M. C., 2006, Educational Technology, V46, P54; Linn M.-C., 2000, COMPUTERS TEACHERS P; Linn MC, 2006, CAMB HANDB PSYCHOL, P243; LINN MC, 2002, INTERNET ENV SCI ED; National Research Council (NRC), 1996, NAT SCI ED STAND; Shepard L.A., 2000, EDUC RESEARCHER, V29, P4, DOI [10.3102/0013189X029007004, DOI 10.3102/0013189X029007004]; SHYMANSKY JA, 1983, J RES SCI TEACH, V20, P387, DOI 10.1002/tea.3660200504; Singer S. R., 2005, AM LAB REPORT; Stern L, 2002, J RES SCI TEACH, V39, P889, DOI 10.1002/tea.10050; WALKER DF, 1974, REV EDUC RES, V44, P83; Xie Q, 2006, J CHEM EDUC, V83, P77, DOI 10.1021/ed083p77; SCIENCE ONLINE	17	147	148	3	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 25	2006	313	5790					1049	1050		10.1126/science.1131408	http://dx.doi.org/10.1126/science.1131408			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	076ZT	16931740				2022-12-28	WOS:000239998200022
J	Byers, T				Byers, Tim			Focus on research: Overweight and mortality among baby boomers - Now we're getting personal	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Colorado, Sch Med, Denver, CO 80202 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Byers, T (corresponding author), Univ Colorado, Sch Med, Denver, CO 80202 USA.							Calle EE, 1999, NEW ENGL J MED, V341, P1097, DOI 10.1056/NEJM199910073411501; Manson JE, 2004, ARCH INTERN MED, V164, P249, DOI 10.1001/archinte.164.3.249; MANSON JE, 1995, NEW ENGL J MED, V333, P677, DOI 10.1056/NEJM199509143331101	3	10	11	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 24	2006	355	8					758	760		10.1056/NEJMp068156	http://dx.doi.org/10.1056/NEJMp068156			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	076KA	16926277				2022-12-28	WOS:000239955200003
J	Silk, J				Silk, Joseph			A journey through time	SCIENCE			English	Editorial Material									Univ Oxford, Dept Phys, Oxford OX1 3RH, England	University of Oxford	Silk, J (corresponding author), Univ Oxford, Dept Phys, Oxford OX1 3RH, England.	silk@astro.ox.ac.uk		silk, joe/0000-0002-1566-8148				Bennett CL, 2003, ASTROPHYS J SUPPL S, V148, P1, DOI 10.1086/377253; BOND JR, 1984, ASTROPHYS J LETT, V285, P45; HARRISON E, 1970, PHYS REV D, V10, P2726; Knox L, 2000, PHYS REV LETT, V85, P1366, DOI 10.1103/PhysRevLett.85.1366; SACHS RK, 1967, ASTROPHYS J, V147, P73, DOI 10.1086/148982; SILK J, 1968, ASTROPHYS J, V151, P459, DOI 10.1086/149449; SILK J, 1967, NATURE, V215, P1155, DOI 10.1038/2151155a0; Smoot G.F., 1992, APJ, V396, pL1; VITTORIO N, 1984, APJ, V285, P39; ZELDOVICH YB, 1972, MON NOT R ASTRON SOC, V160, P1	10	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 18	2006	313	5789					925	926		10.1126/science.1127780	http://dx.doi.org/10.1126/science.1127780			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	074MR	16917049				2022-12-28	WOS:000239817000028
J	Mundy, GR; Elefteriou, F				Mundy, Gregory R.; Elefteriou, Florent			Boning up on ephrin signaling	CELL			English	Editorial Material							CAUSE CRANIOFRONTONASAL SYNDROME; HOMEOSTASIS; RESORPTION; MUTATIONS; SKELETAL	The activities of osteoclasts, which degrade bone, and osteoblasts, which form bone, are coordinated to maintain bone homeostasis. Zhao et al. (2006) now demonstrate bidirectional signaling between these two cell populations via the transmembrane ligand ephrinB2 expressed by osteoclasts and its receptor Ephl34 expressed by osteoblasts. Such bidirectional signaling limits osteoclast activity while stimulating osteoblast differentiation.	Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Bone Biol, Nashville, TN 37212 USA	Vanderbilt University	Mundy, GR (corresponding author), Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Bone Biol, Nashville, TN 37212 USA.	gregory.r.mundy@vanderbilt.edu	Elefteriou, Florent/P-2586-2017; Elefteriou, Florent/GMW-8429-2022	Elefteriou, Florent/0000-0002-2972-5633; Elefteriou, Florent/0000-0002-2972-5633				Compagni A, 2003, DEV CELL, V5, P217, DOI 10.1016/S1534-5807(03)00198-9; HATTNER R., 1962, JOUR SURG RES, V2, P262, DOI 10.1016/S0022-4804(62)80019-5; HAYDEN JM, 1995, BONE, V17, P93; Martin TJ, 2005, TRENDS MOL MED, V11, P76, DOI 10.1016/j.molmed.2004.12.004; Parfitt AM, 1996, J BONE MINER RES, V11, P150; RASMUSSEN H, 1974, AM J MED, V56, P751, DOI 10.1016/0002-9343(74)90802-X; Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122; Twigg SRF, 2004, P NATL ACAD SCI USA, V101, P8652, DOI 10.1073/pnas.0402819101; Wieland I, 2004, AM J HUM GENET, V74, P1209, DOI 10.1086/421532; Wilkinson DG, 2000, INT REV CYTOL, V196, P177; Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012	11	88	98	0	7	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 11	2006	126	3					441	443		10.1016/j.cell.2006.07.015	http://dx.doi.org/10.1016/j.cell.2006.07.015			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	075KI	16901775	Bronze			2022-12-28	WOS:000239883400002
J	Burton, DR; Dwek, RA				Burton, Dennis R.; Dwek, Raymond A.			Immunology - Sugar determines antibody activity	SCIENCE			English	Editorial Material							RHEUMATOID-ARTHRITIS; IGG; BINDING; GLYCOSYLATION; GLYCOFORMS; FUCOSE	Understanding the functional consequences of the identity and sequence of the sugars attached to antibodies may be useful in designing therapies for a range of disorders.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England	Scripps Research Institute; Scripps Research Institute; University of Oxford	Burton, DR (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	burton@scripps.edu; raymond.dwek@exeter.ox.ac.uk						Bruhns P, 2003, IMMUNITY, V18, P573, DOI 10.1016/S1074-7613(03)00080-3; Ferrara C, 2006, J BIOL CHEM, V281, P5032, DOI 10.1074/jbc.M510171200; Kaneko Y, 2006, SCIENCE, V313, P670, DOI 10.1126/science.1129594; Krapp S, 2003, J MOL BIOL, V325, P979, DOI 10.1016/S0022-2836(02)01250-0; MALHOTRA R, 1995, NAT MED, V1, P237, DOI 10.1038/nm0395-237; Mimura Y, 2001, J BIOL CHEM, V276, P45539, DOI 10.1074/jbc.M107478200; Nimmerjahn F, 2005, SCIENCE, V310, P1510, DOI 10.1126/science.1118948; Niwa R, 2005, J IMMUNOL METHODS, V306, P151, DOI 10.1016/j.jim.2005.08.009; PAREKH RB, 1985, NATURE, V316, P452, DOI 10.1038/316452a0; Presta LG, 2005, J ALLERGY CLIN IMMUN, V116, P731, DOI 10.1016/j.jaci.2005.08.003; Shields RL, 2002, J BIOL CHEM, V277, P26733, DOI 10.1074/jbc.M202069200; Woof JM, 2005, SCIENCE, V310, P1442, DOI 10.1126/science.1122009	12	67	71	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 4	2006	313	5787					627	628		10.1126/science.1131712	http://dx.doi.org/10.1126/science.1131712			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	072IQ	16888131				2022-12-28	WOS:000239667500031
J	Crowder, LB; Osherenko, G; Young, OR; Airame, S; Norse, EA; Baron, N; Day, JC; Bouvere, F; Ehler, CN; Halpern, BS; Langdon, SJ; McLeod, KL; Ogden, JC; Peach, RE; Rosenberg, AA; Wilson, JA				Crowder, L. B.; Osherenko, G.; Young, O. R.; Airame, S.; Norse, E. A.; Baron, N.; Day, J. C.; Bouvere, F.; Ehler, C. N.; Halpern, B. S.; Langdon, S. J.; McLeod, K. L.; Ogden, J. C.; Peach, R. E.; Rosenberg, A. A.; Wilson, J. A.			Sustainability - Resolving mismatches in US ocean governance	SCIENCE			English	Editorial Material							GULF-OF-MEXICO; CONSEQUENCES; MANAGEMENT; FISHERIES	Problems in ocean resource management derive from governance, not science. Ocean zoning would replace mismatched and fragmented approaches with integrated regulatory domains.	Duke Univ, Marine Lab, Nicholas Sch Environm & Earth Sci, Ctr Marine Conservat, Beaufort, NC 28516 USA; Univ Calif Santa Barbara, Inst Marine Sci, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Donald Bren Sch Environm Sci & Management, Santa Barbara, CA 93106 USA; Marine Conservat Biol Inst, Bellevue, WA 98004 USA; Natl Ctr Ecol Anal & Synth, Santa Barbara, CA 93101 USA; Great Barrier Reef Marine Pk Author, Townsville, Qld 4810, Australia; UNESCO, Man & Biosphere Program, F-75732 Paris 15, France; Univ Alaska, Dept Anthropol, Anchorage, AK 99508 USA; Oregon State Univ, Dept Zool, Corvallis, OR 97331 USA; Florida Inst Oceanog, St Petersburg, FL 33701 USA; Harvard Univ, John F Kennedy Sch Govt, Cambridge, MA 02138 USA; Univ New Hampshire, Inst Study Earth Oceans & Space, Durham, NH 03824 USA; Univ Maine, Sch Marine Sci, Orono, ME 04469 USA	Duke University; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; National Center for Ecological Analysis & Synthesis; University of Alaska System; University of Alaska Anchorage; Oregon State University; Harvard University; University System Of New Hampshire; University of New Hampshire; University of Maine System; University of Maine Orono	Crowder, LB (corresponding author), Duke Univ, Marine Lab, Nicholas Sch Environm & Earth Sci, Ctr Marine Conservat, Beaufort, NC 28516 USA.	lcrowder@duke.edu	Day, Jon C/H-3276-2016	Day, Jon C/0000-0003-3906-0759				Baum JK, 2004, ECOL LETT, V7, P135, DOI 10.1111/j.1461-0248.2003.00564.x; Block BA, 2005, NATURE, V434, P1121, DOI 10.1038/nature03463; Craig JK, 2005, MAR ECOL PROG SER, V294, P79, DOI 10.3354/meps294079; Davis GE, 1996, T AM FISH SOC, V125, P42, DOI 10.1577/1548-8659(1996)125<0042:SATOWA>2.3.CO;2; Day JC, 2002, OCEAN COAST MANAGE, V45, P139, DOI 10.1016/S0964-5691(02)00052-2; DOUVERE F, 2006, IN PRESS MAR POLICY; Hilborn R, 2003, P NATL ACAD SCI USA, V100, P6564, DOI 10.1073/pnas.1037274100; Hutchings JA, 2004, BIOSCIENCE, V54, P297, DOI 10.1641/0006-3568(2004)054[0297:MFPCCF]2.0.CO;2; Jackson JBC, 2001, SCIENCE, V293, P629, DOI 10.1126/science.1059199; Lewison RL, 2004, ECOL LETT, V7, P221, DOI 10.1111/j.1461-0248.2004.00573.x; McLeod K.L., 2005, SCI CONSENSUS STATEM; *MEA UN ENV PROGR, 2005, LIV OUR MEANS NAT AS; Norse Elliott A., 2005, P422; Pikitch EK, 2004, SCIENCE, V305, P346, DOI 10.1126/science.1098222; Rosenberg AA, 2005, MAR ECOL PROG SER, V300, P270; Young O.R., 2002, I DIMENSIONS ENV CHA, V1st ed., DOI DOI 10.7551/MITPRESS/3807.001.0001; YOUNG OR, 2002, MATCHING I ECOSYSTEM	17	324	333	1	78	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 4	2006	313	5787					617	618		10.1126/science.1129706	http://dx.doi.org/10.1126/science.1129706			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	072IQ	16888124				2022-12-28	WOS:000239667500024
J	Goossen, LJ; Deng, GJ; Levy, LM				Goossen, Lukas J.; Deng, Guojun; Levy, Laura M.			Synthesis of biaryls via catalytic decarboxylative coupling	SCIENCE			English	Article							ORGANOBORON COMPOUNDS; QUINOLINE	We present a safe and convenient cross-coupling strategy for the large-scale synthesis of biaryls, commercially important structures often found in biologically active molecules. In contrast to traditional cross-couplings, which require the prior preparation of organometallic reagents, we use a copper catalyst to generate the carbon nucleophiles in situ, via decarboxylation of easily accessible arylcarboxylic acid salts. The scope and potential economic impact of the reaction are demonstrated by the synthesis of 26 biaryls, one of which is an intermediate in the large-scale production of the agricultural fungicide Boscalid.	Tech Univ Kaiserslautern, Inst Organ Chem, D-67663 Kaiserslautern, Germany	University of Kaiserslautern	Goossen, LJ (corresponding author), Tech Univ Kaiserslautern, Inst Organ Chem, Erwin Schrodinger Str,Bldg 54, D-67663 Kaiserslautern, Germany.	goossen@chemie.uni-kl.de	Goossen, Lukas J./L-9764-2015	Goossen, Lukas J./0000-0002-2547-3037				*BASF AG, 2005, SHAP FUT FIN REP 200; Begley TP, 2004, CURR OPIN CHEM BIOL, V8, P508, DOI 10.1016/j.cbpa.2004.08.004; Bringmann G., 2001, PROGR CHEM ORGANIC N, P82; COHEN T, 1970, J AM CHEM SOC, V92, P3189, DOI 10.1021/ja00713a047; COHEN T, 1978, J ORG CHEM, V43, P837, DOI 10.1021/jo00399a010; Croom Katherine F, 2004, Am J Cardiovasc Drugs, V4, P395, DOI 10.2165/00129784-200404060-00008; Diederich F., 1998, METAL CATALYZED CROS; GOOSSEN LJ, 2005, Patent No. 2006001014; Hajduk PJ, 2000, J MED CHEM, V43, P3443, DOI 10.1021/jm000164q; Hassan J, 2002, CHEM REV, V102, P1359, DOI 10.1021/cr000664r; Heath RJ, 2002, NAT PROD REP, V19, P581, DOI 10.1039/b110221b; Horton DA, 2003, CHEM REV, V103, P893, DOI 10.1021/cr020033s; Iding H, 1998, BBA-PROTEIN STRUCT M, V1385, P307, DOI 10.1016/S0167-4838(98)00076-4; MARCH J, 1985, ADV ORG CHEM, P627; Markham A, 1997, DRUGS, V54, P299, DOI 10.2165/00003495-199754020-00009; Matheron ME, 2004, PLANT DIS, V88, P665, DOI 10.1094/PDIS.2004.88.6.665; MIYAURA N, 1995, CHEM REV, V95, P2457, DOI 10.1021/cr00039a007; MIYAURA N, 1979, TETRAHEDRON LETT, V20, P3437, DOI 10.1016/S0040-4039(01)95429-2; Miyaura N, 2002, TOP CURR CHEM, V219, P11; Miyaura N., 1979, CHEM COMMUN, P866, DOI DOI 10.1039/C39790000866; NILSSON M, 1966, ACTA CHEM SCAND, V20, P423, DOI 10.3891/acta.chem.scand.20-0423; Poetsch E., 1988, KONTAKTE, V, 1988, P15; Rouhi AM, 2004, CHEM ENG NEWS, V82, P49, DOI 10.1021/cen-v082n036.p049; Sha L, 2004, J AM CHEM SOC, V126, P11440, DOI 10.1021/ja045981k; Sharpe M, 2001, DRUGS, V61, P1501, DOI 10.2165/00003495-200161100-00009; Suzuki A, 1999, J ORGANOMET CHEM, V576, P147, DOI 10.1016/S0022-328X(98)01055-9; Tsuji J., 2004, PALLADIUM REAGENTS C; Ward OP, 2000, CURR OPIN BIOTECH, V11, P520, DOI 10.1016/S0958-1669(00)00139-7; Yusuf S, 2002, AM J CARDIOL, V89, p18A; 2005, 5 ANN CONTRACT PHARM	31	772	777	8	217	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 4	2006	313	5787					662	664		10.1126/science.1128684	http://dx.doi.org/10.1126/science.1128684			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	072IQ	16888137				2022-12-28	WOS:000239667500041
J	Gordon, WC; Leach, MTJ				Gordon, William C.; Leach, Michael T. J.			Lung carcinoma with anti-Hu paraneoplastic syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Stobhill Hosp, Glasgow G21 3UW, Lanark, Scotland		Gordon, WC (corresponding author), Stobhill Hosp, Glasgow G21 3UW, Lanark, Scotland.								0	3	3	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 3	2006	355	5					E4	E4		10.1056/NEJMicm050672	http://dx.doi.org/10.1056/NEJMicm050672			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	069FT	16885544				2022-12-28	WOS:000239432500010
J	Yannopoulos, SN; Johari, GP				Yannopoulos, Spyros N.; Johari, G. P.			Glass behaviour - Poisson's ratio and liquid's fragility	NATURE			English	Letter							BRILLOUIN-SCATTERING; STRUCTURAL RELAXATION; PHYSICAL-PROPERTIES; ELASTIC PROPERTIES; LIGHT-SCATTERING; VISCOSITY; CONDUCTIVITY; ATTENUATION; CONSTANTS		Fdn Res & Technol Hellas, Inst Chem Engn & High Temp Chem Proc, Patras 26504, Greece; McMaster Univ, Dept Mat Sci & Engn, Hamilton, ON L8S 4L7, Canada	Foundation for Research & Technology - Hellas (FORTH); Institute of Chemical Engineering Sciences (ICE-HT); McMaster University	Yannopoulos, SN (corresponding author), Fdn Res & Technol Hellas, Inst Chem Engn & High Temp Chem Proc, POB 1414, Patras 26504, Greece.	sny@iceht.forth.gr	Yannopoulos, Spyros/C-3909-2012	Yannopoulos, Spyros/0000-0001-6684-3172				Abd El-Moneim A, 2003, PHYSICA B, V325, P319, DOI 10.1016/S0921-4526(02)01545-4; Avramov I, 1998, J NON-CRYST SOLIDS, V238, P6, DOI 10.1016/S0022-3093(98)00672-3; Bernatz KM, 2002, J NON-CRYST SOLIDS, V307, P790, DOI 10.1016/S0022-3093(02)01522-3; CHEN HS, 1975, J NON-CRYST SOLIDS, V18, P157, DOI 10.1016/0022-3093(75)90018-6; CHRYSSIKOS GD, 1994, J NON-CRYST SOLIDS, V172, P378, DOI 10.1016/0022-3093(94)90460-X; El-Adawy A, 1999, J PHYS D APPL PHYS, V32, P2791, DOI 10.1088/0022-3727/32/21/312; HASSAN AK, 1994, J NON-CRYST SOLIDS, V172, P154, DOI 10.1016/0022-3093(94)90427-8; HASZ WC, 1993, J NON-CRYST SOLIDS, V161, P127, DOI 10.1016/0022-3093(93)90683-O; HEIMAN D, 1979, PHYS REV B, V19, P6583, DOI 10.1103/PhysRevB.19.6583; Huang DH, 2001, J CHEM PHYS, V114, P5621, DOI 10.1063/1.1348029; ITO Y, 1988, SOLID STATE COMMUN, V65, P449, DOI 10.1016/0038-1098(88)90431-0; KOMATSU T, 1995, J NON-CRYST SOLIDS, V185, P199, DOI 10.1016/0022-3093(95)00237-5; LAMBSON EF, 1986, PHYS REV B, V33, P2380, DOI 10.1103/PhysRevB.33.2380; LOROSCH J, 1984, J NON-CRYST SOLIDS, V69, P1, DOI 10.1016/0022-3093(84)90119-4; MACEDO PB, 1968, J CHEM PHYS, V49, P1887, DOI 10.1063/1.1670321; Malek J, 2005, J NON-CRYST SOLIDS, V351, P3458, DOI 10.1016/j.jnoncrysol.2005.09.004; Malek J, 1998, THERMOCHIM ACTA, V311, P183, DOI 10.1016/S0040-6031(97)00466-8; Malek J, 1999, J NON-CRYST SOLIDS, V243, P116, DOI 10.1016/S0022-3093(98)00823-0; Mazurin O.V., 1983, HDB GLASS DATA A; MOYNIHAN CT, 1971, J CHEM PHYS, V55, P3013, DOI 10.1063/1.1676531; NEMANICH RJ, 1977, PHYS REV B, V16, P1655, DOI 10.1103/PhysRevB.16.1655; NEMANICH RJ, 1977, SOLID STATE COMMUN, V21, P277, DOI 10.1016/0038-1098(77)90186-7; Novikov VN, 2004, NATURE, V431, P961, DOI 10.1038/nature02947; Perera DN, 1999, J PHYS-CONDENS MAT, V11, P3807, DOI 10.1088/0953-8984/11/19/303; Pohl RO, 2002, REV MOD PHYS, V74, P991, DOI 10.1103/RevModPhys.74.991; Schilling FR, 2001, CONTRIB MINERAL PETR, V141, P297, DOI 10.1007/s004100100253; SCHROEDER J, 1987, ELECTRON LETT, V23, P1128, DOI 10.1049/el:19870787; TANNER LE, 1977, SCRIPTA METALL MATER, V11, P783, DOI 10.1016/0036-9748(77)90076-X; TORELL LM, 1983, J NON-CRYST SOLIDS, V56, P93, DOI 10.1016/0022-3093(83)90452-0; Wang WH, 2004, MAT SCI ENG R, V44, P45, DOI 10.1016/j.mser.2004.03.001; Wang WH, 2001, APPL PHYS LETT, V79, P3947, DOI 10.1063/1.1426272; WANG WH, 2005, J MATER RES, V20, P2037; Zhang B, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.224208; Zhao ZF, 2003, APPL PHYS LETT, V82, P4699, DOI 10.1063/1.1588367	34	77	79	3	66	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 3	2006	442	7102					E7	E8		10.1038/nature04967x	http://dx.doi.org/10.1038/nature04967x			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	069NQ	16888850				2022-12-28	WOS:000239455900034
J	Holgate, ST; Polosa, R				Holgate, Stephen T.; Polosa, Riccardo			The mechanisms, diagnosis, and management of severe asthma in adults	LANCET			English	Review							LUNG-FUNCTION DECLINE; NECROSIS-FACTOR-ALPHA; GROWTH-FACTOR RECEPTOR; AIRWAY SMOOTH-MUSCLE; QUALITY-OF-LIFE; ADD-ON THERAPY; SEVERE PERSISTENT; TNF-ALPHA; INTRAVENOUS IMMUNOGLOBULIN; INHALED CORTICOSTEROIDS	There has been a recent increase in the prevalence of asthma worldwide; however, the 5-10% of patients with severe disease account for a substantial proportion of the health costs. Although most asthma cases can be satisfactorily managed with a combination of anti-inflammatory drugs and bronchodilators, patients who remain symptomatic despite maximum combination treatment represent a heterogeneous group consisting of those who are under-treated or non-adherent with their prescribed medication. After excluding under-treatment and poor compliance, corticosteroid refractory asthma can be identified as a subphenotype characterised by a heightened neutrophilic airway inflammatory response in the presence or absence of eosinophils, with evidence of increased tissue injury and remodelling. Although a wide range of environmental factors such as allergens, smoking, air pollution, infection, hormones, and specific drugs can contribute to this phenotype, other features associated with changes in the airway inflammatory response should be taken into account. Aberrant communication between an injured airway epithelium and underlying mesenchyme contributes to disease chronicity and refractoriness to corticosteroids. The importance of identifying underlying causative factors and the recent introduction of novel therapeutic approaches, including the targeting of immunoglobulin E and tumour necrosis factor a with biological agents, emphasise the need for careful phenotyping of patients with severe disease to target improved management of the individual patient's needs.	Southampton Gen Hosp, AIR Div, Southampton SO16 6YD, Hants, England; Univ Catania, Dipartimento Med Interna & Specialist, Catania, Italy	University of Southampton; University of Catania	Holgate, ST (corresponding author), Southampton Gen Hosp, AIR Div, MP810,F Level,S Block, Southampton SO16 6YD, Hants, England.	sth@soton.ac.uk			MRC [G19/34] Funding Source: UKRI; Medical Research Council [G0800766, G19/34] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abraham B, 2003, EUR RESPIR J, V22, P470, DOI 10.1183/09031936.03.00261903; Adcock IM, 2003, J ENDOCRINOL, V178, P347, DOI 10.1677/joe.0.1780347; Amrani Y, 2000, Respir Res, V1, P49, DOI 10.1186/rr12; An SS, 2006, AM J RESP CELL MOL, V35, P55, DOI 10.1165/rcmb.2005-0453OC; Atherton HC, 2003, AM J PHYSIOL-LUNG C, V285, pL730, DOI 10.1152/ajplung.00089.2003; Ayres Jon G, 2004, Paediatr Respir Rev, V5, P40, DOI 10.1016/j.prrv.2003.09.003; Babu KS, 2004, IMMUNOL ALLERGY CLIN, V24, P583, DOI 10.1016/j.iac.2004.06.010; Bachert C, 2006, CURR OPIN ALLERGY CL, V6, P29, DOI 10.1097/01.all.0000200504.54425.0e; Bachert C, 2002, ALLERGY, V57, P1208; Balzar S, 2005, AM J RESP CRIT CARE, V171, P431, DOI 10.1164/rccm.200407-949OC; Barnes N, 2006, PAEDIATR RESPIR REV, V7, P141, DOI 10.1016/j.prrv.2006.03.008; Barton CA, 2005, J ASTHMA, V42, P249, DOI 10.1081/JAS-200057881; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Bel EH, 2004, CURR OPIN PULM MED, V10, P44, DOI 10.1097/00063198-200401000-00008; Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; Berry MA, 2006, NEW ENGL J MED, V354, P697, DOI 10.1056/NEJMoa050580; Bisgaard H, 2006, LANCET, V367, P286, DOI 10.1016/S0140-6736(06)68051-3; Bochner BS, 2004, J ALLERGY CLIN IMMUN, V113, P868, DOI 10.1016/j.jaci.2004.02.016; Bousquet J, 2005, B WORLD HEALTH ORGAN, V83, P548; Brenner BE, 2005, THORAX, V60, P806, DOI 10.1136/thx.2004.033928; Bresciani M, 2001, J ALLERGY CLIN IMMUN, V107, P73, DOI 10.1067/mai.2001.111593; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Brunekreef B, 2002, LANCET, V360, P1233, DOI 10.1016/S0140-6736(02)11274-8; Bumbacea D, 2004, EUR RESPIR J, V24, P122, DOI 10.1183/09031936.04.00077803; Busse PJ, 2005, J ALLERGY CLIN IMMUN, V116, P1256, DOI 10.1016/j.jaci.2005.08.059; Campbell MJ, 1997, BRIT MED J, V314, P1439, DOI 10.1136/bmj.314.7092.1439; Carroll NG, 2002, EUR RESPIR J, V19, P879, DOI 10.1183/09031936.02.00275802; Casalino-Matsuda SM, 2006, AM J RESP CELL MOL, V34, P581, DOI 10.1165/rcmb.2005-0386OC; Cazzola M, 2006, CURR OPIN ALLERGY CL, V6, P43, DOI 10.1097/01.all.0000199798.10047.74; Cohn L, 2006, J CLIN INVEST, V116, P306, DOI 10.1172/JCI27690; Comhair SAA, 2005, AM J PATHOL, V166, P663, DOI 10.1016/S0002-9440(10)62288-2; Corne JM, 2002, LANCET, V359, P831, DOI 10.1016/S0140-6736(02)07953-9; Coughlan JL, 2001, THORAX, V56, P198, DOI 10.1136/thorax.56.3.198; Currie GP, 2005, CHEST, V128, P2954, DOI 10.1378/chest.128.4.2954; Dahlen SE, 2002, AM J RESP CRIT CARE, V165, P9, DOI 10.1164/ajrccm.165.1.2010080; Davies H, 2000, COCHRANE DB SYST REV, V2; de Marco R, 2005, INT ARCH ALLERGY IMM, V138, P225, DOI 10.1159/000088723; Dijkstra A, 2006, J ALLERGY CLIN IMMUN, V117, P604, DOI 10.1016/j.jaci.2005.11.023; Dijkstra A, 2006, THORAX, V61, P105, DOI 10.1136/thx.2004.039271; Djukanovic R, 2004, AM J RESP CRIT CARE, V170, P583, DOI 10.1164/rccm.200312-1651OC; Dolan CM, 2004, ANN ALLERG ASTHMA IM, V92, P32, DOI 10.1016/S1081-1206(10)61707-3; Erzurum SC, 2006, NEW ENGL J MED, V354, P754, DOI 10.1056/NEJMe058266; Fedorov IA, 2005, THORAX, V60, P389, DOI 10.1136/thx.2004.030262; Frey U, 2005, NATURE, V438, P667, DOI 10.1038/nature04176; Gerdtham UG, 1996, MED CARE, V34, P1188, DOI 10.1097/00005650-199612000-00004; Gibson PG, 2006, SEM RESP CRIT CARE M, V27, P185, DOI 10.1055/s-2006-939521; Gibson PG, 2001, CHEST, V119, P1329, DOI 10.1378/chest.119.5.1329; Gibson PG, 2003, COCHRANE DATABASE SY, pCD001496, DOI DOI 10.1002/14651858.CD001496; Gibson PG, 2005, COCHRANE DB SYST REV, V4; Global Initiative for Asthma, NIH PUBL, V02-3659; Godard P, 2002, EUR RESPIR J, V19, P61, DOI 10.1183/09031936.02.00232001; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Green RH, 2002, THORAX, V57, P875, DOI 10.1136/thorax.57.10.875; Greene R, 2005, MED MYCOL, V43, pS147, DOI 10.1080/13693780500064771; GRUNBERG K, 2001, AM J RESP CRIT CARE, V109, P35; HAMILTON L, 2003, CLIN EXP ALLERGY, V33, P1; Haque S, 2003, INTERN MED J, V33, P341, DOI 10.1046/j.1445-5994.2003.t01-1-00419.x; Harju TH, 2006, THORAX, V61, P579, DOI 10.1136/thx.2005.056291; Harrison BDW, 2005, INTERN MED J, V35, P543, DOI 10.1111/j.1445-5994.2005.00901.x; Hawrylowicz C, 2002, J ALLERGY CLIN IMMUN, V109, P369, DOI 10.1067/mai.2002.121455; Heaney LG, 2005, LANCET, V365, P974, DOI 10.1016/S0140-6736(05)71087-4; Holgate S, 2005, J ALLERGY CLIN IMMUN, V115, P459, DOI 10.1016/j.jaci.2004.11.053; Holgate ST, 2006, J ALLERGY CLIN IMMUN, V117, P496, DOI 10.1016/j.jaci.2006.01.039; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P193, DOI 10.1016/S0091-6749(00)90066-6; Holgate Stephen T, 2004, Proc Am Thorac Soc, V1, P93, DOI 10.1513/pats.2306034; Howarth Peter H, 2004, J Allergy Clin Immunol, V114, pS32, DOI 10.1016/j.jaci.2004.04.041; Howarth PH, 2005, THORAX, V60, P1012, DOI 10.1136/thx.2005.045260; Humbert M, 2005, ALLERGY, V60, P309, DOI 10.1111/j.1398-9995.2004.00772.x; Humbert M, 1999, IMMUNOL TODAY, V20, P528, DOI 10.1016/S0167-5699(99)01535-2; INTVEEN JCC, AM J RESP CRIT CARE, V158, P1134; Israel E, 2004, LANCET, V364, P1505, DOI 10.1016/S0140-6736(04)17273-5; Jain S, 2006, J ASTHMA, V43, P207, DOI 10.1080/02770900600566892; James AL, 2005, AM J RESP CRIT CARE, V171, P109, DOI 10.1164/rccm.200402-230OC; Janson C, 2005, EUR RESPIR J, V26, P1047, DOI 10.1183/09031936.05.00031905; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532, DOI 10.1164/ajrccm.160.5.9806170; Johnston SL, 2006, NEW ENGL J MED, V354, P1589, DOI 10.1056/NEJMoa044080; Jongepier H, 2004, CLIN EXP ALLERGY, V34, P757, DOI 10.1111/j.1365-2222.2004.1938.x; Kawakami T, 2005, ARCH DERMATOL, V141, P873, DOI 10.1001/archderm.141.7.873; Kiljander TO, 2006, AM J RESP CRIT CARE, V173, P1091, DOI 10.1164/rccm.200507-1167OC; KING S, 2005, CLIN EXP ALLERGY, V35, P672; Knight DA, 2003, RESPIROLOGY, V8, P432, DOI 10.1046/j.1440-1843.2003.00493.x; Koga T, 2006, RESP MED, V100, P273, DOI 10.1016/j.rmed.2005.05.017; Kraft M, 2002, CHEST, V121, P1782, DOI 10.1378/chest.121.6.1782; Kraft M, 1996, AM J RESP CRIT CARE, V154, P1505, DOI 10.1164/ajrccm.154.5.8912772; Kroegel C, 2006, RESPIRATION, V73, P566, DOI 10.1159/000088660; Lee YM, 2004, CHEST, V126, P1840, DOI 10.1378/chest.126.6.1840; Lehrer P, 2002, J CONSULT CLIN PSYCH, V70, P691, DOI 10.1037//0022-006X.70.3.691; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Littner MR, 2005, CHEST, V128, P1128, DOI 10.1378/chest.128.3.1128; Luong KVQ, 2000, J ASTHMA, V37, P125, DOI 10.3109/02770900009055435; Malo JL, 2005, AM J RESP CRIT CARE, V172, P406, DOI 10.1164/rccm.2506006; Marchac V, 2002, AM J ROENTGENOL, V179, P1245, DOI 10.2214/ajr.179.5.1791245; Martinez FD, 2005, NEW ENGL J MED, V353, P2637, DOI 10.1056/NEJMp058299; Mascia K, 2005, J ALLERGY CLIN IMMUN, V116, P970, DOI 10.1016/j.jaci.2005.08.035; Mauad T, 2004, AM J RESP CRIT CARE, V170, P857, DOI 10.1164/rccm.200403-305OC; Miller MK, 2005, J ALLERGY CLIN IMMUN, V116, P990, DOI 10.1016/j.jaci.2005.08.018; Min JW, 2005, CHEST, V128, P3127, DOI 10.1378/chest.128.5.3127; Mitsunobu F, 2005, CURR OPIN ALLERGY CL, V5, P85, DOI 10.1097/00130832-200502000-00015; Mjaanes CM, 2006, CLIN CHEST MED, V27, P119, DOI 10.1016/j.ccm.2005.10.005; Moore WC, 2006, J ALLERGY CLIN IMMUN, V117, P487, DOI 10.1016/j.jaci.2006.01.033; Mortimer KJ, 2005, IMMUNOL ALLERGY CLIN, V25, P523, DOI 10.1016/j.iac.2005.05.002; Neffen H, 2006, RESP MED, V100, P1431, DOI 10.1016/j.rmed.2005.11.004; Nguyen LT, 2005, RESP MED, V99, P200, DOI 10.1016/j.rmed.2004.06.007; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; Niebauer K, 2006, ANN ALLERG ASTHMA IM, V96, P316, DOI 10.1016/S1081-1206(10)61242-2; Nieves A, 2005, RESP MED, V99, P347, DOI 10.1016/j.rmed.2004.08.004; Nouwen A, 1999, BEHAV MODIF, V23, P217, DOI 10.1177/0145445599232002; Oswald H, 1997, PEDIATR PULM, V23, P14, DOI 10.1002/(SICI)1099-0496(199701)23:1<14::AID-PPUL2>3.0.CO;2-P; Pavord ID, 1997, THORAX, V52, P498, DOI 10.1136/thx.52.6.498; Pedersen B, 1996, AM J RESP CRIT CARE, V153, P1519, DOI 10.1164/ajrccm.153.5.8630596; Pepe C, 2005, J ALLERGY CLIN IMMUN, V116, P544, DOI 10.1016/j.jaci.2005.06.011; Proceedings of the ATS workshop on refractory asthma, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Puddicombe SM, 2000, FASEB J, V14, P1362, DOI 10.1096/fj.14.10.1362; Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541; Richeldi L, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002997.pub3; Roth M, 2004, NEW ENGL J MED, V351, P560, DOI 10.1056/NEJMoa021660; Russo C, 2005, CLIN SCI, V109, P135, DOI 10.1042/CS20050038; SAGLANI S, 2006, EUR RESP J      0426, pV4051; Saint-Pierre P, 2006, ALLERGY, V61, P79, DOI 10.1111/j.1398-9995.2005.00953.x; Salmun LM, 1999, J ALLERGY CLIN IMMUN, V103, P810, DOI 10.1016/S0091-6749(99)70424-0; Sanak M, 2000, THORAX, V55, pS45, DOI 10.1136/thorax.55.suppl_2.S45; Schatz M, 1999, J ALLERGY CLIN IMMUN, V103, pS330, DOI 10.1016/S0091-6749(99)70258-7; Shah L, 2003, COCHRANE DB SYST REV, V3; Shore SA, 2006, PHARMACOL THERAPEUT, V110, P83, DOI 10.1016/j.pharmthera.2005.10.002; Silkoff PE, 2005, J ALLERGY CLIN IMMUN, V116, P1249, DOI 10.1016/j.jaci.2005.09.029; Silverman RA, 2003, CHEST, V123, P1472, DOI 10.1378/chest.123.5.1472; Simon HU, 2006, CURR ALLERGY ASTHM R, V6, P117, DOI 10.1007/s11882-006-0049-9; Sood A, 2006, THORAX, V61, P300, DOI 10.1136/thx.2004.031468; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; Sturdy PM, 2005, THORAX, V60, P909, DOI 10.1136/thx.2004.025593; Sutherland ER, 2004, J ALLERGY CLIN IMMUN, V113, P1046, DOI 10.1016/j.jaci.2004.03.016; Szczeklik A, 2006, EUR J PHARMACOL, V533, P145, DOI 10.1016/j.ejphar.2005.12.053; Szczeklik A, 2000, EUR RESPIR J, V16, P432, DOI 10.1034/j.1399-3003.2000.016003432.x; Szefler S, 2005, CHEST, V128, P1104, DOI 10.1378/chest.128.3.1104; Takigawa N, 2005, J ASTHMA, V42, P639, DOI 10.1080/02770900500263822; ten Brinke A, 2001, J ALLERGY CLIN IMMUN, V107, P449, DOI 10.1067/mai.2001.113047; ten Brinke A, 2004, AM J RESP CRIT CARE, V170, P601, DOI 10.1164/rccm.200404-440OC; ten Brinke A, 2001, AM J RESP CRIT CARE, V164, P744, DOI 10.1164/ajrccm.164.5.2011026; Thomson NC, 2005, CURR OPIN ALLERGY CL, V5, P57, DOI 10.1097/00130832-200502000-00011; Tinkelman DG, 2006, J ASTHMA, V43, P75, DOI 10.1080/02770900500448738; Tough SC, 1998, J ASTHMA, V35, P657, DOI 10.3109/02770909809048968; Truyen E, 2006, THORAX, V61, P202, DOI 10.1136/thx.2005.052399; Tulic MK, 2003, CHEST, V123, p348S, DOI 10.1378/chest.123.3_suppl.348S; van Diemen CC, 2005, AM J RESP CRIT CARE, V172, P329, DOI 10.1164/rccm.200411-1486OC; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; van Rensen ELJ, 2005, AM J RESP CRIT CARE, V172, P837, DOI 10.1164/rccm.200504-619OC; Vrugt B, 1997, THORAX, V52, P662, DOI 10.1136/thx.52.7.662; Ward C, 2005, CURR OPIN ALLERGY CL, V5, P43, DOI 10.1097/00130832-200502000-00009; Wardlaw AJ, 2005, CLIN EXP ALLERGY, V35, P1254, DOI 10.1111/j.1365-2222.2005.02344.x; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Wark PAB, 2002, EUR RESPIR J, V19, P68, DOI 10.1183/09031936.02.00226302; Waserman S, 2000, Can Respir J, V7, P229; Webster JC, 2001, P NATL ACAD SCI USA, V98, P6865, DOI 10.1073/pnas.121455098; Wechsler ME, 2006, AM J RESP CRIT CARE, V173, P519, DOI 10.1164/rccm.200509-1519OC; Weiss Scott T, 2004, Proc Am Thorac Soc, V1, P364, DOI 10.1513/pats.200409-043MS; Wenzel S, 2005, AM J RESP CRIT CARE, V172, P149, DOI 10.1164/rccm.200409-1181PP; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; Westby M., 2004, COCHRANE DB SYST REV, V3; Wirtz HR, 2005, J HEART LUNG TRANSPL, V24, P1700, DOI 10.1016/j.healun.2005.01.015; Woodcock A, 2003, NEW ENGL J MED, V349, P225, DOI 10.1056/NEJMoa023175; Wright AL, 2006, PEDIATR PULM, V41, P318, DOI 10.1002/ppul.20373; Yigla M, 2003, J ASTHMA, V40, P865, DOI 10.1081/JAS-120023577	162	281	314	0	24	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG-SEP	2006	368	9537					780	793		10.1016/S0140-6736(06)69288-X	http://dx.doi.org/10.1016/S0140-6736(06)69288-X			18	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	080ID	16935689				2022-12-28	WOS:000240240200030
J	Chappuis, F; Rijal, S; Soto, A; Menten, J; Boelaert, M				Chappuis, Francois; Rijal, Suman; Soto, Alonso; Menten, Joris; Boelaert, Marleen			A meta-analysis of the diagnostic performance of the direct agglutination test and rK39 dipstick for visceral leishmaniasis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LINKED-IMMUNOSORBENT-ASSAY; FREEZE-DRIED ANTIGEN; K-39 STRIP TEST; KALA-AZAR; TEST DAT; FIELD DIAGNOSIS; SERO-DIAGNOSIS; SERODIAGNOSIS; DONOVANI; ACCURACY	Objective To compare the performance of the direct agglutination test and rK39 dipstick for the diagnosis of visceral leishmaniasis. Data sources Medline, citation tracking, January 1986 to December 2004. Selection criteria Original studies evaluating the direct agglutination test or the rK39 dipstick with clinical visceral leishmaniasis as target condition; adequate reference classification; and absolute numbers of true positive, true negative, false positive, and false negative observations available or derivable front die data presented. Results 30 studies evaluating the direct agglutination test and 13 studies evaluating the rK39 dipstick met the inclusion criteria. The combined sensitivity estimates of the direct agglutination test and the rK39 dipstick were 94.8% (95% confidence interval 92.7% to 96.4%) and 93.9% (87.7% to 97.1%), respectively. Sensitivity seemed higher and more homogenous in tire studies carried out in South Asia. Specificity estimates were influenced by the type of controls. In phase Ell studies carried out on patients with clinically suspected disease, the estimated specificity of the direct agglutination test was 85.9% (72.3% to 93.4%) and of the rK39 dipstick was 90.6% (66.8% to 97.9%). Conclusion The diagnostic performance of the direct agglutination test and the rK39 dipstick for visceral leishmaniasis is good to excellent and seem comparable.	Univ Hosp Geneva, Travel & Migrat Med Unit, CH-1211 Geneva 14, Switzerland; BP Koirala Inst Hlth Sci, Dharan, Nepal; Univ Peruana Cayetano Heredia, Hosp Nacl Hipolito Unanue, Lima, Peru; Inst Trop Med, B-2000 Antwerp, Belgium	University of Geneva; B.P. Koirala Institute of Health Sciences; Universidad Peruana Cayetano Heredia; Institute of Tropical Medicine (ITM)	Chappuis, F (corresponding author), Univ Hosp Geneva, Travel & Migrat Med Unit, Rue Micheli du Crest 24, CH-1211 Geneva 14, Switzerland.	francois.chappuis@hcuge.ch	Boelaert, Marleen/E-2698-2012; Soto, Alonso/ABB-7707-2021	Boelaert, Marleen/0000-0001-8051-6776; Soto, Alonso/0000-0001-8648-8032; Chappuis, Francois/0000-0003-0442-7610				Abdallah KAA, 2004, TROP MED INT HEALTH, V9, P1127, DOI 10.1111/j.1365-3156.2004.01308.x; ABDELHAMEED AA, 1989, TROP MED PARASITOL, V40, P470; Agarwal Mamta, 1996, Indian Journal of Experimental Biology, V34, P734; Alam M J, 1996, Bangladesh Med Res Counc Bull, V22, P27; ALLAIN DS, 1975, AM J TROP MED HYG, V24, P232, DOI 10.4269/ajtmh.1975.24.232; ANDRADE CR, 1989, BRAZ J MED BIOL RES, V22, P611; Aoun K, 2000, Tunis Med, V78, P719; Badaro R, 1996, J INFECT DIS, V173, P758, DOI 10.1093/infdis/173.3.758; Bagchi AK, 1998, ANN TROP MED PARASIT, V92, P159, DOI 10.1080/00034989859997; Bern C, 2000, AM J TROP MED HYG, V63, P153, DOI 10.4269/ajtmh.2000.63.153; Boelaert M, 2004, AM J TROP MED HYG, V70, P72, DOI 10.4269/ajtmh.2004.70.72; Boelaert M, 1999, TROP MED INT HEALTH, V4, P395, DOI 10.1046/j.1365-3156.1999.00421.x; Boelaert M, 1999, AM J TROP MED HYG, V60, P129, DOI 10.4269/ajtmh.1999.60.129; Boelaert M, 1999, B WORLD HEALTH ORGAN, V77, P667; Bossuyt PM, 2003, ANN INTERN MED, V138, P40, DOI 10.7326/0003-4819-138-1-200301070-00010; Brandonisio O, 2002, EUR J CLIN MICROBIOL, V21, P461, DOI 10.1007/s10096-002-0739-8; Carvalho SFG, 2003, AM J TROP MED HYG, V68, P321; Chappuis F, 2003, TROP MED INT HEALTH, V8, P277, DOI 10.1046/j.1365-3156.2003.01026.x; Chappuis F, 2005, J CLIN MICROBIOL, V43, P5973, DOI 10.1128/JCM.43.12.5973-5977.2005; COLIET D, 2003, MODELLING BINARY DAT; CoLLEt D, 2003, MODELLING BINARY DAT; Deeks JJ, 2001, BRIT MED J, V323, P157, DOI 10.1136/bmj.323.7305.157; Deeks JJ, 2001, SYSTEMATIC REV HLTH, P285, DOI DOI 10.1002/9780470693926.CH15; Deeks JJ., 2001, SYSTEMATIC REV HLTH, P248, DOI DOI 10.1002/9780470693926.CH14; DEKORTE PM, 1990, PARASITOL RES, V76, P526, DOI 10.1007/BF00931059; Desjeux P, 1996, CLIN DERMATOL, V14, P417, DOI 10.1016/0738-081X(96)00057-0; ELSAFI SH, 1989, T ROY SOC TROP MED H, V83, P334, DOI 10.1016/0035-9203(89)90493-8; Garcez Lourdes M., 1996, Revista da Sociedade Brasileira de Medicina Tropical, V29, P165, DOI 10.1590/S0037-86821996000200009; Goswami R P, 2003, J Assoc Physicians India, V51, P759; Hailu A, 2002, ACTA TROP, V83, P93, DOI 10.1016/S0001-706X(02)00063-3; HARITH AE, 1987, T ROY SOC TROP MED H, V81, P603, DOI 10.1016/0035-9203(87)90423-8; HARITH AE, 1986, T ROY SOC TROP MED H, V80, P583, DOI 10.1016/0035-9203(86)90149-5; Iqbal J, 2002, J CLIN MICROBIOL, V40, P475, DOI 10.1128/JCM.40.3.475-479.2001; Jha T K, 1996, J Assoc Physicians India, V44, P606; Joshi A. B., 1999, Southeast Asian Journal of Tropical Medicine and Public Health, V30, P583; Lito Gjeorgjina, 2002, International Journal of Infectious Diseases, V6, P66, DOI 10.1016/S1201-9712(02)90139-6; Mabey D, 2004, NAT REV MICROBIOL, V2, P231, DOI 10.1038/nrmicro841; MAHEY D, 2004, NAT REV MICROBIOL, V2, P231; MEREDITH SEO, 1995, J CLIN MICROBIOL, V33, P1742, DOI 10.1128/JCM.33.7.1742-1745.1995; Newcombe RG, 1998, STAT MED, V17, P873, DOI 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I; NYAKUNDI PM, 1994, E AFR MED J, V71, P598; Oskam L, 1999, T ROY SOC TROP MED H, V93, P275, DOI 10.1016/S0035-9203(99)90021-4; PAL A, 1991, J CLIN LAB ANAL, V5, P303, DOI 10.1002/jcla.1860050502; *R DEV COR TEAM, 2004, R FDN STAT COMP; Ritmeijer K, 2006, AM J TROP MED HYG, V74, P76, DOI 10.4269/ajtmh.2006.74.76; Sarker C B, 2003, Mymensingh Med J, V12, P93; Schallig HDFH, 2002, MEM I OSWALDO CRUZ, V97, P1015, DOI 10.1590/S0074-02762002000700015; Singh S, 1995, J PARASITOL, V81, P1000, DOI 10.2307/3284056; SINGLA N, 1993, T ROY SOC TROP MED H, V87, P276, DOI 10.1016/0035-9203(93)90125-A; SINHA R, 1994, J TROP MED HYG, V97, P333; Sundar S, 1998, LANCET, V351, P563, DOI 10.1016/S0140-6736(97)04350-X; Sundar S, 2006, J CLIN MICROBIOL, V44, P251, DOI 10.1128/JCM.44.1.251-253.2006; Sundar S, 2002, ANN TROP MED PARASIT, V96, P19, DOI 10.1179/000349802125000466; Veeken H, 2003, TROP MED INT HEALTH, V8, P164, DOI 10.1046/j.1365-3156.2003.00996.x; Whiting Penny, 2003, BMC Med Res Methodol, V3, P25, DOI 10.1186/1471-2288-3-25; Zhou X.H., 2002, STAT METHODS DIAGNOS, DOI 10.1002/9780470317082; ZIJLSTRA EE, 1992, T ROY SOC TROP MED H, V86, P505, DOI 10.1016/0035-9203(92)90086-R; Zijlstra EE, 2001, TROP MED INT HEALTH, V6, P108, DOI 10.1046/j.1365-3156.2001.00680.x; Zijlstra EE, 1998, CLIN DIAGN LAB IMMUN, V5, P717, DOI 10.1128/CDLI.5.5.717-720.1998; ZIJLSTRA EE, 1991, T ROY SOC TROP MED H, V85, P474, DOI 10.1016/0035-9203(91)90224-M	60	193	200	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 7	2006	333	7571					723	726		10.1136/bmj.38917.503056.7C	http://dx.doi.org/10.1136/bmj.38917.503056.7C			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	094OK	16882683	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000241248600017
J	Pollard, KS; Salama, SR; Lambert, N; Lambot, MA; Coppens, S; Pedersen, JS; Katzman, S; King, B; Onodera, C; Siepel, A; Kern, AD; Dehay, C; Igel, H; Ares, M; Vanderhaeghen, P; Haussler, D				Pollard, Katherine S.; Salama, Sofie R.; Lambert, Nelle; Lambot, Marie-Alexandra; Coppens, Sandra; Pedersen, Jakob S.; Katzman, Sol; King, Bryan; Onodera, Courtney; Siepel, Adam; Kern, Andrew D.; Dehay, Colette; Igel, Haller; Ares, Manuel, Jr.; Vanderhaeghen, Pierre; Haussler, David			An RNA gene expressed during cortical development evolved rapidly in humans	NATURE			English	Article							MARGINAL ZONE; LAYER-I; EVOLUTION; REELIN; NEURONS; VERTEBRATE; MOUSE; ISOCHORES; ORIGIN; SYSTEM	The developmental and evolutionary mechanisms behind the emergence of human-specific brain features remain largely unknown. However, the recent ability to compare our genome to that of our closest relative, the chimpanzee, provides new avenues to link genetic and phenotypic changes in the evolution of the human brain. We devised a ranking of regions in the human genome that show significant evolutionary acceleration. Here we report that the most dramatic of these 'human accelerated regions', HAR1, is part of a novel RNA gene (HAR1F) that is expressed specifically in Cajal Retzius neurons in the developing human neocortex from 7 to 19 gestational weeks, a crucial period for cortical neuron specification and migration. HAR1F is co-expressed with reelin, a product of Cajal - Retzius neurons that is of fundamental importance in specifying the six-layer structure of the human cortex. HAR1 and the other human accelerated regions provide new candidates in the search for uniquely human biology.	Univ Calif Santa Cruz, Ctr Biomol Sci & Engn, Santa Cruz, CA 95064 USA; Univ Calif Santa Cruz, Howard Hughes Med Inst, Santa Cruz, CA 95064 USA; Univ Calif Santa Cruz, Ctr Mol Biol RNA, Dept Mol Cell & Dev Biol, Santa Cruz, CA 95064 USA; Free Univ Brussels, IRIBHM, B-1070 Brussels, Belgium; Free Univ Brussels, Erasme Hosp, Dept Psychiat, B-1070 Brussels, Belgium; INSERM, U371, F-69500 Bron, France; Univ Lyon 1, F-69500 Bron, France	University of California System; University of California Santa Cruz; Howard Hughes Medical Institute; University of California System; University of California Santa Cruz; University of California System; University of California Santa Cruz; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Haussler, D (corresponding author), Univ Calif Santa Cruz, Ctr Biomol Sci & Engn, Santa Cruz, CA 95064 USA.	haussler@soe.ucsc.edu	Pedersen, Jakob/G-3382-2012; Salama, Sofie/K-6412-2019; Dehay, Colette/H-4437-2014; Pedersen, Jakob/C-4985-2009	Pedersen, Jakob/0000-0002-7236-4001; Dehay, Colette/0000-0002-5196-1464; , Nelle/0000-0003-1137-9725; Vanderhaeghen, Pierre/0000-0001-7899-5720; Coppens, Sandra/0000-0001-9155-7506; Siepel, Adam/0000-0002-3557-7219; Ares, Manny/0000-0002-2552-9168; Salama, Sofie/0000-0001-6999-7193	NIGMS NIH HHS [R01 GM040478] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alfano G, 2005, HUM MOL GENET, V14, P913, DOI 10.1093/hmg/ddi084; Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; Bernardi G, 2000, GENE, V241, P3, DOI 10.1016/S0378-1119(99)00485-0; Bond J, 2006, CURR OPIN CELL BIOL, V18, P95, DOI 10.1016/j.ceb.2005.11.004; *CHIMP SEQ AN CONS, 2005, NATURE, V0437; Clark AG, 2003, SCIENCE, V302, P1960, DOI 10.1126/science.1088821; Collins FS, 1998, GENOME RES, V8, P1229, DOI 10.1101/gr.8.12.1229; de Bergeyck V, 1998, J NEUROSCI METH, V82, P17, DOI 10.1016/S0165-0270(98)00024-7; Depaepe V, 2005, NATURE, V435, P1244, DOI 10.1038/nature03651; Dorus S, 2004, CELL, V119, P1027, DOI 10.1016/j.cell.2004.11.040; Duret L, 2002, GENETICS, V162, P1837; Enard W, 2002, NATURE, V418, P869, DOI 10.1038/nature01025; Evans PD, 2004, HUM MOL GENET, V13, P489, DOI 10.1093/hmg/ddh055; Griffiths-Jones S, 2005, NUCLEIC ACIDS RES, V33, pD121, DOI 10.1093/nar/gki081; Hedges SB, 2002, SCIENCE, V297, P1283; Hill RS, 2005, NATURE, V437, P64, DOI 10.1038/nature04103; Hillier LW, 2004, NATURE, V432, P695, DOI 10.1038/nature03154; Impagnatiello F, 1998, P NATL ACAD SCI USA, V95, P15718, DOI 10.1073/pnas.95.26.15718; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kimura M., 1983, NEUTRAL THEORY MOL E; KING MC, 1975, SCIENCE, V188, P107, DOI 10.1126/science.1090005; Kudla G, 2006, PLOS BIOL, V4, P933, DOI 10.1371/journal.pbio.0040180; Lambot MA, 2005, J NEUROSCI, V25, P7232, DOI 10.1523/JNEUROSCI.0802-05.2005; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lukaszewicz A, 2005, NEURON, V47, P353, DOI 10.1016/j.neuron.2005.06.032; Merryman C, 1998, PRACT APPROACH SER, V192, P237; Meyer G, 1999, EUR J NEUROSCI, V11, P3937, DOI 10.1046/j.1460-9568.1999.00818.x; Meyer G, 1998, J COMP NEUROL, V397, P493; Meyer G, 1998, J COMP NEUROL, V397, P29; Nielsen R, 2005, PLOS BIOL, V3, P976, DOI 10.1371/journal.pbio.0030170; Nobrega MA, 2003, SCIENCE, V302, P413, DOI 10.1126/science.1088328; Pedersen JS, 2006, PLOS COMPUT BIOL, V2, P251, DOI 10.1371/journal.pcbi.0020033; Perez-Garcia CG, 2004, EUR J NEUROSCI, V20, P2827, DOI 10.1111/j.1460-9568.2004.03733.x; Ptak SE, 2005, NAT GENET, V37, P429, DOI 10.1038/ng1529; Rakic S, 2003, CEREB CORTEX, V13, P1072, DOI 10.1093/cercor/13.10.1072; Siepel A, 2005, GENOME RES, V15, P1034, DOI 10.1101/gr.3715005; Stajich JE, 2005, MOL BIOL EVOL, V22, P63, DOI 10.1093/molbev/msh252; Tissir F, 2003, NAT REV NEUROSCI, V4, P496, DOI 10.1038/nrn1113; Wang XX, 2006, PLOS BIOL, V4, P366, DOI 10.1371/journal.pbio.0040052; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Zecevic N, 2001, J NEUROSCI, V21, P5607, DOI 10.1523/JNEUROSCI.21-15-05607.2001	41	634	665	1	92	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 14	2006	443	7108					167	172		10.1038/nature05113	http://dx.doi.org/10.1038/nature05113			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	083OB	16915236				2022-12-28	WOS:000240467000037
J	Boyle, P				Boyle, Peter			The globalisation of cancer	LANCET			English	Editorial Material									Int Agcy Res Canc, F-69372 Lyon, France	World Health Organization; International Agency for Research on Cancer (IARC)	Boyle, P (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.	director@iarc.fr	Boyle, Peter/A-4380-2014	Boyle, Peter/0000-0001-6251-0610				[Anonymous], 1966, CANC INCIDENCE 5 CON, DOI DOI 10.1001/jamaoncol.2019.2996; [Anonymous], 2005, MILLENNIUM DEV GOALS; Ferlay J, 2004, GLOBOCAN 2002 CANC I; International Agency for Research on Cancer, 2004, MON EV CARC RISKS HU, V83; Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9	5	40	43	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 19	2006	368	9536					629	630		10.1016/S0140-6736(06)69225-8	http://dx.doi.org/10.1016/S0140-6736(06)69225-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	074YT	16920452				2022-12-28	WOS:000239849200009
J	Sliwa, K; Fett, J; Elkayam, U				Sliwa, Karen; Fett, James; Elkayam, Uri			Peripartum cardiomyopathy	LANCET			English	Review							POSTPARTUM CARDIAC-FAILURE; LEFT-VENTRICULAR FUNCTION; HEART-FAILURE; IDIOPATHIC CARDIOMYOPATHY; DILATED CARDIOMYOPATHY; SUBSEQUENT PREGNANCY; MYOCARDITIS; THERAPY; WOMEN; PREVALENCE	Peripartum cardiomyopathy (PPCM) is a disorder in which initial left ventricular systolic dysfunction and symptoms of heart failure occur between the late stages of pregnancy and the early postpartum period. It is common in some countries and rare in others. The causes and pathogenesis are poorly understood. Molecular markers of an inflammatory process are found in most patients. Clinical presentation includes usual signs and symptoms of heart failure, and unusual presentations relating to thromboembolism. Clinicians should consider PPCM in any peripartum patient with unexplained disease. Conventional heart failure treatment includes use of diuretics, beta blockers, and angiotensin-converting enzyme inhibitors. Effective treatment reduces mortality rates and increases the number of women who fully recover left ventricular systolic function. Outcomes for subsequent pregnancy after PPCM are better in women who have first fully recovered heart function. Areas for future research include immune system dysfunction, the role of viruses, non-conventional treatments such as immunosuppression, immunoadsorption, apheresis, antiviral treatment, suppression of proinflammatory cytokines, and strategies for control and prevention.	Univ Witwatersrand, Chris Hani Baragwanath Hosp, Soweto Cardiovasc Res Unit, ZA-2013 Johannesburg, South Africa; Hop Albert Schweitzer, Dept Adult Med, Deschapelles, Haiti; Univ So Calif, Keck Sch Med, Div Cardiovasc Med, Los Angeles, CA USA	University of Witwatersrand; University of Southern California	Sliwa, K (corresponding author), Univ Witwatersrand, Chris Hani Baragwanath Hosp, Soweto Cardiovasc Res Unit, PO Bertsham, ZA-2013 Johannesburg, South Africa.	sliwak@medicine.wits.ac.za		Sliwa, Karen/0000-0002-8272-0911				Adams KF, 2005, J AM COLL CARDIOL, V46, P497, DOI 10.1016/j.jacc.2005.02.091; Albert MA, 2004, AM J CARDIOL, V93, P1238, DOI 10.1016/j.amjcard.2004.01.067; Ansari AA, 2002, CLIN REV ALLERG IMMU, V23, P301, DOI 10.1385/CRIAI:23:3:301; ANSARI AA, 1993, CLIN IMMUNOL IMMUNOP, V68, P208, DOI 10.1006/clin.1993.1120; Ardehali H, 2005, AM HEART J, V149, P7, DOI 10.1016/j.ahj.2004.06.007; Aziz TM, 1999, CARDIOVASC SURG, V7, P565, DOI 10.1016/S0967-2109(99)00014-9; Box LC, 2004, TEX HEART I J, V31, P442; Brown CS, 1998, AM J OBSTET GYNECOL, V178, P409, DOI 10.1016/S0002-9378(98)80034-3; Bultmann BD, 2005, AM J OBSTET GYNECOL, V193, P363, DOI 10.1016/j.ajog.2005.01.022; Cenac A, 2006, INT J CARDIOL, V108, P269, DOI 10.1016/j.ijcard.2005.02.049; Cenac A, 1998, AM J TROP MED HYG, V58, P319, DOI 10.4269/ajtmh.1998.58.319; COOPER LT, 2005, J CLIN APHERESIS, V19, P1; CUNNINGHAM FG, 1986, OBSTET GYNECOL, V67, P157; Danbauchi SS, 2002, TROP DOCT, V32, P24, DOI 10.1177/004947550203200112; DEMAKIS JG, 1971, CIRCULATION, V44, P964, DOI 10.1161/01.CIR.44.5.964; DEMAKIS JG, 1971, CIRCULATION, V44, P1053, DOI 10.1161/01.CIR.44.6.1053; DESAI D, 1995, TROP DOCT, V25, P118, DOI 10.1177/004947559502500310; Diao M, 2004, ARCH MAL COEUR VAISS, V97, P25; Dickfeld T, 2002, MAYO CLIN PROC, V77, P500; Elkayam U, 2005, CIRCULATION, V111, P2050, DOI 10.1161/01.CIR.0000162478.36652.7E; Elkayam U, 2001, NEW ENGL J MED, V344, P1567, DOI 10.1056/NEJM200105243442101; Eriksson U, 2003, NAT MED, V9, P1484, DOI 10.1038/nm960; Fairweather D, 2003, J IMMUNOL, V170, P4731, DOI 10.4049/jimmunol.170.9.4731; Feldman AM, 2000, NEW ENGL J MED, V343, P1388, DOI 10.1056/NEJM200011093431908; Felix SB, 2002, J AM COLL CARDIOL, V39, P646, DOI 10.1016/S0735-1097(01)01794-6; Felker GM, 2000, NEW ENGL J MED, V342, P1077, DOI 10.1056/NEJM200004133421502; Fett JD, 2006, ANN INTERN MED, V145, P30, DOI 10.7326/0003-4819-145-1-200607040-00007; Fett JD, 2005, MAYO CLIN PROC, V80, P1602, DOI 10.4065/80.12.1602; Fett JD, 2005, INT J GYNECOL OBSTET, V90, P161, DOI 10.1016/j.ijgo.2005.05.004; Fett JD, 2002, INT J CARDIOL, V86, P311, DOI 10.1016/S0167-5273(02)00359-5; Fett JD, 2002, AM J OBSTET GYNECOL, V186, P1005, DOI 10.1067/mob.2002.122423; Ford L, 1998, QJM-MON J ASSOC PHYS, V91, P93, DOI 10.1093/qjmed/91.2.93; Frustaci A, 2003, CIRCULATION, V107, P857, DOI 10.1161/01.CIR.0000048147.15962.31; Fussell KM, 2005, CRIT CARE MED, V33, P891, DOI 10.1097/01.CCM.0000158517.25962.8E; Gagne PJ, 2003, CARDIOL YOUNG, V13, P209, DOI 10.1017/S1047951103000416; Godsel LM, 2003, CURR PHARM DESIGN, V9, P723, DOI 10.2174/1381612033455440; Hayakawa Y, 2003, CIRCULATION, V108, P3036, DOI 10.1161/01.CIR.0000101920.72665.58; Helms AK, 2005, CNS SPECTRUMS, V10, P580, DOI 10.1017/S1092852900010221; Hibbard JU, 1999, OBSTET GYNECOL, V94, P311, DOI 10.1016/S0029-7844(99)00293-8; HOMANS DC, 1985, NEW ENGL J MED, V312, P1432, DOI 10.1056/NEJM198505303122206; Huber SA, 2003, MYOCARDITIS: FROM BENCH TO BEDSIDE, P55; Isezuo S A, 2005, Niger Postgrad Med J, V12, P237; Kane A, 2000, Dakar Med, V45, P131; Kothari SS, 1997, INT J CARDIOL, V60, P111; Kuhl U, 2005, CIRCULATION, V112, P1965, DOI 10.1161/CIRCULATIONAHA.105.548156; Maisch B, 2003, MYOCARDITIS: FROM BENCH TO BEDSIDE, P77; Mason JW, 2002, J MOL CELL CARDIOL, V34, P695, DOI 10.1006/jmcc.2002.2026; MELVIN KR, 1982, NEW ENGL J MED, V307, P731, DOI 10.1056/NEJM198209163071207; MIDEI MG, 1990, CIRCULATION, V81, P922, DOI 10.1161/01.CIR.81.3.922; Mielniczuk LM, 2006, AM J CARDIOL, V97, P1765, DOI 10.1016/j.amjcard.2006.01.039; Murali Srinivas, 2005, Crit Care Med, V33, pS340, DOI 10.1097/01.CCM.0000183500.47273.8E; OCONNELL JB, 1986, J AM COLL CARDIOL, V8, P52, DOI 10.1016/S0735-1097(86)80091-2; Ohtsuka T, 2001, J AM COLL CARDIOL, V37, P412, DOI 10.1016/S0735-1097(00)01121-9; Pauschinger M, 2005, EUR J HEART FAIL, V7, P444, DOI 10.1016/j.ejheart.2004.07.002; Pearson GD, 2000, JAMA-J AM MED ASSOC, V283, P1183, DOI 10.1001/jama.283.9.1183; Phillips Sabrina D, 2004, Curr Treat Options Cardiovasc Med, V6, P481, DOI 10.1007/s11936-004-0005-8; PODEWSKI E, 2004, EUR SOC CARD M; Rathore SS, 2002, NEW ENGL J MED, V347, P1403, DOI 10.1056/NEJMoa021266; RAVIKISHORE AG, 1991, INT J CARDIOL, V32, P377, DOI 10.1016/0167-5273(91)90301-5; RIZEQ MN, 1994, AM J CARDIOL, V74, P474, DOI 10.1016/0002-9149(94)90906-7; SANDERSON JE, 1986, BRIT HEART J, V56, P285; SANDERSON JE, 1979, AM HEART J, V97, P613, DOI 10.1016/0002-8703(79)90189-3; Sliwa K, 2006, EUR HEART J, V27, P441, DOI 10.1093/eurheartj/ehi481; Sliwa K, 2005, CIRCULATION, V112, P3577, DOI 10.1161/CIRCULATIONAHA.105.542894; Sliwa K, 2004, AM J CARDIOL, V93, P1441, DOI 10.1016/j.amjcard.2004.02.053; Sliwa K, 2002, EUR J HEART FAIL, V4, P305, DOI 10.1016/S1388-9842(02)00008-9; Sliwa K, 2000, J AM COLL CARDIOL, V35, P701, DOI 10.1016/S0735-1097(99)00624-5; Staudt A, 2001, CIRCULATION, V103, P2681; Warraich RS, 2005, AM HEART J, V150, P263, DOI 10.1016/j.ahj.2004.09.008; Yagoro A, 1999, J INTERN MED, V245, P199, DOI 10.1046/j.1365-2796.1999.00423.x; Zimmermann O, 2005, INT J CARDIOL, V104, P92, DOI 10.1016/j.ijcard.2005.02.052	71	329	345	0	29	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 19	2006	368	9536					687	693		10.1016/S0140-6736(06)69253-2	http://dx.doi.org/10.1016/S0140-6736(06)69253-2			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	074YT	16920474				2022-12-28	WOS:000239849200036
J	Younger, JM; Chen, LL; Ren, HY; Rosser, MFN; Turnbull, EL; Fan, CY; Patterson, C; Cyr, DM				Younger, J. Michael; Chen, Liling; Ren, Hong-Yu; Rosser, Meredith F. N.; Turnbull, Emma L.; Fan, Chun-Yang; Patterson, Cam; Cyr, Douglas M.			Sequential quality-control checkpoints triage misfolded cystic fibrosis transmembrane conductance regulator	CELL			English	Article							RING FINGER PROTEIN; UBIQUITIN LIGASES; WILD-TYPE; CFTR; DEGRADATION; RETROTRANSLOCATION; DISLOCATION; PROTEASOME; COMPLEXES; P97	Cystic fibrosis arises from the misfolding and premature degradation of CFTRAF508, a Cl(-)ion channel with a single amino acid deletion. Yet, the quality-control machinery that selects CFTRAF508 for degradation and the mechanism for its misfolding are not well defined. We identified an ER membrane-associated ubiquitin ligase complex containing the E3 RMA1, the E2 Ubc6e, and Derlin-1 that cooperates with the cytosolic Hsc70/CHIP E3 complex to triage CFTR and CFTRAF508. Derlin-1 serves to retain CFTR in the ER membrane and interacts with RMA1 and Ubc6e to promote CFTIR's proteasomal degradation. RMA1 is capable of recognizing folding defects in CFTRAF508 coincident with translation, whereas the CHIP E3 appears to act posttranslationally. A folding defect in CFTR Delta F508 detected by RMA1 involves the inability of CFTR's second membrane-spanning domain to productively interact with amino-terminal domains. Thus, the RMA1 and CHIP E3 ubiquitin ligases act sequentially in ER membrane and cytosol to monitor the folding status of CFTR and CFTRAF508.	Univ N Carolina, Sch Med, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Cyst Fibrosis Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Carolina Cardiovasc Biol Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Cyr, DM (corresponding author), Univ N Carolina, Sch Med, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA.	dmcyr@med.unc.edu		Cyr, Douglas/0000-0002-4928-3414	NIGMS NIH HHS [R01 GM056981] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brown CR, 1996, CELL STRESS CHAPERON, V1, P117, DOI 10.1379/1466-1268(1996)001<0117:CCCTMP>2.3.CO;2; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Chen EY, 2004, J BIOL CHEM, V279, P39620, DOI 10.1074/jbc.M407887200; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Cyr DM, 2005, NAT STRUCT MOL BIOL, V12, P2, DOI 10.1038/nsmb0105-2; Dalal S, 2004, MOL BIOL CELL, V15, P637, DOI 10.1091/mbc.E03-02-0097; Dalbey RE, 2004, J CELL BIOL, V166, P769, DOI 10.1083/jcb.200405161; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Didier C, 2003, MOL CELL BIOL, V23, P5331, DOI 10.1128/MCB.23.15.5331-5345.2003; Du K, 2005, NAT STRUCT MOL BIOL, V12, P17, DOI 10.1038/nsmb882; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Katiyar S, 2005, MOL BIOL CELL, V16, P4584, DOI 10.1091/mbc.E05-04-0345; Kreda SM, 2005, MOL BIOL CELL, V16, P2154, DOI 10.1091/mbc.E04-11-1010; Lenk U, 2002, J CELL SCI, V115, P3007; Lilley BN, 2005, P NATL ACAD SCI USA, V102, P14296, DOI 10.1073/pnas.0505014102; Lilley BN, 2004, NATURE, V429, P834, DOI 10.1038/nature02592; Lord JM, 2005, CURR BIOL, V15, pR169, DOI 10.1016/j.cub.2005.02.043; Matsuda N, 2001, J CELL SCI, V114, P1949; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; Meacham GC, 1999, EMBO J, V18, P1492, DOI 10.1093/emboj/18.6.1492; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Meacham Geoffrey C, 2002, Methods Mol Med, V70, P245; Oda Y, 2006, J CELL BIOL, V172, P383, DOI 10.1083/jcb.200507057; Ostedgaard LS, 1997, BIOCHEMISTRY-US, V36, P1287, DOI 10.1021/bi962174s; Pedemonte N, 2005, J CLIN INVEST, V115, P2564, DOI 10.1172/JCI24898; RIORDAN JR, 1989, SCIENCE, V245, P1066; Rowe SM, 2005, NEW ENGL J MED, V352, P1992, DOI 10.1056/NEJMra043184; Sato S, 1998, J BIOL CHEM, V273, P7189, DOI 10.1074/jbc.273.13.7189; Schuberth C, 2005, NAT CELL BIOL, V7, P999, DOI 10.1038/ncb1299; Sharma M, 2004, J CELL BIOL, V164, P923, DOI 10.1083/jcb.200312018; Song BL, 2005, MOL CELL, V19, P829, DOI 10.1016/j.molcel.2005.08.009; Thibodeau PH, 2005, NAT STRUCT MOL BIOL, V12, P10, DOI 10.1038/nsmb881; Van Goor F, 2006, AM J PHYSIOL-LUNG C, V290, pL1117, DOI 10.1152/ajplung.00169.2005; Varga K, 2004, J BIOL CHEM, V279, P22578, DOI 10.1074/jbc.M401522200; WARD CL, 1994, J BIOL CHEM, V269, P25710; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Welsh MJ, 1998, NAT STRUCT BIOL, V5, P167, DOI 10.1038/nsb0398-167; Xiong XM, 1997, J CLIN INVEST, V100, P1079, DOI 10.1172/JCI119618; Ye YH, 2005, P NATL ACAD SCI USA, V102, P14132, DOI 10.1073/pnas.0505006102; Ye YH, 2004, NATURE, V429, P841, DOI 10.1038/nature02656; Younger J. Michael, 2005, V301, P293; Younger JM, 2004, J CELL BIOL, V167, P1075, DOI 10.1083/jcb.200410065; Zhang F, 1998, NAT STRUCT BIOL, V5, P180, DOI 10.1038/nsb0398-180	44	350	357	0	32	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 11	2006	126	3					571	582		10.1016/j.cell.2006.06.041	http://dx.doi.org/10.1016/j.cell.2006.06.041			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	075KI	16901789	Green Submitted, Bronze			2022-12-28	WOS:000239883400016
J	Maraganore, DM; de Andrade, M; Elbaz, A; Farrer, MJ; Ioannidis, JPA; Kruger, R; Rocca, WA; Schneider, NK; Lesnick, TG; Lincoln, SJ; Hulihan, MM; Aasly, JO; Ashizawa, T; Chartier-Harlin, MC; Checkoway, H; Ferrarese, C; Hadjigeorgiou, G; Hattori, N; Kawakami, H; Lambert, JC; Lynch, T; Mellick, GD; Papapetropoulos, S; Parsian, A; Quattrone, A; Riess, O; Tan, EK; Van Broeckhoven, C				Maraganore, Demetrius M.; de Andrade, Mariza; Elbaz, Alexis; Farrer, Matthew J.; Ioannidis, John P.A.; Krueger, Rejko; Rocca, Walter A.; Schneider, Nicole K.; Lesnick, Timothy G.; Lincoln, Sarah J.; Hulihan, Mary M.; Aasly, Jan O.; Ashizawa, Tetsuo; Chartier-Harlin, Marie-Christine; Checkoway, Harvey; Ferrarese, Carlo; Hadjigeorgiou, Georgios; Hattori, Nobutaka; Kawakami, Hideshi; Lambert, Jean-Charles; Lynch, Timothy; Mellick, George D.; Papapetropoulos, Spiridon; Parsian, Abbas; Quattrone, Aldo; Riess, Olaf; Tan, Eng-King; Van Broeckhoven, Christine		GEO-PD Consortium	Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	58th Annual Meeting of the American-Academy-of-Neurology	APR 01-08, 2006	San Diego, CA	Amer Acad Neurol			HARDY-WEINBERG EQUILIBRIUM; MAYO-CLINIC FAMILY; DIAGNOSTIC-CRITERIA; SEQUENCE-ANALYSIS; ALLELIC VARIATION; OLMSTED COUNTY; LEWY BODY; ASSOCIATION; METAANALYSIS; SUSCEPTIBILITY	Context Identification and replication of susceptibility genes for Parkinson disease at the population level have been hampered by small studies with potential biases. alpha-Synuclein (SNCA) has been one of the most promising susceptibility genes, but largescale studies have been lacking. Objective To determine whether allele-length variability in the dinucleotide repeat sequence (REP1) of the SNCA gene promoter is associated with Parkinson disease susceptibility, whether SNCA promoter haplotypes are associated with Parkinson disease, and whether REP1 variability modifies age at onset. Design, Setting, and Participants We performed a collaborative analysis of individual-level data on SNCA REP1 and flanking markers in patients with Parkinson disease and controls. Study site recruitment, data collection, and analyses were performed between April 5, 2004, and December 31, 2005. Eighteen participating sites of a global genetics consortium provided clinical data. Genotyping was performed for SNCA REP1, -770, and -116 markers at individual sites; however, each site also provided 20 DNA samples for regenotyping centrally. Main Outcome Measures Measures included estimations of Hardy-Weinberg equilibrium in controls; a test of heterogeneity; analyses for association of single variants or haplotypes; and survival analyses for age at onset. Results Of the 18 sites, 11 met stringent criteria for concordance with Hardy-Weinberg equilibrium and low genotyping error rate. These 11 sites provided complete data for 2692 cases and 2652 controls. There was no heterogeneity across studies (P > .60). The SNCA REP1 alleles differed in frequency for cases and controls (P < .001). Genotypes defined by the 263 base-pair allele were associated with Parkinson disease (odds ratio, 1.43; 95% confidence interval, 1.22-1.69; P < .001 for trend). Multilocus haplotypes differed in frequency for cases and controls (global score statistic, P < .001). Two- loci haplotypes were associated with Parkinson disease only when they included REP1 as one of the loci. However, genotypes defined by REP1 alleles did not modify age at onset (P = .55). Conclusion This large-scale collaborative analysis demonstrates that SNCA REP1 allele-length variability is associated with an increased risk of Parkinson disease.	Mayo Clin, Coll Med, Dept Neurol, Rochester, MN 55905 USA; Mayo Clin, Coll Med, Dept Hlth Sci Res, Rochester, MN 55905 USA; Univ Paris 06, Inst Natl Sante, Paris, France; Univ Paris 06, Rech Med Unit 708, Paris, France; Mayo Clin, Coll Med, Dept Neurosci, Jacksonville, FL USA; [Ioannidis, John P.A.] Univ Ioannina, Sch Med, Inst Biomed Res, Fdn Res & Technol Hellas, GR-45110 Ioannina, Greece; [Ioannidis, John P.A.] Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, GR-45110 Ioannina, Greece; Univ Tubingen, Ctr Neurol, Tubingen, Germany; Univ Tubingen, Hertie Inst Clin Brain Res, Tubingen, Germany; Univ Trondheim Hosp, Dept Neurol, Trondheim, Norway; Univ Texas, Med Branch, Galveston, TX 77550 USA; Inst Rech Canc, Lille, France; Univ Washington, Dept Environm & Occupat Hlth Sci, Seattle, WA 98195 USA; Univ Milano Bicocca, Dept Neurol, Monza, Italy; Univ Thessaly, Sch Med, Larisa, Greece; Juntendo Univ, Sch Med, Tokyo 113, Japan; Hiroshima Univ, Dept Epidemiol, Res Inst Radiat Biol & Med, Hiroshima, Japan; Univ Lille 2, Inst Natl Sante, Lille, France; Univ Lille 2, Rech Med Unit 744, Inst Pasteur Lille, Lille, France; Univ Coll Dublin, Dept Neurol, Mater Misericordiae Univ Hosp, Dublin 2, Ireland; Univ Coll Dublin, Conway Inst, Dublin 2, Ireland; Univ Queensland, Dept Neurol, Brisbane, Qld, Australia; Univ Miami, Dept Neurol, Miami, FL 33152 USA; Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA; CNR, Inst Neurol Sci, Cosenza, Italy; Magna Graecia Univ Catanzaro, Neurol Inst, Catanzaro, Italy; Univ Tubingen, Dept Med Genet, Tubingen, Germany; Singapore Gen Hosp, Dept Neurol, Singapore 0316, Singapore; Univ Antwerp VIB, Neurodegenerat Brain Dis Grp, B-2020 Antwerp, Belgium	Mayo Clinic; Mayo Clinic; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; Mayo Clinic; Foundation for Research & Technology - Hellas (FORTH); University of Ioannina; University of Ioannina; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Norwegian University of Science & Technology (NTNU); University of Texas System; University of Texas Medical Branch Galveston; University of Washington; University of Washington Seattle; University of Milano-Bicocca; University of Thessaly; Juntendo University; Hiroshima University; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Mater Misericordiae University Hospital; University College Dublin; University College Dublin; University of Queensland; University of Miami; University of Arkansas System; University of Arkansas Medical Sciences; Consiglio Nazionale delle Ricerche (CNR); Istituto di Scienze Neurologiche (ISN-CNR); Magna Graecia University of Catanzaro; Eberhard Karls University of Tubingen; Singapore General Hospital; Flanders Institute for Biotechnology (VIB); University of Antwerp	Maraganore, DM (corresponding author), Mayo Clin, Coll Med, Dept Neurol, 200 1st St SW, Rochester, MN 55905 USA.	dmaraganore@mayo.edu	Mellick, George D./A-7650-2010; Hattori, Nobutaka/ACR-0069-2022; lambert, jean-charles/F-8787-2013; Elbaz, Alexis/F-8952-2017; Rocca, Walter/Z-5335-2019; Van Broeckhoven, Christine/G-8362-2017; Kawakami, Hideshi/ABE-4077-2021; Ioannidis, John P. A./G-9836-2011; Lynch, Timothy/M-1316-2019; Chartier-Harlin, Marie-Christine/L-4527-2018; Kawakami, Hideshi/A-2086-2009; Morino, Hiroyuki/H-9583-2013; Ferrarese, Carlo/AAC-4903-2022; LICEND, CEMND/F-1296-2015; QUATTRONE, Aldo/A-6734-2016; Van Broeckhoven, Christine/M-7853-2019; Lambert, jean-charles/A-9553-2014	Mellick, George D./0000-0002-7211-4651; lambert, jean-charles/0000-0003-0829-7817; Elbaz, Alexis/0000-0001-9724-5490; Van Broeckhoven, Christine/0000-0003-0183-7665; Kawakami, Hideshi/0000-0002-1405-0901; Chartier-Harlin, Marie-Christine/0000-0001-6416-6526; Kawakami, Hideshi/0000-0002-1405-0901; Morino, Hiroyuki/0000-0002-5190-3547; QUATTRONE, Aldo/0000-0003-2001-957X; Van Broeckhoven, Christine/0000-0003-0183-7665; Lambert, jean-charles/0000-0003-0829-7817; Krueger, Rejko/0000-0003-4258-6241; Farrer, Matthew/0000-0003-1159-5321	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010751, R01ES010750, P42ES004696] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039913, R01NS041509, R01NS033978] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R29AA009515] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA09515] Funding Source: Medline; NIEHS NIH HHS [ES10750, ES10751, ES04696] Funding Source: Medline; NINDS NIH HHS [NS33978, NS39913, NS41509] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bower JH, 1999, NEUROLOGY, V52, P1214, DOI 10.1212/WNL.52.6.1214; Bower JH, 2000, MOVEMENT DISORD, V15, P819, DOI 10.1002/1531-8257(200009)15:5<819::AID-MDS1009>3.0.CO;2-P; Chartier-Harlin MC, 2004, LANCET, V364, P1167, DOI 10.1016/S0140-6736(04)17103-1; Chiba-Falek O, 2003, HUM GENET, V113, P426, DOI 10.1007/s00439-003-1002-9; Chiba-Falek O, 2001, HUM MOL GENET, V10, P3101, DOI 10.1093/hmg/10.26.3101; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Elbaz A, 2003, ARCH NEUROL-CHICAGO, V60, P91, DOI 10.1001/archneur.60.1.91; Farrer M, 2004, ANN NEUROL, V55, P174, DOI 10.1002/ana.10846; Farrer M, 2001, HUM MOL GENET, V10, P1847, DOI 10.1093/hmg/10.17.1847; Gelb DJ, 1999, ARCH NEUROL-CHICAGO, V56, P33, DOI 10.1001/archneur.56.1.33; GIBB WRG, 1988, J NEUROL NEUROSUR PS, V51, P745, DOI 10.1136/jnnp.51.6.745; Hadjigeorgiou GM, 2006, MOVEMENT DISORD, V21, P534, DOI 10.1002/mds.20752; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Ibanez P, 2004, LANCET, V364, P1169, DOI 10.1016/S0140-6736(04)17104-3; Ioannidis JPA, 2005, PLOS MED, V2, P696, DOI 10.1371/journal.pmed.0020124; Ioannidis JPA, 2006, NAT GENET, V38, P3, DOI 10.1038/ng0106-3; Ioannidis JPA, 2001, NAT GENET, V29, P306, DOI 10.1038/ng749; Ioannidis JPA, 2002, AM J EPIDEMIOL, V156, P204, DOI 10.1093/aje/kwf031; Ioannidis JPA, 2003, TRENDS MOL MED, V9, P135, DOI 10.1016/S1471-4914(03)00030-3; Izumi Y, 2001, NEUROSCI LETT, V300, P125, DOI 10.1016/S0304-3940(01)01557-9; Khan N, 2001, ANN NEUROL, V49, P665; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Kruger R, 1999, ANN NEUROL, V45, P611, DOI 10.1002/1531-8249(199905)45:5<611::AID-ANA9>3.0.CO;2-X; LANGSTON JW, 1992, MOVEMENT DISORD, V7, P2, DOI 10.1002/mds.870070103; Mamah CE, 2005, ANN NEUROL, V57, P439, DOI 10.1002/ana.20387; Maraganore DM, 2004, ANN NEUROL, V55, P512, DOI 10.1002/ana.20017; Maraganore DM, 2003, MOVEMENT DISORD, V18, P631, DOI 10.1002/mds.10431; Maraganore DM, 2005, AM J HUM GENET, V77, P685, DOI 10.1086/496902; McDonnell SK, 2006, ANN NEUROL, V59, P788, DOI 10.1002/ana.20844; Mellick GD, 2005, NEUROSCI LETT, V375, P112, DOI 10.1016/j.neulet.2004.10.078; Mizuta I, 2002, J NEUROL NEUROSUR PS, V73, P350, DOI 10.1136/jnnp.73.3.350; Mueller JC, 2005, ANN NEUROL, V57, P535, DOI 10.1002/ana.20438; Neale BM, 2004, AM J HUM GENET, V75, P353, DOI 10.1086/423901; Nishioka K, 2006, ANN NEUROL, V59, P298, DOI 10.1002/ana.20753; Outeiro TF, 2003, SCIENCE, V302, P1772, DOI 10.1126/science.1090439; Pals P, 2004, ANN NEUROL, V56, P591, DOI 10.1002/ana.20268; Pals P, 2003, EUR J EPIDEMIOL, V18, P1133, DOI 10.1023/B:EJEP.0000006639.05690.92; Parashos SA, 2002, MAYO CLIN PROC, V77, P918; Parsian A, 1998, NEUROLOGY, V51, P1757, DOI 10.1212/WNL.51.6.1757; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rocca WA, 2004, ANN NEUROL, V56, P495, DOI 10.1002/ana.20228; Rocca WA, 2001, INVESTIGATING NEUROLOGICAL DISEASE, P26, DOI 10.1017/CBO9780511526909.005; Salanti G, 2005, EUR J HUM GENET, V13, P840, DOI 10.1038/sj.ejhg.5201410; Sapru MK, 2006, EXP NEUROL, V198, P382, DOI 10.1016/j.expneurol.2005.12.024; Schaid DJ, 2002, AM J HUM GENET, V70, P425, DOI 10.1086/338688; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Spadafora P, 2003, NEUROSCI LETT, V351, P75, DOI 10.1016/S0304-3940(03)00859-0; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Tan EK, 2004, NEUROLOGY, V62, P128, DOI 10.1212/01.WNL.0000101721.25345.DC; Tan EK, 2003, NEUROSCI LETT, V336, P70, DOI 10.1016/S0304-3940(02)01178-3; Touchman JW, 2001, GENOME RES, V11, P78, DOI 10.1101/gr.165801; Trikalinos TA, 2006, AM J EPIDEMIOL, V163, P300, DOI 10.1093/aje/kwj046; Wacholder S, 2004, J NATL CANCER I, V96, P434, DOI 10.1093/jnci/djh075; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795	56	401	411	0	30	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 9	2006	296	6					661	670		10.1001/jama.296.6.661	http://dx.doi.org/10.1001/jama.296.6.661			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	071LN	16896109	Bronze			2022-12-28	WOS:000239603800028
J	Shah, JS; Maisel, WH				Shah, Jignesh S.; Maisel, William H.			Recalls and safety alerts affecting automated external defibrillators	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PUBLIC-ACCESS DEFIBRILLATION; CARDIAC-ARREST; RAPID DEFIBRILLATION; SURVIVAL; CHILDREN	Context Automated external defibrillators (AEDs) play a key role in the community resuscitation of persons with cardiac arrest and are of proven clinical benefit. Although AEDs are complex medical devices designed to function during life-threatening emergencies, little is known about their reliability. Objectives To determine the number and rate of AED recalls and safety alerts, to identify trends in these rates, and to identify the types of malfunctions prompting AED and AED accessory advisories. Design and Setting Analysis of weekly US Food and Drug Administration (FDA) Enforcement Reports between January 1996 and December 2005 was performed to identify all recalls and safety alerts (collectively referred to as "advisories") involving AEDs and AED accessories. Confirmed AED device malfunctions were identified by reviewing AED-related adverse events reported to the FDA. Main Outcome Measures Number of AEDs and AED accessories subject to FDA recall or safety alert between January 1996 and December 2005; annual AED advisory rates; and number of confirmed fatal AED-related device malfunctions reported to the FDA. Results During 2.78 million AED device-years of observation, 52 advisories (median [25th and 75th percentiles], 4.5 [3.0 and 5.0] per year) affecting 385 922 AEDs and AED accessories were issued. The mean (SE) annual number of AEDs affected by advisories was 5.1 (1.5) devices per 100 AED device-years. Overall, 21.2% of AEDs distributed during the study period were recalled, most often because of electrical or software problems. The AED advisory rate did not significantly increase during the study period, although the annual number of AED advisories (P for trend = .02) and AED advisory devices (P for trend = .01) did increase. Confirmed fatal AED-related device malfunctions occurred in 370 patients. Conclusions Automated external defibrillators and AED accessory advisories occur frequently and affect many devices. Actual AED malfunctions do occur occasionally, although the number of observed malfunctions is small compared with the number of lives saved by these important devices. As the prevalence of AEDs continues to increase, the number of devices affected by advisories can also be expected to increase. Efforts should be directed at developing a reliable system to locate and repair potentially defective devices in a timely fashion.	Beth Israel Deaconess Med Ctr, Div Cardiovasc, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Maisel, WH (corresponding author), Beth Israel Deaconess Med Ctr, Div Cardiovasc, Dept Med, 185 Pilgrim Rd,Baker 4, Boston, MA 02215 USA.	wmaisel@bidmc.harvard.edu	Shah, Jignesh/AAE-9716-2019					*ACC CARD INC, 2004, ISS WORLDW AED REC; [Anonymous], 2005, CIRCULATION, V112, pIV1, DOI 10.1161/CIRCULATIONAHA.105.166550; ARROW AK, 2004, US EQUITY RES MED TE, P78; Atkins DL, 2004, PEDIATR CLIN N AM, V51, P1443, DOI 10.1016/j.pcl.2004.04.006; *CARD SCI CORP, CARD SCI WEB SIT; Gundry JW, 1999, CIRCULATION, V100, P1703, DOI 10.1161/01.CIR.100.16.1703; Hallstrom AP, 2004, NEW ENGL J MED, V351, P637; *HARTS TECHN INC, 2005, ISS WORLDW REC CERT; Hazinski MF, 2005, CIRCULATION, V111, P3336, DOI 10.1161/CIRCULATIONAHA.105.165674; *KON PHIL EL NV WE, 2004, COMM SIMPL ANN REV 2; Maisel WH, 2005, JAMA-J AM MED ASSOC, V294, P955, DOI 10.1001/jama.294.8.955; Maisel WH, 2004, ANN INTERN MED, V140, P296, DOI 10.7326/0003-4819-140-4-200402170-00012; Maisel WH, 2001, JAMA-J AM MED ASSOC, V286, P793, DOI 10.1001/jama.286.7.793; Marenco JP, 2001, JAMA-J AM MED ASSOC, V285, P1193, DOI 10.1001/jama.285.9.1193; *MEDTR INC WEB SIT, 2006, URG MED DEV REC LIFE; Page RL, 2000, NEW ENGL J MED, V343, P1210, DOI 10.1056/NEJM200010263431702; Stiell IG, 1999, JAMA-J AM MED ASSOC, V281, P1175, DOI 10.1001/jama.281.13.1175; *SURV CORP, PROSP COMM BUS COMB; US Food and Drug Administration (FDA), MAN US FAC DEV EXP D; *US FOOD DRUG ADM, PHILL HEARTSTART HOM; *US FOOD DRUG ADM, FDA ENF REP IND; *US FOOD DRUG ADM, FDA CLEARS OV THE CO; *US SEC EXCH COMM, 2005, FORM 10 K US SEC EXC; *US SEC EXCH COMM, 2004, FORM 10 K US SEC EXC; *US SEC EXCH COMM, FORM 10 K US SEC EXC; Valenzuela TD, 2000, NEW ENGL J MED, V343, P1206, DOI 10.1056/NEJM200010263431701; White RD, 1996, ANN EMERG MED, V28, P480, DOI 10.1016/S0196-0644(96)70109-9	27	30	30	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 9	2006	296	6					655	660		10.1001/jama.296.6.655	http://dx.doi.org/10.1001/jama.296.6.655			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	071LN	16896108				2022-12-28	WOS:000239603800027
J	Simon, V; Ho, DD; Karim, QA				Simon, Viviana; Ho, David D.; Karim, Quarraisha Abdool			HIV/AIDS epidemiology, pathogenesis, prevention, and treatment	LANCET			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; TO-CHILD TRANSMISSION; ACTIVE ANTIRETROVIRAL THERAPY; SEXUALLY-TRANSMITTED-DISEASES; DRUG-RESISTANT HIV-1; CYCLE STRUCTURED INTERMITTENT; SINGLE-DOSE NEVIRAPINE; MESSENGER-RNA LEVELS; SCALING-UP TREATMENT; MALE CIRCUMCISION	The HIV-1 pandemic is a complex mix of diverse epidemics within and between countries and regions of the world, and is undoubtedly the defining public-health crisis of our time. Research has deepened our understanding of how the virus replicates, manipulates, and hides in an infected person. Although our understanding of pathogenesis and transmission dynamics has become more nuanced and prevention options have expanded, a cure or protective vaccine remains elusive. Antiretroviral treatment has transformed AIDS from an inevitably fatal condition to a chronic, manageable disease in some settings. This transformation has yet to be realised in those parts of the world that continue to bear a disproportionate burden of new HIV-1 infections and are most affected by increasing morbidity and mortality. This Seminar provides an update on epidemiology, pathogenesis, treatment, and prevention interventions pertinent to HIV-1.	Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10021 USA; Univ Kwazulu Natal, Ctr AIDS Programme Res S Africa, Durban, South Africa; Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA	Rockefeller University; University of Kwazulu Natal; Columbia University	Simon, V (corresponding author), Mt Sinai Sch Med, Dept Med, Div Infect Dis, New York, NY 10029 USA.	viviana.simon@mssm.edu	Abdool Karim, Quarraisha/GVS-1160-2022; simon, viviana/A-9131-2008	Abdool Karim, Quarraisha/0000-0002-0985-477X; simon, viviana/0000-0002-6416-5096	FIC NIH HHS [D43 TW00231, D43 TW000231] Funding Source: Medline; NIAID NIH HHS [1 U19AI51794, R01AI064001, R01 AI064001, R01 AI064001-01A2, R01 AI064001-02, U19 AI051794] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [D43TW000231] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI064001, U19AI051794] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abbas UL, 2002, P NATL ACAD SCI USA, V99, P13377, DOI 10.1073/pnas.212518999; [Anonymous], 13 C RETR OPP INF DE; Aral SO, 2005, J INFECT DIS, V191, pS1, DOI 10.1086/425290; Aral SO, 1996, INT J STD AIDS, V7, P30, DOI 10.1258/0956462961917753; Auvert B, 2005, PLOS MED, V2, P1112, DOI 10.1371/journal.pmed.0020298; Bachmann MO, 2006, AIDS CARE, V18, P109, DOI 10.1080/09540120500159334; Badri M, 2004, AIDS, V18, P1159, DOI 10.1097/00002030-200405210-00009; Bailey Robert C, 2005, AIDS Read, V15, P136; Balabanian K, 2004, J IMMUNOL, V173, P7150, DOI 10.4049/jimmunol.173.12.7150; BarreSinoussi F, 1996, LANCET, V348, P31, DOI 10.1016/S0140-6736(96)09058-7; Bassett IV, 2004, CLIN INFECT DIS, V39, P395, DOI 10.1086/422459; Berger A, 2005, J CLIN VIROL, V33, P43, DOI 10.1016/j.jcv.2004.09.025; Bieniasz PD, 2006, VIROLOGY, V344, P55, DOI 10.1016/j.virol.2005.09.044; Bieniasz PD, 2004, NAT IMMUNOL, V5, P1109, DOI 10.1038/ni1125; Blackard JT, 2002, CLIN INFECT DIS, V34, P1108, DOI 10.1086/339547; Bloom SS, 2002, SEX TRANSM INFECT, V78, P261, DOI 10.1136/sti.78.4.261; Blower SM, 2000, SCIENCE, V287, P650, DOI 10.1126/science.287.5453.650; Briggs JAG, 2006, STRUCTURE, V14, P15, DOI 10.1016/j.str.2005.09.010; Buchbinder SP, 2005, JAIDS-J ACQ IMM DEF, V39, P82, DOI 10.1097/01.qai.0000134740.41585.f4; Calmy A, 2004, AIDS, V18, P2353; Calza L, 2004, J ANTIMICROB CHEMOTH, V53, P10, DOI 10.1093/jac/dkh013; Cantin R, 2005, J VIROL, V79, P6577, DOI 10.1128/JVI.79.11.6577-6587.2005; Carrington M, 1999, HUM MOL GENET, V8, P1939, DOI 10.1093/hmg/8.10.1939; Cates W, 2005, JAIDS-J ACQ IMM DEF, V38, pS8, DOI 10.1097/01.qai.0000167025.87783.31; Ceffa S, 2005, J BIOL REG HOMEOS AG, V19, P169; Centlivre M, 2006, AIDS, V20, P657, DOI 10.1097/01.aids.0000216365.38572.2f; Chaix ML, 2006, J INFECT DIS, V193, P482, DOI 10.1086/499966; Chan DJ, 2005, CURR HIV RES, V3, P223, DOI 10.2174/1570162054368075; Chiu YL, 2005, NATURE, V435, P108, DOI 10.1038/nature03493; Cho SJ, 2006, J VIROL, V80, P2069, DOI 10.1128/JVI.80.4.2069-2072.2006; Chohan B, 2005, J VIROL, V79, P10701, DOI 10.1128/JVI.79.16.10701-10708.2005; Cicala C, 2002, P NATL ACAD SCI USA, V99, P9380, DOI 10.1073/pnas.142287999; Ciuffi A, 2005, NAT MED, V11, P1287, DOI 10.1038/nm1329; Coetzee D, 2004, AIDS, V18, P887, DOI 10.1097/00002030-200404090-00006; Coffin J, 1997, RETROVIRUSES; Coffin JM, 1996, FIELDS VIROLOGY, P1767; Cohen J, 2003, SCIENCE, V299, P1290, DOI 10.1126/science.299.5611.1290; Cohen MS, 2005, J INFECT DIS, V191, P1391, DOI 10.1086/429414; Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621; Corey L, 2004, JAIDS-J ACQ IMM DEF, V35, P435, DOI 10.1097/00126334-200404150-00001; Corey L, 2004, NEW ENGL J MED, V350, P11, DOI 10.1056/NEJMoa035144; Cressey TR, 2005, JAIDS-J ACQ IMM DEF, V38, P283; Cullen BR, 2006, J VIROL, V80, P1067, DOI 10.1128/JVI.80.3.1067-1076.2006; De Boer RJ, 2003, J IMMUNOL, V170, P2479, DOI 10.4049/jimmunol.170.5.2479; Deeks SG, 2003, LANCET, V362, P2002, DOI 10.1016/S0140-6736(03)15022-2; DEVINCENZI I, 1994, NEW ENGL J MED, V331, P341, DOI 10.1056/NEJM199408113310601; Dhawan D, 2006, J INFECT DIS, V193, P36, DOI 10.1086/499163; Douek DC, 2003, ANNU REV IMMUNOL, V21, P265, DOI 10.1146/annurev.immunol.21.120601.141053; Duerr A, 2005, LANCET, V366, P261, DOI 10.1016/S0140-6736(05)66917-6; Duffy Lynne, 2005, J Transcult Nurs, V16, P23, DOI 10.1177/1043659604270962; Dybul M, 2003, J INFECT DIS, V188, P388, DOI 10.1086/376535; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; Ekouevi Didier K, 2005, AIDS Read, V15, P479; Emerman M, 1998, SCIENCE, V280, P1880, DOI 10.1126/science.280.5371.1880; Eshleman Susan H., 2002, AIDS Reviews, V4, P59; Ferradini L, 2006, LANCET, V367, P1335, DOI 10.1016/S0140-6736(06)68580-2; FLYS TS, 2006, J ACQ IMMUN DEF SYND, DOI DOI 10.1097/01.QAI.0000221686.67810.20; Francis DP, 2003, AIDS, V17, P147, DOI 10.1097/00002030-200301240-00003; French MA, 2004, AIDS, V18, P1615, DOI 10.1097/01.aids.0000131375.21070.06; Galvin SR, 2004, NAT REV MICROBIOL, V2, P33, DOI 10.1038/nrmicro794; Garber DA, 2004, LANCET INFECT DIS, V4, P397, DOI 10.1016/S1473-3099(04)01056-4; Garenne M, 2006, PLOS MED, V3, P143, DOI 10.1371/journal.pmed.0030078; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Giorgi JV, 1999, J INFECT DIS, V179, P859, DOI 10.1086/314660; Gonzalez E, 2005, SCIENCE, V307, P1434, DOI 10.1126/science.1101160; Gottlieb GS, 2004, LANCET, V363, P619, DOI 10.1016/S0140-6736(04)15596-7; Gray RH, 2005, LANCET, V366, P1182, DOI 10.1016/S0140-6736(05)67481-8; Gray RH, 1998, LANCET, V351, P98, DOI 10.1016/S0140-6736(97)09381-1; Gray RH, 2001, LANCET, V357, P1149, DOI 10.1016/S0140-6736(00)04331-2; Greenwald Jeffrey L, 2006, Curr Infect Dis Rep, V8, P125, DOI 10.1007/s11908-006-0008-6; Gregson S, 2006, SCIENCE, V311, P664, DOI 10.1126/science.1121054; Grosskurth H, 2000, LANCET, V355, P1981, DOI 10.1016/S0140-6736(00)02336-9; Gupta R, 2004, J INFECT DIS, V190, P1374, DOI 10.1086/424519; Gupta R, 2004, LANCET, V363, P320, DOI 10.1016/S0140-6736(03)15394-9; Haase AT, 2005, NAT REV IMMUNOL, V5, P783, DOI 10.1038/nri1706; Halperin DT, 2005, SEX TRANSM DIS, V32, P238, DOI 10.1097/01.olq.0000149782.47456.5b; Halperin DT, 2004, LANCET, V364, P4, DOI 10.1016/S0140-6736(04)16606-3; Harris RS, 2004, NAT REV IMMUNOL, V4, P868, DOI 10.1038/nri1489; Hayes R, 2006, SCIENCE, V311, P620, DOI 10.1126/science.1124072; Hillier SL, 2005, JAIDS-J ACQ IMM DEF, V39, P1, DOI 10.1097/01.qai.0000159671.25950.74; Hirschel B, 2001, Lancet Infect Dis, V1, P53, DOI 10.1016/S1473-3099(01)00022-6; *HO, 2004, SCAL ANT THER RES LT; Ho DD, 2002, CELL, V110, P135, DOI 10.1016/S0092-8674(02)00832-2; Hogg RS, 1998, JAMA-J AM MED ASSOC, V279, P450, DOI 10.1001/jama.279.6.450; Hosken NA, 2005, VACCINE, V23, P2395, DOI 10.1016/j.vaccine.2005.01.017; Huthoff H, 2005, VIROLOGY, V334, P147, DOI 10.1016/j.virol.2005.01.038; Inciardi JA, 2005, AIDS CARE, V17, pS1, DOI 10.1080/09540120500120435; Jamieson BD, 2006, VACCINE, V24, P3426, DOI 10.1016/j.vaccine.2006.02.023; Jarmuz A, 2002, GENOMICS, V79, P285, DOI 10.1006/geno.2002.6718; Jennings C, 2005, J CLIN MICROBIOL, V43, P5950, DOI 10.1128/JCM.43.12.5950-5956.2005; Jin X, 2005, J VIROL, V79, P11513, DOI 10.1128/JVI.79.17.11513-11516.2005; Kantor R, 2005, PLOS MED, V2, P325, DOI 10.1371/journal.pmed.0020112; KARIM QA, 1992, AIDS, V6, P1535, DOI 10.1097/00002030-199212000-00018; Karim QA, 2002, INT J EPIDEMIOL, V31, P37, DOI 10.1093/ije/31.1.37; KEELE BF, 2006, SCIENCE; Kieffer TL, 2005, J VIROL, V79, P1975, DOI 10.1128/JVI.79.3.1975-1980.2005; Kim JY, 2005, NEW ENGL J MED, V353, P2392, DOI 10.1056/NEJMe058261; Kober K, 2004, LANCET, V364, P103, DOI 10.1016/S0140-6736(04)16597-5; Korber B, 2001, BRIT MED BULL, V58, P19, DOI 10.1093/bmb/58.1.19; Korenromp EL, 2005, J INFECT DIS, V191, pS168, DOI 10.1086/425274; Kovacs JA, 2001, J EXP MED, V194, P1731, DOI 10.1084/jem.194.12.1731; Kulkarni Prasad S., 2003, AIDS Reviews, V5, P87; LAEYENDECKER O, 2006, 13 C RETR OPP INF DE; Lalezari JP, 2003, NEW ENGL J MED, V348, P2175, DOI 10.1056/NEJMoa035026; Lazzarin A, 2003, NEW ENGL J MED, V348, P2186, DOI 10.1056/NEJMoa035211; Lee EJ, 2005, J INFECT DIS, V192, P1260, DOI 10.1086/444424; Lehrman G, 2005, LANCET, V366, P549, DOI 10.1016/S0140-6736(05)67098-5; Levy NC, 2005, J URBAN HEALTH, V82, P498, DOI 10.1093/jurban/jti090; Libamba E, 2005, INT J TUBERC LUNG D, V9, P1062; Lombart JP, 2005, AIDS, V19, P1273, DOI 10.1097/01.aids.0000180098.58017.48; Lurie MN, 2003, SEX TRANSM DIS, V30, P149, DOI 10.1097/00007435-200302000-00011; Luzuriaga K, 2005, CLIN INFECT DIS, V40, P466; Magoni M, 2005, AIDS, V19, P433, DOI 10.1097/01.aids.0000161773.29029.c0; Mahalingam S, 2002, J LEUKOCYTE BIOL, V72, P429; Malcolm RK, 2005, J ANTIMICROB CHEMOTH, V56, P954, DOI 10.1093/jac/dki326; Mangeat B, 2005, HUM GENE THER, V16, P913, DOI 10.1089/hum.2005.16.913; Manzi M, 2005, TROP MED INT HEALTH, V10, P1242, DOI 10.1111/j.1365-3156.2005.01526.x; Martin-Serrano J, 2003, J VIROL, V77, P4794, DOI 10.1128/JVI.77.8.4794-4804.2003; Martin-Serrano J, 2001, NAT MED, V7, P1313, DOI 10.1038/nm1201-1313; McCutchan FE, 2005, J VIROL, V79, P11693, DOI 10.1128/JVI.79.18.11693-11704.2005; McIntyre J, 2006, CURR OPIN INFECT DIS, V19, P33, DOI 10.1097/01.qco.0000200290.99790.72; Mehandru S, 2005, J ALLERGY CLIN IMMUN, V116, P419, DOI 10.1016/j.jaci.2005.05.040; Mehandru S, 2004, J EXP MED, V200, P761, DOI 10.1084/jem.20041196; Mitchell RS, 2004, PLOS BIOL, V2, P1127, DOI 10.1371/journal.pbio.0020234; Mocroft A, 2004, J ANTIMICROB CHEMOTH, V54, P10, DOI 10.1093/jac/dkh290; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; Mofenson LM, 2003, LANCET, V362, P1625, DOI 10.1016/S0140-6736(03)14825-8; Mohri H, 2001, J EXP MED, V194, P1277, DOI 10.1084/jem.194.9.1277; Myer L, 2005, J INFECT DIS, V192, P1372, DOI 10.1086/462427; Nagot N, 2005, JAIDS-J ACQ IMM DEF, V39, P632; Navarro F, 2005, VIROLOGY, V333, P374, DOI 10.1016/j.virol.2005.01.011; Newell ML, 2006, T ROY SOC TROP MED H, V100, P1, DOI 10.1016/j.trstmh.2005.05.012; Newell ML, 2003, JAIDS-J ACQ IMM DEF, V32, P380, DOI 10.1097/00126334-200304010-00006; NICOLOSI A, 1994, EPIDEMIOLOGY, V5, P570, DOI 10.1097/00001648-199411000-00003; Nisole S, 2005, NAT REV MICROBIOL, V3, P799, DOI 10.1038/nrmicro1248; Nolan David, 2005, Sex Health, V2, P153, DOI 10.1071/SH04058; NUNN AJ, 1995, AIDS, V9, P503, DOI 10.1097/00002030-199509050-00013; Orrell Catherine, 2005, Curr HIV/AIDS Rep, V2, P171, DOI 10.1007/s11904-005-0012-8; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Palmer S, 2006, P NATL ACAD SCI USA, V103, P7094, DOI 10.1073/pnas.0602033103; Pantophlet R, 2006, ANNU REV IMMUNOL, V24, P739, DOI 10.1146/annurev.immunol.24.021605.090557; Parkin NT, 2004, ANTIVIR THER, V9, P3; Patterson BK, 2002, AM J PATHOL, V161, P867, DOI 10.1016/S0002-9440(10)64247-2; Perez-Caballero D, 2005, J VIROL, V79, P15567, DOI 10.1128/JVI.79.24.15567-15572.2005; Petersen-Mahrt SK, 2003, J BIOL CHEM, V278, P19583, DOI 10.1074/jbc.C300114200; Pettifor AE, 2005, AIDS, V19, P1525, DOI 10.1097/01.aids.0000183129.16830.06; Platt EJ, 2005, J VIROL, V79, P4347, DOI 10.1128/JVI.79.7.4347-4356.2005; Powers AE, 2006, AIDS, V20, P837, DOI 10.1097/01.aids.0000218547.39339.13; Price MA, 2004, J INFECT DIS, V190, P1448, DOI 10.1086/424470; Puro V, 2004, EUR J EPIDEMIOL, V19, P577, DOI 10.1023/B:EJEP.0000032349.57057.8a; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Quinn TC, 2005, SCIENCE, V308, P1582, DOI 10.1126/science.1112489; Ramratnam B, 1999, LANCET, V354, P1782, DOI 10.1016/S0140-6736(99)02035-8; Ray N, 2006, CURR TOP MICROBIOL, V303, P97, DOI 10.1007/978-3-540-33397-5_5; Read JS, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005479; Rennie S, 2006, B WORLD HEALTH ORGAN, V84, P52, DOI 10.2471/BLT.05.025536; Roberts DM, 2006, NATURE, V441, P239, DOI 10.1038/nature04721; Rodriguez WR, 2005, PLOS MED, V2, P663, DOI 10.1371/journal.pmed.0020182; Rollins N, 2004, JAIDS-J ACQ IMM DEF, V35, P188, DOI 10.1097/00126334-200402010-00014; Rottingen JA, 2001, SEX TRANSM DIS, V28, P579; Sawyer SL, 2004, PLOS BIOL, V2, P1278, DOI 10.1371/journal.pbio.0020275; SCHERDIN U, 1990, J VIROL, V64, P907, DOI 10.1128/JVI.64.2.907-912.1990; Schindler M, 2006, CELL, V125, P1055, DOI 10.1016/j.cell.2006.04.033; Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4; Schrofelbauer B, 2004, AIDS REV, V6, P34; Schwebke JR, 2005, J INFECT DIS, V192, P1315, DOI 10.1086/462430; Sharghi N, 2005, JAIDS-J ACQ IMM DEF, V40, P472, DOI 10.1097/01.qai.0000164246.49098.47; Shattock RJ, 2003, NAT REV MICROBIOL, V1, P25, DOI 10.1038/nrmicro729; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Sheppard Haynes W., 2005, Current Drug Targets - Infectious Disorders, V5, P131, DOI 10.2174/1568005054201599; Shisana O, 2004, B WORLD HEALTH ORGAN, V82, P812; Siegfried N, 2005, LANCET INFECT DIS, V5, P165, DOI 10.1016/S1473-3099(05)01309-5; Siegfried N, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003362.pub2; Simon V, 2003, NAT REV MICROBIOL, V1, P181, DOI 10.1038/nrmicro772; Simon V, 2005, PLOS PATHOG, V1, P20, DOI 10.1371/journal.ppat.0010006; Smith DM, 2005, J INFECT DIS, V192, P438, DOI 10.1086/431682; SotoRamirez LE, 1996, SCIENCE, V271, P1291, DOI 10.1126/science.271.5253.1291; Spacek LA, 2006, JAIDS-J ACQ IMM DEF, V41, P607, DOI 10.1097/01.qai.0000214807.98465.a2; Steain Megan C, 2004, Sex Health, V1, P239, DOI 10.1071/SH04024; STEIN ZA, 1994, LANCET, V343, P362, DOI 10.1016/S0140-6736(94)91205-X; Stremlau M, 2006, P NATL ACAD SCI USA, V103, P5514, DOI 10.1073/pnas.0509996103; Stremlau M, 2004, NATURE, V427, P848, DOI 10.1038/nature02343; Szabo R, 2000, BRIT MED J, V320, P1592, DOI 10.1136/bmj.320.7249.1592; Telenti A, 2006, FUTURE VIROL, V1, P55, DOI 10.2217/17460794.1.1.55; Thomson MM, 2005, AIDS REV, V7, P210; Tian CJ, 2006, J VIROL, V80, P3112, DOI 10.1128/JVI.80.6.3112-3115.2006; Toni TD, 2005, AIDS RES HUM RETROV, V21, P1031, DOI 10.1089/aid.2005.21.1031; Tuaillon E, 2004, JAIDS-J ACQ IMM DEF, V37, P1543, DOI 10.1097/00126334-200412150-00001; Tuomala RE, 2002, NEW ENGL J MED, V346, P1863, DOI 10.1056/NEJMoa991159; Turlure F, 2006, NUCLEIC ACIDS RES, V34, P1653, DOI 10.1093/nar/gkl052; UNAIDS, 2006 REP GLOB AIDS E; Uttayamakul S, 2005, J VIROL METHODS, V128, P128, DOI 10.1016/j.jviromet.2005.04.010; Valdez H, 2002, AIDS, V16, P1113, DOI 10.1097/00002030-200205240-00004; Van Damme L, 2002, LANCET, V360, P971, DOI 10.1016/S0140-6736(02)11079-8; van der Kuyl AC, 2005, NEW ENGL J MED, V352, P2557, DOI 10.1056/NEJM200506163522420; van der Straten A, 2005, SEX TRANSM DIS, V32, P64, DOI 10.1097/01.olq.0000148301.90343.3a; Wawer MJ, 2005, J INFECT DIS, V191, P1403, DOI 10.1086/429411; Weber J, 2005, PLOS MED, V2, P392, DOI 10.1371/journal.pmed.0020142; Weller S, 2002, Cochrane Database Syst Rev, pCD003255; Welty TK, 2005, JAIDS-J ACQ IMM DEF, V40, P486, DOI 10.1097/01.qai.0000163196.36199.89; Wensing Annemarie M. J., 2003, AIDS Reviews, V5, P140; Winston A, 2005, HIV MED, V6, P191, DOI 10.1111/j.1468-1293.2005.00288.x; Wyatt CM, 2006, EXPERT OPIN DRUG SAF, V5, P275, DOI 10.1517/14740338.5.2.275; Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884; Yerly S, 2004, AIDS, V18, P1413, DOI 10.1097/01.aids.0000131330.28762.0c; Ylisastigui L, 2004, AIDS, V18, P1101, DOI 10.1097/00002030-200405210-00003; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453	207	314	342	1	100	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 5	2006	368	9534					489	504		10.1016/S0140-6736(06)69157-5	http://dx.doi.org/10.1016/S0140-6736(06)69157-5			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	071AL	16890836	Green Submitted, Green Accepted			2022-12-28	WOS:000239569000032
J	Ding, WW; Murray, F; Stuart, TE				Ding, Waverly W.; Murray, Fiona; Stuart, Toby E.			Gender differences in patenting in the academic life sciences	SCIENCE			English	Article								We analyzed longitudinal data on academic careers and conducted interviews with faculty members to determine the scope and causes of the gender gap in patenting among life scientists. Our regressions on a random sample of 4227 life scientists over a 30-year period show that women faculty members patent at about 40% of the rate of men. We found that the gender gap has improved over time but remains large.	Harvard Univ, Sch Business, Boston, MA 02163 USA; Univ Calif Berkeley, Haas Sch Business, Berkeley, CA 94720 USA; MIT, Alfred P Sloan Sch Management, Cambridge, MA 02142 USA	Harvard University; University of California System; University of California Berkeley; Massachusetts Institute of Technology (MIT)	Stuart, TE (corresponding author), Harvard Univ, Sch Business, Soldiers Field Rd, Boston, MA 02163 USA.	tstuart@hbs.edu						ALLISON PD, 1990, AM SOCIOL REV, V55, P469, DOI 10.2307/2095801; Cole J. R., 1973, SOCIAL STRATIFICATIO; ETZKOWITZ H, 1994, SCIENCE, V266, P51, DOI 10.1126/science.7939644; Fisher R. L., 2005, RES PRODUCTIVITY SCI; Holden C, 2001, SCIENCE, V294, P396, DOI 10.1126/science.294.5541.396; LONG JS, 1995, ANNU REV SOCIOL, V21, P45, DOI 10.1146/annurev.so.21.080195.000401; *NAT SCI FDN, 2004, 04323 NSF; Shane S, 2002, MANAGE SCI, V48, P154, DOI 10.1287/mnsc.48.1.154.14280; SONNERT G, 1995, WHO SUCCEEDS SCI GEN; Stuart TE, 2006, AM J SOCIOL, V112, P97, DOI 10.1086/502691; Thursby J G, 2005, J TECHNOLOGY TRANSFE, V30, P343, DOI DOI 10.1007/S10961-005-2580-6; Walsh JP, 2003, SCIENCE, V299, P1021, DOI 10.1126/science.299.5609.1021; Xie Y., 2003, WOMEN SCI CAREER PRO	13	208	211	0	77	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 4	2006	313	5787					665	667		10.1126/science.1124832	http://dx.doi.org/10.1126/science.1124832			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	072IQ	16888138				2022-12-28	WOS:000239667500042
J	Pollitz, FF				Pollitz, Fred F.			Geophysics - A new class of earthquake observations	SCIENCE			English	Editorial Material							SUMATRA-ANDAMAN EARTHQUAKE; GPS MEASUREMENTS; GRAVITY; GRACE; DEFORMATION	Advances in satellite technology have improved measurements of Earth's properties. Now changes in local gravity resulting from large earthquakes can be detected.	US Geol Survey, Menlo Pk, CA 94025 USA	United States Department of the Interior; United States Geological Survey	Pollitz, FF (corresponding author), US Geol Survey, 345 Middlefield Rd, Menlo Pk, CA 94025 USA.	fpollitz@usgs.gov						Andersen OB, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2004GL020948; Banerjee P, 2005, SCIENCE, V308, P1769, DOI 10.1126/science.1113746; Burgmann R, 2000, ANNU REV EARTH PL SC, V28, P169, DOI 10.1146/annurev.earth.28.1.169; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; Han SC, 2006, SCIENCE, V313, P658, DOI 10.1126/science.1128661; Jade S, 2005, CURR SCI INDIA, V88, P1980; Mikhailov V, 2004, EARTH PLANET SC LETT, V228, P281, DOI 10.1016/j.epsl.2004.09.035; Plafker G., 2006, SEISMOL RES LETT, V77, P231; Pollitz FF, 1997, PHYS EARTH PLANET IN, V99, P259, DOI 10.1016/S0031-9201(96)03204-9; POLLITZ FF, IN PRESS GEOPHYS J I; SMITH DE, 1993, CONTRIBUTIONS SPACE; STEPHENS M, 2006, 6 ANN NASA EARTH SCI; Subarya C, 2006, NATURE, V440, P46, DOI 10.1038/nature04522; Sun WK, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2003JB002554; Tapley BD, 2004, SCIENCE, V305, P503, DOI 10.1126/science.1099192; Tapley BD, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL019920; Velicogna I, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2001JB001735; Vigny C, 2005, NATURE, V436, P201, DOI 10.1038/nature03937; Wahr J, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL019779	19	7	8	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 4	2006	313	5787					619	620		10.1126/science.1131208	http://dx.doi.org/10.1126/science.1131208			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	072IQ	16888125				2022-12-28	WOS:000239667500025
J	Ogura, Y; Sutterwala, FS; Flavell, RA				Ogura, Yasunori; Sutterwala, Fayyaz S.; Flavell, Richard A.			The inflammasome: First line of the immune response to cell stress	CELL			English	Review							LEGIONELLA-PNEUMOPHILA INFECTION; ACTIVATION; CASPASE-1; FLAGELLIN; RECEPTOR; IPAF; INTERLEUKIN-1-BETA; IDENTIFICATION; RECOGNITION; MACROPHAGES		Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06520 USA; Yale Univ, Sch Med, Infect Dis Sect, New Haven, CT 06520 USA	Yale University; Howard Hughes Medical Institute; Yale University; Yale University	Flavell, RA (corresponding author), Yale Univ, Sch Med, Immunobiol Sect, 333 Cedar St, New Haven, CT 06520 USA.	richard.flavell@yale.edu	Sutterwala, Fayyaz/AAH-5859-2021; Cassel, Suzanne/AAI-3947-2021	Cassel, Suzanne/0000-0003-2492-1923	NIAID NIH HHS [T32 AI-007517] Funding Source: Medline; NIDDK NIH HHS [DK066338-03] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007517] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK066338] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agostini L, 2004, IMMUNITY, V20, P319, DOI 10.1016/S1074-7613(04)00046-9; Boyden ED, 2006, NAT GENET, V38, P240, DOI 10.1038/ng1724; Dinarello CA, 2002, CLIN EXP RHEUMATOL, V20, pS1; Ferrari D, 2006, J IMMUNOL, V176, P3877, DOI 10.4049/jimmunol.176.7.3877; Franchi L, 2006, NAT IMMUNOL, V7, P576, DOI 10.1038/ni1346; Johnston JB, 2005, IMMUNITY, V23, P587, DOI 10.1016/j.immuni.2005.10.003; Kanneganti TD, 2006, NATURE, V440, P233, DOI 10.1038/nature04517; Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664; Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515; Martinon F, 2004, CURR BIOL, V14, P1929, DOI 10.1016/j.cub.2004.10.027; Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Miao EA, 2006, NAT IMMUNOL, V7, P569, DOI 10.1038/ni1344; Miller LS, 2006, IMMUNITY, V24, P79, DOI 10.1016/j.immuni.2005.11.011; Molofsky AB, 2006, J EXP MED, V203, P1093, DOI 10.1084/jem.20051659; Ren T, 2006, PLOS PATHOG, V2, P175, DOI 10.1371/journal.ppat.0020018; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Shi Y, 2003, NATURE, V425, P516, DOI 10.1038/nature01991; Shornick LP, 2001, CELL IMMUNOL, V211, P105, DOI 10.1006/cimm.2001.1834; Smith HR, 2002, CLIN EXP DERMATOL, V27, P138, DOI 10.1046/j.1365-2230.2002.00997.x; Sutterwala FS, 2006, IMMUNITY, V24, P317, DOI 10.1016/j.immuni.2006.02.004; Ting JPY, 2006, NAT REV IMMUNOL, V6, P183, DOI 10.1038/nri1788; Yamamoto M, 2004, GENES CELLS, V9, P1055, DOI 10.1111/j.1365-2443.2004.00789.x; Zamboni DS, 2006, NAT IMMUNOL, V7, P318, DOI 10.1038/ni1305	24	365	381	1	34	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 25	2006	126	4					659	662		10.1016/j.cell.2006.08.002	http://dx.doi.org/10.1016/j.cell.2006.08.002			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	080VN	16923387	Bronze			2022-12-28	WOS:000240276700015
J	Rodolfa, KT; Eggan, K				Rodolfa, Kit T.; Eggan, Kevin			A transcriptional logic for nuclear reprogramming	CELL			English	Editorial Material							EMBRYONIC STEM-CELLS; TUMOR-SUPPRESSOR; SOMATIC-CELLS; ES CELLS; PLURIPOTENCY; EXPRESSION; NANOG; P53		Harvard Univ, Stowers Med Inst, Harvard Stem Cell Inst, Dept Mol & Cell Biol, Cambridge, MA 02138 USA; Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA	Harvard University; Stowers Institute for Medical Research; Harvard University	Eggan, K (corresponding author), Harvard Univ, Stowers Med Inst, Harvard Stem Cell Inst, Dept Mol & Cell Biol, 7 Divin Ave, Cambridge, MA 02138 USA.	eggan@mcb.harvard.edu	Eggan, Kevin/P-7119-2018	Rodolfa, Kit/0000-0002-0829-1282				Cartwright P, 2005, DEVELOPMENT, V132, P885, DOI 10.1242/dev.01670; Cowan CA, 2005, SCIENCE, V309, P1369, DOI 10.1126/science.1116447; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Lin TX, 2005, NAT CELL BIOL, V7, P165, DOI 10.1038/ncb1211; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Rowland BD, 2005, NAT CELL BIOL, V7, P1074, DOI 10.1038/ncb1314; Tada M, 2001, CURR BIOL, V11, P1553, DOI 10.1016/S0960-9822(01)00459-6; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	11	28	31	1	10	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	AUG 25	2006	126	4					652	655		10.1016/j.cell.2006.08.009	http://dx.doi.org/10.1016/j.cell.2006.08.009			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	080VN	16923385	Bronze			2022-12-28	WOS:000240276700013
J	Huang, AL; Chen, XK; Hoon, MA; Chandrashekar, J; Guo, W; Trankner, D; Ryba, NJP; Zuker, CS				Huang, Angela L.; Chen, Xiaoke; Hoon, Mark A.; Chandrashekar, Jayaram; Guo, Wei; Trankner, Dimitri; Ryba, Nicholas J. P.; Zuker, Charles S.			The cells and logic for mammalian sour taste detection	NATURE			English	Article							DIPHTHERIA-TOXIN; RECEPTORS; SWEET; FAMILY; BITTER; CHANNELS; NEURONS; SYSTEM	Mammals taste many compounds yet use a sensory palette consisting of only five basic taste modalities: sweet, bitter, sour, salty and umami ( the taste of monosodium glutamate)(1,2). Although this repertoire may seem modest, it provides animals with critical information about the nature and quality of food. Sour taste detection functions as an important sensory input to warn against the ingestion of acidic ( for example, spoiled or unripe) food sources(1-3). We have used a combination of bioinformatics, genetic and functional studies to identify PKD2L1, a polycystic-kidney-disease-like ion channel(4), as a candidate mammalian sour taste sensor. In the tongue, PKD2L1 is expressed in a subset of taste receptor cells distinct from those responsible for sweet, bitter and umami taste. To examine the role of PKD2L1-expressing taste cells in vivo, we engineered mice with targeted genetic ablations of selected populations of taste receptor cells. Animals lacking PKD2L1-expressing cells are completely devoid of taste responses to sour stimuli. Notably, responses to all other tastants remained unaffected, proving that the segregation of taste qualities even extends to ionic stimuli. Our results now establish independent cellular substrates for four of the five basic taste modalities, and support a comprehensive labelled-line mode of taste coding at the periphery(5-10). Notably, PKD2L1 is also expressed in specific neurons surrounding the central canal of the spinal cord. Here we demonstrate that these PKD2L1-expressing neurons send projections to the central canal, and selectively trigger action potentials in response to decreases in extracellular pH. We propose that these cells correspond to the long-sought components of the cerebrospinal fluid chemosensory system(11). Taken together, our results suggest a common basis for acid sensing in disparate physiological settings.	Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Neurobiol & Neurosci, La Jolla, CA 92093 USA; Natl Inst Dent & Craniofacial Res, NIH, Bethesda, MD 20892 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Zuker, CS (corresponding author), Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA.	charles@flyeye.ucsd.edu	chen, xiaoke/E-5385-2011	Ryba, Nicholas/0000-0002-2060-8393; Chandrashekar, jayaram/0000-0001-6412-0114	NIDCD NIH HHS [R01 DC004861] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000561] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000561] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC004861] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Adler E, 2000, CELL, V100, P693, DOI 10.1016/S0092-8674(00)80705-9; Brockschnieder D, 2004, MOL CELL BIOL, V24, P7636, DOI 10.1128/MCB.24.17.7636-7642.2004; Chandrashekar J, 2000, CELL, V100, P703, DOI 10.1016/S0092-8674(00)80706-0; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; COLLIER RJ, 1975, BACTERIOL REV, V39, P54, DOI 10.1128/MMBR.39.1.54-85.1975; Delmas P, 2005, PFLUG ARCH EUR J PHY, V451, P264, DOI 10.1007/s00424-005-1431-5; DeSimone JA, 2001, RESP PHYSIOL, V129, P231, DOI 10.1016/S0034-5687(01)00293-6; Gosgnach S, 2006, NATURE, V440, P215, DOI 10.1038/nature04545; Hoon MA, 1999, CELL, V96, P541, DOI 10.1016/S0092-8674(00)80658-3; Kinnamon SC, 1996, CURR OPIN NEUROBIOL, V6, P506, DOI 10.1016/S0959-4388(96)80057-2; Lahiri S, 2003, INT J BIOCHEM CELL B, V35, P1413, DOI 10.1016/S1357-2725(03)00050-5; Lee EC, 2001, GENOMICS, V73, P56, DOI 10.1006/geno.2000.6451; Li XD, 2002, P NATL ACAD SCI USA, V99, P4692, DOI 10.1073/pnas.072090199; Lindemann B, 2001, NATURE, V413, P219, DOI 10.1038/35093032; LopezJimenez ND, 2006, J NEUROCHEM, V98, P68, DOI 10.1111/j.1471-4159.2006.03842.x; Lyall V, 2004, J PHYSIOL-LONDON, V558, P147, DOI 10.1113/jphysiol.2004.065656; Matsunami H, 2000, NATURE, V404, P601, DOI 10.1038/35007072; Mueller KL, 2005, NATURE, V434, P225, DOI 10.1038/nature03352; Murakami M, 2005, J BIOL CHEM, V280, P5626, DOI 10.1074/jbc.M411496200; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Nelson G, 2002, NATURE, V416, P199, DOI 10.1038/nature726; Nelson G, 2001, CELL, V106, P381, DOI 10.1016/S0092-8674(01)00451-2; Novak A, 2000, GENESIS, V28, P147, DOI 10.1002/1526-968X(200011/12)28:3/4<147::AID-GENE90>3.0.CO;2-G; Perez CA, 2002, NAT NEUROSCI, V5, P1169, DOI 10.1038/nn952; Richerson GB, 2005, EXP PHYSIOL, V90, P259, DOI 10.1113/expphysiol.2005.029843; Richerson GB, 2005, EXP PHYSIOL, V90, P269, DOI 10.1111/j.1469-445X.2005.t01-2-00135.x; Vigh B, 2004, HISTOL HISTOPATHOL, V19, P607, DOI 10.14670/HH-19.607; Vinnikova AK, 2004, J NEUROPHYSIOL, V91, P1297, DOI 10.1152/jn.00809.2003; Wu GQ, 1998, GENOMICS, V54, P564, DOI 10.1006/geno.1998.5618; Zhang YF, 2003, CELL, V112, P293, DOI 10.1016/S0092-8674(03)00071-0; Zhao GQ, 2003, CELL, V115, P255, DOI 10.1016/S0092-8674(03)00844-4	31	524	546	9	228	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 24	2006	442	7105					934	938		10.1038/nature05084	http://dx.doi.org/10.1038/nature05084			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	076LT	16929298	Green Accepted			2022-12-28	WOS:000239960500041
J	Tarsy, D; Simon, DK				Tarsy, Daniel; Simon, David K.			Current concepts - Dystonia	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							TRAUMA INDUCE DYSTONIA; DEEP-BRAIN-STIMULATION; FOCAL HAND DYSTONIA; TORSION DYSTONIA; GENERALIZED DYSTONIA; BOTULINUM TOXIN; BASAL GANGLIA; PHENOTYPIC VARIABILITY; MOVEMENT-DISORDERS; GLOBUS-PALLIDUS		Beth Israel Deaconess Med Ctr, Dept Neurol, Parkinsons Dis & Movement Disorders Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Tarsy, D (corresponding author), Beth Israel Deaconess Med Ctr, Dept Neurol, Parkinsons Dis & Movement Disorders Ctr, Boston, MA 02215 USA.				NINDS NIH HHS [K02 NS4311] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aguiar PD, 2004, NEURON, V43, P169, DOI 10.1016/j.neuron.2004.06.028; Aguiar PMD, 2002, LANCET NEUROL, V1, P316, DOI 10.1016/S1474-4422(02)00137-0; ALBRIGHT AL, 1992, DYSTONIA ETIOLOGY CL, P87; Bressman SB, 2000, NEUROLOGY, V54, P1746, DOI 10.1212/WNL.54.9.1746; Bressman SB, 2003, REV NEUROL-FRANCE, V159, P849; Bressman Susan B, 2004, Adv Neurol, V94, P101; BURKE RE, 1986, NEUROLOGY, V36, P160, DOI 10.1212/WNL.36.2.160; Byl NN, 2003, ARCH PHYS MED REHAB, V84, P1505, DOI 10.1016/S0003-9993(03)00276-4; Calne D B, 1988, Adv Neurol, V50, P9; Comella CL, 2005, NEUROLOGY, V65, P1423, DOI 10.1212/01.wnl.0000183055.81056.5c; Coubes P, 2004, J NEUROSURG, V101, P189, DOI 10.3171/jns.2004.101.2.0189; Defazio G, 2004, LANCET NEUROL, V3, P673, DOI 10.1016/S1474-4422(04)00907-X; DEMIRKIRAN M, 1995, ANN NEUROL, V38, P571, DOI 10.1002/ana.410380405; DOBYNS WB, 1993, NEUROLOGY, V43, P2596, DOI 10.1212/WNL.43.12.2596; Doheny DO, 2004, DYSTONIA ETIOLOGY CL, P23; Eidelberg D, 1998, ANN NEUROL, V44, P303, DOI 10.1002/ana.410440304; Fahn S, 1998, Adv Neurol, V78, P1; Fahn S, 1988, Adv Neurol, V50, P431; Ford B, 2003, CUR CLIN NEUROL, P287; Friedman J, 2001, NEUROL CLIN, V19, P681, DOI 10.1016/S0733-8619(05)70040-2; Garraux G, 2004, ANN NEUROL, V55, P736, DOI 10.1002/ana.20113; Gasser T, 1998, ANN NEUROL, V44, P126, DOI 10.1002/ana.410440119; Goto S, 2005, ANN NEUROL, V58, P7, DOI 10.1002/ana.20513; GREENE P, 1988, MOVEMENT DISORD, V3, P46, DOI 10.1002/mds.870030107; GREENE P, 1995, MOVEMENT DISORD, V10, P143, DOI 10.1002/mds.870100204; Grundmann K, 2005, ARCH NEUROL-CHICAGO, V62, P682, DOI 10.1001/archneur.62.4.682; Grundmann K, 2003, ARCH NEUROL-CHICAGO, V60, P1266, DOI 10.1001/archneur.60.9.1266; Hallett M, 1998, ARCH NEUROL-CHICAGO, V55, P601, DOI 10.1001/archneur.55.5.601; Jankovic J, 1997, NEUROLOGY, V48, P358, DOI 10.1212/WNL.48.2.358; Jankovic J, 2001, MOVEMENT DISORD, V16, P7, DOI 10.1002/1531-8257(200101)16:1<7::AID-MDS1005>3.0.CO;2-0; Jankovic J, 2004, J NEUROL NEUROSUR PS, V75, P951, DOI 10.1136/jnnp.2003.034702; Jankovic J, 2003, NEUROLOGY, V60, P1186, DOI 10.1212/01.WNL.0000055087.96356.BB; Krauss JK, 2002, J NEUROL NEUROSUR PS, V72, P249, DOI 10.1136/jnnp.72.2.249; LI SC, 1985, ARCH NEUROL-CHICAGO, V42, P655, DOI 10.1001/archneur.1985.04060070045013; MARSDEN CD, 1985, BRAIN, V108, P463, DOI 10.1093/brain/108.2.463; Mink JW, 2003, ARCH NEUROL-CHICAGO, V60, P1365, DOI 10.1001/archneur.60.10.1365; Muller J, 2002, NEUROLOGY, V59, P941, DOI 10.1212/01.WNL.0000026474.12594.0D; Nemeth AH, 2002, BRAIN, V125, P695, DOI 10.1093/brain/awf090; NUTT JG, 1988, MOVEMENT DISORD, V3, P188, DOI 10.1002/mds.870030302; NYGAARD TG, 1991, NEUROLOGY, V41, P174, DOI 10.1212/WNL.41.2_Part_1.174; O'Riordan S, 2004, NEUROLOGY, V63, P1423; Opal P, 2002, MOVEMENT DISORD, V17, P339, DOI 10.1002/mds.10096; Oppenheim H., 1911, NEUROL CENTRALBL, V30, P1090; Ozelius LJ, 1997, NAT GENET, V17, P40, DOI 10.1038/ng0997-40; Priori A, 2001, NEUROLOGY, V57, P405, DOI 10.1212/WNL.57.3.405; Pullman SL, 2005, NEUROLOGY, V64, P186, DOI 10.1212/01.WNL.0000157497.08500.c1; Quinn NP, 1996, MOVEMENT DISORD, V11, P119, DOI 10.1002/mds.870110202; RISCH N, 1995, NAT GENET, V9, P152, DOI 10.1038/ng0295-152; Schrag A, 2004, BRAIN, V127, P2360, DOI 10.1093/brain/awh262; SHALE H, 1987, MOVEMENT DISORD, V2, P321, DOI 10.1002/mds.870020411; Tarsy D, 1998, MOVEMENT DISORD, V13, P481, DOI 10.1002/mds.870130318; TEMPEL LW, 1990, BRAIN, V113, P691, DOI 10.1093/brain/113.3.691; Trottenberg T, 2005, NEUROLOGY, V64, P344, DOI 10.1212/01.WNL.0000149762.80932.55; Vidailhet M, 2005, NEW ENGL J MED, V352, P459, DOI 10.1056/NEJMoa042187; Vitek JL, 1999, ANN NEUROL, V46, P22, DOI 10.1002/1531-8249(199907)46:1<22::AID-ANA6>3.0.CO;2-Z; Weiner WJ, 2001, MOVEMENT DISORD, V16, P13, DOI 10.1002/1531-8257(200101)16:1<13::AID-MDS1016>3.0.CO;2-W; Zeuner KE, 2003, MOVEMENT DISORD, V18, P1044, DOI 10.1002/mds.10490; Zimprich A, 2001, NAT GENET, V29, P66, DOI 10.1038/ng709	58	172	186	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 24	2006	355	8					818	829		10.1056/NEJMra055549	http://dx.doi.org/10.1056/NEJMra055549			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	076KA	16928997				2022-12-28	WOS:000239955200010
J	Zhong, N; Zeng, GQ				Zhong, Nanshan; Zeng, Guangqiao			Epidemics - What we have learnt from SARS epidemics in China	BRITISH MEDICAL JOURNAL			English	Editorial Material							ACUTE RESPIRATORY SYNDROME; SYNDROME CORONAVIRUS; CIVETS		Chinese Med Assoc, Guangzhou Inst Resp Dis, Guangzhou 510120, Peoples R China		Zhong, N (corresponding author), Chinese Med Assoc, Guangzhou Inst Resp Dis, 151 Yanjiang Rd, Guangzhou 510120, Peoples R China.	nanshan@vip.163.com						[Anonymous], BBC NEWS; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P986; Enserink M, 2003, SCIENCE, V301, P294, DOI 10.1126/science.301.5631.294; Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139; HENDERSON M, 2005, END SARS DEADLY THRE; Li BJ, 2005, NAT MED, V11, P944, DOI 10.1038/nm1280; Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391; Song HD, 2005, P NATL ACAD SCI USA, V102, P2430, DOI 10.1073/pnas.0409608102; Tu CC, 2004, EMERG INFECT DIS, V10, P2244, DOI 10.3201/eid1012.040520; Wu DL, 2005, J VIROL, V79, P2620, DOI 10.1128/JVI.79.4.2620-2625.2005; Xu RH, 2004, EMERG INFECT DIS, V10, P1030, DOI 10.3201/eid1006.030852; ZHENG L, 2003, MANAGEMENT STRATEGIE, P106; Zhong NanShan, 2005, SARS: a case study in emerging infections, P31; Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2	15	35	36	0	21	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	AUG 19	2006	333	7564					389	391		10.1136/bmj.333.7564.389	http://dx.doi.org/10.1136/bmj.333.7564.389			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	078OD	16916828	Green Published			2022-12-28	WOS:000240112200020
J	Pawin, G; Wong, KL; Kwon, KY; Bartels, L				Pawin, Greg; Wong, Kin L.; Kwon, Ki-Young; Bartels, Ludwig			A homomolecular porous network at a Cu(111) surface	SCIENCE			English	Article							SCANNING-TUNNELING-MICROSCOPY; NANOSTRUCTURES; SUBSTRATE	Anthraquinone molecules self-assemble on a Cu(111) surface into a large two-dimensional honeycomb network (root 304 x root 304 p)R23 degrees with pore diameters of approximate to 50 angstrom. The spontaneous formation of a pattern containing pores roughly five times larger than the size of the constituent molecules is unprecedented. The network originates from a delicate balance between substrate-mediated repulsion and intermolecular attraction involving an unusual chemical motif: hydrogen bonding between a carbonyl oxygen and an aromatic hydrogen atom. Substrate-mediated long-range adsorbate-adsorbate repulsion has been observed on anisotropic surfaces and in the context of the absence of pattern formation. Its applicability for the design of tailored molecular films is explored here.	Univ Calif Riverside, Riverside, CA 92521 USA	University of California System; University of California Riverside	Bartels, L (corresponding author), Univ Calif Riverside, Pierce Hall, Riverside, CA 92521 USA.	ludwig.bartels@ucr.edu	Bartels, Ludwig/C-2764-2008; Wong, Kin L/F-6907-2011	Wong, Kin L/0000-0001-6776-3852				Barth JV, 2005, NATURE, V437, P671, DOI 10.1038/nature04166; Barth JV, 2000, ANGEW CHEM INT EDIT, V39, P1230, DOI 10.1002/(SICI)1521-3773(20000403)39:7<1230::AID-ANIE1230>3.0.CO;2-I; Bohringer M, 2000, SURF SCI, V444, P199, DOI 10.1016/S0039-6028(99)01039-0; Clair S, 2004, J PHYS CHEM B, V108, P14585, DOI 10.1021/jp049501n; Hyldgaard P, 2005, J CRYST GROWTH, V275, pE1637, DOI 10.1016/j.jcrysgro.2004.11.216; Kuhnle A, 2002, LANGMUIR, V18, P5558, DOI 10.1021/la025661j; Kwon KY, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.166101; Loui A, 2004, APPL SURF SCI, V237, P559, DOI 10.1016/j.apsusc.2004.06.088; Mitsui T, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.036101; Repp J, 2000, PHYS REV LETT, V85, P2981, DOI 10.1103/PhysRevLett.85.2981; RICKMAN JM, 1993, SURF SCI, V284, P211, DOI 10.1016/0039-6028(93)90538-U; STRANICK SJ, 1994, SCIENCE, V266, P99, DOI 10.1126/science.266.5182.99; Theobald JA, 2005, LANGMUIR, V21, P2038, DOI 10.1021/la047533w; Theobald JA, 2003, NATURE, V424, P1029, DOI 10.1038/nature01915; Wan LJ, 1997, LANGMUIR, V13, P7173, DOI 10.1021/la9706936; Wong K, 2004, J AM CHEM SOC, V126, P7762, DOI 10.1021/ja048660h; Wong KL, 2005, J CHEM PHYS, V123, DOI 10.1063/1.2124687; Yokoyama T, 2001, NATURE, V413, P619, DOI 10.1038/35098059	18	240	242	0	92	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 18	2006	313	5789					961	962		10.1126/science.1129309	http://dx.doi.org/10.1126/science.1129309			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	074MR	16917060				2022-12-28	WOS:000239817000041
J	Richer, HB; Anderson, J; Brewer, J; Davis, S; Fahlman, GG; Hansen, BMS; Hurley, J; Kalirai, JS; King, IR; Reitzel, D; Rich, RM; Shara, MM; Stetson, PB				Richer, Harvey B.; Anderson, Jay; Brewer, James; Davis, Saul; Fahlman, Gregory G.; Hansen, Brad M. S.; Hurley, Jarrod; Kalirai, Jasonjot S.; King, Ivan R.; Reitzel, David; Rich, R. Michael; Shara, Michael M.; Stetson, Peter B.			Probing the faintest stars in a globular star cluster	SCIENCE			English	Article							COLLISION-INDUCED ABSORPTION; DWARF COOLING SEQUENCE; MAIN-SEQUENCE; NGC 6397; TEMPERATURES; LUMINOSITY; MODELS; PAIRS; OLD	NGC 6397 is the second closest globular star cluster to the Sun. Using 5 days of time on the Hubble Space Telescope, we have constructed an ultradeep color-magnitude diagram for this cluster. We see a clear truncation in each of its two major stellar sequences. Faint red main-sequence stars run out well above our observational limit and near to the theoretical prediction for the lowest mass stars capable of stable hydrogen burning in their cores. We also see a truncation in the number counts of faint blue stars, namely white dwarfs. This reflects the limit to which the bulk of the white dwarfs can cool over the lifetime of the cluster. There is also a turn toward bluer colors in the least luminous of these objects. This was predicted for the very coolest white dwarfs with hydrogen-rich atmospheres as the formation of H-2 and the resultant collision-induced absorption cause their atmospheres to become largely opaque to infrared radiation.	Univ British Columbia, Dept Phys & Astron, Vancouver, BC V6T 1Z1, Canada; Rice Univ, Dept Phys & Astron, Houston, TX 77005 USA; Natl Res Council Canada, Herzberg Inst Astrophys, Victoria, BC V9E 2E7, Canada; Univ Calif Los Angeles, Div Astron & Astrophys, Los Angeles, CA 90095 USA; Monash Univ, Dept Math & Stat, Clayton, Vic 3800, Australia; Univ Calif Santa Cruz, Dept Astron & Astrophys, Santa Cruz, CA 95064 USA; Univ Washington, Dept Astron, Seattle, WA 98195 USA; Amer Museum Nat Hist, Dept Astrophys, New York, NY 10024 USA	University of British Columbia; Rice University; National Research Council Canada; University of California System; University of California Los Angeles; Monash University; University of California System; University of California Santa Cruz; University of Washington; University of Washington Seattle; American Museum of Natural History (AMNH)	Richer, HB (corresponding author), Univ British Columbia, Dept Phys & Astron, Vancouver, BC V6T 1Z1, Canada.	richer@astro.ubc.ca		Hurley, Jarrod/0000-0003-2694-0415				Baraffe I, 1997, ASTRON ASTROPHYS, V327, P1054; Bedin LR, 2005, ASTROPHYS J, V624, pL45, DOI 10.1086/430310; BERGERON P, 1995, PUBL ASTRON SOC PAC, V107, P1047, DOI 10.1086/133661; Borysow A, 2001, J QUANT SPECTROSC RA, V68, P235, DOI 10.1016/S0022-4073(00)00023-6; BURROWS A, 1993, ASTROPHYS J, V406, P158, DOI 10.1086/172427; Chabrier G, 2000, ANNU REV ASTRON ASTR, V38, P337, DOI 10.1146/annurev.astro.38.1.337; CHABRIER G, 1999, APJ, V513, P103; Fontaine G, 2001, PUBL ASTRON SOC PAC, V113, P409, DOI 10.1086/319535; Gratton RG, 2003, ASTRON ASTROPHYS, V408, P529, DOI 10.1051/0004-6361:20031003; Gustafsson M, 2003, ASTRON ASTROPHYS, V400, P1161, DOI 10.1051/0004-6361:20030100; Hansen B, 2004, PHYS REP, V399, P1, DOI 10.1016/j.physrep.2004.07.001; Hansen BMS, 1999, ASTROPHYS J, V520, P680, DOI 10.1086/307476; Hansen BMS, 2004, ASTROPHYS J SUPPL S, V155, P551, DOI 10.1086/424832; Hansen BMS, 1998, NATURE, V394, P860, DOI 10.1038/29710; Harris HC, 1999, ASTROPHYS J, V524, P1000, DOI 10.1086/307856; Hodgkin ST, 2000, NATURE, V403, P57, DOI 10.1038/47431; King IR, 1998, ASTROPHYS J, V492, pL37, DOI 10.1086/311082; Leggett SK, 1998, ASTROPHYS J, V509, P836, DOI 10.1086/306517; Lepine S, 2004, ASTROPHYS J, V602, pL125, DOI 10.1086/382732; Oppenheimer BR, 2001, ASTROPHYS J, V550, P448, DOI 10.1086/319718; Reid IN, 1998, ASTRON J, V116, P2929, DOI 10.1086/300653; Saumon D, 1999, ASTROPHYS J, V511, pL107, DOI 10.1086/311851; Spergel DN, 2003, ASTROPHYS J SUPPL S, V148, P175, DOI 10.1086/377226; ZHENG CG, 1995, ASTROPHYS J, V441, P960, DOI 10.1086/175415	24	51	51	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 18	2006	313	5789					936	940		10.1126/science.1130691	http://dx.doi.org/10.1126/science.1130691			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	074MR	16917054	Green Submitted			2022-12-28	WOS:000239817000034
J	Drenth, JPH; van der Meer, JWM				Drenth, Joost P. H.; van der Meer, Jos W. M.			The inflammasome - A linebacker of innate defense	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MUTATIONS; ACTIVATE; CIAS1		Radboud Univ Med Ctr, Dept Gastroenterol, Nijmegen, Netherlands; Radboud Univ Med Ctr, Dept Hepatol, Nijmegen, Netherlands; Radboud Univ Med Ctr, Dept Gen Internal Med, Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen	Drenth, JPH (corresponding author), Radboud Univ Med Ctr, Dept Gastroenterol, Nijmegen, Netherlands.		van der Meer, Jos W.M./C-8521-2013; Drenth, J.P.H./H-8025-2014; Drenth, Joost/V-7436-2019	van der Meer, Jos W.M./0000-0001-5120-3690; 				Aksentijevich I, 2002, ARTHRITIS RHEUM-US, V46, P3340, DOI 10.1002/art.10688; Feldmann J, 2002, AM J HUM GENET, V71, P198, DOI 10.1086/341357; Hoffman HM, 2001, NAT GENET, V29, P301, DOI 10.1038/ng756; Kanneganti TD, 2006, NATURE, V440, P233, DOI 10.1038/nature04517; Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515; Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516	6	89	100	1	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 17	2006	355	7					730	732		10.1056/NEJMcibr063500	http://dx.doi.org/10.1056/NEJMcibr063500			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	074AN	16914711	Green Published			2022-12-28	WOS:000239784500015
J	Sisk, JE; Hebert, PL; Horowitz, CR; McLaughlin, MA; Wang, JJ; Chassin, MR				Sisk, Jane E.; Hebert, Paul L.; Horowitz, Carol R.; McLaughlin, Mary Ann; Wang, Jason J.; Chassin, Mark R.			Effects of nurse management on the quality of heart failure care in minority communities - A randomized trial	ANNALS OF INTERNAL MEDICINE			English	Article							DISEASE MANAGEMENT; ELDERLY-PATIENTS; CLINICAL-TRIAL; HIGH-RISK; STRATEGIES; OUTCOMES; READMISSION; PERFORMANCE; IMPUTATION; SURVIVAL	Background: Despite therapies proven effective for heart failure with systolic dysfunction, the condition continues to cause substantial hospitalization, disability, and death, especially among African-American and other nonwhite populations. Objective: To compare the effects of a nurse-led intervention focused on specific management problems versus usual care among ethnically diverse patients with systolic dysfunction in ambulatory care practices. Design: Randomized effectiveness trial conducted from September 2000 to September 2002. Setting: The 4 hospitals in Harlem, New York. Patients: 406 adults (45.8% were non-Hispanic black adults, 32.5% were Hispanic adults, 46.3% were women, and 36.7% were >= 65 years of age) who met eligibility criteria: systolic dysfunction, English- or Spanish-language speakers, community-dwelling patients, and ambulatory care practice patients. Intervention: During a 12-month intervention, bilingual nurses counseled patients on diet, medication adherence, and self-management of symptoms through an initial visit and regularly scheduled follow-up telephone calls and facilitated evidence-based changes to medicabons in discussions with patients' clinicians. Measurements: Hospitalizations (in 406 of 406 patients during follow-up) and self-reported functioning (in 286 of 406 patients during follow-up) at 12 months. Results: At 12 months, nurse management patients had had fewer hospitalizations (143 hospitalizations vs. 180 hospitalizations; adjusted difference, -0.13 hospitalization/ person-year [95% CI, -0.25 to -0.001 hospitalization/person-year]) than usual care patients. They also had better functioning: The Short Form-12 physical component score was 39.9 versus 36.3, respectively (difference, 3.6 [CI, 1.2 to 6.11), and the Minnesota Living with Heart Failure Questionnaire score was 38.6 versus 47.3, respectively (difference, -8.8 [CI, -15.3 to -2.2]). Through 12 months, 22 deaths occurred in each group and percentages of patients who were hospitalized at least once were similar in each group (30.5% of nurse management patients vs. 36.5% of control patients; adjusted difference, -7.1 percentage points [CI, -16.9 to 2.6 percentage points]). Limitations: Three nurses at 4 hospitals delivered interventions in this modest-sized trial, and 75% of the participants were from 1 site. It is not clear which aspects of the complex intervention accounted for the results. Conclusions: Nurse management can improve functioning and modestly lower hospitalizations in ethnically diverse ambulatory care patients who have heart failure with systolic dysfunction. Sustaining improved functioning may require continuing nurse contact.	Ctr Dis Control & Prevent, Div Hlth Care Stat, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA	Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	Sisk, JE (corresponding author), Ctr Dis Control & Prevent, Div Hlth Care Stat, Natl Ctr Hlth Stat, Room 3418,331 Toledo Rd, Hyattsville, MD 20782 USA.	jsisk@cdc.gov	Wang, Jason/AAG-8248-2019		AHRQ HHS [R01 HS010402, R01 HS 10402] Funding Source: Medline; NIMHD NIH HHS [P60 MD000270] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS010402] Funding Source: NIH RePORTER; NATIONAL CENTER ON MINORITY HEALTH AND HEALTH DISPARITIES [P60MD000270] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIMHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CENTER ON MINORITY HEALTH AND HEALTH DISPARITIES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))		*AG HLTH CAR POL R, 1994, CONS GUID AG HLTH CA, V11; American Heart Association, 2005, HEART DIS STROKE STA; Ansari M, 2003, CIRCULATION, V107, P2799, DOI 10.1161/01.CIR.0000070952.08969.5B; Baker DW, 1999, PATIENT EDUC COUNS, V38, P33, DOI 10.1016/S0738-3991(98)00116-5; Benatar D, 2003, ARCH INTERN MED, V163, P347, DOI 10.1001/archinte.163.3.347; Bennett SJ, 2003, NURS RES, V52, P207, DOI 10.1097/00006199-200307000-00001; BILLINGS J, 1993, HEALTH AFFAIR, V12, P162, DOI 10.1377/hlthaff.12.1.162; BILLINGS J, 1993, FINDINGS AMBULATORY; CHARLSON M, 1994, J CLIN EPIDEMIOL, V47, P1389, DOI 10.1016/0895-4356(94)90083-3; DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700; DeBusk RF, 2004, ANN INTERN MED, V141, P606, DOI 10.7326/0003-4819-141-8-200410190-00008; Diggle P., 2002, ANAL LONGITUDINAL DA, DOI DOI 10.2307/2983303; Fonarow GC, 2004, CIRCULATION, V110, P3506, DOI 10.1161/01.CIR.0000151101.17629.20; Galbreath AD, 2004, CIRCULATION, V110, P3518, DOI 10.1161/01.CIR.0000148957.62328.89; GILLUM RF, 1987, AM HEART J, V113, P1043, DOI 10.1016/0002-8703(87)90077-9; Hogan JW, 2004, STAT MED, V23, P1455, DOI 10.1002/sim.1728; Horowitz CR, 2004, SOC SCI MED, V58, P631, DOI 10.1016/S0277-9536(03)00232-6; Hunt Sharon Ann, 2005, J Am Coll Cardiol, V46, pe1, DOI 10.1016/j.jacc.2005.08.022; *ISL PEER REV ORG, 1996, QUAL IMPR STUD CONG; Kasper EK, 2002, J AM COLL CARDIOL, V39, P471, DOI 10.1016/S0735-1097(01)01761-2; KONSTAM M, 1994, CLIN PRACTICE GUIDEL, V11; Kozak LJ, 2001, HEALTH AFFAIR, V20, P225, DOI 10.1377/hlthaff.20.2.225; Liu HH, 2005, HEALTH SERV RES, V40, P905, DOI 10.1111/j.1475-6773.2005.00391.x; McAlister FA, 2004, J AM COLL CARDIOL, V44, P810, DOI 10.1016/j.jacc.2004.05.055; Miller RH, 2002, HEALTH AFFAIR, V21, P63, DOI 10.1377/hlthaff.21.4.63; NAYLOR M, 1994, ANN INTERN MED, V120, P999, DOI 10.7326/0003-4819-120-12-199406150-00005; Naylor MD, 1999, JAMA-J AM MED ASSOC, V281, P613, DOI 10.1001/jama.281.7.613; Newman J, 1997, ARCH INTERN MED, V157, P1103; OXMAN AD, 1995, CAN MED ASSOC J, V153, P1423; Packer M, 1999, AM J CARDIOL, V83, p1A; Philbin EF, 1996, JOINT COMM J QUAL IM, V22, P721, DOI 10.1016/S1070-3241(16)30278-4; Phillips CO, 2004, JAMA-J AM MED ASSOC, V291, P1358, DOI 10.1001/jama.291.11.1358; Pugh LC., 2001, MEDSURG NURS, V10, P71; RETCHIN SM, 1991, AM J MED, V90, P236; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; Stafford RS, 2003, HEALTH SERV RES, V38, P595, DOI 10.1111/1475-6773.00135; Van Buuren S, 1999, STAT MED, V18, P681, DOI 10.1002/(SICI)1097-0258(19990330)18:6<681::AID-SIM71>3.0.CO;2-R; Wagner EH, 2004, ANN INTERN MED, V141, P644, DOI 10.7326/0003-4819-141-8-200410190-00015; Weinberger M, 1996, NEW ENGL J MED, V334, P1441, DOI 10.1056/NEJM199605303342206; West JA, 1997, AM J CARDIOL, V79, P58, DOI 10.1016/S0002-9149(96)00676-5	40	112	114	0	17	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	2006	145	4					273	283		10.7326/0003-4819-145-4-200608150-00007	http://dx.doi.org/10.7326/0003-4819-145-4-200608150-00007			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	075CC	16908918	Green Accepted			2022-12-28	WOS:000239858800005
J	Alerstam, T				Alerstam, Thomas			Conflicting evidence about long-distance animal navigation	SCIENCE			English	Editorial Material							SEA-TURTLES; BIRD NAVIGATION; MIGRATION; ORIENTATION; MAGNETORECEPTION; MIGRANTS; CUES; INFORMATION; ALBATROSSES; MECHANISM	Because of conflicting evidence about several fundamental issues, long-distance animal navigation has yet to be satisfactorily explained. Among the unsolved problems are the nature of genetic spatial control of migration and the relationships between celestial and magnetic compass mechanisms and between different map-related cues in orientation and homing, respectively. In addition, navigation is expected to differ between animal groups depending on sensory capabilities and ecological conditions. Evaluations based on modern long-term tracking techniques of the geometry of migration routes and individual migration history, combined with behavioral experiments and exploration of the sensory and genetic mechanisms, will be crucial for understanding the spatial principles that guide animals on their global journeys.	Lund Univ, Dept Anim Ecol, SE-22362 Lund, Sweden	Lund University	Alerstam, T (corresponding author), Lund Univ, Dept Anim Ecol, Ecol Bldg, SE-22362 Lund, Sweden.	thomas.alerstam@ekol.lu.se						Alerstam T, 2006, ANIM BEHAV, V71, P555, DOI 10.1016/j.anbehav.2005.05.016; Alerstam T, 2001, SCIENCE, V291, P300, DOI 10.1126/science.291.5502.300; Bearhop S, 2005, SCIENCE, V310, P502, DOI 10.1126/science.1115661; Benhamou S, 2003, ANIM BEHAV, V65, P729, DOI 10.1006/anbe.2003.2092; Block BA, 2005, NATURE, V434, P1121, DOI 10.1038/nature03463; Bohning-Gaese K, 1998, EVOL ECOL, V12, P767, DOI 10.1023/A:1006538414645; Boles LC, 2003, NATURE, V421, P60, DOI 10.1038/nature01226; Bonadonna F, 2005, P ROY SOC B-BIOL SCI, V272, P489, DOI 10.1098/rspb.2004.2984; Chernetsov N, 2004, J EXP BIOL, V207, P937, DOI 10.1242/jeb.00853; Cochran WW, 2004, SCIENCE, V304, P405, DOI 10.1126/science.1095844; Croxall JP, 2005, SCIENCE, V307, P249, DOI 10.1126/science.1106042; Emlen S. T., 1975, AVIAN BIOL, VV, P129; Fischer JH, 2001, ANIM BEHAV, V62, P1, DOI 10.1006/anbe.2000.1722; Fransson T, 2005, J AVIAN BIOL, V36, P6, DOI 10.1111/j.0908-8857.2005.03471.x; Fransson T, 2001, NATURE, V414, P35, DOI 10.1038/35102115; GRINNELL JOSEPH, 1931, AUK, V48, P22; Hays GC, 2003, P ROY SOC B-BIOL SCI, V270, pS5, DOI 10.1098/rsbl.2003.0022; Hunter E, 2003, P ROY SOC B-BIOL SCI, V270, P2097, DOI 10.1098/rspb.2003.2473; Johnsen S, 2005, NAT REV NEUROSCI, V6, P703, DOI 10.1038/nrn1745; Lohmann KJ, 2001, SCIENCE, V294, P364, DOI 10.1126/science.1064557; Lohmann KJ, 2004, NATURE, V428, P909, DOI 10.1038/428909a; Luschi P, 2003, MAR BIOL, V143, P793, DOI 10.1007/s00227-003-1117-5; Luschi P, 2001, BEHAV ECOL SOCIOBIOL, V50, P528, DOI 10.1007/s002650100396; Mettke-Hofmann C, 2003, P NATL ACAD SCI USA, V100, P5863, DOI 10.1073/pnas.1037505100; Mouritsen H, 2000, J THEOR BIOL, V207, P283, DOI 10.1006/jtbi.2000.2171; Mouritsen H, 2005, CURR OPIN NEUROBIOL, V15, P406, DOI 10.1016/j.conb.2005.06.003; Mouritsen H, 2003, J EXP BIOL, V206, P4155, DOI 10.1242/jeb.00650; Muheim R, 2006, J EXP BIOL, V209, P2, DOI 10.1242/jeb.01960; Nevitt GA, 2005, BIOL LETT-UK, V1, P303, DOI 10.1098/rsbl.2005.0350; Papi F, 2000, J EXP BIOL, V203, P3435; Sol D, 2005, P ROY SOC B-BIOL SCI, V272, P1433, DOI 10.1098/rspb.2005.3099; Sutherland WJ, 1998, J AVIAN BIOL, V29, P441, DOI 10.2307/3677163; Thorup K, 2003, P ROY SOC B-BIOL SCI, V270, pS8, DOI 10.1098/rsbl.2003.0014; Thorup K, 2001, J AVIAN BIOL, V32, P111, DOI 10.1034/j.1600-048X.2001.320203.x; THORUP K, IN PRESS ANIM BEHAV; Wallraff HG., 2005, AVIAN NAVIGATION PIG; Wiltschko R., 1995, TIEROSYCHOL; Wiltschko W, 2005, J COMP PHYSIOL A, V191, P675, DOI 10.1007/s00359-005-0627-7	38	131	135	5	113	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 11	2006	313	5788					791	794		10.1126/science.1129048	http://dx.doi.org/10.1126/science.1129048			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	072KC	16902128				2022-12-28	WOS:000239671300046
J	Montell, DJ				Montell, Denise J.			A kinase gets caspases into shape	CELL			English	Editorial Material							DROSOPHILA; DIFFERENTIATION	Two new papers (Kuranaga et al., 2006; Oshima et al., 2006) describe a previously uncharacterized Drosophila kinase (DmIKKE) that regulates the abundance of DIAP1, a protein best known for its ability to inhibit apoptosis. However, DmIKK epsilon-mediated degradation of DIAP1 does not regulate apoptosis as might be predicted but instead regulates actin dynamics, cell morphology, and the differentiation of sensory organ precursor cells.	Johns Hopkins Univ, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University	Montell, DJ (corresponding author), Johns Hopkins Univ, Dept Biol Chem, Baltimore, MD 21205 USA.	dmontell@jhmi.edu						Arama E, 2003, DEV CELL, V4, P687, DOI 10.1016/S1534-5807(03)00120-5; Cashio P, 2005, SEMIN CELL DEV BIOL, V16, P225, DOI 10.1016/j.semcdb.2005.01.002; Geisbrecht ER, 2004, CELL, V118, P111, DOI 10.1016/j.cell.2004.06.020; Kanuka H, 2005, EMBO J, V24, P3793, DOI 10.1038/sj.emboj.7600822; KURANAGA E, 2006, CELL; Launay S, 2005, ONCOGENE, V24, P5137, DOI 10.1038/sj.onc.1208524; OSHIMA K, 2006, IN PRESS CURR BIOL; Schwerk C, 2003, BIOCHEM PHARMACOL, V66, P1453, DOI 10.1016/S0006-2952(03)00497-0; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109	9	6	6	1	3	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 11	2006	126	3					450	452		10.1016/j.cell.2006.07.017	http://dx.doi.org/10.1016/j.cell.2006.07.017			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	075KI	16901779	Bronze			2022-12-28	WOS:000239883400006
J	Harris, NS				Harris, N. Stuart			A woman with hypotension after an overdose of amlodipine - Massive overdose of amlodipine (calcium-channel blocker)	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							INTENSIVE INSULIN THERAPY; VERAPAMIL OVERDOSE; NIFEDIPINE; DILTIAZEM; TOXICITY; ANTAGONISTS; GLUCAGON; AMRINONE		Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Surg, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University	Harris, NS (corresponding author), Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.							Barceloux D, 1997, J Toxicol Clin Toxicol, V35, P743; Bower JO, 1936, J AMER MED ASSOC, V106, P1151, DOI 10.1001/jama.1936.02770140013004; Boyer EW, 2002, PEDIATR EMERG CARE, V18, P36, DOI 10.1097/00006565-200202000-00012; Boyer EW, 2001, NEW ENGL J MED, V344, P1721, DOI 10.1056/NEJM200105313442215; Brunton L.B., 2005, GOODMAN GILMANS PHAR, V11th ed; BUCKLEY N, 1993, MED J AUSTRALIA, V158, P202, DOI 10.5694/j.1326-5377.1993.tb121705.x; BUCKLEY N, 1994, BRIT MED J, V308, P1639, DOI 10.1136/bmj.308.6944.1639; Chyka P A, 1997, J Toxicol Clin Toxicol, V35, P721; DEVIS G, 1975, DIABETES, V24, P547, DOI 10.2337/diab.24.6.547; ERICKSON F C, 1991, Journal of Emergency Medicine, V9, P357, DOI 10.1016/0736-4679(91)90380-X; FARAH AE, 1981, LIFE SCI, V29, P975, DOI 10.1016/0024-3205(81)90457-4; FRIERSON J, 1991, CLIN CARDIOL, V14, P933, DOI 10.1002/clc.4960141114; HENDREN WG, 1989, ANN EMERG MED, V18, P984, DOI 10.1016/S0196-0644(89)80465-2; Hockerman GH, 1997, ANNU REV PHARMACOL, V37, P361, DOI 10.1146/annurev.pharmtox.37.1.361; HOLLINGSHEAD LM, 1992, DRUGS, V44, P835, DOI 10.2165/00003495-199244050-00009; HOWARTH DM, 1994, HUM EXP TOXICOL, V13, P161, DOI 10.1177/096032719401300304; KATZ AM, 1993, NEW ENGL J MED, V328, P1244; KAWAI C, 1981, CIRCULATION, V63, P1035, DOI 10.1161/01.CIR.63.5.1035; KENNY J, 1994, BRIT MED J, V308, P992, DOI 10.1136/bmj.308.6935.992; KISSLING G, 1988, EUR HEART J, V9, P800, DOI 10.1093/eurheartj/9.7.800; Kline JA, 1997, TOXICOL APPL PHARM, V145, P357, DOI 10.1006/taap.1997.8195; KLINE JA, 1995, CRIT CARE MED, V23, P1251, DOI 10.1097/00003246-199507000-00016; Krenzelok E, 1997, J TOXICOL-CLIN TOXIC, V35, P695; ORR GM, 1982, LANCET, V2, P1218; PEARIGEN PD, 1991, DRUG SAFETY, V6, P408, DOI 10.2165/00002018-199106060-00003; QUEZADO Z, 1991, CRIT CARE MED, V19, P436, DOI 10.1097/00003246-199103000-00028; RAMOSKA EA, 1993, ANN EMERG MED, V22, P196, DOI 10.1016/S0196-0644(05)80202-1; RAMOSKA EA, 1990, ANN EMERG MED, V19, P649, DOI 10.1016/S0196-0644(05)82469-2; Romano G, 2002, J ANAL TOXICOL, V26, P374, DOI 10.1093/jat/26.6.374; Salhanick SD, 2003, DRUG SAFETY, V26, P65, DOI 10.2165/00002018-200326020-00001; Van den Berghe G, 2006, NEW ENGL J MED, V354, P449, DOI 10.1056/NEJMoa052521; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; WALTER FG, 1993, ANN EMERG MED, V22, P1234, DOI 10.1016/S0196-0644(05)80998-9; WATLING SM, 1992, ANN PHARMACOTHER, V26, P1373, DOI 10.1177/106002809202601106; Watson WA, 2005, AM J EMERG MED, V23, P589, DOI 10.1016/j.ajem.2005.05.001; WOLF LR, 1993, ANN EMERG MED, V22, P1225, DOI 10.1016/S0196-0644(05)80996-5; Yuan TH, 1999, J TOXICOL-CLIN TOXIC, V37, P463, DOI 10.1081/CLT-100102437	37	35	38	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 10	2006	355	6					602	611		10.1056/NEJMcpc069016	http://dx.doi.org/10.1056/NEJMcpc069016			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	071QM	16899781				2022-12-28	WOS:000239616700012
J	Bhutta, ZA				Bhutta, Zulfiqar A.			What does absorption capacity not measure?	LANCET			English	Editorial Material							GLOBAL FUND; HEALTH; MALARIA		Aga Khan Univ, Dept Paediat & Child Hlth, Karachi 74800, Pakistan	Aga Khan University	Bhutta, ZA (corresponding author), Aga Khan Univ, Dept Paediat & Child Hlth, Karachi 74800, Pakistan.	zulfiqar.bhutta@aku.edu						Attaran A, 2004, LANCET, V363, P237, DOI 10.1016/S0140-6736(03)15330-5; BURNSIDE C, 1997, 1777 WORLD BANK POL; *CTR ARMS CONTR NO, US MIL SPEND VERS WO; Ensor T, 2004, HEALTH POLICY PLANN, V19, P69, DOI 10.1093/heapol/czh009; Filmer D, 1999, SOC SCI MED, V49, P1309, DOI 10.1016/S0277-9536(99)00150-1; Gupta S, 2004, HELPING COUNTRIES DEVELOP: THE ROLE OF FISCAL POLICY, P385; Hargreaves S, 2002, LANCET, V359, P2030, DOI 10.1016/S0140-6736(02)08826-8; Kaufmann D., 2005, POLICY RES WORKING P; Lambsdorff J.G., 2005, METHODOLOGY 2005 COR; Lu C, 2006, LANCET, V368, P483, DOI 10.1016/S0140-6736(06)69156-3; Schieber G, 2006, DISEASE CONTROL PRIORITIES IN DEVELOPING COUNTRIES, 2ND EDITION, P225; TANDON A, 2005, 35 ERD AS DEV BANK; World Health Organization (WHO), 2006, STAT INF SYST	13	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 5	2006	368	9534					428	430		10.1016/S0140-6736(06)69129-0	http://dx.doi.org/10.1016/S0140-6736(06)69129-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	071AL	16890811				2022-12-28	WOS:000239569000006
J	Luzuriaga, K; Newell, ML; Dabis, F; Excler, JL; Sullivan, JL				Luzuriaga, Katherine; Newell, Marie-Louise; Dabis, Francois; Excler, Jean-Louis; Sullivan, John L.			Vaccines to prevent transmission of HIV-1 via breastmilk: scientific and logistical priorities	LANCET			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; TO-CHILD TRANSMISSION; VERTICALLY INFECTED INFANTS; DEPENDENT CELLULAR CYTOTOXICITY; POLYMERASE CHAIN-REACTION; IMMUNE-RESPONSES; LYMPHOCYTE RESPONSES; RHESUS MACAQUES; HIV-1-INFECTED CHILDREN; ANTIRETROVIRAL THERAPY	Mother-to-child transmission (MTCT) of HIV-1 is the major mode of paediatric infection. The rapidly increasing incidence of MTCT worldwide has resulted in an urgent need for preventive strategies. Antiretroviral regimens can prevent intrapartum HIV transmission; however, these regimens do not prevent HIV transmission through breastfeeding. Furthermore, children who escape MTCT are again at risk of infection when they become sexually active as adolescents. An infant vaccine regimen, begun at birth, would hence be a more attractive strategy and might also provide the basis for lifetime protection. Unique features of MTCT and paediatric HIV disease could be helpful in understanding correlates of immune protection and could facilitate rapid assessment of vaccine efficacy. Thus, there is compelling rationale to develop safe, effective HIV vaccines for use in infants and children., Here, we discuss the scientific and logistical challenges for the development of paediatric HIV vaccines; available vaccines and completed or planned paediatric vaccine trials are also discussed.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Inst Child Hlth, Ctr Paediat Epidemiol, London, England; Univ Victor Segalen, INSERM, U593, Inst Sante Publ Epidemiol & Dev, Bordeaux, France; Int AIDS Vaccine Initiat, New Delhi, India	University of Massachusetts System; University of Massachusetts Worcester; University of London; University College London; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; International AIDS Vaccine Initiative	Luzuriaga, K (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, 373 Plantat St,Suite 318, Worcester, MA 01605 USA.	katherine.luzuriaga@umassmed.edu	Newell, Marie-Louise/AAE-8222-2019; DABIS, FRANCOIS/S-9298-2019	Newell, Marie-Louise/0000-0002-1074-7699; DABIS, FRANCOIS/0000-0002-1614-8857	NIAID NIH HHS [R01 AI032391] Funding Source: Medline; NICHD NIH HHS [K24 HD01489] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K24HD001489] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032391] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abrams EJ, 1998, J INFECT DIS, V178, P101, DOI 10.1086/515596; Alioum A, 2003, AM J EPIDEMIOL, V158, P596, DOI 10.1093/aje/kwg188; Alonso PL, 2004, LANCET, V364, P1411, DOI 10.1016/S0140-6736(04)17223-1; Amara RR, 2002, VACCINE, V20, P1949, DOI 10.1016/S0264-410X(02)00076-2; Amara RR, 2002, J VIROL, V76, P7625, DOI 10.1128/JVI.76.15.7625-7631.2002; Baba TW, 1999, NAT MED, V5, P590, DOI 10.1038/8859; Borkowsky W, 2000, J INFECT DIS, V181, P890, DOI 10.1086/315298; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; Bulterys M, 2004, J INFECT DIS, V189, P2149, DOI 10.1086/420835; Buseyne F, 2005, J IMMUNOL METHODS, V298, P105, DOI 10.1016/j.jim.2005.01.003; Casimiro DR, 2005, J VIROL, V79, P15547, DOI 10.1128/JVI.79.24.15547-15555.2005; *COMM CLIN RES INV, 2004, ETH COND CLIN RES IN; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Cooper ER, 2002, J ACQ IMMUN DEF SYND, V29, P484, DOI 10.1097/00126334-200204150-00009; Coutsoudis A, 2004, J INFECT DIS, V189, P2154, DOI 10.1086/420834; Crowe JE, 1998, VACCINE, V16, P1423, DOI 10.1016/S0264-410X(98)00103-0; Cunningham CK, 2002, J INFECT DIS, V186, P181, DOI 10.1086/341300; Donnelly JJ, 2005, J IMMUNOL, V175, P633, DOI 10.4049/jimmunol.175.2.633; Erles K, 1999, J MED VIROL, V59, P406, DOI 10.1002/(SICI)1096-9071(199911)59:3&lt;406::AID-JMV22&gt;3.0.CO;2-N; Eshleman SH, 2001, AIDS, V15, P1951, DOI 10.1097/00002030-200110190-00006; Ferrantelli F, 2004, J INFECT DIS, V189, P2167, DOI 10.1086/420833; Flynn MN, 2005, J INFECT DIS, V191, P654, DOI 10.1086/428404; Fowler MG, 2002, J ACQ IMMUN DEF SYND, V30, P230, DOI [10.1097/00042560-200206010-00012, 10.1097/01.QAI.0000018364.28828.14]; Gaillard P, 2004, JAIDS-J ACQ IMM DEF, V35, P178, DOI 10.1097/00126334-200402010-00013; Gans HA, 1998, JAMA-J AM MED ASSOC, V280, P527, DOI 10.1001/jama.280.6.527; Garcia PM, 1999, NEW ENGL J MED, V341, P394, DOI 10.1056/NEJM199908053410602; Giaquinto C, 2005, CLIN INFECT DIS, V40, P458, DOI 10.1086/427287; GILBERT SC, 2002, 14 INT POXV IR WORKS; *GLOB HIV AIDS VAC, 2005, PLOS MED, V2, DOI UNSP 0111-21; Gortmaker SL, 2001, NEW ENGL J MED, V345, P1522, DOI 10.1056/NEJMoa011157; Goulder PJR, 2001, NATURE, V412, P334, DOI 10.1038/35085576; Gray L, 2001, PEDIATRICS, V108, P116, DOI 10.1542/peds.108.1.116; Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7; GUIMARAESWALKER A, 2004, AIDS VACC 2004 INT C; Hofmann-Lehmann R, 2003, AIDS, V17, P157, DOI 10.1097/00002030-200301240-00004; Hsu HY, 1998, PEDIATR INFECT DIS J, V17, P893, DOI 10.1097/00006454-199810000-00009; Jackson JB, 2000, AIDS, V14, pF111, DOI 10.1097/00002030-200007280-00001; JAOKO W, 2004, AIDS VACC 2004 INT C; JENKINS M, 1993, PEDIATR RES, V33, P469, DOI 10.1203/00006450-199305000-00010; Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991; John-Stewart G, 2004, JAIDS-J ACQ IMM DEF, V35, P196, DOI 10.1097/00126334-200402010-00015; Johnson DC, 2005, J INFECT DIS, V192, P2129, DOI 10.1086/498163; Johnson PR, 2005, J VIROL, V79, P955, DOI 10.1128/JVI.79.2.955-965.2005; KENNEDY J, 2005, AIDS VACC 2005 INT C; Klausner RD, 2003, SCIENCE, V300, P2036, DOI 10.1126/science.1086916; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Lohman BL, 2005, J VIROL, V79, P8121, DOI 10.1128/JVI.79.13.8121-8130.2005; Luzuriaga K, 1999, J VIROL, V73, P362, DOI 10.1128/JVI.73.1.362-367.1999; LUZURIAGA K, 1995, J IMMUNOL, V154, P433; Luzuriaga K, 1996, JAMA-J AM MED ASSOC, V275, P1360; McCurdy LH, 2004, CLIN INFECT DIS, V38, P1749, DOI 10.1086/421266; MCFARLAND E, 2005, 12 C RETR OPP INF FE; McFarland EJ, 2001, J INFECT DIS, V184, P1331, DOI 10.1086/323994; McIntosh K, 1996, PEDIATR INFECT DIS J, V15, P1087, DOI 10.1097/00006454-199612000-00006; MCMICHAEL A, 2004, AIDS VACC 2004 INT C; McShane H, 2004, NAT MED, V10, P1240, DOI 10.1038/nm1128; Miotti PG, 1999, JAMA-J AM MED ASSOC, V282, P744, DOI 10.1001/jama.282.8.744; Mofenson LM, 1997, J INFECT DIS, V175, P1029, DOI 10.1086/516441; Mofenson Lynne M, 2003, Semin Pediatr Infect Dis, V14, P295, DOI 10.1053/j.spid.2003.09.003; Moore AC, 2004, IMMUNOL REV, V199, P126, DOI 10.1111/j.0105-2896.2004.00138.x; Nduati R, 2000, JAMA-J AM MED ASSOC, V283, P1167, DOI 10.1001/jama.283.9.1167; Newell ML, 2004, LANCET, V364, P1236, DOI 10.1016/S0140-6736(04)17140-7; Otten GR, 2005, J VIROL, V79, P8189, DOI 10.1128/JVI.79.13.8189-8200.2005; Palumbo PE, 1998, JAMA-J AM MED ASSOC, V279, P756, DOI 10.1001/jama.279.10.756; PALUMBO PE, 1995, J PEDIATR-US, V126, P592, DOI 10.1016/S0022-3476(95)70357-8; Pantaleo G, 2004, NAT MED, V10, P806, DOI 10.1038/nm0804-806; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; Persaud D, 2000, J CLIN INVEST, V105, P995, DOI 10.1172/JCI9006; Pikora CA, 1997, J EXP MED, V185, P1153, DOI 10.1084/jem.185.7.1153; Pillay T, 2005, J VIROL, V79, P12100, DOI 10.1128/JVI.79.18.12100-12105.2005; Pitisuttithum P, 2005, CURR HIV RES, V3, P17, DOI 10.2174/1570162052772933; Pugatch D, 1997, J INFECT DIS, V176, P643, DOI 10.1086/514085; Richardson BA, 2003, J INFECT DIS, V187, P736, DOI 10.1086/374272; Richardson BA, 2003, J VIROL, V77, P7120, DOI 10.1128/JVI.77.12.7120-7123.2003; Rouet F, 2002, AIDS, V16, P2303, DOI 10.1097/00002030-200211220-00010; Rousseau CM, 2004, J INFECT DIS, V190, P1880, DOI 10.1086/425076; Rowland-Jones SL, 1998, J CLIN INVEST, V102, P1758, DOI 10.1172/JCI4314; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; ROWLANDJONES SL, 1993, LANCET, V341, P860, DOI 10.1016/0140-6736(93)93063-7; Ruff CT, 2002, J VIROL, V76, P9481, DOI 10.1128/JVI.76.18.9481-9492.2002; Safrit JT, 2004, JAIDS-J ACQ IMM DEF, V35, P169, DOI 10.1097/00126334-200402010-00012; Sanchez-Merino V, 2005, J IMMUNOL, V175, P6976, DOI 10.4049/jimmunol.175.10.6976; Santra S, 2005, J VIROL, V79, P6516, DOI 10.1128/JVI.79.10.6516-6522.2005; Santra S, 2004, P NATL ACAD SCI USA, V101, P11088, DOI 10.1073/pnas.0401954101; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857; Scott ZA, 2001, J IMMUNOL, V167, P7134, DOI 10.4049/jimmunol.167.12.7134; SHEARER WT, 1997, NEW ENGL J MED, V336, P1137; Shiver JW, 2004, ANNU REV MED, V55, P355, DOI 10.1146/annurev.med.55.091902.104344; Slack C, 2005, SAMJ S AFR MED J, V95, P269; Smith Dawn K., 2005, Morbidity and Mortality Weekly Report, V54, P1; Stahl-Hennig C, 1999, SCIENCE, V285, P1261, DOI 10.1126/science.285.5431.1261; Sullivan NJ, 2003, NATURE, V424, P681, DOI 10.1038/nature01876; Thorne C, 2002, J ACQ IMMUN DEF SYND, V29, P396, DOI 10.1097/00126334-200204010-00011; TOMARAS G, 2005, 12 C RETR OPP INF FE; *UNAIDS, 2004 REP GLOB AIDS E; Van Rompay KKA, 2005, JAIDS-J ACQ IMM DEF, V38, P124, DOI 10.1097/00126334-200502010-00002; Van Rompay KKA, 2002, J INFECT DIS, V186, P1508, DOI 10.1086/344360; Webster DP, 2005, P NATL ACAD SCI USA, V102, P4836, DOI 10.1073/pnas.0406381102; WEINBERG GA, 1988, J PEDIATR-US, V113, P621, DOI 10.1016/S0022-3476(88)80369-X; Weitkamp JH, 2003, J IMMUNOL, V171, P4680, DOI 10.4049/jimmunol.171.9.4680; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Yang OO, 2002, AIDS RES HUM RETROV, V18, P1051, DOI 10.1089/08892220260235416; Zhu YD, 2000, VIROLOGY, V276, P202, DOI 10.1006/viro.2000.0564	103	18	18	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 5	2006	368	9534					511	521		10.1016/S0140-6736(06)69159-9	http://dx.doi.org/10.1016/S0140-6736(06)69159-9			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	071AL	16890838				2022-12-28	WOS:000239569000034
J	Campbell, GK; Mun, J; Boyd, M; Medley, P; Leanhardt, AE; Marcassa, LG; Pritchard, DE; Ketterle, W				Campbell, Gretchen K.; Mun, Jongchul; Boyd, Micah; Medley, Patrick; Leanhardt, Aaron E.; Marcassa, Luis G.; Pritchard, David E.; Ketterle, Wolfgang			Imaging the Mott insulator shells by using atomic clock shifts	SCIENCE			English	Article							FREQUENCY-SHIFT; ULTRACOLD; SUPERFLUID	Microwave spectroscopy was used to probe the superfluid-Mott insulator transition of a Bose-Einstein condensate in a three-dimensional optical lattice. By using density-dependent transition frequency shifts, we were able to spectroscopically distinguish sites With different occupation numbers and to directly image sites With occupation numbers from one to five, revealing the shell structure of the Mott insulator phase. We used this spectroscopy to determine the onsite interaction and lifetime for individual shells.	MIT, Dept Phys, Elect Res Lab, Harvard Ctr Ultracold Atoms, Cambridge, MA 02139 USA; JILA, Boulder, CO 80309 USA; Univ Sao Paulo, Inst Fis Sao Carlos, BR-13560970 Sao Paulo, Brazil	Harvard University; Massachusetts Institute of Technology (MIT); Universidade de Sao Paulo	Campbell, GK (corresponding author), MIT, Dept Phys, Elect Res Lab, Harvard Ctr Ultracold Atoms, Cambridge, MA 02139 USA.	gcampbel@mit.edu	Campbell, Gretchen K/E-8338-2010; Marcassa, Luis/H-3158-2012	Campbell, Gretchen K/0000-0003-2596-1919; Marcassa, Luis/0000-0003-4047-8984				Batrouni GG, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.117203; Baym G, 1996, PHYS REV LETT, V76, P6, DOI 10.1103/PhysRevLett.76.6; Bloch I, 2005, NAT PHYS, V1, P23, DOI 10.1038/nphys138; Fertig C, 2000, PHYS REV LETT, V85, P1622, DOI 10.1103/PhysRevLett.85.1622; FISHER MPA, 1989, PHYS REV B, V40, P546, DOI 10.1063/1.38820; Folling S, 2005, NATURE, V434, P481, DOI 10.1038/nature03500; Gerbier F, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.090401; GIBBLE K, 1993, PHYS REV LETT, V70, P1771, DOI 10.1103/PhysRevLett.70.1771; Greiner M, 2002, NATURE, V419, P51, DOI 10.1038/nature00968; Gygi O, 2006, PHYS REV A, V73, DOI 10.1103/PhysRevA.73.063606; Harber DM, 2002, PHYS REV A, V66, DOI 10.1103/PhysRevA.66.053616; Jack MW, 2005, PHYS REV A, V72, DOI 10.1103/PhysRevA.72.063625; MARCO B, 2005, PHYS REV A, V71; Sortais Y, 2001, PHYS SCRIPTA, VT95, P50, DOI 10.1238/Physica.Topical.095a00050; Stenger J, 1999, PHYS REV LETT, V82, P4569, DOI 10.1103/PhysRevLett.82.4569; Stoferle T, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.130403; van Kempen EGM, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.093201	19	205	206	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 4	2006	313	5787					649	652		10.1126/science.1130365	http://dx.doi.org/10.1126/science.1130365			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	072IQ	16888134	Green Submitted			2022-12-28	WOS:000239667500037
J	Innanen, K				Innanen, Kimmo			Planetary science - Solving Laplace's lunar puzzle	SCIENCE			English	Editorial Material								Given its size and shape, the Moon's present orbit does not make sense. Its shape can be understood if, white the Moon was beginning to solidify, it was closer to Earth, with a more eccentric orbit.	York Univ, Dept Phys & Astron, Toronto, ON M3J 1P3, Canada	York University - Canada	Innanen, K (corresponding author), York Univ, Dept Phys & Astron, Toronto, ON M3J 1P3, Canada.	kiminn@yorku.ca						Belbruno E, 2005, ASTRON J, V129, P1724, DOI 10.1086/427539; Garrick-Bethell I, 2006, SCIENCE, V313, P652, DOI 10.1126/science.1128237; LAPLACE PS, 1798, TRAITE MECANIQUE CEL, V2, pCH2; MACKENZIE D, 2003, BIG SPLAT; Murray C. D., 1999, SOLAR SYSTEM DYNAMIC; MURRAY CD, 1998, CHAOTIC MOTION SOLAR; Valtonen M., 2006, 3 BODY PROBLEM	7	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 4	2006	313	5787					622	623		10.1126/science.1131113	http://dx.doi.org/10.1126/science.1131113			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	072IQ	16888127				2022-12-28	WOS:000239667500027
J	Mohanty, AK; Flannery, MT; Johnson, BL; Brady, PG				Mohanty, Anupam K.; Flannery, Michael T.; Johnson, Brad L.; Brady, Patrick G.			A sharp right turn	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							TOOTHPICK PERFORATION; INGESTION; INTESTINE; FISTULA; COLON		Univ S Florida, Coll Med, Dept Med, Tampa, FL 33606 USA; Univ S Florida, Coll Med, Div Vasc Surg, Tampa, FL 33606 USA; Univ S Florida, Coll Med, Div Gastroenterol, Tampa, FL 33606 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Flannery, MT (corresponding author), Univ S Florida, Coll Med, Dept Internal Med, 4 Columbia Dr,Suite 630, Tampa, FL 33606 USA.	robert_k_mohanty@yahoo.com						BEE DM, 1989, NEW ENGL J MED, V320, P673; BUDNICK LD, 1984, JAMA-J AM MED ASSOC, V252, P796, DOI 10.1001/jama.252.6.796; CALLON RA, 1990, GASTROINTEST ENDOSC, V36, P141, DOI 10.1016/S0016-5107(90)70970-4; Carp L, 1927, ANN SURG, V85, P575, DOI 10.1097/00000658-192704000-00010; COCKERILL FR, 1983, MAYO CLIN PROC, V58, P613; DICICCO BS, 1985, J CLIN GASTROENTEROL, V7, P292, DOI 10.1097/00004836-198508000-00004; Guber MD, 1996, AM J GASTROENTEROL, V91, P789; JUSTINIANI FR, 1974, JAMA-J AM MED ASSOC, V227, P788, DOI 10.1001/jama.227.7.788; Li SF, 2002, J EMERG MED, V23, P35, DOI 10.1016/S0736-4679(02)00458-4; McManus J.E., 1941, AM J SURG, V53, P393; Monkemuller KE, 1996, AM J GASTROENTEROL, V91, P2438; RANTIS PC, 1995, INT J COLORECTAL DIS, V10, P210, DOI 10.1007/BF00346221; SCHWARTZ JT, 1977, ANN SURG, V185, P64, DOI 10.1097/00000658-197701000-00010; Tenner S, 1996, AM J GASTROENTEROL, V91, P1860	14	8	9	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 3	2006	355	5					500	505		10.1056/NEJMcps052000	http://dx.doi.org/10.1056/NEJMcps052000			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	069FT	16885554				2022-12-28	WOS:000239432500011
J	Rabe, KF; Atienza, T; Magyar, P; Larsson, P; Jorup, C; Lalloo, UG				Rabe, Klaus F.; Atienza, Tito; Magyar, Pal; Larsson, Per; Jorup, Carin; Lalloo, Umesh G.			Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study	LANCET			English	Article							SINGLE INHALER; BUDESONIDE/FORMOTEROL; MAINTENANCE; SALMETEROL; SAFETY; BETA(2)-AGONIST; MEDICATION; MODERATE; NEED	Background The contributions of as-needed inhaled corticosteroids and long-acting beta 2 agonists (LABA) to asthma control have not been fully established. We compared the efficacy and safety of three reliever strategies: a traditional short-acting beta 2 agonist; a rapid-onset LABA (formoterol); and a combination of LABA and an inhaled corticosteroid (budesonide-formoterol) in symptomatic patients receiving budesonide-formoterol maintenance therapy. Methods We did a 12-month, double-blind, parallel-group study in 3394 patients (aged 12 years or older), in 289 centres in 20 countries, who were using inhaled corticosteroids at study entry and symptomatic on budesonide-formoterol (160 mu g and 4.5 mu g, respectively), one inhalation twice daily, during a 2-week run-in. After run-in, patients were randomly assigned budesonide-formoterol maintenance therapy plus one of three alternative as-needed medications-terbutaline (0.4 mg), formoterol (4.5 mu g), or budesonide-formoterol (160 mu g and 4.5 mu g). The primary outcome was time to first severe exacerbation, defined as an event resulting in hospitalisation, emergency room treatment, or both, or the need for oral steroids for 3 days or more. Findings Time to first severe exacerbation was longer with as-needed budesonide-formoterol versus formoterol (p=0.0048; log-rank test) and with as-needed formoterol versus terbutaline (p=0.0051). The rate of severe exacerbations was 37, 29, and 19 per 100 patients per year with as-needed terbutaline, formoterol, and budesonide-formoteroll respectively (rate ratios budesonide-formoterol versus formoterol 0.67 [95% CI 0.56-0.80; p<0.0001]; budesonide-formoterol versus terbutaline 0.52 [0.44-0.62; p<0.0001]; formoterol versus terbutaline 0.78 [0.67-0.91; p=0.0012]). Asthma control days increased to a similar extent in all treatment groups. As-needed formoterol did not significantly improve symptoms compared with as-needed terbutaline. All treatments were well tolerated. Interpretation Both monocomponents of budesonide-formoterol given as needed contribute to enhanced protection from severe exacerbations in patients receiving combination therapy for maintenance.	Leiden Univ, Med Ctr, Dept Pulmonol, NL-2333 ZA Leiden, Netherlands; Vet Mem Med Ctr, Dept Pulm Med, Quezon City, Philippines; Semmelweis Univ, Dept Pulmonol, Budapest, Hungary; AstraZeneca, Res & Dev, Lund, Sweden; Univ KwaZulu Natal, Nelson R Mandela Sch Med, Durban, South Africa	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Semmelweis University; AstraZeneca; University of Kwazulu Natal	Rabe, KF (corresponding author), Leiden Univ, Med Ctr, Dept Pulmonol, C3-P,Albinusdreef 2, NL-2333 ZA Leiden, Netherlands.	K.F.Rabe@lumc.nl	Rabe, Klaus F./AAW-6296-2021	Rabe, Klaus F./0000-0002-7020-1401				Angus R, 2005, INT J CLIN PRACT, V59, P156, DOI 10.1111/j.1742-1241.2005.00455.x; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; BISGAARD H, IN PRESS CHEST; Currie GP, 2003, QJM-INT J MED, V96, P435, DOI 10.1093/qjmed/hcg071; FitzGerald JM, 2004, THORAX, V59, P550, DOI 10.1136/thx.2003.014936; Foresi A, 2000, CHEST, V117, P440, DOI 10.1378/chest.117.2.440; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; Harrison TW, 2004, LANCET, V363, P271, DOI 10.1016/S0140-6736(03)15384-6; Juniper EF, 2001, RESP MED, V95, P319, DOI 10.1053/rmed.2001.1034; Maneechotesuwan K, 2005, CHEST, V128, P1936, DOI 10.1378/chest.128.4.1936; Martinez FD, 2005, NEW ENGL J MED, V353, P2637, DOI 10.1056/NEJMp058299; Miller-Larsson A, 1998, DRUG METAB DISPOS, V26, P623; Nelson HS, 2006, CHEST, V129, P15, DOI 10.1378/chest.129.1.15; O'Byrne PM, 2001, AM J RESP CRIT CARE, V164, P1392, DOI 10.1164/ajrccm.164.8.2104102; O'Byrne PM, 2005, AM J RESP CRIT CARE, V171, P129, DOI 10.1164/rccm.200407-884OC; OBYRNE PM, 2005, AM J RESP CRIT CAR S, V171; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Pauwels RA, 2003, EUR RESPIR J, V22, P787, DOI 10.1183/09031936.03.00055803; Rabe KF, 2006, CHEST, V129, P246, DOI 10.1378/chest.129.2.246; Scicchitano R, 2004, CURR MED RES OPIN, V20, P1403, DOI 10.1185/030079904X2051; Seberova E, 2000, RESP MED, V94, P607, DOI 10.1053/rmed.2000.0788; Shrewsbury S, 2000, BMJ-BRIT MED J, V320, P1368, DOI 10.1136/bmj.320.7246.1368; Sin DD, 2004, JAMA-J AM MED ASSOC, V292, P367, DOI 10.1001/jama.292.3.367; SUISSA S, 1994, AM J RESP CRIT CARE, V149, P604, DOI 10.1164/ajrccm.149.3.8118625; Tattersfield AE, 2001, LANCET, V357, P257, DOI 10.1016/S0140-6736(00)03611-4; TOOGOOD JH, 1982, J ALLERGY CLIN IMMUN, V70, P288, DOI 10.1016/0091-6749(82)90065-3; VANDERMOLEN T, 2005, EUR RESPIR J, V26, P49; Vogelmeier C, 2005, EUR RESPIR J, V26, P819, DOI 10.1183/09031936.05.00028305; Wark PAB, 2002, EUR RESPIR J, V19, P68, DOI 10.1183/09031936.02.00226302; Wedzicha JA, 2003, THORAX, V58, P1, DOI 10.1136/thorax.58.1.1; Wilding P, 1997, BRIT MED J, V314, P1441, DOI 10.1136/bmj.314.7092.1441	32	287	303	0	20	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG-SEP	2006	368	9537					744	753		10.1016/S0140-6736(06)69284-2	http://dx.doi.org/10.1016/S0140-6736(06)69284-2			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	080ID	16935685				2022-12-28	WOS:000240240200026
J	Cash, HL; Whitham, CV; Behrendt, CL; Hooper, LV				Cash, Heather L.; Whitham, Cecilia V.; Behrendt, Cassie L.; Hooper, Lora V.			Symbiotic bacteria direct expression of an intestinal bactericidal lectin	SCIENCE			English	Article							INFLAMMATORY-BOWEL-DISEASE; MANNOSE-BINDING LECTIN; ALPHA-DEFENSINS; PEPTIDOGLYCAN; PANETH; FAMILY; RESPONSES; PROTEINS; HIP/PAP; CELLS	The mammalian intestine harbors complex societies of beneficial bacteria that are maintained in the lumen with minimal penetration of mucosal surfaces. Microbial colonization of germ-free mice triggers epithelial expression of RegIII gamma, a secreted C-type lectin. RegIII gamma binds intestinal bacteria but lacks the complement recruitment domains present in other microbe-binding mammalian C-type lectins. We show that RegIII gamma and its human counterpart, HIP/PAP, are directly antimicrobial proteins that bind their bacterial targets via interactions with peptidoglycan carbohydrate. We propose that these proteins represent an evolutionarily primitive form of lectin-mediated innate immunity, and that they reveal intestinal strategies for maintaining symbiotic host-microbial relationships.	Univ Texas, SW Med Ctr, Ctr Immunol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Microbiol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Hooper, LV (corresponding author), Univ Texas, SW Med Ctr, Ctr Immunol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Lora.Hooper@UTSouthwestern.edu	Eckhardt, Erik/G-1567-2010		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK070855] Funding Source: NIH RePORTER; NIAID NIH HHS [T32-AI007520] Funding Source: Medline; NIDDK NIH HHS [R01 DK070855, R01 DK070855-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ayabe T, 2000, NAT IMMUNOL, V1, P113, DOI 10.1038/77783; Cash HL, 2006, PROTEIN EXPRES PURIF, V48, P151, DOI 10.1016/j.pep.2006.01.014; Christa L, 1996, AM J PHYSIOL-GASTR L, V271, pG993, DOI 10.1152/ajpgi.1996.271.6.G993; Dieckgraefe BK, 2002, J INVEST MED, V50, P421, DOI 10.1136/jim-50-06-02; Dodd RB, 2001, GLYCOBIOLOGY, V11, p71R, DOI 10.1093/glycob/11.5.71R; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; Drickamer K, 1999, GLYCOBIOLOGY, V9, P1357, DOI 10.1093/glycob/9.12.1357; Dziarski R, 1998, J BIOL CHEM, V273, P8680, DOI 10.1074/jbc.273.15.8680; Eckburg PB, 2005, SCIENCE, V308, P1635, DOI 10.1126/science.1110591; Ezekowitz RA, 2003, J INFECT DIS, V187, pS335, DOI 10.1086/374746; Harder J, 2001, J BIOL CHEM, V276, P5707, DOI 10.1074/jbc.M008557200; Holm C, 2003, APPL ENVIRON MICROB, V69, P2857, DOI 10.1128/AEM.69.5.2857-2863.2003; Hooper LV, 2002, ANNU REV NUTR, V22, P283, DOI 10.1146/annurev.nutr.22.011602.092259; Liu C, 2000, J BIOL CHEM, V275, P24490, DOI 10.1074/jbc.M001239200; Livesey FJ, 1997, NATURE, V390, P614, DOI 10.1038/37615; Macpherson AJ, 2000, SCIENCE, V288, P2222, DOI 10.1126/science.288.5474.2222; Miyashita H, 1995, FEBS LETT, V377, P429, DOI 10.1016/0014-5793(95)01381-4; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Nadesalingam J, 2005, J IMMUNOL, V175, P1785, DOI 10.4049/jimmunol.175.3.1785; Ogawa H, 2003, INFLAMM BOWEL DIS, V9, P162, DOI 10.1097/00054725-200305000-00003; Porter EM, 1997, INFECT IMMUN, V65, P2396, DOI 10.1128/IAI.65.6.2396-2401.1997; Pull SL, 2005, P NATL ACAD SCI USA, V102, P99, DOI 10.1073/pnas.0405979102; Swidsinski A, 2002, GASTROENTEROLOGY, V122, P44, DOI 10.1053/gast.2002.30294; Syder AJ, 2003, P NATL ACAD SCI USA, V100, P3467, DOI 10.1073/pnas.0230380100; Wehkamp J, 2005, P NATL ACAD SCI USA, V102, P18129, DOI 10.1073/pnas.0505256102; Wehkamp J, 2004, GUT, V53, P1658, DOI 10.1136/gut.2003.032805; Werner T, 2000, P NATL ACAD SCI USA, V97, P13772, DOI 10.1073/pnas.97.25.13772	27	986	1037	7	125	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 25	2006	313	5790					1126	1130		10.1126/science.1127119	http://dx.doi.org/10.1126/science.1127119			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	076ZT	16931762	Green Accepted, Green Submitted			2022-12-28	WOS:000239998200048
J	Ohki, K; Chung, SY; Kara, P; Hubener, M; Bonhoeffer, T; Reid, RC				Ohki, Kenichi; Chung, Sooyoung; Kara, Prakash; Huebener, Mark; Bonhoeffer, Tobias; Reid, R. Clay			Highly ordered arrangement of single neurons in orientation pinwheels	NATURE			English	Article							MONKEY STRIATE CORTEX; PRIMARY VISUAL-CORTEX; IN-VIVO; FUNCTIONAL ARCHITECTURE; OCULAR DOMINANCE; PREFERENCE MAPS; DEPRIVED CATS; DIRECTION; COLUMNS; ORGANIZATION	In the visual cortex of higher mammals, neurons are arranged across the cortical surface in an orderly map of preferred stimulus orientations(1,2). This map contains 'orientation pinwheels', structures that are arranged like the spokes of a wheel such that orientation changes continuously around a centre. Conventional optical imaging(3,4) first demonstrated these pinwheels(3,5), but the technique lacked the spatial resolution to determine the response properties and arrangement of cells near pinwheel centres. Electrophysiological recordings later demonstrated sharply selective neurons near pinwheel centres(6,7), but it remained unclear whether they were arranged randomly or in an orderly fashion. Here we use two-photon calcium imaging in vivo(8-12) to determine the microstructure of pinwheel centres in cat visual cortex with single-cell resolution. We find that pinwheel centres are highly ordered: neurons selective to different orientations are clearly segregated even in the very centre. Thus, pinwheel centres truly represent singularities in the cortical map. This highly ordered arrangement at the level of single cells suggests great precision in the development of cortical circuits underlying orientation selectivity.	Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA; Max Planck Inst Neurobiol, D-82152 Munich, Germany	Harvard University; Harvard Medical School; Max Planck Society	Reid, RC (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA.	clay_reid@hms.harvard.edu	Bonhoeffer, Tobias/B-9481-2009; Aunins, Ainars/H-4927-2011	Bonhoeffer, Tobias/0000-0001-7897-6634; Aunins, Ainars/0000-0002-6051-1879				BLASDEL GG, 1986, NATURE, V321, P579, DOI 10.1038/321579a0; BONHOEFFER T, 1991, NATURE, V353, P429, DOI 10.1038/353429a0; Chapman B, 1996, J NEUROSCI, V16, P6443; Crair MC, 1997, NEURON, V19, P307, DOI 10.1016/S0896-6273(00)80941-1; Crair MC, 1998, SCIENCE, V279, P566, DOI 10.1126/science.279.5350.566; Das A, 1999, NATURE, V399, P655, DOI 10.1038/21371; GILBERT CD, 1989, J NEUROSCI, V9, P2432; Godecke I, 1997, EUR J NEUROSCI, V9, P1754; Gray CM, 1995, J NEUROSCI METH, V63, P43, DOI 10.1016/0165-0270(95)00085-2; GRINVALD A, 1986, NATURE, V324, P361, DOI 10.1038/324361a0; Hickmott PW, 1999, J COMP NEUROL, V409, P385; HUBEL DH, 1974, J COMP NEUROL, V158, P267, DOI 10.1002/cne.901580304; HUBENER M, 1992, J COMP NEUROL, V324, P67, DOI 10.1002/cne.903240106; KATZ LC, 1989, J NEUROSCI, V9, P1389; Kerr JND, 2005, P NATL ACAD SCI USA, V102, P14063, DOI 10.1073/pnas.0506029102; KOSSEL A, 1995, J NEUROSCI, V15, P3913; Maldonado PE, 1997, SCIENCE, V276, P1551, DOI 10.1126/science.276.5318.1551; Marino J, 2005, NAT NEUROSCI, V8, P194, DOI 10.1038/nn1391; Meister M, 2001, J NEUROSCI, V21, P1351; Mooser F, 2004, NAT NEUROSCI, V7, P872, DOI 10.1038/nn1287; Ohki K, 2005, NATURE, V433, P597, DOI 10.1038/nature03274; Schummers J, 2002, NEURON, V36, P969, DOI 10.1016/S0896-6273(02)01012-7; Shmuel A, 1996, J NEUROSCI, V16, P6945; Stosiek C, 2003, P NATL ACAD SCI USA, V100, P7319, DOI 10.1073/pnas.1232232100; Sullivan MR, 2005, J NEUROPHYSIOL, V94, P1636, DOI 10.1152/jn.01013.2004; Svoboda K, 1997, NATURE, V385, P161, DOI 10.1038/385161a0; Swindale NV, 2003, CEREB CORTEX, V13, P225, DOI 10.1093/cercor/13.3.225; SWINDALE NV, 1987, J NEUROSCI, V7, P1414; Weliky M, 1996, NATURE, V379, P725, DOI 10.1038/379725a0	30	228	231	5	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 24	2006	442	7105					925	928		10.1038/nature05019	http://dx.doi.org/10.1038/nature05019			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	076LT	16906137				2022-12-28	WOS:000239960500039
J	Reddy, M; Gill, SS; Rochon, PA				Reddy, Madhuri; Gill, Sudeep S.; Rochon, Paula A.			Preventing pressure ulcers: A systematic review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							RISK-FACTORS; COST-EFFECTIVENESS; SUPPORT SURFACES; NUTRITIONAL SUPPLEMENTATION; QUALITY ASSESSMENT; ELDERLY-PATIENTS; CONTROLLED-TRIAL; INTENSIVE-CARE; SORES; MATTRESSES	Context Pressure ulcers are common in a variety of patient settings and are associated with adverse health outcomes and high treatment costs. Objective To systematically review the evidence examining interventions to prevent pressure ulcers. Data Sources and Study Selection MEDLINE, EMBASE, and CINAHL (from inception through June 2006) and Cochrane databases (through issue 1, 2006) were searched to identify relevant randomized controlled trials (RCTs). UMI Proquest Digital Dissertations, ISI Web of Science, and Cambridge Scientific Abstracts were also searched. All searches used the terms pressure ulcer, pressure sore, decubitus, bedsore, prevention, prophylactic, reduction, randomized, and clinical trials. Bibliographies of identified articles were further reviewed. Data Synthesis Fifty-nine RCTs were selected. Interventions assessed in these studies were grouped into 3 categories, ie, those addressing impairments in mobility, nutrition, or skin health. Methodological quality for the RCTs was variable and generally suboptimal. Effective strategies that addressed impaired mobility included the use of support surfaces, mattress overlays on operating tables, and specialized foam and specialized sheepskin overlays. While repositioning is a mainstay in most pressure ulcer prevention protocols, there is insufficient evidence to recommend specific turning regimens for patients with impaired mobility. In patients with nutritional impairments, dietary supplements may be beneficial. The incremental benefit of specific topical agents over simple moisturizers for patients with impaired skin health is unclear. Conclusions Given current evidence, using support surfaces, repositioning the patient, optimizing nutritional status, and moisturizing sacral skin are appropriate strategies to prevent pressure ulcers. Although a number of RCTs have evaluated preventive strategies for pressure ulcers, many of them had important methodological limitations. There is a need for well-designed RCTs that follow standard criteria for reporting nonpharmacological interventions and that provide data on cost-effectiveness for these interventions.	Hebrew Rehabil Ctr, Dept Med, Boston, MA 02131 USA; Univ Toronto, Div Geriatr Med, Toronto, ON, Canada; Univ Toronto, Div Dermatol, Toronto, ON, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Toronto, Baycrest Kunin Lunenfeld Appl Res Unit, Toronto, ON, Canada; Womens Coll Hosp, Toronto, ON M5S 1B2, Canada; Inst Clin Evaluat Sci, Toronto, ON, Canada; Queens Univ, Div Geriatr Med, Dept Med, Kingston, ON, Canada; Queens Univ, Dept Epidemiol & Community Hlth, Kingston, ON, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Baycrest; University of Toronto; University Toronto Affiliates; Womens College Hospital; University of Toronto; Queens University - Canada; Queens University - Canada	Reddy, M (corresponding author), Hebrew Rehabil Ctr, Dept Med, Boston, MA 02131 USA.	madhuri.reddy@sw.ca	Rochon, Paula A/J-2918-2016	Rochon, Paula A/0000-0002-5973-4151				ALLMAN RM, 1987, ANN INTERN MED, V107, P641, DOI 10.7326/0003-4819-107-5-641; ALLMAN RM, 1995, JAMA-J AM MED ASSOC, V273, P865, DOI 10.1001/jama.273.11.865; ALLMAN RM, 1989, NEW ENGL J MED, V320, P850; ALTMAN DG, 1990, LANCET, V335, P149, DOI 10.1016/0140-6736(90)90014-V; ANDERSEN KE, 1983, ACTA DERM-VENEREOL, V63, P227; [Anonymous], MODERN GERIATRICS; Aronovitch S A, 1999, Ostomy Wound Manage, V45, P34; Aronovitch SA, 1999, OSTOMY WOUND MANAG, V45, P42; Balk EM, 2002, JAMA-J AM MED ASSOC, V287, P2973, DOI 10.1001/jama.287.22.2973; Bates-Jensen BM, 2003, J AM GERIATR SOC, V51, P348, DOI 10.1046/j.1532-5415.2003.51108.x; Bennett RG, 1998, J AM GERIATR SOC, V46, P569, DOI 10.1111/j.1532-5415.1998.tb01072.x; Bergstrom N, 1996, J AM GERIATR SOC, V44, P22, DOI 10.1111/j.1532-5415.1996.tb05633.x; BERGSTROM N, 1992, J AM GERIATR SOC, V40, P747, DOI 10.1111/j.1532-5415.1992.tb01845.x; BERLOWITZ DR, 1989, J AM GERIATR SOC, V37, P1043, DOI 10.1111/j.1532-5415.1989.tb06918.x; Berlowitz DR, 1997, J GERONTOL A-BIOL, V52, pM106, DOI 10.1093/gerona/52A.2.M106; Bourdel-Marchasson I, 2000, NUTRITION, V16, P1, DOI 10.1016/S0899-9007(99)00227-0; Boutron I, 2005, J CLIN EPIDEMIOL, V58, P1233, DOI 10.1016/j.jclinepi.2005.05.004; BRANDEIS GH, 1994, J AM GERIATR SOC, V42, P388, DOI 10.1111/j.1532-5415.1994.tb07486.x; BRANDEIS GH, 1990, JAMA-J AM MED ASSOC, V264, P2905, DOI 10.1001/jama.264.22.2905; Collier M E, 1996, J Wound Care, V5, P207; COLLUM N, 2004, COCHRANE DB SYST REV; Conine T A, 1994, Int J Rehabil Res, V17, P123, DOI 10.1097/00004356-199406000-00003; Conine T A, 1990, Int J Rehabil Res, V13, P57, DOI 10.1097/00004356-199003000-00006; CONINE TA, 1993, OCCUP THER J RES, V13, P101, DOI 10.1177/153944929301300203; Cooper P J, 1998, J Wound Care, V7, P374; Cranney M, 2001, FAM PRACT, V18, P359, DOI 10.1093/fampra/18.4.359; DAECHSEL D, 1985, ARCH PHYS MED REHAB, V66, P246, DOI 10.1016/0003-9993(85)90161-3; Defloor T, 2005, INT J NURS STUD, V42, P37, DOI 10.1016/j.ijnurstu.2004.05.013; DELMI M, 1990, LANCET, V335, P1013, DOI 10.1016/0140-6736(90)91073-J; DOUGHTY D, 1990, PROG DEV OSTOMY WOUN, V2, P3; Dunlop V, 1998, Adv Wound Care, V11, P14; Economides N G, 1995, Adv Wound Care, V8, P49; Egger M, 2003, Health Technol Assess, V7, P1; EK AC, 1991, CLIN NUTR, V10, P245, DOI 10.1016/0261-5614(91)90002-T; EWING MR, 1964, MED J AUSTRALIA, V16, P139; EXTONSMITH AN, 1982, LANCET, V1, P1288; Feuchtinger J, 2006, J CLIN NURS, V15, P162, DOI 10.1111/j.1365-2702.2006.01293.x; Fleurence RL, 2005, INT J TECHNOL ASSESS, V21, P334, DOI 10.1017/S0266462305050440; Gebhardt K, 1994, J TISSUE VIABILITY, V4, P93; GENTILELLO L, 1988, CRIT CARE MED, V16, P783, DOI 10.1097/00003246-198808000-00010; Geyer M J, 2001, Adv Skin Wound Care, V14, P120, DOI 10.1097/00129334-200105000-00008; GOLDBERG J, 1982, BIOFEEDBACK SELF-REG, V7, P545, DOI 10.1007/BF00998893; Gordon MD, 2004, J BURN CARE REHABIL, V25, P388, DOI 10.1097/01.BCR.0000138289.83335.F4; Graves N, 2005, INFECT CONT HOSP EP, V26, P293, DOI 10.1086/502542; Gray D G, 2000, J Wound Care, V9, P29; Gray DG, 1994, J TISSUE VIABILITY, V4, P128, DOI DOI 10.1016/S0965-206X(14)80124-1; Gunningberg L, 2000, J Wound Care, V9, P455; Hampton S, 1997, Br J Nurs, V6, P167; Hartgrink HH, 1998, CLIN NUTR, V17, P287, DOI 10.1016/S0261-5614(98)80321-X; Health Council of the Netherlands, 1999, PUBL HLTH COUNC NETH; HOFMAN A, 1994, LANCET, V343, P568, DOI 10.1016/S0140-6736(94)91521-0; Houwing RH, 2003, CLIN NUTR, V22, P401, DOI 10.1016/S0261-5614(03)00039-6; Iglesias C, 2006, BMJ-BRIT MED J, V332, P1416, DOI 10.1136/bmj.38850.711435.7C; INMAN KJ, 1993, JAMA-J AM MED ASSOC, V269, P1139; Inouye SK, 1999, NEW ENGL J MED, V340, P669, DOI 10.1056/NEJM199903043400901; Jolley DJ, 2004, MED J AUSTRALIA, V180, P324, DOI 10.5694/j.1326-5377.2004.tb05966.x; Juni P, 2002, JAMA-J AM MED ASSOC, V288, P2407; Juni P, 1999, JAMA-J AM MED ASSOC, V282, P1054, DOI 10.1001/jama.282.11.1054; KEMP MG, 1993, RES NURS HEALTH, V16, P89, DOI 10.1002/nur.4770160203; Keogh A, 2001, J Wound Care, V10, P15; Kimura S, 1997, J FAM PRACTICE, V44, P361; Kuhn B A, 1992, Nurs Econ, V10, P353; LAURENT S, 1997, 3 EUR C NURS MAN OCT; Lazzara D J, 1991, Decubitus, V4, P42; Lazzara DJD, 1991, DECUBITUS, V4, P46; LIBERATI A, 1986, J CLIN ONCOL, V4, P942, DOI 10.1200/JCO.1986.4.6.942; Lim R, 1988, J Rehabil Res Dev, V25, P19; Lindgren M, 2005, J ADV NURS, V50, P605, DOI 10.1111/j.1365-2648.2005.03441.x; Lyder CH, 2003, JAMA-J AM MED ASSOC, V289, P223, DOI 10.1001/jama.289.2.223; MAKLEBUST J, 2001, PRESSURE ULCERS GUID, P24; McGowan S., 2000, PRIMARY INTENTION, V8, P1; MOHER D, 1995, CONTROL CLIN TRIALS, V16, P62, DOI 10.1016/0197-2456(94)00031-W; *NAT PRESS ULC ADV, 1989, PRESS ULC INC EC RIS; Nixon J, 1998, INT J NURS STUD, V35, P193, DOI 10.1016/S0020-7489(98)00023-6; Nixon J, 2006, BMJ-BRIT MED J, V332, P1413, DOI 10.1136/bmj.38849.478299.7C; Pieper B, 1995, Adv Wound Care, V8, ppassim; Pieper B, 1995, ADV WOUND CARE, V8, P38; Pieper B, 1995, ADV WOUND CARE, V8, P40; Price P, 1999, J Wound Care, V8, P187; Russell J, 2000, OSTOMY WOUND MANAG, V46, P46; Russell J A, 2000, Ostomy Wound Manage, V46, P46; Russell Linda J, 2003, Adv Skin Wound Care, V16, P317, DOI 10.1097/00129334-200311000-00015; Santy JE, 1994, COMP STUDY 6 TYPES H; Schultz A, 1999, AORN J, V70, P437, DOI 10.1016/S0001-2092(06)62325-9; Schultz A, 1999, AORN J, V70, P443, DOI DOI 10.1016/S0001-2092(06)62325-9; SIDERANKO S, 1992, RES NURS HEALTH, V15, P245, DOI 10.1002/nur.4770150403; Smith WR, 2000, CHEST, V118, p8S, DOI 10.1378/chest.118.2_suppl.8S; STAAS WE, 1991, WESTERN J MED, V154, P539; Stapleton M, 1986, Geriatr Nurs (Lond), V6, P23; SUMMER WR, 1989, J CRIT CARE, V4, P45, DOI 10.1016/0883-9441(89)90091-9; TAKALA J, 1996, J CRIT CARE, V7, P228; Taylor L, 1999, Br J Nurs, V8, P771; Taylor L, 1999, BR J NURS, V8, P776; Theaker C, 2005, ANAESTHESIA, V60, P395, DOI 10.1111/j.1365-2044.2004.04085.x; Thomas DR, 1996, J AM GERIATR SOC, V44, P1435, DOI 10.1111/j.1532-5415.1996.tb04067.x; TINETTI ME, 1995, JAMA-J AM MED ASSOC, V273, P1348, DOI 10.1001/jama.273.17.1348; Torra i Bou J E, 2005, J Wound Care, V14, P117; Tymec A C, 1997, Adv Wound Care, V10, P39; *US DEP HHS, 1992, IN PRESS PRESS ULC A; VANDERCAMMEN TJM, 1987, BRIT J CLIN PRACT, V41, P1009; Vanderwee K, 2005, AGE AGEING, V34, P261, DOI 10.1093/ageing/afi057; Verhagen AP, 2001, J CLIN EPIDEMIOL, V54, P651, DOI 10.1016/S0895-4356(00)00360-7; Voss AC, 2005, J AM GERIATR SOC, V53, P1587, DOI 10.1111/j.1532-5415.2005.53462.x; Vyhlidal SK, 1997, APPL NURS RES, V10, P111, DOI 10.1016/S0897-1897(97)80193-0; Whitfield M D, 2000, J Wound Care, V9, P261; Whitney J D, 1984, J Gerontol Nurs, V10, P20; *WOCN, 2003, WOCN CLIN PRACT GUID, V2; Young Trudie, 2004, J Tissue Viability, V14, P92	108	480	501	3	155	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 23	2006	296	8					974	984		10.1001/jama.296.8.974	http://dx.doi.org/10.1001/jama.296.8.974			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	076AL	16926357				2022-12-28	WOS:000239929300027
J	Genzel, R; Tacconi, LJ; Eisenhauer, F; Schreiber, NMF; Cimatti, A; Daddi, E; Bouche, N; Davies, R; Lehnert, MD; Lutz, D; Nesvadba, N; Verma, A; Abuter, R; Shapiro, K; Sternberg, A; Renzini, A; Kong, X; Arimoto, N; Mignoli, M				Genzel, R.; Tacconi, L. J.; Eisenhauer, F.; Schreiber, N. M. Foerster; Cimatti, A.; Daddi, E.; Bouche, N.; Davies, R.; Lehnert, M. D.; Lutz, D.; Nesvadba, N.; Verma, A.; Abuter, R.; Shapiro, K.; Sternberg, A.; Renzini, A.; Kong, X.; Arimoto, N.; Mignoli, M.			The rapid formation of a large rotating disk galaxy three billion years after the Big Bang	NATURE			English	Article							INTEGRAL FIELD SPECTROSCOPY; MASSIVE GALAXIES; KINEMATICS; STELLAR; RESOLUTION; SINFONI	Observations and theoretical simulations have established a framework for galaxy formation and evolution in the young Universe(1-3). Galaxies formed as baryonic gas cooled at the centres of collapsing dark-matter haloes; mergers of haloes and galaxies then led to the hierarchical build-up of galaxy mass. It remains unclear, however, over what timescales galaxies were assembled and when and how bulges and disks - the primary components of present-day galaxies - were formed. It is also puzzling that the most massive galaxies were more abundant and were forming stars more rapidly at early epochs than expected from models(4-7). Here we report high-angular-resolution observations of a representative luminous star-forming galaxy when the Universe was only 20% of its current age. A large and massive rotating protodisk is channelling gas towards a growing central stellar bulge hosting an accreting massive black hole. The high surface densities of gas, the high rate of star formation and the moderately young stellar ages suggest rapid assembly, fragmentation and conversion to stars of an initially very gas-rich protodisk, with no obvious evidence for a major merger.	Max Planck Inst Extraterr Phys, D-85748 Garching, Germany; Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; Ist Nazl Astrofis, Osservatorio Astrofis Arcetri, I-50125 Florence, Italy; Natl Opt Astron Observ, Tucson, AZ 85719 USA; Univ Calif Berkeley, Dept Astron, Berkeley, CA 94720 USA; Tel Aviv Univ, Sch Phys & Astron, IL-69978 Tel Aviv, Israel; Osserv Astron Padova, I-35122 Padua, Italy; Univ Sci & Technol China, Ctr Astrophys, Hefei 230026, Peoples R China; Natl Astron Observ, Tokyo 1818588, Japan; Ist Nazl Astrofis, Osservatorio Astron Bologna, I-40129 Bologna, Italy	Max Planck Society; University of California System; University of California Berkeley; Istituto Nazionale Astrofisica (INAF); National Optical Astronomy Observatory; University of California System; University of California Berkeley; Tel Aviv University; Istituto Nazionale Astrofisica (INAF); University of Padua; Chinese Academy of Sciences; University of Science & Technology of China, CAS; National Institutes of Natural Sciences (NINS) - Japan; National Astronomical Observatory of Japan (NAOJ); Istituto Nazionale Astrofisica (INAF)	Genzel, R (corresponding author), Max Planck Inst Extraterr Phys, Giessenbachstr 1, D-85748 Garching, Germany.	genzel@mpe.mpg.de	Mignoli, Marco/O-9426-2015; Daddi, Emanuele/D-1649-2012	Mignoli, Marco/0000-0002-9087-2835; Daddi, Emanuele/0000-0002-3331-9590; Lutz, Dieter/0000-0003-0291-9582; Lehnert, Matthew/0000-0003-1939-5885; Davies, Richard/0000-0003-4949-7217; Renzini, Alvio/0000-0002-7093-7355				Bonnet H., 2004, MESSENGER, V117, P17; Chabrier G, 2003, PUBL ASTRON SOC PAC, V115, P763, DOI 10.1086/376392; Chapman SC, 2005, ASTROPHYS J, V622, P772, DOI 10.1086/428082; Cimatti A, 2004, NATURE, V430, P184, DOI 10.1038/nature02668; Daddi E, 2004, ASTROPHYS J, V617, P746, DOI 10.1086/425569; Daigle O, 2006, MON NOT R ASTRON SOC, V367, P469, DOI 10.1111/j.1365-2966.2006.10002.x; DAVIS M, 1985, ASTROPHYS J, V292, P371, DOI 10.1086/163168; Dib S, 2006, ASTROPHYS J, V638, P797, DOI 10.1086/498857; DONGHIA E, 2006, UNPUB MON NOT R ASTR; Eisenhauer F, 2003, P SOC PHOTO-OPT INS, V4841, P1548, DOI 10.1117/12.459468; Ellis R, 2003, GALAXIES AT HIGH REDSHIFT, P1; Fontana A, 2004, ASTRON ASTROPHYS, V424, P23, DOI 10.1051/0004-6361:20035626; Ganda K, 2006, MON NOT R ASTRON SOC, V367, P46, DOI 10.1111/j.1365-2966.2005.09977.x; Glazebrook K, 2004, NATURE, V430, P181, DOI 10.1038/nature02667; Immeli A, 2004, ASTRON ASTROPHYS, V413, P547, DOI 10.1051/0004-6361:20034282; Kennicutt RC, 1998, ASTROPHYS J, V498, P541, DOI 10.1086/305588; KENNICUTT RC, 1989, ASTROPHYS J, V344, P685, DOI 10.1086/167834; Kong X, 2006, ASTROPHYS J, V638, P72, DOI 10.1086/498698; Kroupa P, 2001, MON NOT R ASTRON SOC, V322, P231, DOI 10.1046/j.1365-8711.2001.04022.x; Lindblad PO, 1999, ASTRON ASTROPHYS REV, V9, P221, DOI 10.1007/s001590050018; Monaco P, 2004, MON NOT R ASTRON SOC, V352, P181, DOI 10.1111/j.1365-2966.2004.07916.x; Schreiber J, 2004, ASTR SOC P, V314, P380; Schreiber NMF, 2006, ASTROPHYS J, V645, P1062, DOI 10.1086/504403; Tacconi LJ, 2006, ASTROPHYS J, V640, P228, DOI 10.1086/499933; Thompson TA, 2005, ASTROPHYS J, V630, P167, DOI 10.1086/431923; TOOMRE A, 1964, ASTROPHYS J, V139, P1217, DOI 10.1086/147861; VANDERKRUIT PC, 1978, ANNU REV ASTRON ASTR, V16, P103, DOI 10.1146/annurev.aa.16.090178.000535; Yoachim P, 2006, ASTRON J, V131, P226, DOI 10.1086/497970	29	384	385	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 17	2006	442	7104					786	789		10.1038/nature05052	http://dx.doi.org/10.1038/nature05052			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	074DK	16915282				2022-12-28	WOS:000239792700039
J	Rossler, UK; Bogdanov, AN; Pfleiderer, C				Roessler, U. K.; Bogdanov, A. N.; Pfleiderer, C.			Spontaneous skyrmion ground states in magnetic metals	NATURE			English	Article							CRYSTALS; ORDER; EQUATIONS; MODELS; PHASE; MNSI	Since the 1950s, Heisenberg and others have addressed the problem of how to explain the appearance of countable particles in continuous fields(1). Stable localized field configurations were searched for an ingredient for a general field theory of elementary particles, but the majority of nonlinear field models were unable to predict them. As an exception, Skyrme succeeded in describing nuclear particles as localized states, so-called 'skyrmions'(2). Skyrmions are a characteristic of nonlinear continuum models ranging from microscopic to cosmological scales(3-6). Skyrmionic states have been found under non-equilibrium conditions, or when stabilized by external fields or the proliferation of topological defects. Examples are Turing patterns in classical liquids(7), spin textures in quantum Hall magnets(8), or the blue phases in liquid crystals(9). However, it has generally been assumed that skyrmions cannot form spontaneous ground states, such as ferromagnetic or antiferromagnetic order, in magnetic materials. Here, we show theoretically that this assumption is wrong and that skyrmion textures may form spontaneously in condensed-matter systems with chiral interactions without the assistance of external fields or the proliferation of defects. We show this within a phenomenological continuum model based on a few material-specific parameters that can be determined experimentally. Our model has a condition not considered before: we allow for softened amplitude variations of the magnetization, characteristic of, for instance, metallic magnets. Our model implies that spontaneous skyrmion lattice ground states may exist generally in a large number of materials, notably at surfaces and in thin films, as well as in bulk compounds, where a lack of space inversion symmetry leads to chiral interactions.	IFW Dresden, D-01171 Dresden, Germany; Univ Karlsruhe, Inst Phys, D-76128 Karlsruhe, Germany; Tech Univ Munich, Phys Dept E21, D-85748 Garching, Germany; Forschungszentrum Karlsruhe, Inst Festkorperphys, D-76021 Karlsruhe, Germany; Donetsk Inst Phys & Technol, Donetsk, Ukraine	Institute for Integrative Nanosciences (IIN); Leibniz Institute for Solid State & Materials Research Dresden; Helmholtz Association; Karlsruhe Institute of Technology; Technical University of Munich; Helmholtz Association; Karlsruhe Institute of Technology; National Academy of Sciences Ukraine; Donetsk Institute for Physics & Engineering named after O.O. Galkin of the National Academy of Sciences of Ukraine	Rossler, UK (corresponding author), IFW Dresden, POB 270116, D-01171 Dresden, Germany.	u.roessler@ifw-dresden.de	Pfleiderer, Christian/P-3575-2014	Pfleiderer, Christian/0000-0001-7749-7965				ABRIKOSOV AA, 1957, SOV PHYS JETP-USSR, V5, P1174; Al Khawaja U, 2001, NATURE, V411, P918, DOI 10.1038/35082010; AUERLE C, 1996, NATURE, V382, P332; BAK P, 1980, J PHYS C SOLID STATE, V13, pL881, DOI 10.1088/0022-3719/13/31/002; Binz B, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.207202; BOGDANOV A, 1995, JETP LETT+, V62, P247; BOGDANOV A, 1994, J MAGN MAGN MATER, V138, P255, DOI 10.1016/0304-8853(94)90046-9; Bogdanov AN, 2005, PHYSICA B, V359, P1162, DOI 10.1016/j.physb.2005.01.303; Bogdanov AN, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.214410; Bogdanov AN, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.037203; BOGDANOV AN, 1989, ZH EKSP TEOR FIZ+, V95, P178; BREY L, 1995, PHYS REV LETT, V75, P2562, DOI 10.1103/PhysRevLett.75.2562; Chaikin P.M., 1995, PRINCIPLES CONDENSED, V10, DOI DOI 10.1017/CBO9780511813467; Cross M. C., 1993, REV MOD PHYS, V65, P852; DERRICK GH, 1964, J MATH PHYS, V5, P1252, DOI 10.1063/1.1704233; Durrer R, 2002, PHYS REP, V364, P1, DOI 10.1016/S0370-1573(02)00014-5; DZYALOSHINSKII IE, 1964, SOV PHYS JETP-USSR, V19, P960; Fert A., 1990, MAT SCI FORUM, V59-60, P439, DOI 10.4028/www.scientific.net/MSF.59-60.439; HOBART RH, 1963, P PHYS SOC LOND, V82, P201, DOI 10.1088/0370-1328/82/2/306; HORNREICH RM, 1982, PHYS REV LETT, V48, P1404, DOI 10.1103/PhysRevLett.48.1404; Lebech B., 1993, RECENT ADV MAGNETISM, P167; Pfleiderer C, 2004, NATURE, V427, P227, DOI 10.1038/nature02232; Pfleiderer C, 2001, NATURE, V414, P427, DOI 10.1038/35106527; SKYRME TH, 1961, PROC R SOC LON SER-A, V260, P127, DOI 10.1098/rspa.1961.0018; Tewari S, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.047207; Uchida M, 2006, SCIENCE, V311, P359, DOI 10.1126/science.1120639; WRIGHT DC, 1989, REV MOD PHYS, V61, P385, DOI 10.1103/RevModPhys.61.385; [No title captured]	29	1342	1348	29	663	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 17	2006	442	7104					797	801		10.1038/nature05056	http://dx.doi.org/10.1038/nature05056			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	074DK	16915285	Green Submitted			2022-12-28	WOS:000239792700042
J	Joo, C; McKinney, SA; Nakamura, M; Rasnik, I; Myong, S; Ha, T				Joo, Chirlmin; McKinney, Sean A.; Nakamura, Muneaki; Rasnik, Ivan; Myong, Sua; Ha, Taekjip			Real-time observation of RecA filament dynamics with single monomer resolution	CELL			English	Article							DNA STRAND EXCHANGE; RESONANCE ENERGY-TRANSFER; ESCHERICHIA-COLI; ATP HYDROLYSIS; DUPLEX DNA; FLUORESCENCE SPECTROSCOPY; HOMOLOGOUS RECOMBINATION; RAD51 FILAMENT; MOTOR PROTEIN; BINDING	RecA and its homologs help maintain genomic integrity through recombination. Using singlemolecule fluorescence assays and hidden Markov modeling, we show the most direct evidence that a RecA filament grows and shrinks primarily one monomer at a time and only at the extremities. Both ends grow and shrink, contrary to expectation, but a higher binding rate at one end is responsible for directional filament growth. Quantitative rate determination also provides insights into how RecA might control DNA accessibility in vivo. We find that about five monomers are sufficient for filament nucleation. Although ordinarily single-stranded DNA binding protein (SSB) prevents filament nucleation, single RecA monomers can easily be added to an existing filament and displace SSB from DNA at the rate of filament extension. This supports the proposal for a passive role of RecA-loading machineries in SSB removal.	Univ Illinois, Howard Hughes Med Inst, Urbana, IL 61801 USA; Univ Illinois, Dept Phys, Urbana, IL 61801 USA; Univ Illinois, Dept Chem, Urbana, IL 61801 USA; Emory Univ, Dept Phys, Atlanta, GA 30322 USA	Howard Hughes Medical Institute; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Emory University	Ha, T (corresponding author), Univ Illinois, Howard Hughes Med Inst, Urbana, IL 61801 USA.	tjha@uiuc.edu	Ha, Taekjip/B-9506-2009; Joo, Chirlmin/B-9294-2008	Ha, Taekjip/0000-0003-2195-6258; Joo, Chirlmin/0000-0003-2803-0335; McKinney, Sean/0000-0002-9740-6247	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065367] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM065367, R01 GM065367] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amundsen SK, 2003, CELL, V112, P741, DOI 10.1016/S0092-8674(03)00197-1; Anderson DG, 1997, CELL, V90, P77, DOI 10.1016/S0092-8674(00)80315-3; Arenson TA, 1999, J MOL BIOL, V288, P391, DOI 10.1006/jmbi.1999.2705; Bedale WA, 1996, J BIOL CHEM, V271, P5725, DOI 10.1074/jbc.271.10.5725; Bianco PR, 1996, NUCLEIC ACIDS RES, V24, P4933, DOI 10.1093/nar/24.24.4933; Bork JM, 2001, EMBO J, V20, P7313, DOI 10.1093/emboj/20.24.7313; BRENNER SL, 1990, J MOL BIOL, V216, P949, DOI 10.1016/S0022-2836(99)80013-8; BRENNER SL, 1987, J BIOL CHEM, V262, P4011; Conway AB, 2004, NAT STRUCT MOL BIOL, V11, P791, DOI 10.1038/nsmb795; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Cox MM, 2003, ANNU REV MICROBIOL, V57, P551, DOI 10.1146/annurev.micro.57.030502.090953; Cox MM, 2000, PROG NUCLEIC ACID RE, V63, P311, DOI 10.1016/S0079-6603(08)60726-6; Diez M, 2004, NAT STRUCT MOL BIOL, V11, P135, DOI 10.1038/nsmb718; EGELMAN EH, 1989, SCIENCE, V245, P404, DOI 10.1126/science.2667137; Fulconis R, 2004, BIOPHYS J, V87, P2552, DOI 10.1529/biophysj.104.043059; Ha T, 1996, P NATL ACAD SCI USA, V93, P6264, DOI 10.1073/pnas.93.13.6264; Ha T, 2002, NATURE, V419, P638, DOI 10.1038/nature01083; Ha T, 2001, CURR OPIN STRUC BIOL, V11, P287, DOI 10.1016/S0959-440X(00)00204-9; Ha TJ, 1999, CHEM PHYS, V247, P107, DOI 10.1016/S0301-0104(99)00149-4; Hegner M, 1999, P NATL ACAD SCI USA, V96, P10109, DOI 10.1073/pnas.96.18.10109; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; Kowalczykowski SC, 2005, NATURE, V433, P591, DOI 10.1038/433591a; Kowalczykowski SC, 2000, TRENDS BIOCHEM SCI, V25, P156, DOI 10.1016/S0968-0004(00)01569-3; Kozlov AG, 2002, BIOCHEMISTRY-US, V41, P6032, DOI 10.1021/bi020122z; LEAHY MC, 1986, J BIOL CHEM, V261, P6954; Lee JY, 2005, P NATL ACAD SCI USA, V102, P18938, DOI 10.1073/pnas.0506144102; LINDSLEY JE, 1990, J BIOL CHEM, V265, P9043; McKinney SA, 2005, P NATL ACAD SCI USA, V102, P5715, DOI 10.1073/pnas.0409328102; McKinney SA, 2006, BIOPHYS J, V91, P1941, DOI 10.1529/biophysj.106.082487; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; Morimatsu K, 2003, MOL CELL, V11, P1337, DOI 10.1016/S1097-2765(03)00188-6; Murphy MC, 2004, BIOPHYS J, V86, P2530, DOI 10.1016/S0006-3495(04)74308-8; Myong S, 2005, NATURE, V437, P1321, DOI 10.1038/nature04049; Pellegrini L, 2002, NATURE, V420, P287, DOI 10.1038/nature01230; Prevost C, 2003, Q REV BIOPHYS, V36, P429, DOI 10.1017/S0033583504003956; PUGH BF, 1988, J MOL BIOL, V203, P479, DOI 10.1016/0022-2836(88)90014-9; Raghunathan S, 2000, NAT STRUCT BIOL, V7, P648, DOI 10.1038/77943; REGISTER JC, 1985, J BIOL CHEM, V260, P12306; Shan Q, 1997, J MOL BIOL, V265, P519, DOI 10.1006/jmbi.1996.0748; Shan Q, 1996, J BIOL CHEM, V271, P5712, DOI 10.1074/jbc.271.10.5712; SHANER SL, 1987, J BIOL CHEM, V262, P9211; SHANER SL, 1987, J BIOL CHEM, V262, P9220; Shivashankar GV, 1999, P NATL ACAD SCI USA, V96, P7916, DOI 10.1073/pnas.96.14.7916; Smith GR, 2001, ANNU REV GENET, V35, P243, DOI 10.1146/annurev.genet.35.102401.090509; Sommer S, 1998, MOL MICROBIOL, V28, P281, DOI 10.1046/j.1365-2958.1998.00803.x; Spies M, 2006, MOL CELL, V21, P573, DOI 10.1016/j.molcel.2006.01.007; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; THRESHER RJ, 1988, J MOL BIOL, V201, P101, DOI 10.1016/0022-2836(88)90442-1; Tlusty T, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.258103; UMEZU K, 1993, P NATL ACAD SCI USA, V90, P3875, DOI 10.1073/pnas.90.9.3875; van der Heijden T, 2005, NUCLEIC ACIDS RES, V33, P2099, DOI 10.1093/nar/gki512; Venkitaraman AR, 2004, NAT REV CANCER, V4, P266, DOI 10.1038/nrc1321; WEGNER A, 1982, J MOL BIOL, V161, P607, DOI 10.1016/0022-2836(82)90411-9; Weiss S, 1999, SCIENCE, V283, P1676, DOI 10.1126/science.283.5408.1676; Yang HJ, 2005, NATURE, V433, P653, DOI 10.1038/nature03234; Zhuang XW, 2005, ANNU REV BIOPH BIOM, V34, P399, DOI 10.1146/annurev.biophys.34.040204.144641; ZLOTNICK A, 1993, J BIOL CHEM, V268, P22525	58	227	227	2	54	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 11	2006	126	3					515	527		10.1016/j.cell.2006.06.042	http://dx.doi.org/10.1016/j.cell.2006.06.042			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	075KI	16901785	Bronze			2022-12-28	WOS:000239883400012
J	Nougayrede, JP; Homburg, S; Taieb, F; Boury, M; Brzuszkiewicz, E; Gottschalk, G; Buchrieser, C; Hacker, J; Dobrindt, U; Oswald, E				Nougayrede, Jean-Philippe; Homburg, Stefan; Taieb, Frederic; Boury, Michele; Brzuszkiewicz, Elzbieta; Gottschalk, Gerhard; Buchrieser, Carmen; Hacker, Joerg; Dobrindt, Ulrich; Oswald, Eric			Escherichia coli induces DNA double-strand breaks in eukaryotic cells	SCIENCE			English	Article							ULCERATIVE-COLITIS; POLYKETIDE; VIRULENCE; CYCLE; BIOSYNTHESIS; NISSLE-1917; MESALAZINE; REMISSION; DISEASE; PROTEIN	Transient infection of eukaryotic cells with commensal and extraintestinal pathogenic Escherichia coli of phylogenetic group B2 blocks mitosis and induces megalocytosis. This trait is linked to a widely spread genomic island that encodes giant modular nonribosomal peptide and polyketide synthases. Contact with E. coli expressing this gene cluster causes DNA double-strand breaks and activation of the DNA damage checkpoint pathway, leading to cell cycle arrest and eventually to cell death. Discovery of hybrid peptide-polyketide genotoxins in E. coli will change our view on pathogenesis and commensalism and open new biotechnological applications.	Ecole Natl Vet Toulouse, INRA, UMR 1225, F-31076 Toulouse, France; Univ Wurzburg, Inst Mol Infekt Biol, D-97070 Wurzburg, Germany; Univ Gottingen, Gottingen Genom Lab, D-37077 Gottingen, Germany; Inst Pasteur, Unite Genom Microorganismes Pathogenes, F-75724 Paris, France; CNRS, URA 2171, F-75724 Paris, France	INRAE; Universite de Toulouse; Ecole Nationale Veterinaire de Toulouse; University of Wurzburg; University of Gottingen; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS)	Oswald, E (corresponding author), Ecole Natl Vet Toulouse, INRA, UMR 1225, F-31076 Toulouse, France.	e.oswald@envt.fr	Dobrindt, Ulrich/AEU-2378-2022; Nougayrede, Jean-Philippe/I-6362-2019	Dobrindt, Ulrich/0000-0001-9949-1898; Nougayrede, Jean-Philippe/0000-0002-6802-1890; Oswald, Eric/0000-0002-3017-0081; Buchrieser, Carmen/0000-0003-3477-9190; taieb, frederic/0000-0001-9612-2069				Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Brown MH, 1999, MOL MICROBIOL, V31, P394, DOI 10.1046/j.1365-2958.1999.01162.x; Chen JY, 2005, NAT REV CANCER, V5, P102, DOI 10.1038/nrc1547; Du LH, 2001, METAB ENG, V3, P78, DOI 10.1006/mben.2000.0171; Finlay BB, 1997, SCIENCE, V276, P718, DOI 10.1126/science.276.5313.718; Grozdanov L, 2004, J BACTERIOL, V186, P5432, DOI 10.1128/JB.186.16.5432-5441.2004; Hacker J, 2003, SCIENCE, V301, P790, DOI 10.1126/science.1086802; Hutchinson CR, 2003, P NATL ACAD SCI USA, V100, P3010, DOI 10.1073/pnas.0730689100; Johnson JR, 2002, J INFECT DIS, V185, P774, DOI 10.1086/339343; Kaper JB, 2004, NAT REV MICROBIOL, V2, P123, DOI 10.1038/nrmicro818; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kruis W, 2004, GUT, V53, P1617, DOI 10.1136/gut.2003.037747; Lara-Tejero M, 2000, SCIENCE, V290, P354, DOI 10.1126/science.290.5490.354; Lax AJ, 2005, NAT REV MICROBIOL, V3, P343, DOI 10.1038/nrmicro1130; Malchow HA, 1997, J CLIN GASTROENTEROL, V25, P653, DOI 10.1097/00004836-199712000-00021; Marches O, 2003, MOL MICROBIOL, V50, P1553, DOI 10.1046/j.1365-2958.2003.03821.x; Nougayrede JP, 2005, TRENDS MICROBIOL, V13, P103, DOI 10.1016/j.tim.2005.01.002; Nowrouzian FL, 2005, J INFECT DIS, V191, P1078, DOI 10.1086/427996; OSWALD E, 1994, P NATL ACAD SCI USA, V91, P3814, DOI 10.1073/pnas.91.9.3814; Picard B, 1999, INFECT IMMUN, V67, P546, DOI 10.1128/IAI.67.2.546-553.1999; Rembacken BJ, 1999, LANCET, V354, P635, DOI 10.1016/S0140-6736(98)06343-0; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Sarkaria JN, 1999, CANCER RES, V59, P4375; Walsh CT, 2004, SCIENCE, V303, P1805, DOI 10.1126/science.1094318; Weissman KJ, 2005, NAT REV MICROBIOL, V3, P925, DOI 10.1038/nrmicro1287; WELCH RA, 1981, NATURE, V294, P665, DOI 10.1038/294665a0; Welch RA, 2002, P NATL ACAD SCI USA, V99, P17020, DOI 10.1073/pnas.252529799	28	646	691	9	83	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 11	2006	313	5788					848	851		10.1126/science.1127059	http://dx.doi.org/10.1126/science.1127059			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	072KC	16902142				2022-12-28	WOS:000239671300064
J	Vasterling, JJ; Proctor, SP; Amoroso, P; Kane, R; Heeren, T; White, RF				Vasterling, Jennifer J.; Proctor, Susan P.; Amoroso, Paul; Kane, Robert; Heeren, Timothy; White, Roberta F.			Neuropsychological outcomes of army personnel following deployment to the Iraq War	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRAUMATIC BRAIN-INJURY; MENTAL-HEALTH PROBLEMS; PERSIAN-GULF-WAR; DEPRESSION; IMPAIRMENT; VETERANS; STRESS; MEMORY; AFGHANISTAN; EMPLOYMENT	Context The effects of war-zone deployment on neuropsychological health remain poorly understood. Neuropsychological performance deficits serve as sensitive measures of neural dysfunction and are often associated with psychosocial and occupational problems. Previous studies have not conducted objective neuropsychological assessments both before and after a major war-zone deployment. \ Objective To examine objective neuropsychological outcomes of Iraq War deployment in a large military cohort. Design, Setting, and Participants The Neurocognition Deployment Health Study, a prospective, cohort-controlled study conducted at military installations. This report centers on 961 male and female active-duty Army soldiers drawn from the larger cohort. Deploying Army soldiers (n = 654) were examined prior to deployment to Iraq (April-December 2003) and shortly after return (within a mean of 73 days [median, 75 days]; January-May 2005) from Iraq deployment. A comparison group of soldiers (n=307) similar in military characteristics but not deploying overseas during the study was assessed in sessions timed to be as close as possible to the assessment of deployers. Military unit sampling procedures facilitated representation of combat, combat support, and combat service support functions among both deployers and nondeployers. Main Outcome Measures Individually administered, performance-based neuropsychological tasks. Estimates (P; the unstandardized parameter estimate) for the absolute differences in adjusted mean outcome scores between deployed and nondeployed groups were determined using generalized estimating equations. Results Multiple linear regression analyses adjusted for battalion membership revealed that Iraq deployment, compared with nondeployment, was associated with neuropsychological compromise on tasks of sustained attention (beta =0.11; P<.001), verbal learning (beta =-1.51; P=.003), and visual-spatial memory (beta=-3.82; P<.001). Iraq deployment was also associated with increased negative state affect on measures of confusion (beta = 1.40; P<.001) and tension (beta= 1.24; P<.001). In contrast, deployment was associated with improved simple reaction time (beta=4.30; P=.003). Deployment effects remained statistically significant after taking into account deployment-related head injury and stress and depression symptoms. Conclusions Deployment to Iraq is associated with increased risk of neuropsychological compromise. Findings point to the need to investigate further the impact of deployment on neural functioning. Public health implications include consideration of neuropsychological compromise in health prevention and postdeployment clinical and occupational management.	SE Louisiana Vet Hlth Care Syst, Res Serv COSF, New Orleans, LA 70112 USA; Tulane Univ, Sch Med, New Orleans, LA 70112 USA; VA Boston Healthcare Syst, Boston, MA USA; Boston Univ, Sch Publ Hlth, Boston, MA USA; USA, Environm Med Res Inst, Natick, MA 01760 USA; Madigan Army Med Ctr, Ft Lewis, WA USA; VA Maryland Hlth Care Syst, Baltimore, MD USA; Univ Maryland, Sch Med, Baltimore, MD 21201 USA	Tulane University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; Boston University; Madigan Army Medical Center; University System of Maryland; University of Maryland Baltimore	Vasterling, JJ (corresponding author), SE Louisiana Vet Hlth Care Syst, Res Serv COSF, 1601 Perdido St, New Orleans, LA 70112 USA.	jvaster@tulane.edu		Heeren, Timothy/0000-0001-5643-3559				Arnsten AFT, 1998, SCIENCE, V280, P1711, DOI 10.1126/science.280.5370.1711; Bellinger DC, 2004, ENVIRON RES, V95, P394, DOI 10.1016/j.envres.2003.07.013; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Blokland A, 1995, BRAIN RES REV, V21, P285, DOI 10.1016/0165-0173(95)00016-X; Blood CG, 2001, MIL MED, V166, P648, DOI 10.1093/milmed/166.7.648; BURT DB, 1995, PSYCHOL BULL, V117, P285, DOI 10.1037/0033-2909.117.2.285; Canfield RL, 2003, NEW ENGL J MED, V348, P1517, DOI 10.1056/NEJMoa022848; *DEP VET AFF, 2002, COMB AN VA DOD GULF; Elliott R, 1998, TRENDS COGN SCI, V2, P447, DOI 10.1016/S1364-6613(98)01235-2; GRANDJEAN P, 1998, NEUROTOXICOL TERATOL, V21, P1; Habib KE, 2001, ENDOCRIN METAB CLIN, V30, P695, DOI 10.1016/S0889-8529(05)70208-5; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Hotopf M, 2006, LANCET, V367, P1731, DOI 10.1016/S0140-6736(06)68662-5; Kalechstein AD, 2003, J CLIN EXP NEUROPSYC, V25, P1186, DOI 10.1076/jcen.25.8.1186.16723; Keane T., 1991, PTSD CHECKLIST MILIT; King DW., 2003, MANUAL DEPLOYMENT RI; Letz R, 1996, NEUROTOXICOL TERATOL, V18, P365, DOI 10.1016/0892-0362(96)00041-4; Letz R, 2000, NES3 USERS MANUAL; Machamer J, 2005, J INT NEUROPSYCH SOC, V11, P807, DOI 10.1017/S135561770505099X; Mauss IB, 2004, COGNITION EMOTION, V18, P631, DOI 10.1080/02699930341000112; MCEWEN BS, 1995, CURR OPIN NEUROBIOL, V5, P205, DOI 10.1016/0959-4388(95)80028-X; McNair D., 1971, MANUAL PROFILE MOOD; Morilak DA, 2005, PROG NEURO-PSYCHOPH, V29, P1214, DOI 10.1016/j.pnpbp.2005.08.007; OBRYANT SE, IN PRESS CLIN NEUROP; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Papero P. H., 1992, J DEV PHYS DISABIL, V4, P317; Proctor SP, 2003, J PSYCHOPATHOL BEHAV, V25, P85, DOI 10.1023/A:1023390831355; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Reeves D. L., 2002, ANAM 2001 USERS MANU, VSNRF-SF-2002-1; REEVES DL, IN PRESS MIL MED; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Santor DA, 1997, PSYCHOL ASSESSMENT, V9, P233, DOI 10.1037/1040-3590.9.3.233; Sauro MD, 2003, STRESS, V6, P235, DOI 10.1080/10253890310001616482; Schwartz DA, 1997, JAMA-J AM MED ASSOC, V277, P238, DOI 10.1001/jama.277.3.238; Spreen O, 1998, COMPENDIUM NEUROPSYC; Stewart A.L., 1992, MEASURING FUNCTIONIN; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Unwin C, 1999, LANCET, V353, P169, DOI 10.1016/S0140-6736(98)11338-7; Vasterling J.J., 2005, NEUROPSYCHOLOGY PTSD, P178; Vasterling JJ, 2006, PHILOS T R SOC B, V361, P593, DOI 10.1098/rstb.2006.1819; Vasterling JJ, 2006, MIL MED, V171, P253, DOI 10.7205/MILMED.171.3.253; Wechsler D., 1997, WECHSLER MEMORY SCAL, Vthird; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; WHITE RF, 1992, J OCCUP ENVIRON MED, V34, P140, DOI 10.1097/00043764-199202000-00013; WHITE RF, 1994, NEUROTOXICOL TERATOL, V16, P511, DOI 10.1016/0892-0362(94)90130-9; White RF, 1997, LANCET, V349, P1239, DOI 10.1016/S0140-6736(96)07218-2; WHITE RF, 2001, CLIN OCCUPATIONAL EN, V1, P577	48	291	293	1	22	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 2	2006	296	5					519	529		10.1001/jama.296.5.519	http://dx.doi.org/10.1001/jama.296.5.519			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	069YW	16882958	Bronze			2022-12-28	WOS:000239486900016
J	Beeson, D; Higuchi, O; Palace, J; Cossins, J; Spearman, H; Maxwell, S; Newsom-Davis, J; Burke, G; Fawcett, P; Motomura, M; Muller, JS; Lochmuller, H; Slater, C; Vincent, A; Yamanashi, Y				Beeson, David; Higuchi, Osamu; Palace, Jackie; Cossins, Judy; Spearman, Hayley; Maxwell, Susan; Newsom-Davis, John; Burke, Georgina; Fawcett, Peter; Motomura, Masakatsu; Mueller, Juliane S.; Lochmueller, Hanns; Slater, Clarke; Vincent, Angela; Yamanashi, Yuji			Dok-7 mutations underlie a neuromuscular junction synaptopathy	SCIENCE			English	Article							LIMB-GIRDLE MYASTHENIA; POSTSYNAPTIC APPARATUS; MUSCLE; TRANSMISSION; KINASES; NERVE	Congenital myasthenic syndromes (CMSs) are a group of inherited disorders of neuromuscular transmission characterized by fatigable muscle weakness. One major subgroup of patients shows a characteristic "limb girdle'' pattern of muscle weakness, in which the muscles have small, simplified neuromuscular junctions but normal acetylcholine receptor and acetylcholinesterase function. We showed that recessive inheritance of mutations in Dok-7, which result in a defective structure of the neuromuscular junction, is a cause of CMS with proximal muscle weakness.	Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Neurosci Grp, Oxford OX3 9DS, England; Univ Oxford, Radcliffe Infirm, Dept Clin Neurol, Oxford OX2 6HE, England; Newcastle Univ, Sch Neurol Neurobiol & Psychiat, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Tokyo Med & Dent Univ, Med Res Inst, Dept Cell Regulat, Tokyo 1138510, Japan; Nagasaki Univ, Dept Internal Med 1, Nagasaki 8528501, Japan; Univ Munich, Friedrich Baur Inst, Dept Neurol, Munich, Germany	University of Oxford; Radcliffe Infirmary; University of Oxford; Newcastle University - UK; Tokyo Medical & Dental University (TMDU); Nagasaki University; University of Munich	Beeson, D (corresponding author), Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Neurosci Grp, Oxford OX3 9DS, England.	dbeeson@hammer.imm.ox.ac.uk	Vincent, Angela/AAE-7310-2019	Lochmuller, Hanns/0000-0003-2324-8001	MRC [G117/490] Funding Source: UKRI; Medical Research Council [G117/490] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Antolik C, 2006, NEUROSCIENCE, V141, P87, DOI 10.1016/j.neuroscience.2006.03.035; Beeson David, 2005, Neuromuscul Disord, V15, P498, DOI 10.1016/j.nmd.2005.05.001; Cartaud A, 2004, J CELL BIOL, V165, P505, DOI 10.1083/jcb.200307164; Engel AG, 2005, CURR OPIN PHARMACOL, V5, P308, DOI 10.1016/j.coph.2004.12.007; Finn AJ, 2003, NAT NEUROSCI, V6, P717, DOI 10.1038/nn1071; Kummer TT, 2006, CURR OPIN NEUROBIOL, V16, P74, DOI 10.1016/j.conb.2005.12.003; Kummer TT, 2004, J CELL BIOL, V164, P1077, DOI 10.1083/jcb.200401115; Lin WC, 2001, NATURE, V410, P1057, DOI 10.1038/35074025; Mohamed AS, 2001, J NEUROSCI, V21, P3806, DOI 10.1523/JNEUROSCI.21-11-03806.2001; OH SJ, 1992, NEUROLOGY, V42, P1153, DOI 10.1212/WNL.42.6.1153; Okada K, 2006, SCIENCE, V312, P1802, DOI 10.1126/science.1127142; Rodolico C, 2002, NEUROMUSCULAR DISORD, V12, P964, DOI 10.1016/S0960-8966(02)00137-2; Sanes JR, 2001, NAT REV NEUROSCI, V2, P791, DOI 10.1038/35097557; Shankar A, 2002, NEUROL INDIA, V50, P500; Slater CR, 2006, BRAIN, V129, P2061, DOI 10.1093/brain/awl200; Slater CR, 2003, J NEUROCYTOL, V32, P505, DOI 10.1023/B:NEUR.0000020607.17881.9b; VINCENT A, 1993, ANN NY ACAD SCI, V681, P451, DOI 10.1111/j.1749-6632.1993.tb22929.x; Yang X, 2001, NEURON, V30, P399, DOI 10.1016/S0896-6273(01)00287-2	18	182	190	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 29	2006	313	5795					1975	1978		10.1126/science.1130837	http://dx.doi.org/10.1126/science.1130837			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	088SU	16917026				2022-12-28	WOS:000240832200055
J	Chmiola, J; Yushin, G; Gogotsi, Y; Portet, C; Simon, P; Taberna, PL				Chmiola, J.; Yushin, G.; Gogotsi, Y.; Portet, C.; Simon, P.; Taberna, P. L.			Anomalous increase in carbon capacitance at pore sizes less than 1 nanometer	SCIENCE			English	Article							CARBIDE-DERIVED CARBONS; ELECTROCHEMICAL CHARACTERISTICS; ACTIVATED CARBONS; STORAGE; ENERGY; ELECTROLYTES; POROSITY; ION	Carbon supercapacitors, which are energy storage devices that use ion adsorption on the surface of highly porous materials to store charge, have numerous advantages over other power-source technologies, but could realize further gains if their electrodes were properly optimized. Studying the effect of the pore size on capacitance could potentially improve performance by maximizing the electrode surface area accessible to electrolyte ions, but until recently, no studies had addressed the lower size limit of accessible pores. Using carbide-derived carbon, we generated pores with average sizes from 0.6 to 2.25 nanometer and studied double-layer capacitance in an organic electrolyte. The results challenge the long-held axiom that pores smaller than the size of solvated electrolyte ions are incapable of contributing to charge storage.	Drexel Univ, Dept Mat Sci & Engn, Philadelphia, PA 19104 USA; Drexel Univ, AJ Drexel Nanotechnol Inst, Philadelphia, PA 19104 USA; Univ Toulouse 3, CIRIMAT, CNRS, UMR 5085, F-31062 Toulouse 4, France	Drexel University; Drexel University; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Universite de Toulouse; Universite Federale Toulouse Midi-Pyrenees (ComUE); Universite Toulouse III - Paul Sabatier; Institut National Polytechnique de Toulouse	Gogotsi, Y (corresponding author), Drexel Univ, Dept Mat Sci & Engn, Philadelphia, PA 19104 USA.	gogotsi@drexel.edu	SIMON, Patrice/N-6777-2016; Gogotsi, Yury/B-2167-2008; Yushin, Gleb/B-4529-2013	SIMON, Patrice/0000-0002-0461-8268; Gogotsi, Yury/0000-0001-9423-4032; Yushin, Gleb/0000-0002-3274-9265				Arico AS, 2005, NAT MATER, V4, P366, DOI 10.1038/nmat1368; Barisci JN, 2004, ELECTROCHEM COMMUN, V6, P22, DOI 10.1016/j.elecom.2003.09.015; Baughman RH, 2002, SCIENCE, V297, P787, DOI 10.1126/science.1060928; Beguin F., 2006, NANOMATERIALS HDB, P713; Brodd RJ, 2004, J ELECTROCHEM SOC, V151, pK1, DOI 10.1149/1.1641042; Carrillo-Tripp M, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.168104; Chmiola J, 2006, J POWER SOURCES, V158, P765, DOI 10.1016/j.jpowsour.2005.09.008; Chmiola J, 2005, ELECTROCHEM SOLID ST, V8, pA357, DOI 10.1149/1.1921134; CONWAY BE, 1999, ELECTROCHEMICAL CAPA; Dash RK, 2005, MICROPOR MESOPOR MAT, V86, P50, DOI 10.1016/j.micromeso.2005.05.047; DELEVIE R, 1992, J ELECTROANAL CHEM, V341, P353, DOI 10.1016/0022-0728(92)80493-N; Di Leo JM, 2005, J MOL STRUC-THEOCHEM, V729, P53, DOI 10.1016/j.theochem.2005.02.070; Dzubiella J, 2005, J CHEM PHYS, V122, DOI 10.1063/1.1927514; Endo M, 2001, J ELECTROCHEM SOC, V148, pA910, DOI 10.1149/1.1382589; Frackowiak E, 2001, CARBON, V39, P937, DOI 10.1016/S0008-6223(00)00183-4; Gamby J, 2001, J POWER SOURCES, V101, P109, DOI 10.1016/S0378-7753(01)00707-8; Gogotsi Y, 2003, NAT MATER, V2, P591, DOI 10.1038/nmat957; Gogotsi Y, 2005, J AM CHEM SOC, V127, P16006, DOI 10.1021/ja0550529; Janes A, 2004, ELECTROCHEM COMMUN, V6, P313, DOI 10.1016/j.elecom.2003.01.009; LAUDISIO G, IN PRESS LANGMUIR; Ohkubo T, 2002, J AM CHEM SOC, V124, P11860, DOI 10.1021/ja027144t; RUDGE A, 1994, J POWER SOURCES, V47, P89, DOI 10.1016/0378-7753(94)80053-7; Salitra G, 2000, J ELECTROCHEM SOC, V147, P2486, DOI 10.1149/1.1393557; Shi H, 1996, ELECTROCHIM ACTA, V41, P1633, DOI 10.1016/0013-4686(95)00416-5; Taberna PL, 2003, J ELECTROCHEM SOC, V150, pA292, DOI 10.1149/1.1543948; Vix-Guterl C, 2005, CARBON, V43, P1293, DOI 10.1016/j.carbon.2004.12.028; WOOLFE G, 2005, BATTERIES ENERGY STO, V3, P107; Yushin G, 2006, NANOMATERIALS HDB, P237; Zetterstrom P, 2005, J PHYS-CONDENS MAT, V17, P3509, DOI 10.1088/0953-8984/17/23/004; Zhou HS, 2003, J POWER SOURCES, V122, P219, DOI 10.1016/S0378-7753(03)00439-7	30	2945	3046	65	1689	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 22	2006	313	5794					1760	1763		10.1126/science.1132195	http://dx.doi.org/10.1126/science.1132195			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	086ED	16917025				2022-12-28	WOS:000240655700040
J	Herzberg, RD; Greenlees, PT; Butler, PA; Jones, GD; Venhart, M; Darby, IG; Eeckhaudt, S; Eskola, K; Grahn, T; Gray-Jones, C; Hessberger, FP; Jones, P; Julin, R; Juutinen, S; Ketelhut, S; Korten, W; Leino, M; Leppanen, AP; Moon, S; Nyman, M; Page, RD; Pakarinen, J; Pritchard, A; Rahkila, P; Saren, J; Scholey, C; Steer, A; Sun, Y; Theisen, C; Uusitalo, J				Herzberg, R. -D.; Greenlees, P. T.; Butler, P. A.; Jones, G. D.; Venhart, M.; Darby, I. G.; Eeckhaudt, S.; Eskola, K.; Grahn, T.; Gray-Jones, C.; Hessberger, F. P.; Jones, P.; Julin, R.; Juutinen, S.; Ketelhut, S.; Korten, W.; Leino, M.; Leppanen, A. -P.; Moon, S.; Nyman, M.; Page, R. D.; Pakarinen, J.; Pritchard, A.; Rahkila, P.; Saren, J.; Scholey, C.; Steer, A.; Sun, Y.; Theisen, Ch.; Uusitalo, J.			Nuclear isomers in superheavy elements as stepping stones towards the island of stability	NATURE			English	Article							STATES; FM-250; BANDS	A long-standing prediction of nuclear models is the emergence of a region of long-lived, or even stable, superheavy elements beyond the actinides. These nuclei owe their enhanced stability to closed shells in the structure of both protons and neutrons(1-3). However, theoretical approaches to date do not yield consistent predictions of the precise limits of the 'island of stability'; experimental studies are therefore crucial. The bulk of experimental effort so far has been focused on the direct creation of superheavy elements in heavy ion fusion reactions, leading to the production of elements up to proton number Z = 118 ( refs 4, 5). Recently, it has become possible to make detailed spectroscopic studies(6,7) of nuclei beyond fermium (Z = 100), with the aim of understanding the underlying single-particle structure of superheavy elements. Here we report such a study of the nobelium isotope 254 No, with 102 protons and 152 neutrons - the heaviest nucleus studied in this manner to date. We find three excited structures, two of which are isomeric (metastable). One of these structures is firmly assigned to a two-proton excitation. These states are highly significant as their location is sensitive to single-particle levels above the gap in shell energies predicted at Z = 114, and thus provide a microscopic benchmark for nuclear models of the superheavy elements.	Univ Liverpool, Dept Phys, Liverpool L69 7ZE, Merseyside, England; Univ Jyvaskyla, Dept Phys, FI-40014 Jyvaskyla, Finland; Comenius Univ, Dept Nucl Phys & Biophys, Bratislava 84248, Slovakia; Univ Helsinki, Dept Phys Sci, FI-00014 Helsinki, Finland; Gesell Schwerionenforsch GSI, D-64291 Darmstadt, Germany; CEA Saclay, DAPNIA SPhN, F-91191 Gif Sur Yvette, France; Univ Notre Dame, Dept Phys, Notre Dame, IN 46556 USA; Univ Notre Dame, Joint Inst Nucl Astrophys, Notre Dame, IN 46556 USA	University of Liverpool; University of Jyvaskyla; Comenius University Bratislava; University of Helsinki; Helmholtz Association; GSI Helmholtz-Center for Heavy Ion Research; CEA; UDICE-French Research Universities; Universite Paris Saclay; University of Notre Dame; University of Notre Dame	Herzberg, RD (corresponding author), Univ Liverpool, Dept Phys, Liverpool L69 7ZE, Merseyside, England.	rdh@ns.ph.liv.ac.uk	Sun, Yang/P-2417-2015; Jones, Pete/AAC-9580-2019; Scholey, Catherine/G-2720-2014; Herzberg, Rolf-Dietmar/E-1558-2011; Butler, Peter/AAL-1876-2021; THEISEN, Christophe/A-9343-2015; Venhart, Martin/AAA-7249-2019; KORTEN, Wolfram/H-3043-2013; Pakarinen, Janne/F-6695-2010; Darby, Iain G/B-8161-2019; Grahn, Tuomas/AAH-9629-2019	Jones, Pete/0000-0001-7480-6603; Scholey, Catherine/0000-0002-8743-6071; THEISEN, Christophe/0000-0002-8509-1022; Venhart, Martin/0000-0003-2362-7079; KORTEN, Wolfram/0000-0002-3940-0816; Pakarinen, Janne/0000-0001-8944-8757; Darby, Iain G/0000-0003-2091-2616; Grahn, Tuomas/0000-0002-6255-2279; Butler, Peter/0000-0001-6080-9205; Greenlees, Paul/0000-0002-5986-5274; Uusitalo, Juha/0000-0003-3780-7222; Rahkila, Panu/0000-0003-4392-0782	STFC [EP/D002257/1] Funding Source: UKRI; Science and Technology Facilities Council [EP/D002257/1] Funding Source: researchfish	STFC(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC)); Science and Technology Facilities Council(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC))		Afanasjev AV, 2003, PHYS REV C, V67, DOI 10.1103/PhysRevC.67.024309; Armbruster P, 2000, ANNU REV NUCL PART S, V50, P411, DOI 10.1146/annurev.nucl.50.1.411; Bender M, 2003, NUCL PHYS A, V723, P354, DOI 10.1016/S0375-9474(03)01081-9; Bender M, 2001, PHYS LETT B, V515, P42, DOI 10.1016/S0370-2693(01)00863-2; Bender M, 1999, PHYS REV C, V60, DOI 10.1103/PhysRevC.60.034304; Butler PA, 2003, ACTA PHYS POL B, V34, P2107; Butler PA, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.202501; Cwiok S, 2005, NATURE, V433, P705, DOI 10.1038/nature03336; Duguet T, 2001, NUCL PHYS A, V679, P427, DOI 10.1016/S0375-9474(00)00370-5; Eeckhaudt S, 2005, EUR PHYS J A, V26, P227, DOI 10.1140/epja/i2005-10163-6; Egido JL, 2000, PHYS REV LETT, V85, P1198, DOI 10.1103/PhysRevLett.85.1198; GHIORSO A, 1973, PHYS REV C, V7, P2032, DOI 10.1103/PhysRevC.7.2032; Hara K, 1995, INT J MOD PHYS E, V4, P637, DOI 10.1142/S0218301395000250; Herzberg RD, 2004, J PHYS G NUCL PARTIC, V30, pR123, DOI 10.1088/0954-3899/30/4/R01; Hessberger FP, 2006, INT J MOD PHYS E, V15, P284, DOI 10.1142/S0218301306004119; Hofmann S, 2001, PROG PART NUCL PHYS, V46, P293, DOI 10.1016/S0146-6410(01)00134-X; Jones GD, 2002, NUCL INSTRUM METH A, V488, P471, DOI 10.1016/S0168-9002(02)00469-2; LAZAREV YA, 1989, PHYS SCRIPTA, V39, P422, DOI 10.1088/0031-8949/39/4/002; Leino M, 2004, ANNU REV NUCL PART S, V54, P175, DOI 10.1146/annurev.nucl.53.041002.110332; LEINO M, 1995, NUCL INSTRUM METH B, V99, P653, DOI 10.1016/0168-583X(94)00573-7; Morita K, 2004, J PHYS SOC JPN, V73, P2593, DOI 10.1143/JPSJ.73.2593; Oganessian YT, 2004, PHYS REV C, V70, DOI 10.1103/PhysRevC.70.064609; Page RD, 2003, NUCL INSTRUM METH B, V204, P634, DOI 10.1016/S0168-583X(02)02143-2; Reiter P, 1999, PHYS REV LETT, V82, P509, DOI 10.1103/PhysRevLett.82.509; Soloviev V. G., 1991, SOV J NUCL PHYS, V54, P1232; Sun Y, 2006, AIP CONF PROC, V819, P30; Sun Y, 2004, PHYS LETT B, V589, P83, DOI 10.1016/j.physletb.2004.03.066; TANDEL SK, UNPUB PHYS REV LETT; Walker P, 1999, NATURE, V399, P35, DOI 10.1038/19911; Xu FR, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.252501	30	176	183	1	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 24	2006	442	7105					896	899		10.1038/nature05069	http://dx.doi.org/10.1038/nature05069			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	076LT	16929293				2022-12-28	WOS:000239960500032
J	Nicastro, D; Schwartz, C; Pierson, J; Gaudette, R; Porter, ME; McIntosh, JR				Nicastro, Daniela; Schwartz, Cindi; Pierson, Jason; Gaudette, Richard; Porter, Mary E.; McIntosh, J. Richard			The molecular architecture of axonemes revealed by cryoelectron tomography	SCIENCE			English	Article							DYNEIN-REGULATORY-COMPLEX; RADIAL SPOKES; ARM DYNEIN; CHLAMYDOMONAS-FLAGELLA; ELECTRON TOMOGRAPHY; MUTANTS LACKING; SPERM FLAGELLUM; HEAVY-CHAIN; MOTOR; COMPONENTS	Eukaryotic flagella and cilia are built on a 9 + 2 array of microtubules plus 9250 accessory proteins, forming a biological machine called the axoneme. Here we describe the three-dimensional structure of rapidly frozen axonemes from Chlamydomonas and sea urchin sperm, using cryoelectron tomography and image processing to focus on the motor enzyme dynein. Our images suggest a model for the way dynein generates force to slide microtubules. They also reveal two dynein linkers that may provide "hard-wiring'' to coordinate motor enzyme action, both circumferentially and along the axoneme. Periodic densities were also observed inside doublet microtubules; these may contribute to doublet stability.	Univ Colorado, Dept Mol Cellular & Dev Biol, Lab 3D Electron Microscopy Cells, Boulder, CO 80309 USA; Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA	University of Colorado System; University of Colorado Boulder; University of Minnesota System; University of Minnesota Twin Cities	Nicastro, D (corresponding author), Brandeis Univ, 415 South St, Waltham, MA 02454 USA.	nicastro@colorado.edu	McIntosh, Richard/GLN-3533-2022	Nicastro, Daniela/0000-0002-0122-7173; McIntosh, Richard/0000-0002-7165-9748	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM055667] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 000592] Funding Source: Medline; NIGMS NIH HHS [2R37-GM55667, R37 GM055667] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AFZELIUS BA, 1995, TISSUE CELL, V27, P241, DOI 10.1016/S0040-8166(95)80044-1; Burgess SA, 2004, CURR OPIN STRUC BIOL, V14, P138, DOI 10.1016/j.sbi.2004.03.013; Burgess SA, 2003, NATURE, V421, P715, DOI 10.1038/nature01377; BURGESS SA, 1991, J CELL SCI, V98, P17; DiBella LM, 2004, MOL BIOL CELL, V15, P4633, DOI 10.1091/mbc.E04-06-0461; Downing KH, 2000, ANNU REV CELL DEV BI, V16, P89, DOI 10.1146/annurev.cellbio.16.1.89; GARDNER LC, 1994, J CELL BIOL, V127, P1311, DOI 10.1083/jcb.127.5.1311; GIBBONS IR, 1981, J CELL BIOL, V91, pS107, DOI 10.1083/jcb.91.3.107s; GOODENOUGH UW, 1989, CELL MOVEMENT, V1; Kamiya R, 2002, INT REV CYTOL, V219, P115; Koonce MP, 2004, TRENDS CELL BIOL, V14, P612, DOI 10.1016/j.tcb.2004.09.013; Koster AJ, 1997, J STRUCT BIOL, V120, P276, DOI 10.1006/jsbi.1997.3933; Lindemann CB, 2005, BIOPHYS J, V89, P1165, DOI 10.1529/biophysj.105.060681; Lupetti P, 2005, CELL MOTIL CYTOSKEL, V62, P69, DOI 10.1002/cm.20084; Luther P.K., 1992, ELECT TOMOGRAPHY 3 D, P39; MASTRONARDE DN, 1992, J CELL BIOL, V118, P1145, DOI 10.1083/jcb.118.5.1145; Myster SH, 1997, MOL BIOL CELL, V8, P607, DOI 10.1091/mbc.8.4.607; Nicastro D, 2005, P NATL ACAD SCI USA, V102, P15889, DOI 10.1073/pnas.0508274102; NOJIMA D, 1995, CURR BIOL, V5, P158, DOI 10.1016/S0960-9822(95)00037-6; Pan JM, 2005, LAB INVEST, V85, P452, DOI 10.1038/labinvest.3700253; PIPERNO G, 1994, J CELL BIOL, V125, P1109, DOI 10.1083/jcb.125.5.1109; Porter ME, 2000, J CELL BIOL, V151, pF37, DOI 10.1083/jcb.151.5.F37; SAKAKIBARA H, 1993, J CELL BIOL, V122, P653, DOI 10.1083/jcb.122.3.653; Sakato M, 2004, J STRUCT BIOL, V146, P58, DOI 10.1016/j.jsb.2003.09.026; Smith EF, 2004, CELL MOTIL CYTOSKEL, V57, P8, DOI 10.1002/cm.10155; Sui HX, 2006, NATURE, V442, P475, DOI 10.1038/nature04816; TAKADA S, 1994, J CELL BIOL, V126, P737, DOI 10.1083/jcb.126.3.737; WITMAN GB, 1978, J CELL BIOL, V76, P729, DOI 10.1083/jcb.76.3.729; WITMAN GB, 1982, SYM SOC EXP BIOL, P203; WITMAN GB, 1972, J CELL BIOL, V54, P507, DOI 10.1083/jcb.54.3.507; Woolley DM, 1997, J CELL SCI, V110, P85; Yanagisawa H, 2004, MOL BIOL CELL, V15, P2105, DOI 10.1091/mbc.E03-11-0854	32	592	595	1	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 18	2006	313	5789					944	948		10.1126/science.1128618	http://dx.doi.org/10.1126/science.1128618			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	074MR	16917055				2022-12-28	WOS:000239817000036
J	Stringer, JSA; Zulu, I; Levy, J; Stringer, EM; Mwango, A; Chi, BH; Mtonga, V; Reid, S; Cantrell, RA; Bulterys, M; Saag, MS; Marlink, RG; Mwinga, A; Ellerbrock, TV; Sinkala, M				Stringer, Jeffrey S. A.; Zulu, Isaac; Levy, Jens; Stringer, Elizabeth M.; Mwango, Albert; Chi, Benjamin H.; Mtonga, Vilepe; Reid, Stewart; Cantrell, Ronald A.; Bulterys, Marc; Saag, Michael S.; Marlink, Richard G.; Mwinga, Alwyn; Ellerbrock, Tedd V.; Sinkala, Moses			Rapid scale-up of Antiretroviral therapy at primary care sites in Zambia - Feasibility and early outcomes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNOLOGICAL RESPONSE; TUBERCULOSIS PATIENTS; RURAL DISTRICT; SURVIVAL; AFRICA; COHORT; INFECTION; MALAWI; HIV; PROGRESSION	Context The Zambian Ministry of Health has scaled-up human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) care and treatment services at primary care clinics in Lusaka, using predominately nonphysician clinicians. Objective To report on the feasibility and early outcomes of the program. Design, Setting, and Patients Open cohort evaluation of antiretroviral-naive adults treated at 18 primary care facilities between April 26, 2004, and November 5, 2005. Data were entered in real time into an electronic patient tracking system. Intervention Those meeting criteria for antiretroviral therapy ( ART) received drugs according to Zambian national guidelines. Main Outcome Measures Survival, regimen failure rates, and CD4 cell response. Results We enrolled 21 755 adults into HIV care, and 16 198 (75%) started ART. Among those starting ART, 9864 (61%) were women. Of 15 866 patients with documented World Health Organization ( WHO) staging, 11 573 (73%) were stage III or IV, and the mean (SD) entry CD4 cell count among the 15 336 patients with a baseline result was 143/mu L (123/mu L). Of 1142 patients receiving ART who died, 1120 had a reliable date of death. Of these patients, 792 (71%) died within 90 days of starting therapy ( early mortality rate: 26 per 100 patient-years), and 328 (29%) died after 90 days (post-90-day mortality rate: 5.0 per 100 patient-years). In multivariable analysis, mortality was strongly associated with CD4 cell count between 50/mu L and 199/mu L ( adjusted hazard ratio [AHR], 1.4; 95% confidence interval [CI], 1.0-2.0), CD4 cell count less than 50/mu L ( AHR, 2.2; 95% CI, 1.5-3.1), WHO stage III disease ( AHR, 1.8; 95% CI, 1.3-2.4), WHO stage IV disease ( AHR, 2.9; 95% CI, 2.0-4.3), low body mass index ( <16; AHR, 2.4; 95% CI, 1.8-3.2), severe anemia (<8.0 g/ dL; AHR, 3.1; 95% CI, 2.3-4.0), and poor adherence to therapy ( AHR, 2.9; 95% CI, 2.2-3.9). Of 11 714 patients at risk, 861 failed therapy by clinical criteria ( rate, 13 per 100 patient-years). The mean ( SD) CD4 cell count increase was 175/mu L (174/mu L) in 1361 of 1519 patients (90%) receiving treatment long enough to have a 12-month repeat. Conclusion Massive scale-up of HIV and AIDS treatment services with good clinical outcomes is feasible in primary care settings in sub-Saharan Africa. Most mortality occurs early, suggesting that earlier diagnosis and treatment may improve outcomes.	Ctr Infect Dis Res Zambia, Lusaka, Zambia; Univ Alabama Birmingham, Sch Med, Birmingham, AL USA; Univ Alabama Birmingham, Sch Publ Hlth, Birmingham, AL 35294 USA; Univ Teaching Hosp, Lusaka, Zambia; Univ N Carolina, Sch Publ Hlth, Chapel Hill, NC USA; Zambian Minist Hlth, Lusaka, Zambia; US Ctr Dis Control & Prevent, Global AIDS Program, Lusaka, Zambia; Elizabeth Glaser Pediat AIDS Fdn, Santa Monica, CA USA; US Ctr Dis Control & Prevent, Global AIDS Program, Atlanta, GA USA; Lusaka Urban Dist Hlth Management Board, Lusaka, Zambia	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Zambia; University of North Carolina; University of North Carolina Chapel Hill; Centers for Disease Control & Prevention - USA	Stringer, JSA (corresponding author), Ctr Infect Dis Res Zambia, Plot 1275 Lubutu Rd,POB 34681, Lusaka, Zambia.	stringer@uab.edu	Stringer, Jeffrey S. A./AAU-2342-2021	Stringer, Jeffrey/0000-0002-9590-7216; Reid, Stewart/0000-0001-7779-4820	FIC NIH HHS [K01-TW06670, K01-TW05708] Funding Source: Medline; NIAID NIH HHS [K23-AI01411, P30-AI027767] Funding Source: Medline; PHS HHS [U62/CCU12354] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [K01TW005708, K01TW006670] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001411, P30AI027767] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allison P. D., 1995, SURVIVAL ANAL USING; Anabwani G, 2005, NUTRITION, V21, P96, DOI 10.1016/j.nut.2004.09.013; Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2; Chi BH, 2005, JAIDS-J ACQ IMM DEF, V40, P381, DOI 10.1097/01.qai.0000159515.39982.c0; *CLINT HIV AIDS IN, CHANG EC CAR TREATM; Coetzee D, 2004, AIDS, V18, P887, DOI 10.1097/00002030-200404090-00006; Cozzi-Lepri A, 2002, J INFECT DIS, V185, P1062, DOI 10.1086/339821; De Cock KM, 2003, LANCET, V362, P1847, DOI 10.1016/S0140-6736(03)14906-9; DeSimone JA, 2000, ANN INTERN MED, V133, P447, DOI 10.7326/0003-4819-133-6-200009190-00013; Fairley CK, 2005, HIV MED, V6, P366, DOI 10.1111/j.1468-1293.2005.00322.x; Fawzi WW, 2004, NEW ENGL J MED, V351, P23, DOI 10.1056/NEJMoa040541; Ferradini L, 2006, LANCET, V367, P1335, DOI 10.1016/S0140-6736(06)68580-2; FUSCO H, 2005, 3 IAS C HIV PATH TRE; *GLOB FUND, FIGHT AIDS TUB MAL Z; Grabar S, 2000, ANN INTERN MED, V133, P401, DOI 10.7326/0003-4819-133-6-200009190-00007; Grossberg R, 2004, J CLIN EPIDEMIOL, V57, P1107, DOI 10.1016/j.jclinepi.2004.04.002; Harries AD, 2004, BMJ-BRIT MED J, V329, P1163, DOI 10.1136/bmj.329.7475.1163; Hirsch M, 1999, J INFECT DIS, V180, P659, DOI 10.1086/314948; Kitchen CM, 2001, CLIN INFECT DIS, V33, P466, DOI 10.1086/321900; Kober K, 2004, LANCET, V364, P103, DOI 10.1016/S0140-6736(04)16597-5; Langford K, 2003, Lab Hematol, V9, P29; Leroy V, 1997, AM J EPIDEMIOL, V145, P293; Lucas GM, 1999, ANN INTERN MED, V131, P81, DOI 10.7326/0003-4819-131-2-199907200-00002; Mayo J, 2002, ARCH INTERN MED, V162, P1095, DOI 10.1001/archinte.162.10.1095; McNutt LA, 2003, AM J EPIDEMIOL, V157, P940, DOI 10.1093/aje/kwg074; Mocroft A, 1999, J ACQ IMMUN DEF SYND, V22, P369; MQHAYI M, 2006, 13 C RETR OPP INF FE; PERNEGER TV, 1995, BMJ-BRIT MED J, V311, P1468, DOI 10.1136/bmj.311.7018.1468; SINKALA M, 2006, 13 C RETR OPP INF FE; STONEBURNER R, 1992, ARCH INTERN MED, V152, P2033, DOI 10.1001/archinte.152.10.2033; STRINGER JSA, 2005, 12 C RETR OPP INF FE; UNAIDS, 2004, 4 UNAIDS; *UNAIDS, LIV POS HIV AIDS; Weidle PJ, 2002, LANCET, V360, P34, DOI 10.1016/S0140-6736(02)09330-3; *WORLD BANK, REG FACT SHEET WORLD; World Health Organization, 2004, SCAL ANT THER RES LT; World Health Organization, 2003, TREATM TUB GUID NAT, DOI DOI 10.1016/S0035-9203(99)90185-2; Zachariah R, 2005, INT J TUBERC LUNG D, V9, P238; Zambian National AIDS Council, 2004, NAT GUID MAN CAR PAT; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	40	534	548	1	26	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 16	2006	296	7					782	793		10.1001/jama.296.7.782	http://dx.doi.org/10.1001/jama.296.7.782			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	073SR	16905784	Bronze			2022-12-28	WOS:000239763400019
J	Davies, C; Collins, R				Davies, Christina; Collins, Rory			Confidentiality and consent in medical research - Balancing potential risks and benefits of using confidential data	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Oxford, MRC, BHF, Canc Res UK,Clin Trial Serv Unit, Oxford OX3 7LF, England; Univ Oxford, Epidemiol Studies Unit, Oxford OX3 7LF, England	Cancer Research UK; University of Oxford; University of Oxford	Collins, R (corresponding author), Univ Oxford, MRC, BHF, Canc Res UK,Clin Trial Serv Unit, Oxford OX3 7LF, England.	secretary@ctsu.ox.ac.uk						*AC MED SCI, 2006, PERS DAT PUBL GOOD U, P1211; Calle EE, 1996, LANCET, V347, P1713, DOI 10.1016/S0140-6736(96)90806-5; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; *DEP HLTH, 2003, NHS COD PRACT CONF, P1211; Hewison J, 2006, BMJ-BRIT MED J, V333, P300, DOI 10.1136/bmj.333.7562.300; Kalra D, 2006, BRIT MED J, V333, P196, DOI 10.1136/bmj.333.7560.196; Molarius A, 1999, INT J OBESITY, V23, P116, DOI 10.1038/sj.ijo.0800772; *UK BIOB, ETH GOV FRAM, P1211	8	15	15	1	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 12	2006	333	7563					349	351		10.1136/bmj.333.7563.349	http://dx.doi.org/10.1136/bmj.333.7563.349			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	073VI	16902218	Green Published			2022-12-28	WOS:000239770300022
J	Nestle, M				Nestle, Marion			Food industry and health: mostly promises, little action	LANCET			English	Editorial Material									NYU, Dept Nutr Food Studies & Publ Hlth, New York, NY 10012 USA	New York University	Nestle, M (corresponding author), NYU, Dept Nutr Food Studies & Publ Hlth, 550 1st Ave, New York, NY 10012 USA.	marion.nestle@nyu.edu						*57 WORLD HLTH ASS, 2004, GLOB STRAT DIET; [Anonymous], 2004, LANCET, V363, P339; CANNON G, 1962, FOOD HLTH EXPERTS AG; Institute of Medicine, 2006, FOOD MARK CHILDR YOU; Lang T, 2006, FOOD IND DIET PHYS A; Mello MM, 2006, NEW ENGL J MED, V354, P2601, DOI 10.1056/NEJMhpr060227; NAIK G, 2004, WALL STREET J   0121, pD12; NESTLE M, 2013, FOOD POLITICS FOOD I; Waxman A., 2004, Development (London), V47, P75, DOI 10.1057/palgrave.development.1100032; WHO, 2003, DIET NUTR PREVENTION, V916; World Health Organization (WHO), 2013, WORLD HLTH REPORT 20; Zarocostas J, 2004, LANCET, V363, P1373, DOI 10.1016/S0140-6736(04)16090-X	12	17	18	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 12	2006	368	9535					564	565		10.1016/S0140-6736(06)69177-0	http://dx.doi.org/10.1016/S0140-6736(06)69177-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	074OF	16905005				2022-12-28	WOS:000239821000009
J	Ngondi, J; Onsarigo, A; Matthews, F; Reacher, M; Brayne, C; Baba, S; Solomon, AW; Zingeser, J; Emerson, PM				Ngondi, Jeremiah; Onsarigo, Alice; Matthews, Fiona; Reacher, Mark; Brayne, Carol; Baba, Samson; Solomon, Anthony W.; Zingeser, James; Emerson, Paul M.			Effect of 3 years of SAFE (surgery, antibiotics, facial cleanliness, and environmental change) strategy for trachoma control in southern Sudan: a cross-sectional study	LANCET			English	Article							BLINDING TRACHOMA; PROGRAM; TESTS	Background A trachoma control programme was started in southern Sudan in 2001. We did a 3-year evaluation to quantify uptake of SAFE (surgery, antibiotics, facial cleanliness, and environmental change) interventions, and to assess the prevalence of active trachoma and unclean faces. Methods Cross-sectional surveys, including clinical assessment of trachoma (WHO simplified system) and structured questionnaires, were done in four intervention areas at baseline and follow-up. Process indicators were uptake of SAFE components; primary outcome indicators included trachomatous inflammation-follicular (TF) and unclean face in children aged 1-9 years. Findings There was heterogeneous uptake of SAFE between intervention areas. Surgical coverage was low in all areas (range 0.5% of 428 individuals in Katigiri to 6% of 5002 in Kiech Kuon), antibiotic uptake ranged from 14% of 1257 individuals in Kiech Kuon to 75% of 954 in Katigiri, health education ranged from 49% of 190 households in Kiech Kuon to 90% of 182 in Padak, and latrine coverage from 3% of households in Tali to 16% in Katigiri. Substantial decreases in prevalence of TF and unclean faces were recorded in Katigiri and Tali, two of three sites where uptake of antibiotics and health education was high: TF decreased by 92% (95% Cl 87-96) and 91% (86-95), respectively, and unclean face decreased by 87% (78-94) and 38% (22-52), respectively. Moderate effects were recorded in Padak, an area with high coverage, with a 28% (14-41) decrease in TF and a 16% (7-25) decrease in unclean face. No evidence of decline was seen in Kiech Kuon, where uptake of antibiotics and health education was low, with a 2% (-10 to 12) decrease in TF and a 10% (-3 to 23) decrease in unclean face. Interpretation Our results show that substantial falls in active trachoma can occur where SAFE is implemented, and that good results could be achieved with the SAFE strategy in other trachoma-endemic areas.	Univ Cambridge, Inst Publ Hlth, Dept Publ Hlth & Primary Care, Cambridge CB2 2SR, England; Inst Publ Hlth, MRC, Biostat Unit, Cambridge, England; Carter Ctr, Nairobi, Kenya; Govt S Sudan, Minist Hlth, Juba, Sudan; London Sch Hyg & Trop Med, London WC1, England; Emory Univ, Carter Ctr, Atlanta, GA 30322 USA	University of Cambridge; MRC Biostatistics Unit; University of Cambridge; University of London; London School of Hygiene & Tropical Medicine; Emory University	Ngondi, J (corresponding author), Univ Cambridge, Inst Publ Hlth, Dept Publ Hlth & Primary Care, Robinson Way, Cambridge CB2 2SR, England.	jn250@cam.ac.uk	Brayne, Carol/AAA-4285-2020; Matthews, Fiona/O-6932-2015; Reacher, Mark/Y-6979-2018	Brayne, Carol/0000-0001-5307-663X; Matthews, Fiona/0000-0002-1728-2388; Reacher, Mark/0000-0001-6871-7903; Solomon, Anthony/0000-0001-7101-6649; Ngondi, Jeremiah/0000-0003-4357-4816; Emerson, Paul/0000-0002-6478-8816	Medical Research Council [MC_U105292687] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		[Anonymous], 2004, 8 M WHO ALL GLOB EL; Armitage P, 2002, STAT METHODS MED RES, P648; BLAND JM, 1995, BRIT MED J, V310, P170, DOI 10.1136/bmj.310.6973.170; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Dawson CR, 1997, CLIN INFECT DIS, V24, P363, DOI 10.1093/clinids/24.3.363; EFRON B, 1987, J AM STAT ASSOC, V82, P171, DOI 10.2307/2289144; Ewald DP, 2003, MED J AUSTRALIA, V178, P65, DOI 10.5694/j.1326-5377.2003.tb05065.x; Francis V., 1995, ACHIEVING COMMUNITY; *INT TRACH IN, 2002, ZITHR CONTR TRACH PR; Kumaresan JA, 2003, AM J TROP MED HYG, V69, P24, DOI 10.4269/ajtmh.2003.69.24; Mabey DCW, 2003, LANCET, V362, P223, DOI 10.1016/S0140-6736(03)13914-1; Mariotti S. P., 2001, WHOPBDGET007REV1; Mariotti SP, 2004, NEW ENGL J MED, V351, P2004, DOI 10.1056/NEJMe048205; Munoz B, 1997, EPIDEMIOL REV, V19, P205, DOI 10.1093/oxfordjournals.epirev.a017953; Ngondi J, 2005, B WORLD HEALTH ORGAN, V83, P904; REACHER M, 1998, WHOPBL9329; Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844; Solomon AW, 2004, CLIN MICROBIOL REV, V17, P982, DOI 10.1128/CMR.17.4.982-1011.2004; *STARBASE, WHO POL CAMP NIDS 20; *STAT CORP, 2003, STAT 8 US GUID, P270; THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477; Turner AG, 1996, INT J EPIDEMIOL, V25, P198, DOI 10.1093/ije/25.1.198; West SK, 2005, LANCET, V366, P1296, DOI 10.1016/S0140-6736(05)67529-0; *WHO, 1997, WHOPBL9656; Woodard S.H., 2001, DESCRIPTION COMP MET; World Health Organization, 1997, WHOPBL9760; *WORLD HLTH ASS, 1998, 51 WORLD HLTH ASS; Wright HR, 2005, LANCET INFECT DIS, V5, P313, DOI 10.1016/S1473-3099(05)70116-X; [No title captured]	29	44	44	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 12	2006	368	9535					589	595		10.1016/S0140-6736(06)69202-7	http://dx.doi.org/10.1016/S0140-6736(06)69202-7			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	074OF	16905023				2022-12-28	WOS:000239821000032
J	Henderson, GM				Henderson, Gideon M.			Climate - Caving in to new chronologies	SCIENCE			English	Editorial Material							LATE PLEISTOCENE; GLACIAL TERMINATIONS; MONSOON RECORD; HULU CAVE	Speleothems formed in caves,,such as stalagmites, can be dated precisely and are increasingly providing detailed and accurate records of past climates.	Univ Oxford, Dept Earth Sci, Oxford OX1 3PR, England	University of Oxford	Henderson, GM (corresponding author), Univ Oxford, Dept Earth Sci, Oxford OX1 3PR, England.	gideonh@earth.ox.ac.uk		Henderson, Gideon/0000-0002-6279-7137	Natural Environment Research Council [NE/B503925/1] Funding Source: researchfish	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Cheng H, 2006, GEOLOGY, V34, P217, DOI 10.1130/G22289.1; Fleitmann D, 2003, SCIENCE, V300, P1737, DOI 10.1126/science.1083130; Henderson GM, 2000, NATURE, V404, P61, DOI 10.1038/35003541; Huybers P, 2005, NATURE, V434, P491, DOI 10.1038/nature03401; IMBRIE J, 1984, MILANKOVITCH CLIMA 1, P269; MARTINSON DG, 1987, QUATERNARY RES, V27, P1, DOI 10.1016/0033-5894(87)90046-9; McManus JF, 1999, SCIENCE, V283, P971, DOI 10.1126/science.283.5404.971; Siegenthaler U, 2005, SCIENCE, V310, P1313, DOI 10.1126/science.1120130; Wang XF, 2004, NATURE, V432, P740, DOI 10.1038/nature03067; Wang YJ, 2001, SCIENCE, V294, P2345, DOI 10.1126/science.1064618; Yuan DX, 2004, SCIENCE, V304, P575, DOI 10.1126/science.1091220	11	77	98	2	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 4	2006	313	5787					620	622		10.1126/science.1128980	http://dx.doi.org/10.1126/science.1128980			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	072IQ	16888126				2022-12-28	WOS:000239667500026
J	Sanchez-Fructuoso, AI; Marques, M; Prats, D; Conesa, J; Calvo, N; Perez-Contin, MJ; Blazquez, J; Fernandez, C; Corral, E; Del Rio, F; Nunez, JR; Barrientos, A				Sanchez-Fructuoso, Ana I.; Marques, Maria; Prats, Dolores; Conesa, Jose; Calvo, Natividad; Perez-Contin, M. Jesus; Blazquez, Jesus; Fernandez, Cristina; Corral, Ervigio; Del Rio, Francisco; Nunez, Jose R.; Barrientos, Alberto			Victims of cardiac arrest occurring outside the hospital: A source of transplantable kidneys	ANNALS OF INTERNAL MEDICINE			English	Article							HEART-BEATING DONORS; NONHEARTBEATING DONORS; ORGAN DONORS; EXPERIENCE; RECIPIENTS; PRESERVATION; INDUCTION; SHORTAGE; SURVIVAL; PROGRAM	Background: The use of non-heart-beating donors could help shorten the list of patients who are waiting for a kidney transplant. Several reports describe acceptable results of transplantations from non-heart-beating donors who had in-hospital cardiac arrest, but few reports describe results of transplantations from non-heart-beating donors who had cardiac arrest that occurred outside of the hospital (Maastricht type I and type II donors). Objective: To compare graft survival rates among patients receiving kidneys from heart-beating donors versus type I or type II non-heart-beating donors. Design: Retrospective cohort study of transplantations performed from January 1989 to December 2004. Setting: Kidney transplant program of a teaching hospital in Madrid, Spain. Patients: 320 patients who received a kidney transplant from non-heart-beating donors (273 type I donors and 47 type 11 donors) and 584 patients who received a kidney transplant from heart-beating donors divided into 2 groups according to donor age (age < 60 years [n = 458] and age 60 years [n = 126]). Measurements: The primary outcome measure was graft survival. The median follow-up time was 68 months (range, 9 to 198 months). Results: One- and 5-year graft survival rates were 90.7% and 85.5%, respectively, for transplants from heart-beating donors younger than 60 years of age; 79.8% and 73.3%, respectively, for transplants from heart-beating donors 60 years of age or older (P < 0.001); and 87.4% and 82.1%, respectively, for transplants from non-heart-beating donors (P = 0.22 [vs. those from heart-beating donors < 60 years of age] and P = 0.014 [vs. those from heart-beating donors : 60 years of age]). Graft survival did not differ between patients who received kidneys from heart-beating donors younger than 60 years of age and patients who received kidneys from non-heart-beating donors. Limitations: This single-site, observational study was retrospective, and immunosuppressive therapy regimens given to transplant recipients varied over time. Conclusions: Outcomes of transplants from non-heart-beating donors and younger heart-beating donors are similar, and results for transplants from non-heart-beating donors improved compared with those from older heart-beating donors. on the basis of these results, the authors encourage other transplant units to adopt the use of type I and type 11 non-heart-beating donors.	Univ Complutense Madrid, Dept Nephrol, Hosp Clin San Carlos, E-28040 Madrid 28040, Spain; Serv Atenc Municipal Urgencias Madrid, Madrid, Spain	Complutense University of Madrid; Hospital Clinico San Carlos	Sanchez-Fructuoso, AI (corresponding author), Univ Complutense Madrid, Dept Nephrol, Hosp Clin San Carlos, Ave Martin Lagos SN, E-28040 Madrid 28040, Spain.	sanchezfruct@telefonica.net	Fructuoso, Ana Isabel i Sanchez/U-5623-2017; Marques, María/E-1902-2017; Pérez, Cristina Fernández/I-2220-2015	Fructuoso, Ana Isabel i Sanchez/0000-0001-7017-9729; Marques, María/0000-0001-9691-2546; Pérez, Cristina Fernández/0000-0001-9853-6257				BOOSTER MH, 1993, TRANSPLANTATION, V56, P613, DOI 10.1097/00007890-199309000-00022; Brook NR, 2003, AM J TRANSPLANT, V3, P614, DOI 10.1034/j.1600-6143.2003.00113.x; Cho YW, 1998, NEW ENGL J MED, V338, P221, DOI 10.1056/NEJM199801223380403; COLPART JJ, 1991, ETCO NEWSLETTER, V9, P5; DAEMEN JHC, 1995, TRANSPLANT P, V27, P2906; Daemen JHC, 1996, TRANSPL P, V28, P105; Danovitch GM, 2002, J AM SOC NEPHROL, V13, P528, DOI 10.1681/ASN.V132528; DIDLAKE RH, 1984, TRANSPLANTATION, V38, P90; FUJITA T, 1989, TRANSPLANT P, V21, P1215; GARVIN PJ, 1980, ARCH SURG-CHICAGO, V115, P180; Gok MA, 2002, TRANSPLANTATION, V74, P664, DOI 10.1097/00007890-200209150-00013; Gomez M, 1997, TRANSPLANT P, V29, P3478, DOI 10.1016/S0041-1345(97)01116-0; Gonzalez-Segura C, 1998, TRANSPLANTATION, V65, P1465, DOI 10.1097/00007890-199806150-00010; KOFFMAN CG, 1993, TRANSPLANT P, V25, P1527; KOOTSTRA G, 1995, TRANSPLANT P, V27, P2893; KOOTSTRA G, 1991, TRANSPLANT P, V23, P910; KOOTSTRA G, 1986, TRANSPLANT P, V18, P1410; Lagiewska B, 1996, TRANSPLANT P, V28, P165; Mizutani K, 2001, TRANSPLANTATION, V72, P1376, DOI 10.1097/00007890-200110270-00007; Nicholson ML, 1997, TRANSPL P, V29, P1386, DOI 10.1016/S0041-1345(96)00605-7; Ojo AO, 2001, J AM SOC NEPHROL, V12, P589, DOI 10.1681/ASN.V123589; Racusen LC, 1999, KIDNEY INT, V55, P713, DOI 10.1046/j.1523-1755.1999.00299.x; RUERS TJM, 1986, TRANSPLANT P, V18, P408; Sanchez-Fructuoso AI, 2005, TRANSPLANT INT, V18, P596, DOI 10.1111/j.1432-2277.2005.00100.x; Sanchez-Fructuoso AI, 2003, J NEPHROL, V16, P387; Sanchez-Fructuoso AI, 2000, J AM SOC NEPHROL, V11, P350, DOI 10.1681/ASN.V112350; SCHLUMPF R, 1995, TRANSPLANT P, V27, P2942; STRONG RW, 1995, LANCET, V345, P1064, DOI 10.1016/S0140-6736(95)90812-9; Sudhindran S, 2003, CLIN TRANSPLANT, V17, P93, DOI 10.1034/j.1399-0012.2003.00014.x; van der Hoeven JAB, 1999, TRANSPLANTATION, V68, P1884, DOI 10.1097/00007890-199912270-00012; Weber M, 2002, NEW ENGL J MED, V347, P248, DOI 10.1056/NEJMoa020274; WIJNEN RMH, 1995, LANCET, V345, P1067, DOI 10.1016/S0140-6736(95)90815-3; Wilson CH, 2005, BRIT J SURG, V92, P681, DOI 10.1002/bjs.4976	33	134	139	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	2006	145	3					157	164		10.7326/0003-4819-145-3-200608010-00003	http://dx.doi.org/10.7326/0003-4819-145-3-200608010-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	070MN	16880457				2022-12-28	WOS:000239526800001
J	Klimanskaya, I; Chung, Y; Becker, S; Lu, SJ; Lanza, R				Klimanskaya, Irina; Chung, Young; Becker, Sandy; Lu, Shi-Jiang; Lanza, Robert			Human embryonic stem cell lines derived from single blastomeres	NATURE			English	Article							MOUSE BLASTOMERES; HUMAN BLASTOCYSTS; IN-VITRO; STAGE; DERIVATION; EXPRESSION; DIAGNOSIS; BIOPSY; DNA	The derivation of human embryonic stem (hES) cells currently requires the destruction of ex utero embryos(1-4). A previous study in mice indicates that it might be possible to generate embryonic stem (ES) cells using a single-cell biopsy similar to that used in preimplantation genetic diagnosis (PGD), which does not interfere with the embryo's developmental potential(5). By growing the single blastomere overnight, the resulting cells could be used for both genetic testing and stem cell derivation without affecting the clinical outcome of the procedure. Here we report a series of ten separate experiments demonstrating that hES cells can be derived from single blastomeres. In this proof-of-principle study, multiple biopsies were taken from each embryo using micromanipulation techniques and none of the biopsied embryos were allowed to develop in culture. Nineteen ES-cell-like outgrowths and two stable hES cell lines were obtained. The latter hES cell lines maintained undifferentiated proliferation for more than eight months, and showed normal karyotype and expression of markers of pluri-potency, including Oct-4, SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, nanog and alkaline phosphatase. These cells retained the potential to form derivatives of all three embryonic germ layers both in vitro and in teratomas. The ability to create new stem cell lines and therapies without destroying embryos would address the ethical concerns of many, and allow the generation of matched tissue for children and siblings born from transferred PGD embryos.	Adv Cell Technol, Worcester, MA 01605 USA		Lanza, R (corresponding author), Adv Cell Technol, 381 Plantat St, Worcester, MA 01605 USA.	rlanza@advancedcell.com	Chung, Young Gie/AAC-8149-2020	Lanza, Robert/0000-0002-3047-3074				Chung Y, 2006, NATURE, V439, P216, DOI 10.1038/nature04277; Cowan CA, 2004, NEW ENGL J MED, V350, P1353, DOI 10.1056/NEJMsr040330; Deb K, 2006, SCIENCE, V311, P992, DOI 10.1126/science.1120925; Fredsted T, 2004, AM J PRIMATOL, V64, P345, DOI 10.1002/ajp.20083; GEBER S, 1995, HUM REPROD, V10, P1492, DOI 10.1093/HUMREP/10.6.1492; HANDYSIDE AH, 1990, NATURE, V344, P768, DOI 10.1038/344768a0; Hansis C, 2001, MOL HUM REPROD, V7, P155, DOI 10.1093/molehr/7.2.155; HARDY K, 1990, HUM REPROD, V5, P708, DOI 10.1093/oxfordjournals.humrep.a137173; Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/clo.2004.6.217; Klimanskaya I, 2004, HDB STEM CELLS, V1, P437; KLIMANSKAYA I, 2005, LANCET, V361, P1496; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; Lanza R., 2006, ESSENTIALS STEM CELL; Lanzendorf SE, 2001, FERTIL STERIL, V76, P132, DOI 10.1016/S0015-0282(01)01825-8; Ludwig TE, 2006, NAT BIOTECHNOL, V24, P185, DOI 10.1038/nbt1177; Magli MC, 2006, HUM REPROD, V21, P2656, DOI 10.1093/humrep/del228; Mitalipova M, 2003, STEM CELLS, V21, P521, DOI 10.1634/stemcells.21-5-521; Nagy A., 2002, MANIPULATING MOUSE E; Piotrowska-Nitsche K, 2005, DEVELOPMENT, V132, P479, DOI 10.1242/dev.01602; Richards M, 2002, NAT BIOTECHNOL, V20, P933, DOI 10.1038/nbt726; Sills ES, 2005, THEOR BIOL MED MODEL, V2, DOI 10.1186/1742-4682-2-25; Staessen C, 2004, HUM REPROD, V19, P2849, DOI 10.1093/humrep/deh536; Strelchenko N, 2004, REPROD BIOMED ONLINE, V9, P623, DOI 10.1016/S1472-6483(10)61772-5; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Veeck LL., 1999, ATLAS HUMAN GAMETES; WEBER DJ, IN PRESS METHODS ENZ, V420; YOUNG H, 2006, ESSENTIALS STEM CELL, P317	27	367	428	0	62	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 23	2006	444	7118					481	485		10.1038/nature05142	http://dx.doi.org/10.1038/nature05142			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	108BQ	16929302				2022-12-28	WOS:000242215700045
J	Tramer, MR; von Elm, E; Loubeyre, P; Hauser, C				Tramer, Martin R.; von Elm, Erik; Loubeyre, Pierre; Hauser, Conrad			Pharmacological prevention of serious anaphylactic reactions due to iodinated contrast media: systematic review	BRITISH MEDICAL JOURNAL			English	Review							HIGH-RISK PATIENTS; ADVERSE-REACTIONS; GENERALIZED REACTIONS; ALLEVIATE REACTIONS; CONTROLLED TRIALS; CORTICOSTEROIDS; PRETREATMENT; PREMEDICATION; QUALITY	Objective 16 review the efficacy of pharmacological prevention of serious reactions to iodinated contrast media. Design Systematic review. Data sources Systematic search (multiple databases, bibliographies, all languages, to October 2005) for randomised comparisons of pretreatment with placebo or no treatment (control) in patients receiving iodinated contrast media. Review methods Trial quality was assessed by all investigators. Information on trial design, population, interventions, and outcomes was abstracted by one investigator and cross checked by the others. Data were combined by using Peto odds ratios with 95% confidence intervals. Results Nine trials (1975-96, 10 011 adults) tested H, antihistamines, corticosteroids, and an HI-H, combination. No trial included exclusively patients with a history of allergic reactions. Many outcomes were not allergy related, and only a few were potentially life threatening. No reports on death, cardiopulmonary resuscitation, irreversible neurological deficit, or prolonged hospital stays were found. In two trials, 3/778 (0.4%) patients who received oral methylprednisolone 2x32 mg or intravenous prednisolone 250 mg had laryngeal oedemia compared with 11/769 (1.4%) controls (odds ratio 0.31, 95% confidence interval 0.11 to 0.88). In two trials, 7/3093 (0.2%) patients who received oral methylprednisolone 2x32 mg had a composite outcome (including shock, bronchospasm, and laryngospasm) compared with 20/2178 (0.9%) controls (odds ratio 0.28, 0.13 to 0.60). In one trial, 1/196 (0.5%) patients who received intravenous clemastine 0.03 mg/kg and cimetidine 2-5 mg/kg had angio-oedema compared with 8/194 (4.1%) controls (odds ratio 0.20, 0.05 to 0.76). Conclusions Life threatening anaphylactic reactions due to iodinated contrast media are rare. In unselected patients, the usefulness of premedication is doubtful, as a large number of patients need to receive premedication to prevent one potentially serious reaction. Data supporting the use of premedication in patients with a history of allergic reactions arc lacking. Physicians who are dealing with these patients should not rely on the efficacy of premedication.	Univ Hosp Geneva, Div Anaesthesiol, CH-1211 Geneva, Switzerland; Univ Hosp Geneva, Dept Radiol, CH-1211 Geneva, Switzerland; Univ Hosp Geneva, Div Immunol & Allergy, Allergy Unit, CH-1211 Geneva, Switzerland; Univ Bern, Dept Social & Prevent Med, CH-3012 Bern, Switzerland	University of Geneva; University of Geneva; University of Geneva; University of Bern	Tramer, MR (corresponding author), Univ Hosp Geneva, Div Anaesthesiol, CH-1211 Geneva, Switzerland.	martin.tramer@hcuge.ch		von Elm, Erik/0000-0002-7412-0406				American College of Radiology, MAN CONTR MED; Andrew E, 2004, J TOXICOL-CLIN TOXIC, V42, P325, DOI 10.1081/CLT-120037430; Bartlett Murray J, 2003, Australas Radiol, V47, P363, DOI 10.1046/j.1440-1673.2003.01203.x; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; BERTRAND PR, 1992, RADIOLOGY, V184, P383, DOI 10.1148/radiology.184.2.1620832; CHEVROT A, 1988, ANN RADIOL, V31, P193; Dewachter P, 2003, CAH DANESTHESIOL, V51, P341, DOI [10.1136/bmj.38905.634132, DOI 10.1136/BMJ.38905.634132]; Freed KS, 2001, AM J ROENTGENOL, V176, P1389, DOI 10.2214/ajr.176.6.1761389; Ginsberg L, 1996, BRIT J NEUROSURG, V10, P285, DOI 10.1080/02688699650040151; GREENBERGER PA, 1991, J ALLERGY CLIN IMMUN, V87, P867, DOI 10.1016/0091-6749(91)90135-B; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; KATAYAMA H, 1990, RADIOLOGY, V175, P621, DOI 10.1148/radiology.175.3.2343107; Laroche D, 1998, RADIOLOGY, V209, P183, DOI 10.1148/radiology.209.1.9769830; LASSER EC, 1994, AM J ROENTGENOL, V162, P523, DOI 10.2214/ajr.162.3.8109489; LASSER EC, 1987, NEW ENGL J MED, V317, P845, DOI 10.1056/NEJM198710013171401; LASSER EC, 1988, INVEST RADIOL, V23, pS193, DOI 10.1097/00004424-198809001-00035; LIEBERMAN P, 2005, J ALLERGY CLIN IMMUN, V115, pS483, DOI DOI 10.1016/J.JACI.2005.01.010; MOHAN JC, 1984, CATHETER CARDIO DIAG, V10, P465, DOI 10.1002/ccd.1810100507; Montori VM, 2005, BMJ-BRIT MED J, V330, P594, DOI 10.1136/bmj.330.7491.594; Morcos SK, 2001, EUR RADIOL, V11, P1720, DOI 10.1007/s003300000778; Munechika H, 2003, EUR RADIOL, V13, P185, DOI 10.1007/s00330-002-1339-9; O'Neill JM, 2001, CLIN RADIOL, V56, P321, DOI 10.1053/crad.2000.0669; Pasternak JJ, 2004, J NEUROSURG ANESTH, V16, P122, DOI 10.1097/00008506-200404000-00003; RING J, 1985, INT ARCH ALLER A IMM, V78, P9, DOI 10.1159/000233854; Robertson PS, 1997, SURG NEUROL, V48, P292, DOI 10.1016/S0090-3019(97)00161-4; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SMALL P, 1982, CLIN ALLERGY, V12, P289, DOI 10.1111/j.1365-2222.1982.tb02530.x; SMITH DC, 1995, CAN ASSOC RADIOL J, V46, P449; Wicke L, 1975, Wien Med Wochenschr, V725, P698	29	126	139	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 30	2006	333	7570					675	679B		10.1136/bmj.38905.634132.AE	http://dx.doi.org/10.1136/bmj.38905.634132.AE			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	092AA	16880193	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000241068200014
J	Murakami, S; Nakashima, R; Yamashita, E; Matsumoto, T; Yamaguchi, A				Murakami, Satoshi; Nakashima, Ryosuke; Yamashita, Eiki; Matsumoto, Takashi; Yamaguchi, Akihito			Crystal structures of a multidrug transporter reveal a functionally rotating mechanism	NATURE			English	Article							EFFLUX PUMP; PROTEIN; ACRB; RESISTANCE; TOLC; REFINEMENT; SOFTWARE; SYSTEM; GENES; PERIPLASM	AcrB is a principal multidrug efflux transporter in Escherichia coli that cooperates with an outer-membrane channel, TolC, and a membrane-fusion protein, AcrA. Here we describe crystal structures of AcrB with and without substrates. The AcrB - drug complex consists of three protomers, each of which has a different conformation corresponding to one of the three functional states of the transport cycle. Bound substrate was found in the periplasmic domain of one of the three protomers. The voluminous binding pocket is aromatic and allows multi-site binding. The structures indicate that drugs are exported by a three-step functionally rotating mechanism in which substrates undergo ordered binding change.	Osaka Univ, Inst Sci & Ind Res, Dept Cell Membrane Biol, Osaka 5670047, Japan; Japan Sci & Technol Agcy, CREST, Kawaguchi, Saitama 3320012, Japan; Japan Sci & Technol Agcy, PRESTO, Kawaguchi, Saitama 3320012, Japan; Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; Osaka Univ, Fac Pharmaceut Sci, Suita, Osaka 5650871, Japan; SOSHO Inc, Osaka 5410053, Japan	Osaka University; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST); Osaka University; Osaka University	Murakami, S (corresponding author), Osaka Univ, Inst Sci & Ind Res, Dept Cell Membrane Biol, Osaka 5670047, Japan.	mura@sanken.osaka-u.ac.jp	Yamashita, Eiki/V-6758-2019; Murakami, Satoshi/E-8155-2015	Yamashita, Eiki/0000-0002-4278-0039; Murakami, Satoshi/0000-0001-5553-7663				Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Akama H, 2004, J BIOL CHEM, V279, P25939, DOI 10.1074/jbc.C400164200; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BOYER PD, 1989, FASEB J, V3, P2164, DOI 10.1096/fasebj.3.10.2526771; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Grkovic S, 2003, BIOCHEMISTRY-US, V42, P15226, DOI 10.1021/bi035447+; Guan L, 2001, J BACTERIOL, V183, P1734, DOI 10.1128/JB.183.5.1734-1739.2001; Higgins MK, 2004, P NATL ACAD SCI USA, V101, P9994, DOI 10.1073/pnas.0400375101; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1999, ACTA CRYSTALLOGR D, V55, P941, DOI 10.1107/S0907444999001031; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; Koronakis V, 2000, NATURE, V405, P914, DOI 10.1038/35016007; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Li XZ, 2004, DRUGS, V64, P159, DOI 10.2165/00003495-200464020-00004; MA D, 1993, J BACTERIOL, V175, P6299, DOI 10.1128/JB.175.19.6299-6313.1993; MA D, 1995, MOL MICROBIOL, V16, P45, DOI 10.1111/j.1365-2958.1995.tb02390.x; Mao WM, 2002, MOL MICROBIOL, V46, P889, DOI 10.1046/j.1365-2958.2002.03223.x; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mikolosko J, 2006, STRUCTURE, V14, P577, DOI 10.1016/j.str.2005.11.015; Murakami S, 2004, J BIOL CHEM, V279, P3743, DOI 10.1074/jbc.M308893200; Murakami S, 2003, CURR OPIN STRUC BIOL, V13, P443, DOI 10.1016/S0959-440X(03)00109-X; Murakami S, 2002, NATURE, V419, P587, DOI 10.1038/nature01050; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nikaido H, 2000, TRENDS MICROBIOL, V8, P481, DOI 10.1016/S0966-842X(00)01864-3; Nishino K, 2001, J BACTERIOL, V183, P5803, DOI 10.1128/JB.183.20.5803-5812.2001; Okusu H, 1996, J BACTERIOL, V178, P306, DOI 10.1128/JB.178.1.306-308.1996; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Poole K, 2001, CURR OPIN MICROBIOL, V4, P500, DOI 10.1016/S1369-5274(00)00242-3; Schumacher MA, 2001, SCIENCE, V294, P2158, DOI 10.1126/science.1066020; Schumacher MA, 2002, MOL MICROBIOL, V45, P885, DOI 10.1046/j.1365-2958.2002.03039.x; Sulavik MC, 2001, ANTIMICROB AGENTS CH, V45, P1126, DOI 10.1128/AAC.45.4.1126-1136.2001; Tamura N, 2005, BIOCHEMISTRY-US, V44, P11115, DOI 10.1021/bi050452u; Thanassi DG, 1997, J BACTERIOL, V179, P2512, DOI 10.1128/jb.179.8.2512-2518.1997; Tikhonova EB, 2004, J BIOL CHEM, V279, P32116, DOI 10.1074/jbc.M402230200; Touze T, 2004, MOL MICROBIOL, V53, P697, DOI 10.1111/j.1365-2958.2004.04158.x; Tseng Tsai-Tien, 1999, Journal of Molecular Microbiology and Biotechnology, V1, P107; Yao M, 2006, ACTA CRYSTALLOGR D, V62, P189, DOI 10.1107/S0907444905038965; Zgurskaya HI, 1999, P NATL ACAD SCI USA, V96, P7190, DOI 10.1073/pnas.96.13.7190	43	545	568	1	60	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 14	2006	443	7108					173	179		10.1038/nature05076	http://dx.doi.org/10.1038/nature05076			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	083OB	16915237				2022-12-28	WOS:000240467000038
J	Russell, RJ; Haire, LF; Stevens, DJ; Collins, PJ; Lin, YP; Blackburn, GM; Hay, AJ; Gamblin, SJ; Skehel, JJ				Russell, Rupert J.; Haire, Lesley F.; Stevens, David J.; Collins, Patrick J.; Lin, Yi Pu; Blackburn, G. Michael; Hay, Alan J.; Gamblin, Steven J.; Skehel, John J.			The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design	NATURE			English	Article							OSELTAMIVIR CARBOXYLATE; 3-DIMENSIONAL STRUCTURE; VIRUS NEURAMINIDASE; INHIBITORS; SENSITIVITY; POTENT; RESISTANCE; COMPLEX	The worldwide spread of H5N1 avian influenza has raised concerns that this virus might acquire the ability to pass readily among humans and cause a pandemic. Two anti-influenza drugs currently being used to treat infected patients are oseltamivir (Tamiflu) and zanamivir (Relenza), both of which target the neuraminidase enzyme of the virus. Reports of the emergence of drug resistance make the development of new anti-influenza molecules a priority. Neuraminidases from influenza type A viruses form two genetically distinct groups: group-1 contains the N1 neuraminidase of the H5N1 avian virus and group-2 contains the N2 and N9 enzymes used for the structure-based design of current drugs. Here we show by X-ray crystallography that these two groups are structurally distinct. Group-1 neuraminidases contain a cavity adjacent to their active sites that closes on ligand binding. Our analysis suggests that it may be possible to exploit the size and location of the group-1 cavity to develop new anti-influenza drugs.	MRC, Natl Inst Med Res, London NW7 1AA, England; Univ Sheffield, Dept Chem, Sheffield S3 7HF, S Yorkshire, England	MRC National Institute for Medical Research; University of Sheffield	Skehel, JJ (corresponding author), MRC, Natl Inst Med Res, Mill Hill, London NW7 1AA, England.	mbrenna@nimr.mrc.ac.uk		Gamblin, Steve/0000-0001-5331-639X	MRC [MC_U117584222, MC_U117512708, MC_U117512711] Funding Source: UKRI; Medical Research Council [MC_U117512708, MC_U117584222, MC_U117512711] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		[Anonymous], 1980, B WORLD HEALTH ORGAN, V58, P585; Aubin JT, 2005, EMERG INFECT DIS, V11, P1515; Babu YS, 2000, J MED CHEM, V43, P3482, DOI 10.1021/jm0002679; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAKER AT, 1987, PROTEINS, V2, P111, DOI 10.1002/prot.340020205; Bender C, 1999, VIROLOGY, V254, P115, DOI 10.1006/viro.1998.9529; BOSSARTWHITAKER P, 1993, J MOL BIOL, V232, P1069, DOI 10.1006/jmbi.1993.1461; Brouillette WJ, 2003, BIOORGAN MED CHEM, V11, P2739, DOI 10.1016/S0968-0896(03)00271-2; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURMEISTER WP, 1993, STRUCTURE, V1, P19, DOI 10.1016/0969-2126(93)90005-2; BURMEISTER WP, 1992, EMBO J, V11, P49, DOI 10.1002/j.1460-2075.1992.tb05026.x; Carr J, 2002, ANTIVIR RES, V54, P79, DOI 10.1016/S0166-3542(01)00215-7; COLMAN PM, 1983, NATURE, V303, P41, DOI 10.1038/303041a0; Crawford PC, 2005, SCIENCE, V310, P482, DOI 10.1126/science.1117950; de Jong MD, 2005, NEW ENGL J MED, V353, P2667, DOI 10.1056/NEJMoa054512; Gubareva LV, 2001, J INFECT DIS, V183, P523, DOI 10.1086/318537; Ha Y, 2001, P NATL ACAD SCI USA, V98, P11181, DOI 10.1073/pnas.201401198; Ives J, 2000, J CLIN VIROL, V18, P251; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim CU, 1997, J AM CHEM SOC, V119, P681, DOI 10.1021/ja963036t; Kiso M, 2004, LANCET, V364, P759, DOI 10.1016/S0140-6736(04)16934-1; Le QM, 2005, NATURE, V437, P1108, DOI 10.1038/4371108a; MEINDL P, 1974, VIROLOGY, V58, P457, DOI 10.1016/0042-6822(74)90080-4; Mishin VP, 2005, ANTIMICROB AGENTS CH, V49, P4515, DOI 10.1128/AAC.49.11.4515-4520.2005; Murphy B.R, 1996, FIELDS VIROLOGY, P1397; Otwinowski Z., 1993, DATA COLLECTION PROC, P556; THOMPSON JD, 1994, COMPUT APPL BIOSCI, V10, P19; Varghese JN, 1998, STRUCT FOLD DES, V6, P735, DOI 10.1016/S0969-2126(98)00075-6; VARGHESE JN, 1983, NATURE, V303, P35, DOI 10.1038/303035a0; VONITZSTEIN M, 1993, NATURE, V363, P418, DOI 10.1038/363418a0; Wang MZ, 2002, ANTIMICROB AGENTS CH, V46, P3809, DOI 10.1128/AAC.46.12.3809-3816.2002; Ward P, 2005, J ANTIMICROB CHEMOTH, V55, P5, DOI 10.1093/jac/dki018; Webster RG, 2006, EMERG INFECT DIS, V12, P3, DOI 10.3201/eid1201.051024; Yen HL, 2005, ANTIMICROB AGENTS CH, V49, P4075, DOI 10.1128/AAC.49.10.4075-4084.2005	34	628	709	6	192	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 7	2006	443	7107					45	49		10.1038/nature05114	http://dx.doi.org/10.1038/nature05114			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	081JM	16915235				2022-12-28	WOS:000240313900035
J	Freitas, R; Zhang, GJ; Cohn, MJ				Freitas, Renata; Zhang, GuangJun; Cohn, Martin J.			Evidence that mechanisms of fin development evolved in the midline of early vertebrates	NATURE			English	Article							HOX GENE-EXPRESSION; TRUNK NEURAL CREST; PETROMYZON-MARINUS; ZEBRAFISH; ORIGIN; LAMPREY; EMBRYOS; REGENERATION; ORGANIZATION; MESENCHYME	The origin of paired appendages was a major evolutionary innovation for vertebrates, marking the first step towards fin( and later limb-) driven locomotion. The earliest vertebrate fossils lack paired fins but have well-developed median fins(1,2), suggesting that the mechanisms of fin development were assembled first in the midline. Here we show that shark median fin development involves the same genetic programs that operate in paired appendages. Using molecular markers for different cell types, we show that median fins arise predominantly from somitic ( paraxial) mesoderm, whereas paired appendages develop from lateral plate mesoderm. Expression of Hoxd and Tbx18 genes, which specify paired limb positions(3,4), also delineates the positions of median fins. Proximodistal development of median fins occurs beneath an apical ectodermal ridge, the structure that controls outgrowth of paired appendages(5-7). Each median fin bud then acquires an anteroposteriorly-nested pattern of Hoxd expression similar to that which establishes skeletal polarity in limbs(8,9). Thus, despite their different embryonic origins, paired and median fins utilize a common suite of developmental mechanisms. We extended our analysis to lampreys, which diverged from the lineage leading to gnathostomes before the origin of paired appendages(2,10), and show that their median fins also develop from somites and express orthologous Hox and Tbx genes. Together these results suggest that the molecular mechanisms for fin development originated in somitic mesoderm of early vertebrates, and that the origin of paired appendages was associated with re-deployment of these mechanisms to lateral plate mesoderm.	Univ Florida, Dept Zool, Gainesville, FL 32611 USA; Univ Florida, Dept Anat & Cell Biol, Gainesville, FL 32611 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Cohn, MJ (corresponding author), Univ Florida, Dept Zool, POB 118525, Gainesville, FL 32611 USA.	cohn@zoo.ufl.edu	Zhang, GuangJun/K-2056-2012; Freitas, Renata/I-5917-2013	Freitas, Renata/0000-0002-0123-7232; Zhang, GuangJun/0000-0002-0839-5161				AKIMENKO MA, 1995, DEVELOPMENT, V121, P347; AKIMENKO MA, 1994, J NEUROSCI, V14, P3475; ATCHINI B, 2006, DEV CELL, V10, P93; Brent AE, 2003, CELL, V113, P235, DOI 10.1016/S0092-8674(03)00268-X; Brent AE, 2004, DEVELOPMENT, V131, P3885, DOI 10.1242/dev.01275; COATES MI, 1994, DEVELOPMENT, P169; Cohn MJ, 1997, NATURE, V387, P97, DOI 10.1038/387097a0; Donoghue PCJ, 2000, BIOL REV, V75, P191, DOI 10.1017/S0006323199005472; Force A, 2002, J EXP ZOOL, V294, P30, DOI 10.1002/jez.10091; Freitas R, 2004, DEV GENES EVOL, V214, P466, DOI 10.1007/s00427-004-0426-0; Furukawa S, 1999, NUTRITION, V15, P29; Grandel H, 1998, MECH DEVELOP, V79, P99, DOI 10.1016/S0925-4773(98)00176-2; Grandel H, 2000, DEVELOPMENT, V127, P4169; Hirata M, 1997, ZOOL SCI, V14, P305, DOI 10.2108/zsj.14.305; Lacosta AM, 2005, PIGM CELL RES, V18, P243, DOI 10.1111/j.1600-0749.2005.00238.x; Mabee PM, 2002, J EXP ZOOL, V294, P77, DOI 10.1002/JEZ.10076; McCauley DW, 2003, DEVELOPMENT, V130, P2317, DOI 10.1242/dev.00451; Nelson CE, 1996, DEVELOPMENT, V122, P1449; Rhodes LSS, 2006, GENE EXPR PATTERNS, V6, P539, DOI 10.1016/j.modgep.2005.10.006; Richardson MK, 2003, J MORPHOL, V257, P348, DOI 10.1002/jmor.10119; SAUNDERS JW, 1948, J EXP ZOOL, V108, P363, DOI 10.1002/jez.1401080304; SMITH M, 1994, P ROY SOC B-BIOL SCI, V256, P137, DOI 10.1098/rspb.1994.0061; Sobkow L, 2006, DEV BIOL, V290, P386, DOI 10.1016/j.ydbio.2005.11.037; SORDINO P, 1995, NATURE, V375, P678, DOI 10.1038/375678a0; Sun X, 2002, NATURE, V418, P501, DOI 10.1038/nature00902; Tanaka M, 2004, DEV BIOL, V268, P470, DOI 10.1016/j.ydbio.2003.12.036; TREVARROW B, 1990, NEURON, V4, P669, DOI 10.1016/0896-6273(90)90194-K; Tucker AS, 2004, DEV DYNAM, V230, P461, DOI 10.1002/dvdy.20071; Zakany J, 2004, SCIENCE, V304, P1669, DOI 10.1126/science.1096049; Zhang XG, 2004, J EVOLUTION BIOL, V17, P1162, DOI 10.1111/j.1420-9101.2004.00741.x	30	148	157	2	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 31	2006	442	7106					1033	1037		10.1038/nature04984	http://dx.doi.org/10.1038/nature04984			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	078YF	16878142				2022-12-28	WOS:000240142000048
J	Molinier, J; Ries, G; Zipfel, C; Hohn, B				Molinier, Jean; Ries, Gerhard; Zipfel, Cyril; Hohn, Barbara			Transgeneration memory of stress in plants	NATURE			English	Article							INTRACHROMOSOMAL HOMOLOGOUS RECOMBINATION; GENOME; ARABIDOPSIS; FREQUENCY; MUTATIONS; MAIZE	Owing to their sessile nature, plants are constantly exposed to a multitude of environmental stresses to which they react with a battery of responses. The result is plant tolerance to conditions such as excessive or inadequate light, water, salt and temperature, and resistance to pathogens. Not only is plant physiology known to change under abiotic or biotic stress, but changes in the genome have also been identified(1-5). However, it was not determined whether plants from successive generations of the original, stressed plants inherited the capacity for genomic change. Here we show that in Arabidopsis thaliana plants treated with short-wavelength radiation (ultraviolet-C) or flagellin ( an elicitor of plant defences(6)), somatic homologous recombination of a transgenic reporter is increased in the treated population and these increased levels of homologous recombination persist in the subsequent, untreated generations. The epigenetic trait of enhanced homologous recombination could be transmitted through both the maternal and the paternal crossing partner, and proved to be dominant. The increase of the hyper-recombination state in generations subsequent to the treated generation was independent of the presence of the transgenic allele ( the recombination substrate under consideration) in the treated plant. We conclude that environmental factors lead to increased genomic flexibility even in successive, untreated generations, and may increase the potential for adaptation.	Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Hohn, B (corresponding author), Friedrich Miescher Inst Biomed Res, Maulbeerstr 66, CH-4058 Basel, Switzerland.	barbara.hohn@fmi.ch	ZIPFEL, CYRIL/ABD-5076-2021; ZIPFEL, CYRIL B/D-7103-2011	ZIPFEL, CYRIL/0000-0003-4935-8583; ZIPFEL, CYRIL B/0000-0003-4935-8583				Cubas P, 1999, NATURE, V401, P157, DOI 10.1038/43657; Cullis CA, 2005, ANN BOT-LONDON, V95, P201, DOI 10.1093/aob/mci013; Felix G, 1999, PLANT J, V18, P265, DOI 10.1046/j.1365-313X.1999.00265.x; Gherbi H, 2001, EMBO REP, V2, P287, DOI 10.1093/embo-reports/kve069; Grandbastien M, 2005, CYTOGENET GENOME RES, V110, P229, DOI 10.1159/000084957; Jablonka E., 1995, EPIGENETIC INHERITAN; Jacobsen SE, 1997, SCIENCE, V277, P1100, DOI 10.1126/science.277.5329.1100; Jefferson RA, 1987, PLANT MOL BIOL REP, V5, P387, DOI [DOI 10.1007/BF02667740, 10.1007/bf02667740]; Jorgensen RA, 2004, COLD SPRING HARB SYM, V69, P349, DOI 10.1101/sqb.2004.69.349; Klumpp A, 2004, HEREDITAS, V141, P142, DOI 10.1111/j.1601-5223.2004.01806.x; Kovalchuk I, 2000, EMBO J, V19, P4431, DOI 10.1093/emboj/19.17.4431; Kovalchuk I, 2003, NATURE, V423, P760, DOI 10.1038/nature01683; LEBEL EG, 1993, P NATL ACAD SCI USA, V90, P422, DOI 10.1073/pnas.90.2.422; Lucht JM, 2002, NAT GENET, V30, P311, DOI 10.1038/ng846; Madlung A, 2004, ANN BOT-LONDON, V94, P481, DOI 10.1093/aob/mch172; MCCLINTOCK B, 1984, SCIENCE, V226, P792, DOI 10.1126/science.15739260; Molinier J, 2004, PLANT CELL, V16, P342, DOI 10.1105/tpc.019042; MOTTINGER JP, 1984, MOL GEN GENET, V195, P367, DOI 10.1007/BF00332775; PUCHTA H, 1995, PLANT J, V7, P203, DOI 10.1046/j.1365-313X.1995.7020203.x; PUCHTA H, 1995, PLANT MOL BIOL, V28, P281, DOI 10.1007/BF00020247; Ries G, 2000, NATURE, V406, P98, DOI 10.1038/35017595; Schuermann D, 2005, TRENDS GENET, V21, P172, DOI 10.1016/j.tig.2005.01.002; SWOBODA P, 1994, EMBO J, V13, P484, DOI 10.1002/j.1460-2075.1994.tb06283.x; Walbot V, 1996, TRENDS PLANT SCI, V1, P27, DOI 10.1016/S1360-1385(96)80020-3; WALBOT V, 1992, MOL GEN GENET, V234, P353, DOI 10.1007/BF00538694; Zipfel C, 2004, NATURE, V428, P764, DOI 10.1038/nature02485	26	455	492	4	256	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 31	2006	442	7106					1046	1049		10.1038/nature05022	http://dx.doi.org/10.1038/nature05022			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	078YF	16892047				2022-12-28	WOS:000240142000051
J	Lansbury, PT				Lansbury, Peter T., Jr.			Improving synaptic function in a mouse model of AD	CELL			English	Editorial Material							TERMINAL HYDROLASE-L1 GENE; PARKINSONS-DISEASE; UCH-L1		Harvard Med Sch, Dept Neurol, Cambridge, MA 02139 USA		Lansbury, PT (corresponding author), Harvard Med Sch, Dept Neurol, 65 Landsdowne St, Cambridge, MA 02139 USA.	plansbury@rics.bwh.harvard.edu						Das C, 2006, P NATL ACAD SCI USA, V103, P4675, DOI 10.1073/pnas.0510403103; GONG B, 2006, CELL; Kurihara LJ, 2001, HUM MOL GENET, V10, P1963, DOI 10.1093/hmg/10.18.1963; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; Liu YC, 2003, CHEM BIOL, V10, P837, DOI 10.1016/j.chembiol.2003.08.010; Liu YC, 2002, CELL, V111, P209, DOI 10.1016/S0092-8674(02)01012-7; Osaka H, 2003, HUM MOL GENET, V12, P1945, DOI 10.1093/hmg/ddg211; Satoh J, 2001, J NEUROL SCI, V189, P113, DOI 10.1016/S0022-510X(01)00555-X; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Xue SF, 2006, BRAIN RES, V1087, P28, DOI 10.1016/j.brainres.2006.02.121	10	16	17	0	0	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 25	2006	126	4					655	657		10.1016/j.cell.2006.08.011	http://dx.doi.org/10.1016/j.cell.2006.08.011			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	080VN	16923386	Bronze			2022-12-28	WOS:000240276700014
J	Schumacher, MA; Karamooz, E; Zikova, A; Trantirek, L; Lukes, J				Schumacher, Maria A.; Karamooz, Ellharn; Zikova, Alena; Trantirek, Lukas; Lukes, Julius			Crystal structures of T-brucei MRP1/MRP2 guide-RNA binding complex reveal RNA matchmaking mechanism	CELL			English	Article							KINETOPLASTID MITOCHONDRIA; MESSENGER-RNA; CYTOCHROME-B; IN-VITRO; PROTEIN; LEISHMANIA; TRANSCRIPT; GRNA; INTERFERENCE; RECOGNITION	The mitochondrial RNA binding proteins MRP1 and MRP2 form a heteromeric complex that functions in kinetoplastid RNA editing. In this process, MRPl/MRP2 serves as a matchmaker by binding to guide RNAs and facilitating their hybridization with cognate preedited rnRNAs. To understand the mechanism by which this complex performs RNA matchmaking, we determined structures of Trypanosoma brucei apoMRPl/MRP2 and an MRPl/MRP2-gRNA complex. The structures show that MRP1/ MRP2 is a heterotetramer and, despite little sequence homology, each MRP subunit exhibits the same "Whirly" transcription-factor fold. The gRNA molecule binds to the highly basic beta sheet surface of the MRP complex via nonspecific, electrostatic contacts. Strikingly, while the gRNA stem/loop II base is anchored to the basic surface, stem/loop I (the anchor sequence) is unfolded and its bases exposed to solvent. Thus, MRPl/MRP2 acts as an RNA matchmaker by stabilizing the RNA molecule in an unfolded conformation suitable for RNARNA hybridization.	Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Czech Acad Sci, Inst Parasitol, Ctr Biol, Ceske Budejovice 37005, Budweis, Czech Republic; Univ S Bohemia, Fac Biol, Ceske Budejovice 37005, Budweis, Czech Republic; Univ Illinois, Coll Med, Urbana, IL 61801 USA; Seattle Biomed Res Inst, Seattle, WA 98103 USA	University of Texas System; UTMD Anderson Cancer Center; Czech Academy of Sciences; Biology Centre of the Czech Academy of Sciences; University of South Bohemia Ceske Budejovice; University of Illinois System; University of Illinois Urbana-Champaign; Center for Infectious Disease Research	Schumacher, MA (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Unit 1000, Houston, TX 77030 USA.	maschuma@mdanderson.org	Lukes, Julius/H-6760-2012; Trantirek, Lukas/F-9923-2014; Zikova, Alena/G-7855-2014	Lukes, Julius/0000-0002-0578-6618; Zikova, Alena/0000-0002-8686-0225; Karamooz, Elham/0000-0002-7185-5490	FIC NIH HHS [5R03TW6445] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R03TW006445] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Aphasizhev R, 2003, RNA, V9, P62, DOI 10.1261/rna.2134303; Aphasizhev R, 2003, EMBO J, V22, P913, DOI 10.1093/emboj/cdg083; BAEYENS KJ, 1995, NAT STRUCT BIOL, V2, P56, DOI 10.1038/nsb0195-56; BENNE R, 1986, CELL, V46, P819, DOI 10.1016/0092-8674(86)90063-2; Blom D, 2001, NUCLEIC ACIDS RES, V29, P2950, DOI 10.1093/nar/29.14.2950; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BLUM B, 1990, CELL, V62, P391, DOI 10.1016/0092-8674(90)90375-O; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen XG, 2004, J MOL MED, V82, P232, DOI 10.1007/s00109-004-0529-0; CORELL RA, 1993, NUCLEIC ACIDS RES, V21, P4313, DOI 10.1093/nar/21.18.4313; Corell RA, 1996, MOL CELL BIOL, V16, P1410; DeLano W.L, PYMOL MOL GRAPHICS S; Desveaux D, 2002, NAT STRUCT BIOL, V9, P512, DOI 10.1038/nsb814; FEAGIN JE, 1988, P NATL ACAD SCI USA, V85, P539, DOI 10.1073/pnas.85.2.539; FEAGIN JE, 1988, CELL, V53, P413, DOI 10.1016/0092-8674(88)90161-4; Hermann T, 1997, NUCLEIC ACIDS RES, V25, P2311, DOI 10.1093/nar/25.12.2311; Hoffmann KM, 2005, J BACTERIOL, V187, P5008, DOI 10.1128/JB.187.14.5008-5012.2005; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Hong M, 2003, PROTIST, V154, P265, DOI 10.1078/143446103322166554; Horvath A, 2000, SCIENCE, V287, P1639, DOI 10.1126/science.287.5458.1639; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; Koller J, 1997, J BIOL CHEM, V272, P3749, DOI 10.1074/jbc.272.6.3749; KOSLOWSKY DJ, 1992, MOL CELL BIOL, V12, P2043, DOI 10.1128/MCB.12.5.2043; Krause K, 2005, FEBS LETT, V579, P3707, DOI 10.1016/j.febslet.2005.05.059; Lambert L, 1999, NUCLEIC ACIDS RES, V27, P1429, DOI 10.1093/nar/27.6.1429; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liu YN, 2005, J BIOL CHEM, V280, P35513, DOI 10.1074/jbc.M507296200; LOWMAN HB, 1986, J BIOL CHEM, V261, P5396; Lukes J, 2005, CURR GENET, V48, P277, DOI 10.1007/s00294-005-0027-0; Madison-Antenucci S, 2002, CELL, V108, P435, DOI 10.1016/S0092-8674(02)00653-0; MASLOV DA, 1992, CELL, V70, P459, DOI 10.1016/0092-8674(92)90170-H; Muller UF, 2002, NUCLEIC ACIDS RES, V30, P447, DOI 10.1093/nar/30.2.447; Muller UF, 2001, EMBO J, V20, P1394, DOI 10.1093/emboj/20.6.1394; Nagai K, 1996, CURR OPIN STRUC BIOL, V6, P53, DOI 10.1016/S0959-440X(96)80095-9; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Panigrahi AK, 2003, RNA, V9, P484, DOI 10.1261/rna.2194603; Panigrahi AK, 2001, MOL CELL BIOL, V21, P6833, DOI 10.1128/MCB.21.20.6833-6840.2001; SCHMID B, 1995, NUCLEIC ACIDS RES, V23, P3093, DOI 10.1093/nar/23.16.3093; SEIWERT SD, 1994, SCIENCE, V266, P114, DOI 10.1126/science.7524149; Seiwert SD, 1996, CELL, V84, P831, DOI 10.1016/S0092-8674(00)81062-4; SHAW JM, 1988, CELL, V53, P401, DOI 10.1016/0092-8674(88)90160-2; SIMPSON AGB, 2006, IN PRESS TRENDS PARA; Simpson L, 2004, RNA, V10, P159, DOI 10.1261/rna.5170704; Simpson L, 2003, RNA, V9, P265, DOI 10.1261/rna.2178403; Stein AJ, 2005, CELL, V121, P529, DOI 10.1016/j.cell.2005.03.009; Stuart KD, 2005, TRENDS BIOCHEM SCI, V30, P97, DOI 10.1016/j.tibs.2004.12.006; STURM NR, 1990, CELL, V61, P879, DOI 10.1016/0092-8674(90)90198-N; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Vondruskova E, 2005, J BIOL CHEM, V280, P2429, DOI 10.1074/jbc.M405933200	50	96	102	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 25	2006	126	4					701	711		10.1016/j.cell.2006.06.047	http://dx.doi.org/10.1016/j.cell.2006.06.047			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	080VN	16923390	Bronze			2022-12-28	WOS:000240276700019
J	Whibley, AC; Langlade, NB; Andalo, C; Hanna, AI; Bangham, A; Thebaud, C; Coen, E				Whibley, Annabel C.; Langlade, Nicolas B.; Andalo, Christophe; Hanna, Andrew I.; Bangham, Andrew; Thebaud, Christophe; Coen, Enrico			Evolutionary paths underlying flower color variation in Antirrhinum	SCIENCE			English	Article							MONKEYFLOWERS; APPEARANCE; GENES	To understand evolutionary paths connecting diverse biological forms, we defined a three-dimensional genotypic space separating two flower color morphs of Antirrhinum. A hybrid zone between morphs showed a steep cline specifically at genes controlling flower color differences, indicating that these loci are under selection. Antirrhinum species with diverse floral phenotypes formed a U-shaped cloud within the genotypic space. We propose that this cloud defines an evolutionary path that allows flower color to evolve while circumventing less-adaptive regions. Hybridization between morphs located in different arms of the U-shaped path yields low-fitness genotypes, accounting for the observed steep clines at hybrid zones.	John Innes Ctr Plant Sci Res, Dept Cell & Dev Biol, Norwich NR4 7UH, Norfolk, England; Univ Toulouse 3, Lab Evolut & Divers Biol, CNRS, UMR 5174, F-31062 Toulouse 9, France; Univ E Anglia, Sch Comp Sci, Norwich NR4 7TJ, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); Universite de Toulouse; Universite Federale Toulouse Midi-Pyrenees (ComUE); Universite Toulouse III - Paul Sabatier; Ecole Nationale Formation Agronomique (ENSFEA); University of East Anglia	Coen, E (corresponding author), John Innes Ctr Plant Sci Res, Dept Cell & Dev Biol, Colney Lane, Norwich NR4 7UH, Norfolk, England.	enrico.coen@bbsrc.ac.uk	Langlade, Nicolas/C-6191-2008; Thébaud, Christophe/N-3916-2016; Whibley, Annabel/P-2509-2017; Whibley, Annabel/G-2836-2011	Langlade, Nicolas/0000-0002-5651-1446; Thébaud, Christophe/0000-0002-8586-1234; Whibley, Annabel/0000-0003-1878-7705; 				BARTON N, 1986, HEREDITY, V57, P357, DOI 10.1038/hdy.1986.135; BARTON NH, 1985, ANNU REV ECOL SYST, V16, P113, DOI 10.1146/annurev.es.16.110185.000553; BAUR E, 1924, BIBLIOTHECA GENET, V4, P1; Bradshaw HD, 2003, NATURE, V426, P176, DOI 10.1038/nature02106; Chittka L., 2001, ANIMAL BEHAV FLORAL; COEN ES, 1986, CELL, V47, P285, DOI 10.1016/0092-8674(86)90451-4; Cootes TF, 2001, IEEE T PATTERN ANAL, V23, P681, DOI 10.1109/34.927467; Gavrilets S, 1997, TRENDS ECOL EVOL, V12, P307, DOI 10.1016/S0169-5347(97)01098-7; GAVRILETS S, 2004, MONOGRAPHS POPULATIO, V41; Gubitz T, 2003, MOL BIOL EVOL, V20, P1537, DOI 10.1093/molbev/msg166; Hackbarth J., 1942, ZEIT SCHR INDUKT ABSTAMM U VERERBUNGSL, V80, P1, DOI 10.1007/BF01741978; Horgan GW, 2001, COMPUT ELECTRON AGR, V31, P169, DOI 10.1016/S0168-1699(00)00190-3; Langlade NB, 2005, P NATL ACAD SCI USA, V102, P10221, DOI 10.1073/pnas.0504210102; Luo D, 1999, CELL, V99, P367, DOI 10.1016/S0092-8674(00)81523-8; Mateu-Andres I, 2003, ANN BOT-LONDON, V92, P647, DOI 10.1093/aob/mcg184; MOORE WS, 1993, HYBRID ZONES AND THE EVOLUTIONARY PROCESS, P196; Rothmaler W., 1956, TAXONOMISCHE MONOGRA; Schemske DW, 1999, P NATL ACAD SCI USA, V96, P11910, DOI 10.1073/pnas.96.21.11910; Schwarz-Sommer Z, 2003, NAT REV GENET, V4, P657, DOI 10.1038/nrg1127; Schwinn K, 2006, PLANT CELL, V18, P831, DOI 10.1105/tpc.105.039255; STUBBE H, 1966, GENETIK ZYTOLOGIE AN; Sutton D. A., 1988, REVISION TRIBE ANTIR; Vargas P, 2004, PLANT SYST EVOL, V249, P151, DOI 10.1007/s00606-004-0216-1; Webb DA, 1972, FLORA EUROPAEA, V3; WRIGHT SEWALL, 1932, PROC SIXTH INTERNAT CONGR GENETICS ITHACA NEW YORK, V1, P356	25	127	131	2	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 18	2006	313	5789					963	966		10.1126/science.1129161	http://dx.doi.org/10.1126/science.1129161			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	074MR	16917061				2022-12-28	WOS:000239817000042
J	Boss, AP				Boss, Alan P.			George W. Wetherill (1925-2006) - Geochemist, planetary scientist and astrobiologist - Obituary	NATURE			English	Biographical-Item									Carnegie Inst Washington, Dept Terr Magnetism, Washington, DC 20015 USA	Carnegie Institution for Science	Boss, AP (corresponding author), Carnegie Inst Washington, Dept Terr Magnetism, 5421 Broad Branch Rd NW, Washington, DC 20015 USA.	boss@dtm.ciw.edu							0	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 17	2006	442	7104					756	756		10.1038/442756a	http://dx.doi.org/10.1038/442756a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	074DK	16915277	Bronze			2022-12-28	WOS:000239792700031
J	Thior, I; Lockman, S; Smeaton, LM; Shapiro, RL; Wester, C; Heymann, SJ; Gilbert, PB; Stevens, L; Peter, T; Kim, S; van Widenfelt, E; Moffat, C; Ndase, P; Arimi, P; Kebaabetswe, P; Mazonde, P; Makhema, J; McIntosh, K; Novitsky, V; Lee, TH; Marlink, R; Lagakos, S; Essex, M				Thior, Ibou; Lockman, Shahin; Smeaton, Laura M.; Shapiro, Roger L.; Wester, Carolyn; Heymann, S. Jody; Gilbert, Peter B.; Stevens, Lisa; Peter, Trevor; Kim, Soyeon; van Widenfelt, Erik; Moffat, Claire; Ndase, Patrick; Arimi, Peter; Kebaabetswe, Poloko; Mazonde, Patson; Makhema, Joseph; McIntosh, Kenneth; Novitsky, Vladimir; Lee, Tun-Hou; Marlink, Richard; Lagakos, Stephen; Essex, Max		Mashi Study Team	Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana - A randomized trial: The Mashi study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SINGLE-DOSE NEVIRAPINE; PERINATAL TRANSMISSION; TYPE-1 TRANSMISSION; ORAL ZIDOVUDINE; CLINICAL-TRIAL; HEAT-TREATMENT; COTE-DIVOIRE; SOUTH-AFRICA; DOUBLE-BLIND	Context Postnatal transmission of human immunodeficiency virus-1 (HIV) via breast-feeding reverses gains achieved by perinatal antiretroviral interventions. Objective To compare the efficacy and safety of 2 infant feeding strategies for the prevention of postnatal mother-to-child HIV transmission. Design, Setting, and Patients A 2 x 2 factorial randomized clinical trial with peripartum (single-dose nevirapine vs placebo) and postpartum infant feeding ( formula vs breastfeeding with infant zidovudine prophylaxis) interventions. In Botswana between March 27, 2001, and October 29, 2003, 1200 HIV-positive pregnant women were randomized from 4 district hospitals. Infants were evaluated at birth, monthly until age 7 months, at age 9 months, then every third month through age 18 months. Intervention All of the mothers received zidovudine 300 mg orally twice daily from 34 weeks' gestation and during labor. Mothers and infants were randomized to receive single-dose nevirapine or placebo. Infants were randomized to 6 months of breastfeeding plus prophylactic infant zidovudine (breastfed plus zidovudine), or formula feeding plus 1 month of infant zidovudine ( formula fed). Main Outcome Measures Primary efficacy ( HIV infection by age 7 months and HIV-free survival by age 18 months) and safety ( occurrence of infant adverse events by 7 months of age) end points were evaluated in 1179 infants. Results The 7-month HIV infection rates were 5.6% ( 32 infants in the formula-fed group) vs 9.0% ( 51 infants in the breastfed plus zidovudine group) (P=. 04; 95% confidence interval for difference, - 6.4% to - 0.4%). Cumulative mortality or HIV infection rates at 18 months were 80 infants ( 13.9%, formula fed) vs 86 infants (15.1% breastfed plus zidovudine) ( P=. 60; 95% confidence interval for difference, - 5.3% to 2.9%). Cumulative infant mortality at 7 months was significantly higher for the formula-fed group than for the breastfed plus zidovudine group (9.3% vs 4.9%; P=. 003), but this difference diminished beyond month 7 such that the time-to-mortality distributions through age 18 months were not significantly different ( P=. 21). Conclusions Breastfeeding with zidovudine prophylaxis was not as effective as formula feeding in preventing postnatal HIV transmission, but was associated with a lower mortality rate at 7 months. Both strategies had comparable HIV-free survival at 18 months. These results demonstrate the risk of formula feeding to infants in sub-Saharan Africa, and the need for studies of alternative strategies.	Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA; Botswana Harvard Sch Publ Hlth AIDS Initiat Partn, Gaborone, Botswana; Brigham & Womens Hosp, Infect Dis Unit, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Botswana Minist Hlth, Gaborone, Botswana; Childrens Hosp, Div Infect Dis, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; Harvard University; Boston Children's Hospital	Essex, M (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, FXB 402,651 Huntington Ave, Boston, MA 02115 USA.	messex@hsph.harvard.edu			FIC NIH HHS [TW00004] Funding Source: Medline; NICHD NIH HHS [R01 HD37793] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD037793] Funding Source: NIH RePORTER; FOGARTY INTERNATIONAL CENTER [D43TW000004] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		AlAli FM, 1997, PUBLIC HEALTH, V111, P239, DOI 10.1016/S0033-3506(97)00041-3; Baggaley R, 2002, EVAL PROGRAM PLANN, V25, P421; BEAUDRY M, 1995, J PEDIATR-US, V126, P191, DOI 10.1016/S0022-3476(95)70544-9; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P929; Chantry CJ, 2000, J ACQ IMMUN DEF SYND, V24, P325, DOI 10.1097/00126334-200008010-00005; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Coutsoudis A, 1999, LANCET, V354, P471, DOI 10.1016/S0140-6736(99)01101-0; Coutsoudis A, 2004, J INFECT DIS, V189, P2154, DOI 10.1086/420834; Coutsoudis A, 2000, ANN NY ACAD SCI, V918, P136; Dabis F, 1999, LANCET, V353, P786, DOI 10.1016/S0140-6736(98)11046-2; Dickover RE, 1996, JAMA-J AM MED ASSOC, V275, P599, DOI 10.1001/jama.275.8.599; DUNCAN B, 1993, PEDIATRICS, V91, P867; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; Fawzi W, 2002, JAIDS-J ACQ IMM DEF, V31, P331, DOI 10.1097/00126334-200211010-00010; FORD JE, 1977, J PEDIATR-US, V90, P29, DOI 10.1016/S0022-3476(77)80759-2; Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7; HOWIE PW, 1990, BRIT MED J, V300, P11, DOI 10.1136/bmj.300.6716.11; Iliff PJ, 2005, AIDS, V19, P699, DOI 10.1097/01.aids.0000166093.16446.c9; Jackson JB, 2003, LANCET, V362, P859, DOI 10.1016/S0140-6736(03)14341-3; John GC, 2001, J INFECT DIS, V183, P206, DOI 10.1086/317918; John-Stewart GC, 2005, J INFECT DIS, V192, P492, DOI 10.1086/431514; KILEWO C, 2005, 3 IAS C HIV PATH TRE; Lallemant M, 2000, NEW ENGL J MED, V343, P982, DOI 10.1056/NEJM200010053431401; Lallemant M, 2004, NEW ENGL J MED, V351, P217, DOI 10.1056/NEJMoa033500; Leroy V, 2002, AIDS, V16, P631, DOI 10.1097/00002030-200203080-00016; Miotti PG, 1999, JAMA-J AM MED ASSOC, V282, P744, DOI 10.1001/jama.282.8.744; Montano M, 2003, J INFECT DIS, V188, P406, DOI 10.1086/376838; Moodley D, 2003, J INFECT DIS, V187, P725, DOI 10.1086/367898; Mukadi YD, 1997, AIDS, V11, P1151, DOI 10.1097/00002030-199709000-00011; Nduati R, 2000, JAMA-J AM MED ASSOC, V283, P1167, DOI 10.1001/jama.283.9.1167; NICOLL A, 1990, AIDS, V4, P661, DOI 10.1097/00002030-199007000-00009; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Orloff S L, 1993, J Hum Lact, V9, P13, DOI 10.1177/089033449300900125; Renjifo B, 2004, AIDS, V18, P1629, DOI 10.1097/01.aids.0000131392.68597.34; ROSENBAUM PR, 1984, J ROY STAT SOC A STA, V147, P656, DOI 10.2307/2981697; Saba J, 2002, LANCET, V359, P1178; Semba RD, 1999, J INFECT DIS, V180, P93, DOI 10.1086/314854; Shaffer N, 1999, NEW ENGL J MED, V340, P1042; Shaffer N, 1999, LANCET, V353, P773, DOI 10.1016/S0140-6736(98)10411-7; Shapiro RL, 2003, AIDS EDUC PREV, V15, P221, DOI 10.1521/aeap.15.4.221.23830; Shapiro RL, 2006, AIDS, V20, P1281, DOI 10.1097/01.aids.0000232236.26630.35; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; Taha TE, 2003, LANCET, V362, P1171, DOI 10.1016/S0140-6736(03)14538-2; Urdaneta S, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-28; Victora CG, 2000, LANCET, V355, P451, DOI 10.1016/S0140-6736(00)82011-5; Vyankandondera J, 2003, 2 IAS C HIV PATH TRE; Wade NA, 1998, NEW ENGL J MED, V339, P1409, DOI 10.1056/NEJM199811123392001; Wiktor SZ, 1999, LANCET, V353, P781, DOI 10.1016/S0140-6736(98)10412-9	48	290	297	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 16	2006	296	7					794	805		10.1001/jama.296.7.794	http://dx.doi.org/10.1001/jama.296.7.794			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	073SR	16905785	Green Accepted, Bronze			2022-12-28	WOS:000239763400020
J	MacDonald, R; Das, A				MacDonald, Rhona; Das, Aditi			UK classification of drugs of abuse: an un-evidence-based mess	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England; Univ Manchester, Sch Med, Manchester, Lancs, England	University of Manchester	MacDonald, R (corresponding author), The Lancet, London NW1 7BY, England.							House of Commons Science and Technology Committee, 2006, 5 HOUS COMM SCI TECH; *UN OFF DRUGS CRIM, 2006, UN DRUGS CHIEF SOUND; 2006, RETHINK CANNABIS ED	3	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 12	2006	368	9535					559	561		10.1016/S0140-6736(06)69175-7	http://dx.doi.org/10.1016/S0140-6736(06)69175-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	074OF	16905003				2022-12-28	WOS:000239821000007
J	Kearns, M; Suri, S; Montfort, N				Kearns, Michael; Suri, Siddharth; Montfort, Nick			An experimental study of the coloring problem on human subject networks	SCIENCE			English	Article							SMALL-WORLD	Theoretical work suggests that structural properties of naturally occurring networks are important in shaping behavior and dynamics. However, the relationships between structure and behavior are difficult to establish through empirical studies, because the networks in such studies are typically fixed. We studied networks of human subjects attempting to solve the graph or network coloring problem, which models settings in which it is desirable to distinguish one's behavior from that of one's network neighbors. Networks generated by preferential attachment made solving the coloring problem more difficult than did networks based on cyclical structures, and "small worlds'' networks were easier still. We also showed that providing more information can have opposite effects on performance, depending on network structure.	Univ Penn, Dept Comp & Informat Sci, Philadelphia, PA 19104 USA	University of Pennsylvania	Kearns, M (corresponding author), Univ Penn, Dept Comp & Informat Sci, 3330 Walnut St, Philadelphia, PA 19104 USA.	mkearns@cis.upenn.edu		Montfort, Nick/0000-0001-7558-5160				Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509; Broder A, 2000, COMPUT NETW, V33, P309, DOI 10.1016/S1389-1286(00)00083-9; Camerer C, 2003, BEHAV GAME THEORY; Dodds PS, 2003, SCIENCE, V301, P827, DOI 10.1126/science.1081058; Feige U, 1998, J COMPUT SYST SCI, V57, P187, DOI 10.1006/jcss.1998.1587; Garey M.R., 1979, COMPUTERS INTRACTABI; GRANOVETTER MS, 1973, AM J SOCIOL, V78, P1360, DOI 10.1086/225469; Huberman BA, 2004, LECT NOTES PHYS, V650, P371; Janssen J, 2000, J ALGORITHM, V36, P119, DOI 10.1006/jagm.1999.1068; Karp R. M., 1972, P COMPL COMP COMP, P85; KHOT S, 2001, P 42 IEEE S FDN COMP; Kleinberg J., 2000, Proceedings of the Thirty Second Annual ACM Symposium on Theory of Computing, P163, DOI 10.1145/335305.335325; Kleinberg JM, 2000, NATURE, V406, P845, DOI 10.1038/35022643; MILGRAM S, 1967, PSYCHOL TODAY, V1, P61; Planning Institute of Australia, 2018, LENS TIPP POINT CANB; Sporns O, 2000, CEREB CORTEX, V10, P127, DOI 10.1093/cercor/10.2.127; TRAVERS J, 1969, SOCIOMETRY, V32, P425, DOI 10.2307/2786545; Wagner A, 2001, P ROY SOC B-BIOL SCI, V268, P1803, DOI 10.1098/rspb.2001.1711; Watts D.J., 1999, SMALL WORLDS DYNAMIC; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918; Zoellner J. A., 1977, IEEE Transactions on Electromagnetic Compatibility, VEMC-19, P313, DOI 10.1109/TEMC.1977.303601	21	138	139	4	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 11	2006	313	5788					824	827		10.1126/science.1127207	http://dx.doi.org/10.1126/science.1127207			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	072KC	16902134				2022-12-28	WOS:000239671300056
J	Piot, P				Piot, Peter			AIDS: from crisis management to sustained strategic response	LANCET			English	Editorial Material							HIV PREVENTION		Joint UN Programme HIV AIDS UNAIDS, CH-1211 Geneva 27, Switzerland	UNAIDS	Piot, P (corresponding author), Joint UN Programme HIV AIDS UNAIDS, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.	dubes@unaids.org						CAMERON E, 2006, KWAZ NAT U FOR LECT; *DEP INT DEV, 2006, KEEP OUR PROM DEL ED; GARRETT L, 2005, HARVARD INT REV, V27, P64; GOULD SJ, 1987, NY TIMES        0419; Klausner RD, 2003, SCIENCE, V300, P2036, DOI 10.1126/science.1086916; Kumar R, 2006, LANCET, V367, P1164, DOI 10.1016/S0140-6736(06)68435-3; PIOT D, 2006, DIVERSE VOICES COMMO; PIOT P, 2005, EPIDEMIE SIDA MONDIS; Pisani E, 2003, BRIT MED J, V326, P1384, DOI 10.1136/bmj.326.7403.1384; Salomon JA, 2005, PLOS MED, V2, P50, DOI 10.1371/journal.pmed.0020016; Stover J, 2006, SCIENCE, V311, P1474, DOI 10.1126/science.1121176; *UN DEV PROGR, 2005, HUM DEV REP 2005; *UNAIDS, 2006, GLOB COAL WOM AIDS K; *UNAIDS, 2005, AIDS AFR 3 SCEN 2025; UNAIDS, 2005, INT HIV PREV; *UNAIDS, 2006, REP GLOB AIDS EP MAY; *UNAIDS, 2005, COMM NAIR THINK TANK; *UNAIDS, 2005, FIN REP GLOB TASK TE; *UNAIDS, 2005, RES NEEDS EXP RESP A; *UNAIDS, 2006, UN ACC UNAIDS ASS SC; *USAID UNAIDS WHO, 2004, PROJ COV SEL SERV HI; WHO/UNAIDS (World Health Organisation/United Nations Program on HIV/AIDS), 2006, PROGR GLOB ACC HIV A; World Health Organization, 2005, HLTH MILL DEV GOALS; World Health Organization (WHO), 2006, WORLD HLTH REP 2006	24	49	52	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 5	2006	368	9534					526	530		10.1016/S0140-6736(06)69161-7	http://dx.doi.org/10.1016/S0140-6736(06)69161-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	071AL	16890840				2022-12-28	WOS:000239569000036
J	Razzaghi, E; Nassirimanesh, B; Afshar, P; Ohiri, K; Claeson, M; Power, R				Razzaghi, Emran; Nassirimanesh, Bijan; Afshar, Parviz; Ohiri, Kelechi; Claeson, Mariam; Power, Robert			HIV/AIDS harm reduction in Iran	LANCET			English	Editorial Material									World Bank, Washington, DC 20433 USA; Univ Tehran Med Sci, Iranian Natl Ctr Addict Studies, Tehran, Iran; Persepolis NGO, Tehran, Iran; Iran Prison Org, Tehran, Iran; Burnet Inst, Melbourne, Vic, Australia	The World Bank; Tehran University of Medical Sciences; Burnet Institute	Claeson, M (corresponding author), World Bank, 1818 H St NW, Washington, DC 20433 USA.	mclaeson@worldbank.org						Aceijas C, 2004, AIDS, V18, P2295, DOI 10.1097/00002030-200411190-00010; NASSIRIMANESH B, 2005, RISE HARM REDUCT ISL; OHIRI K, 2006, PREVENTING HIV AIDS; Razzaghi EM, 2000, RAPID ASSESSMENT DRU; RAZZAGHI EM, 2005, INJECTION DRUG USE T; Razzaghi Emran M, 2006, Harm Reduct J, V3, P12; VAZIRIAN M, 2002, HARM REDUCT J, V2, P19; WHO Regional Office for the Eastern Mediterranean, 2004, BEST PRACT HIV AIDS; 2005, MONITORING AIDS PAND	9	62	62	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 5	2006	368	9534					434	435		10.1016/S0140-6736(06)69132-0	http://dx.doi.org/10.1016/S0140-6736(06)69132-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	071AL	16890814				2022-12-28	WOS:000239569000009
J	Hall, IP; Blakey, JD; Al Balushi, KA; Wheatley, A; Sayers, I; Pembrey, ME; Ring, SM; McArdle, WL; Strachan, DP				Hall, Ian P.; Blakey, John D.; Al Balushi, Khalid A.; Wheatley, Amanda; Sayers, Ian; Pembrey, Marcus E.; Ring, Susan M.; McArdle, Wnedy L.; Strachan, David P.			beta 2-adrenoceptor polymorphisms and asthma from childhood to middle age in the British 1958 birth cohort: a genetic association study	LANCET			English	Article							BETA(2)-ADRENERGIC RECEPTOR POLYMORPHISMS; WHEEZING ILLNESS; LUNG-FUNCTION; GENOTYPES; DISEQUILIBRIUM; METAANALYSIS; FREQUENCIES; CHILDREN; ATOPY; IGE	Background Functionally relevant polymorphisms of the beta 2-adrenoceptor gene (ADRB2) are common in white populations, but their contribution to the burden of airways disease in the population is uncertain. We aimed to relate the long-term prevalence of asthma or wheeze to functional coding region polymorphisms in the ADRB2 gene. Methods The British 1958 birth cohort consisted of all people born in Britain during a week in 1958. Asthma, wheezy bronchitis, and wheezing were ascertained by interview at ages 7, 11, 16, 23, 33, and 42 years, and lung function tests at 35 and 45 years. DNA samples from 8018 participants in the 45-year follow-up were genotyped for three coding variants in the ADRB2 gene. We extend the follow-up of this nationwide cohort by a further 10 years and relate asthma prevalence, prognosis, and lung function to functional coding region polymorphisms in the ADRB2 gene in the cohort members who contributed DNA samples. We also compared and combined our findings with those reaching significance in two previous meta-analyses. Findings Half the cohort (4105 of 8018) had some history of wheezing illness by age 42 years. Neither lifetime prevalence nor age at onset were related to ADRB2 coding variants. However, the common polymorphisms Arg16Gly (rs1042713, Arg 16 allele frequency 36.3%) and Gln27Glu (rs1042714, Glu 27 allele frequency 44.6%) were significantly associated with persistence of asthmatic symptoms from childhood to middle age. Among homozygotes for the Arg16-Gln27 haplotype at these loci, 19.3% (41 of 212) childhood wheezers had five or more wheezing episodes in the past year at age 42, compared with 11.9% (71 of 599) with no copy of this haplotype. However, only 3% of all frequent adult wheezing was statistically attributable to this haplotype. The less common Thr164Ile polymorphism (rs1800888, Ile allele frequency 1.5%) was not a major predictor of either frequency or prognosis of asthma. Our data do not support the findings of previous meta-analyses when considered in isolation or when combined with their contributory studies. Interpretation ADRB2 polymorphisms might predict a small component of the long-term prognosis in childhood asthma, but are not important determinants of asthma incidence or prevalence in the British population.	Univ Nottingham, Div Therapeut & Mol Med, Nottingham NG7 2RD, England; Univ Bristol, Dept Community Based Med, Bristol BS8 1TH, Avon, England; Univ London, St Georges, Div Community Hlth Sci, London WC1E 7HU, England; UCL, Inst Child Hlth, Clin & Mol Genet Unit, London, England	University of Nottingham; University of Bristol; St Georges University London; University of London; University of London; University College London	Hall, IP (corresponding author), Univ Nottingham Hosp, Div Therapeut & Mol Med, D Floor S Block, Nottingham NG7 2UH, England.	Ian.Hall@nottingham.ac.uk		Hall, Ian/0000-0001-9933-3216; Henry, Amanda/0000-0001-6299-7676; Sayers, Ian/0000-0001-5601-5410	MRC [G0000934] Funding Source: UKRI; Medical Research Council [G0000934] Funding Source: Medline; Asthma UK [05/055] Funding Source: researchfish	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Asthma UK		ANDERSON HR, 1992, THORAX, V47, P537, DOI 10.1136/thx.47.7.537; Binaei S, 2003, CHEST, V123, p375S, DOI 10.1016/S0012-3692(15)35221-1; Clayton DG, 2005, NAT GENET, V37, P1243, DOI 10.1038/ng1653; Contopoulos-Ioannidis DG, 2005, J ALLERGY CLIN IMMUN, V115, P963, DOI 10.1016/j.jaci.2004.12.1119; Dewar JC, 1997, J ALLERGY CLIN IMMUN, V100, P261, DOI 10.1016/S0091-6749(97)70234-3; Dewar JC, 1998, CLIN EXP ALLERGY, V28, P442; Gao Guangkai, 2000, Zhonghua Jiehe He Huxi Zazhi, V23, P93; GREEN SA, 1994, BIOCHEMISTRY-US, V33, P9414, DOI 10.1021/bi00198a006; GREEN SA, 1993, J BIOL CHEM, V268, P23116; GREEN SA, 1995, AM J RESP CELL MOL, V13, P25, DOI 10.1165/ajrcmb.13.1.7598936; Hakonarson H, 2001, AM J RESP CRIT CARE, V164, P2036, DOI 10.1164/ajrccm.164.11.2101086; HIGGINS JPT, 2005, COCHRANE LIB; Holloway JW, 2000, CLIN EXP ALLERGY, V30, P1097; Hopes E, 1998, BRIT MED J, V316, P664, DOI 10.1136/bmj.316.7132.664; Ioannidis JPA, 2003, LANCET, V361, P567, DOI 10.1016/S0140-6736(03)12516-0; Johnston IDA, 1998, NEW ENGL J MED, V338, P581, DOI 10.1056/NEJM199802263380904; Leung TF, 2002, PEDIATR PULM, V34, P419, DOI 10.1002/ppul.10210; Lin YC, 2003, J ASTHMA, V40, P265, DOI 10.1081/JAS-120018323; MANTEL N, 1959, J NATL CANCER I, V22, P719; Martinez FD, 1997, J CLIN INVEST, V100, P3184, DOI 10.1172/JCI119874; Migita O, 2004, INT ARCH ALLERGY IMM, V134, P150, DOI 10.1159/000078648; Nolte H, 1997, ANN ALLERG ASTHMA IM, V79, P27, DOI 10.1016/S1081-1206(10)63080-3; Power C, 2006, INT J EPIDEMIOL, V35, P34, DOI 10.1093/ije/dyi183; REIHSAUS E, 1993, AM J RESP CELL MOL, V8, P334, DOI 10.1165/ajrcmb/8.3.334; Santillan AA, 2003, J ALLERGY CLIN IMMUN, V112, P1095, DOI 10.1016/j.jaci.2003.09.029; Sato R, 2000, Hokkaido Igaku Zasshi, V75, P81; Shachor J, 2003, ISRAEL MED ASSOC J, V5, P821; Strachan DP, 1996, BRIT MED J, V312, P1195; Strachan DP, 1996, AM J RESP CRIT CARE, V154, P1629, DOI 10.1164/ajrccm.154.6.8970346; Tattersfield AE, 2004, LANCET, V364, P1464, DOI 10.1016/S0140-6736(04)17286-3; Thakkinstian A, 2005, AM J EPIDEMIOL, V162, P201, DOI 10.1093/aje/kwi184; Turner SW, 2004, CLIN EXP ALLERGY, V34, P1043, DOI 10.1111/j.1365-2222.2004.02001.x; Wang ZX, 2001, AM J RESP CRIT CARE, V163, P1404, DOI 10.1164/ajrccm.163.6.2001101; Weir TD, 1998, AM J RESP CRIT CARE, V158, P787, DOI 10.1164/ajrccm.158.3.9801035	34	87	87	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG-SEP	2006	368	9537					771	779		10.1016/S0140-6736(06)69287-8	http://dx.doi.org/10.1016/S0140-6736(06)69287-8			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	080ID	16935688				2022-12-28	WOS:000240240200029
J	Thiel, S; Hammerl, G; Schmehl, A; Schneider, CW; Mannhart, J				Thiel, S.; Hammerl, G.; Schmehl, A.; Schneider, C. W.; Mannhart, J.			Tunable quasi-two-dimensional electron gases in oxide heterostructures	SCIENCE			English	Article							SRTIO3; FILMS; PEROVSKITE; MODULATION; INSULATOR; INTERFACES; MOBILITY; TITANATE	We report on a large electric-field response of quasi-two-dimensional electron gases generated at interfaces in epitaxial heterostructures grown from insulating oxides. These device structures are characterized by doping layers that are spatially separated from high-mobility quasi-two-dimensional electron gases and therefore present an oxide analog to semiconducting high - electron mobility transistors. By applying a gate voltage, the conductivity of the electron gases can be modulated through a quantum phase transition from an insulating to a metallic state.	Univ Augsburg, Inst Phys, Ctr Elect Correlat & Magnetism, D-86135 Augsburg, Germany; Penn State Univ, Dept Mat Sci & Engn, University Pk, PA 16802 USA	University of Augsburg; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Mannhart, J (corresponding author), Univ Augsburg, Inst Phys, Ctr Elect Correlat & Magnetism, D-86135 Augsburg, Germany.	jochen.mannhart@physik.uni-augsburg.de	Schneider, Christof/AAC-9106-2020; Hammerl, German/E-9358-2017; Schneider, Christof W/I-5857-2014	Schneider, Christof/0000-0002-4292-8574; Schneider, Christof W/0000-0002-4292-8574; Mannhart, Jochen/0000-0001-6331-2640; Hammerl, German/0000-0002-2010-5163				Ahn CH, 1999, SCIENCE, V284, P1152, DOI 10.1126/science.284.5417.1152; Ahn CH, 2003, NATURE, V424, P1015, DOI 10.1038/nature01878; Bhattacharya A, 2004, APPL PHYS LETT, V85, P997, DOI 10.1063/1.1777415; CHRISTEN HM, 1994, PHYS REV B, V49, P12095, DOI 10.1103/PhysRevB.49.12095; Haeni JH, 2004, NATURE, V430, P758, DOI 10.1038/nature02773; Huijben M, 2006, NAT MATER, V5, P556, DOI 10.1038/nmat1675; Koerting V, 2005, PHYS REV B, V71, DOI 10.1103/PhysRevB.71.104510; Koinuma H, 2005, THIN SOLID FILMS, V486, P2, DOI 10.1016/j.tsf.2004.11.243; MANNHART J, 1991, Z PHYS B CON MAT, V83, P307, DOI 10.1007/BF01313398; MULLER KA, 1979, PHYS REV B, V19, P3593, DOI 10.1103/PhysRevB.19.3593; Nakagawa N, 2006, NAT MATER, V5, P204, DOI 10.1038/nmat1569; Ohtomo A, 2002, NATURE, V419, P378, DOI 10.1038/nature00977; Ohtomo A, 2006, NATURE, V441, P120, DOI 10.1038/nature04773; Ohtomo A, 2004, NATURE, V427, P423, DOI 10.1038/nature02308; Okamoto S, 2004, NATURE, V428, P630, DOI 10.1038/nature02450; Pallecchi I, 2001, APPL PHYS LETT, V78, P2244, DOI 10.1063/1.1363690; Sawa A, 2004, ANN PHYS-BERLIN, V13, P595, DOI 10.1002/andp.200310100; Stormer HL, 1999, REV MOD PHYS, V71, P875, DOI 10.1103/RevModPhys.71.875; Sze S. M., 1990, HIGH SPEED SEMICONDU; Takahashi KS, 2004, APPL PHYS LETT, V84, P1722, DOI 10.1063/1.1667279; TUFTE ON, 1967, PHYS REV, V155, P796, DOI 10.1103/PhysRev.155.796; Ueno K, 2003, APPL PHYS LETT, V83, P1755, DOI 10.1063/1.1605806	22	1297	1315	22	488	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 29	2006	313	5795					1942	1945		10.1126/science.1131091	http://dx.doi.org/10.1126/science.1131091			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	088SU	16931719				2022-12-28	WOS:000240832200045
J	Fenwick, A				Fenwick, Alan			Waterborne infectious diseases - Could they be consigned to history?	SCIENCE			English	Editorial Material							DRACUNCULIASIS ERADICATION; PUBLIC-HEALTH; SCHISTOSOMIASIS; MALARIA; ELIMINATION; FILARIASIS; PROGRAMS; SENEGAL; DAMS	The development of water resources, particularly in Africa, has changed the face of the continent, opening up land for agriculture, providing electric power, encouraging settlements adjacent to water bodies, and bringing prosperity to poor people. Unfortunately, the created or altered water bodies provide ideal conditions for the transmission of waterborne diseases and a favorable habitat for intermediate hosts of tropical parasitic infections that cause disease and suffering. The recent progress in control of these waterborne and vector-borne diseases, such as guinea worm, schistosomiasis, lymphatic filariasis, and onchocerciasis, suggests that many of them could be controlled effectively by 2015, which is the target for reaching the Millennium Development Goals. Donations of safe and effective drugs by several pharmaceutical companies, funds for delivering these donated drugs from foundations and bilateral donors, and effective global health partnerships should make these diseases history.	Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, London WC2 1PG, England	Imperial College London	Fenwick, A (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, London WC2 1PG, England.	a.fenwick@imperial.ac.uk						Barry M, 2006, AM J TROP MED HYG, V75, P1; Crichton-Harris Ann, 2006, J Med Biogr, V14, P8; Dadzie K Y, 1997, Afr Health, V19, P13; Dadzie Yankum, 2003, Filaria J, V2, P2, DOI 10.1186/1475-2883-2-2; de Silva NR, 2003, TRENDS PARASITOL, V19, P547, DOI 10.1016/j.pt.2003.10.002; Druilhe P, 2005, TRENDS PARASITOL, V21, P359, DOI 10.1016/j.pt.2005.06.011; Edwards G, 2006, BRIT J CLIN PHARMACO, V61, P690, DOI 10.1111/j.1365-2125.2006.02674.x; ELGADDAL AA, 1989, MEM I OSWALDO CRUZ, V84, P117, DOI 10.1590/S0074-02761989000500012; ELGADDAL AA, 1985, J TROP MED HYG, V88, P47; Engels D, 2002, ACTA TROP, V82, P139, DOI 10.1016/S0001-706X(02)00045-1; Fenwick A, 2006, T ROY SOC TROP MED H, V100, P200, DOI 10.1016/j.trstmh.2005.03.014; Garba A, 2006, TRENDS PARASITOL, V22, P322, DOI 10.1016/j.pt.2006.04.007; GREANY WH, 1952, ANN TROP MED PARASIT, V46, P298, DOI 10.1080/00034983.1952.11685535; GREANY WH, 1952, ANN TROP MED PARASIT, V46, P250, DOI 10.1080/00034983.1952.11685530; Gyapong JO, 2005, EXPERT OPIN PHARMACO, V6, P179, DOI 10.1517/14656566.6.2.179; HOMEIDA M, 1988, AM J TROP MED HYG, V39, P196, DOI 10.4269/ajtmh.1988.39.196; HOMEIDA MA, 1988, LANCET, V2, P437; Hopkins DR, 2005, AM J TROP MED HYG, V73, P669, DOI 10.4269/ajtmh.2005.73.669; Hotez P, 2005, LANCET, V365, P2089, DOI 10.1016/S0140-6736(05)66730-X; Hotez PJ, 2006, PLOS MED, V3, P576, DOI 10.1371/journal.pmed.0030102; Hotez PJ, 1997, EMERG INFECT DIS, V3, P303, DOI 10.3201/eid0303.970306; KABATEREINE BS, IN PRESS B WHO; Keiser J, 2005, AM J TROP MED HYG, V72, P392, DOI 10.4269/ajtmh.2005.72.392; Kjetland EF, 2005, AM J TROP MED HYG, V72, P311, DOI 10.4269/ajtmh.2005.72.311; Lakwo TL, 2006, MED VET ENTOMOL, V20, P93, DOI 10.1111/j.1365-2915.2006.00603.x; LEIPER R. T., 1915, Journal of the Royal Army Medical Corps, V25, P1; Molyneux David, 2003, Filaria J, V2, P13, DOI 10.1186/1475-2883-2-13; O'Ryan Miguel, 2005, Semin Pediatr Infect Dis, V16, P125, DOI 10.1053/j.spid.2005.12.008; Paperna I, 1970, Z Tropenmed Parasitol, V21, P411; Ramzy RMR, 2006, LANCET, V367, P992, DOI 10.1016/S0140-6736(06)68426-2; Savioli L, 2005, LANCET, V365, P1520, DOI 10.1016/S0140-6736(05)66433-1; Southgate VR, 1997, J HELMINTHOL, V71, P125, DOI 10.1017/S0022149X00015790; Steinmann P, 2006, LANCET INFECT DIS, V6, P411, DOI 10.1016/S1473-3099(06)70521-7; TALLA I, 1990, ANN SOC BELG MED TR, V70, P173; van der Werf MJ, 2003, ACTA TROP, V86, P125, DOI 10.1016/S0001-706X(03)00029-9; von Schirnding Y, 2002, B WORLD HEALTH ORGAN, V80, P970; Zagaria N, 2002, ANN TROP MED PARASIT, V96, pS3, DOI [10.1179/0034980215002347, 10.1179/00034980215002347]; 1973, WHO TECH REP SER, V515; 2002, WHO TECH REP SER, V912	39	135	139	1	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 25	2006	313	5790					1077	1081		10.1126/science.1127184	http://dx.doi.org/10.1126/science.1127184			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	076ZT	16931751				2022-12-28	WOS:000239998200033
J	Peterson, BJ; McClelland, J; Curry, R; Holmes, RM; Walsh, JE; Aagaard, K				Peterson, Bruce J.; McClelland, James; Curry, Ruth; Holmes, Robert M.; Walsh, John E.; Aagaard, Knut			Trajectory shifts in the Arctic and subarctic freshwater cycle	SCIENCE			English	Review							ATLANTIC CLIMATE-CHANGE; THERMOHALINE CIRCULATION; OBSERVATIONAL EVIDENCE; RIVER DISCHARGE; FRAM STRAIT; ICE-SHEET; PART II; SEA-ICE; OCEAN; VARIABILITY	Manifold changes in the freshwater cycle of high-latitude lands and oceans have been reported in the past few years. A synthesis of these changes in freshwater sources and in ocean freshwater storage illustrates the complementary and synoptic temporal pattern and magnitude of these changes over the past 50 years. Increasing river discharge anomalies and excess net precipitation on the ocean contributed similar to 20,000 cubic kilometers of fresh water to the Arctic and high-latitude North Atlantic oceans from lows in the 1960s to highs in the 1990s. Sea ice attrition provided another similar to 15,000 cubic kilometers, and glacial melt added similar to 2000 cubic kilometers. The sum of anomalous inputs from these freshwater sources matched the amount and rate at which fresh water accumulated in the North Atlantic during much of the period from 1965 through 1995. The changes in freshwater inputs and ocean storage occurred in conjunction with the amplifying North Atlantic Oscillation and rising air temperatures. Fresh water may now be accumulating in the Arctic Ocean and will likely be exported southward if and when the North Atlantic Oscillation enters into a new high phase.	Marine Biol Lab, Ctr Ecosyst, Woods Hole, MA 02543 USA; Univ Texas, Inst Marine Sci, Port Aransas, TX 78373 USA; Woods Hole Oceanog Inst, Woods Hole, MA 02543 USA; Woods Hole Res Ctr, Falmouth, MA 02540 USA; Int Arctic Res Ctr, Fairbanks, AK 99775 USA; Univ Washington, Appl Phys Lab, Seattle, WA 98105 USA	Marine Biological Laboratory - Woods Hole; University of Texas System; Woods Hole Oceanographic Institution; Woods Hole Research Center; University of Washington; University of Washington Seattle	Peterson, BJ (corresponding author), Marine Biol Lab, Ctr Ecosyst, Woods Hole, MA 02543 USA.	peterson@mbl.edu	McClelland, James W/C-5396-2008	McClelland, James W/0000-0001-9619-8194; Holmes, Robert Max/0000-0002-6413-9154; Walsh, John/0000-0001-9541-5927				AAGAARD K, 1989, J GEOPHYS RES-OCEANS, V94, P14485, DOI 10.1029/JC094iC10p14485; ACIA, 2005, ARCT CLIM IMP ASS SC; Alley RB, 2005, SCIENCE, V310, P456, DOI 10.1126/science.1114613; Baringer MO, 2001, GEOPHYS RES LETT, V28, P3179, DOI 10.1029/2001GL013246; Box JE, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2003JD004451; Bryden HL, 2005, NATURE, V438, P655, DOI 10.1038/nature04385; Bryden HL, 2003, SCIENCE, V300, P2086, DOI 10.1126/science.1083980; Curry R, 2003, NATURE, V426, P826, DOI 10.1038/nature02206; Curry R, 2005, SCIENCE, V308, P1772, DOI 10.1126/science.1109477; Curry RG, 1998, NATURE, V391, P575, DOI 10.1038/35356; Dery SJ, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL022845; Dery SJ, 2005, J CLIMATE, V18, P2540, DOI 10.1175/JCLI3440.1; Dickson B, 2002, NATURE, V416, P832, DOI 10.1038/416832a; DICKSON RR, 1988, PROG OCEANOGR, V20, P103, DOI 10.1016/0079-6611(88)90049-3; Dyurgerov MB, 2004, ARCT ANTARCT ALP RES, V36, P117, DOI 10.1657/1523-0430(2004)036[0117:OEOIIF]2.0.CO;2; Hatun H, 2005, SCIENCE, V309, P1841, DOI 10.1126/science.1114777; Hoerling M, 2003, SCIENCE, V299, P691, DOI 10.1126/science.1079053; Hoerling MP, 2001, SCIENCE, V292, P90, DOI 10.1126/science.1058582; Houghton J. T., 2001, CLIMATE CHANGE 2001; Hurrell JW, 2004, CLIM DYNAM, V23, P371, DOI 10.1007/s00382-004-0432-y; Josey SA, 2005, J GEOPHYS RES-OCEANS, V110, DOI 10.1029/2004JC002521; Marotzke J, 2000, P NATL ACAD SCI USA, V97, P1347, DOI 10.1073/pnas.97.4.1347; MEIER W, 2005, EOS, V86, P326, DOI DOI 10.1029/2005E0360003; Meredith M, 2001, GEOPHYS RES LETT, V28, P1615, DOI 10.1029/2000GL011992; Mysak LA, 1998, GEOPHYS RES LETT, V25, P3607, DOI 10.1029/98GL02782; Overpeck JT, 2005, EOS, V86, P309, DOI [10.1029/2005EO340001, DOI 10.1029/2005EO340001]; Peterson BJ, 2002, SCIENCE, V298, P2171, DOI 10.1126/science.1077445; PRINSENBERG SJ, 2001, ATMOS OCEAN, V43; Proshutinsky A, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2002GL015847; Proshutinsky A., 2005, EOS T AGU, V86, P368, DOI [10.1029/2005EO400003, DOI 10.1029/2005E0400003]; Proshutinsky AY, 1997, J GEOPHYS RES-OCEANS, V102, P12493, DOI 10.1029/97JC00738; Rahmstorf S, 1996, CLIM DYNAM, V12, P799, DOI 10.1007/s003820050144; Rignot E, 2006, SCIENCE, V311, P986, DOI 10.1126/science.1121381; Rigor IG, 2002, J CLIMATE, V15, P2648, DOI 10.1175/1520-0442(2002)015<2648:ROSITT>2.0.CO;2; Rogers AN, 2001, J CLIMATE, V14, P2414, DOI 10.1175/1520-0442(2001)014<2414:TAHCOT>2.0.CO;2; Rothrock DA, 2005, J GEOPHYS RES-OCEANS, V110, DOI 10.1029/2004JC002282; Semenov VA, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017112; Serreze MC, 2006, CLIMATIC CHANGE, V76, P241, DOI 10.1007/s10584-005-9017-y; Serreze MC, 2000, CLIMATIC CHANGE, V46, P159, DOI 10.1023/A:1005504031923; SERREZE MC, IN PRESS J GEOPHYS R; Shindell D, 1999, SCIENCE, V284, P305, DOI 10.1126/science.284.5412.305; Swift JH, 2005, J GEOPHYS RES-OCEANS, V110, DOI 10.1029/2004JC002312; Thompson DWJ, 2000, J CLIMATE, V13, P1018, DOI 10.1175/1520-0442(2000)013<1018:AMITEC>2.0.CO;2; Thompson DWJ, 2001, SCIENCE, V293, P85, DOI 10.1126/science.1058958; Uppala SM, 2005, Q J ROY METEOR SOC, V131, P2961, DOI 10.1256/qj.04.176; Vinje T, 1998, J GEOPHYS RES-OCEANS, V103, P10437, DOI 10.1029/97JC03360; Wadhams P, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020039; Wong APS, 1999, NATURE, V400, P440, DOI 10.1038/22733; Woodgate RA, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2004GL021747; Woodgate RA, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2004GL021880; Wu PL, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2003GL018584; Wu PL, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2004GL021570	52	249	260	2	94	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 25	2006	313	5790					1061	1066		10.1126/science.1122593	http://dx.doi.org/10.1126/science.1122593			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	076ZT	16931747				2022-12-28	WOS:000239998200029
J	Whitlock, JR; Heynen, AJ; Shuler, MG; Bear, MF				Whitlock, Jonathan R.; Heynen, Arnold J.; Shuler, Marshall G.; Bear, Mark F.			Learning induces long-term potentiation in the hippocampus	SCIENCE			English	Article							SYNAPTIC TRANSMISSION; FIELD POTENTIALS; MEMORY CONSOLIDATION; BRAIN TEMPERATURE; PASSIVE-AVOIDANCE; PERFORANT PATH; FASCIA-DENTATA; GLUR1 SUBUNIT; ENHANCEMENT; RATS	Years of intensive investigation have yielded a sophisticated understanding of long-term potentiation (LTP) induced in hippocampal area CA1 by high-frequency stimulation (HFS). These efforts have been motivated by the belief that similar synaptic modifications occur during memory formation, but it has never been shown that learning actually induces LTP in CA1. We found that one-trial inhibitory avoidance learning in rats produced the same changes in hippocampal glutamate receptors as induction of LTP with HFS and caused a spatially restricted increase in the amplitude of evoked synaptic transmission in CA1 in vivo. Because the learning-induced synaptic potentiation occluded HFS-induced LTP, we conclude that inhibitory avoidance training induces LTP in CA1.	MIT, Howard Hughes Med Inst, Picower Inst Learning & Memory, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA; Brown Univ, Dept Neurosci, Providence, RI 02912 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Northwell Health; Brown University	Bear, MF (corresponding author), MIT, Howard Hughes Med Inst, Picower Inst Learning & Memory, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA.	mbear@mit.edu		Bear, Mark/0000-0002-9903-2541				Abraham WC, 2003, NEUROSCIENTIST, V9, P463, DOI 10.1177/1073858403259119; Andersen P, 1995, HIPPOCAMPUS, V5, P491, DOI 10.1002/hipo.450050602; Bear MF, 1996, P NATL ACAD SCI USA, V93, P13453, DOI 10.1073/pnas.93.24.13453; Bevilaqua LR, 2005, NEUROSCIENCE, V136, P397, DOI 10.1016/j.neuroscience.2005.08.007; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; Bliss TVP, 2003, PHILOS T ROY SOC B, V358, P607, DOI 10.1098/rstb.2003.1282; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Cammarota M, 1998, EUR J NEUROSCI, V10, P2669, DOI 10.1046/j.1460-9568.1998.t01-1-00254.x; CAMMAROTA M, 1995, NEUROBIOL LEARN MEM, V64, P257, DOI 10.1006/nlme.1995.0008; Cammarota M, 1996, NEUROBIOL LEARN MEM, V66, P85, DOI 10.1006/nlme.1996.0046; ERICKSON CA, 1993, BRAIN RES, V615, P275, DOI 10.1016/0006-8993(93)90038-O; FANSELOW MS, 1986, LEARN MOTIV, V17, P16, DOI 10.1016/0023-9690(86)90018-4; FANSELOW MS, 1990, ANIM LEARN BEHAV, V18, P264, DOI 10.3758/BF03205285; GREEN EJ, 1990, J NEUROSCI, V10, P1455; Gruart A, 2006, J NEUROSCI, V26, P1077, DOI 10.1523/JNEUROSCI.2834-05.2006; Heynen AJ, 2000, NEURON, V28, P527, DOI 10.1016/S0896-6273(00)00130-6; Impey S, 1998, NAT NEUROSCI, V1, P595, DOI 10.1038/2830; ISAACSON RL, 1962, SCIENCE, V138, P1104, DOI 10.1126/science.138.3545.1104; IZQUIERDO I, 1992, BEHAV NEURAL BIOL, V58, P16, DOI 10.1016/0163-1047(92)90847-W; Lee HK, 1998, NEURON, V21, P1151, DOI 10.1016/S0896-6273(00)80632-7; Lee HK, 2000, NATURE, V405, P955, DOI 10.1038/35016089; Lomo T, 2003, PHILOS T R SOC B, V358, P617, DOI 10.1098/rstb.2002.1226; Lorenzini CA, 1996, BRAIN RES, V730, P32, DOI 10.1016/0006-8993(96)00427-1; Louie K, 2001, NEURON, V29, P145, DOI 10.1016/S0896-6273(01)00186-6; MARR D, 1971, PHILOS T ROY SOC B, V262, P23, DOI 10.1098/rstb.1971.0078; Martin SJ, 2000, ANNU REV NEUROSCI, V23, P649, DOI 10.1146/annurev.neuro.23.1.649; MCNAUGHTON BL, 1978, BRAIN RES, V157, P277, DOI 10.1016/0006-8993(78)90030-6; MCNAUGHTON BL, 1986, J NEUROSCI, V6, P563; Morris RGM, 2003, PHILOS T R SOC B, V358, P773, DOI 10.1098/rstb.2002.1264; MOSER E, 1993, SCIENCE, V259, P1324, DOI 10.1126/science.8446900; Moser EI, 1995, BEHAV BRAIN RES, V71, P11, DOI 10.1016/0166-4328(95)00051-8; Sacchetti B, 2002, EUR J NEUROSCI, V15, P143, DOI 10.1046/j.0953-816x.2001.01844.x; SHARP PE, 1985, BRAIN RES, V339, P361, DOI 10.1016/0006-8993(85)90105-2; Taubenfeld SM, 1999, NAT NEUROSCI, V2, P309, DOI 10.1038/7217; Taubenfeld SM, 2001, J NEUROSCI, V21, P84, DOI 10.1523/JNEUROSCI.21-01-00084.2001; WEISZ DJ, 1984, BEHAV BRAIN RES, V12, P145, DOI 10.1016/0166-4328(84)90037-8	36	1315	1377	2	222	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 25	2006	313	5790					1093	1097		10.1126/science.1128134	http://dx.doi.org/10.1126/science.1128134			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	076ZT	16931756				2022-12-28	WOS:000239998200038
J	Rassi, A; Rassi, A; Little, WC; Xavier, SS; Rassi, SG; Rassi, AG; Rassi, GG; Hasslocher-Moreno, A; Sousa, AS; Scanavacca, MI				Rassi, Anis, Jr.; Rassi, Anis; Little, William C.; Xavier, Sergio S.; Rassi, Sergio G.; Rassi, Alexandre G.; Rassi, Gustavo G.; Hasslocher-Moreno, Alejandro; Sousa, Andrea S.; Scanavacca, Mauricio I.			Development and validation of a risk score for predicting death in Chagas' heart disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MORTALITY; CARDIOMYOPATHY; ECHOCARDIOGRAPHY; FAILURE	Background: Chagas' disease is an important health problem in Latin America, and cardiac involvement is associated with substantial morbidity and mortality. We developed a model to predict the risk of death in patients with Chagas' heart disease. Methods: We retrospectively evaluated 424 outpatients from a regional Brazilian cohort. The association of potential risk factors with death was tested by Cox proportional-hazards analysis, and a risk score was created. The model was validated in 153 patients from a separate community hospital. Results: During a mean follow-up of 7.9 years, 130 patients in the development cohort died. Six independent prognostic factors were identified, and each was assigned a number of points proportional to its regression coefficient: New York Heart Association class III or IV (5 points), evidence of cardiomegaly on radiography (5 points), left ventricular systolic dysfunction on echocardiography (3 points), nonsustained ventricular tachycardia on 24-hour Holter monitoring (3 points), low QRS voltage on electrocardiography (2 points), and male sex (2 points). We calculated risk scores for each patient and defined three risk groups: low risk (0 to 6 points), intermediate risk (7 to 11 points), and high risk (12 to 20 points). In the development cohort, the 10-year mortality rates for these three groups were 10 percent, 44 percent, and 84 percent, respectively. In the validation cohort, the corresponding mortality rates were 9 percent, 37 percent, and 85 percent. The C statistic for the point system was 0.84 in the development cohort and 0.81 in the validation cohort. Conclusions: A simple risk score was developed to predict death in Chagas' heart disease and was validated in an independent cohort.	Anis Rassi Hosp, Div Cardiol, BR-74110029 Goiania, Go, Brazil; Wake Forest Univ, Sch Med, Cardiol Sect, Winston Salem, NC 27109 USA; Oswaldo Cruz Fdn, Evandro Chagas Clin Res Inst, Rio De Janeiro, Brazil; Univ Sao Paulo, Sch Med, Inst Coracao, Sao Paulo, Brazil	Wake Forest University; Fundacao Oswaldo Cruz; Universidade de Sao Paulo	Rassi, A (corresponding author), Anis Rassi Hosp, Div Cardiol, Ave Jose Alves 453,Setor Oeste, BR-74110029 Goiania, Go, Brazil.	arassijr@arh.com.br; arassijr@arh.com.br	Hasslocher-Moreno, Alejandro Marcel/F-3414-2011; Scanavacca, Mauricio Ibrahim/F-7693-2012; Rassi, Anis/AAJ-3368-2020; Sousa, Andrea S/K-7885-2012	Hasslocher-Moreno, Alejandro Marcel/0000-0002-5430-7222; Scanavacca, Mauricio Ibrahim/0000-0001-7327-2275; Sousa, Andrea S/0000-0001-8266-4801				ACQUATELLA H, 1980, CIRCULATION, V62, P787, DOI 10.1161/01.CIR.62.4.787; Altman DG, 2000, STAT MED, V19, P453, DOI 10.1002/(SICI)1097-0258(20000229)19:4<453::AID-SIM350>3.0.CO;2-5; BESTETTI RB, 1994, CARDIOLOGY, V84, P261, DOI 10.1159/000176409; CARRASCO HA, 1994, INT J CARDIOL, V43, P27, DOI 10.1016/0167-5273(94)90087-6; DEPAOLA AAV, 1995, BRIT HEART J, V74, P293; DIAS J C P, 1968, Revista do Instituto de Medicina Tropical de Sao Paulo, V10, P158; ESPINOSA RA, 1991, INT J CARDIOL, V30, P195, DOI 10.1016/0167-5273(91)90095-7; Garzon S A, 1995, Sao Paulo Med J, V113, P802; Garzon SAC., 1998, J AM COLL CARDIOL, V31, p107C; HAGAR JM, 1991, NEW ENGL J MED, V325, P763, DOI 10.1056/NEJM199109123251103; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; MADY C, 1994, CIRCULATION, V90, P3098, DOI 10.1161/01.CIR.90.6.3098; Maguire J H, 1982, Bull Pan Am Health Organ, V16, P47; MAGUIRE JH, 1987, CIRCULATION, V75, P1140, DOI 10.1161/01.CIR.75.6.1140; Rassi A Jr, 2001, Arq Bras Cardiol, V76, P75; Rodriguez-Salas LA, 1998, ECHOCARDIOGR-J CARD, V15, P271, DOI 10.1111/j.1540-8175.1998.tb00607.x; Salles G, 2003, CIRCULATION, V108, P305, DOI 10.1161/01.CIR.0000079174.13444.9C; Silva R M, 2000, Arq Bras Cardiol, V75, P33; Viotti RJ, 2004, HEART, V90, P655, DOI 10.1136/hrt.2003.018960; *WHO EXP COMM, 2002, WHO EXP COMM TECHN R, V905	20	395	420	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 24	2006	355	8					799	808		10.1056/NEJMoa053241	http://dx.doi.org/10.1056/NEJMoa053241			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	076KA	16928995				2022-12-28	WOS:000239955200008
J	Vastenhouw, NL; Brunschwig, K; Okihara, KL; Muller, F; Tijsterman, M; Plasterk, RHA				Vastenhouw, Nadine L.; Brunschwig, Karin; Okihara, Kristy L.; Mueller, Fritz; Tijsterman, Marcel; Plasterk, Ronald H. A.			Long-term gene silencing by RNAi	NATURE			English	Article							C-ELEGANS; INTERFERENCE; INHERITANCE		Hubrecht Lab KNAW, NL-3584 CT Utrecht, Netherlands; Univ Utrecht, NL-3584 CT Utrecht, Netherlands; Univ Fribourg, Inst Zool, CH-1700 Fribourg, Switzerland	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Utrecht University; University of Fribourg	Vastenhouw, NL (corresponding author), Hubrecht Lab KNAW, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.	plasterk@niob.knaw.nl	Tijsterman, Marcel/H-5663-2018	Tijsterman, Marcel/0000-0001-8465-9002; Platt, Thomas/0000-0003-0082-1127; Shaulsky, Gad/0000-0002-0532-0551; Kalla, Sara/0000-0003-2437-5352				Grishok A, 2000, SCIENCE, V287, P2494, DOI 10.1126/science.287.5462.2494; Kennedy S, 2004, NATURE, V427, P645, DOI 10.1038/nature02302; Lippman Z, 2004, NATURE, V431, P364, DOI 10.1038/nature02875; Matzke MA, 2005, NAT REV GENET, V6, P24, DOI 10.1038/nrg1500; Rassoulzadegan M, 2006, NATURE, V441, P469, DOI 10.1038/nature04674; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X	6	198	217	1	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 24	2006	442	7105					882	882		10.1038/442882a	http://dx.doi.org/10.1038/442882a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	076LT	16929289	Bronze, Green Submitted			2022-12-28	WOS:000239960500026
J	Sack, DA; Sack, RB; Chaignat, C				Sack, David A.; Sack, R. Bradley; Chaignat, Claire-Lise			Getting serious about cholera	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh; Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; WHO, Global Task Force Cholera Control, Geneva, Switzerland	International Centre for Diarrhoeal Disease Research (ICDDR); Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; World Health Organization	Sack, DA (corresponding author), Int Ctr Diarrhoeal Dis Res, GPO Box 128, Dhaka 1000, Bangladesh.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039129] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI039129] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ali M, 2005, LANCET, V366, P44, DOI 10.1016/S0140-6736(05)66550-6; COLOMBO MM, 1993, EUR J EPIDEMIOL, V9, P563, DOI 10.1007/BF00209537; Kalluri P, 2006, TROP MED INT HEALTH, V11, P49, DOI 10.1111/j.1365-3156.2005.01539.x; Sack DA, 2004, LANCET, V363, P223, DOI 10.1016/S0140-6736(03)15328-7; *WHO, 2006, CHOL ANG UPD 5	5	76	80	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 17	2006	355	7					649	651		10.1056/NEJMp068144	http://dx.doi.org/10.1056/NEJMp068144			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	074AN	16914700				2022-12-28	WOS:000239784500003
J	Kokko, H; Lopez-Sepulcre, A				Kokko, Hanna; Lopez-Sepulcre, Andres			From individual dispersal to species ranges: Perspectives for a changing world	SCIENCE			English	Editorial Material							DEPENDENT DISPERSAL; ECOLOGICAL TRAPS; EVOLUTION; CONSEQUENCES; DYNAMICS; SPEED		Univ Helsinki, Dept Biol & Environm Sci, Lab Ecol & Evolutionary Dynam, FIN-00014 Helsinki, Finland; Univ Jyvaskyla, Dept Biol & Environm Sci, Evolutionary Ecol Unit, FI-40014 Jyvaskyla, Finland	University of Helsinki; University of Jyvaskyla	Kokko, H (corresponding author), Univ Helsinki, Dept Biol & Environm Sci, Lab Ecol & Evolutionary Dynam, POB 65,Viikinkaari 1, FIN-00014 Helsinki, Finland.	hanna.kokko@helsinki.fi	Sepulcre, Andres Lopez/G-2404-2010; Kokko, Hanna/C-7861-2009	Sepulcre, Andres Lopez/0000-0001-9708-0788; Kokko, Hanna/0000-0002-5772-4881				Arim M, 2006, P NATL ACAD SCI USA, V103, P374, DOI 10.1073/pnas.0504272102; Baglione V, 2006, P ROY SOC B-BIOL SCI, V273, P1529, DOI 10.1098/rspb.2006.3481; Baguette M, 2006, ECOLOGY, V87, P648, DOI 10.1890/04-1631; Battin J, 2004, CONSERV BIOL, V18, P1482, DOI 10.1111/j.1523-1739.2004.00417.x; Bohning-Gaese K, 2006, AM NAT, V167, P555, DOI 10.1086/501078; Bowler DE, 2005, BIOL REV, V80, P205, DOI 10.1017/S1464793104006645; Dwyer G, 2006, AM NAT, V167, P165, DOI 10.1086/498944; Ekman J, 2002, P ROY SOC B-BIOL SCI, V269, P1709, DOI 10.1098/rspb.2002.2082; Ekman J, 2002, ANIM BEHAV, V64, P453, DOI 10.1006/anbe.2002.3075; French DR, 2001, OIKOS, V95, P125, DOI 10.1034/j.1600-0706.2001.950114.x; Guo QF, 2005, OIKOS, V108, P47, DOI 10.1111/j.0030-1299.2005.13149.x; Gyllenberg M, 2002, J MATH BIOL, V45, P79, DOI 10.1007/s002850200151; Haag CR, 2005, P ROY SOC B-BIOL SCI, V272, P2449, DOI 10.1098/rspb.2005.3235; HAMILTON WD, 1977, NATURE, V269, P578, DOI 10.1038/269578a0; Hanski I, 2004, ECOL LETT, V7, P958, DOI 10.1111/j.1461-0248.2004.00654.x; Heino M, 2001, AM NAT, V157, P495, DOI 10.1086/319927; Holt RD, 2003, EVOL ECOL RES, V5, P159; Horvath G, 1998, NATURWISSENSCHAFTEN, V85, P292, DOI 10.1007/s001140050503; Keitt TH, 2002, ECOGRAPHY, V25, P616, DOI 10.1034/j.1600-0587.2002.250509.x; Kirkpatrick M, 1997, AM NAT, V150, P1, DOI 10.1086/286054; Kokko H, 2001, EVOL ECOL RES, V3, P537; Matthiopoulos J, 2005, J ANIM ECOL, V74, P716, DOI 10.1111/j.1365-2656.2005.00970.x; Nichols J., 2001, DISPERSAL; Nocera JJ, 2006, P ROY SOC B-BIOL SCI, V273, P349, DOI 10.1098/rspb.2005.3318; Phillips BL, 2006, NATURE, V439, P803, DOI 10.1038/439803a; Simmons AD, 2004, AM NAT, V164, P378, DOI 10.1086/423430; Studds CE, 2005, ECOLOGY, V86, P2380, DOI 10.1890/04-1145; Sutherland WJ, 2004, TRENDS ECOL EVOL, V19, P305, DOI 10.1016/j.tree.2004.03.018; Vuilleumier S, 2006, OIKOS, V113, P139, DOI 10.1111/j.0030-1299.2006.14405.x	29	274	278	1	167	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 11	2006	313	5788					789	791		10.1126/science.1128566	http://dx.doi.org/10.1126/science.1128566			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	072KC	16902127				2022-12-28	WOS:000239671300045
J	Tour, E; McGinnis, W				Tour, Ella; McGinnis, William			Gap peptides: A new way to control embryonic patterning?	CELL			English	Editorial Material							SEGMENTATION; DROSOPHILA	Gap genes encode transcription factors involved in the patterning of the head-tail axis of insect embryos. In this issue of Cell, Savard et al. (2006) identify a beetle gap gene, mille-pattes, that encodes an unusual polycistronic transcript predicted to produce four conserved peptides. These results have interesting implications for the control of embryonic patterning in insects.	Univ Calif San Diego, Sect Cell & Dev Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	McGinnis, W (corresponding author), Univ Calif San Diego, Sect Cell & Dev Biol, La Jolla, CA 92093 USA.	wmcginnis@ucsd.edu						Bosch TCG, 2001, BIOESSAYS, V23, P420, DOI 10.1002/bies.1060; Brown SJ, 2003, GENET RES, V82, P155, DOI 10.1017/S0016672303006451; Bucher G, 2004, DEVELOPMENT, V131, P1729, DOI 10.1242/dev.01073; Cerny AC, 2005, DEVELOPMENT, V132, P5353, DOI 10.1242/dev.02154; Liu PZ, 2005, EVOL DEV, V7, P629, DOI 10.1111/j.1525-142X.2005.05066.x; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; SAVARD J, 2006, CELL; Sulston IA, 1996, DEVELOPMENT, V122, P805; Tupy JL, 2005, P NATL ACAD SCI USA, V102, P5495, DOI 10.1073/pnas.0501422102	10	4	4	0	3	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 11	2006	126	3					448	449		10.1016/j.cell.2006.07.021	http://dx.doi.org/10.1016/j.cell.2006.07.021			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	075KI	16901778	Bronze			2022-12-28	WOS:000239883400005
J	Ananworanich, J; Gayet-Ageron, A; Le Braz, M; Prasithsirikul, W; Chetchotisakd, P; Kiertiburanakul, S; Munsakul, W; Raksakulkarn, P; Tansuphasawasdikul, S; Sirivichayakul, S; Cavassini, M; Karrer, U; Genne, D; Nuesch, R; Vernazza, P; Bernasconi, E; Leduc, D; Satchell, C; Yerly, S; Perrin, L; Hill, A; Perneger, T; Phanuphak, P; Furrer, H; Cooper, D; Ruxrungtham, K; Hirschel, B				Ananworanich, Jintanat; Gayet-Ageron, Angele; Le Braz, Michelle; Prasithsirikul, Wisit; Chetchotisakd, Ploenchan; Kiertiburanakul, Sasisopin; Munsakul, Warangkana; Raksakulkarn, Phitsanu; Tansuphasawasdikul, Somboon; Sirivichayakul, Sunee; Cavassini, Matthias; Karrer, Urs; Genne, Daniel; Nueesch, Reto; Vernazza, Pietro; Bernasconi, Enos; Leduc, Dominic; Satchell, Claudette; Yerly, Sabine; Perrin, Luc; Hill, Andrew; Perneger, Thomas; Phanuphak, Praphan; Furrer, Hansjakob; Cooper, David; Ruxrungtham, Kiat; Hirschel, Bernard		Staccato Study Grp; Swiss HIV Cohort Study	CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial	LANCET			English	Article							STRUCTURED TREATMENT INTERRUPTIONS; CD4 CELL COUNT; ANTIRETROVIRAL THERAPY; COHORT; COST	Background Stopping antiretroviral therapy in patients with HIV-1 infection can reduce costs and side-effects, but carries the risk of increased immune suppression and emergence of resistance. Methods 430 patients with CD4-positive T-lymphocyte (CD4) counts greater than 350 cells per mu L, and viral load less than 50 copies per mL were randomised to continued therapy (n=146) or scheduled treatment interruptions (n=284). Median time on randomised treatment was 21.9 months (range 16.4-25.3). Primary endpoints were proportion of patients with viral load less than 50 copies per mL at the end of the trial, and amount of drugs used. Analysis was intention-to-treat. This study is registered at ClinicalTrials.gov with the identifier NCT00113126. Findings Drug savings in the scheduled treatment interruption group, compared with continuous treatment, amounted to 61.5%. 257 of 284 (90.5%) patients in the scheduled treatment interruption group reached a viral load less than 50 copies per mL, compared with 134 of 146 (91.8%) in the continued treatment group (difference 1.3%, 95% CI-4.3 to 6.9, p=0.90). No AIDS-defining events occurred. Diarrhoea and neuropathy were more frequent with continuous treatment; candidiasis was more frequent with scheduled treatment interruption. Ten patients (2.3%) had resistance mutations, with no significant differences between groups. Interpretation Drug savings with scheduled treatment interruption were substantial, and no evidence of increased treatment resistance emerged. Treatment-related adverse events were more frequent with continuous treatment, but low CD4 counts and minor manifestations of HIV infection were more frequent with scheduled treatment interruption.	Univ Hosp Geneva, Div Infect Dis, CH-1211 Geneva 14, Switzerland; HIV Netherlands Australia Thailand Res Collaborat, Bangkok, Thailand; Bamrasnaradura Inst, Nonthaburi, Thailand; Khon Kaen Univ, Khon Kaen, Thailand; Mahidol Univ, Ramathibodi Hosp, Bangkok 10700, Thailand; Bangkok Metropolitan Adm Med Coll, Bangkok, Thailand; Vajira Hosp, Bangkok, Thailand; Sanpatong Hosp, Chiang Mai, Thailand; Buddhachinnaraj Hosp, Phitsanulok, Thailand; Univ Hosp, Bern, Switzerland; Univ Liverpool, Liverpool L69 3BX, Merseyside, England; Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia; Chulalongkorn Univ, Bangkok, Thailand; Univ Hosp, Lausanne, Switzerland; Univ Hosp, Zurich, Switzerland; La Chaux de Fonds Hosp, La Chaux De Fonds, Switzerland; Univ Spital Basel, Basel, Switzerland; Kantonsspital St Gallen, St Gallen, Switzerland; Osped Civico, Lugano, Switzerland; Hop Annemasse, Annemasse, France	University of Geneva; Khon Kaen University; Mahidol University; University of Bern; University Hospital of Bern; University of Liverpool; University of New South Wales Sydney; Kirby Institute; Chulalongkorn University; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Zurich; University Zurich Hospital; University of Basel	Hirschel, B (corresponding author), Univ Hosp Geneva, Div Infect Dis, CH-1211 Geneva 14, Switzerland.	bernard.hirschel@hcuge.ch	Ananworanich, Jintanat/AAC-6348-2021; Prasithsirikul, Wisit/AAH-6284-2020; Genne, Daniel/O-2305-2014; VALLET, Yannick/F-9979-2011; Furrer, Hansjakob/G-6768-2013; cavassini, matthias/F-8987-2017	Ananworanich, Jintanat/0000-0003-1369-3224; Furrer, Hansjakob/0000-0002-1375-3146; cavassini, matthias/0000-0003-0933-7833; Gayet-Ageron, Angele/0000-0002-6164-9693				Ananworanich J, 2003, AIDS, V17, pF33, DOI 10.1097/00002030-200310170-00001; Armitage P., 1987, STAT METHODS MED RES; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; Colven R, 2000, ANN INTERN MED, V133, P430, DOI 10.7326/0003-4819-133-6-200009190-00010; Creese A, 2002, LANCET, V359, P1635, DOI 10.1016/S0140-6736(02)08595-1; Fagard C, 2005, AIDS, V19, P439, DOI 10.1097/01.aids.0000161774.29029.0e; Fagard C, 2003, ARCH INTERN MED, V163, P1220, DOI 10.1001/archinte.163.10.1220; Fellay J, 2001, LANCET, V358, P1322, DOI 10.1016/S0140-6736(01)06413-3; Hellinger FJ, 2000, J ACQ IMMUN DEF SYND, V24, P182; Hogg RS, 2002, AIDS, V16, P1051, DOI 10.1097/00002030-200205030-00012; Kinloch-de Loes S, 2005, J INFECT DIS, V192, P607, DOI 10.1086/432002; Ledergerber B, 1999, JAMA-J AM MED ASSOC, V282, P2220, DOI 10.1001/jama.282.23.2220; Molto J, 2004, AIDS RES HUM RETROV, V20, P1283, DOI 10.1089/aid.2004.20.1283; *NAT I ALL INF DIS, 2005, COMP 2 WAYS MAN ANT; *NAT I ALL INF DIS, 2006, INT HIV AIDS TRIAL F; Nuesch R, 2005, CLIN INFECT DIS, V40, P728, DOI 10.1086/427878; TAYLOR S, 2004, 11 C RETR OPP INF; Walmsley Sharon, 2002, J Int Assoc Physicians AIDS Care (Chic), V1, P95, DOI 10.1177/154510970200100304	19	172	174	0	13	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 5	2006	368	9534					459	465		10.1016/S0140-6736(06)69153-8	http://dx.doi.org/10.1016/S0140-6736(06)69153-8			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	071AL	16890832				2022-12-28	WOS:000239569000028
J	Lovell, K; Cox, D; Haddock, G; Jones, C; Raines, D; Garvey, R; Roberts, C; Hadley, S				Lovell, Karina; Cox, Debbie; Haddock, Gillian; Jones, Christopher; Raines, David; Garvey, Rachel; Roberts, Clrris; Hadley, Sarah			Telephone administered cognitive behaviour therapy for treatment of obsessive compulsive disorder: randomised controlled non-inferiority trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SELF-HELP; EXPOSURE		Univ Manchester, Dept Nursing Midwifery & Social Work, Manchester M13 9PL, Lancs, England; Univ Manchester, Sch Psychol Sci, Manchester M15 6SZ, Lancs, England; Univ Manchester, Div Epidemiol & Hlth Sci, Biostat Grp, Manchester M13 9PT, Lancs, England; Macclesfield Hosp, Cheshire & Wirral NHS Partnership NHS Trust, CBT Dept, Macclesfield SK10 3BL, Cheshire, England; UCL, Subdept Clin Hlth Psychol, Ctr Clin Outcomes Res & Effectiveness, British Psychol Soc, London WC1E 6BT, England; Stepping Hill Hosp, Pennine Care NHS Trust, Dept Clin Psychol, Stockport SK2 7JE, Lancs, England; Leicestershire Partnership NHS Trust, Dept Cognit & Behav Psychotherapy, Leicester, Leics, England	University of Manchester; University of Manchester; University of Manchester; University of London; University College London; Leicestershire Partnership NHS Trust	Lovell, K (corresponding author), Univ Manchester, Dept Nursing Midwifery & Social Work, Manchester M13 9PL, Lancs, England.	Karina.Lovell@manchester.ac.uk	Lovell, Karina S E/E-6410-2012	Lovell, Karina S E/0000-0001-8821-895X; Haddock, Professor Gillian/0000-0001-6234-5774				Attkisson C C, 1982, Eval Program Plann, V5, P233, DOI 10.1016/0149-7189(82)90074-X; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Cordioli AV, 2003, PSYCHOTHER PSYCHOSOM, V72, P211, DOI 10.1159/000070785; Den Boer PCAM, 2004, PSYCHOL MED, V34, P959, DOI 10.1017/S003329170300179X; DuPont R L, 1995, Med Interface, V8, P102; ELASHOFF JD, 2002, NQUERY ADVISOR VERSI; FALSSTEWART W, 1993, J NERV MENT DIS, V181, P189, DOI 10.1097/00005053-199303000-00007; GOODMAN WK, 1989, ARCH GEN PSYCHIAT, V46, P1006; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Jones E, 1996, BMJ-BRIT MED J, V313, P36, DOI 10.1136/bmj.313.7048.36; Jones MK, 1998, BEHAV RES THER, V36, P959, DOI 10.1016/S0005-7967(98)00057-6; Kaltenthaler E, 2004, BEHAV COGN PSYCHOTH, V32, P31, DOI 10.1017/S135246580400102X; LAVORI PW, 1992, NEUROPSYCHOPHARMACOL, V6, P29; Lindsay M, 1997, BRIT J PSYCHIAT, V171, P135, DOI 10.1192/bjp.171.2.135; Lovell K., 2000, BEHAV COGN PSYCHOTH, V28, P87; Lovell K., 2000, BEHAV COGN PSYCHOTH, V28, P379, DOI [DOI 10.1017/S1352465800004070, 10.1017/S1352465800004070]; Marks I, 1987, FEARS PHOBIAS RITUAL; MCNAMEE G, 1989, BEHAV THER, V20, P491, DOI 10.1016/S0005-7894(89)80128-5; Mohr DC, 2000, J CONSULT CLIN PSYCH, V68, P356, DOI 10.1037//0022-006X.68.2.356; *NAT I HLTH CLIN E, OBS COMP DIS; O'Connor K, 1999, CAN J PSYCHIAT, V44, P64, DOI 10.1177/070674379904400108; Palmer RL, 2002, BRIT J PSYCHIAT, V181, P230, DOI 10.1192/bjp.181.3.230; Piaggio G, 2006, JAMA-J AM MED ASSOC, V295, P1152, DOI 10.1001/jama.295.10.1152; POCOCK S, 1990, CLIN TRIALS; SHROUT PE, 1992, NEUROPSYCHOPHARMACOL, V6, P49; Taylor Steven, 2003, Cognitive Behaviour Therapy, V32, P13, DOI 10.1080/16506070310003639; van Balkom AJLM, 1998, J NERV MENT DIS, V186, P492, DOI 10.1097/00005053-199808000-00007; Vogel PA, 2004, BEHAV COGN PSYCHOTH, V32, P275, DOI 10.1017/S1352465804001353	28	112	112	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 28	2006	333	7574					883	886		10.1136/bmj.38940.355602.80	http://dx.doi.org/10.1136/bmj.38940.355602.80			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	101WT	16935946	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000241772600014
J	Chen, JL; Wilson, CR; Tapley, BD				Chen, J. L.; Wilson, C. R.; Tapley, B. D.			Satellite gravity measurements confirm accelerated melting of Greenland ice sheet	SCIENCE			English	Article							GRACE; EARTH; SURFACE; MODEL	Using time-variable gravity measurements from the Gravity Recovery and Climate Experiment ( GRACE) satellite mission, we estimate ice mass changes over Greenland during the period April 2002 to November 2005. After correcting for the effects of spatial filtering and limited resolution of GRACE data, the estimated total ice melting rate over Greenland is - 239 +/- 23 cubic kilometers per year, mostly from East Greenland. This estimate agrees remarkably well with a recent assessment of - 224 +/- 41 cubic kilometers per year, based on satellite radar interferometry data. GRACE estimates in southeast Greenland suggest accelerated melting since the summer of 2004, consistent with the latest remote sensing measurements.	Univ Texas, Ctr Space Res, Austin, TX 78712 USA; Univ Texas, Dept Geol Sci, Jackson Sch Geosci, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Chen, JL (corresponding author), Univ Texas, Ctr Space Res, Austin, TX 78712 USA.	chen@csr.utexas.edu		Chen, Jianli/0000-0001-5405-8441; Tapley, Byron/0000-0003-3689-5750				Bettadpur S., 2003, LEVEL 2 GRAVITY FIEL; Chambers DP, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020461; Chapin FS, 2005, SCIENCE, V310, P657, DOI 10.1126/science.1117368; Chen JL, 2006, EARTH PLANET SC LETT, V248, P368, DOI 10.1016/j.epsl.2006.05.039; Chen JL, 2006, J GEOPHYS RES-SOL EA, V111, DOI 10.1029/2005JB004064; Chen JL, 2005, J GEODESY, V79, P532, DOI 10.1007/s00190-005-0005-9; Church JA, 2001, CLIMATE CHANGE 2001: THE SCIENTIFIC BASIS, P639; Huybrechts P, 2004, GLOBAL PLANET CHANGE, V42, P83, DOI 10.1016/j.gloplacha.2003.11.011; Krabill W, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL021533; Peltier WR, 2004, ANNU REV EARTH PL SC, V32, P111, DOI 10.1146/annurev.earth.32.082503.144359; Ramillien G, 2006, GLOBAL PLANET CHANGE, V53, P198, DOI 10.1016/j.gloplacha.2006.06.003; Reigber C, 2005, J GEODYN, V39, P1, DOI 10.1016/j.jog.2004.07.001; Rignot E, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL019474; Rignot E, 2006, SCIENCE, V311, P986, DOI 10.1126/science.1121381; Sato T, 2006, GEOPHYS J INT, V165, P729, DOI 10.1111/J.1365-246X.2006.02992.X; Schmidt R, 2006, GLOBAL PLANET CHANGE, V50, P112, DOI 10.1016/j.gloplacha.2004.11.018; Tamisiea ME, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL023961; Tapley BD, 2004, SCIENCE, V305, P503, DOI 10.1126/science.1099192; Tapley BD, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL019920; Velicogna I, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL023955; Velicogna I, 2006, SCIENCE, V311, P1754, DOI 10.1126/science.1123785; Wahr J, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL019779; Zwally HJ, 2005, J GLACIOL, V51, P509, DOI 10.3189/172756505781829007	23	279	305	7	86	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 29	2006	313	5795					1958	1960		10.1126/science.1129007	http://dx.doi.org/10.1126/science.1129007			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	088SU	16902089				2022-12-28	WOS:000240832200050
J	Schneider, H; Downey, J; Smith, A; Zinselmeyer, BH; Rush, C; Brewer, JM; Wei, B; Hogg, N; Garside, P; Rudd, CE				Schneider, Helga; Downey, Jos; Smith, Andrew; Zinselmeyer, Bernd H.; Rush, Catherine; Brewer, James M.; Bin Wei; Hogg, Nancy; Garside, Paul; Rudd, Christopher E.			Reversal of the TCR stop signal by CTLA-4	SCIENCE			English	Article							LYMPHOCYTE-ASSOCIATED ANTIGEN-4; REGULATORY T-CELLS; IN-VIVO; DENDRITIC CELLS; IMMUNOLOGICAL SYNAPSE; TOLERANCE; INDUCTION; NODES; CD28; ACTIVATION	The coreceptor cytotoxic T lymphocyte - associated antigen 4 (CTLA-4) is pivotal in regulating the threshold of signals during T cell activation, although the underlying mechanism is still not fully understood. Using in vitro migration assays and in vivo two-photon laser scanning microscopy, we showed that CTLA-4 increases T cell motility and overrides the T cell receptor (TCR)- induced stop signal required for stable conjugate formation between T cells and antigen-presenting cells. This event led to reduced contact periods between T cells and antigen-presenting cells that in turn decreased cytokine production and proliferation. These results suggest a fundamentally different model of reverse stop signaling, by which CTLA-4 modulates the threshold for T cell activation and protects against autoimmunity.	Univ Cambridge, Dept Pathol, Div Immunol, Cell Signalling Sect, Cambridge CB2 1QP, England; Univ London Imperial Coll Sci Technol & Med, Div Invest Sci, Dept Immunol, Mol Immunol Sect, London W12 0NN, England; Canc Res UK London Res Inst, London WC2A 3PX, England; Univ Glasgow, Western Infirm, Div Immunol Infect & Inflammat, Glasgow G11 6NT, Lanark, Scotland; Univ Strathclyde, Ctr Biophoton, Glasgow G4 0NR, Lanark, Scotland	University of Cambridge; Imperial College London; Cancer Research UK; University of Glasgow; University of Strathclyde	Rudd, CE (corresponding author), Univ Cambridge, Dept Pathol, Div Immunol, Cell Signalling Sect, Tennis Court Rd, Cambridge CB2 1QP, England.	cer51@cam.ac.uk	Rudd, Christopher E/GOH-2021-2022; Rush, Catherine M/L-4308-2013; Brewer, James/A-7186-2010; Rudd, Christopher E/ABF-7259-2021; Garside, Paul/A-4227-2009; Zinselmeyer, Bernd/X-4802-2018	Rudd, Christopher E/0000-0001-5295-9019; Rush, Catherine M/0000-0002-3044-9488; Brewer, James/0000-0001-7933-0915; Zinselmeyer, Bernd/0000-0003-4172-6767; Smith, Andrew/0000-0002-4691-5973	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bousso P, 2003, NAT IMMUNOL, V4, P579, DOI 10.1038/ni928; Cantrell DA, 2003, IMMUNOL REV, V192, P122, DOI 10.1034/j.1600-065X.2003.00028.x; Chikuma S, 2003, J EXP MED, V197, P129, DOI 10.1084/jem.20021646; Chuang E, 2000, IMMUNITY, V13, P313, DOI 10.1016/S1074-7613(00)00031-5; Darlington PJ, 2002, J EXP MED, V195, P1337, DOI 10.1084/jem.20011868; Dustin ML, 1997, P NATL ACAD SCI USA, V94, P3909, DOI 10.1073/pnas.94.8.3909; Egen JG, 2002, NAT IMMUNOL, V3, P611, DOI 10.1038/ni0702-611; Fallarino F, 2003, NAT IMMUNOL, V4, P1206, DOI 10.1038/ni1003; Fehervari Z, 2004, J CLIN INVEST, V114, P1209, DOI 10.1172/JCI200434495; Greenwald RJ, 2005, ANNU REV IMMUNOL, V23, P515, DOI 10.1146/annurev.immunol.23.021704.115611; Hugues S, 2004, NAT IMMUNOL, V5, P1235, DOI 10.1038/ni1134; Lee KM, 1998, SCIENCE, V282, P2263, DOI 10.1126/science.282.5397.2263; Lohr J, 2003, NAT IMMUNOL, V4, P664, DOI 10.1038/ni939; Marengere LEM, 1996, SCIENCE, V272, P1170, DOI 10.1126/science.272.5265.1170; Masteller EL, 2000, J IMMUNOL, V164, P5319, DOI 10.4049/jimmunol.164.10.5319; Mempel TR, 2004, NATURE, V427, P154, DOI 10.1038/nature02238; Miller MJ, 2002, SCIENCE, V296, P1869, DOI 10.1126/science.1070051; Negulescu PA, 1996, IMMUNITY, V4, P421, DOI 10.1016/S1074-7613(00)80409-4; Pentcheva-Hoang T, 2004, IMMUNITY, V21, P401, DOI 10.1016/j.immuni.2004.06.017; Perez VL, 1997, IMMUNITY, V6, P411, DOI 10.1016/S1074-7613(00)80284-8; Read S, 2000, J EXP MED, V192, P295, DOI 10.1084/jem.192.2.295; RICHARDSON B, 1994, ARTHRITIS RHEUM, V37, P1363, DOI 10.1002/art.1780370915; Rudd CE, 2003, NAT REV IMMUNOL, V3, P544, DOI 10.1038/nri1131; RUDD CE, 2002, SCI STKE, pPE18; Salomon B, 2001, ANNU REV IMMUNOL, V19, P225, DOI 10.1146/annurev.immunol.19.1.225; Schneider H, 2005, P NATL ACAD SCI USA, V102, P12861, DOI 10.1073/pnas.0505802102; Schneider H, 2002, J IMMUNOL, V169, P3475, DOI 10.4049/jimmunol.169.7.3475; Shakhar G, 2005, NAT IMMUNOL, V6, P707, DOI 10.1038/ni1210; Tadokoro CE, 2006, J EXP MED, V203, P505, DOI 10.1084/jem.20050783; Thompson CB, 1997, IMMUNITY, V7, P445, DOI 10.1016/S1074-7613(00)80366-0; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; Yung Raymond L., 2003, Biol Proced Online, V5, P211, DOI 10.1251/bpo64; Zinselmeyer BH, 2005, J EXP MED, V201, P1815, DOI 10.1084/jem.20050203	34	458	478	2	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 29	2006	313	5795					1972	1975		10.1126/science.1131078	http://dx.doi.org/10.1126/science.1131078			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	088SU	16931720				2022-12-28	WOS:000240832200054
J	Nassar, N; Roberts, CL; Cameron, CA; Olive, EC				Nassar, Natasha; Roberts, Christine L.; Cameron, Carolyn A.; Olive, Emily C.			Diagnostic accuracy of clinical examination for detection of non-cephalic presentation in late pregnancy: cross sectional analytic study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LEOPOLD MANEUVERS; FETAL PRESENTATION	Objective To examine the diagnostic accuracy of clinical examination to determine fetal presentation in late pregnancy. Design Cross sectional analytic study with index test of clinical examination and reference standard of ultrasonography. Setting Antenatal clinic in tertiary obstetric hospital in Sydney, Australia. Participants 1633 women with a singleton pregnancy between 35 and 37 weeks' gestation attending antenatal clinics. Intervention Fetal presentation assessed by clinical examination during routine antenatal care, followed by ultrasonography to confirm the diagnosis. Main outcome measures Sensitivity, specificity, and positive and negative predictive values of clinical examination compared with ultrasonography. Diagnostic rates by maternal characteristics. Results Ultrasonography identified non-cephalic presentation in 130 (8%) women, comprising 103 (6.3%) With breech and 27 (1.7%) with transverse or oblique lie. Sensitivity of clinical examination for detecting non-cephalic presentation was 70% (95% confidence interval 62% to 78%) and specificity was 95% (94% to 96%). The positive predictive value and negative predictive value were 55% and 97%, respectively. Conclusions Clinical examination is not sensitive enough for detection and timely management of non-cephalic presentation.	Univ Sydney, Sch Publ Hlth, Ctr Perinatal Hlth Serv Res, Sydney, NSW 2006, Australia	University of Sydney	Nassar, N (corresponding author), Univ Sydney, Sch Publ Hlth, Ctr Perinatal Hlth Serv Res, Sydney, NSW 2006, Australia.	natashan@ichr.uwa.edu.au	Nassar, Natasha/K-3918-2019	Nassar, Natasha/0000-0002-3720-9655				ALTMAN DG, 1994, BRIT MED J, V309, P102, DOI 10.1136/bmj.309.6947.102; Hofmeyr GJ, 1996, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000083; LYDONROCHELLE M, 1993, BIRTH-ISS PERINAT C, V20, P132, DOI 10.1111/j.1523-536X.1993.tb00437.x; MCFARLIN BL, 1985, J NURSE-MIDWIFERY, V30, P280, DOI 10.1016/0091-2182(85)90043-6; NASSAR N, 2005, THESIS U SYDNEY SYDN; Roberts C, 2003, AUST NZ J OBSTET GYN, V43, P173, DOI 10.1046/j.0004-8666.2003.00043.x; SCHEER K, 1976, AM J OBSTET GYNECOL, V125, P269, DOI 10.1016/0002-9378(76)90609-8; THORP JM, 1991, OBSTET GYNECOL, V78, P394; Waterstone M, 2001, BMJ-BRIT MED J, V322, P1089, DOI 10.1136/bmj.322.7294.1089; Watson WJ, 2004, J REPROD MED, V49, P294	10	27	30	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 16	2006	333	7568					578	580		10.1136/bmj.38919.681563.4F	http://dx.doi.org/10.1136/bmj.38919.681563.4F			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	089KB	16891327	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000240878200015
J	Laslo, P; Spooner, CJ; Warmflash, A; Lancki, DW; Lee, HJ; Sciammas, R; Gantner, BN; Dinner, AR; Singh, H				Laslo, Peter; Spooner, Chauncey J.; Warmflash, Aryeh; Lancki, David W.; Lee, Hyun-Jun; Sciammas, Roger; Gantner, Benjamin N.; Dinner, Aaron R.; Singh, Harinder			Multilineage transcriptional priming and determination of alternate hematopoietic cell fates	CELL			English	Article							COLONY-STIMULATING FACTOR; FACTOR-RECEPTOR PROMOTER; STEM-CELLS; REGULATORY NETWORKS; LINEAGE COMMITMENT; ESCHERICHIA-COLI; PU.1; DIFFERENTIATION; MACROPHAGE; GFI-1	Hematopoietic stem cells and their progenitors exhibit multilineage patterns of gene expression. Molecular mechanisms underlying the generation and refinement of these patterns during cell fate determination remain unexplored because of the absence of suitable experimental systems. Using PU.1(-/-) progenitors, we demonstrate that at subthreshold levels, this Ets transcription factor regulates a mixed pattern (macrophage/neutrophil) of gene expression within individual myeloid progenitors. Increased PU.1 levels refine the pattern and promote macrophage differentiation by modulating a novel regulatory circuit comprised of counter antagonistic repressors, Egr-1,2/Nab2 and Gfi-1. Egr-1 and Egr-2 function redundantly to activate macrophage genes and to repress the neutrophil program. These results are used to assemble and mathematically model a gene regulatory network that exhibits both graded and bistable behaviors and accounts for the onset and resolution of mixed lineage patterns during cell fate determination.	Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; Univ Chicago, Dept Phys, Chicago, IL 60637 USA; Univ Chicago, Dept Chem, Chicago, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago; University of Chicago	Dinner, AR (corresponding author), Univ Chicago, Howard Hughes Med Inst, 929 E 57th St,GCIS W522, Chicago, IL 60637 USA.	dinner@uchicago.edu; hsingh@uchicago.edu	Warmflash, Aryeh/Y-6763-2019	Warmflash, Aryeh/0000-0002-5679-2268	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007090] Funding Source: NIH RePORTER; NIAID NIH HHS [T32 AI07090] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Acar M, 2005, NATURE, V435, P228, DOI 10.1038/nature03524; Angeli D, 2004, P NATL ACAD SCI USA, V101, P1822, DOI 10.1073/pnas.0308265100; Biggar SR, 2001, EMBO J, V20, P3167, DOI 10.1093/emboj/20.12.3167; Busslinger M, 2004, ANNU REV IMMUNOL, V22, P55, DOI 10.1146/annurev.immunol.22.012703.104807; Cantor AB, 2002, ONCOGENE, V21, P3368, DOI 10.1038/sj.onc.1205326; Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8; Dahl R, 2003, NAT IMMUNOL, V4, P1029, DOI 10.1038/ni973; DeKoter RP, 2002, IMMUNITY, V16, P297, DOI 10.1016/S1074-7613(02)00269-8; DeKoter RP, 1998, EMBO J, V17, P4456, DOI 10.1093/emboj/17.15.4456; Duan Zhijun, 2003, Hematology, V8, P339, DOI 10.1080/10245330310001612116; Elowitz MB, 2000, NATURE, V403, P335, DOI 10.1038/35002125; Enver T, 1998, BLOOD, V92, P348, DOI 10.1182/blood.V92.2.348.Con3_348_351; Gardner TS, 2000, NATURE, V403, P339, DOI 10.1038/35002131; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; Giudicelli F, 2001, GENE DEV, V15, P567, DOI 10.1101/gad.189801; Godfrey DI, 2000, IMMUNOL TODAY, V21, P573, DOI 10.1016/S0167-5699(00)01735-7; Grimes HL, 1996, MOL CELL BIOL, V16, P6263; Grose R, 2002, DEV DYNAM, V223, P371, DOI 10.1002/dvdy.10064; Hock H, 2004, NATURE, V431, P1002, DOI 10.1038/nature02994; Hock H, 2003, IMMUNITY, V18, P109, DOI 10.1016/S1074-7613(02)00501-0; Hu M, 1997, GENE DEV, V11, P774, DOI 10.1101/gad.11.6.774; Lee SL, 1996, MOL CELL BIOL, V16, P4566; Metcalf D, 1998, BLOOD, V92, P345, DOI 10.1182/blood.V92.2.345b.Con2_345_347; Miyamoto T, 2002, DEV CELL, V3, P137, DOI 10.1016/S1534-5807(02)00201-0; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; Nutt SL, 2005, J EXP MED, V201, P221, DOI 10.1084/jem.20041535; Orkin S H, 1998, Stem Cells, V16 Suppl 2, P79; Orkin SH, 2000, NAT REV GENET, V1, P57, DOI 10.1038/35049577; Ozbudak EM, 2004, NATURE, V427, P737, DOI 10.1038/nature02298; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; RUSSO MW, 1995, P NATL ACAD SCI USA, V92, P6873, DOI 10.1073/pnas.92.15.6873; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Shroyer NF, 2005, GENE DEV, V19, P2412, DOI 10.1101/gad.1353905; Singh H, 2005, P NATL ACAD SCI USA, V102, P4949, DOI 10.1073/pnas.0500480102; Smith LT, 1996, BLOOD, V88, P1234, DOI 10.1182/blood.V88.4.1234.bloodjournal8841234; Starck J, 2003, MOL CELL BIOL, V23, P1390, DOI 10.1128/MCB.23.4.1390-1402.2003; Stathopoulos A, 2005, DEV CELL, V9, P449, DOI 10.1016/j.devcel.2005.09.005; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Svaren J, 1996, MOL CELL BIOL, V16, P3545; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; Voiculescu O, 2001, DEVELOPMENT, V128, P4967; Wallis D, 2003, DEVELOPMENT, V130, P221, DOI 10.1242/dev.00190; Walsh JC, 2002, IMMUNITY, V17, P665, DOI 10.1016/S1074-7613(02)00452-1; Xie HF, 2004, CELL, V117, P663, DOI 10.1016/S0092-8674(04)00419-2; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705	47	478	489	0	25	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 25	2006	126	4					755	766		10.1016/j.cell.2006.06.052	http://dx.doi.org/10.1016/j.cell.2006.06.052			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	080VN	16923394	Bronze			2022-12-28	WOS:000240276700023
J	Oyadomari, S; Yun, C; Fisher, EA; Kreglinger, N; Kreibich, G; Oyadomari, M; Harding, HP; Goodman, AG; Harant, H; Garrison, JL; Taunton, J; Katze, MG; Ron, D				Oyadomari, Seiichi; Yun, Chi; Fisher, Edward A.; Kreglinger, Nicola; Kreibich, Gert; Oyadomari, Miho; Harding, Heather P.; Goodman, Alan G.; Harant, Hanna; Garrison, Jennifer L.; Taunton, Jack; Katze, Michael G.; Ron, David			Cotranslocational degradation protects the stressed endoplasmic reticulum from protein overload	CELL			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; SECRETORY PROTEINS; CELLULAR INHIBITOR; QUALITY-CONTROL; APOPROTEIN-B; TRANSLOCATION; CHAPERONE; KINASE; PATHWAY; BIP	The ER's capacity to process proteins is limited, and stress caused by accumulation of unfolded and misfolded proteins (ER stress) contributes to human disease. ER stress elicits the unfolded protein response (UPR), whose components attenuate protein synthesis, increase folding capacity, and enhance misfolded protein degradation. Here, we report that P58(IPK)/DNAJC3, a UPIR-responsive gene previously implicated in translational control, encodes a cytosolic cochaperone that associates with the ER protein translocation channel Sec61. P58(IPK) recruits HSP70 chaperones to the cytosolic face of Sec61 and can be crosslinked to proteins entering the ER that are delayed at the translocon. Proteasonne-mediated cytosolic degradation of translocating proteins delayed at Sec61 is cochaperone dependent. In P58(IPK-/-) mice, cells with a high secretory burden are markedly compromised in their ability to cope with ER stress. Thus, P58(IPK) is a key mediator of cotranslocational ER protein degradation, and this process likely contributes to ER homeostasis in stressed cells.	NYU, Sch Med, Skiball Inst Biomol Med, New York, NY 10016 USA; NYU, Sch Med, Dept Med, New York, NY 10016 USA; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA; Novartis Inst BioMed Res, A-1235 Vienna, Austria; Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94107 USA	New York University; New York University; New York University; New York University; University of Washington; University of Washington Seattle; Novartis; University of California System; University of California San Francisco	Ron, D (corresponding author), NYU, Sch Med, Skiball Inst Biomol Med, New York, NY 10016 USA.	ron@saturn.med.nyu.edu	Oyadomari, Seiichi/GZA-7157-2022; Fisher, Edward/ABE-7469-2020; Goodman, Alan/AAQ-1108-2020; Oyadomari, Seiichi/GZA-7072-2022	Goodman, Alan/0000-0001-6394-332X; Ron, David/0000-0002-3014-5636; Fisher, Edward/0000-0001-9802-143X; Harding, Heather P/0000-0002-7359-7974	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK047119, R29DK047119, R01DK047119] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008681] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58541] Funding Source: Medline; NIDDK NIH HHS [DK47119] Funding Source: Medline; NIEHS NIH HHS [ES08681] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BARBER GN, 1994, P NATL ACAD SCI USA, V91, P4278, DOI 10.1073/pnas.91.10.4278; Besemer J, 2005, NATURE, V436, P290, DOI 10.1038/nature03670; BRODSKY JL, 1995, P NATL ACAD SCI USA, V92, P9643, DOI 10.1073/pnas.92.21.9643; Brychzy A, 2003, EMBO J, V22, P3613, DOI 10.1093/emboj/cdg362; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; Fisher EA, 2002, J BIOL CHEM, V277, P17377, DOI 10.1074/jbc.R100068200; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; Fons RD, 2003, J CELL BIOL, V160, P529, DOI 10.1083/jcb.200210095; Garrison JL, 2005, NATURE, V436, P285, DOI 10.1038/nature03821; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; Gusarova V, 2001, J BIOL CHEM, V276, P24891, DOI 10.1074/jbc.M100633200; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Hegde RS, 1996, CELL, V85, P217, DOI 10.1016/S0092-8674(00)81098-3; Hussain MM, 2003, J LIPID RES, V44, P22, DOI 10.1194/jlr.R200014-JLR200; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Ladiges WC, 2005, DIABETES, V54, P1074, DOI 10.2337/diabetes.54.4.1074; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; LEE TG, 1994, MOL CELL BIOL, V14, P2331, DOI 10.1128/MCB.14.4.2331; Matlack KES, 1999, CELL, V97, P553, DOI 10.1016/S0092-8674(00)80767-9; Melville MW, 1999, J BIOL CHEM, V274, P3797, DOI 10.1074/jbc.274.6.3797; Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766; Misselwitz B, 1998, MOL CELL, V2, P593, DOI 10.1016/S1097-2765(00)80158-6; Mitchell DM, 1998, P NATL ACAD SCI USA, V95, P14733, DOI 10.1073/pnas.95.25.14733; Oyadomari S, 2002, J CLIN INVEST, V109, P525, DOI 10.1172/JCI200214550; Pariyarath R, 2001, J BIOL CHEM, V276, P541, DOI 10.1074/jbc.M007944200; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Shen XH, 2001, CELL, V107, P893, DOI 10.1016/S0092-8674(01)00612-2; Sitia R, 2003, NATURE, V426, P891, DOI 10.1038/nature02262; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; van Anken E, 2005, CRIT REV BIOCHEM MOL, V40, P191, DOI 10.1080/10409230591008161; van Huizen R, 2003, J BIOL CHEM, V278, P15558, DOI 10.1074/jbc.M212074200; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; Yan W, 2002, P NATL ACAD SCI USA, V99, P15920, DOI 10.1073/pnas.252341799; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Yu H, 1997, J BIOL CHEM, V272, P20800, DOI 10.1074/jbc.272.33.20800; Zhang JX, 1997, MOL BIOL CELL, V8, P1943, DOI 10.1091/mbc.8.10.1943	39	196	204	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 25	2006	126	4					727	739		10.1016/j.cell.2006.06.051	http://dx.doi.org/10.1016/j.cell.2006.06.051			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	080VN	16923392	Bronze			2022-12-28	WOS:000240276700021
J	Pastalkova, E; Serrano, P; Pinkhasova, D; Wallace, E; Fenton, AA; Sacktor, TC				Pastalkova, Eva; Serrano, Peter; Pinkhasova, Deana; Wallace, Emma; Fenton, Andre Antonio; Sacktor, Todd Charlton			Storage of spatial information by the maintenance mechanism of LTP	SCIENCE			English	Article							LONG-TERM-POTENTIATION; KINASE-M-ZETA; SYNAPTIC-TRANSMISSION; PLACE AVOIDANCE; MESSENGER-RNA; MEMORY; HIPPOCAMPUS; RETRIEVAL; RECONSOLIDATION; CONSOLIDATION	Analogous to learning and memory storage, long-term potentiation (LTP) is divided into induction and maintenance phases. Testing the hypothesis that the mechanism of LTP maintenance stores information requires reversing this mechanism in vivo and finding out whether long-term stored information is lost. This was not previously possible. Recently however, persistent phosphorylation by the atypical protein kinase C isoform, protein kinase Mzeta (PKM zeta), has been found to maintain late LTP in hippocampal slices. Here we show that a cell-permeable PKM zeta inhibitor, injected in the rat hippocampus, both reverses LTP maintenance in vivo and produces persistent loss of 1-day-old spatial information. Thus, the mechanism maintaining LTP sustains spatial memory.	Suny Downstate Med Ctr, Robert F Furchgott Ctr Neural & Behav Sci, Dept Physiol, Brooklyn, NY 11203 USA; Suny Downstate Med Ctr, Robert F Furchgott Ctr Neural & Behav Sci, Dept Pharmacol, Brooklyn, NY 11203 USA; Suny Downstate Med Ctr, Robert F Furchgott Ctr Neural & Behav Sci, Dept Neurol, Brooklyn, NY 11203 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Fenton, AA (corresponding author), Suny Downstate Med Ctr, Robert F Furchgott Ctr Neural & Behav Sci, Dept Physiol, 450 Clarkson Ave, Brooklyn, NY 11203 USA.	afenton@downstate.edu; tsacktor@downstate.edu		Fenton, Andre/0000-0002-5063-1156	NIMH NIH HHS [R01 MH53576, MH57068] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH053576, R37MH057068, R01MH057068] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Ahmed T, 2004, NEUROSCIENCE, V124, P857, DOI 10.1016/j.neuroscience.2004.01.005; Alberini CM, 2005, TRENDS NEUROSCI, V28, P51, DOI 10.1016/j.tins.2004.11.001; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; Brun VH, 2001, J NEUROSCI, V21, P356, DOI 10.1523/JNEUROSCI.21-01-00356.2001; Cimadevilla JM, 2000, NEUROSCI LETT, V285, P53, DOI 10.1016/S0304-3940(00)01019-3; Cimadevilla JM, 2001, P NATL ACAD SCI USA, V98, P3531, DOI 10.1073/pnas.051628398; Crary JF, 2006, J NEUROPATH EXP NEUR, V65, P319, DOI 10.1097/01.jnen.0000218442.07664.04; Day M, 2003, NATURE, V424, P205, DOI 10.1038/nature01769; Drier EA, 2002, NAT NEUROSCI, V5, P316, DOI 10.1038/nn820; Frey S, 2001, J NEUROSCI, V21, P3697, DOI 10.1523/JNEUROSCI.21-10-03697.2001; Hernandez AI, 2003, J BIOL CHEM, V278, P40305, DOI 10.1074/jbc.M307065200; Jezek K, 2002, PHYSIOL RES, V51, pS35; Kubik S, 2005, J NEUROSCI, V25, P9205, DOI 10.1523/JNEUROSCI.1707-05.2005; Ling DSF, 2006, HIPPOCAMPUS, V16, P443, DOI 10.1002/hipo.20171; Ling DSF, 2002, NAT NEUROSCI, V5, P295, DOI 10.1038/nn829; Martin SJ, 2000, ANNU REV NEUROSCI, V23, P649, DOI 10.1146/annurev.neuro.23.1.649; Moser EI, 1998, SCIENCE, V281, P2038, DOI 10.1126/science.281.5385.2038; Moser MB, 1998, J NEUROSCI, V18, P7535; Muslimov IA, 2004, J BIOL CHEM, V279, P52613, DOI 10.1074/jbc.M409240200; Nader K, 2000, NATURE, V406, P722, DOI 10.1038/35021052; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; Paulsen O, 2002, NAT NEUROSCI, V5, P289, DOI 10.1038/nn0402-289; SACKTOR TC, 1993, P NATL ACAD SCI USA, V90, P8342, DOI 10.1073/pnas.90.18.8342; Sajikumar S, 2005, J NEUROSCI, V25, P5750, DOI 10.1523/JNEUROSCI.1104-05.2005; Sanes JR, 1999, NAT NEUROSCI, V2, P597, DOI 10.1038/10154; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; Serrano P, 2005, J NEUROSCI, V25, P1979, DOI 10.1523/JNEUROSCI.5132-04.2005	27	625	662	4	133	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 25	2006	313	5790					1141	1144		10.1126/science.1128657	http://dx.doi.org/10.1126/science.1128657			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	076ZT	16931766				2022-12-28	WOS:000239998200052
J	Rembold, M; Loosli, F; Adams, RJ; Wittbrodt, J				Rembold, Martina; Loosli, Felix; Adams, Richard J.; Wittbrodt, Joachim			Individual cell migration serves as the driving force for optic vesicle evagination	SCIENCE			English	Article							MEDAKA ORYZIAS-LATIPES; EYE MORPHOGENESIS; NEURAL PLATE; ZEBRAFISH EYE; AXON GUIDANCE; FATE MAP; XENOPUS; MICROSCOPY; CHOKH/RX3; MUTATION	The cellular mechanisms underlying organ formation are largely unknown. We visualized early vertebrate eye morphogenesis at single-cell resolution by in vivo imaging in medaka ( Oryzias latipes). Before optic vesicle evagination, retinal progenitor cells (RPCs) modulate their convergence in a fate-specific manner. Presumptive forebrain cells converge toward the midline, whereas medial RPCs remain stationary, predetermining the site of evagination. Subsequent optic vesicle evagination is driven by the active migration of individual RPCs. The analysis of mutants demonstrated that the retina-specific transcription factor rx3 determines the convergence and migration behaviors of RPCs. Hence, the migration of individual cells mediates essential steps of organ morphogenesis.	European Mol Biol Lab, Dev Biol Unit, D-69117 Heidelberg, Germany; Univ Cambridge, Dept Physiol Dev & Neurosci, Cambridge CB2 3DY, England	European Molecular Biology Laboratory (EMBL); University of Cambridge	Wittbrodt, J (corresponding author), European Mol Biol Lab, Dev Biol Unit, Meyerhofstr 1, D-69117 Heidelberg, Germany.	jochen.wittbrodt@embl.de	Loosli, Felix/H-7415-2013; Wittbrodt, Joachim/D-4735-2014	Wittbrodt, Joachim/0000-0001-8550-7377; Adams, Richard/0000-0003-0280-0901	MRC [G0400709] Funding Source: UKRI; Medical Research Council [G0400709] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Andreazzoli M, 1999, DEVELOPMENT, V126, P2451; Brose K, 2000, CURR OPIN NEUROBIOL, V10, P95, DOI 10.1016/S0959-4388(99)00066-5; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Chow RL, 2001, ANNU REV CELL DEV BI, V17, P255, DOI 10.1146/annurev.cellbio.17.1.255; Deschet K, 1999, MECH DEVELOP, V83, P179, DOI 10.1016/S0925-4773(99)00037-4; Dickson BJ, 2002, SCIENCE, V298, P1959, DOI 10.1126/science.1072165; Easter SS, 2002, RES PRO CEL, V40, P346; Elul T, 2000, DEV BIOL, V224, P3, DOI 10.1006/dbio.2000.9746; Ezin AM, 2003, DEV BIOL, V256, P100, DOI 10.1016/S0012-1606(02)00130-6; Hirose Y, 2004, DEVELOPMENT, V131, P2553, DOI 10.1242/dev.01140; IWAMATSU T, 1994, ZOOL SCI, V11, P825; Kennedy BN, 2004, DEV BIOL, V270, P336, DOI 10.1016/j.ydbio.2004.02.026; Li Z, 2000, DEV DYNAM, V218, P175, DOI 10.1002/(SICI)1097-0177(200005)218:1<175::AID-DVDY15>3.0.CO;2-K; Loosli F, 2003, EMBO REP, V4, P894, DOI 10.1038/sj.embor.embor919; Loosli F, 2001, DEVELOPMENT, V128, P4035; Mathers PH, 1997, NATURE, V387, P603, DOI 10.1038/42475; Megason SG, 2003, MECH DEVELOP, V120, P1407, DOI 10.1016/j.mod.2003.07.005; MORSE DE, 1984, INVEST OPHTH VIS SCI, V25, P899; Rojas-Munoz A, 2005, DEV BIOL, V288, P348, DOI 10.1016/j.ydbio.2005.08.046; SCHMITT EA, 1994, J COMP NEUROL, V344, P532, DOI 10.1002/cne.903440404; Spemann H, 1901, VERH ANAT GESELLSCH, V15, P61; SVOBODA KKH, 1987, DEVELOPMENT, V100, P185; Varga ZM, 1999, DEVELOPMENT, V126, P5533; Winkler S, 2000, DEVELOPMENT, V127, P1911; WOO K, 1995, DEVELOPMENT, V121, P2595	25	128	130	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 25	2006	313	5790					1130	1134		10.1126/science.1127144	http://dx.doi.org/10.1126/science.1127144			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	076ZT	16931763				2022-12-28	WOS:000239998200049
J	Schaefer, H; Whiticar, MJ; Brook, EJ; Petrenko, VV; Ferretti, DF; Severinghaus, JP				Schaefer, Hinrich; Whiticar, Michael J.; Brook, Edward J.; Petrenko, Vasilii V.; Ferretti, Dominic F.; Severinghaus, Jeffrey P.			Ice record of delta C-13 for atmospheric CH4 across the Younger Dryas-Preboreal transition	SCIENCE			English	Article							ISOTOPIC COMPOSITION; METHANE; DYNAMICS; INCREASE	We report atmospheric methane carbon isotope ratios (delta(CH4)-C-13) from the Western Greenland ice margin spanning the Younger Dryas - to - Preboreal (YD-PB) transition. Over the recorded similar to 800 years, delta(CH4)-C-13 was around - 46 per mil (parts per thousand); that is, similar to 1 parts per thousand higher than in the modern atmosphere and similar to 5.5 parts per thousand higher than would be expected from budgets without C-13-rich anthropogenic emissions. This requires higher natural C-13-rich emissions or stronger sink fractionation than conventionally assumed. Constant delta(CH4)-C-13 during the rise in methane concentration at the YD-PB transition is consistent with additional emissions from tropical wetlands, or aerobic plant CH4 production, or with a multisource scenario. A marine clathrate source is unlikely.	Univ Victoria, Sch Earth & Ocean Sci, Victoria, BC V8W 3P6, Canada; Oregon State Univ, Dept Geosci, Corvallis, OR 97331 USA; Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA; Univ Colorado, Inst Arctic & Alpine Res, Boulder, CO 80309 USA; Natl Inst Water & Atmospher Res Ltd, Wellington, New Zealand	University of Victoria; Oregon State University; University of California System; University of California San Diego; Scripps Institution of Oceanography; University of Colorado System; University of Colorado Boulder; National Institute of Water & Atmospheric Research (NIWA) - New Zealand	Schaefer, H (corresponding author), Univ Victoria, Sch Earth & Ocean Sci, POB 3055, Victoria, BC V8W 3P6, Canada.	schaefeh@geo.oregonstate.edu	Brook, Edward/AAB-7807-2021	Petrenko, Vasilii/0000-0002-0263-8759; Schaefer, Hinrich/0000-0002-1163-2818				Allan W, 2005, J GEOPHYS RES-ATMOS, V110, DOI 10.1029/2004JD005650; Archer D, 2005, GEOCHEM GEOPHY GEOSY, V6, DOI 10.1029/2004GC000854; Brook EJ, 2000, GLOBAL BIOGEOCHEM CY, V14, P559, DOI 10.1029/1999GB001182; Carcaillet C, 2002, CHEMOSPHERE, V49, P845, DOI 10.1016/S0045-6535(02)00385-5; CHAPPELLAZ JA, 1993, TELLUS B, V45, P228, DOI 10.1034/j.1600-0889.1993.t01-2-00002.x; CRAIG H, 1988, SCIENCE, V242, P1535, DOI 10.1126/science.242.4885.1535; Etiope G, 2004, ENVIRON GEOL, V46, P997, DOI 10.1007/s00254-004-1085-1; Ferretti DF, 2005, SCIENCE, V309, P1714, DOI 10.1126/science.1115193; Francois LM, 1998, GLOBAL PLANET CHANGE, V17, P37; Grant NJ, 2002, GLOBAL BIOGEOCHEM CY, V16, DOI 10.1029/2001GB001851; Hein R, 1997, GLOBAL BIOGEOCHEM CY, V11, P43, DOI 10.1029/96GB03043; Hughen KA, 2004, SCIENCE, V304, P1955, DOI 10.1126/science.1092995; Kaplan JO, 2006, GLOBAL BIOGEOCHEM CY, V20, DOI 10.1029/2005GB002590; Kaplan JO, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL013366; Kennett JP, 2003, METHANE HYDRATES QUA; Keppler F, 2006, NATURE, V439, P187, DOI 10.1038/nature04420; Luyendyk B, 2005, MAR PETROL GEOL, V22, P591, DOI 10.1016/j.marpetgeo.2004.08.005; Miller JB, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD000630; Peteet D, 2000, P NATL ACAD SCI USA, V97, P1359, DOI 10.1073/pnas.97.4.1359; Petrenko VV, 2006, QUATERNARY SCI REV, V25, P865, DOI 10.1016/j.quascirev.2005.09.005; Quay PD, 1991, GLOBAL BIOGEOCHEM CY, V5, P25, DOI 10.1029/91GB00003; Rice AL, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD003042; Scholze M, 2003, HOLOCENE, V13, P327, DOI 10.1191/0959683603hl625rp; Severinghaus JP, 1998, NATURE, V391, P141, DOI 10.1038/34346; Sowers T, 2005, GLOBAL BIOGEOCHEM CY, V19, DOI 10.1029/2004GB002408; Sowers T, 2006, SCIENCE, V311, P838, DOI 10.1126/science.1121235; Tans PP, 1997, GLOBAL BIOGEOCHEM CY, V11, P77, DOI 10.1029/96GB03940; THOMPSON AM, 1993, TELLUS B, V45, P242, DOI 10.1034/j.1600-0889.1993.t01-2-00003.x; Wang YJ, 2001, SCIENCE, V294, P2345, DOI 10.1126/science.1064618; Whiticar M. J., 1993, ATMOSPHERIC METHANE, P138, DOI DOI 10.1007/978-3-642-84605-2_8	30	60	62	2	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 25	2006	313	5790					1109	1112		10.1126/science.1126562	http://dx.doi.org/10.1126/science.1126562			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	076ZT	16931759				2022-12-28	WOS:000239998200043
J	Savill, NJ; St Rose, SG; Keeling, MJ; Woolhouse, MEJ				Savill, Nicholas J.; St Rose, Suzanne G.; Keeling, Matthew J.; Woolhouse, Mark E. J.			Silent spread of H5N1 in vaccinated poultry	NATURE			English	Article							AVIAN INFLUENZA; EPIDEMIOLOGY; NETHERLANDS		Univ Edinburgh, Ctr Infect Dis, Ashworth Labs, Edinburgh EH9 3JT, Midlothian, Scotland; Univ Warwick, Inst Math, Coventry CV4 7AL, W Midlands, England; Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England	University of Edinburgh; University of Warwick; University of Warwick	Savill, NJ (corresponding author), Univ Edinburgh, Ctr Infect Dis, Ashworth Labs, Kings Bldg, Edinburgh EH9 3JT, Midlothian, Scotland.	nick.savill@ed.ac.uk	Keeling, Matt J/J-9280-2012	Keeling, Matt J/0000-0003-4639-4765; Woolhouse, Mark/0000-0003-3765-8167				Butler D, 2005, NATURE, V434, P810, DOI 10.1038/4344810a; Elbers ARW, 2004, AVIAN DIS, V48, P691, DOI 10.1637/7149; Ellis TM, 2004, AVIAN PATHOL, V33, P405, DOI 10.1080/03079450410001724012; *EUR COMM, 2006, VACC POULTR HIGH PAT; Garcia A, 1998, AVIAN DIS, V42, P248, DOI 10.2307/1592474; Marangon S, 2003, AVIAN DIS, V47, P1006, DOI 10.1637/0005-2086-47.s3.1006; Stegeman A, 2004, J INFECT DIS, V190, P2088, DOI 10.1086/425583; Suarez DL, 2005, BIOLOGICALS, V33, P221, DOI 10.1016/j.biologicals.2005.08.003; Woolhouse M, 2001, NATURE, V411, P258, DOI 10.1038/35077149; Woolhouse MEJ, 1997, VET J, V153, P41, DOI 10.1016/S1090-0233(97)80007-X	10	112	115	1	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 17	2006	442	7104					757	757		10.1038/442757a	http://dx.doi.org/10.1038/442757a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	074DK	16915278	Bronze			2022-12-28	WOS:000239792700032
J	Levey, AS; Coresh, J; Greene, T; Stevens, LA; Zhang, YP; Hendriksen, S; Kusek, JW; Van Lente, F				Levey, Andrew S.; Coresh, Josef; Greene, Tom; Stevens, Lesley A.; Lucy Zhang, Yaping; Hendriksen, Stephen; Kusek, John W.; Van Lente, Frederick		Chronic Kidney Dis Epidemiology Co	Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate	ANNALS OF INTERNAL MEDICINE			English	Article							CHRONIC KIDNEY-DISEASE; COCKCROFT-GAULT EQUATIONS; PREDICTIVE PERFORMANCE; GFR; FORMULA; CLEARANCE; CLASSIFICATION; CALIBRATION; ACCURACY; HEALTH	Background: Glomerular filtration rate (GFR) estimates facilitate detection of chronic kidney disease but require calibration of the serum creatinine assay to the laboratory that developed the equation. The 4-variable equation from the Modification of Diet in Renal Disease (MDRD) Study has been reexpressed for use with a standardized assay. Objective: To describe the performance of the revised 4-variable MDRD Study equation and compare it with the performance of the 6-variable MDRD Study and Cockcroft-Gault equations. Design: Comparison of estimated and measured GFR. Setting: 15 clinical centers participating in a randomized, controlled trial. Patients: 1628 patients with chronic kidney disease participating in the MDRD Study. Measurements: Serum creatinine levels were calibrated to an assay traceable to isotope-dilution mass spectrometry. Glomerular filtraton rate was measured as urinary clearance of I-125-iothalamate. Results: Mean measured GFR was 39.8 mL/min per 1.73 m(2) (SD, 21.2). Accuracy and precision of the revised 4-variable equation were similar to those of the original 6-variable equation and better than in the Cockcroft-Gault equation, even when the latter was corrected for bias, with 90%, 91%, 60%, and 83% of estimates within 30% of measured GFR, respectively. Differences between measured and estimated GFR were greater for all equations when the estimated GFR was 60 mL/min per 1.73 m(2) or greater. Limitations: The MDRD Study included few patients with a GFR greater than 90 mL/min per 1.73 m(2). Equations were not compared in a separate study sample. Conclusions: The 4-variable MDRD Study equation provides reasonably accurate GFR estimates in patients with chronic kidney disease and a measured GFR of less than 90 mL/min per 1.73 m(2). By using the reexpressed MDRD Study equation with the standardized serum creatinine assay, clinical laboratories can report more accurate GFR estimates.	Tufts Univ, New England Med Ctr, Div Nephrol, Boston, MA 02111 USA; Johns Hopkins Med Inst, Baltimore, MD 21205 USA; Cleveland Clin Fdn, Cleveland, OH 44195 USA; NIDDK, Bethesda, MD USA	Tufts Medical Center; Tufts University; Johns Hopkins University; Johns Hopkins Medicine; Cleveland Clinic Foundation; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Levey, AS (corresponding author), Tufts Univ, New England Med Ctr, Div Nephrol, 750 Washington St,Box 391, Boston, MA 02111 USA.				NIDDK NIH HHS [UO1 DK 053869, UO1 DK 067651, UO1 DK 35073] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK067651, U01DK053869, U01DK035073] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anavekar N, 2005, MED J AUSTRALIA, V183, P138, DOI 10.5694/j.1326-5377.2005.tb06958.x; Bostom AG, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000022011.35035.F3; *CAISS NAT ASS MAL, AV CONV NAT DIR LAB; Cirillo M, 2005, NEPHROL DIAL TRANSPL, V20, P1791, DOI 10.1093/ndt/gfh962; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Coresh J, 2002, AM J KIDNEY DIS, V39, P920, DOI 10.1053/ajkd.2002.32765; Coresh J, 2005, J AM SOC NEPHROL, V16, P180, DOI 10.1681/ASN.2004070539; Coresh J, 2006, CURR OPIN NEPHROL HY, V15, P276, DOI 10.1097/01.mnh.0000222695.84464.61; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Fehrman-Ekholm I, 2004, SCAND J UROL NEPHROL, V38, P73, DOI 10.1080/00365590310015750; Froissart M, 2005, J AM SOC NEPHROL, V16, P763, DOI 10.1681/ASN.2004070549; Gaspari F, 2004, AM J TRANSPLANT, V4, P1826, DOI 10.1111/j.1600-6143.2004.00579.x; Gonwa T, 2004, LIVER TRANSPLANT, V10, P301, DOI 10.1002/lt.20017; GREENE T, 2005, J AM SOC NEPHROL, V16, pA319; Grubb A, 2005, SCAND J CLIN LAB INV, V65, P153, DOI 10.1080/00365510510013596; Hallan S, 2004, AM J KIDNEY DIS, V44, P84, DOI 10.1053/j.ajkd.2004.03.027; Ibrahim H, 2005, J AM SOC NEPHROL, V16, P1051, DOI 10.1681/ASN.2004080692; Jafar TH, 2005, J AM SOC NEPHROL, V16, P1413, DOI 10.1681/ASN.2004121100; Junge W, 2004, CLIN CHIM ACTA, V344, P137, DOI 10.1016/j.cccn.2004.02.007; KLAHR S, 1994, NEW ENGL J MED, V330, P877, DOI 10.1056/NEJM199403313301301; Lamb EJ, 2003, J AM GERIATR SOC, V51, P1012, DOI 10.1046/j.1365-2389.2003.51330.x; Levey Andrew S., 2000, Journal of the American Society of Nephrology, V11, p155A; Levey AS, 2003, ANN INTERN MED, V139, P137, DOI 10.7326/0003-4819-139-2-200307150-00013; Levey AS, 2005, KIDNEY INT, V67, P2089, DOI 10.1111/j.1523-1755.2005.00365.x; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Lewis J, 2001, AM J KIDNEY DIS, V38, P744, DOI 10.1053/ajkd.2001.27691; Lin J, 2003, J AM SOC NEPHROL, V14, P2573, DOI 10.1097/01.ASN.0000088721.98173.4B; Miller WG, 2005, ARCH PATHOL LAB MED, V129, P297; Murthy K, 2005, KIDNEY INT, V68, P1884, DOI 10.1111/j.1523-1755.2005.00608.x; Myers GL, 2006, CLIN CHEM, V52, P5, DOI 10.1373/clinchem.2005.0525144; *NAT KIDN DIS ED P, INF HLTH PROF CREATL; *NAT KIDN FDN, 2002, AM J KIDNEY DIS S, V1, pS1; Poge U, 2005, AM J TRANSPLANT, V5, P1306, DOI 10.1111/j.1600-6143.2005.00861.x; Poggio ED, 2005, J AM SOC NEPHROL, V16, P459, DOI 10.1681/ASN.2004060447; Rigalleau V, 2005, DIABETES CARE, V28, P838, DOI 10.2337/diacare.28.4.838; Rule AD, 2004, ANN INTERN MED, V141, P929, DOI 10.7326/0003-4819-141-12-200412210-00009; Rule AD, 2004, AM J KIDNEY DIS, V43, P112, DOI 10.1053/j.ajkd.2003.09.026; SIEGEL N, RENAL EXPRESS; Skluzacek PA, 2003, AM J KIDNEY DIS, V42, P1169, DOI 10.1053/j.ajkd.2003.08.017; Stevens LA, 2005, NEW ENGL J MED, V352, P2122, DOI 10.1056/NEJMe058035; Stevens LA, 2004, ANN INTERN MED, V141, P959, DOI 10.7326/0003-4819-141-12-200412210-00013; Verhave JC, 2005, AM J KIDNEY DIS, V46, P233, DOI 10.1053/j.ajkd.2005.05.011; Vervoort G, 2002, NEPHROL DIAL TRANSPL, V17, P1909, DOI 10.1093/ndt/17.11.1909; Wesson LG., 1969, PHYSL HUMAN KIDNEY; Zuo L, 2005, AM J KIDNEY DIS, V45, P463, DOI 10.1053/j.ajkd.2004.11.012	45	3954	4046	1	82	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	2006	145	4					247	254		10.7326/0003-4819-145-4-200608150-00004	http://dx.doi.org/10.7326/0003-4819-145-4-200608150-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	075CC	16908915				2022-12-28	WOS:000239858800002
J	Foulger, GR				Foulger, Gillian R.			Toward "supervolcano" technology	SCIENCE			English	Editorial Material							GEYSERS GEOTHERMAL AREA; CALIFORNIA		Univ Durham, Dept Earth Sci, Durham DH1 3LE, England	Durham University	Foulger, GR (corresponding author), US Geol Survey, Volcano Hazards Team, 345 Middlefield Rd, Menlo Pk, CA 94025 USA.	g.r.foulger@durham.ac.uk						Foulger GR, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2000JB000041; Foulger GR, 1997, GEOPHYS RES LETT, V24, P135, DOI 10.1029/96GL03152; FOULGER GR, 2004, GEOTHERM RESOUR COUN, V33, P120; Gunasekera RC, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2001JB000638; Patane D, 2006, SCIENCE, V313, P821, DOI 10.1126/science.1127724	5	1	1	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 11	2006	313	5788					768	769		10.1126/science.1131790	http://dx.doi.org/10.1126/science.1131790			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	072KC	16902114				2022-12-28	WOS:000239671300032
J	Patane, D; Barberi, G; Cocina, O; De Gori, P; Chiarabba, C				Patane, D.; Barberi, G.; Cocina, O.; De Gori, P.; Chiarabba, C.			Time-resolved seismic tomography detects magma intrusions at Mount Etna	SCIENCE			English	Article							VELOCITY; ATTENUATION; SYSTEM; FLUIDS; IMAGE; ZONE	The continuous volcanic and seismic activity at Mount Etna makes this volcano an important laboratory for seismological and geophysical studies. We used repeated three-dimensional tomography to detect variations in elastic parameters during different volcanic cycles, before and during the October 2002 - January 2003 flank eruption. Well-defined anomalous low P- to S-wave velocity ratio volumes were revealed. Absent during the pre-eruptive period, the anomalies trace the intrusion of volatile-rich (>= 4 weight percent) basaltic magma, most of which rose up only a few months before the onset of eruption. The observed time changes of velocity anomalies suggest that four-dimensional tomography provides a basis for more efficient volcano monitoring and short- and midterm eruption forecasting of explosive activity.	Ist Nazl Geofis & Vulcanol, Sez Catania, I-95123 Catania, Italy; Ctr Nazl Terremoti, Ist Nazl Geofis & Vulcanol, I-00143 Rome, Italy	Istituto Nazionale Geofisica e Vulcanologia (INGV); Istituto Nazionale Geofisica e Vulcanologia (INGV)	Patane, D (corresponding author), Ist Nazl Geofis & Vulcanol, Sez Catania, Piazza Roma 2, I-95123 Catania, Italy.	patane@ct.ingv.it	chiarabba, claudio/G-4780-2011	chiarabba, claudio/0000-0002-8111-3466; PATANE', Domenico/0000-0001-9410-5126; Cocina, Ornella/0000-0003-1856-830X; Barberi, Graziella/0000-0002-8273-0458				Aloisi M, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL018896; Andronico D, 2005, B VOLCANOL, V67, P314, DOI 10.1007/s00445-004-0372-8; Chiarabba C, 2004, GEOPH MONOG SERIES, V143, P191; CHRISTENSEN NI, 1989, MEM GEOL SOC AM, V172, P91; Clocchiatti R, 2004, EARTH PLANET SC LETT, V226, P397, DOI 10.1016/j.epsl.2004.07.039; Coltelli M, 2000, INT J EARTH SCI, V89, P665, DOI 10.1007/s005310000117; Dvorkin J, 1999, GEOPHYS RES LETT, V26, P3417, DOI 10.1029/1999GL008382; Foulger GR, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2000JB000041; FULIAN BR, 1998, GEOPHYS J INT, V133, pF7; Gambino S, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020499; GUERIN G, 2000 OFFSH TECHN C; Laigle M, 2000, J GEOPHYS RES-SOL EA, V105, P21633, DOI 10.1029/2000JB900190; Martinez-Arevalo C, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL023736; MAVKO GM, 1980, J GEOPHYS RES, V85, P5173, DOI 10.1029/JB085iB10p05173; MICHELINI A, 1991, B SEISMOL SOC AM, V81, P524; NUR A, 1972, B SEISMOL SOC AM, V62, P1217; OCONNELL RJ, 1974, J GEOPHYS RES, V79, P5412, DOI 10.1029/JB079i035p05412; Patane D, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2004GL021773; Patane D, 2003, SCIENCE, V299, P2061, DOI 10.1126/science.1080653; Reyners M, 1999, GEOPHYS J INT, V137, P873, DOI 10.1046/j.1365-246x.1999.00842.x; SANDERS CO, 1995, J GEOPHYS RES-SOL EA, V100, P8311, DOI 10.1029/95JB00152; SATO H, 1989, J GEOPHYS RES-SOLID, V94, P5689, DOI 10.1029/JB094iB05p05689; Spilliaert N, 2006, J GEOPHYS RES-SOL EA, V111, DOI 10.1029/2005JB003934; Thurber C, 1997, GEOPHYS RES LETT, V24, P1591, DOI 10.1029/97GL01435; Thurber C., 1993, SEISMIC TOMOGRAPHY T, P563; Wang Z., 1989, SPE RESERV ENG, V3, P429, DOI [10.2118/17345-pa, DOI 10.2118/17345-PA]	26	190	195	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 11	2006	313	5788					821	823		10.1126/science.1127724	http://dx.doi.org/10.1126/science.1127724			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	072KC	16902133				2022-12-28	WOS:000239671300055
J	Fan, C; Oh, DS; Wessels, L; Weigelt, B; Nuyten, DSA; Nobel, AB; van't Veer, LJ; Perou, CM				Fan, Cheng; Oh, Daniel S.; Wessels, Lodewyk; Weigelt, Britta; Nuyten, Dimitry S. A.; Nobel, Andrew B.; van't Veer, Laura J.; Perou, Charles M.			Concordance among gene-expression-based predictors for breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	4th Annual Future of Breast Cancer Meeting	JUL   21, 2005	Southampton, BERMUDA				MOLECULAR PORTRAITS; TAMOXIFEN; SURVIVAL; RECURRENCE; SIGNATURE; PROFILES; SUBTYPES; TUMORS; RATIO	BACKGROUND: Gene-expression-profiling studies of primary breast tumors performed by different laboratories have resulted in the identification of a number of distinct prognostic profiles, or gene sets, with little overlap in terms of gene identity. METHODS: To compare the predictions derived from these gene sets for individual samples, we obtained a single data set of 295 samples and applied five gene-expression-based models: intrinsic subtypes, 70-gene profile, wound response, recurrence score, and the two-gene ratio (for patients who had been treated with tamoxifen). RESULTS: We found that most models had high rates of concordance in their outcome predictions for the individual samples. In particular, almost all tumors identified as having an intrinsic subtype of basal-like, HER2-positive and estrogen-receptor-negative, or luminal B (associated with a poor prognosis) were also classified as having a poor 70-gene profile, activated wound response, and high recurrence score. The 70-gene and recurrence-score models, which are beginning to be used in the clinical setting, showed 77 to 81 percent agreement in outcome classification. CONCLUSIONS: Even though different gene sets were used for prognostication in patients with breast cancer, four of the five tested showed significant agreement in the outcome predictions for individual patients and are probably tracking a common set of biologic phenotypes.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Genet, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Stat & Operat Res, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; Netherlands Canc Inst, Div Diagnost Oncol, Amsterdam, Netherlands; Netherlands Canc Inst, Div Radiotherapy, Amsterdam, Netherlands	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Netherlands Cancer Institute; Netherlands Cancer Institute	Perou, CM (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Genet, Campus Box 7295, Chapel Hill, NC 27599 USA.	cperou@med.unc.edu	Perou, Charles M/H-9934-2014	Perou, Charles M/0000-0001-9827-2247	NCI NIH HHS [R01-CA-101227-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA101227] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bertucci F, 2005, CANCER RES, V65, P2170, DOI 10.1158/0008-5472.CAN-04-4115; Chang HY, 2005, P NATL ACAD SCI USA, V102, P3738, DOI 10.1073/pnas.0409462102; Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007; Goetz MP, 2006, CLIN CANCER RES, V12, P2080, DOI 10.1158/1078-0432.CCR-05-1263; Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96; Ma XJ, 2004, CANCER CELL, V5, P607, DOI 10.1016/j.ccr.2004.05.015; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; PAIK S, IN PRESS J CLIN ONCO; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Reid JF, 2005, JNCI-J NATL CANCER I, V97, P927, DOI 10.1093/jnci/dji153; Son CG, 2005, GENOME RES, V15, P443, DOI 10.1101/gr.3124505; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100; Van Belle G., 2004, BIOSTATISTICS METHOD; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1	18	1003	1057	1	38	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 10	2006	355	6					560	569		10.1056/NEJMoa052933	http://dx.doi.org/10.1056/NEJMoa052933			10	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	071QM	16899776	Green Published			2022-12-28	WOS:000239616700006
J	Bhutta, MF				Bhutta, Mahmood F.			Fair trade for surgical instruments	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Guys & St Thomas Hosp, Dept ENT, London SE1 7EH, England	Guy's & St Thomas' NHS Foundation Trust	Bhutta, MF (corresponding author), Guys & St Thomas Hosp, Dept ENT, London SE1 7EH, England.	m.bhutta@doctors.org.uk		Bhutta, Mahmood/0000-0002-4688-1670				*AM FED STAT, 1999, AFCSME NEWS; *CTR IMPR WORK CON, 2003, ANN REP ACT 2003, P33; *DEP ENV FOOD RUR, 2005, ON FUT DIFF PATHS UK; Dwyer J, 2005, BIOETHICS, V19, P460, DOI 10.1111/j.1467-8519.2005.00458.x; Germanotta P, 1999, Int Nurs Rev, V46, P112; GHANI JA, 1996, 9610 CTR MAN EC RES; Henry D, 2002, LANCET, V360, P1590, DOI 10.1016/S0140-6736(02)11527-3; ILO Tripartite Declaration of Principles on Multinational Enterprises and Social Policy, 1998, ILM, V37, P1233; *INT LAB ORG, 2004, INT PROGR EL CHILD L; Nadvi K, 1999, WORLD DEV, V27, P1605, DOI 10.1016/S0305-750X(99)00078-9; NADVI K, 1999, OXFORD DEV STUDIES, V27; NADVI K, 2002, 152 I DEV STUD; *NHS PURCH SUPPL A, 2005, SUST DEV POL; *PUBL SERV INT, 1999, CHILDR WORK HDB CHIL; Sass HM, 1998, ARTIF ORGANS, V22, P263, DOI 10.1046/j.1525-1594.1998.06024.x; Yamey G, 2000, BRIT MED J, V320, P1357, DOI 10.1136/bmj.320.7246.1357	16	22	22	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 5	2006	333	7562					297	299		10.1136/bmj.38901.619074.55	http://dx.doi.org/10.1136/bmj.38901.619074.55			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	073MV	16877453	Green Published			2022-12-28	WOS:000239748200019
J	Hewison, J; Haines, A				Hewison, Jenny; Haines, Andy			Confidentiality and consent in medical research - Overcoming barriers to recruitment in health research	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							INFORMED-CONSENT; RESPONSE RATES		Univ Leeds, Inst Hlth Sci & Publ Hlth Res, Leeds LS2 9LT, W Yorkshire, England; London Sch Hyg & Trop Med, London WC1, England	University of Leeds; University of London; London School of Hygiene & Tropical Medicine	Hewison, J (corresponding author), Univ Leeds, Inst Hlth Sci & Publ Hlth Res, Leeds LS2 9LT, W Yorkshire, England.	j.hewison@leeds.ac.uk		Haines, Andy/0000-0002-8053-4605				Aaronson NK, 1996, J CLIN ONCOL, V14, P984, DOI 10.1200/JCO.1996.14.3.984; Angus VC, 2003, BMC HEALTH SERV RES, V3, DOI 10.1186/1472-6963-3-21; Barrett G, 2006, BMJ-BRIT MED J, V332, P1068, DOI 10.1136/bmj.38805.473738.7C; Boynton PM, 2004, BMJ-BRIT MED J, V328, P1372, DOI 10.1136/bmj.328.7452.1372; Edwards P, 2002, BRIT MED J, V324, P1183, DOI 10.1136/bmj.324.7347.1183; HUSSAINGAMBLES M, 2004, HLTH TECHNOL ASSESS, V8; INSKIP H, 2005, INT J EPIDEMIOL, P1; Joffe S, 2001, LANCET, V358, P1772, DOI 10.1016/S0140-6736(01)06805-2; Junghans C, 2005, BMJ-BRIT MED J, V331, P940, DOI 10.1136/bmj.38583.625613.AE; McColl E, 2001, Health Technol Assess, V5, P1; Prescott RJ, 1999, HEALTH TECHNOL ASSES, V3, P1, DOI DOI 10.3310/hta3200; SINGLETON P, 2006, BMJ-BRIT MED J, V332, P255; SOUHAMI R, 2006, PERSONAL DATA PUBLIC; Ubel PA, 1997, SOC SCI MED, V44, P647, DOI 10.1016/S0277-9536(96)00217-1; WALTERS PR, 2005, BMJ; Ward HJT, 2004, BRIT MED J, V329, P277, DOI 10.1136/bmj.329.7460.277	16	91	90	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 5	2006	333	7562					300	302		10.1136/bmj.333.7562.300	http://dx.doi.org/10.1136/bmj.333.7562.300			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	073MV	16888308	Green Accepted, Green Published			2022-12-28	WOS:000239748200022
J	Stone, A; Jiang, SB				Stone, Alan; Jiang, Shibo			Microbicides: stopping HIV at the gate	LANCET			English	Editorial Material							FUSION		MEDSA, London NW3 7QN, England; New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10021 USA; So Med Univ, Antiviral Res Ctr, Guangzhou, Peoples R China	New York Blood Center; Southern Medical University - China	Stone, A (corresponding author), MEDSA, London NW3 7QN, England.	alan.stoneX@virgin.net	Jiang, Shibo/L-4500-2014	Jiang, Shibo/0000-0001-8283-7135	MRC [MC_U122861322] Funding Source: UKRI; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U19HD048957, P01HD041761] Funding Source: NIH RePORTER; Medical Research Council [MC_U122861322] Funding Source: Medline; NICHD NIH HHS [U19 HD048957-03, U19 HD048957, P01 HD041761] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		*ALL MICR DEV, MICR RES DEV DAT; Chang TLY, 2003, P NATL ACAD SCI USA, V100, P11672, DOI 10.1073/pnas.1934747100; D'Cruz OJ, 2006, J ANTIMICROB CHEMOTH, V57, P411, DOI 10.1093/jac/dki464; *GLOB CAMP MICR, 2006, RETH ETH ROADM CLIN; *JOINT UN PROGR HI, 2005, AIDS EP UPD DEC 2005; Liu SW, 2005, ANTIMICROB AGENTS CH, V49, P1830, DOI 10.1128/AAC.49.5.1830-1836.2005; Malcolm RK, 2005, J ANTIMICROB CHEMOTH, V56, P954, DOI 10.1093/jac/dki326; MATTHEWS J, 2006, MICROBICIDE Q, V4, P7; Mayer KH, 2006, AIDS, V20, P543, DOI 10.1097/01.aids.0000210608.70762.c3; Rao S, 2005, P NATL ACAD SCI USA, V102, P11993, DOI 10.1073/pnas.0504881102; Stone A, 2002, NAT REV DRUG DISCOV, V1, P977, DOI 10.1038/nrd959; STONE A, 2003, MICROBICIDE Q, V1, P13; Veazey RS, 2005, NATURE, V438, P99, DOI 10.1038/nature04055; 2006, MICR 2006 C CAP TOWN	14	26	34	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 5	2006	368	9534					431	433		10.1016/S0140-6736(06)69131-9	http://dx.doi.org/10.1016/S0140-6736(06)69131-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	071AL	16890813	Green Accepted			2022-12-28	WOS:000239569000008
J	Norlund, A; Marke, LA; af Geijerstam, JL; Oredsson, S; Britton, M				Norlund, Anders; Marke, Lars-Ake; af Geijerstam, Jean-Luc; Oredsson, Sven; Britton, Mona		OCTOPUS Study Investigators	Cost comparison of immediate computed tomography or admission for observation after mild head injury: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MANAGEMENT; SCAN	Objective To compare the costs of immediate computed tomography during triage for admission with those of observation in hospital in patients with mild head injury. Design Prospective cost effectiveness analysis within a multicentre, pragmatic randomised trial. Setting 39 acute hospitals in Sweden Participants 2602 patients (aged >= 6) with mild head injury. Interventions Immediate computed tomography or admission for observation. Main outcome measures Direct and indirect costs related to the mild head injury during the acute and three month follow-up period. Results Outcome after three months was similar for both strategies (non-significantly in favour of computed tomography). For the acute stage and complications, the cost was E461 (314 pound,$582) per patient in the computed tomography group and E677 (462 pound,$854) in the observation group; an average of 32% less in the computed tomography group (E216,95% confidence interval -272 to -164; P< 0.001). Sensitivity analysis showed that computed tomography was the most cost effective strategy under a broad range of assumptions. After three months, total costs were E718 and E914 per patient-that is, E196 less in the computed tomography group (- 281 to - 114; P < 0.001). The lower cost of the computed tomography strategy at the acute stage thus remained unchanged during follow-up. Conclusion Patients with mild head injury attending an emergency department can be managed more cost effectively with computed tomography rather than admission for observation in hospital.	Karolinska Univ Hosp, Clin Epidemiol Unit, Dept Med, S-17176 Stockholm, Sweden; Helsingborg Hosp, Emergency Dept, Helsingborg, Sweden; Swedish Council Technol Assessement Hlth Care, Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Helsingborgs Hospital	af Geijerstam, JL (corresponding author), Karolinska Univ Hosp, Clin Epidemiol Unit, Dept Med, S-17176 Stockholm, Sweden.	jean-luc.af.geijerstam@ki.se						Brell M, 2001, NEUROCIRUGIA, V12, P105; *FED SWED COUNT CO, 2004, COST ADM PAT REP 197; *FED SWED COUNT CO, 1981, COST ADM PAT REP 197; *FED SWED COUNT CO, 1991, COSP ADM PAT REP 197; *FED SWED COUNT CO, 2005, STAT YB COUNT COUNC; GEIJERSTAM JL, 2006, BRIT MED J, V333, P465; GEIJERSTAM JLA, 2000, EUR J SURG, V166, P526; GEIJERSTAM JLA, 2004, EMERG MED J, V21, P54; Greenhalgh T, 1997, BMJ-BRIT MED J, V315, P596, DOI 10.1136/bmj.315.7108.596; Ingebrigtsen T, 1996, ACTA NEUROL SCAND, V93, P207; Livingston DH, 2000, ANN SURG, V232, P126, DOI 10.1097/00000658-200007000-00018; Oostenbrink JB, 2003, PHARMACOECONOMICS, V21, P263, DOI 10.2165/00019053-200321040-00004; Peloso PM, 2004, J REHABIL MED, V36, P22, DOI 10.1080/16501960410023714; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; *STAT SWED, PRIC IND WAG; *SWED COUNC TECHN, 2000, MILD HEAD INJ INH OB; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Thompson SG, 2000, BRIT MED J, V320, P1197, DOI 10.1136/bmj.320.7243.1197	18	61	62	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 2	2006	333	7566					469	471		10.1136/bmj.38918.659120.4F	http://dx.doi.org/10.1136/bmj.38918.659120.4F			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	085QP	16895945	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000240618900018
J	Dornan, D; Shimizu, H; Mah, A; Dudhela, T; Eby, M; O'Rourke, K; Seshagiri, S; Dixit, VM				Dornan, David; Shimizu, Harumi; Mah, Angie; Dudhela, Tanay; Eby, Michael; O'Rourke, Karen; Seshagiri, Somasekar; Dixit, Vishva M.			ATM engages autodegradation of the E3 ubiquitin ligase COP1 after DNA damage	SCIENCE			English	Article							DEPENDENT PHOSPHORYLATION; NEGATIVE REGULATOR; P53 PROTEIN; MDM2	The ataxia telangiectasia mutated (ATM) protein kinase is a critical component of a DNA-damage response network configured to maintain genomic integrity. The abundance of an essential downstream effecter of this pathway, the tumor suppressor protein p53, is tightly regulated by controlled degradation through COP1 and other E3 ubiquitin ligases, such as MDM2 and Pirh2; however, the signal transduction pathway that regulates the COP1-p53 axis following DNA damage remains enigmatic. We observed that in response to DNA damage, ATM phosphorylated COP1 on Ser(387) and stimulated a rapid autodegradation mechanism. Ionizing radiation triggered an ATM-dependent movement of COP1 from the nucleus to the cytoplasm, and ATM-dependent phosphorylation of COP1 on Ser(387) was both necessary and sufficient to disrupt the COP1-p53 complex and subsequently to abrogate the ubiquitination and degradation of p53. Furthermore, phosphorylation of COP1 on Ser(387) was required to permit p53 to become stabilized and to exert its tumor suppressor properties in response to DNA damage.	Genentech Inc, Dept Physiol Chem, San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Biol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	Dixit, VM (corresponding author), Genentech Inc, Dept Physiol Chem, 1 DNA Way, San Francisco, CA 94080 USA.	dixit@gene.com	dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326; Seshagiri, Somasekar/0000-0003-4272-6443				Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; Dornan D, 2004, CANCER RES, V64, P7226, DOI 10.1158/0008-5472.CAN-04-2601; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; KASTAN MB, 1991, CANCER RES, V51, P6304; KASTAN MB, 1991, CANCER RES, V51, P4279; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Levine AJ, 2006, CELL DEATH DIFFER, V13, P1027, DOI 10.1038/sj.cdd.4401910; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Pereg Y, 2005, P NATL ACAD SCI USA, V102, P5056, DOI 10.1073/pnas.0408595102; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94	17	114	119	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 25	2006	313	5790					1122	1126		10.1126/science.1127335	http://dx.doi.org/10.1126/science.1127335			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	076ZT	16931761				2022-12-28	WOS:000239998200047
J	Camilo, F; Ransom, SM; Halpern, JP; Reynolds, J; Helfand, DJ; Zimmerman, N; Sarkissian, J				Camilo, Fernando; Ransom, Scott M.; Halpern, Jules P.; Reynolds, John; Helfand, David J.; Zimmerman, Neil; Sarkissian, John			Transient pulsed radio emission from a magnetar	NATURE			English	Article							X-RAY PULSARS; XTE J1810-197; XTE-J1810-197; DISCOVERY; ELECTRODYNAMICS; COUNTERPART; REPEATERS; BANK	Anomalous X-ray pulsars (AXPs) are slowly rotating neutron stars with very bright and highly variable X-ray emission that are believed to be powered by ultra-strong magnetic fields of >10(14) G, according to the 'magnetar' model(1). The radio pulsations that have been observed from more than 1,700 neutron stars with weaker magnetic fields have never been detected from any of the dozen known magnetars. The X-ray pulsar XTE J1810-197 was revealed ( in 2003) as the first AXP with transient emission when its luminosity increased 100-fold from the quiescent level(2); a coincident radio source of unknown origin was detected one year later(3). Here we show that XTE J1810-197 emits bright, narrow, highly linearly polarized radio pulses, observed at every rotation, thereby establishing that magnetars can be radio pulsars. There is no evidence of radio emission before the 2003 X-ray outburst ( unlike ordinary pulsars, which emit radio pulses all the time), and the flux varies from day to day. The flux at all radio frequencies is approximately equal - and at > 20 GHz XTE J1810-197 is currently the brightest neutron star known. These observations link magnetars to ordinary radio pulsars, rule out alternative accretion models for AXPs, and provide a new window into the coronae of magnetars.	Columbia Univ, Columbia Astrophys Lab, New York, NY 10027 USA; Natl Radio Astron Observ, Charlottesville, VA 22903 USA; CSIRO, Parkes Observ, Australia Telescope Natl Facil, Parkes, NSW 2870, Australia	Columbia University; National Radio Astronomy Observatory (NRAO); Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Camilo, F (corresponding author), Columbia Univ, Columbia Astrophys Lab, 550 W 120th St, New York, NY 10027 USA.	fernando@astro.columbia.edu		Zimmerman, Neil/0000-0001-5484-1516; Ransom, Scott/0000-0001-5799-9714				Backer DC, 1997, PUBL ASTRON SOC PAC, V109, P61, DOI 10.1086/133859; BACKER DC, 1970, NATURE, V228, P1297, DOI 10.1038/2281297a0; BELOBORODOV AM, 2006, UNPUB ASTROPHYS J; Cordes J. M., 2002, NE2001 1 NEW MODEL G; Cordes JM, 2004, ASTROPHYS J, V612, P375, DOI 10.1086/422495; DRAKE FD, 1968, NATURE, V220, P231, DOI 10.1038/220231a0; DUNCAN RC, 1992, APJ, V392, P9; DURANT M, 2006, IN PRESS ASTROPHYS J; Eichler D, 2002, ASTROPHYS J, V578, pL121, DOI 10.1086/344564; EICHLER D, 2003, PULSARS AXPS SGRS OB, P215; GOLDREICH P, 1969, ASTROPHYS J, V157, P869, DOI 10.1086/150119; Gotthelf EV, 2005, ASTROPHYS J, V632, P1075, DOI 10.1086/432709; Gotthelf EV, 2004, ASTROPHYS J, V605, P368, DOI 10.1086/382232; Halpern JP, 2005, ASTROPHYS J, V632, pL29, DOI 10.1086/497537; Halpern JP, 2005, ASTROPHYS J, V618, P874, DOI 10.1086/426130; Ibrahim AI, 2004, ASTROPHYS J, V609, pL21, DOI 10.1086/422636; Israel GL, 2004, ASTROPHYS J, V603, pL97, DOI 10.1086/382875; Kaplan DL, 2005, PUBL ASTRON SOC PAC, V117, P643, DOI 10.1086/430368; Kaspi VM, 2005, ASTROPHYS J, V618, pL41, DOI 10.1086/427628; LORIMER DR, 1995, MON NOT R ASTRON SOC, V273, P411, DOI 10.1093/mnras/273.2.411; Lyutikov M, 2002, ASTROPHYS J, V580, pL65, DOI 10.1086/345493; Manchester RN, 2001, MON NOT R ASTRON SOC, V328, P17, DOI 10.1046/j.1365-8711.2001.04751.x; McLaughlin MA, 2006, NATURE, V439, P817, DOI 10.1038/nature04440; NARAYAN R, 1992, PHILOS T ROY SOC A, V341, P151, DOI 10.1098/rsta.1992.0090; Rea N, 2004, ASTRON ASTROPHYS, V425, pL5, DOI 10.1051/0004-6361:200400052; Reynolds SP, 2006, ASTROPHYS J, V639, pL71, DOI 10.1086/502648; RICKETT BJ, 1990, ANNU REV ASTRON ASTR, V28, P561, DOI 10.1146/annurev.aa.28.090190.003021; Thompson C, 2002, ASTROPHYS J, V574, P332, DOI 10.1086/340586; Thompson C, 2005, ASTROPHYS J, V634, P565, DOI 10.1086/432245; Zhang B, 2001, ASTROPHYS J, V562, pL59, DOI 10.1086/338051	30	305	312	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 24	2006	442	7105					892	895		10.1038/nature04986	http://dx.doi.org/10.1038/nature04986			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	076LT	16929292				2022-12-28	WOS:000239960500031
J	Jee, SH; Sull, JW; Park, J; Lee, S; Ohrr, H; Guallar, E; Samet, JM				Jee, Sun Ha; Sull, Jae Woong; Park, Jungyong; Lee, Sang-Yi; Ohrr, Heechoul; Guallar, Eliseo; Samet, Jonathan M.			Body-mass index and mortality in Korean men and women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; PROGNOSTIC VALUE; WEIGHT; US; OVERWEIGHT; DEATHS; CANCER; RISK; METAANALYSIS; OBESITY	Background: Obesity is associated with diverse health risks, but the role of body weight as a risk factor for death remains controversial. Methods: We examined the association between body weight and the risk of death in a 12-year prospective cohort study of 1,213,829 Koreans between the ages of 30 and 95 years. We examined 82,372 deaths from any cause and 48,731 deaths from specific diseases (including 29,123 from cancer, 16,426 from atherosclerotic cardiovascular disease, and 3362 from respiratory disease) in relation to the body-mass index (BMI) (the weight in kilograms divided by the square of the height in meters). Results: In both sexes, the average baseline BMI was 23.2, and the rate of death from any cause had a J-shaped association with the BMI, regardless of cigarette-smoking history. The risk of death from any cause was lowest among patients with a BMI of 23.0 to 24.9. In all groups, the risk of death from respiratory causes was higher among subjects with a lower BMI, and the risk of death from atherosclerotic cardiovascular disease or cancer was higher among subjects with a higher BMI. The relative risk of death associated with BMI declined with increasing age. Conclusions: Underweight, overweight, and obese men and women had higher rates of death than men and women of normal weight. The association of BMI with death varied according to the cause of death and was modified by age, sex, and smoking history.	Yonsei Univ, Grad Sch Publ Hlth, Dept Epidemiol & Hlth Promot, Seoul 120749, South Korea; Natl Hlth Insurance Corp, Seoul, South Korea; Jeju Natl Univ, Coll Med, Dept Hlth Policy & Management, Cheju, South Korea; Yonsei Univ, Coll Med, Dept Prevent Med & Publ Hlth, Seoul, South Korea; Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA	Yonsei University; Yonsei University Health System; Jeju National University; Yonsei University; Yonsei University Health System; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Jee, SH (corresponding author), Yonsei Univ, Grad Sch Publ Hlth, Dept Epidemiol & Hlth Promot, Seoul 120749, South Korea.	jsunha@yumc.yonsei.ac.kr	Guallar, Eliseo/D-3807-2014	Guallar, Eliseo/0000-0002-4471-9565; Jee, Sun Ha/0000-0001-9519-3068	NATIONAL CANCER INSTITUTE [R03CA094771] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ajani UA, 2004, ANN EPIDEMIOL, V14, P731, DOI 10.1016/j.annepidem.2003.10.008; Allison DB, 1997, AM J EPIDEMIOL, V146, P672; Bender R, 1999, JAMA-J AM MED ASSOC, V281, P1498, DOI 10.1001/jama.281.16.1498; Calle EE, 1999, NEW ENGL J MED, V341, P1097, DOI 10.1056/NEJM199910073411501; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; COX DR, 1972, J R STAT SOC B, V34, P187; Deurenberg P, 1998, INT J OBESITY, V22, P1164, DOI 10.1038/sj/ijo/0800741; Deurenberg P, 1999, INT J OBESITY, V23, P537, DOI 10.1038/sj.ijo.0800868; Dorn JM, 1997, AM J EPIDEMIOL, V146, P919, DOI 10.1093/oxfordjournals.aje.a009218; Flegal KM, 2005, JAMA-J AM MED ASSOC, V293, P1861, DOI 10.1001/jama.293.15.1861; Garcia-Garcia MD, 2002, EMERG INFECT DIS, V8, P1327; Gomez SL, 2003, CANCER CAUSE CONTROL, V14, P167, DOI 10.1023/A:1023046121214; Gu DF, 2006, JAMA-J AM MED ASSOC, V295, P776, DOI 10.1001/jama.295.7.776; He J, 2005, NEW ENGL J MED, V353, P1124, DOI 10.1056/NEJMsa050467; Hu FB, 2004, NEW ENGL J MED, V351, P2694, DOI 10.1056/NEJMoa042135; Institute of Medicine, 2005, PREV CHILDH OB HLTH; *INT STAT CLASS DI, 1992, INT CLASS DIS REL HL; Jee SH, 2005, AM J EPIDEMIOL, V162, P42, DOI 10.1093/aje/kwi166; Jee SH, 2004, JNCI-J NATL CANCER I, V96, P1851, DOI 10.1093/jnci/djh334; Jee SH, 2005, JAMA-J AM MED ASSOC, V293, P194, DOI 10.1001/jama.293.2.194; Katzmarzyk P T, 2003, Obes Rev, V4, P257, DOI 10.1046/j.1467-789X.2003.00120.x; Landbo C, 1999, AM J RESP CRIT CARE, V160, P1856, DOI 10.1164/ajrccm.160.6.9902115; Macallan DC, 1999, DIAGN MICR INFEC DIS, V34, P153, DOI 10.1016/S0732-8893(99)00007-3; MANSON JE, 1987, JAMA-J AM MED ASSOC, V257, P353, DOI 10.1001/jama.257.3.353; MANSON JE, 1995, NEW ENGL J MED, V333, P677, DOI 10.1056/NEJM199509143331101; Mcgee DL, 2005, ANN EPIDEMIOL, V15, P87, DOI 10.1016/j.annepidem.2004.05.012; Olshansky SJ, 2005, NEW ENGL J MED, V352, P1138, DOI 10.1056/NEJMsr043743; Prescott E, 2002, EUR RESPIR J, V20, P539, DOI 10.1183/09031936.02.00532002; Sacks LV, 1998, ARCH INTERN MED, V158, P1916, DOI 10.1001/archinte.158.17.1916; Stevens J, 1998, NEW ENGL J MED, V338, P1, DOI 10.1056/NEJM199801013380101; Stevens J, 2003, INT J OBESITY, V27, P1297, DOI 10.1038/sj.ijo.0802417; STEVENS J, 2003, PROGR OBESITY RES, P554; Thorogood M, 2003, J EPIDEMIOL COMMUN H, V57, P130, DOI 10.1136/jech.57.2.130; Villareal DT, 2005, OBES RES, V13, P1849, DOI 10.1038/oby.2005.228; WHO, 2004, LANCET, V363, P902; Widlansky ME, 2004, ARCH INTERN MED, V164, P2326, DOI 10.1001/archinte.164.21.2326; WILSON DO, 1989, AM REV RESPIR DIS, V139, P1435, DOI 10.1164/ajrccm/139.6.1435; World Health Organization, 2000, AS PAC PERSP RED OB	38	621	633	0	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 24	2006	355	8					779	787		10.1056/NEJMoa054017	http://dx.doi.org/10.1056/NEJMoa054017			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	076KA	16926276	Bronze			2022-12-28	WOS:000239955200006
J	Sharp, D				Sharp, David			Ethics at Porton Down	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Sharp, D (corresponding author), The Lancet, London NW1 7BY, England.							Allender S, 2006, OCCUP MED-OXFORD, V56, P329, DOI 10.1093/occmed/kql059; CARE A, 2005, PI FOCUS ASS PER JAN, P1; *CROWN PROS SERV, 2006, CPS DEC NO PROS RER; Evans R., 2000, GASSED BRIT CHEM WAR; *MIN DEF, 2006, NEWS ART MOD PUBL PO; *MIN DEF, 2006, HIST SURV PORT DOWN; Sharp D, 2006, LANCET, V367, P95, DOI 10.1016/S0140-6736(06)67942-7	7	2	2	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 19	2006	368	9536					631	632		10.1016/S0140-6736(06)69227-1	http://dx.doi.org/10.1016/S0140-6736(06)69227-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	074YT	16920454				2022-12-28	WOS:000239849200011
J	Crutsinger, GM; Collins, MD; Fordyce, JA; Gompert, Z; Nice, CC; Sanders, NJ				Crutsinger, Gregory M.; Collins, Michael D.; Fordyce, James A.; Gompert, Zachariah; Nice, Chris C.; Sanders, Nathan J.			Plant genotypic diversity predicts community structure and governs an ecosystem process	SCIENCE			English	Article							GENETIC DIVERSITY	Theory predicts, and recent empirical studies have shown, that the diversity of plant species determines the diversity of associated herbivores and mediates ecosystem processes, such as aboveground net primary productivity ( ANPP). However, an often-overlooked component of plant diversity, namely population genotypic diversity, may also have wide-ranging effects on community structure and ecosystem processes. We showed experimentally that increasing population genotypic diversity in a dominant old-field plant species, Solidago altissima, determined arthropod diversity and community structure and increased ANPP. The effects of genotypic diversity on arthropod diversity and ANPP were comparable to the effects of plant species diversity measured in other studies.	Univ Tennessee, Dept Ecol & Evolutionary Biol, Knoxville, TN 37996 USA; SW Texas State Univ, Dept Biol, San Marcos, TX 78666 USA	University of Tennessee System; University of Tennessee Knoxville; Texas State University System; Texas State University San Marcos	Crutsinger, GM (corresponding author), Univ Tennessee, Dept Ecol & Evolutionary Biol, Knoxville, TN 37996 USA.	gcrutsin@utk.edu	Sanders, Nathan/A-6945-2009; Sanders, Nathan/ABE-4335-2020	Sanders, Nathan/0000-0001-6220-6731; Gompert, Zachariah/0000-0003-2248-2488; Fordyce, James/0000-0002-2731-0418				BERNAYS E, 1988, ECOLOGY, V69, P886, DOI 10.2307/1941237; Gotelli N. J., 1996, NULL MODELS ECOLOGY, P21; Haddad NM, 2001, AM NAT, V158, P17, DOI 10.1086/320866; Hooper DU, 2005, ECOL MONOGR, V75, P3, DOI 10.1890/04-0922; Hubbell Stephen P., 2001, V32, pi; Hughes AR, 2004, P NATL ACAD SCI USA, V101, P8998, DOI 10.1073/pnas.0402642101; HUNTER MD, 1992, ECOLOGY, V73, P724; Huston MA, 1997, OECOLOGIA, V110, P449, DOI 10.1007/s004420050180; HUTCHINSON GE, 1959, AM NAT, V93, P145, DOI 10.1086/282070; Johnson MTJ, 2006, ECOL LETT, V9, P24, DOI 10.1111/j.1461-0248.2005.00833.x; Loreau M, 2002, BIODIVERSITY AND ECOSYSTEM FUNCTIONING: SYNTHESIS AND PERSPECTIVES, P237; Loreau M, 2001, NATURE, V413, P548, DOI 10.1038/35097128; Luck GW, 2003, TRENDS ECOL EVOL, V18, P331, DOI 10.1016/S0169-5347(03)00100-9; MacArthur R.H., 1972, pvii; Price P.W., 1983, P559; Reusch TBH, 2005, P NATL ACAD SCI USA, V102, P2826, DOI 10.1073/pnas.0500008102; SCHEINER SM, 1993, DESIGN ANAL ECOLOGIC, P347; Schweitzer JA, 2005, ECOLOGY, V86, P2834, DOI 10.1890/04-1955; Siemann E, 1998, AM NAT, V152, P738, DOI 10.1086/286204; Srivastava DS, 1998, AM NAT, V152, P510, DOI 10.1086/286187; Whitham TG, 2003, ECOLOGY, V84, P559, DOI 10.1890/0012-9658(2003)084[0559:CAEGAC]2.0.CO;2; Wimp GM, 2004, ECOL LETT, V7, P776, DOI 10.1111/j.1461-0248.2004.00635.x; Zhu YY, 2000, NATURE, V406, P718, DOI 10.1038/35021046	23	575	597	5	370	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 18	2006	313	5789					966	968		10.1126/science.1128326	http://dx.doi.org/10.1126/science.1128326			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	074MR	16917062				2022-12-28	WOS:000239817000043
J	Teodoro, JG; Parker, AE; Zhu, XC; Green, MR				Teodoro, Jose G.; Parker, Albert E.; Zhu, Xiaochun; Green, Michael R.			p53-mediated inhibition of angiogenesis through up-regulation of a collagen prolyl hydroxylase	SCIENCE			English	Article							P53; SUPPRESSION; EXPRESSION; GROWTH	Recent evidence suggests that antiangiogenic therapy is sensitive to p53 status in tumors, implicating a role for p53 in the regulation of angiogenesis. Here we show that p53 transcriptionally activates the alpha(II) collagen prolyl-4-hydroxylase [alpha(II) PH] gene, resulting in the extracellular release of antiangiogenic fragments of collagen type 4 and 18. Conditioned media from cells ectopically expressing either p53 or alpha(II) PH selectively inhibited growth of primary human endothelial cells. When expressed intracellularly or exogenously delivered, alpha(II) PH significantly inhibited tumor growth in mice. Our results reveal a genetic and biochemical linkage between the p53 tumor suppressor pathway and the synthesis of antiangiogenic collagen fragments.	Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Program Gene Funct & Express, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Program Mol Med, Worcester, MA 01605 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester	Green, MR (corresponding author), Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Program Gene Funct & Express, 364 Plantat St, Worcester, MA 01605 USA.	michael.green@umassmed.edu	Teodoro, Joe/AFT-2440-2022	Teodoro, Joe/0000-0002-3713-6839				Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIDLER IJ, 1975, CANCER RES, V35, P218; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; Maeshima Y, 2002, SCIENCE, V295, P140, DOI 10.1126/science.1065298; Marneros AG, 2001, MATRIX BIOL, V20, P337, DOI 10.1016/S0945-053X(01)00151-2; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Ravi R, 2000, GENE DEV, V14, P34; Saarela J, 1998, MATRIX BIOL, V16, P319, DOI 10.1016/S0945-053X(98)90003-8; Sund M, 2005, P NATL ACAD SCI USA, V102, P2934, DOI 10.1073/pnas.0500180102; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Zhang LL, 2000, CANCER RES, V60, P3655	14	143	148	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 18	2006	313	5789					968	971		10.1126/science.1126391	http://dx.doi.org/10.1126/science.1126391			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	074MR	16917063				2022-12-28	WOS:000239817000044
J	Eerenstein, W; Mathur, ND; Scott, JF				Eerenstein, W.; Mathur, N. D.; Scott, J. F.			Multiferroic and magnetoelectric materials	NATURE			English	Review							EARTH IRON-ALLOYS; PIEZOELECTRIC CERAMICS; MAGNETIC-PROPERTIES; PHASE-TRANSITIONS; THIN-FILMS; PEROVSKITE; FERROELECTRICITY; POLARIZATION; COMPOSITE; REVERSAL	A ferroelectric crystal exhibits a stable and switchable electrical polarization that is manifested in the form of cooperative atomic displacements. A ferromagnetic crystal exhibits a stable and switchable magnetization that arises through the quantum mechanical phenomenon of exchange. There are very few 'multiferroic' materials that exhibit both of these properties, but the 'magnetoelectric' coupling of magnetic and electrical properties is a more general and widespread phenomenon. Although work in this area can be traced back to pioneering research in the 1950s and 1960s, there has been a recent resurgence of interest driven by long-term technological aspirations.	Univ Cambridge, Dept Mat Sci, Cambridge CB2 3QZ, England; Univ Cambridge, Dept Earth Sci, Ctr Ferroics, Cambridge CB2 3EQ, England	University of Cambridge; University of Cambridge	Mathur, ND (corresponding author), Univ Cambridge, Dept Mat Sci, Pembroke St, Cambridge CB2 3QZ, England.	ndm12@cam.ac.uk	CHOUDHARY, RENU/B-6420-2014					ASCHER E, 1966, J APPL PHYS, V37, P1404, DOI 10.1063/1.1708493; ASTROV DN, 1960, SOV PHYS JETP-USSR, V11, P708; Bai FM, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1851612; BALTZER PK, 1965, PHYS REV LETT, V15, P493, DOI 10.1103/PhysRevLett.15.493; Bea H, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.2009808; Bichurin MI, 1997, FERROELECTRICS, V204, pXVII; Bichurin MI, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.132408; Borisov P, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.117203; BROWN WF, 1968, PHYS REV, V168, P574, DOI 10.1103/PhysRev.168.574; Cai N, 2004, APPL PHYS LETT, V84, P3516, DOI 10.1063/1.1739277; Catalan G, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2177543; CHEN A, 1967, PHYS REV, V154, P493, DOI 10.1103/PhysRev.154.493; Chiba H, 1997, J SOLID STATE CHEM, V132, P139, DOI 10.1006/jssc.1997.7432; Dawber M, 2005, REV MOD PHYS, V77, P1083, DOI 10.1103/RevModPhys.77.1083; DEJONGH LJ, 1974, ADV PHYS, V23, P1, DOI 10.1080/00018739700101558; Dong SX, 2004, APPL PHYS LETT, V85, P3534, DOI 10.1063/1.1786631; Dong SX, 2003, APPL PHYS LETT, V83, P2265, DOI 10.1063/1.1611276; dos Santos AM, 2002, SOLID STATE COMMUN, V122, P49, DOI 10.1016/S0038-1098(02)00087-X; DZYALOSHINSKII IE, 1960, SOV PHYS JETP-USSR, V10, P628; Eerenstein W, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.2039988; Eerenstein W, 2005, SCIENCE, V307, P1203, DOI 10.1126/science.1105422; Efremov DV, 2004, NAT MATER, V3, P853, DOI 10.1038/nmat1236; Fiebig M, 2000, PHYS REV LETT, V84, P5620, DOI 10.1103/PhysRevLett.84.5620; Fiebig M, 2002, NATURE, V419, P818, DOI 10.1038/nature01077; Fiebig M, 2005, J PHYS D APPL PHYS, V38, pR123, DOI 10.1088/0022-3727/38/8/R01; FOLEN VJ, 1961, PHYS REV LETT, V6, P607, DOI 10.1103/PhysRevLett.6.607; FOX DL, 1980, PHYS REV B, V21, P2926, DOI 10.1103/PhysRevB.21.2926; FOX DL, 1977, J PHYS C SOLID STATE, V10, pL329, DOI 10.1088/0022-3719/10/11/011; Gajek M, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.020406; GINZBURG VL, 1984, SOLID STATE COMMUN, V50, P339, DOI 10.1016/0038-1098(84)90381-8; Gorbatsevich A. A., 1994, Ferroelectrics, V161, P321, DOI 10.1080/00150199408213381; GRIMMER H, 1992, ACTA CRYSTALLOGR A, V48, P266, DOI 10.1107/S0108767391012709; Hemberger J, 2005, NATURE, V434, P364, DOI 10.1038/nature03348; Hill NA, 2000, J PHYS CHEM B, V104, P6694, DOI [10.1021/jp000114x, 10.1021/jpc00114x]; Hontsu S, 1999, SUPERCOND SCI TECH, V12, P836, DOI 10.1088/0953-2048/12/11/343; HOU SL, 1965, PHYS REV, V138, P1218, DOI 10.1103/PhysRev.138.A1218; Hur N, 2004, NATURE, V429, P392, DOI 10.1038/nature02572; INOUE M, 2005, MAT RES SOC S P, V834; Iwasaki Y, 2002, J MAGN MAGN MATER, V240, P395, DOI 10.1016/S0304-8853(01)00841-1; Jaynes E. T., 1953, FERROELECTRICITY; KATO K, 1983, J MAGN MAGN MATER, V31-4, P783, DOI 10.1016/0304-8853(83)90683-2; Kim SK, 2003, J MAGN MAGN MATER, V267, P127, DOI 10.1016/S0304-8853(03)00297-X; Kimel AV, 2005, NATURE, V435, P655, DOI [10.1038/nature03564, 10.1038/nature03S64]; Kimura T, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.137201; Kimura T, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.180401; Kimura T, 2003, NATURE, V426, P55, DOI 10.1038/nature02018; KINGSMITH RD, 1993, PHYS REV B, V47, P1651, DOI 10.1103/PhysRevB.47.1651; KITTEL C, 1946, PHYS REV, V70, P965, DOI 10.1103/PhysRev.70.965; Krichevtsov B. B., 1994, FERROELECTRICS, V161, P65; LAUKMIN V, 2006, ELECT FIELD CONTROL; Lee MK, 2000, APPL PHYS LETT, V77, P3547, DOI 10.1063/1.1328762; Lines M.E., 2001, PRINCIPLES APPL FERR; LITTLEWOOD PB, 1979, J PHYS C SOLID STATE, V12, P4431, DOI 10.1088/0022-3719/12/21/011; Lorenz B, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.212412; Lottermoser T, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.220407; Lottermoser T, 2004, NATURE, V430, P541, DOI 10.1038/nature02728; Mathews S, 1997, SCIENCE, V276, P238, DOI 10.1126/science.276.5310.238; Mathur ND, 1998, NATURE, V394, P39, DOI 10.1038/27838; MERMIN ND, 1979, REV MOD PHYS, V51, P591, DOI 10.1103/RevModPhys.51.591; Murashov V. A., 1994, Ferroelectrics, V162, P11, DOI 10.1080/00150199408245085; Nan CW, 2002, APPL PHYS LETT, V81, P3831, DOI 10.1063/1.1521247; Naumov II, 2004, NATURE, V432, P737, DOI 10.1038/nature03107; Novosad V, 2000, J APPL PHYS, V87, P6400, DOI 10.1063/1.372719; O'Dell T.H., 1970, ELECTRODYNAMICS MAGN; Palkar VR, 2005, SOLID STATE COMMUN, V134, P783, DOI 10.1016/j.ssc.2005.01.032; Palkar VR, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.212102; Ponomarev B. K., 1994, Ferroelectrics, V161, P43, DOI 10.1080/00150199408213350; Popov Yu. F., 1994, Ferroelectrics, V162, P135, DOI 10.1080/00150199408245098; RADO GT, 1977, PHYS REV B, V15, P290, DOI 10.1103/PhysRevB.15.290; Rivera J.-P., 1994, Ferroelectrics, V161, P165, DOI 10.1080/00150199408213365; Ryu J, 2001, JPN J APPL PHYS 1, V40, P4948, DOI 10.1143/JJAP.40.4948; SAIFI MA, 1970, PHYS REV B, V2, P677, DOI 10.1103/PhysRevB.2.677; Schmid H, 2001, FERROELECTRICS, V252, P253; Schmid H., 1974, International Journal of Magnetism, V4, P337; Schmid H., 1994, FERROELECTRICS, V162, P665; SCHMID H, 1994, FERROELECTRICS, V161, P1, DOI DOI 10.1080/00150199408213348; SCHRODER K, 1982, J APPL PHYS, V53, P2759, DOI 10.1063/1.330957; SCIAU P, 1990, FERROELECTRICS, V105, P201, DOI 10.1080/00150199008224642; Scott JF, 2005, NAT MATER, V4, P13, DOI 10.1038/nmat1287; SCOTT JF, 1977, PHYS REV B, V16, P2329, DOI 10.1103/PhysRevB.16.2329; SCOTT JF, 1979, REP PROG PHYS, V42, P1055, DOI 10.1088/0034-4885/42/6/003; SMOLENSKY GA, 1959, FIZ TVERD TELA, V1, P150; SOSNOWSKA I, 1982, J PHYS C SOLID STATE, V15, P4835, DOI 10.1088/0022-3719/15/23/020; Srinivasan G, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.134402; SUGAWARA F, 1968, J PHYS SOC JPN, V25, P1553, DOI 10.1143/JPSJ.25.1553; Sugie H, 2002, J PHYS SOC JPN, V71, P1558, DOI 10.1143/JPSJ.71.1558; Sun JZ, 1999, J MAGN MAGN MATER, V202, P157, DOI 10.1016/S0304-8853(99)00289-9; Tabares-Munoz C., 1985, Japanese Journal of Applied Physics, Supplement, V24, P1051; Tabata H, 1997, IEICE T ELECTRON, VE80C, P918; TEAGUE JR, 1970, SOLID STATE COMMUN, V8, P1073, DOI 10.1016/0038-1098(70)90262-0; Valasek J., 1920, PHYS REV, V15, P537; VANRUN AMJG, 1974, J MATER SCI, V9, P1710, DOI 10.1007/BF00540771; Wang J, 2003, SCIENCE, V299, P1719, DOI 10.1126/science.1080615; WANG J, 2005, SCIENCE, V307, pB1203, DOI DOI 10.1126/SCIENCE.1080615; Wu T, 2001, PHYS REV LETT, V86, P5998, DOI 10.1103/PhysRevLett.86.5998; Yamada H, 2002, APPL PHYS LETT, V81, P4793, DOI 10.1063/1.1530734; Zavaliche F, 2005, NANO LETT, V5, P1793, DOI 10.1021/nl051406i; ZHELUDEV IS, 1974, JETP LETT+, V20, P129; Zheng H, 2004, SCIENCE, V303, P661, DOI 10.1126/science.1094207	99	6336	6484	129	3778	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 17	2006	442	7104					759	765		10.1038/nature05023	http://dx.doi.org/10.1038/nature05023			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	074DK	16915279				2022-12-28	WOS:000239792700035
J	Liu, AY; Grant, RM; Buchbinder, SP				Liu, Albert Y.; Grant, Robert M.; Buchbinder, Susan P.			Preexposure prophylaxis for HIV - Unproven promise and potential pitfalls	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							IMMUNODEFICIENCY VIRUS-INFECTION; PROTECT NEWBORN MACAQUES; HEPATITIS-B; TENOFOVIR; PREVENTION; TRIALS		San Francisco Dept Publ Hlth, AIDS Off, HIV Res Sect, San Francisco, CA 94102 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA USA; Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94143 USA	San Francisco Department of Public Health; University of California System; University of California San Francisco; University of California System; University of California San Francisco; The J David Gladstone Institutes	Liu, AY (corresponding author), San Francisco Dept Publ Hlth, AIDS Off, HIV Res Sect, 25 Van Ness Ave,Suite 500, San Francisco, CA 94102 USA.	albert.liu@sfdph.org		Grant, Robert/0000-0002-0851-7085	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI064002, R01AI062333] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI062333, UO1 AI064002] Funding Source: Medline; PHS HHS [200-2003-03007] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		*AIDS VACC CLEAR, PREP WATCH; Celum CL, 2001, J INFECT DIS, V183, P23, DOI 10.1086/317658; COHEN J, 2006, NY TIMES MAGAZI 0122; COSTELLO D, 2005, LOS ANGELES TIM 1219, pF1; Gallant JE, 2004, JAMA-J AM MED ASSOC, V292, P191, DOI 10.1001/jama.292.2.191; GARCIALERMA J, 2006, 13 C RETR OPP INF FE; GUEST J, 2006, 13 C RETR OPP INF FE; HEFFELFINGER J, 2006, 13 C RETR OPP INF FE; JOHNSON J, 2006, 13 C RETR OPP INF FE; KEEGAN A, 2006, SO VOICE        0407; Kindrick A., 2006, 13 C RETR OPP INF FE; Lim SG, 2006, ARCH INTERN MED, V166, P49, DOI 10.1001/archinte.166.1.49; MARCHIONE M, 2006, AIDS DRUGS SHOW PREV; Mondou E, 2005, CLIN INFECT DIS, V41, pE45, DOI 10.1086/432581; OSBORNE D, 2006, GAY CITY NEWS   0427; Roland ME, 2005, CLIN INFECT DIS, V41, P1507, DOI 10.1086/497268; Schechter M, 2002, 9 C RETR OPP INF FEB; Smith Dawn K., 2005, Morbidity and Mortality Weekly Report, V54, P1; TSAI CC, 1995, SCIENCE, V270, P1197, DOI 10.1126/science.270.5239.1197; Tsai CC, 1998, J VIROL, V72, P4265, DOI 10.1128/JVI.72.5.4265-4273.1998; U. S. Food and Drug Administration, VIR; van Bommel F, 2004, HEPATOLOGY, V40, P1421, DOI 10.1002/hep.20464; Van Rompay KKA, 1998, AIDS, V12, pF79, DOI 10.1097/00002030-199809000-00001; Van Rompay KKA, 2001, J INFECT DIS, V184, P429, DOI 10.1086/322781; *WHO JOINT UN PROG, 2006, 2006 REP GLOB AIDS E; Youle Mike, 2003, J Int Assoc Physicians AIDS Care (Chic), V2, P102, DOI 10.1177/154510970300200302; Zimmermann AE, 2006, CLIN INFECT DIS, V42, P283, DOI 10.1086/499048	27	51	60	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 16	2006	296	7					863	865		10.1001/jama.296.7.863	http://dx.doi.org/10.1001/jama.296.7.863			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	073SR	16905792				2022-12-28	WOS:000239763400027
J	Dagenais, GR; Pogue, J; Fox, K; Simoons, ML; Yusuf, S				Dagenais, Gilles R.; Pogue, Janice; Fox, Kim; Simoons, Marteen L.; Yusuf, Salim			Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials	LANCET			English	Article							MYOCARDIAL-INFARCTION	Background Angiotensin-converting-enzyme (ACE) inhibitors reduce cardiovascular mortality and morbidity in patients with heart failure or left ventricular systolic dysfunction (LVSD). Three large trials have assessed the effect of ACE inhibitors in stable patients without these conditions but with atherosclerosis. We undertook a systematic review of the Heart Outcomes Prevention Evaluation (HOPE), the European trial on Reduction Of cardiac events with Perindopril among patients with stable coronary Artery disease (EUROPA), and the Prevention of Events with ACE inhibition (PEACE) studies to determine the consistency with which ACE inhibitors reduce total mortality and fatal and non-fatal cardiovascular events. Methods We computed cardiovascular outcomes and total mortality in the 29 805 patients of these three trials, randomly assigned an ACE inhibitor or placebo and followed up for a mean of about 4.5 years. The results were also analysed within the context of five large trials of ACE inhibitors in patients with heart failure or LVSD. Findings When the findings of the HOPE, EUROPA, and PEACE trials were combined, ACE inhibitors significantly reduced all-cause mortality (7.8 vs 8.9%, p = 0.0004), cardiovascular mortality (4.3 vs 5.2%, p = 0.0002), non-fatal myocardial infarction (5.3 vs 6.4%, p = 0.0001), all stroke (2.2 vs 2.8%, p = 0.0004), heart failure (2.1 vs 2.7%, p = 0.0007), coronary-artery bypass surgery (6.0 vs 6.9%, p = 0.0036) but not percutaneous coronary intervention (7.4 vs 7.6%, p = 0.481). The composite outcomes of cardiovascular mortality, non-fatal myocardial infarction, or stroke occurred in 1599 (10.7%) of the patients allocated ACE inhibitor and in 1910 (12.8%) of those allocated placebo (odds ratio, 0.82; 95% CIs 0.76-0.88; p < 0.0001). Except for stroke and revascularisation, these results were similar to those of the five trials in patients with heart failure or LVSD. Interpretation ACE inhibitors reduce serious vascular events in patients with atherosclerosis without known evidence of LVSD or heart failure. Results showing these benefits in intermediate-risk patients complement existing evidence of similar benefit in higher-risk patients with LVSD or heart failure. Therefore, use of ACE inhibitors should be considered in all patients with atherosclerosis.	Univ Laval, Heart & Lung Inst, Laval Hosp, Ste Foy, PQ G1V 4G5, Canada; McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada; Royal Brompton Hosp, London SW3 6LY, England; Univ Med Ctr, ERASMUS MC, Thoraxctr, Rotterdam, Netherlands	Laval University; McMaster University; Population Health Research Institute; Royal Brompton Hospital; Erasmus University Rotterdam; Erasmus MC	Dagenais, GR (corresponding author), Univ Laval, Heart & Lung Inst, Laval Hosp, Ste Foy, PQ G1V 4G5, Canada.	gilles.dagenais@crhl.ulaval.ca		Yusuf, Salim/0000-0003-4776-5601				BALL SG, 1993, LANCET, V342, P821; Braunwald E, 2004, NEW ENGL J MED, V351, P2058; Deckers JW, 2006, EUR HEART J, V27, P796, DOI 10.1093/eurheartj/ehi809; Flather MD, 2000, LANCET, V355, P1575, DOI 10.1016/S0140-6736(00)02212-1; Fox KM, 2003, LANCET, V362, P782; Gomma AH, 2001, CARDIOVASC DRUG THER, V15, P169, DOI 10.1023/A:1011131130922; MacMahon S, 2001, LANCET, V358, P1033, DOI 10.1016/S0140-6736(01)06178-5; MANTEL N, 1959, J NATL CANCER I, V22, P719; Mindlen F, 1996, CAN J CARDIOL, V12, P127; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; Pfeffer MA, 1998, AM J CARDIOL, V82, p25H; Torp-Pedersen C, 1999, LANCET, V354, P9, DOI 10.1016/S0140-6736(98)09374-X; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; Yusuf S, 2000, NEW ENGL J MED, V342, P145	16	377	398	0	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 12	2006	368	9535					581	588		10.1016/S0140-6736(06)69201-5	http://dx.doi.org/10.1016/S0140-6736(06)69201-5			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	074OF	16905022				2022-12-28	WOS:000239821000031
J	Kuranaga, E; Kanuka, H; Tonoki, A; Takemoto, K; Tomioka, T; Kobayashi, M; Hayashi, S; Miura, M				Kuranaga, Erina; Kanuka, Hirotaka; Tonoki, Ayako; Takemoto, Kiwamu; Tomioka, Takeyasu; Kobayashi, Masatomo; Hayashi, Shigeo; Miura, Masayuki			Drosophila IKK-related kinase regulates nonapoptotic function of caspases, via degradation of IAPs	CELL			English	Article							PROGRAMMED CELL-DEATH; DOUBLE-STRANDED-RNA; PROMOTES APOPTOSIS; WING DISC; DIAP1; PROLIFERATION; REAPER; ACTIVATION; PATHWAY; PROTEIN	Caspase activation has been extensively studied in the context of apoptosis. However, caspases also control other cellular functions, although the mechanisms regulating caspases in nonapoptotic contexts remain obscure. Drosophila IAP1 (DIAP1) is an endogenous caspase inhibitor that is crucial for regulating cell death during development. Here we describe Drosophila IKK-related kinase (DmIKK epsilon) as a regulator of caspase activation in a nonapoptotic context. We show that DmIKK epsilon promotes degradation of DIAP1 through direct phosphorylation. Knockdown of DmIKK epsilon in the proneural clusters of the wing imaginal disc, in which nonapoptotic caspase activity is required for proper sensory organ precursor (SOP) development, stabilizes endogenous DIAP1 and affects Drosophila SOP development. Our results demonstrate that DmIKK epsilon is a determinant of DIAP1 protein levels and that it establishes the threshold of activity required for the execution of nonapoptotic caspase functions.	Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Genet, Bunkyo Ku, Tokyo 1130033, Japan; Obihiro Univ Agr & Vet Med, Natl Res Ctr Protozoan Dis, Obihiro, Hokkaido 0808555, Japan; Hokkaido Univ, Res Inst Elect Sci, Sapporo, Hokkaido 0600808, Japan; Natl Inst Genet, Gene Network Lab, Mishima, Shizuoka 4118540, Japan; RIKEN, Ctr Dev Biol, Chuo Ku, Kobe, Hyogo 6500047, Japan	University of Tokyo; Obihiro University of Agriculture & Veterinary Medicine; Hokkaido University; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; RIKEN	Miura, M (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Genet, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	miura@mol.f.u-tokyo.ac.jp	Hayashi, Shigeo/N-5128-2015; Kuranaga, Erina/AAE-4309-2019; Hayashi, Shigeo/J-9628-2019; Takemoto, Kiwamu/AAE-9926-2019; Takemoto, Kiwamu/HGD-3429-2022	Hayashi, Shigeo/0000-0001-7785-1290; Kuranaga, Erina/0000-0001-6300-2087; Hayashi, Shigeo/0000-0001-7785-1290; Takemoto, Kiwamu/0000-0002-3301-3268				Arama E, 2003, DEV CELL, V4, P687, DOI 10.1016/S1534-5807(03)00120-5; Bello BC, 2003, NEURON, V37, P209, DOI 10.1016/S0896-6273(02)01181-9; Ditzel M, 2003, NAT CELL BIOL, V5, P467, DOI 10.1038/ncb984; Fernando P, 2005, FASEB J, V19, P1671, DOI 10.1096/fj.04-2981fje; Geisbrecht ER, 2004, CELL, V118, P111, DOI 10.1016/j.cell.2004.06.020; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; Harlin H, 2001, MOL CELL BIOL, V21, P3604, DOI 10.1128/MCB.21.10.3604-3608.2001; Harvey KF, 2003, CELL, V114, P457, DOI 10.1016/S0092-8674(03)00557-9; Hay BA, 2004, NAT REV GENET, V5, P911, DOI 10.1038/nrg1491; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Hays R, 2002, NAT CELL BIOL, V4, P425, DOI 10.1038/ncb794; Holley CL, 2002, NAT CELL BIOL, V4, P439, DOI 10.1038/ncb798; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Huh JR, 2004, PLOS BIOL, V2, P43, DOI 10.1371/journal.pbio.0020015; Igaki T, 2002, J BIOL CHEM, V277, P23103, DOI 10.1074/jbc.C200222200; Igaki T, 2000, P NATL ACAD SCI USA, V97, P662, DOI 10.1073/pnas.97.2.662; Ito K, 1997, DEVELOPMENT, V124, P761; Kanuka H, 1999, MOL CELL, V4, P757, DOI 10.1016/S1097-2765(00)80386-X; Kanuka H, 2005, EMBO J, V24, P3793, DOI 10.1038/sj.emboj.7600822; Kanuka H, 2005, BBA-GEN SUBJECTS, V1726, P225, DOI 10.1016/j.bbagen.2005.06.020; Kanuka H, 1999, P NATL ACAD SCI USA, V96, P145, DOI 10.1073/pnas.96.1.145; Kawai T, 2006, NAT IMMUNOL, V7, P131, DOI 10.1038/ni1303; Kennerdell JR, 2000, NAT BIOTECHNOL, V18, P896, DOI 10.1038/78531; Kozlova T, 1998, GENETICS, V149, P1465; Kuranaga E, 2002, NAT CELL BIOL, V4, P705, DOI 10.1038/ncb842; Leulier F, 2002, CURR BIOL, V12, P996, DOI 10.1016/S0960-9822(02)00873-4; Milan M, 1997, P NATL ACAD SCI USA, V94, P5691, DOI 10.1073/pnas.94.11.5691; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Nolo R, 2000, CELL, V102, P349, DOI 10.1016/S0092-8674(00)00040-4; Oshima K, 2006, CURR BIOL, V16, P1531, DOI 10.1016/j.cub.2006.06.032; Pantalacci S, 2003, NAT CELL BIOL, V5, P921, DOI 10.1038/ncb1051; Quinn LM, 2000, J BIOL CHEM, V275, P40416, DOI 10.1074/jbc.M002935200; Reddy GV, 1999, DEVELOPMENT, V126, P2083; Rodriguez A, 2002, EMBO J, V21, P2189, DOI 10.1093/emboj/21.9.2189; Ryoo HD, 2002, NAT CELL BIOL, V4, P432, DOI 10.1038/ncb795; Sanna MG, 2002, J BIOL CHEM, V277, P30454, DOI 10.1074/jbc.M203312200; Schwerk C, 2003, BIOCHEM PHARMACOL, V66, P1453, DOI 10.1016/S0006-2952(03)00497-0; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Takemoto K, 2003, J CELL BIOL, V160, P235, DOI 10.1083/jcb.200207111; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; Udan RS, 2003, NAT CELL BIOL, V5, P914, DOI 10.1038/ncb1050; Vaux DL, 2005, NAT REV MOL CELL BIO, V6, P287, DOI 10.1038/nrm1621; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; Wilson R, 2002, NAT CELL BIOL, V4, P445, DOI 10.1038/ncb799; Wing JP, 2002, NAT CELL BIOL, V4, P451, DOI 10.1038/ncb800; Wu S, 2003, CELL, V114, P445, DOI 10.1016/S0092-8674(03)00549-X; Yanagawa SI, 1997, J BIOL CHEM, V272, P25243, DOI 10.1074/jbc.272.40.25243; Yoo SJ, 2002, NAT CELL BIOL, V4, P416, DOI 10.1038/ncb793; Zhou L, 1997, P NATL ACAD SCI USA, V94, P5131, DOI 10.1073/pnas.94.10.5131	49	109	110	0	4	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 11	2006	126	3					583	596		10.1016/j.cell.2006.05.048	http://dx.doi.org/10.1016/j.cell.2006.05.048			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	075KI	16887178	Bronze			2022-12-28	WOS:000239883400017
J	Van der Borght, S; de Wit, TFR; Janssens, V; van der Loeff, MFS; Rijckborst, H; Lange, JMA				Van der Borght, Stefaan; de Wit, Tobias F. Rinke; Janssens, Vincent; van der Loeff, Maarten F. Schim; Rijckborst, Henk; Lange, Joep M. A.			HAART for the HIV-infected employees of large companies in Africa	LANCET			English	Editorial Material							ANTIRETROVIRAL THERAPY; AIDS; MORTALITY; COSTS		Heineken Int Hlth Affairs, NL-1017 HL Amsterdam, Netherlands; PharmAccess Fdn, Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Ctr Poverty Related Communicable Dis, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Van der Borght, S (corresponding author), Heineken Int Hlth Affairs, Vijzelstr 72, NL-1017 HL Amsterdam, Netherlands.	S.vanderBorght@heineken.com	de Wit, Tobias TF Rinke/A-1224-2013					Akileswaran C, 2005, CLIN INFECT DIS, V41, P376, DOI 10.1086/431482; BLOOM DE, 2006, BUISNESS HIV AIDS HL; Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2; Byakika-Tusiime J, 2005, INT J STD AIDS, V16, P38, DOI 10.1258/0956462052932548; Dror DM., 2002, SOCIAL REINSURANCE N; Dybul Mark, 2002, MMWR Recomm Rep, V51, P1; Harries AD, 2001, LANCET, V358, P410, DOI 10.1016/S0140-6736(01)05551-9; Kimball AM, 2005, LANCET, V365, P1213, DOI 10.1016/S0140-6736(05)74792-9; Lavalle C, 2000, ARCH MED RES, V31, P515, DOI 10.1016/S0188-4409(00)00097-7; Little SJ, 2002, NEW ENGL J MED, V347, P385, DOI 10.1056/NEJMoa013552; Marseille E, 2006, AIDS, V20, P907, DOI 10.1097/01.aids.0000218556.36661.47; Mocroft A, 2004, HIV MED, V5, P437, DOI 10.1111/j.1468-1293.2004.00250.x; Orrell Catherine, 2005, Curr HIV/AIDS Rep, V2, P171, DOI 10.1007/s11904-005-0012-8; Paul S, 2002, AIDS RES HUM RETROV, V18, P501, DOI 10.1089/088922202317406646; Piot P, 2004, SCIENCE, V304, P1909, DOI 10.1126/science.1101137; Stevens W, 2004, BMJ-BRIT MED J, V328, P280, DOI 10.1136/bmj.328.7434.280; Teixeira PR, 2004, AIDS, V18, pS5, DOI 10.1097/00002030-200406003-00002; Venter L, 2005, LANCET, V365, P1215, DOI 10.1016/S0140-6736(05)74793-0; Victora CG, 2000, LANCET, V356, P1093, DOI 10.1016/S0140-6736(00)02741-0; *WORLD BANK, 1999, MILL DEV GOALS MDG; World Health Organization, 2003, SCAL ANT THER RES LT; 2001, BOSTON GLOBE    0607, pA8	22	16	16	1	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 5	2006	368	9534					547	550		10.1016/S0140-6736(06)69165-4	http://dx.doi.org/10.1016/S0140-6736(06)69165-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	071AL	16890844				2022-12-28	WOS:000239569000040
J	Garrick-Bethell, I; Wisdom, J; Zuber, MT				Garrick-Bethell, Ian; Wisdom, Jack; Zuber, Maria T.			Evidence for a past high-eccentricity lunar orbit	SCIENCE			English	Article							EARTH-MOON SYSTEM; GRAVITY-FIELD; SOLAR SYSTEM; DISSIPATION; EVOLUTION; CONVECTION; BODY	The large differences between the Moon's three principal moments of inertia have been a mystery since Laplace considered them in 1799. Here we present calculations that show how past high-eccentricity orbits can account for the moment differences, represented by the low-order lunar gravity field and libration parameters. One of our solutions is that the Moon may have once been in a 3:2 resonance of orbit period to spin period, similar to Mercury's present state. The possibility of past high-eccentricity orbits suggests a rich dynamical history and may influence our understanding of the early thermal evolution of the Moon.	MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Garrick-Bethell, I (corresponding author), MIT, Dept Earth Atmospher & Planetary Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	iang@mit.edu	Garrick-Bethell, Ian/E-7051-2013	Garrick-Bethell, Ian/0000-0002-6327-5867				ANDERSON JD, 1987, ICARUS, V71, P337, DOI 10.1016/0019-1035(87)90033-9; CASSEN P, 1978, GEOPHYS RES LETT, V5, P294, DOI 10.1029/GL005i004p00294; GOLDREICH P, 1969, J GEOPHYS RES, V74, P2555, DOI 10.1029/JB074i010p02555; GOLDREICH P, 1966, ASTRON J, V71, P425, DOI 10.1086/109947; GOLDREICH P, 1963, MON NOT R ASTRON SOC, V126, P257, DOI 10.1093/mnras/126.3.257; Jeffreys H., 1970, EARTH; JEFFREYS H, 1937, MON NOT R ASTRON S S, V4, P1; Jeffreys H., 1915, MEM ROYAL ASTRO SOC, V60, P187; KAULA WM, 1966, THEORY STATELLITE GE; Kleine T, 2005, SCIENCE, V310, P1671, DOI 10.1126/science.1118842; Kokubo E, 2000, ICARUS, V148, P419, DOI 10.1006/icar.2000.6496; Konopliv AS, 1998, SCIENCE, V281, P1476, DOI 10.1126/science.281.5382.1476; KOPAL Z, 1967, PROC R SOC LON SER-A, V296, P254, DOI 10.1098/rspa.1967.0019; LAMBECK K, 1980, PHYS EARTH PLANET IN, V22, P29, DOI 10.1016/0031-9201(80)90097-7; LAPLACE PS, 1798, TRAITE MECANIQUE CEL, V2, pCH2; LEFFTZ M, 1993, PHYS EARTH PLANET IN, V76, P317, DOI 10.1016/0031-9201(93)90020-A; Murray C. D., 1999, SOLAR SYSTEM DYNAMIC; Neumann GA, 1996, J GEOPHYS RES-PLANET, V101, P16841, DOI 10.1029/96JE01246; Peale SJ, 2003, CELEST MECH DYN ASTR, V87, P129, DOI 10.1023/A:1026187917994; PEALE SJ, 1978, ICARUS, V36, P245, DOI 10.1016/0019-1035(78)90109-4; PEALE SJ, 1978, SATELLITES, P87; Plummer H. C., 1960, INTRO TREATISE DYNAM; RUNCORN SK, 1962, NATURE, V195, P1150, DOI 10.1038/1951150a0; Sedgwick W. F., 1898, MESSENGER MATH, V27, P171; STEVENSON DJ, 2001, P LUN PLAN SCI C, V32; TOUMA J, 1994, ASTRON J, V108, P1943, DOI 10.1086/117209; Touma J, 1998, ASTRON J, V115, P1653, DOI 10.1086/300312; Williams JG, 2001, J GEOPHYS RES-PLANET, V106, P27933, DOI 10.1029/2000JE001396; Yoder C., 1995, GLOBAL EARTH PHYS HD, V1, P1; Zhong SJ, 2000, J GEOPHYS RES-PLANET, V105, P4153, DOI 10.1029/1999JE001075	31	41	41	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 4	2006	313	5787					652	655		10.1126/science.1128237	http://dx.doi.org/10.1126/science.1128237			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	072IQ	16888135				2022-12-28	WOS:000239667500038
J	Mair, GR; Braks, JAM; Garver, LS; Wiegant, LCAG; Hall, N; Dirks, RW; Khan, SM; Dimopoulos, G; Janse, CJ; Waters, AP				Mair, Gunnar R.; Braks, Joanna A. M.; Garver, Lindsey S.; Wiegant, Loop C. A. G.; Hall, Neil; Dirks, Roeland W.; Khan, Shahid M.; Dimopoulos, George; Janse, Chris J.; Waters, Andrew P.			Regulation of sexual development of Plasmodium by translational repression	SCIENCE			English	Article							CYTOPLASMIC PROCESSING BODIES; IN-SITU HYBRIDIZATION; DEAD BOX HELICASE; MESSENGER-RNA; MALARIA PARASITE; SURFACE PROTEIN; BERGHEI; EXPRESSION; OOKINETE; PBS21	Translational repression of messenger RNAs (mRNAs) plays an important role in sexual differentiation and gametogenesis in multicellular eukaryotes. Translational repression and mRNA turnover were shown to influence stage-specific gene expression in the protozoan Plasmodium. The DDX6-class RNA helicase, DOZI (development of zygote inhibited), is found in a complex with mRNA species in cytoplasmic bodies of female, blood-stage gametocytes. These translationally repressed complexes are normally stored for translation after fertilization Genetic disruption of pbdozi inhibits the formation of the ribonucleoprotein complexes, and instead, at least 370 transcripts are diverted to a degradation pathway.	Leiden Univ, Med Ctr, Dept Parasitol, NL-2333 ZA Leiden, Netherlands; Johns Hopkins Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; Leiden Univ, Med Ctr, Dept Mol Cell Biol, NL-2333 ZA Leiden, Netherlands; Inst Genom Res, Rockville, MD 20850 USA	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; J. Craig Venter Institute	Waters, AP (corresponding author), Leiden Univ, Med Ctr, Dept Parasitol, NL-2333 ZA Leiden, Netherlands.	waters@lumc.nl	Waters, Andy P/C-9377-2009; Hall, Neil/A-8717-2013	Waters, Andy P/0000-0001-8900-2982; Hall, Neil/0000-0002-7995-3810; Mair, Gunnar/0000-0002-5187-3691; Khan, Shahid/0000-0002-0533-4670; Dimopoulos, George/0000-0001-6755-8111; Janse, Chris J/0000-0002-6410-6205; Hall, Neil/0000-0003-2808-0009	NIAID NIH HHS [1R01AI061576-01A1] Funding Source: Medline; Wellcome Trust [066742] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI061576] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome Trust); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abraham EG, 2004, J BIOL CHEM, V279, P5573, DOI 10.1074/jbc.M307582200; ALMOUZNI G, 1995, EMBO J, V14, P1752, DOI 10.1002/j.1460-2075.1995.tb07164.x; Billker O, 2004, CELL, V117, P503, DOI 10.1016/S0092-8674(04)00449-0; Brengues M, 2005, SCIENCE, V310, P486, DOI 10.1126/science.1115791; Colegrove-Otero LJ, 2005, CRIT REV BIOCHEM MOL, V40, P21, DOI 10.1080/10409230590918612; Coller J, 2005, CELL, V122, P875, DOI 10.1016/j.cell.2005.07.012; Coller JM, 2001, RNA, V7, P1717, DOI 10.1017/S135583820101994X; CORDIN O, 2005, GENE; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Hall N, 2005, SCIENCE, V307, P82, DOI 10.1126/science.1103717; Khan SM, 2005, CELL, V121, P675, DOI 10.1016/j.cell.2005.03.027; Ladomery M, 1997, NUCLEIC ACIDS RES, V25, P965, DOI 10.1093/nar/25.5.965; Minshall N, 2001, RNA, V7, P1728, DOI 10.1017/S135583820101158X; Nakamura A, 2001, DEVELOPMENT, V128, P3233; PATON MG, 1993, MOL BIOCHEM PARASIT, V59, P263, DOI 10.1016/0166-6851(93)90224-L; Rodriguez MD, 2000, MOL BIOCHEM PARASIT, V110, P147, DOI 10.1016/S0166-6851(00)00265-6; Shaw MK, 1996, EUR J CELL BIOL, V71, P270; Sheth U, 2003, SCIENCE, V300, P805, DOI 10.1126/science.1082320; Siden-Kiamos I, 2000, J CELL SCI, V113, P3419; THOMPSON J, 1994, MOL BIOCHEM PARASIT, V68, P189, DOI 10.1016/0166-6851(94)90164-3; van Dijk MR, 2001, CELL, V104, P153, DOI 10.1016/S0092-8674(01)00199-4; VANDIJK M, COMMUNICATION; VERVENNE RAW, 1994, MOL BIOCHEM PARASIT, V68, P259, DOI 10.1016/0166-6851(94)90170-8; Yuda M, 2001, MOL BIOCHEM PARASIT, V116, P65, DOI 10.1016/S0166-6851(01)00304-8	24	323	327	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 4	2006	313	5787					667	669		10.1126/science.1125129	http://dx.doi.org/10.1126/science.1125129			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	072IQ	16888139	Green Accepted			2022-12-28	WOS:000239667500043
J	Kitsis, RN; Jialal, I				Kitsis, Richard N.; Jialal, Ishwarlal			Limiting myocardial damage during acute myocardial infarction by inhibiting C-reactive protein	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							COMPLEMENT		Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10467 USA; Albert Einstein Coll Med, Cardiovasc Res Ctr, Bronx, NY 10467 USA; Albert Einstein Coll Med, Ctr Canc, Bronx, NY 10467 USA; Montefiore Med Ctr, Bronx, NY 10467 USA; Univ Calif Davis, Dept Pathol, Davis, CA 95616 USA; Univ Calif Davis, Dept Med, Davis, CA 95616 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; University of California System; University of California Davis; University of California System; University of California Davis	Kitsis, RN (corresponding author), Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA.		Jialal, Ishwarlal/AAG-6218-2019					Griselli M, 1999, J EXP MED, V190, P1733, DOI 10.1084/jem.190.12.1733; Lagrand WK, 1997, CIRCULATION, V95, P97, DOI 10.1161/01.CIR.95.1.97; Pepys MB, 2006, NATURE, V440, P1217, DOI 10.1038/nature04672; Suleiman M, 2006, J AM COLL CARDIOL, V47, P962, DOI 10.1016/j.jacc.2005.10.055	4	29	35	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 3	2006	355	5					513	515		10.1056/NEJMcibr063197	http://dx.doi.org/10.1056/NEJMcibr063197			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	069FT	16885557				2022-12-28	WOS:000239432500014
J	Parker, AA; Staggs, W; Dayan, GH; Ortega-Sanchez, IR; Rota, PA; Lowe, L; Boardman, P; Teclaw, R; Graves, C; LeBaron, CW				Parker, Amy A.; Staggs, Wayne; Dayan, Gustavo H.; Ortega-Sanchez, Ismael R.; Rota, Paul A.; Lowe, Luis; Boardman, Patricia; Teclaw, Robert; Graves, Charlene; LeBaron, Charles W.			Implications of a 2005 measles outbreak in Indiana for sustained elimination of measles in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VACCINE FAILURES; IMMUNIZATION; IMPACT; TRANSMISSION; POLICY	BACKGROUND: Measles was declared eliminated from the United States in 2000 but remains endemic worldwide. In 2005, a 17-year-old unvaccinated girl who was incubating measles returned from Romania, creating the largest documented outbreak of measles in the United States since 1996. METHODS: We conducted a case-series investigation, molecular typing of viral isolates, surveys of rates of vaccination coverage, interviews regarding attitudes toward vaccination, and cost surveys. RESULTS: Approximately 500 persons attended a gathering with the index patient one day after her return home. Approximately 50 lacked evidence of measles immunity, of whom 16 (32 percent) acquired measles at the gathering. During the six weeks after the gathering, a total of 34 cases of measles were confirmed. Of the patients with confirmed measles, 94 percent were unvaccinated, 88 percent were less than 20 years of age, and 9 percent were hospitalized. Of the 28 patients who were 5 to 19 years of age, 71 percent were home-schooled. Vaccine failure occurred in two persons. The virus strain was genotype D4, which is endemic in Romania. Although containment measures began after 20 persons were already infectious, measles remained confined mostly to children whose parents had refused to have them vaccinated, primarily out of concern for adverse events from the vaccine. Seventy-one percent of patients were from four households. Levels of measles-vaccination coverage in Indiana were 92 percent for preschoolers and 98 percent for sixth graders. Estimated costs of containing the disease were at least $167,685, including $113,647 at a hospital with an infected employee. CONCLUSIONS: This outbreak was caused by the importation of measles into a population of children whose parents had refused to have them vaccinated because of safety concerns about the vaccine. High vaccination levels in the surrounding community and low rates of vaccine failure averted an epidemic. Maintenance of high rates of vaccination coverage, including improved strategies of communication with persons who refuse vaccination, is necessary to prevent future outbreaks and sustain the elimination of measles in the United States.	Ctr Dis Control & Prevent, Epidem Intelligence Serv, Epidemiol Program Off, Atlanta, GA USA; Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA; Indiana State Dept Hlth, Indianapolis, IN 46202 USA; Home Hosp, Lafaeytte, IN USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Parker, AA (corresponding author), CDC, NCIRD, MS A-47,1600 Clifton Rd, Atlanta, GA 30333 USA.							Abramson JS, 2002, JAMA-J AM MED ASSOC, V287, P505, DOI 10.1001/jama.287.4.505; [Anonymous], 2005, WKLY EPIDEMIOL REC, V80, P347; [Anonymous], 1998, MMWR MORB MORTAL WKL, V47, P1; ATKINSON WL, 1992, ANNU REV MED, V43, P451, DOI 10.1146/annurev.med.43.1.451; Bellini WJ, 2005, J INFECT DIS, V192, P1686, DOI 10.1086/497169; Centers for Disease Control and Prevention, TRAV HLTH; Centers for Disease Control and Prevention, NAT IMM SURV; COHN ML, 1994, PEDIATR INFECT DIS J, V13, P34, DOI 10.1097/00006454-199401000-00008; CUTTS FT, 1992, ANNU REV PUBL HEALTH, V13, P385, DOI 10.1146/annurev.publhealth.13.1.385; Dayan GH, 2005, PEDIATRICS, V116, pE1, DOI 10.1542/peds.2004-2512; *EPI, 1998, WKLY EPIDEMIOL REC, V73, P265; FARIZO KM, 1991, PEDIATRICS, V87, P74; Gangarosa EJ, 1998, LANCET, V351, P356, DOI 10.1016/S0140-6736(97)04334-1; GINDLER JS, 1992, PEDIATR INFECT DIS J, V11, P841, DOI 10.1097/00006454-199210000-00007; HENKE RR, 2001, ED STAT Q, V2; Hyde TB, 2006, INT J EPIDEMIOL, V35, P299, DOI 10.1093/ije/dyi222; Jansen VAA, 2003, SCIENCE, V301, P804, DOI 10.1126/science.1086726; Katz SL, 2004, J INFECT DIS, V189, pS43, DOI 10.1086/377696; KLICKA C, 2005, IMMUNIZATIONS PARENT; Marin M, 2006, CLIN INFECT DIS, V42, P315, DOI 10.1086/498902; McBrien J, 2003, PEDIATR INFECT DIS J, V22, P580, DOI 10.1097/00006454-200307000-00002; Mossong J, 1999, AM J EPIDEMIOL, V150, P1238, DOI 10.1093/oxfordjournals.aje.a009951; Orenstein W A, 1990, J Health Care Poor Underserved, V1, P315; Oster NV, 2004, J INFECT DIS, V189, pS48, DOI 10.1086/374854; PAPANIA M, 2002, VPD SURVEILLANCE MAN; Paunio M, 2000, EPIDEMIOL INFECT, V124, P263, DOI 10.1017/S0950268899003222; PICKERING LK, 2000, RED BOOK REPORT COMM, P386; Ratnam S, 2000, J CLIN MICROBIOL, V38, P99; SMITH PJ, 2005, VITAL HLTH STAT 2, V138, P1; 1997, MMWR MORB MORTAL WKL, V46, P766; 2000, MMWR MORB MORTAL WKL, V49, P299; 2005, MEASLES HITS ROMANIA; 2004, MMWR MORB MORTAL WKL, V53, P309	33	190	202	0	22	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 3	2006	355	5					447	455		10.1056/NEJMoa060775	http://dx.doi.org/10.1056/NEJMoa060775			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	069FT	16885548				2022-12-28	WOS:000239432500004
J	Whitlock, EP; Garlitz, BA; Harris, EL; Beil, TL; Smith, PR				Whitlock, Evelyn P.; Garlitz, Betsy A.; Harris, Emily L.; Beil, Tracy L.; Smith, Paula R.			Screening for hereditary hemochromatosis: A systematic review for the US Preventive Services Task Force	ANNALS OF INTERNAL MEDICINE			English	Article							IRON-BINDING-CAPACITY; PRIMARY-CARE PATIENTS; LONG-TERM SURVIVAL; TRANSFERRIN SATURATION; PUBLIC-HEALTH; HFE MUTATIONS; VENESECTION THERAPY; GENERAL-POPULATION; AMERICAN-COLLEGE; HIGH PREVALENCE	Background: The U.S. Preventive Services Task Force (USPSTF) has not previously considered screening for hereditary hemochromatosis for a recommendation as a clinical preventive service for primary care clinicians. Purpose: To conduct a focused systematic review of hereditary hemochromatosis screening relating to 2 USPSTF criteria, the burden of suffering and the potential effectiveness of a preventive intervention, to determine whether evidence is sufficient for a USPSTF recommendation. Data Sources: MEDLINE, CINAHL, and Cochrane Library databases from 1966 through February 2005. The authors supplemented literature searches with source materials from experts in the field and the bibliographies of key reviews and included studies. Study Selection: Studies were retrieved to answer 3 key questions: 1) What is the risk for developing clinical hemochromatosis among those with a homozygous C282Y genotype? 2) Does earlier therapeutic phlebotomy of individuals with primary iron overload due to hereditary hemochromatosis reduce morbidity and mortality compared with treatment after diagnosis in routine clinical care? 3) Are there groups at increased risk for developing hereditary hemochromatosis that can be readily identified before genetic screening? The authors critically appraised studies using quality criteria specific to their design. Data Extraction: The authors abstracted all studies into evidence tables using condition definitions and diagnostic criteria. Data Synthesis: Data were insufficient to define a very precise estimate of penetrance. Available data suggest that up to 38% to 50% of C282Y homozygotes may develop iron overload, with up to 10% to 33% eventually developing hemochromatosis-associated morbidity. Prevalence of C282Y homozygosity is higher in family members of probands and other high-risk patient groups defined by signs, symptoms, and phenotypic screening. Limitations: This review considered genetic screening for HFE-related hereditary hemochromatosis in C282Y homozygotes only. Available research is limited, is based solely on observational designs, and is plagued by poor or inconsistent reporting. Conclusions: Research addressing genetic screening for hereditary hemochromatosis remains insufficient to confidently project the impact of, or estimate the benefit from, widespread or high-risk genetic screening for hereditary hemochromatosis.	Kaiser Permanente, Oregon Evidence Based Practice Ctr, Ctr Hlth Res, Portland, OR USA	Kaiser Permanente	Whitlock, EP (corresponding author), Kaiser Permanente, Oregon Evidence Based Practice Ctr, Ctr Hlth Res, Portland, OR USA.				PHS HHS [290-02-0024] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adams P, 2000, J HEPATOL, V33, P487, DOI 10.1016/S0168-8278(01)80874-6; Adams Paul C, 2004, Clin Liver Dis, V8, P735, DOI 10.1016/j.cld.2004.06.002; Adams PC, 2000, HEPATOLOGY, V31, P1160, DOI 10.1053/he.2000.6984; Adams PC, 2005, NEW ENGL J MED, V352, P1769, DOI 10.1056/NEJMoa041534; Adams PC, 1998, GASTROENTEROLOGY, V114, P319, DOI 10.1016/S0016-5085(98)70483-4; ADAMS PC, 1991, GASTROENTEROLOGY, V101, P368, DOI 10.1016/0016-5085(91)90013-B; Adams PC, 2001, AM J GASTROENTEROL, V96, P567; Ajioka RS, 2002, SEMIN HEMATOL, V39, P235, DOI 10.1053/shem.2002.35634; Andersen RV, 2004, BLOOD, V103, P2914, DOI 10.1182/blood-2003-10-3564; Asberg A, 2001, SCAND J GASTROENTERO, V36, P1108; Baldus WP, 2000, HEMOCHROMATOSIS: GENETICS, PATHOPHYSIOLOGY, DIAGNOSIS AND TREATMENT, P187; Barton JC, 1999, GENET MED, V1, P89; Baynes RD, 2000, HEMOCHROMATOSIS: GENETICS, PATHOPHYSIOLOGY, DIAGNOSIS AND TREATMENT, P468; Beutler E, 2002, LANCET, V359, P211, DOI 10.1016/S0140-6736(02)07447-0; Beutler E, 2002, ACTA HAEMATOL-BASEL, V107, P145, DOI 10.1159/000057632; Beutler E, 2000, ANN INTERN MED, V133, P329, DOI 10.7326/0003-4819-133-5-200009050-00008; BOMFORD A, 1976, Q J MED, V45, P611; Bradley L A, 1996, J Med Screen, V3, P178; Brissot P, 2000, HEMOCHROMATOSIS: GENETICS, PATHOPHYSIOLOGY, DIAGNOSIS AND TREATMENT, P250; Brittenham GM, 1998, ANN INTERN MED, V129, P993, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00011; Brown AS, 2001, GENET MED, V3, P109, DOI 10.1097/00125817-200103000-00004; Burt MJ, 1998, GUT, V43, P830, DOI 10.1136/gut.43.6.830; Cadet E, 2005, J MED GENET, V42, P390, DOI 10.1136/jmg.2004.027284; Cadet E, 2003, J INTERN MED, V253, P217, DOI 10.1046/j.1365-2796.2003.01094.x; *CDCP, HEM HLTH CAR PROF DI; Chambers V, 2003, J HEPATOL, V39, P925, DOI 10.1016/S0168-8278(03)00471-9; Cogswell ME, 1998, ANN INTERN MED, V129, P971, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00008; Cogswell ME, 1999, AM J PREV MED, V16, P134, DOI 10.1016/S0749-3797(98)00141-X; Delatycki MB, 2005, LANCET, V366, P314, DOI 10.1016/S0140-6736(05)63012-7; Deugnier Y, 2002, BRIT J HAEMATOL, V118, P1170, DOI 10.1046/j.1365-2141.2002.03718.x; Distante S, 1999, SCAND J GASTROENTERO, V34, P529, DOI 10.1080/003655299750026290; DuBois S, 2004, ALIMENT PHARM THER, V20, P1, DOI 10.1111/j.1365-2036.2004.02024.x; Edwards CQ, 2000, HEMOCHROMATOSIS: GENETICS, PATHOPHYSIOLOGY, DIAGNOSIS AND TREATMENT, P8; EDWARDS CQ, 1993, NEW ENGL J MED, V328, P1616; Eijkelkamp EJ, 2000, CAN J GASTROENTEROL, V14, P121, DOI 10.1155/2000/360372; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Feldman M, 2002, SLEISENGER FORDTRANS; Hanson EH, 2001, AM J EPIDEMIOL, V154, P193, DOI 10.1093/aje/154.3.193; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; Harrison H, 2002, CAN FAM PHYSICIAN, V48, P1326; Imperatore G, 2003, GENET MED, V5, P1, DOI 10.1097/00125817-200301000-00001; McDonnell SM, 1999, AM J MED, V106, P619, DOI 10.1016/S0002-9343(99)00120-5; McDonnell SM, 2003, ARCH INTERN MED, V163, P2421, DOI 10.1001/archinte.163.20.2421; McDonnell SM, 1998, ANN INTERN MED, V129, P987, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00010; McDonnell SM, 1999, AM J MED, V107, P30, DOI 10.1016/S0002-9343(99)00163-1; McLaren CE, 2003, AM J MED SCI, V325, P53, DOI 10.1097/00000441-200302000-00001; Moodie SJ, 2002, EUR J GASTROEN HEPAT, V14, P223, DOI 10.1097/00042737-200203000-00004; Niederau C, 1996, GASTROENTEROLOGY, V110, P1107, DOI 10.1053/gast.1996.v110.pm8613000; Niederau C, 1998, ANN INTERN MED, V128, P337, DOI 10.7326/0003-4819-128-5-199803010-00001; NIEDERAU C, 1985, NEW ENGL J MED, V313, P1256, DOI 10.1056/NEJM198511143132004; Njajou OT, 2004, EUR J EPIDEMIOL, V19, P101, DOI 10.1023/B:EJEP.0000017664.96394.b9; Olynyk JK, 1999, NEW ENGL J MED, V341, P718, DOI 10.1056/NEJM199909023411002; Olynyk JK, 2004, MAYO CLIN PROC, V79, P309, DOI 10.4065/79.3.309; Phatak PD, 2002, BLOOD CELL MOL DIS, V29, P41, DOI 10.1006/bcmd.2002.0536; Phatak PD, 1998, ANN INTERN MED, V129, P954, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00006; Pietrangelo A, 2004, NEW ENGL J MED, V350, P2383, DOI 10.1056/NEJMra031573; Piperno A, 2000, HEMOCHROMATOSIS: GENETICS, PATHOPHYSIOLOGY, DIAGNOSIS AND TREATMENT, P177; Poullis A, 2003, ANN CLIN BIOCHEM, V40, P521, DOI 10.1258/000456303322326434; Powell LW, 2006, ARCH INTERN MED, V166, P294, DOI 10.1001/archinte.166.3.294; Powell LW, 1998, ANN INTERN MED, V129, P925, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00002; POWELL LW, 2001, HARRISONS PRINCIPLES, P2257; Qaseem A, 2005, ANN INTERN MED, V143, P517, DOI 10.7326/0003-4819-143-7-200510040-00010; Sanchez M, 2003, J HEPATOL, V38, P745, DOI 10.1016/S0168-8278(03)00123-5; Schmitt B, 2005, ANN INTERN MED, V143, P522, DOI 10.7326/0003-4819-143-7-200510040-00011; Sham RL, 2000, BLOOD, V96, P3707, DOI 10.1182/blood.V96.12.3707.h8003707_3707_3711; STROHMEYER G, 1988, ANN NY ACAD SCI, V526, P245, DOI 10.1111/j.1749-6632.1988.tb55510.x; Swinkels DW, 2002, NETH J MED, V60, P429; Tavill AS, 2001, HEPATOLOGY, V33, P1321, DOI 10.1053/jhep.2001.24783; U.S. Preventive Service Task Force, 1989, GUID CLIN PREV SERV; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; Waalen J, 2005, BEST PRACT RES CL HA, V18, P203, DOI 10.1016/j.beha.2004.08.023; Waalen J, 2002, BLOOD CELL MOL DIS, V29, P418, DOI 10.1006/bcmd.2002.0596; Waalen J, 2002, AM J MED, V113, P472, DOI 10.1016/S0002-9343(02)01249-4; Wetterhall SF, 1998, ANN INTERN MED, V129, P980, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00009; WHITLOCK EP, 2006, SCREENING HEREDITARY; WILLIAMS R, 1969, Q J MED, V38, P1; Willis G, 2002, RHEUMATOLOGY, V41, P176, DOI 10.1093/rheumatology/41.2.176; Witte DL, 1996, CLIN CHIM ACTA, V245, P139, DOI 10.1016/0009-8981(95)06212-2; Wojcik JP, 2002, CAN J GASTROENTEROL, V16, P297, DOI 10.1155/2002/161569; Yang QH, 1998, ANN INTERN MED, V129, P946, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00005	80	132	134	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	2006	145	3					209	223		10.7326/0003-4819-145-3-200608010-00009	http://dx.doi.org/10.7326/0003-4819-145-3-200608010-00009			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	070MN	16880463				2022-12-28	WOS:000239526800007
J	Montgomery, RA; Gentry, SE; Marks, WH; Warren, DS; Hiller, J; Houp, J; Zachary, AA; Melancon, JK; Maley, WR; Rabb, H; Simpkins, C; Segev, DL				Montgomery, Robert A.; Gentry, Sommer E.; Marks, William H.; Warren, Daniel S.; Hiller, Janet; Houp, Julie; Zachary, Andrea A.; Melancon, J. Keith; Maley, Warren R.; Rabb, Hamid; Simpkins, Christopher; Segev, Dorry L.			Domino paired kidney donation: a strategy to make best use of live non-directed donation	LANCET			English	Article							LIVING-DONOR; EXCHANGE PROGRAM; UNITED-STATES; TRANSPLANTATION		Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; USN Acad, Dept Math, Annapolis, MD 21402 USA; Swedish Med Ctr, Dept Organ Transplantat, Seattle, WA USA	Johns Hopkins University; Johns Hopkins University; United States Department of Defense; United States Navy; United States Naval Academy; Swedish Medical Center	Montgomery, RA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA.	rmonty@jhmi.edu	Gentry, Sommer/H-7101-2019	Gentry, Sommer/0000-0003-4530-8917				Adams PL, 2002, TRANSPLANTATION, V74, P582, DOI 10.1097/00007890-200208270-00030; de Klerk M, 2005, AM J TRANSPLANT, V5, P2302, DOI 10.1111/j.1600-6143.2005.01024.x; Delmonico FL, 2004, AM J TRANSPLANT, V4, P1628, DOI 10.1111/j.1600-6143.2004.00572.x; Delmonico FL, 2004, NEW ENGL J MED, V350, P1812, DOI 10.1056/NEJMp038228; Gilbert JC, 2005, AM J TRANSPLANT, V5, P167, DOI 10.1111/j.1600-6143.2004.00660.x; Gohh RY, 2001, NEPHROL DIAL TRANSPL, V16, P619, DOI 10.1093/ndt/16.3.619; Henderson AJZ, 2003, AM J TRANSPLANT, V3, P203, DOI 10.1034/j.1600-6143.2003.00019.x; Jacobs CL, 2004, AM J TRANSPLANT, V4, P1110, DOI 10.1111/j.1600-6143.2004.00478.x; Landolt MA, 2001, TRANSPLANTATION, V71, P1690, DOI 10.1097/00007890-200106150-00034; MARKS WH, 2004, S LIV NOND DON OCT 2; Matas AJ, 2000, NEW ENGL J MED, V343, P433, DOI 10.1056/NEJM200008103430611; Montgomery RA, 2005, JAMA-J AM MED ASSOC, V294, P1655, DOI 10.1001/jama.294.13.1655; Park K, 1999, TRANSPLANTATION, V67, P336, DOI 10.1097/00007890-199901270-00027; Ross LF, 2002, TRANSPLANTATION, V74, P418; Ross LF, 1997, NEW ENGL J MED, V336, P1752, DOI 10.1056/NEJM199706123362412; Segev DL, 2005, AM J TRANSPLANT, V5, P2448, DOI 10.1111/j.1600-6143.2005.01048.x; Segev DL, 2005, JAMA-J AM MED ASSOC, V293, P1883, DOI 10.1001/jama.293.15.1883; Spital A, 2003, TRANSPLANTATION, V76, P1252, DOI 10.1097/01.TP.0000087852.74220.9A; Spital A, 2001, TRANSPLANTATION, V71, P1061, DOI 10.1097/00007890-200104270-00009	19	130	130	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL-AUG	2006	368	9533					419	421		10.1016/S0140-6736(06)69115-0	http://dx.doi.org/10.1016/S0140-6736(06)69115-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	069JJ	16876670	Green Submitted			2022-12-28	WOS:000239441900035
J	Hazir, T; Bin Nisar, Y; Qazi, SA; Khan, SF; Raza, M; Zameer, S; Masood, SA				Hazir, Tabish; Bin Nisar, Yasir; Qazi, Shamim A.; Khan, Shazia F.; Raza, Mujahid; Zameer, Shehla; Masood, Syed Asif			Chest radiography in children aged 2-59 months diagnosed with non-severe pneumonia as defined by World Health Organization: descriptive multicentre study in Pakistan	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RESPIRATORY-TRACT INFECTIONS; SIMPLE CLINICAL SIGNS; BRONCHIOLITIS; MANAGEMENT; ETIOLOGY	Objectives To evaluate the chest radiographs of children diagnosed with non-severe pneumonia on the basis of the current World Health Organization guidelines (fast breathing alone) for radiological evidence of pneumonia. Design Descriptive analysis. Setting Outpatient departments of six hospitals in four cities in Pakistan. Participants 2000 children with non-severe pneumonia were enrolled; 1932 children were selected for chest radiography. Interventions Two consultant radiologists used standardised WHO definitions to evaluate chest radiographs; no clinical information was made available to them. If they disagreed, the radiographs were read by a third radiologist; the final classification was based on agreement between two of the three radiologists. Main outcome measures Presence or absence of pneumonia on radiographs. Results Chest radiographs were reported normal in 1519 children (82%). Radiological evidence of pneumonia was reported in only 263 (14%) children, most of whom had interstitial pneumonitis. Lobar consolidation was present in only 26 children. The duration of illness did not correlate significantly with the presence of radiological changes (relative risk 1.17, 95% confidence interval 0.91 to 1.49). Conclusion Most children diagnosed with non-severe pneumonia on the basis of the current WHO definition had normal chest radiographs.	Pakistan Inst Med Sci, Childrens Hosp, ARI Res Cell, Islamabad, Pakistan; Pakistan Inst Med Sci, Dept Radiol, Islamabad, Pakistan; World Hlth Org, Dept Child & Adolescent Hlth & Dev, Geneva, Switzerland; Aga Khan Univ Hosp, Dept Paediat, Karachi, Pakistan	Pakistan Institute of Medical Sciences; Pakistan Institute of Medical Sciences; University of Geneva; World Health Organization; Aga Khan University	Hazir, T (corresponding author), Pakistan Inst Med Sci, Childrens Hosp, ARI Res Cell, Islamabad, Pakistan.	arichi99@ariresearch.edu.pk	Nisar, Yasir Bin/AFO-2407-2022					CAMPBELL H, 1989, LANCET, V1, P297, DOI 10.1016/S0140-6736(89)91308-1; CAMPBELL H, 1988, LANCET, V2, P742; CHERIAN T, 1988, LANCET, V2, P125; DEMPSEY TJO, 1993, ARCH DIS CHILD, V68, P492; El-Radhi AS, 1999, ARCH DIS CHILD, V81, P231, DOI 10.1136/adc.81.3.231; FRIIS B, 1990, ACTA PAEDIATR SCAND, V79, P219, DOI 10.1111/j.1651-2227.1990.tb11442.x; FRIIS B, 1984, ARCH DIS CHILD, V59, P1038, DOI 10.1136/adc.59.11.1038; GHAFOOR A, 1990, REV INFECT DIS, V12, pS907; Hazir T, 2002, LANCET, V360, P835; KELLNER JD, 2000, COCHRANE DB SYST REV; MORLEY CJ, 1990, ARCH DIS CHILD, V65, P834, DOI 10.1136/adc.65.8.834; MORLEY CJ, 1991, RECENT ADV PAEDIAT, P137; *NIH, 1998, NIH PUBL; Qazi SA, 1996, B WORLD HEALTH ORGAN, V74, P501; Sazawal S, 2003, LANCET INFECT DIS, V3, P547, DOI 10.1016/S1473-3099(03)00737-0; SHANN F, 1986, PEDIATR INFECT DIS J, V5, P247, DOI 10.1097/00006454-198603000-00017; STICKLER GB, 1984, CLIN PEDIATR, V23, P398, DOI 10.1177/000992288402300707; TUPASI TE, 1990, REV INFECT DIS, V12, pS929; *WHO, 1990, WHOARI9013; *WHO, 1991, PNEUM REL INF YOUNG, V1, P71; *WHO, 1990, WHOARI90; *WHO, 1990, M RAD WORK GROUP GEN; WHO, 1992, OV CLIN PRES TREATM; Williams BG, 2002, LANCET INFECT DIS, V2, P25, DOI 10.1016/S1473-3099(01)00170-0	24	99	101	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 23	2006	333	7569					629	631		10.1136/bmj.38915.673322.80	http://dx.doi.org/10.1136/bmj.38915.673322.80			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	089KD	16923771	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000240878500016
J	Day, CL; Kaufmann, DE; Kiepiela, P; Brown, JA; Moodley, ES; Reddy, S; Mackey, EW; Miller, JD; Leslie, AJ; DePierres, C; Mncube, Z; Duraiswamy, J; Zhu, BG; Eichbaum, Q; Altfeld, M; Wherry, EJ; Coovadia, HM; Goulder, PJR; Klenerman, P; Ahmed, R; Freeman, GJ; Walker, BD				Day, Cheryl L.; Kaufmann, Daniel E.; Kiepiela, Photini; Brown, Julia A.; Moodley, Eshia S.; Reddy, Sharon; Mackey, Elizabeth W.; Miller, Joseph D.; Leslie, Alasdair J.; DePierres, Chantal; Mncube, Zenele; Duraiswamy, Jaikumar; Zhu, Baogong; Eichbaum, Quentin; Altfeld, Marcus; Wherry, E. John; Coovadia, Hoosen M.; Goulder, Philip J. R.; Klenerman, Paul; Ahmed, Rafi; Freeman, Gordon J.; Walker, Bruce D.			PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression	NATURE			English	Article							LYMPHOCYTES; INFECTION; PROLIFERATION; PHENOTYPE; RESPONSES; PERFORIN; MARKER	Functional impairment of T cells is characteristic of many chronic mouse and human viral infections. The inhibitory receptor programmed death 1 (PD-1; also known as PDCD1), a negative regulator of activated T cells(1-4), is markedly upregulated on the surface of exhausted virus-specific CD8 T cells in mice(5). Blockade of this pathway using antibodies against the PD ligand 1 (PD-L1, also known as CD274) restores CD8 T-cell function and reduces viral load(5). To investigate the role of PD-1 in a chronic human viral infection, we examined PD-1 expression on human immunodeficiency virus (HIV)-specific CD8 T cells in 71 clade-C-infected people who were naive to anti-HIV treatments, using ten major histocompatibility complex (MHC) class I tetramers specific for frequently targeted epitopes. Here we report that PD-1 is significantly upregulated on these cells, and expression correlates with impaired HIV-specific CD8 T-cell function as well as predictors of disease progression: positively with plasma viral load and inversely with CD4 T-cell count. PD-1 expression on CD4 T cells likewise showed a positive correlation with viral load and an inverse correlation with CD4 T-cell count, and blockade of the pathway augmented HIV-specific CD4 and CD8 T-cell function. These data indicate that the immunoregulatory PD-1/PD-L1 pathway is operative during a persistent viral infection in humans, and define a reversible defect in HIV-specific T-cell function. Moreover, this pathway of reversible T-cell impairment provides a potential target for enhancing the function of exhausted T cells in chronic HIV infection.	Univ KwaZulu Natal, Doris Duke Med Res Inst, HIV Pathogenesis Programme, ZA-4013 Durban, South Africa; Massachusetts Gen Hosp, Partner AIDS Res Ctr, Boston, MA 02114 USA; Harvard Univ, Sch Med, Div Aids, Boston, MA 02115 USA; Univ Oxford, Nuffield Dept Med, Oxford OX1 3SY, England; Harvard Univ, Sch Med, Dept Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA; Wistar Inst Anat & Biol, Program Immunol, Philadelphia, PA 19104 USA; Howard Hughes Med Inst, Chevy Chase, MD 20185 USA	University of Kwazulu Natal; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Oxford; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Emory University; Emory University; The Wistar Institute; Howard Hughes Medical Institute	Walker, BD (corresponding author), Univ KwaZulu Natal, Doris Duke Med Res Inst, HIV Pathogenesis Programme, ZA-4013 Durban, South Africa.	bwalker@partners.org	Wherry, John/ABI-1280-2020; Freeman, Gordon/AAC-5380-2019; Day, Cheryl L/J-9844-2012; Day, Cheryl/GQQ-9720-2022; Altfeld, Marcus/AAE-7306-2019	Freeman, Gordon/0000-0002-7210-5616; Day, Cheryl L/0000-0002-6497-4846; Altfeld, Marcus/0000-0001-5972-2997; klenerman, paul/0000-0003-4307-9161; leslie, alasdair/0000-0003-2538-6467				Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379; Appay V, 2000, J EXP MED, V192, P63, DOI 10.1084/jem.192.1.63; Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444; Brown JA, 2003, J IMMUNOL, V170, P1257, DOI 10.4049/jimmunol.170.3.1257; Champagne P, 2001, NATURE, V410, P106, DOI 10.1038/35065118; Chen LP, 2004, NAT REV IMMUNOL, V4, P336, DOI 10.1038/nri1349; Day CL, 2003, J EXP MED, V198, P1773, DOI 10.1084/jem.20031947; Dorfman DM, 2006, AM J SURG PATHOL, V30, P802, DOI 10.1097/01.pas.0000209855.28282.ce; Goepfert PA, 2000, J VIROL, V74, P10249, DOI 10.1128/JVI.74.21.10249-10255.2000; Hess C, 2004, LANCET, V363, P863, DOI 10.1016/S0140-6736(04)15735-8; ISHIDA Y, 1992, EMBO J, V11, P3887, DOI 10.1002/j.1460-2075.1992.tb05481.x; Kiepiela P, 2004, NATURE, V432, P769, DOI 10.1038/nature03113; Kostense S, 2002, BLOOD, V99, P2505, DOI 10.1182/blood.V99.7.2505; Kostense S, 2001, EUR J IMMUNOL, V31, P677, DOI 10.1002/1521-4141(200103)31:3<677::AID-IMMU677>3.0.CO;2-M; Lichterfeld M, 2004, J EXP MED, V200, P701, DOI 10.1084/jem.20041270; Loffredo JT, 2005, J VIROL, V79, P14986, DOI 10.1128/JVI.79.23.14986-14991.2005; Migueles SA, 2002, NAT IMMUNOL, V3, P1061, DOI 10.1038/ni845; Nishimura H, 1999, IMMUNITY, V11, P141, DOI 10.1016/S1074-7613(00)80089-8; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Sharpe AH, 2002, NAT REV IMMUNOL, V2, P116, DOI 10.1038/nri727; Steiner K, 1999, CLIN EXP IMMUNOL, V115, P451; Trabattoni D, 2003, BLOOD, V101, P2514, DOI 10.1182/blood-2002-10-3065; TSOMIDES TJ, 1994, J EXP MED, V180, P1283, DOI 10.1084/jem.180.4.1283; Yang OO, 1996, J VIROL, V70, P5799, DOI 10.1128/JVI.70.9.5799-5806.1996; Zhang D, 2003, BLOOD, V101, P226, DOI 10.1182/blood-2002-03-0791	26	1995	2114	0	188	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 21	2006	443	7109					350	354		10.1038/nature05115	http://dx.doi.org/10.1038/nature05115			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	085RL	16921384				2022-12-28	WOS:000240622000049
J	Prakriya, M; Feske, S; Gwack, Y; Srikanth, S; Rao, A; Hogan, PG				Prakriya, Murali; Feske, Stefan; Gwack, Yousang; Srikanth, Sonal; Rao, Anjana; Hogan, Patrick G.			Orai1 is an essential pore subunit of the CRAC channel	NATURE			English	Article							ACTIVATED CA2+ CHANNELS; T-LYMPHOCYTES; CALCIUM-CHANNELS; PLASMA-MEMBRANE; I-CRAC; STORE; SELECTIVITY; PERMEATION; CELLS; STIM1	Stimulation of immune cells causes depletion of Ca2+ from endoplasmic reticulum ( ER) stores, thereby triggering sustained Ca2+ entry through store-operated Ca2+ release-activated Ca2+ ( CRAC) channels, an essential signal for lymphocyte activation and proliferation(1,2). Recent evidence indicates that activation of CRAC current is initiated by STIM proteins, which sense ER Ca2+ levels through an EF-hand located in the ER lumen and relocalize upon store depletion into puncta closely associated with the plasma membrane(3-5). We and others recently identified Drosophila Orai and human Orai1 ( also called TMEM142A) as critical components of store- operated Ca2+ entry downstream of STIM6-8. Combined overexpression of Orai and Stim in Drosophila cells(8), or Orai1 and STIM1 in mammalian cells(9-11), leads to a marked increase in CRAC current. However, these experiments did not establish whether Orai is an essential intracellular link between STIM and the CRAC channel, an accessory protein in the plasma membrane, or an actual pore subunit. Here we show that Orai1 is a plasma membrane protein, and that CRAC channel function is sensitive to mutation of two conserved acidic residues in the transmembrane segments. E106D and E190Q substitutions in transmembrane helices 1 and 3, respectively, diminish Ca2+ influx, increase current carried by monovalent cations, and render the channel permeable to Cs+. These changes in ion selectivity provide strong evidence that Orai1 is a pore subunit of the CRAC channel.	Harvard Univ, Sch Med, Boston, MA 02115 USA; CBR Inst Biomed Res, Boston, MA 02115 USA; Northwestern Univ, Feinberg Sch Med, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Northwestern University; Feinberg School of Medicine	Rao, A (corresponding author), Harvard Univ, Sch Med, 200 Longwood Ave, Boston, MA 02115 USA.	arao@cbr.med.harvard.edu	Feske, stefan/ABB-3554-2021	Feske, stefan/0000-0001-5431-8178; Prakriya, Murali/0000-0003-0781-4480				Bakowski D, 2002, PFLUG ARCH EUR J PHY, V443, P892, DOI 10.1007/s00424-001-0775-8; Corry B, 2006, CELL MOL LIFE SCI, V63, P301, DOI 10.1007/s00018-005-5405-8; Eisenberg B, 2003, BIOPHYS CHEM, V100, P507, DOI 10.1016/S0301-4622(02)00302-2; ELLINOR PT, 1995, NEURON, V15, P1121, DOI 10.1016/0896-6273(95)90100-0; Feske S, 2001, NAT IMMUNOL, V2, P316, DOI 10.1038/86318; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; Feske S, 2005, J EXP MED, V202, P651, DOI 10.1084/jem.20050687; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; LeppleWienhues A, 1996, BIOPHYS J, V71, P787, DOI 10.1016/S0006-3495(96)79278-0; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; MERCER JC, 2006, J BIOL CHEM     0628; Owsianik G, 2006, ANNU REV PHYSIOL, V68, P685, DOI 10.1146/annurev.physiol.68.040204.101406; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Peinelt C, 2006, NAT CELL BIOL, V8, P771, DOI 10.1038/ncb1435; Prakriya M, 2002, J GEN PHYSIOL, V119, P487, DOI 10.1085/jgp.20028551; PRAKRIYA M, IN PRESS J GEN PHYSL; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; Sather WA, 2003, ANNU REV PHYSIOL, V65, P133, DOI 10.1146/annurev.physiol.65.092101.142345; Soboloff J, 2006, J BIOL CHEM, V281, P20661, DOI 10.1074/jbc.C600126200; Su ZC, 2004, BIOPHYS J, V86, P805, DOI 10.1016/S0006-3495(04)74156-9; Vig M, 2006, SCIENCE, V312, P1220, DOI 10.1126/science.1127883; Voets T, 2004, J BIOL CHEM, V279, P15223, DOI 10.1074/jbc.M312076200; Voets T, 2003, J GEN PHYSIOL, V121, P245, DOI 10.1085/jgp.20028752; Voets T, 2001, J BIOL CHEM, V276, P47767, DOI 10.1074/jbc.C100607200; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; YEROMIN AV, 2006, NATURE          0820; Zhang SL, 2006, P NATL ACAD SCI USA, V103, P9357, DOI 10.1073/pnas.0603161103; Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	30	1042	1076	2	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 14	2006	443	7108					230	233		10.1038/nature05122	http://dx.doi.org/10.1038/nature05122			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	083OB	16921383				2022-12-28	WOS:000240467000051
J	De Angeli, A; Monachello, D; Ephritikhine, G; Frachisse, JM; Thomine, S; Gambale, F; Barbier-Brygoo, H				De Angeli, A.; Monachello, D.; Ephritikhine, G.; Frachisse, J. M.; Thomine, S.; Gambale, F.; Barbier-Brygoo, H.			The nitrate/proton antiporter AtCLCa mediates nitrate accumulation in plant vacuoles	NATURE			English	Article							TRAIT LOCI ANALYSIS; ANION CHANNEL GENE; CHLORIDE CHANNEL; FUNCTIONAL EXPRESSION; PROKARYOTIC HOMOLOG; ARABIDOPSIS; TRANSPORTER; STORAGE; CLONING	Nitrate, the major nitrogen source for most plants, is widely used as a fertilizer and as a result has become a predominant freshwater pollutant. Plants need nitrate for growth and store most of it in the central vacuole(1). Some members of the chloride channel (CLC) protein family, such as the torpedo-fish ClC-0 and mammalian ClC-1, are anion channels(2,3), whereas the bacterial ClC-ec1 and mammalian ClC-4 and ClC-5 have recently been characterized as Cl-/H+ exchangers with unknown cellular functions(4-6). Plant members of the CLC family are proposed to be anion channels(7,8) involved in nitrate homeostasis(9); however, direct evidence for anion transport mediated by a plant CLC is still lacking. Here we show that Arabidopsis thaliana CLCa (AtCLCa) is localized to an intracellular membrane, the tonoplast of the plant vacuole, which is amenable to electrophysiological studies, and we provide direct evidence for its anion transport ability. We demonstrate that AtCLCa is able to accumulate specifically nitrate in the vacuole and behaves as a NO3-/H+ exchanger. For the first time, to our knowledge, the transport activity of a plant CLC is revealed, the antiporter mechanism of a CLC protein is investigated in a native membrane system, and this property is directly connected with its physiological role.	CNRS, UPR 2355, Inst Sci Vegetal, F-91198 Gif Sur Yvette, France; Univ Paris 07, UFR Biol Sci Nat, F-75251 Paris 05, France; CNR, Ist Biofis, I-16149 Genoa, Italy	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Cite; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biofisica (IBF-CNR)	Barbier-Brygoo, H (corresponding author), CNRS, UPR 2355, Inst Sci Vegetal, 1 Ave Terrasse, F-91198 Gif Sur Yvette, France.	brygoo@isv.cnrs-gif.fr	Jean-Marie, Frachisse/AAE-4350-2022; Frachisse, Jean Marie/AAY-7177-2020; BARBIER-BRYGOO, HELENE/A-8435-2013; Thomine, Sébastien/V-9029-2019	Frachisse, Jean Marie/0000-0002-9755-6536; Thomine, Sebastien/0000-0003-0045-1701				Accardi A, 2005, J GEN PHYSIOL, V126, P563, DOI 10.1085/jgp.200509417; Accardi A, 2004, J GEN PHYSIOL, V123, P109, DOI 10.1085/jgp.200308935; Accardi A, 2004, NATURE, V427, P803, DOI 10.1038/nature02314; BERTL A, 1992, SCIENCE, V258, P873, DOI 10.1126/science.1439795; CERANA R, 1995, AUST J PLANT PHYSIOL, V22, P115, DOI 10.1071/PP9950115; Cookson SJ, 2005, PLANT PHYSIOL, V138, P1097, DOI 10.1104/pp.105.062349; Geelen D, 2000, PLANT J, V21, P259, DOI 10.1046/j.1365-313x.2000.00680.x; Gross E, 1996, J MEMBRANE BIOL, V152, P245, DOI 10.1007/s002329900102; Hafke JB, 2003, PLANT J, V35, P116, DOI 10.1046/j.1365-313X.2003.01781.x; Harada H, 2004, J EXP BOT, V55, P2005, DOI 10.1093/jxb/erh224; Hechenberger M, 1996, J BIOL CHEM, V271, P33632, DOI 10.1074/jbc.271.52.33632; Hurth MA, 2005, PLANT PHYSIOL, V137, P901, DOI 10.1104/pp.104.058453; LANGENHEIM J H, 1973, Acta Amazonica, V3, P5; Loudet O, 2003, GENETICS, V163, P711; Lurin C, 2000, BIOCHEM J, V348, P291, DOI 10.1042/0264-6021:3480291; Lurin C, 1996, PLANT CELL, V8, P701, DOI 10.1105/tpc.8.4.701; MARTINOIA E, 1981, NATURE, V289, P292, DOI 10.1038/289292a0; Miller C., 1980, Annals of the New York Academy of Sciences, V341, P534, DOI 10.1111/j.1749-6632.1980.tb47197.x; Miller C, 2006, NATURE, V440, P484, DOI 10.1038/nature04713; NEHER E, 1992, METHOD ENZYMOL, V207, P123; Pei ZM, 1996, EMBO J, V15, P6564, DOI 10.1002/j.1460-2075.1996.tb01047.x; Picollo A, 2005, NATURE, V436, P420, DOI 10.1038/nature03720; SARAFIAN V, 1992, P NATL ACAD SCI USA, V89, P1775, DOI 10.1073/pnas.89.5.1775; Scheel O, 2005, NATURE, V436, P424, DOI [10.1038/nature03860, 10.1038/nature0386O]; Song WY, 2003, NAT BIOTECHNOL, V21, P914, DOI 10.1038/nbt850; STEINMEYER K, 1991, NATURE, V354, P301, DOI 10.1038/354301a0; Teardo E, 2005, FEBS LETT, V579, P4991, DOI 10.1016/j.febslet.2005.08.005; Thomine S, 2003, PLANT J, V34, P685, DOI 10.1046/j.1365-313X.2003.01760.x	28	349	356	12	152	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 24	2006	442	7105					939	942		10.1038/nature05013	http://dx.doi.org/10.1038/nature05013			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	076LT	16878138				2022-12-28	WOS:000239960500042
J	Loeys, BL; Schwarze, U; Holm, T; Callewaert, BL; Thomas, GH; Pannu, H; De Backer, JF; Oswald, GL; Symoens, S; Manouvrier, S; Roberts, AE; Faravelli, F; Greco, MA; Pyeritz, RE; Milewicz, DM; Coucke, PJ; Cameron, DE; Braverman, AC; Byers, PH; De Paepe, AM; Dietz, HC				Loeys, Bart L.; Schwarze, Ulrike; Holm, Tammy; Callewaert, Bert L.; Thomas, George H.; Pannu, Hariyadarshi; De Backer, Julie F.; Oswald, Gretchen L.; Symoens, Sofie; Manouvrier, Sylvie; Roberts, Amy E.; Faravelli, Francesca; Greco, M. Alba; Pyeritz, Reed E.; Milewicz, Dianna M.; Coucke, Paul J.; Cameron, Duke E.; Braverman, Alan C.; Byers, Peter H.; De Paepe, Anne M.; Dietz, Harry C.			Aneurysm syndromes caused by mutations in the TGF-beta receptor	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SYNDROME TYPE-IV; THORACIC AORTIC-ANEURYSMS; MARFAN-SYNDROME; GENE; DISSECTIONS; DEFECTS	Background: The Loeys-Dietz syndrome is a recently described autosomal dominant aortic-aneurysm syndrome with widespread systemic involvement. The disease is characterized by the triad of arterial tortuosity and aneurysms, hypertelorism, and bifid uvula or cleft palate and is caused by heterozygous mutations in the genes encoding transforming growth factor (beta) receptors 1 and 2 (TGFBR1 and TGFBR2, respectively). Methods: We undertook the clinical and molecular characterization of 52 affected families. Forty probands presented with typical manifestations of the Loeys-Dietz syndrome. In view of the phenotypic overlap between this syndrome and vascular Ehlers-Danlos syndrome, we screened an additional cohort of 40 patients who had vascular Ehlers-Danlos syndrome without the characteristic type III collagen abnormalities or the craniofacial features of the Loeys-Dietz syndrome. Results: We found a mutation in TGFBR1 or TGFBR2 in all probands with typical Loeys-Dietz syndrome (type I) and in 12 probands presenting with vascular Ehlers-Danlos syndrome (Loeys-Dietz syndrome type II). The natural history of both types was characterized by aggressive arterial aneurysms (mean age at death, 26.0 years) and a high incidence of pregnancy-related complications (in 6 of 12 women). Patients with Loeys-Dietz syndrome type I, as compared with those with type II, underwent cardiovascular surgery earlier (mean age, 16.9 years vs. 26.9 years) and died earlier (22.6 years vs. 31.8 years). There were 59 vascular surgeries in the cohort, with one death during the procedure. This low rate of intraoperative mortality distinguishes the Loeys-Dietz syndrome from vascular Ehlers-Danlos syndrome. Conclusions: Mutations in either TGFBR1 or TGFBR2 predispose patients to aggressive and widespread vascular disease. The severity of the clinical presentation is predictive of the outcome. Genotyping of patients presenting with symptoms like those of vascular Ehlers-Danlos syndrome may be used to guide therapy, including the use and timing of prophylactic vascular surgery.	State Univ Ghent Hosp, Ctr Genet Med, B-9000 Ghent, Belgium; Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA; Kennedy Krieger Inst, Baltimore, MD USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA USA; Univ Texas, Dept Med, Houston, TX USA; Univ Hosp, Dept Clin Genet, Lille, France; Harvard Univ, Sch Med, Dept Clin Genet, Boston, MA USA; Osped Galliera, Dept Human Genet, Genoa, Italy; NYU, Sch Med, Dept Pathol, New York, NY USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Howard Hughes Med Inst, Chevy Chase, MD USA	Ghent University; Ghent University Hospital; Johns Hopkins University; Johns Hopkins University; Kennedy Krieger Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Texas System; Universite de Lille - ISITE; CHU Lille; Harvard University; Harvard Medical School; Ente Ospedaliero Ospedali Galliera; New York University; University of Pennsylvania; Washington University (WUSTL); Howard Hughes Medical Institute	Loeys, BL (corresponding author), State Univ Ghent Hosp, Ctr Genet Med, Bldg 0K5,De Pintelaan 185, B-9000 Ghent, Belgium.	bart.loeys@ugent.be	De Backer, Julie/B-2897-2014; Callewaert, Bert/J-6357-2014; Loeys, Bart/B-3236-2017; Coucke, Paul J/AAO-2954-2020	De Backer, Julie/0000-0001-8878-1507; Callewaert, Bert/0000-0002-9743-4205; Loeys, Bart/0000-0003-3703-9518; Coucke, Paul J/0000-0001-7119-586X; Byers, Peter H./0000-0001-7786-7030	NIAMS NIH HHS [AR41135, AR049698] Funding Source: Medline; NICHD NIH HHS [HD24061] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR049698] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Disabella E, 2006, EUR J HUM GENET, V14, P34, DOI 10.1038/sj.ejhg.5201502; Habashi JP, 2006, SCIENCE, V312, P117, DOI 10.1126/science.1124287; Hasham SN, 2003, CIRCULATION, V107, P3184, DOI 10.1161/01.CIR.0000078634.33124.95; Judge DP, 2005, LANCET, V366, P1965, DOI 10.1016/S0140-6736(05)67789-6; Loeys BL, 2005, NAT GENET, V37, P275, DOI 10.1038/ng1511; Lucke CD, 2001, CANCER RES, V61, P482; Mizuguchi T, 2004, NAT GENET, V36, P855, DOI 10.1038/ng1392; Oderich GS, 2005, J VASC SURG, V42, P98, DOI 10.1016/j.jvs.2005.03.053; Pannu H, 2005, CIRCULATION, V112, P513, DOI 10.1161/CIRCULATIONAHA.105.537340; Pepin M, 2000, NEW ENGL J MED, V342, P673, DOI 10.1056/NEJM200003093421001; Pepin M, 2001, NEW ENGL J MED, V344, P392; Schwarze U, 1997, AM J HUM GENET, V61, P1276, DOI 10.1086/301641; SILVERMAN DI, 1995, AM J CARDIOL, V75, P157, DOI 10.1016/S0002-9149(00)80066-1; Wang D, 1997, CARCINOGENESIS, V18, P2285, DOI 10.1093/carcin/18.11.2285	14	1072	1103	4	63	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 24	2006	355	8					788	798		10.1056/NEJMoa055695	http://dx.doi.org/10.1056/NEJMoa055695			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	076KA	16928994				2022-12-28	WOS:000239955200007
J	Schlacher, K; Cox, MM; Woodgate, R; Goodman, MF				Schlacher, Katharina; Cox, Michael M.; Woodgate, Roger; Goodman, Myron F.			RecA acts in trans to allow replication of damaged DNA by DNA polymerase V	NATURE			English	Article							ESCHERICHIA-COLI; TRANSLESION SYNTHESIS; BIOCHEMICAL BASIS; UV-MUTAGENESIS; LESION BYPASS; IN-VITRO; POL V; PROTEIN; COMPLEX; REPAIR	The DNA polymerase V (pol V) and RecA proteins are essential components of a mutagenic translesion synthesis pathway in Escherichia coli designed to cope with DNA damage. Previously, it has been assumed that RecA binds to the DNA template strand being copied. Here we show, however, that pol-V-catalysed translesion synthesis, in the presence or absence of the beta-processivity-clamp, occurs only when RecA nucleoprotein filaments assemble or RecA protomers bind on separate single-stranded ( ss) DNA molecules in trans. A 3'-proximal RecA filament end on trans DNA is essential for stimulation; however, synthesis is strengthened by further pol V - RecA interactions occurring elsewhere along a trans nucleoprotein filament. We suggest that trans-stimulation of pol V by RecA bound to ssDNA reflects a distinctive regulatory mechanism of mutation that resolves the paradox of RecA filaments assembled in cis on a damaged template strand obstructing translesion DNA synthesis despite the absolute requirement of RecA for SOS mutagenesis.	Univ So Calif, Dept Biol Sci & Chem, Los Angeles, CA 90089 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; NICHHD, Sect DNA Replicat Repair & Mutagenesis, NIH, Bethesda, MD 20892 USA	University of Southern California; University of Wisconsin System; University of Wisconsin Madison; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Goodman, MF (corresponding author), Univ So Calif, Dept Biol Sci & Chem, Univ Pk, Los Angeles, CA 90089 USA.	mgoodman@usc.edu		Woodgate, Roger/0000-0001-5581-4616; SCHLACHER, KATHARINA/0000-0001-7226-6391	Intramural NIH HHS Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES029680] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAILONE A, 1991, BIOCHIMIE, V73, P479, DOI 10.1016/0300-9084(91)90115-H; Boudsocq F, 1997, J MOL BIOL, V270, P201, DOI 10.1006/jmbi.1997.1098; BRIDGES BA, 1984, MOL GEN GENET, V196, P364, DOI 10.1007/BF00328073; Drees JC, 2004, MOL CELL, V15, P789, DOI 10.1016/j.molcel.2004.08.026; DUTREIX M, 1989, J BACTERIOL, V171, P2415, DOI 10.1128/jb.171.5.2415-2423.1989; Eggler AL, 2003, J BIOL CHEM, V278, P16389, DOI 10.1074/jbc.M212920200; Frank EG, 2000, J MOL BIOL, V297, P585, DOI 10.1006/jmbi.2000.3591; Friedberg E.C., 2006, DNA REPAIR MUTAGENES, P461; Fujii S, 2004, J MOL BIOL, V341, P405, DOI 10.1016/j.jmb.2004.06.017; Fujii S, 2004, EMBO J, V23, P4342, DOI 10.1038/sj.emboj.7600438; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; Kuzminov A, 1999, MICROBIOL MOL BIOL R, V63, P751, DOI 10.1128/MMBR.63.4.751-813.1999; LAVERY PE, 1992, J BIOL CHEM, V267, P20648; Maor-Shoshani A, 2000, P NATL ACAD SCI USA, V97, P565, DOI 10.1073/pnas.97.2.565; Maor-Shoshani A, 2002, BIOCHEMISTRY-US, V41, P14438, DOI 10.1021/bi0262909; NOHMI T, 1988, P NATL ACAD SCI USA, V85, P1816, DOI 10.1073/pnas.85.6.1816; Pham P, 2001, NATURE, V409, P366, DOI 10.1038/35053116; Pham P, 2002, P NATL ACAD SCI USA, V99, P11061, DOI 10.1073/pnas.172197099; Radman M, 1974, MOL ENV ASPECTS MUTA, P128; Reuven NB, 2001, J BIOL CHEM, V276, P5511, DOI 10.1074/jbc.M006828200; Reuven NB, 1999, J BIOL CHEM, V274, P31763, DOI 10.1074/jbc.274.45.31763; RUPP WD, 1968, J MOL BIOL, V31, P291, DOI 10.1016/0022-2836(68)90445-2; Schlacher K, 2005, MOL CELL, V17, P561, DOI 10.1016/j.molcel.2005.01.006; Sommer S, 1998, MOL MICROBIOL, V28, P281, DOI 10.1046/j.1365-2958.1998.00803.x; SOMMER S, 1993, MOL MICROBIOL, V10, P963, DOI 10.1111/j.1365-2958.1993.tb00968.x; Stohl EA, 2003, J BIOL CHEM, V278, P2278, DOI 10.1074/jbc.M210496200; SWEASY JB, 1990, J BACTERIOL, V172, P3030, DOI 10.1128/jb.172.6.3030-3036.1990; Tang MJ, 1999, P NATL ACAD SCI USA, V96, P8919, DOI 10.1073/pnas.96.16.8919; Tang MJ, 1998, P NATL ACAD SCI USA, V95, P9755, DOI 10.1073/pnas.95.17.9755; VanLoock MS, 2003, STRUCTURE, V11, P187, DOI 10.1016/S0969-2126(03)00003-0; WITKIN EM, 1976, BACTERIOL REV, V40, P869, DOI 10.1128/MMBR.40.4.869-907.1976	31	78	78	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 24	2006	442	7105					883	887		10.1038/nature05042	http://dx.doi.org/10.1038/nature05042			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	076LT	16929290				2022-12-28	WOS:000239960500029
J	Stroscio, JA; Tavazza, F; Crain, JN; Celotta, RJ; Chaka, AM				Stroscio, Joseph A.; Tavazza, Francesca; Crain, Jason N.; Celotta, Robert J.; Chaka, Anne M.			Electronically induced atom motion engineered CoCun nanostructures	SCIENCE			English	Article							SCANNING TUNNELING MICROSCOPE; SINGLE-MOLECULE CHEMISTRY; MANIPULATION; EXCITATION; DYNAMICS; TIP	We have measured the quantum yield for exciting the motion of a single Co atom in CoCun linear molecules constructed on a Cu(111) surface. The Co atom switched between two lattice positions during electron excitation from the tip of a scanning tunneling microscope. The tip location with highest probability for inducing motion was consistent with the position of an active state identified through electronic structure calculations. Atom motion within the molecule decreased with increased molecular length and reflected the corresponding variation in electronic structure.	Natl Inst Stand & Technol, Ctr Nanoscale Sci & Technol, Gaithersburg, MD 20899 USA; Natl Inst Stand & Technol, Chem Sci & Technol Lab, Gaithersburg, MD 20899 USA	National Institute of Standards & Technology (NIST) - USA; National Institute of Standards & Technology (NIST) - USA	Stroscio, JA (corresponding author), Natl Inst Stand & Technol, Ctr Nanoscale Sci & Technol, Gaithersburg, MD 20899 USA.	joseph.stroscio@nist.gov						Bartels L, 1997, PHYS REV LETT, V79, P697, DOI 10.1103/PhysRevLett.79.697; EIGLER DM, 1991, NATURE, V352, P600, DOI 10.1038/352600a0; EIGLER DM, 1990, NATURE, V344, P524, DOI 10.1038/344524a0; Folsch S, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.056803; GADZUK JW, 1991, PHYS REV B, V44, P13466, DOI 10.1103/PhysRevB.44.13466; Gao SW, 1997, PHYS REV B, V55, P4825, DOI 10.1103/PhysRevB.55.4825; Heinrich AJ, 2002, SCIENCE, V298, P1381, DOI 10.1126/science.1076768; Ho W, 2002, J CHEM PHYS, V117, P11033, DOI 10.1063/1.1521153; Komeda T, 2002, SCIENCE, V295, P2055, DOI 10.1126/science.1069016; Kwon KY, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.166101; Lastapis M, 2005, SCIENCE, V308, P1000, DOI 10.1126/science.1108048; Pascual JI, 2003, NATURE, V423, P525, DOI 10.1038/nature01649; PERSSON BNJ, 1987, PHYS REV LETT, V59, P339, DOI 10.1103/PhysRevLett.59.339; SALAM GP, 1994, PHYS REV B, V49, P10655, DOI 10.1103/PhysRevB.49.10655; Stipe BC, 1998, SCIENCE, V279, P1907, DOI 10.1126/science.279.5358.1907; STROSCIO JA, 1991, SCIENCE, V254, P1319, DOI 10.1126/science.254.5036.1319; Stroscio JA, 2004, SCIENCE, V306, P242, DOI 10.1126/science.1102370	17	53	53	1	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 18	2006	313	5789					948	951		10.1126/science.1129788	http://dx.doi.org/10.1126/science.1129788			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	074MR	16917056				2022-12-28	WOS:000239817000037
J	Woodward, LJ; Anderson, PJ; Austin, NC; Howard, K; Inder, TE				Woodward, Lianne J.; Anderson, Peter J.; Austin, Nicola C.; Howard, Kelly; Inder, Terrie E.			Neonatal MRI to predict neurodevelopmental outcomes in preterm infants	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOW-BIRTH-WEIGHT; WHITE-MATTER INJURY; EARLY BRAIN-INJURY; PREMATURE-INFANT; SCHOOL-AGE; CEREBRAL-PALSY; CRANIAL ULTRASOUND; LUNG-DISEASE; CHILDREN; TERM	BACKGROUND: Very preterm infants are at high risk for adverse neurodevelopmental outcomes. Magnetic resonance imaging (MRI) has been proposed as a means of predicting neurodevelopmental outcomes in this population. METHODS: We studied 167 very preterm infants (gestational age at birth, 30 weeks or less) to assess the associations between qualitatively defined white-matter and gray-matter abnormalities on MRI at term equivalent (gestational age of 40 weeks) and the risks of severe cognitive delay, severe psychomotor delay, cerebral palsy, and neurosensory (hearing or visual) impairment at 2 years of age (corrected for prematurity). RESULTS: At two years of age, 17 percent of infants had severe cognitive delay, 10 percent had severe psychomotor delay, 10 percent had cerebral palsy, and 11 percent had neurosensory impairment. Moderate-to-severe cerebral white-matter abnormalities present in 21 percent of infants at term equivalent were predictive of the following adverse outcomes at two years of age: cognitive delay (odds ratio, 3.6; 95 percent confidence interval, 1.5 to 8.7), motor delay (odds ratio, 10.3; 95 percent confidence interval, 3.5 to 30.8), cerebral palsy (odds ratio, 9.6; 95 percent confidence interval, 3.2 to 28.3), and neurosensory impairment (odds ratio, 4.2; 95 percent confidence interval, 1.6 to 11.3). Gray-matter abnormalities (present in 49 percent of infants) were also associated, but less strongly, with cognitive delay, motor delay, and cerebral palsy. Moderate-to-severe white-matter abnormalities on MRI were significant predictors of severe motor delay and cerebral palsy after adjustment for other measures during the neonatal period, including findings on cranial ultrasonography. CONCLUSIONS: Abnormal findings on MRI at term equivalent in very preterm infants strongly predict adverse neurodevelopmental outcomes at two years of age. These findings suggest a role for MRI at term equivalent in risk stratification for these infants.	Univ Canterbury, Canterbury Child Dev Res Grp, Dept Psychol, Christchurch 1, New Zealand; Van der Veer Inst Parkinsons & Brain Res, Christchurch, New Zealand; Christchurch Womens Hosp, Christchurch, New Zealand; Murdoch Childrens Res Inst, Melbourne, Vic, Australia; Univ Melbourne, Dept Psychol, Melbourne, Vic, Australia; Washington Univ, St Louis Childrens Hosp, Dept Pediat, St Louis, MO USA; Washington Univ, St Louis Childrens Hosp, Dept Neurol, St Louis, MO USA; Washington Univ, St Louis Childrens Hosp, Dept Radiol, St Louis, MO USA	University of Canterbury; Murdoch Children's Research Institute; University of Melbourne; St. Louis Children's Hospital; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL)	Woodward, LJ (corresponding author), Univ Canterbury, Canterbury Child Dev Res Grp, Dept Psychol, Private Bag 4800, Christchurch 1, New Zealand.	lianne.woodward@canterbury.ac.nz	Anderson, Peter John/O-5302-2019; Anderson, Peter J/B-6839-2015; Fahimifar, Sepideh/M-5303-2019	Anderson, Peter John/0000-0001-7430-868X; Anderson, Peter J/0000-0001-7430-868X; 				Aida N, 1998, AM J NEURORADIOL, V19, P1909; Ajayi-Obe M, 2000, LANCET, V356, P1162, DOI 10.1016/S0140-6736(00)02761-6; Allen MC, 2002, MENT RETARD DEV D R, V8, P221, DOI 10.1002/mrdd.10044; Anderson NG, 2004, ULTRASOUND MED BIOL, V30, P11, DOI 10.1016/j.ultrasmedbio.2003.10.001; Anderson P, 2003, JAMA-J AM MED ASSOC, V289, P3264, DOI 10.1001/jama.289.24.3264; Bayley N, 1993, BAYLEY SCALES INFANT; Bracewell M, 2002, MENT RETARD DEV D R, V8, P241, DOI 10.1002/mrdd.10049; Hack M, 2005, PEDIATRICS, V116, P333, DOI 10.1542/peds.2005-0173; Hintz SR, 2005, PEDIATRICS, V115, P1645, DOI 10.1542/peds.2004-2215; Horbar JD, 2002, PEDIATRICS, V110, P143, DOI 10.1542/peds.110.1.143; Huppi PS, 1996, PEDIATR RES, V39, P895; Inder TE, 1999, ANN NEUROL, V46, P755, DOI 10.1002/1531-8249(199911)46:5<755::AID-ANA11>3.0.CO;2-0; Inder TE, 2003, AM J NEURORADIOL, V24, P805; Inder TE, 2003, J PEDIATR-US, V143, P171, DOI 10.1067/S0022-3476(03)00357-3; Inder TE, 2005, PEDIATRICS, V115, P286, DOI 10.1542/peds.2004-0326; Kwong KL, 2004, PEDIATR NEUROL, V31, P172, DOI 10.1016/j.pediatrneurol.2004.02.005; Laptook AR, 2005, PEDIATRICS, V115, P673, DOI 10.1542/peds.2004-0667; Maalouf EF, 2001, PEDIATRICS, V107, P719, DOI 10.1542/peds.107.4.719; Maalouf EF, 1999, J PEDIATR-US, V135, P351, DOI 10.1016/S0022-3476(99)70133-2; Marlow N, 2005, NEW ENGL J MED, V352, P9, DOI 10.1056/NEJMoa041367; Mercuri E, 1999, NEUROPEDIATRICS, V30, P83, DOI 10.1055/s-2007-973465; Miller SP, 2005, J PEDIATR-US, V147, P609, DOI 10.1016/j.jpeds.2005.06.033; Mirmiran M, 2004, PEDIATRICS, V114, P992, DOI 10.1542/peds.2003-0772-L; Msall ME, 2002, MENT RETARD DEV D R, V8, P258, DOI 10.1002/mrdd.10046; Murphy BP, 2001, PEDIATRICS, V107, P217, DOI 10.1542/peds.107.2.217; O'Shea TM, 1999, PEDIATRICS, V104, P15, DOI 10.1542/peds.104.1.15; Palisano R, 1997, DEV MED CHILD NEUROL, V39, P214, DOI 10.1111/j.1469-8749.1997.tb07414.x; Peterson BS, 2003, PEDIATRICS, V111, P939, DOI 10.1542/peds.111.5.939; Shin'oka T, 1998, ANN THORAC SURG, V65, P155, DOI 10.1016/S0003-4975(97)00909-0; Taylor HG, 2000, CHILD DEV, V71, P1495, DOI 10.1111/1467-8624.00242; Woodward LJ, 2005, BRAIN, V128, P2578, DOI 10.1093/brain/awh618; Woodward LJ, 2004, J DEV BEHAV PEDIATR, V25, P326, DOI 10.1097/00004703-200410000-00004; Yeh TF, 2004, NEW ENGL J MED, V350, P1304, DOI 10.1056/NEJMoa032089	33	876	891	0	75	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 17	2006	355	7					685	694		10.1056/NEJMoa053792	http://dx.doi.org/10.1056/NEJMoa053792			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	074AN	16914704				2022-12-28	WOS:000239784500007
J	Chang, HK; King, SK; Liang, JS; Wu, PS; Lin, LCC; Chiu, JL				Chang, Hsiang-Kuang; King, Sun-Kun; Liang, Jau-Shian; Wu, Ping-Shien; Lin, Lupin Chun-Che; Chiu, Jeng-Lun			Occultation of X-rays from Scorpius X-1 by small trans-neptunian objects	NATURE			English	Article							QUASI-PERIODIC OSCILLATIONS; KUIPER-BELT OBJECTS; SIZE DISTRIBUTION; DISCOVERY	Since the discovery(1) of the trans- neptunian objects ( TNOs) in 1992, nearly one thousand new members have been added to our Solar System(2,3), several of which are as big as - or even larger than - Pluto(4,5). The properties of the population of TNOs, such as the size distribution and the total number, are valuable information for understanding the formation of the Solar System, but direct observation is only possible for larger objects with diameters above several tens of kilometres. Smaller objects, which are expected to be more abundant, might be found when they occult background stars(6-10), but hitherto there have been no definite detections. Here we report the discovery of such occultation events at millisecond timescales in the X- ray light curve of Scorpius X- 1. The estimated sizes of these occulting TNOs are <= 100 m. Their abundance is in line with an extrapolation of the distribution(2) of sizes of larger TNOs.	Natl Tsing Hua Univ, Dept Phys, Hsinchu 30013, Taiwan; Natl Tsing Hua Univ, Inst Astron, Hsinchu 30013, Taiwan; Acad Sinica, Inst Astron & Astrophys, Taipei 10617, Taiwan	National Tsing Hua University; National Tsing Hua University; Academia Sinica - Taiwan	Chang, HK (corresponding author), Natl Tsing Hua Univ, Dept Phys, Hsinchu 30013, Taiwan.	hkchang@phys.nthu.edu.tw		Lin, Lupin Chun-Che/0000-0003-4083-9567; Chang, Hsiang-Kuang/0000-0002-5617-3117				Alcock C, 2003, EARTH MOON PLANETS, V92, P459, DOI 10.1023/B:MOON.0000031960.82021.26; BAILEY ME, 1976, NATURE, V259, P290, DOI 10.1038/259290a0; Barnard R, 2003, ASTRON ASTROPHYS, V405, P237, DOI 10.1051/0004-6361:20030539; Bernstein GM, 2004, ASTRON J, V128, P1364, DOI 10.1086/422919; Bertoldi F, 2006, NATURE, V439, P563, DOI 10.1038/nature04494; Bradshaw CF, 1999, ASTROPHYS J, V512, pL121, DOI 10.1086/311889; Bradshaw CF, 2003, ASTROPHYS J, V592, P486, DOI 10.1086/375577; BRADT HV, 1993, ASTRON ASTROPHYS SUP, V97, P355; BROWN ME, 2005, 8577 IAU; Brown MJI, 1997, MON NOT R ASTRON SOC, V289, P783, DOI 10.1093/mnras/289.4.783; Cooray A, 2003, ASTROPHYS J, V587, pL125, DOI 10.1086/375288; GIACCONI R, 1962, PHYS REV LETT, V9, P439, DOI 10.1103/PhysRevLett.9.439; Gierlinski M, 2003, MON NOT R ASTRON SOC, V343, pL84, DOI 10.1046/j.1365-8711.2003.06890.x; Jahoda K, 1999, NUCL PHYS B-PROC SUP, V69, P210, DOI 10.1016/S0920-5632(98)00210-2; JEWITT D, 1993, NATURE, V362, P730, DOI 10.1038/362730a0; Kenyon SJ, 2004, ASTRON J, V128, P1916, DOI 10.1086/423697; Kenyon SJ, 2002, PUBL ASTRON SOC PAC, V114, P265, DOI 10.1086/339188; Luu JX, 2002, ANNU REV ASTRON ASTR, V40, P63, DOI 10.1146/annurev.astro.40.060401.093818; MIDDLEDITCH J, 1986, ASTROPHYS J, V306, P230, DOI 10.1086/164335; Roques F, 2003, ASTROPHYS J, V594, pL63, DOI 10.1086/378576; SCARGLE JD, 1993, ASTROPHYS J, V411, pL91, DOI 10.1086/186920; Steeghs D, 2002, ASTROPHYS J, V568, P273, DOI 10.1086/339224; Trujillo CA, 2001, ASTRON J, V122, P457, DOI 10.1086/321117; Uttley P, 2005, MON NOT R ASTRON SOC, V359, P345, DOI 10.1111/j.1365-2966.2005.08886.x; vanderKlis M, 1997, ASTROPHYS J, V481, pL97, DOI 10.1086/310656	25	28	28	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 10	2006	442	7103					660	663		10.1038/nature04941	http://dx.doi.org/10.1038/nature04941			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	071UU	16900194				2022-12-28	WOS:000239630200039
J	Carrese, JA				Carrese, Joseph A.			Refusal of care: Patients' well-being and physicians' ethical obligations - "But doctor, I want to go home"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PREFERENCES; STABILITY; ATTITUDES	Honoring patients' wishes becomes difficult when doing so threatens their well-being. In this article, the case of a hospitalized elderly woman is presented. The patient, ready for discharge, insists on returning home, yet she is bedbound and lacks adequate social support and financial resources to manage safely. The medical team, troubled by this situation, requests an ethics consultation. The article discusses several issues related to the difficult ethical problem posed by this case, including a brief historical review of the patient's role in decision making, current thinking about patients' rights vis-a-vis patients' well-being, assessing patients' capacity to make sound decisions, consideration of physician values, and, finally, responding to patients' refusal of care.	Johns Hopkins Univ, Johns Hopkins Bayview Med Ctr, Dept Med, Div Gen Internal Med, Baltimore, MD 21224 USA; Johns Hopkins Univ, Phoebe R Berman Bioeth Inst, Program Eth Clin Practice, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	Carrese, JA (corresponding author), Johns Hopkins Univ, Johns Hopkins Bayview Med Ctr, Dept Med, Div Gen Internal Med, 4940 Eastern Ave, Baltimore, MD 21224 USA.	jcarrese@jhmi.edu						Beauchamp T L, 2012, PRINCIPLES BIOMEDICA; Bekelman DB, 2006, J FAM PRACTICE, V55, P403; BROCK DW, 1990, NEW ENGL J MED, V322, P1595, DOI 10.1056/NEJM199005313222209; Buchanan Allen E., 1989, DECIDING OTHERS ETHI; Carmel S, 1999, SOC SCI MED, V49, P303, DOI 10.1016/S0277-9536(99)00121-5; Carrese JA, 2000, J GEN INTERN MED, V15, P92, DOI 10.1046/j.1525-1497.2000.03399.x; FITTS WT, 1953, JAMA-J AM MED ASSOC, V153, P901, DOI 10.1001/jama.1953.02940270007002; Grisso T, 1997, PSYCHIATR SERV, V48, P1415; GRISSO T, 1908, ASSESSING COMPETENCE; JECKER NS, 1995, HASTINGS CENT REP, V25, P6, DOI 10.2307/3562484; Jonsen A R, 1986, Crit Care Clin, V2, P91; JONSEN AR, 2002, CLIN ETHICS, P55; McParland E, 2003, MT SINAI J MED, V70, P85; NOVACK DH, 1979, JAMA-J AM MED ASSOC, V241, P897, DOI 10.1001/jama.241.9.897; OKEN D, 1961, JAMA-J AM MED ASSOC, V175, P1120, DOI 10.1001/jama.1961.03040130004002; Pellegrino E., 1988, PATIENTS GOOD RESTOR; QUILL TE, 1995, ANN INTERN MED, V122, P368, DOI 10.7326/0003-4819-122-5-199503010-00008; REICH WT, 1995, PRINCIPLES MED ETHIC, V5, P2649; REICH WT, 1995, ENCY BIOETHICS, V5, P2641; Rosenfeld KE, 1996, ARCH INTERN MED, V156, P1558, DOI 10.1001/archinte.156.14.1558; Snyder L, 2005, ANN INTERN MED, V142, P560, DOI 10.7326/0003-4819-142-7-200504050-00014; Starr P, 1982, SOCIAL TRANSFORMATIO; Weissman JS, 1999, MED DECIS MAKING, V19, P16, DOI 10.1177/0272989X9901900103	23	31	32	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 9	2006	296	6					691	695		10.1001/jama.296.6.691	http://dx.doi.org/10.1001/jama.296.6.691			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	071LN	16896112				2022-12-28	WOS:000239603800031
J	Mills, EJ; Nachega, JB; Buchan, I; Orbinski, J; Attaran, A; Singh, S; Rachlis, B; Wu, P; Cooper, C; Thabane, L; Wilson, K; Guyatt, GH; Bangsberg, DR				Mills, Edward J.; Nachega, Jean B.; Buchan, Iain; Orbinski, James; Attaran, Amir; Singh, Sonal; Rachlis, Beth; Wu, Ping; Cooper, Curtis; Thabane, Lehana; Wilson, Kumanan; Guyatt, Gordon H.; Bangsberg, David R.			Adherence to antiretroviral therapy in sub-Saharan Africa and North America - A meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HIV-INFECTED PERSONS; QUALITY-OF-LIFE; MEDICATION ADHERENCE; SOUTH-AFRICA; PROTEASE INHIBITORS; REPORTED ADHERENCE; DRUG-RESISTANCE; HAART ADHERENCE; SUBSTANCE USE; VIRAL LOAD	Context Adherence to antiretroviral therapy is a powerful predictor of survival for individuals living with human immunodeficiency virus (HIV) and AIDS. Concerns about incomplete adherence among patients living in poverty have been an important consideration in expanding the access to antiretroviral therapy in sub-Saharan Africa. Objective To evaluate estimates of antiretroviral therapy adherence in sub-Saharan Africa and North America. Data Sources Eleven electronic databases were searched along with major conference abstract databases (inclusion dates: inception of database up until April 18, 2006) for all English-language articles and abstracts; and researchers and treatment advocacy groups were contacted. Study Selection and Data Abstraction To best reflect the general population, studies of mixed populations in both North America and Africa were selected. Studies evaluating specific populations such as men only, homeless individuals, or drug users, were excluded. The data were abstracted in duplicate on study adherence outcomes, thresholds used to determine adherence, and characteristics of the populations. A random-effects meta-analysis was performed in which heterogeneity was examined using multivariable random-effects logistic regression. A sensitivity analysis was performed using Bayesian methods. Data Synthesis Thirty-one studies from North America (28 full-text articles and 3 abstracts) and 27 studies (9 full-text articles and 18 abstracts) from sub-Saharan Africa were included. African studies represented 12 sub-Saharan countries. Of the North American studies, 71% used patient self-report to assess adherence; this was true of 66% of the African assessments. Studies reported similar thresholds for adherence monitoring (eg, 100%, > 95%, > 90%, > 80%). A pooled analysis of the North American studies (17 573 patients total) indicated a pooled estimate of 55% (95% confidence interval, 49%-62%; I-2, 98.6%) of the populations achieving adequate levels of adherence. Our pooled analysis of African studies (12 116 patients total) indicated a pooled estimate of 77% (95% confidence interval, 68%-85%; I-2, 98.4%). Study continent, adherence thresholds, and study quality were significant predictors of heterogeneity. Bayesian analysis was used as an alternative statistical method for combining adherence rates and provided similar findings. Conclusion Our findings indicate that favorable levels of adherence, much of which was assessed via patient self-report, can be achieved in sub-Saharan African settings and that adherence remains a concern in North America.	Ctr Int Hlth & Human Rights Studies, Toronto, ON, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; Univ Cape Town, Dept Med, Div Clin Pharmacol, ZA-7925 Cape Town, South Africa; Univ Manchester, Sch Med, NW Inst Biohlth Informat, Manchester, Lancs, England; St Michaels Hosp, Toronto, ON M5B 1W8, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Ottawa, Ctr Global Hlth, Ottawa, ON, Canada; Univ Ottawa, Ottawa Hosp, Div Infect Dis, Ottawa, ON, Canada; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, MPH Program, Baltimore, MD USA; Wake Forest Univ, Dept Med, Winston Salem, NC 27109 USA; St Pauls Hosp, British Columbia Ctr Excellence HIV AIDS, Vancouver, BC V6Z 1Y6, Canada; London Sch Hyg & Trop Med, Dept Epidemiol, London WC1, England; Univ Calif San Francisco, San Francisco Gen Hosp, Epidemiol & Prevent Intervent Ctr, San Francisco, CA USA	McMaster University; University of Cape Town; University of Manchester; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Wake Forest University; B.C. Centre for Excellence in HIV/AIDS; St. Paul's Hospital; University of Saskatchewan; University of London; London School of Hygiene & Tropical Medicine; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	Mills, EJ (corresponding author), Ctr Int Hlth & Human Rights Studies, 1255 Sheppard Ave E, N York, ON M2K 1E2, Canada.	emills@cihhrs.org	Buchan, Iain E/H-5767-2013; Singh, Sonal/A-4614-2008; Franzeck, Fabian C/B-5055-2011; Cooper, Curtis/M-9320-2019	Buchan, Iain E/0000-0003-3392-1650; Singh, Sonal/0000-0003-0912-941X; Nachega, Jean/0000-0002-2862-4443	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027763] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH054907] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [K24AA015287] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA015287] Funding Source: Medline; NIAID NIH HHS [AI27763, AI005535901] Funding Source: Medline; NIMH NIH HHS [R01 MH054907, MH54907] Funding Source: Medline; PHS HHS [K23A106858201] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Acri T, 2005, AIDS PATIENT CARE ST, V19, P167, DOI 10.1089/apc.2005.19.167; ADEDAYO A, 2005, 12 C RETR OPP INF FE; AKAM A, 2004, 15 INT AIDS C JUL 11; Akileswaran C, 2005, CLIN INFECT DIS, V41, P376, DOI 10.1086/431482; Altice FL, 2001, J ACQ IMMUN DEF SYND, V28, P47, DOI 10.1097/00042560-200109010-00008; Attaran A, 2001, WASHINGTON POST 0615, pA33; Bangsberg DR, 2006, AIDS, V20, P140, DOI 10.1097/01.aids.0000196168.50303.31; Bangsberg DR, 2003, AIDS, V17, P1925, DOI 10.1097/00002030-200309050-00011; Bangsberg DR, 2000, AIDS, V14, P357, DOI 10.1097/00002030-200003100-00008; Bangsberg DR, 2001, AIDS, V15, P1181, DOI 10.1097/00002030-200106150-00015; Becker Stephen L, 2002, MedGenMed, V4, P21; Berlin JA, 1997, LANCET, V350, P185, DOI 10.1016/S0140-6736(05)62352-5; BOILEU C, 2005, 12 C RETR OPP INF FE; Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2; BROWN S, 2004, 15 INT AIDS C JUL 11; BYAKIKA J, 2005, 12 C RETR OPP INF FE; Byakika-Tusiime J, 2005, INT J STD AIDS, V16, P38, DOI 10.1258/0956462052932548; Castillo E, 2004, AIDS CARE, V16, P446, DOI 10.1080/09540120410001683385; Cook RL, 2001, J GEN INTERN MED, V16, P83, DOI 10.1111/j.1525-1497.2001.00122.x; CRANE JT, 2006, AIDS BEHAV      0425; DANIEL O, 2004, 15 INT AIDS C JUL 11; DARDER M, 2004, 15 INT AIDS C JUL 11; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Diamond C, 2005, JAIDS-J ACQ IMM DEF, V39, P211; EHOLIE E, 2004, 15 INT AIDS C JUL 11; Eldred LJ, 1998, J ACQ IMMUN DEF SYND, V18, P117, DOI 10.1097/00042560-199806010-00003; Farmer P, 2001, LANCET, V358, P404, DOI 10.1016/S0140-6736(01)05550-7; Ferguson TF, 2002, AIDS CARE, V14, P607, DOI 10.1080/0954012021000005434; FERRIS D, 2004, 15 INT AIDS C JUL 11; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; Gebo KA, 2003, J GEN INTERN MED, V18, P104, DOI 10.1046/j.1525-1497.2003.10801.x; Gifford AL, 2000, J ACQ IMMUN DEF SYND, V23, P386; Gill CJ, 2005, AIDS, V19, P1243, DOI 10.1097/01.aids.0000180094.04652.3b; Graney Marshall J, 2003, Tenn Med, V96, P73; Harries AD, 2001, LANCET, V358, P410, DOI 10.1016/S0140-6736(01)05551-9; Heckman BD, 2004, AIDS CARE, V16, P219, DOI 10.1080/09540120410001641066; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hinkin CH, 2004, AIDS, V18, pS19, DOI 10.1097/00002030-200418001-00004; HOSSEINIPOUR MC, 2004, EJOURNAL INT AIDS SO; Idigbe EO, 2005, JAIDS-J ACQ IMM DEF, V40, P65, DOI 10.1097/01.qai.0000159516.39982.1b; Iliyasu Z, 2005, Niger J Med, V14, P290; Ingersoll KS, 2005, AIDS BEHAV, V9, P89, DOI 10.1007/s10461-005-1684-1; Jaynes E.T., 1976, FDN PROBABILITY THEO, VII, P175, DOI DOI 10.1007/978-94-010-1436-6_6; Johnson MO, 2005, J PAIN SYMPTOM MANAG, V29, P193, DOI 10.1016/j.jpainsymman.2004.05.005; *JOINT UN PROGR HI, UN WORLD AIDS; Kalichman SC, 2005, HEALTH EDUC RES, V20, P24, DOI 10.1093/her/cyg106; KARCHER H, 2004, EJOURNAL INT AIDS SO; Laniece I, 2003, AIDS, V17, pS103, DOI 10.1097/00002030-200317003-00014; Laurent C, 2002, AIDS, V16, P1363, DOI 10.1097/00002030-200207050-00008; Laurent C, 2004, LANCET, V364, P29, DOI 10.1016/S0140-6736(04)16586-0; Levine AJ, 2005, AIDS BEHAV, V9, P355, DOI 10.1007/s10461-005-9009-y; Liechty CA, 2003, AIDS, V17, P1383, DOI 10.1097/00002030-200306130-00013; Liu HH, 2001, ANN INTERN MED, V134, P968, DOI 10.7326/0003-4819-134-10-200105150-00011; Mannheimer SB, 2005, AIDS CARE, V17, P10, DOI 10.1080/09540120412331305098; Meade MO, 2001, AM J RESP CRIT CARE, V163, P490, DOI 10.1164/ajrccm.163.2.2006067; MILLS E, 2005, ONT HIV TREATM NETW; Mohammed H, 2004, AIDS PATIENT CARE ST, V18, P289, DOI 10.1089/108729104323076025; MONTESSORI V, 2000, 7 C RETR OPP INF FEB; Moss AR, 2004, CLIN INFECT DIS, V39, P1190, DOI 10.1086/424008; MUGANZI A, 2004, 15 INT AIDS C JUL 11; NACHEGA J, 2005, 12 C RETR OPP INF FE; Nachega JB, 2005, JAIDS-J ACQ IMM DEF, V38, P196, DOI 10.1097/00126334-200502010-00011; Nachega JB, 2004, AIDS RES HUM RETROV, V20, P1053, DOI 10.1089/aid.2004.20.1053; NACHEGA JB, 2005, STAT SCI M RES IMPR; OKONGO B, 2004, 15 INT AIDS C JUL 11; OMES C, 2004, 15 INT AIDS C JUL 11; Orrell C, 2003, AIDS, V17, P1369, DOI 10.1097/00002030-200306130-00011; Orrell Catherine, 2005, Curr HIV/AIDS Rep, V2, P171, DOI 10.1007/s11904-005-0012-8; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; Palepu A, 2003, JAIDS-J ACQ IMM DEF, V32, P522, DOI 10.1097/00126334-200304150-00009; Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004; Penedo FJ, 2003, J PSYCHOSOM RES, V54, P271, DOI 10.1016/S0022-3999(02)00482-8; Power R, 2003, AIDS PATIENT CARE ST, V17, P245, DOI 10.1089/108729103321655890; RAMADHANI HO, 2006, 13 C RETR OPP INF FE; Robert C.P., 2000, TECHNOMETRICS, V42, P430, DOI [10.2307/1270959, DOI 10.2307/1270959]; ROBERTSON K, 2006, 13 C RETR OPP INF FE; RUEDA S, 2005, ONT HIV TREATM NETW; Russell J, 2004, J ASSOC NURSE AIDS C, V15, P40, DOI 10.1177/1055329004269283; Samet JH, 2004, ALCOHOL CLIN EXP RES, V28, P572, DOI 10.1097/01.ALC.0000122103.74491.78; Schneider J, 2004, J GEN INTERN MED, V19, P1096, DOI 10.1111/j.1525-1497.2004.30418.x; Severe P, 2005, NEW ENGL J MED, V353, P2325, DOI 10.1056/NEJMoa051908; SHIHAB H, 2004, 15 INT AIDS C JUL 11; Stuart A, 1994, KENDALLS ADV THEORY; TEMOSHOK L, 2004, 15 INT AIDS C JUL 11; Tesoriero J, 2003, JAIDS-J ACQ IMM DEF, V33, P484, DOI 10.1097/00126334-200308010-00009; TRAORE A, 2004, 15 INT AIDS C JUL 11; TU D, 2004, 15 INT AIDS C JUL 11; Tucker JS, 2003, AM J MED, V114, P573, DOI 10.1016/S0002-9343(03)00093-7; van Oosterhout JJ, 2005, TROP MED INT HEALTH, V10, P464, DOI 10.1111/j.1365-3156.2005.01409.x; Vist GE, 2005, BMJ-BRIT MED J, V330, P1175, DOI 10.1136/bmj.330.7501.1175; Wagner GJ, 2002, AIDS CARE, V14, P105, DOI 10.1080/09540120220097973; Weiser S, 2003, JAIDS-J ACQ IMM DEF, V34, P281, DOI 10.1097/00126334-200311010-00004; Weiss L, 2003, AIDS CARE, V15, P673, DOI 10.1080/09540120310001595159; *WHO WEB SIT, 3 5 IN COUNTR PROF; Wilson IB, 2001, J ACQ IMMUN DEF SYND, V28, P259, DOI 10.1097/00042560-200111010-00009; Wood E, 2003, CAN MED ASSOC J, V169, P656; Wood E, 2003, AIDS, V17, P711, DOI 10.1097/00002030-200303280-00009; Wood E, 2002, AIDS, V16, P2065, DOI 10.1097/00002030-200210180-00012; 2005, LANCET, V365, P1597	99	641	654	1	45	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 9	2006	296	6					679	690		10.1001/jama.296.6.679	http://dx.doi.org/10.1001/jama.296.6.679			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	071LN	16896111				2022-12-28	WOS:000239603800030
J	Wenzel, SE				Wenzel, Sally E.			Asthma: defining of the persistent adult phenotypes	LANCET			English	Review							EXHALED NITRIC-OXIDE; EOSINOPHILIC AIRWAY INFLAMMATION; LEUKOTRIENE C-4 SYNTHASE; ASPIRIN-INDUCED ASTHMA; BRONCHIAL BIOPSIES; INDUCED SPUTUM; NEUTROPHILIC INFLAMMATION; MESSENGER-RNA; LUNG-FUNCTION; INHALED CORTICOSTEROIDS	The common disease asthma is probably not a single disease, but rather a complex of multiple, separate syndromes that overlap. Although clinicians have recognised these different phenotypes for many years, they have remained poorly characterised, with little known about the underlying pathobiology contributing to them. Development of targeted therapies for asthma, and phenotype-specific clinical trials have raised interest in these phenotypes. Improved understanding of these phenotypes in complex diseases such as asthma will also improve our ability to link specific genotypes to their associated disease, which should help development of biomarkers. However, there is no standardised method to define asthma phenotypes. This Review analyses some of the methods that have been used to define asthma phenotypes and proposes an integrated method of classification to improve our understanding of these phenotypes.	Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA	National Jewish Health	Wenzel, SE (corresponding author), Natl Jewish Med & Res Ctr, Dept Med, 1400 Jackson St, Denver, CO 80206 USA.	wenzels@njc.org						Abraham B, 2003, EUR RESPIR J, V22, P470, DOI 10.1183/09031936.03.00261903; Adcock IM, 2004, CURR OPIN PHARMACOL, V4, P257, DOI 10.1016/j.coph.2004.02.001; Ayres JG, 1998, THORAX, V53, P315, DOI 10.1136/thx.53.4.315; Bacci E, 2006, CHEST, V129, P565, DOI 10.1378/chest.129.3.565; Balkissoon RC, 2006, AM THOR SOC ANN M SA, pA15; Balzar S, 2005, J ALLERGY CLIN IMMUN, V115, P110, DOI 10.1016/j.jaci.2004.09.034; Barnes PJ, 2005, EUR RESPIR J, V25, P1084, DOI 10.1183/09031936.05.00139104; Barreiro E, 2004, EUR RESPIR J, V24, P219, DOI 10.1183/09031936.04.00074703; Berry M, 2005, EUR RESPIR J, V25, P986, DOI 10.1183/09031936.05.00132404; Berry MA, 2006, NEW ENGL J MED, V354, P697, DOI 10.1056/NEJMoa050580; Berry MA, 2005, CLIN EXP ALLERGY, V35, P1175, DOI 10.1111/j.1365-2222.2005.02314.x; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; Chan MTS, 1998, J ALLERGY CLIN IMMUN, V101, P594, DOI 10.1016/S0091-6749(98)70165-4; Chu H. W., 2002, Clinical and Experimental Allergy, V32, P1558, DOI 10.1046/j.1365-2222.2002.01477.x; Covar RA, 2004, AM J RESP CRIT CARE, V170, P234, DOI 10.1164/rccm.200308-1174OC; Cowburn AS, 1998, J CLIN INVEST, V101, P834, DOI 10.1172/JCI620; COX G, 1995, J IMMUNOL, V154, P4719; Cox G, 1999, CHEST, V115, P1271, DOI 10.1378/chest.115.5.1271; Cundall M, 2003, J ALLERGY CLIN IMMUN, V112, P1064, DOI 10.1016/j.jaci.2003.08.013; Dahlen B, 1998, AM J RESP CRIT CARE, V157, P1187, DOI 10.1164/ajrccm.157.4.9707089; Dahlen SE, 2002, AM J RESP CRIT CARE, V165, P9, DOI 10.1164/ajrccm.165.1.2010080; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P669, DOI 10.1164/ajrccm/145.3.669; FABBRI LM, 1987, AM REV RESPIR DIS, V136, P36, DOI 10.1164/ajrccm/136.1.36; FREW AJ, 1995, AM J RESP CRIT CARE, V151, P340, DOI 10.1164/ajrccm.151.2.7842189; Gibson PG, 2001, CHEST, V119, P1329, DOI 10.1378/chest.119.5.1329; Gibson PG, 2003, THORAX, V58, P116, DOI 10.1136/thorax.58.2.116; *GINA, 2002, 023659 GINA NIH NAT; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Green RH, 2002, THORAX, V57, P875, DOI 10.1136/thorax.57.10.875; Grootendorst DC, 1997, CLIN EXP ALLERGY, V27, P769, DOI 10.1111/j.1365-2222.1997.tb01211.x; Hallstrand TS, 2005, J ALLERGY CLIN IMMUN, V116, P586, DOI 10.1016/j.jaci.2005.04.035; HASELKORN T, AM THOR SOC ANN M, pA626; Heaney LG, 2005, LANCET, V365, P974, DOI 10.1016/S0140-6736(05)71087-4; Hellings PW, 2003, CLIN EXP ALLERGY, V33, P1457, DOI 10.1046/j.1365-2222.2003.01743.x; Howarth PH, 2005, THORAX, V60, P1012, DOI 10.1136/thx.2005.045260; Humbert M, 1996, AM J RESP CRIT CARE, V153, P1931, DOI 10.1164/ajrccm.153.6.8665058; Humbert M, 1997, J ALLERGY CLIN IMMUN, V99, P657, DOI 10.1016/S0091-6749(97)70028-9; Humbert M, 1996, AM J RESP CRIT CARE, V154, P1497, DOI 10.1164/ajrccm.154.5.8912771; James AL, 2005, EUR RESPIR J, V26, P429, DOI 10.1183/09031936.05.00146404; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532, DOI 10.1164/ajrccm.160.5.9806170; Jayaram L, 2006, EUR RESPIR J, V27, P483, DOI 10.1183/09031936.06.00137704; Jongepier H, 2004, CLIN EXP ALLERGY, V34, P757, DOI 10.1111/j.1365-2222.2004.1938.x; Karjalainen EM, 2000, AM J RESP CRIT CARE, V161, P2086, DOI 10.1164/ajrccm.161.6.9907025; Kawana K, 2005, MOL ENDOCRINOL, V19, P2047, DOI 10.1210/me.2004-0489; Keatings VM, 1997, AM J RESP CRIT CARE, V155, P449, DOI 10.1164/ajrccm.155.2.9032177; KIKUCHI Y, 1994, NEW ENGL J MED, V330, P1329, DOI 10.1056/NEJM199405123301901; Kraft M, 2001, AM J RESP CRIT CARE, V163, P1219, DOI 10.1164/ajrccm.163.5.2002058; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; Lane SJ, 1998, J CLIN INVEST, V102, P2156, DOI 10.1172/JCI2680; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lemiere C, 1997, EUR RESPIR J, V10, P241, DOI 10.1183/09031936.97.10010241; Louis R, 2000, AM J RESP CRIT CARE, V161, P9, DOI 10.1164/ajrccm.161.1.9802048; MAESTRELLI P, 1995, AM J RESP CRIT CARE, V152, P1926, DOI 10.1164/ajrccm.152.6.8520757; Mapp CE, 2005, AM J RESP CRIT CARE, V172, P280, DOI 10.1164/rccm.200311-1575SO; Martinez-Moragon E, 2004, J ALLERGY CLIN IMMUN, V113, P242, DOI 10.1016/j.jaci.2003.11.002; MATSUMOTO K, 1994, CHEST, V105, P681, DOI 10.1378/chest.105.3.681; McFadden ER, 1999, AM J RESP CRIT CARE, V160, P221, DOI 10.1164/ajrccm.160.1.9810055; Melgert BN, 2005, CLIN EXP ALLERGY, V35, P1496, DOI 10.1111/j.1365-2222.2005.02362.x; Miller MK, 2005, J ALLERGY CLIN IMMUN, V116, P990, DOI 10.1016/j.jaci.2005.08.018; Minshall E, 2000, J ALLERGY CLIN IMMUN, V105, P232, DOI 10.1016/S0091-6749(00)90070-8; Miranda C, 2004, J ALLERGY CLIN IMMUN, V113, P101, DOI 10.1016/j.jaci.2003.10.041; Moore W, 2006, AM THOR SOC ANN M SA, pA473; Moore W, 2006, AM THOR SOC ANN M SA, pA663; Nguyen LT, 2005, RESP MED, V99, P200, DOI 10.1016/j.rmed.2004.06.007; Oguzulgen IK, 2002, J ASTHMA, V39, P517, DOI 10.1081/JAS-120004921; Ordonez CL, 2000, AM J RESP CRIT CARE, V161, P1185, DOI 10.1164/ajrccm.161.4.9812061; Pavord ID, 1999, LANCET, V353, P2213, DOI 10.1016/S0140-6736(99)01813-9; Payne DNR, 2001, AM J RESP CRIT CARE, V164, P1376, DOI 10.1164/ajrccm.164.8.2101145; Pepe C, 2005, J ALLERGY CLIN IMMUN, V116, P544, DOI 10.1016/j.jaci.2005.06.011; Pulleyn LJ, 2001, HUM GENET, V109, P623, DOI 10.1007/s00439-001-0617-y; Rosi E, 1999, J ALLERGY CLIN IMMUN, V103, P232, DOI 10.1016/S0091-6749(99)70496-3; SAETTA M, 1992, AM REV RESPIR DIS, V145, P160, DOI 10.1164/ajrccm/145.1.160; Sanak M, 2000, AM J RESP CELL MOL, V23, P290, DOI 10.1165/ajrcmb.23.3.4051; Sandford AJ, 2000, J ALLERGY CLIN IMMUN, V106, P135, DOI 10.1067/mai.2000.107926; Schaefer TM, 2005, J IMMUNOL, V175, P6509, DOI 10.4049/jimmunol.175.10.6509; Schoene RB, 1997, CLIN J SPORT MED, V7, P257, DOI 10.1097/00042752-199710000-00003; Silkoff PE, 2005, J ALLERGY CLIN IMMUN, V116, P1249, DOI 10.1016/j.jaci.2005.09.029; SIM TC, 1994, AM J RESP CRIT CARE, V149, P339, DOI 10.1164/ajrccm.149.2.8306027; Simpson JL, 2005, AM J RESP CRIT CARE, V172, P559, DOI 10.1164/rccm.200503-369OC; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; SMITH CM, 1989, AM REV RESPIR DIS, V140, P598, DOI 10.1164/ajrccm/140.3.598; Soler M, 2001, EUR RESPIR J, V18, P254, DOI 10.1183/09031936.01.00092101; Sorkness C, 2002, CLIN EXP ALLERGY, V32, P1355, DOI 10.1046/j.1365-2222.2002.01471.x; Sousa AR, 1997, AM J RESP CRIT CARE, V156, P1384, DOI 10.1164/ajrccm.156.5.9702072; Sousa AR, 2002, NEW ENGL J MED, V347, P1493, DOI 10.1056/NEJMoa013508; Sunday L, 2006, AM J PHYSIOL-ENDOC M, V291, pE261, DOI 10.1152/ajpendo.00550.2005; SUR S, 1993, AM REV RESPIR DIS, V148, P713, DOI 10.1164/ajrccm/148.3.713; SZCZEKLIK A, 1988, CLIN ALLERGY, V18, P15, DOI 10.1111/j.1365-2222.1988.tb02838.x; Szczeklik A, 2003, J ALLERGY CLIN IMMUN, V111, P913, DOI 10.1067/mai.2003.1487; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; Tang EA, 2003, MIDDLETONS ALLERGY P, V1, P1127; ten Brinke A, 2004, AM J RESP CRIT CARE, V170, P601, DOI 10.1164/rccm.200404-440OC; ten Brinke A, 2001, AM J RESP CRIT CARE, V164, P744, DOI 10.1164/ajrccm.164.5.2011026; ten Brinke A, 2001, AM J RESP CRIT CARE, V163, P1093, DOI 10.1164/ajrccm.163.5.2004020; Thomson NC, 2004, EUR RESPIR J, V24, P822, DOI 10.1183/09031936.04.00039004; Truyen E, 2006, THORAX, V61, P202, DOI 10.1136/thx.2005.052399; ULRIK CS, 1992, J ASTHMA, V29, P29, DOI 10.3109/02770909209110638; ULRIK CS, 1992, THORAX, V47, P14, DOI 10.1136/thx.47.1.14; *US DEP HHS, 1997, PUBL US DEP HHS; van Veen HP, 2005, AM THOR SOC ANN M SA, pA241; VIRCHOW JC, 1995, AM J RESP CRIT CARE, V151, P960; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; Wark PAB, 2002, EUR RESPIR J, V19, P68, DOI 10.1183/09031936.02.00226302; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; Wenzel SE, 2003, J ALLERGY CLIN IMMUN, V111, P1345, DOI 10.1067/mai.2003.1464; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737, DOI 10.1164/ajrccm.156.3.9610046; WENZEL SE, 2005, AM THOR SOC ANN M 20, pA676; Ying S, 1997, J IMMUNOL, V158, P5050; Zacharasiewicz A, 2005, AM J RESP CRIT CARE, V171, P1077, DOI 10.1164/rccm.200409-1242OC; 1999, ENCARTA WORLD DICT	113	707	740	2	41	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG-SEP	2006	368	9537					804	813		10.1016/S0140-6736(06)69290-8	http://dx.doi.org/10.1016/S0140-6736(06)69290-8			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	080ID	16935691				2022-12-28	WOS:000240240200032
J	Rollow, W; Lied, TR; McGann, P; Poyer, J; LaVoie, L; Kambic, RT; Bratzler, DW; Ma, A; Huff, ED; Ramunno, LD				Rollow, William; Lied, Terry R.; McGann, Paul; Poyer, James; LaVoie, Lawrence; Kambic, Robert T.; Bratzler, Dale W.; Ma, Allen; Huff, Edwin D.; Ramunno, Lawrence D.			Assessment of the Medicare Quality Improvement Organization program	ANNALS OF INTERNAL MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; INFECTION PREVENTION PROJECT; OF-CARE; ANTIMICROBIAL PROPHYLAXIS; IMPROVING QUALITY; HOSPITAL-CARE; HEALTH-CARE; BENEFICIARIES; PNEUMONIA; SURGERY	Background: Studies have shown improvement in quality of health care in the United States. However, the factors responsible for this improvement are largely unknown. Objective: To evaluate the effect of the Medicare Quality Improvement Organization (QIO) Program in 4 clinical settings by using performance data for 41 quality measures during the 7th Scope of Work. Design: Observational study in which differences in quality measures were compared between baseline and remeasurement periods for providers that received different levels of QIO interventions. Setting: Nursing homes, home health agencies, hospitals, and physician offices in the 50 U.S. states, the District of Columbia, and 2 U.S. territories. Participants: Providers receiving focused QIO assistance related to quality measures and providers receiving general informational assistance from QIOs. Measurements: 5 nursing home quality measures, 11 home health measures, 21 hospital measures, and 4 physician office measures. Results: For nursing home, home health, and physician office measures, providers recruited specifically by QIOs for receipt of assistance showed greater improvement in performance on 18 of 20 measures than did providers who were not recruited; similar improvement was seen on the other 2 measures. Nursing homes and home health agencies improved more in all measures on which they chose to work with the QIO than in other measures. Nineteen of 21 hospital measures showed improvement; in this setting, QIOs were contracted for improvement initiatives solely at the statewide level. Overall, improvement was seen in 34 of 41 measures from baseline to remeasurement in the 7th Scope of Work. Limitations: As in any observational study, selection bias, regression to the mean, and secular trends may have influenced the results. Conclusions: These findings are consistent with an impact of the QIO Program and QIO technical assistance on the observed improvement. Future evaluations of the QIO Program will attempt to better address the limitations of the design of this study.	Ctr Medicaid Serv, Baltimore, MD 21244 USA; Ctr Medicare Serv, Baltimore, MD 21244 USA; Ctr Medicare Serv, Kansas City, MO USA; Ctr Medicaid Serv, Kansas City, MO USA; Ctr Medicare Serv, Boston, MA USA; Ctr Medicaid Serv, Boston, MA USA; Oklahoma Fdn Med Qual, Oklahoma City, OK USA; Northeast Hlth Care Qual Fdn, Dover, New Hants, England	Centers for Medicare & Medicaid Services; Centers for Medicare & Medicaid Services; Centers for Medicare & Medicaid Services; Centers for Medicare & Medicaid Services; Centers for Medicare & Medicaid Services; Centers for Medicare & Medicaid Services	Rollow, W (corresponding author), Ctr Medicare Serv, Mail Stop S3-02-01,7500 Security Blvd, Baltimore, MD 21244 USA.	william.rollow@cms.hhs.gov						*AG HEALTHC RES QU, 2005, 2005 NAT HEALTHC QUA; *AG HEALTHC RES QU, 2004, NAT HELTHC QUAL REP; Allen BL, 2004, J NURS CARE QUAL, V19, P149, DOI 10.1097/00001786-200404000-00012; Bradley EH, 2005, HEALTH SERV RES, V40, P459, DOI 10.1111/j.1475-6773.2005.0y368.x; Bratzler DW, 2004, CLIN INFECT DIS, V38, P1706, DOI 10.1086/421095; Bratzler DW, 2005, ARCH SURG-CHICAGO, V140, P174, DOI 10.1001/archsurg.140.2.174; Centers for Medicare and Medicaid Services, 2011, MIN DAT SETS 2 0 OV; Centers for Medicare & Medicaid Services, HOM HLTH QUAL IN OAS; Chu LA, 2003, ARCH INTERN MED, V163, P326, DOI 10.1001/archinte.163.3.326; *CTR MED MED SERV, 2006, HOM HLTH QUAL IN OV; Dellinger EP, 2005, AM J SURG, V190, P9, DOI 10.1016/j.amjsurg.2004.12.001; Ellerbeck EF, 2000, INT J QUAL HEALTH C, V12, P305, DOI 10.1093/intqhc/12.4.305; Hayes R, 2001, Jt Comm J Qual Improv, V27, P155; Hertz Kenneth T, 2005, MGMA Connex, V5, P42; *I MED, 2006, MED QUAL IMPR ORG PR; Institute of Medicine Committee on Quality of Health Care in America, 2001, CROSS QUAL CHASM NEW; Jencks SF, 2003, JAMA-J AM MED ASSOC, V289, P305, DOI 10.1001/jama.289.3.305; Jencks SF, 2005, JAMA-J AM MED ASSOC, V294, P2028, DOI 10.1001/jama.294.16.2028-a; Kiefe CI, 2001, JAMA-J AM MED ASSOC, V285, P2871, DOI 10.1001/jama.285.22.2871; Kilo C M, 1998, Qual Manag Health Care, V6, P1; Kinatukara S, 2005, HOME HEALTH CARE SER, V24, P23, DOI 10.1300/J027v24n03_02; Kissam Stephanie, 2003, BMC Geriatr, V3, P2, DOI 10.1186/1471-2318-3-2; Lee D, 1997, JOINT COMM J QUAL IM, V23, P334, DOI 10.1016/S1070-3241(16)30323-6; Marciniak TA, 1998, JAMA-J AM MED ASSOC, V279, P1351, DOI 10.1001/jama.279.17.1351; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; *MED, 2006, NURS HOM COMP; Mehta RH, 2002, JAMA-J AM MED ASSOC, V287, P1269, DOI 10.1001/jama.287.10.1269; Mouchawar J, 2004, MED CARE RES REV, V61, P116, DOI 10.1177/1077558703260182; *NAT COMM QUAL ASS, 2004, 2004 STAT HLTH CAR Q; Pace KB, 2006, AM J NURS, V106, P38; Polk HC, 2005, AM J SURG, V190, P16, DOI 10.1016/j.amjsurg.2005.04.001; Sangl J, 2005, MED CARE, V43, P24; Simpson RJ, 1997, AM J CARDIOL, V80, pH80, DOI 10.1016/S0002-9149(97)00827-8; Snyder C, 2005, JAMA-J AM MED ASSOC, V293, P2900, DOI 10.1001/jama.293.23.2900; Sprague Lisa, 2002, NHPF Issue Brief, P1; Sugarman JR, 2005, JAMA-J AM MED ASSOC, V294, P2029, DOI 10.1001/jama.294.16.2029-a; *US DEP HHS, 2006, HOSP COMP; Weingarten JP, 2004, AM J MED QUAL, V19, P157, DOI 10.1177/106286060401900404; Williams SC, 2005, NEW ENGL J MED, V353, P255, DOI 10.1056/NEJMsa043778	39	38	41	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 5	2006	145	5					342	353		10.7326/0003-4819-145-5-200609050-00134	http://dx.doi.org/10.7326/0003-4819-145-5-200609050-00134			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	080NZ	16908911				2022-12-28	WOS:000240255900004
J	Bono, F; Ebert, J; Lorentzen, E; Conti, E				Bono, Fulvia; Ebert, Judith; Lorentzen, Esben; Conti, Elena			The crystal structure of the exon junction complex reveals how it maintains a stable grip on mRNA	CELL			English	Article							NONSENSE-MEDIATED DECAY; MAMMALIAN-CELLS; MAGO NASHI; MOLECULAR INSIGHTS; GENE-EXPRESSION; PROTEIN; DROSOPHILA; TRANSLATION; CORE; Y14	The exon junction complex (EJC) plays a major role in posttranscriptionall regulation of mRNA in metazoa. The EJC is deposited onto mRNA during splicing and is transported to the cytoplasm where it influences translation, surveillance, and localization of the spliced mRNA. The complex is formed by the association of four proteins (eIF4AIII, Barentsz [Btz], Mago, and Y14), mRNA, and ATP. The 2.2 angstrom resolution structure of the EJC reveals how it stably locks onto mRNA. The DEAD-box protein eIF4AIII encloses an ATP molecule and provides the binding sites for six ribonucleotides. Btz wraps around eIF4AIII and stacks against the 5' nucleotide. An intertwined network of interactions anchors Mago-Y14 and Btz at the interface between the two domains of eIF4AIII, effectively stabilizing the ATP bound state. Comparison with the structure of the eIF4aIII-Btz: subcomplex that we have also determined reveals that large conformational changes are required upon EJC assembly and disassembly.	European Mol Biol Lab, D-69117 Heidelberg, Germany; Max Planck Inst Biochem, D-82152 Martinsried, Germany	European Molecular Biology Laboratory (EMBL); Max Planck Society	Conti, E (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.	conti@embl.de	Lorentzen, Esben/AAX-8077-2020	Conti, Elena/0000-0003-1254-5588; Lorentzen, Esben/0000-0001-6493-7220				Ballut L, 2005, NAT STRUCT MOL BIOL, V12, P861, DOI 10.1038/nsmb990; BELGRADER P, 1994, MOL CELL BIOL, V14, P8219, DOI 10.1128/MCB.14.12.8219; Bono F, 2004, EMBO REP, V5, P304, DOI 10.1038/sj.embor.7400091; Conti E, 2005, CURR OPIN CELL BIOL, V17, P316, DOI 10.1016/j.ceb.2005.04.005; Cordin O, 2006, GENE, V367, P17, DOI 10.1016/j.gene.2005.10.019; Degot S, 2004, J BIOL CHEM, V279, P33702, DOI 10.1074/jbc.M402754200; Dostie J, 2002, CURR BIOL, V12, P1060, DOI 10.1016/S0960-9822(02)00902-8; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Ferraiuolo MA, 2004, P NATL ACAD SCI USA, V101, P4118, DOI 10.1073/pnas.0400933101; Fribourg S, 2003, NAT STRUCT BIOL, V10, P433, DOI 10.1038/nsb926; Gatfield D, 2003, EMBO J, V22, P3960, DOI 10.1093/emboj/cdg371; Gehring NH, 2003, MOL CELL, V11, P939, DOI 10.1016/S1097-2765(03)00142-4; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Hachet O, 2004, NATURE, V428, P959, DOI 10.1038/nature02521; Hachet O, 2001, CURR BIOL, V11, P1666, DOI 10.1016/S0960-9822(01)00508-5; Hall KB, 2002, CURR OPIN STRUC BIOL, V12, P283, DOI 10.1016/S0959-440X(02)00323-8; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kataoka N, 2001, EMBO J, V20, P6424, DOI 10.1093/emboj/20.22.6424; Kim VN, 2001, EMBO J, V20, P2062, DOI 10.1093/emboj/20.8.2062; Lau CK, 2003, CURR BIOL, V13, P933, DOI 10.1016/S0960-9822(03)00328-2; Le Hir H, 2003, TRENDS BIOCHEM SCI, V28, P215, DOI 10.1016/S0968-0004(03)00052-5; Le Hir H, 2000, EMBO J, V19, P6860, DOI 10.1093/emboj/19.24.6860; Le Hir H, 2001, EMBO J, V20, P4987, DOI 10.1093/emboj/20.17.4987; Lejeune F, 2005, CURR OPIN CELL BIOL, V17, P309, DOI 10.1016/j.ceb.2005.03.002; Lejeune F, 2002, EMBO J, V21, P3536, DOI 10.1093/emboj/cdf345; Li QY, 1999, MOL CELL BIOL, V19, P7336; Lu SH, 2003, RNA, V9, P618, DOI 10.1261/rna.5260303; Lykke-Andersen J, 2000, CELL, V103, P1121, DOI 10.1016/S0092-8674(00)00214-2; Macchi P, 2003, J NEUROSCI, V23, P5778; McCoy AJ, 2004, ACTA CRYSTALLOGR D, V60, P1220, DOI 10.1107/S0907444904009990; Mohr SE, 2001, GENE DEV, V15, P2886; Moore MJ, 2005, SCIENCE, V309, P1514, DOI 10.1126/science.1111443; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NEWMARK PA, 1994, DEVELOPMENT, V120, P1303; Nott A, 2004, GENE DEV, V18, P210, DOI 10.1101/gad.1163204; Nott A, 2003, RNA, V9, P607, DOI 10.1261/rna.5250403; Oberer M, 2005, GENE DEV, V19, P2212, DOI 10.1101/gad.1335305; Palacios IM, 2004, NATURE, V427, P753, DOI 10.1038/nature02351; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Radaev S, 2006, ACTA CRYSTALLOGR D, V62, P605, DOI 10.1107/S0907444906011735; Reichert VL, 2002, GENE DEV, V16, P2778, DOI 10.1101/gad.1030602; Sengoku T, 2006, CELL, V125, P287, DOI 10.1016/j.cell.2006.01.054; Shi H, 2003, GENE DEV, V17, P971, DOI 10.1101/gad.260403; Shibuya T, 2006, RNA, V12, P360, DOI 10.1261/rna.2190706; Shibuya T, 2004, NAT STRUCT MOL BIOL, V11, P346, DOI 10.1038/nsmb750; Tange TO, 2005, RNA, V11, P1869, DOI 10.1261/rna.2155905; Tange TO, 2004, CURR OPIN CELL BIOL, V16, P279, DOI 10.1016/j.ceb.2004.03.012; Tanner NK, 2001, MOL CELL, V8, P251, DOI 10.1016/S1097-2765(01)00329-X; van Eeden FJM, 2001, J CELL BIOL, V154, P511, DOI 10.1083/jcb.200105056; Wiegand HL, 2003, P NATL ACAD SCI USA, V100, P11327, DOI 10.1073/pnas.1934877100	51	300	310	0	19	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 25	2006	126	4					713	725		10.1016/j.cell.2006.08.006	http://dx.doi.org/10.1016/j.cell.2006.08.006			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	080VN	16923391	Bronze, Green Accepted			2022-12-28	WOS:000240276700020
J	Adams, KF; Schatzkin, A; Harris, TB; Kipnis, V; Mouw, T; Ballard-Barbash, R; Hollenbeck, A; Leitzmann, MF				Adams, Kenneth F.; Schatzkin, Arthur; Harris, Tamara B.; Kipnis, Victor; Mouw, Traci; Ballard-Barbash, Rachel; Hollenbeck, Albert; Leitzmann, Michael F.			Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BODY-MASS INDEX; FOLLOW-UP; WEIGHT; MEN; UNDERWEIGHT; ADULTS; GUIDELINES; ACCURACY; CANCER; TRENDS	Background: Obesity, defined by a body-mass index (BMI) (the weight in kilograms divided by the square of the height in meters) of 30.0 or more, is associated with an increased risk of death, but the relation between overweight (a BMI of 25.0 to 29.9) and the risk of death has been questioned. Methods: We prospectively examined BMI in relation to the risk of death from any cause in 527,265 U.S. men and women in the National Institutes of Health-AARP cohort who were 50 to 71 years old at enrollment in 1995-1996. BMI was calculated from self-reported weight and height. Relative risks and 95 percent confidence intervals were adjusted for age, race or ethnic group, level of education, smoking status, physical activity, and alcohol intake. We also conducted alternative analyses to address potential biases related to preexisting chronic disease and smoking status. Results: During a maximum follow-up of 10 years through 2005, 61,317 participants (42,173 men and 19,144 women) died. Initial analyses showed an increased risk of death for the highest and lowest categories of BMI among both men and women, in all racial or ethnic groups, and at all ages. When the analysis was restricted to healthy people who had never smoked, the risk of death was associated with both overweight and obesity among men and women. In analyses of BMI during midlife (age of 50 years) among those who had never smoked, the associations became stronger, with the risk of death increasing by 20 to 40 percent among overweight persons and by two to at least three times among obese persons; the risk of death among underweight persons was attenuated. Conclusions: Excess body weight during midlife, including overweight, is associated with an increased risk of death.	NCI, Nutr Epidemiol Branch, NIH, Bethesda, MD 20892 USA; NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA; NCI, Biometry Res Grp, NIH, Bethesda, MD 20892 USA; NCI, Div Canc Prevent, NIH, Bethesda, MD 20892 USA; NCI, Div Canc Control & Populat Sci, NIH, Bethesda, MD 20892 USA; NIA, Lab Epidemiol Demog & Biometry, NIH, Bethesda, MD 20892 USA; AARP, Washington, DC USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); American Association of Retired Persons (AARP)	Adams, KF (corresponding author), Nutr Epidemiol Branch, 6120 Execut Blvd,Suite 320, Rockville, MD 20852 USA.	adamske@mail.nih.gov	Hollenbeck, Albert/AAG-9461-2020		Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Ajani UA, 2004, ANN EPIDEMIOL, V14, P731, DOI 10.1016/j.annepidem.2003.10.008; Arterburn DE, 2004, J AM GERIATR SOC, V52, P1907, DOI 10.1111/j.1532-5415.2004.52517.x; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Calle EE, 1999, NEW ENGL J MED, V341, P1097, DOI 10.1056/NEJM199910073411501; Calle EE, 2004, NAT REV CANCER, V4, P579, DOI 10.1038/nrc1408; FerroLuzzi A, 1995, WHO TECH REP SER, V854, P1; Flegal KM, 2004, AM J EPIDEMIOL, V160, P331, DOI 10.1093/aje/kwh222; Flegal KM, 2005, JAMA-J AM MED ASSOC, V293, P1861, DOI 10.1001/jama.293.15.1861; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Gu DF, 2006, JAMA-J AM MED ASSOC, V295, P776, DOI 10.1001/jama.295.7.776; Harrell F.E., 2015, REGRESSION MODELING, DOI [10.1007/978-3-319-19425-7, DOI 10.1007/978-3-319-19425-7, 10.1007/978-1-4757-3462-1]; Haslam DW, 2005, LANCET, V366, P1197, DOI 10.1016/S0140-6736(05)67483-1; Hauser TH, 2001, J CLIN EPIDEMIOL, V54, P1267, DOI 10.1016/S0895-4356(01)00421-8; Katzmarzyk P T, 2003, Obes Rev, V4, P257, DOI 10.1046/j.1467-789X.2003.00120.x; Katzmarzyk PT, 2001, J CLIN EPIDEMIOL, V54, P916, DOI 10.1016/S0895-4356(01)00356-0; LEE IM, 1993, JAMA-J AM MED ASSOC, V270, P2823, DOI 10.1001/jama.270.23.2823; Leveille SG, 2005, AM J PUBLIC HEALTH, V95, P1607, DOI 10.2105/AJPH.2004.060418; Lindsted KD, 1998, INT J OBESITY, V22, P544, DOI 10.1038/sj.ijo.0800623; MANSON JE, 1995, NEW ENGL J MED, V333, P677, DOI 10.1056/NEJM199509143331101; Mcgee DL, 2005, ANN EPIDEMIOL, V15, P87, DOI 10.1016/j.annepidem.2004.05.012; Meyer HE, 2002, MED SCI SPORT EXER, V34, P1065, DOI 10.1097/00005768-200207000-00002; Michaud D, 2005, J REGISTRY MANAGE, V2, P70; Niedhammer I, 2000, INT J OBESITY, V24, P1111, DOI 10.1038/sj.ijo.0801375; Peeters A, 2003, ANN INTERN MED, V138, P24, DOI 10.7326/0003-4819-138-1-200301070-00008; ROTHMAN KJ, 1972, J R STAT SOC B, V34, P187; Schatzkin A, 2001, AM J EPIDEMIOL, V154, P1119, DOI 10.1093/aje/154.12.1119; Singh PN, 1999, AM J EPIDEMIOL, V150, P1152, DOI 10.1093/oxfordjournals.aje.a009942; Society of Actuaries, 1959, BUILD BLOOD PRESS ST; STEVENS J, 1990, AM J EPIDEMIOL, V132, P1156, DOI 10.1093/oxfordjournals.aje.a115758; Strawbridge WJ, 2000, AM J PUBLIC HEALTH, V90, P340, DOI 10.2105/AJPH.90.3.340; Strickler HD, 2005, JAMA-J AM MED ASSOC, V294, P551, DOI 10.1001/jama.294.5.551-b; Villareal DT, 2005, AM J CLIN NUTR, V82, P923, DOI 10.1093/ajcn/82.5.923; Visscher TLS, 2000, AM J EPIDEMIOL, V151, P660, DOI 10.1093/oxfordjournals.aje.a010260; Willett WC, 1999, NEW ENGL J MED, V341, P427, DOI 10.1056/NEJM199908053410607; WILLETT WC, 1998, MONOGRAPHS EPIDEMIOL, V30, P514; Yan LJL, 2006, JAMA-J AM MED ASSOC, V295, P190, DOI 10.1001/jama.295.2.190; Yuan JM, 1998, INT J EPIDEMIOL, V27, P824, DOI 10.1093/ije/27.5.824	37	1533	1586	4	121	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 24	2006	355	8					763	778		10.1056/NEJMoa055643	http://dx.doi.org/10.1056/NEJMoa055643			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	076KA	16926275				2022-12-28	WOS:000239955200005
J	Chang, DC; Grant, GB; O'Donnell, K; Wannemuehler, KA; Noble-Wang, J; Rao, CY; Jacobson, LM; Crowell, CS; Sneed, RS; Lewis, FMT; Schaffzin, JK; Kainer, MA; Genese, CA; Alfonso, EC; Jones, DB; Srinivasan, A; Fridkin, SK; Park, BJ				Chang, Douglas C.; Grant, Gavin B.; O'Donnell, Kerry; Wannemuehler, Kathleen A.; Noble-Wang, Judith; Rao, Carol Y.; Jacobson, Lara M.; Crowell, Claudia S.; Sneed, Rodlescia S.; Lewis, Felicia M. T.; Schaffzin, Joshua K.; Kainer, Marion A.; Genese, Carol A.; Alfonso, Eduardo C.; Jones, Dan B.; Srinivasan, Arjun; Fridkin, Scott K.; Park, Benjamin J.		Fusarium Keratitis Investigation T	Multistate outbreak of Fusarium keratitis associated with use of a contact lens solution	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ULCERATIVE KERATITIS; MICROBIAL KERATITIS; FUNGAL KERATITIS; DAILY-WEAR; RISK; SPECTRUM; MEMBERS; COMPLEX; TRENDS	Context Fusarium keratitis is a serious corneal infection, most commonly associated with corneal injury. Beginning in March 2006, the Centers for Disease Control and Prevention received multiple reports of Fusarium keratitis among contact lens wearers. Objective To define the specific activities, contact lens hygiene practices, or products associated with this outbreak. Design, Setting, and Participants Epidemiological investigation of Fusarium keratitis occurring in the United States. A confirmed case was defined as keratitis with illness onset after June 1, 2005, with no history of recent ocular trauma and a corneal culture growing Fusarium species. Data were obtained by patient and ophthalmologist interviews for case patients and neighborhood-matched controls by trained personnel. Available Fusarium isolates from patients' clinical and environmental specimens were genotyped by multilocus sequence typing. Environmental sampling for Fusarium was conducted at a contact lens solution manufacturing plant. Main Outcome Measures Keratitis infection with Fusarium species. Results As of June 30, 2006, we identified 164 confirmed case patients in 33 states and 1 US territory. Median age was 41 years (range, 12-83 years). Corneal transplantation was required or planned in 55 (34%). One hundred fifty-four (94%) of the confirmed case patients wore soft contact lenses. Forty-five case patients and 78 controls were included in the case-control study. Case patients were significantly more likely than controls to report using a specific contact lens solution, ReNu with MoistureLoc (69% vs 15%; odds ratio, 13.3; 95% confidence interval, 3.1-119.5). The prevalence of reported use of ReNu MultiPlus solution was similar between case patients and controls (18% vs 20%; odds ratio, 0.7; 95% confidence interval, 0.2-2.8). Fusarium was not recovered from the factory, warehouse, solution filtrate, or unopened solution bottles; production of implicated lots was not clustered in time. Among 39 isolates tested, at least 10 different Fusarium species were identified, comprising 19 unique multilocus genotypes. Conclusions The findings from this investigation indicate that this outbreak of Fusarium keratitis was associated with use of ReNu with MoistureLoc contact lens solution. Contact lens users should not use ReNu with MoistureLoc.	Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA USA; Ctr Dis Control & Prevent, Resp Dis Branch, Atlanta, GA USA; Ctr Dis Control & Prevent, Biostat Off, Atlanta, GA USA; Ctr Dis Control & Prevent, Div Bacterial & Mycot Dis, Atlanta, GA USA; Ctr Dis Control & Prevent, Epidemiol & Lab Branch, Atlanta, GA USA; Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Natl Ctr Infect Dis & Epidem Intelligence Serv, Atlanta, GA USA; Ctr Dis Control & Prevent, Epidemiol Elect Program, Atlanta, GA USA; Ctr Dis Control & Prevent, Career Dev Div, Off Workforce & Career Dev, Atlanta, GA USA; ARS, Microbial Genom Res Unit, Natl Ctr Agr Utilizat Res, USDA, Peoria, IL USA; Miami Dade Cty Hlth Dept, Miami, FL USA; Philadelphia Dept Hlth, Philadelphia, PA USA; New York State Dept Hlth, Albany, NY USA; Tennessee Dept Hlth, Nashville, TN USA; New Jersey Dept Hlth & Senior Serv, Trenton, NJ USA; Univ Miami, Sch Med, Bascom Palmer Eye Inst, Miami, FL USA; Baylor Coll Med, Cullen Eye Inst, Houston, TX 77030 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; United States Department of Agriculture (USDA); State University of New York (SUNY) System; Tennessee Department Health; New Jersey Department of Health & Senior Services; Bascom Palmer Eye Institute; University of Miami; Baylor College of Medicine	Chang, DC (corresponding author), 1600 Clifton Rd,MS C-09, Atlanta, GA 30333 USA.	DChang@cdc.gov	Sneed, PhD, MPH, Rodlescia/ABG-8963-2021; Schaffzin, Joshua K/AAZ-9243-2021	Schaffzin, Joshua K/0000-0002-1190-1854; Wannemuehler, Kathleen/0000-0001-9535-6277; Kainer, Marion/0000-0001-7678-8744; Sneed, Rodlescia/0000-0001-7732-6197; Grant, Gavin/0000-0002-3271-5735; Rao, Carol/0000-0001-7187-2189				ALFONSO E, 1986, AM J OPHTHALMOL, V101, P429, DOI 10.1016/0002-9394(86)90641-0; Alfonso EC, 2006, AM J OPHTHALMOL, V142, P154, DOI 10.1016/j.ajo.2006.04.025; Alfonso EC, 2006, ARCH OPHTHALMOL-CHIC, V124, P941, DOI 10.1001/archopht.124.7.ecs60039; Anaissie EJ, 2001, CLIN INFECT DIS, V33, P1871, DOI 10.1086/324501; ASBELL P, 1982, ARCH OPHTHALMOL-CHIC, V100, P77, DOI 10.1001/archopht.1982.01030030079005; Bernal MD, 2006, ARCH OPHTHALMOL-CHIC, V124, P1051, DOI 10.1001/archopht.124.7.ecr60006; Centers for Disease Control and Prevention (CDC), 2006, MMWR Morb Mortal Wkly Rep, V55, P400; Cheng KH, 1999, LANCET, V354, P181, DOI 10.1016/S0140-6736(98)09385-4; *CONT LENS COUNC, STAT CONT LENS WEAR; Dart J, 1999, LANCET, V354, P174, DOI 10.1016/S0140-6736(99)90104-6; DART JKG, 1991, LANCET, V338, P650, DOI 10.1016/0140-6736(91)91231-I; De Hoog G. S., 2000, ATLAS CLIN FUNGI; Driebe William T Jr, 2003, Ophthalmol Clin North Am, V16, P485, DOI 10.1016/S0896-1549(03)00052-X; Foulks GN, 2006, AM J OPHTHALMOL, V141, P369, DOI 10.1016/j.ajo.2005.08.047; Geiser DM, 2004, EUR J PLANT PATHOL, V110, P473, DOI 10.1023/B:EJPP.0000032386.75915.a0; Khor WB, 2006, JAMA-J AM MED ASSOC, V295, P2867, DOI 10.1001/jama.295.24.2867; KOIDOUTSILIGIANNI A, 1989, AM J OPHTHALMOL, V108, P64, DOI 10.1016/S0002-9394(14)73262-3; LIESEGANG TJ, 1980, AM J OPHTHALMOL, V90, P38, DOI 10.1016/S0002-9394(14)75075-5; Mah-Sadorra JH, 2005, CORNEA, V24, P51, DOI 10.1097/01.ico.0000138839.29823.57; McLaughlin-Borlace L, 1998, J APPL MICROBIOL, V84, P827; *MIN HLTH SING, PUBL AL INCR INC CON; NELSON PE, 1994, CLIN MICROBIOL REV, V7, P479, DOI 10.1128/CMR.7.4.479-504.1994; Nilsson Sven Erik G., 1994, CLAO Journal, V20, P225; O'Donnell K, 2004, J CLIN MICROBIOL, V42, P5109, DOI 10.1128/JCM.42.11.5109-5120.2004; POGGIO EC, 1989, NEW ENGL J MED, V321, P779, DOI 10.1056/NEJM198909213211202; Rattanatam T, 2001, CORNEA, V20, P290, DOI 10.1097/00003226-200104000-00010; Reeb V, 2004, MOL PHYLOGENET EVOL, V32, P1036, DOI 10.1016/j.ympev.2004.04.012; ROSA RH, 1994, OPHTHALMOLOGY, V101, P1005; SCHEIN OD, 1994, ARCH OPHTHALMOL-CHIC, V112, P186, DOI 10.1001/archopht.1994.01090140062024; SCHEIN OD, 1989, NEW ENGL J MED, V321, P773, DOI 10.1056/NEJM198909213211201; SCHEIN OD, 1989, CORNEA, V8, P281; Schein OD, 2005, OPHTHALMOLOGY, V112, P2172, DOI 10.1016/j.ophtha.2005.09.014; SCHEIN OD, 1990, CORNEA, V9, pS55; SIMMONS RB, 1986, J CLIN MICROBIOL, V24, P21, DOI 10.1128/JCM.24.1.21-25.1986; SWOFFORD DL, 2001, PAUP PHYLOGENIETIC A; THOMPSON TTT, 2006, TYLERS Q SOFT CONTEC, V23; TSANG T, 2006, COMMUNICABLE DI 0205; *US FDA, 2006, FDA PUBL HLTH NOT FU; *US PHARM NAT FORM, 2003, STER TEST, pCH71; WILSON LA, 1991, ARCH OPHTHALMOL-CHIC, V109, P1155, DOI 10.1001/archopht.1991.01080080115043; Wong TY, 1997, INT OPHTHALMOL, V21, P127, DOI 10.1023/A:1026462631716; Zhang N, 2006, J CLIN MICROBIOL, V44, P2186, DOI 10.1128/JCM.00120-06	42	409	422	1	30	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 23	2006	296	8					953	963		10.1001/jama.296.8.953	http://dx.doi.org/10.1001/jama.296.8.953			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	076AL	16926355	Bronze			2022-12-28	WOS:000239929300025
J	Newman, MF; Mathew, JP; Grocott, HP; Mackensen, GB; Monk, T; Welsh-Bohmer, KA; Blumenthal, JA; Laskowitz, DT; Mark, DB				Newman, Mark F.; Mathew, Joseph P.; Grocott, Hilary P.; Mackensen, G. Burkhard; Monk, Terri; Welsh-Bohmer, Kathleen A.; Blumenthal, James A.; Laskowitz, Daniel T.; Mark, Daniel B.			Central nervous system injury associated with cardiac surgery	LANCET			English	Review							CORONARY-ARTERY-BYPASS; ATRIAL-FIBRILLATION; COGNITIVE DECLINE; GRAFT-SURGERY; RISK-FACTOR; OFF-PUMP; NEUROCOGNITIVE FUNCTION; CARDIOPULMONARY BYPASS; BRAIN MICROEMBOLI; ELDERLY-PATIENTS	Millions of individuals with coronary artery or valvular heart disease have been given a new chance at life by heart surgery, but the potential for neurological injury is an Achilles heel. Technological advancements and innovations in surgical and anaesthetic technique have allowed us to offer surgical treatment to patients at the extremes of age and infirmity-the group at greatest risk for neurological injury. Neurocognitive dysfunction is a complication of cardiac surgery that can restrict the improved quality of life that patients usually experience after heart surgery. With a broader understanding of the frequency and effects of neurological injury from cardiac surgery and its implications for patients in both the short term and the long term, we should be able to give personalised treatments and thus preserve both their quantity and quality of life. We describe these issues and the controversies that merit continued investigation.	Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Newman, MF (corresponding author), Duke Univ, Med Ctr, Dept Anesthesiol, Box 3094, Durham, NC 27710 USA.	newma005@mc.duke.edu	Welsh-Bohmer, Kathleen/AAA-3178-2020; Mackensen, G. Burkhard/AAJ-3951-2021	Mathew, Joseph/0000-0002-3815-4131; Mark, Daniel/0000-0001-6340-8087				Ahlgren E, 2003, EUR J CARDIO-THORAC, V23, P334, DOI 10.1016/S1010-7940(02)00807-2; Ancelin ML, 2001, BRIT J PSYCHIAT, V178, P360, DOI 10.1192/bjp.178.4.360; Aranki SF, 1996, CIRCULATION, V94, P390, DOI 10.1161/01.CIR.94.3.390; Arrowsmith JE, 2000, BRIT J ANAESTH, V84, P378, DOI 10.1093/oxfordjournals.bja.a013444; Bar-Yosef S, 2004, ANN THORAC SURG, V78, P1556, DOI 10.1016/j.athoracsur.2004.05.002; Blackstone EH, 2000, J THORAC CARDIOV SUR, V120, P629, DOI 10.1067/mtc.2000.110252; Blumenthal JA, 2003, LANCET, V362, P604, DOI 10.1016/S0140-6736(03)14190-6; Boeken U, 2005, THORAC CARDIOV SURG, V53, P33, DOI 10.1055/s-2004-830426; Brooker RF, 1998, ANN THORAC SURG, V65, P1651, DOI 10.1016/S0003-4975(98)00289-6; Brown WR, 2000, STROKE, V31, P707, DOI 10.1161/01.STR.31.3.707; Bucerius J, 2003, ANN THORAC SURG, V75, P472, DOI 10.1016/S0003-4975(02)04370-9; Caplan LR, 1998, ARCH NEUROL-CHICAGO, V55, P1475, DOI 10.1001/archneur.55.11.1475; CHALLA VR, 1993, J NEUROL SCI, V117, P224, DOI 10.1016/0022-510X(93)90177-Z; Challa VR, 1998, J NEUROPATH EXP NEUR, V57, P140, DOI 10.1097/00005072-199802000-00005; Cheng DC, 2005, ANESTHESIOLOGY, V102, P188, DOI 10.1097/00000542-200501000-00028; Cleveland JC, 2001, ANN THORAC SURG, V72, P1282, DOI 10.1016/S0003-4975(01)03006-5; COSGROVE DM, 1984, J THORAC CARDIOV SUR, V88, P673; Creswell L L, 1999, Semin Thorac Cardiovasc Surg, V11, P303; CRESWELL LL, 1993, ANN THORAC SURG, V56, P539, DOI 10.1016/0003-4975(93)90894-N; CROSBY LH, 1990, AM J CARDIOL, V66, P1520, DOI 10.1016/0002-9149(90)90550-K; DeRose JJ, 2005, J THORAC CARDIOV SUR, V129, P314, DOI 10.1016/j.jtcvs.2004.05.022; Eckenhoff RG, 2004, ANESTHESIOLOGY, V101, P703, DOI 10.1097/00000542-200409000-00019; Ferguson TB, 2002, ANN THORAC SURG, V73, P480, DOI 10.1016/S0003-4975(01)03339-2; Fitch JCK, 1999, CIRCULATION, V100, P2499, DOI 10.1161/01.CIR.100.25.2499; Friday G, 2005, HEART SURG FORUM, V8, pE105, DOI 10.1532/HSF98.20041146; FULLER JA, 1989, J THORAC CARDIOV SUR, V97, P821; GILMAN S, 1965, NEW ENGL J MED, V272, P489, DOI 10.1056/NEJM196503112721001; GOLD JP, 1995, J THORAC CARDIOV SUR, V110, P1302, DOI 10.1016/S0022-5223(95)70053-6; Goto T, 2001, ANN THORAC SURG, V72, P137, DOI 10.1016/S0003-4975(01)02676-5; Grover FL, 2001, ANN SURG, V234, P464, DOI 10.1097/00000658-200110000-00006; HAMMERMEISTER KE, 1990, CIRCULATION, V82, P380; Hannan EL, 2005, NEW ENGL J MED, V352, P2174, DOI 10.1056/NEJMoa040316; Hanning CD, 2003, EUR J ANAESTH, V20, P93, DOI 10.1097/00003643-200302000-00002; Hartman GS, 1996, ANESTH ANALG, V83, P701, DOI 10.1097/00000539-199610000-00007; HINEMAN BJ, 2002, HEART SURG FORUM, V5, P249; Hlatky MA, 1997, CIRCULATION, V96, P11; Hogue CW, 1999, CIRCULATION, V100, P642, DOI 10.1161/01.CIR.100.6.642; Hogue CW, 2001, CIRCULATION, V103, P2133; Iglesias I, 2001, Semin Thorac Cardiovasc Surg, V13, P158, DOI 10.1053/stcs.2001.24076; JONES EL, 1991, J THORAC CARDIOV SUR, V101, P108; Jones TJ, 2002, ANN THORAC SURG, V74, P2132, DOI 10.1016/S0003-4975(02)04081-X; Knipp SC, 2004, EUR J CARDIO-THORAC, V25, P791, DOI 10.1016/j.ejcts.2004.02.012; LEITCH JW, 1990, J THORAC CARDIOV SUR, V100, P338; Lett HS, 2004, PSYCHOSOM MED, V66, P305, DOI 10.1097/01.psy.0000126207.43307.c0; Lyketsos CG, 2006, INT J GERIATR PSYCH, V21, P509, DOI 10.1002/gps.1502; Mack MJ, 2004, ANN THORAC SURG, V77, P761, DOI 10.1016/j.athoracsur.2003.06.019; Mahanna EP, 1996, ANN THORAC SURG, V61, P1342, DOI 10.1016/0003-4975(95)01095-5; Malenka DJ, 2005, CIRCULATION, V112, pI371, DOI 10.1161/CIRCULATIONAHA.104.526392; MANGANO DT, 1990, ANESTHESIOLOGY, V72, P153, DOI 10.1097/00000542-199001000-00025; MARK DB, 2002, JAMA-J AM MED ASSOC, P1448; Mathew JP, 1996, JAMA-J AM MED ASSOC, V276, P300, DOI 10.1001/jama.276.4.300; Mathew JP, 2004, STROKE, V35, P2335, DOI 10.1161/01.STR.0000141938.00524.83; Mathew JP, 2003, STROKE, V34, P508, DOI 10.1161/01.STR.0000053844.09493.58; Mathew JP, 2001, ANN THORAC SURG, V71, P663, DOI 10.1016/S0003-4975(00)02335-3; MATHEW JP, 2004, ANESTHESIOLOGY; McKhann GM, 2005, NEUROLOGY, V65, P991, DOI 10.1212/01.wnl.0000175220.78475.99; McKhann GM, 1997, LANCET, V349, P1282, DOI 10.1016/S0140-6736(96)09466-4; MOHAN R, 1992, CARDIOLOGY, V80, P215, DOI 10.1159/000175005; Moller JT, 1998, LANCET, V351, P857, DOI 10.1016/S0140-6736(97)07382-0; MONK TG, 2004, ANESTHESIOLOGY, V101, pA62; MOODY DM, 1995, ANN THORAC SURG, V59, P1304, DOI 10.1016/0003-4975(95)00057-R; MOODY DM, 1990, ANN NEUROL, V28, P477, DOI 10.1002/ana.410280403; Murkin JM, 1997, ANN THORAC SURG, V64, P904, DOI 10.1016/S0003-4975(97)00743-1; MURKIN JM, 1995, ANN THORAC SURG, V59, P1289, DOI 10.1016/0003-4975(95)00106-U; MURKIN JM, 1995, J THORAC CARDIOV SUR, V110, P340, DOI 10.1016/S0022-5223(95)70229-6; Neville MJ, 2001, J THORAC CARDIOV SUR, V121, P125, DOI 10.1067/mtc.2001.111378; Newman MF, 2004, CIRCULATION, V110, P3402, DOI 10.1161/01.CIR.0000150860.91937.ED; Newman MF, 1996, CIRCULATION, V94, P74; Newman MF, 2001, STROKE, V32, P2874, DOI 10.1161/hs1201.099803; Newman MF, 2001, NEW ENGL J MED, V344, P395, DOI 10.1056/NEJM200102083440601; Phillips-Bute B, 2006, PSYCHOSOM MED, V68, P369, DOI 10.1097/01.psy.0000221272.77984.e2; Potter GG, 2004, NEUROLOGY, V63, P2245, DOI 10.1212/01.WNL.0000147291.49404.0A; Puskas JD, 2004, JAMA-J AM MED ASSOC, V291, P1841, DOI 10.1001/jama.291.15.1841; Ridker PM, 1997, LANCET, V349, P385, DOI 10.1016/S0140-6736(97)80010-4; Roach GW, 1996, NEW ENGL J MED, V335, P1857, DOI 10.1056/NEJM199612193352501; Selnes OA, 2005, ANN THORAC SURG, V79, P1201, DOI 10.1016/j.athoracsur.2004.10.011; Selnes OA, 1999, LANCET, V353, P1601, DOI 10.1016/S0140-6736(98)07576-X; Stamou SC, 2001, STROKE, V32, P1508, DOI 10.1161/01.STR.32.7.1508; Stanley TO, 2002, ANESTH ANALG, V94, P290, DOI 10.1097/00000539-200202000-00011; Steed L, 2001, ANN THORAC SURG, V71, P823, DOI 10.1016/S0003-4975(00)02511-X; Stygall J, 2003, HEALTH PSYCHOL, V22, P579, DOI 10.1037/0278-6133.22.6.579; Tardiff BE, 1997, ANN THORAC SURG, V64, P715, DOI 10.1016/S0003-4975(97)00757-1; TUMAN KJ, 1992, J THORAC CARDIOV SUR, V104, P1510, DOI 10.1016/S0022-5223(19)33877-2; van der Linden J, 2001, J AM COLL CARDIOL, V38, P131, DOI 10.1016/S0735-1097(01)01328-6; Van Dijk D, 2002, JAMA-J AM MED ASSOC, V287, P1405, DOI 10.1001/jama.287.11.1405; van Dijk D, 2000, J THORAC CARDIOV SUR, V120, P632, DOI 10.1067/mtc.2000.108901; Wahrborg P, 2004, CIRCULATION, V110, P3411, DOI 10.1161/01.CIR.0000148366.80443.2B; WAREING TH, 1992, J THORAC CARDIOV SUR, V103, P453; WAREING TH, 1993, ANN THORAC SURG, V55, P1400, DOI 10.1016/0003-4975(93)91079-3; WEINTRAUB WS, 1989, CIRCULATION, V80, P276, DOI 10.1161/01.CIR.80.2.276; Weiss EJ, 1996, NEW ENGL J MED, V334, P1090, DOI 10.1056/NEJM199604253341703; Westaby S, 2001, ANN THORAC SURG, V71, P667, DOI 10.1016/S0003-4975(00)02405-X; Whelihan WM, 2005, ARCH CLIN NEUROPSYCH, V20, P217, DOI 10.1016/j.acn.2004.07.002; WILLIAMSRUSSO P, 1995, JAMA-J AM MED ASSOC, V274, P44, DOI 10.1001/jama.274.1.44; Wolman RL, 1999, STROKE, V30, P514, DOI 10.1161/01.STR.30.3.514; YOUSIF H, 1990, INT J CARDIOL, V26, P313, DOI 10.1016/0167-5273(90)90087-L	96	215	235	1	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 19	2006	368	9536					694	703		10.1016/S0140-6736(06)69254-4	http://dx.doi.org/10.1016/S0140-6736(06)69254-4			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	074YT	16920475				2022-12-28	WOS:000239849200037
J	Gulick, RM; Ribaudo, HJ; Shikuma, CM; Lalama, C; Schackman, BR; Meyer, WA; Acosta, EP; Schouten, J; Squires, KE; Pilcher, CD; Murphy, RL; Koletar, SL; Carlson, M; Reichman, RC; Bastow, B; Klingman, KL; Kuritzkes, DR				Gulick, Roy M.; Ribaudo, Heather J.; Shikuma, Cecilia M.; Lalama, Christina; Schackman, Bruce R.; Meyer, William A., III; Acosta, Edward P.; Schouten, Jeffrey; Squires, Kathleen E.; Pilcher, Christopher D.; Murphy, Robert L.; Koletar, Susan L.; Carlson, Margrit; Reichman, Richard C.; Bastow, Barbara; Klingman, Karin L.; Kuritzkes, Daniel R.		ACTG A5095 Study Team	Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; REVERSE-TRANSCRIPTASE INHIBITOR; SOCIETY-USA PANEL; NAIVE PATIENTS; ABACAVIR HYPERSENSITIVITY; PROTEASE INHIBITORS; DRUG-RESISTANCE; CLINICAL-TRIALS; PLUS INDINAVIR; THERAPY	Context Three-drug antiretroviral regimens are standard of care for initial treatment of human immunodeficiency virus 1 (HIV-1) infection, but a 4-drug regimen could improve antiretroviral activity and be more effective than a 3-drug regimen. Objective To compare the safety/efficacy of 3-drug vs 4-drug regimens for initial treatment of HIV-1 infection. Design The AIDS Clinical Trials Group (ACTG) A5095 study, a randomized, double-blind, placebo-controlled study with enrollment and follow-up conducted from March 22, 2001, to March 1, 2005, and enrolling treatment-naive, HIV-1-infected patients with HIV-1 RNA levels of 400 copies/mL or greater from US clinical trials units of the ACTG. Interventions Zidovudine/lamivudine plus efavirenz (3-drug regimen) vs zidovudine/ lamivudine/abacavir plus efavirenz (4-drug regimen). Main Outcome Measures Time to virologic failure ( defined as time to first of 2 successive HIV-1 RNA levels >= 200 copies/mL at or after week 16), CD4 cell count changes, and grade 3 or 4 adverse events. HIV-1 RNA data were intent-to-treat, regardless of treatment changes. Results Seven hundred sixty-five patients with a baseline mean HIV-1 RNA level of 4.86 log(10) ( 72 444) copies/mL and CD4 cell count of 240 cells/mm(3) were randomized. After a median 3-year follow-up, 99 (26%) of 382 and 94 (25%) of 383 patients receiving the 3-drug and 4-drug regimens, respectively, reached protocol-defined virologic failure; time to virologic failure was not significantly different ( hazard ratio, 0.95; 97.5% confidence interval, 0.69-1.33; P=. 73). In planned subgroup analyses, increased risk for virologic failure was seen in non-Hispanic black patients ( adjusted hazard ratio, 1.66; 95% confidence interval, 1.18-2.34; P=. 003). At 3 years, the HIV-1 RNA level was less than 200 copies/mL in 152 (90%) of 169 and 143 (92%) of 156 patients receiving the 3-drug and 4-drug regimens, respectively ( P=. 59), and less than 50 copies/mL in 144 (85%) of 169 and 137 (88%) of 156 patients ( P=. 39). CD4 cell count increases and grade 3 or 4 adverse events were not significantly different. Conclusions In treatment-naive patients, there were no significant differences between the 3-drug and 4-drug antiretroviral regimens; overall, at least approximately 80% of patients had HIV-1 RNA levels less than 50 copies/mL through 3 years. These results support current guidelines recommending 2 nucleosides plus efavirenz for initial treatment of HIV-1 infection; adding abacavir as a fourth drug provided no additional benefit.	Cornell Univ, Weill Med Coll, Div Int Med & Infect Dis, Cornell HIV Clin Trials Unit, New York, NY 10021 USA; Harvard Univ, Sch Publ Hlth, Stat & Data Anal Ctr, Boston, MA 02115 USA; Univ Hawaii, Honolulu, HI 96822 USA; QuestDiagnost Inc, Baltimore, MD USA; Univ Alabama, Birmingham, AL USA; Univ Washington, Seattle, WA 98195 USA; Univ So Calif, Med Ctr, Los Angeles, CA USA; Univ N Carolina, Chapel Hill, NC USA; Northwestern Univ, Chicago, IL 60611 USA; Ohio State Univ, Columbus, OH 43210 USA; Univ Calif Los Angeles, Los Angeles, CA USA; Univ Rochester, Rochester, NY USA; Social & Sci Syst Inc, Silver Spring, MD USA; NIAID, Div AIDS, Bethesda, MD 20892 USA; Harvard Univ, Sch Med, Boston, MA USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA	Cornell University; Harvard University; Harvard T.H. Chan School of Public Health; University of Hawaii System; University of Alabama System; University of Alabama Birmingham; University of Washington; University of Washington Seattle; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of Southern California; University of North Carolina; University of North Carolina Chapel Hill; Northwestern University; University System of Ohio; Ohio State University; University of California System; University of California Los Angeles; University of Rochester; Social & Scientific Systems; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Jefferson University	Gulick, RM (corresponding author), Cornell Univ, Weill Med Coll, Div Int Med & Infect Dis, Cornell HIV Clin Trials Unit, Box 566,525 E 68th St, New York, NY 10021 USA.	rgulick@med.cornell.edu	Schackman, Bruce R./J-8208-2019	Schackman, Bruce R./0000-0002-1132-2932; Murphy, Robert/0000-0003-3936-2052	NCRR NIH HHS [RR00046, RR00047, RR00052, RR00096, RR00865, RR02635, RR00044] Funding Source: Medline; NIAID NIH HHS [AI 46339, AI 42851, AI 42848, AI 39156, AI 38858, AI 38855, AI 34832, AI 32782, AI 32775, AI 28697, AI 27767, AI 27675, AI 27673, AI 27670, AI 27668, AI 27664, AI 27661, AI 27659, AI 27658, AI 25924, AI 25915, AI 25903, AI 25897, AI 25879, AI 25868, AI 25859, AI 01781, AI 46370, AI 46376, AI 46381, AI 46386, AI 50410, AI 51966, AI, 27660] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000865, M01RR002635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027661, P30AI042851, U01AI025924, U01AI027664, U01AI038855, U01AI027675, U01AI027659, U01AI046376, U01AI025897, U01AI025903, U01AI027668, U01AI025868, P30AI028697, U01AI032775, U01AI032782, U01AI025879, P30AI050410, U01AI027670, U01AI046370, U01AI034832, P30AI027767, U01AI046381, U01AI027658, U01AI027660, U01AI046386, U01AI027673, U01AI025859, K24AI051966, P30AI042848, K23AI001781, U01AI039156, U01AI025915, U01AI046339, U01AI038858] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Albrecht MA, 2001, NEW ENGL J MED, V345, P398, DOI 10.1056/NEJM200108093450602; Barreiro P, 2002, AIDS, V16, P245, DOI 10.1097/00002030-200201250-00014; Bossi P, 2000, CLIN INFECT DIS, V30, P227, DOI 10.1086/313629; Chesney MA, 2000, AIDS CARE, V12, P255, DOI 10.1080/09540120050042891; Clavel F, 2004, NEW ENGL J MED, V350, P1023, DOI 10.1056/NEJM2ra025195; Clay PG, 2002, CLIN THER, V24, P1502, DOI 10.1016/S0149-2918(02)80057-1; Dornadula G, 1999, JAMA-J AM MED ASSOC, V282, P1627, DOI 10.1001/jama.282.17.1627; Fischl MA, 2003, J INFECT DIS, V188, P625, DOI 10.1086/377311; Furtado MR, 1999, NEW ENGL J MED, V340, P1614, DOI 10.1056/NEJM199905273402102; Gallant JE, 2004, JAMA-J AM MED ASSOC, V292, P191, DOI 10.1001/jama.292.2.191; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Gulick RM, 2004, NEW ENGL J MED, V350, P1850, DOI 10.1056/NEJMoa031772; Haas DW, 2004, AIDS, V18, P2391; Haddy TB, 1999, J LAB CLIN MED, V133, P15, DOI 10.1053/lc.1999.v133.a94931; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hicks C, 2004, AIDS, V18, P775, DOI 10.1097/00002030-200403260-00008; Hirsch MS, 2003, CLIN INFECT DIS, V37, P113, DOI 10.1086/375597; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Louie M, 2003, J INFECT DIS, V187, P896, DOI 10.1086/368164; LUPO LJ, 2002, 6 INT C DRUG THER HI; Mallal S, 2002, LANCET, V359, P727, DOI 10.1016/S0140-6736(02)07873-X; Manfredi R, 2004, AIDS, V18, P2331, DOI 10.1097/00002030-200411190-00017; Markowitz M, 2003, J VIROL, V77, P5037, DOI 10.1128/JVI.77.8.5037-5038.2003; MOORE RD, 2005, 12 C RETR OPP INF FE; Mouton Y, 1997, AIDS, V11, pF101, DOI 10.1097/00002030-199712000-00003; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Panel on Clinical Practices for the Treatment of HIV Infection and DHHS Guidelines, 2006, GUID US ANT AG HIV I; Phillips EJ, 2005, AIDS, V19, P979, DOI 10.1097/01.aids.0000171414.99409.fb; Ramratnam B, 2004, JAIDS-J ACQ IMM DEF, V35, P33, DOI 10.1097/00126334-200401010-00004; *REG COMPL CTR, 1992, DIV AIDS TABL GRAD S; Robbins GK, 2003, NEW ENGL J MED, V349, P2293, DOI 10.1056/NEJMoa030264; Shafer RW, 2003, NEW ENGL J MED, V349, P2304, DOI 10.1056/NEJMoa030265; Staszewski S, 1999, NEW ENGL J MED, V341, P1865, DOI 10.1056/NEJM199912163412501; Torti C, 2005, J ANTIMICROB CHEMOTH, V56, P190, DOI 10.1093/jac/dki172; van Praag RME, 2002, AIDS, V16, P719, DOI 10.1097/00002030-200203290-00007; WEGNER S, 2002, 9 C RETR OPP INF FEB; Weverling GJ, 1998, AIDS, V12, pF117, DOI 10.1097/00002030-199811000-00003; World Health Organization, 2005, SCAL ANT THER RES LT; Yeni P, 2006, LANCET, V368, P287, DOI 10.1016/S0140-6736(06)69074-0; Yeni PG, 2004, JAMA-J AM MED ASSOC, V292, P251, DOI 10.1001/jama.292.2.251	41	175	178	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 16	2006	296	7					769	781		10.1001/jama.296.7.769	http://dx.doi.org/10.1001/jama.296.7.769			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	073SR	16905783	Bronze			2022-12-28	WOS:000239763400018
J	Butler, PEM; Hettiaratchy, S; Clarke, A				Butler, Peter E. M.; Hettiaratchy, Shehan; Clarke, Alex			Managing the risks of facial transplantation	LANCET			English	Editorial Material							HUMAN FACE; EXPERIENCE; ALLOGRAFT		Royal Free Hosp, Dept Plast Surg, London NW3 20G, England; Queen Victoria Hosp, Dept Plast Surg, Surrey, England	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Butler, PEM (corresponding author), Royal Free Hosp, Dept Plast Surg, London NW3 20G, England.	pembutler@gmail.com		Butler, Peter/0000-0001-7419-1493				*ASRM ASPS, 2006, FAC TRANSPL ASRMS AS; Brill Simon E, 2006, Body Image, V3, P1, DOI 10.1016/j.bodyim.2005.12.002; Carosella ED, 2006, LANCET, V368, P183, DOI 10.1016/S0140-6736(06)68938-1; Clarke A, 2005, EXPERT OPIN BIOL TH, V5, P1539, DOI 10.1517/14712598.5.12.1539; Clarke A., 2004, PSYCHOL HEALTH MED, V9, P315, DOI [10.1080/13548500410001721882, DOI 10.1080/13548500410001721882]; Devauchelle B, 2006, LANCET, V368, P203, DOI 10.1016/S0140-6736(06)68935-6; Dubernard JM, 1999, LANCET, V353, P1315, DOI 10.1016/S0140-6736(99)02062-0; Haddad-Tame JL, 2000, MICROSURG, V20, P211, DOI 10.1002/1098-2752(2000)20:4<211::AID-MICR13>3.0.CO;2-3; Hettiaratchy S, 2004, BRIT J PLAST SURG, V57, P381, DOI 10.1016/j.bjps.2004.02.012; Hettiaratchy S, 2001, LANCET, V357, P494, DOI 10.1016/S0140-6736(00)04037-X; Klein MB, 2005, BURNS, V31, P257, DOI 10.1016/j.burns.2004.11.013; MACARTNEY J, 2006, TIMES           0415; Morris PJ, 2004, TRANSPLANTATION, V77, P330, DOI 10.1097/01.TP.0000113810.54865.BE; RANDALL C, 2005, DAILY TELEGRAPH 1219; Thomas A, 1998, PLAST RECONSTR SURG, V102, P2085, DOI 10.1097/00006534-199811000-00041; Warnke PH, 2006, LANCET, V368, P181, DOI 10.1016/S0140-6736(06)68937-X	16	18	18	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 12	2006	368	9535					561	563		10.1016/S0140-6736(06)69176-9	http://dx.doi.org/10.1016/S0140-6736(06)69176-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	074OF	16905004				2022-12-28	WOS:000239821000008
J	Remuzzi, G; Ruggenenti, P				Remuzzi, Giuseppe; Ruggenenti, Piero			Overview of randomised trials of ACE inhibitors	LANCET			English	Editorial Material							CORONARY-ARTERY-DISEASE; CONVERTING-ENZYME-INHIBITION; CARDIOVASCULAR EVENTS; METAANALYSIS; HETEROGENEITY; NEPHROPATHY; RAMIPRIL		Osped Riuniti Bergamo, Mario Negri Inst Pharmacol Res, I-24125 Bergamo, Italy; Osped Riuniti Bergamo, Unit Nephrol & Dialysis, I-24125 Bergamo, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Ospedali Riuniti di Bergamo; Ospedali Riuniti di Bergamo	Remuzzi, G (corresponding author), Osped Riuniti Bergamo, Mario Negri Inst Pharmacol Res, I-24125 Bergamo, Italy.	gremuzzi@marionegri.it	Remuzzi, Giuseppe/V-9766-2017	Remuzzi, Giuseppe/0000-0002-6194-3446				Al-Mallah MH, 2006, J AM COLL CARDIOL, V47, P1576, DOI 10.1016/j.jacc.2005.11.073; Braunwald E, 2004, NEW ENGL J MED, V351, P2058; Casas JP, 2005, LANCET, V366, P2026, DOI 10.1016/S0140-6736(05)67814-2; Dagenais GR, 2006, LANCET, V368, P581, DOI 10.1016/S0140-6736(06)69201-5; Flather MD, 2000, LANCET, V355, P1575, DOI 10.1016/S0140-6736(00)02212-1; Fox KM, 2003, LANCET, V362, P782; Hardy RJ, 1998, STAT MED, V17, P841, DOI 10.1002/(SICI)1097-0258(19980430)17:8<841::AID-SIM781>3.0.CO;2-D; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; Ruggenenti P, 2004, NEW ENGL J MED, V351, P1941, DOI 10.1056/NEJMoa042167; Ruggenenti P, 1998, LANCET, V352, P1252, DOI 10.1016/S0140-6736(98)04433-X; Thompson SG, 1999, STAT MED, V18, P2693, DOI 10.1002/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V; Yusuf S, 2000, NEW ENGL J MED, V342, P145	12	27	29	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 12	2006	368	9535					555	556		10.1016/S0140-6736(06)69172-1	http://dx.doi.org/10.1016/S0140-6736(06)69172-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	074OF	16905000				2022-12-28	WOS:000239821000004
J	West, SK; Emerson, PM; Mkocha, H; Mchiwa, W; Munoz, B; Bailey, R; Mabey, D				West, Sheila K.; Emerson, Paul M.; Mkocha, Harran; Mchiwa, Wilson; Munoz, Beatriz; Bailey, Robin; Mabey, David			Intensive insecticide spraying for fly control after mass antibiotic treatment for trachoma in a hyperendemic setting: a randomised trial	LANCET			English	Article							CHLAMYDIA-TRACHOMATIS; CENTRAL TANZANIA; INFECTION; COMMUNITY; DIARRHEA; TRANSMISSION; VECTOR; IMPACT	Background There are no data on the cumulative effect of fly control and antibiotic distribution on trachoma in hyperendemic communities. We sought to determine whether insecticide spray intervention after mass antibiotic treatment could reduce trachoma and ocular infection with Chlamydia trachomatis in hyperendemic neighbourhoods in Tanzania. Methods We did a single-blind, randomised clinical trial in 16 neighbourhoods (balozi) in Kongwa, Tanzania. All children aged 1-7 years were enrolled, with 119 children in the eight balozi of the intervention group and 183 in the eight control balozi. Children were examined at baseline, 6 months, and 1 year for clinical trachoma and ocular C trachomatis infection. one dose of azithromycin was offered to all residents of both intervention and control balozi after the baseline survey. Households (and surrounding areas) in the intervention group were then sprayed with insecticide throughout the ensuing year and monitored for reductions in fly counts. This study is registered at ClinicalTrials.gov, number NCT00347763. Findings The intervention balozi had significantly lower fly counts than controls at all monitored weeks (p < 0.05), apart from weeks 7-9. The trachoma rate did not differ significantly in the intervention and control balozi at 6 months post-treatment (20% vs 33%, p = 0.07), nor did it at 1 year (43% vs 44%, p = 0.90). Infection with C trachomatis did not differ between groups at 6 months post-treatment (9% vs 7%, p = 0.45). Interpretation Intensive insecticide spraying reduced flies in the environment, but our results suggest that fly reduction after mass antibiotic treatment has no added benefit on reduction of trachoma.	Johns Hopkins Univ, Wilmer Eye Inst, Dana Ctr Prevent Ophthalmol, Baltimore, MD 21287 USA; MRC, Fajara, Gambia; Kongwa Trachoma Project, Kongwa, Tanzania; London Sch Hyg & Trop Med, London WC1, England	Johns Hopkins University; Johns Hopkins Medicine; University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine	West, SK (corresponding author), Johns Hopkins Univ, Wilmer Eye Inst, Dana Ctr Prevent Ophthalmol, Room 129,600 N Wolfe St, Baltimore, MD 21287 USA.	shwest@jhmi.edu		Emerson, Paul/0000-0002-6478-8816; Mabey, David/0000-0002-0031-8276	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Chavasse DC, 1999, LANCET, V353, P22, DOI 10.1016/S0140-6736(98)03366-2; COHEN D, 1991, LANCET, V337, P993, DOI 10.1016/0140-6736(91)92657-N; COURTRIGHT P, 1991, BRIT J OPHTHALMOL, V75, P322, DOI 10.1136/bjo.75.6.322; Emerson PM, 2000, T ROY SOC TROP MED H, V94, P28, DOI 10.1016/S0035-9203(00)90427-9; Emerson PM, 2004, LANCET, V363, P1093, DOI 10.1016/S0140-6736(04)15891-1; Emerson PM, 2001, MED VET ENTOMOL, V15, P314, DOI 10.1046/j.0269-283x.2001.00318.x; Emerson PM, 1999, LANCET, V353, P1401, DOI 10.1016/S0140-6736(98)09158-2; ESREY SA, 1991, B WORLD HEALTH ORGAN, V69, P609; Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844; Solomon AW, 2003, LANCET, V362, P198, DOI 10.1016/S0140-6736(03)13909-8; TAYLOR HR, 1989, ARCH OPHTHALMOL-CHIC, V107, P1821, DOI 10.1001/archopht.1989.01070020903037; THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477; West ES, 2005, INVEST OPHTH VIS SCI, V46, P83, DOI 10.1167/iovs.04-0327; WEST S, 1995, LANCET, V345, P155, DOI 10.1016/S0140-6736(95)90167-1; West SK, 2005, LANCET, V366, P1296, DOI 10.1016/S0140-6736(05)67529-0; West SK, 2004, PROG RETIN EYE RES, V23, P381, DOI 10.1016/j.preteyeres.2004.04.001; WEST SK, 1991, INT J EPIDEMIOL, V20, P1088, DOI 10.1093/ije/20.4.1088; World Health Assembly, 1998, WHA5111	18	41	41	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 12	2006	368	9535					596	600		10.1016/S0140-6736(06)69203-9	http://dx.doi.org/10.1016/S0140-6736(06)69203-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	074OF	16905024				2022-12-28	WOS:000239821000033
J	Horsley, V; O'Carroll, D; Tooze, R; Ohinata, Y; Saitou, M; Obukhanych, T; Nussenzweig, M; Tarakhovsky, A; Fuchs, E				Horsley, Valerie; O'Carroll, Donal; Tooze, Reuben; Ohinata, Yasuhide; Saitou, Mitinori; Obukhanych, Tetyana; Nussenzweig, Michel; Tarakhovsky, Alexander; Fuchs, Elaine			Blimp1 defines a progenitor population that governs cellular input to the sebaceous gland	CELL			English	Article							EPIDERMAL STEM-CELLS; HAIR FOLLICLE BULGE; C-MYC; MOUSE SKIN; IN-VITRO; DIFFERENTIATION; REPRESSION; EXPRESSION; LINEAGE; MECHANISMS	Epidermal lineage commitment occurs when multipotent stem cells are specified to three lineages: the epidermis, the hair follicle, and the sebaceous gland (SG). How and when a lineage becomes specified remains unknown. Here, we report the existence of a population of unipotent progenitor cells that reside in the SG and express the transcriptional repressor Blimp1. Using cell-culture studies and genetic lineage tracing, we demonstrate that Blimp1-expressing cells are upstream from other cells of the SG lineage. Blimp1 appears to govern cellular input into the gland since its loss leads to elevated c-myc expression, augmented cell proliferation, and SG hyperplasia. Finally, BrdU labeling experiments demonstrate that the SG defects associated with loss of Blimp1 lead to enhanced bulge stem cell activity, suggesting that when normal SG homeostasis is perturbed, multipotent stem cells in the bulge can be mobilized to correct this imbalance.	Rockefeller Univ, Howard Hughes Med Inst, Lab Mammalian Cell Biol & Dev, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, Lab Lymphocyte Signaling, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, Lab Mol Immunol, New York, NY 10021 USA; Univ Leeds, Leeds Inst Mol Med, Div Expt Haematol, Leeds LS9 7TF, W Yorkshire, England; RIKEN, Kobe Inst, Ctr Dev Biol, Lab Mammalian Germ Cell Biol,Chuo Ku, Kobe, Hyogo 6500047, Japan	Howard Hughes Medical Institute; Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; University of Leeds; RIKEN	Fuchs, E (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, Lab Mammalian Cell Biol & Dev, New York, NY 10021 USA.	fuchslb@rockefeller.edu	Nussenzweig, Michel/AAE-7292-2019; Fuchs, Elaine/G-1565-2016	Tooze, Reuben/0000-0003-2915-7119; O'Carroll, Donal/0000-0002-8626-2217	MRC [G108/500] Funding Source: UKRI; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050452, R01AR031737] Funding Source: NIH RePORTER; Medical Research Council [G108/500] Funding Source: Medline; NIAMS NIH HHS [R01 AR031737, R01 AR031737-24, R01-AR050452, R01 AR050452] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Allen M, 2003, AM J PATHOL, V163, P2173, DOI 10.1016/S0002-9440(10)63574-2; Alonso LC, 2003, HORM RES, V60, P1, DOI 10.1159/000070821; Arnold I, 2001, CURR BIOL, V11, P558, DOI 10.1016/S0960-9822(01)00154-3; Blanpain C, 2004, CELL, V118, P635, DOI 10.1016/j.cell.2004.08.012; Bull JJ, 2005, BRIT J DERMATOL, V152, P1125, DOI 10.1111/j.1365-2133.2005.06458.x; Chang DH, 2002, MECH DEVELOP, V117, P305, DOI 10.1016/S0925-4773(02)00189-2; Dai X, 2004, CURR OPIN GENET DEV, V14, P485, DOI 10.1016/j.gde.2004.07.002; Fuchs E, 2001, DEV CELL, V1, P13, DOI 10.1016/S1534-5807(01)00022-3; Ghazizadeh S, 2001, EMBO J, V20, P1215, DOI 10.1093/emboj/20.6.1215; Gyory I, 2004, NAT IMMUNOL, V5, P299, DOI 10.1038/ni1046; HUANG S, 1994, CELL, V78, P9, DOI 10.1016/0092-8674(94)90565-7; Ito M, 2005, NAT MED, V11, P1351, DOI 10.1038/nm1328; Kaufman CK, 2003, GENE DEV, V17, P2108, DOI 10.1101/gad.1115203; KELLER AD, 1991, GENE DEV, V5, P868, DOI 10.1101/gad.5.5.868; Lee SC, 2003, MOL IMMUNOL, V39, P923, DOI 10.1016/S0161-5890(03)00029-4; Levy V, 2005, DEV CELL, V9, P855, DOI 10.1016/j.devcel.2005.11.003; Lin KI, 2000, MOL CELL BIOL, V20, P8684, DOI 10.1128/MCB.20.23.8684-8695.2000; Lin Y, 1997, SCIENCE, V276, P596, DOI 10.1126/science.276.5312.596; Michalik L, 2001, J CELL BIOL, V154, P799, DOI 10.1083/jcb.200011148; Morris RJ, 2004, NAT BIOTECHNOL, V22, P411, DOI 10.1038/nbt950; Niemann C, 2003, P NATL ACAD SCI USA, V100, P11873, DOI 10.1073/pnas.1834202100; Ohinata Y, 2005, NATURE, V436, P207, DOI 10.1038/nature03813; Olivera-Martinez I, 2004, INT J DEV BIOL, V48, P93, DOI 10.1387/ijdb.15272374; Oshima H, 2001, CELL, V104, P233, DOI 10.1016/S0092-8674(01)00208-2; Pan YH, 2004, DEV CELL, V7, P731, DOI 10.1016/j.devcel.2004.09.014; Panteleyev AA, 2000, ARCH DERMATOL RES, V292, P573, DOI 10.1007/s004030000182; Ren B, 1999, GENE DEV, V13, P125, DOI 10.1101/gad.13.1.125; Rendl M, 2005, PLOS BIOL, V3, P1910, DOI 10.1371/journal.pbio.0030331; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Rosenfield RL, 2002, IN VITRO CELL DEV-AN, V38, P54, DOI 10.1290/1071-2690(2002)038<0054:SECDRC>2.0.CO;2; Rosenfield RL, 1998, DERMATOLOGY, V196, P43, DOI 10.1159/000017864; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; STEWART ME, 1992, SEMIN DERMATOL, V11, P100; Taylor G, 2000, CELL, V102, P451, DOI 10.1016/S0092-8674(00)00050-7; Trempus CS, 2003, J INVEST DERMATOL, V120, P501, DOI 10.1046/j.1523-1747.2003.12088.x; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; Tunyaplin C, 2004, J IMMUNOL, V173, P1158, DOI 10.4049/jimmunol.173.2.1158; Vasioukhin V, 1999, P NATL ACAD SCI USA, V96, P8551, DOI 10.1073/pnas.96.15.8551; Vincent SD, 2005, DEVELOPMENT, V132, P1315, DOI 10.1242/dev.01711; Waikel RL, 2001, NAT GENET, V28, P165, DOI 10.1038/88889; Yu J, 2000, MOL CELL BIOL, V20, P2592, DOI 10.1128/MCB.20.7.2592-2603.2000; Zanet J, 2005, J CELL SCI, V118, P1693, DOI 10.1242/jcs.02298	42	331	337	0	12	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 11	2006	126	3					597	609		10.1016/j.cell.2006.06.048	http://dx.doi.org/10.1016/j.cell.2006.06.048			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	075KI	16901790	Bronze, Green Accepted			2022-12-28	WOS:000239883400018
J	Miller, JD; Scott, EC; Okamoto, S				Miller, Jon D.; Scott, Eugenie C.; Okamoto, Shinji			Public acceptance of evolution	SCIENCE			English	Editorial Material							SCIENCE		Michigan State Univ, E Lansing, MI 48824 USA; Natl Ctr Sci Educ, Oakland, CA 94609 USA; Kobe Univ, Rokkaido, Hyogo, Japan	Michigan State University; Kobe University	Miller, JD (corresponding author), Michigan State Univ, E Lansing, MI 48824 USA.	jdmiller@msu.edu		Scott, Eugenie Carol/0000-0003-3795-8207				Barr Stephen M., 2005, 1 THINGS, V156, P9; Blalock H., 1960, SOCIAL STAT; Hayduk L. A., 1987, STRUCTURAL EQUATION; Joreskog, 1993, NEW FEATURE LISREL 8; Miller J.D., 2001, BIOMEDICAL COMMUNICA; Miller J. D, 2001, FREE CHOICE SCI ED W, P93; Miller J.D., 1997, PUBLIC PERCEPTIONS S; Miller JD, 2001, SCI COMMUN, V22, P256, DOI 10.1177/1075547001022003003; Paterson FRA, 1999, AM BIOL TEACH, V61, P358; Pollak SD, 2004, DEVELOPMENTAL SCI, V7, P10, DOI 10.1111/j.1467-7687.2004.00317.x; Scott E. C., 2004, EVOLUTION VS CREATIO; 2004, NEW YORK TIMES  1118	12	385	398	3	103	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 11	2006	313	5788					765	766		10.1126/science.1126746	http://dx.doi.org/10.1126/science.1126746			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	072KC	16902112				2022-12-28	WOS:000239671300030
J	Muthuswamy, SK				Muthuswamy, Senthil K.			ErbB2 makes beta 4 integrin an accomplice in tumorigenesis	CELL			English	Editorial Material							BETA-1-INTEGRIN; PROLIFERATION; DISRUPTION	Integrins modulate signaling by growth factor receptors, but their role during tumorigenesis is not clear. Guo et al. (2006) now demonstrate that alpha 6 beta 4 integrin cooperates with ErbB2 in the formation of mammary tumors and discover distinct pathways that regulate cellular proliferation and adhesion downstream of the ErbB2-integrin complex.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Muthuswamy, SK (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	muthuswa@cshl.edu	Muthuswamy, Senthil K/AGY-2834-2022	Muthuswamy, Senthil K/0000-0001-6564-9634				Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; GUO W, 2006, CELL; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Liu H, 2004, J CELL BIOL, V164, P603, DOI 10.1083/jcb.200306090; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Owens DM, 2003, J CELL SCI, V116, P3783, DOI 10.1242/jcs.00725; Simon AR, 2000, SCIENCE, V290, P144, DOI 10.1126/science.290.5489.144; Wang F, 1998, P NATL ACAD SCI USA, V95, P14821, DOI 10.1073/pnas.95.25.14821; White DE, 2004, CANCER CELL, V6, P159, DOI 10.1016/j.ccr.2004.06.025	11	10	10	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 11	2006	126	3					443	445		10.1016/j.cell.2006.07.020	http://dx.doi.org/10.1016/j.cell.2006.07.020			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	075KI	16901776	Bronze			2022-12-28	WOS:000239883400003
J	Cavalleri, A; Wall, S; Simpson, C; Statz, E; Ward, DW; Nelson, KA; Rini, M; Schoenlein, RW				Cavalleri, A.; Wall, S.; Simpson, C.; Statz, E.; Ward, D. W.; Nelson, K. A.; Rini, M.; Schoenlein, R. W.			Tracking the motion of charges in a terahertz light field by femtosecond X-ray diffraction	NATURE			English	Article							SYNCHROTRON-RADIATION; CHERENKOV RADIATION; PHONON-POLARITONS; RAMAN-SCATTERING; PULSES; DYNAMICS; LITAO3; MEDIA; MODES	In condensed matter, light propagation near resonances is described in terms of polaritons, electro- mechanical excitations in which the time- dependent electric field is coupled to the oscillation of charged masses(1,2). This description underpins our understanding of the macroscopic optical properties of solids, liquids and plasmas, as well as of their dispersion with frequency. In ferroelectric materials, terahertz radiation propagates by driving infrared- active lattice vibrations, resulting in phononpolariton waves. Electro- optic sampling with femtosecond optical pulses(3-5) can measure the time- dependent electrical polarization, providing a phase- sensitive analogue to optical Raman scattering(6,7). Here we use femtosecond time- resolved X- ray diffraction(8-10), a phase- sensitive analogue to inelastic X- ray scattering(11-13), to measure the corresponding displacements of ions in ferroelectric lithium tantalate, LiTaO3. Amplitude and phase of all degrees of freedom in a light field are thus directly measured in the time domain. Notably, extension of other X- ray techniques to the femtosecond timescale ( for example, magnetic or anomalous scattering) would allow for studies in complex systems, where electric fields couple to multiple degrees of freedom(14).	Univ Oxford, Dept Phys, Clarendon Lab, Oxford OX1 3PU, England; Rutherford Appleton Lab, Cent Laser Facil & Diamond Light Source, Didcot OX11 0QX, Oxon, England; MIT, Dept Chem, Cambridge, MA 02139 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Mat Sci, Berkeley, CA 94720 USA	University of Oxford; UK Research & Innovation (UKRI); Science & Technology Facilities Council (STFC); STFC Rutherford Appleton Laboratory; Massachusetts Institute of Technology (MIT); United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Cavalleri, A (corresponding author), Univ Oxford, Dept Phys, Clarendon Lab, Oxford OX1 3PU, England.	a.cavalleri1@physics.ox.ac.uk	Kim, Yu Jin/A-2433-2012; Wall, Simon/E-3771-2012; Schoenlein, Robert W/D-1301-2014	Wall, Simon/0000-0002-6136-0224; Schoenlein, Robert W/0000-0002-6066-7566; Millson, Chris/0000-0002-5304-0108				AUSTON DH, 1984, PHYS REV LETT, V53, P1555, DOI 10.1103/PhysRevLett.53.1555; BAKKER HJ, 1993, PHYS REV B, V48, P13524, DOI 10.1103/PhysRevB.48.13524; Bargheer M, 2004, SCIENCE, V306, P1771, DOI 10.1126/science.1104739; BARKER AS, 1972, REV MOD PHYS, V44, P18, DOI 10.1103/RevModPhys.44.18; Bucksbaum PH, 1999, SOLID STATE COMMUN, V111, P535, DOI 10.1016/S0038-1098(99)00235-5; Cavalleri A, 2000, PHYS REV LETT, V85, P586, DOI 10.1103/PhysRevLett.85.586; Cavalleri A, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.067405; Cavalleri A, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.237401; Crimmins TF, 2002, J CHEM PHYS, V117, P2882, DOI 10.1063/1.1491948; DOUGHERTY TP, 1992, SCIENCE, V258, P770, DOI 10.1126/science.258.5083.770; Feurer T, 2003, SCIENCE, V299, P374, DOI 10.1126/science.1078726; Kimel AV, 2005, NATURE, V435, P655, DOI [10.1038/nature03564, 10.1038/nature03S64]; Kimel AV, 2004, NATURE, V429, P850, DOI 10.1038/nature02659; Kimura T, 2003, NATURE, V426, P55, DOI 10.1038/nature02018; Lindenberg AM, 2005, SCIENCE, V308, P392, DOI 10.1126/science.1107996; Lindenberg AM, 2000, PHYS REV LETT, V84, P111, DOI 10.1103/PhysRevLett.84.111; Lottermoser T, 2004, NATURE, V430, P541, DOI 10.1038/nature02728; MILLS DL, 1974, REP PROG PHYS, V37, P817, DOI 10.1088/0034-4885/37/7/001; Nazarkin A, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.207401; Rischel C, 1997, NATURE, V390, P490, DOI 10.1038/37317; Schoenlein RW, 2000, SCIENCE, V287, P2237, DOI 10.1126/science.287.5461.2237; Sokolowski-Tinten K, 2003, NATURE, V422, P287, DOI 10.1038/nature01490; Stevens TE, 2001, SCIENCE, V291, P627, DOI 10.1126/science.291.5504.627; Stoyanov NS, 2002, NAT MATER, V1, P95, DOI 10.1038/nmat725; Wahlstrand JK, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.054301; Zholents AA, 1996, PHYS REV LETT, V76, P912, DOI 10.1103/PhysRevLett.76.912	26	82	82	1	84	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 10	2006	442	7103					664	666		10.1038/nature05041	http://dx.doi.org/10.1038/nature05041			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	071UU	16900195				2022-12-28	WOS:000239630200040
J	Roche, PA; Annas, GJ				Roche, Patricia A.; Annas, George J.			DNA testing, banking, and genetic privacy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Boston Univ, Sch Publ Hlth, Dept Hlth Law Bioeth & Human Rights, Boston, MA 02118 USA	Boston University	Roche, PA (corresponding author), Boston Univ, Sch Publ Hlth, Dept Hlth Law Bioeth & Human Rights, Boston, MA 02118 USA.			Roche, Patricia/0000-0001-7884-480X; Annas, George/0000-0001-5836-7831				ANNAS GJ, 1993, JAMA-J AM MED ASSOC, V270, P2346, DOI 10.1001/jama.270.19.2346; Begley Sharon, 2006, Wall St J (East Ed), pB8; HARMON A, 2006, NY TIMES        0412, pA1; Roche PA, 2001, NAT REV GENET, V2, P392, DOI 10.1038/35072029	4	27	31	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 10	2006	355	6					545	546		10.1056/NEJMp068136	http://dx.doi.org/10.1056/NEJMp068136			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	071QM	16899773	Green Published			2022-12-28	WOS:000239616700003
J	Wolfberg, AJ				Wolfberg, Adam J.			Genes on the Web - Direct-to-consumer marketing of genetic testing	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																			0	52	56	1	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 10	2006	355	6					543	545		10.1056/NEJMp068079	http://dx.doi.org/10.1056/NEJMp068079			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	071QM	16899772				2022-12-28	WOS:000239616700002
J	Gilks, CF; Crowley, S; Ekpini, R; Gove, S; Perriens, J; Souteyrand, Y; Sutherland, D; Vitoria, M; Guerma, T; De Cock, K				Gilks, Charles F.; Crowley, Siobhan; Ekpini, Rene; Gove, Sandy; Perriens, Jos; Souteyrand, Yves; Sutherland, Don; Vitoria, Marco; Guerma, Teguest; De Cock, Kevin			The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings	LANCET			English	Article							THERAPY	WHO has proposed a public-health approach to antiretroviral therapy (ART) to enable scaling-up access to treatment for HIV-positive people in developing countries, recognising that the western model of specialist physician management and advanced laboratory monitoring is not feasible in resource-poor settings. In this approach, standardised simplified treatment protocols and decentralised service delivery enable treatment to be delivered to large numbers of HIV-positive adults and children through the public and private sector. Simplified tools and approaches to clinical decision-making, centred on the "four Ss"-when to: start drug treatment; substitute for toxicity; switch after treatment failure; and stop-enable lower level health-care workers to deliver care. Simple limited formularies have driven large-scale production of fixed-dose combinations for first-line treatment for adults and lowered prices, but to ensure access to ART in the poorest countries, the care and drugs should be given free at point of service delivery. Population-based surveillance for acquired and transmitted resistance is needed to address concerns that switching regimens on the basis of clinical criteria for failure alone could lead to widespread emergence of drug-resistant virus strains. The integrated management of adult or childhood illness (IMAI/IMCI) facilitates decentralised implementation that is integrated within existing health systems. Simplified operational guidelines, tools, and training materials enable clinical teams in primary-care and second-level facilities to deliver HIV prevention, HIV care, and ART, and to use a standardised patient-tracking system.	WHO, Dept HIV AIDS, CH-1211 Geneva, Switzerland	World Health Organization	Gilks, CF (corresponding author), WHO, Dept HIV AIDS, CH-1211 Geneva, Switzerland.	gilksc@who.int	Gilks, Charles/B-4184-2012	Gilks, Charles/0000-0002-8953-3123				Beaglehole R, 2004, LANCET, V363, P2084, DOI 10.1016/S0140-6736(04)16461-1; BECK EJ, IN PRESS AIDS; Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2; Ferradini L, 2006, LANCET, V367, P1335, DOI 10.1016/S0140-6736(06)68580-2; Gallant JE, 2005, J INFECT DIS, V192, P1921, DOI 10.1086/498069; Gazzard B, 2005, HIV MED, V6, P1, DOI 10.1111/j.1468-1293.2005.0311b.x; Gulick RM, 2004, NEW ENGL J MED, V350, P1850, DOI 10.1056/NEJMoa031772; Kaleebu P, 2006, AIDS, V20, P1391, DOI 10.1097/01.aids.0000233572.59522.45; Libamba E, 2006, B WORLD HEALTH ORGAN, V84, P320; Mundy C, 2000, T ROY SOC TROP MED H, V94, P583, DOI 10.1016/S0035-9203(00)90098-1; RAMACHANDRAN G, 2006, J ACQ IMMUN DEF SYND, V41, P1; *US DHHS, 2006, GUID US ANT AG HIV 1; WHO, 2006, ANT DRUGS TREAT PREG; WHO, 2022, ANT DRUGS TREAT PREG; *WHO, 2003, PUBL HLTH APPR ART O; *WHO, 2006, REC DIAGN HIV INF IN; WHO, HIV DRUG RES; *WHO, IMAI IMCI TOOLK CAN; *WHO, 2003, TREAT 3 MILL 2005 MA; WHO, 2005, PRACT CHARG US FEES; *WHO, 2005, PAT MON GUID HIV CAR; *WHO, 2006, WHO UNAIDS PROGR GLO; World Health Organisation, 2006, ANT THER HIV INF INF; World Health Organization, 2004, GUID ETH EQ ACC HIV; World Health Organization, 2004, SCAL ANT THER RES LT; World Health Organization, 2002, SCAL ANT THER RES LT; World Health Organization, 2006, ANT THER HIV INF AD; World Health Organization (WHO), 2006, GUID COTR PROPH HIV; World health organization (WHO), 2006, REV WHO CLIN STAG IM; World Health Organization (WHO), 2006, WORLD HLTH REP 2006	30	494	508	2	35	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 5	2006	368	9534					505	510		10.1016/S0140-6736(06)69158-7	http://dx.doi.org/10.1016/S0140-6736(06)69158-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	071AL	16890837				2022-12-28	WOS:000239569000033
J	Asher, MI; Montefort, S; Bjorksten, B; Lai, CKW; Strachan, DP; Weiland, SK; Williams, H				Asher, M. Innes; Montefort, Stephen; Bjorksten, Bengt; Lai, Christopher K. W.; Strachan, David P.; Weiland, Stephan K.; Williams, Hywel		ISAAC Phase Three Study Grp	Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys	LANCET			English	Article							ATOPIC ECZEMA; RESPIRATORY SYMPTOMS; CHILDREN; DISEASES; RATIONALE; RHINITIS; SENSITIZATION	Background Data for trends in prevalence of asthma, allergic rhinoconjunctivitis, and eczema over time are scarce. We repeated the International Study of Asthma and Allergies in Childhood (ISAAC) at least 5 years after Phase One, to examine changes in the prevalence of symptoms of these disorders. Methods For the ISAAC Phase Three study, between 2002 and 2003, we did a cross-sectional questionnaire survey of 193 404 children aged 6-7 years from 66 centres in 37 countries, and 304 679 children aged 13-14 years from 106 centres in 56 countries, chosen from a random sample of schools in a defined geographical area. Findings Phase Three was completed a mean of 7 years after Phase One. Most centres showed a change in prevalence of 1 or more SE for at least one disorder, with increases being twice as common as decreases, and increases being more common in the 6-7 year age-group than in the 13-14 year age-group, and at most levels of mean prevalence. An exception was asthma symptoms in the older age-group, in which decreases were more common at high prevalence. For both age-groups, more centres showed increases in all three disorders more often than showing decreases, but most centres had mixed changes. Interpretation The rise in prevalence of symptoms in many centres is concerning, but the absence of increases in prevalence of asthma symptoms for centres with existing high prevalence in the older age-group is reassuring. The divergent trends in prevalence of symptoms of allergic diseases form the basis for further research into the causes of such disorders.	Univ Auckland, Fac Med & Hlth Sci, Dept Paediat, Auckland 1010, New Zealand; Univ Malta, Dept Med, Msida, Malta; Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China; Univ London, St Georges, Div Community Hlth Sci, London WC1E 7HU, England; Univ Ulm, Dept Epidemiol, Ulm, Germany; Univ Nottingham Hosp, Queens Med Ctr, Ctr Evidence Based Dermatol, Nottingham NG7 2UH, England	University of Auckland; University of Malta; Karolinska Institutet; Chinese University of Hong Kong; St Georges University London; University of London; Ulm University; University of Nottingham	Asher, MI (corresponding author), Univ Auckland, Fac Med & Hlth Sci, Dept Paediat, Auckland 1010, New Zealand.	mi.asher@auckland.ac.nz	Ellwood, Philippa/G-7555-2015; Fahimifar, Sepideh/M-5303-2019; Asher, Innes/O-2604-2016; Anderson, Hugh R/A-7417-2016; Clayton, Tadd O/B-7914-2009	Ellwood, Philippa/0000-0002-1994-4023; Asher, Innes/0000-0003-1768-3832; williams, hywel/0000-0002-5646-3093				Anderson HR, 2001, AM J PUBLIC HEALTH, V91, P1126, DOI 10.2105/AJPH.91.7.1126; Asher MI, 1998, EUR RESPIR J, V12, P315; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bjorksten B, 2004, SPRINGER SEMIN IMMUN, V25, P257, DOI 10.1007/s00281-003-0142-2; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Burr ML, 2003, CLIN EXP ALLERGY, V33, P1675, DOI 10.1111/j.1365-2222.2003.01816.x; Devenny A, 2004, BMJ-BRIT MED J, V329, P489, DOI 10.1136/bmj.38139.666447.F7; Ellwood P, 2005, INT J TUBERC LUNG D, V9, P10; Ellwood P, 2001, EUR RESPIR J, V17, P436, DOI 10.1183/09031936.01.17304360; Enarson DA, 2005, INT J TUBERC LUNG D, V9, P1; Foliaki S, 2004, INT J EPIDEMIOL, V33, P558, DOI 10.1093/ije/dyh031; Heinrich J, 2002, EUR RESPIR J, V19, P1040, DOI 10.1183/09031936.02.00261802; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Kalyoncu AF, 1999, PEDIATR ALLERGY IMMU, V10, P261, DOI 10.1034/j.1399-3038.1999.00031.x; Mallol J, 2000, PEDIATR PULM, V30, P439, DOI 10.1002/1099-0496(200012)30:6<439::AID-PPUL1>3.0.CO;2-E; Mitchell EA, 2001, EUR J EPIDEMIOL, V17, P667, DOI 10.1023/A:1015500508261; RAO JNK, 1992, BIOMETRICS, V48, P577, DOI 10.2307/2532311; Riikjarv MA, 2000, EUR RESPIR J, V16, P86, DOI 10.1034/j.1399-3003.2000.16a15.x; Selnes A, 2005, ALLERGY, V60, P894, DOI 10.1111/j.1398-9995.2005.00797.x; Stewart AW, 2001, INT J EPIDEMIOL, V30, P173, DOI 10.1093/ije/30.1.173; Strachan DP, 1997, PEDIAT ALLERG IMM-UK, V8, P161, DOI 10.1111/j.1399-3038.1997.tb00156.x; Thomason MJ, 2000, THORAX, V55, P785, DOI 10.1136/thorax.55.9.785; von Mutius E, 2000, THORAX, V55, P449, DOI 10.1136/thorax.55.6.449; von Mutius E, 1998, LANCET, V351, P862, DOI 10.1016/S0140-6736(97)10100-3; Weiland SK, 2004, EUR RESPIR J, V24, P406, DOI 10.1183/09031936.04.00090303; Weiland SK, 1999, LANCET, V353, P2040, DOI 10.1016/S0140-6736(99)01609-8; Weiland SK, 2004, OCCUP ENVIRON MED, V61, P609, DOI 10.1136/oem.2002.006809; Williams H, 1999, J ALLERGY CLIN IMMUN, V103, P125, DOI 10.1016/S0091-6749(99)70536-1; Zollner IK, 2005, THORAX, V60, P545, DOI 10.1136/thx.2004.029561	30	2860	3021	7	38	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG-SEP	2006	368	9537					733	743		10.1016/S0140-6736(06)69283-0	http://dx.doi.org/10.1016/S0140-6736(06)69283-0			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	080ID	16935684				2022-12-28	WOS:000240240200025
J	Freedman, DJ; Assad, JA				Freedman, David J.; Assad, John A.			Experience-dependent representation of visual categories in parietal cortex	NATURE			English	Article							LATERAL INTRAPARIETAL AREA; PERCEPTUAL DECISION; PREFRONTAL CORTEX; SINGLE NEURONS; MONKEY; ATTENTION; STIMULI; SIGNALS; MOTION	Categorization is a process by which the brain assigns meaning to sensory stimuli. Through experience, we learn to group stimuli into categories, such as 'chair', 'table' and 'vehicle', which are critical for rapidly and appropriately selecting behavioural responses(1,2). Although much is known about the neural representation of simple visual stimulus features (for example, orientation, direction and colour), relatively little is known about how the brain learns and encodes the meaning of stimuli. We trained monkeys to classify 360 degrees of visual motion directions into two discrete categories, and compared neuronal activity in the lateral intraparietal (LIP) and middle temporal (MT) areas, two interconnected brain regions(3) known to be involved in visual motion processing(4-6). Here we show that neurons in LIP-an area known to be centrally involved in visuo-spatial attention(7-9), motor planning(10-13) and decision-making(14-16)-robustly reflect the category of motion direction as a result of learning. The activity of LIP neurons encoded directions of motion according to their category membership, and that encoding shifted after the monkeys were retrained to group the same stimuli into two new categories. In contrast, neurons in area MT were strongly direction selective but carried little, if any, explicit category information. This indicates that LIP might be an important nexus for the transformation of visual direction selectivity to more abstract representations that encode the behavioural relevance, or meaning, of stimuli.	Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Freedman, DJ (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, 220 Longwood Ave, Boston, MA 02115 USA.	davidfreedman@alum.mit.edu						Andersen RA, 2002, ANNU REV NEUROSCI, V25, P189, DOI 10.1146/annurev.neuro.25.112701.142922; Ashby EG, 2005, ANNU REV PSYCHOL, V56, P149, DOI 10.1146/annurev.psych.56.091103.070217; Barsalou L. W., 1992, COGNITIVE PSYCHOL OV; Batista AP, 1999, SCIENCE, V285, P257, DOI 10.1126/science.285.5425.257; Bisley JW, 2003, SCIENCE, V299, P81, DOI 10.1126/science.1077395; Bisley JW, 2004, J NEUROSCI, V24, P1833, DOI 10.1523/JNEUROSCI.5007-03.2004; Born RT, 2005, ANNU REV NEUROSCI, V28, P157, DOI 10.1146/annurev.neuro.26.041002.131052; Buneo CA, 2002, NATURE, V416, P632, DOI 10.1038/416632a; Colby CL, 1999, ANNU REV NEUROSCI, V22, P319, DOI 10.1146/annurev.neuro.22.1.319; Colby CL, 1996, J NEUROPHYSIOL, V76, P2841, DOI 10.1152/jn.1996.76.5.2841; Freedman DJ, 2001, SCIENCE, V291, P312, DOI 10.1126/science.291.5502.312; Freedman DJ, 2002, J NEUROPHYSIOL, V88, P929, DOI 10.1152/jn.2002.88.2.929; Freedman DJ, 2003, J NEUROSCI, V23, P5235; FREEDMAN DJ, IN PRESS CEREB CORTE; Ghose GM, 2004, CURR OPIN NEUROBIOL, V14, P513, DOI 10.1016/j.conb.2004.07.003; Huk AC, 2005, J NEUROSCI, V25, P10420, DOI 10.1523/JNEUROSCI.4684-04.2005; Lewis JW, 2000, J COMP NEUROL, V428, P112, DOI 10.1002/1096-9861(20001204)428:1<112::AID-CNE8>3.0.CO;2-9; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Nieder A, 2004, P NATL ACAD SCI USA, V101, P7457, DOI 10.1073/pnas.0402239101; Platt ML, 1999, NATURE, V400, P233, DOI 10.1038/22268; Shadlen MN, 2001, J NEUROPHYSIOL, V86, P1916, DOI 10.1152/jn.2001.86.4.1916; Sigala N, 2002, NATURE, V415, P318, DOI 10.1038/415318a; Snyder LH, 1997, NATURE, V386, P167, DOI 10.1038/386167a0; Stoet G, 2004, NEURON, V42, P1003, DOI 10.1016/j.neuron.2004.06.003; Toth LJ, 2002, NATURE, V415, P165, DOI 10.1038/415165a; Vogels R, 1999, EUR J NEUROSCI, V11, P1223, DOI 10.1046/j.1460-9568.1999.00530.x; Williams ZM, 2003, NAT NEUROSCI, V6, P616, DOI 10.1038/nn1055	28	351	354	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 7	2006	443	7107					85	88		10.1038/nature05078	http://dx.doi.org/10.1038/nature05078			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	081JM	16936716				2022-12-28	WOS:000240313900044
J	Lopatin, AV; Averianov, AO				Lopatin, Alexey V.; Averianov, Alexander O.			An aegialodontid upper molar and the evolution of mammal dentition	SCIENCE			English	Article							TRIBOSPHENIC MAMMALS; MONGOLIA		Russian Acad Sci, Inst Paleontol, Moscow 117997, Russia; Russian Acad Sci, Inst Zool, St Petersburg 199034, Russia	Russian Academy of Sciences; Russian Academy of Sciences; Zoological Institute of the Russian Academy of Sciences	Lopatin, AV (corresponding author), Russian Acad Sci, Inst Paleontol, Profsojuznaya Ul 123, Moscow 117997, Russia.	lepus@zin.ru	Averianov, Alexander/M-8490-2013; Lopatin, Alexey/P-7465-2015	Averianov, Alexander/0000-0001-5948-0799; 				Crompton A., 1971, EARLY MAMMALS, P65; DASHZEVEG D, 1984, ZOOL J LINN SOC-LOND, V82, P217, DOI 10.1111/j.1096-3642.1984.tb00544.x; DASHZEVEG D, 1975, NATURE, V256, P402, DOI 10.1038/256402a0; KERMACK KA, 1965, PROC R SOC SER B-BIO, V162, P535, DOI 10.1098/rspb.1965.0055; Luo ZX, 2001, NATURE, V409, P53, DOI 10.1038/35051023; MARSHALL LG, 1992, LETHAIA, V25, P361, DOI 10.1111/j.1502-3931.1992.tb01639.x	6	27	32	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 25	2006	313	5790					1092	1092		10.1126/science.1128530	http://dx.doi.org/10.1126/science.1128530			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	076ZT	16931755				2022-12-28	WOS:000239998200037
J	Bishop, G; Brodkey, AC				Bishop, Gene; Brodkey, Amy C.			Personal responsibility and physician responsibility - West Virginia's Medicaid plan	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Penn Hosp, Philadelphia, PA 19107 USA; Penn Hlth Law Project, Philadelphia, PA USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA; Family Practice & Counseling Network, Behav Hlth Serv, Philadelphia, PA USA	University of Pennsylvania; University of Pennsylvania	Bishop, G (corresponding author), Penn Hosp, Philadelphia, PA 19107 USA.							Daly R., 2006, PSYCHIAT NEWS, V41, P10; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; Sox HC, 2002, ANN INTERN MED, V136, P243, DOI 10.7326/0003-4819-136-3-200202050-00012; 2006, CHARLESTON DAIL 0602	4	47	47	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 24	2006	355	8					756	758		10.1056/NEJMp068170	http://dx.doi.org/10.1056/NEJMp068170			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	076KA	16928992				2022-12-28	WOS:000239955200002
J	Devalia, V				Devalia, Vinod			Lesson of the week - Diagnosing vitamin B-12 deficiency on the basis of serum B-12 assay	BMJ-BRITISH MEDICAL JOURNAL			English	Article							COBALAMIN DEFICIENCY; METHYLMALONIC ACID; HIGH PREVALENCE; HOLOTRANSCOBALAMIN; DISORDERS; ANEMIA; FOLATE; OLDER		Princess Wales Hosp, Bridgend CF31 1RQ, Wales		Devalia, V (corresponding author), Princess Wales Hosp, Bridgend CF31 1RQ, Wales.	Vinod.Devalia@bromor-tr.wales.nhs.uk						Carmel R, 2000, CLIN CHEM, V46, P2017; Carmel R, 2000, ANNU REV MED, V51, P357, DOI 10.1146/annurev.med.51.1.357; Clarke R, 2003, AM J CLIN NUTR, V77, P1241, DOI 10.1093/ajcn/77.5.1241; Guralnik JM, 2004, BLOOD, V104, P2263, DOI 10.1182/blood-2004-05-1812; Henning BF, 2001, GERONTOLOGY, V47, P30, DOI 10.1159/000052767; Herrmann W, 2003, CLIN CHEM LAB MED, V41, P1478, DOI 10.1515/CCLM.2003.227; LINDENBAUM J, 1988, NEW ENGL J MED, V318, P1720, DOI 10.1056/NEJM198806303182604; LINDENBAUM J, 1990, AM J HEMATOL, V34, P99, DOI 10.1002/ajh.2830340205; Nilsson K, 2004, CLIN CHEM LAB MED, V42, P637, DOI 10.1515/CCLM.2004.109; PENNYPACKER LC, 1992, J AM GERIATR SOC, V40, P1197, DOI 10.1111/j.1532-5415.1992.tb03641.x; Refsum H, 2001, AM J CLIN NUTR, V74, P233; Solomon LR, 2005, BLOOD, V105, P978, DOI 10.1182/blood-2004-04-1641; Ward PCJ, 2002, CLIN LAB MED, V22, P435, DOI 10.1016/S0272-2712(01)00003-8	13	29	31	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 19	2006	333	7564					385	386		10.1136/bmj.333.7564.385	http://dx.doi.org/10.1136/bmj.333.7564.385			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	078OD	16916826	Green Published			2022-12-28	WOS:000240112200019
J	Severn, PS; Fraser, SG				Severn, Philip S.; Fraser, Scott G.			Bilateral cataracts and glaucoma induced by long-term use of oral prednisolone bought over the internet	LANCET			English	Editorial Material									Sunderland Eye Infirm, Sunderland SR2 9HP, England		Severn, PS (corresponding author), Sunderland Eye Infirm, Queen Alexandra Rd, Sunderland SR2 9HP, England.	pssevern@hotmail.com						BUTCHER JM, 1994, BRIT MED J, V309, P43, DOI 10.1136/bmj.309.6946.43; Gordon SM, 2006, J SUBST ABUSE TREAT, V30, P271, DOI 10.1016/j.jsat.2005.08.013; Jobling Andrew I, 2002, Clin Exp Optom, V85, P61; SIEGELITZKOVICH J, 1997, BRIT MED J, V314, P1501	4	12	12	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 12	2006	368	9535					618	618		10.1016/S0140-6736(06)69207-6	http://dx.doi.org/10.1016/S0140-6736(06)69207-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	074OF	16905028				2022-12-28	WOS:000239821000037
J	Hayashi, T				Hayashi, Tetsuya			Breaking the barrier between commensalism and pathogenicity	SCIENCE			English	Editorial Material							ESCHERICHIA-COLI; COLORECTAL-CANCER; POLYKETIDE		Miyazaki Univ, Frontier Sci Res Ctr, Div Bioenvironm Sci, Miyazaki 8891692, Japan	University of Miyazaki	Hayashi, T (corresponding author), Miyazaki Univ, Frontier Sci Res Ctr, Div Bioenvironm Sci, 5200 Kiyotake, Miyazaki 8891692, Japan.	thayash@med.miyazaki-u.ac.jp	Hayashi, Tetsuya/ABA-1074-2020					Du LH, 2001, METAB ENG, V3, P78, DOI 10.1006/mben.2000.0171; Escobar-Paramo P, 2004, APPL ENVIRON MICROB, V70, P5698, DOI 10.1128/AEM.70.9.5698-5700.2004; Hope ME, 2005, FEMS MICROBIOL LETT, V244, P1, DOI 10.1016/j.femsle.2005.01.029; Kaper JB, 2004, NAT REV MICROBIOL, V2, P123, DOI 10.1038/nrmicro818; Lax AJ, 2005, NAT REV MICROBIOL, V3, P343, DOI 10.1038/nrmicro1130; McDonald SAC, 2006, NAT CLIN PRACT GASTR, V3, P267, DOI 10.1038/ncpgasthep0473; Nougayrede JP, 2006, SCIENCE, V313, P848, DOI 10.1126/science.1127059; Nowrouzian FL, 2005, J INFECT DIS, V191, P1078, DOI 10.1086/427996; Walsh CT, 2004, SCIENCE, V303, P1805, DOI 10.1126/science.1094318	9	10	11	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 11	2006	313	5788					772	773		10.1126/science.1131752	http://dx.doi.org/10.1126/science.1131752			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	072KC	16902117				2022-12-28	WOS:000239671300035
J	Ito, Y; Nakanomyo, I; Motose, H; Iwamoto, K; Sawa, S; Dohmae, N; Fukuda, H				Ito, Yasuko; Nakanomyo, Ikuko; Motose, Hiroyasu; Iwamoto, Kuninori; Sawa, Shinichiro; Dohmae, Naoshi; Fukuda, Hiroo			Dodeca-CLE peptides as suppressors of plant stem cell differentiation	SCIENCE			English	Article							TRACHEARY ELEMENT DIFFERENTIATION; ROOT-MERISTEM; ARABIDOPSIS; CLAVATA3; SHOOT; CLV3; PATHWAY; FAMILY; DOMAIN; GENES	In plants and animals, small peptide ligands that signal in cell-cell communication have been suggested to be a crucial component of development. A bioassay of single-cell transdifferentation demonstrates that a dodecapeptide with two hydroxyproline residues is the functional product of genes from the CLE family, which includes CLAVATA3 in Arabidopsis. The dodecapeptide suppresses xylem cell development at a concentration of 10(-11) M and promotes cell division. An application, corresponding to all 26 Arabidopsis CLE protein family members, of synthetic dodecapeptides reveals two counteracting signaling pathways involved in stem cell fate.	Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, Tokyo 1130033, Japan; RIKEN, Biomol Characterizat Team, Wako, Saitama 3510198, Japan	University of Tokyo; RIKEN	Fukuda, H (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	fukuda@biol.s.u-tokyo.ac.jp	Dohmae, Naoshi/C-2040-2011; MOTOSE, Hiroyasu/B-1474-2011	Dohmae, Naoshi/0000-0002-5242-9410; Sawa, Shinichiro/0000-0002-9309-9104				Brand U, 2000, SCIENCE, V289, P617, DOI 10.1126/science.289.5479.617; Casamitjana-Martinez E, 2003, CURR BIOL, V13, P1435, DOI 10.1016/S0960-9822(03)00533-5; Clark SE, 1997, CELL, V89, P575, DOI 10.1016/S0092-8674(00)80239-1; Cock JM, 2001, PLANT PHYSIOL, V126, P939, DOI 10.1104/pp.126.3.939; Dievart A, 2004, DEVELOPMENT, V131, P251, DOI 10.1242/dev.00998; Fiers M, 2005, PLANT CELL, V17, P2542, DOI 10.1105/tpc.105.034009; Fletcher LC, 1999, SCIENCE, V283, P1911, DOI 10.1126/science.283.5409.1911; Fukuda H, 2004, NAT REV MOL CELL BIO, V5, P379, DOI 10.1038/nrm1364; Fukuda H, 1997, PLANT CELL, V9, P1147, DOI 10.1105/tpc.9.7.1147; Hobe M, 2003, DEV GENES EVOL, V213, P371, DOI 10.1007/s00427-003-0329-5; Kepinski S, 2006, CURR OPIN PLANT BIOL, V9, P28, DOI 10.1016/j.pbi.2005.11.001; Kondo T, 2006, SCIENCE, V313, P845, DOI 10.1126/science.1128439; Lenhard M, 2003, DEVELOPMENT, V130, P3163, DOI 10.1242/dev.00525; Matsubayashi Y, 2006, ANNU REV PLANT BIOL, V57, P649, DOI 10.1146/annurev.arplant.56.032604.144204; Motose H, 2004, NATURE, V429, P873, DOI 10.1038/nature02613; Ni J, 2006, PLANT PHYSIOL, V140, P726, DOI 10.1104/pp.105.072678; Olsen AN, 2003, TRENDS PLANT SCI, V8, P55, DOI 10.1016/S1360-1385(03)00003-7; Shimizu M, 2005, PLANT J, V42, P877, DOI 10.1111/j.1365-313X.2005.02419.x; Strabala TJ, 2006, PLANT PHYSIOL, V140, P1331, DOI 10.1104/pp.105.075515; Torii KU, 2004, INT REV CYTOL, V234, P1, DOI 10.1016/S0074-7696(04)34001-5; Williams L, 2005, CURR OPIN PLANT BIOL, V8, P582, DOI 10.1016/j.pbi.2005.09.010; Yamamoto R, 1997, PLANT CELL PHYSIOL, V38, P980, DOI 10.1093/oxfordjournals.pcp.a029262	22	463	515	4	99	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 11	2006	313	5788					842	845		10.1126/science.1128436	http://dx.doi.org/10.1126/science.1128436			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	072KC	16902140				2022-12-28	WOS:000239671300062
J	Shibata, Y; Voeltz, GK; Rapoport, TA				Shibata, Yoko; Voeltz, Gia K.; Rapoport, Tom A.			Rough sheets and smooth tubules	CELL			English	Editorial Material							ENDOPLASMIC-RETICULUM; ELECTRON-MICROSCOPY; FUNCTIONAL DOMAINS; MEMBRANE CURVATURE; PROTEINS; DYNAMICS; ER; MICROTUBULES; ORGANIZATION; CELLS	The endoplasmic reticulum (ER) has distinct morphological domains composed of sheets and tubules, which differ in their characteristic membrane curvature. Key proteins may drive the formation of these structural morphologies, which in turn could generate the rough and smooth functional domains of the ER.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School	Rapoport, TA (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA.	tom_rapoport@hms.harvard.edu						Baumann O, 2001, INT REV CYTOL, V205, P149, DOI 10.1016/S0074-7696(01)05004-5; Becker F, 1999, J CELL BIOL, V146, P273, DOI 10.1083/jcb.146.2.273; Borgese N, 2006, CURR OPIN CELL BIOL, V18, P358, DOI 10.1016/j.ceb.2006.06.008; Christensen AK, 1999, ANAT REC, V255, P116, DOI 10.1002/(SICI)1097-0185(19990601)255:2<116::AID-AR2>3.0.CO;2-O; Crisp M, 2006, J CELL BIOL, V172, P41, DOI 10.1083/jcb.200509124; Dreier L, 2000, J CELL BIOL, V148, P883, DOI 10.1083/jcb.148.5.883; Du YR, 2004, J CELL SCI, V117, P2871, DOI 10.1242/jcs.01286; Hetzer MW, 2005, ANNU REV CELL DEV BI, V21, P347, DOI 10.1146/annurev.cellbio.21.090704.151152; JORDAN EG, 1977, EXP CELL RES, V104, P446, DOI 10.1016/0014-4827(77)90114-8; Klopfenstein DR, 2001, J CELL BIOL, V153, P1287, DOI 10.1083/jcb.153.6.1287; McMahon HT, 2005, NATURE, V438, P590, DOI 10.1038/nature04396; Nehls S, 2000, NAT CELL BIOL, V2, P288, DOI 10.1038/35010558; Nikonov AV, 2002, J CELL BIOL, V158, P497, DOI 10.1083/jcb.200201116; Ogata T, 1997, ANAT REC, V248, P214; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; Rolls MM, 2002, MOL BIOL CELL, V13, P1778, DOI 10.1091/mbc.01-10-0514; Senda T, 1998, ANAT REC, V251, P339; Short B, 2005, BBA-MOL CELL RES, V1744, P383, DOI 10.1016/j.bbamcr.2005.02.001; Snapp EL, 2003, J CELL BIOL, V163, P257, DOI 10.1083/jcb.200306020; Staehelin LA, 1997, PLANT J, V11, P1151, DOI 10.1046/j.1365-313X.1997.11061151.x; TERASAKI M, 1986, J CELL BIOL, V103, P1557, DOI 10.1083/jcb.103.4.1557; Voeltz GK, 2006, CELL, V124, P573, DOI 10.1016/j.cell.2005.11.047; Voeltz GK, 2002, EMBO REP, V3, P944, DOI 10.1093/embo-reports/kvf202; Zimmerberg J, 2006, NAT REV MOL CELL BIO, V7, P9, DOI 10.1038/nrm1784	24	298	301	10	52	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 11	2006	126	3					435	439		10.1016/j.cell.2006.07.019	http://dx.doi.org/10.1016/j.cell.2006.07.019			5	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	075KI	16901774	Bronze			2022-12-28	WOS:000239883400001
J	Rosmarin, D; Tan, CS				Rosmarin, David; Tan, Chen S.			Inguinal hernia	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									NYU, Sch Med, New York, NY 10016 USA	New York University	Rosmarin, D (corresponding author), NYU, Sch Med, New York, NY 10016 USA.								0	0	0	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 10	2006	355	6					601	601		10.1056/NEJMicm050827	http://dx.doi.org/10.1056/NEJMicm050827			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	071QM	16899780				2022-12-28	WOS:000239616700010
J	Kaneko, Y; Nimmerjahn, F; Ravetch, EV				Kaneko, Yoshikatsu; Nimmerjahn, Falk; Ravetch, Jeffrey V.			Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation	SCIENCE			English	Article							RHEUMATOID-ARTHRITIS; IMMUNE-SYSTEM; SERUM IGG; RECEPTOR; GLYCOSYLATION; PROTECTION; GLOBULIN; BINDING	Immunoglobulin G (IgG) mediates pro- and anti-inflammatory activities through the engagement of its Fc fragment (Fc) with distinct Fc gamma receptors (Fc gamma Rs). One class of Fc-Fc gamma R interactions generates pro-inflammatory effects of immune complexes and cytotoxic antibodies. In contrast, therapeutic intravenous gamma globulin and its Fc fragments are anti-inflammatory. We show here that these distinct properties of the IgG Fc result from differential sialylation of the Fc core polysaccharide. IgG acquires anti-inflammatory properties upon Fc sialylation, which is reduced upon the induction of an antigen-specific immune response. This differential sialylation may provide a switch from innate anti-inflammatory activity in the steady state to generating adaptive pro-inflammatory effects upon antigenic challenge.	Rockefeller Univ, Lab Mol Genet & Immunol, New York, NY 10021 USA	Rockefeller University	Ravetch, EV (corresponding author), Rockefeller Univ, Lab Mol Genet & Immunol, 1230 York Ave, New York, NY 10021 USA.	ravetch@rockefeller.edu	Nimmerjahn, Falk/J-4986-2013; Ravetch, Jeffrey/Z-1596-2019	Ravetch, Jeffrey/0000-0003-2024-9041; Nimmerjahn, Falk/0000-0002-5418-316X				Bruhns P, 2003, IMMUNITY, V18, P573, DOI 10.1016/S1074-7613(03)00080-3; DWYER JM, 1992, NEW ENGL J MED, V326, P107; Han S, 2005, NAT CHEM BIOL, V1, P93, DOI 10.1038/nchembio713; HOLLAND M, 2005, BIOCHIM BIOPHYS ACTA, V1760, P669; IMBACH P, 1981, LANCET, V1, P1228; Jefferis R, 2002, IMMUNOL LETT, V82, P57, DOI 10.1016/S0165-2478(02)00019-6; Ji H, 2002, IMMUNITY, V16, P157, DOI 10.1016/S1074-7613(02)00275-3; Kaneko Y, 2006, J EXP MED, V203, P789, DOI 10.1084/jem.20051900; Lastra GC, 1998, AUTOIMMUNITY, V28, P25, DOI 10.3109/08916939808993842; Matsumoto A, 2000, J BIOCHEM-TOKYO, V128, P621, DOI 10.1093/oxfordjournals.jbchem.a022794; Nimmerjahn F, 2006, IMMUNITY, V24, P19, DOI 10.1016/j.immuni.2005.11.010; Nimmerjahn F, 2005, SCIENCE, V310, P1510, DOI 10.1126/science.1118948; Nimmerjahn F, 2005, IMMUNITY, V23, P41, DOI 10.1016/j.immuni.2005.05.010; PAREKH RB, 1985, NATURE, V316, P452, DOI 10.1038/316452a0; RADEMACHER TW, 1994, P NATL ACAD SCI USA, V91, P6123, DOI 10.1073/pnas.91.13.6123; Routier FH, 1998, J IMMUNOL METHODS, V213, P113, DOI 10.1016/S0022-1759(98)00032-5; Samuelsson A, 2001, SCIENCE, V291, P484, DOI 10.1126/science.291.5503.484; Shields RL, 2002, J BIOL CHEM, V277, P26733, DOI 10.1074/jbc.M202069200; Shikata K, 1998, GLYCOCONJUGATE J, V15, P683, DOI 10.1023/A:1006936431276; Sondermann P, 2001, J MOL BIOL, V309, P737, DOI 10.1006/jmbi.2001.4670; Wright A, 1997, TRENDS BIOTECHNOL, V15, P26, DOI 10.1016/S0167-7799(96)10062-7	21	1288	1430	1	122	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 4	2006	313	5787					670	673		10.1126/science.1129594	http://dx.doi.org/10.1126/science.1129594			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	072IQ	16888140				2022-12-28	WOS:000239667500044
J	Austin, AT; Vivanco, L				Austin, Amy T.; Vivanco, Lucia			Plant litter decomposition in a semi-arid ecosystem controlled by photodegradation	NATURE			English	Article							ULTRAVIOLET-B RADIATION; RAINFALL GRADIENT; INORGANIC CARBON; ORGANIC-MATTER; DYNAMICS; DESERT; INCREASES; NITROGEN; STORAGE; IMPACT	The carbon balance in terrestrial ecosystems is determined by the difference between inputs from primary production and the return of carbon to the atmosphere through decomposition of organic matter(1). Our understanding of the factors that control carbon turnover in water-limited ecosystems is limited, however, as studies of litter decomposition have shown contradictory results and only a modest correlation with precipitation(2-5). Here we evaluate the influence of solar radiation, soil biotic activity and soil resource availability on litter decomposition in the semi-arid Patagonian steppe using the results of manipulative experiments carried out under ambient conditions of rainfall and temperature. We show that intercepted solar radiation was the only factor that had a significant effect on the decomposition of organic matter, with attenuation of ultraviolet-B and total radiation causing a 33 and 60 per cent reduction in decomposition, respectively. We conclude that photodegradation is a dominant control on above-ground litter decomposition in this semi-arid ecosystem. Losses through photochemical mineralization may represent a short-circuit in the carbon cycle, with a substantial fraction of carbon fixed in plant biomass being lost directly to the atmosphere without cycling through soil organic matter pools. Furthermore, future changes in radiation interception due to decreased cloudiness, increased stratospheric ozone depletion, or reduced vegetative cover may have a more significant effect on the carbon balance in these water-limited ecosystems than changes in temperature or precipitation.	Univ Buenos Aires, Inst Invest Fisiol & Ecol Vinculadas Agr, RA-1417 Buenos Aires, DF, Argentina; Univ Buenos Aires, Fac Agron, CONICET, RA-1417 Buenos Aires, DF, Argentina	University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires	Austin, AT (corresponding author), Univ Buenos Aires, Inst Invest Fisiol & Ecol Vinculadas Agr, Av San Martin 4453, RA-1417 Buenos Aires, DF, Argentina.	austin@ifeva.edu.ar	Vivanco, Lucia/AAQ-6127-2020; Austin, Amy/E-7988-2011	Vivanco, Lucia/0000-0001-7615-8865; Austin, Amy/0000-0002-7468-5861				ABER JD, 1982, CAN J BOT, V60, P2263, DOI 10.1139/b82-277; Anesio AM, 1999, ECOLOGY, V80, P1852, DOI 10.1890/0012-9658(1999)080[1852:POICFA]2.0.CO;2; Austin AT, 2002, ECOLOGY, V83, P328, DOI 10.1890/0012-9658(2002)083[0328:DEOPOP]2.0.CO;2; GEHRKE C, 1995, OIKOS, V72, P213, DOI 10.2307/3546223; Gholz HL, 2000, GLOBAL CHANGE BIOL, V6, P751, DOI 10.1046/j.1365-2486.2000.00349.x; Jackson RB, 2002, NATURE, V418, P623, DOI 10.1038/nature00910; Johnson D, 2002, NATURE, V416, P82, DOI 10.1038/416082a; KIEBER DJ, 1989, NATURE, V341, P637, DOI 10.1038/341637a0; MEENTEMEYER V, 1978, ECOLOGY, V59, P465, DOI 10.2307/1936576; MILLER WL, 1995, GEOPHYS RES LETT, V22, P417, DOI 10.1029/94GL03344; MONTANA C, 1988, J ARID ENVIRON, V14, P55, DOI 10.1016/S0140-1963(18)31096-6; Moody SA, 2001, PLANT ECOL, V154, P27, DOI 10.1023/A:1012965610170; MOORHEAD DL, 1994, BIOL FERT SOILS, V18, P19, DOI 10.1007/BF00336439; MOORHEAD DL, 1989, J ARID ENVIRON, V16, P157, DOI 10.1016/S0140-1963(18)31022-X; MOPPER K, 1991, NATURE, V353, P60, DOI 10.1038/353060a0; Nemani RR, 2003, SCIENCE, V300, P1560, DOI 10.1126/science.1082750; OLSON JS, 1963, ECOLOGY, V44, P322, DOI 10.2307/1932179; Pancotto VA, 2005, GLOBAL CHANGE BIOL, V11, P1982, DOI 10.1111/j.1365-2486.2005.01027.x; Pancotto VA, 2003, GLOBAL CHANGE BIOL, V9, P1465, DOI 10.1046/j.1365-2486.2003.00667.x; SALA OE, 1989, OECOLOGIA, V81, P501, DOI 10.1007/BF00378959; Schade GW, 1999, TELLUS B, V51, P889, DOI 10.1034/j.1600-0889.1999.t01-4-00003.x; Schlesinger WH, 2001, NATURE, V411, P466, DOI 10.1038/35078060; Smith SD, 2000, NATURE, V408, P79, DOI 10.1038/35040544; STEINBERGER Y, 1990, OECOLOGIA, V82, P322, DOI 10.1007/BF00317478; Swift M.J., 1979, DECOMPOSITION TERRES, V5; TARR MA, 1995, J GEOPHYS RES-ATMOS, V100, P11403, DOI 10.1029/94JD03324; Thomas DSG, 2005, NATURE, V435, P1218, DOI 10.1038/nature03717; VOSSBRINCK CR, 1979, ECOLOGY, V60, P265, DOI 10.2307/1937654; WHITFORD WG, 1986, OECOLOGIA, V68, P512, DOI 10.1007/BF00378764; Yahdjian L, 2006, ECOSYSTEMS, V9, P128, DOI 10.1007/s10021-004-0118-7	30	545	614	22	380	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 3	2006	442	7102					555	558		10.1038/nature05038	http://dx.doi.org/10.1038/nature05038			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	069NQ	16885982				2022-12-28	WOS:000239455900041
J	Singh, S; Houston, J; van Swol, F; Brinker, CJ				Singh, Seema; Houston, Jack; van Swol, Frank; Brinker, C. Jeffrey			Superhydrophobicity - Drying transition of confined water	NATURE			English	Article							HYDROPHOBIC SURFACES; LONG-RANGE; FORCE		Sandia Natl Labs, Albuquerque, NM 87185 USA; Univ New Mexico, Albuquerque, NM 87131 USA	United States Department of Energy (DOE); Sandia National Laboratories; University of New Mexico	Singh, S (corresponding author), Sandia Natl Labs, POB 5800, Albuquerque, NM 87185 USA.	cjbrink@sandia.gov						BLAKE TD, 1972, J CHEM SOC FARAD T 1, V68, P1435, DOI 10.1039/f19726801435; Christenson HK, 2001, ADV COLLOID INTERFAC, V91, P391, DOI 10.1016/S0001-8686(00)00036-1; CHRISTENSON HK, 1988, SCIENCE, V239, P390, DOI 10.1126/science.239.4838.390; Doshi DA, 2005, LANGMUIR, V21, P7805, DOI 10.1021/la050750s; ISRAELACHVILI J, 1982, NATURE, V300, P341, DOI 10.1038/300341a0; JOYCE SA, 1991, REV SCI INSTRUM, V62, P710, DOI 10.1063/1.1142072; Lafuma A, 2003, NAT MATER, V2, P457, DOI 10.1038/nmat924; Lum K, 1999, J PHYS CHEM B, V103, P4570, DOI 10.1021/jp984327m; Luzar A, 2004, J PHYS CHEM B, V108, P19859, DOI 10.1021/jp0470703; PARKER JL, 1994, J PHYS CHEM-US, V98, P8468, DOI 10.1021/j100085a029; PASHLEY RM, 1985, SCIENCE, V229, P1088, DOI 10.1126/science.4035349; Stevens H, 2005, LANGMUIR, V21, P6399, DOI 10.1021/la0507535	12	110	114	1	97	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 3	2006	442	7102					526	526		10.1038/442526a	http://dx.doi.org/10.1038/442526a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	069NQ	16885976	Bronze			2022-12-28	WOS:000239455900033
J	Steinberg, D				Steinberg, David			The allocation of organs donated by altruistic strangers	ANNALS OF INTERNAL MEDICINE			English	Article							KIDNEY-TRANSPLANTATION; UNITED NETWORK; DONORS; PARADIGM; RESOURCE; SURVIVAL; POLICY; GRAFT; RATES	In many transplant centers, organ retrieval from altruistic strangers is accepted practice; patients use Internet Web sites and other public media to locate strangers willing to give them an organ. It is argued that altruistic strangers should be permitted to select the recipients of their organs because 1) personal relationships are morally important; 2) it increases the number of available organs; and 3) no one is hurt by the process. Nonetheless, using public media to obtain organs may undermine equity in organ allocation. Organs donated by altruistic strangers do not go necessarily to patients who have the best immunologic match or the most urgent need or who have waited the longest. A publicly chartered organization should be established to coordinate live organ donation, including donation by altruistic strangers. Altruistic strangers should be educated to allocate their donated organs according to a prudent balance of equity and utility rather than their emotional response to a particular patient's plight, identity, or circumstances.	Lahey Clin Fdn, Burlington, MA 01805 USA	Lahey Hospital & Medical Center	Steinberg, D (corresponding author), Lahey Clin Fdn, 41 Mall Rd, Burlington, MA 01805 USA.	david.steinberg@lahey.org						Alexander S., 1962, LIFE, P102; *AM SOC TRANSPL SU, ASTS POS STAT AD AD; Ankeny RA, 2001, CAMB Q HEALTHC ETHIC, V10, P387, DOI 10.1017/S096318010100408X; [Anonymous], ORGAN PROCUREMENT TR; BEAUCHAMP TL, 1994, PRINCIPLES BIOMEDICA, P47; Brauer CA, 2005, FUND CLIN PHARMACOL, V19, P603, DOI 10.1111/j.1472-8206.2005.00369.x; Calandrillo SP, 2004, AM J BIOETHICS, V4, P17, DOI 10.1080/15265160490906556; Daar AS, 2000, TRANSPLANTATION, V70, P704, DOI 10.1097/00007890-200008270-00034; Delmonico FL, 2004, AM J TRANSPLANT, V4, P1628, DOI 10.1111/j.1600-6143.2004.00572.x; Gohh RY, 2001, NEPHROL DIAL TRANSPL, V16, P619, DOI 10.1093/ndt/16.3.619; Gubernatis G, 2000, TRANSPLANTATION, V70, P699, DOI 10.1097/00007890-200008270-00032; Hallie Philip, 1994, LEST INNOCENT BLOOD; Henderson AJZ, 2003, AM J TRANSPLANT, V3, P203, DOI 10.1034/j.1600-6143.2003.00019.x; Hilhorst Medard T, 2005, Ethical Theory Moral Pract, V8, P197, DOI 10.1007/s10677-005-3295-3; Hilhorst MT, 2005, TRANSPLANTATION, V79, P1470, DOI 10.1097/01.TP.0000164150.53036.A1; *J HOPK MED I, 2000, 80 PEOPL OFF KIDN ST; Jacobs CL, 2004, AM J TRANSPLANT, V4, P1110, DOI 10.1111/j.1600-6143.2004.00478.x; JARVIS R, 1995, J MED ETHICS, V21, P199, DOI 10.1136/jme.21.4.199; JONSEN AR, 1998, BIRTH BIOETHICS, P211; KAMM FM, 1993, MORALITY MORTALITY D, P239; KAMM FM, 1993, MORTALITY DEATH WHOM, P233; Karcher H, 1996, BRIT MED J, V313, P443; KLEINMAN I, 1992, ARCH INTERN MED, V152, P1484, DOI 10.1001/archinte.152.7.1484; Lin HM, 1998, JAMA-J AM MED ASSOC, V280, P1153, DOI 10.1001/jama.280.13.1153; Matas AJ, 2000, NEW ENGL J MED, V343, P433, DOI 10.1056/NEJM200008103430611; Meier-Kriesche HU, 2005, AM J TRANSPLANT, V5, P1725, DOI 10.1111/j.1600-6143.2005.00923.x; Mutinga N, 2005, AM J TRANSPLANT, V5, P1090, DOI 10.1111/j.1600-6143.2005.00802.x; Oliner Samuel P., 1988, ALTRUISTIC PERSONALI; Organ Procurement and Transplantation Network, POLICIES; Pirsch JD, 1996, TRANSPLANTATION, V61, P1581, DOI 10.1097/00007890-199606150-00006; Roberts JP, 2004, NEW ENGL J MED, V350, P545, DOI 10.1056/NEJMoa025056; RONSON J, 2002, GUARIDAN UNLIMI 0406; Ross LF, 2002, PERSPECT BIOL MED, V45, P329, DOI 10.1353/pbm.2002.0055; Ross LF, 1997, NEW ENGL J MED, V336, P1752, DOI 10.1056/NEJM199706123362412; Spital A, 2003, TRANSPLANTATION, V76, P1252, DOI 10.1097/01.TP.0000087852.74220.9A; Steinberg D, 2004, AM J BIOETHICS, V4, P4, DOI 10.1080/15265160490518557; Steinberg D, 2003, HEALTH AFFAIR, V22, P184, DOI 10.1377/hlthaff.22.4.184; Steinbrook R, 2005, NEW ENGL J MED, V353, P441, DOI 10.1056/NEJMp058151; Terasaki PI, 1996, TRANSPLANTATION, V62, P441, DOI 10.1097/00007890-199608270-00003; Truog RD, 2005, AM J BIOETHICS, V5, P14, DOI 10.1080/15265160500194584; *UN NETW ORG SHAR, LIV DON TRANSPL DON; *UN NETW ORG SHAR, OPTN UNOS BOARD OPP; Veatch R, 2000, TRANSPLANTATION ETHI, P352; Veatch RM, 2003, KENNEDY INST ETHIC J, V13, P19, DOI 10.1353/ken.2003.0007; Veatch RM, 2005, HASTINGS CENT REP, V35, P6, DOI 10.2307/3528791; VEATCH RM, 2000, TRANSPLANTATION ETHI, P287; VEATCH RM, 2000, TRANSPLANTATION ETHI, P277; VEATCH RM, 2000, TRANSPLANTATION ETHI, P388; Wiesner RH, 2005, LIVER TRANSPLANT, V11, P261, DOI 10.1002/lt.20362; Wright L, 2006, SEMIN DIALYSIS, V19, P5, DOI 10.1111/j.1525-139X.2006.00110.x; 2005, MATCHING DONORS 0222	51	19	19	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	2006	145	3					197	203		10.7326/0003-4819-145-3-200608010-00007	http://dx.doi.org/10.7326/0003-4819-145-3-200608010-00007			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	070MN	16880461				2022-12-28	WOS:000239526800005
J	Fransen, M; Anderson, C; Douglas, J; MacMahon, S; Neal, B; Norton, R; Woodward, M; Cameron, ID; Crawford, R; Lo, SK; Tregonning, G; Windolf, M				Fransen, Marlene; Anderson, Craig; Douglas, Jan; MacMahon, Stephen; Neal, Bruce; Norton, Robyn; Woodward, Mark; Cameron, Ian D.; Crawford, Ross; Lo, Sing Kai; Tregonning, Garnet; Windolf, Margaret		HIPAID Collaborative Grp	Safety and efficacy of routine postoperative ibuprofen for pain and disability related to ectopic bone formation after hip replacement surgery (HIPAID): randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							UNITED-KINGDOM; OSSIFICATION; ARTHROPLASTY; SCORES	Objectives To determine the benefits and risks of a non-steroidal anti-inflammatory drug (NSAID) as prophylaxis for ectopic bone formation in patients undergoing total hip replacement (or revision) surgery. Design Double blind randomised placebo controlled clinical trial, stratified by treatment site and surgery (primary or revision). Setting 20 orthopaedic surgery centres in Australia and New Zealand. Participants 902 patients undergoing elective primary or revision total hip replacement surgery. Intervention 14 days' treatment with ibuprofen (1200 mg daily) or matching placebo started within 24 hours of surgery. Main outcome measures Changes in self reported hip pain and physical function 6 to 12 months after surgery (Western Ontario and McMaster University Arthritis index). Results There were no significant differences between the groups for improvements in hip pain (mean difference - 0.1, 95% confidence interval - 0.4 to 0.2, P = 0.6) or physical function (- 0.1, - 0.4 to 0.2, P = 0.5), despite a decreased risk of ectopic bone formation (relative risk 0.69, 0.56 to 0.83) associated with ibuprofen. There was a significantly increased risk of major bleeding complications in the ibuprofen group during the admission period (2.09, 1.00 to 4.39). Conclusions These data do not support the use of routine prophylaxis with NSAIDs in patients undergoing total hip replacement surgery.	Univ Sydney, George Inst Int Hlth, Neurol & Mental Hlth Div, Sydney, NSW 2006, Australia; Univ Sydney, Fac Med, Sydney, NSW 2006, Australia; Queensland Univ Technol, Brisbane, Qld, Australia; Deakin Univ, Melbourne, Vic, Australia; Middlemore Hosp, Auckland 6, New Zealand; Royal Prince Alfred Hosp, Camperdown, NSW 2050, Australia	University of Sydney; University of Sydney; Queensland University of Technology (QUT); Deakin University; University of Sydney	Fransen, M (corresponding author), Univ Sydney, George Inst Int Hlth, Neurol & Mental Hlth Div, Sydney, NSW 2006, Australia.	mfransen@george.org.au	Woodward, Mark/D-8492-2015; Fransen, Marlene/E-5987-2010; Woodward, Mark/L-6817-2017	Crawford, Ross/0000-0001-6079-1316; MacMahon, Stephen/0000-0003-2064-7699; LO, Sing Kai/0000-0001-8401-1759; Anderson, Craig/0000-0002-7248-4863; Woodward, Mark/0000-0001-9800-5296; Neal, Bruce/0000-0002-0490-7465				Bellamy N, 1988, J ORTHOP RHEUMATOL, V1, P95; BROOKER AF, 1973, J BONE JOINT SURG AM, VA 55, P1629, DOI 10.2106/00004623-197355080-00006; BRYANT MJ, 1993, J BONE JOINT SURG BR, V75, P705, DOI 10.1302/0301-620X.75B5.8376424; Collins R, 2001, LANCET, V357, P373, DOI 10.1016/S0140-6736(00)03651-5; FRANSEN M, 2006, COCHRANE DB SYST REV, P1160; *HIPAID COLL GROUP, 2004, CONT CLIN TRIALS, V25, P223; Horlocker TT, 1998, ANESTH ANALG, V86, P1153, DOI 10.1097/00000539-199806000-00001; Jenkinson C, 1997, MED CARE, V35, P410, DOI 10.1097/00005650-199704000-00010; Jenkinson C, 1999, J EPIDEMIOL COMMUN H, V53, P46, DOI 10.1136/jech.53.1.46; Neal B, 2003, ANZ J SURG, V73, P422, DOI 10.1046/j.1445-2197.2003.02647.x; Neal B, 2002, ANZ J SURG, V72, P808, DOI 10.1046/j.1445-2197.2002.02549.x; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; Romano CL, 2004, J ARTHROPLASTY, V19, P14, DOI 10.1016/S0883-5403(03)00279-1; Schafer Andrew I., 1999, American Journal of Medicine, V106, p25S, DOI 10.1016/S0002-9343(99)00114-X; Sell S, 1998, J ARTHROPLASTY, V13, P854, DOI 10.1016/S0883-5403(98)90189-9; Stichtenoth DO, 1996, EUR J CLIN PHARMACOL, V51, P231, DOI 10.1007/s002280050189; Woodward M., 2013, EPIDEMIOLOGY STUDY D	17	58	59	1	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 9	2006	333	7567					519	521		10.1136/bmj.38925.471146.4F	http://dx.doi.org/10.1136/bmj.38925.471146.4F			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	084LD	16885182	Green Published, Green Submitted			2022-12-28	WOS:000240533500014
J	Lissauer, JJ				Lissauer, Jack J.			Growing apart in lock step	SCIENCE			English	Editorial Material							PLUTO; ORIGIN		NASA, Ames Res Ctr, Moffett Field, CA 94035 USA	National Aeronautics & Space Administration (NASA); NASA Ames Research Center	Lissauer, JJ (corresponding author), NASA, Ames Res Ctr, Moffett Field, CA 94035 USA.	jlissauer@mail.arc.nasa.gov						Canup RM, 2005, SCIENCE, V307, P546, DOI 10.1126/science.1106818; Goldreich P, 1965, MON NOT R ASTRON SOC, V130, P159; LISSAUER JJ, 1984, ICARUS, V58, P159, DOI 10.1016/0019-1035(84)90034-4; MALHOTRA R, 1993, NATURE, V365, P819, DOI 10.1038/365819a0; PEALE SJ, 1976, ANNU REV ASTRON ASTR, V14, P215, DOI 10.1146/annurev.aa.14.090176.001243; Pollack J.B., 1985, PROTOSTARS PLANETS; Ward WR, 2006, SCIENCE, V313, P1107, DOI 10.1126/science.1127293; Weaver HA, 2006, NATURE, V439, P943, DOI 10.1038/nature04547	9	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 25	2006	313	5790					1054	1055		10.1126/science.1128447	http://dx.doi.org/10.1126/science.1128447			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	076ZT	16931743				2022-12-28	WOS:000239998200025
J	Gaziano, TA; Opie, LH; Weinstein, MC				Gaziano, Thomas A.; Opie, Lionel H.; Weinstein, Milton C.			Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis	LANCET			English	Article							RANDOMIZED CONTROLLED-TRIAL; CORONARY-HEART-DISEASE; BLOOD-PRESSURE; MYOCARDIAL-INFARCTION; HYPERTENSIVE PATIENTS; VASCULAR-DISEASE; SOUTH-AFRICA; RISK-FACTORS; STROKE; OUTCOMES	Background Cardiovascular disease is the leading cause of death, with 80% of cases occurring in developing countries. We therefore aimed to establish whether use of evidence-based multidrug regimens for patients at high risk for cardiovascular disease would be cost-effective in low-income and middle-income countries. Methods We used a Markov model to do a cost-effectiveness analysis with two combination regimens. For primary prevention, we used aspirin, a calcium-channel blocker, an angiotensin-converting-enzyme inhibitor, and a statin, and assessed them in four groups with different thresholds of absolute risks for cardiovascular disease. For secondary prevention, we assessed the same combination of drugs in one group, but substituted a (3 blocker for the calcium-channel blocker. To compare strategies, we report incremental cost-effectiveness ratios (ICER), in US$ per quality-adjusted life-year (QALY). Findings We recorded that preventive strategies could result in a 2-year gain in life expectancy. Across six developing World Bank regions, primary prevention yielded ICERs of US$746-890/QALY gained for patients with a 10-year absolute risk of cardiovascular disease greater than 25%, and $1039-1221/QALY gained for those with an absolute risk greater than 5%. ICERs for secondary prevention ranged from $306/QALY to $388/QALY gained. Interpretation Regimens of aspirin, two blood-pressure drugs, and a statin could halve the risk of death from cardiovascular disease in high-risk patients. This approach is cost-effective according to WHO recommendations, and is robust across several estimates of drug efficacy and of treatment cost. Developing countries should encourage the use of these inexpensive drugs that are currently available for both primary and secondary prevention.	Harvard Univ, Sch Med, Div Cardiovasc Med, Boston, MA 02120 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Social Med & Hlth Inequal, Boston, MA 02120 USA; Univ Cape Town, Fac Hlth Sci, Hatter Inst, ZA-7925 Cape Town, South Africa; Univ Cape Town, Hatter Inst Heart Res, Dept Med, ZA-7925 Cape Town, South Africa; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Cape Town; University of Cape Town; Harvard University; Harvard T.H. Chan School of Public Health	Gaziano, TA (corresponding author), Harvard Univ, Sch Med, Div Cardiovasc Med, Boston, MA 02120 USA.	tgaziano@partners.org			FOGARTY INTERNATIONAL CENTER [K01TW007141] Funding Source: NIH RePORTER; FIC NIH HHS [K01 TW007141-01, K01 TW007141, K01 TW007141-02] Funding Source: Medline; NIMHD NIH HHS [263-MD-416765] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIMHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))		Amit G, 2004, AM J CARDIOL, V93, P1558, DOI 10.1016/j.amjcard.2004.02.071; [Anonymous], 1996, GLOBAL BURDEN DIS CO; BATUSSEN RM, 2002, GEN COST EFFECTIVENE; Bonaa KH, 2006, NEW ENGL J MED, V354, P1578, DOI 10.1056/NEJMoa055227; Carlberg B, 2004, LANCET, V364, P1684, DOI 10.1016/S0140-6736(04)17355-8; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; Connor J, 2004, B WORLD HEALTH ORGAN, V82, P935; Dahlof B, 2005, LANCET, V366, P895, DOI 10.1016/S0140-6736(05)67185-1; *DCPP SECR, 2004, DIS CONTR PRIOR PROJ; Doubilet P, 1985, Med Decis Making, V5, P293, DOI 10.1177/0272989X8500500305; Furberg CD, 2002, JAMA-J AM MED ASSOC, V288, P2981; Fuster V, 2005, LANCET, V366, P1512, DOI 10.1016/S0140-6736(05)67610-6; Gaziano TA, 2005, CIRCULATION, V112, P3569, DOI 10.1161/CIRCULATIONAHA.105.535922; Gold MR, 1996, COST EFFECTIVENESS H; Gress TW, 2000, NEW ENGL J MED, V342, P905, DOI 10.1056/NEJM200003303421301; Horton R, 2005, LANCET, V366, P1514, DOI 10.1016/S0140-6736(05)67454-5; Jamison DT, 2006, DISEASE CONTROL PRIORITIES IN DEVELOPING COUNTRIES, 2ND EDITION, P1; Jandeleit-Dahm KAM, 2005, J HYPERTENS, V23, P463, DOI 10.1097/01.hjh.0000160198.05416.72; Law MR, 2003, BRIT MED J, V326, P1427, DOI 10.1136/bmj.326.7404.1427; Law MR, 2003, BRIT MED J, V326, P1423, DOI 10.1136/bmj.326.7404.1423; Lindholm LH, 2005, LANCET, V366, P1545, DOI 10.1016/S0140-6736(05)67573-3; Lonn E, 2006, NEW ENGL J MED, V354, P1567, DOI 10.1056/NEJMoa060900; Loscalzo J, 2006, NEW ENGL J MED, V354, P1629, DOI 10.1056/NEJMe068060; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; Mathers C, 2005, 18 WORLD BANK COUNTR; McFayden JE, 2005, INT DRUG PRICE INDIC; Mendis S, 2005, B WORLD HEALTH ORGAN, V83, P820; MULLIGAN J, 2004, 9 DIS CONTR PRIOR; Murray CJL, 2003, LANCET, V361, P717, DOI 10.1016/S0140-6736(03)12655-4; *NIH CLIN EXC, CLIN GUID 34 HYP MAN; Opie LH, 2004, J HYPERTENS, V22, P1453, DOI 10.1097/01.hjh.0000133732.24501.9e; Pereira JA, 2005, ANN PHARMACOTHER, V39, P1188, DOI 10.1345/aph.1G003; Ridker PM, 2005, NEW ENGL J MED, V352, P1293, DOI 10.1056/NEJMoa050613; Sever PS, 2003, LANCET, V361, P1149, DOI 10.1016/S0140-6736(03)12948-0; Smith GD, 2005, LANCET, V366, P1679, DOI 10.1016/S0140-6736(05)67676-3; Steyn K, 2004, ETHNIC DIS, V14, P233; Wald NJ, 2003, BMJ-BRIT MED J, V326, P1419, DOI 10.1136/bmj.326.7404.1419; Williams B, 2006, LANCET, V368, P6, DOI 10.1016/S0140-6736(06)68943-5; *WORLD BANK, 2002, WORLD DEV IND; World Health Organization (WHO), 2006, WORLD HLTH REP 2006; Yusuf S, 2002, LANCET, V360, P2, DOI 10.1016/S0140-6736(02)09358-3; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9	42	199	203	0	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 19	2006	368	9536					679	686		10.1016/S0140-6736(06)69252-0	http://dx.doi.org/10.1016/S0140-6736(06)69252-0			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	074YT	16920473	Green Accepted			2022-12-28	WOS:000239849200035
J	Tang, JL				Tang, Jin-Ling			Research priorities in traditional Chinese medicine	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							CONTROLLED-TRIAL; EQUIPOISE		Chinese Univ Hong Kong, Hong Kong Cochrane Branch, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong	Tang, JL (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Fac Med,Sch Publ Hlth, Chinese Cochrane Ctr Hong Kong Branch, Shatin, Hong Kong, Peoples R China.	jltang@cuhk.edu.hk	Tang, Jin-Ling/AAJ-4090-2021; Tang, JL/G-1759-2013					[Anonymous], 2000, LANCET, V356, P2023; Dingwall R, 1992, RES HLTH CARE, P161; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; Haynes RB, 1999, BRIT MED J, V319, P1632; HAYVEY AL, 1998, ADV DRUG DISCOVERY T, P1; Hien TT, 1996, NEW ENGL J MED, V335, P76, DOI 10.1056/NEJM199607113350202; HILL AB, 1952, NEW ENGL J MED, V247, P113, DOI 10.1056/NEJM195207242470401; KUHN TS, 1970, STRUCTURE SCI REVOLU, P77; Liang MX, 1998, PREDICAMENTS FUTURE, P1; Rapola JM, 1996, JAMA-J AM MED ASSOC, V275, P693, DOI 10.1001/jama.275.9.693; SHE JB, 1990, DIFFERENCES PERPLEXI; SHEEHAN MP, 1992, LANCET, V340, P13, DOI 10.1016/0140-6736(92)92424-E; Steele VE, 1998, HEMATOL ONCOL CLIN N, V12, P943, DOI 10.1016/S0889-8588(05)70035-6; Tang JL, 1999, BMJ-BRIT MED J, V319, P160, DOI 10.1136/bmj.319.7203.160; TIAO KY, 1997, PHILOS CONSIDERATION; Ulett GA, 1998, BIOL PSYCHIAT, V44, P129, DOI 10.1016/S0006-3223(97)00394-6; WARREN KS, 1993, ANN NY ACAD SCI, V703, P1, DOI 10.1111/j.1749-6632.1993.tb26327.x; Weijer C, 2000, BMJ-BRIT MED J, V321, P756, DOI 10.1136/bmj.321.7263.756; World Health Organization, 2004, WORLD REP KNOWL BETT; WYNDER EL, 1994, AM J EPIDEMIOL, V139, P547, DOI 10.1093/oxfordjournals.aje.a117045; YUAN Z, 1997, RATIONAL THINKING DE, P36	21	39	45	7	28	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 19	2006	333	7564					391	394		10.1136/bmj.333.7564.391	http://dx.doi.org/10.1136/bmj.333.7564.391			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	078OD	16916829	Green Published			2022-12-28	WOS:000240112200021
J	Park, KS; Mohapatra, DP; Misonou, H; Trimmer, JS				Park, Kang-Sik; Mohapatra, Durga P.; Misonou, Hiroaki; Trimmer, James S.			Graded regulation of the Kv2.1 potassium channel by variable phosphorylation	SCIENCE			English	Article							K+ CHANNEL; PROTEIN-PHOSPHORYLATION; NEURONAL EXCITABILITY; LOCALIZATION; MODULATION; PROTEOMICS; MECHANISM	Dynamic modulation of ion channels by phosphorylation underlies neuronal plasticity. The Kv2.1 potassium channel is highly phosphorylated in resting mammalian neurons. Activity-dependent Kv2.1 dephosphorylation by calcineurin induces graded hyperpolarizing shifts in voltage-dependent activation, causing suppression of neuronal excitability. Mass spectrometry-SILAC ( stable isotope labeling with amino acids in cell culture) identified 16 Kv2.1 phosphorylation sites, of which 7 were dephosphorylated by calcineurin. Mutation of individual calcineurin-regulated sites to alanine produced incremental shifts mimicking dephosphorylation, whereas mutation to aspartate yielded equivalent resistance to calcineurin. Mutations at multiple sites were additive, showing that variable phosphorylation of Kv2.1 at a large number of sites allows graded activity-dependent regulation of channel gating and neuronal firing properties.	Univ Calif Davis, Sch Med, Dept Pharmacol, Davis, CA 95616 USA	University of California System; University of California Davis	Trimmer, JS (corresponding author), Univ Calif Davis, Sch Med GBSF 3502, Dept Pharmacol, 451 E Hlth Sci Dr, Davis, CA 95616 USA.	jtrimmer@ucdavis.edu	Durga, Mohapatra/B-3620-2008; Park, Kang-Sik/AAK-2486-2020; Mohapatra, Durga/M-2133-2017	Mohapatra, Durga/0000-0001-5016-1281; Misono, Hiroaki/0000-0001-5892-1804	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042225] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS042225-06, R01 NS042225, NS42225] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Blagoev B, 2003, NAT BIOTECHNOL, V21, P315, DOI 10.1038/nbt790; Du J, 2000, J PHYSIOL-LONDON, V522, P19, DOI 10.1111/j.1469-7793.2000.t01-2-00019.xm; Kratchmarova I, 2005, SCIENCE, V308, P1472, DOI 10.1126/science.1107627; Malin SA, 2002, J NEUROSCI, V22, P10094; Mann M, 2002, TRENDS BIOTECHNOL, V20, P261, DOI 10.1016/S0167-7799(02)01944-3; Misonou H, 2005, NEUROTOXICOLOGY, V26, P743, DOI 10.1016/j.neuro.2005.02.003; Misonou H, 2005, J NEUROSCI, V25, P11184, DOI 10.1523/JNEUROSCI.3370-05.2005; Misonou H, 2004, NAT NEUROSCI, V7, P711, DOI 10.1038/nn1260; Mohapatra DP, 2006, J NEUROSCI, V26, P685, DOI 10.1523/JNEUROSCI.4620-05.2006; Morishita W, 2005, NAT NEUROSCI, V8, P1043, DOI 10.1038/nn1506; Murakoshi H, 1999, J NEUROSCI, V19, P1728; Murakoshi H, 1997, MOL PHARMACOL, V52, P821, DOI 10.1124/mol.52.5.821; Ong SE, 2002, MOL CELL PROTEOMICS, V1, P376, DOI 10.1074/mcp.M200025-MCP200; Pongs O, 1999, FEBS LETT, V452, P31, DOI 10.1016/S0014-5793(99)00535-9; Pufall MA, 2005, SCIENCE, V309, P142, DOI 10.1126/science.1111915; Surmeier DJ, 2004, NAT NEUROSCI, V7, P691, DOI 10.1038/nn0704-691; WALAAS SI, 1991, PHARMACOL REV, V43, P299	17	225	229	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 18	2006	313	5789					976	979		10.1126/science.1124254	http://dx.doi.org/10.1126/science.1124254			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	074MR	16917065				2022-12-28	WOS:000239817000046
J	Lederman, MM; Penn-Nicholson, A; Cho, M; Mosier, D				Lederman, Michael M.; Penn-Nicholson, Adam; Cho, Michael; Mosier, Donald			Biology of CCR5 and its role in HIV infection and treatment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CHEMOKINE RECEPTOR CCR5; PROTEIN-COUPLED RECEPTOR; T-CELL DEPLETION; GASTROINTESTINAL-TRACT; SIV INFECTION; HEPATITIS-C; NEUTRALIZING ANTIBODIES; ANTIRETROVIRAL THERAPY; RHEUMATOID-ARTHRITIS	Chemokine receptors are found on cell surfaces and promote cellular migration by chemotaxis. The CC chemokine receptor 5 (CCR5) is used by the human immunodeficiency virus (HIV) to infect cells. Strategies that target human CCR5 are therefore being developed to prevent and treat HIV infection. Antiviral strategies that target a host element necessary for viral replication may be predicted to interfere with the function of that element and may therefore adversely affect the host. We conducted a review of the literature between November 2005 and April 2006 with a focus on articles addressing the genetics and function of CCR5, the effects of CCR5 deletion in human and murine systems, and treatment strategies for HIV infection that target this coreceptor. English-language articles in the human and murine literature published between March 1996 and April 2006 were identified through a search of MEDLINE using CCR5 as the search term. Relevant articles as judged by their titles and abstracts were reviewed in detail. In addition, based on our knowledge of the field and with permission, unpublished work was also reviewed. In this article, we explore the effects that targeting CCR5 may have on host defenses in individuals with immunity already compromised by HIV infection.	Case Western Reserve Univ, Sch Med, Univ Hosp Cleveland, Ctr AIDS Res, Cleveland, OH USA; Scripps Res Inst, La Jolla, CA 92037 USA	Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Scripps Research Institute	Lederman, MM (corresponding author), Case Western Reserve Univ, Div Infect Dis, 2061 Cornell Rd, Cleveland, OH 44106 USA.	MXL6@case.edu		Penn-Nicholson, Adam/0000-0002-1883-0059; Cho, Michael/0000-0003-0522-345X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI051649, P30AI036219, U01AI025879] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 51649, AI 36219, AI 25879] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahlenstiel G, 2004, J ANTIMICROB CHEMOTH, V53, P895, DOI 10.1093/jac/dkh239; Akashi S, 2005, TRANSPLANTATION, V80, P378, DOI 10.1097/01.tp.0000166338.99933.e1; Algood HMS, 2004, J IMMUNOL, V173, P3287; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Ank N, 2005, J VIROL, V79, P9831, DOI 10.1128/JVI.79.15.9831-9841.2005; Anonymous, 2005, Antiviral Chemistry & Chemotherapy, V16, P339; Aramori I, 1997, EMBO J, V16, P4606, DOI 10.1093/emboj/16.15.4606; ArenzanaSeisdedos F, 1996, NATURE, V383, P400, DOI 10.1038/383400a0; Barr Erika L., 2005, Journal of Microbiology Immunology and Infection, V38, P244; Belnoue E, 2003, BLOOD, V101, P4253, DOI 10.1182/blood-2002-05-1493; Blanpain C, 1999, BLOOD, V94, P1899; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bongartz T, 2006, JAMA-J AM MED ASSOC, V295, P2275, DOI 10.1001/jama.295.19.2275; Brenchley JM, 2004, J EXP MED, V200, P749, DOI 10.1084/jem.20040874; Castagna A, 2005, DRUGS, V65, P879, DOI 10.2165/00003495-200565070-00001; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621; Dairaghi DJ, 1998, BLOOD, V91, P2905, DOI 10.1182/blood.V91.8.2905.2905_2905_2913; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Dean M, 1999, CANCER RES, V59, P3561; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deeks SG, 2006, LANCET, V367, P711, DOI 10.1016/S0140-6736(06)68280-9; Del Corno M, 2001, BLOOD, V98, P2909, DOI 10.1182/blood.V98.10.2909; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Elvin SJ, 2004, NATURE, V430, P417, DOI 10.1038/nature02822; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Feng Z, 2006, J IMMUNOL, V177, P782, DOI 10.4049/jimmunol.177.2.782; Fischereder M, 2001, LANCET, V357, P1758, DOI 10.1016/S0140-6736(00)04898-4; French MA, 2004, AIDS, V18, P1615, DOI 10.1097/01.aids.0000131375.21070.06; Glass WG, 2005, J EXP MED, V202, P1087, DOI 10.1084/jem.20042530; Glass WG, 2001, VIROLOGY, V288, P8, DOI 10.1006/viro.2001.1050; Glass WG, 2006, J EXP MED, V203, P35, DOI 10.1084/jem.20051970; Gonzalez E, 2005, SCIENCE, V307, P1434, DOI 10.1126/science.1101160; Gorry PR, 2002, LANCET, V359, P1832, DOI 10.1016/S0140-6736(02)08681-6; Goulding C, 2005, GUT, V54, P1157, DOI 10.1136/gut.2004.055699; GREAVES W, 2006, 13 C RETR OPP INF FE; Grone HJ, 1999, FASEB J, V13, P1371, DOI 10.1096/fasebj.13.11.1371; Handel TM, 2005, ANNU REV BIOCHEM, V74, P385, DOI 10.1146/annurev.biochem.72.121801.161747; Hartley O, 2004, P NATL ACAD SCI USA, V101, P16460, DOI 10.1073/pnas.0404802101; Hasler P, 2006, SPRINGER SEMIN IMMUN, V27, P443, DOI 10.1007/s00281-006-0013-8; HEISE C, 1993, J MED PRIMATOL, V22, P187; Howard OMZ, 1999, J BIOL CHEM, V274, P16228, DOI 10.1074/jbc.274.23.16228; Hummel S, 2005, GENES IMMUN, V6, P371, DOI 10.1038/sj.gene.6364172; HUSSON RN, 1992, J PEDIATR-US, V121, P627, DOI 10.1016/S0022-3476(05)81161-8; Ioannidis JPA, 2001, ANN INTERN MED, V135, P782, DOI 10.7326/0003-4819-135-9-200111060-00008; Jacobson JM, 2004, ANTIMICROB AGENTS CH, V48, P423, DOI 10.1128/AAC.48.2.423-429.2004; JASIN M, 1991, J VIROL, V65, P440, DOI 10.1128/JVI.65.1.440-444.1991; Kish-Catalone TM, 2006, ANTIMICROB AGENTS CH, V50, P1497, DOI 10.1128/AAC.50.4.1497-1509.2006; KOOT M, 1993, ANN INTERN MED, V118, P681, DOI 10.7326/0003-4819-118-9-199305010-00004; Korber B, 2000, SCIENCE, V288, P1789, DOI 10.1126/science.288.5472.1789; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Lalani AS, 1999, SCIENCE, V286, P1968, DOI 10.1126/science.286.5446.1968; Lange CG, 2003, AIDS, V17, P2015, DOI 10.1097/00002030-200309260-00002; LEDERMAN MM, 1995, ANN INTERN MED, V122, P218, DOI 10.7326/0003-4819-122-3-199502010-00010; Lederman MM, 2006, NAT REV IMMUNOL, V6, P371, DOI 10.1038/nri1848; Lederman MM, 2004, SCIENCE, V306, P485, DOI 10.1126/science.1099288; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Luster AD, 2002, CURR OPIN IMMUNOL, V14, P129, DOI 10.1016/S0952-7915(01)00308-9; Luther SA, 2001, NAT IMMUNOL, V2, P102, DOI 10.1038/84205; Machado FS, 2005, J INFECT DIS, V191, P627, DOI 10.1086/427515; Margolis L, 2006, NAT REV MICROBIOL, V4, P312, DOI 10.1038/nrmicro1387; Marmor M, 2001, J ACQ IMMUN DEF SYND, V27, P472, DOI 10.1097/00126334-200108150-00009; Marozsan AJ, 2005, VIROLOGY, V338, P182, DOI 10.1016/j.virol.2005.04.035; Mattapallil JJ, 2005, NATURE, V434, P1093, DOI 10.1038/nature03501; Matthews T, 2004, NAT REV DRUG DISCOV, V3, P215, DOI 10.1038/nrd1331; Mecsas J, 2004, NATURE, V427, P606, DOI 10.1038/427606a; Michael NL, 1998, J VIROL, V72, P6040, DOI 10.1128/JVI.72.7.6040-6047.1998; Miller DH, 2003, NEW ENGL J MED, V348, P15, DOI 10.1056/NEJMoa020696; Molon B, 2005, NAT IMMUNOL, V6, P465, DOI 10.1038/ni1191; Moyle GJ, 2005, J INFECT DIS, V191, P866, DOI 10.1086/428096; Mueller A, 2004, INT J BIOCHEM CELL B, V36, P35, DOI 10.1016/S1357-2725(03)00172-9; Murphy, 2003, FUNDAMENTAL IMMUNOLO, P801; MUSTER T, 1993, J VIROL, V67, P6642, DOI 10.1128/JVI.67.11.6642-6647.1993; Nansen A, 2002, BLOOD, V99, P1237, DOI 10.1182/blood.V99.4.1237; Nash PT, 2005, MED J AUSTRALIA, V183, P205, DOI 10.5694/j.1326-5377.2005.tb06998.x; Nieto M, 1998, J IMMUNOL, V161, P3330; Oppermann M, 2004, CELL SIGNAL, V16, P1201, DOI 10.1016/j.cellsig.2004.04.007; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Promrat K, 2003, GASTROENTEROLOGY, V124, P352, DOI 10.1053/gast.2003.50061; Quillent C, 1998, LANCET, V351, P14, DOI 10.1016/S0140-6736(97)09185-X; Quinones-Mateu ME, 2003, AIDS, V17, pF39, DOI [10.1097/00002030-200311070-00001, 10.1097/01.aids.0000096878.73209.4f]; ROBEN P, 1994, J VIROL, V68, P4821, DOI 10.1128/JVI.68.8.4821-4828.1994; ROSCHKE V, 2004, 44 ANN INT C ANT AG; Ruderman EM, 2005, ARTHRITIS RES THER, V7, pS21, DOI 10.1186/ar1688; Salkowitz JR, 2001, CLIN IMMUNOL, V98, P200, DOI 10.1006/clim.2000.4969; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; SCHACKER T, 1994, J INFECT DIS, V169, P37, DOI 10.1093/infdis/169.1.37; Shelburne Samuel A. III, 2003, AIDS Reviews, V5, P67; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; Stephens JC, 1998, AM J HUM GENET, V62, P1507, DOI 10.1086/301867; TERSMETTE M, 1989, VIROLOGY, V168, P267, DOI 10.1016/0042-6822(89)90266-3; Towie N, 2005, NATURE, V438, P6, DOI 10.1038/438006b; Trkola A, 2005, NAT MED, V11, P615, DOI 10.1038/nm1244; Trkola A, 1998, J VIROL, V72, P1876, DOI 10.1128/JVI.72.3.1876-1885.1998; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Unutmaz D, 1998, SEMIN IMMUNOL, V10, P225, DOI 10.1006/smim.1998.0134; Valdez H, 2000, AIDS, V14, P11, DOI 10.1097/00002030-200001070-00002; Veazey RS, 2005, NATURE, V438, P99, DOI 10.1038/nature04055; Veazey RS, 1998, SCIENCE, V280, P427, DOI 10.1126/science.280.5362.427; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; Wang HGH, 2004, CURR PHARM DESIGN, V10, P1785, DOI 10.2174/1381612043384565; Watson C, 2005, MOL PHARMACOL, V67, P1268, DOI 10.1124/mol.104.008565; WEINER DB, 1991, PATHOBIOLOGY, V59, P361, DOI 10.1159/000163679; Wong MM, 2003, SEMIN IMMUNOL, V15, P5, DOI 10.1016/S1044-5323(02)00123-9; Yousry TA, 2006, NEW ENGL J MED, V354, P924, DOI 10.1056/NEJMoa054693; Zhao J, 1998, J CELL BIOCHEM, V71, P36, DOI 10.1002/(SICI)1097-4644(19981001)71:1<36::AID-JCB4>3.0.CO;2-2; Zimmerman PA, 1997, MOL MED, V3, P23, DOI 10.1007/BF03401665; Zwick MB, 2001, J VIROL, V75, P10892, DOI 10.1128/JVI.75.22.10892-10905.2001	111	184	201	0	29	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 16	2006	296	7					815	826		10.1001/jama.296.7.815	http://dx.doi.org/10.1001/jama.296.7.815			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	073SR	16905787				2022-12-28	WOS:000239763400022
J	Check, E				Check, Erika			Silent running: the race to the clinic	NATURE			English	News Item							RNAI											Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; Zimmermann TS, 2006, NATURE, V441, P111, DOI 10.1038/nature04688	3	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 10	2006	442	7103					614	615		10.1038/442614a	http://dx.doi.org/10.1038/442614a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	071UU	16900171				2022-12-28	WOS:000239630200014
J	Gangopadhyay, KK; Sundram, F; De, P				Gangopadhyay, Kalyan Kumar; Sundram, Francis; De, Parijat			Lesson of the week - Triggering radiation alarms after radioiodine treatment	BMJ-BRITISH MEDICAL JOURNAL			English	Article							AIRPORT		City Hosp, Dept Med Diabet & Endocrinol, Birmingham B18 7QH, W Midlands, England; City Hosp, Dept Nucl Med, Birmingham, W Midlands, England	University of Birmingham; University of Birmingham	Gangopadhyay, KK (corresponding author), 87 Thorncroft Way, Walsall WS5 4EF, W Midlands, England.	jaykal69@hotmail.com						Iqbal MB, 2005, LANCET, V366, P342, DOI 10.1016/S0140-6736(05)66994-2; Lazarus JH, 1995, J ROY COLL PHYS LOND, V29, P464; LEVIN ME, 1988, NEW ENGL J MED, V315, P587; Sinzinger H, 2005, NUCL MED COMMUN, V26, P67, DOI 10.1097/00006231-200501000-00011; TOLTZIS RJ, 1986, NEW ENGL J MED, V315, P836; ZUCKIER L, 2004, RADIOLOGICAL SOC N A	6	17	17	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 5	2006	333	7562					293	294		10.1136/bmj.333.7562.293	http://dx.doi.org/10.1136/bmj.333.7562.293			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	073MV	16888306	Green Published			2022-12-28	WOS:000239748200018
J	Jewkes, R				Jewkes, Rachel			Beyond stigma: social responses to HIV in South Africa	LANCET			English	Editorial Material									MRC, Gender & Hlth Res Unit, ZA-0001 Pretoria, South Africa		Jewkes, R (corresponding author), MRC, Gender & Hlth Res Unit, ZA-0001 Pretoria, South Africa.	rjewkes@mrc.ac.za		Jewkes, Rachel/0000-0002-4330-6267				Brown L, 2003, AIDS EDUC PREV, V15, P49, DOI 10.1521/aeap.15.1.49.23844; CAMERON E, 2000, 13 INT AIDS C DURB S; Campbell C, 2005, AM J PUBLIC HEALTH, V95, P808, DOI 10.2105/AJPH.2003.037499; Kalichman SC, 2005, AIDS BEHAV, V9, P135, DOI 10.1007/s10461-005-3895-x; *S AFR DEP HLTH, 2005, NAT HIV SYPH ANT SER; SHISANA O, 2005, S AFRICAN NATL HIV P; WOOD K, 2003, THESIS LONDON SCH HY	7	27	29	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 5	2006	368	9534					430	431		10.1016/S0140-6736(06)69130-7	http://dx.doi.org/10.1016/S0140-6736(06)69130-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	071AL	16890812				2022-12-28	WOS:000239569000007
J	Bliss, TVP; Collingridge, GL; Laroche, S				Bliss, Tim V. P.; Collingridge, Graham L.; Laroche, Serge			ZAP and ZIP, a story to forget	SCIENCE			English	Editorial Material							KINASE-M-ZETA; LONG-TERM POTENTIATION; SYNAPTIC-TRANSMISSION; MEMORY; HIPPOCAMPUS; LTP		Natl Inst Med Res, MRC, Div Neurophysiol, London NW7 1AA, England; Univ Bristol, MRC, Ctr Synapt Plast, Bristol BS8 1TD, Avon, England; Univ Paris 11, CNRS, UMR 8620, NAMC, F-91405 Orsay, France	MRC National Institute for Medical Research; University of Bristol; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Bliss, TVP (corresponding author), Natl Inst Med Res, MRC, Div Neurophysiol, Mill Hill, London NW7 1AA, England.	tbliss@nimr.mrc.ac.uk; g.l.collingridge@bristol.ac.uk; serge.laroche@ibaic.u-psud.fr	Collingridge, Graham L/C-4605-2015; collingridge, graham/AAI-8362-2020	Collingridge, Graham L/0000-0002-9572-5359; 	Medical Research Council [MC_U117512674] Funding Source: Medline; MRC [MC_U117512674] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; Gruart A, 2006, J NEUROSCI, V26, P1077, DOI 10.1523/JNEUROSCI.2834-05.2006; Hernandez AI, 2003, J BIOL CHEM, V278, P40305, DOI 10.1074/jbc.M307065200; Izquierdo I, 1997, NEUROBIOL LEARN MEM, V68, P285, DOI 10.1006/nlme.1997.3799; Jones MW, 2001, NAT NEUROSCI, V4, P289, DOI 10.1038/85138; Ling DSF, 2006, HIPPOCAMPUS, V16, P443, DOI 10.1002/hipo.20171; Ling DSF, 2002, NAT NEUROSCI, V5, P295, DOI 10.1038/nn829; Martin SJ, 2000, ANNU REV NEUROSCI, V23, P649, DOI 10.1146/annurev.neuro.23.1.649; Pastalkova E, 2006, SCIENCE, V313, P1141, DOI 10.1126/science.1128657; Serrano P, 2005, J NEUROSCI, V25, P1979, DOI 10.1523/JNEUROSCI.5132-04.2005; Whitlock JR, 2006, SCIENCE, V313, P1093, DOI 10.1126/science.1128134; Wiltgen BJ, 2004, NEURON, V44, P101, DOI 10.1016/j.neuron.2004.09.015	14	36	38	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 25	2006	313	5790					1058	1059		10.1126/science.1132538	http://dx.doi.org/10.1126/science.1132538			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	076ZT	16931746				2022-12-28	WOS:000239998200028
J	Steinbrook, R				Steinbrook, Robert			Imposing personal responsibility for health	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material												rsteinbrook@attglobal.net						*CTR MED MED SERV, 2006, ROADM MED REF NEW OP; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; SOLOMON J, 2006, W VIRGINIAS MEDICAID; *WV MED STAT PLAN, 2006, 0602 WV MED STAT PLA; 2006, WALL STREET J O 0719	5	64	66	1	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 24	2006	355	8					753	756		10.1056/NEJMp068141	http://dx.doi.org/10.1056/NEJMp068141			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	076KA	16928991	Bronze			2022-12-28	WOS:000239955200001
J	Tuthill, P; Monnier, J; Tanner, A; Figer, D; Ghez, A; Danchi, W				Tuthill, Peter; Monnier, John; Tanner, Angelle; Figer, Donald; Ghez, Andrea; Danchi, William			Pinwheels in the quintuplet cluster	SCIENCE			English	Article							GALACTIC-CENTER; NEBULA; STARS		Univ Sydney, Dept Phys, Sydney, NSW 2006, Australia; Univ Michigan, Dept Astron, Ann Arbor, MI 48109 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91125 USA; Rochester Inst Technol, COS Ctr Imaging Sci, Rochester, NY 14623 USA; Univ Calif Los Angeles, Los Angeles, CA 90095 USA; NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA	University of Sydney; University of Michigan System; University of Michigan; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Rochester Institute of Technology; University of California System; University of California Los Angeles; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center	Tuthill, P (corresponding author), Univ Sydney, Dept Phys, Sydney, NSW 2006, Australia.	p.tuthill@physics.usyd.edu.au		Tuthill, Peter/0000-0001-7026-6291; Monnier, John D/0000-0002-3380-3307				Figer DF, 1999, ASTROPHYS J, V525, P750, DOI 10.1086/307937; Figer DF, 1999, ASTROPHYS J, V514, P202, DOI 10.1086/306931; Harries TJ, 2004, MON NOT R ASTRON SOC, V350, P565, DOI 10.1111/j.1365-2966.2004.07668.x; HOWARTH ID, 1992, ASTRON ASTROPHYS, V261, P503; MONNIER JD, 1999, APJ, V525, P97; Moran JA, 2005, ASTROPHYS J, V632, P438, DOI 10.1086/432634; OKUDA H, 1990, ASTROPHYS J, V351, P89, DOI 10.1086/168447; REID MJ, 1993, ANNU REV ASTRON ASTR, V31, P345; Ryder SD, 2004, MON NOT R ASTRON SOC, V349, P1093, DOI 10.1111/j.1365-2966.2004.07589.x; Tuthill PG, 1999, NATURE, V398, P487, DOI 10.1038/19033	10	52	52	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 18	2006	313	5789					935	935		10.1126/science.1128731	http://dx.doi.org/10.1126/science.1128731			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	074MR	16917053	Green Submitted			2022-12-28	WOS:000239817000033
J	de Nijs, RNJ; Jacobs, JWG; Lems, WF; Laan, RFJ; Algra, A; Huisman, A; Buskens, E; de Laet, CED; Oostveen, ACM; Geusens, PPMM; Bruyn, GAW; Dijkmans, BAC; Bijlsma, JWJ				de Nijs, Ron N. J.; Jacobs, Johannes W. G.; Lems, Willem F.; Laan, Roland F. J.; Algra, Ale; Huisman, Anne-Margriet; Buskens, Erik; de laet, Chris E. D.; Oostveen, Ans C. M.; Geusens, Piet P. M. M.; Bruyn, George A. W.; Dijkmans, Ben A. C.; Bijlsma, Johannes W. J.		STOP Investigators	Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORTICOSTEROID-INDUCED OSTEOPOROSIS; LOW-DOSE CORTICOSTEROIDS; RHEUMATOID-ARTHRITIS; BONE LOSS; PREVENTION; CALCIUM; CALCITRIOL; FRACTURES; DENSITY; RISK	BACKGROUND: Treatment with glucocorticoids is associated with bone loss starting soon after therapy is initiated and an increased risk of fracture. METHODS: We performed a randomized, double-placebo, double-blind clinical trial of 18 months' duration among patients with a rheumatic disease who were starting glucocorticoids at a daily dose that was equivalent to at least 7.5 mg of prednisone. A total of 201 patients were assigned to receive either alendronate (10 mg) and a placebo capsule of alfacalcidol daily or alfacalcidol (1 mu g) and a placebo tablet of alendronate daily. The primary outcome was the change in bone mineral density of the lumbar spine in 18 months; the secondary outcome was the incidence of morphometric vertebral deformities. RESULTS: A total of 100 patients received alendronate, and 101 received alfacalcidol; 163 patients completed the study. The bone mineral density of the lumbar spine increased by 2.1 percent in the alendronate group (95 percent confidence interval, 1.1 to 3.1 percent) and decreased by 1.9 percent in the alfacalcidol group (95 percent confidence interval, -3.1 to -0.7 percent). At 18 months, the mean difference of change in bone mineral density between the two groups was 4.0 percent (95 percent confidence interval, 2.4 to 5.5 percent). Three patients in the alendronate group had a new vertebral deformity, as compared with eight patients in the alfacalcidol group (of whom three had symptomatic vertebral fractures) (hazard ratio, 0.4; 95 percent confidence interval, 0.1 to 1.4). CONCLUSIONS: During this 18-month trial in patients with rheumatic diseases, alendronate was more effective in the prevention of glucocorticoid-induced bone loss than was alfacalcidol.	Univ Med Ctr Utrecht, Dept Rheumatol & Clin Immunol, NL-3508 GA Utrecht, Netherlands; Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, NL-3508 GA Utrecht, Netherlands; Free Univ Amsterdam, Med Ctr, Dept Rheumatol, Amsterdam, Netherlands; Radboud Univ Nijmegen Med Ctr, Dept Rheumatol, Nijmegen, Netherlands; St Franciscus Hosp, Dept Rheumatol, Rotterdam, Netherlands; Twente Twenteborg Hosp, Dept Rheumatol Twente, Almelo, Netherlands; Univ Hosp Maastricht, Dept Rheumatol, Maastricht, Netherlands; Med Ctr Leeuwarden, Dept Rheumatol, Leeuwarden, Netherlands; Sci Inst Publ Hlth, Dept Epidemiol, Brussels, Belgium	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Vrije Universiteit Amsterdam; Radboud University Nijmegen; Franciscus Gasthuis; Maastricht University; Maastricht University Medical Centre (MUMC); Medical Center Leeuwarden	de Nijs, RNJ (corresponding author), Univ Med Ctr Utrecht, Dept Rheumatol & Clin Immunol, F02 127,POB 85500, NL-3508 GA Utrecht, Netherlands.	r.denijs@mmc.nl	Scillitani, Alfredo/AAB-8948-2019; de Nijs, Ron/AAV-3045-2021; Laan, R.F.J.M./H-8064-2014	Scillitani, Alfredo/0000-0001-9954-4187; De Laet, Chris/0000-0002-1951-2079; buskens, erik/0000-0002-6463-1106				Adachi JD, 2001, ARTHRITIS RHEUM, V44, P202, DOI 10.1002/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W; AERSSENS J, 1994, CALCIFIED TISSUE INT, V55, P443, DOI 10.1007/BF00298558; Canalis E, 2002, ANN NY ACAD SCI, V966, P73, DOI 10.1111/j.1749-6632.2002.tb04204.x; de Nijs RNJ, 2004, OSTEOPOROSIS INT, V15, P589, DOI 10.1007/s00198-004-1614-5; de Nijs RNJ, 2001, RHEUMATOLOGY, V40, P1375, DOI 10.1093/rheumatology/40.12.1375; Giannini S, 2001, J BONE MINER RES, V16, P2111, DOI 10.1359/jbmr.2001.16.11.2111; Gonnelli S, 1997, CALCIFIED TISSUE INT, V61, P382, DOI 10.1007/s002239900352; Jeffery JR, 2003, TRANSPLANTATION, V76, P1498, DOI 10.1097/01.TP.0000092523.30277.13; Kleerekoper M, 1984, P COPENHAGEN INT S O, P103; KLEIN RG, 1977, J CLIN INVEST, V60, P253, DOI 10.1172/JCI108762; Kovac D, 2001, TRANSPL P, V33, P1144, DOI 10.1016/S0041-1345(00)02464-7; Manolagas SC, 1999, J BONE MINER RES, V14, P1061, DOI 10.1359/jbmr.1999.14.7.1061; MICHEL BA, 1993, J RHEUMATOL, V20, P1666; PAYNE RB, 1973, BMJ-BRIT MED J, V4, P643, DOI 10.1136/bmj.4.5893.643; Pearce G, 1998, BRIT J RHEUMATOL, V37, P292; Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800; Reginster JY, 1999, OSTEOPOROSIS INT, V9, P75, DOI 10.1007/s001980050118; Ringe JD, 1999, CALCIFIED TISSUE INT, V65, P337, DOI 10.1007/s002239900708; Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640; Rubin MR, 2002, J CLIN ENDOCR METAB, V87, P4033, DOI 10.1210/jc.2002-012101; Saag KG, 1998, NEW ENGL J MED, V339, P292, DOI 10.1056/NEJM199807303390502; Sambrook PN, 2003, J BONE MINER RES, V18, P919, DOI 10.1359/jbmr.2003.18.5.919; SATO F, 1991, RES EXP MED, V191, P235, DOI 10.1007/BF02576679; Schacht E, 1999, CALCIFIED TISSUE INT, V65, P317, DOI 10.1007/s002239900705; Shane E, 2004, NEW ENGL J MED, V350, P767, DOI 10.1056/NEJMoa035617; Shiraishi A, 2000, J BONE MINER RES, V15, P770, DOI 10.1359/jbmr.2000.15.4.770; SUZUKI Y, 1983, METABOLISM, V32, P151, DOI 10.1016/0026-0495(83)90221-4; van Staa TP, 2002, OSTEOPOROSIS INT, V13, P777, DOI 10.1007/s001980200108; Van Staa TP, 2000, J BONE MINER RES, V15, P993, DOI 10.1359/jbmr.2000.15.6.993; VERSTRAETEN A, 1986, ANN RHEUM DIS, V45, P852, DOI 10.1136/ard.45.10.852; Vestergaard P, 2003, J INTERN MED, V254, P486, DOI 10.1046/j.1365-2796.2003.01219.x; Weinstein RS, 2002, J CLIN INVEST, V109, P1041, DOI 10.1172/JCI200214538	32	148	154	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 17	2006	355	7					675	684		10.1056/NEJMoa053569	http://dx.doi.org/10.1056/NEJMoa053569			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	074AN	16914703	Green Published			2022-12-28	WOS:000239784500006
J	Chourrout, D; Delsuc, F; Chourrout, P; Edvardsen, RB; Rentzsch, F; Renfer, E; Jensen, MF; Zhu, B; de Jong, P; Steele, RE; Technau, U				Chourrout, D.; Delsuc, F.; Chourrout, P.; Edvardsen, R. B.; Rentzsch, F.; Renfer, E.; Jensen, M. F.; Zhu, B.; de Jong, P.; Steele, R. E.; Technau, U.			Minimal ProtoHox cluster inferred from bilaterian and cnidarian Hox complements	NATURE			English	Article							CLASS HOMEOBOX GENES; EARLY EVOLUTION; SEA-ANEMONE; ORIGIN; EXPRESSION; ZOOTYPE; HYDRA	Bilaterian animals have a Hox gene cluster essential for patterning the main body axis, and a ParaHox gene cluster. Comparison of Hox and ParaHox genes has led workers to postulate that both clusters originated from the duplication of an ancient cluster named ProtoHox, which contained up to four genes with at least the precursors of anterior and posterior Hox/ ParaHox genes(1-3). However, the way in which genes diversified within the ProtoHox, Hox and ParaHox clusters remains unclear because no systematic study of non- bilaterian animals exists. Here we characterize the full Hox/ ParaHox gene complements and genomic organization in two cnidarian species ( Nematostella vectensis and Hydra magnipapillata), and suggest a ProtoHox cluster simpler than originally thought on the basis of three arguments. First, both species possess bilaterian- like anterior Hox genes, but their non-anterior genes do not appear as counterparts of either bilaterian central or posterior genes; second, two clustered ParaHox genes, Gsx and a gene related to Xlox and Cdx, are found in Nematostella vectensis; and third, we do not find clear phylogenetic support for a common origin of bilaterian Cdx and posterior genes, which might therefore have appeared after the ProtoHox cluster duplication. Consequently, the ProtoHox cluster might have consisted of only two anterior genes. Non- anterior genes could have appeared independently in the Hox and ParaHox clusters, possibly after the separation of bilaterians and cnidarians.	Univ Bergen, Sars Inst Ctr Marine Mol Biol, N-5008 Bergen, Norway; Univ Montpellier 2, CNRS, UMR5554,Inst Sci Evolut, Lab Paleontol Phylogenie & Paleobiol, F-34095 Montpellier 05, France; Amer Hosp Paris, F-92202 Neuilly Sur Seine, France; Childrens Hosp & Res Ctr Oakland, Oakland, CA 94609 USA; Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA	University of Bergen; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); Institut de Recherche pour le Developpement (IRD); Universite de Montpellier; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; University of California System; University of California Irvine	Chourrout, D (corresponding author), Univ Bergen, Sars Inst Ctr Marine Mol Biol, Thormoehlengst 55, N-5008 Bergen, Norway.	Daniel.chourrout@sars.uib.no; Ulrich.technau@sars.uib.no	Delsuc, Frederic/B-4381-2009	Delsuc, Frederic/0000-0002-6501-6287; Edvardsen, Rolf/0000-0001-8430-8042; Technau, Ulrich/0000-0003-4472-8258				Brooke NM, 1998, NATURE, V392, P920, DOI 10.1038/31933; Castro LFC, 2003, EVOL DEV, V5, P459, DOI 10.1046/j.1525-142X.2003.03052.x; Collins AG, 2002, J EVOLUTION BIOL, V15, P418, DOI 10.1046/j.1420-9101.2002.00403.x; Collins AG, 1998, P NATL ACAD SCI USA, V95, P15458, DOI 10.1073/pnas.95.26.15458; Darling JA, 2005, BIOESSAYS, V27, P211, DOI 10.1002/bies.20181; Ferrier DEK, 2001, NAT REV GENET, V2, P33, DOI 10.1038/35047605; Finnerty JR, 2004, SCIENCE, V304, P1335, DOI 10.1126/science.1091946; Finnerty JR, 1999, EVOL DEV, V1, P16, DOI 10.1046/j.1525-142x.1999.99010.x; Finnerty JR, 2003, EVOL DEV, V5, P331, DOI 10.1046/j.1525-142X.2003.03041.x; GARCIACALLEJA JM, 1992, AIDS, V6, P881, DOI 10.1097/00002030-199208000-00020; Gauchat D, 2000, P NATL ACAD SCI USA, V97, P4493, DOI 10.1073/pnas.97.9.4493; Kuhn K, 1999, J EXP ZOOL, V285, P63, DOI 10.1002/(SICI)1097-010X(19990415)285:1<63::AID-JEZ8>3.0.CO;2-X; Kuhn K, 1996, MOL PHYLOGENET EVOL, V6, P30, DOI 10.1006/mpev.1996.0055; Martinez DE, 1998, NATURE, V393, P748, DOI 10.1038/31616; MILLER DJ, 1993, NATURE, V365, P215, DOI 10.1038/365215b0; Monteiro AS, 2006, EVOL DEV, V8, P174, DOI 10.1111/j.1525-142X.2006.00087.x; Philippe H, 2005, MOL BIOL EVOL, V22, P1246, DOI 10.1093/molbev/msi111; Seipel K, 2005, DEV BIOL, V282, P14, DOI 10.1016/j.ydbio.2005.03.032; SHENK MA, 1993, DEVELOPMENT, V117, P657; Technau U, 2005, TRENDS GENET, V21, P633, DOI 10.1016/j.tig.2005.09.007	20	144	146	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 10	2006	442	7103					684	687		10.1038/nature04863	http://dx.doi.org/10.1038/nature04863			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	071UU	16900199	Green Submitted			2022-12-28	WOS:000239630200045
J	Katz, RF; Spiegelman, M; Holtzman, B				Katz, Richard F.; Spiegelman, Marc; Holtzman, Benjamin			The dynamics of melt and shear localization in partially molten aggregates	NATURE			English	Article							UPWELLING MANTLE; BENEATH; EXTRACTION; SEGREGATION; COMPACTION; BASALT; ROCKS; RIDGE; MODEL; FLOW	The volcanoes that lie along the Earth's tectonic boundaries are fed by melt generated in the mantle. How this melt is extracted and focused to the volcanoes, however, remains an unresolved question. Here we present new theoretical results with implications for melt focusing beneath mid- ocean ridges. By modelling laboratory experiments(1,2), we test a formulation for magma dynamics and provide an explanation for localized bands of high- porosity and concentrated shear deformation observed in experiments. These bands emerge and persist at 15 degrees - 25 degrees to the plane of shear. Past theoretical work on this system predicted the emergence of melt bands(3,4) but at an angle inconsistent with experiments. Our results suggest that the observed band angle results from a balance of porosity- weakening and strain- rate- weakening deformation mechanisms. Lower band angles are predicted for greater strain-rate weakening. From these lower band angles, we estimate the orientation of melt bands beneath mid- ocean ridges and show that they may enhance magma focusing toward the ridge axis.	Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA; Columbia Univ, Dept Appl Phys & Appl Math, New York, NY 10027 USA	Columbia University; Columbia University	Katz, RF (corresponding author), Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA.	katz@ldeo.columbia.edu	Katz, Richard/D-3364-2009; Holtzman, Benjamin/E-8423-2010	Katz, Richard/0000-0001-8746-5430; Holtzman, Benjamin/0000-0002-6226-7689				Balay S., 2001, PORTABLE EXTENSIBLE; Bercovici D, 2001, J GEOPHYS RES-SOL EA, V106, P8887, DOI 10.1029/2000JB900430; Daines MJ, 1997, J GEOPHYS RES-SOL EA, V102, P10257, DOI 10.1029/97JB00393; Forsyth DW, 1998, SCIENCE, V280, P1215, DOI 10.1126/science.280.5367.1235; Fowler AC, 1985, GEOPHYS ASTRO FLUID, V33, P63, DOI 10.1080/03091928508245423; Hall CE, 2000, GEOPHYS RES LETT, V27, P9, DOI 10.1029/1999GL008393; Hirth G., 2003, INSIDE SUBDUCTION FA, V138, P83, DOI [10.1029/138GM06, DOI 10.1029/138GM06]; Holtzman BK, 2005, J PETROL, V46, P2569, DOI 10.1093/petrology/egi065; Holtzman BK, 2003, GEOCHEM GEOPHY GEOSY, V4, DOI 10.1029/2001GC000258; KARATO S, 1993, SCIENCE, V260, P771, DOI 10.1126/science.260.5109.771; Katz RF, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020388; Kelemen PB, 1997, PHILOS T R SOC A, V355, P283, DOI 10.1098/rsta.1997.0010; KELEMEN PB, 1995, NATURE, V375, P747, DOI 10.1038/375747a0; KNEPLEY M, 2006, LECT NOTES COMPUTATI, V51, P413; MCKENZIE D, 1984, J PETROL, V25, P713, DOI 10.1093/petrology/25.3.713; Mei S, 2002, EARTH PLANET SC LETT, V201, P491, DOI 10.1016/S0012-821X(02)00745-8; MORGAN JP, 1987, GEOPHYS RES LETT, V14, P1238, DOI 10.1029/GL014i012p01238; Richardson CN, 1998, GEOPHYS RES LETT, V25, P1099, DOI 10.1029/98GL50565; SCOTT DR, 1986, J GEOPHYS RES-SOLID, V91, P9283, DOI 10.1029/JB091iB09p09283; SPARKS DW, 1991, EARTH PLANET SC LETT, V105, P368, DOI 10.1016/0012-821X(91)90178-K; Spiegelman M, 2003, GEOCHEM GEOPHY GEOSY, V4, DOI 10.1029/2002GC000499; SPIEGELMAN M, 1987, EARTH PLANET SC LETT, V83, P137, DOI 10.1016/0012-821X(87)90057-4; STEVENSON DJ, 1989, GEOPHYS RES LETT, V16, P1067, DOI 10.1029/GL016i009p01067; Zimmerman ME, 1999, GEOPHYS RES LETT, V26, P1505, DOI 10.1029/1999GL900259	24	189	199	0	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 10	2006	442	7103					676	679		10.1038/nature05039	http://dx.doi.org/10.1038/nature05039			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	071UU	16900197				2022-12-28	WOS:000239630200043
J	Dore, GJ; Cooper, DA				Dore, Gregory J.; Cooper, David A.			HAART's first decade: success brings further challenges	LANCET			English	Editorial Material							HIV; RESISTANCE; INFECTION; AUSTRALIA		Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW 2010, Australia	University of New South Wales Sydney; Kirby Institute	Dore, GJ (corresponding author), Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW 2010, Australia.	gdore@nchecr.unsw.edu.au	Dore, Gregory John/ABD-5665-2021	Dore, Gregory John/0000-0002-4741-2622				Carr A, 1998, AIDS, V12, pF51, DOI 10.1097/00002030-199807000-00003; Dore GJ, 2001, J ACQ IMMUN DEF SYND, V26, P283, DOI 10.1097/00126334-200103010-00012; ELSADR W, 2006, 13 C RETR OPP INF 20; Friis-Moller N, 2003, NEW ENGL J MED, V349, P1993, DOI 10.1056/NEJMoa030218; Gallant JE, 2006, NEW ENGL J MED, V354, P251, DOI 10.1056/NEJMoa051871; May MT, 2006, LANCET, V368, P451, DOI 10.1016/S0140-6736(06)69152-6; McDonald AM, 2003, AUST NZ J PUBL HEAL, V27, P608, DOI 10.1111/j.1467-842X.2003.tb00607.x; Michailidis C, 2005, ANTIVIR THER, V10, P417; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Pillay D, 2006, AIDS, V20, P21, DOI 10.1097/01.aids.0000196172.35056.b7; Pozniak AL, 2005, HIV MED, V6, P62, DOI 10.1111/j.1468-1293.2005.00293.x	11	13	13	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 5	2006	368	9534					427	428		10.1016/S0140-6736(06)69128-9	http://dx.doi.org/10.1016/S0140-6736(06)69128-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	071AL	16890810				2022-12-28	WOS:000239569000005
J	Hashemian, F; Khoshnood, K; Desai, MM; Falahati, F; Kasl, S; Southwick, S				Hashemian, Farnoosh; Khoshnood, Kaveh; Desai, Mayur M.; Falahati, Faralmaz; Kasl, Stanislav; Southwick, Steven			Anxiety, depression, and posttraumatic stress in Iranian survivors of chemical warfare	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WORLD-WAR-II; PTSD SYMPTOMS; MENTAL-HEALTH; MUSTARD GAS; DISORDER; COMORBIDITY; AFGHANISTAN; PREDICTORS; VETERANS; PATTERNS	Context In the 1980-1988 Iran-Iraq War, extensive use of chemical weapons resulted in high rates of morbidity and mortality. While much is known about the physical consequences of chemical warfare, there is a paucity of information about the long-term effects of chemical attacks on mental health. Objective To assess the long-term psychological impact of chemical warfare on a civilian population. Design, Setting, and Participants Cross-sectional randomized survey conducted in July 2004 of 153 civilians in 3 towns exposed to warfare in northwestern Iran: Oshnaviyeh (low-intensity conventional warfare), Rabat (high-intensity conventional warfare), and Sardasht (both high-intensity conventional warfare and chemical weapons). Main Outcome Measures Full or partial posttraumatic stress disorder (PTSD) diagnosis, anxiety symptoms, and depressive symptoms were assessed using Farsi versions of the Clinician-Administered PTSD Scale, Hamilton Scale for Anxiety, and Beck Depression Inventory, respectively. Results Overall participation rate was 93%. Respondents had a mean age of 45 years and were all of Kurdish ethnicity. Among individuals exposed to both high-intensity warfare and chemical weapons, prevalence rates for lifetime PTSD, current PTSD, major anxiety symptoms, and severe depressive symptoms were 59%, 33%, 65%, and 41%, respectively. Among the low-intensity warfare group, the corresponding rates were 8%,2%,18%, and 6%, respectively, while intermediate rates were found among those exposed to high-intensity warfare but not to chemical weapons (31%, 8%, 26%, and 12%, respectively). Compared with individuals exposed to low-intensity warfare, those exposed to both high-intensity warfare and chemical weapons were at higher risk for lifetime PTSD (odds ratio [OR], 18.6; 95% confidence interval [CI], 5.8-59.4), current PTSD (OR, 27.4; 95% Cl, 3.4-218.2), increased anxiety symptoms (OR, 14.6; 95% Cl, 6.0-35.6), and increased depressive symptoms (OR, 7.2; 95% Cl, 3.3-15.9). Exposure to high-intensity warfare but not to chemical weapons was also significantly associated with lifetime PTSD (OR, 5.4; 95% Cl, 1.7-17.6), compared with those in the low-intensity warfare group. Further, compared with individuals exposed to high-intensity warfare alone, those exposed to both high-intensity warfare and chemical weapons were at higher risk for lifetime PTSD (OR, 3.4; 95% Cl, 1.5-7.4), current PTSD (OR, 6.2; 95% Cl, 2.0-20.1), increased anxiety symptoms (OR, 5.6; 95% Cl, 2.5-12.6), and increased depressive symptoms (OR, 3.7; 95% Cl, 1.8-7.2). Conclusion Exposure to chemical warfare is an extreme traumatic event that has long-lasting adverse consequences on mental health.	Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA; VA Connecticut Healthcare Syst, NE Program Evaluat Ctr, West Haven, CT USA; VA Connecticut Healthcare Syst, Mental Illness Res Educ & Clin Ctr, West Haven, CT USA; VA Connecticut Healthcare Syst, Natl Ctr PTSD, West Haven, CT USA; Org Vet Affairs, Chem Warfare Victims Unit, Tehran, Iran	Yale University; Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System	Hashemian, F (corresponding author), Yale Univ, Sch Publ Hlth, 60 Coll St, New Haven, CT 06511 USA.	farnoosh.hashemian@aya.yale.edu	Khoshnood, Kaveh/AAX-1402-2020	Khoshnood, Kaveh/0000-0003-2795-0447; Desai, Mayur/0000-0001-6616-0945				BECK AT, 1972, POSTGRAD MED, V52, P81, DOI 10.1080/00325481.1972.11713319; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Cardozo BL, 2004, JAMA-J AM MED ASSOC, V292, P575, DOI 10.1001/jama.292.5.575; *CBW ARM ARMS, 1995, Q J HARVARD SUSSEX P, V28, P20; DAVIDSON JRT, 1990, COMPR PSYCHIAT, V31, P162, DOI 10.1016/0010-440X(90)90020-S; de Jong JTVM, 2001, JAMA-J AM MED ASSOC, V286, P555, DOI 10.1001/jama.286.5.555; Deering CG, 1996, COMPR PSYCHIAT, V37, P336, DOI 10.1016/S0010-440X(96)90015-2; Fazel M, 2005, LANCET, V365, P1309, DOI 10.1016/S0140-6736(05)61027-6; GHANEI M, 2003, J BURN SURG WOUND CA, V2, P1; Ghassemzadeh H, 2005, DEPRESS ANXIETY, V21, P185, DOI 10.1002/da.20070; GREEN BL, 1985, J NERV MENT DIS, V173, P406, DOI 10.1097/00005053-198507000-00004; Hamilton M, 1969, BRIT J PSYCHIAT, V3, P76, DOI DOI 10.1037/T04100-000; Kavyani H, 2001, PSYCHOL SCALES INTER, P179; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Kessler RC, 2000, J CLIN PSYCHIAT, V61, P4; Khateri S, 2003, J OCCUP ENVIRON MED, V45, P1136, DOI 10.1097/01.jom.0000094993.20914.d1; Kulka R.A., 1990, TRAUMA VIETNAM WAR G; Malekzai ASB, 1996, J TRAUMA STRESS, V9, P891, DOI 10.1007/BF02104111; McCall GJ, 2003, J TRAUMA STRESS, V16, P445, DOI 10.1023/A:1025702326392; Norris FH, 2002, PSYCHIATRY, V65, P207, DOI 10.1521/psyc.65.3.207.20173; Ohtani T, 2004, PSYCHIAT CLIN NEUROS, V58, P624, DOI 10.1111/j.1440-1819.2004.01313.x; SCHNURR PP, 1993, AM J PSYCHIAT, V150, P479; Schnurr PP, 1996, MIL MED, V161, P131, DOI 10.1093/milmed/161.3.131; Schnurr PP, 2000, J CONSULT CLIN PSYCH, V68, P258, DOI 10.1037//0022-006X.68.2.258; Scholte WF, 2004, JAMA-J AM MED ASSOC, V292, P585, DOI 10.1001/jama.292.5.585; Scott SC, 1997, J CLIN EPIDEMIOL, V50, P45, DOI 10.1016/S0895-4356(96)00312-5; SHEMIRANI ST, 1993, IRAN IRAQ WAR POLITI; HOLT WORLD HIST HUMA; [No title captured]	29	103	104	6	31	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 2	2006	296	5					560	566		10.1001/jama.296.5.560	http://dx.doi.org/10.1001/jama.296.5.560			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	069YW	16882962	Bronze			2022-12-28	WOS:000239486900020
J	Brown, K				Brown, Kevin			Anaemia, parvovirus, and malaria	LANCET			English	Editorial Material							INFECTION; B19; PREVALENCE; CHILDREN		Hlth Protect Agcy, London NW9 5EQ, England	Health Protection Agency	Brown, K (corresponding author), Hlth Protect Agcy, London NW9 5EQ, England.	Kevin.Brown@HPA.org.uk		Brown, Kevin/0000-0002-1568-683X				ANDERSON MJ, 1985, J INFECT DIS, V152, P257, DOI 10.1093/infdis/152.2.257; Ballou WR, 2003, J INFECT DIS, V187, P675, DOI 10.1086/368382; COHEN BJ, 1988, J MED MICROBIOL, V25, P151, DOI 10.1099/00222615-25-2-151; COSSART YE, 1975, LANCET, V1, P72; JONES PH, 1990, J TROP MED HYG, V93, P67; Kelly HA, 2000, EPIDEMIOL INFECT, V124, P449, DOI 10.1017/S0950268899003817; POTTER CG, 1987, J CLIN INVEST, V79, P1486, DOI 10.1172/JCI112978; SERJEANT GR, 1981, LANCET, V2, P595; Wildig J, 2006, J INFECT DIS, V194, P146, DOI 10.1086/505082; Young NS, 2004, NEW ENGL J MED, V350, P586, DOI 10.1056/NEJMra030840	10	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG-SEP	2006	368	9537					714	716		10.1016/S0140-6736(06)69265-9	http://dx.doi.org/10.1016/S0140-6736(06)69265-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	080ID	16935671				2022-12-28	WOS:000240240200009
J	Yeromin, AV; Zhang, SYL; Jiang, WH; Yu, Y; Safrina, O; Cahalan, MD				Yeromin, Andriy V.; Zhang, Shenyuan L.; Jiang, Weihua; Yu, Ying; Safrina, Olga; Cahalan, Michael D.			Molecular identification of the CRAC channel by altered ion selectivity in a mutant of Orai	NATURE			English	Article							OPERATED CALCIUM-CHANNEL; ACTIVATED CA2+ CHANNELS; PLASMA-MEMBRANE; T-LYMPHOCYTES; MIC CHANNELS; I-CRAC; STORE; CELLS; STIM1; POTENTIATION	Recent RNA interference screens have identified several proteins that are essential for store-operated Ca2+ influx and Ca2+ release-activated Ca2+ ( CRAC) channel activity in Drosophila and in mammals, including the transmembrane proteins Stim ( stromal interaction molecule)(1,2) and Orai(3-5). Stim probably functions as a sensor of luminal Ca2+ content and triggers activation of CRAC channels in the surface membrane after Ca2+ store depletion(1,6). Among three human homologues of Orai ( also known as olf186-F), ORAI1 on chromosome 12 was found to be mutated in patients with severe combined immunodeficiency disease, and expression of wild-type Orai1 restored Ca2+ influx and CRAC channel activity in patient T cells(3). The overexpression of Stim and Orai together markedly increases CRAC current(5,7-9). However, it is not yet clear whether Stim or Orai actually forms the CRAC channel, or whether their expression simply limits CRAC channel activity mediated by a different channel-forming subunit. Here we show that interaction between wild-type Stim and Orai, assessed by coimmunoprecipitation, is greatly enhanced after treatment with thapsigargin to induce Ca2+ store depletion. By site-directed mutagenesis, we show that a point mutation from glutamate to aspartate at position 180 in the conserved S1 - S2 loop of Orai transforms the ion selectivity properties of CRAC current from being Ca2+-selective with inward rectification to being selective for monovalent cations and outwardly rectifying. A charge-neutralizing mutation at the same position ( glutamate to alanine) acts as a dominant-negative non-conducting subunit. Other charge-neutralizing mutants in the same loop express large inwardly rectifying CRAC current, and two of these exhibit reduced sensitivity to the channel blocker Gd3+. These results indicate that Orai itself forms the Ca2+-selectivity filter of the CRAC channel.	Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA; Univ Calif Irvine, Ctr Immunol, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Cahalan, MD (corresponding author), Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA.	mcahalan@uci.edu			NINDS NIH HHS [R37 NS014609, R37 NS014609-28] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS014609] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALMERS W, 1984, J PHYSIOL-LONDON, V353, P585, DOI 10.1113/jphysiol.1984.sp015352; Bakowski D, 2002, PFLUG ARCH EUR J PHY, V443, P892, DOI 10.1007/s00424-001-0775-8; ELLINOR PT, 1995, NEURON, V15, P1121, DOI 10.1016/0896-6273(95)90100-0; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; Kozak JA, 2002, J GEN PHYSIOL, V120, P221, DOI 10.1085/jgp.20028601; LeppleWienhues A, 1996, BIOPHYS J, V71, P787, DOI 10.1016/S0006-3495(96)79278-0; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; MERCER JC, 2006, J BIOL CHEM     0628; Peinelt C, 2006, NAT CELL BIOL, V8, P771, DOI 10.1038/ncb1435; Prakriya M, 2002, J GEN PHYSIOL, V119, P487, DOI 10.1085/jgp.20028551; Prakriya M, 2001, J PHYSIOL-LONDON, V536, P3, DOI 10.1111/j.1469-7793.2001.t01-1-00003.x; Prakriya M, 2006, NATURE, V443, P230, DOI 10.1038/nature05122; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; Soboloff J, 2006, J BIOL CHEM, V281, P20661, DOI 10.1074/jbc.C600126200; Vig M, 2006, SCIENCE, V312, P1220, DOI 10.1126/science.1127883; Voets T, 2004, J BIOL CHEM, V279, P15223, DOI 10.1074/jbc.M312076200; Yeromin AV, 2004, J GEN PHYSIOL, V123, P167, DOI 10.1085/jgp.200308982; Zhang SL, 2006, P NATL ACAD SCI USA, V103, P9357, DOI 10.1073/pnas.0603161103; Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147; Zweifach A, 1996, J GEN PHYSIOL, V107, P597, DOI 10.1085/jgp.107.5.597; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	23	646	673	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 14	2006	443	7108					226	229		10.1038/nature05108	http://dx.doi.org/10.1038/nature05108			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	083OB	16921385	Green Accepted			2022-12-28	WOS:000240467000050
J	Pessiglione, M; Seymour, B; Flandin, G; Dolan, RJ; Frith, CD				Pessiglione, Mathias; Seymour, Ben; Flandin, Guillaume; Dolan, Raymond J.; Frith, Chris D.			Dopamine-dependent prediction errors underpin reward-seeking behaviour in humans	NATURE			English	Article							NUCLEUS-ACCUMBENS DOPAMINE; BASAL GANGLIA; NEURONAL-ACTIVITY; PRIMATE STRIATUM; REPRESENTATION; EXPECTATION; MOTIVATION; RESPONSES; PARALLEL	Theories of instrumental learning are centred on understanding how success and failure are used to improve future decisions(1). These theories highlight a central role for reward prediction errors in updating the values associated with available actions(2). In animals, substantial evidence indicates that the neurotransmitter dopamine might have a key function in this type of learning, through its ability to modulate cortico-striatal synaptic efficacy(3). However, no direct evidence links dopamine, striatal activity and behavioural choice in humans. Here we show that, during instrumental learning, the magnitude of reward prediction error expressed in the striatum is modulated by the administration of drugs enhancing (3,4-dihydroxy-L-phenylalanine; L-DOPA) or reducing ( haloperidol) dopaminergic function. Accordingly, subjects treated with L-DOPA have a greater propensity to choose the most rewarding action relative to subjects treated with haloperidol. Furthermore, incorporating the magnitude of the prediction errors into a standard action-value learning algorithm accurately reproduced subjects' behavioural choices under the different drug conditions. We conclude that dopamine-dependent modulation of striatal activity can account for how the human brain uses reward prediction errors to improve future decisions.	Wellcome Dept Imaging Neurosci, London WC1N 3BG, England	University of London; University College London	Pessiglione, M (corresponding author), Wellcome Dept Imaging Neurosci, 12 Queen Sq, London WC1N 3BG, England.	m.pessiglione@fil.ion.ucl.ac.uk	Frith, Chris D/A-2171-2009; Pessiglione, Mathias/E-2141-2017	Frith, Chris D/0000-0002-8665-0690; Pessiglione, Mathias/0000-0002-6992-3677; Dolan, Ray/0000-0001-9356-761X; Seymour, Ben/0000-0003-1724-5832	Wellcome Trust [078865] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; Bayer HM, 2005, NEURON, V47, P129, DOI 10.1016/j.neuron.2005.05.020; Calabresi P, 2000, PROG NEUROBIOL, V61, P231, DOI 10.1016/S0301-0082(99)00030-1; COOK L, 1955, J PHARMACOL EXP THER, V113, P11; Dickinson A., 1980, CONT ANIMAL LEARNING; Everitt BJ, 1999, ANN NY ACAD SCI, V877, P412, DOI 10.1111/j.1749-6632.1999.tb09280.x; Frank MJ, 2004, SCIENCE, V306, P1940, DOI 10.1126/science.1102941; Haber SN, 2003, J CHEM NEUROANAT, V26, P317, DOI 10.1016/j.jchemneu.2003.10.003; Hollerman JR, 1998, NAT NEUROSCI, V1, P304, DOI 10.1038/1124; Hollerman JR, 1998, J NEUROPHYSIOL, V80, P947, DOI 10.1152/jn.1998.80.2.947; Ikemoto S, 1999, BRAIN RES REV, V31, P6, DOI 10.1016/S0165-0173(99)00023-5; Jueptner M, 1998, BRAIN, V121, P1437, DOI 10.1093/brain/121.8.1437; Knutson B, 2005, J NEUROSCI, V25, P4806, DOI 10.1523/JNEUROSCI.0642-05.2005; Lauwereyns J, 2002, NATURE, V418, P413, DOI 10.1038/nature00892; Lehericy S, 2006, CEREB CORTEX, V16, P149, DOI 10.1093/cercor/bhi089; Molina JA, 2000, MOVEMENT DISORD, V15, P869, DOI 10.1002/1531-8257(200009)15:5<869::AID-MDS1016>3.0.CO;2-I; Nakahara H, 2004, NEURON, V41, P269, DOI 10.1016/S0896-6273(03)00869-9; O'Doherty J, 2004, SCIENCE, V304, P452, DOI 10.1126/science.1094285; O'Doherty JP, 2002, NEURON, V33, P815, DOI 10.1016/S0896-6273(02)00603-7; SALAMONE JD, 1994, BEHAV BRAIN RES, V61, P117, DOI 10.1016/0166-4328(94)90153-8; Samejima K, 2005, SCIENCE, V310, P1337, DOI 10.1126/science.1115270; Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593; Seymour B, 2004, NATURE, V429, P664, DOI 10.1038/nature02581; SMITH AD, 1990, TRENDS NEUROSCI, V13, P259; Tanaka SC, 2004, NAT NEUROSCI, V7, P887, DOI 10.1038/nn1279; Thorndike EL., 1911, ANIMAL INTELLIGENCE, DOI DOI 10.4324/9781351321044; Tremblay L, 1998, J NEUROPHYSIOL, V80, P964, DOI 10.1152/jn.1998.80.2.964; Ungless MA, 2004, SCIENCE, V303, P2040, DOI 10.1126/science.1093360; Waelti P, 2001, NATURE, V412, P43, DOI 10.1038/35083500; Wise RA, 2004, NAT REV NEUROSCI, V5, P483, DOI 10.1038/nrn1406	30	973	982	6	140	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 31	2006	442	7106					1042	1045		10.1038/nature05051	http://dx.doi.org/10.1038/nature05051			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	078YF	16929307	Green Published, Green Accepted			2022-12-28	WOS:000240142000050
J	Irvine, DV; Zaratiegui, M; Tolia, NH; Goto, DB; Chitwood, DH; Vaughn, MW; Joshua-Tor, L; Martienssen, RA				Irvine, Danielle V.; Zaratiegui, Mikel; Tolia, Niraj H.; Goto, Derek B.; Chitwood, Daniel H.; Vaughn, Matthew W.; Joshua-Tor, Leemor; Martienssen, Robert A.			Argonaute slicing is required for heterochromatic silencing and spreading	SCIENCE			English	Article							FISSION YEAST; RNA INTERFERENCE; HISTONE H3; METHYLATION; DROSOPHILA; RISC; TRANSCRIPTION; COMPLEX; RITS; DNA	Small interfering RNA ( siRNA) guides dimethylation of histone H3 lysine-9 (H3K9me2) via the Argonaute and RNA-dependent RNA polymerase complexes, as well as base-pairing with either RNA or DNA. We show that Argonaute requires the conserved aspartate-aspartate-histidine motif for heterochromatic silencing and for ribonuclease H - like cleavage ( slicing) of target messages complementary to siRNA. In the fission yeast Schizosaccharomyces pombe, heterochromatic repeats are transcribed by polymerase II. We show that H3K9me2 spreads into silent reporter genes when they are embedded within these transcripts and that spreading requires read-through transcription, as well as slicing by Argonaute. Thus, siRNA guides histone modification by base-pairing interactions with RNA.	Cold Spring Harbor Lab, Watson Sch Biol Sci, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Martienssen, RA (corresponding author), Cold Spring Harbor Lab, Watson Sch Biol Sci, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	martiens@cshl.edu	Tolia, Niraj H/D-2332-2014; Chitwood, Daniel/M-2841-2013; Goto, Derek B/B-7053-2009	Tolia, Niraj H/0000-0002-2689-1337; Chitwood, Daniel/0000-0003-4875-1447; Zaratiegui, Mikel/0000-0002-0342-0268; Joshua-Tor, Leemor/0000-0001-8185-8049; Vaughn, Matthew/0000-0002-1384-4283	NIGMS NIH HHS [R01 GM076396-01A1, R01-GM067014, R01-GM072659, R01 GM076396] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM076396, R01GM067014, R01GM072659] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad K, 2001, CELL, V104, P839, DOI 10.1016/S0092-8674(01)00281-1; ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; BARKAN A, 1991, P NATL ACAD SCI USA, V88, P3502, DOI 10.1073/pnas.88.8.3502; Djupedal I, 2005, GENE DEV, V19, P2301, DOI 10.1101/gad.344205; Gazzani S, 2004, SCIENCE, V306, P1046, DOI 10.1126/science.1101092; Grewal SIS, 2003, SCIENCE, V301, P798, DOI 10.1126/science.1086887; Hampsey M, 2003, CELL, V113, P429, DOI 10.1016/S0092-8674(03)00360-X; Hieronymus H, 2004, GENE DEV, V18, P2652, DOI 10.1101/gad.1241204; LI F, 2002, CURR BIOL; Lippman Z, 2004, NATURE, V431, P364, DOI 10.1038/nature02875; Liu JD, 2004, SCIENCE, V305, P1437, DOI 10.1126/science.1102513; MARTIENSSEN R, 2003, RNAI GUIDE GENE SILE; Motamedi MR, 2004, CELL, V119, P789, DOI 10.1016/j.cell.2004.11.034; Orban TI, 2005, RNA, V11, P459, DOI 10.1261/rna.7231505; Pal-Bhadra M, 2004, SCIENCE, V303, P669, DOI 10.1126/science.1092653; Partridge JF, 2002, CURR BIOL, V12, P1652, DOI 10.1016/S0960-9822(02)01177-6; Rivas FV, 2005, NAT STRUCT MOL BIOL, V12, P340, DOI 10.1038/nsmb918; Sadaie M, 2004, EMBO J, V23, P3825, DOI 10.1038/sj.emboj.7600401; Song JJ, 2004, SCIENCE, V305, P1434, DOI 10.1126/science.1102514; Talbert PB, 2000, GENETICS, V154, P259; Tomari Y, 2005, GENE DEV, V19, P517, DOI 10.1101/gad.1284105; Verdel A, 2004, SCIENCE, V303, P672, DOI 10.1126/science.1093686; Volpe T, 2003, CHROMOSOME RES, V11, P137, DOI 10.1023/A:1022815931524; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; Yamada T, 2005, MOL CELL, V20, P173, DOI 10.1016/j.molcel.2005.10.002; Zilberman D, 2003, SCIENCE, V299, P716, DOI 10.1126/science.1079695	27	156	172	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 25	2006	313	5790					1134	1137		10.1126/science.1128813	http://dx.doi.org/10.1126/science.1128813			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	076ZT	16931764				2022-12-28	WOS:000239998200050
J	Strober, W				Strober, Warren			Unraveling gut inflammation	SCIENCE			English	Editorial Material							BOWEL-DISEASE; CELLS; DEFENSINS; INTESTINE; BACTERIA		NIH, Host Def Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA	Strober, W (corresponding author), NIH, Host Def Lab, Bethesda, MD 20892 USA.	wstrober@niaid.nih.gov			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000432, Z01AI000354, ZIAAI000354, ZIAAI000872, ZIAAI000432, Z01AI000872] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bouma G, 2003, NAT REV IMMUNOL, V3, P521, DOI 10.1038/nri1132; Cash HL, 2006, SCIENCE, V313, P1126, DOI 10.1126/science.1127119; Di Giacinto C, 2005, J IMMUNOL, V174, P3237, DOI 10.4049/jimmunol.174.6.3237; HERMISTON ML, 1995, SCIENCE, V270, P1203, DOI 10.1126/science.270.5239.1203; Ley RE, 2006, CELL, V124, P837, DOI 10.1016/j.cell.2006.02.017; Macpherson AJ, 2004, SCIENCE, V303, P1662, DOI 10.1126/science.1091334; Niess JH, 2005, SCIENCE, V307, P254, DOI 10.1126/science.1102901; Norkina O, 2004, INFECT IMMUN, V72, P6040, DOI 10.1128/IAI.72.10.6040-6049.2004; Ogawa H, 2003, INFLAMM BOWEL DIS, V9, P162, DOI 10.1097/00054725-200305000-00003; Rescigno M, 2001, NAT IMMUNOL, V2, P361, DOI 10.1038/86373; Selsted ME, 2005, NAT IMMUNOL, V6, P551, DOI 10.1038/ni1206; Strober W, 2006, NAT REV IMMUNOL, V6, P9, DOI 10.1038/nri1747; Wehkamp J, 2005, P NATL ACAD SCI USA, V102, P18129, DOI 10.1073/pnas.0505256102; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113	14	34	35	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 25	2006	313	5790					1052	1054		10.1126/science.1131997	http://dx.doi.org/10.1126/science.1131997			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	076ZT	16931742				2022-12-28	WOS:000239998200024
J	Tuffs, A				Tuffs, Annette			Giving German universities a boost	CELL			English	Editorial Material																			0	0	0	0	2	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 25	2006	126	4					635	636		10.1016/j.cell.2006.08.010	http://dx.doi.org/10.1016/j.cell.2006.08.010			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	080VN	16923378	Bronze			2022-12-28	WOS:000240276700006
J	Ohmoto, H; Watanabe, Y; Ikemi, H; Poulson, SR; Taylor, BE				Ohmoto, Hiroshi; Watanabe, Yumiko; Ikemi, Hiroaki; Poulson, Simon R.; Taylor, Bruce E.			Sulphur isotope evidence for an oxic Archaean atmosphere	NATURE			English	Article							FRACTIONATION; MICROPROBE; RISE	The presence of mass-independently fractionated sulphur isotopes (MIF-S) in many sedimentary rocks older than similar to 2.4 billion years (Gyr), and the absence of MIF-S in younger rocks, has been considered the best evidence for a dramatic change from an anoxic to oxic atmosphere around 2.4 Gyr ago(1-9). This is because the only mechanism known to produce MIF-S has been ultraviolet photolysis of volcanic sulphur dioxide gas in an oxygen-poor atmosphere. Here we report the absence of MIF-S throughout similar to 100-m sections of 2.76-Gyr-old lake sediments and 2.92-Gyr-old marine shales in the Pilbara Craton, Western Australia. We propose three possible interpretations of the MIF-S geologic record: ( 1) the level of atmospheric oxygen fluctuated greatly during the Archaean era; ( 2) the atmosphere has remained oxic since similar to 3.8 Gyr ago, and MIF-S in sedimentary rocks represents times and regions of violent volcanic eruptions that ejected large volumes of sulphur dioxide into the stratosphere; or ( 3) MIF-S in rocks was mostly created by non-photochemical reactions during sediment diagenesis, and thus is not linked to atmospheric chemistry.	Penn State Univ, NASA Astrobiol Inst, University Pk, PA 16802 USA; Penn State Univ, Dept Geosci, University Pk, PA 16802 USA; Kyushu Univ, Inst Technol, Fukuoka 8128581, Japan; Univ Nevada, Dept Geol Sci & Engn, Reno, NV 89557 USA; Geol Survey Canada, Ottawa, ON K1A 0E8, Canada	National Aeronautics & Space Administration (NASA); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Kyushu University; Nevada System of Higher Education (NSHE); University of Nevada Reno; Natural Resources Canada; Lands & Minerals Sector - Natural Resources Canada; Geological Survey of Canada	Ohmoto, H (corresponding author), Penn State Univ, NASA Astrobiol Inst, University Pk, PA 16802 USA.	ohmoto@geosc.psu.edu	Ikemi, Hiroaki/AAX-5903-2021	Ikemi, Hiro/0000-0002-6557-051X				Bekker A, 2004, NATURE, V427, P117, DOI 10.1038/nature02260; BUICK R, 2005, 16 JOINT M EARTH PLA; Deines P, 2003, CHEM GEOL, V199, P179, DOI 10.1016/S0009-2541(03)00076-7; Farquhar J, 2000, SCIENCE, V289, P756, DOI 10.1126/science.289.5480.756; Farquhar J, 2003, EARTH PLANET SC LETT, V213, P1, DOI 10.1016/S0012-821X(03)00296-6; Farquhar J, 2001, J GEOPHYS RES-PLANET, V106, P32829, DOI 10.1029/2000JE001437; Farquhar J, 2003, GEOBIOLOGY, V1, P27, DOI 10.1046/j.1472-4669.2003.00007.x; Habicht KS, 2002, SCIENCE, V298, P2372, DOI 10.1126/science.1078265; HICKMAN AH, 1983, GSWA B, V127, P83; Hu GX, 2003, GEOCHIM COSMOCHIM AC, V67, P3101, DOI 10.1016/S0016-7037(02)00929-8; HULSTON JR, 1965, J GEOPHYS RES, V70, P3475, DOI 10.1029/JZ070i014p03475; Kasting James F., 1998, P35; Kasting JF, 2001, SCIENCE, V293, P819, DOI 10.1126/science.1063811; Mojzsis SJ, 2003, GEOCHIM COSMOCHIM AC, V67, P1635, DOI 10.1016/S0016-7037(03)00059-0; Nisbet E.G., 1987, YOUNG EARTH INTRO AR, V1; Ohmoto H., 1997, GEOCHEMISTRY HYDROTH, P517; Ohmoto H, 1990, PUBLICATION U W AUST, V23, P70; Ono S, 2006, GEOCHIM COSMOCHIM AC, V70, P2238, DOI 10.1016/j.gca.2006.01.022; Ono S, 2003, EARTH PLANET SC LETT, V213, P15, DOI 10.1016/S0012-821X(03)00295-4; Pavlov AA, 2002, ASTROBIOLOGY, V2, P27, DOI 10.1089/153110702753621321; Pickard AL, 2004, SEDIMENT GEOL, V170, P37, DOI 10.1016/j.sedgeo.2004.06.007; Savarino J, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL018134; THORNE AM, 2001, GSWA B, V144, P21; Tomlinson KY, 2001, GEOL S AM S, P341; Tyson R.V., 1995, SEDIMENTARY ORGANIC, P81; VANKRANENDONK MJ, 2004, GEOLOGICAL SURVEY W, P49; WATANABE Y, 2006, EOS S, V87; WING BA, 2004, ABSTR PROGR GEOL SOC, V36	28	175	178	2	86	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 24	2006	442	7105					908	911		10.1038/nature05044	http://dx.doi.org/10.1038/nature05044			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	076LT	16929296				2022-12-28	WOS:000239960500035
J	Schawinski, K; Khochfar, S; Kaviraj, S; Yi, SK; Boselli, A; Barlow, T; Conrow, T; Forster, K; Friedman, PG; Martin, DC; Morrissey, P; Neff, S; Schiminovich, D; Seibert, M; Small, T; Wyder, TK; Bianchi, L; Donas, J; Heckman, T; Lee, YW; Madore, B; Milliard, B; Rich, RM; Szalay, A				Schawinski, Kevin; Khochfar, Sadegh; Kaviraj, Sugata; Yi, Sukyoung K.; Boselli, Alessandro; Barlow, Tom; Conrow, Tim; Forster, Karl; Friedman, Peter G.; Martin, D. Chris; Morrissey, Patrick; Neff, Susan; Schiminovich, David; Seibert, Mark; Small, Todd; Wyder, Ted K.; Bianchi, Luciana; Donas, Jose; Heckman, Tim; Lee, Young-Wook; Madore, Barry; Milliard, Bruno; Rich, R. Michael; Szalay, Alex			Suppression of star formation in early-type galaxies by feedback from supermassive black holes	NATURE			English	Article							DIGITAL SKY SURVEY; GALACTIC NUCLEI; EVOLUTION; MERGERS; COLORS; ORIGIN	Detailed high-resolution observations of the innermost regions of nearby galaxies have revealed the presence of supermassive black holes(1-4). These black holes may interact with their host galaxies by means of 'feedback' in the form of energy and material jets; this feedback affects the evolution of the host and gives rise to observed relations between the black hole and the host(5). Here we report observations of the ultraviolet emissions of massive early-type galaxies. We derive an empirical relation for a critical black-hole mass ( as a function of velocity dispersion) above which the outflows from these black holes suppress star formation in their hosts by heating and expelling all available cold gas. Supermassive black holes are negligible in mass compared to their hosts but nevertheless seem to play a critical role in the star formation history of galaxies.	Yonsei Univ, Ctr Space Astrophys, Seoul 120749, South Korea; Univ Oxford, Dept Phys, Oxford OX1 3RH, England; Lab Astrophys Marseille, F-13376 Marseille 12, France; CALTECH, Pasadena, CA 91125 USA; NASA, Goddard Space Flight Ctr, Astron & Solar Phys Lab, Greenbelt, MD 20771 USA; Columbia Univ, Dept Astron, New York, NY 10027 USA; Johns Hopkins Univ, Dept Phys & Astron, Baltimore, MD 21218 USA; Carnegie Inst Washington Observ, Pasadena, CA 91101 USA; Univ Calif Los Angeles, Dept Phys & Astron, Los Angeles, CA 90095 USA	Yonsei University; University of Oxford; UDICE-French Research Universities; Aix-Marseille Universite; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Columbia University; Johns Hopkins University; Carnegie Institution for Science; University of California System; University of California Los Angeles	Yi, SK (corresponding author), Yonsei Univ, Ctr Space Astrophys, Seoul 120749, South Korea.	yi@yonsei.ac.kr	Schawinski, Kevin/N-7057-2016; Khochfar, Sadegh/AAD-6530-2022; Yi, Sukyoung/AAO-7826-2020	Schawinski, Kevin/0000-0001-5464-0888; Lee, Young-Wook/0000-0002-2210-1238; Kaviraj, Sugata/0000-0002-5601-575X; Szalay, Alexander/0000-0002-4108-3282; Seibert, Mark/0000-0002-1143-5515; Morrissey, Patrick/0000-0001-8177-1023				Bernardi M, 2003, ASTRON J, V125, P1866, DOI 10.1086/367794; BOSE, 2005, ASTROPHYS J, V629, pL29; Croton DJ, 2006, MON NOT R ASTRON SOC, V365, P11, DOI 10.1111/j.1365-2966.2005.09675.x; Di Matteo T, 2005, NATURE, V433, P604, DOI 10.1038/nature03335; Ferrarese L, 2005, SPACE SCI REV, V116, P523, DOI 10.1007/s11214-005-3947-6; Gebhardt K, 2000, ASTROPHYS J, V539, pL13, DOI 10.1086/312840; Hopkins PF, 2005, ASTROPHYS J, V630, P705, DOI 10.1086/432438; KAVIRAJ S, 2006, UV OPTICAL COLOURS P; Kennicutt RC, 1998, ASTROPHYS J, V498, P541, DOI 10.1086/305588; Khochfar S, 2005, MON NOT R ASTRON SOC, V359, P1379, DOI 10.1111/j.1365-2966.2005.08988.x; Khochfar S, 2003, ASTROPHYS J, V597, pL117, DOI 10.1086/379845; KHOCHFAR S, 2005, ORIGIN STARS BULGES; Lauer TR, 2005, ASTRON J, V129, P2138, DOI 10.1086/429565; Merritt D, 2001, ASTROPHYS J, V547, P140, DOI 10.1086/318372; Morrissey P, 2005, ASTROPHYS J, V619, pL7, DOI 10.1086/424734; SCHAWINSKI K, 2006, EFFECT ENV UV COLOUR; Silk J, 1998, ASTRON ASTROPHYS, V331, pL1; Springel V, 2005, MON NOT R ASTRON SOC, V361, P776, DOI 10.1111/j.1365-2966.2005.09238.x; Springel V, 2001, MON NOT R ASTRON SOC, V328, P726, DOI 10.1046/j.1365-8711.2001.04912.x; Tremaine S, 2002, ASTROPHYS J, V574, P740, DOI 10.1086/341002; Yi SK, 2003, ASTROPHYS J, V582, P202, DOI 10.1086/344640; Yi SK, 2005, ASTROPHYS J, V619, pL111, DOI 10.1086/422811; York DG, 2000, ASTRON J, V120, P1579, DOI 10.1086/301513	25	114	114	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 24	2006	442	7105					888	891		10.1038/nature04934	http://dx.doi.org/10.1038/nature04934			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	076LT	16929291	Green Submitted			2022-12-28	WOS:000239960500030
J	Romero-Corral, A; Montori, VM; Somers, VK; Korinek, J; Thomas, RJ; Allison, TG; Mookadam, F; Lopez-Jimenez, F				Romero-Corral, Abel; Montori, Victor M.; Somers, Virend K.; Korinek, Josef; Thomas, Randal J.; Allison, Thomas G.; Mookadam, Farouk; Lopez-Jimenez, Francisco			Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies	LANCET			English	Article							BODY-MASS INDEX; ACUTE MYOCARDIAL-INFARCTION; LONG-TERM OUTCOMES; FOLLOW-UP; RISK-FACTORS; FAT DISTRIBUTION; BYPASS-SURGERY; HEART-DISEASE; OBESITY; IMPACT	Background Studies of the association between obesity, and total mortality and cardiovascular events in patients with coronary artery disease (CAD) have shown contradictory results. We undertook a systematic review to determine the extent and nature of this association. Methods We selected cohort studies that provided risk estimates for total mortality, with or without cardiovascular events, on the basis of bodyweight or obesity measures in patients with CAD, and with at least 6 months' follow-up. CAD was defined as history of percutaneous coronary intervention, coronary artery bypass graft, or myocardial infarction. We obtained risk estimates for five predetermined bodyweight groups: low, normal weight (reference), overweight, obese, and severely obese. Findings We found 40 studies with 250,152 patients that had a mean follow-up of 3.8 years. Patients with a low body-mass index (BMI) (ie, <20) had an increased relative risk (RR) for total mortality (RR=1.37 [95% CI 1.32-1.43), and cardiovascular mortality (1.45 [1.16-1.81]), overweight (BMI 25-29.9) had the lowest risk for total mortality (0.87 [0.81-0.94]) and cardiovascular mortality (0.88 [0.75-1.02]) compared with those for people with a normal BMI. Obese patients (BMI 30-35) had no increased risk for total mortality (0.93 [0.85-1.03]) or cardiovascular mortality (0.97 [0.82-1.15]). Patients with severe obesity (>= 35) did not have increased total mortality (1.10 [0.87-1.41]) but they had the highest risk for cardiovascular mortality (1.88 [1.05-3.34]). Interpretation The better outcomes for cardiovascular and total mortality seen in the overweight and mildly obese groups could not be explained by adjustment for confounding factors. These findings could be explained by the lack of discriminatory power of BMI to differentiate between body fat and lean mass.	Mayo Clin & Mayo Fdn, Mayo Clin Coll Med, Div Cardiovasc Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Clin Coll Med, Dept Internal Med Knowledge & Encounter Res, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Lopez-Jimenez, F (corresponding author), Mayo Clin & Mayo Fdn, Mayo Clin Coll Med, Div Cardiovasc Dis, 200 1st St SW, Rochester, MN 55905 USA.		Korinek, Josef/C-9936-2016	Korinek, Josef/0000-0002-4712-4444; Montori, Victor/0000-0003-0595-2898; Thomas, Randal/0000-0003-1448-7182	NCRR NIH HHS [M01-RR00585] Funding Source: Medline; NHLBI NIH HHS [HL65176, HL 70302, HL73211] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000585] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073211, R01HL065176, R01HL070302] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARORA RR, 1990, CATHETER CARDIO DIAG, V19, P17, DOI 10.1002/ccd.1810190106; Birkmeyer JO, 2000, J AM COLL CARDIOL, V35, p551A; Blew RM, 2002, OBES RES, V10, P799, DOI 10.1038/oby.2002.108; Dagenais GR, 2005, AM HEART J, V149, P54, DOI 10.1016/j.ahj.2004.07.009; De Bacquer D, 2003, EUR J CARDIOV PREV R, V10, P289, DOI 10.1097/00149831-200308000-00012; De Martini M, 1990, G Ital Cardiol, V20, P215; Domanski M, 2005, J AM COLL CARDIOL, V45, p204A; Eisenstein EL, 2005, AM J MED, V118, P981, DOI 10.1016/j.amjmed.2005.02.017; Ellat-Adar S, 2005, AM J EPIDEMIOL, V161, P352, DOI 10.1093/aje/kwi045; Ennker J, 2001, DEUT MED WOCHENSCHR, V126, P419, DOI 10.1055/s-2001-12730; Flegal KM, 2005, JAMA-J AM MED ASSOC, V293, P1861, DOI 10.1001/jama.293.15.1861; Goldberg AP, 2000, J GERONTOL A-BIOL, V55, pM342, DOI 10.1093/gerona/55.6.M342; Goldman LE, 2004, CAN J CARDIOL, V20, P608; Gruberg L, 2005, AM J CARDIOL, V95, P439, DOI 10.1016/j.amjcard.2004.10.007; Gruberg L, 2002, J AM COLL CARDIOL, V39, P578, DOI 10.1016/S0735-1097(01)01802-2; Gurm HS, 2002, J AM COLL CARDIOL, V39, P834, DOI 10.1016/S0735-1097(02)01687-X; Gurm HS, 2002, AM J CARDIOL, V90, P42, DOI 10.1016/S0002-9149(02)02384-6; HOIT BD, 1987, AM HEART J, V114, P1334, DOI 10.1016/0002-8703(87)90534-5; HSIEH SD, 1995, INT J OBESITY, V19, P585; Johnston JM, 2003, J AM COLL CARDIOL, V41, p47A; Kaplan RC, 2002, J CLIN EPIDEMIOL, V55, P654, DOI 10.1016/S0895-4356(02)00405-5; Kassirer JP, 1998, NEW ENGL J MED, V338, P52, DOI 10.1056/NEJM199801013380109; Kennedy LMA, 2005, J AM COLL CARDIOL, V45, P156, DOI 10.1016/j.jacc.2004.10.001; KHAN KS, 2003, SYSTEMATIC REV SUPPO, P136; Kim J, 2003, AM HEART J, V146, P555, DOI 10.1016/S0002-8703(03)00185-6; Kragelund C, 2005, INT J CARDIOL, V98, P123, DOI 10.1016/j.ijcard.2004.03.042; Krauss R M, 1998, Circulation, V98, P1472; Krumholz HM, 2001, J AM COLL CARDIOL, V38, P453, DOI 10.1016/S0735-1097(01)01395-X; Kuduvalli M, 2003, EUR J CARDIO-THORAC, V23, P368, DOI 10.1016/S1010-7940(02)00827-8; Lauretani F, 2003, J APPL PHYSIOL, V95, P1851, DOI 10.1152/japplphysiol.00246.2003; Lopez-Jimenez F, 2005, INT J OBESITY, V29, P137, DOI 10.1038/sj.ijo.0802831; Lopez-Jimenez F, 2004, CHEST, V125, P1205, DOI 10.1378/chest.125.4.1205; Martin JL, 2004, J AM COLL CARDIOL, V43, p81A, DOI 10.1016/S0735-1097(04)90336-1; Mcgee DL, 2005, ANN EPIDEMIOL, V15, P87, DOI 10.1016/j.annepidem.2004.05.012; Mehta LS, 2002, CIRCULATION, V106, P402; Montori VM, 2000, MAYO CLIN PROC, V75, P1284, DOI 10.4065/75.12.1284; MULCAHY R, 1977, AM HEART J, V93, P556, DOI 10.1016/S0002-8703(77)80003-3; Ness AR, 2002, J EPIDEMIOL COMMUN H, V56, P218, DOI 10.1136/jech.56.3.218; Nigam A, 2006, INT J CARDIOL, V110, P153, DOI 10.1016/j.ijcard.2005.06.040; Nikolsky E, 2004, J AM COLL CARDIOL, V43, p244A, DOI 10.1016/S0735-1097(04)91037-6; *NORD COCHR CTR TC, 2003, REV MAN REVMAN; NORRIS RM, 1970, LANCET, V2, P485; O'Donovan G, 2005, INT J OBESITY, V29, P1063, DOI 10.1038/sj.ijo.0803004; Ottervanger JP, 2003, CIRCULATION, V107, P437, DOI 10.1161/01.CIR.0000046487.06811.5E; Pi-Sunyer FX, 2002, OBES RES, V10, p97S, DOI 10.1038/oby.2002.202; Poston WSC, 2004, INT J OBESITY, V28, P1011, DOI 10.1038/sj.ijo.0802703; Powell BD, 2003, AM J CARDIOL, V91, P472, DOI 10.1016/S0002-9149(02)03252-6; PRASAD US, 1991, EUR J CARDIO-THORAC, V5, P67, DOI 10.1016/1010-7940(91)90003-3; Rana JS, 2004, AM HEART J, V147, P841, DOI 10.1016/j.ahj.2003.12.015; Rea TD, 2001, AM J CARDIOL, V88, P467, DOI 10.1016/S0002-9149(01)01720-9; RIMM EB, 1995, AM J EPIDEMIOL, V141, P1117, DOI 10.1093/oxfordjournals.aje.a117385; ROMEROCORRAL A, 2006, CIRCULATION, V113, P351; Roubenoff R, 2000, EUR J CLIN NUTR, V54, pS40, DOI 10.1038/sj.ejcn.1601024; Schwann TA, 2001, ANN THORAC SURG, V71, P521, DOI 10.1016/S0003-4975(00)02038-5; Shamsuzzaman ASM, 2003, JAMA-J AM MED ASSOC, V290, P1906, DOI 10.1001/jama.290.14.1906; Sierra-Johnson J, 2005, AM J CARDIOL, V96, P211, DOI 10.1016/j.ajmcard.2005.03.046; Sinnaeve P, 2003, AM HEART J, V146, P27, DOI 10.1016/S0002-8703(03)00117-0; Sinnaeve PR, 2004, AM HEART J, V147, P993, DOI 10.1016/j.ahj.2003.12.028; SMITH LR, 1991, CIRCULATION, V84, P245; Smith SC, 2001, J AM COLL CARDIOL, V38, P1581, DOI 10.1016/S0735-1097(01)01682-5; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Stuck AE, 1998, BRIT MED J, V316, P469, DOI 10.1136/bmj.316.7129.469; TAKKUNEN J, 1969, Annals of Clinical Research, V1, P246; van Brussel BL, 2003, EUR HEART J, V24, P927, DOI 10.1016/S0195-668X(03)00004-6; VANBRUSSEL BL, 1993, CIRCULATION, V88, P87; Veledar E, 2004, J AM COLL CARDIOL, V43, p411A, DOI 10.1016/S0735-1097(04)91739-1; Wallner S, 1999, EUR J CLIN INVEST, V29, P372; Wellens RI, 1996, OBES RES, V4, P35, DOI 10.1002/j.1550-8528.1996.tb00510.x; Wen KC, 2004, J AM COLL CARDIOL, V43, p410A, DOI 10.1016/S0735-1097(04)91733-0; Wessel TR, 2004, JAMA-J AM MED ASSOC, V292, P1179, DOI 10.1001/jama.292.10.1179; Widlansky ME, 2004, ARCH INTERN MED, V164, P2326, DOI 10.1001/archinte.164.21.2326; Wilhelmsen L, 2001, EUR HEART J, V22, P1119, DOI 10.1053/euhj.2000.2481; Yataco AR, 1997, AGING-CLIN EXP RES, V9, P88, DOI 10.1007/BF03340132; Yusuf S, 2005, LANCET, V366, P1640, DOI 10.1016/S0140-6736(05)67663-5	74	1091	1155	0	48	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 19	2006	368	9536					666	678		10.1016/S0140-6736(06)69251-9	http://dx.doi.org/10.1016/S0140-6736(06)69251-9			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	074YT	16920472				2022-12-28	WOS:000239849200034
J	Scott, DL; Kingsley, GH				Scott, D. L.; Kingsley, G. H.			Tumor necrosis factor inhibitors for rheumatoid arthritis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALPHA MONOCLONAL-ANTIBODY; RECEIVING CONCOMITANT METHOTREXATE; MODIFYING ANTIRHEUMATIC DRUGS; DOUBLE-BLIND; BLOCKING-AGENTS; HEART-FAILURE; TNF-ALPHA; COST-EFFECTIVENESS; BIOLOGICAL AGENTS; CLINICAL-TRIALS		Kings Coll London, Kings Coll London Sch Med, Dept Rheumatol, London, England; Kings Coll Hosp London, Dept Rheumatol, London, England; Univ Hosp Lewisham, Dept Rheumatol, London, England	University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	Scott, DL (corresponding author), Kings Coll London, Kings Coll London Sch Med, Dept Rheumatol, London, England.							Askling J, 2005, ARTHRITIS RHEUM-US, V52, P1986, DOI 10.1002/art.21137; Askling J, 2005, ANN RHEUM DIS, V64, P1414, DOI 10.1136/ard.2004.033241; Askling J, 2005, ANN RHEUM DIS, V64, P1421, DOI 10.1136/ard.2004.033993; Baecklund E, 2006, ARTHRITIS RHEUM, V54, P692, DOI 10.1002/art.21675; Barton P, 2004, HEALTH TECHNOL ASSES, V8, P1; Bathon JM, 2000, NEW ENGL J MED, V343, P1586, DOI 10.1056/NEJM200011303432201; Bathon JM, 2001, NEW ENGL J MED, V344, P240; Bongartz T, 2006, JAMA-J AM MED ASSOC, V295, P2275, DOI 10.1001/jama.295.19.2275; Botsios C, 2005, AUTOIMMUN REV, V4, P162, DOI 10.1016/j.autrev.2004.09.001; Breedveld FC, 2006, ARTHRITIS RHEUM-US, V54, P26, DOI 10.1002/art.21519; Brennan A, 2004, RHEUMATOLOGY, V43, P62, DOI 10.1093/rheumatology/keg451; Bruce B, 2003, J RHEUMATOL, V30, P167; Callahan LF, 1995, ARTHRIT CARE RES, V8, P28, DOI 10.1002/art.1790080108; Carmona L, 2005, ARTHRITIS RHEUM-US, V52, P1766, DOI 10.1002/art.21043; Chakravarty EF, 2003, J RHEUMATOL, V30, P241; Choy EHS, 2005, RHEUMATOLOGY, V44, P1414, DOI 10.1093/rheumatology/kei031; Clair EWS, 2004, ARTHRITIS RHEUM-US, V50, P3432, DOI 10.1002/art.20568; Cush JJ, 2004, CLIN EXP RHEUMATOL, V22, pS141; Dixon WG, 2005, ANN RHEUM DIS, V64, P426; Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661; Furst DE, 2005, ANN RHEUM DIS, V64, P2, DOI 10.1136/ard.2005.044941; Furst DE, 2003, J RHEUMATOL, V30, P2563; Goekoop-Ruiterman YPM, 2005, ARTHRITIS RHEUM-US, V52, P3381, DOI [10.1002/art.21405, 10.1002/art.23364]; Hochberg MC, 2005, SEMIN ARTHRITIS RHEU, V34, P819, DOI 10.1016/j.semarthrit.2004.11.006; Keystone EC, 2004, ARTHRITIS RHEUM, V50, P353, DOI 10.1002/art.20019; Keystone EC, 2004, ARTHRITIS RHEUM, V50, P1400, DOI 10.1002/art.20217; Kingsley GH, 2005, RHEUMATOLOGY, V44, P629, DOI 10.1093/rheumatology/keh565; Klareskog L, 2004, LANCET, V363, P675, DOI 10.1016/S0140-6736(04)15640-7; Kobelt G, 2003, RHEUMATOLOGY, V42, P326, DOI 10.1093/rheumatology/keg107; Kwoh CK, 2002, ARTHRITIS RHEUM-US, V46, P328; Ledingham J, 2005, RHEUMATOLOGY, V44, P157, DOI 10.1093/rheumatology/keh464; Lipsky PE, 2000, NEW ENGL J MED, V343, P1594, DOI 10.1056/NEJM200011303432202; Listing J, 2005, ARTHRITIS RHEUM-US, V52, P3403, DOI 10.1002/art.21386; Maini R, 1999, LANCET, V354, P1932, DOI 10.1016/S0140-6736(99)05246-0; Maini RN, 1998, ARTHRITIS RHEUM, V41, P1552, DOI 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W; Marshall NJ, 2004, RHEUMATOLOGY, V43, P1034, DOI 10.1093/rheumatology/keh237; Moreland LW, 1999, ANN INTERN MED, V130, P478, DOI 10.7326/0003-4819-130-6-199903160-00004; *NAT I CLIN EXC, 2002, GUID US ET INFL TREA; Pugner KM, 2000, SEMIN ARTHRITIS RHEU, V29, P305, DOI 10.1016/S0049-0172(00)80017-7; Quinn MA, 2005, ARTHRITIS RHEUM-US, V52, P27, DOI 10.1002/art.20712; Sarzi-Puttini P, 2005, AUTOIMMUN REV, V4, P153, DOI 10.1016/j.autrev.2004.09.004; Sokka T, 2003, ARTHRITIS RHEUM-US, V48, P313, DOI 10.1002/art.10817; van de Putte BA, 2004, ANN RHEUM DIS, V63, P508, DOI 10.1136/ard.2003.013052; van Vollenhoven RF, 2004, CLIN EXP RHEUMATOL, V22, pS122; VANDERHEIJDE DM, 2004, RHEUM DIS CLIN N AM, V30, P385; Ware JE, 2000, SPINE, V25, P3130, DOI 10.1097/00007632-200012150-00008; Watson KD, 2006, RHEUMATOLOGY, V45, pI10; Weinblatt ME, 1999, NEW ENGL J MED, V340, P253, DOI 10.1056/NEJM199901283400401; Weinblatt ME, 2003, ARTHRITIS RHEUM-US, V48, P35, DOI 10.1002/art.10697; Wolfe F, 2004, AM J MED, V116, P305, DOI 10.1016/j.amjmed.2003.09.039; Wolfe F, 2005, RHEUMATOLOGY, V44, P18, DOI 10.1093/rheumatology/kei056; Wolfe F, 2005, ARTHRITIS RHEUM, V52, P3873, DOI 10.1002/art.21494; Wolfe F, 2004, ARTHRITIS RHEUM-US, V50, P1740, DOI 10.1002/art.20311	53	351	378	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 17	2006	355	7					704	712		10.1056/NEJMct055183	http://dx.doi.org/10.1056/NEJMct055183			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	074AN	16914706				2022-12-28	WOS:000239784500009
J	Foger, N; Rangell, L; Danilenko, DM; Chan, AC				Foeger, Niko; Rangell, Linda; Danilenko, Dimitry M.; Chan, Andrew C.			Requirement for coronin 1 in T lymphocyte trafficking and cellular homeostasis	SCIENCE			English	Article							ARP2/3 COMPLEX; ACTIN NUCLEATION; PROTEIN CORONIN; ACTIVATION; MOTILITY; POLYMERIZATION; CYTOSKELETON; CYTOKINESIS; APOPTOSIS; FILAMENTS	The evolutionarily conserved actin-related protein (Arp2/3) complex is a key component of actin filament networks that is dynamically regulated by nucleation-promoting and inhibitory factors. Although much is known about actin assembly, the physiologic functions of inhibitory proteins are unclear. We generated coronin 1(-/-) mice and found that coronin 1 exerted an inhibitory effect on cellular steady-state F-actin formation via an Arp2/3-dependent mechanism. Whereas coronin 1 was required for chemokine-mediated migration, it was dispensable for T cell antigen receptor functions in T cells. Moreover, actin dynamics, through a mitochondrial pathway, was linked to lymphocyte homeostasis.	Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA; Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	Chan, AC (corresponding author), Genentech Inc, Dept Immunol, 1 DNA Way, San Francisco, CA 94080 USA.	acc@gene.com	Föger, Niko/HII-5983-2022	Danilenko, Dimitry/0000-0002-8326-1921; Foger, Niko/0000-0002-1022-7108				Blanchoin L, 2001, CURR BIOL, V11, P1300, DOI 10.1016/S0960-9822(01)00395-5; BROCK MA, 1993, J CELL PHYSIOL, V157, P367, DOI 10.1002/jcp.1041570221; Cai L, 2005, J BIOL CHEM, V280, P31913, DOI 10.1074/jbc.M504146200; de Hostos EL, 1999, TRENDS CELL BIOL, V9, P345, DOI 10.1016/S0962-8924(99)01620-7; DEHOSTOS EL, 1993, J CELL BIOL, V120, P163, DOI 10.1083/jcb.120.1.163; Ferrari G, 1999, CELL, V97, P435, DOI 10.1016/S0092-8674(00)80754-0; Fukui Y, 2001, NATURE, V412, P826, DOI 10.1038/35090591; Fukui Y, 1999, CELL MOTIL CYTOSKEL, V42, P204, DOI 10.1002/(SICI)1097-0169(1999)42:3<204::AID-CM4>3.0.CO;2-L; Goode BL, 1999, J CELL BIOL, V144, P83, DOI 10.1083/jcb.144.1.83; Gourlay CW, 2004, J CELL BIOL, V164, P803, DOI 10.1083/jcb.200310148; Grogan A, 1997, J CELL SCI, V110, P3071; Humphries CL, 2002, J CELL BIOL, V159, P993, DOI 10.1083/jcb.200206113; MANIAK M, 1995, CELL, V83, P915, DOI 10.1016/0092-8674(95)90207-4; Millard TH, 2004, BIOCHEM J, V380, P1, DOI 10.1042/BJ20040176; Nal B, 2004, INT IMMUNOL, V16, P231, DOI 10.1093/intimm/dxh022; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Posey SC, 1999, J BIOL CHEM, V274, P4259, DOI 10.1074/jbc.274.7.4259; RAO KMK, 1992, J GERONTOL, V47, P37; Rengan R, 2000, BLOOD, V95, P1283, DOI 10.1182/blood.V95.4.1283.004k44_1283_1292; Rodal AA, 2005, NAT STRUCT MOL BIOL, V12, P26, DOI 10.1038/nsmb870; Rybakin V, 2005, BIOESSAYS, V27, P625, DOI 10.1002/bies.20235; Rybakin V, 2004, FEBS LETT, V573, P161, DOI 10.1016/j.febslet.2004.07.066; Snapper SB, 1998, IMMUNITY, V9, P81, DOI 10.1016/S1074-7613(00)80590-7; Welch MD, 2002, ANNU REV CELL DEV BI, V18, P247, DOI 10.1146/annurev.cellbio.18.040202.112133; Yamakita Y, 2003, J BIOL CHEM, V278, P17937, DOI 10.1074/jbc.M208739200	25	189	203	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 11	2006	313	5788					839	842		10.1126/science.1130563	http://dx.doi.org/10.1126/science.1130563			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	072KC	16902139				2022-12-28	WOS:000239671300061
J	Savard, J; Marques-Souza, H; Aranda, M; Tautz, D				Savard, Joel; Marques-Souza, Henrique; Aranda, Manuel; Tautz, Diethard			A segmentation gene in Tribolium produces a polycistronic mRNA that codes for multiple conserved peptides	CELL			English	Article							CELL-PENETRATING PEPTIDES; DROSOPHILA-MELANOGASTER; BEETLE TRIBOLIUM; HYBRIDIZATION; EXPRESSION; HUNCHBACK; DATABASE; EMBRYO	Segmentation genes in insects are required for generating the subdivisions of the early embryo. We describe here a new member of the gap family of segmentation genes in the flour beetle Tribolium, mille-pattes (mlpt). mlpt knockdown leads to transformation of the abdominal segments into thoracic segments, providing embryos with up to ten pairs of legs. We show that there are crossregulatory interactions between mlpt and the known gap genes in Tribolium, suggesting that mlpt is itself a gap gene. The mlpt gene reveals an unusual structure, as it encodes a polycistronic mRNA that codes for four peptides. mlpt appears to be the prototype of this previously unknown gene structure in eukaryotes, as we find homologous genes with the same polycistronic arrangement in other insect genomes; as well.	Univ Cologne, Dept Genet, D-50674 Cologne, Germany	University of Cologne	Tautz, D (corresponding author), Univ Cologne, Dept Genet, Zulpicerstr 47, D-50674 Cologne, Germany.	tautz@uni-koeln.de	Marques-Souza, Henrique/X-5865-2019; Aranda Lastra, Manuel/D-9530-2011; Tautz, Diethard/H-8436-2014; Tautz, Diethard/D-4304-2011	Aranda Lastra, Manuel/0000-0001-6673-016X; Tautz, Diethard/0000-0002-0460-5344; Marques-Souza, Henrique/0000-0002-5008-8413				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andrews J, 1996, GENETICS, V143, P1699; Blumenthal Thomas, 2004, Briefings in Functional Genomics & Proteomics, V3, P199, DOI 10.1093/bfgp/3.3.199; Bosch TCG, 2001, BIOESSAYS, V23, P420, DOI 10.1002/bies.1060; Brogna S, 1997, EMBO J, V16, P2023, DOI 10.1093/emboj/16.8.2023; Brown SJ, 2003, GENET RES, V82, P155, DOI 10.1017/S0016672303006451; Bucher G, 2004, DEVELOPMENT, V131, P1729, DOI 10.1242/dev.01073; Bucher G, 2002, CURR BIOL, V12, pR85, DOI 10.1016/S0960-9822(02)00666-8; Cerny AC, 2005, DEVELOPMENT, V132, P5353, DOI 10.1242/dev.02154; Eckert C, 2004, EMBO REP, V5, P638, DOI 10.1038/sj.embor.7400148; El-Andaloussi S, 2005, CURR PHARM DESIGN, V11, P3597, DOI 10.2174/138161205774580796; Erdmann VA, 1999, NUCLEIC ACIDS RES, V27, P192, DOI 10.1093/nar/27.1.192; Handel K, 2000, DEV GENES EVOL, V210, P167, DOI 10.1007/s004270050301; HULSKAMP M, 1991, BIOESSAYS, V13, P261, DOI 10.1002/bies.950130602; Klingler M, 2004, CURR BIOL, V14, pR639, DOI 10.1016/j.cub.2004.08.004; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEHMANN R, 1994, METHOD CELL BIOL, V44, P575, DOI 10.1016/S0091-679X(08)60933-4; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; Melikov K, 2005, CELL MOL LIFE SCI, V62, P2739, DOI 10.1007/s00018-005-5293-y; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Pang KC, 2005, NUCLEIC ACIDS RES, V33, pD125, DOI 10.1093/nar/gri089; PANKRATZ MJ, 1990, TRENDS GENET, V6, P287, DOI 10.1016/0168-9525(90)90234-W; Peel AD, 2005, NAT REV GENET, V6, P905, DOI 10.1038/nrg1724; Rohrig H, 2002, P NATL ACAD SCI USA, V99, P1915, DOI 10.1073/pnas.022664799; Ryabova LA, 2002, PROG NUCLEIC ACID RE, V72, P1, DOI 10.1016/S0079-6603(02)72066-7; SAVARD J, 2004, THESIS U COLOGNE COL; Schroder R, 2000, P NATL ACAD SCI USA, V97, P6591, DOI 10.1073/pnas.100005497; Tautz D, 2004, DEV CELL, V7, P301, DOI 10.1016/j.devcel.2004.08.008; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Tupy JL, 2005, P NATL ACAD SCI USA, V102, P5495, DOI 10.1073/pnas.0501422102; Wolff C, 1995, DEVELOPMENT, V121, P4227	31	106	110	0	15	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 11	2006	126	3					559	569		10.1016/j.cell.2006.05.053	http://dx.doi.org/10.1016/j.cell.2006.05.053			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	075KI	16901788	Bronze			2022-12-28	WOS:000239883400015
J	Whyte, MP				Whyte, Michael P.			Paget's disease of bone	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BISPHOSPHONATE THERAPY; ETIDRONATE; MANAGEMENT; RISEDRONATE; ALENDRONATE; COMPLICATIONS; MULTICENTER; PAMIDRONATE; PREVALENCE; DEFICIENCY	A 69-year-old man reports increasing pain in the right leg. Physical examination reveals warmth and anterolateral bowing of the right shin. The serum alkaline phosphatase level is 260 U per liter ( normal, 38 to 126 U per liter). A skeletal scintigraphic scan reveals enhanced uptake in only the deformed tibia, where a radiograph shows changes indicative of Paget's disease. His sister, whose alkaline phosphatase level is 160 U per liter, has asymptomatic Paget's disease confined to the left iliac wing. How should their conditions be managed?	Shriners Hosp Children, Ctr Metab Bone Dis & Mol Res, St Louis, MO 63131 USA; Washington Univ, Sch Med, Barnes Jewish Hosp, Div Bone & Mineral Dis, St Louis, MO USA	Barnes-Jewish Hospital; Washington University (WUSTL)	Whyte, MP (corresponding author), Shriners Hosp Children, Ctr Metab Bone Dis & Mol Res, 2001 S Lindbergh Blvd, St Louis, MO 63131 USA.	mwhyte@shrinenet.org						ALTMAN RD, 1985, AM J MED, V79, P583, DOI 10.1016/0002-9343(85)90055-5; ALTMAN RD, 1980, ARTHRITIS RHEUM-US, V23, P1121, DOI 10.1002/art.1780231008; ALTMAN RD, 2002, DISORDERS BONE MINER, P985; Alvarez L, 2004, RHEUMATOLOGY, V43, P869, DOI 10.1093/rheumatology/keh185; BASLE MF, 1986, J GEN VIROL, V67, P907, DOI 10.1099/0022-1317-67-5-907; Cavey JR, 2005, J BONE MINER RES, V20, P619, DOI 10.1359/JBMR.041205; Chitnavis BP, 2001, J ROY SOC MED, V94, P157, DOI 10.1177/014107680109400319; DOYLE FH, 1980, ARTHRITIS RHEUM, V23, P1205, DOI 10.1002/art.1780231019; Doyle T, 2002, BONE, V31, P616, DOI 10.1016/S8756-3282(02)00876-1; Drake WM, 2001, CLIN THER, V23, P620, DOI 10.1016/S0149-2918(01)80065-5; Eastell R, 1999, BONE, V24, p49S, DOI 10.1016/S8756-3282(99)00053-8; FOGELMAN I, 1981, METAB BONE DIS RELAT, V3, P243, DOI 10.1016/0221-8747(81)90040-0; Gold DT, 1999, J BONE MINER RES, V14, P99, DOI 10.1002/jbmr.5650140221; GORDON MT, 1992, BONE MINER, V19, P159, DOI 10.1016/0169-6009(92)90923-2; Grimer RJ, 2003, EUR J CANCER, V39, P157, DOI 10.1016/S0959-8049(02)00478-1; Hadjipavlou AG, 2002, J BONE JOINT SURG BR, V84B, P160, DOI 10.1302/0301-620X.84B2.13047; Helfrich MH, 2000, J BONE MINER RES, V15, P2315, DOI 10.1359/jbmr.2000.15.12.2315; Helliwell PS, 1999, ANN RHEUM DIS, V58, P762, DOI 10.1136/ard.58.12.762; Kanis J., 1998, PATHOPHYSIOLOGY TREA, VSecond; Kirsh G, 2001, ACTA ORTHOP SCAND, V72, P127, DOI 10.1080/000164701317323363; Laroche M, 2005, CALCIFIED TISSUE INT, V77, P129, DOI 10.1007/s00223-005-0250-1; Licata AA, 2005, ANN PHARMACOTHER, V39, P668, DOI 10.1345/aph.1E357; Lyles KW, 2003, ARTHRITIS RHEUM, V48, P2097, DOI 10.1002/art.11135; Lyles KW, 2001, J BONE MINER RES, V16, P1379, DOI 10.1359/jbmr.2001.16.8.1379; MacGowan JR, 2000, SKELETAL RADIOL, V29, P279, DOI 10.1007/s002560050608; Monsell EM, 2004, LARYNGOSCOPE, V114, P598, DOI 10.1097/00005537-200404000-00002; Morales-Piga AA, 2000, CLIN EXP RHEUMATOL, V18, P31; PAGET J, 1877, T R MED CHIR SOC LON, V60, P37; Parvizi J, 2003, J BONE JOINT SURG AM, V85A, P697, DOI 10.2106/00004623-200304000-00017; Poncelet A, 1999, J BONE MINER RES, V14, P88, DOI 10.1002/jbmr.5650140218; Reid IR, 1996, AM J MED, V101, P341, DOI 10.1016/S0002-9343(96)00227-6; Reid IR, 2005, NEW ENGL J MED, V353, P898, DOI 10.1056/NEJMoa044241; REID IR, 1997, AM J MED, V102, P322; Rendina D, 2004, CALCIFIED TISSUE INT, V75, P189, DOI 10.1007/s00223-004-0103-3; Roodman GD, 2005, J CLIN INVEST, V115, P200, DOI 10.1172/JCI200524281; Rosen CJ, 2003, NEW ENGL J MED, V348, P1503, DOI 10.1056/NEJM200304103481521; ROUX C, 1995, ARTHRITIS RHEUM, V38, P851, DOI 10.1002/art.1780380620; SELB, 2002, BONE, V31, P437; Selby PL, 2002, BONE, V31, P366, DOI 10.1016/S8756-3282(02)00817-7; Siris E, 1996, J CLIN ENDOCR METAB, V81, P961, DOI 10.1210/jc.81.3.961; Siris ES, 1999, J BONE MINER RES, V14, P49, DOI 10.1002/jbmr.5650140211; SIRIS ES, 1991, J BONE MINER RES, V6, P495; Siris ES, 1998, J BONE MINER RES, V13, P1032, DOI 10.1359/jbmr.1998.13.6.1032; Smith SE, 2002, RADIOGRAPHICS, V22, P1191, DOI 10.1148/radiographics.22.5.g02se281191; Spieth ME, 2003, CLIN NUCL MED, V28, P773, DOI 10.1097/01.rlu.0000082671.73091.db; Sundaram M, 2001, SKELETAL RADIOL, V30, P378, DOI 10.1007/s002560100360; Takata S, 2004, J BONE MINER METAB, V22, P519, DOI 10.1007/s00774-004-0518-y; Van Staa TP, 2002, J BONE MINER RES, V17, P465, DOI 10.1359/jbmr.2002.17.3.465; Walsh JP, 2004, BONE, V34, P747, DOI 10.1016/j.bone.2003.12.011; Watts GDJ, 2004, NAT GENET, V36, P377, DOI 10.1038/ng1332; Whyte MP, 2002, NEW ENGL J MED, V347, P175, DOI 10.1056/NEJMoa013096; Woo SB, 2006, ANN INTERN MED, V144, P753, DOI 10.7326/0003-4819-144-10-200605160-00009	52	80	84	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 10	2006	355	6					593	600		10.1056/NEJMcp060278	http://dx.doi.org/10.1056/NEJMcp060278			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	071QM	16899779				2022-12-28	WOS:000239616700009
J	Thienkrua, W; Cardozo, BL; Chakkraband, MLS; Guadamuz, TE; Pengjuntr, W; Tantipiwatanaskul, P; Sakornsatian, S; Ekassawin, S; Panyayong, B; Varangrat, A; Tappero, JW; Schreiber, M; van Griensven, F				Thienkrua, Warunee; Lopes Cardozo, Barbara; Chakkraband, M. L. Somchai; Guadamuz, Thomas E.; Pengjuntr, Wachira; Tantipiwatanaskul, Prawate; Sakornsatian, Suchada; Ekassawin, Suparat; Panyayong, Benjaporn; Varangrat, Anchalee; Tappero, Jordan W.; Schreiber, Merritt; van Griensven, Frits		Thailand Post-Tsunami Mental	Symptoms of posttraumatic stress disorder and depression among children in tsunami-affected areas in southern Thailand	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ELEMENTARY-SCHOOL-CHILDREN; RATING SCALE DSRS; ADOLESCENTS; DISASTER; EARTHQUAKE; TRAUMA; PTSD	Context On December 26, 2004, an undersea earthquake occurred off the northwestern coast of Sumatra, Indonesia. The tsunami that followed severely impacted all 6 southwestern provinces of Thailand, where approximately 20 000 children were directly affected. Objective To assess trauma experiences and the prevalence of symptoms of posttraumatic stress disorder (PTSD) and depression among children in tsunami-affected provinces in southern Thailand. Design, Setting, and Participants Population-based mental health surveys were conducted among children aged 7 to 14 years in Phang Nga, Phuket, and Krabi provinces from February 15-22, 2005 (2 months posttsunami), and September 7-12, 2005 (9 months posttsunami). Main Outcome Measures Trauma experiences and symptoms of PTSD and depression as measured by a tsunami-modified version of the PsySTART Rapid Triage System, the UCLA PTSD Reaction Index, and the Birleson Depression Self-Rating Scale. Results A total of 371 children (167 displaced and living in camps, 99 not displaced from villages affected by the tsunami, and 105 not displaced from unaffected villages) participated in the first survey. The prevalence rates of PTSD symptoms were 13% among children living in camps, 11% among children from affected villages, and 6% among children from unaffected villages (camps vs unaffected villages, P=.25); for depression symptoms, the prevalence rates were 11%, 5 %, and 8 %, respectively (P=.39). In multivariate analysis of the first assessment, having had a delayed evacuation, having felt one's own or a family member's life to have been in danger, and having felt extreme panic or fear were significantly associated with PTSD symptoms. Older age and having felt that their own or a family member's life had been in danger were significantly associated with depression symptoms. in the follow-up survey, 72% (151/210) of children from Phang Nga participated. Prevalence rates of symptoms of PTSD and depression among these children did not decrease significantly over time. Conclusions This assessment documents the prevalence of mental health problems among children in tsunami-affected provinces in southern Thailand at 2 and 9 months posttsunami. Traumatic events experienced during the tsunami were significantly associated with symptoms of PTSD and depression. These data may be useful to target mental health services for children and may inform the design of these interventions.	Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA; Thailand Minist Publ Hlth US Ctr Dis Control & Pr, Nonthaburi, Thailand; Minist Publ Hlth, Dept Mental Hlth, Nonthaburi, Thailand; Univ Calif Los Angeles, David Geffen Sch Med, Neuropsychiat Inst & Hosp, Los Angeles, CA USA	Centers for Disease Control & Prevention - USA; Ministry of Public Health - Thailand; Ministry of Public Health - Thailand; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Cardozo, BL (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, 1600 Clifton Rd NE,Mailstop E-97, Atlanta, GA 30333 USA.	bhc8@cdc.gov	van Griensven, Frits/G-4719-2013	van Griensven, Frits/0000-0002-0971-2843	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F31AI064144] Funding Source: NIH RePORTER; NIAID NIH HHS [F31 AI064144] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Beauchesne Michelle A, 2002, J Pediatr Health Care, V16, P213, DOI 10.1067/mph.2002.127353; Chemtob CM, 2002, ARCH PEDIAT ADOL MED, V156, P211, DOI 10.1001/archpedi.156.3.211; Chemtob CM, 2002, J CLIN PSYCHOL, V58, P99, DOI 10.1002/jclp.1131; *DEP MENT HLTH, PROJ CONT PROV MENT; *DEP MENT HLTH, PROJ ORG MENT HLTH C; Goenjian AK, 2001, AM J PSYCHIAT, V158, P788, DOI 10.1176/appi.ajp.158.5.788; Goenjian AK, 1997, AM J PSYCHIAT, V154, P536; GREEN BL, 1991, J AM ACAD CHILD PSY, V30, P945, DOI 10.1097/00004583-199111000-00012; Gurwitch Robin H, 2004, Prehosp Disaster Med, V19, P21; Ivarsson T, 1997, J AFFECT DISORDERS, V42, P59, DOI 10.1016/S0165-0327(96)00098-5; IVARSSON T, 1994, J AFFECT DISORDERS, V32, P115, DOI 10.1016/0165-0327(94)90069-8; Karakaya Isil, 2004, Turk Psikiyatri Derg, V15, P257; Kitayama Shinji, 2000, Kobe Journal of Medical Sciences, V46, P189; Lee Insook, 2004, Taehan Kanho Hakhoe Chi, V34, P636; Lubit Roy, 2003, J Psychiatr Pract, V9, P128, DOI 10.1097/00131746-200303000-00004; McDermott BM, 2002, AUST NZ J PSYCHIAT, V36, P754, DOI 10.1046/j.1440-1614.2002.01090.x; McDermott BM, 2005, CAN J PSYCHIAT, V50, P137, DOI 10.1177/070674370505000302; *NAT ASS SCH PSYCH, 2006, HELP CHILDR NAT DIS; Pynoos R., 2004, COMPREHENSIVE TXB PS, V8; PYNOOS RS, 1993, BRIT J PSYCHIAT, V163, P239, DOI 10.1192/bjp.163.2.239; Roussos A, 2005, AM J PSYCHIAT, V162, P530, DOI 10.1176/appi.ajp.162.3.530; Steinberg Alan M, 2004, Curr Psychiatry Rep, V6, P96, DOI 10.1007/s11920-004-0048-2; Uemoto M, 2000, Seishin Shinkeigaku Zasshi, V102, P459; *US AG INT DEV, IND OC EARTHHQ TSUN; van Griensven F, 2006, JAMA-J AM MED ASSOC, V296, P537, DOI 10.1001/jama.296.5.537; Veenema Tener Goodwin, 2002, J Pediatr Health Care, V16, P235; VOGEL JM, 1993, J CLIN CHILD PSYCHOL, V22, P464, DOI 10.1207/s15374424jccp2204_7; *WHOSEA, EM PREP RESP SE AS E; Yule W, 2000, J CHILD PSYCHOL PSYC, V41, P503, DOI 10.1017/S0021963099005570	29	204	216	2	22	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 2	2006	296	5					549	559		10.1001/jama.296.5.549	http://dx.doi.org/10.1001/jama.296.5.549			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	069YW	16882961	Bronze			2022-12-28	WOS:000239486900019
J	Blennow, K; de Leon, MJ; Zetterberg, H				Blennow, Kaj; de Leon, Mony J.; Zetterberg, Henrik			Alzheimer's disease	LANCET			English	Review							MILD COGNITIVE IMPAIRMENT; AMYLOID PRECURSOR PROTEIN; RANDOMIZED CONTROLLED-TRIAL; QUALITY STANDARDS SUBCOMMITTEE; ESTROGEN REPLACEMENT THERAPY; ALPHA-SECRETASE CLEAVAGE; PLACEBO-CONTROLLED-TRIAL; TRANSGENIC MOUSE MODEL; ACADEMY-OF-NEUROLOGY; DOUBLE-BLIND TRIAL	Alzheimer's disease is the most common cause of dementia. Research advances have enabled detailed understanding of the molecular pathogenesis of the hallmarks of the disease-ie, plaques, composed of amyloid beta (A beta), and tangles, composed of hyperphosphorylated tau. However, as our knowledge increases so does our appreciation for the pathogenic complexity of the disorder. Familial Alzheimer's disease is a very rare autosomal dominant disease with early onset, Caused by mutations in the amyloid precursor protein and presenilin genes, both linked to A beta metabolism. By contrast with familial disease, sporadic Alzheimer's disease is very common with more than 15 million people affected worldwide. The cause of the sporadic form of the disease is unknown, probably because the disease is heterogeneous, caused by ageing in concert with a complex interaction of both genetic and environmental risk factors. This seminar reviews the key aspects of the disease, including epidemiology, genetics, pathogenesis, diagnosis, and treatment, as well as recent developments and controversies.	Sahlgrens Univ Hosp, Clin Neurochem Lab, Dept Neurosci & Physiol, SE-43180 Molndal, Sweden; NYU, Sch Med, Ctr Brain Hlth, Dept Psychiat, New York, NY USA; Nathan S Kline Inst Psychiat Res, New York, NY USA	Sahlgrenska University Hospital; New York University; Nathan Kline Institute for Psychiatric Research	Blennow, K (corresponding author), Sahlgrens Univ Hosp, Clin Neurochem Lab, Dept Neurosci & Physiol, SE-43180 Molndal, Sweden.	kaj.blennow@neuro.gu.se	de Leon, Mony/AAP-7890-2021	de Leon, Mony/0000-0003-2245-4380	NATIONAL INSTITUTE ON AGING [R01AG022374] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG022374] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aisen PS, 2003, JAMA-J AM MED ASSOC, V289, P2819, DOI 10.1001/jama.289.21.2819; Aisen PS, 2002, LANCET NEUROL, V1, P279, DOI 10.1016/S1474-4422(02)00133-3; Almeida OP, 2005, INT PSYCHOGERIATR, V17, P155, DOI 10.1017/S1041610205001559; Alzheimers Assoc, 1998, NEUROBIOL AGING, V19, P109; Areosa SA, 2005, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003154.PUB4; Arnaiz E, 2001, NEUROREPORT, V12, P851, DOI 10.1097/00001756-200103260-00045; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Bayer TA, 2003, P NATL ACAD SCI USA, V100, P14187, DOI 10.1073/pnas.2332818100; Bentham P, 2004, LANCET, V363, P2105; Bergamaschini L, 2004, J NEUROSCI, V24, P4181, DOI 10.1523/JNEUROSCI.0550-04.2004; Birks J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005593; BLENNOW K, 1991, INT J GERIATR PSYCH, V6, P147, DOI 10.1002/gps.930060306; Blennow K, 2003, LANCET NEUROL, V2, P605, DOI 10.1016/S1474-4422(03)00530-1; Blennow Kaj, 2004, NeuroRx, V1, P213, DOI 10.1602/neurorx.1.2.213; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; Blomqvist MEL, 2006, HUM GENET, V119, P29, DOI 10.1007/s00439-005-0078-9; Braak E, 1999, EUR ARCH PSY CLIN N, V249, P14; BRAYNE C, 1988, LANCET, V1, P1265; Brodaty H, 2003, J CLIN PSYCHIAT, V64, P134, DOI 10.4088/JCP.v64n0205; Bullock R, 2005, INT J CLIN PRACT, V59, P817, DOI 10.1111/j.1368-5031.2005.00562.x; Bullock R, 2005, CURR MED RES OPIN, V21, P1317, DOI 10.1185/030079905X56565; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Caccamo A, 2006, NEURON, V49, P671, DOI 10.1016/j.neuron.2006.01.020; CARRO E, IN PRESS NEUROBIOL A; Carson JA, 2002, J NEUROCHEM, V81, P1, DOI 10.1046/j.1471-4159.2002.00855.x; Casadesus G, 2006, BBA-MOL BASIS DIS, V1762, P447, DOI 10.1016/j.bbadis.2006.01.008; Chang WP, 2004, J NEUROCHEM, V89, P1409, DOI 10.1111/j.1471-4159.2004.02452.x; Chauhan NB, 2005, NEUROPHARMACOLOGY, V48, P93, DOI 10.1016/j.neuropharm.2004.09.014; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8; Chetelat G, 2003, NEUROLOGY, V60, P1374, DOI 10.1212/01.WNL.0000055847.17752.E6; Chong MS, 2005, LANCET NEUROL, V4, P576, DOI 10.1016/S1474-4422(05)70168-X; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DAVIES L, 1988, NEUROLOGY, V38, P1688, DOI 10.1212/WNL.38.11.1688; de Leon MJ, 2001, P NATL ACAD SCI USA, V98, P10966, DOI 10.1073/pnas.191044198; De Santi S, 2001, NEUROBIOL AGING, V22, P529, DOI 10.1016/S0197-4580(01)00230-5; Deane R, 2003, NAT MED, V9, P907, DOI 10.1038/nm890; Del Bo R, 2005, ANN NEUROL, V57, P373, DOI 10.1002/ana.20390; DELEON MJ, 1988, LANCET, V2, P391; deToledo-Morrell L, 2004, NEUROBIOL AGING, V25, P1197, DOI 10.1016/j.neurobiolaging.2003.12.007; Doody RS, 2001, NEUROLOGY, V56, P1154, DOI 10.1212/WNL.56.9.1154; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Duff Karen, 2004, Briefings in Functional Genomics & Proteomics, V3, P47, DOI 10.1093/bfgp/3.1.47; Engelhart MJ, 2002, JAMA-J AM MED ASSOC, V287, P3223, DOI 10.1001/jama.287.24.3223; Eriksen JL, 2003, J CLIN INVEST, V112, P440, DOI 10.1172/JCI200318162; Esiri MM, 2001, LANCET, V357, P169; Etcheberrigaray R, 2004, P NATL ACAD SCI USA, V101, P11141, DOI 10.1073/pnas.0403921101; Farkas E, 2001, PROG NEUROBIOL, V64, P575, DOI 10.1016/S0301-0082(00)00068-X; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.1997.03550160069041; Ferri CP, 2005, LANCET, V366, P2112, DOI 10.1016/S0140-6736(05)67889-0; Frisoni GB, 1999, NEUROLOGY, V52, P91, DOI 10.1212/WNL.52.1.91; Gandy S, 2005, J CLIN INVEST, V115, P1121, DOI 10.1172/JCI200525100; Gatz M, 2006, ARCH GEN PSYCHIAT, V63, P168, DOI 10.1001/archpsyc.63.2.168; Gauthier S, 2006, LANCET, V367, P1262, DOI 10.1016/S0140-6736(06)68542-5; Geerts Hugo, 2004, Curr Opin Investig Drugs, V5, P95; Gibson GE, 2005, NEUROBIOL AGING, V26, P575, DOI 10.1016/j.neurobiolaging.2004.07.017; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; Greig NH, 2005, P NATL ACAD SCI USA, V102, P17213, DOI 10.1073/pnas.0508575102; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Hampel H, 2004, ARCH GEN PSYCHIAT, V61, P95, DOI 10.1001/archpsyc.61.1.95; HANSEN LA, 1988, NEUROLOGY, V38, P48, DOI 10.1212/WNL.38.1.48; Hansson O, 2006, LANCET NEUROL, V5, P228, DOI 10.1016/S1474-4422(06)70355-6; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Harvey RJ, 2003, J NEUROL NEUROSUR PS, V74, P1206, DOI 10.1136/jnnp.74.9.1206; Haugabook SJ, 2001, FASEB J, V15, P16; HENDERSON VW, 1994, ARCH NEUROL-CHICAGO, V51, P896, DOI 10.1001/archneur.1994.00540210068014; Heneka MT, 2005, BRAIN, V128, P1442, DOI 10.1093/brain/awh452; Herber DL, 2004, EXP NEUROL, V190, P245, DOI 10.1016/j.expneurol.2004.07.007; Herholz K, 2002, NEUROIMAGE, V17, P302, DOI 10.1006/nimg.2002.1208; Hoglund K, 2005, DEMENT GERIATR COGN, V19, P256, DOI 10.1159/000084550; Holtzman DM, 2000, P NATL ACAD SCI USA, V97, P2892, DOI 10.1073/pnas.050004797; Howland DS, 1998, J BIOL CHEM, V273, P16576, DOI 10.1074/jbc.273.26.16576; Hutter-Paier B, 2004, NEURON, V44, P227, DOI 10.1016/j.neuron.2004.08.043; Iadecola C, 2004, NAT REV NEUROSCI, V5, P347, DOI 10.1038/nrn1387; ICHIHARA N, 1995, BRAIN RES, V695, P173, DOI 10.1016/0006-8993(95)00729-A; Iqbal K, 2005, BBA-MOL BASIS DIS, V1739, P198, DOI 10.1016/j.bbadis.2004.09.008; Jack CR, 2005, NEUROLOGY, V65, P1227, DOI 10.1212/01.wnl.0000180958.22678.91; Jagust William, 2006, Alzheimers Dement, V2, P36, DOI 10.1016/j.jalz.2005.11.002; Jantzen PT, 2002, J NEUROSCI, V22, P2246, DOI 10.1523/JNEUROSCI.22-06-02246.2002; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; JENDROSKA K, 1995, ACTA NEUROPATHOL, V90, P461, DOI 10.1007/bf00294806; Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Klunk WE, 2004, ANN NEUROL, V55, P306, DOI 10.1002/ana.20009; Knopman DS, 2001, NEUROLOGY, V56, P1143, DOI 10.1212/WNL.56.9.1143; Koldamova T, 2005, J BIOL CHEM, V280, P4079, DOI 10.1074/jbc.M411420200; Laakso MP, 1996, NEUROLOGY, V46, P678, DOI 10.1212/WNL.46.3.678; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lazarov O, 2005, CELL, V120, P701, DOI 10.1016/j.cell.2005.01.015; Lee JY, 2004, NEUROBIOL AGING, V25, P1315, DOI 10.1016/j.neurobiolaging.2004.01.005; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; Levin-Allerhand JA, 2002, J ALZHEIMERS DIS, V4, P449; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Lim A, 1999, J AM GERIATR SOC, V47, P564, DOI 10.1111/j.1532-5415.1999.tb02571.x; Lim GP, 2005, J NEUROSCI, V25, P3032, DOI 10.1523/JNEUROSCI.4225-04.2005; Lim GP, 2001, J NEUROSCI, V21, P8370, DOI 10.1523/JNEUROSCI.21-21-08370.2001; Lopez OL, 2002, ARCH NEUROL-CHICAGO, V59, P43, DOI 10.1001/archneur.59.1.43; Luchsinger JA, 2004, LANCET NEUROL, V3, P579, DOI 10.1016/S1474-4422(04)00878-6; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; MANN DMA, 1984, NEUROPATH APPL NEURO, V10, P185, DOI 10.1111/j.1365-2990.1984.tb00351.x; Markesbery WR, 2006, ARCH NEUROL-CHICAGO, V63, P38, DOI 10.1001/archneur.63.1.38; Marr RA, 2003, J NEUROSCI, V23, P1992; Masterman Donna, 2003, J Am Med Dir Assoc, V4, pS146, DOI 10.1097/01.JAM.0000095364.74360.2E; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Matsubara E, 2003, J NEUROCHEM, V85, P1101, DOI 10.1046/j.1471-4159.2003.01654.x; Mayeux R, 2003, ANNU REV NEUROSCI, V26, P81, DOI 10.1146/annurev.neuro.26.043002.094919; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Meyer MR, 1998, NAT GENET, V19, P321, DOI 10.1038/1206; Minoshima S, 2001, ANN NEUROL, V50, P358, DOI 10.1002/ana.1133; Moller HJ, 1998, EUR ARCH PSY CLIN N, V248, P111, DOI 10.1007/s004060050027; Morris JC, 2006, ARCH NEUROL-CHICAGO, V63, P15, DOI 10.1001/archneur.63.1.15; Morris MC, 2002, JAMA-J AM MED ASSOC, V287, P3230, DOI 10.1001/jama.287.24.3230; Mortimer JA, 2003, J CLIN EXP NEUROPSYC, V25, P671, DOI 10.1076/jcen.25.5.671.14584; Mulnard RI, 2000, JAMA-J AM MED ASSOC, V283, P1007, DOI 10.1001/jama.283.8.1007; Nakagawa Y, 2000, EXP NEUROL, V163, P244, DOI 10.1006/exnr.2000.7375; Nestor PJ, 2004, NAT MED, V10, pS34, DOI 10.1038/nrn1433; Nordberg A, 2004, LANCET NEUROL, V3, P519, DOI 10.1016/S1474-4422(04)00853-1; Nordberg A, 2002, J NEUROCHEM, V81, P655, DOI 10.1046/j.1471-4159.2002.00874.x; NUKINA N, 1986, J BIOCHEM-TOKYO, V99, P1541, DOI 10.1093/oxfordjournals.jbchem.a135625; Orgogozo JM, 2003, NEUROLOGY, V61, P46, DOI 10.1212/01.WNL.0000073623.84147.A8; Park JH, 2006, J NEUROSCI, V26, P1386, DOI 10.1523/JNEUROSCI.3291-05.2006; Patel NV, 2005, NEUROBIOL AGING, V26, P995, DOI 10.1016/j.neurobiolaging.2004.09.014; Pedersen WA, 2006, EXP NEUROL, V199, P265, DOI 10.1016/j.expneurol.2006.01.018; Pennanen C, 2004, NEUROBIOL AGING, V25, P303, DOI 10.1016/S0197-4580(03)00084-8; Permanne B, 2002, FASEB J, V16, P860, DOI 10.1096/fj.01-0841fje; Petersen RC, 2005, NEW ENGL J MED, V352, P2379, DOI 10.1056/NEJMoa050151; Petersen RC, 2004, J INTERN MED, V256, P183, DOI 10.1111/j.1365-2796.2004.01388.x; Petit A, 2001, NAT CELL BIOL, V3, P507, DOI 10.1038/35074581; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; Prince JA, 2004, NEUROLOGY, V62, P2116, DOI 10.1212/01.WNL.0000128088.08695.05; Prohovnik I, 2006, NEUROLOGY, V66, P49, DOI 10.1212/01.wnl.0000191298.68045.50; Raber J, 2004, NEUROBIOL AGING, V25, P641, DOI 10.1016/j.neurobiolaging.2003.12.023; Rea TD, 2005, ARCH NEUROL-CHICAGO, V62, P1047, DOI 10.1001/archneur.62.7.1047; Reddy PH, 2005, BRAIN RES REV, V49, P618, DOI 10.1016/j.brainresrev.2005.03.004; Refolo LM, 2001, NEUROBIOL DIS, V8, P890, DOI 10.1006/nbdi.2001.0422; Refolo LM, 2000, NEUROBIOL DIS, V7, P321, DOI 10.1006/nbdi.2000.0304; Rezai-Zadeh K, 2005, J NEUROSCI, V25, P8807, DOI 10.1523/JNEUROSCI.1521-05.2005; Riekse RG, 2004, J AM GERIATR SOC, V52, P1442, DOI 10.1111/j.1532-5415.2004.52405.x; Ritchie CW, 2003, ARCH NEUROL-CHICAGO, V60, P1685, DOI 10.1001/archneur.60.12.1685; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Rockenstein E, 2005, J NEURAL TRANSM, V112, P269, DOI 10.1007/s00702-004-0181-4; ROTH M, 1986, BRIT MED BULL, V42, P42, DOI 10.1093/oxfordjournals.bmb.a072097; Rovelet-Lecrux A, 2006, NAT GENET, V38, P24, DOI 10.1038/ng1718; Sadowski M, 2004, AM J PATHOL, V165, P937, DOI 10.1016/S0002-9440(10)63355-X; Sadowski M, 2004, NEUROCHEM RES, V29, P1257, DOI 10.1023/B:NERE.0000023612.66691.e6; Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704; Sanz, 2001, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD001749; Schenk D, 2004, CURR OPIN IMMUNOL, V16, P599, DOI 10.1016/j.coi.2004.07.012; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; SEAB JP, 1988, MAGN RESON MED, V8, P200, DOI 10.1002/mrm.1910080210; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Shumaker SA, 2004, JAMA-J AM MED ASSOC, V291, P2947, DOI 10.1001/jama.291.24.2947; Siemers E, 2005, CLIN NEUROPHARMACOL, V28, P126, DOI 10.1097/01.wnf.0000167360.27670.29; Silverman DHS, 2001, JAMA-J AM MED ASSOC, V286, P2120, DOI 10.1001/jama.286.17.2120; Simons M, 2002, ANN NEUROL, V52, P346, DOI 10.1002/ana.10292; Snowdon DA, 1997, JAMA-J AM MED ASSOC, V277, P813, DOI 10.1001/jama.277.10.813; SPARKS DL, 1994, EXP NEUROL, V126, P88, DOI 10.1006/exnr.1994.1044; Sparks DL, 2005, ARCH NEUROL-CHICAGO, V62, P753, DOI 10.1001/archneur.62.5.753; Stokin GB, 2005, SCIENCE, V307, P1282, DOI 10.1126/science.1105681; Street JS, 2000, ARCH GEN PSYCHIAT, V57, P968, DOI 10.1001/archpsyc.57.10.968; Su Y, 2004, BIOCHEMISTRY-US, V43, P6899, DOI 10.1021/bi035627j; Sunderland T, 2003, JAMA-J AM MED ASSOC, V289, P2094, DOI 10.1001/jama.289.16.2094; Sung S, 2003, FASEB J, V17, P323, DOI 10.1096/fj.03-0961fje; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; Tanzi RE, 2004, NEURON, V43, P605, DOI 10.1016/j.neuron.2004.08.024; Tariot PN, 2004, JAMA-J AM MED ASSOC, V291, P317, DOI 10.1001/jama.291.3.317; Terry AV, 2003, J PHARMACOL EXP THER, V306, P821, DOI 10.1124/jpet.102.041616; Tucker Stephanie, 2005, Current Alzheimer Research, V2, P249, DOI 10.2174/1567205053585855; van de Pol LA, 2006, NEUROLOGY, V66, P236, DOI 10.1212/01.wnl.0000194240.47892.4d; Van der Auwera Ingrid, 2005, Nutr Metab (Lond), V2, P28, DOI 10.1186/1743-7075-2-28; van Horssen J, 2003, LANCET NEUROL, V2, P482, DOI 10.1016/S1474-4422(03)00484-8; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Visser PJ, 2005, J NEUROL NEUROSUR PS, V76, P1348, DOI 10.1136/jnnp.2004.047720; Walsh DM, 2004, NEURON, V44, P181, DOI 10.1016/j.neuron.2004.09.010; Webber KM, 2005, MECH AGEING DEV, V126, P1019, DOI 10.1016/j.mad.2005.03.024; Wilcock GK, 2003, LANCET NEUROL, V2, P503, DOI 10.1016/S1474-4422(03)00486-1; WILCOCK GK, 1982, J NEUROL SCI, V56, P343, DOI 10.1016/0022-510X(82)90155-1; Winblad B, 2006, LANCET, V367, P1057, DOI 10.1016/S0140-6736(06)68350-5; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439; Wu ZH, 2005, NAT MED, V11, P959, DOI 10.1038/nm1287; Zandi PP, 2005, ARCH GEN PSYCHIAT, V62, P217, DOI 10.1001/archpsyc.62.2.217	184	2496	2648	34	1609	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL-AUG	2006	368	9533					387	403		10.1016/S0140-6736(06)69113-7	http://dx.doi.org/10.1016/S0140-6736(06)69113-7			17	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	069JJ	16876668				2022-12-28	WOS:000239441900033
J	Singh, SB; Davis, AS; Taylor, GA; Deretic, V				Singh, Sudha B.; Davis, Alexander S.; Taylor, Gregory A.; Deretic, Vojo			Human IRGM induces autophagy to eliminate intracellular mycobacteria	SCIENCE			English	Article							3-KINASE COMPLEX; IMMUNE CONTROL; P47 GTPASES; TUBERCULOSIS; INDUCTION; MECHANISM; INFECTION; BECLIN-1; DEFENSE; INNATE	Immunity-related p47 guanosine triphosphatases (IRG) play a role in defense against intracellular pathogens. We found that the murine Irgm1 (LRG-47) guanosine triphosphatase induced autophagy and generated large autolysosomal organelles as a mechanism for the elimination of intracellular Mycobacterium tuberculosis. We also identified a function for a human IRG protein in the control of intracellular pathogens and report that the human Irgm1 ortholog, IRGM, plays a role in autophagy and in the reduction of intracellular bacillary load.	Univ New Mexico, Sch Med, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA; Univ New Mexico, Sch Med, Dept Cell Biol & Physiol, Albuquerque, NM 87131 USA; Duke Univ, Dept Med, Durham, NC 27710 USA; Duke Univ, Dept Microbiol & Mol Genet, Durham, NC 27710 USA; Duke Univ, Dept Immunol, Durham, NC 27710 USA; Duke Univ, Ctr Study Aging, Durham, NC 27710 USA; Dept Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Durham, NC 27710 USA	University of New Mexico; University of New Mexico; Duke University; Duke University; Duke University; Duke University; Geriatric Research Education & Clinical Center	Deretic, V (corresponding author), Univ New Mexico, Sch Med, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA.	vderetic@salud.unm.edu		Deretic, Vojo/0000-0002-3624-5208	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007538, R01AI042999, R01AI045148, R01AI057831] Funding Source: NIH RePORTER; NIAID NIH HHS [AI45148, AI42999, T32 AI007538, AI57831, R01 AI057831] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bekpen C, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-11-r92; Birmingham CL, 2006, J BIOL CHEM, V281, P11374, DOI 10.1074/jbc.M509157200; Deretic V, 2005, TRENDS IMMUNOL, V26, P523, DOI 10.1016/j.it.2005.08.003; Deretic V., 2006, AUTOPHAGY IMMUNITY I; Elmore SP, 2001, FASEB J, V15, P2286, DOI 10.1096/fj.01-0206fje; Feng CG, 2004, J IMMUNOL, V172, P1163, DOI 10.4049/jimmunol.172.2.1163; Furuya N, 2005, AUTOPHAGY, V1, P46, DOI 10.4161/auto.1.1.1542; Gutierrez MG, 2004, CELL, V119, P753, DOI 10.1016/j.cell.2004.11.038; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061; Levine B, 2005, CELL, V120, P159, DOI 10.1016/j.cell.2005.01.005; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Liu Y, 2005, CELL, V121, P567, DOI 10.1016/j.cell.2005.03.007; MacMicking JD, 2005, CURR OPIN MICROBIOL, V8, P74, DOI 10.1016/j.mib.2004.12.012; MacMicking JD, 2003, SCIENCE, V302, P654, DOI 10.1126/science.1088063; Martens S, 2005, PLOS PATHOG, V1, P187, DOI 10.1371/journal.ppat.0010024; Nakagawa I, 2004, SCIENCE, V306, P1037, DOI 10.1126/science.1103966; Ogawa M, 2005, SCIENCE, V307, P727, DOI 10.1126/science.1106036; Paludan C, 2005, SCIENCE, V307, P593, DOI 10.1126/science.1104904; Seglen P O, 1990, Semin Cell Biol, V1, P441; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Taylor GA, 2004, NAT REV IMMUNOL, V4, P100, DOI 10.1038/nri1270; Zeng XH, 2006, J CELL SCI, V119, P259, DOI 10.1242/jcs.02735	23	691	717	1	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 8	2006	313	5792					1438	1441		10.1126/science.1129577	http://dx.doi.org/10.1126/science.1129577			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	081WQ	16888103				2022-12-28	WOS:000240348700043
J	Engler, AJ; Sen, S; Sweeney, HL; Discher, DE				Engler, Adam J.; Sen, Shamik; Sweeney, H. Lee; Discher, Dennis E.			Matrix elasticity directs stem cell lineage specification	CELL			English	Article							MARROW STROMAL CELLS; IN-VITRO; OSTEOBLAST DIFFERENTIATION; FOCAL ADHESIONS; TISSUE; EXPRESSION; STIFFNESS; FIBROBLASTS; GROWTH; CONTRACTILITY	Microenvironments appear important in stem cell lineage specification but can be difficult to adequately characterize or control with soft tissues. Naive mesenchymal stem cells (MSCs) are shown hereto specify lineage and commit to phenotypes with extreme sensitivity to tissue-level elasticity. Soft matrices that mimic brain are neurogenic, stiffer matrices that mimic muscle are myogenic, and comparatively rigid matrices that mimic collagenous bone prove osteogenic. During the initial week in culture, reprogramming of these lineages is possible with addition of soluble induction factors, but after several weeks in culture, the cells commit to the lineage specified by matrix elasticity, consistent with the elasticity-insensitive commitment of differentiated cell types. Inhibition of nonmuscle myosin II blocks all elasticity-directed lineage specification-without strongly perturbing many other aspects of cell function and shape. The results have significant implications for understanding physical effects of the in vivo microenvironment and also for therapeutic uses of stem cells.	Univ Penn, Muscle Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Engn & Appl Sci, Philadelphia, PA 19104 USA; Univ Penn, Cell & Mol Biol Grad Grp, Philadelphia, PA 19104 USA; Univ Penn, Phys Grad Grp, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Discher, DE (corresponding author), Univ Penn, Muscle Inst, Philadelphia, PA 19104 USA.	discher@seas.upenn.edu	Sweeney, H Lee/F-1862-2010; Engler, Adam/AAF-4016-2019	Engler, Adam/0000-0003-1642-5380; Sen, Shamik/0000-0002-8639-8659; discher, dennis/0000-0001-6163-2229				Alenghat Francis J, 2002, Sci STKE, V2002, ppe6, DOI 10.1126/stke.2002.119.pe6; Allingham JS, 2005, NAT STRUCT MOL BIOL, V12, P378, DOI 10.1038/nsmb908; Andrades JA, 2001, INT J DEV BIOL, V45, P689; Beningo KA, 2001, J CELL BIOL, V153, P881, DOI 10.1083/jcb.153.4.881; Berry MF, 2006, AM J PHYSIOL-HEART C, V290, pH2196, DOI 10.1152/ajpheart.01017.2005; Bershadsky AD, 2003, ANNU REV CELL DEV BI, V19, P677, DOI 10.1146/annurev.cellbio.19.111301.153011; Conti MA, 2004, J BIOL CHEM, V279, P41263, DOI 10.1074/jbc.C400352200; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; Deng J, 2006, STEM CELLS, V24, P1054, DOI 10.1634/stemcells.2005-0370; Dhawan J, 2004, J CELL SCI, V117, P3735, DOI 10.1242/jcs.01197; Dinsmore J, 1996, CELL TRANSPLANT, V5, P131, DOI 10.1016/0963-6897(95)02040-3; Discher DE, 2005, SCIENCE, V310, P1139, DOI 10.1126/science.1116995; Engler AJ, 2004, SURF SCI, V570, P142, DOI 10.1016/j.susc.2004.06.179; Engler AJ, 2004, J CELL BIOL, V166, P877, DOI 10.1083/jcb.200405004; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Flanagan LA, 2002, NEUROREPORT, V13, P2411, DOI 10.1097/00001756-200212200-00007; Gang EJ, 2004, STEM CELLS, V22, P617, DOI 10.1634/stemcells.22-4-617; Garcia AJ, 2005, J DENT RES, V84, P407, DOI 10.1177/154405910508400502; Georges PC, 2006, BIOPHYS J, V90, P3012, DOI 10.1529/biophysj.105.073114; Gilbert L, 2002, J BIOL CHEM, V277, P2695, DOI 10.1074/jbc.M106339200; Griffin MA, 2004, J CELL SCI, V117, P5855, DOI 10.1242/jcs.01496; Hinz B, 2001, MOL BIOL CELL, V12, P2730, DOI 10.1091/mbc.12.9.2730; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097-4644(199702)64:2<295::AID-JCB12>3.0.CO;2-I; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Katayama Y, 2006, CELL, V124, P407, DOI 10.1016/j.cell.2005.10.041; Kim KY, 2005, J BIOL CHEM, V280, P22769, DOI 10.1074/jbc.M503488200; Kondo T, 2005, P NATL ACAD SCI USA, V102, P4789, DOI 10.1073/pnas.0408239102; Kong HJ, 2005, P NATL ACAD SCI USA, V102, P4300, DOI 10.1073/pnas.0405873102; Lariviere RC, 2004, J NEUROBIOL, V58, P131, DOI 10.1002/neu.10270; Lee Michael S, 2004, Rev Cardiovasc Med, V5, P82; Limouze J, 2004, J MUSCLE RES CELL M, V25, P337, DOI 10.1007/s10974-004-6060-7; Lo CM, 2000, BIOPHYS J, V79, P144, DOI 10.1016/S0006-3495(00)76279-5; Maitra A, 2005, NAT GENET, V37, P1099, DOI 10.1038/ng1631; McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534-5807(04)00075-9; Morinobu M, 2003, J BONE MINER RES, V18, P1706, DOI 10.1359/jbmr.2003.18.9.1706; Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446; NAKAGAWA S, 1989, EXP CELL RES, V182, P572, DOI 10.1016/0014-4827(89)90260-7; Neuhuber B, 2004, J NEUROSCI RES, V77, P192, DOI 10.1002/jnr.20147; Pelham RJ, 1997, P NATL ACAD SCI USA, V94, P13661, DOI 10.1073/pnas.94.25.13661; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Raisz LG, 1999, CLIN CHEM, V45, P1353; Rattner A, 2000, CALCIFIED TISSUE INT, V66, P35, DOI 10.1007/s002230050007; Roeder BA, 2002, J BIOMECH ENG-T ASME, V124, P214, DOI 10.1115/1.1449904; Rosania GR, 2000, NAT BIOTECHNOL, V18, P304, DOI 10.1038/73753; Rosenfeld SS, 2003, J BIOL CHEM, V278, P27449, DOI 10.1074/jbc.M302555200; Rotsch C, 1999, P NATL ACAD SCI USA, V96, P921, DOI 10.1073/pnas.96.3.921; RUTISHAUSER U, 1984, NATURE, V310, P549, DOI 10.1038/310549a0; Sanger JW, 2002, CLIN ORTHOP RELAT R, pS153, DOI 10.1097/01.blo.0000031973.69509.21; Straight AF, 2003, SCIENCE, V299, P1743, DOI 10.1126/science.1081412; Tamada M, 2004, DEV CELL, V7, P709, DOI 10.1016/j.devcel.2004.08.021; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; VERKHOVSKY AB, 1995, J CELL BIOL, V131, P989, DOI 10.1083/jcb.131.4.989; Wang N, 2002, AM J PHYSIOL-CELL PH, V282, pC606, DOI 10.1152/ajpcell.00269.2001; Weitzer G, 1995, DEV BIOL, V172, P422, DOI 10.1006/dbio.1995.8070; Wislet-Gendebien S, 2005, BRAIN RES BULL, V68, P95, DOI 10.1016/j.brainresbull.2005.08.016; Woodbury D, 2002, J NEUROSCI RES, V69, P908, DOI 10.1002/jnr.10365; Wozniak MA, 2003, J CELL BIOL, V163, P583, DOI 10.1083/jcb.200305010	60	9646	9936	83	2192	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 25	2006	126	4					677	689		10.1016/j.cell.2006.06.044	http://dx.doi.org/10.1016/j.cell.2006.06.044			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	080VN	16923388	Bronze			2022-12-28	WOS:000240276700017
J	Kitching, RL				Kitching, R. L.			Crafting the pieces of the diversity jigsaw puzzle	SCIENCE			English	Editorial Material							APPARENT COMPETITION; TROPICAL FOREST		Griffith Univ, Australian Sch Environm Studies, Brisbane, Qld 4111, Australia	Griffith University	Kitching, RL (corresponding author), Griffith Univ, Australian Sch Environm Studies, Brisbane, Qld 4111, Australia.	r.kitching@griffith.edu.au	Kitching, Roger/C-5102-2009					Darwin Charles, 1845, J RES; Dobzhansky T., 1950, American Scientist, V38, P209; Hattenschwiler S, 2005, ANNU REV ECOL EVOL S, V36, P191, DOI 10.1146/annurev.ecolsys.36.112904.151932; Hubbell Stephen P., 2001, V32, pi; Kitching R.L., 2000, FOOD WEBS CONTAINER, DOI [10.1017/CBO9780511542107, DOI 10.1017/CBO9780511542107]; Morris RJ, 2005, ANN ZOOL FENN, V42, P449; Morris RJ, 2004, NATURE, V428, P310, DOI 10.1038/nature02394; Novotny V, 2002, NATURE, V416, P841, DOI 10.1038/416841a; Novotny V, 2006, SCIENCE, V313, P1115, DOI 10.1126/science.1129237; Stork N.E., 1997, CANOPY ARTHROPODS; STORK NE, 1988, BIOL J LINN SOC, V35, P321, DOI 10.1111/j.1095-8312.1988.tb00474.x; Wilf P, 2006, SCIENCE, V313, P1112, DOI 10.1126/science.1129569	12	22	25	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 25	2006	313	5790					1055	1057		10.1126/science.1131117	http://dx.doi.org/10.1126/science.1131117			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	076ZT	16931744				2022-12-28	WOS:000239998200026
J	Maguire, JH				Maguire, James H.			Focus on research: Chagas' disease - Can we stop the deaths?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							TRYPANOSOMA-CRUZI; BENZNIDAZOLE		Univ Maryland, Sch Med, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Maguire, JH (corresponding author), Univ Maryland, Sch Med, Baltimore, MD 21201 USA.							Andrade ALSS, 2004, AM J TROP MED HYG, V71, P594, DOI 10.4269/ajtmh.2004.71.594; El-Sayed NM, 2005, SCIENCE, V309, P409, DOI 10.1126/science.1112631; MAGUIRE JH, 1987, CIRCULATION, V75, P1140, DOI 10.1161/01.CIR.75.6.1140; Viotti R, 2006, ANN INTERN MED, V144, P724, DOI 10.7326/0003-4819-144-10-200605160-00006; World Health Organization (WHO), 2002, WHO TECH REP SER, V905, P1	5	47	50	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 24	2006	355	8					760	761		10.1056/NEJMp068130	http://dx.doi.org/10.1056/NEJMp068130			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	076KA	16928993				2022-12-28	WOS:000239955200004
J	Venna, N; Sims, KB; Grant, PE; Alcalay, RN				Venna, Nagagopal; Sims, Katherine B.; Grant, P. Ellen; Alcalay, Roy N.			A 19-year-old woman with difficulty walking - Dopamine-responsive dystonia caused by a mutation (E6 del GT635-636) in the GCH1 gene.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							GTP-CYCLOHYDROLASE-I; DIAGNOSIS; DEFICIENCY; PROTEIN		Massachusetts Gen Hosp, Neurol Serv, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pediat Radiol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Venna, N (corresponding author), Massachusetts Gen Hosp, Neurol Serv, Boston, MA 02114 USA.		Grant, Peter/HIR-3733-2022	Grant, Patricia/0000-0003-1005-4013				Bandmann O, 2003, NEUROLOGY, V60, P700, DOI 10.1212/01.WNL.0000048205.18445.98; Bhidayasiri R, 2006, NEUROLOGIST, V12, P74, DOI 10.1097/01.nrl.0000195831.46000.2d; Binder J, 2003, BRAIN, V126, P1814, DOI 10.1093/brain/awg174; Blau N, 2001, MOL GENET METAB, V74, P172, DOI 10.1006/mgme.2001.3213; BLAU N, 2005, PHYS GUIDE TREATMENT; Blau N., 2001, METABOLIC MOL BASIS, P1725; Colosimo C, 2005, J NEUROL NEUROSUR PS, V76, P1591, DOI 10.1136/jnnp.2004.056614; DENNYBROWN D, 1968, HDB CLIN NEUROLOGY, P133; ETGEN T, IN PRESS J NEUROL NE; Furukawa Y, 1998, NEUROLOGY, V50, P1015, DOI 10.1212/WNL.50.4.1015; Furukawa Y, 2004, ANN NEUROL, V55, P147, DOI 10.1002/ana.10820; Furukawa Y, 2005, CUR CLIN NEUROL, P209; Furukawa Y, 2003, ADV NEUROL, V91, P401; FURUKAWA Y, 2006, GENEREVIEWS GENETEST; Furukawa Yoshiaki, 2004, Adv Neurol, V94, P127; Gesierich A, 2003, BASIC RES CARDIOL, V98, P69, DOI 10.1007/s00395-003-0394-y; Hartmann A, 1998, J NEUROL, V245, P511, DOI 10.1007/s004150050235; Head RA, 2005, ANN NEUROL, V58, P234, DOI 10.1002/ana.20550; ICHINOSE H, 1995, J BIOL CHEM, V270, P10062, DOI 10.1074/jbc.270.17.10062; Ichinose H, 2000, BRAIN DEV-JPN, V22, pS107; Jan MMS, 2004, PEDIATR NEUROL, V31, P298, DOI 10.1016/j.pediatrneurol.2004.03.017; Jarman PR, 1997, J NEUROL NEUROSUR PS, V63, P304, DOI 10.1136/jnnp.63.3.304; Mink Jonathan W., 2003, Curr Treat Options Neurol, V5, P279, DOI 10.1007/s11940-003-0033-9; Naviaux RK, 2000, EUR J PEDIATR, V159, pS219, DOI 10.1007/PL00014407; Nemeth AH, 2002, BRAIN, V125, P695, DOI 10.1093/brain/awf090; NYGAARD TG, 1991, NEUROLOGY, V41, P174, DOI 10.1212/WNL.41.2_Part_1.174; RAJPUT AH, 1994, ANN NEUROL, V35, P396, DOI 10.1002/ana.410350405; Saunders-Pullman R, 2004, MOL GENET METAB, V83, P207, DOI 10.1016/j.ymgme.2004.07.010; Segawa M, 1976, Adv Neurol, V14, P215; Segawa M, 2003, ANN NEUROL, V54, pS32, DOI 10.1002/ana.10630; Swoboda KJ, 2002, NEUROL CLIN, V20, P1143, DOI 10.1016/S0733-8619(02)00018-X; Tarsy D, 2006, NEW ENGL J MED, V355, P818, DOI 10.1056/NEJMra055549; Uc Ergun Y, 2003, Semin Pediatr Neurol, V10, P52, DOI 10.1016/S1071-9091(02)00010-4; Van Hove JLK, 2006, J NEUROL NEUROSUR PS, V77, P18, DOI 10.1136/jnnp.2004.051664; WOJCIK JD, 1991, AM J PSYCHIAT, V148, P1055	35	5	5	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 24	2006	355	8					831	839		10.1056/NEJMcpc069015	http://dx.doi.org/10.1056/NEJMcpc069015			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	076KA	16928999				2022-12-28	WOS:000239955200013
J	Rosner, SA; Stampfer, MJ				Rosner, Sarah A.; Stampfer, Meir J.			The heart-breaking news about tobacco: it's all bad	LANCET			English	Editorial Material							MYOCARDIAL-INFARCTION; RISK		Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Stampfer, MJ (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.	stampfer@hsph.harvard.edu		Preis, Sarah/0000-0002-9360-4166				PETO R, 2000, CRITICAL ISSUES GLOB, P151; Rastogi T, 2005, TOB CONTROL, V14, P356, DOI 10.1136/tc.2005.011965; Teo KK, 2006, LANCET, V368, P647, DOI 10.1016/S0140-6736(06)69249-0; U.S. Department of Health and Human Services, 2004, HLTH CONS SMOK REP U; U.S. Department of Health and Human Services, 2006, HLTH CONS INV EXP TO; WILLETT WC, 1987, NEW ENGL J MED, V317, P1303, DOI 10.1056/NEJM198711193172102	6	7	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 19	2006	368	9536					621	622		10.1016/S0140-6736(06)69220-9	http://dx.doi.org/10.1016/S0140-6736(06)69220-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	074YT	16920447				2022-12-28	WOS:000239849200004
J	Kramer, EM; Donohue, K				Kramer, Elena M.; Donohue, Kathleen			Traversing the adaptive landscape in snapdragons	SCIENCE			English	Editorial Material									Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA	Harvard University	Kramer, EM (corresponding author), Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA.	ekramer@oeb.harvard.edu						LANDE R, 1979, EVOLUTION, V33, P402, DOI 10.2307/2407630; Schluter D., 2000, ECOLOGY ADAPTIVE RAD; Simpson G.G., 1944, TEMPO MODE EVOLUTION, DOI DOI 10.1073/pnas.1821292116; Whibley AC, 2006, SCIENCE, V313, P963, DOI 10.1126/science.1129161; WRIGHT SEWALL, 1932, PROC SIXTH INTERNAT CONGR GENETICS ITHACA NEW YORK, V1, P356	5	4	4	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 18	2006	313	5789					924	925		10.1126/science.1130958	http://dx.doi.org/10.1126/science.1130958			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	074MR	16917048				2022-12-28	WOS:000239817000027
J	Liu, YX; Jessop, PG; Cunningham, M; Eckert, CA; Liotta, CL				Liu, Yingxin; Jessop, Philip G.; Cunningham, Michael; Eckert, Charles A.; Liotta, Charles L.			Switchable surfactants	SCIENCE			English	Article							CRUDE-OIL; REDOX; ASPHALTENES	Many industrial applications that rely on emulsions would benefit from an efficient, rapid method of breaking these emulsions at a specific desired stage. We report that long-chain alkyl amidine compounds can be reversibly transformed into charged surfactants by exposure to an atmosphere of carbon dioxide, thereby stabilizing water/alkane emulsions or, for the purpose of microsuspension polymerization, styrene-in-water emulsions. Bubbling nitrogen, argon, or air through the amidinium bicarbonate solutions at 65 degrees C reverses the reaction, releasing carbon dioxide and breaking the emulsion. We also find that the neutral amidines function as switchable demulsifiers of an aqueous crude oil emulsion, enhancing their practical potential.	Queens Univ, Dept Chem, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Chem Engn, Kingston, ON K7L 3N6, Canada; Georgia Inst Technol, Sch Chem & Chem Engn, Atlanta, GA 30332 USA	Queens University - Canada; Queens University - Canada; University System of Georgia; Georgia Institute of Technology	Jessop, PG (corresponding author), Queens Univ, Dept Chem, Kingston, ON K7L 3N6, Canada.	jessop@chem.queensu.ca	Jessop, Philip/AAB-5265-2020; Cunningham, Michael/Y-1764-2019	Jessop, Philip/0000-0002-5323-5095; Cunningham, Michael/0000-0001-8226-5990				Acevedo S, 2005, ENERG FUEL, V19, P1948, DOI 10.1021/ef050036i; ANTON P, 1992, PROG COLL POL SCI S, V89, P56; ANTON P, 1995, POLYM BULL, V34, P331, DOI 10.1007/BF00294152; Austad T, 2000, SURFACTANT FLOODING, P203; Aydogan N, 2001, LANGMUIR, V17, P5703, DOI 10.1021/la010178e; Cunningham MF, 2000, J POLYM SCI POL CHEM, V38, P345, DOI 10.1002/(SICI)1099-0518(20000115)38:2<345::AID-POLA9>3.0.CO;2-#; Cunningham MF, 1999, POLYM REACT ENG, V7, P231, DOI 10.1080/10543414.1999.10744509; Datwani SS, 2003, LANGMUIR, V19, P8292, DOI 10.1021/la020813w; DEGROOTE M, 1951, Patent No. 2574537; Fitch R. M., 1997, POLYM COLLOIDS COMPR; Heldebrant DJ, 2005, J ORG CHEM, V70, P5335, DOI 10.1021/jo0503759; Holmberg K, 2001, SURF SCI SERIES, V100, P45; Jessop PG, 2005, NATURE, V436, P1102, DOI 10.1038/4361102a; Langevin D, 2004, OIL GAS SCI TECHNOL, V59, P511, DOI 10.2516/ogst:2004036; LOCHHEAD RY, 1987, SOAP COSMET CHEM SPE, V63, P28; Masliyah J, 2004, CAN J CHEM ENG, V82, P628, DOI 10.1002/cjce.5450820403; Poteau S, 2005, ENERG FUEL, V19, P1337, DOI 10.1021/ef0497560; SAJI T, 1985, J AM CHEM SOC, V107, P6865, DOI 10.1021/ja00310a020; Sakai H, 2005, SURF SCI CRC, V124, P507; Schmittel M, 2005, CHEM COMMUN, P5650, DOI 10.1039/b511923e; SCHRAMM LL, 2000, SURFACTANTS FUNDAMEN, P79; Urban D, 2005, CHEMISTRY AND TECHNOLOGY OF EMULSION POLYMERISATION, P226, DOI 10.1002/9780470988466.ch10; Yaghi BM, 2002, ENERG SOURCE, V24, P93, DOI 10.1080/00908310252774417	23	657	718	22	442	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 18	2006	313	5789					958	960		10.1126/science.1128142	http://dx.doi.org/10.1126/science.1128142			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	074MR	16917059				2022-12-28	WOS:000239817000040
J	Morse, CG; Kovacs, JA				Morse, Caryn G.; Kovacs, Joseph A.			Metabolic and skeletal complications of HIV infection - The price of success	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMBINATION ANTIRETROVIRAL THERAPY; REVERSE-TRANSCRIPTASE INHIBITORS; LIPID-LOWERING THERAPY; BONE-MINERAL DENSITY; DISEASE RISK-FACTORS; PROTEASE-INHIBITOR; INSULIN-RESISTANCE; ADIPOSE-TISSUE; FAT REDISTRIBUTION; DIABETES-MELLITUS	Over the past 10 years, in conjunction with the broad availability of potent antiretroviral regimens, the care of human immunodeficiency virus (HIV) infected patients has shifted from prevention and treatment of opportunistic infections and malignancies to management of the metabolic and related complications associated with HIV infection and its treatment. Metabolic disorders, including lipodystrophy, dyslipidemia, and insulin resistance, occur at a high rate in HIV-infected individuals receiving highly active antiretroviral therapy ( HAART). These disorders are associated with increased risk of cardiovascular disease and have become an important cause of morbidity and mortality in HIV-infected patients. Herein, we present the case of a patient with HIV infection who responded well to HAART but developed multiple complications potentially related to this therapy. This article reviews the clinical characteristics of the metabolic and skeletal disturbances observed in HIV infection and discusses strategies for their management.	NIAID, Ctr Clin, HIV AIDS Program, Crit Care Med Dept,NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); NIH National Institute of Allergy & Infectious Diseases (NIAID)	Kovacs, JA (corresponding author), NIAID, Ctr Clin, HIV AIDS Program, Crit Care Med Dept,NIH, Bldg 10,Room 2C145,MSC 1662, Bethesda, MD 20892 USA.	jkovacs@nih.gov	Kovacs, Joseph/AAU-6105-2021	Kovacs, Joseph/0000-0002-5191-9880; Morse, Caryn/0000-0002-1177-4365	CLINICAL CENTER [ZIACL008075, Z01CL001159, ZIACL001159, Z01CL008075] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	CLINICAL CENTER; Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Ammassari A, 2002, JAIDS-J ACQ IMM DEF, V31, pS140, DOI 10.1097/00126334-200212153-00011; Amorosa V, 2006, CLIN INFECT DIS, V42, P108, DOI 10.1086/498511; Bacchetti P, 2005, JAIDS-J ACQ IMM DEF, V40, P121, DOI 10.1097/01.qai.0000182230.47819.aa; Bauer M, 2000, PHARMACOEPIDEM DR S, V9, P187, DOI 10.1002/1099-1557(200005/06)9:3<187::AID-PDS494>3.0.CO;2-J; Behrens G, 1999, AIDS, V13, pF63, DOI 10.1097/00002030-199907090-00001; Blanch J, 2004, CLIN INFECT DIS, V38, P1469; Bozzette SA, 2003, NEW ENGL J MED, V348, P702, DOI 10.1056/NEJMoa022048; Bruera D, 2003, AIDS, V17, P1917, DOI 10.1097/00002030-200309050-00010; Bucher HC, 2003, AIDS, V17, P2451, DOI 10.1097/00002030-200311210-00007; Calza L, 2005, AIDS, V19, P1051, DOI 10.1097/01.aids.0000174451.78497.8f; Calza L, 2005, AIDS, V19, P1103, DOI 10.1097/01.aids.0000174458.86121.43; Caron M, 2001, DIABETES, V50, P1378, DOI 10.2337/diabetes.50.6.1378; Carr A, 2002, JAMA-J AM MED ASSOC, V288, P207, DOI 10.1001/jama.288.2.207; Carr A, 2003, LANCET, V361, P726, DOI 10.1016/S0140-6736(03)12656-6; Carr A, 1999, LANCET, V353, P2093, DOI 10.1016/S0140-6736(98)08468-2; Carr A, 1998, AIDS, V12, pF51, DOI 10.1097/00002030-199807000-00003; Carr A, 2004, LANCET, V363, P429, DOI 10.1016/S0140-6736(04)15489-5; Carr A, 2001, AIDS, V15, P1811, DOI 10.1097/00002030-200109280-00010; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; den Boer MAM, 2006, ARTERIOSCL THROM VAS, V26, P124, DOI 10.1161/01.ATV.0000194073.87647.10; Despres JP, 1996, NEW ENGL J MED, V334, P952, DOI 10.1056/NEJM199604113341504; *DHHS PAN ANT GUID, GUID US ANT AG HIV 1; Dube MP, 2002, CLIN INFECT DIS, V35, P475, DOI 10.1086/341489; Dube MP, 1997, LANCET, V350, P713, DOI 10.1016/S0140-6736(05)63513-1; ELSADR W, 2006, 13 C RETR OPP INF FE; Falutz J, 2005, AIDS, V19, P1279, DOI 10.1097/01.aids.0000180099.35146.30; Fontas E, 2004, J INFECT DIS, V189, P1056, DOI 10.1086/381783; Friis-Moller N, 2003, NEW ENGL J MED, V349, P1993, DOI 10.1056/NEJMoa030218; Friis-Moller N, 2003, AIDS, V17, P1179, DOI 10.1097/00002030-200305230-00010; FRIISMOLLER N, 2006, 13 C RETR OPP INF FE; Gallant JE, 2004, JAMA-J AM MED ASSOC, V292, P191, DOI 10.1001/jama.292.2.191; Galli M, 2002, ARCH INTERN MED, V162, P2621, DOI 10.1001/archinte.162.22.2621; Gerber MT, 2004, CLIN INFECT DIS, V39, P419, DOI 10.1086/422144; GRUNFELD C, 1989, AM J MED, V86, P27, DOI 10.1016/0002-9343(89)90225-8; Guaraldi G, 2001, CLIN INFECT DIS, V33, P414, DOI 10.1086/321870; GUARALDI G, 2005, 7 WORKSH ADV DRUG RE; Hadigan C, 2004, ANN INTERN MED, V140, P786, DOI 10.7326/0003-4819-140-10-200405180-00008; Hadigan C, 2001, CLIN INFECT DIS, V32, P130, DOI 10.1086/317541; Hadigan C, 2000, JAMA-J AM MED ASSOC, V284, P472, DOI 10.1001/jama.284.4.472; Hadigan C, 2001, J CLIN ENDOCR METAB, V86, P939, DOI 10.1210/jc.86.2.939; Heath KV, 2002, J ACQ IMMUN DEF SYND, V30, P440, DOI [10.1097/00042560-200208010-00010, 10.1097/01.QAI.0000021701.48448.20]; Jemsek JG, 2006, CLIN INFECT DIS, V42, P273, DOI 10.1086/498505; Jones PH, 2005, AM J CARDIOL, V95, P120, DOI 10.1016/j.amjcard.2004.08.076; KLEIN D, 2006, 13 C RETR OPP INF FE; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Koller E, 2000, AIDS PATIENT CARE ST, V14, P405, DOI 10.1089/108729100416614; Lafaurie M, 2005, JAIDS-J ACQ IMM DEF, V38, P393, DOI 10.1097/01.qai.0000152834.02912.98; Lai KA, 2005, J BONE JOINT SURG AM, V87A, P2155, DOI 10.2106/JBJS.D.02959; LEE G, 2005, 7 WORKSH ADV DRUG RE; Lee GA, 2004, AIDS, V18, P641, DOI 10.1097/00002030-200403050-00008; Lenhard JM, 2000, ARTERIOSCL THROM VAS, V20, P2625, DOI 10.1161/01.ATV.20.12.2625; Lichtenstein K, 2006, 13 C RETR OPP INF FE; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; Lo JC, 1998, LANCET, V351, P867, DOI 10.1016/S0140-6736(97)11443-X; Mallal SA, 2000, AIDS, V14, P1309, DOI 10.1097/00002030-200007070-00002; Mallon PWG, 2003, AIDS, V17, P971, DOI 10.1097/00002030-200305020-00005; Martin A, 2004, AIDS, V18, P1029, DOI 10.1097/00002030-200404300-00011; Martinez E, 1999, AIDS, V13, P805, DOI 10.1097/00002030-199905070-00009; Martinez E, 2001, LANCET, V357, P592, DOI 10.1016/S0140-6736(00)04056-3; Mary-Krause M, 2003, AIDS, V17, P2479, DOI 10.1097/00002030-200311210-00010; McComsey GA, 2004, CLIN INFECT DIS, V38, P263, DOI 10.1086/380790; Meigs JB, 2000, JAMA-J AM MED ASSOC, V283, P221, DOI 10.1001/jama.283.2.221; Miller KD, 2002, ANN INTERN MED, V137, P17, DOI 10.7326/0003-4819-137-1-200207020-00008; Mondy K, 2003, CLIN INFECT DIS, V36, P482, DOI 10.1086/367569; Monier P, 2000, CLIN INFECT DIS, V31, P1488, DOI 10.1086/317503; MORSE C, 2005, 7 WORKSH ADV DRUG RE; Mulligan K, 2006, JAIDS-J ACQ IMM DEF, V41, P590, DOI 10.1097/01.qai.0000214811.72916.67; MULLIGAN K, 2005, 7 WORKSH ADV DRUG RE; Murata H, 2000, J BIOL CHEM, V275, P20251, DOI 10.1074/jbc.C000228200; Mussini C, 2005, AIDS, V19, P287; Nolan D, 2003, AIDS, V17, P1329, DOI 10.1097/00002030-200306130-00007; NOOR M, 2005, 7 WORKSH ADV DRUG RE; Noordam JC, 2002, J CHEMOMETR, V16, P1, DOI 10.1002/cem.656; Palacios R, 2002, J ACQ IMMUN DEF SYND, V30, P536, DOI 10.1097/00126334-200208150-00012; Palella FJ, 2004, CLIN INFECT DIS, V38, P903, DOI 10.1086/381684; Rodriguez-French A, 2004, JAIDS-J ACQ IMM DEF, V35, P22, DOI 10.1097/00126334-200401010-00003; Ruiz L, 2001, J ACQ IMMUN DEF SYND, V27, P229, DOI 10.1097/00126334-200107010-00003; Saint-Marc T, 1999, AIDS, V13, P1659, DOI 10.1097/00002030-199909100-00009; Sanne I, 2003, JAIDS-J ACQ IMM DEF, V32, P18, DOI 10.1097/00126334-200301010-00004; Schambelan M, 2002, JAIDS-J ACQ IMM DEF, V31, P257, DOI 10.1097/00126334-200211010-00001; Shankar SS, 2005, AM HEART J, V150, DOI 10.1016/j.ahj.2005.06.005; Shikuma CM, 2001, AIDS, V15, P1801, DOI 10.1097/00002030-200109280-00009; SLAMA L, 2006, 13 C RETR OPP INF FE; Stein JH, 2003, AM J CARDIOL, V92, P270, DOI 10.1016/S0002-9149(03)00622-2; Stein JH, 2001, CIRCULATION, V104, P257, DOI 10.1161/01.CIR.104.3.257; Sutinen J, 2003, ANTIVIR THER, V8, P199; Tebas P, 2000, AIDS, V14, pF63, DOI 10.1097/00002030-200003100-00005; Tien PC, 2003, JAIDS-J ACQ IMM DEF, V34, P461, DOI 10.1097/00126334-200312150-00003; van der Valk M, 2001, AIDS, V15, P847, DOI 10.1097/00002030-200105040-00005; van Leth F, 2004, PLOS MED, V1, P64, DOI 10.1371/journal.pmed.0010019; Walli R, 1998, AIDS, V12, pF167, DOI 10.1097/00002030-199815000-00001; Wanke C, 1999, AIDS, V13, P2099, DOI 10.1097/00002030-199910220-00013; Wood R, 2004, JAIDS-J ACQ IMM DEF, V36, P684, DOI 10.1097/00126334-200406010-00005; Yanovski JA, 1999, J CLIN ENDOCR METAB, V84, P1925, DOI 10.1210/jc.84.6.1925; 2006, DIABETES CARE S1, V29, pS3	95	72	75	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 16	2006	296	7					844	854		10.1001/jama.296.7.844	http://dx.doi.org/10.1001/jama.296.7.844			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	073SR	16905789				2022-12-28	WOS:000239763400024
J	Spechko, PL				Spechko, Phyllis L.			Knowing Ron	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		SPECHKO PL, 1985, JAMA-J AM MED ASSOC, V253, P985, DOI 10.1001/jama.1985.03350310067026	1	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 16	2006	296	7					738	738		10.1001/jama.296.7.738	http://dx.doi.org/10.1001/jama.296.7.738			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	073SR	16905774				2022-12-28	WOS:000239763400001
J	Wilson, JF				Wilson, Jennifer Fisher			Health Insurance Portability and Accountability Act Privacy Rule causes ongoing concerns among clinicians and researchers	ANNALS OF INTERNAL MEDICINE			English	News Item							IMPACT					jenwilson@acponline.org	Wilson, Jennifer/Q-3623-2019	Wilson, Jennifer/0000-0003-4025-3136				Armstrong D, 2005, ARCH INTERN MED, V165, P1125, DOI 10.1001/archinte.165.10.1125; Lazarus D., 2003, SAN FRANCISCO C 1022, pA; McGuire AL, 2006, SCIENCE, V312, P370, DOI 10.1126/science.1125339; Shalowitz D, 2006, ANN INTERN MED, V144, P685, DOI 10.7326/0003-4819-144-9-200605020-00012; Slutsman J, 2005, HEALTH AFFAIR, V24, P832, DOI 10.1377/hlthaff.24.3.832; Wolf MS, 2006, CANCER-AM CANCER SOC, V106, P474, DOI 10.1002/cncr.21599	6	28	28	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	2006	145	4					313	316		10.7326/0003-4819-145-4-200608150-00019	http://dx.doi.org/10.7326/0003-4819-145-4-200608150-00019			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	075CC	16908928				2022-12-28	WOS:000239858800015
J	Bonell, C; Oakley, A; Hargreaves, J; Strange, V; Rees, R				Bonell, C.; Oakley, A.; Hargreaves, J.; Strange, V.; Rees, R.			Research methodology - Assessment of generalisability in trials of health interventions: suggested framework and systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							GAY MEN; SEXUAL-BEHAVIOR; PEER EDUCATION; HIV PREVENTION; AIDS; CARE		Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; Univ London, Inst Educ, Social Sci Res Unit, London WC1E 7HU, England	University of London; London School of Hygiene & Tropical Medicine; University of London; University College London; UCL Institute of Education	Bonell, C (corresponding author), Univ London London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.	chris.bonell@lshtm.ac.uk		Hargreaves, James/0000-0002-3509-3572	Economic and Social Research Council [RES-576-25-5008] Funding Source: researchfish	Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC))		ALTMAN DG, 1995, HEALTH PSYCHOL, V14, P526, DOI 10.1037/0278-6133.14.6.526; Bartlett C, 2005, HLTH TECHNOL ASSESS, V9; Calnan M, 2003, POLICY POLIT, V31, P185, DOI 10.1332/030557303765371672; Campbell M, 2000, BRIT MED J, V321, P694, DOI 10.1136/bmj.321.7262.694; Chinnock P, 2005, PLOS MED, V2, P367, DOI 10.1371/journal.pmed.0020107; Dilley JW, 2002, J ACQ IMMUN DEF SYND, V30, P177, DOI [10.1097/01.QAI.0000016823.19906.41, 10.1097/00042560-200206010-00006]; Elford J, 2002, AIDS CARE, V14, P351, DOI 10.1080/09540120220123739; Elford J, 2001, AIDS, V15, P535, DOI 10.1097/00002030-200103090-00018; Elford J, 2000, RESEARCHING HEALTH PROMOTION, P207; Flowers P, 1999, SOC AS AIDS, P83; Flowers P, 2002, INT J STD AIDS, V13, P102, DOI 10.1258/0956462021924721; Gold RS, 1998, INT J STD AIDS, V9, P208, DOI 10.1258/0956462981922052; Grosskurth H, 2000, LANCET, V355, P1981, DOI 10.1016/S0140-6736(00)02336-9; GROSSKURTH H, 2003, EFFECTIVE SEXUAL HLT, P169; Herbert RD, 2005, BMJ-BRIT MED J, V331, P507, DOI 10.1136/bmj.331.7515.507; Imrie J, 2001, BRIT MED J, V322, P1451, DOI 10.1136/bmj.322.7300.1451; Kelly JA, 2004, AIDS CARE, V16, P139, DOI 10.1080/09540120410001640986; Kraft JM, 2000, AIDS EDUC PREV, V12, P7; Langley A, 2003, POLICY POLIT, V31, P195, DOI 10.1332/030557303765371681; MAYS N, 2005, J HEALTH SERV RES PO, V10, P6, DOI DOI 10.1258/1355819054308576; Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3; Munguti K, 1997, SOC SCI MED, V44, P1553, DOI 10.1016/S0277-9536(97)00014-2; Oakley A, 2006, BRIT MED J, V332, P413, DOI 10.1136/bmj.332.7538.413; Pawson Ray, 2005, J Health Serv Res Policy, V10 Suppl 1, P21, DOI 10.1258/1355819054308530; Picciano JF, 2001, AIDS BEHAV, V5, P251, DOI DOI 10.1023/A:1011392610578; Rees R, 2004, HIV HLTH PROMOTION M; ROSSER BRS, 2002, AIDS ED PREV SA, V14, P69; Shepherd J, 1999, SOC AS AIDS, P163; SHEPHERD J, 1997, HLTH ED, V6, P204; Weiser S, 2003, JAIDS-J ACQ IMM DEF, V34, P281, DOI 10.1097/00126334-200311010-00004	30	104	104	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 12	2006	333	7563					346	349		10.1136/bmj.333.7563.346	http://dx.doi.org/10.1136/bmj.333.7563.346			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	073VI	16902217	Green Published, Green Accepted			2022-12-28	WOS:000239770300021
J	Mellars, P				Mellars, Paul			Going east: New genetic and archaeological perspectives on the modern human colonization of Eurasia	SCIENCE			English	Review							MODERN HUMAN ORIGINS; MODERN HUMAN-BEHAVIOR; KLASIES RIVER; HOMO-SAPIENS; STONE-AGE; EVOLUTION; SOUTH; SETTLEMENT; AFRICA; NEANDERTHALS	The pattern of dispersal of biologically and behaviorally modern human populations from their African origins to the rest of the occupied world between similar to 60,000 and 40,000 years ago is at present a topic of lively debate, centering principally on the issue of single versus multiple dispersals. Here I argue that the archaeological and genetic evidence points to a single successful dispersal event, which took genetically and culturally modern populations fairly rapidly across southern and southeastern Asia into Australasia, and with only a secondary and later dispersal into Europe.	Univ Cambridge, Dept Archaeol, Cambridge CB2 3DZ, England	University of Cambridge	Mellars, P (corresponding author), Univ Cambridge, Dept Archaeol, Cambridge CB2 3DZ, England.	pam59@cam.ac.uk	Carroll, Joseph/D-1158-2011	Carroll, Joseph/0000-0003-2656-1378				Ambrose SH, 1998, J ARCHAEOL SCI, V25, P377, DOI 10.1006/jasc.1997.0277; AMBROSE SH, 2004, THINKING SMALL GLOBA, P9; BARKER G, 2002, P PREHIST SOC, V68, P147, DOI [10.1017/s0079497x00001481, DOI 10.1017/S0079497X00001481]; BARYOSEF O, 2000, GEOGRAPHY NEONDERTAL; Bowdler S, 1977, SUNDA SAHUL, P204; Bowler JM, 2003, NATURE, V421, P837, DOI 10.1038/nature01383; Brumm A, 2005, CAMB ARCHAEOL J, V15, P157, DOI 10.1017/S0959774305000089; BULBECK F, 2003, CANOPY ARCHAEOLOGY T; de Sonneville-Bordes D, 1960, PALEOLITHIQUE SUPERI; Deacon H.J., 1999, HUMAN BEGINNINGS S A; Deraniyagala S. U., 1992, PREHISTORY SRI LANKA, V2nd; DIAMOND JM, 1978, NATURE, V273, P185, DOI 10.1038/273185a0; ENDICOTT P, IN PRESS S ASIA CROS; Eswaran V, 2005, J HUM EVOL, V49, P1, DOI 10.1016/j.jhevol.2005.02.006; Eswaran V, 2002, CURR ANTHROPOL, V43, P749, DOI 10.1086/342639; Feathers JK, 2002, J ARCHAEOL SCI, V29, P177, DOI 10.1006/jasc.2001.0685; Field JS, 2005, J WORLD PREHIST, V19, P1, DOI 10.1007/s10963-005-9000-6; Flood J., 1983, ARCHAEOLOGY DREAMTIM; Foley R, 1997, CAMB ARCHAEOL J, V7, P3, DOI 10.1017/S0959774300001451; Forster P, 2005, SCIENCE, V308, P965, DOI 10.1126/science.1113261; Forster P, 2004, PHILOS T R SOC B, V359, P255, DOI 10.1098/rstb.2003.1394; Goldstein DB, 2002, ANNU REV GENOM HUM G, V3, P129, DOI 10.1146/annurev.genom.3.022502.103200; Harpending H, 2005, SCIENCE, V309, P1995; Henrich J, 2004, AM ANTIQUITY, V69, P197, DOI 10.2307/4128416; Henshilwood CS, 2002, SCIENCE, V295, P1278, DOI 10.1126/science.1067575; Hovers E, 2003, CURR ANTHROPOL, V44, P491, DOI 10.1086/375869; James HVA, 2005, CURR ANTHROPOL, V46, pS3, DOI 10.1086/444365; JOBLING M, 2004, HUMAN EVOLUTIONARY G, P15253; Jones R., 1977, EXPLORATIONS ETHNOAR, P11; Jones R., 1998, P BRIT ACAD, V99, P37; KENNEDY KAR, 1987, AM J PHYS ANTHROPOL, V72, P441, DOI 10.1002/ajpa.1330720405; Kivisild T, 2006, GENETICS, V172, P373, DOI 10.1534/genetics.105.043901; Klein R.G., 1999, HUMAN CAREER; Lahr Marta Mirazon, 1994, Evolutionary Anthropology, V3, P48, DOI 10.1002/evan.1360030206; Lahr MM, 1998, YEARB PHYS ANTHROPOL, V41, P137; Liu H, 2006, AM J HUM GENET, V79, P230, DOI 10.1086/505436; LOURANDOS H, 1997, CONTINENT HUNTERGATH; Macaulay V, 2005, SCIENCE, V308, P1034, DOI 10.1126/science.1109792; Marean C.W., 2005, TOOLS SYMBOLS EARLY, P333; McBrearty S, 2000, J HUM EVOL, V39, P453, DOI 10.1006/jhev.2000.0435; McDougall I, 2005, NATURE, V433, P733, DOI 10.1038/nature03258; Mehlman M.J., 1991, CULTURAL BEGINNINGS, P177; Mellars P, 2006, NATURE, V439, P931, DOI 10.1038/nature04521; Mellars P, 2004, NATURE, V432, P461, DOI 10.1038/nature03103; Mellars P, 2003, P BRIT ACAD, V106, P31; MELLARS PA, IN PRESS EVOL ANTHR; Mellars P, 2006, P NATL ACAD SCI USA, V103, P9381, DOI 10.1073/pnas.0510792103; Mellars Paul A., 1996, NEANDERTHAL LEGACY A; Metspalu M, 2004, BMC GENET, V5, DOI 10.1186/1471-2156-5-26; Mulvaney JK, 1999, PREHISTORY AUSTR; O'Connell JF, 2004, J ARCHAEOL SCI, V31, P835, DOI 10.1016/j.jas.2003.11.005; Oppenheimer S., 2003, PEOPLING WORLD; Parkington J.E., 2005, TOOLS SYMBOLS EARLY, P475; PETRAGLIA M, COMMUNICATION; Petraglia MD, 2003, ANTIQUITY, V77, P671, DOI 10.1017/S0003598X00061639; Prugnolle F, 2005, CURR BIOL, V15, pR159, DOI 10.1016/j.cub.2005.02.038; Quintana-Murci L, 2004, AM J HUM GENET, V74, P827, DOI 10.1086/383236; Quintana-Murci L, 1999, NAT GENET, V23, P437, DOI 10.1038/70550; Ray N, 2005, GENOME RES, V15, P1161, DOI 10.1101/gr.3708505; Richards M, 2000, AM J HUM GENET, V67, P1251, DOI 10.1016/S0002-9297(07)62954-1; Sali S.A., 1989, UPPER PALAEOLITHIC M; SAUER CARL O., 1962, PROC AMER PHIL SOC, V106, P41; SCHICK KD, 1995, MAKING SILENT STONES; SHAWCROSS W, 1998, ARCHAEOL OCEAN, V33, P103; Shea JJ, 2003, EVOL ANTHROPOL, V12, P173, DOI 10.1002/evan.10101; Singer R., 1982, MIDDLE STONE AGE KLA; Stringer C, 2000, NATURE, V405, P24, DOI 10.1038/35011166; Stringer C, 2002, PHILOS T R SOC B, V357, P563, DOI 10.1098/rstb.2001.1057; Thangaraj K, 2005, SCIENCE, V308, P996, DOI 10.1126/science.1109987; Tishkoff SA, 2002, NAT REV GENET, V3, P611, DOI 10.1038/nrg865; Tribolo C., 2005, TOOLS SYMBOLS EARLY, P493; Underhill PA, 2001, ANN HUM GENET, V65, P43, DOI 10.1046/j.1469-1809.2001.6510043.x; Vanhaeren M, 2006, SCIENCE, V312, P1785, DOI 10.1126/science.1128139; VANPEER P, 2004, ANTHROPOLOGIE, V42, P241; White TD, 2003, NATURE, V423, P742, DOI 10.1038/nature01669; Wurz S, 1999, S AFR ARCHAEOL BULL, V54, P38, DOI 10.2307/3889138	76	334	348	0	98	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 11	2006	313	5788					796	800		10.1126/science.1128402	http://dx.doi.org/10.1126/science.1128402			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	072KC	16902130				2022-12-28	WOS:000239671300048
J	Muheim, R; Phillips, JB; Akesson, S				Muheim, Rachel; Phillips, John B.; Akesson, Susanne			Polarized light cues underlie compass calibration in migratory songbirds	SCIENCE			English	Article							MAGNETIC COMPASS; SKYLIGHT POLARIZATION; CONFLICT EXPERIMENTS; CELESTIAL CUES; SUN COMPASS; EUROPEAN ROBINS; SYLVIA-BORIN; ORIENTATION; BIRDS; PATTERNS	Migratory songbirds use the geomagnetic field, stars, the Sun, and polarized light patterns to determine their migratory direction. To prevent navigational errors, it is necessary to calibrate all of these compass systems to a common reference. We show that migratory Savannah sparrows use polarized light cues from the region of sky near the horizon to recalibrate the magnetic compass at both sunrise and sunset. We suggest that skylight polarization patterns are used to derive an absolute (i.e., geographic) directional system that provides the primary calibration reference for all of the compasses of migratory songbirds.	Lund Univ, Dept Anim Ecol, SE-22362 Lund, Sweden; Virginia Polytech Inst & State Univ, Dept Biol Sci, Blacksburg, VA 24061 USA	Lund University; Virginia Polytechnic Institute & State University	Muheim, R (corresponding author), Lund Univ, Dept Anim Ecol, Ecol Bldg, SE-22362 Lund, Sweden.	rmuheim@vt.edu	Muheim, Rachel/D-3521-2009; Akesson, Susanne/F-3175-2015	Muheim, Rachel/0000-0002-2079-6443; Akesson, Susanne/0000-0001-9039-2180				ABLE KP, 1990, ANIM BEHAV, V39, P905, DOI 10.1016/S0003-3472(05)80955-8; ABLE KP, 1993, NATURE, V364, P523, DOI 10.1038/364523a0; ABLE KP, 1995, NATURE, V375, P230, DOI 10.1038/375230a0; ABLE KP, 1982, NATURE, V299, P550, DOI 10.1038/299550a0; ABLE KP, 1993, TRENDS ECOL EVOL, V8, P367, DOI 10.1016/0169-5347(93)90221-A; AKESSON S, 1994, ANIM BEHAV, V48, P1379, DOI 10.1006/anbe.1994.1374; Alerstam T, 2001, SCIENCE, V291, P300, DOI 10.1126/science.291.5502.300; ALERSTAM T, 2005, P RINO 5 C ROYAL I N, P1; Batschelet E., 1981, CIRCULAR STAT BIOL; BEASON RC, 1987, J ORNITHOL, V128, P317, DOI 10.1007/BF01640301; BINGMAN VP, 1987, AUK, V104, P523, DOI 10.2307/4087555; BINGMAN VP, 1988, ETHOLOGY, V77, P1; BINGMAN VP, 1983, BEHAVIOUR, V87, P43, DOI 10.1163/156853983X00110; BRINES ML, 1982, J EXP BIOL, V96, P69; Cochran WW, 2004, SCIENCE, V304, P405, DOI 10.1126/science.1095844; EMLEN ST, 1970, SCIENCE, V170, P1198, DOI 10.1126/science.170.3963.1198; GWINNER E, 1978, J COMP PHYSIOL, V125, P267, DOI 10.1007/BF00656605; HELBIG AJ, 1989, ETHOLOGY, V82, P307; Horvath G., 2004, POLARIZED LIGHT ANIM; Kramer G., 1949, ORNITHOLOGIE ALS BIO, P269; MOORE FR, 1987, BIOL REV, V62, P65, DOI 10.1111/j.1469-185X.1987.tb00626.x; Muheim R, 2006, J EXP BIOL, V209, P2, DOI 10.1242/jeb.01960; PHILLIPS JB, 1988, J THEOR BIOL, V131, P55, DOI 10.1016/S0022-5193(88)80120-6; PHILLIPS JB, 1992, BEHAV ECOL SOCIOBIOL, V31, P189; PRINZ K, 1992, ANIM BEHAV, V44, P539, DOI 10.1016/0003-3472(92)90063-F; Sandberg R, 2000, ANIM BEHAV, V60, P453, DOI 10.1006/anbe.2000.1582; Sauer F., 1957, Z TIERPSYCHOL, V14, P20, DOI [10.1111/j.1439-0310.1957.tb00525.x, DOI 10.1111/J.1439-0310.1957.TB00525.X]; Weindler P, 1996, NATURE, V383, P158, DOI 10.1038/383158a0; Weindler P, 1998, BEHAV ECOL SOCIOBIOL, V42, P289, DOI 10.1007/s002650050441; Weindler P., 1999, P 22 INT ORN C BIRDL, P979; WILTSCHK.W, 1972, SCIENCE, V176, P62, DOI 10.1126/science.176.4030.62; Wiltschko R, 1999, J AVIAN BIOL, V30, P56, DOI 10.2307/3677243; Wiltschko R, 2001, ANIM BEHAV, V62, P245, DOI 10.1006/anbe.2001.1751; Wiltschko W, 1998, J COMP PHYSIOL A, V182, P521, DOI 10.1007/s003590050199; Wiltschko W, 1998, J AVIAN BIOL, V29, P606, DOI 10.2307/3677181; WILTSCHKO W, 1987, ETHOLOGY, V74, P285; WILTSCHKO W, 1976, J COMP PHYSIOL, V109, P91, DOI 10.1007/BF00663437	37	183	200	7	73	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 11	2006	313	5788					837	839		10.1126/science.1129709	http://dx.doi.org/10.1126/science.1129709			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	072KC	16902138				2022-12-28	WOS:000239671300060
J	Narita, M; Narita, M; Krizhanovsky, V; Nunez, S; Chicas, A; Hearn, SA; Myers, MP; Lowe, SW				Narita, Masashi; Narita, Masako; Krizhanovsky, Vale; Nunez, Sabrina; Chicas, Agustin; Hearn, Stephen A.; Myers, Michael P.; Lowe, Scott W.			A novel role for high-mobility group A proteins in cellular senescence and heterochromatin formation	CELL			English	Article							ARCHITECTURAL TRANSCRIPTION FACTOR; HISTONE H3; GENE; CHROMATIN; GROWTH; CELLS; P53; METHYLATION; SUPPRESSION; ONSET	Cellular senescence is a stable state of proliferative arrest that provides a barrier to malignant transformation and contributes to the antitumor activity of certain chemotherapies. Senescent cells can accumulate senescence-associated heterochromatic foci (SAHFs), which may provide a chromatin buffer that prevents activation of proliferation-associated genes by mitogenic transcription factors. Surprisingly, we show that the High-Mobility Group A (HMGA) proteins, which can promote tumorigenesis, accumulate on the chromatin of senescent fibroblasts and are essential structural components of SAHFs. HMGA proteins cooperate with the p16 INK4a tumor suppressor to promote SAHF formation and proliferative arrest and stabilize senescence by contributing to the repression of proliferation-associated genes. These antiproliferative activities are canceled by coexpression of the HDM2 and CDK4 oncogenes, which are often coamplified with HMGA2 in human cancers. Our results identify a component of the senescence machinery that contributes to heterochromatin formation and imply that HMGA proteins also act in tumor suppressor networks.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Cold Spring Harbor Lab, Howard Hughes Med Inst, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory; Cold Spring Harbor Laboratory; Howard Hughes Medical Institute	Lowe, SW (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	lowe@cshl.edu	; Krizhanovsky, Valery/D-1336-2010	Narita, Masashi/0000-0001-7764-577X; Hearn, Stephen/0000-0002-2489-2424; Narita, Masako/0000-0002-9774-4908; Krizhanovsky, Valery/0000-0002-3977-5482	NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016379, R56AG016379] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA008748] Funding Source: Medline; NIA NIH HHS [AG16379] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Baldassarre G, 2001, P NATL ACAD SCI USA, V98, P7970, DOI 10.1073/pnas.141224998; Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; Ben-Porath I, 2004, J CLIN INVEST, V113, P8, DOI 10.1172/JCI200420663; Berner JM, 1997, ONCOGENE, V14, P2935, DOI 10.1038/sj.onc.1201135; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; Chadwick BP, 2003, HUM MOL GENET, V12, P2167, DOI 10.1093/hmg/ddg229; Chan HM, 2005, GENE DEV, V19, P196, DOI 10.1101/gad.1280205; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Denchi EL, 2005, MOL CELL BIOL, V25, P2660, DOI 10.1128/MCB.25.7.2660-2672.2005; Dillon N, 2004, BIOL CELL, V96, P631, DOI 10.1016/j.biolcel.2004.06.003; DIMRI GP, 1994, J BIOL CHEM, V269, P16180; Fedele M, 2006, CANCER RES, V66, P2536, DOI 10.1158/0008-5472.CAN-05-1889; Fedele M, 2005, ONCOGENE, V24, P3427, DOI 10.1038/sj.onc.1208501; Fedele M, 2002, ONCOGENE, V21, P3190, DOI 10.1038/sj.onc.1205428; Harrer M, 2004, J CELL SCI, V117, P3459, DOI 10.1242/jcs.01160; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Heard E, 2001, CELL, V107, P727, DOI 10.1016/S0092-8674(01)00598-0; Hoyos JM, 2004, CANCER RES, V64, P5728, DOI 10.1158/0008-5472.CAN-04-1410; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Munshi N, 2001, SCIENCE, V293, P1133, DOI 10.1126/science.293.5532.1133; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; RADIC MZ, 1992, CHROMOSOMA, V101, P602, DOI 10.1007/BF00360537; Reeves R, 2001, GENE, V277, P63, DOI 10.1016/S0378-1119(01)00689-8; Reeves R, 2001, MOL CELL BIOL, V21, P575, DOI 10.1128/MCB.21.2.575-594.2001; Roninson IB, 2003, CANCER RES, V63, P2705; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Seger YR, 2002, CANCER CELL, V2, P401, DOI 10.1016/S1535-6108(02)00183-6; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sgarra R, 2004, FEBS LETT, V574, P1, DOI 10.1016/j.febslet.2004.08.013; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Takaha N, 2004, PROSTATE, V60, P160, DOI 10.1002/pros.20049; Vandel L, 2001, MOL CELL BIOL, V21, P6484, DOI 10.1128/MCB.21.19.6484-6494.2001; Zhang RG, 2005, DEV CELL, V8, P19, DOI 10.1016/j.devcel.2004.10.019; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	40	444	457	0	31	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 11	2006	126	3					503	514		10.1016/j.cell.2006.05.052	http://dx.doi.org/10.1016/j.cell.2006.05.052			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	075KI	16901784	Bronze			2022-12-28	WOS:000239883400011
J	Korn, AJ; Grundahl, F; Richard, O; Barklem, PS; Mashonkina, L; Collet, R; Piskunov, N; Gustafsson, B				Korn, A. J.; Grundahl, F.; Richard, O.; Barklem, P. S.; Mashonkina, L.; Collet, R.; Piskunov, N.; Gustafsson, B.			A probable stellar solution to the cosmological lithium discrepancy	NATURE			English	Article							METAL-POOR STARS; RADIATIVE ACCELERATIONS; LI ABUNDANCE; NUCLEOSYNTHESIS; SUBGIANTS; EVOLUTION; PLATEAU; MODELS; LIGHT	The measurement of the cosmic microwave background has strongly constrained the cosmological parameters of the Universe(1). When the measured density of baryons ( ordinary matter) is combined with standard Big Bang nucleosynthesis calculations(2,3), the amounts of hydrogen, helium and lithium produced shortly after the Big Bang can be predicted with unprecedented precision(1,4). The predicted primordial lithium abundance is a factor of two to three higher than the value measured in the atmospheres of old stars(5,6). With estimated errors of 10 to 25%, this cosmological lithium discrepancy seriously challenges our understanding of stellar physics, Big Bang nucleosynthesis or both. Certain modifications to nucleosynthesis have been proposed(7), but found experimentally not to be viable(8). Diffusion theory, however, predicts atmospheric abundances of stars to vary with time(9), which offers a possible explanation of the discrepancy. Here we report spectroscopic observations of stars in the metal-poor globular cluster NGC6397 that reveal trends of atmospheric abundance with evolutionary stage for various elements. These element- specific trends are reproduced by stellar- evolution models with diffusion and turbulent mixing(10). We thus conclude that diffusion is predominantly responsible for the low apparent stellar lithium abundance in the atmospheres of old stars by transporting the lithium deep into the star.	Uppsala Univ, Dept Space Phys & Astron, S-75120 Uppsala, Sweden; Univ Aarhus, Dept Phys & Astron, DK-8000 Aarhus, Denmark; Univ Montpellier 2, CNRS, ISTEEM, UMR5024,GRAAL, F-34095 Montpellier, France; Russian Acad Sci, Inst Astron, Moscow 119017, Russia	Uppsala University; Aarhus University; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Institute of Astronomy of the Russian Academy of Sciences; Russian Academy of Sciences	Korn, AJ (corresponding author), Uppsala Univ, Dept Space Phys & Astron, Box 515, S-75120 Uppsala, Sweden.	akorn@astro.uu.se	Richard, Olivier A/B-9301-2012; Piskunov, Nikolai/U-3831-2019; Mashonkina, Lyudmila/AAZ-9318-2020	Richard, Olivier A/0000-0002-0342-5093; Piskunov, Nikolai/0000-0001-5742-7767; Korn, Andreas/0000-0002-3881-6756; Collet, Remo/0000-0001-6093-8402				ALLER LH, 1960, ASTROPHYS J, V132, P461, DOI 10.1086/146943; Alonso A, 1999, ASTRON ASTROPHYS SUP, V140, P261, DOI 10.1051/aas:1999521; Angulo C, 2005, ASTROPHYS J, V630, pL105, DOI 10.1086/491732; Barklem PS, 2003, ASTRON ASTROPHYS, V409, pL1, DOI 10.1051/0004-6361:20031199; Barklem PS, 2000, ASTRON ASTROPHYS, V363, P1091; Burles S, 2001, ASTROPHYS J, V552, pL1, DOI 10.1086/320251; Charbonnel C, 2005, SCIENCE, V309, P2189, DOI 10.1126/science.1116849; Coc A, 2004, ASTROPHYS J, V600, P544, DOI 10.1086/380121; Cohen JG, 2005, ASTRON J, V129, P303, DOI 10.1086/426369; Cyburt RH, 2003, PHYS LETT B, V567, P227, DOI 10.1016/j.physletb.2003.06.026; Frebel A, 2005, NATURE, V434, P871, DOI 10.1038/nature03455; FUHRMANN K, 1993, ASTRON ASTROPHYS, V271, P451; Gratton RG, 2001, ASTRON ASTROPHYS, V369, P87, DOI 10.1051/0004-6361:20010144; GUZIK JA, 1992, ASTROPHYS J, V386, P729, DOI 10.1086/171054; King JR, 1998, ASTRON J, V115, P666, DOI 10.1086/300209; Korn AJ, 2003, ASTRON ASTROPHYS, V407, P691, DOI 10.1051/0004-6361:20030907; MICHAUD G, 1984, ASTROPHYS J, V282, P206, DOI 10.1086/162193; Piau L, 2006, ASTROPHYS J, V653, P300, DOI 10.1086/508445; Richard O, 2005, ASTROPHYS J, V619, P538, DOI 10.1086/426470; Richard O, 2002, ASTROPHYS J, V580, P1100, DOI 10.1086/343733; Richer J, 2000, ASTROPHYS J, V529, P338, DOI 10.1086/308274; Ryan SG, 1999, ASTROPHYS J, V523, P654, DOI 10.1086/307769; SPERGEL DN, 2006, UNPUB ASTROPHYS J; SPITE M, 1982, NATURE, V297, P483, DOI 10.1038/297483a0; STROMGREN B, 1982, PUBL ASTRON SOC PAC, V94, P5, DOI 10.1086/130932; VandenBerg DA, 2002, ASTROPHYS J, V571, P487, DOI 10.1086/339895; WAGONER RV, 1967, ASTROPHYS J, V148, P3, DOI 10.1086/149126; [No title captured]	30	240	243	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 10	2006	442	7103					657	659		10.1038/nature05011	http://dx.doi.org/10.1038/nature05011			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	071UU	16900193				2022-12-28	WOS:000239630200038
J	Cowgill, KD; Ndiritu, M; Nyiro, J; Slack, MPE; Chiphatsi, S; Ismail, A; Kamau, T; Mwangi, I; English, M; Newton, CRJC; Feikin, DR; Scott, JAG				Cowgill, Karen D.; Ndiritu, Moses; Nyiro, Joyce; Slack, Mary P. E.; Chiphatsi, Salome; Ismail, Amina; Kamau, Tatu; Mwangi, Isaiah; English, Mike; Newton, Charles R. J. C.; Feikin, Daniel R.; Scott, J. Anthony G.			Effectiveness of Haemophilus influenzae type b conjugate vaccine introduction into routine childhood immunization in Kenya	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE BACTERIAL-MENINGITIS; INVASIVE DISEASE; RANDOMIZED-TRIAL; UNITED-STATES; CHILDREN; INFANTS; POLYSACCHARIDE; EFFICACY; AFRICA; GAMBIA	Context Haemophilus influenzae type b (Hib) conjugate vaccine is not perceived as a public health priority in Africa because data on Hib disease burden and vaccine effectiveness are scarce. Hib immunization was introduced in Kenyan infants in 2001. Objective To define invasive Hib disease incidence and Hib vaccine program effectiveness in Kenya. Design, Setting, and Patients Culture-based surveillance for invasive Hib disease at Kilifi District Hospital from 2000 through 2005 was linked to demographic surveillance of 38 000 children younger than 5 years in Kilifi District, Kenya. Human immunodeficiency virus (HIV) infection and Hib vaccination status were determined for children with Hib disease admitted 2002-2005. Interventions Introduction of conjugate Hib vaccine within the routine childhood immunization program at ages 6, 10, and 14 weeks beginning November 2001. Main Outcome Measures Incidence of culture-proven Hib invasive disease before and after vaccine introduction and vaccine program effectiveness. Results Prior to vaccine introduction, the median age of children with Hib was 8 months; case fatality was 23%. Among children younger than 5 years, the annual incidence of invasive Hib disease 1 year before and 1 and 3 years after vaccine introduction was 66, 47, and 7.6 per 100 000, respectively. For children younger than 2 years, incidence was 119, 82, and 16 per 100 000, respectively. In 2004-2005, vaccine effectiveness was 88% (95% confidence interval, 73%-96%) among children younger than 5 years and 87% (95% confidence interval, 66%-96%) among children younger than 2 years. Of 53 children with Hib admitted during 2002-2005, 29 (55%) were age-ineligible to have received vaccine, 12 (23%) had not been vaccinated despite being eligible, and 12 (23%) had received 2 or more doses of vaccine (2 were HIV positive). Conclusions In Kenya, introduction of Hib vaccine into the routine childhood immunization program reduced Hib disease incidence among children younger than 5 years to 12% of its baseline level. This impact was not observed until the third year after vaccine introduction.	Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England; Ctr Dis Control & Prevent, Epidem Intelligence Serv, Epidemiol Program Off, Div Appl Publ Hlth Training,Natl Ctr Infect Dis, Atlanta, GA USA; Ctr Dis Control & Prevent, Resp Dis Branch, Natl Ctr Infect Dis, Atlanta, GA USA; Kilifi Dist Hosp, Wellcome Trust Kenya Med Res Inst, Kilifi, Kenya; Kilifi Dist Hosp, Dist Publ Hlth Off, Kilifi, Kenya; Hlth Protect Agcy Ctr Infect, Resp & Systemic Infect Lab, Haemophilus Reference Unit, WHO Collaborating Ctr Haemophilus Influenzae, London, England; Minist Hlth, Kenya Expanded Programme Immunizat, Nairobi, Kenya; Univ Oxford, John Radcliffe Hosp, Dept Paediat, Oxford OX3 9DU, England; Univ London, Inst Child Hlth, London WC1N 1EH, England	University of Oxford; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Kenya Medical Research Institute; Health Protection Agency; University of Oxford; University of London; University College London	Scott, JAG (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England.	ascott@ikilifi.net	Newton, Charles RJC/B-7578-2014; Newton, Charles/V-7872-2019	Newton, Charles RJC/0000-0002-6999-5507; Newton, Charles/0000-0002-6999-5507; Cowgill, Karen/0000-0002-4188-3757	Wellcome Trust [050563, 081835, 061089] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Adegbola RA, 2005, LANCET, V366, P144, DOI 10.1016/S0140-6736(05)66788-8; Adegbola RA, 1999, LANCET, V354, P1091, DOI 10.1016/S0140-6736(99)03010-X; BARBOUR ML, 1995, J INFECT DIS, V171, P93, DOI 10.1093/infdis/171.1.93; Berkley JA, 2005, NEW ENGL J MED, V352, P39, DOI 10.1056/NEJMoa040275; Berkley JA, 2004, PEDIATRICS, V114, pE713, DOI 10.1542/peds.2004-0007; Berkley JA, 2001, LANCET, V357, P1753, DOI 10.1016/S0140-6736(00)04897-2; BIJLMER HA, 1990, J INFECT DIS, V161, P1210, DOI 10.1093/infdis/161.6.1210; Bisgard KM, 1998, EMERG INFECT DIS, V4, P229, DOI 10.3201/eid0402.980210; BLACK SB, 1991, PEDIATR INFECT DIS J, V10, P97, DOI 10.1097/00006454-199102000-00004; Campagne G, 1998, AM J TROP MED HYG, V59, P837, DOI 10.4269/ajtmh.1998.59.837; *CBS MOH ORC MACR, 2005, KEN DEM HLTH SURV 20; ESKOLA J, 1987, NEW ENGL J MED, V317, P717, DOI 10.1056/NEJM198709173171201; FALLA TJ, 1994, J CLIN MICROBIOL, V32, P2382, DOI 10.1128/JCM.32.10.2382-2386.1994; HUSSEY G, 1994, ANN TROP PAEDIATR, V14, P97, DOI 10.1080/02724936.1994.11747700; Lagos R, 1996, PEDIATR INFECT DIS J, V15, P216, DOI 10.1097/00006454-199603000-00008; Lagos R, 1998, LANCET, V351, P1472, DOI 10.1016/S0140-6736(97)07456-4; Madhi SA, 2005, VACCINE, V23, P5517, DOI 10.1016/j.vaccine.2005.07.038; Moulton LH, 2000, INT J EPIDEMIOL, V29, P753, DOI 10.1093/ije/29.4.753; Mulholland K, 1997, LANCET, V349, P1191, DOI 10.1016/S0140-6736(96)09267-7; Mulholland K, 1999, EPIDEMIOL REV, V21, P43, DOI 10.1093/oxfordjournals.epirev.a017987; MURPHY TV, 1993, JAMA-J AM MED ASSOC, V269, P246, DOI 10.1001/jama.269.2.246; Mwangi I, 2002, PEDIATR INFECT DIS J, V21, P1042, DOI 10.1097/00006454-200211000-00013; Ndiritu M, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-132; NEWELL C, 1988, METHODS MODELS DEMOG, P180; Peltola H, 2000, CLIN MICROBIOL REV, V13, P302, DOI 10.1128/CMR.13.2.302-317.2000; PELTOLA H, 1992, LANCET, V340, P592, DOI 10.1016/0140-6736(92)92117-X; SANTOSHAM M, 1991, NEW ENGL J MED, V324, P1767, DOI 10.1056/NEJM199106203242503; SNOW RW, 1994, INT J EPIDEMIOL, V23, P1013, DOI 10.1093/ije/23.5.1013; Sow SO, 2005, PEDIATR INFECT DIS J, V24, P533, DOI 10.1097/01.inf.0000164768.28135.0d; URWIN G, 1994, BRIT MED J, V309, P1412, DOI 10.1136/bmj.309.6966.1412; *US BUR CENS POP D, INT DAT BAS	31	136	136	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 9	2006	296	6					671	678		10.1001/jama.296.6.671	http://dx.doi.org/10.1001/jama.296.6.671			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	071LN	16896110	Green Accepted, Bronze			2022-12-28	WOS:000239603800029
J	Gayle, HD				Gayle, Helene D.			AIDS anniversaries in 2006 mark the time to deliver	LANCET			English	Editorial Material									Int AIDS Soc, CH-1216 Cointrin, Switzerland		Gayle, HD (corresponding author), Int AIDS Soc, CH-1216 Cointrin, Switzerland.	Hgayle@care.org						[Anonymous], 1981, MORBIDITY MORTALITY, V30, P250; G GLEN, 2005, GLEN COMM AFR CLIM C; Gayle HD, 2003, NEW ENGL J MED, V348, P1802, DOI 10.1056/NEJMsb030352; *GLOB FUND FIGHT A, HOW FUND WORKS; *GLOB HIV PREV WOR, 2002, GLOB MOB HIV PREV BL; Global HIV Prevention Working Group, 2004, HIV PREV ER EXP TREA; *INT AIDS SOC, FUT DIR PROJ MAX IMP; Salomon JA, 2005, PLOS MED, V2, P50, DOI 10.1371/journal.pmed.0020016; Schwartlander B, 2001, SCIENCE, V292, P2434, DOI 10.1126/science.1062876; *UNAIDS WHO, 2006, PROGR GLOB ACC HIV A; *UNAIDS WHO, 2005, AIDS EP UPD SPEC REP; United Nations General Assembly, 2001, DECL COMM HIV AIDS	12	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 5	2006	368	9534					425	427		10.1016/S0140-6736(06)69127-7	http://dx.doi.org/10.1016/S0140-6736(06)69127-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	071AL	16890809				2022-12-28	WOS:000239569000004
J	Khakh, BS; North, RA				Khakh, Baljit S.; North, R. Alan			P2X receptors as cell-surface ATP sensors in health and disease	NATURE			English	Review							NICOTINIC ACETYLCHOLINE-RECEPTOR; EXTRACELLULAR ATP; ADENOSINE-TRIPHOSPHATE; MEDIATED ENHANCEMENT; EXCITATORY SYNAPSES; GLUTAMATE RELEASE; STRUCTURAL MOTIF; BINDING-SITE; CHANNEL; SUBUNITS	P2X receptors are membrane ion channels activated by the binding of extracellular adenosine triphosphate ( ATP). For years their functional significance was consigned to distant regions of the autonomic nervous system, but recent work indicates several further key roles, such as afferent signalling, chronic pain, and in autocrine loops of endothelial and epithelial cells. P2X receptors have a molecular architecture distinct from other ion channel protein families, and have several unique functional properties.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA; Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England	MRC Laboratory Molecular Biology; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Manchester	Khakh, BS (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	bkhakh@mednet.ucla.edu; r.a.north@manchester.ac.uk	North, Richard/GQA-6156-2022		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Agboh KC, 2004, J BIOL CHEM, V279, P41650, DOI 10.1074/jbc.M408203200; Barrera NP, 2005, J BIOL CHEM, V280, P10759, DOI 10.1074/jbc.M412265200; BLEEHEN T, 1977, PAIN, V3, P367, DOI 10.1016/0304-3959(77)90066-5; Bo XN, 2003, MOL PHARMACOL, V63, P1407, DOI 10.1124/mol.63.6.1407; Bowser DN, 2004, J NEUROSCI, V24, P8606, DOI 10.1523/JNEUROSCI.2660-04.2004; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; BURNSTOCK G, 1972, PHARMACOL REV, V24, P509; Chaumont S, 2004, J BIOL CHEM, V279, P29628, DOI 10.1074/jbc.M403940200; CHEN CC, 1995, NATURE, V377, P428, DOI 10.1038/377428a0; Chessell IP, 2005, PAIN, V114, P386, DOI 10.1016/j.pain.2005.01.002; Cockayne DA, 2000, NATURE, V407, P1011, DOI 10.1038/35039519; COCKCROFT S, 1979, NATURE, V279, P541, DOI 10.1038/279541a0; Coull JAM, 2005, NATURE, V438, P1017, DOI 10.1038/nature04223; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Denlinger LC, 2001, J IMMUNOL, V167, P1871, DOI 10.4049/jimmunol.167.4.1871; Ding S, 1999, J MEMBRANE BIOL, V172, P215, DOI 10.1007/s002329900598; Doyle DA, 2004, MOL MEMBR BIOL, V21, P221, DOI 10.1080/09687680410001716844; Doyle DA, 2004, TRENDS NEUROSCI, V27, P298, DOI 10.1016/j.tins.2004.04.004; Dulla CG, 2005, NEURON, V48, P1011, DOI 10.1016/j.neuron.2005.11.009; EDWARDS FA, 1992, NATURE, V359, P144, DOI 10.1038/359144a0; Egan TM, 2004, J NEUROSCI, V24, P3413, DOI 10.1523/JNEUROSCI.5429-03.2004; Eickhorst AN, 2002, J GEN PHYSIOL, V120, P119, DOI 10.1085/jgp.20028535; Elliott JI, 2005, NAT CELL BIOL, V7, P808, DOI 10.1038/ncb1279; Finger TE, 2005, SCIENCE, V310, P1495, DOI 10.1126/science.1118435; Fisher JA, 2004, J NEUROSCI, V24, P10475, DOI 10.1523/JNEUROSCI.3250-04.2004; Galligan JJ, 2004, BRIT J PHARMACOL, V141, P1294, DOI 10.1038/sj.bjp.0705761; Gordon GRJ, 2005, NAT NEUROSCI, V8, P1078, DOI 10.1038/nn1498; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; Gourine AV, 2005, J PHYSIOL-LONDON, V568, P715, DOI 10.1113/jphysiol.2005.095968; Gourine AV, 2005, NATURE, V436, P108, DOI 10.1038/nature03690; Gu JGG, 1997, NATURE, V389, P749, DOI 10.1038/39639; Hamilton SG, 2000, BRAIN, V123, P1238, DOI 10.1093/brain/123.6.1238; HOLTON P, 1959, J PHYSIOL-LONDON, V145, P494, DOI 10.1113/jphysiol.1959.sp006157; Jarvis MF, 2002, P NATL ACAD SCI USA, V99, P17179, DOI 10.1073/pnas.252537299; Jiang LH, 2005, AM J PHYSIOL-CELL PH, V289, pC1295, DOI 10.1152/ajpcell.00253.2005; Jiang LH, 2003, J NEUROSCI, V23, P8903; Jo YH, 2002, J NEUROSCI, V22, P4794, DOI 10.1523/JNEUROSCI.22-12-04794.2002; Jo YH, 1999, NAT NEUROSCI, V2, P241, DOI 10.1038/6344; Kawamura M, 2004, J NEUROSCI, V24, P10835, DOI 10.1523/JNEUROSCI.3028-04.2004; Ke HZ, 2003, MOL ENDOCRINOL, V17, P1356, DOI 10.1210/me.2003-0021; KHAKH BS, 1995, J PHYSIOL-LONDON, V484, P385, DOI 10.1113/jphysiol.1995.sp020672; Khakh BS, 2003, J NEUROSCI, V23, P7426; Khakh BS, 1999, NAT NEUROSCI, V2, P322, DOI 10.1038/7233; Khakh BS, 1998, MOL PHARMACOL, V54, P372, DOI 10.1124/mol.54.2.372; Kim M, 2001, EMBO J, V20, P6347, DOI 10.1093/emboj/20.22.6347; Kirkup AJ, 1999, J PHYSIOL-LONDON, V520, P551, DOI 10.1111/j.1469-7793.1999.00551.x; Labasi JM, 2002, J IMMUNOL, V168, P6436, DOI 10.4049/jimmunol.168.12.6436; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; Ma WY, 2006, J PHYSIOL-LONDON, V571, P503, DOI 10.1113/jphysiol.2005.103408; Madden DR, 2002, NAT REV NEUROSCI, V3, P91, DOI 10.1038/nrn725; Masin M, 2006, J BIOL CHEM, V281, P4100, DOI 10.1074/jbc.M507735200; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Miyazawa A, 1999, J MOL BIOL, V288, P765, DOI 10.1006/jmbi.1999.2721; Mulryan K, 2000, NATURE, V403, P86, DOI 10.1038/47495; Nagaya N, 2005, J BIOL CHEM, V280, P25982, DOI 10.1074/jbc.M504545200; Nakatsuka T, 2001, J NEUROSCI, V21, P6522, DOI 10.1523/JNEUROSCI.21-17-06522.2001; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; North R Alan, 2003, Curr Opin Investig Drugs, V4, P833; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Pankratov YV, 2002, J NEUROSCI, V22, P8363; Ralevic V, 1998, PHARMACOL REV, V50, P413; Ren JH, 2003, J PHYSIOL-LONDON, V552, P809, DOI 10.1113/jphysiol.2003.047944; Roberts JA, 2004, J BIOL CHEM, V279, P9043, DOI 10.1074/jbc.M308964200; Royle SJ, 2002, J BIOL CHEM, V277, P35378, DOI 10.1074/jbc.M204844200; Rubio ME, 2001, J NEUROSCI, V21, P641, DOI 10.1523/JNEUROSCI.21-02-00641.2001; Shigetomi E, 2004, J NEUROSCI, V24, P3125, DOI 10.1523/JNEUROSCI.0090-04.2004; Solle M, 2001, J BIOL CHEM, V276, P125, DOI 10.1074/jbc.M006781200; Souslova V, 2000, NATURE, V407, P1015, DOI 10.1038/35039526; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Tsuda M, 2003, NATURE, V424, P778, DOI 10.1038/nature01786; Unwin N, 2005, J MOL BIOL, V346, P967, DOI 10.1016/j.jmb.2004.12.031; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; Virginio C, 1999, NAT NEUROSCI, V2, P315, DOI 10.1038/7225; Wang XH, 2004, NAT MED, V10, P821, DOI 10.1038/nm1082; WIERASZKO A, 1989, BRAIN RES, V485, P244, DOI 10.1016/0006-8993(89)90567-2; Yamamoto K, 2006, NAT MED, V12, P133, DOI 10.1038/nm1338; Zimmermann H, 2000, N-S ARCH PHARMACOL, V362, P299, DOI 10.1007/s002100000309	77	660	692	2	78	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 3	2006	442	7102					527	532		10.1038/nature04886	http://dx.doi.org/10.1038/nature04886			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	069NQ	16885977				2022-12-28	WOS:000239455900035
J	Lee, J; Fujita, K; McElroy, K; Slezak, JA; Wang, M; Aiura, Y; Bando, H; Ishikado, M; Masui, T; Zhu, JX; Balatsky, AV; Eisaki, H; Uchida, S; Davis, JC				Lee, Jinho; Fujita, K.; McElroy, K.; Slezak, J. A.; Wang, M.; Aiura, Y.; Bando, H.; Ishikado, M.; Masui, T.; Zhu, J. -X.; Balatsky, A. V.; Eisaki, H.; Uchida, S.; Davis, J. C.			Interplay of electron-lattice interactions and superconductivity in Bi2Sr2CaCu2O8+delta	NATURE			English	Article							TRANSITION-TEMPERATURE SUPERCONDUCTOR; COPPER-OXIDE SUPERCONDUCTORS; LINE-SHAPE; T-C; DISPERSION; EXCITATIONS; SPECTROSCOPY	Formation of electron pairs is essential to superconductivity. For conventional superconductors, tunnelling spectroscopy has established that pairing is mediated by bosonic modes (phonons); a peak in the second derivative of tunnel current d(2)I/dV(2) corresponds to each phonon mode(1-3). For high-transition-temperature (high-T-c) superconductivity, however, no boson mediating electron pairing has been identified. One explanation could be that electron pair formation(4) and related electron - boson interactions are heterogeneous at the atomic scale and therefore challenging to characterize. However, with the latest advances in d(2)I/dV(2) spectroscopy using scanning tunnelling microscopy, it has become possible to study bosonic modes directly at the atomic scale(5). Here we report d(2)I/dV(2) imaging(6-8) studies of the high-T-c superconductor Bi2Sr2CaCu2O8+delta. We find intense disorder of electron - boson interaction energies at the nanometre scale, along with the expected modulations in d(2) I/dV(2) ( refs 9, 10). Changing the density of holes has minimal effects on both the average mode energies and the modulations, indicating that the bosonic modes are unrelated to electronic or magnetic structure. Instead, the modes appear to be local lattice vibrations, as substitution of O-18 for O-16 throughout the material reduces the average mode energy by approximately 6 per cent - the expected effect of this isotope substitution on lattice vibration frequencies(5). Significantly, the mode energies are always spatially anticorrelated with the superconducting pairing-gap energies, suggesting an interplay between these lattice vibration modes and the superconductivity.	Cornell Univ, Dept Phys, LASSP, Ithaca, NY 14853 USA; Univ Tokyo, Dept Phys, Tokyo 1138656, Japan; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Mat Sci, Berkeley, CA 94720 USA; AIST, Tsukuba, Ibaraki 3058568, Japan; Osaka Univ, Dept Phys, Osaka 5600043, Japan; Los Alamos Natl Lab, Div Theoret, Los Alamos, NM 87545 USA	Cornell University; University of Tokyo; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; National Institute of Advanced Industrial Science & Technology (AIST); Osaka University; United States Department of Energy (DOE); Los Alamos National Laboratory	Davis, JC (corresponding author), Cornell Univ, Dept Phys, LASSP, Ithaca, NY 14853 USA.	jcdavis@ccmr.cornell.edu	Aiura, Yoshihiro/K-8382-2018; mcelroy, kyle/D-1816-2013; Eisaki, Hiroshi/F-6317-2018	Aiura, Yoshihiro/0000-0002-4478-7680; Eisaki, Hiroshi/0000-0002-8299-6416; McElroy, Kyle/0000-0003-4799-2820; Zhu, Jianxin/0000-0001-7991-3918				Balatsky AV, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.214506; Bogdanov PV, 2000, PHYS REV LETT, V85, P2581, DOI 10.1103/PhysRevLett.85.2581; Borisenko SV, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.207001; Carbotte JP, 1999, NATURE, V401, P354, DOI 10.1038/43843; CARBOTTE JP, 1990, REV MOD PHYS, V62, P1027, DOI 10.1103/RevModPhys.62.1027; Cuk T, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.117003; Egami T, 2001, AIP CONF PROC, V554, P38, DOI 10.1063/1.1363057; ELIASHBERG GM, 1960, SOV PHYS JETP-USSR, V11, P696; Gromko AD, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.174520; Gweon GH, 2004, NATURE, V430, P187, DOI 10.1038/nature02731; Han JH, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.094506; Hayden SM, 2004, NATURE, V429, P531, DOI 10.1038/nature02576; Hwang J, 2004, NATURE, V427, P714, DOI 10.1038/nature02347; Johnson PD, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.177007; Kaminski A, 2001, PHYS REV LETT, V86, P1070, DOI 10.1103/PhysRevLett.86.1070; Lanzara A, 2001, NATURE, V412, P510, DOI 10.1038/35087518; McMillan W., 1969, SUPERCONDUCTIVITY, V1, P561; McQueeney RJ, 1999, PHYS REV LETT, V82, P628, DOI 10.1103/PhysRevLett.82.628; Miyakawa N, 1999, PHYS REV LETT, V83, P1018, DOI 10.1103/PhysRevLett.83.1018; Morr DK, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.060505; Norman MR, 1997, PHYS REV LETT, V79, P3506, DOI 10.1103/PhysRevLett.79.3506; Nunner TS, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.177003; PILGRAM S, 2006, ROLE INELASTIC TUNNE; Reznik D, 2006, NATURE, V440, P1170, DOI 10.1038/nature04704; ROMANO P, 2006, MODELLING STUDY DIP; Scalapino D. J., 1969, Superconductivity vol 1, P449; Sidis Y, 2004, PHYS STATUS SOLIDI B, V241, P1204, DOI 10.1002/pssb.200304498; Stipe BC, 1998, SCIENCE, V280, P1732, DOI 10.1126/science.280.5370.1732; Tranquada JM, 2004, NATURE, V429, P534, DOI 10.1038/nature02574; Zhu JX, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.017002; ZHU JX, 2005, EFFECTS TAU SCATTERI; ZHU JX, 2006, LOCAL STRONG COUPLIN	32	300	303	0	75	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 3	2006	442	7102					546	550		10.1038/nature04973	http://dx.doi.org/10.1038/nature04973			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	069NQ	16885980	Green Submitted			2022-12-28	WOS:000239455900039
J	Stafford, N				Stafford, Ned			Gas for the greenhouse	NATURE			English	News Item																			0	0	0	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 3	2006	442	7102					499	499		10.1038/442499a	http://dx.doi.org/10.1038/442499a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	069NQ	16885956	Bronze			2022-12-28	WOS:000239455900013
J	McClellan, JM; Susser, E; King, MC				McClellan, Jack M.; Susser, Ezra; King, Mary-Claire			Maternal famine, de novo mutations, and schizophrenia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HUMAN GENOME; FOLIC-ACID; PRENATAL FAMINE; DISEASE; RISK; POLYMORPHISM; FOLATE		Univ Washington, Dept Psychiat, Seattle, WA 98195 USA; Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA; New York State Psychiat Inst & Hosp, New York, NY 10032 USA; Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA USA	University of Washington; University of Washington Seattle; Columbia University; New York State Psychiatry Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	McClellan, JM (corresponding author), Univ Washington, Dept Psychiat, Box 356560, Seattle, WA 98195 USA.	drjack@u.washington.edu		King, Mary-Claire/0000-0001-9426-1743				Beetstra S, 2005, MUTAT RES-FUND MOL M, V578, P317, DOI 10.1016/j.mrfmmm.2005.05.012; Botstein D, 2003, NAT GENET, V33, P228, DOI 10.1038/ng1090; Callinan PA, 2006, HUM MOL GENET, V15, pR95, DOI 10.1093/hmg/ddl095; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; Crow JF, 2000, NAT REV GENET, V1, P40, DOI 10.1038/35049558; Goldstein DB, 2003, COLD SPRING HARB SYM, V68, P395, DOI 10.1101/sqb.2003.68.395; Gottesman I.I., 1982, SCHIZOPHRENIA EPIGEN; HOEK H, 1999, PRENATAL EXPOSURES S; KING MC, 2006, PSYCHIAT EPIDEMIOLOG; Lewis SJ, 2005, AM J MED GENET B, V135B, P2, DOI 10.1002/ajmg.b.30170; Lucock M, 2004, BMJ-BRIT MED J, V328, P211, DOI 10.1136/bmj.328.7433.211; Lucock M, 2000, MOL GENET METAB, V71, P121, DOI 10.1006/mgme.2000.3027; Malaspina D, 2001, ARCH GEN PSYCHIAT, V58, P361, DOI 10.1001/archpsyc.58.4.361; McKay JA, 2004, BIOCHEM SOC T, V32, P1006, DOI 10.1042/BST0321006; Murray R. M., 2002, EPIDEMIOLOGY SCHIZOP; Nimgaonkar VL, 1998, ACTA PSYCHIAT SCAND, V98, P348, DOI 10.1111/j.1600-0447.1998.tb10097.x; Picker JD, 2005, HARVARD REV PSYCHIAT, V13, P197, DOI 10.1080/10673220500243372; Sebat J, 2004, SCIENCE, V305, P525, DOI 10.1126/science.1098918; Sharp AJ, 2005, AM J HUM GENET, V77, P78, DOI 10.1086/431652; Smil V, 1999, BMJ-BRIT MED J, V319, P1619, DOI 10.1136/bmj.319.7225.1619; Spiegelstein O, 2004, NEUROCHEM RES, V29, P1105, DOI 10.1023/B:NERE.0000023597.37698.13; St Clair D, 2005, JAMA-J AM MED ASSOC, V294, P557, DOI 10.1001/jama.294.5.557; Stein Z., 1975, FAMINE HUM DEV DUTCH; Susser E, 1998, AM J EPIDEMIOL, V147, P213; Susser E, 1996, ARCH GEN PSYCHIAT, V53, P25	25	52	52	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 2	2006	296	5					582	584		10.1001/jama.296.5.582	http://dx.doi.org/10.1001/jama.296.5.582			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	069YW	16882967				2022-12-28	WOS:000239486900025
J	van Griensven, F; Chakkraband, MLS; Thienkrua, W; Pengjuntr, W; Cardozo, BL; Tantipiwatanaskul, P; Mock, PA; Ekassawin, S; Varangrat, A; Gotway, C; Sabin, M; Tappero, JW				van Griensven, Frits; Chakkraband, M. L. Somchai; Thienkrua, Warunee; Pengjuntr, Wachira; Lopes Cardozo, Barbara; Tantipiwatanaskul, Prawate; Mock, Philip A.; Ekassawin, Suparat; Varangrat, Anchalee; Gotway, Carol; Sabin, Miriam; Tappero, Jordan W.		Thailand Post-Tsunami Mental	Mental health problems among adults in tsunami-affected areas in southern Thailand	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTTRAUMATIC-STRESS-DISORDER; HOPKINS SYMPTOM CHECKLIST-25; HARVARD TRAUMA QUESTIONNAIRE; 10 COUNTRIES; EARTHQUAKE; REFUGEES; TORTURE; SF-36; DEPRESSION; INSTRUMENT	Context On December 26, 2004, an undersea earthquake occurred off the northwestern coast of Sumatra, Indonesia. The tsunami that followed severely affected all 6 southwestern provinces of Thailand, where 5395 individuals died, 2991 were unaccounted for, and 8457 were injured. Objective To assess the prevalence of symptoms of posttraumatic stress disorder (PTSD), anxiety, and depression among individuals residing in areas affected by the tsunami in southern Thailand as part of a public health emergency response and rapid assessment. Design, Setting, and Participants A multistage, cluster, population-based mental health survey was conducted from February 15 to 22, 2005, of random samples of displaced (n=371) and nondisplaced persons in Phang Nga province (n=322) and nondisplaced persons in the provinces of Krabi and Phuket (n=368). Data were collected using an interviewer-administered questionnaire on handheld computers. A surveillance follow-up survey of the displaced persons (n=371) and nondisplaced persons (n=322) in Phang Na was conducted in September 2005. Main Outcomes Measures Medical Outcomes Study-36 Short-Form Health Survey SF-36 to assess self-perceived general health, bodily pain, and social and emotional functioning; the Harvard Trauma Questionnaire to assess tsunami-specific traumatic events; and the Hopkins Checklist-25 to detect symptoms of anxiety and depression. Results Participation rates for displaced and nondisplaced persons in the rapid assessment survey were 69% and 58%, respectively. Symptoms of PTSD were reported by 12% of displaced and 7% of nondisplaced persons in Phang Nga and 3% of nondisplaced persons in Krabi and Phuket. Anxiety symptoms were reported by 37% of displaced and 30% of nondisplaced persons in Phang Nga and 22% of nondisplaced persons in Krabi and Phuket. Symptoms of depression were reported by 30% of displaced and 21% of nondisplaced persons in Phang Nga and 10% of nondisplaced persons in Krabi and Phuket. In multivariate analysis, loss of livelihood was independently and significantly associated with symptoms of all 3 mental health outcomes (PTSD, anxiety, and depression). In the 9-month follow-up surveillance survey of 270 (73%) displaced and 250 (80%) nondisplaced participants in Phang Nga, prevalence rates of symptoms of PTSD, anxiety, and depression among displaced persons decreased to 7%, 24.8%, and 16.7%, respectively, and among nondisplaced persons, prevalence rates decreased to 2.3%, 25.9%, and 14.3%, respectively. Conclusions Among survivors of the tsunami in southern Thailand, elevated rates of symptoms of PTSD, anxiety, and depression were reported 8 weeks after the disaster, with higher rates for anxiety and depression than PTSD symptoms. Nine months after the disaster, the rates of those reporting these symptoms decreased but were still elevated. This information is important for directing, strengthening, and evaluating posttsunami mental health needs and interventions.	Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA; Thailand Minist Publ Hlth US Ctr Dis Control & Pr, Nonthaburi, Thailand; Thailand Minist Publ Hlth, Dept Mental Hlth, Nonthaburi, Thailand	Centers for Disease Control & Prevention - USA; Ministry of Public Health - Thailand; Ministry of Public Health - Thailand	Cardozo, BL (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, 1600 Clifton Rd NE,Mailstop E-97, Atlanta, GA 30333 USA.	bhc8@cdc.gov	; van Griensven, Frits/G-4719-2013	Sabin, Miriam/0000-0002-7758-8338; van Griensven, Frits/0000-0002-0971-2843				American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Babbie E., 2010, PRACTICE SOCIAL RES, V10th; Basoglu M, 2004, J TRAUMA STRESS, V17, P133, DOI 10.1023/B:JOTS.0000022619.31615.e8; Cardozo BL, 2000, JAMA-J AM MED ASSOC, V284, P569, DOI 10.1001/jama.284.5.569; Cardozo BL, 2004, JAMA-J AM MED ASSOC, V292, P575, DOI 10.1001/jama.292.5.575; Cardozo BL, 2004, SOC SCI MED, V58, P2637, DOI 10.1016/j.socscimed.2003.09.024; *CDCP, 2005, MMWR-MORBID MORTAL W, V54, P349; Centers for Disease Control and Prevention (CDC), 2005, MMWR Morb Mortal Wkly Rep, V54, P61; Chang CM, 2005, J NERV MENT DIS, V193, P40, DOI 10.1097/01.nmd.0000149217.67211.ab; DEROGATIS LR, 1974, BEHAV SCI, V19, P1, DOI 10.1002/bs.3830190102; Fawzi MCS, 1997, ACTA PSYCHIAT SCAND, V95, P87, DOI 10.1111/j.1600-0447.1997.tb00379.x; Gandek, 1997, SF 36 HLTH SURVEY MA; Goenjian AK, 2000, AM J PSYCHIAT, V157, P911, DOI 10.1176/appi.ajp.157.6.911; Holtz TH, 1998, J NERV MENT DIS, V186, P24, DOI 10.1097/00005053-199801000-00005; Kilic C, 2003, ACTA PSYCHIAT SCAND, V108, P232, DOI 10.1034/j.1600-0447.2003.00119.x; Kleijn WC, 2001, PSYCHOL REP, V88, P527, DOI 10.2466/PR0.88.2.527-532; Lee Insook, 2003, Taehan Kanho Hakhoe Chi, V33, P829; MOLLICA RF, 1992, J NERV MENT DIS, V180, P111, DOI 10.1097/00005053-199202000-00008; MOLLICA RF, 1987, AM J PSYCHIAT, V144, P497; Mollica RF, 2004, LANCET, V364, P2058, DOI 10.1016/S0140-6736(04)17519-3; Mollica RF, 1999, JAMA-J AM MED ASSOC, V282, P433, DOI 10.1001/jama.282.5.433; MOLLICA RF, 1993, JAMA-J AM MED ASSOC, V270, P581, DOI 10.1001/jama.270.5.581; Mulder Niels, 2000, INSIDE THAI SOC RELI; Norris FH, 2004, J TRAUMA STRESS, V17, P283, DOI 10.1023/B:JOTS.0000038476.87634.9b; Shrestha NM, 1998, JAMA-J AM MED ASSOC, V280, P443, DOI 10.1001/jama.280.5.443; *US AG INT DEV, IND OC EARTHQ TSUN; *US LIB C, BUDDH DOCTR POP REL; Wagner AK, 1998, J CLIN EPIDEMIOL, V51, P925, DOI 10.1016/S0895-4356(98)00083-3; Wang XD, 2000, AM J PSYCHIAT, V157, P1260, DOI 10.1176/appi.ajp.157.8.1260; Ware JE, 1998, J CLIN EPIDEMIOL, V51, P1159, DOI 10.1016/S0895-4356(98)00107-3; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Ware Jr JE, 2001, SCORE VERSION 2 SF 3; *WHO, EM PREP RESP SE AS E; WHO, MENT HLTH ASS POP AF	34	231	236	6	28	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 2	2006	296	5					537	548		10.1001/jama.296.5.537	http://dx.doi.org/10.1001/jama.296.5.537			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	069YW	16882960	Bronze			2022-12-28	WOS:000239486900018
J	Arnlov, J; Pencina, MJ; Amin, S; Nam, BH; Benjamin, EJ; Murabito, JM; Wang, TJ; Knapp, PE; D'Agostino, RB; Bhasin, S; Vasan, RS				Arnlov, Johan; Pencina, Michael J.; Amin, Shreyasee; Nam, Byung-Ho; Benjamin, Emelia J.; Murabito, Joanne M.; Wang, Thomas J.; Knapp, Philip E.; D'Agostino, Ralph B., Sr.; Bhasin, Shalendar; Vasan, Ramachandran S.			Endogenous sex hormones and cardiovascular disease incidence in men	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY-ARTERY-DISEASE; ISCHEMIC-HEART-DISEASE; ALPHA GENE VARIATION; MIDDLE-AGED MEN; DEHYDROEPIANDROSTERONE-SULFATE; MYOCARDIAL-INFARCTION; RISK-FACTORS; ELDERLY MEN; FREE TESTOSTERONE; ESTROGEN	Background: Data suggest that endogenous sex hormones (testosterone, dehydroepiandrosterone sulfate [DHEA-S], and estradiol) influence cardiovascular disease (CVD) risk factors and vascular function. Yet, prospective studies relating sex hormones to CVD incidence in men have yielded inconsistent results. Objective: To examine the association of circulating sex hormone levels and CVD risk in men. Design: Prospective cohort study. Setting: Community-based study in Framingham, Massachusetts. Participants: 2084 middle-aged white men without CVD at baseline. Measurements: The authors used multivariable Cox regression to relate baseline levels of testosterone, DHEA-S, and estradiol to the incidence of CVD (coronary, cerebrovascular, or peripheral vascular disease or heart failure) during 10 years of follow-up. Results: During follow-up, 386 men (18.5%) experienced a first CVD event. After adjustment for baseline standard CVD risk factors, higher estradiol level was associated with lower risk for CVD (hazard ratio per SD increment in log estradiol, 0.90 [95% Cl, 0.82 to 0.99]; P = 0.035). The authors observed effect modification by age: Higher estradiol levels were associated with lower CVD risk in older (median age > 56 years) men (hazard ratio per SD increment, 0.86 [Cl, 0.78 to 0.96]; P = 0.005) but not in younger (median age <= 56 years) men (hazard ratio per SD increment, 1.11 [Cl, 0.89 to 1.38]; P = 0.36). The association of higher estradiol level with lower CVD incidence remained robust in time-dependent Cox models (updating standard CVD risk factors during follow-up). Serum testosterone and DHEA-S levels were not statistically significantly associated with incident CVD. Limitations: Sex hormone levels were measured only at baseline, and the findings may not be generalizable to women and nonwhite people. Conclusions: In the community-based sample, a higher serum estradiol level was associated with lower risk for CVD events in older men. The findings are consistent with the hypothesis that endogenous estrogen has vasculoprotective influences in men.	Boston Univ, Sch Med, Framingham Heart Study, Massachusetts Gen Hosp, Framingham, MA 01702 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Mayo Clin, Coll Med, Rochester, MN USA; Uppsala Univ, Uppsala, Sweden; NHLBI, Framingham Heart Study, NIH, Bethesda, MD 20892 USA	Boston University; Framingham Heart Study; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Mayo Clinic; Uppsala University; Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Vasan, RS (corresponding author), Boston Univ, Sch Med, Framingham Heart Study, Massachusetts Gen Hosp, 73 Mt Wayte Ave,Suite 2, Framingham, MA 01702 USA.	vasan@bu.edu	Ärnlöv, Johan/AAF-2746-2019; Ramachandran, Vasan/Y-2527-2019; Benjamin, Emelia/E-7103-2011	Ärnlöv, Johan/0000-0002-6933-4637; Ramachandran, Vasan/0000-0001-7357-5970; Murabito, Joanne/0000-0002-0192-7516; Knapp, Philip/0000-0002-5290-6125; Pencina, Michael/0000-0001-5798-8855; Benjamin, Emelia/0000-0003-4076-2336	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC025195] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL074077, K24HL004334] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017950] Funding Source: NIH RePORTER; NHLBI NIH HHS [2K24 HL04334, N01-HC-25195, K23 HL074077] Funding Source: Medline; NINDS NIH HHS [6R01-NS 17950] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abate N, 2002, J CLIN ENDOCR METAB, V87, P4522, DOI 10.1210/jc.2002-020567; Amin S, 2000, ANN INTERN MED, V133, P951, DOI 10.7326/0003-4819-133-12-200012190-00010; Baker L, 2003, J SURG RES, V115, P325, DOI 10.1016/S0022-4804(03)00215-4; BARRETTCONNOR E, 1986, NEW ENGL J MED, V315, P1519, DOI 10.1056/NEJM198612113152405; BARRETTCONNOR E, 1988, CIRCULATION, V78, P539, DOI 10.1161/01.CIR.78.3.539; Berr C, 1996, P NATL ACAD SCI USA, V93, P13410, DOI 10.1073/pnas.93.23.13410; CAULEY JA, 1987, AM J CARDIOL, V60, P771, DOI 10.1016/0002-9149(87)91021-6; CHANG IM, 1982, J CHRON DIS, V35, P669, DOI 10.1016/0021-9681(82)90019-4; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; CONTOREGGI CS, 1990, J ANDROL, V11, P460; Cox D. R., 1984, ANAL SURVIVAL DATA; Cupples LA, 1987, FRAMINGHAM STUDY EPI; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; Feldman HA, 2002, J CLIN ENDOCR METAB, V87, P589, DOI 10.1210/jc.87.2.589; Feldman HA, 2001, AM J EPIDEMIOL, V153, P79, DOI 10.1093/aje/153.1.79; Giri S, 1998, ATHEROSCLEROSIS, V137, P359, DOI 10.1016/S0021-9150(98)00022-7; GREENLAND S, 1995, EPIDEMIOLOGY, V6, P356, DOI 10.1097/00001648-199507000-00005; Gyllenborg J, 2001, METABOLISM, V50, P882, DOI 10.1053/meta.2001.24916; Hak AE, 2002, J CLIN ENDOCR METAB, V87, P3632, DOI 10.1210/jc.87.8.3632; Harman SM, 2001, J CLIN ENDOCR METAB, V86, P724, DOI 10.1210/jc.86.2.724; Hastie T, 1995, Stat Methods Med Res, V4, P187, DOI 10.1177/096228029500400302; HAUTANEN A, 1994, ATHEROSCLEROSIS, V105, P191, DOI 10.1016/0021-9150(94)90049-3; Hougaku H, 2006, AM J PHYSIOL-ENDOC M, V290, pE234, DOI 10.1152/ajpendo.00059.2005; Jilma B, 1996, J CLIN ENDOCR METAB, V81, P2350, DOI 10.1210/jc.81.6.2350; Kajinami K, 2004, CORONARY ARTERY DIS, V15, P199; KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813; Kiechl S, 2000, ARTERIOSCL THROM VAS, V20, P1094, DOI 10.1161/01.ATV.20.4.1094; Komesaroff PA, 2001, HYPERTENSION, V38, P1011, DOI 10.1161/hy1101.095006; LACROIX AZ, 1992, CIRCULATION, V86, P1529, DOI 10.1161/01.CIR.86.5.1529; Lee TM, 2000, J MOL CELL CARDIOL, V32, P1147, DOI 10.1006/jmcc.2000.1167; Liu PY, 2005, J CLIN ENDOCR METAB, V90, P1041, DOI 10.1210/jc.2004-1211; Liu PY, 2003, ENDOCR REV, V24, P313, DOI 10.1210/er.2003-0005; Maffei L, 2004, J CLIN ENDOCR METAB, V89, P61, DOI 10.1210/jc.2003-030313; Mendelsohn ME, 1999, NEW ENGL J MED, V340, P1801, DOI 10.1056/NEJM199906103402306; MITCHELL LE, 1994, CIRCULATION, V89, P89, DOI 10.1161/01.CIR.89.1.89; Muller M, 2004, CIRCULATION, V109, P2074, DOI 10.1161/01.CIR.0000125854.51637.06; Muller M, 2003, J CLIN ENDOCR METAB, V88, P5076, DOI 10.1210/jc.2003-030611; NEWCOMER LM, 1994, AM J EPIDEMIOL, V140, P870, DOI 10.1093/oxfordjournals.aje.a117175; Ohshige A, 1996, ARTERY, V22, P115; Orshal JM, 2004, AM J PHYSIOL-REG I, V286, pR233, DOI 10.1152/ajpregu.00338.2003; Phillips GB, 2005, J CLIN ENDOCR METAB, V90, P2708, DOI 10.1210/jc.2004-2011; Phillips GB, 2003, METABOLISM, V52, P784, DOI 10.1016/S0026-0495(03)00072-6; PHILLIPS GB, 1988, J CLIN EPIDEMIOL, V41, P1151, DOI 10.1016/0895-4356(88)90018-2; Schuit SCE, 2004, JAMA-J AM MED ASSOC, V291, P2969, DOI 10.1001/jama.291.24.2969; Shearman AM, 2006, CIRC RES, V98, P590, DOI 10.1161/01.RES.0000210578.62102.a6; Shearman AM, 2003, JAMA-J AM MED ASSOC, V290, P2263, DOI 10.1001/jama.290.17.2263; Shono N, 1996, J Atheroscler Thromb, V3, P45; Sudhir K, 1999, J CLIN ENDOCR METAB, V84, P3411, DOI 10.1210/jc.84.10.3411; Sudhir K, 1997, CIRCULATION, V96, P3774; The Coronary Drug Project, 1973, JAMA-J AM MED ASSOC, V226, P652, DOI DOI 10.1001/JAMA.1973.03230060030009; Tilvis RS, 1999, AGING CLIN EXP RES, V11, P30, DOI 10.1007/BF03399633; Toung TJK, 1998, STROKE, V29, P1666, DOI 10.1161/01.STR.29.8.1666; Trivedi DP, 2001, J CLIN ENDOCR METAB, V86, P4171, DOI 10.1210/jc.86.9.4171; Tukey J.W, 1977, EXPLORATORY DATA ANA, P43; VERMEULEN A, 1992, J CLIN ENDOCR METAB, V74, P939, DOI 10.1210/jc.74.4.939; Vermeulen A, 2002, Aging Male, V5, P98, DOI 10.1080/713604678; Vermeulen A, 1999, J CLIN ENDOCR METAB, V84, P3666, DOI 10.1210/jc.84.10.3666; *VET ADM COOP UR R, 1967, SURG GYNECOL OBSTET, V124, P1011; Wu FCW, 2003, ENDOCR REV, V24, P183, DOI 10.1210/er.2001-0025; YARNELL JWG, 1993, ARTERIOSCLER THROMB, V13, P517, DOI 10.1161/01.ATV.13.4.517	60	168	173	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	2006	145	3					176	184		10.7326/0003-4819-145-3-200608010-00005	http://dx.doi.org/10.7326/0003-4819-145-3-200608010-00005			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	070MN	16880459				2022-12-28	WOS:000239526800003
J	Syken, J; GrandPre, T; Kanold, PO; Shatz, CJ				Syken, Josh; GrandPre, Tadzia; Kanold, Patrick O.; Shatz, Carla J.			PirB restricts ocular-dominance plasticity in visual cortex	SCIENCE			English	Article							IMMUNOGLOBULIN-LIKE RECEPTOR; CLASS-I MHC; NEGATIVELY REGULATES NEUTROPHIL; LONG-TERM POTENTIATION; INHIBITORY RECEPTORS; GENE-EXPRESSION; CRITICAL PERIOD; CELLS; MICE; REQUIREMENT	Experience can alter synaptic connectivity throughout life, but the degree of plasticity present at each age is regulated by mechanisms that remain largely unknown. Here, we demonstrate that Paired-immunoglobulin-like receptor B (PirB), a major histocompatibility complex class I (MHCI) receptor, is expressed in subsets of neurons throughout the brain. Neuronal PirB protein is associated with synapses and forms complexes with the phosphatases Shp-1 and Shp-2. Soluble PirB fusion protein binds to cortical neurons in an MHCI-dependent manner. In mutant mice lacking functional PirB, cortical ocular-dominance plasticity is more robust at all ages. Thus, an MHCI receptor is expressed in central nervous system neurons and functions to limit the extent of experience-dependent plasticity in the visual cortex throughout life. PirB is also expressed in many other regions of the central nervous system, suggesting that it may function broadly to stabilize neural circuits.	Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Shatz, CJ (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, 220 Longwood Ave, Boston, MA 02115 USA.	carla_shatz@hms.harvard.edu		Kanold, Patrick/0000-0002-7529-5435	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [F32EY013526, R01EY002858, R37EY002858] Funding Source: NIH RePORTER; NEI NIH HHS [F32 EY013526, EY02858, F32 EY013526-01, F32EY1352] Funding Source: Medline; NICHD NIH HHS [HD18655] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Barco A, 2005, NEURON, V48, P123, DOI 10.1016/j.neuron.2005.09.005; Boyington JC, 2000, NATURE, V405, P537, DOI 10.1038/35014520; CAVINESS VS, 1975, J COMP NEUROL, V164, P247, DOI 10.1002/cne.901640207; Chan CS, 2003, J NEUROSCI, V23, P7107, DOI 10.1523/JNEUROSCI.23-18-07107.2003; Chun D, 2001, NEUROSCIENCE, V105, P815, DOI 10.1016/S0306-4522(01)00173-7; Corriveau RA, 1998, NEURON, V21, P505, DOI 10.1016/S0896-6273(00)80562-0; Dorfman JR, 1997, J IMMUNOL, V159, P5219; DRAGER UC, 1975, J COMP NEUROL, V160, P269, DOI 10.1002/cne.901600302; Frenkel MY, 2004, NEURON, V44, P917, DOI 10.1016/j.neuron.2004.12.003; Hayami K, 1997, J BIOL CHEM, V272, P7320, DOI 10.1074/jbc.272.11.7320; Hensch TK, 2003, NEUROSCI RES, V47, P17, DOI 10.1016/S0168-0102(03)00164-0; Hensch TK, 2004, ANNU REV NEUROSCI, V27, P549, DOI 10.1146/annurev.neuro.27.070203.144327; HUBEL DH, 1977, PHILOS T ROY SOC B, V278, P377, DOI 10.1098/rstb.1977.0050; Huh GS, 2000, SCIENCE, V290, P2155, DOI 10.1126/science.290.5499.2155; Katz LC, 2002, NAT REV NEUROSCI, V3, P34, DOI 10.1038/nrn703; Kramar EA, 2002, NEUROSCIENCE, V110, P29, DOI 10.1016/S0306-4522(01)00540-1; Kramar EA, 2003, J BIOL CHEM, V278, P10722, DOI 10.1074/jbc.M210225200; Kubagawa H, 1997, P NATL ACAD SCI USA, V94, P5261, DOI 10.1073/pnas.94.10.5261; Lanier LL, 1998, ANNU REV IMMUNOL, V16, P359, DOI 10.1146/annurev.immunol.16.1.359; Liang SY, 2002, EUR J IMMUNOL, V32, P2418, DOI 10.1002/1521-4141(200209)32:9<2418::AID-IMMU2418>3.0.CO;2-L; Loconto J, 2003, CELL, V112, P607, DOI 10.1016/S0092-8674(03)00153-3; Long EO, 1999, ANNU REV IMMUNOL, V17, P875, DOI 10.1146/annurev.immunol.17.1.875; Maeda A, 1999, ONCOGENE, V18, P2291, DOI 10.1038/sj.onc.1202552; Maeda A, 1998, J EXP MED, V187, P1355, DOI 10.1084/jem.187.8.1355; Malenka RC, 2004, NEURON, V44, P5, DOI 10.1016/j.neuron.2004.09.012; Mataga N, 2002, P NATL ACAD SCI USA, V99, P7717, DOI 10.1073/pnas.102088899; McGee AW, 2005, SCIENCE, V309, P2222, DOI 10.1126/science.1114362; Nakamura A, 2004, NAT IMMUNOL, V5, P623, DOI 10.1038/ni1074; Pereira S, 2003, J IMMUNOL, V171, P1319, DOI 10.4049/jimmunol.171.3.1319; Pereira S, 2004, J IMMUNOL, V173, P5757, DOI 10.4049/jimmunol.173.9.5757; Pham TA, 2004, LEARN MEMORY, V11, P738, DOI 10.1101/lm.75304; Pizzorusso T, 2002, SCIENCE, V298, P1248, DOI 10.1126/science.1072699; Sawtell NB, 2003, NEURON, V38, P977, DOI 10.1016/S0896-6273(03)00323-4; Tagawa Y, 2005, NAT NEUROSCI, V8, P380, DOI 10.1038/nn1410; Taha SA, 2005, PROG BRAIN RES, V147, P103, DOI 10.1016/S0079-6123(04)47008-3; Takai T, 2005, IMMUNOLOGY, V115, P433, DOI 10.1111/j.1365-2567.2005.02177.x; Takai T, 2001, IMMUNOL REV, V181, P215, DOI 10.1034/j.1600-065X.2001.1810118.x; Timms JF, 1998, MOL CELL BIOL, V18, P3838, DOI 10.1128/MCB.18.7.3838; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Zhang H, 2005, IMMUNITY, V22, P235, DOI 10.1016/j.immuni.2005.01.004	40	263	283	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 22	2006	313	5794					1795	1800		10.1126/science.1128232	http://dx.doi.org/10.1126/science.1128232			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	086ED	16917027				2022-12-28	WOS:000240655700051
J	Akkad, A; Jackson, C; Kenyon, S; Dixon-Woods, M; Taub, N; Habiba, M				Akkad, Andrea; Jackson, Clare; Kenyon, Sara; Dixon-Woods, Mary; Taub, Nick; Habiba, Marwan			Patients' perceptions of written consent: questionnaire study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INFORMED-CONSENT; INFORMATION; SURGERY	Objective To examine patients' understanding of the status, function, and remit of written consent to surgery. Design Prospective questionnaire study. Questionnaires were sent to patients within one month of surgery. Responses were analysed with frequencies and single variable analyses. Setting Large teaching hospital. Participants 732 patients who had undergone surgery in obstetrics and gynaecology over a six month period. Main outcome measures Patients' awareness of the legal implications of written consent and their views on the function and remit of the consent form. Results Patients had limited understanding of the legal standing of written consent. Nearly half (46%, 95% confidence interval 43% to 50%) of patients believed the primary function of consent forms was to protect hospitals and 68% (65% to 71%) thought consent forms allowed doctors to assume control. Only 41% (37% to 44%) of patients believed consent forms made their wishes known. Conclusions Many patients seem to have limited awareness of the legal implications of signing or not signing consent forms, and they do not recognise Written consent as primarily serving their interests. Current consent procedures seem inadequate as a means for the expression of autonomous choice, and their ethical standing and credibility. can be called into question.	Univ Leicester, Dept Canc Studies & Mol Med, Reprod Sci Sect, Leicester LE2 7LX, Leics, England; Univ Leicester, Dept Hlth Sci, Leicester LE1 6TP, Leics, England	University of Leicester; University of Leicester	Habiba, M (corresponding author), Univ Leicester, Dept Canc Studies & Mol Med, Reprod Sci Sect, Leicester LE2 7LX, Leics, England.	mah6@le.ac.uk	Jackson, Clare/A-1421-2013	Kenyon, Sara/0000-0002-0756-9617; Dixon-Woods, Mary/0000-0002-5915-0041				Akkad A, 2004, BJOG-INT J OBSTET GY, V111, P1133, DOI 10.1111/j.1471-0528.2004.00240.x; BYRNE DJ, 1988, BRIT MED J, V296, P839, DOI 10.1136/bmj.296.6625.839; Courtney MJ, 2001, AUST NZ J SURG, V71, P24, DOI 10.1046/j.1440-1622.2001.02026.x; *DEP HLTH, CONS FORMS; Department of Health, 2001, REF GUID CONS EX TRE; Dixon-Woods M, 2001, SOC SCI MED, V52, P1417, DOI 10.1016/S0277-9536(00)00247-1; Habiba M, 2004, QUAL SAF HEALTH CARE, V13, P422, DOI 10.1136/qshc.2004.010652; Mayberry MK, 2001, EUR J GASTROEN HEPAT, V13, P1467, DOI 10.1097/00042737-200112000-00010; Schouten B, 2002, PATIENT EDUC COUNS, V46, P47, DOI 10.1016/S0738-3991(01)00158-6; Worthington R, 2002, J MED ETHICS, V28, P377, DOI 10.1136/jme.28.6.377	10	78	80	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 9	2006	333	7567					528	529		10.1136/bmj.38922.516204.55	http://dx.doi.org/10.1136/bmj.38922.516204.55			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	084LD	16880192	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000240533500017
J	Sharpe, AH; Abbas, AK				Sharpe, Arlene H.; Abbas, Abul K.			Focus on research: T-cell costimulation - Biology, therapeutic potential, and challenges	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CD28 SUPERAGONISTS		Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA USA	Harvard University; Harvard Medical School; University of California System; University of California San Francisco	Sharpe, AH (corresponding author), Harvard Univ, Sch Med, Boston, MA 02115 USA.							Beyersdorf N, 2005, J EXP MED, V202, P445, DOI 10.1084/jem.20051060; Bluestone JA, 2006, IMMUNITY, V24, P233, DOI 10.1016/j.immuni.2006.03.001; Bluestone JA, 2003, NAT REV IMMUNOL, V3, P253, DOI 10.1038/nri1032; Greenwald RJ, 2005, ANNU REV IMMUNOL, V23, P515, DOI 10.1146/annurev.immunol.23.021704.115611; Hunig T, 2005, IMMUNOL LETT, V100, P21, DOI 10.1016/j.imlet.2005.06.012	5	157	173	1	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 7	2006	355	10					973	975		10.1056/NEJMp068087	http://dx.doi.org/10.1056/NEJMp068087			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	080UF	16908487				2022-12-28	WOS:000240273300001
J	Even-Ram, S; Artym, V; Yamada, KM				Even-Ram, Sharona; Artym, Vira; Yamada, Kenneth M.			Matrix control of stem cell fate	CELL			English	Editorial Material							MORPHOGENESIS		NIH, Craniofacial Dev Biol & Regenerat Branch, Natl Inst Dental & Craniofacial Res, Bethesda, MD 20892 USA; Georgetown Univ, Sch Med, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20057 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Georgetown University	Yamada, KM (corresponding author), NIH, Craniofacial Dev Biol & Regenerat Branch, Natl Inst Dental & Craniofacial Res, Bldg 10, Bethesda, MD 20892 USA.	kyamada@mail.nih.gov		Even-Ram, Sharona/0000-0002-5540-3822; Yamada, Kenneth/0000-0003-1512-6805	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000525] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000525] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; ENGLER AJ, 2006, CELL; Fuchs E, 2004, CELL, V116, P769, DOI 10.1016/S0092-8674(04)00255-7; Griffith LG, 2006, NAT REV MOL CELL BIO, V7, P211, DOI 10.1038/nrm1858; Ingber DE, 2006, INT J DEV BIOL, V50, P255, DOI 10.1387/ijdb.052044di; Lutolf MP, 2005, NAT BIOTECHNOL, V23, P47, DOI 10.1038/nbt1055; Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010; Vogel V, 2006, NAT REV MOL CELL BIO, V7, P265, DOI 10.1038/nrm1890; Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427	9	209	223	6	64	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 25	2006	126	4					645	647		10.1016/j.cell.2006.08.008	http://dx.doi.org/10.1016/j.cell.2006.08.008			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	080VN	16923382	Bronze			2022-12-28	WOS:000240276700010
J	Pinkston, JM; Garigan, D; Hansen, M; Kenyon, C				Pinkston, Julie M.; Garigan, Delia; Hansen, Malene; Kenyon, Cynthia			Mutations that increase the life span of C-elegans inhibit tumor growth	SCIENCE			English	Article							DAMAGE-INDUCED APOPTOSIS; CAENORHABDITIS-ELEGANS; GENETIC-ANALYSIS; CELL-DEATH; GERMLINE; MUTANTS; PATHWAY; LONG; P53; LONGEVITY	Mutations in gld-1 cause lethal germline tumors in the nematode Caenorhabditis elegans. We find that a wide variety of mutations that extend C. elegans' life span confer resistance to these tumors. The long life spans of daf-2/insulin-receptor mutants were not shortened at all by gld-1 mutations; we attribute this finding to decreased cell division and increased DAF-16/p53 dependent apoptosis within the tumors. Mutations that increase life span by restricting food intake or inhibiting respiration did not affect apoptosis but reduced tumor cell division. Unexpectedly, none of these longevity mutations affected mitosis in normal germlines; this finding suggests that cellular changes that lead to longevity preferentially antagonize tumor cell growth.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94158 USA	University of California System; University of California San Francisco	Kenyon, C (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94158 USA.	ckenyon@biochem.ucsf.edu		Kenyon, Cynthia/0000-0003-3446-2636	NIA NIH HHS [AG000278] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ajiro K, 1996, J BIOL CHEM, V271, P13197, DOI 10.1074/jbc.271.22.13197; Braeckman BP, 2002, MECH AGEING DEV, V123, P1447, DOI 10.1016/S0047-6374(02)00085-4; Deng XZ, 2004, NAT GENET, V36, P906, DOI 10.1038/ng1396; Essafi A, 2005, ONCOGENE, V24, P2317, DOI 10.1038/sj.onc.1208421; Felkai S, 1999, EMBO J, V18, P1783, DOI 10.1093/emboj/18.7.1783; Feng JL, 2001, DEV CELL, V1, P633, DOI 10.1016/S1534-5807(01)00071-5; FRANCIS R, 1995, GENETICS, V139, P607; Garigan D, 2002, GENETICS, V161, P1101; Gartner A, 2000, MOL CELL, V5, P435, DOI 10.1016/S1097-2765(00)80438-4; Gems D, 1998, GENETICS, V150, P129; Gumienny TL, 1999, DEVELOPMENT, V126, P1011; Hekimi S, 2003, SCIENCE, V299, P1351, DOI 10.1126/science.1082358; Inoki K, 2005, NAT GENET, V37, P19, DOI 10.1038/ng1494; Jonassen T, 2001, P NATL ACAD SCI USA, V98, P421, DOI 10.1073/pnas.021337498; Kenyon C, 2005, CELL, V120, P449, DOI 10.1016/j.cell.2005.02.002; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; LaFever L, 2005, SCIENCE, V309, P1071, DOI 10.1126/science.1111410; Lakowski B, 1998, P NATL ACAD SCI USA, V95, P13091, DOI 10.1073/pnas.95.22.13091; Liu XX, 2005, GENE DEV, V19, P2424, DOI 10.1101/gad.1352905; McElwee J, 2003, AGING CELL, V2, P111, DOI 10.1046/j.1474-9728.2003.00043.x; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; Pepper ASR, 2003, GENETICS, V163, P115; Ramsey MM, 2002, ENDOCRINOLOGY, V143, P4139, DOI 10.1210/en.2002-220717; Schumacher B, 2005, CELL, V120, P357, DOI 10.1016/j.cell.2004.12.009; Schumacher B, 2001, CURR BIOL, V11, P1722, DOI 10.1016/S0960-9822(01)00534-6; Tatar M, 2003, SCIENCE, V299, P1346, DOI 10.1126/science.1081447; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	28	174	196	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 18	2006	313	5789					971	975		10.1126/science.1121908	http://dx.doi.org/10.1126/science.1121908			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	074MR	16917064				2022-12-28	WOS:000239817000045
J	Berners-Lee, T; Hall, W; Hendler, J; Shadbolt, N; Weitzner, DJ				Berners-Lee, Tim; Hall, Wendy; Hendler, James; Shadbolt, Nigel; Weitzner, Daniel J.			Creating a science of the Web	SCIENCE			English	Editorial Material							COMPLEX NETWORKS		MIT, Comp Sci & Artificial Intelligence Lab, Cambridge, MA 02139 USA; Univ Southampton, Sch Elect & Comp Sci, Southampton SO17 1BJ, Hants, England; Univ Maryland, Dept Comp Sci, College Pk, MD 20742 USA	Massachusetts Institute of Technology (MIT); University of Southampton; University System of Maryland; University of Maryland College Park	Berners-Lee, T (corresponding author), MIT, Comp Sci & Artificial Intelligence Lab, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	hendler@cs.umd.edu		Hall, Wendy/0000-0003-4327-7811; Berners-Lee, Timothy/0000-0003-1279-3709; Hendler, James/0000-0003-3056-1960				Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509; Brin S., 1998, COMPUT NETW ISDN SYS, V30, P107, DOI [DOI 10.1016/S0169-7552(98)00110-X, 10.1016/s0169-7552(98)00110-x]; Kleinberg JM, 2000, NATURE, V406, P845, DOI 10.1038/35022643; LESSIG LAWRENCE, 1999, CODE OTHER LAWS CYBE; Milo R, 2004, SCIENCE, V303, P1538, DOI 10.1126/science.1089167; Milo R, 2002, SCIENCE, V298, P824, DOI 10.1126/science.298.5594.824; Oltvai ZN, 2002, SCIENCE, V298, P763, DOI 10.1126/science.1078563; Strogatz SH, 2001, NATURE, V410, P268, DOI 10.1038/35065725	8	147	152	1	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 11	2006	313	5788					769	771		10.1126/science.1126902	http://dx.doi.org/10.1126/science.1126902			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	072KC	16902115				2022-12-28	WOS:000239671300033
J	Nemhauser, JL; Hong, FX; Chory, J				Nemhauser, Jennifer L.; Hong, Fangxin; Chory, Joanne			Different plant hormones regulate similar processes through largely nonoverlapping transcriptional responses	CELL			English	Article							GROWTH-RESPONSES; AUXIN; ETHYLENE; GENES; GIBBERELLIN; POWERFUL; ROLES	Small-molecule hormones govern every aspect of the biology of plants. Many processes, such as growth, are regulated in similar ways by multiple hormones, and recent studies have revealed extensive crosstalk among different hormonal signaling pathways. These results have led to the proposal that a common set of signaling components may integrate inputs from multiple hormones to regulate growth. In this study, we tested this proposal by asking whether different hormones converge on a common set of transcriptional targets in Arabidopsis seedlings. Using publicly available microarray data, we analyzed the transcriptional effects of seven hormones, including abscisic acid, gibberellin, auxin, ethylene, cytokinin, brassinosteroid, and jasmonate. A high-sensitivity analysis revealed a surprisingly low number of common target genes. Instead, different hormones appear to regulate distinct members of protein families. We conclude that there is not a core transcriptional growth-regulatory module in young Arabidopsis seedlings.	Salk Inst Biol Studies, Plant Biol Lab, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA	Salk Institute; Howard Hughes Medical Institute; Salk Institute	Chory, J (corresponding author), Salk Inst Biol Studies, Plant Biol Lab, La Jolla, CA 92037 USA.	chory@salk.edu						Achard P, 2006, SCIENCE, V311, P91, DOI 10.1126/science.1118642; Achard P, 2003, PLANT CELL, V15, P2816, DOI 10.1105/tpc.015685; ALONSO JM, 2001, SCI STKE, pRE1; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Binder BM, 2004, PLANT PHYSIOL, V136, P2921, DOI 10.1104/pp.104.050393; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Breitling R, 2004, FEBS LETT, V573, P83, DOI 10.1016/j.febslet.2004.07.055; Cosgrove DJ, 2000, NATURE, V407, P321, DOI 10.1038/35030000; Finkelstein RR, 2002, PLANT CELL, V14, pS15, DOI 10.1105/tpc.010441; Folta KM, 2001, PLANT J, V26, P471, DOI 10.1046/j.1365-313x.2001.01038.x; Force A, 1999, GENETICS, V151, P1531; Friedrichsen DM, 2002, GENETICS, V162, P1445; Fu XD, 2003, NATURE, V421, P740, DOI 10.1038/nature01387; Gazzarrini S, 2003, ANN BOT-LONDON, V91, P605, DOI 10.1093/aob/mcg064; Guo HW, 2004, CURR OPIN PLANT BIOL, V7, P40, DOI 10.1016/j.pbi.2003.11.011; Halliday KJ, 2004, CURR BIOL, V14, pR1008, DOI 10.1016/j.cub.2004.11.025; Hansen H, 2000, PLANT PHYSIOL, V124, P1437, DOI 10.1104/pp.124.3.1437; Nakamura A, 2006, PLANT J, V45, P193, DOI 10.1111/j.1365-313X.2005.02582.x; Rolland F, 2005, BIOCHEM SOC T, V33, P269, DOI 10.1042/BST0330269; Sampedro J, 2006, J PLANT RES, V119, P11, DOI 10.1007/s10265-005-0253-z; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Steber CM, 1998, GENETICS, V149, P509; Steber CM, 2001, PLANT PHYSIOL, V125, P763, DOI 10.1104/pp.125.2.763; Sun TP, 2004, ANNU REV PLANT BIOL, V55, P197, DOI 10.1146/annurev.arplant.55.031903.141753; Swarup R, 2005, NAT CELL BIOL, V7, P1057, DOI 10.1038/ncb1316; Vert G, 2005, ANNU REV CELL DEV BI, V21, P177, DOI 10.1146/annurev.cellbio.21.090704.151241; Wang KLC, 2002, PLANT CELL, V14, pS131, DOI 10.1105/tpc.001768; Wilson CL, 2005, BIOINFORMATICS, V21, P3683, DOI 10.1093/bioinformatics/bti605; Woodward AW, 2005, ANN BOT-LONDON, V95, P707, DOI 10.1093/aob/mci083; Wu Z, 2004, MODEL BASED BACKGROU; Yang T, 1996, PLANT PHYSIOL, V110, P1029, DOI 10.1104/pp.110.3.1029; Yokoyama R, 2001, PLANT CELL PHYSIOL, V42, P1025, DOI 10.1093/pcp/pce154; ZUREK DM, 1994, PLANT PHYSIOL, V104, P505, DOI 10.1104/pp.104.2.505	33	671	724	10	158	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 11	2006	126	3					467	475		10.1016/j.cell.2006.05.050	http://dx.doi.org/10.1016/j.cell.2006.05.050			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	075KI	16901781	Bronze			2022-12-28	WOS:000239883400008
J	Hagemann, G; Bartke, T				Hagemann, Georg; Bartke, Thomas			Adie's pupil in the Ross syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Jena, D-07740 Jena, Germany	Friedrich Schiller University of Jena	Hagemann, G (corresponding author), Univ Jena, D-07740 Jena, Germany.								0	2	2	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 10	2006	355	6					E5	E5		10.1056/NEJMicm040986	http://dx.doi.org/10.1056/NEJMicm040986			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	071QM	16899770				2022-12-28	WOS:000239616700011
J	Hyun, I				Hyun, Insoo			Fair payment or undue inducement?	NATURE			English	Editorial Material									Case Western Reserve Univ, Sch Med, Dept Bioeth, Cleveland, OH 44109 USA	Case Western Reserve University	Hyun, I (corresponding author), Case Western Reserve Univ, Sch Med, Dept Bioeth, Cleveland, OH 44109 USA.							[Anonymous], 1993, IRB GUID; Delvigne A, 2002, HUM REPROD UPDATE, V8, P559, DOI 10.1093/humupd/8.6.559; Emanuel EJ, 2004, J LAW MED ETHICS, V32, P100, DOI 10.1111/j.1748-720X.2004.tb00453.x; *FOOD DRUG ADM, 2001, IRB INF SHEETS; Halpern SD, 2004, ARCH INTERN MED, V164, P801, DOI 10.1001/archinte.164.7.801; McGee Glenn, 2006, AM J BIOETHICS, V6, pW33; *NIH, 2006, CLIN RES VOL PROGR H; *NIH, 2000, REM RES SUBJ INTR RE; Steinbrook R, 2006, NEW ENGL J MED, V354, P324, DOI 10.1056/NEJMp058313	9	51	51	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 10	2006	442	7103					629	630		10.1038/442629a	http://dx.doi.org/10.1038/442629a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	071UU	16900181				2022-12-28	WOS:000239630200023
J	Xu, K; Xu, X; Fukao, T; Canlas, P; Maghirang-Rodriguez, R; Heuer, S; Ismail, AM; Bailey-Serres, J; Ronald, PC; Mackill, DJ				Xu, Kenong; Xu, Xia; Fukao, Takeshi; Canlas, Patrick; Maghirang-Rodriguez, Reycel; Heuer, Sigrid; Ismail, Abdelbagi M.; Bailey-Serres, Julia; Ronald, Pamela C.; Mackill, David J.			Sub1A is an ethylene-response-factor-like gene that confers submergence tolerance to rice	NATURE			English	Article							ORYZA-SATIVA L.; TRANSCRIPTION FACTORS; LINKAGE MAP; DEEP-WATER; GENOME; EXPRESSION; SEQUENCE; MARKER; PLANTS; ACTIVATION	Most Oryza sativa cultivars die within a week of complete submergence - a major constraint to rice production in south and southeast Asia that causes annual losses of over US$ 1 billion and affects disproportionately the poorest farmers in the world(1,2). A few cultivars, such as the O. sativa ssp. indica cultivar FR13A, are highly tolerant and survive up to two weeks of complete submergence owing to a major quantitative trait locus designated Submergence 1 ( Sub1) near the centromere of chromosome 9 ( refs 3 - 6). Here we describe the identification of a cluster of three genes at the Sub1 locus, encoding putative ethylene response factors. Two of these genes, Sub1B and Sub1C, are invariably present in the Sub1 region of all rice accessions analysed. In contrast, the presence of Sub1A is variable. A survey identified two alleles within those indica varieties that possess this gene: a tolerance- specific allele named Sub1A- 1 and an intolerance- specific allele named Sub1A- 2. Overexpression of Sub1A- 1 in a submergence- intolerant O. sativa ssp. japonica conferred enhanced tolerance to the plants, downregulation of Sub1C and upregulation of Alcohol dehydrogenase 1 ( Adh1), indicating that Sub1A- 1 is a primary determinant of submergence tolerance. The FR13A Sub1 locus was introgressed into a widely grown Asian rice cultivar using marker- assisted selection. The new variety maintains the high yield and other agronomic properties of the recurrent parent and is tolerant to submergence. Cultivation of this variety is expected to provide protection against damaging floods and increase crop security for farmers.	Univ Calif Davis, Dept Plant Pathol, Davis, CA 95616 USA; Univ Calif Riverside, Dept Bot & Plant Sci, Ctr Plant Cell Biol, Riverside, CA 92521 USA; Int Rice Res Inst, Manila, Philippines	University of California System; University of California Davis; University of California System; University of California Riverside; CGIAR; International Rice Research Institute (IRRI)	Ronald, PC (corresponding author), Univ Calif Davis, Dept Plant Pathol, Davis, CA 95616 USA.	pcronald@ucdavis.edu; d.mackill@cgiar.org	Fukao, Takeshi/H-6548-2016; Mackill, David/AAB-7176-2022; Bailey-Serres, Julia/A-2470-2010; Ronald, Pamela/AAK-7664-2020; Mackill, David/C-6368-2014	Fukao, Takeshi/0000-0002-9930-1318; Mackill, David/0000-0003-4224-6781; Bailey-Serres, Julia/0000-0002-8568-7125				[Anonymous], [No title captured]; Arumuganathan K., 1991, PLANT MOL BIOL REP, V9, P229, DOI [10.1007/BF02672073, DOI 10.1007/BF02672073]; CATLING D, 1992, RICE DEEP WATER, P5; Chen MS, 2002, PLANT CELL, V14, P537, DOI 10.1105/tpc.010485; Chen X, 1997, THEOR APPL GENET, V95, P553, DOI 10.1007/s001220050596; Cheong YH, 2003, PLANT PHYSIOL, V132, P1961, DOI 10.1104/pp.103.023176; Chern M, 2005, MOL PLANT MICROBE IN, V18, P511, DOI 10.1094/MPMI-18-0511; Christensen AH, 1996, TRANSGENIC RES, V5, P213, DOI 10.1007/BF01969712; Fujimoto SY, 2000, PLANT CELL, V12, P393, DOI 10.1105/tpc.12.3.393; Fukao T, 2004, TRENDS PLANT SCI, V9, P449, DOI 10.1016/j.tplants.2004.07.005; FUKAO T, IN PRESS PLANT CELL; Gutterson N, 2004, CURR OPIN PLANT BIOL, V7, P465, DOI 10.1016/j.pbi.2004.04.007; Harushima Y, 1998, GENETICS, V148, P479; Herdt R. W., 1991, Rice biotechnology., P19; Jackson MB, 2003, ANN BOT-LONDON, V91, P227, DOI 10.1093/aob/mcf242; Kende H, 1998, PLANT PHYSIOL, V118, P1105, DOI 10.1104/pp.118.4.1105; Magnani E, 2004, PLANT CELL, V16, P2265, DOI 10.1105/tpc.104.023135; Matsumoto T, 2005, NATURE, V436, P793, DOI 10.1038/nature03895; McGrath KC, 2005, PLANT PHYSIOL, V139, P949, DOI 10.1104/pp.105.068544; Parnell SC, 2005, BIOCHEMISTRY-US, V44, P8159, DOI 10.1021/bi0503091; Ram PC, 2002, FIELD CROP RES, V76, P131, DOI 10.1016/S0378-4290(02)00035-7; Sauter M, 2000, NATURWISSENSCHAFTEN, V87, P289, DOI 10.1007/s001140050725; Setter TL, 1997, ANN BOT-LONDON, V79, P67, DOI 10.1006/anbo.1996.0304; Siangliw M, 2003, ANN BOT-LONDON, V91, P255, DOI 10.1093/aob/mcf123; Song CP, 2005, PLANT CELL, V17, P2384, DOI 10.1105/tpc.105.033043; Temnykh S, 2000, THEOR APPL GENET, V100, P697, DOI 10.1007/s001220051342; Wu JZ, 2002, PLANT CELL, V14, P525, DOI 10.1105/tpc.010274; Xu K, 2000, MOL GEN GENET, V263, P681, DOI 10.1007/s004380051217; Xu KN, 1996, MOL BREEDING, V2, P219, DOI 10.1007/BF00564199; Xu KN, 2004, CROP SCI, V44, P248, DOI 10.2135/cropsci2004.0248	30	952	1053	18	284	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 10	2006	442	7103					705	708		10.1038/nature04920	http://dx.doi.org/10.1038/nature04920			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	071UU	16900200	Green Published			2022-12-28	WOS:000239630200050
J	Hajduk, SL				Hajduk, Stephen L.			Microbiology - Timing the sexual development of parasites	SCIENCE			English	Editorial Material							PLASMODIUM	Like other eukaryotes, the malaria parasite stores maternal RNA in the female gamete for Later use in directing early development. An RNA helicase is a key regulator of this process.	Josephine Bay Paul Ctr, Woods Hole, MA 02543 USA		Hajduk, SL (corresponding author), Josephine Bay Paul Ctr, Woods Hole, MA 02543 USA.	shajduk@mbl.edu						Abraham EG, 2004, J BIOL CHEM, V279, P5573, DOI 10.1074/jbc.M307582200; Colegrove-Otero LJ, 2005, CRIT REV BIOCHEM MOL, V40, P21, DOI 10.1080/10409230590918612; GAVIS ER, 1994, NATURE, V369, P315, DOI 10.1038/369315a0; Khan SM, 2005, CELL, V121, P675, DOI 10.1016/j.cell.2005.03.027; Mair GR, 2006, SCIENCE, V313, P667, DOI 10.1126/science.1125129; PATON MG, 1993, MOL BIOCHEM PARASIT, V59, P263, DOI 10.1016/0166-6851(93)90224-L	6	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 4	2006	313	5787					626	627		10.1126/science.1131299	http://dx.doi.org/10.1126/science.1131299			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	072IQ	16888130				2022-12-28	WOS:000239667500030
J	Singla, V; Reiter, JF				Singla, Veena; Reiter, Jeremy F.			The primary cilium as the cell's antenna: Signaling at a sensory organelle	SCIENCE			English	Review							POLYCYSTIC KIDNEY-DISEASE; INTRAFLAGELLAR TRANSPORT PROTEINS; BARDET-BIEDL-SYNDROME; LEFT-RIGHT ASYMMETRY; C-ELEGANS NEURONS; KINESIN-II; CHLAMYDOMONAS-REINHARDTII; ODORANT RECEPTORS; MITOTIC SPINDLE; NODAL CILIA	Almost every vertebrate cell has a specialized cell surface projection called a primary cilium. Although these structures were first described more than a century ago, the full scope of their functions remains poorly understood. Here, we review emerging evidence that in addition to their well-established roles in sight, smell, and mechanosensation, primary cilia are key participants in intercellular signaling. This new appreciation of primary cilia as cellular antennae that sense a wide variety of signals could help explain why ciliary defects underlie such a wide range of human disorders, including retinal degeneration, polycystic kidney disease, Bardet-Biedl syndrome, and neural tube defects.	Univ Calif San Francisco, Program Dev & Stem Cell Biol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Reiter, JF (corresponding author), Univ Calif San Francisco, Program Dev & Stem Cell Biol, San Francisco, CA 94143 USA.	jreiter@diabetes.ucsf.edu		Singla, Veena/0000-0002-5107-0717	NIDDK NIH HHS [R21 DK069423, R21DK69423] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK069423] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alvarez-Buylla A, 1998, J NEUROSCI, V18, P1020; ANDERSON RG, 1972, J CELL BIOL, V54, P246, DOI 10.1083/jcb.54.2.246; Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; Barr MM, 2001, CURR BIOL, V11, P1341, DOI 10.1016/S0960-9822(01)00423-7; Beales PL, 2005, CURR OPIN GENET DEV, V15, P315, DOI 10.1016/j.gde.2005.04.006; Bellaiche Y, 2001, NAT CELL BIOL, V3, P50, DOI 10.1038/35050558; Benton R, 2006, PLOS BIOL, V4, P240, DOI 10.1371/journal.pbio.0040020; Besharse JC., 1990, CILIARY FLAGELLAR ME, P389; Bisceglia M, 2006, ADV ANAT PATHOL, V13, P26, DOI 10.1097/01.pap.0000201831.77472.d3; BOEKHOFF I, 1990, EMBO J, V9, P2453, DOI 10.1002/j.1460-2075.1990.tb07422.x; BRONSHTEIN AA, 1977, TSITOLOGIYA+, V19, P33; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Chang P, 2003, NAT CELL BIOL, V5, P71, DOI 10.1038/ncb900; Chauvet V, 2004, J CLIN INVEST, V114, P1433, DOI 10.1172/JCI200421753; Corbit KC, 2005, NATURE, V437, P1018, DOI 10.1038/nature04117; Das G, 2004, DEVELOPMENT, V131, P4467, DOI 10.1242/dev.01317; di Magliano MP, 2003, NAT REV CANCER, V3, P903, DOI 10.1038/nrc1229; ECKERT R, 1972, J EXP BIOL, V56, P683; Eley L, 2005, CURR OPIN GENET DEV, V15, P308, DOI 10.1016/j.gde.2005.04.008; Elias R, 2004, MOL VIS, V10, P672; Fischer E, 2006, NAT GENET, V38, P21, DOI 10.1038/ng1701; Gong Y, 2004, NATURE, V430, P689, DOI 10.1038/nature02796; Gong ZF, 2004, J NEUROSCI, V24, P9059, DOI 10.1523/JNEUROSCI.1645-04.2004; Guo N, 2004, P NATL ACAD SCI USA, V101, P9277, DOI 10.1073/pnas.0402802101; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; HAND WG, 1975, J PROTOZOOL, V22, P494, DOI 10.1111/j.1550-7408.1975.tb05217.x; Haycraft CJ, 2005, PLOS GENET, V1, P480, DOI 10.1371/journal.pgen.0010053; Huang KY, 2004, MOL BIOL CELL, V15, P3605, DOI 10.1091/mbc.E04-01-0010; Huangfu DW, 2003, NATURE, V426, P83, DOI 10.1038/nature02061; Iomini C, 2006, CURR BIOL, V16, P1147, DOI 10.1016/j.cub.2006.04.035; Jenny A, 2005, NAT CELL BIOL, V7, P691, DOI 10.1038/ncb1271; Kim JC, 2004, NAT GENET, V36, P462, DOI 10.1038/ng1352; King N, 2004, DEV CELL, V7, P313, DOI 10.1016/j.devcel.2004.08.010; Klein TJ, 2005, ANNU REV CELL DEV BI, V21, P155, DOI 10.1146/annurev.cellbio.21.012704.132806; KOZMINSKI KG, 1995, J CELL BIOL, V131, P1517, DOI 10.1083/jcb.131.6.1517; Kreimer G, 1999, PROTIST, V150, P311, DOI 10.1016/S1434-4610(99)70032-5; KRIEGER J, 1994, EUR J BIOCHEM, V219, P829, DOI 10.1111/j.1432-1033.1994.tb18564.x; Kulaga HM, 2004, NAT GENET, V36, P994, DOI 10.1038/ng1418; Kyttala M, 2006, NAT GENET, V38, P155, DOI 10.1038/ng1714; Li TS, 1996, P NATL ACAD SCI USA, V93, P14176, DOI 10.1073/pnas.93.24.14176; Lin FM, 2003, P NATL ACAD SCI USA, V100, P5286, DOI 10.1073/pnas.0836980100; Liu AM, 2005, DEVELOPMENT, V132, P3103, DOI 10.1242/dev.01894; Liu Q, 2004, J NEUROSCI, V24, P6427, DOI 10.1523/JNEUROSCI.1335-04.2004; Low SH, 2006, DEV CELL, V10, P57, DOI 10.1016/j.devcel.2005.12.005; Lum L, 2004, SCIENCE, V304, P1755, DOI 10.1126/science.1098020; Marszalek JR, 2000, CELL, V102, P175, DOI 10.1016/S0092-8674(00)00023-4; Menco BPM, 2005, J NEUROCYTOL, V34, P11, DOI 10.1007/s11068-005-5045-9; Morgan D, 1998, NAT GENET, V20, P149, DOI 10.1038/2450; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Nonaka S, 1998, CELL, V95, P829, DOI 10.1016/S0092-8674(00)81705-5; Nusse R, 2003, DEVELOPMENT, V130, P5297, DOI 10.1242/dev.00821; O'Toole ET, 2003, MOL BIOL CELL, V14, P2999, DOI 10.1091/mbc.E02-11-0755; Otto EA, 2003, NAT GENET, V34, P413, DOI 10.1038/ng1217; Pan JM, 2003, J CELL SCI, V116, P2179, DOI 10.1242/jcs.00438; Park TJ, 2006, NAT GENET, V38, P303, DOI 10.1038/ng1753; Pazour GJ, 1998, J CELL BIOL, V141, P979, DOI 10.1083/jcb.141.4.979; Praetorius HA, 2001, J MEMBRANE BIOL, V184, P71, DOI 10.1007/s00232-001-0075-4; Rosenbaum JL, 2002, NAT REV MOL CELL BIO, V3, P813, DOI 10.1038/nrm952; Ross AJ, 2005, NAT GENET, V37, P1135, DOI 10.1038/ng1644; Saadi-Kheddouci S, 2001, ONCOGENE, V20, P5972, DOI 10.1038/sj.onc.1204825; Sarpal R, 2003, CURR BIOL, V13, P1687, DOI 10.1016/j.cub.2003.09.025; Schlesinger A, 1999, GENE DEV, V13, P2028, DOI 10.1101/gad.13.15.2028; Shimada Y, 2006, DEV CELL, V10, P209, DOI 10.1016/j.devcel.2005.11.016; Simons M, 2005, NAT GENET, V37, P537, DOI 10.1038/ng1552; Smith UM, 2006, NAT GENET, V38, P191, DOI 10.1038/ng1713; Snow JJ, 2004, NAT CELL BIOL, V6, P1109, DOI 10.1038/ncb1186; Strissel KJ, 2005, J BIOL CHEM, V280, P29250, DOI 10.1074/jbc.M501789200; Tobin DM, 2002, NEURON, V35, P307, DOI 10.1016/S0896-6273(02)00757-2; Yost HJ, 2003, CURR BIOL, V13, pR808, DOI 10.1016/j.cub.2003.09.051	70	784	809	8	117	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 4	2006	313	5787					629	633		10.1126/science.1124534	http://dx.doi.org/10.1126/science.1124534			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	072IQ	16888132				2022-12-28	WOS:000239667500032
J	Abzhanov, A; Kuo, WP; Hartmann, C; Grant, BR; Grant, PR; Tabin, CJ				Abzhanov, Arhat; Kuo, Winston P.; Hartmann, Christine; Grant, B. Rosemary; Grant, Peter R.; Tabin, Clifford J.			The calmodulin pathway and evolution of elongated beak morphology in Darwin's finches	NATURE			English	Article							THREESPINE STICKLEBACKS; HOX GENES	A classic textbook example of adaptive radiation under natural selection is the evolution of 14 closely related species of Darwin's finches (Fringillidae, Passeriformes), whose primary diversity lies in the size and shape of their beaks(1-6). Thus, ground finches have deep and wide beaks, cactus finches have long and pointed beaks ( low depth and narrower width), and warbler finches have slender and pointed beaks, reflecting differences in their respective diets(6). Previous work has shown that even small differences in any of the three major dimensions ( depth, width and length) of the beak have major consequences for the overall fitness of the birds(3-7). Recently we used a candidate gene approach to explain one pathway involved in Darwin's finch beak morphogenesis(8). However, this type of analysis is limited to molecules with a known association with craniofacial and/or skeletogenic development. Here we use a less constrained, complementary DNA microarray analysis of the transcripts expressed in the beak primordia to find previously unknown genes and pathways whose expression correlates with specific beak morphologies. We show that calmodulin (CaM), a molecule involved in mediating Ca2+ signalling, is expressed at higher levels in the long and pointed beaks of cactus finches than in more robust beak types of other species. We validated this observation with in situ hybridizations. When this upregulation of the CaM-dependent pathway is artificially replicated in the chick frontonasal prominence, it causes an elongation of the upper beak, recapitulating the beak morphology of the cactus finches. Our results indicate that local upregulation of the CaM-dependent pathway is likely to have been a component of the evolution of Darwin's finch species with elongated beak morphology and provide a mechanistic explanation for the independence of beak evolution along different axes. More generally, our results implicate the CaM-dependent pathway in the developmental regulation of craniofacial skeletal structures.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Decis Syst Grp, Boston, MA 02115 USA; Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA; Inst Mol Pathol, A-1030 Vienna, Austria; Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard School of Dental Medicine; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Princeton University	Tabin, CJ (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.	tabin@genetics.med.harvard.edu	Grant, Peter/HIR-3733-2022	Hartmann, Christine/0000-0002-6854-8633				Abzhanov A, 2004, SCIENCE, V305, P1462, DOI 10.1126/science.1098095; Abzhanov A, 1999, DEVELOPMENT, V126, P1121; Abzhanov A, 2000, DEVELOPMENT, V127, P2239; Averof M, 1997, NATURE, V388, P682, DOI 10.1038/41786; BOWMAN ROBERT I., 1961, UNIV CALIFORNIA PUBL ZOOL, V58, P1; BURKE AC, 1995, DEVELOPMENT, V121, P333; Darwin C., 1845, J RES GEOLOGY NATURA, V2; Dudoit S, 2002, STAT SINICA, V12, P111; Freeman S., 2003, EVOLUTIONARY ANAL; Futuyma D. J., 1998, EVOLUTIONARY BIOL; Grant B. R., 1989, EVOLUTIONARY DYNAMIC; Grant P.R., 1999, RECOGNITION STATES L, V2; GRANT PR, 1994, EVOLUTION, V48, P297, DOI 10.1111/j.1558-5646.1994.tb01313.x; Grant PR, 2002, SCIENCE, V296, P707, DOI 10.1126/science.1070315; GRANT PR, 1981, PROC R SOC SER B-BIO, V212, P403, DOI 10.1098/rspb.1981.0046; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Kimmel CB, 2005, P NATL ACAD SCI USA, V102, P5791, DOI 10.1073/pnas.0408533102; Kirschner M, 2005, PLAUSIBILITY LIFE RE; Lack D., 1947, DARWINS FINCHES; O'Day DH, 2003, CELL SIGNAL, V15, P347, DOI 10.1016/S0898-6568(02)00116-X; Petren K, 1999, P ROY SOC B-BIOL SCI, V266, P321, DOI 10.1098/rspb.1999.0641; PRICE TD, 1985, AM NAT, V125, P169, DOI 10.1086/284336; Shapiro MD, 2004, NATURE, V428, P717, DOI 10.1038/nature02415	23	395	402	2	304	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 3	2006	442	7102					563	567		10.1038/nature04843	http://dx.doi.org/10.1038/nature04843			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	069NQ	16885984				2022-12-28	WOS:000239455900043
J	Moyen, JF; Stevens, G; Kisters, A				Moyen, Jean-Francois; Stevens, Gary; Kisters, Alexander			Record of mid-Archaean subduction from metamorphism in the Barberton terrain, South Africa	NATURE			English	Article							GREENSTONE-BELT; EXHUMATION; TECTONICS; GRANITES	Although plate tectonics is the central geological process of the modern Earth, its form and existence during the Archaean era (4.0 - 2.5 Gyr ago) are disputed(1,2). The existence of subduction during this time is particularly controversial because characteristic subduction-related mineral assemblages, typically documenting apparent geothermal gradients of 15 degrees C km(-1) or less(3), have not yet been recorded from in situ Archaean rocks ( the lowest recorded apparent geothermal gradients(4) are greater than 25 degrees C km(-1)). Despite this absence from the rock record, low Archaean geothermal gradients are suggested by eclogitic nodules in kimberlites(5,6) and circumstantial evidence for subduction processes, including possible accretion-related structures(2), has been reported in Archaean terrains. The lack of spatially and temporally well-constrained high-pressure, low-temperature metamorphism continues, however, to cast doubt on the relevance of subduction-driven tectonics during the first 1.5 Gyr of the Earth's history(7). Here we report garnet-albite-bearing mineral assemblages that record pressures of 1.2 - 1.5 GPa at temperatures of 600 - 650 degrees C from supracrustal amphibolites from the mid-Archaean Barberton granitoid-greenstone terrain. These conditions point to apparent geothermal gradients of 12 - 15 degrees C - similar to those found in recent subduction zones - that coincided with the main phase of terrane accretion in the structurally overlying Barberton greenstone belt(8). These high-pressure, low-temperature conditions represent metamorphic evidence for cold and strong lithosphere, as well as subduction-driven tectonic processes, during the evolution of the early Earth.	Univ Stellenbosch, Dept Geol, ZA-7602 Matieland, South Africa	Stellenbosch University	Moyen, JF (corresponding author), Univ Stellenbosch, Dept Geol, South Africa Private Bag X-1, ZA-7602 Matieland, South Africa.	moyen@sun.ac.za; gs@sun.ac.za	Stevens, Gary/I-2622-2014; Moyen, Jean-Francois/E-2043-2012	Stevens, Gary/0000-0003-1593-9419; Moyen, Jean-Francois/0000-0002-0065-2442				Bjornerud MG, 2004, GEOLOGY, V32, P765, DOI 10.1130/G20590.1; Chemenda AI, 1996, EARTH PLANET SC LETT, V143, P173, DOI 10.1016/0012-821X(96)00123-9; De Ronde CEJ, 2000, J AFR EARTH SCI, V30, P219, DOI 10.1016/S0899-5362(00)00017-8; de Wit MJ, 1998, PRECAMBRIAN RES, V91, P181, DOI 10.1016/S0301-9268(98)00043-6; DEWIT MJ, 1992, NATURE, V357, P553, DOI 10.1038/357553a0; Diener JFA, 2005, PRECAMBRIAN RES, V143, P87, DOI 10.1016/j.precamres.2005.10.001; DIENER JFA, 2005, AGU GEOPHYS MONOGRAP, V164, P239; Dziggel A, 2002, PRECAMBRIAN RES, V114, P221, DOI 10.1016/S0301-9268(01)00225-X; DZIGGEL A, 2006, MINERAL MAG, V69, P1021; ERNST WG, 1988, GEOLOGY, V16, P1081, DOI 10.1130/0091-7613(1988)016<1081:THOSZI>2.3.CO;2; Hamilton WB, 1998, PRECAMBRIAN RES, V91, P143, DOI 10.1016/S0301-9268(98)00042-4; HOLLAND T, 1994, CONTRIB MINERAL PETR, V116, P433, DOI 10.1007/BF00310910; Holland TJB, 1998, J METAMORPH GEOL, V16, P309, DOI 10.1111/j.1525-1314.1998.00140.x; IRELAND TR, 1994, EARTH PLANET SC LETT, V128, P199, DOI 10.1016/0012-821X(94)90145-7; KAMO SL, 1994, TECTONICS, V13, P167, DOI 10.1029/93TC02254; Kisters AFM, 2003, PRECAMBRIAN RES, V127, P355, DOI 10.1016/j.precamres.2003.08.002; KOHN MJ, 1989, AM MINERAL, V74, P77; NICOLLET C, 1978, CAN J EARTH SCI, V15, P695; Powell R, 1998, J METAMORPH GEOL, V16, P577, DOI 10.1111/j.1525-1314.1998.00157.x; RICIPUTI LR, 1990, J METAMORPH GEOL, V8, P171, DOI 10.1111/j.1525-1314.1990.tb00464.x; Rollinson H, 1997, NATURE, V389, P173, DOI 10.1038/38266; SPEAR FS, 1993, METAMORPHIC PHASE EQ, P535; Stevens G, 2002, S AFR J GEOL, V105, P271, DOI 10.2113/1050271; [No title captured]	24	210	218	0	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 3	2006	442	7102					559	562		10.1038/nature04972	http://dx.doi.org/10.1038/nature04972			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	069NQ	16885983				2022-12-28	WOS:000239455900042
J	Andersen, CBF; Becker, T; Blau, M; Anand, M; Halic, M; Balar, B; Mielke, T; Boesen, T; Pedersen, JS; Spahn, CMT; Kinzy, TG; Andersen, GR; Beckmann, R				Andersen, Christian B. F.; Becker, Thomas; Blau, Michael; Anand, Monika; Halic, Mario; Balar, Bharvi; Mielke, Thorsten; Boesen, Thomas; Pedersen, Jan Skov; Spahn, Christian M. T.; Kinzy, Terri Goss; Andersen, Gregers R.; Beckmann, Roland			Structure of eEF3 and the mechanism of transfer RNA release from the E-site	NATURE			English	Article							ATP-BINDING CASSETTE; ELONGATION-FACTOR 3; RAY SOLUTION SCATTERING; ANGSTROM RESOLUTION; ELECTRON-MICROSCOPY; ESCHERICHIA-COLI; ABC TRANSPORTERS; 80S RIBOSOME; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE	Elongation factor eEF3 is an ATPase that, in addition to the two canonical factors eEF1A and eEF2, serves an essential function in the translation cycle of fungi. eEF3 is required for the binding of the aminoacyl-tRNA-eEF1A-GTP ternary complex to the ribosomal A-site and has been suggested to facilitate the clearance of deacyl-tRNA from the E-site. Here we present the crystal structure of Saccharomyces cerevisiae eEF3, showing that it consists of an amino-terminal HEAT repeat domain, followed by a four-helix bundle and two ABC-type ATPase domains, with a chromodomain inserted in ABC2. Moreover, we present the cryo-electron microscopy structure of the ATP-bound form of eEF3 in complex with the post-translocational-state 80S ribosome from yeast. eEF3 uses an entirely new factor binding site near the ribosomal E-site, with the chromodomain likely to stabilize the ribosomal L1 stalk in an open conformation, thus allowing tRNA release.	Humboldt Univ, Inst Biochem, Charite, Univ Med Sch, D-10117 Berlin, Germany; Aarhus Univ, Dept Mol Biol, Ctr Struct Biol, DK-8000 Aarhus, Denmark; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet Microbiol & Immunol, Piscataway, NJ 08854 USA; Max Planck Inst Mol Genet, UltraStruct Network, D-14195 Berlin, Germany; Aarhus Univ, Dept Chem, DK-8000 Aarhus, Denmark; Aarhus Univ, iNANO Interdisciplinary Nanosci Ctr, DK-8000 Aarhus, Denmark; Humboldt Univ, Inst Med Phys & Biophys, Charite, Univ Med Sch, D-10117 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Hamburg; University Medical Center Hamburg-Eppendorf; Aarhus University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Max Planck Society; Aarhus University; Aarhus University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Hamburg; University Medical Center Hamburg-Eppendorf	Beckmann, R (corresponding author), Humboldt Univ, Inst Biochem, Charite, Univ Med Sch, Monbijoustr 2, D-10117 Berlin, Germany.	gra@mb.au.dk; beckmann@lmb.uni-muenchen.de	Halic, Mario/X-2163-2018; Andersen, Christian/G-9954-2011; Pedersen, Jan Skov/A-8346-2008	Pedersen, Jan Skov/0000-0002-7768-0206; Kinzy, Terri/0000-0003-1394-9226; Boesen, Thomas/0000-0002-5633-6844; Andersen, Gregers Rom/0000-0001-6292-3319	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062789, R01GM057483] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM057483, R01 GM062789] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersen CF, 2004, ACTA CRYSTALLOGR D, V60, P1304, DOI 10.1107/S0907444904010716; Andrade MA, 2001, J MOL BIOL, V309, P1, DOI 10.1006/jmbi.2001.4624; Beckmann R, 2001, CELL, V107, P361, DOI 10.1016/S0092-8674(01)00541-4; Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; Brehm A, 2004, BIOESSAYS, V26, P133, DOI 10.1002/bies.10392; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; DeLano WL, 2002, PYMOL USERS MANUAL; Frank J, 2000, NATURE, V406, P318, DOI 10.1038/35018597; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Gomez-Lorenzo MG, 2000, EMBO J, V19, P2710, DOI 10.1093/emboj/19.11.2710; Gontarek RR, 1998, J BIOL CHEM, V273, P10249, DOI 10.1074/jbc.273.17.10249; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; Halic M, 2004, NATURE, V427, P808, DOI 10.1038/nature02342; Harms J, 2001, CELL, V107, P679, DOI 10.1016/S0092-8674(01)00546-3; Higgins CF, 2004, NAT STRUCT MOL BIOL, V11, P918, DOI 10.1038/nsmb836; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Jones PM, 2002, P NATL ACAD SCI USA, V99, P12639, DOI 10.1073/pnas.152439599; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 2001, INT TABLES CRYSTALLO; KAMATH A, 1989, J BIOL CHEM, V264, P15423; Kambampati R, 1997, J BIOL CHEM, V272, P6377, DOI 10.1074/jbc.272.10.6377; Kambampati R, 2000, J BIOL CHEM, V275, P16963, DOI 10.1074/jbc.M001157200; Karcher A, 2005, STRUCTURE, V13, P649, DOI 10.1016/j.str.2005.02.008; Kovalchuke O, 1998, EUR J BIOCHEM, V258, P986, DOI 10.1046/j.1432-1327.1998.2580986.x; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Lu G, 2005, P NATL ACAD SCI USA, V102, P17969, DOI 10.1073/pnas.0506039102; Morgan DG, 2002, J MOL BIOL, V324, P871, DOI 10.1016/S0022-2836(02)01111-7; Mueller F, 1995, BIOCHEM CELL BIOL, V73, P767, DOI 10.1139/o95-085; Ogle JM, 2005, ANNU REV BIOCHEM, V74, P129, DOI 10.1146/annurev.biochem.74.061903.155440; Pedersen JS, 2004, J APPL CRYSTALLOGR, V37, P369, DOI 10.1107/S0021889804004170; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Reyes CL, 2005, SCIENCE, V308, P1028, DOI 10.1126/science.1107733; Robinson H, 1998, NATURE, V392, P202, DOI 10.1038/32455; Sarthy AV, 1997, ANAL BIOCHEM, V254, P288, DOI 10.1006/abio.1997.2456; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Spahn CMT, 2001, CELL, V107, P373, DOI 10.1016/S0092-8674(01)00539-6; Spahn CMT, 2004, EMBO J, V23, P1008, DOI 10.1038/sj.emboj.7600102; Stein AJ, 2005, CELL, V121, P529, DOI 10.1016/j.cell.2005.03.009; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Svergun DI, 2001, BIOPHYS J, V80, P2946, DOI 10.1016/S0006-3495(01)76260-1; Terwilliger T, 2004, J SYNCHROTRON RADIAT, V11, P49, DOI 10.1107/S0909049503023938; TRIANAALONSO FJ, 1995, J BIOL CHEM, V270, P20473, DOI 10.1074/jbc.270.35.20473; Valle M, 2003, CELL, V114, P123, DOI 10.1016/S0092-8674(03)00476-8; WAGENKNECHT T, 1988, J MOL BIOL, V199, P137, DOI 10.1016/0022-2836(88)90384-1; Wriggers W, 1999, J STRUCT BIOL, V125, P185, DOI 10.1006/jsbi.1998.4080; Yuan YR, 2001, J BIOL CHEM, V276, P32313, DOI 10.1074/jbc.M100758200; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089	49	110	111	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 12	2006	443	7112					663	668		10.1038/nature05126	http://dx.doi.org/10.1038/nature05126			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	093HX	16929303	Green Published			2022-12-28	WOS:000241160500039
J	Andersen, CBF; Ballut, L; Johansen, JS; Chamieh, H; Nielsen, KH; Oliveira, CLP; Pedersen, JS; Seraphin, B; Le Hir, H; Andersen, GR				Andersen, Christian B. F.; Ballut, Lionel; Johansen, Jesper S.; Chamieh, Hala; Nielsen, Klaus H.; Oliveira, Cristiano L. P.; Pedersen, Jan Skov; Seraphin, Bertrand; Le Hir, Herve; Andersen, Gregers Rom			Structure of the exon junction core complex with a trapped DEAD-box ATPase bound to RNA	SCIENCE			English	Article							MESSENGER-RNA; HELICASE ACTIVITY; MOLECULAR INSIGHTS; CRYSTAL-STRUCTURE; MAMMALIAN-CELLS; BINDING; DECAY; TRANSLATION; EIF4A; DISTINCT	In higher eukaryotes, a multiprotein exon junction complex is deposited on spliced messenger RNAs. The complex is organized around a stable core, which serves as a binding platform for numerous factors that influence messenger RNA function. Here, we present the crystal structure of a tetrameric exon junction core complex containing the DEAD-box adenosine triphosphatase ( ATPase) eukaryotic initiation factor 4AIII (eIF4AIII) bound to an ATP analog, MAGOH, Y14, a fragment of MLN51, and a polyuracil mRNA mimic. eIF4AIII interacts with the phosphate-ribose backbone of six consecutive nucleotides and prevents part of the bound RNA from being double stranded. The MAGOH and Y14 subunits lock eIF4AIII in a prehydrolysis state, and activation of the ATPase probably requires only modest conformational changes in eIF4AIII motif I.	Univ Paris 06, Ctr Genet Mol, Equipe Labelisee Ligue, CNRS,UPR2167, F-91198 Gif Sur Yvette, France; Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus, Denmark; Aarhus Univ, Ctr mRNP Biogenesis & Metab, DK-8000 Aarhus, Denmark; Aarhus Univ, Dept Chem, DK-8000 Aarhus, Denmark; Aarhus Univ, iNANO Interdisciplinary Nanosci Ctr, DK-8000 Aarhus, Denmark	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; Aarhus University; Aarhus University; Aarhus University; Aarhus University	Andersen, GR (corresponding author), Univ Paris 06, Ctr Genet Mol, Equipe Labelisee Ligue, CNRS,UPR2167, Ave Terrasse, F-91198 Gif Sur Yvette, France.	herve.lehir@cgm.cnrs-gif.fr; gra@mb.au.dk	Pedersen, Jan Skov/A-8346-2008; Oliveira, Cristiano L P/B-4403-2008; Andersen, Christian/G-9954-2011	Pedersen, Jan Skov/0000-0002-7768-0206; Oliveira, Cristiano L P/0000-0002-3426-6507; Le Hir, Herve/0000-0001-7964-9221; Ballut, Lionel/0000-0002-3982-9321; Andersen, Gregers Rom/0000-0001-6292-3319; Seraphin, Bertrand/0000-0002-5168-1921				ABRAMSON RD, 1987, J BIOL CHEM, V262, P3826; Ballut L, 2005, NAT STRUCT MOL BIOL, V12, P861, DOI 10.1038/nsmb990; Bono F, 2004, EMBO REP, V5, P304, DOI 10.1038/sj.embor.7400091; Caruthers JM, 2000, P NATL ACAD SCI USA, V97, P13080, DOI 10.1073/pnas.97.24.13080; Conti E, 2005, CURR OPIN CELL BIOL, V17, P316, DOI 10.1016/j.ceb.2005.04.005; Cordin O, 2006, GENE, V367, P17, DOI 10.1016/j.gene.2005.10.019; Cordin O, 2004, EMBO J, V23, P2478, DOI 10.1038/sj.emboj.7600272; Degot S, 2004, J BIOL CHEM, V279, P33702, DOI 10.1074/jbc.M402754200; Dostie J, 2002, CURR BIOL, V12, P1060, DOI 10.1016/S0960-9822(02)00902-8; Fairman ME, 2004, SCIENCE, V304, P730, DOI 10.1126/science.1095596; Fribourg S, 2003, NAT STRUCT BIOL, V10, P433, DOI 10.1038/nsb926; Gehring NH, 2005, MOL CELL, V20, P65, DOI 10.1016/j.molcel.2005.08.012; Gehring NH, 2003, MOL CELL, V11, P939, DOI 10.1016/S1097-2765(03)00142-4; Jankowsky E, 2001, SCIENCE, V291, P121, DOI 10.1126/science.291.5501.121; Lau CK, 2003, CURR BIOL, V13, P933, DOI 10.1016/S0960-9822(03)00328-2; Le Hir H, 2000, EMBO J, V19, P6860, DOI 10.1093/emboj/19.24.6860; Lejeune F, 2005, CURR OPIN CELL BIOL, V17, P309, DOI 10.1016/j.ceb.2005.03.002; Lejeune F, 2002, EMBO J, V21, P3536, DOI 10.1093/emboj/cdf345; Li QY, 1999, MOL CELL BIOL, V19, P7336; Lorsch JR, 1998, BIOCHEMISTRY-US, V37, P2180, DOI 10.1021/bi972430g; Oberer M, 2005, GENE DEV, V19, P2212, DOI 10.1101/gad.1335305; PAUSE A, 1993, MOL CELL BIOL, V13, P6789, DOI 10.1128/MCB.13.11.6789; Rogers GW, 2001, J BIOL CHEM, V276, P12598, DOI 10.1074/jbc.M007560200; Sengoku T, 2006, CELL, V125, P287, DOI 10.1016/j.cell.2006.01.054; Shi H, 2003, GENE DEV, V17, P971, DOI 10.1101/gad.260403; Shibuya T, 2006, RNA, V12, P360, DOI 10.1261/rna.2190706; Tange TO, 2004, CURR OPIN CELL BIOL, V16, P279, DOI 10.1016/j.ceb.2004.03.012	27	307	313	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 29	2006	313	5795					1968	1972		10.1126/science.1131981	http://dx.doi.org/10.1126/science.1131981			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	088SU	16931718				2022-12-28	WOS:000240832200053
J	Axelrod, JD				Axelrod, Jeffrey D.			Cell shape in proliferating epithelia: A multifaceted problem	CELL			English	Editorial Material							DROSOPHILA; SIZE		Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA	Stanford University	Axelrod, JD (corresponding author), Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA.	jaxelrod@stanford.edu						Baena-Lopez LA, 2005, CURR BIOL, V15, P1640, DOI 10.1016/j.cub.2005.07.062; Bertet C, 2004, NATURE, V429, P667, DOI 10.1038/nature02590; de la Cova C, 2004, CELL, V117, P107, DOI 10.1016/S0092-8674(04)00214-4; GIBSON MC, 2006, IN PRESS NATURE; Hayashi T, 2004, NATURE, V431, P647, DOI 10.1038/nature02952; Moreno E, 2002, NATURE, V416, P755, DOI 10.1038/416755a; Resino J, 2002, P NATL ACAD SCI USA, V99, P7502, DOI 10.1073/pnas.072208199; Rolland-Lagan AG, 2003, NATURE, V422, P161, DOI 10.1038/nature01443; TAYLOR JE, 1976, ANN MATH, V103, P489, DOI 10.2307/1970949; Zallen JA, 2004, J PHYS-CONDENS MAT, V16, pS5073, DOI 10.1088/0953-8984/16/44/005	10	19	19	1	5	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 25	2006	126	4					643	645		10.1016/j.cell.2006.07.018	http://dx.doi.org/10.1016/j.cell.2006.07.018			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	080VN	16923381	Bronze			2022-12-28	WOS:000240276700009
J	Lee, SH; Stephens, JL; Paul, KS; Englund, PT				Lee, Soo Hee; Stephens, Jennifer L.; Paul, Kimberly S.; Englund, Paul T.			Fatty acid synthesis by elongases in trypanosomes.	CELL			English	Article							VARIANT SURFACE GLYCOPROTEIN; SACCHAROMYCES-CEREVISIAE; AFRICAN TRYPANOSOMES; CULTURE FORMS; BRUCEI; ELONGATION; GENE; MYRISTATE; BIOSYNTHESIS; EXPRESSION	All eukaryotic and prokaryotic organisms are thought to synthesize fatty acids using a type I or type II synthase. In addition, eukaryotes extend pre-existing long chain fatty acids using microsomal elongases (ELOs). We have found that Trypanosoma brucei, a eukaryotic human parasite that causes sleeping sickness, uses three elongases instead of type I or type II synthases for the synthesis of nearly all its fatty acids. Trypanosomes encounter diverse environments during their life cycle with different fatty acid requirements. The tsetse vector form requires synthesis of stearate (C18), whereas the bloodstream form needs myristate (C14). We find that trypanosome fatty acid synthesis is modular, with EL01 converting C4 to C10, EL02 extending C1 0 to C14, and EL03 elongating C14 to C18. In blood, EL03 downregulation favors myristate synthesis, whereas low concentrations of exogenous fatty acids in cultured parasites cause upregulation of the entire pathway, allowing the parasite to adapt to different environments.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University	Englund, PT (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA.	penglund@jhmi.edu	Paul, Kimberly/AAO-4275-2020; Lee, Soo Hee/E-9494-2012	Guler, Jennifer/0000-0001-6301-4563	NIAID NIH HHS [AI21334] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021334] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BRUN R, 1979, ACTA TROP, V36, P289; Dittrich F, 1998, EUR J BIOCHEM, V252, P477, DOI 10.1046/j.1432-1327.1998.2520477.x; DIXON H, 1971, COMP BIOCHEM PHYSIOL, V39, P247, DOI 10.1016/0305-0491(71)90168-4; DOERING TL, 1993, J BIOL CHEM, V268, P9215; Donelson JE, 2003, ACTA TROP, V85, P391, DOI 10.1016/S0001-706X(02)00237-1; Duffieux F, 2000, J BIOL CHEM, V275, P27559; Ferguson MAJ, 1997, PHILOS T ROY SOC B, V352, P1295, DOI 10.1098/rstb.1997.0113; FERGUSON MAJ, 1984, J BIOL CHEM, V259, P3011; FIELD MC, 1991, EMBO J, V10, P2731, DOI 10.1002/j.1460-2075.1991.tb07821.x; FOSBROOKE AS, 1968, CLIN CHIM ACTA, V20, P517, DOI 10.1016/0009-8981(68)90311-2; GRAB DJ, 1982, ACTA TROP, V39, P363; Gu PD, 1997, COMP BIOCHEM PHYS B, V118, P447, DOI 10.1016/S0305-0491(97)00112-0; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; JUAREZ P, 1992, ARCH BIOCHEM BIOPHYS, V293, P333, DOI 10.1016/0003-9861(92)90403-J; KLEIN RA, 1976, BIOCHEM SOC T, V4, P48, DOI 10.1042/bst0040048; Kohlwein SD, 2001, MOL CELL BIOL, V21, P109, DOI 10.1128/MCB.21.1.109-125.2001; Lamb JR, 2001, J BIOL CHEM, V276, P21512, DOI 10.1074/jbc.M100235200; LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7; Lentner C, 1981, GEIGY SCI TABLES UNI, V1; Leonard AE, 2004, PROG LIPID RES, V43, P36, DOI 10.1016/S0163-7827(03)00040-7; Marchetti MA, 2000, J CELL SCI, V113, P899; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; MCCARTHYBURKE C, 1991, EXP PARASITOL, V73, P385, DOI 10.1016/0014-4894(91)90112-A; Moon YA, 2001, J BIOL CHEM, V276, P45358, DOI 10.1074/jbc.M108413200; Morita YS, 2000, SCIENCE, V288, P140, DOI 10.1126/science.288.5463.140; Morita YS, 2001, MOL BIOCHEM PARASIT, V115, P157, DOI 10.1016/S0166-6851(01)00279-1; Oh CS, 1997, J BIOL CHEM, V272, P17376, DOI 10.1074/jbc.272.28.17376; PARSONS M, 1990, MOL BIOCHEM PARASIT, V42, P197, DOI 10.1016/0166-6851(90)90162-F; Paul KS, 2004, EUKARYOT CELL, V3, P855, DOI 10.1128/EC.3.4.855-861.2004; Paul KS, 2001, TRENDS PARASITOL, V17, P381, DOI 10.1016/S1471-4922(01)01984-5; SMITH S, 1994, FASEB J, V8, P1248, DOI 10.1096/fasebj.8.15.8001737; Toke DA, 1996, J BIOL CHEM, V271, P18413, DOI 10.1074/jbc.271.31.18413; van Weelden SWH, 2005, J BIOL CHEM, V280, P12451, DOI 10.1074/jbc.M412447200; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; White SW, 2005, ANNU REV BIOCHEM, V74, P791, DOI 10.1146/annurev.biochem.74.082803.133524; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; Zhang L, 2005, J BIOL CHEM, V280, P12422, DOI 10.1074/jbc.M413686200; Zingales B, 1997, MEM I OSWALDO CRUZ, V92, P811, DOI 10.1590/S0074-02761997000600016	38	105	120	1	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 25	2006	126	4					691	699		10.1016/j.cell.2006.06.045	http://dx.doi.org/10.1016/j.cell.2006.06.045			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	080VN	16923389	Bronze			2022-12-28	WOS:000240276700018
J	Tal, A				Tal, Alon			Seeking sustainability: Israel's evolving water management strategy	SCIENCE			English	Editorial Material								The water management policies adopted to address Israel's chronic scarcity have not been without environmental consequences. Yet, through a trial-and-error process, a combined strategy of water transport, rainwater harvesting, and wastewater reuse and desalination, along with a variety of water conservation measures, have put the country on a more sustainable path for the future.	Ben Gurion Univ Negev, Jacob Blaustein Inst Desert Res, Mitrani Dept Desert Ecol, IL-84990 Sede Boqer, Israel	Ben Gurion University	Tal, A (corresponding author), Ben Gurion Univ Negev, Jacob Blaustein Inst Desert Res, Mitrani Dept Desert Ecol, IL-84990 Sede Boqer, Israel.	alontal@bgu.ac.il						BECKER N, 2004, INITIAL ASSESSMENT Q; Ben-Gal A, 2004, VADOSE ZONE J, V3, P1407; Dalhuisen JM, 2003, LAND ECON, V79, P292, DOI 10.2307/3146872; DEVILLIERS M, 1999, WATER; DREIZIN Y, 2004, WAT LIF MIDDL E C AN; FALKENMARK M, 1989, NAT RESOUR FORUM, V13, P258, DOI 10.1111/j.1477-8947.1989.tb00348.x; FATTAL B, 1981, DEV ARID ZONE ECOLOG; FEDLER J, 2002, ISRAELS AGR 21 CENTU; Feitelson E, 2002, POLIT GEOGR, V21, P293, DOI 10.1016/S0962-6298(01)00038-5; *FRIENDS EARTH MID, 2005, LET JORD RIV FLOW; GABBAY S, 2002, ENV ISRAEL; GLEICK P, 2002, WORLDS WATER BIENNIA; Glennon Robert Jerome, 2002, WATER FOLLIES GROUND; GVIRTSMAN C, 2002, WATER RESOURCES ISRA; HASSON N, 2006, HAARETZ         0412, P1; Hillel D., 2000, SALINITY MANAGEMENT; *ISR MIN ENV PROT, 2006, SOURC WAT POLL; *ISR UN ENV DEF, 2005, ENV POV REP; *JEW NAT FUND, 2004, WAT LIF KKL POL EST; Juanico M, 1999, WATER SCI TECHNOL, V40, P43, DOI 10.2166/wst.1999.0573; Kronenberg G, 2004, DESALINATION, V166, P457, DOI 10.1016/S0011-9164(04)00329-7; MUSZKOT L, 1990, ADV MASS SPECTROM, V11, P1728; National Research Council, 1996, USE RECLAIMED WATER, DOI [10.17226/5175, DOI 10.17226/5175]; Pearce F, 2006, RIVERS RUN DRY WATER; Reisner M., 1986, CADILLAC DESERT AM W; Shamir U, 1999, IAHS-AISH P, P409; Shuval H., 1980, WATER QUALITY MANAGE; Tal A, 2002, POLLUTION PROMISED L; TAL A, 2005, SUSTAINABLE WATER MA; Ward D.R., 2002, WATER WARS DROUGHT F; ZASLAVSKY D, 2002, BELOW RED LINE REGAR; 2006, AGAMIT, V176, P4	32	146	150	5	134	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 25	2006	313	5790					1081	1084		10.1126/science.1126011	http://dx.doi.org/10.1126/science.1126011			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	076ZT	16931752				2022-12-28	WOS:000239998200034
J	Bernhard, H; Fischbacher, U; Fehr, E				Bernhard, Helen; Fischbacher, Urs; Fehr, Ernst			Parochial altruism in humans	NATURE			English	Article							INDIRECT RECIPROCITY; SOCIAL NORMS; EVOLUTION; PUNISHMENT; ENFORCEMENT; BEHAVIOR	Social norms and the associated altruistic behaviours are decisive for the evolution of human cooperation(1-9) and the maintenance of social order(10), and they affect family life, politics(11) and economic interactions(12). However, as altruistic norm compliance and norm enforcement often emerge in the context of inter-group conflicts(13,14), they are likely to be shaped by parochialism(15) - a preference for favouring the members of one's ethnic, racial or language group. We have conducted punishment experiments(16), which allow 'impartial' observers to punish norm violators, with indigenous groups in Papua New Guinea. Here we show that these experiments confirm the prediction of parochialism. We found that punishers protect ingroup victims - who suffer from a norm violation - much more than they do outgroup victims, regardless of the norm violator's group affiliation. Norm violators also expect that punishers will be lenient if the latter belong to their social group. As a consequence, norm violations occur more often if the punisher and the norm violator belong to the same group. Our results are puzzling for evolutionary multi-level selection theories based on selective group extinction(2-5) as well as for theories of individual selection(17-19); they also indicate the need to explicitly examine the interactions between individuals stemming from different groups in evolutionary models.	Univ Zurich, Inst Empir Res Econ, CH-8006 Zurich, Switzerland; Coll Helveticum, CH-8092 Zurich, Switzerland	University of Zurich	Fehr, E (corresponding author), Univ Zurich, Inst Empir Res Econ, Blumlisalpstr 10, CH-8006 Zurich, Switzerland.	fiba@iew.unizh.ch; efehr@iew.unizh.ch	Fischbacher, Urs/H-2693-2014	Fischbacher, Urs/0000-0002-5115-8815				BOEHM C, 1993, CURR ANTHROPOL, V34, P227, DOI 10.1086/204166; Bornstein G, 2003, PERS SOC PSYCHOL REV, V7, P129, DOI 10.1207/S15327957PSPR0702_129-145; Bowles S, 2003, J THEOR BIOL, V223, P135, DOI 10.1016/S0022-5193(03)00060-2; BOWLES S, 2004, CULTURAL DIVERSITY V, P81; Boyd R, 2003, P NATL ACAD SCI USA, V100, P3531, DOI 10.1073/pnas.0630443100; BREWER MB, 1979, PSYCHOL BULL, V86, P307, DOI 10.1037/0033-2909.86.2.307; Elster J, 1989, CEMENT SOC STUDY SOC; Fehr E, 2002, NATURE, V415, P137, DOI 10.1038/415137a; Fehr E, 2004, EVOL HUM BEHAV, V25, P63, DOI 10.1016/S1090-5138(04)00005-4; Fehr E, 2003, NATURE, V425, P785, DOI 10.1038/nature02043; Gintis H, 2000, J THEOR BIOL, V206, P169, DOI 10.1006/jtbi.2000.2111; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; HAMILTON WD, 1964, J THEOR BIOL, V7, P26; Henrich J, 2001, AM ECON REV, V91, P73, DOI 10.1257/aer.91.2.73; Henrich J, 2001, J THEOR BIOL, V208, P79, DOI 10.1006/jtbi.2000.2202; HENRICH J, IN PRESS SCIENCE; KAPLAN H, 1985, CURR ANTHROPOL, V26, P223, DOI 10.1086/203251; Kaplan H.S., 2005, MORAL SENTIMENTS MAT, P75; Lindbeck A, 1999, Q J ECON, V114, P1, DOI 10.1162/003355399555936; Milinski M, 2002, NATURE, V415, P424, DOI 10.1038/415424a; Nowak MA, 2005, NATURE, V437, P1291, DOI 10.1038/nature04131; Nowak MA, 1998, NATURE, V393, P573, DOI 10.1038/31225; Otterbein KF., 1985, EVOLUTION WAR CROSS, V2nd edn; RABBIE JM, 1989, EUR J SOC PSYCHOL, V19, P171, DOI 10.1002/ejsp.2420190302; Shinada M, 2004, EVOL HUM BEHAV, V25, P379, DOI 10.1016/j.evolhumbehav.2004.08.001; Sigmund K, 2001, P NATL ACAD SCI USA, V98, P10757, DOI 10.1073/pnas.161155698; Sober E., 1998, OTHERS EVOLUTION PSY; Stutzer A, 2004, J EUR ECON ASSOC, V2, P696, DOI 10.1162/1542476041423331; TAJFEL H, 1971, EUR J SOC PSYCHOL, V1, P149, DOI 10.1002/ejsp.2420010202; TRIVERS RL, 1971, Q REV BIOL, V46, P35, DOI 10.1086/406755; Wiessner P, 2005, HUM NATURE-INT BIOS, V16, P115, DOI 10.1007/s12110-005-1000-9; WIESSNER P, 1998, HIST VINES EGNA NETW; Yamagishi T, 1999, ADV GROUP, V16, P161	33	438	447	7	154	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 24	2006	442	7105					912	915		10.1038/nature04981	http://dx.doi.org/10.1038/nature04981			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	076LT	16929297				2022-12-28	WOS:000239960500036
J	Woolley, KL; Ely, JA; Woolley, MJ; Findlay, L; Lynch, FA; Choi, Y; McDonald, JM				Woolley, Karen L.; Ely, Julie A.; Woolley, Mark J.; Findlay, Leigh; Lynch, Felicity A.; Choi, Yoonah; McDonald, Jane M.			Declaration of medical writing assistance in international peer-reviewed publications	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							ARTICLES; TRIALS		ProScribe Med Commun, Tokyo, Japan			kw@proscribe.com.au	Woolley, Karen/F-6975-2014; Woolley, Karen/K-5041-2013	Woolley, Karen/0000-0003-4626-7723; Woolley, Karen/0000-0003-4626-7723				Camacho LH, 2005, CANCER, V104, P1497, DOI 10.1002/cncr.21337; Flanagin A, 1998, JAMA-J AM MED ASSOC, V280, P222, DOI 10.1001/jama.280.3.222; Hamilton C, 2003, AMWA J, V18, P13; Hamilton CW, 2005, J GEN INTERN MED, V20, P972, DOI 10.1111/j.1525-1497.2005.051391_1.x; Healy DT, 2004, BMJ-BRIT MED J, V329, P1345, DOI 10.1136/bmj.329.7478.1345; *INT COMM MED J ED, UNPUB UNF REQ; Jacobs A, 2005, CURR MED RES OPIN, V21, P317, DOI 10.1185/030079905X25578; KOREITH K, 2004, CENTERWATCH MONTHLY, V11, P104; PHILLIPS SG, 2001, AMWA J, V16, P10; Wager E, 2003, CURR MED RES OPIN, V19, P149, DOI 10.1185/030079903125001767; Wise P, 1996, BRIT MED J, V313, P1245, DOI 10.1136/bmj.313.7067.1245	11	19	20	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 23	2006	296	8					932	934		10.1001/jama.296.8.932-b	http://dx.doi.org/10.1001/jama.296.8.932-b			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	076AL	16926352				2022-12-28	WOS:000239929300020
J	Fowler, VG; Boucher, HW; Corey, GR; Abrutyn, E; Karchmer, AW; Rupp, ME; Levine, DP; Chambers, HF; Tally, FP; Vigliani, GA; Cabell, CH; Link, AS; DeMeyer, I; Filler, SG; Zervos, M; Cook, P; Parsonnet, J; Bernstein, JM; Price, CS; Forrest, GN; Fakenheuer, G; Gareca, M; Rehm, SJ; Brodt, HR; Tice, A; Cosgrove, SE				Fowler, Vance G., Jr.; Boucher, Helen W.; Corey, G. Ralph; Abrutyn, Elias; Karchmer, Adolf W.; Rupp, Mark E.; Levine, Donald P.; Chambers, Henry F.; Tally, Francis P.; Vigliani, Gloria A.; Cabell, Christopher H.; Link, Arthur Stanley; DeMeyer, Ignace; Filler, Scott G.; Zervos, Marcus; Cook, Paul; Parsonnet, Jeffrey; Bernstein, Jack M.; Price, Connie Savor; Forrest, Graeme N.; Faetkenheuer, Gerd; Gareca, Marcelo; Rehm, Susan J.; Brodt, Hans Reinhardt; Tice, Alan; Cosgrove, Sara E.		S aureus Endocarditis Bacteremia	Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IN-VITRO ACTIVITIES; INFECTIVE ENDOCARDITIS; ANTIMICROBIAL THERAPY; VANCOMYCIN; RESISTANCE; DIAGNOSIS; IMPACT	BACKGROUND: Alternative therapies for Staphylococcus aureus bacteremia and endocarditis are needed. METHODS: We randomly assigned 124 patients with S. aureus bacteremia with or without endocarditis to receive 6 mg of daptomycin intravenously per kilogram of body weight daily and 122 to receive initial low-dose gentamicin plus either an antistaphylococcal penicillin or vancomycin. The primary efficacy end point was treatment success 42 days after the end of therapy. RESULTS: Forty-two days after the end of therapy in the modified intention-to-treat analysis, a successful outcome was documented for 53 of 120 patients who received daptomycin as compared with 48 of 115 patients who received standard therapy (44.2 percent vs. 41.7 percent; absolute difference, 2.4 percent; 95 percent confidence interval, -10.2 to 15.1 percent). Our results met prespecified criteria for the noninferiority of daptomycin. The success rates were similar in subgroups of patients with complicated bacteremia, right-sided endocarditis, and methicillin-resistant S. aureus. Daptomycin therapy was associated with a higher rate of microbiologic failure than was standard therapy (19 vs. 11 patients, P=0.17). In 6 of the 19 patients with microbiologic failure in the daptomycin group, isolates with reduced susceptibility to daptomycin emerged; similarly, a reduced susceptibility to vancomycin was noted in isolates from patients treated with vancomycin. As compared with daptomycin therapy, standard therapy was associated with a nonsignificantly higher rate of adverse events that led to treatment failure due to the discontinuation of therapy (17 vs. 8, P=0.06). Clinically significant renal dysfunction occurred in 11.0 percent of patients who received daptomycin and in 26.3 percent of patients who received standard therapy (P=0.004). CONCLUSIONS: Daptomycin (6 mg per kilogram daily) is not inferior to standard therapy for S. aureus bacteremia and right-sided endocarditis.	Duke Univ, Med Ctr, Div Infect Dis, Durham, NC 27710 USA; Tufts Univ New England Med Ctr, Boston, MA USA; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Drexel Univ, Coll Med, Philadelphia, PA 19104 USA; Univ Nebraska, Med Ctr, Omaha, NE USA; Wayne State Univ, Sch Med, Detroit, MI USA; San Francisco Gen Hosp, San Francisco, CA 94110 USA; Cubist Pharmaceut, Lexington, MA USA; Forsyth Med Ctr, Winston Salem, NC USA; Onze Lieve Vrouwe Zienkenhuis, Aalst, Belgium; Harbor UCLA Med Ctr, Torrance, CA 90509 USA; William Beaumont Hosp, Royal Oak, MI 48072 USA; E Carolina Univ, Greenville, NC USA; Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA; Vet Affairs Med Ctr, Dayton, OH USA; Denver Hlth Med, Denver, CO USA; Univ Maryland, Sch Med, Baltimore, MD 21201 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD USA; Klinikum Univ Cologne, Cologne, Germany; Lehigh Valley Hosp Trauma & Crit Care Res, Allentown, PA USA; Cleveland Clin Fdn, Cleveland, OH 44195 USA; Goethe Univ Frankfurt, D-6000 Frankfurt, Germany; Univ Hawaii, Honolulu, HI 96822 USA; Queens Med Ctr, Honolulu, HI USA	Duke University; Tufts Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Drexel University; University of Nebraska System; University of Nebraska Medical Center; Wayne State University; San Francisco General Hospital Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Beaumont Health; University of North Carolina; East Carolina University; Dartmouth College; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Denver Health Medical Center; University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; University of Cologne; Lehigh Valley Hospital; Cleveland Clinic Foundation; Goethe University Frankfurt; University of Hawaii System; The Queen's Medical Center	Fowler, VG (corresponding author), Duke Univ, Med Ctr, Div Infect Dis, Durham, NC 27710 USA.	vance.fowler@duke.edu	Forrest, Graeme/C-8293-2014; Filler, Scott G/A-2779-2009; Fowler, Vance/AAW-2017-2021	Forrest, Graeme/0000-0002-6235-8978; Filler, Scott G/0000-0001-7278-3700; 				Arbeit RD, 2004, CLIN INFECT DIS, V38, P1673, DOI 10.1086/420818; Baddour, 2005, CIRCULATION, V112, P2373, DOI 10.1161/CIRCULATIONHA.105.167942; Baddour LM, 2005, CIRCULATION, V111, P3167, DOI 10.1161/CIRCULATIONAHA.105.165563; BARRY AL, 2001, ANTIMICROB AGENTS CH, V45, P1019; Carpenter CF, 2004, CLIN INFECT DIS, V38, P994, DOI 10.1086/383472; Chang FY, 2003, MEDICINE, V82, P333, DOI 10.1097/01.md.0000091184.93122.09; Chang FY, 2003, MEDICINE, V82, P322, DOI 10.1097/01.md.0000091185.93122.40; Charles PGP, 2004, CLIN INFECT DIS, V38, P448, DOI 10.1086/381093; *CLSI NCCLS, 2005, M100S15 CLSINCCLS S; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Critchley IA, 2003, ANTIMICROB AGENTS CH, V47, P1689, DOI 10.1128/AAC.47.5.1689-1693.2003; Fluit AC, 2000, CLIN INFECT DIS, V30, P454, DOI 10.1086/313710; Fowler VG, 2005, JAMA-J AM MED ASSOC, V293, P3012, DOI 10.1001/jama.293.24.3012; Fowler VG, 2003, ARCH INTERN MED, V163, P2066, DOI 10.1001/archinte.163.17.2066; Fowler VG, 2005, JAMA-J AM MED ASSOC, V294, P900; Fowler VG, 2004, J INFECT DIS, V190, P1140, DOI 10.1086/423145; Fowler VG, 1999, J INFECT DIS, V179, P1157, DOI 10.1086/314712; Hayden MK, 2005, J CLIN MICROBIOL, V43, P5285, DOI 10.1128/JCM.43.10.5285-5287.2005; Howden BP, 2004, CLIN INFECT DIS, V38, P521, DOI 10.1086/381202; KORZENIOWSKI O, 1982, ANN INTERN MED, V97, P496, DOI 10.7326/0003-4819-97-4-496; LEVINE DP, 1991, ANN INTERN MED, V115, P674, DOI 10.7326/0003-4819-115-9-674; Li JS, 2000, CLIN INFECT DIS, V30, P633, DOI 10.1086/313753; Miro JM, 2005, CLIN INFECT DIS, V41, P1075; Miro JM, 2005, CLIN INFECT DIS, V41, P507, DOI 10.1086/431979; REX JH, 1994, NEW ENGL J MED, V331, P1325, DOI 10.1056/NEJM199411173312001; SMALL PM, 1990, ANTIMICROB AGENTS CH, V34, P1227, DOI 10.1128/AAC.34.6.1227; Smith TL, 1999, NEW ENGL J MED, V340, P493, DOI 10.1056/NEJM199902183400701; Snydman DR, 2000, ANTIMICROB AGENTS CH, V44, P3447, DOI 10.1128/AAC.44.12.3447-3450.2000; Wisplinghoff H, 2004, CLIN INFECT DIS, V39, P309, DOI 10.1086/421946; 2002, MMWR MORB MORTAL WKL, V51, P565; 2002, MMWR MORB MROTAL WKL, V51, P902	31	1041	1091	2	91	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 17	2006	355	7					653	665		10.1056/NEJMoa053783	http://dx.doi.org/10.1056/NEJMoa053783			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	074AN	16914701				2022-12-28	WOS:000239784500004
J	Langevin, Y; Doute, S; Vincendon, M; Poulet, F; Bibring, JP; Gondet, B; Schmitt, B; Forget, F				Langevin, Yves; Doute, Sylvain; Vincendon, Mathieu; Poulet, Francois; Bibring, Jean-Pierre; Gondet, Brigitte; Schmitt, Bernard; Forget, F.			No signature of clear CO2 ice from the 'cryptic' regions in Mars' south seasonal polar cap	NATURE			English	Article							WAVELENGTHS; ABSORPTION; AEROSOL; ALBEDO; FROST; MODEL; TES	The seasonal polar ice caps of Mars are composed mainly of CO2 ice(1,2). A region of low (< 30%) albedo has been observed within the south seasonal cap during early to mid-spring(3,4). The low temperature of this 'cryptic region' has been attributed to a clear slab of nearly pure CO2 ice, with the low albedo resulting from absorption by the underlying surface(4). Here we report near-infrared imaging spectroscopy of the south seasonal cap. The deep and broad CO2 absorption bands that are expected in the near-infrared with a thick transparent slab of CO2 ice are not observed. Models of the observed spectra indicate that the low albedo results from extensive dust contamination close to the surface of a CO2 ice layer, which could be linked to atmospheric circulation patterns(5,6). The strength of the CO2 absorption increases after mid-spring, so part of the dust is either carried away or buried more deeply in the ice layer during the CO2 ice sublimation process.	Univ Paris 11, CNRS, Inst Astrophys Spatiale, F-91405 Orsay, France; Univ Grenoble 1, CNRS, Lab Planetol Grenoble, F-38400 Grenoble, France; Univ Paris 06, CNRS, Meteorol Dynam Lab, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Langevin, Y (corresponding author), Univ Paris 11, CNRS, Inst Astrophys Spatiale, Orsay Campus, F-91405 Orsay, France.	yves.langevin@ias.u-psud.fr	Schmitt, Bernard/A-1064-2009	Schmitt, Bernard/0000-0002-1230-6627				Aharonson O, 2004, J GEOPHYS RES-PLANET, V109, DOI 10.1029/2003JE002223; Benson JL, 2005, ICARUS, V174, P513, DOI 10.1016/j.icarus.2004.08.025; Bibring JP, 2004, NATURE, V428, P627, DOI 10.1038/nature02461; Clancy RT, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2003JE002058; Colaprete A, 2005, NATURE, V435, P184, DOI 10.1038/nature03561; Doute S, 1998, J GEOPHYS RES-PLANET, V103, P31367, DOI 10.1029/98JE01894; DROSSART P, 1991, ANN GEOPHYS, V9, P754; Eluszkiewicz J, 2005, ICARUS, V174, P524, DOI 10.1016/j.icarus.2004.05.025; Forget F, 1998, ICARUS, V131, P302, DOI 10.1006/icar.1997.5874; Grundy WM, 1998, J GEOPHYS RES-PLANET, V103, P25809, DOI 10.1029/98JE00738; Hansen GB, 2005, J GEOPHYS RES-PLANET, V110, DOI 10.1029/2005JE002531; HERR KC, 1969, SCIENCE, V166, P496, DOI 10.1126/science.166.3904.496; JAMES PB, 1992, MARS, P934; Kieffer HH, 2000, J GEOPHYS RES-PLANET, V105, P9653, DOI 10.1029/1999JE001136; LARSON HP, 1972, ASTROPHYS J, V171, pL91, DOI 10.1086/180875; Neumann GA, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2002JE001849; OckertBell ME, 1997, J GEOPHYS RES-PLANET, V102, P9039, DOI 10.1029/96JE03991; Piqueux S, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2002JE002007; PRETTYMAN TH, 2005, LUNAR PLANET SCI C, V36; Quirico E, 1997, ICARUS, V127, P354, DOI 10.1006/icar.1996.5663; TITUS TN, 2002, LUNAR PLANET SCI C, V33	21	44	45	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 17	2006	442	7104					790	792		10.1038/nature05012	http://dx.doi.org/10.1038/nature05012			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	074DK	16915283				2022-12-28	WOS:000239792700040
J	Moran, GJ; Krishnadasan, A; Gorwitz, RJ; Fosheim, GE; McDougal, LK; Carey, RB; Talan, DA				Moran, Gregory J.; Krishnadasan, Anusha; Gorwitz, Rachel J.; Fosheim, Gregory E.; McDougal, Linda K.; Carey, Roberta B.; Talan, David A.		EMERGEncy ID Net Study Grp	Methicillin-resistant S-aureus infections among patients in the emergency department	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INDUCIBLE CLINDAMYCIN RESISTANCE; VALENTINE LEUKOCIDIN GENES; SOFT-TISSUE INFECTIONS; SKIN INFECTIONS; CHILDREN; PNEUMONIA; ABSCESSES; STRAINS; DISEASE; SEPSIS	BACKGROUND: Methicillin-resistant Staphylococcus aureus (MRSA) is increasingly recognized in infections among persons in the community without established risk factors for MRSA. METHODS: We enrolled adult patients with acute, purulent skin and soft-tissue infections presenting to 11 university-affiliated emergency departments during the month of August 2004. Cultures were obtained, and clinical information was collected. Available S. aureus isolates were characterized by antimicrobial-susceptibility testing, pulsed-field gel electrophoresis, and detection of toxin genes. On MRSA isolates, we performed typing of the staphylococcal cassette chromosome mec (SCCmec), the genetic element that carries the mecA gene encoding methicillin resistance. RESULTS S. aureus: was isolated from 320 of 422 patients with skin and soft-tissue infections (76 percent). The prevalence of MRSA was 59 percent overall and ranged from 15 to 74 percent. Pulsed-field type USA300 isolates accounted for 97 percent of MRSA isolates; 74 percent of these were a single strain (USA300-0114). SCCmec type IV and the Panton-Valentine leukocidin toxin gene were detected in 98 percent of MRSA isolates. Other toxin genes were detected rarely. Among the MRSA isolates, 95 percent were susceptible to clindamycin, 6 percent to erythromycin, 60 percent to fluoroquinolones, 100 percent to rifampin and trimethoprim-sulfamethoxazole, and 92 percent to tetracycline. Antibiotic therapy was not concordant with the results of susceptibility testing in 100 of 175 patients with MRSA infection who received antibiotics (57 percent). Among methicillin-susceptible S. aureus isolates, 31 percent were USA300 and 42 percent contained pvl genes. CONCLUSIONS: MRSA is the most common identifiable cause of skin and soft-tissue infections among patients presenting to emergency departments in 11 U.S. cities. When antimicrobial therapy is indicated for the treatment of skin and soft-tissue infections, clinicians should consider obtaining cultures and modifying empirical therapy to provide MRSA coverage.	Olive View UCLA Med Ctr, Dept Emergency Med, Sylmar, CA 91342 USA; Olive View UCLA Med Ctr, Div Infect Dis, Sylmar, CA 91342 USA; Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Div Healthcare Qual Promot, Atlanta, GA USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Centers for Disease Control & Prevention - USA	Moran, GJ (corresponding author), Olive View UCLA Med Ctr, Dept Emergency Med, 14445 Olive View Dr,N Annex, Sylmar, CA 91342 USA.	idnet@ucla.edu		Sullivan, D. Matthew/0000-0001-5537-6986; Chiang, William/0000-0003-3562-8896	PHS HHS [U50/CCU912342] Funding Source: Medline; NCPDCID CDC HHS [U01 CI000353] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NCPDCID CDC HHS		Adem PV, 2005, NEW ENGL J MED, V353, P1245, DOI 10.1056/NEJMoa044194; Bannerman TM, 2003, MANUAL CLIN MICROBIO, P384; BERNARD P, 1989, ARCH DERMATOL, V125, P779, DOI 10.1001/archderm.125.6.779; Carpenter CF, 2004, CLIN INFECT DIS, V38, P994, DOI 10.1086/383472; CHAMBERS HF, 1991, INFECT CONT HOSP EP, V12, P29, DOI 10.2307/30147086; Chavez-Bueno S, 2005, ANTIMICROB AGENTS CH, V49, P2283, DOI 10.1128/AAC.49.6.2283-2288.2005; Daum RS, 2002, J INFECT DIS, V186, P1344, DOI 10.1086/344326; Drinkovic D, 2001, J ANTIMICROB CHEMOTH, V48, P315, DOI 10.1093/jac/48.2.315; Francis JS, 2005, CLIN INFECT DIS, V40, P100, DOI 10.1086/427148; Frazee BW, 2005, ANN EMERG MED, V45, P311, DOI 10.1016/j.annemergmed.2004.10.011; Fridkin SK, 2005, NEW ENGL J MED, V352, P2362; Fridkin SK, 2005, NEW ENGL J MED, V352, P1436, DOI 10.1056/NEJMoa043252; Garner JS, 1996, AM J INFECT CONTROL, V24, P24; Gonzalez BE, 2005, PEDIATRICS, V115, P642, DOI 10.1542/peds.2004-2300; Herold BC, 1998, JAMA-J AM MED ASSOC, V279, P593, DOI 10.1001/jama.279.8.593; Issartel B, 2005, J CLIN MICROBIOL, V43, P3203, DOI 10.1128/JCM.43.7.3203-3207.2005; Kaplan SL, 2005, PEDIATR INFECT DIS J, V24, P457, DOI 10.1097/01.inf.0000164162.00163.9d; Kazakova SV, 2005, NEW ENGL J MED, V352, P468, DOI 10.1056/NEJMoa042859; Lee MC, 2004, PEDIATR INFECT DIS J, V23, P123, DOI 10.1097/01.inf.0000109288.06912.21; Lina G, 1999, CLIN INFECT DIS, V29, P1128, DOI 10.1086/313461; Martinez-Aguilar G, 2003, PEDIATR INFECT DIS J, V22, P593, DOI 10.1097/00006454-200307000-00006; McDougal LK, 2003, J CLIN MICROBIOL, V41, P5113, DOI 10.1128/JCM.41.11.5113-5120.2003; Mishaan AMA, 2005, PEDIATR INFECT DIS J, V24, P201, DOI 10.1097/01.inf.0000151107.29132.70; Mongkolrattanothai K, 2003, CLIN INFECT DIS, V37, P1050, DOI 10.1086/378277; Moran GJ, 2005, EMERG INFECT DIS, V11, P928; Naimi TS, 2003, JAMA-J AM MED ASSOC, V290, P2976, DOI 10.1001/jama.290.22.2976; Naimi TS, 2001, CLIN INFECT DIS, V33, P990, DOI 10.1086/322693; *NAT COMM CLIN LAB, 2004, M1000S14 NAT COMM CL; *NAT COMM CLIN LAB, 2006, M100S16 NAT COMM CL; Nathwani D, 2005, INT J ANTIMICROB AG, V25, P185, DOI 10.1016/j.ijantimicag.2004.11.006; Pan ES, 2005, J INFECT DIS, V192, P811, DOI 10.1086/432072; Rybak MJ, 2005, PHARMACOTHERAPY, V25, P74, DOI 10.1592/phco.25.1.74.55620; Siberry GK, 2003, CLIN INFECT DIS, V37, P1257, DOI 10.1086/377501; Talan DA, 1998, ANN EMERG MED, V32, P703, DOI 10.1016/S0196-0644(98)70071-X; Weigelt J, 2005, ANTIMICROB AGENTS CH, V49, P2260, DOI 10.1128/AAC.49.6.2260-2266.2005; Yamasaki O, 2005, CLIN INFECT DIS, V40, P381, DOI 10.1086/427290; Zinderman CE, 2004, EMERG INFECT DIS, V10, P941, DOI 10.3201/eid1005.030604; 2003, MMWR MORB MORTAL WK, V52, P88	39	1778	1839	1	332	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 17	2006	355	7					666	674		10.1056/NEJMoa055356	http://dx.doi.org/10.1056/NEJMoa055356			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	074AN	16914702	Bronze			2022-12-28	WOS:000239784500005
J	Marum, E; Taegtmeyer, M; Chebet, K				Marum, Elizabeth; Taegtmeyer, Miriam; Chebet, Kenneth			Scale-up of voluntary HIV counseling and testing in Kenya	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Ctr Dis Control & Prevent, US Hlth & Human Serv, Global AIDS Program, Nairobi, Kenya; Liverpool Voluntary Counseling & Testing & Care, Nairobi, Kenya; Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England; Natl AIDS & STD Control Programme, Nairobi, Kenya	Liverpool School of Tropical Medicine; University of Liverpool	Marum, E (corresponding author), Ctr Dis Control & Prevent, US Hlth & Human Serv, Global AIDS Program, POB 606,00621 Village Market, Nairobi, Kenya.	emarum@ke.cdc.gov		Taegtmeyer, Miriam/0000-0002-5377-2536				Arthur GR, 2005, JAIDS-J ACQ IMM DEF, V40, P329, DOI 10.1097/01.qai.0000166376.23846.38; Coates TJ, 2000, LANCET, V356, P103, DOI 10.1016/S0140-6736(00)02446-6; Forsythe S, 2002, HEALTH POLICY PLANN, V17, P187, DOI 10.1093/heapol/17.2.187; Frieden TR, 2005, NEW ENGL J MED, V353, P2397, DOI 10.1056/NEJMsb053133; *GOV KEN, 2001, NAT GUID VOL COUNS T; *GOV KEN MIN HLTH, 2001, AIDS KEN BACKGR PROJ; *GOV KEN MIN PLANN, 2003, DEM HLTH SURV; Kanal Koum, 2005, AIDS Res Ther, V2, P5, DOI 10.1186/1742-6405-2-5; Kim JY, 2005, NEW ENGL J MED, V353, P2392, DOI 10.1056/NEJMe058261; LARA AM, 2004, INT AIDS EC NETW 3 I; MARUM E, 2002, AIDS AFRICA, P527; MUTURA C, 2005, CDC HIV DIAGN C MARC; *NAT AIDS STD CONT, 2005, NAT REG VCT SIT KEN; *NAT AIDS STD CONT, 2004, KEN NAT STRAT VCT SC; *NAT COUNC POP DEV, 1999, DEM HLTH SURV 1998; National AIDS and STD Control Programme (NASCOP)/Ministry of Health, 2005, AIDS KEN TRENDS INT; OCHIENG E, 2005, INT C AIDS STDS AFR; *POP COUNC FAM HLT, 1999, HIV AIDS COUNS TEST; Taegtmeyer M, 2006, T ROY SOC TROP MED H, V100, P305, DOI 10.1016/j.trstmh.2005.06.001; Taegtmeyer M, 2003, INT C AIDS STDS AFR; Taegtmeyer M., 2003, QUALITY ASSURANCE RE; TUKEI P, 2002, 12 ASS KEN MED LAB S; *WHO, 1997, JOINT UN PROGR HIV A, P72	23	51	52	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 16	2006	296	7					859	862		10.1001/jama.296.7.859	http://dx.doi.org/10.1001/jama.296.7.859			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	073SR	16905791				2022-12-28	WOS:000239763400026
J	Uitterlinden, AG; Ralston, SH; Brandi, ML; Carey, AH; Grinberg, D; Langdahl, BL; Lips, P; Lorenc, R; Obermayer-Pietsch, B; Reeve, J; Reid, DM; Amidei, A; Bassiti, A; Bustamante, M; Husted, UB; Diez-Perez, A; Dobnig, H; Dunning, AM; Enjuanes, A; Fahrleitner-Pammer, A; Fang, Y; Karczmarewicz, E; Kruk, M; van Leeuwen, JPTM; Mavilia, C; van Meurs, JBJ; Mangion, J; McGuigan, FEA; Pols, HAP; Renner, W; Rivadeneira, F; van Schoor, NM; Scollen, S; Sherlock, RE; Ioannidis, JPA				Uitterlinden, Andre G.; Ralston, Stuart H.; Brandi, Maria Luisa; Carey, Alisoun H.; Grinberg, Daniel; Langdahl, Bente L.; Lips, Paul; Lorenc, Roman; Obermayer-Pietsch, Barbara; Reeve, Jonathan; Reid, David M.; Amidei, Antonietta; Bassiti, Amelia; Bustamante, Mariona; Husted, Use Bjerre; Diez-Perez, Adolfo; Dobnig, Harald; Dunning, Alison M.; Enjuanes, Anna; Fahrleitner-Pammer, Astrid; Fang, Yue; Karczmarewicz, Elzbieta; Kruk, Marcin; van Leeuwen, Johannes P. T. M.; Mavilia, Carmelo; van Meurs, Joyce B. J.; Mangion, Jon; McGuigan, Fiona E. A.; Pols, Huibert A. P.; Renner, Wilfried; Rivadeneira, Fernando; van Schoor, Natasja M.; Scollen, Serena; Sherlock, Rachael E.; Ioannidis, John P. A.		APOSS Investigators; EPOS Investigators; EPOLOS Investigators; FAMOS Investigators; LASA Investigators; Rotterdam Study Investigators; GENOMOS Study	The association between common vitamin D receptor gene variations and osteoporosis: A participant-level meta-analysis	ANNALS OF INTERNAL MEDICINE			English	Article							BONE-MINERAL DENSITY; VERTEBRAL DEFORMITY; SP1 POLYMORPHISM; CLINICAL-TRIALS; POPULATION; WOMEN; FALSE; MEN; EPIDEMIOLOGY; ROTTERDAM	Background: Polymorphisms of the vitamin D receptor (VDR) gene have been implicated in the genetic regulation of bone mineral density (BMD). However, the clinical impact of these variants remains unclear. Objective: To evaluate the relation between VDR polymorphisms, BMD, and fractures. Design: Prospective multicenter large-scale association study. Setting: The Genetic Markers for Osteoporosis consortium, involving 9 European research teams. Participants: 26242 participants (18405 women). Measurements: Cdx2 promoter, FokI, BsmI, ApaI, and TaqI polymorphisms; BMD at the femoral neck and the lumbar spine by dual x-ray absorptiometry; and fractures. Results: Comparisons of BMD at the lumbar spine and femoral neck showed nonsignificant differences less than 0.011 g/cm(2) for any genotype with or without adjustments. A total of 6067 participants reported a history of fracture, and 2088 had vertebral fractures. For all VDR alleles, odds ratios for fractures were very close to 1.00 (range, 0.98 to 1.02) and collectively the 95% CIs ranged from 0.94 (lowest) to 1.07 (highest). For vertebral fractures, we observed a 9% (95% CI, 0% to 18%; P = 0.039) risk reduction for the Cdx2 A-allele (13% risk reduction in a dominant model). Limitations: The authors analyzed only selected VDR polymorphisms. Heterogeneity was detected in some analyses and may reflect some differences in collection of fracture data across cohorts. Not all fractures were related to osteoporosis. Conclusions: The FokI, BsmI, ApaI, and TaqI VDR polymorphisms are not associated with BMD or with fractures, but the Cdx2 polymorphism may be associated with risk for vertebral fractures.	Katholieke Univ Leuven Hosp, Louvain, Belgium; Charles Univ Prague, Prague, Czech Republic; Hosp San Joao, Oporto, Portugal; Univ Athens, GR-10679 Athens, Greece; Inst Rheumat Dis, Piestany, Slovakia; Acad Med Szczecin, Szczecin, Poland; Univ Siena, I-53100 Siena, Italy; Natl Inst Rheumatism & Physiotherapy, Budapest, Hungary; Univ Hosp Graz, Graz, Austria	Flanders Institute for Biotechnology (VIB); KU Leuven; University Hospital Leuven; Charles University Prague; Sao Joao Hospital; National & Kapodistrian University of Athens; Pomeranian Medical University; University of Siena; National Institute Rheumatology & Physiotherapy	Ioannidis, JPA (corresponding author), Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, GR-45110 Ioannina, Greece.	jioannid@cc.uoi.gr	Duncan, Emma L/L-1224-2013; van Leeuwen, Johannes/D-5015-2014; Miazgowski, Tomasz/H-9448-2014; Lewinski, Andrzej Krzysztof/S-9985-2016; Todd, Chris/AAD-8661-2022; Todd, Chris/A-7904-2010; Bustamante, Mariona/ABB-9142-2021; ENJUANES, Anna/H-3245-2015; Reeve, Jonathan/C-7551-2012; Bustamante, Mariona/M-7277-2015; Ioannidis, John P. A./G-9836-2011; Breteler, Monique M.B./J-5058-2014; Grinberg, Daniel/F-3641-2010; Stepan, Jan/A-7280-2013; Rivadeneira, Fernando/O-5385-2015; Lunt, Mark/A-7132-2014; Da Silva, Jose/K-9769-2018	Duncan, Emma L/0000-0002-8143-4403; van Leeuwen, Johannes/0000-0002-2282-4006; Miazgowski, Tomasz/0000-0002-4819-9376; Lewinski, Andrzej Krzysztof/0000-0002-8748-3337; Todd, Chris/0000-0001-6645-4505; Todd, Chris/0000-0001-6645-4505; Bustamante, Mariona/0000-0003-0127-2860; ENJUANES, Anna/0000-0002-4679-6687; Reeve, Jonathan/0000-0002-4364-2682; Bustamante, Mariona/0000-0003-0127-2860; Breteler, Monique M.B./0000-0002-0626-9305; Grinberg, Daniel/0000-0001-9859-2590; Stepan, Jan/0000-0003-1541-8306; Rivadeneira, Fernando/0000-0001-9435-9441; O'Neill, Terence/0000-0002-8896-4677; Dunning, Alison Margaret/0000-0001-6651-7166; Jaworski, Maciej/0000-0002-6758-371X; Diez-Perez, Adolfo/0000-0001-8162-0209; Scollen, Serena/0000-0002-9311-1337; Lunt, Mark/0000-0002-2391-5575; Da Silva, Jose/0000-0002-2782-6780; van Meurs, Joyce/0000-0001-6245-2123; Marcinowska-Suchowierska, Ewa/0000-0002-9047-8731				Arai H, 2001, J BONE MINER RES, V16, P1256, DOI 10.1359/jbmr.2001.16.7.1256; Burger H, 1998, AM J EPIDEMIOL, V147, P871, DOI 10.1093/oxfordjournals.aje.a009541; Cooper GS, 1996, J BONE MINER RES, V11, P1841; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Fang Y, 2005, AM J HUM GENET, V77, P807, DOI 10.1086/497438; Fang Y, 2003, J BONE MINER RES, V18, P1632, DOI 10.1359/jbmr.2003.18.9.1632; Gong G, 1999, OSTEOPOROSIS INT, V9, P55, DOI 10.1007/s001980050116; Gross C, 1996, J BONE MINER RES, V11, P1850; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Ioannidis JPA, 2003, LANCET, V361, P567, DOI 10.1016/S0140-6736(03)12516-0; Ioannidis JPA, 2004, JAMA-J AM MED ASSOC, V292, P2105, DOI 10.1001/jama.292.17.2105; Ioannidis JPA, 2005, PLOS MED, V2, P696, DOI 10.1371/journal.pmed.0020124; Ioannidis JPA, 2001, NAT GENET, V29, P306, DOI 10.1038/ng749; Ioannidis JPA, 2003, TRENDS MOL MED, V9, P135, DOI 10.1016/S1471-4914(03)00030-3; Ismail AA, 1998, OSTEOPOROSIS INT, V8, P291, DOI 10.1007/s001980050067; Kudlacek S, 2003, EUR J CLIN INVEST, V33, P332, DOI 10.1046/j.1365-2362.2003.01128.x; Little J, 2003, AM J EPIDEMIOL, V157, P667, DOI 10.1093/aje/kwg048; Little J, 2003, LANCET, V362, P930, DOI 10.1016/S0140-6736(03)14396-6; MCCLOSKEY EV, 1993, OSTEOPOROSIS INT, V3, P138, DOI 10.1007/BF01623275; McCulloch C. E., 2001, GEN LINEAR MIXED MOD; MORRISON NA, 1994, NATURE, V367, P284, DOI 10.1038/367284a0; Morrison NA, 1997, NATURE, V387, P106; Pan ZL, 2005, PLOS MED, V2, P1309, DOI 10.1371/journal.pmed.0020334; Pettiti D, 1999, METAANALYSIS DECISIO; Pluijm SMF, 2004, ANN RHEUM DIS, V63, P71, DOI 10.1136/ard.2002.002287; Ralston SH, 2005, HUM MOL GENET, V14, P943, DOI 10.1093/hmg/ddi088; Ralston SH, 2006, PLOS MED, V3, P515, DOI 10.1371/journal.pmed.0030090; Rebbeck TR, 2004, NAT REV GENET, V5, P589, DOI 10.1038/nrg1403; Reid DM, 2006, OSTEOPOROSIS INT, V17, P125, DOI 10.1007/s00198-005-1936-y; ROUSSET F, 1995, GENETICS, V140, P1413; Stephens M, 2003, AM J HUM GENET, V73, P1162, DOI 10.1086/379378; Thakkinstian A, 2004, J BONE MINER RES, V19, P419, DOI 10.1359/JBMR.0301265; Torgerson DJ, 1997, ARCH INTERN MED, V157, P2121, DOI 10.1001/archinte.157.18.2121; Uitterlinden AG, 1996, J BONE MINER RES, V11, P1241; Wacholder S, 2004, J NATL CANCER I, V96, P434, DOI 10.1093/jnci/djh075	35	201	220	0	16	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	2006	145	4					255	264		10.7326/0003-4819-145-4-200608150-00005	http://dx.doi.org/10.7326/0003-4819-145-4-200608150-00005			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	075CC	16908916				2022-12-28	WOS:000239858800003
J	Guo, WJ; Pylayeva, Y; Pepe, A; Yoshioka, T; Muller, WJ; Inghirami, G; Giancotti, FG				Guo, Wenjun; Pylayeva, Yuliya; Pepe, Angela; Yoshioka, Toshiaki; Muller, William J.; Inghirami, Giorgio; Giancotti, Filippo G.			beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis	CELL			English	Article							HUMAN-BREAST-CANCER; NF-KAPPA-B; ALPHA-6-BETA-4 INTEGRIN; C-JUN; ALPHA(6)BETA(4) INTEGRIN; CARCINOMA INVASION; NEU ONCOGENE; CELLS; STAT3; PROLIFERATION	Amplification of the ErbB2 locus, which encodes a receptor tyrosine kinase, is common in aggressive breast tumors and correlates with poor prognosis. The mechanisms underlying ErbB2-mediated breast carcinoma progression remain incompletely defined. To examine the role of the signaling and cell-adhesion receptor beta 4 integrin during ErbB2-mediated tumorigenesis, we introduced a targeted deletion of the beta 4 signaling domain into a mouse model of ErbB2-induced mammary carcinoma. Loss of beta 4 signaling suppresses mammary tumor onset and invasive growth. Ex vivo studies indicate that beta 4 forms a complex with ErbB2 and enhances activation of the transcription factors STAT3 and c-Jun. STAT3 contributes to disruption of epithelial adhesion and polarity, while c-Jun is required for hyperproliferation. Finally, deletion of the beta 4 signaling domain enhances the efficacy of ErbB2-targeted therapy. These results indicate that beta 4 integrin promotes tumor progression by amplifying ErbB2 signaling and identify beta 4 as a potential target for molecular therapy of breast cancer.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Cornell Univ, Sloan Kettering Div, Weill Grad Sch Med Sci, New York, NY 10021 USA; McGill Univ, Royal Victoria Hosp, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; Univ Turin, Dept Pathol, I-10060 Turin, Italy; Univ Turin, Ctr Expt Res & Med Studies, I-10060 Turin, Italy; NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; NYU, Sch Med, Inst Canc, New York, NY 10016 USA	Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center; McGill University; Royal Victoria Hospital; University of Turin; University of Turin; New York University; New York University	Giancotti, FG (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave, New York, NY 10021 USA.	f-giancotti@ski.mskcc.org			NCI NIH HHS [P30 CA08748, R37 CA58976] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA058976, P30CA008748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bachelder RE, 1999, J BIOL CHEM, V274, P20733, DOI 10.1074/jbc.274.29.20733; Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; BERGER MS, 1988, CANCER RES, V48, P1238; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Bissell MJ, 2003, CURR OPIN CELL BIOL, V15, P753, DOI 10.1016/j.ceb.2003.10.016; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Chan KS, 2004, J CLIN INVEST, V114, P720, DOI 10.1172/JCI200421032; Chiarle R, 2005, NAT MED, V11, P623, DOI 10.1038/nm1249; Dankort D, 2001, MOL CELL BIOL, V21, P1540, DOI 10.1128/MCB.21.5.1540-1551.2001; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; Dechow TN, 2004, P NATL ACAD SCI USA, V101, P10602, DOI 10.1073/pnas.0404100101; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; Falcioni R, 1997, EXP CELL RES, V236, P76, DOI 10.1006/excr.1997.3695; GARNALLO C, 1993, AM J PATHOL, V142, P987; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Liu H, 2004, J CELL BIOL, V164, P603, DOI 10.1083/jcb.200306090; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Ludes-Meyers JH, 2001, ONCOGENE, V20, P2771, DOI 10.1038/sj.onc.1204377; Macara IG, 2004, NAT REV MOL CELL BIO, V5, P220, DOI 10.1038/nrm1332; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; Mariotti A, 2001, J CELL BIOL, V155, P447, DOI 10.1083/jcb.200105017; Moasser MM, 2001, CANCER RES, V61, P7184; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Nateri AS, 2005, NATURE, V437, P281, DOI 10.1038/nature03914; Nikolopoulos SN, 2005, MOL CELL BIOL, V25, P6090, DOI 10.1128/MCB.25.14.6090-6102.2005; Nikolopoulos SN, 2004, CANCER CELL, V6, P471, DOI 10.1016/j.ccr.2004.09.029; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; White DE, 2004, CANCER CELL, V6, P159, DOI 10.1016/j.ccr.2004.06.025; Yamashita S, 2002, DEV CELL, V2, P363, DOI 10.1016/S1534-5807(02)00126-0; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Zahir N, 2003, J CELL BIOL, V163, P1397, DOI 10.1083/jcb.200302023	46	359	375	0	11	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 11	2006	126	3					489	502		10.1016/j.cell.2006.05.047	http://dx.doi.org/10.1016/j.cell.2006.05.047			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	075KI	16901783	Bronze			2022-12-28	WOS:000239883400010
J	Feachem, RGA; Sabot, OJ				Feachem, Richard G. A.; Sabot, Oliver J.			An examination of the Global Fund at 5 years	LANCET			English	Editorial Material									Global Fund Fight AIDS TB & Malaria, CH-1214 Geneva, Switzerland; Univ Calif San Francisco & Berkeley, Inst Global Hlth, San Francisco, CA USA	University of California System; University of California San Francisco	Sabot, OJ (corresponding author), Global Fund Fight AIDS TB & Malaria, Chemin Blandonnet 8, CH-1214 Geneva, Switzerland.	oliver.sabot@theglobalfund.org						*AFR DEV BANK, 2006, 2004 ANN PORTF PERF; [Anonymous], 2004, HUM RES HLTH OV CRIS; Brugha R., 2005, GLOBAL FUND TRACKING; Chen L, 2005, B WORLD HEALTH ORGAN, V83, P243; *GOV ACC OFF, 2005, GAO05639; Komatsu R, 2006, INVESTING IMPACT MID; Lu C, 2006, LANCET, V368, P483, DOI 10.1016/S0140-6736(06)69156-3; *POL STRAT COMM GL, 2006, BOARD M DOC 13 BOARD; Sachs JD, 2001, MACR HLTH INV HLTH E; SHAKOW A, GLOBAL FUND WORLD BA; Stillman K, 2005, SYSTEMWIDE EFFECTS G	11	22	24	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 5	2006	368	9534					537	540		10.1016/S0140-6736(06)69163-0	http://dx.doi.org/10.1016/S0140-6736(06)69163-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	071AL	16890842				2022-12-28	WOS:000239569000038
J	Schwartlander, B; Grubb, I; Perriens, J				Schwartlaender, Bernhard; Grubb, Ian; Perriens, Jos			The 10-year struggle to provide antiretroviral treatment to people with HIV in the developing world	LANCET			English	Editorial Material									Global Fund Fight AIDS TB & Malaria, CH-1214 Geneva, Switzerland; WHO, HIV Dept, CH-1211 Geneva, Switzerland	World Health Organization	Schwartlander, B (corresponding author), Global Fund Fight AIDS TB & Malaria, Chemmin Blandonnet 8, CH-1214 Geneva, Switzerland.	Bernhard.Schwartlander@TheGlobalFund.org						CHIRAC J, 1997, 10 INT C STD AIDS AF; Farmer P, 2001, B WORLD HEALTH ORGAN, V79, P1145; *INT HIV AIDS TREA, 2002, WHOHIV200224; MWAURA P, AIDS DRUGS PLAN STAR; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; Salomon JA, 2005, PLOS MED, V2, P50, DOI 10.1371/journal.pmed.0020016; Schwartlander B, 2001, SCIENCE, V292, P2434, DOI 10.1126/science.1062876; *UN GEN ASS, 1999, KEY ACT IMPL PROGR A; *UN GEN ASS, 2006, HIGH LEV M AIDS UN W; *UN GEN ASS, DECL COMM HIV AIDS G; *UN SECR GEN, 2001, SECR GEN PROP GLOB F; *UNAIDS, 1998, REP GLOB HIV AIDS EP; United Nations, 2000, UN MILL DECL GEN ASS; *US DEP STAT, 2005, PRES EM PLAN AIDS RE; *WHO, 2006, GLOB PRIC REP MECH P; *WHO, 2003, WHO STRAT TREAT 3 MI; *WHO, WHO SAYS FAIL DEL AI; *WHO, 2002, TECHN REP SER, V914; WHO/UNAIDS (World Health Organisation/United Nations Program on HIV/AIDS), 2006, PROGR GLOB ACC HIV A; World Health Organization, 2002, SCAL ANT THER RES LT; World Health Organization, 2003, ANT THER PRIM HLTH C	21	55	56	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 5	2006	368	9534					541	546		10.1016/S0140-6736(06)69164-2	http://dx.doi.org/10.1016/S0140-6736(06)69164-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	071AL	16890843				2022-12-28	WOS:000239569000039
J	Freedman, J				Freedman, Julie			Heart opening	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												julie.freedman@gmail.com							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 2	2006	296	5					483	484		10.1001/jama.296.5.483	http://dx.doi.org/10.1001/jama.296.5.483			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	069YW	16882949				2022-12-28	WOS:000239486900001
J	Bosch, X; Guilabert, A; Font, J				Bosch, Xavier; Guilabert, Antonio; Font, Josep			Antineutrophil cytoplasmic antibodies	LANCET			English	Review							NECROSIS-FACTOR-ALPHA; BACTERICIDAL/PERMEABILITY-INCREASING PROTEIN; INTERNATIONAL CONSENSUS STATEMENT; RECOGNIZE RESTRICTED EPITOPES; MIDLINE DESTRUCTIVE LESIONS; WEGENERS-GRANULOMATOSIS; SYSTEMIC VASCULITIS; APOPTOTIC NEUTROPHILS; DISEASE-ACTIVITY; TARGET ANTIGENS	Much like other autoantibodies (eg, anti-double stranded DNA in systemic lupus erythematosus or antiglomerular basement membrane antibodies in Goodpasture's syndrome), antineutrophil cytoplasmic antibodies (ANCA) have provided doctors with a useful serological test to assist in diagnosis of small-vessel vasculitides, including Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome, and their localised forms (eg, pauci-immune necrotising and crescentic glomerulonephritis). 85-95% of patients with Wegener's granulomatosis, microscopic polyangiitis, and pauci-immune necrotising and crescentic glomerulonephritis have serum ANCA. ANCA directed to either proteinase 3 or myeloperoxidase are clinically relevant, yet the relevance of other ANCA remains unknown. Besides their diagnostic potential, ANCA might be valuable in disease monitoring. In addition, data seem to confirm the long-disputed pathogenic role of these antibodies. Present treatments for ANCA-associated vasculitis are not free from side-effects and as many as 50% of patients relapse within 5 years. Accurate understanding of the key pathogenic points of ANCA-associated vasculitis can undoubtedly provide a more rational therapeutic approach.	Univ Barcelona, IDIBAPS, Hosp Clin, Dept Internal Med, Barcelona, Spain; Univ Barcelona, IDIBAPS, Hosp Clin, Dept Dermatol, Barcelona, Spain; Univ Barcelona, IDIBAPS, Hosp Clin, Dept System Autoimmune Dis, Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Bosch, X (corresponding author), Univ Barcelona, IDIBAPS, Hosp Clin, Dept Internal Med, Barcelona, Spain.	xavbosch@ub.edu		Guilabert, Antonio/0000-0002-3520-2169				Abdel-Salam B, 2004, KIDNEY INT, V66, P1009, DOI 10.1111/j.1523-1755.2004.00849.x; Aikoh T, 1998, INT J ONCOL, V12, P1355; Ardiles LG, 1997, CLIN NEPHROL, V47, P1; Attia S, 2005, ANN BIOL CLIN-PARIS, V63, P209; Ayoub N, 2004, ARCH DERMATOL, V140, P931, DOI 10.1001/archderm.140.8.931; BAKE AWL, 1989, APMIS S, V6, P25; BALEVA M, 1994, NEPHROL DIAL TRANSPL, V9, P876; BARANGER TAR, 1995, AUTOIMMUNITY, V20, P33, DOI 10.3109/08916939508993337; Booth A, 2004, J AM SOC NEPHROL, V15, P717, DOI 10.1097/01.ASN.0000114554.67106.28; Borgmann S, 2004, CLIN EXP RHEUMATOL, V22, pS79; BOSCH X, 1991, CLIN NEPHROL, V36, P107; BOSCH X, 1991, J RHEUMATOL, V18, P787; BOSCH X, 1995, J RHEUMATOL, V22, P2038; BROUWER E, 1991, KIDNEY INT, V39, P1055; BURROWS NP, 1994, J AM ACAD DERMATOL, V31, P825, DOI 10.1016/S0190-9622(09)80058-3; Byrd RP, 1998, AM J MED, V104, P101, DOI 10.1016/S0002-9343(97)00348-3; Calderwood JW, 2005, J LEUKOCYTE BIOL, V77, P33, DOI 10.1189/jlb.0104054; CARLSSON M, 2003, CLIN EXP RHEUMAT S32, V21, P95; CHEVAILLER A, 1992, J IMMUNOL METHODS, V147, P101, DOI 10.1016/S0022-1759(12)80034-2; CHO CD, 1995, ARCH PATHOL LAB MED, V119, P558; Choi HK, 1998, CLIN EXP RHEUMATOL, V16, P743; Choi HK, 2000, ARTHRITIS RHEUM, V43, P226, DOI 10.1002/1529-0131(200001)43:1<226::AID-ANR27>3.0.CO;2-Q; Chou TNK, 2000, LUPUS, V9, P551, DOI 10.1177/096120330000900714; Clayton AR, 2003, ARTHRITIS RHEUM, V48, P2362, DOI 10.1002/art.11130; Constantin A, 1996, J RHEUMATOL, V23, P411; Cooper T, 2000, RHEUMATOL INT, V19, P129, DOI 10.1007/s002960050116; Csernok E, 2003, AUTOIMMUN REV, V2, P158, DOI 10.1016/S1568-9972(03)00010-7; Csernok E, 2004, RHEUMATOLOGY, V43, P174, DOI 10.1093/rheumatology.keh028; Csernok E, 2002, RHEUMATOLOGY, V41, P1313, DOI 10.1093/rheumatology/41.11.1313; DAOUK GH, 1995, KIDNEY INT, V47, P1528, DOI 10.1038/ki.1995.216; DAVIES DJ, 1982, BMJ-BRIT MED J, V285, P606, DOI 10.1136/bmj.285.6342.606; Day CJ, 2003, CLIN EXP RHEUMATOL, V21, pS35; Dijstelbloem HM, 1999, ARTHRITIS RHEUM, V42, P1823, DOI 10.1002/1529-0131(199909)42:9<1823::AID-ANR5>3.0.CO;2-X; DOLMAN KM, 1993, CLIN EXP IMMUNOL, V93, P405, DOI 10.1111/j.1365-2249.1993.tb08192.x; Duna GE, 1998, CLIN EXP RHEUMATOL, V16, P669; Dwyer KM, 2001, CLIN NEPHROL, V56, P394; Elkayam O, 1996, ANN RHEUM DIS, V55, P769, DOI 10.1136/ard.55.10.769; ESNAULT VLM, 1990, J CLIN LAB IMMUNOL, V32, P153; FALK RJ, 1990, P NATL ACAD SCI USA, V87, P4115, DOI 10.1073/pnas.87.11.4115; FALK RJ, 1988, NEW ENGL J MED, V318, P1651, DOI 10.1056/NEJM198806233182504; Falk RJ, 2002, J AM SOC NEPHROL, V13, P1977, DOI 10.1681/ASN.V1371977; FALK RJ, 2004, J NEPHROL S8, V17, P3; Flores-Suarez LF, 2003, RHEUMATOLOGY, V42, P223, DOI 10.1093/rheumatology/keg066; Font J, 1998, BRIT J RHEUMATOL, V37, P1287; Forde AM, 1998, BRIT J BIOMED SCI, V55, P247; Gencik M, 2000, KIDNEY INT, V58, P2473, DOI 10.1046/j.1523-1755.2000.00430.x; Gencik M, 2000, CLIN IMMUNOL, V94, P9, DOI 10.1006/clim.1999.4811; Gilligan HM, 1996, J EXP MED, V184, P2231, DOI 10.1084/jem.184.6.2231; Giscombe R, 2002, J RHEUMATOL, V29, P950; GREGORINI G, 1993, ADV EXP MED BIOL, V336, P435; Griffith ME, 2001, CLIN EXP IMMUNOL, V123, P170, DOI 10.1046/j.1365-2249.2001.01420.x; Guma M, 2003, J CLIN ENDOCR METAB, V88, P2141, DOI 10.1210/jc.2002-021383; Haas M, 2004, KIDNEY INT, V65, P2145, DOI 10.1111/j.1523-1755.2004.00632.x; Hagen EC, 1998, KIDNEY INT, V53, P743, DOI 10.1046/j.1523-1755.1998.00807.x; Han WK, 2003, KIDNEY INT, V63, P1079, DOI 10.1046/j.1523-1755.2003.00821.x; Heeringa P, 2004, KIDNEY INT, V65, P1564, DOI 10.1111/j.1523-1755.2004.05412.x; Hellmich B, 2001, CLIN RHEUMATOL, V20, P441, DOI 10.1007/PL00011214; Hogan SL, 2001, J AM SOC NEPHROL, V12, P134, DOI 10.1681/ASN.V121134; Huang D, 2000, J RHEUMATOL, V27, P397; Jagiello P, 2004, HUM GENET, V114, P468, DOI 10.1007/s00439-004-1092-z; Jayne D, 2003, NEW ENGL J MED, V349, P36, DOI 10.1056/NEJMoa020286; JAYNE DRW, 1990, KIDNEY INT, V37, P965, DOI 10.1038/ki.1990.72; JENNE DE, 1990, NATURE, V346, P520, DOI 10.1038/346520a0; Jennette JC, 1997, NEW ENGL J MED, V337, P1512, DOI 10.1056/NEJM199711203372106; JENNETTE JC, 1994, ARTHRITIS RHEUM-US, V37, P187, DOI 10.1002/art.1780370206; Jennette JC, 1998, KIDNEY INT, V53, P796, DOI 10.1038/ki.1998.36; JENNETTE JC, 1990, BLOOD, V75, P2263; JUBY A, 1992, BRIT J RHEUMATOL, V31, P185; Kamesh L, 2002, J AM SOC NEPHROL, V13, P1953, DOI 10.1097/01.ASN.0000016442.33680.3E; Keogh KA, 2005, ARTHRITIS RHEUM-US, V52, P262, DOI 10.1002/art.20718; KLAASSEN RJL, 1992, CLIN EXP IMMUNOL, V87, P24, DOI 10.1111/j.1365-2249.1992.tb06408.x; Lamprecht P, 1998, CLIN EXP RHEUMATOL, V16, P513; Lane SE, 2003, ARTHRITIS RHEUM-US, V48, P814, DOI 10.1002/art.10830; LANGFORD CA, 2004, CLIN EXP RHEUMAT S36, V22, P3; Leigh J, 1997, ENVIRON HEALTH PERSP, V105, P1241, DOI 10.2307/3433540; Levy JB, 2004, KIDNEY INT, V66, P1535, DOI 10.1111/j.1523-1755.2004.00917.x; Locht H, 1999, CLIN EXP IMMUNOL, V117, P568; Mandl LA, 2002, ARCH INTERN MED, V162, P1509, DOI 10.1001/archinte.162.13.1509; McLaren JS, 2001, QJM-INT J MED, V94, P615, DOI 10.1093/qjmed/94.11.615; Mead GE, 1998, J INFECTION, V37, P73, DOI 10.1016/S0163-4453(98)90905-7; Medina F, 1998, BRIT J RHEUMATOL, V37, P270; Merkel PA, 1997, ANN INTERN MED, V126, P866, DOI 10.7326/0003-4819-126-11-199706010-00003; Miller R M, 1998, Australas J Dermatol, V39, P96, DOI 10.1111/j.1440-0960.1998.tb01257.x; Moosig F, 2000, CLIN EXP IMMUNOL, V122, P499, DOI 10.1046/j.1365-2249.2000.01410.x; Mulder L, 1997, J RHEUMATOL, V24, P568; NUYTS GD, 1995, NEPHROL DIAL TRANSPL, V10, P1162, DOI 10.1093/ndt/10.7.1162; PAPO T, 1993, ANN RHEUM DIS, V52, P384, DOI 10.1136/ard.52.5.384-b; Patry YC, 2001, J AM SOC NEPHROL, V12, P1764, DOI 10.1681/ASN.V1281764; Pelclova D, 2003, ARCH ENVIRON HEALTH, V58, P662, DOI 10.3200/AEOH.58.10.662-668; Pendergraft WF, 2004, NAT MED, V10, P72, DOI 10.1038/nm968; Persson U, 1999, CLIN EXP IMMUNOL, V116, P379; Pieters K, 2004, CLIN EXP IMMUNOL, V138, P266, DOI 10.1111/j.1365-2249.2004.02608.x; PUDIFIN DJ, 1994, CLIN EXP IMMUNOL, V97, P48, DOI 10.1111/j.1365-2249.1994.tb06578.x; Rarok AA, 2003, J LEUKOCYTE BIOL, V74, P3, DOI 10.1189/jlb.1202611; Rarok AA, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000028642.26222.00; Rauova L, 2002, CLIN IMMUNOL, V103, P69, DOI 10.1006/clim.2002.5194; RIDER LG, 1993, CLIN EXP RHEUMATOL, V11, P445; Ruffatti A, 2002, J RHEUMATOL, V29, P918; Sakemi T, 1998, NEPHRON, V78, P218, DOI 10.1159/000044915; SAULSBURY FT, 1991, AM J NEPHROL, V11, P295, DOI 10.1159/000168325; Savige J, 2000, KIDNEY INT, V57, P846, DOI 10.1046/j.1523-1755.2000.057003846.x; Savige J, 2003, AM J CLIN PATHOL, V120, P312, DOI 10.1309/WAEPADW0K4LPUHFN; Savige J, 1999, AM J CLIN PATHOL, V111, P507; SAVIGE JA, 1994, AUST NZ J MED, V24, P282, DOI 10.1111/j.1445-5994.1994.tb02173.x; SAXON A, 1990, J ALLERGY CLIN IMMUN, V86, P202, DOI 10.1016/S0091-6749(05)80067-3; Schmitt Wilhelm H., 2004, Current Opinion in Rheumatology, V16, P9, DOI 10.1097/00002281-200401000-00004; SCHNABEL A, 1995, ANN RHEUM DIS, V54, P233, DOI 10.1136/ard.54.3.233-a; SCHNABEL A, 1995, ARTHRITIS RHEUM-US, V38, P633, DOI 10.1002/art.1780380509; Schreiber A, 2004, KIDNEY INT, V65, P2172, DOI 10.1111/j.1523-1755.2004.00640.x; Schreiber A, 2003, J AM SOC NEPHROL, V14, P68, DOI 10.1097/01.ASN.0000040751.83734.D1; Schultz H, 2001, J LEUKOCYTE BIOL, V69, P505; Schwarze C, 2003, CLIN EXP IMMUNOL, V133, P283, DOI 10.1046/j.1365-2249.2003.02195.x; Segelmark M, 2003, NEPHRON CLIN PRACT, V94, pC59, DOI 10.1159/000072022; SEGELMARK M, 1995, KIDNEY INT, V48, P844, DOI 10.1038/ki.1995.360; SHORT AK, 1995, QJM-MON J ASSOC PHYS, V88, P775; Slot MC, 2005, ARTHRIT RHEUM-ARTHR, V53, P108, DOI 10.1002/art.20927; Sobajima J, 1999, GUT, V44, P867, DOI 10.1136/gut.44.6.867; SPECKS U, 2004, CLIN EXP RHEUMAT S36, V22, P7; Spriewald BM, 2005, ANN RHEUM DIS, V64, P457, DOI 10.1136/ard.2004.025809; STEGEMAN CA, 1994, ANN INTERN MED, V120, P12, DOI 10.7326/0003-4819-120-1-199401010-00003; Stegeman CA, 2002, NEPHROL DIAL TRANSPL, V17, P2077, DOI 10.1093/ndt/17.12.2077; Steiner K, 2001, CLIN EXP IMMUNOL, V126, P143, DOI 10.1046/j.1365-2249.2001.01575.x; ten Holder SM, 2002, ANN PHARMACOTHER, V36, P130, DOI 10.1345/1542-6270(2002)036<0130:CASMOD>2.0.CO;2; TERVAERT JWC, 1990, LANCET, V336, P709; Trimarchi M, 2001, MEDICINE, V80, P391, DOI 10.1097/00005792-200111000-00005; Tse WY, 2005, KIDNEY INT, V67, P130, DOI 10.1111/j.1523-1755.2005.00063.x; Uppal SS, 2003, CLIN EXP RHEUMATOL, V21, pS112; Van der Geld YM, 2004, CLIN EXP IMMUNOL, V137, P451, DOI 10.1111/j.1365-2249.2004.02572.x; Van der Geld YM, 2002, CLIN EXP IMMUNOL, V129, P562; VANDERWOUDE FJ, 1985, LANCET, V1, P425; Vassilopoulos D, 2003, ARTHRIT RHEUM-ARTHR, V49, P151, DOI 10.1002/art.10997; Weidner S, 2004, ARTHRITIS RHEUM-US, V50, P3651, DOI 10.1002/art.20607; Wiesner O, 2004, ARTHRITIS RHEUM-US, V50, P2954, DOI 10.1002/art.20479; Wiik A, 2002, RHEUMATOLOGY, V41, P481, DOI 10.1093/rheumatology/41.5.481; Wiik Allan, 2002, Autoimmunity Reviews, V1, P67, DOI 10.1016/S1568-9972(01)00007-6; Williams JM, 2005, CLIN SCI, V108, P101, DOI 10.1042/CS20040232; Williams JM, 2005, J AM SOC NEPHROL, V16, P90, DOI 10.1681/ASN.2004040264; Williams JM, 2003, J AM SOC NEPHROL, V14, P661, DOI 10.1097/01.ASN.0000050223.34749.F4; Witko-Sarsat V, 1999, J AM SOC NEPHROL, V10, P1224; Wu YY, 2002, CLIN EXP IMMUNOL, V128, P347, DOI 10.1046/j.1365-2249.2002.01827.x; Xiao H, 2002, J CLIN INVEST, V110, P955, DOI 10.1172/JCI200215918; Yahya TM, 1997, CLIN EXP IMMUNOL, V110, P41, DOI 10.1111/j.1365-2249.1997.498-ce1395.x; Yang JJ, 2004, J AM SOC NEPHROL, V15, P2103, DOI 10.1097/01.ASN.0000135058.46193.72; Yang JJ, 2002, KIDNEY INT, V62, P1638, DOI 10.1046/j.1523-1755.2002.00619.x; Yang JJ, 2000, CLIN EXP IMMUNOL, V121, P165, DOI 10.1046/j.1365-2249.2000.01228.x; Ye H, 2004, CLIN EXP IMMUNOL, V138, P179, DOI 10.1111/j.1365-2249.2004.02557.x; Zhou YH, 2002, J RHEUMATOL, V29, P317	147	235	253	1	19	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL-AUG	2006	368	9533					404	418		10.1016/S0140-6736(06)69114-9	http://dx.doi.org/10.1016/S0140-6736(06)69114-9			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	069JJ	16876669				2022-12-28	WOS:000239441900034
J	Dourakis, SP; Tsochatzis, E; Alexopoulou, A; Archimandritis, AJ				Dourakis, Spiros P.; Tsochatzis, Emmanuel; Alexopoulou, Alexandra; Archimandritis, Athanasios J.			Pylephlebitis complicating silent diverticulitis	LANCET			English	Editorial Material							ERA		Hippokrateion Hosp, Dept Internal Med 2, Athens 11527, Greece	Hippokration General Hospital	Tsochatzis, E (corresponding author), Hippokrateion Hosp, Dept Internal Med 2, Athens 11527, Greece.	mtsochatzis@med.uoa.gr	Alexopoulou, Alexandra/AAB-7698-2021; Tsochatzis, Emmanuel A/A-1651-2012	Tsochatzis, Emmanuel A/0000-0001-5069-2461; ALEXOPOULOU, ALEXANDRA/0000-0003-1991-7436				Baril N, 1996, AM J SURG, V172, P449, DOI 10.1016/S0002-9610(96)00220-6; Chirinos Julio A, 2006, Am J Cardiovasc Drugs, V6, P9, DOI 10.2165/00129784-200606010-00002; Kasper DL, 2005, NEW ENGL J MED, V353, P713, DOI 10.1056/NEJMcpc059020; PLEMMONS RM, 1995, CLIN INFECT DIS, V21, P1114, DOI 10.1093/clinids/21.5.1114; Saxena R, 1996, AM J GASTROENTEROL, V91, P1251	5	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL-AUG	2006	368	9533					422	422		10.1016/S0140-6736(06)69116-2	http://dx.doi.org/10.1016/S0140-6736(06)69116-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	069JJ	16876671				2022-12-28	WOS:000239441900036
J	Suntharalingam, G; Perry, MR; Ward, S; Brett, SJ; Castello-Cortes, A; Brunner, MD; Panoskaltsis, N				Suntharalingam, Ganesh; Perry, Meghan R.; Ward, Stephen; Brett, Stephen J.; Castello-Cortes, Andrew; Brunner, Michael D.; Panoskaltsis, Nicki			Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONSENSUS CONFERENCE; CD28 SUPERAGONISTS; RELEASE SYNDROME; DEFINITIONS; FAILURE; SEPSIS; CELLS; GAMMA	Six healthy young male volunteers at a contract research organization were enrolled in the first phase 1 clinical trial of TGN1412, a novel superagonist anti-CD28 monoclonal antibody that directly stimulates T cells. Within 90 minutes after receiving a single intravenous dose of the drug, all six volunteers had a systemic inflammatory response characterized by a rapid induction of proinflammatory cytokines and accompanied by headache, myalgias, nausea, diarrhea, erythema, vasodilatation, and hypotension. Within 12 to 16 hours after infusion, they became critically ill, with pulmonary infiltrates and lung injury, renal failure, and disseminated intravascular coagulation. Severe and unexpected depletion of lymphocytes and monocytes occurred within 24 hours after infusion. All six patients were transferred to the care of the authors at an intensive care unit at a public hospital, where they received intensive cardiopulmonary support (including dialysis), high-dose methylprednisolone, and an anti-interleukin-2 receptor antagonist antibody. Prolonged cardiovascular shock and acute respiratory distress syndrome developed in two patients, who required intensive organ support for 8 and 16 days. Despite evidence of the multiple cytokine-release syndrome, all six patients survived. Documentation of the clinical course occurring over the 30 days after infusion offers insight into the systemic inflammatory response syndrome in the absence of contaminating pathogens, endotoxin, or underlying disease.	Northwick Pk & St Marks Hosp, Dept Intens Care Med, Harrow HA1 3UJ, Middx, England; Hammersmith Hosp, Dept Intens Care Med, London, England; Northwick Pk & St Marks Hosp, Imperial Coll London, Dept Haematol, Harrow HA1 3UJ, Middx, England	Imperial College London; Imperial College London; Imperial College London	Suntharalingam, G (corresponding author), Northwick Pk & St Marks Hosp, Dept Intens Care Med, Rm 4J007,Watford Rd, Harrow HA1 3UJ, Middx, England.	ganesh.suntharalingam@nwlh.nhs.uk; n.panoskaltsis@imperial.ac.uk		Suntharalingam, Ganesh/0000-0002-8189-8320				BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Beyersdorf N, 2005, J EXP MED, V202, P445, DOI 10.1084/jem.20051060; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; Brivet FG, 1996, CRIT CARE MED, V24, P192, DOI 10.1097/00003246-199602000-00003; CHELEN CJ, 1995, J CLIN INVEST, V95, P1415, DOI 10.1172/JCI117796; GASTON RS, 1991, KIDNEY INT, V39, P141, DOI 10.1038/ki.1991.18; Gon Y, 2005, P NATL ACAD SCI USA, V102, P9270, DOI 10.1073/pnas.0501997102; Hotchkiss RS, 2001, J IMMUNOL, V166, P6952, DOI 10.4049/jimmunol.166.11.6952; HUDSON LD, 1995, AM J RESP CRIT CARE, V151, P293, DOI 10.1164/ajrccm.151.2.7842182; Hunig T, 2005, IMMUNOL LETT, V100, P21, DOI 10.1016/j.imlet.2005.06.012; Luhder F, 2003, J EXP MED, V197, P955, DOI 10.1084/jem.20021024; Offner PJ, 2003, J TRAUMA, V55, P285, DOI 10.1097/01.TA.0000078695.35172.79; Rodriguez-Palmero M, 1999, EUR J IMMUNOL, V29, P3914; Theron M, 2005, CYTOKINE, V32, P30, DOI 10.1016/j.cyto.2005.07.007; Wing MG, 1996, J CLIN INVEST, V98, P2819, DOI 10.1172/JCI119110; Winkler U, 1999, BLOOD, V94, P2217, DOI 10.1182/blood.V94.7.2217.419k02_2217_2224	16	1431	1560	1	97	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 7	2006	355	10					1018	1028		10.1056/NEJMoa063842	http://dx.doi.org/10.1056/NEJMoa063842			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	080UF	16908486	Bronze			2022-12-28	WOS:000240273300007
J	Sutherland, K; Leatherman, S				Sutherland, Kim; Leatherman, Sheila			Professional regulation - Does certification improve medical standards?	BRITISH MEDICAL JOURNAL			English	Editorial Material							SPECIALTY BOARD CERTIFICATION; ACUTE MYOCARDIAL-INFARCTION; PATIENT OUTCOMES; EXPERIENCE; QUALITY; CARE		Univ Cambridge, Judge Business Sch, Cambridge CB2 1AG, England; Univ N Carolina, Sch Publ Hlth, Chapel Hill, NC 27599 USA	University of Cambridge; University of North Carolina; University of North Carolina Chapel Hill	Sutherland, K (corresponding author), Univ Cambridge, Judge Business Sch, Cambridge CB2 1AG, England.	k.sutherland@jbs.cam.ac.uk						Brennan TA, 2005, NEW ENGL J MED, V353, P1989, DOI 10.1056/NEJMp058223; Brennan TA, 2004, JAMA-J AM MED ASSOC, V292, P1038, DOI 10.1001/jama.292.9.1038; Cassel CK, 2006, JAMA-J AM MED ASSOC, V295, P939, DOI 10.1001/jama.295.8.939; Chen J, 2006, J GEN INTERN MED, V21, P238, DOI 10.1111/j.1525-1497.2006.00326.x; Choudhry NK, 2005, ANN INTERN MED, V142, P260, DOI 10.7326/0003-4819-142-4-200502150-00008; Clay Steven W, 2003, J Am Osteopath Assoc, V103, P81; *DEP HLTH, 2006, GOOD DOCT SAF PAT; *HEALTHC COMM, 2005, PERF RAT 2005; Horowitz SD, 2004, MED EDUC, V38, P10, DOI 10.1046/j.1365-2923.2004.01702.x; Khaliq AA, 2005, AM J MED, V118, P773, DOI 10.1016/j.amjmed.2005.01.051; Kohatsu ND, 2004, ARCH INTERN MED, V164, P653, DOI 10.1001/archinte.164.6.653; LEATHERMAN S, 2005, QUEST QUALITY NHS CH; LEATHERMAN S, 2003, QUEST QUALITY NHS MI; Norcini JJ, 2002, MED EDUC, V36, P853, DOI 10.1046/j.1365-2923.2002.01293.x; *ORG EC COOP DEV, 2005, HLTH DAT 2005; Prystowsky JB, 2002, SURGERY, V132, P663, DOI 10.1067/msy.2002.127550; Sharp LK, 2002, ACAD MED, V77, P534, DOI 10.1097/00001888-200206000-00011; Silber JH, 2002, ANESTHESIOLOGY, V96, P1044, DOI 10.1097/00000542-200205000-00004; SMITH J, 2004, SAFEGUARDING PATIENT	19	33	35	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	AUG 26	2006	333	7565					439	441		10.1136/bmj.38933.377824.802	http://dx.doi.org/10.1136/bmj.38933.377824.802			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	081AO	16931845	Green Published			2022-12-28	WOS:000240289800024
J	Whitfield, HN				Whitfield, Hugh N.			ABC of urology - Urological evaluation	BRITISH MEDICAL JOURNAL			English	Editorial Material									Royal Berkshire Hosp, Reading RG1 5AN, Berks, England	Royal Berkshire Hospital	Whitfield, HN (corresponding author), Royal Berkshire Hosp, Reading RG1 5AN, Berks, England.								0	1	1	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	AUG 26	2006	333	7565					432	435		10.1136/bmj.333.7565.432	http://dx.doi.org/10.1136/bmj.333.7565.432			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	081AO	16931842	Green Published			2022-12-28	WOS:000240289800023
J	Umeda, K; Ikenouchi, J; Katahira-Tayama, S; Furuse, K; Sasaki, H; Nakayama, M; Matsui, T; Tsukita, S; Furuse, M; Tsukita, S				Umeda, Kazuaki; Ikenouchi, Junichi; Katahira-Tayama, Sayaka; Furuse, Kyoko; Sasaki, Hiroyuki; Nakayama, Mayumi; Matsui, Takeshi; Tsukita, Sachiko; Furuse, Mikio; Tsukita, Shoichiro			ZO-1 and ZO-2 independently determine where claudins are polymerized in tight-junction strand formation	CELL			English	Article							TUMOR-SUPPRESSOR PROTEIN; GUANYLATE KINASE DOMAINS; EPITHELIAL-CELLS; INTRAMOLECULAR INTERACTION; INTERCELLULAR-JUNCTIONS; ADHERENS JUNCTIONS; MOLECULAR ARCHITECTURE; PERIPHERAL COMPONENT; ADHESION MOLECULE; ZONULA OCCLUDENS	A fundamental question in cell and developmental biology is how epithelial cells construct the diffusion barrier allowing them to separate different body compartments. Formation of tight junction (TJ) strands, which are crucial for this barrier, involves the polymerization of claudins, TJ adhesion molecules, in temporal and spatial manners. ZO-1 and ZO-2 are major PDZ-domain-containing TJ proteins and bind directly to claudins, yet their functional roles are poorly understood. We established cultured epithelial cells (1(ko)/2(kd)) in which the expression of ZO-1/ZO-2 was suppressed by homologous recombination and RNA interference, respectively. These cells were well polarized, except for a complete lack of TJs. When exogenously expressed in, l(ko)/2(kd) cells, ZO-1 and ZO-2 were recruited to junctional areas where claudins were polymerized, but truncated ZO-1 (NZO-1) containing only domains PDZ1-3 was not. When NZO-1 was forcibly recruited to lateral membranes and dimerized, claudins were dramatically polymerized. These findings indicate that ZO-1 and ZO-2 can independently determine whether and where claudins are polymerized.	Kyoto Univ, Fac Med, Dept Cell Biol, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Fac Med, Sch Hlth Sci, Sakyo Ku, Kyoto 6068501, Japan; KAN Res Inst Inc, Shimogyo Ku, Kyoto 6008515, Japan; Japan Sci & Technol Corp, Sakyo Ku, Kyoto 6068501, Japan; Jikei Univ, Sch Med, Inst DNA Med, Dept Mol Cell Biol,Minato Ku, Tokyo 0158461, Japan	Kyoto University; Kyoto University; KAN Research Institute; Japan Science & Technology Agency (JST); Jikei University	Tsukita, S (corresponding author), Kyoto Univ, Fac Med, Dept Cell Biol, Sakyo Ku, Kyoto 6068501, Japan.	atsukita@mfour.med.kyoto-u.ac.jp	Ikenouchi, Junichi/X-2871-2019; Matsui, Takeshi/C-4730-2017; Ikenouchi, Junichi/A-3256-2011	Ikenouchi, Junichi/0000-0002-2936-3548; Furuse, Mikio/0000-0003-2847-8156; Sasaki, Hiroyuki/0000-0002-5358-5853; Furuse, Kyoko/0000-0003-4304-6204				Adams CL, 1996, J CELL BIOL, V135, P1899, DOI 10.1083/jcb.135.6.1899; ANDERSON JM, 1995, BIOCHEM SOC T, V23, P470, DOI 10.1042/bst0230470; Anderson JM, 2004, CURR OPIN CELL BIOL, V16, P140, DOI 10.1016/j.ceb.2004.01.005; Ando-Akatsuka Y, 1999, J CELL PHYSIOL, V179, P115, DOI 10.1002/(SICI)1097-4652(199905)179:2<115::AID-JCP1>3.0.CO;2-T; Baas AF, 2004, CELL, V116, P457, DOI 10.1016/S0092-8674(04)00114-X; BALDA MS, 1993, J CELL BIOL, V123, P293, DOI 10.1083/jcb.123.2.293; Balda MS, 1998, J CELL SCI, V111, P541; Baldini A, 2000, ZEI STUD EU ECON LAW, V2, P19; Benais-Pont G, 2003, J CELL BIOL, V160, P729, DOI 10.1083/jcb.200211047; Borg JP, 2000, NAT CELL BIOL, V2, P407, DOI 10.1038/35017038; Cereijido M, 2000, AM J PHYSIOL-GASTR L, V279, pG477, DOI 10.1152/ajpgi.2000.279.3.G477; Chen YH, 1997, J CELL BIOL, V138, P891, DOI 10.1083/jcb.138.4.891; CITI S, 1988, NATURE, V333, P272, DOI 10.1038/333272a0; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; Furuse M, 1998, J CELL BIOL, V143, P391, DOI 10.1083/jcb.143.2.391; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1999, J CELL BIOL, V147, P891, DOI 10.1083/jcb.147.4.891; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; Gonzalez-Mariscal L, 2000, SEMIN CELL DEV BIOL, V11, P315, DOI 10.1006/scdb.2000.0178; GROVER A, 1983, J CELL BIOL, V96, P1690, DOI 10.1083/jcb.96.6.1690; GUMBINER B, 1991, P NATL ACAD SCI USA, V88, P3460, DOI 10.1073/pnas.88.8.3460; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; Hurd TW, 2003, NAT CELL BIOL, V5, P137, DOI 10.1038/ncb923; Ikenouchi J, 2005, J CELL BIOL, V171, P939, DOI 10.1083/jcb.200510043; Imamura Y, 1999, J CELL BIOL, V144, P1311, DOI 10.1083/jcb.144.6.1311; Itoh M, 2001, J CELL BIOL, V154, P491, DOI 10.1083/jcb.200103047; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; Itoh M, 1999, J BIOL CHEM, V274, P5981, DOI 10.1074/jbc.274.9.5981; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; KIM SK, 1995, CURR OPIN CELL BIOL, V7, P641, DOI 10.1016/0955-0674(95)80105-7; Komiya S, 2005, GENES CELLS, V10, P1065, DOI 10.1111/j.1365-2443.2005.00899.x; Kuhlendahl S, 1998, EUR J BIOCHEM, V252, P305, DOI 10.1046/j.1432-1327.1998.2520305.x; Low SH, 1996, MOL BIOL CELL, V7, P2007, DOI 10.1091/mbc.7.12.2007; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Masuko N, 1999, J BIOL CHEM, V274, P5782, DOI 10.1074/jbc.274.9.5782; Matter K, 2003, NAT REV MOL CELL BIO, V4, P225, DOI 10.1038/nrm1055; McGee AW, 2001, MOL CELL, V8, P1291, DOI 10.1016/S1097-2765(01)00411-7; McGee AW, 1999, J BIOL CHEM, V274, P17431, DOI 10.1074/jbc.274.25.17431; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511; Nagafuchi A, 2001, CURR OPIN CELL BIOL, V13, P600, DOI 10.1016/S0955-0674(00)00257-X; Nelson W J, 1990, Semin Cell Biol, V1, P359; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; REICHMANN E, 1989, J CELL BIOL, V108, P1127, DOI 10.1083/jcb.108.3.1127; Roh MH, 2003, AM J PHYSIOL-RENAL, V285, pF377, DOI 10.1152/ajprenal.00086.2003; Saitou M, 1997, EUR J CELL BIOL, V73, P222; Schneeberger EE, 2004, AM J PHYSIOL-CELL PH, V286, pC1213, DOI 10.1152/ajpcell.00558.2003; Shin HW, 2000, J NEUROSCI, V20, P3580, DOI 10.1523/JNEUROSCI.20-10-03580.2000; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; STAEHELIN LA, 1974, INT REV CYTOL, V39, P191, DOI 10.1016/S0074-7696(08)60940-7; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; Takai Y, 2003, J CELL SCI, V116, P17, DOI 10.1242/jcs.00167; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; Tavares GA, 2001, MOL CELL, V8, P1313, DOI 10.1016/S1097-2765(01)00416-6; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Tsukita S, 1999, TRENDS CELL BIOL, V9, P268, DOI 10.1016/S0962-8924(99)01578-0; Turksen K, 2004, J CELL SCI, V117, P2435, DOI 10.1242/jcs.01235; Umeda K, 2004, J BIOL CHEM, V279, P44785, DOI 10.1074/jbc.M406563200; VOLK T, 1984, EMBO J, V3, P2249, DOI 10.1002/j.1460-2075.1984.tb02123.x; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7; Yamamoto T, 1997, J CELL BIOL, V139, P785, DOI 10.1083/jcb.139.3.785; YONEMURA S, 1995, J CELL SCI, V108, P127	66	563	581	2	24	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	AUG 25	2006	126	4					741	754		10.1016/j.cell.2006.06.043	http://dx.doi.org/10.1016/j.cell.2006.06.043			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	080VN	16923393	Bronze			2022-12-28	WOS:000240276700022
J	Nicolaidis, C				Nicolaidis, Christina			My mother's choice	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												nicolaid@ohsu.edu	Nicolaidis, Christina/X-6468-2019; Nicolaidis, Christina/CAC-0028-2022	Nicolaidis, Christina/0000-0002-9394-5956; Nicolaidis, Christina/0000-0002-9394-5956					0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 23	2006	296	8					907	908		10.1001/jama.296.8.907	http://dx.doi.org/10.1001/jama.296.8.907			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	076AL	16926344				2022-12-28	WOS:000239929300001
J	Koppens, FHL; Buizert, C; Tielrooij, KJ; Vink, IT; Nowack, KC; Meunier, T; Kouwenhoven, LP; Vandersypen, LMK				Koppens, F. H. L.; Buizert, C.; Tielrooij, K. J.; Vink, I. T.; Nowack, K. C.; Meunier, T.; Kouwenhoven, L. P.; Vandersypen, L. M. K.			Driven coherent oscillations of a single electron spin in a quantum dot	NATURE			English	Article							REAL-TIME DETECTION; RESONANCE	The ability to control the quantum state of a single electron spin in a quantum dot is at the heart of recent developments towards a scalable spin-based quantum computer. In combination with the recently demonstrated controlled exchange gate between two neighbouring spins, driven coherent single spin rotations would permit universal quantum operations. Here, we report the experimental realization of single electron spin rotations in a double quantum dot. First, we apply a continuous-wave oscillating magnetic field, generated on-chip, and observe electron spin resonance in spin-dependent transport measurements through the two dots. Next, we coherently control the quantum state of the electron spin by applying short bursts of the oscillating magnetic field and observe about eight oscillations of the spin state ( so-called Rabi oscillations) during a microsecond burst. These results demonstrate the feasibility of operating single-electron spins in a quantum dot as quantum bits.	Delft Univ Technol, Kavli Inst Nanosci, NL-2600 GA Delft, Netherlands	Delft University of Technology	Vandersypen, LMK (corresponding author), Delft Univ Technol, Kavli Inst Nanosci, POB 5046, NL-2600 GA Delft, Netherlands.	f.h.l.koppens@tudelft.nl	Koppens, Frank/X-4422-2018; Tielrooij, Klaas-Jan/R-7133-2019	Koppens, Frank/0000-0001-9764-6120; Tielrooij, Klaas-Jan/0000-0002-0055-6231; Buizert, Christo/0000-0002-2227-1747				Atature M, 2006, SCIENCE, V312, P551, DOI 10.1126/science.1126074; Austing DG, 1998, PHYSICA B, V249, P206, DOI 10.1016/S0921-4526(98)00099-4; Bayer M, 2001, SCIENCE, V291, P451, DOI 10.1126/science.291.5503.451; Blaauboer M, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.160402; Ciorga M, 2000, PHYS REV B, V61, P16315, DOI 10.1103/PhysRevB.61.R16315; Coish WA, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.195340; De Franceschi S, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.156801; DIVINCENZO DP, 1995, SCIENCE, V270, P255, DOI 10.1126/science.270.5234.255; Dutt MVG, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.227403; Elzerman JM, 2004, NATURE, V430, P431, DOI 10.1039/nature02693; Elzerman JM, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.161308; Engel HA, 2005, SCIENCE, V309, P586, DOI 10.1126/science.1113203; Engel HA, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.106804; Engel HA, 2001, PHYS REV LETT, V86, P4648, DOI 10.1103/PhysRevLett.86.4648; Fujisawa T, 2002, NATURE, V419, P278, DOI 10.1038/nature00976; GIEDKE G, 2005, QUANTUM MEASUREMENT; GOLOVACH VN, 2006, ELECT DIPOLE INDUCED; Greilich A, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.227401; Hanson R, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.196802; Holleitner AW, 2003, APPL PHYS LETT, V82, P1887, DOI 10.1063/1.1563731; Imamoglu A, 1999, PHYS REV LETT, V83, P4204, DOI 10.1103/PhysRevLett.83.4204; Jelezko F, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.076401; Jiang HW, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.041307; Johnson AC, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.165308; Johnson AC, 2005, NATURE, V435, P925, DOI 10.1038/nature03815; Jouravlev ON, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.176804; Kato Y, 2004, NATURE, V427, P50, DOI 10.1038/nature02202; Kogan A, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.166602; Koppens FHL, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.106803; Koppens FHL, 2005, SCIENCE, V309, P1346, DOI 10.1126/science.1113719; Kroutvar M, 2004, NATURE, V432, P81, DOI 10.1038/nature03008; Loss D, 1998, PHYS REV A, V57, P120, DOI 10.1103/PhysRevA.57.120; Nielsen Michael A., 2002, QUANTUM COMPUTATION; Ono K, 2002, SCIENCE, V297, P1313, DOI 10.1126/science.1070958; Petta JR, 2005, SCIENCE, V309, P2180, DOI 10.1126/science.1116955; Poole C., 1983, ELECT SPIN RESONANCE, V2nd; Potok RM, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.016802; Rugar D, 2004, NATURE, V430, P329, DOI 10.1038/nature02658; Salis G, 2001, NATURE, V414, P619, DOI 10.1038/414619a; Schleser R, 2004, APPL PHYS LETT, V85, P2005, DOI 10.1063/1.1784875; SHOR PW, 1994, AN S FDN CO, P124; Stepanenko D, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.136401; Tokura Y, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.047202; van Beveren LHW, 2005, NEW J PHYS, V7, DOI 10.1088/1367-2630/7/1/182; Vandersypen LMK, 2004, REV MOD PHYS, V76, P1037, DOI 10.1103/RevModPhys.76.1037; Vandersypen LMK, 2004, APPL PHYS LETT, V85, P4394, DOI 10.1063/1.1815041; Xiao M, 2004, NATURE, V430, P435, DOI 10.1038/nature02727; Zoller P, 2005, EUR PHYS J D, V36, P203, DOI 10.1140/epjd/e2005-00251-1	50	1110	1118	8	206	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 17	2006	442	7104					766	771		10.1038/nature05065	http://dx.doi.org/10.1038/nature05065			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	074DK	16915280	Green Submitted			2022-12-28	WOS:000239792700036
J	Weitzel, T; Jelinek, T				Weitzel, Thomas; Jelinek, Tomas			Loiasis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Inst Trop Med, D-14050 Berlin, Germany		Weitzel, T (corresponding author), Inst Trop Med, D-14050 Berlin, Germany.			Weitzel, Thomas/0000-0002-9804-2123					0	1	1	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 17	2006	355	7					E6	E6		10.1056/NEJMicm050865	http://dx.doi.org/10.1056/NEJMicm050865			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	074AN	16914697				2022-12-28	WOS:000239784500011
J	Petersen, LA; Woodard, LD; Urech, T; Daw, C; Sookanan, S				Petersen, Laura A.; Woodard, LeChauncy D.; Urech, Tracy; Daw, Christina; Sookanan, Supicha			Does pay-for-performance improve the quality of health care?	ANNALS OF INTERNAL MEDICINE			English	Article							PHYSICIAN FINANCIAL INCENTIVES; MEDICAID MANAGED CARE; CHRONIC ILLNESS; NURSING-HOMES; CHILDHOOD IMMUNIZATION; INFLUENZA IMMUNIZATION; PREVENTIVE CARE; INNER-CITY; INTERVENTIONS; PROGRAM	Background: Most physicians and hospitals are paid the same regardless of the quality of the health care they provide. This produces no financial incentives and, in some cases, produces disincentives for quality. Increasing numbers of programs link payment to performance. Purpose: To systematically review studies assessing the effect of explicit financial incentives for improved performance on measures of health care quality. Data Sources: PubMed search of English-language literature (1 January 1980 to 14 November 2005), and reference lists of retrieved articles. Study Selection: Empirical studies of the relationship between explicit financial incentives designed to improve health care quality and a quantitative measure of health care quality. Data Extraction: The authors categorized studies according to the level of the incentive (individual physician, provider group, or health care payment system) and the type of quality measure rewarded. Data Synthesis: Thirteen of 17 studies examined process-of-care quality measures, most of which were for preventive services. Five of the 6 studies of physician-level financial incentives and 7 of the 9 studies of provider group-level financial incentives found partial or positive effects on measures of quality. One of the 2 studies of incentives at the payment-system level found a positive effect on access to care, and 1 showed evidence of a negative effect on access to care for the sickest patients. In all, 4 studies suggested unintended effects of incentives. The authors found no studies examining the optimal duration of financial incentives for quality or the persistence of their effects after termination. Only 1 study addressed cost-effectiveness. Limitations: Few empirical studies of explicit financial incentives for quality were available for review. Conclusions: Ongoing monitoring of incentive programs is critical to determine the effectiveness of financial incentives and their possible unintended effects on quality of care. Further research is needed to guide implementation of financial incentives and to assess their cost-effectiveness.	Michael E DeBakey VA Med Ctr, Hlth Serv Res & Dev 152, Houston, TX 77030 USA; Baylor Coll Med, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Petersen, LA (corresponding author), Michael E DeBakey VA Med Ctr, Hlth Serv Res & Dev 152, 2002 Holcombe Blvd, Houston, TX 77030 USA.	laurap@bcm.edu	Greiver, Michelle/N-8764-2015; Abrams, William R/A-5782-2008	Greiver, Michelle/0000-0001-8957-0285; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079173] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL079173-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abelson Reed, 2003, N Y Times Web, P18; Agency Healthc. Res. Quality (AHRQ), NAT QUAL MEAS CLEAR; Amundson Gail, 2003, Jt Comm J Qual Saf, V29, P59; Armour BS, 2004, AM J MANAG CARE, V10, P617; ARROW KJ, 1963, AM ECON REV, V53, P941; Beaulieu ND, 2005, HEALTH SERV RES, V40, P1318, DOI 10.1111/j.1475-6773.2005.00414.x; Berlin JA, 1997, LANCET, V350, P185, DOI 10.1016/S0140-6736(05)62352-5; Berwick DM, 2003, HEALTH AFFAIR, V22, P8, DOI 10.1377/hlthaff.22.6.8; BLOMQVIST A, 1991, J HEALTH ECON, V10, P411, DOI 10.1016/0167-6296(91)90023-G; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1775, DOI 10.1001/jama.288.14.1775; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1909, DOI 10.1001/jama.288.15.1909; BURNS BJ, 1991, HOSP COMMUNITY PSYCH, V42, P1228; Cameron PA, 1999, MED J AUSTRALIA, V171, P243, DOI 10.5694/j.1326-5377.1999.tb123630.x; Casalino L, 2003, JAMA-J AM MED ASSOC, V289, P434, DOI 10.1001/jama.289.4.434; Christensen D B, 2000, J Am Pharm Assoc (Wash), V40, P609; CLARK RE, 1995, MED CARE, V33, P729; Commons M, 1997, HEALTH SERV RES, V32, P631; Deci E. L., 1985, INTRINSIC MOTIVATION; Donabedian A, 1980, EXPLORATIONS QUALITY, V1; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; DRANOVE D, 1987, INQUIRY-J HEALTH CAR, V24, P405; Dudley RA, 1998, MILBANK Q, V76, P649, DOI 10.1111/1468-0009.00109; EISENBERG JM, 1985, MED CARE, V23, P461, DOI 10.1097/00005650-198505000-00010; Epstein AM, 2004, NEW ENGL J MED, V350, P406, DOI 10.1056/NEJMsb035374; Fairbrother G, 1997, ARCH PEDIAT ADOL MED, V151, P1229, DOI 10.1001/archpedi.1997.02170490055010; Fairbrother G, 2001, AMBUL PEDIATR, V1, P206, DOI 10.1367/1539-4409(2001)001<0206:IOFIOD>2.0.CO;2; Fairbrother G, 1999, AM J PUBLIC HEALTH, V89, P171, DOI 10.2105/AJPH.89.2.171; FANNING T, 1993, J HEALTH POLIT POLIC, V18, P27, DOI 10.1215/03616878-18-1-27; FOX MH, 1995, PUBLIC HEALTH REP, V110, P319; GERON SM, 1991, GERONTOLOGIST, V31, P292, DOI 10.1093/geront/31.3.292; GINGRICH N, 2004, NY TIMES        0503, pA25; Gold M, 1999, MILBANK Q, V77, P3, DOI 10.1111/1468-0009.00123; Grabowski DC, 2002, INQUIRY-J HEALTH CAR, V39, P258, DOI 10.5034/inquiryjrnl_39.3.258; Grady KE, 1997, PREV MED, V26, P791, DOI 10.1006/pmed.1997.0219; Greene RA, 2004, AM J MANAG CARE, V10, P670; Grimshaw JM, 2001, MED CARE, V39, pII2; Hanchak NA, 1996, HEALTH CARE FINANC R, V17, P143; Hillman AL, 1999, PEDIATRICS, V104, P931, DOI 10.1542/peds.104.4.931; Hillman AL, 1998, AM J PUBLIC HEALTH, V88, P1699, DOI 10.2105/AJPH.88.11.1699; HILLMAN AL, 1991, HEALTH AFFAIR, V10, P205, DOI 10.1377/hlthaff.10.4.207; Institute of Medicine, 2001, CROSSING QUALITY CHA; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Kouides RW, 1998, AM J PREV MED, V14, P89, DOI 10.1016/S0749-3797(97)00028-7; KOUIDES RW, 1993, AM J PREV MED, V9, P250, DOI 10.1016/S0749-3797(18)30723-2; Kuhn M, 2003, QUALITY PRIMARY CARE; Leatherman S, 2003, HEALTH AFFAIR, V22, P17, DOI 10.1377/hlthaff.22.2.17; Lohr KN, 1990, MEDICARE STRATEGY QU; Lu MS, 2003, HEALTH ECON, V12, P339, DOI 10.1002/hec.734; LYNCH ML, 1994, HEALTH ECON, V3, P117, DOI 10.1002/hec.4730030208; McMenamin SB, 2003, MED CARE, V41, P1396, DOI 10.1097/01.MLR.0000100585.27288.CD; Morrow R W, 1995, Arch Fam Med, V4, P165, DOI 10.1001/archfami.4.2.165; NORTON EC, 1992, J HEALTH ECON, V11, P105, DOI 10.1016/0167-6296(92)90030-5; OXMAN AD, 1995, CAN MED ASSOC J, V153, P1423; PEAR R, 2002, NY TIMES        1031, pA21; Pourat N, 2005, AM J MANAG CARE, V11, P426; RITCHIE LD, 1992, BRIT MED J, V304, P816, DOI 10.1136/bmj.304.6830.816; Rosenthal MB, 2005, JAMA-J AM MED ASSOC, V294, P1788, DOI 10.1001/jama.294.14.1788; Roski J, 2003, PREV MED, V36, P291, DOI 10.1016/S0091-7435(02)00052-X; Roter DL, 1998, MED CARE, V36, P1138, DOI 10.1097/00005650-199808000-00004; Safran DG, 2000, ARCH INTERN MED, V160, P69, DOI 10.1001/archinte.160.1.69; Scott A, 2001, J HEALTH ECON, V20, P329, DOI 10.1016/S0167-6296(00)00083-7; Shen YJ, 2003, HEALTH SERV RES, V38, P535, DOI 10.1111/1475-6773.00132; Wagner EH, 2001, HEALTH AFFAIR, V20, P64, DOI 10.1377/hlthaff.20.6.64; WENNBERG JE, 1982, SOC SCI MED, V16, P811, DOI 10.1016/0277-9536(82)90234-9	64	511	515	4	91	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	2006	145	4					265	272		10.7326/0003-4819-145-4-200608150-00006	http://dx.doi.org/10.7326/0003-4819-145-4-200608150-00006			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	075CC	16908917				2022-12-28	WOS:000239858800004
J	Rosenbloom, AL				Rosenbloom, Arlan L.			Is there a role for recombinant insulin-like growth factor-I in the treatment of idiopathic short stature?	LANCET			English	Editorial Material							HORMONE INSENSITIVITY SYNDROME; IGF-I; RECEPTOR DEFICIENCY; CHILDREN; THERAPY; SERUM; GH; HYPOGLYCEMIA; RESISTANCE; SYSTEM		Univ Florida, Coll Med, Dept Pediat, Div Endocrinol, Gainesville, FL 32608 USA	State University System of Florida; University of Florida	Rosenbloom, AL (corresponding author), Univ Florida, Coll Med, Dept Pediat, Div Endocrinol, Gainesville, FL 32608 USA.	rosenal@peds.ufl.edu	Rosenbloom, Arlan L./A-8194-2009					ATTIE KM, 1995, J PEDIATR-US, V127, P244, DOI 10.1016/S0022-3476(95)70302-0; Backeljauw PF, 2001, J CLIN ENDOCR METAB, V86, P1504, DOI 10.1210/jc.86.4.1504; Ben-Dov I, 2003, CLIN ENDOCRINOL, V59, P763, DOI 10.1046/j.1365-2265.2003.01920.x; Camacho-Hubner C, 2001, HORM RES, V55, P17, DOI 10.1159/000063457; CAMACHOHUBNER C, 2003, PHIL 85 ANN M END SO; Clark RG, 2005, PEDIATR NEPHROL, V20, P290, DOI 10.1007/s00467-004-1714-7; COHEN P, 2005, PAS, V57, P785; Cotterill AM, 1998, CLIN ENDOCRINOL, V48, P719, DOI 10.1046/j.1365-2265.1998.00407.x; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; Domene HM, 2004, NEW ENGL J MED, V350, P570, DOI 10.1056/NEJMoa013100; Fielder PJ, 1996, ENDOCRINOLOGY, V137, P1913, DOI 10.1210/en.137.5.1913; Firth SM, 2002, ENDOCRINOLOGY, V143, P1669, DOI 10.1210/en.143.5.1669; Goddard AD, 1997, J PEDIATR-US, V131, pS51, DOI 10.1016/S0022-3476(97)70012-X; Guevara-Aguirre J, 2006, ACTA PAEDIATR, V95, P199, DOI 10.1080/08035250500352177; GUEVARAAGUIRRE J, 1995, J CLIN ENDOCR METAB, V80, P1393, DOI 10.1210/jc.80.4.1393; GuevaraAguirre J, 1997, J CLIN ENDOCR METAB, V82, P629, DOI 10.1210/jc.82.2.629; *INCR, TERC; *INSM, 2005, SEC EXCH COMM FORM 1; *IPLEX, INSM; Katz LEL, 2002, J CLIN ENDOCR METAB, V87, P2978, DOI 10.1210/jc.87.6.2978; Kemp Stephen F, 2005, Curr Opin Investig Drugs, V6, P373; KLINGER B, 1997, J PEDIAT ENDOCRINOL, V82, P629; LARON Z, 1999, PAEDIAT DRUGS, V3, P155; Nwosu BU, 2004, HORM RES, V62, P97, DOI 10.1159/000079711; Park P, 2005, GROWTH HORM IGF RES, V15, pS13, DOI 10.1016/j.ghir.2005.06.011; Poulton A, 2003, J PAEDIATR CHILD H, V39, P180, DOI 10.1046/j.1440-1754.2003.00107.x; Ranke MB, 1999, HORM RES, V51, P128, DOI 10.1159/000023345; RATNER ML, 2004, START UP, V9, P1; ROSENBLOOM AL, 2003, PEDIAT ENDOCRINOLOGY, P47; Rosenfeld RG, 2005, ENDOCRIN DEV, V9, P1, DOI 10.1159/000085716; Ross JL, 2004, J CLIN ENDOCR METAB, V89, P4873, DOI 10.1210/jc.2004-0791; *TERC, 2005, FDA APPR TERC INCR S; *TERC, 2003, SEC EXCH COMM; *TERC, TERC SUBM MARK AUTH; UNDERWOOD L, 2004, 86 ANN M END SOC NEW; US Food and Drug Administration, CDER NEW MOL ENT NME; VACCARELLO MA, 1993, J CLIN ENDOCR METAB, V77, P273, DOI 10.1210/jc.77.1.273; Walenkamp MJE, 2005, J CLIN ENDOCR METAB, V90, P2855, DOI 10.1210/jc.2004-1254; Woods KA, 2000, J CLIN ENDOCR METAB, V85, P1407, DOI 10.1210/jc.85.4.1407; Wudy SA, 2005, PEDIATRICS, V116, pE52, DOI 10.1542/peds.2004-1684; 1994, DORLANDS ILLUSTRATED	41	24	25	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 12	2006	368	9535					612	616		10.1016/S0140-6736(06)69205-2	http://dx.doi.org/10.1016/S0140-6736(06)69205-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	074OF	16905026				2022-12-28	WOS:000239821000035
J	Steinbrook, R				Steinbrook, Robert			Turning the page at CMAJ	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							INDEPENDENCE					rsteinbrook@attglobal.net						*GOV REV PAN, 2006, CMAJ; Hoey J, 2006, NEW ENGL J MED, V354, P1982, DOI 10.1056/NEJMp068104; Shuchman M, 2006, NEW ENGL J MED, V354, P1337, DOI 10.1056/NEJMp068056; *WORLD ASS MED ED, 2006, REL J ED IN CHIEF OW	4	2	2	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 10	2006	355	6					547	547		10.1056/NEJMp068174	http://dx.doi.org/10.1056/NEJMp068174			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	071QM	16899774				2022-12-28	WOS:000239616700004
J	Han, SC; Shum, CK; Bevis, M; Ji, C; Kuo, CY				Han, Shin-Chan; Shum, C. K.; Bevis, Michael; Ji, Chen; Kuo, Chung-Yen			Crustal dilatation observed by GRACE after the 2004 Sumatra-Andaman earthquake	SCIENCE			English	Article							TENSILE FAULTS; HALF-SPACE; ART.; GRAVITY; DEFORMATION; RECOVERY; SHEAR	We report the detection of an earthquake by a space-based measurement. The Gravity Recovery and Climate Experiment (GRACE) satellites observed a +/-15-microgalileo gravity change induced by the great December. 2004 Sumatra-Andaman earthquake. Coseismic deformation produces sudden changes in the gravity field by vertical displacement of Earth's layered density structure and by changing the densities of the crust and mantle. GRACE's sensitivity to the long spatial. wavelength of gravity changes resulted in roughly equal contributions of vertical displacement and dilatation effects in the gravity measurements. The GRACE observations provide evidence of crustal dilatation resulting from an undersea earthquake.	Ohio State Univ, Dept Geol Sci, Columbus, OH 43210 USA; Univ Calif Santa Barbara, Dept Earth Sci, Santa Barbara, CA 93106 USA	University System of Ohio; Ohio State University; University of California System; University of California Santa Barbara	Han, SC (corresponding author), Ohio State Univ, Dept Geol Sci, 275 Mendenhall Lab,125 S Oval Mall, Columbus, OH 43210 USA.	han.104@osu.edu	Han, Shin-Chan/A-2022-2009	Han, Shin-Chan/0000-0003-1810-1670; Shum, C K/0000-0001-9378-4067				Ammon CJ, 2005, SCIENCE, V308, P1133, DOI 10.1126/science.1112260; BETTADPUR S, 2004, LEVEL 2 GRAVITY FIEL; Chambers DP, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020461; Han SC, 2006, J GEOPHYS RES-SOL EA, V111, DOI 10.1029/2005JB003719; Han SC, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL024296; Han SC, 2005, GEOPHYS J INT, V163, P18, DOI 10.1111/j.1365-246X.2005.02756.x; Han SC, 2005, J GEODYN, V39, P11, DOI 10.1016/j.jog.2004.08.002; Han SC, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL022382; HAN SC, 2005, EOS, V86, DOI UNSP G22A05; Lay T, 2005, SCIENCE, V308, P1127, DOI 10.1126/science.1112250; OKADA Y, 1992, B SEISMOL SOC AM, V82, P1018; OKADA Y, 1985, B SEISMOL SOC AM, V75, P1135; Park J, 2005, SCIENCE, V308, P1139, DOI 10.1126/science.1112305; Rowlands DD, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2004GL021908; Tapley BD, 2004, SCIENCE, V305, P503, DOI 10.1126/science.1099192; Tapley BD, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL019920; Vigny C, 2005, NATURE, V436, P201, DOI 10.1038/nature03937; Wahr J, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL019779	18	238	287	5	74	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 4	2006	313	5787					658	662		10.1126/science.1128661	http://dx.doi.org/10.1126/science.1128661			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	072IQ	16888136				2022-12-28	WOS:000239667500040
J	Dyer, AG; Whitney, HM; Arnold, SEJ; Glover, BJ; Chittka, L				Dyer, Adrian G.; Whitney, Heather M.; Arnold, Sarah E. J.; Glover, Beverley J.; Chittka, Lars			Bees associate warmth with floral colour	NATURE			English	Article							POLLINATION; REWARD; HEAT		Univ Cambridge, Dept Plant Sci, Cambridge CB2 3EA, England; Univ London, Queen Mary Coll, London E1 4NS, England	University of Cambridge; University of London; Queen Mary University London	Dyer, AG (corresponding author), Univ Cambridge, Dept Plant Sci, Cambridge CB2 3EA, England.	l.chittka@qmul.ac.uk	Arnold, Sarah/H-6490-2019; Chittka, Lars/C-3110-2012	Arnold, Sarah/0000-0001-7345-0529; Chittka, Lars/0000-0001-8153-1732; Whitney, Heather/0000-0001-6450-8266	Natural Environment Research Council [NE/C000552/1] Funding Source: researchfish	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Chittka L, 2003, NATURE, V424, P388, DOI 10.1038/424388a; Comba L, 2000, PLANT CELL ENVIRON, V23, P639, DOI 10.1046/j.1365-3040.2000.00580.x; Giurfa M, 2004, NATURWISSENSCHAFTEN, V91, P228, DOI 10.1007/s00114-004-0530-z; HEINRICH B, 1994, AM SCI, V82, P164; KEVAN PG, 1975, SCIENCE, V189, P723, DOI 10.1126/science.189.4204.723; MILLER GA, 1986, OECOLOGIA, V70, P155, DOI 10.1007/BF00377126; Sapir Y, 2006, OECOLOGIA, V147, P53, DOI 10.1007/s00442-005-0246-6; Seymour RS, 2003, NATURE, V426, P243, DOI 10.1038/426243a; Thien LB, 2000, INT J PLANT SCI, V161, pS225, DOI 10.1086/317575; [No title captured]	10	112	118	4	91	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 3	2006	442	7102					525	525		10.1038/442525a	http://dx.doi.org/10.1038/442525a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	069NQ	16885975	Bronze, Green Published			2022-12-28	WOS:000239455900032
J	Ordi, J; Alonso, PL; de Zulueta, J; Esteban, J; Velasco, M; Mas, E; Campo, E; Fernandez, PL				Ordi, Jaume; Alonso, Pedro L.; de Zulueta, Julian; Esteban, Jordi; Velasco, Martin; Mas, Ernest; Campo, Elias; Fernandez, Pedro L.			The severe gout of Holy Roman Emperor Charles V	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DIAGNOSIS; FIXATION; URATE		Univ Barcelona, Hosp Clin Invest Biomed August Pi & Sunyer, Dept Pathol, Barcelona, Spain; Univ Barcelona, Hosp Clin Invest Biomed August Pi & Sunyer, Dept Radiol, Barcelona, Spain; Univ Barcelona, Hosp Clin Invest Biomed August Pi & Sunyer, Dept Biochem, Barcelona, Spain; Univ Barcelona, Hosp Clin Invest Biomed August Pi & Sunyer, Ctr Int Hlth, Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Ordi, J (corresponding author), Univ Barcelona, Hosp Clin Invest Biomed August Pi & Sunyer, Dept Pathol, Barcelona, Spain.		Ordi, Jaume/X-4524-2018; Fernandez, Pedro L/H-2594-2017; Alonso, Pedro L/AAZ-3645-2020; Campo, Elias/AAC-5593-2019	Ordi, Jaume/0000-0002-4820-7954; Alonso, Pedro L/0000-0003-3292-3443; Campo, Elias/0000-0001-9850-9793; Fernandez, Pedro Luis/0000-0002-8618-4597				Boonen A, 2005, ANN RHEUM DIS, V64, P528, DOI 10.1136/ard.2004.030353; Darby AJ, 1998, HISTOPATHOLOGY, V32, P382; Eulderink F, 1997, HISTOPATHOLOGY, V30, P195; FERNANDEZALVARE.M, 2003, CORUS DOCUMENTAL CAR, V4, P483; FERNANDEZALVARE.M, 2003, CORPUS DOCUMENTAL CA, V3, P635; FERNANDEZALVARE.M, 2003, CORPUS DOCUMENTAL CA, V4, P332; GUERREROCABANIL.V, 2005, SALUD CARLOS 5, P203; GUERREROCABANIL.V, 2005, SALUD CARLOS 5, P157; Mekota AM, 2005, BIOTECH HISTOCHEM, V80, P7, DOI 10.1080/10520290500051146; Rothschild BM, 1997, NATURE, V387, P357, DOI 10.1038/387357a0; ROTHSCHILD BM, 1995, AM J PHYS ANTHROPOL, V98, P519, DOI 10.1002/ajpa.1330980411; SANDISON AT, 1966, J CLIN PATHOL, V19, P522, DOI 10.1136/jcp.19.5.522	12	27	28	2	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 3	2006	355	5					516	520		10.1056/NEJMon060780	http://dx.doi.org/10.1056/NEJMon060780			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	069FT	16885558				2022-12-28	WOS:000239432500015
J	Alam, NH; Yunus, M; Faruque, ASG; Gyr, N; Sattar, S; Parvin, S; Ahmed, JU; Salam, MA; Sack, DA				Alam, Nur H.; Yunus, Mohammed; Faruque, Abu S. G.; Gyr, Niklaus; Sattar, Samima; Parvin, Shahanaz; Ahmed, Jamal U.; Salam, Mohammed A.; Sack, David A.			Symptomatic hyponatremia during treatment of dehydrating diarrheal disease with reduced osmolarity oral rehydration. solution	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK-FACTORS; EFFICACY; HYPOGLYCEMIA; CHILDREN; SURVEILLANCE; SHIGELLOSIS; PREVALENCE; ABSORPTION; CHILDHOOD; STANDARD	Context In May 2002, the World Health Organization and the United Nations Children's Fund recommended that the formulation of oral rehydration solution (ORS) for treatment of patients with diarrhea be changed to one with a reduced osmolarity and that safety of the new formulation, particularly development of symptomatic hyponatremia, be monitored. Objective To measure the rates of symptomatic hyponatremia during treatment of patients with diarrhea with reduced osmolarity ORS. Design, Settings, and Patients A phase 4 trial conducted at the Dhaka hospital (December 1, 2002-November 30, 2003) and Matlab hospital (February 2, 2003-January 31, 2004) of the International Centre for Diarrhoeal Disease Research Bangladesh: Centre for Health and Population Research, Dhaka, Bangladesh. All patients admitted with uncomplicated watery diarrhea were treated with the newly recommended ORS and monitored. Patients developing neurological symptoms (seizure or altered consciousness) were transferred to the special care ward for treatment and investigated to identify the cause of the symptoms. Patient records of the Dhaka hospital were reviewed during the previous year when the old ORS formulation was used. Intervention Reduced osmolarity ORS. Main Outcome Measure Incidence rate of symptomatic hyponatremia in a 1-year period. Results A total of 53 280 patients, including 22 536 children younger than 60 months, were monitored at the Dhaka and Matlab hospitals. Twenty-four patients, none older than 36 months, developed seizures or altered consciousness associated with hyponatremia, with an overall incidence rate of 0.05% (95% confidence interval [CI], 0.03%-0.07%) at the Dhaka hospital and 0.03% (95% Cl, 0.01 %-0.09%) at the Matlab hospital. During the previous year, 47 patients at the Dhaka hospital had symptoms associated with hyponatremia, for an estimated incidence rate of 0.10% (95% Cl, 0.07%-0.13%). The reduction in the rates was statistically significant (odds ratio, 0.50; 95% Cl, 0.29-0.85; P=.009). Conclusion The risk of symptoms associated with hyponatremia in patients treated with the reduced osmolarity ORS is minimal and did not increase with the change in formulation.	Int Ctr Diarrhoeal Dis Res, Ctr Hlth & Populat Res, Div Clin Sci, Dhaka 1000, Bangladesh; Int Ctr Diarrhoeal Dis Res, Ctr Hlth & Populat Res, Div Publ Hlth Sci, Dhaka 1000, Bangladesh; Univ Basel Hosp, Dept Internal Med, CH-4031 Basel, Switzerland	International Centre for Diarrhoeal Disease Research (ICDDR); International Centre for Diarrhoeal Disease Research (ICDDR); University of Basel	Alam, NH (corresponding author), Int Ctr Diarrhoeal Dis Res, Ctr Hlth & Populat Res, Div Clin Sci, GPO Box 128, Dhaka 1000, Bangladesh.	nhalam@icddrb.org						Alam NH, 1999, LANCET, V354, P296, DOI 10.1016/S0140-6736(98)09332-5; Alam NH, 2001, PEDIATRICS, V107, P613, DOI 10.1542/peds.107.4.613; AVERY ME, 1990, NEW ENGL J MED, V323, P891, DOI 10.1056/NEJM199009273231307; BENNISH ML, 1990, NEW ENGL J MED, V322, P1357, DOI 10.1056/NEJM199005103221905; CHEN LC, 1981, POPUL DEV REV, V7, P55, DOI 10.2307/1972764; Duggan C, 2004, JAMA-J AM MED ASSOC, V291, P2628, DOI 10.1001/jama.291.21.2628; ELMOUGI M, 1994, J PEDIATR GASTR NUTR, V19, P83, DOI 10.1097/00005176-199407000-00013; Farthing M J, 1989, Acta Paediatr Scand Suppl, V364, P23; Faruque ASG, 1996, SCAND J INFECT DIS, V28, P87, DOI 10.3109/00365549609027156; FAYAD IM, 1992, LANCET, V339, P389, DOI 10.1016/0140-6736(92)90079-I; Fontaine O, 2000, COCHRANE DB SYST REV; GORE SM, 1992, BMJ-BRIT MED J, V304, P287, DOI 10.1136/bmj.304.6822.287; Hahn S, 2001, BMJ-BRIT MED J, V323, P81, DOI 10.1136/bmj.323.7304.81; HIRSCHHORN N, 1966, LANCET, V2, P128; HUNT JB, 1989, ALIMENT PHARM THERAP, V3, P565; HUNT JB, 1994, GUT, V35, P211, DOI 10.1136/gut.35.2.211; HUNT JB, 1992, GUT, V33, P1652, DOI 10.1136/gut.33.12.1652; HUSKINS WC, 1994, J PEDIATR-US, V125, P14, DOI 10.1016/S0022-3476(94)70115-6; ISLAM SS, 1986, T ROY SOC TROP MED H, V80, P748, DOI 10.1016/0035-9203(86)90374-3; JONES RG, 1966, LANCET, V2, P643; Khan WA, 1999, PEDIATRICS, V103, part. no., DOI 10.1542/peds.103.2.e18; Mahalanabis D, 1974, J Trop Pediatr Environ Child Health, V20, P82; MITRA AK, 1991, T ROY SOC TROP MED H, V85, P685, DOI 10.1016/0035-9203(91)90396-G; Molla A M, 1981, Indian Pediatr, V18, P181; MOLLA AM, 1981, J PEDIATR-US, V98, P835, DOI 10.1016/S0022-3476(81)80863-3; Murphy C, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003754.PUB2; Nalin DR, 2004, JAMA-J AM MED ASSOC, V291, P2632, DOI 10.1001/jama.291.21.2632; RAHAMAN MM, 1982, AM J PUBLIC HEALTH, V72, P1124, DOI 10.2105/AJPH.72.10.1124; RAIZADA N, 1992, Indian Pediatrics, V29, P461; RAUTANEN T, 1993, ACTA PAEDIATR, V82, P52, DOI 10.1111/j.1651-2227.1993.tb12516.x; ROLSTON DDK, 1990, GUT, V31, P1115, DOI 10.1136/gut.31.10.1115; SAMADI AR, 1985, BRIT MED J, V290, P1615, DOI 10.1136/bmj.290.6482.1615; Santosham M, 1996, J PEDIATR-US, V128, P45, DOI 10.1016/S0022-3476(96)70426-2; STOLL BJ, 1982, BRIT MED J, V285, P1185, DOI 10.1136/bmj.285.6349.1185; Thillainayagam AV, 1998, GASTROENTEROLOGY, V114, P197, DOI 10.1016/S0016-5085(98)70647-X; Uemura N, 2002, BRAIN DEV-JPN, V24, P745, DOI 10.1016/S0387-7604(02)00097-9; Victora CG, 2000, B WORLD HEALTH ORGAN, V78, P1246; WALKERSMITH JA, 1992, J PEDIATR GASTR NUTR, V14, P113, DOI 10.1097/00005176-199201000-00023; Wang Y C, 1993, Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi, V34, P451; WHO, 1995, WHOCDR953; *WHO, 2001, WHOFCHCAH0122 UNICEF	41	27	29	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 2	2006	296	5					567	573		10.1001/jama.296.5.567	http://dx.doi.org/10.1001/jama.296.5.567			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	069YW	16882963	Bronze			2022-12-28	WOS:000239486900021
J	Murray, CS; Woodcock, A; Langley, S; Morris, J; Custovic, A				Murray, Clare S.; Woodcock, Ashley; Langley, Stephen; Morris, Julie; Custovic, Adnan		IFWIN Study Team	Secondary prevention of asthma by the use of inhaled fluticasone propionate in wheezy infants (IFWIN): double-blind, randomised, controlled study	LANCET			English	Article							MILD PERSISTENT ASTHMA; 2 YEARS OLD; LUNG-FUNCTION; 3-YEAR-OLD CHILDREN; PRESCHOOL-CHILDREN; EARLY INTERVENTION; PULMONARY-FUNCTION; SYSTEMIC ACTIVITY; CORTICOSTEROIDS; BUDESONIDE	Background Wheezing and asthma often begins in early childhood, but it is difficult to predict whether or not a wheezy infant will develop asthma. Some researchers suggest that treatment with inhaled corticosteroids at the first signs of wheezing in childhood could prevent the development of asthma later in life. However, other investigators have reported that although such treatment could help control symptoms, the benefits can disappear within months of stopping treatment. We tested our hypothesis that to prevent loss of lung function and worsening asthma later in childhood, anti-inflammatory treatment needs to be started early in life. Methods We did a randomised, double-blind, controlled study of inhaled fluticasone propionate 100 mu g twice daily in young children who were followed prospectively and randomised after either one prolonged (>1 month) or two medically confirmed wheezy episodes. The dose of study drug was reduced every 3 months to the minimum needed. If the symptoms were not under control by 3 months, open-label fluticasone propionate 100 mu g twice daily was added to the treatment. Children were followed-up to 5 years of age, at which point we gave their parents or guardians questionnaires, and measured the children's lung function (specific airways resistance [sR(aw)], forced expiratory volume in 1s [FEV1]) and airway reactivity (eucapnic voluntary hyperventilation [EVH] challenge). This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN86717853. Findings We followed 1073 children prospectively, of whom 333 were eligible, and 200 of these began treatment (130 male, median age 1.2 years [range 0.5-4.9]; 101 placebo, 99 treatment); 173 (85 treatment, 88 placebo) completed the follow-up at age five years. The groups did not differ significantly in the proportion of children with current wheeze, physician-diagnosed asthma or use of asthma medication, lung function, or airway reactivity (percentage change in FEV1, adjusted mean for placebo 5.5% [95% CI -2.5 to 13.4]) vs for treatment 5.0% [-2.2 to 12.2], p=0.87). There were no differences in the results after adjustment for open-label fluticasone propionate, nor between the two groups in the time before the open-label drug was added (estimated hazard ratio 1.12 [95% CI 0.73-1.73], p=0.60), or the proportion needing the open-label drug (43 [42.57%] placebo, 41 [41.41%] treatment). Interpretation The early use of inhaled fluticasone propionate for wheezing in preschool children had no effect on the natural history of asthma or wheeze later in childhood, and did not prevent lung function decline or reduce airway reactivity.	Univ Manchester, Wythenshawe Hosp, NW Lung Ctr, Manchester M23 9LT, Lancs, England; S Manchester Univ Hosp NHS Trust, Dept Med Stat, Educ & Res Ctr, Manchester, Lancs, England	University of Manchester; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; Wythenshawe Hospital NHS Foundation Trust	Murray, CS (corresponding author), Univ Manchester, Wythenshawe Hosp, NW Lung Ctr, Manchester M23 9LT, Lancs, England.	clare.murray@manchester.ac.uk	Custovic, Adnan/A-2435-2012	Custovic, Adnan/0000-0001-5218-7071; Woodcock, Ashley/0000-0002-5428-8578; Murray, Clare/0000-0002-8961-8055				AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; Anhoj J, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.3.e40; Bisgaard H, 1999, AM J RESP CRIT CARE, V160, P126, DOI 10.1164/ajrccm.160.1.9811024; Bisgaard H, 2004, PEDIATRICS, V113, P87; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; BISGAARD H, 1993, ACTA PAEDIATR, V82, P1066, DOI 10.1111/j.1651-2227.1993.tb12814.x; Cane RS, 2000, ARCH DIS CHILD, V82, P327, DOI 10.1136/adc.82.4.327; Chavasse RJ, 2001, ARCH DIS CHILD, V85, P143, DOI 10.1136/adc.85.2.143; Chen YZ, 2006, PEDIAT ALLERG IMM-UK, V17, P7, DOI 10.1111/j.1600-5562.2006.00379.x; *CHILDH ASTHM MAN, 2000, NEW ENGLAND J MED, V0343; Custovic A, 2002, PEDIAT ALLERG IMM-UK, V13, P32, DOI 10.1034/j.1399-3038.13.s.15.3.x; Dezateux C, 1997, BRIT MED BULL, V53, P40; FREEMAN JV, 1995, ARCH DIS CHILD, V73, P17, DOI 10.1136/adc.73.1.17; GODFREY S, 2003, WHEEZY INFANT, P1; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Hofhuis W, 2005, AM J RESP CRIT CARE, V171, P328, DOI 10.1164/rccm.200402-227OC; Lowe L, 2004, ARCH DIS CHILD, V89, P540, DOI 10.1136/adc.2003.038539; Lowe L, 2002, LANCET, V359, P1904, DOI 10.1016/S0140-6736(02)08781-0; Lowe LA, 2005, AM J RESP CRIT CARE, V171, P231, DOI 10.1164/rccm.200406-695OC; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Nielsen KG, 2001, AM J RESP CRIT CARE, V164, P554, DOI 10.1164/ajrccm.164.4.2006119; Oswald H, 1997, PEDIATR PULM, V23, P14, DOI 10.1002/(SICI)1099-0496(199701)23:1<14::AID-PPUL2>3.0.CO;2-P; Pao CS, 2002, AM J RESP CRIT CARE, V166, P945, DOI 10.1164/rccm.200203-265OC; Pauwels RA, 2003, LANCET, V361, P1071, DOI 10.1016/S0140-6736(03)12891-7; PEARCE N, 1993, EUR RESPIR J, V6, P1455; Roorda RJ, 2001, J ALLERGY CLIN IMMUN, V108, P540, DOI 10.1067/mai.2001.118789; Stick S, 2000, THORAX, V55, P587, DOI 10.1136/thorax.55.7.587; STICK SM, 1995, ARCH DIS CHILD, V73, P327, DOI 10.1136/adc.73.4.327; Teper AM, 2005, AM J RESP CRIT CARE, V171, P587, DOI 10.1164/rccm.200408-1088OC; Teper AM, 2004, PEDIATR PULM, V37, P111, DOI 10.1002/ppul.10400; VANBEVER HP, 1990, PEDIATR PULM, V9, P177, DOI 10.1002/ppul.1950090310	31	237	257	1	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG-SEP	2006	368	9537					754	762		10.1016/S0140-6736(06)69285-4	http://dx.doi.org/10.1016/S0140-6736(06)69285-4			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	080ID	16935686				2022-12-28	WOS:000240240200027
J	Emoto, K; Parrish, JZ; Jan, LY; Jan, YN				Emoto, Kazuo; Parrish, Jay Z.; Jan, Lily Yeh; Jan, Yuh-Nung			The tumour suppressor Hippo acts with the NDR kinases in dendritic tiling and maintenance	NATURE			English	Article							DROSOPHILA SENSORY NEURONS; CELL-PROLIFERATION; PROMOTES APOPTOSIS; PROTEIN-KINASE; SIGNALING PATHWAY; FAMILY; ENCODES; GROWTH; SHAPE; MORPHOGENESIS	Precise patterning of dendritic fields is essential for neuronal circuit formation and function, but how neurons establish and maintain their dendritic fields during development is poorly understood. In Drosophila class IV dendritic arborization neurons, dendritic tiling, which allows for the complete but nonoverlapping coverage of the dendritic fields(1-3), is established through a 'like-repels-like' behaviour of dendrites mediated by Tricornered (Trc), one of two NDR ( nuclear Dbf2-related) family kinases in Drosophila(4-7). Here we report that the other NDR family kinase, the tumour suppressor Warts/Lats (Wts)(8-10), regulates the maintenance of dendrites; in wts mutants, dendrites initially tile the body wall normally, but progressively lose branches at later larval stages, whereas the axon shows no obvious defects. We further provide biochemical and genetic evidence for the tumour suppressor kinase Hippo (Hpo)(11-15) as an upstream regulator of Wts and Trc for dendrite maintenance and tiling, respectively, thereby revealing important functions of tumour suppressor genes of the Hpo signalling pathway in dendrite morphogenesis.	Univ Calif San Francisco, Howard Hughes Med Inst, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Biochem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Biophys, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Jan, YN (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Dept Physiol, San Francisco, CA 94143 USA.	yuhnung.jan@ucsf.edu	EMOTO, KAZUO/G-4992-2014	Jan, Lily/0000-0003-3938-8498; Jan, Yuh Nung/0000-0003-1367-6299	NATIONAL INSTITUTE OF MENTAL HEALTH [F32MH071101] Funding Source: NIH RePORTER; NIMH NIH HHS [F32 MH071101, F32 MH071101-02] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BECKER LE, 1986, ANN NEUROL, V20, P520, DOI 10.1002/ana.410200413; Chan EH, 2005, ONCOGENE, V24, P2076, DOI 10.1038/sj.onc.1208445; Cline HT, 2001, CURR OPIN NEUROBIOL, V11, P118, DOI 10.1016/S0959-4388(00)00182-3; Emoto K, 2004, CELL, V119, P245, DOI 10.1016/j.cell.2004.09.036; Gallegos ME, 2004, NEURON, V44, P239, DOI 10.1016/j.neuron.2004.09.021; Grueber WB, 2003, CURR BIOL, V13, P618, DOI 10.1016/S0960-9822(03)00207-0; Grueber WB, 2002, DEVELOPMENT, V129, P2867; Harvey KF, 2003, CELL, V114, P457, DOI 10.1016/S0092-8674(03)00557-9; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Jan YN, 2003, NEURON, V40, P229, DOI 10.1016/S0896-6273(03)00631-7; Jia JH, 2003, GENE DEV, V17, P2514, DOI 10.1101/gad.1134003; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; Kaufmann WE, 2000, CEREB CORTEX, V10, P981, DOI 10.1093/cercor/10.10.981; Lai ZC, 2005, CELL, V120, P675, DOI 10.1016/j.cell.2004.12.036; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; MacNeil MA, 1998, NEURON, V20, P971, DOI 10.1016/S0896-6273(00)80478-X; Mikeladze-Dvali T, 2005, CELL, V122, P775, DOI 10.1016/j.cell.2005.07.026; Pantalacci S, 2003, NAT CELL BIOL, V5, P921, DOI 10.1038/ncb1051; Ruan WJ, 1999, NEURON, V24, P595, DOI 10.1016/S0896-6273(00)81115-0; Scott EK, 2001, NAT NEUROSCI, V4, P359, DOI 10.1038/86006; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Stegert MR, 2005, MOL CELL BIOL, V25, P11019, DOI 10.1128/MCB.25.24.11019-11029.2005; Sugimura K, 2003, J NEUROSCI, V23, P3752; Tamaskovic R, 2003, FEBS LETT, V546, P73, DOI 10.1016/S0014-5793(03)00474-5; Udan RS, 2003, NAT CELL BIOL, V5, P914, DOI 10.1038/ncb1050; WASSLE H, 1981, NATURE, V292, P344, DOI 10.1038/292344a0; Wu S, 2003, CELL, V114, P445, DOI 10.1016/S0092-8674(03)00549-X; XU TA, 1995, DEVELOPMENT, V121, P1053; Zallen JA, 2000, MOL BIOL CELL, V11, P3177, DOI 10.1091/mbc.11.9.3177	29	158	161	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 14	2006	443	7108					210	213		10.1038/nature05090	http://dx.doi.org/10.1038/nature05090			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	083OB	16906135				2022-12-28	WOS:000240467000046
J	Wu, JYF; Leung, WYS; Chang, S; Lee, B; Zee, B; Tong, PCY; Chan, JCN				Wu, Jennifer Y. F.; Leung, Wilson Y. S.; Chang, Sophie; Lee, Benjamin; Zee, Benny; Tong, Peter C. Y.; Chan, Juliana C. N.			Effectiveness of telephone counselling by a pharmacist in reducing mortality in patients receiving polypharmacy: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TYPE-2 DIABETES-MELLITUS; INTERVENTION; HYPERTENSION; BEHAVIORS; THERAPY; SYSTEM; CARE	Objective To investigate the effects of compliance and periodic telephone counselling by a pharmacist on mortality in patients receiving polypharmacy. Design Two year randomised controlled trial. Setting Hospital,medical clinic. Participants 502 of 1011 patients receiving five or more drugs for chronic disease found to be non-compliant at the screening visit were invited for randomisation to either the telephone counselling group (n = 219) or control group (n = 223) at enrolment 12-16 weeks later. Main outcome measures Primary outcome was all cause mortality in randomised patients. Associations between compliance and mortality in the entire cohort of 10 11 patients were also examined. Patients were defined as compliant with a drug if they took 80-120% of the prescribed daily dose. To calculate a compliance score for the whole treatment regimen, the number of drugs that the patient was fully compliant with was divided by the total number of prescribed drugs and expressed as a percentage. Only patients who complied with all recommended drugs were considered compliant (100% score). Results 60 of the 502 eligible patients defaulted and only 442 patients were randomised. After two years, 31 (52%) of the defaulters had died, 38 (17%) of the control group had died, and 25 (11%) of the intervention group had died. After adjustment for confounders, telephone counselling was associated with a 41% reduction in the risk of death (relative risk 0.59, 95% confidence interval 0.35 to 0.97; P = 0.039). The number needed to treat to prevent one death at two years was 16. Other predictors included old age, living alone, rate of admission to hospital, compliance score, number of drugs for chronic disease, and non-treatment with lipid lowering drugs at screening visit. In the cohort of 10 11 patients, the adjusted relative risk for death was 1.61 (1.05 to 2.48; P = 0.029) and 2.87 (1.80 to 2.57; P < 0.001) in patients with compliance scores of 34-66% and 0-33% compared with those who had a compliance score of 67% or more. Conclusion In patients receiving polypharmacy, poor compliance was associated with increased mortality. Periodic telephone counselling by the pharmacist improved compliance and reduced mortality.	Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China; Prince Wales Hosp, Dept Pharm, Sydney, NSW, Australia; Chinese Univ Hong Kong, Sch Pharm, Hong Kong, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Ctr Clin Trials, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Chinese University of Hong Kong	Chan, JCN (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China.	jchan@cuhk.edu.hk	Chan, Juliana/B-7918-2016; Wu, Jennifer/GRX-1831-2022; Zee, Benny Chung Ying/G-5606-2017	Chan, Juliana/0000-0003-1325-1194; Zee, Benny Chung Ying/0000-0002-7238-845X				COLLEY CA, 1993, J GEN INTERN MED, V8, P278, DOI 10.1007/BF02600099; Day SJ, 2000, BRIT MED J, V321, P504, DOI 10.1136/bmj.321.7259.504; De Geest S, 2003, EUR J CARDIOVASC NUR, V2, P323, DOI [DOI 10.1016/S1474-5151(03)00091-4, 10.1016/S1474-5151(03)00091-4]; Friedman RH, 1996, AM J HYPERTENS, V9, P285, DOI 10.1016/0895-7061(95)00353-3; Grancelli H, 2003, J CARD FAIL, V9, P172, DOI 10.1054/jcaf.2003.33; Grol R, 2003, LANCET, V362, P1225, DOI 10.1016/S0140-6736(03)14546-1; Guthrie RM, 2001, CLIN THER, V23, P970, DOI 10.1016/S0149-2918(01)80084-9; Haynes RB, 1996, LANCET, V348, P383; Muhlhauser I, 2002, DIABETOLOGIA, V45, P1723, DOI 10.1007/s00125-002-0987-2; PROCHASKA JO, 1994, HEALTH PSYCHOL, V13, P39, DOI 10.1037/0278-6133.13.1.39; Robinson JG, 2000, AM J CARDIOL, V85, P305, DOI 10.1016/S0002-9149(99)00737-7; Schwarzer R, 2001, CURR DIR PSYCHOL SCI, V10, P47, DOI 10.1111/1467-8721.00112; Vijan S, 2003, ANN INTERN MED, V138, P593, DOI 10.7326/0003-4819-138-7-200304010-00018; Vijan S, 2004, ANN INTERN MED, V140, P650, DOI 10.7326/0003-4819-140-8-200404200-00013	14	144	154	1	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 9	2006	333	7567					522	525		10.1136/bmj.38905.447118.2F	http://dx.doi.org/10.1136/bmj.38905.447118.2F			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	084LD	16916809	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000240533500015
J	Huang, HY; Caballero, B; Chang, S; Alberg, AJ; Semba, RD; Schneyer, CR; Wilson, RF; Cheng, TY; Vassy, J; Prokopowicz, G; Barnes, GJ; Bass, EB				Huang, Han-Yao; Caballero, Benjamin; Chang, Stephanie; Alberg, Anthony J.; Semba, Richard D.; Schneyer, Christine R.; Wilson, Renee F.; Cheng, Ting-Yuan; Vassy, Jason; Prokopowicz, Gregory; Barnes, George J., II; Bass, Eric B.			The efficacy and safety of multivitamin and mineral supplement use to prevent cancer and chronic disease in adults: A systematic review for a National Institutes of Health State-of-the-Science Conference	ANNALS OF INTERNAL MEDICINE			English	Review							BETA-CAROTENE; LONG-TERM; CARDIOVASCULAR-DISEASE; COGNITIVE PERFORMANCE; CONTROLLED-TRIAL; VITAMIN; NUTRITION; SU.VI.MAX; LINXIAN; STROKE	Background: Multivitamin and mineral supplements are the most commonly used dietary supplements in the United States. Purpose: To synthesize studies on the efficacy and safety of multivitamin/mineral supplement use in primary prevention of cancer and chronic disease in the general population. Data Sources: English-language literature search of the MEDLINE, EMBASE, and Cochrane databases through February 2006 and hand-searching of pertinent journals and articles. Study Selection: Randomized, controlled trials in adults were reviewed to assess efficacy, and randomized, controlled trials and observational studies in adults or children were reviewed to assess safety. Data Extraction: Paired reviewers extracted data and independently assessed study quality. Data Synthesis: 12 articles from 5 randomized, controlled trials that assessed efficacy and 8 articles from 4 randomized, controlled trials and 3 case reports on adverse effects were identified. Study quality was rated fair for the studies on cancer, cardiovascular disease, cataracts, or age-related macular degeneration and poor for the studies on hypertension. In a poorly nourished Chinese population, combined supplementation with beta-carotene, alpha-tocopherol, and selenium reduced the incidence of and mortality rate from gastric cancer and the overall mortality rate from cancer by 13% to 21%. In a French trial, combined supplementation with vitamin C, vitamin E, beta-carotene, selenium, and zinc reduced the rate of cancer by 31% in men but not in women. Multivitamin and mineral supplements had no significant effect on cardiovascular disease or cataracts, except that combined beta-carotene, selenium, a-tocopherol, retinol, and zinc supplementation reduced the mortality rate from stroke by 29% in the Linxian study and that a combination of 7 vitamins and minerals stabilized visual acuity loss in a small trial. Combined zinc and antioxidants slowed the progression of advanced age-related macular degeneration in high-risk persons. No consistent adverse effects of multivitamin and mineral supplements were evident. Limitations: Only randomized, controlled trials were considered for efficacy assessment. Special nutritional needs, such as use of folic acid by pregnant women to prevent birth defects, were not addressed. Findings may not apply to use of commercial multivitamin supplements by the general U.S. population. Conclusions: Evidence is insufficient to prove the presence or absence of benefits from use of multivitamin and mineral supplements to prevent cancer and chronic disease.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University	Huang, HY (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, 615 N Wolfe St,E-6144, Baltimore, MD 21205 USA.	hyhuang@jhsph.edu	Vassy, Jason L./AAC-8220-2019	Bass, Eric/0000-0001-9106-527X; Vassy, Jason/0000-0001-6113-5564	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032247] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD032247] Funding Source: Medline; PHS HHS [290-02-0018] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMES BN, 1992, ANN NY ACAD SCI, V663, P85, DOI 10.1111/j.1749-6632.1992.tb38652.x; Atkins D, 2004, BMJ-BRIT MED J, V328, P1490; BLOT WJ, 1995, AM J CLIN NUTR, V62, P1424, DOI 10.1093/ajcn/62.6.1424S; BLOT WJ, 1993, JNCI-J NATL CANCER I, V85, P1483, DOI 10.1093/jnci/85.18.1483; BREIMER LH, 1990, MOL CARCINOGEN, V3, P188, DOI 10.1002/mc.2940030405; Chylack LT, 2002, OPHTHAL EPIDEMIOL, V9, P49; Czernichow S, 2005, J HYPERTENS, V23, P2013, DOI 10.1097/01.hjh.0000187259.94448.8a; Diaz MN, 1997, NEW ENGL J MED, V337, P408, DOI 10.1056/NEJM199708073370607; Duthie SJ, 2002, J NUTR, V132, p2444S, DOI 10.1093/jn/132.8.2444S; Gordis L., 2000, EPIDEMIOLOGY, V2; Granger DN, 2004, HYPERTENSION, V43, P924, DOI 10.1161/01.HYP.0000123070.31763.55; Grouhi M, 2000, ANN ALLERG ASTHMA IM, V85, P269, DOI 10.1016/S1081-1206(10)62528-8; Gulati R, 1999, J Assoc Physicians India, V47, P253; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; Hercberg S, 2004, ARCH INTERN MED, V164, P2335, DOI 10.1001/archinte.164.21.2335; HUANG HY, 2006, AHRQ PUBLICATION; *I MED NAT AC, 2006, DIET REF INT VIT; Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439; Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417; KELLOFF GJ, 1994, J CELL BIOCHEM, P1; Key T, 2004, PUBLIC HEALTH NUTR, V7, P187, DOI 10.1079/PHN2003588; Lee IM, 1999, J NATL CANCER I, V91, P2102, DOI 10.1093/jnci/91.24.2102; Lee IM, 2005, JAMA-J AM MED ASSOC, V294, P56, DOI 10.1001/jama.294.1.56; Leppala JM, 2000, ARTERIOSCL THROM VAS, V20, P230, DOI 10.1161/01.ATV.20.1.230; Lewerin C, 2005, AM J CLIN NUTR, V81, P1155; Loke YK, 2006, BMJ-BRIT MED J, V332, P335, DOI 10.1136/bmj.38701.399942.63; Mark SD, 1998, EPIDEMIOLOGY, V9, P9, DOI 10.1097/00001648-199801000-00005; Meyer F, 2005, INT J CANCER, V116, P182, DOI 10.1002/ijc.21058; Morris CD, 2003, ANN INTERN MED, V139, P56, DOI 10.7326/0003-4819-139-1-200307010-00014; *NAT CTR CHRON DIS, 2006, GRANTM HLTH ADDR CHR; Ohtake T, 2005, CLIN NEPHROL, V64, P236; OMENN GS, 1994, CANCER EPIDEM BIOMAR, V3, P711; Radimer K, 2004, AM J EPIDEMIOL, V160, P339, DOI 10.1093/aje/kwh207; Reddy BS, 1996, IARC SCI PUBL, P221; Richer S, 1996, J Am Optom Assoc, V67, P30; Selhub J, 2000, AM J CLIN NUTR, V71, p614S; SHI FL, 1989, STROKE, V20, P1581, DOI 10.1161/01.STR.20.11.1581; SLOAN E, 2006, NAT I HLTH STAT SCI, P25; SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P1246, DOI 10.1001/archopht.1993.01090090098027; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; WANG GQ, 1994, CANCER EPIDEM BIOMAR, V3, P161; White E, 2004, AM J EPIDEMIOL, V159, P83, DOI 10.1093/aje/kwh010; Wolters M, 2005, PREV MED, V41, P253, DOI 10.1016/j.ypmed.2004.11.007; XUAN XZ, 1991, CANCER CAUSE CONTROL, V2, P175, DOI 10.1007/BF00056211	44	158	170	1	20	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 5	2006	145	5					372	385		10.7326/0003-4819-145-5-200609050-00135	http://dx.doi.org/10.7326/0003-4819-145-5-200609050-00135			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	080NZ	16880453				2022-12-28	WOS:000240255900008
J	Bianchi, MT; Alexander, BM				Bianchi, Matt T.; Alexander, Brian M.			Diagnostic skills - Evidence based diagnosis: does language reflect the theory?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							CLINICAL DECISION-MAKING; EVIDENCE-BASED MEDICINE; LIKELIHOOD RATIOS; PROBABILITY; DISEASE; UTILITY		Massachusetts Gen Hosp, Partners Neurol, Boston, MA 02114 USA; Brigham & Womens Hosp, Boston, MA 02114 USA; Massachusetts Gen Hosp, Partners Radiat Oncol, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital	Bianchi, MT (corresponding author), Massachusetts Gen Hosp, Partners Neurol, Boston, MA 02114 USA.	mtbianchi@partners.org						Attia JR, 2004, MED J AUSTRALIA, V180, P449, DOI 10.5694/j.1326-5377.2004.tb06020.x; BOYKO EJ, 1994, MED DECIS MAKING, V14, P175, DOI 10.1177/0272989X9401400210; Cahan A, 2003, QJM-INT J MED, V96, P763, DOI 10.1093/qjmed/hcg122; Delalande S, 2004, MEDICINE, V83, P280, DOI 10.1097/01.md.0000141099.53742.16; DOLAN JG, 1986, MED DECIS MAKING, V6, P216, DOI 10.1177/0272989X8600600406; Gallagher EJ, 1998, ANN EMERG MED, V31, P391, DOI 10.1016/S0196-0644(98)70352-X; Ghosh AK, 2004, QJM-INT J MED, V97, P53, DOI 10.1093/qjmed/hch010; Green AJE, 2002, BIOCHEM SOC T, V30, P382, DOI 10.1042/bst0300382; Green ML, 2000, J EVAL CLIN PRACT, V6, P121, DOI 10.1046/j.1365-2753.2000.00239.x; Halkin A, 1998, QJM-INT J MED, V91, P247, DOI 10.1093/qjmed/91.4.247; Heller RF, 2004, FAM PRACT, V21, P155, DOI 10.1093/fampra/cmh209; KASSIRER JP, 1989, AM J MED, V86, P433, DOI 10.1016/0002-9343(89)90342-2; Kelly J, 2003, J THROMB HAEMOST, V1, P1888, DOI 10.1046/j.1538-7836.2003.00382.x; Lyman G H, 1993, J Cancer Educ, V8, P297; LYMAN GH, 1994, J GEN INTERN MED, V9, P488, DOI 10.1007/BF02599218; Noguchi Y, 2002, J GEN INTERN MED, V17, P848, DOI 10.1046/j.1525-1497.2002.20139.x; PAUKER SG, 1980, NEW ENGL J MED, V302, P1109, DOI 10.1056/NEJM198005153022003; Phelps MA, 2004, ACAD EMERG MED, V11, P692, DOI 10.1197/j.aem.2003.08.022; Richardson WS, 1999, JAMA-J AM MED ASSOC, V281, P1214, DOI 10.1001/jama.281.13.1214; WEST SG, 1995, AM J MED, V99, P153, DOI 10.1016/S0002-9343(99)80135-1	20	35	35	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 26	2006	333	7565					442	445		10.1136/bmj.38915.558738.55	http://dx.doi.org/10.1136/bmj.38915.558738.55			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	081AO	16931846	Green Submitted, Green Published			2022-12-28	WOS:000240289800025
J	Heyman, I; Mataix-Cols, D; Fineberg, NA				Heyman, I.; Mataix-Cols, D.; Fineberg, N. A.			Obsessive-compulsive disorder	BMJ-BRITISH MEDICAL JOURNAL			English	Review							PHARMACOTHERAPY; CHILDHOOD		Maudsley Hosp & Inst Psychiat, Childrens Dept, Natl & Specialist OCD Serv Young People, London, England; Kings Coll London, Inst Psychiat, London WC2R 2LS, England; Univ Hertfordshire, Postgrad Med Sch, Hatfield AL10 9AB, Herts, England	South London & Maudsley NHS Trust; University of London; King's College London; University of London; King's College London; University of Hertfordshire	Heyman, I (corresponding author), Inst Psychiat, Childrens Dept, POB 085,DeCrespigny Pk, London SE5 8AF, England.	i.heyman@iop.kcl.ac.uk	Mataix-Cols, David/G-3843-2010; Mataix-Cols, David/AAF-3347-2021; Fineberg, Naomi/ABI-5522-2020	Mataix-Cols, David/0000-0002-4545-0924; Mataix-Cols, David/0000-0002-4545-0924; Heyman, Isobel/0000-0001-7358-9766				[Anonymous], 1997, BRAIN LOCK FREE YOUR; Barrett P, 2004, J AM ACAD CHILD PSY, V43, P46, DOI 10.1097/00004583-200401000-00014; BLOCH MH, 2006, MOL PSYCHIATR, V11, P1; Clark DA, 2003, COGNITIVE BEHAV THER; Fineberg N, 2004, EUR NEUROPSYCHOPHARM, V14, pS191, DOI 10.1016/S0924-977X(04)80133-0; FINEBERG N, 2001, OBSESSIVE COMPULSIVE; Fineberg NA, 2005, INT J NEUROPSYCHOPH, V8, P107, DOI 10.1017/S1461145704004675; FOA EB, 1978, BEHAV THER, V9, P821, DOI 10.1016/S0005-7894(78)80013-6; Geller DA, 2003, AM J PSYCHIAT, V160, P1919, DOI 10.1176/appi.ajp.160.11.1919; GOODMAN WK, 1989, ARCH GEN PSYCHIAT, V46, P1006; Heyman I, 2001, BRIT J PSYCHIAT, V179, P324, DOI 10.1192/bjp.179.4.324; HOLLANDER E, 1993, PSYCHIAT ANN, V23, P355, DOI 10.3928/0048-5713-19930701-05; Hollander E., 1998, CNS SPECTRUMS, V3, P48, DOI [10.1017/S1092852900007239, DOI 10.1017/S1092852900007239]; HUPPERT JD, 2006, J ANXIETY DISOR 0628; Hyman B. M., 2005, OCD WORKBOOK YOUR GU; Koran LM, 2002, AM J PSYCHIAT, V159, P88, DOI 10.1176/appi.ajp.159.1.88; Layard R, 2006, BRIT MED J, V332, P1030, DOI 10.1136/bmj.332.7548.1030; March JS, 1998, OCD CHILDREN ADOLESC; Mataix-Cols D, 2004, ARCH GEN PSYCHIAT, V61, P564, DOI 10.1001/archpsyc.61.6.564; Mataix-Cols D, 2005, AM J PSYCHIAT, V162, P228, DOI 10.1176/appi.ajp.162.2.228; *NIH CLIN EXC, 2005, CLIN GUID NICE, V31; Pediatric O. C. D., 2004, JAMA-J AM MED ASSOC, V292, P1969, DOI DOI 10.1001/JAMA.292.16.1969; PIGOTT TA, 1994, J CLIN PSYCHIAT, V55, P15; Salkovskis PM, 1999, BEHAV RES THER, V37, pS29, DOI 10.1016/S0005-7967(99)00049-2; Saxena S, 2004, AM J PSYCHIAT, V161, P1038, DOI 10.1176/appi.ajp.161.6.1038; Scahill L, 1997, J AM ACAD CHILD PSY, V36, P844, DOI 10.1097/00004583-199706000-00023; Skoog G, 1999, ARCH GEN PSYCHIAT, V56, P121, DOI 10.1001/archpsyc.56.2.121; Stein DJ, 2002, LANCET, V360, P397, DOI 10.1016/S0140-6736(02)09620-4; Swedo SE, 2004, PEDIATRICS, V113, P907, DOI 10.1542/peds.113.4.907; Veale D., 2005, OVERCOMING OBSESSIVE; WAGNER A, 2002, WORRY HILL CHILDRENS; WEVER C, 1996, SECRET PROBLEM; Wittchen HU, 2005, EUR NEUROPSYCHOPHARM, V15, P357, DOI 10.1016/j.euroneuro.2005.04.012; Zohar J, 1996, BRIT J PSYCHIAT, V169, P468, DOI 10.1192/bjp.169.4.468	34	103	109	3	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 26	2006	333	7565					424	429		10.1136/bmj.333.7565.424	http://dx.doi.org/10.1136/bmj.333.7565.424			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	081AO	16931840	Green Published			2022-12-28	WOS:000240289800021
J	Gong, B; Cao, ZX; Zheng, P; Vitolo, OV; Liu, SM; Staniszewski, A; Moolman, D; Zhang, H; Shelanski, M; Arancio, O				Gong, Bing; Cao, Zixuan; Zheng, Ping; Vitolo, Ottavio V.; Liu, Shumin; Staniszewski, Agnieszka; Moolman, Donna; Zhang, Hong; Shelanski, Michael; Arancio, Ottavio			Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory	CELL			English	Article							LONG-TERM POTENTIATION; ELEMENT-BINDING PROTEIN; ALZHEIMERS-DISEASE; IN-VIVO; PROTEASOME SYSTEM; PRECURSOR PROTEIN; OXIDATIVE STRESS; MOUSE MODEL; DEGRADATION; MICE	The neuronal ubiquitin/proteasomal pathway has been implicated in the pathogenesis of Alzheimer's disease (AD). We now show that a component of the pathway, ubiquitin C-terminal hydrolase L1 (Uch-L1), is required for normal synaptic and cognitive function. Transduction of Uch-L1 protein fused to the transduction domain of HIV-transactivator protein (TAT) restores normal enzymatic activity and synaptic function both in hippocampal slices treated with oligomeric A beta and in the APP/PS1 mouse model of AD. Moreover, intraperitoneal injections with the fusion protein improve the retention of contextual learning in APP/PS1 mice over time. The beneficial effect of the Uch-L1 fusion protein is associated with restoration of normal levels of the PKA-regulatory subunit II alpha, PKA activity, and CREB phosphorylation.	Columbia Univ, Dept Pathol, New York, NY 10032 USA; Columbia Univ, Taub Inst, New York, NY 10032 USA; NYU, Sch Med, Dept Rheumatol, Hosp Joint Dis, New York, NY 10003 USA	Columbia University; Columbia University; New York University; NYU Langone Medical Center; Hospital for Joint Disease NYULMC	Shelanski, M (corresponding author), Columbia Univ, Dept Pathol, New York, NY 10032 USA.	mls7@columbia.edu; oa1@columbia.edu	arancio, ottavio/AAB-7959-2019	arancio, ottavio/0000-0001-6335-164X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015076] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG008702] Funding Source: NIH RePORTER; NIA NIH HHS [AG008702] Funding Source: Medline; NINDS NIH HHS [NS015076] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Almeida CG, 2006, J NEUROSCI, V26, P4277, DOI 10.1523/JNEUROSCI.5078-05.2006; Aravamudan B, 2003, J NEUROBIOL, V54, P417, DOI 10.1002/neu.10142; Barad M, 1998, P NATL ACAD SCI USA, V95, P15020, DOI 10.1073/pnas.95.25.15020; Bourtchouladze R, 2003, P NATL ACAD SCI USA, V100, P10518, DOI 10.1073/pnas.1834280100; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; Chain DG, 1999, NEURON, V22, P147, DOI 10.1016/S0896-6273(00)80686-8; Choi J, 2004, J BIOL CHEM, V279, P13256, DOI 10.1074/jbc.M314124200; CLECHANOVER A, 2003, NEURON, V40, P427; Dang LC, 1998, BIOCHEMISTRY-US, V37, P1868, DOI 10.1021/bi9723360; de Vrij FMS, 2004, PROG NEUROBIOL, V74, P249, DOI 10.1016/j.pneurobio.2004.10.001; Dineley KT, 2001, J NEUROSCI, V21, P4125, DOI 10.1523/JNEUROSCI.21-12-04125.2001; Dineley KT, 2002, J BIOL CHEM, V277, P22768, DOI 10.1074/jbc.M200164200; Gong B, 2004, J CLIN INVEST, V114, P1624, DOI 10.1172/JCI200422831; GREGORI L, 1995, J BIOL CHEM, V270, P19702, DOI 10.1074/jbc.270.34.19702; GRUNE T, 1995, J BIOL CHEM, V270, P2344, DOI 10.1074/jbc.270.5.2344; Hegde AN, 1997, CELL, V89, P115, DOI 10.1016/S0092-8674(00)80188-9; ICHIHARA N, 1995, BRAIN RES, V695, P173, DOI 10.1016/0006-8993(95)00729-A; Itoh A, 1999, EUR J PHARMACOL, V382, P167, DOI 10.1016/S0014-2999(99)00601-9; Keller JN, 2000, J NEUROCHEM, V75, P436, DOI 10.1046/j.1471-4159.2000.0750436.x; Kim TW, 1997, J BIOL CHEM, V272, P11006; Lin CH, 2001, NEURON, V31, P841, DOI 10.1016/S0896-6273(01)00433-0; Liu YC, 2002, CELL, V111, P209, DOI 10.1016/S0092-8674(02)01012-7; Markesbery WR, 1997, FREE RADICAL BIO MED, V23, P134, DOI 10.1016/S0891-5849(96)00629-6; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; Nishikawa K, 2003, BIOCHEM BIOPH RES CO, V304, P176, DOI 10.1016/S0006-291X(03)00555-2; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; Puzzo D, 2005, J NEUROSCI, V25, P6887, DOI 10.1523/JNEUROSCI.5291-04.2005; Saigoh K, 1999, NAT GENET, V23, P47, DOI 10.1038/12647; Trinchese F, 2004, ANN NEUROL, V55, P801, DOI 10.1002/ana.20101; Tully T, 2003, NAT REV DRUG DISCOV, V2, P267, DOI 10.1038/nrd1061; Vitolo OV, 2002, P NATL ACAD SCI USA, V99, P13217, DOI 10.1073/pnas.172504199; Wada H, 1998, BIOCHEM BIOPH RES CO, V251, P688, DOI 10.1006/bbrc.1998.9532; Wadia JS, 2003, CURR PROTEIN PEPT SC, V4, P97, DOI 10.2174/1389203033487289; Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; Wood MA, 2005, HIPPOCAMPUS, V15, P610, DOI 10.1002/hipo.20082	38	329	351	2	38	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 25	2006	126	4					775	788		10.1016/j.cell.2006.06.046	http://dx.doi.org/10.1016/j.cell.2006.06.046			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	080VN	16923396	Bronze			2022-12-28	WOS:000240276700025
J	Oerlemans, J; Dahl-Jensen, D; Masson-Delmotte, V				Oerlemans, Johannes; Dahl-Jensen, Dorthe; Masson-Delmotte, Valerie			Ice sheets and sea level	SCIENCE			English	Letter									Univ Utrecht, Inst Marine & Atmospher Res, NL-3584 CC Utrecht, Netherlands; Univ Copenhagen, Niels Bohr Inst, DK-2100 Copenhagen OE, Denmark; CEA Saclay, CNRS,UVSQ, IPSL,CEA, Lab Sci Climat & Environm, F-91191 Gif Sur Yvette, France	Utrecht University; University of Copenhagen; Niels Bohr Institute; UDICE-French Research Universities; Universite Paris Cite; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS)	Oerlemans, J (corresponding author), Univ Utrecht, Inst Marine & Atmospher Res, Princetonpl 5, NL-3584 CC Utrecht, Netherlands.		Dahl-Jensen, Dorthe/AAO-6951-2020	Dahl-Jensen, Dorthe/0000-0002-1474-1948; Masson-Delmotte, Valerie/0000-0001-8296-381X				DANSGAARD W, 1985, GREENLAND ICE CORE G, P71; OERLEMANS J, IN PRESS ANN GLACIOL; Oppenheimer M, 1998, NATURE, V393, P325, DOI 10.1038/30661	3	6	6	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 25	2006	313	5790					1043	1044						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	076ZT	16931738				2022-12-28	WOS:000239998200017
J	McNally, RJ				McNally, Richard J.			Psychiatric casualties of war	SCIENCE			English	Editorial Material									Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA	Harvard University	McNally, RJ (corresponding author), Harvard Univ, Dept Psychol, 33 Kirkland St, Cambridge, MA 02138 USA.	rjm@wjh.harvard.edu						[Anonymous], 1988, JAMA, V259, P2701; [Anonymous], 2005, 0500765137 DEP VET A; Dean Eric T., 1997, SHOOK HELL POSTTRAUM; Dohrenwend BP, 2006, SCIENCE, V313, P979, DOI 10.1126/science.1128944; Frueh BC, 2005, BRIT J PSYCHIAT, V186, P467, DOI 10.1192/bjp.186.6.467; KILPATRICK D, 2006, TRAUMATIC STRESS POI, V20, P2; Kulka R.A., 1990, TRAUMA VIETNAM WAR G; Marlowe David H., 2001, PSYCHOL PSYCHOSOCIAL; McNally Richard J., 2003, REMEMBERING TRAUMA; Shephard Ben, 2001, WAR NERVES SOLDIERS	10	24	24	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 18	2006	313	5789					923	924		10.1126/science.1132242	http://dx.doi.org/10.1126/science.1132242			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	074MR	16917047				2022-12-28	WOS:000239817000026
J	Kieffer, HH; Christensen, PR; Titus, TN				Kieffer, Hugh H.; Christensen, Philip R.; Titus, Timothy N.			CO2 jets formed by sublimation beneath translucent slab ice in Mars' seasonal south polar ice cap	NATURE			English	Article							SURFACE; TES; THEMIS	The martian polar caps are among the most dynamic regions on Mars, growing substantially in winter as a significant fraction of the atmosphere freezes out in the form of CO2 ice. Unusual dark spots, fans and blotches form as the south-polar seasonal CO2 ice cap retreats during spring and summer. Small radial channel networks are often associated with the location of spots once the ice disappears. The spots have been proposed to be simply bare, defrosted ground(1-3); the formation of the channels has remained uncertain. Here we report infrared and visible observations that show that the spots and fans remain at CO2 ice temperatures well into summer, and must be granular materials that have been brought up to the surface of the ice, requiring a complex suite of processes to get them there. We propose that the seasonal ice cap forms an impermeable, translucent slab of CO2 ice that sublimates from the base, building up high-pressure gas beneath the slab. This gas levitates the ice, which eventually ruptures, producing high-velocity CO2 vents that erupt sand-sized grains in jets to form the spots and erode the channels. These processes are unlike any observed on Earth.	Arizona State Univ, Dept Geol Sci, Tempe, AZ 85287 USA; Celestial Reasonings, Carson City, NV 89703 USA; US Geol Survey, Flagstaff, AZ 86001 USA	Arizona State University; Arizona State University-Tempe; United States Department of the Interior; United States Geological Survey	Christensen, PR (corresponding author), Arizona State Univ, Dept Geol Sci, Tempe, AZ 85287 USA.	phil.christensen@asu.edu		Kieffer, Hugh/0000-0002-2485-0339				Bibring JP, 2004, NATURE, V428, P627, DOI 10.1038/nature02461; Boynton WV, 2002, SCIENCE, V297, P81, DOI 10.1126/science.1073722; Cantor B, 2002, J GEOPHYS RES-PLANET, V107, DOI 10.1029/2001JE001588; Christensen P. R., 2006, THEMIS PUBLIC DATA R; Christensen PR, 2004, SPACE SCI REV, V110, P85, DOI 10.1023/B:SPAC.0000021008.16305.94; Christensen PR, 2003, SCIENCE, V300, P2056, DOI 10.1126/science.1080885; Christensen PR, 2001, J GEOPHYS RES-PLANET, V106, P23823, DOI 10.1029/2000JE001370; CHRISTENSEN PR, 2005, EOS FALL M S, V86; Edgett K. S, 2000, 2 INT C MARS POL SCI, P34; Feldman WC, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2003JE002101; Haberle RM, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL019445; KIEFFER H, 1970, J GEOPHYS RES, V75, P510, DOI 10.1029/JC075i003p00510; Kieffer HH, 2000, J GEOPHYS RES-PLANET, V105, P9653, DOI 10.1029/1999JE001136; Kieffer HH, 2001, ICARUS, V154, P162, DOI 10.1006/icar.2001.6670; KIEFFER HH, 2003, 6 INT C MARS PAS CAL; KIEFFER HH, 2000, 2 INT C MARS POL SCI, P93; KIRK RL, 1990, SCIENCE, V250, P424, DOI 10.1126/science.250.4979.424; Kossacki KJ, 2004, ICARUS, V168, P201, DOI 10.1016/j.icarus.2003.11.010; Malin MC, 2001, J GEOPHYS RES-PLANET, V106, P23429, DOI 10.1029/2000JE001455; Mitrofanov IG, 2003, SCIENCE, V300, P2081, DOI 10.1126/science.1084350; MLAIN MC, 2000, LUNAR PLANET SCI, V31; Piqueux S, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2002JE002007; Smith DE, 2001, SCIENCE, V294, P2141, DOI 10.1126/science.1066556; SODERBLOM LA, 1990, SCIENCE, V250, P410, DOI 10.1126/science.250.4979.410; SUPULVER KD, 2001, LUNAR PLANET SCI, V32; Titus TN, 2003, SCIENCE, V299, P1048, DOI 10.1126/science.1080497; Titus TN, 2001, J GEOPHYS RES-PLANET, V106, P23181, DOI 10.1029/2000JE001284	27	124	124	2	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 17	2006	442	7104					793	796		10.1038/nature04945	http://dx.doi.org/10.1038/nature04945			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	074DK	16915284				2022-12-28	WOS:000239792700041
J	Van Dam, JA; Nazarov, YV; Bakkers, EPAM; De Franceschi, S; Kouwenhoven, LP				Van Dam, Jorden A.; Nazarov, Yuli V.; Bakkers, Erik P. A. M.; De Franceschi, Silvano; Kouwenhoven, Leo P.			Supercurrent reversal in quantum dots	NATURE			English	Article							SEMICONDUCTOR NANOWIRES; JOSEPHSON CURRENT; SUPERCONDUCTORS; PARTICLES; JUNCTION; GROWTH; STATE; GAP	When two superconductors are electrically connected by a weak link - such as a tunnel barrier - a zero- resistance supercurrent can flow(1,2). This supercurrent is carried by Cooper pairs of electrons with a combined charge of twice the elementary charge, e. The 2e charge quantum is clearly visible in the height of voltage steps in Josephson junctions under microwave irradiation, and in the magnetic flux periodicity of h/ 2e ( where h is Planck's constant) in superconducting quantum interference devices(2). Here we study supercurrents through a quantum dot created in a semiconductor nanowire by local electrostatic gating. Owing to strong Coulomb interaction, electrons only tunnel one- by- one through the discrete energy levels of the quantum dot. This nevertheless can yield a supercurrent when subsequent tunnel events are coherent(3-7). These quantum coherent tunnelling processes can result in either a positive or a negative supercurrent, that is, in a normal or a pi-junction(8-10), respectively. We demonstrate that the supercurrent reverses sign by adding a single electron spin to the quantum dot. When excited states of the quantum dot are involved in transport, the supercurrent sign also depends on the character of the orbital wavefunctions.	Delft Univ Technol, Kavli Inst Nanosci, NL-2600 GA Delft, Netherlands; Philips Res Labs, NL-5656 AE Eindhoven, Netherlands; CNR, INFM, Lab Nazl TASC, I-34012 Trieste, Italy	Delft University of Technology; Philips; Philips Research; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR)	Kouwenhoven, LP (corresponding author), Delft Univ Technol, Kavli Inst Nanosci, POB 5046, NL-2600 GA Delft, Netherlands.	L.P.Kouwenhoven@TUDelft.nl	Nazarov, Yuli V/F-6511-2011					AVERIN DV, 1991, P NATO ASI B, V294, P217; Baselmans JJA, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.207002; Baselmans JJA, 1999, NATURE, V397, P43, DOI 10.1038/16204; BAUERNSCHMITT R, 1994, PHYS REV B, V49, P4076, DOI 10.1103/PhysRevB.49.4076; Bjork MT, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.201307; Bjork MT, 2002, APPL PHYS LETT, V80, P1058, DOI 10.1063/1.1447312; Black CT, 1996, PHYS REV LETT, V76, P688, DOI 10.1103/PhysRevLett.76.688; Buitelaar MR, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.057005; Buitelaar MR, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.256801; BULAEVSKII LN, 1977, JETP LETT+, V25, P290; Choi MS, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.020502; Cronenwett SM, 1998, SCIENCE, V281, P540, DOI 10.1126/science.281.5376.540; Doh YJ, 2005, SCIENCE, V309, P272, DOI 10.1126/science.1113523; Goldhaber-Gordon D, 1998, NATURE, V391, P156, DOI 10.1038/34373; Jarillo-Herrero P, 2006, NATURE, V439, P953, DOI 10.1038/nature04550; JOSEPHSON BD, 1962, PHYS LETT, V1, P251, DOI 10.1016/0031-9163(62)91369-0; Morales AM, 1998, SCIENCE, V279, P208, DOI 10.1126/science.279.5348.208; RALPH DC, 1995, PHYS REV LETT, V74, P3241, DOI 10.1103/PhysRevLett.74.3241; Rozhkov AV, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.233301; Ryazanov VV, 2001, PHYS REV LETT, V86, P2427, DOI 10.1103/PhysRevLett.86.2427; Shimizu Y, 1998, J PHYS SOC JPN, V67, P1525, DOI 10.1143/JPSJ.67.1525; Siano F, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.047002; Sohn L.L., 1997, MESOSCOPIC ELECT TRA; SPIVAK BI, 1991, PHYS REV B, V43, P3740, DOI 10.1103/PhysRevB.43.3740; Tinkham M., 1996, INTRO SUPERCONDUCTIV, V2nd ed.; VANHARLINGEN DJ, 1995, REV MOD PHYS, V67, P515, DOI 10.1103/RevModPhys.67.515; Verheijen MA, 2006, J AM CHEM SOC, V128, P1353, DOI 10.1021/ja057157h; WAGNER RS, 1964, APPL PHYS LETT, V4, P89, DOI 10.1063/1.1753975	29	344	346	1	87	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 10	2006	442	7103					667	670		10.1038/nature05018	http://dx.doi.org/10.1038/nature05018			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	071UU	16900196	Green Submitted			2022-12-28	WOS:000239630200041
J	Srivastava, R				Srivastava, Ranjana			No refuge for the ailing	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																			0	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 3	2006	355	5					443	445		10.1056/NEJMp068032	http://dx.doi.org/10.1056/NEJMp068032			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	069FT	16885547				2022-12-28	WOS:000239432500003
J	MacMillan, HL; Wathen, CN; Jamieson, E; Boyle, M; McNutt, LA; Worster, A; Lent, B; Webb, M				MacMillan, Harriet L.; Wathen, C. Nadine; Jamieson, Ellen; Boyle, Michael; McNutt, Louise-Anne; Worster, Andrew; Lent, Barbara; Webb, Michelle		McMaster Violence Women Re	Approaches to screening for intimate partner violence in health care settings - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DOMESTIC VIOLENCE; PROFESSIONALS SCREEN; SELF-REPORT; WOMEN; COMPUTER; ABUSE; EMERGENCY; QUESTIONNAIRE; PREVALENCE; FAMILY	Context Screening for intimate partner violence (IPV) in healthcare settings has been recommended by some professional organizations, although there is limited information regarding the accuracy, acceptability, and completeness of different screening methods and instruments. Objective To determine the optimal method for IPV screening in health care settings. Design and Setting Cluster randomized trial conducted from May 2004 to January 2005 at 2 each of emergency departments, family practices, and women's health clinics in Ontario, Canada. Participants English-speaking women aged 18 to 64 years who were well enough to participate and could be seen individually were eligible. Of 2602 eligible women, 141 (5%) refused participation. Intervention Participants were randomized by clinic day or shift to 1 of 3 screening approaches: a face-to-face interview with a health care provider (physician or nurse), written self-completed questionnaire, and computer-based self-completed questionnaire. Two screening instruments-the Partner Violence Screen (PVS) and the Woman Abuse Screening Tool (WAST)-were administered and compared with the Composite Abuse Scale (CAS) as the criterion standard. Main Outcome Measures The approaches were evaluated on prevalence, extent of missing data, and participant preference. Agreement between the screening instruments and the CAS was examined. Results The 12-month prevalence of IPV ranged from 4.1% to 17.7%, depending on screening method, instrument, and health care setting. Although no statistically significant main effects on prevalence were found for method or screening instrument, a significant interaction between method and instrument was found: prevalence was lower on the written WAST vs other combinations. The face-to-face approach was least preferred by participants. The WAST and the written format yielded significantly less missing data than the PVS and other methods. The PVS and WAST had similar sensitivities (49.2% and 47.0%, respectively) and specificities (93.7% and 95.6%, respectively). Conclusions In screening for IPV, women preferred self-completed approaches over face-to-face questioning; computer-based screening did not increase prevalence; and written screens had fewest missing data. These are important considerations for both clinical and research efforts in IPV screening.	McMaster Univ, Dept Psychiat & Behav Neurosci, Offord Ctr Child Studies, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Pediat, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Emergency Med, Hamilton, ON L8N 3Z5, Canada; SUNY Albany, Dept Epidemiol & Biostat, Albany, NY 12222 USA; Univ Western Ontario, Dept Family Med, London, ON, Canada	McMaster University; McMaster University; McMaster University; State University of New York (SUNY) System; State University of New York (SUNY) Albany; Western University (University of Western Ontario)	MacMillan, HL (corresponding author), McMaster Univ, Dept Psychiat & Behav Neurosci, Offord Ctr Child Studies, Patterson Bldg,Chedoke Site,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	macmilnh@mcmaster.ca	MacMillan, Harriet/B-4530-2016	MacMillan, Harriet/0000-0002-1223-706X				Anders J, 2004, CLIN PEDIATR, V43, P103, DOI 10.1177/000992280404300115; Bair-Merritt MH, 2006, ARCH PEDIAT ADOL MED, V160, P311, DOI 10.1001/archpedi.160.3.311; Brown JB, 2000, J FAM PRACTICE, V49, P896; Chuang CH., 2002, JCOM WAYNE PA, V9, P565; Clark JP, 2003, CAN J PUBLIC HEALTH, V94, P52, DOI 10.1007/BF03405053; Datner EM, 2004, EUR J EMERG MED, V11, P35, DOI 10.1097/00063110-200402000-00007; Dearwater SR, 1998, JAMA-J AM MED ASSOC, V280, P433, DOI 10.1001/jama.280.5.433; Feldhaus KM, 1997, JAMA-J AM MED ASSOC, V277, P1357, DOI 10.1001/jama.277.17.1357; Glass N, 2001, J Emerg Nurs, V27, P141, DOI 10.1067/men.2001.114387; HASLEY S, 1995, OBSTET GYNECOL, V85, P494, DOI 10.1016/0029-7844(95)00012-G; Hegarty K, 1999, J FAM VIOLENCE, V14, P399, DOI 10.1023/A:1022834215681; Hegarty Kelsey, 2005, Violence Vict, V20, P529, DOI 10.1891/088667005780927548; MacMillan H. L, 2001, CANADIAN TASK FORCE; MCFARLANE J, 1991, PUBLIC HEALTH NURS, V8, P245, DOI 10.1111/j.1525-1446.1991.tb00664.x; Nelson HD, 2004, ANN INTERN MED, V140, P387, DOI 10.7326/0003-4819-140-5-200403020-00015; Ramsay J, 2002, BRIT MED J, V325, P314, DOI 10.1136/bmj.325.7359.314; Rasbash J., 2004, USERS GUIDE MLWIN VE; Rhodes KV, 2006, ARCH INTERN MED, V166, P1107, DOI 10.1001/archinte.166.10.1107; Rhodes KV, 2002, ANN EMERG MED, V40, P476, DOI 10.1067/mem.2002.127181; *STAT CAN, 2002, 85224XIE STAT CAN CA; Taket A, 2004, PLOS MED, V1, P7, DOI 10.1371/journal.pmed.0010004; Tjaden P., 2000, FULL REPORT PREVALEN; Turner CF, 1998, SCIENCE, V280, P867, DOI 10.1126/science.280.5365.867; Wathen CN, 2003, JAMA-J AM MED ASSOC, V289, P589, DOI 10.1001/jama.289.5.589; Webster J, 2004, OBSTET GYNECOL, V103, P299, DOI 10.1097/01.AOG.0000110245.83404.3d	25	224	230	0	23	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 2	2006	296	5					530	536		10.1001/jama.296.5.530	http://dx.doi.org/10.1001/jama.296.5.530			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	069YW	16882959	Bronze			2022-12-28	WOS:000239486900017
J	Martinez, FD				Martinez, Fernando D.			Inhaled corticosteroids and asthma prevention	LANCET			English	Editorial Material							PRESCHOOL-CHILDREN; INFANTS		Univ Arizona, Arizona Resp Ctr, Tucson, AZ 85724 USA	University of Arizona	Martinez, FD (corresponding author), Univ Arizona, Arizona Resp Ctr, Tucson, AZ 85724 USA.	fernando@arc.arizona.edu						Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; CLINE MG, 1994, CHEST, V106, P1089, DOI 10.1378/chest.106.4.1089; Cookson W, 2004, NAT REV IMMUNOL, V4, P978, DOI 10.1038/nri1500; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Martinez FD, 2005, IMMUNOL ALLERGY CLIN, V25, P709, DOI 10.1016/j.iac.2005.09.001; Martinez FD, 2002, PEDIATRICS, V109, P362; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; Murray CS, 2006, LANCET, V368, P754, DOI 10.1016/S0140-6736(06)69285-4; Saglani S, 2005, AM J RESP CRIT CARE, V171, P722, DOI 10.1164/rccm.200410-1404OC; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Turner SW, 2004, AM J RESP CRIT CARE, V169, P921, DOI 10.1164/rccm.200307-891OC; WEISS ST, 1992, AM REV RESPIR DIS, V145, P58, DOI 10.1164/ajrccm/145.1.58; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888	14	6	7	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG-SEP	2006	368	9537					708	710		10.1016/S0140-6736(06)69261-1	http://dx.doi.org/10.1016/S0140-6736(06)69261-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	080ID	16935667				2022-12-28	WOS:000240240200005
J	Dunkelberg, S				Dunkelberg, Sandra			A patient's journey: Our special girl	BRITISH MEDICAL JOURNAL			English	Article									Univ Hamburg Hosp, Inst Gen Practice, Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf	Dunkelberg, S (corresponding author), Bergkoppelweg 2, D-22335 Hamburg, Germany.	dunkelbe@uke.uni-haruburg.de							0	8	8	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	AUG 26	2006	333	7565					430	431		10.1136/bmj.38937.455949.55	http://dx.doi.org/10.1136/bmj.38937.455949.55			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	081AO	16931841	Green Published			2022-12-28	WOS:000240289800022
J	Tashiro, A; Sandler, VM; Toni, N; Zhao, CM; Gage, FH				Tashiro, Ayumu; Sandler, Vladislav M.; Toni, Nicolas; Zhao, Chunmei; Gage, Fred H.			NMDA-receptor-mediated, cell-specific integration of new neurons in adult dentate gyrus	NATURE			English	Article							LONG-TERM POTENTIATION; HIPPOCAMPAL-NEURONS; NERVOUS-SYSTEM; NEUROGENESIS; DEATH; MICE; MEMORY; BRAIN; DIFFERENTIATION; APOPTOSIS	New neurons are continuously integrated into existing neural circuits in adult dentate gyrus of the mammalian brain(1-4). Accumulating evidence indicates that these new neurons are involved in learning and memory(5-8). A substantial fraction of newly born neurons die before they mature(9,10) and the survival of new neurons is regulated in an experience-dependent manner(5,6,11), raising the possibility that the selective survival or death of new neurons has a direct role in a process of learning and memory such as information storage - through the information-specific construction of new circuits. However, a critical assumption of this hypothesis is that the survival or death decision of new neurons is information-specific. Because neurons receive their information primarily through their input synaptic activity, we investigated whether the survival of new neurons is regulated by input activity in a cell-specific manner. Here we developed a retrovirus-mediated, single-cell gene knockout technique in mice and showed that the survival of new neurons is competitively regulated by their own NMDA-type glutamate receptor during a short, critical period soon after neuronal birth. This finding indicates that the survival of new neurons and the resulting formation of new circuits are regulated in an input-dependent, cell-specific manner. Therefore, the circuits formed by new neurons may represent information associated with input activity within a short time window in the critical period. This information-specific addition of new circuits through selective survival or death of new neurons may be a unique attribute of new neurons that enables them to play a critical role in learning and memory.	Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA	Salk Institute	Gage, FH (corresponding author), Salk Inst Biol Studies, Genet Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	gage@salk.edu	Tashiro, Ayumu/Z-2900-2019; Tashiro, Ayumu/A-2675-2008; Toni, Nicolas/M-2057-2014	Tashiro, Ayumu/0000-0001-7967-7409; Tashiro, Ayumu/0000-0001-7967-7409; Toni, Nicolas/0000-0001-5585-268X				Biebl M, 2000, NEUROSCI LETT, V291, P17, DOI 10.1016/S0304-3940(00)01368-9; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Brandt MD, 2003, MOL CELL NEUROSCI, V24, P603, DOI 10.1016/S1044-7431(03)00207-0; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; Dayer AG, 2003, J COMP NEUROL, V460, P563, DOI 10.1002/cne.10675; Esposito MS, 2005, J NEUROSCI, V25, P10074, DOI 10.1523/JNEUROSCI.3114-05.2005; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Ge SY, 2006, NATURE, V439, P589, DOI 10.1038/nature04404; Gould E, 1999, NAT NEUROSCI, V2, P260, DOI 10.1038/6365; GOULD E, 1994, J COMP NEUROL, V340, P551, DOI 10.1002/cne.903400408; Gould E, 2002, J NEUROSCI, V22, P619, DOI 10.1523/JNEUROSCI.22-03-00619.2002; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Hardingham GE, 2003, TRENDS NEUROSCI, V26, P81, DOI 10.1016/S0166-2236(02)00040-1; Hasbani MJ, 2001, J NEUROSCI, V21, P2393, DOI 10.1523/JNEUROSCI.21-07-02393.2001; Jessberger S, 2003, EUR J NEUROSCI, V18, P2707, DOI 10.1111/j.1460-9568.2003.02986.x; Kaspar BK, 2002, P NATL ACAD SCI USA, V99, P2320, DOI 10.1073/pnas.042678699; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Kempermann G, 2003, DEVELOPMENT, V130, P391, DOI 10.1242/dev.00203; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; NARUSE I, 1995, PROG NEUROBIOL, V47, P135, DOI 10.1016/0301-0082(95)00024-P; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; Snyder JS, 2005, NEUROSCIENCE, V130, P843, DOI 10.1016/j.neuroscience.2004.10.009; Sun W, 2004, J NEUROSCI, V24, P11205, DOI 10.1523/JNEUROSCI.1436-04.2004; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zhao CM, 2006, J NEUROSCI, V26, P3, DOI 10.1523/JNEUROSCI.3648-05.2006	30	464	487	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 24	2006	442	7105					929	933		10.1038/nature05028	http://dx.doi.org/10.1038/nature05028			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	076LT	16906136				2022-12-28	WOS:000239960500040
J	Koren, G; Cairns, J; Chitayak, D; Gaedigk, A; Leeder, SJ				Koren, Gideon; Cairns, James; Chitayak, David; Gaedigk, Andrea; Leeder, Steven J.			Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother	LANCET			English	Editorial Material									Hosp Sick Children, Motherisk Program, Toronto, ON M5G 1X8, Canada; Off Chief Coroner, Toronto, ON, Canada; Mt Sinai Hosp, Prenatal Diag Program, Toronto, ON M5G 1X5, Canada; Childrens Mercy Hosp, Kansas City, MO 64108 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Children's Mercy Hospital	Koren, G (corresponding author), Hosp Sick Children, Motherisk Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	gkoren@sickkids.ca	Leeder, James Steven/ABD-5438-2021; Koren, Gideon/AAG-7726-2019	Leeder, James Steven/0000-0001-6688-0504; Koren, Gideon/0000-0002-9234-0875				Cascorbi I, 2003, EUR J CLIN INVEST, V33, P17, DOI 10.1046/j.1365-2362.33.s2.3.x; Gasche Y, 2004, NEW ENGL J MED, V351, P2827, DOI 10.1056/NEJMoa041888; Meny R G, 1993, J Hum Lact, V9, P237, DOI 10.1177/089033449300900423; Meyer UA, 2000, LANCET, V356, P1667, DOI 10.1016/S0140-6736(00)03167-6; Ward RM, 2001, PEDIATRICS, V108, P1020	5	418	428	0	26	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 19	2006	368	9536					704	704		10.1016/S0140-6736(06)69255-6	http://dx.doi.org/10.1016/S0140-6736(06)69255-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	074YT	16920476				2022-12-28	WOS:000239849200038
J	Murgia, C; Pritchard, JK; Kim, SY; Fassati, A; Weiss, RA				Murgia, Claudio; Pritchard, Jonathan K.; Kim, Su Yeon; Fassati, Ariberto; Weiss, Robin A.			Clonal origin and evolution of a transmissible cancer	CELL			English	Article							VENEREAL TUMOR-CELLS; MULTILOCUS GENOTYPE DATA; POPULATION-STRUCTURE; DOMESTIC DOG; GENETIC INSTABILITY; SARCOMA; PROGRESSION; KARYOTYPE; INFERENCE; INSERTION	The transmissible agent causing canine transmissible venereal tumor (CTVT) is thought to be the tumor cell itself. To test this hypothesis, we analyzed genetic markers including major histocompatibility (MHC) genes, microsatellites, and mitochondrial DNA (mtDNA) in naturally occurring tumors and matched blood samples. In each case, the tumor is genetically distinct from its host. Moreover, tumors collected from 40 dogs in 5 continents are derived from a single neoplastic clone that has diverged into two subclades. Phylogenetic analyses indicate that CTVT most likely originated from a wolf or an East Asian breed of dog between 200 and 2500 years ago. Although CTVT is highly aneuploid, it has a remarkably stable genotype. During progressive growth, CTVT down-modulates MHC antigen expression. Our findings have implications for understanding genome instability in cancer, natural transplantation of allografts, and the capacity of a somatic cell to evolve into a transmissible parasite.	UCL, MRC, Ctr Med Mol Virol, Div Infect & Immun, London W1T 4JF, England; Univ Chicago, Dept Stat, Chicago, IL 60637 USA; Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA	University of London; University College London; University of Chicago; University of Chicago	Weiss, RA (corresponding author), UCL, MRC, Ctr Med Mol Virol, Div Infect & Immun, 46 Cleveland St, London W1T 4JF, England.	r.weiss@ucl.ac.uk	Pepper, John W/O-1662-2013	Pepper, John W/0000-0001-9888-0437; Fassati, Ariberto/0000-0003-1934-5327	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG002772] Funding Source: NIH RePORTER; Medical Research Council [G8712499] Funding Source: Medline; NHGRI NIH HHS [R01 HG002772-03, R01 HG002772] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [G8712499] Funding Source: UKRI	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Affolter VK, 2002, VET PATHOL, V39, P74, DOI 10.1354/vp.39-1-74; [Anonymous], 2003, PAUP 4 0 PHYLOGENETI; BANFIELD WG, 1965, SCIENCE, V148, P1239, DOI 10.1126/science.148.3674.1239; Barozzi P, 2003, NAT MED, V9, P554, DOI 10.1038/nm862; Battistacci M., 1974, Nuova Veterinaria, V50, P226; Brooks MB, 2003, MAMM GENOME, V14, P788, DOI 10.1007/s00335-003-2290-z; Brumer Y, 2006, J THEOR BIOL, V241, P216, DOI 10.1016/j.jtbi.2005.11.018; Chu RM, 2001, ANTICANCER RES, V21, P4017; COHEN D, 1985, ADV CANCER RES, V43, P75, DOI 10.1016/S0065-230X(08)60943-4; COHEN D, 1984, JNCI-J NATL CANCER I, V72, P395; COOPER HL, 1964, J NATL CANCER I, V33, P691; Das U, 2000, VET RES COMMUN, V24, P545, DOI 10.1023/A:1006491918910; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Falush D, 2003, GENETICS, V164, P1567; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Frank SA, 1996, Q REV BIOL, V71, P37, DOI 10.1086/419267; Greaves M, 2002, LANCET ONCOL, V3, P244, DOI 10.1016/S1470-2045(02)00716-7; Harmelin A, 2001, AM J VET RES, V62, P907, DOI 10.2460/ajvr.2001.62.907; HOLMES JM, 1981, RES VET SCI, V30, P248, DOI 10.1016/S0034-5288(18)32592-X; Hsiao YW, 2004, J IMMUNOL, V172, P1508, DOI 10.4049/jimmunol.172.3.1508; Huang QY, 2002, AM J HUM GENET, V70, P625, DOI 10.1086/338997; Jones ME, 2004, MOL ECOL, V13, P2197, DOI 10.1111/j.1365-294X.2004.02239.x; KATZIR N, 1987, ONCOGENE, V1, P445; KATZIR N, 1985, P NATL ACAD SCI USA, V82, P1054, DOI 10.1073/pnas.82.4.1054; Kauffman HM, 2002, TRANSPLANTATION, V74, P358, DOI 10.1097/00007890-200208150-00011; Kennedy LJ, 2002, TISSUE ANTIGENS, V60, P43, DOI 10.1034/j.1399-0039.2002.600106.x; Kennedy LJ, 2002, TISSUE ANTIGENS, V59, P194, DOI 10.1034/j.1399-0039.2002.590303.x; Khong HT, 2002, NAT IMMUNOL, V3, P999, DOI 10.1038/ni1102-999; Liao KW, 2003, J VET DIAGN INVEST, V15, P399, DOI 10.1177/104063870301500501; Lindblad-Toh K, 2005, NATURE, V438, P803, DOI 10.1038/nature04338; LOMBARD C, 1967, B CANCER, V54, P357; MacKie RM, 2003, NEW ENGL J MED, V348, P567, DOI 10.1056/NEJM200302063480620; Marchal T, 1997, VET IMMUNOL IMMUNOP, V57, P1, DOI 10.1016/S0165-2427(96)05757-1; Michor F, 2004, NAT REV CANCER, V4, P197, DOI 10.1038/nrc1295; MULLER HJ, 1964, MUTAT RES, V1, P2, DOI 10.1016/0027-5107(64)90047-8; MURRAY M, 1969, RES VET SCI, V10, P565; Nowinsky M., 1876, ZENTRALBL MED WISS, V14, P790; OSHIMURA M, 1973, J NATL CANCER I, V51, P1197, DOI 10.1093/jnci/51.4.1197; OWEN D, 2006, TASMANIAN DEVIL UNIQ; Parker HG, 2004, SCIENCE, V304, P1160, DOI 10.1126/science.1097406; Pearse AM, 2006, NATURE, V439, P549, DOI 10.1038/439549a; Pritchard JK, 2000, GENETICS, V155, P945; Raptis S, 2006, EXP SUPPL, V96, P303; Rinkevich B, 2004, IMMUNOL REV, V198, P25, DOI 10.1111/j.0105-2896.2004.0114.x; Rosenberg N, 2004, MOL ECOL, V4, P127; Savolainen P, 2002, SCIENCE, V298, P1610, DOI 10.1126/science.1073906; Seddon JM, 2002, IMMUNOGENETICS, V54, P490, DOI 10.1007/s00251-002-0489-x; Sundqvist AK, 2006, GENETICS, V172, P1121, DOI 10.1534/genetics.105.042358; Vega A, 2004, ONCOGENE, V23, P1314, DOI 10.1038/sj.onc.1207214; Vila C, 1997, SCIENCE, V276, P1687, DOI 10.1126/science.276.5319.1687; WEBER W. T., 1965, J NAT CANCER INST, V35, P537	52	274	288	1	76	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 11	2006	126	3					477	487		10.1016/j.cell.2006.05.051	http://dx.doi.org/10.1016/j.cell.2006.05.051			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	075KI	16901782	Green Submitted, Bronze, Green Accepted			2022-12-28	WOS:000239883400009
J	Donoghue, PCJ; Bengtson, S; Dong, XP; Gostling, NJ; Huldtgren, T; Cunningham, JA; Yin, C; Yue, Z; Peng, F; Stampanoni, M				Donoghue, Philip C. J.; Bengtson, Stefan; Dong, Xi-Ping; Gostling, Neil J.; Huldtgren, Therese; Cunningham, John A.; Yin, Chongyu; Yue, Zhao; Peng, Fan; Stampanoni, Marco			Synchrotron X-ray tomographic microscopy of fossil embryos	NATURE			English	Article							PHOSPHATIZED EMBRYOS; DOUSHANTUO-FORMATION; SOUTHERN SHAANXI; PRESERVATION; LARVAE	Fossilized embryos from the late Neoproterozoic and earliest Phanerozoic have caused much excitement because they preserve the earliest stages of embryology of animals that represent the initial diversification of metazoans(1-4). However, the potential of this material has not been fully realized because of reliance on traditional, non- destructive methods that allow analysis of exposed surfaces only(1-4), and destructive methods that preserve only a single two- dimensional view of the interior of the specimen(5,6). Here, we have applied synchrotron- radiation X- ray tomographic microscopy ( SRXTM)(7), obtaining complete three-dimensional recordings at submicrometre resolution. The embryos are preserved by early diagenetic impregnation and encrustation with calcium phosphate, and differences in X- ray attenuation provide information about the distribution of these two diagenetic phases. Three- dimensional visualization of blastomere arrangement and diagenetic cement in cleavage embryos resolves outstanding questions about their nature, including the identity of the columnar blastomeres. The anterior and posterior anatomy of embryos of the bilaterian worm- like Markuelia confirms its position as a scalidophoran, providing new insights into body- plan assembly among constituent phyla. The structure of the developing germ band in another bilaterian, Pseudooides, indicates a unique mode of germ- band development. SRXTM provides a method of non- invasive analysis that rivals the resolution achieved even by destructive methods, probing the very limits of fossilization and providing insight into embryology during the emergence of metazoan phyla.	Univ Bristol, Dept Earth Sci, Bristol BS8 1RJ, Avon, England; Swedish Museum Nat Hist, Dept Palaeozool, S-10405 Stockholm, Sweden; Peking Univ, Sch Earth & Space Sci, Beijing 100871, Peoples R China; Dept Earth & Ocean Sci, Liverpool L69 3GP, Merseyside, England; Chinese Acad Geol Sci, Inst Geol, Beijing, Peoples R China; Paul Scherrer Inst, Swiss Light Source, CH-5232 Villigen, Switzerland	University of Bristol; Swedish Museum of Natural History; Peking University; University of Liverpool; Chinese Academy of Geological Sciences; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute	Donoghue, PCJ (corresponding author), Univ Bristol, Dept Earth Sci, Bristol BS8 1RJ, Avon, England.	phil.donoghue@bristol.ac.uk; marco.stampanoni@psi.ch	Stampanoni, Marco/GRR-9695-2022; Stampanoni, Marco/AAZ-3033-2021; Dong, Xi-ping/N-5741-2014; Stampanoni, Marco/J-4099-2013; Donoghue, Philip/A-3873-2008	Stampanoni, Marco/0000-0001-7486-6681; Stampanoni, Marco/0000-0001-7486-6681; Dong, Xi-ping/0000-0001-5917-7159; Stampanoni, Marco/0000-0001-7486-6681; Donoghue, Philip/0000-0003-3116-7463; Gostling, Neil J./0000-0002-5960-7769; Cunningham, John/0000-0002-2870-1832; Bengtson, Stefan/0000-0003-0206-5791	Natural Environment Research Council [NE/C511256/1] Funding Source: researchfish	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Adrianov A.V., 1994, P1; Bengston S., 2003, P289; Bengtson S, 2004, SCIENCE, V306; Bengtson S, 1997, SCIENCE, V277, P1645, DOI 10.1126/science.277.5332.1645; Briggs DEG, 2003, ANNU REV EARTH PL SC, V31, P275, DOI 10.1146/annurev.earth.31.100901.144746; Chen, 2004, DAWN ANIMAL WORLD, P1; Chen JG, 2000, P NATL ACAD SCI USA, V97, P1044, DOI 10.1073/pnas.97.3.1044; Chen JY, 2004, SCIENCE, V306; Chen JY, 2005, CHINESE SCI BULL, V50, P2193, DOI 10.1360/982004-727; Chen JY, 2004, SCIENCE, V305, P218, DOI 10.1126/science.1099213; Chen JY, 2004, PROG NAT SCI, V14, P167, DOI 10.1080/10020070412331343311; Chen JY, 2002, DEV BIOL, V248, P182, DOI 10.1006/dbio.2002.0714; Chipman AD, 2004, EVOL DEV, V6, P78, DOI 10.1111/j.1525-142X.2004.04016.x; Dong XP, 2005, EVOL DEV, V7, P468, DOI 10.1111/j.1525-142X.2005.05050.x; Dong XP, 2004, NATURE, V427, P237, DOI 10.1038/nature02215; Donoghue PCJ, 2006, EVOL DEV, V8, P232, DOI 10.1111/j.1525-142X.2006.00093.x; DZIK J, 1989, LETHAIA, V22, P169, DOI 10.1111/j.1502-3931.1989.tb01679.x; HAMMOND RA, 1970, J ZOOL, V162, P469; LEMBURG C, 1999, ULTRASTRUKTURELLE UN, P1; Raff EC, 2006, P NATL ACAD SCI USA, V103, P5846, DOI 10.1073/pnas.0601536103; Schmidt-Rhaesa A, 1998, ZOOL ANZ, V236, P203; Stampanoni M, 2002, NUCL INSTRUM METH A, V491, P291, DOI 10.1016/S0168-9002(02)01167-1; Steiner M, 2004, GEOLOGY, V32, P833, DOI 10.1130/G20567.1; Steiner M, 2004, GEOBIOS-LYON, V37, P259, DOI 10.1016/j.geobios.2003.08.001; Waloszek Dieter, 2003, Paleontological Research, V7, P71, DOI 10.2517/prpsj.7.71; Xiao SH, 2000, P NATL ACAD SCI USA, V97, P13684, DOI 10.1073/pnas.250491697; Xiao SH, 1998, NATURE, V391, P553, DOI 10.1038/35318; Yue Z., 1999, LETHAIA, V32, P181, DOI DOI 10.1111/J.1502-3931.1999.TB00538.X	28	203	228	3	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 10	2006	442	7103					680	683		10.1038/nature04890	http://dx.doi.org/10.1038/nature04890			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	071UU	16900198				2022-12-28	WOS:000239630200044
J	Lu, C; Michaud, CM; Khan, K; Murray, CJL				Lu, Chunling; Michaud, Catherine M.; Khan, Kashif; Murray, Christopher J. L.			Absorptive capacity and disbursements by the Global Fund to Fight AIDS, Tuberculosis and Malaria: analysis of grant implementation	LANCET			English	Article							GROWTH; POLICIES; HEALTH	Background The Global Fund to Fight AIDS, Tuberculosis and Malaria was launched in 2002 to attract and rapidly disburse money to fight these diseases. However, some commentators believe that poor countries cannot effectively use such resources to increase delivery of their health programmes-referred to as a lack of absorptive capacity. We aimed to investigate the major determinants of grant implementation in developing countries. Methods With information available publicly on the Global Fund's website, we did random-effects analysis to investigate the effect of grant characteristics, types of primary recipient and local fund agent, and country attributes on disbursements that were made between 2003 and 2005 (phase one of Global Fund payments). To check the robustness of findings, regression results from alternative estimation methods and model specifications were also tested. Findings Grant characteristics-such as size of commitment, lag time between signature and first disbursement, and funding round-had significant effects on grant implementation. Enhanced political stability was associated with high use of grants. Low-income countries, and those with less-developed health systems for a given level of income, were more likely to have a higher rate of grant implementation than nations with higher incomes or more-developed health systems. Interpretation The higher rate of grant implementation seen in countries with low income and low health-spending lends support to proponents of major increases in health assistance for the poorest countries and argues that focusing resources on low-income nations, particularly those with political stability, will not create difficulties of absorptive capacity. Our analysis was restricted to grant implementation, which is one part of the issue of absorptive capacity In the future, assessment of the effect of Global Fund grants on intervention coverage will be vital.	Harvard Initiat Global Hlth, Cambridge, MA 02138 USA	Harvard University	Michaud, CM (corresponding author), Harvard Initiat Global Hlth, 104 Mt Auburn St, Cambridge, MA 02138 USA.	cmichaud@hsph.harvard.edu						[Anonymous], 2002, LANCET, V359, P367; BEZANSON KA, REPLENISHING GLOBAL; Brugha R, 2005, TROP MED INT HEALTH, V10, P623, DOI 10.1111/j.1365-3156.2005.01437.x; Brugha R, 2004, LANCET, V364, P95, DOI 10.1016/S0140-6736(04)16595-1; Burnside C, 2000, AM ECON REV, V90, P847, DOI 10.1257/aer.90.4.847; Caines K, 2004, ASSESSING IMPACT GLO; Collier P, 2002, EUR ECON REV, V46, P1475, DOI 10.1016/S0014-2921(01)00187-8; Devarajan S., 2001, Aid and reform in Africa: lessons from ten case studies; DOLALR D, 1999, WORLD BANK POLICY RE, V2070; DOLLAR D, 2004, 3299 WORLD BANK; Easterly W, 2004, AM ECON REV, V94, P774, DOI 10.1257/0002828041464560; *GLOB FUND, 2005, MON EV TOOLK HIV AID; Hansen H, 2001, J DEV ECON, V64, P547, DOI 10.1016/S0304-3878(00)00150-4; Heller P., 2002, WORLD ECON, V3, P131; *INT FIN FAC IMM, NEW INT FIN FAC IMM; KAUFMANN D, 2004, GOVERNANCE MATTERS, V4; MICHAUD C, 2003, 2 CONS COMM MACR HLT; Mills A, 2002, B WORLD HEALTH ORGAN, V80, P325; Nossal GJ, 2003, IMMUNOL CELL BIOL, V81, P20, DOI 10.1046/j.0818-9641.2002.01139.x; RADELET S, 2003, CHALLENGING FOREIGN; Radelet S., 2004, GLOBAL FUND FIGHT AI; RADELET S, 2004, 39 DTR GLOB DEV; RADELT S, 2005, GLOBAL FUND FIGHT AI; Ramsay S, 2002, LANCET, V359, P1581, DOI 10.1016/S0140-6736(02)08531-8; Sachs JD, 2004, B WORLD HEALTH ORGAN, V82, P947; Shengelia B, 2005, SOC SCI MED, V61, P97, DOI 10.1016/j.socscimed.2004.11.055; *US DEP STAT, ACT TOD FDN TOM; *WORLD BANK, 2004, INT MON FUND AID EFF; *WORLD BANK, 2005, HLTH FIN REV C DRAFT	29	43	43	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 5	2006	368	9534					483	488		10.1016/S0140-6736(06)69156-3	http://dx.doi.org/10.1016/S0140-6736(06)69156-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	071AL	16890835				2022-12-28	WOS:000239569000031
J	Bergan, JJ; Schmid-Schonbein, GW; Smith, PDC; Nicolaides, AN; Boisseau, MR; Eklof, B				Bergan, John J.; Schmid-Schoenbein, Geert W.; Smith, Philip D. Coleridge; Nicolaides, Andrew N.; Boisseau, Michel R.; Eklof, Bo			Mechanisms of disease: Chronic venous disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							QUALITY-OF-LIFE; FLUID SHEAR-STRESS; SMOOTH-MUSCLE-CELLS; MATRIX METALLOPROTEINASE INDUCER; ENDOTHELIAL GROWTH-FACTOR; VARICOSE-VEINS; GENE-EXPRESSION; EDINBURGH VEIN; LEG ULCERS; CLINICAL CLASSIFICATION		Univ Calif San Diego, Dept Surg, La Jolla, CA 92093 USA; Univ Calif San Diego, Whitehead Inst Biomed Res, La Jolla, CA 92093 USA; UCL Royal Free & Univ Coll Med Sch, Middlesex Hosp, Dept Vasc Surg, London, England; Univ Cyprus, Imperial Coll London, Dept Surg, Nicosia, Cyprus; Vasc Screening & Diagnost Ctr, Nicosia, Cyprus; Univ Bordeaux 2, Dept Vasc Biol & Pharmacol, F-33076 Bordeaux, France; Lund Univ, Dept Surg, Lund, Sweden	University of California System; University of California San Diego; Massachusetts Institute of Technology (MIT); Whitehead Institute; University of California System; University of California San Diego; University of London; University College London; UCL Medical School; University of Cyprus; UDICE-French Research Universities; Universite de Bordeaux; Lund University	Bergan, JJ (corresponding author), 9850 Genesee,Suite 410, La Jolla, CA 92037 USA.	jbergan@ucsd.edu						ACKERMAN Z, 1988, ARCH DERMATOL, V124, P1376, DOI 10.1001/archderm.124.9.1376; Andreozzi GM, 2005, INT ANGIOL, V24, P325; Andreozzi GM, 2005, INT ANGIOL, V24, P272; ASAKURA T, 1990, CIRC RES, V66, P1045, DOI 10.1161/01.RES.66.4.1045; Badier-Commander C, 2000, J PATHOL, V192, P105, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH670>3.0.CO;2-1; Badier-Commander C, 2001, J PATHOL, V193, P398, DOI 10.1002/path.819; Barwell JR, 2004, LANCET, V363, P1854, DOI 10.1016/S0140-6736(04)16353-8; Bates DO, 1996, AM J PHYSIOL-HEART C, V271, pH2520, DOI 10.1152/ajpheart.1996.271.6.H2520; Berk BC, 2001, ANN NY ACAD SCI, V947, P93; Boisseau MR, 2000, ANGIOLOGIE, V52, P71; BRAND FN, 1988, AM J PREV MED, V4, P96, DOI 10.1016/S0749-3797(18)31203-0; BURNAND KG, 1981, BRIT J SURG, V68, P297, DOI 10.1002/bjs.1800680502; BURNAND KG, 1982, BMJ-BRIT MED J, V285, P1071, DOI 10.1136/bmj.285.6348.1071; CALLAM MJ, 1987, BRIT MED J, V294, P1389, DOI 10.1136/bmj.294.6584.1389; Carpentier PH, 2003, J VASC SURG, V37, P827, DOI 10.1067/mva.2003.147; Chiesa R, 2005, EUR J VASC ENDOVASC, V30, P674, DOI 10.1016/j.ejvs.2005.06.016; Coleridge Smith P D, 1997, Vasc Med, V2, P203; Criqui MH, 2003, AM J EPIDEMIOL, V158, P448, DOI 10.1093/aje/kwg166; Eberhardt RT, 2005, CIRCULATION, V111, P2398, DOI 10.1161/01.CIR.0000164199.72440.08; Eklof B, 2004, J VASC SURG, V40, P1248, DOI 10.1016/j.jvs.2004.09.027; Evans CJ, 1999, J EPIDEMIOL COMMUN H, V53, P149, DOI 10.1136/jech.53.3.149; Fowkes FGR, 2001, INT J EPIDEMIOL, V30, P846, DOI 10.1093/ije/30.4.846; Franks PJ, 2001, QUAL LIFE RES, V10, P693, DOI 10.1023/A:1013825924765; Fukuda S, 2003, P NATL ACAD SCI USA, V100, P13152, DOI 10.1073/pnas.2336130100; Fukuda S, 2000, CIRC RES, V86, pE13, DOI 10.1161/01.RES.86.1.e13; Hahn TL, 1999, J SURG RES, V81, P38, DOI 10.1006/jsre.1998.5518; Herouy Y, 1998, J INVEST DERMATOL, V111, P822, DOI 10.1046/j.1523-1747.1998.00369.x; Ibegbuna V, 2003, J VASC SURG, V37, P420, DOI 10.1067/mva.2003.104; Jacob MP, 2001, PATHOL BIOL, V49, P326, DOI 10.1016/S0369-8114(01)00151-1; Johnson JL, 1998, ARTERIOSCL THROM VAS, V18, P1707, DOI 10.1161/01.ATV.18.11.1707; Junger M, 1994, Wien Med Wochenschr, V144, P206; Kahn SR, 2004, J VASC SURG, V39, P823, DOI 10.1016/j.jvs.2003.12.007; Kaplan RM, 2003, J VASC SURG, V37, P1047, DOI 10.1067/mva.2003.168; Kistner RL, 1996, MAYO CLIN PROC, V71, P338, DOI 10.4065/71.4.338; Kurz X, 1999, INT ANGIOL, V18, P83; Labropoulos N., 2003, PHLEBOLYMPHOLOGY, V40, P130; Lalka SG, 1998, J SURG RES, V74, P59, DOI 10.1006/jsre.1997.5189; Laurikka JO, 2002, WORLD J SURG, V26, P648, DOI 10.1007/s00268-001-0283-1; Lee AJ, 2003, J CLIN EPIDEMIOL, V56, P171, DOI 10.1016/S0895-4356(02)00518-8; LEES M, 1994, EUR J BIOCHEM, V223, P171, DOI 10.1111/j.1432-1033.1994.tb18980.x; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; Lurie F, 2003, J VASC SURG, V38, P955, DOI 10.1016/S0741-5214(03)00711-0; McGuckin M, 2002, AM J SURG, V183, P132, DOI 10.1016/S0002-9610(01)00856-X; Moazzam F, 1997, P NATL ACAD SCI USA, V94, P5338, DOI 10.1073/pnas.94.10.5338; Moffatt CJ, 2004, QJM-INT J MED, V97, P431, DOI 10.1093/qjmed/hch075; MOORE JE, 1994, ATHEROSCLEROSIS, V110, P225, DOI 10.1016/0021-9150(94)90207-0; MOROZOV KM, 2005, VESTN ROS AKAD MED+, V4, P81; Motykie GD, 1999, DERMATOL SURG, V25, P116, DOI 10.1046/j.1524-4725.1999.08095.x; MOYSES C, 1987, INT J MICROCIRC, V5, P311; Mulivor AW, 2004, AM J PHYSIOL-HEART C, V286, pH1672, DOI 10.1152/ajpheart.00832.2003; Mulivor AW, 2002, AM J PHYSIOL-HEART C, V283, pH1282, DOI 10.1152/ajpheart.00117.2002; Mwaura B, 2006, EUR J VASC ENDOVASC, V31, P306, DOI 10.1016/j.ejvs.2005.08.007; Nemeth Kathleen A, 2004, Ostomy Wound Manage, V50, P34; NICOLAIDES AN, 1993, J VASC SURG, V17, P414, DOI 10.1016/0741-5214(93)90426-M; Nicolaides AN, 2003, ANGIOLOGY, V54, pS33, DOI 10.1177/0003319703054001S05; Norgauer J, 2002, BRIT J DERMATOL, V147, P1180, DOI 10.1046/j.1365-2133.2002.05025.x; Ohura Norihiko, 2003, J Atheroscler Thromb, V10, P304; Ono T, 1998, J VASC SURG, V27, P158, DOI 10.1016/S0741-5214(98)70303-9; OVERALL CM, 1991, J BIOL CHEM, V266, P14064; Pappas PJ, 1999, J VASC SURG, V30, P1129, DOI 10.1016/S0741-5214(99)70054-6; Pappas PJ, 1997, J VASC SURG, V26, P784, DOI 10.1016/S0741-5214(97)70091-0; Pascarella L, 2005, J VASC SURG, V41, P303, DOI 10.1016/j.jvs.2004.10.038; Passerini AG, 2003, J VASC SURG, V37, P182, DOI 10.1067/mva.2003.66; Payne SPK, 1996, EUR J VASC ENDOVASC, V11, P195, DOI 10.1016/S1078-5884(96)80051-7; PORTER JM, 1995, J VASC SURG, V21, P635, DOI 10.1016/S0741-5214(95)70195-8; Porto LC, 1998, ANGIOLOGY, V49, P391, DOI 10.1177/000331979804900508; QUI YC, 1995, ANN BIOMED ENG, V23, P750, DOI 10.1007/BF02584474; Ruckley CV, 1997, ANGIOLOGY, V48, P67, DOI 10.1177/000331979704800111; Saharay M, 1997, J VASC SURG, V26, P265, DOI 10.1016/S0741-5214(97)70188-5; Saharay M, 1998, EUR J VASC ENDOVASC, V15, P342, DOI 10.1016/S1078-5884(98)80039-7; Sales CM, 1998, ANN VASC SURG, V12, P153, DOI 10.1007/s100169900133; Sansilvestri-Morel P, 2001, J VASC RES, V38, P560, DOI 10.1159/000051092; Sansilvestri-Morel P, 2002, CIRCULATION, V106, P479, DOI 10.1161/01.CIR.0000022846.22923.46; Secomb TW, 2001, BIORHEOLOGY, V38, P143; Shoab SS, 1999, EUR J VASC ENDOVASC, V18, P334, DOI 10.1053/ejvs.1999.0890; Shoab SS, 1998, J VASC SURG, V28, P535, DOI 10.1016/S0741-5214(98)70141-7; Sorescu GP, 2003, J BIOL CHEM, V278, P31128, DOI 10.1074/jbc.M300703200; Takase S, 1999, J VASC SURG, V30, P148, DOI 10.1016/S0741-5214(99)70187-4; Takase S, 2000, ANN VASC SURG, V14, P427, DOI 10.1007/s100169910092; Takase S, 2004, J VASC SURG, V39, P1329, DOI 10.1016/j.jvs.2004.02.044; Takase S, 2004, EUR J VASC ENDOVASC, V28, P484, DOI 10.1016/j.ejvs.2004.05.012; Takase S, 2000, MICROCIRCULATION, V7, P41, DOI 10.1038/sj.mn.7300083; Takase S, 2002, AM J PHYSIOL-HEART C, V282, pH1387, DOI 10.1152/ajpheart.01003.2000; Takase S, 1999, J VASC RES, V36, P3, DOI 10.1159/000054068; Tassiopoulos AK, 2000, EUR J VASC ENDOVASC, V20, P227, DOI 10.1053/ejvs.2000.1157; TenBrook JA, 2004, J VASC SURG, V39, P583, DOI 10.1016/j.jvs.2003.09.017; THOMAS PRS, 1988, BRIT MED J, V296, P1693, DOI 10.1136/bmj.296.6638.1693; Traub O, 1998, ARTERIOSCL THROM VAS, V18, P677, DOI 10.1161/01.ATV.18.5.677; Travers JP, 1996, EUR J VASC ENDOVASC, V11, P230, DOI 10.1016/S1078-5884(96)80058-X; Van den Oever R, 1998, INT ANGIOL, V17, P161; van Korlaar I, 2003, THROMB HAEMOSTASIS, V90, P27; VANCLEEF JF, 1992, J MAL VASCUL, V17, P113; Wali MA, 2002, INT ANGIOL, V21, P337; Wenk J, 2001, J INVEST DERMATOL, V116, P833, DOI 10.1046/j.1523-1747.2001.01345.x; WILKINSON LS, 1993, J VASC SURG, V17, P669, DOI 10.1016/0741-5214(93)90109-Y; Yeoh-Ellerton S, 2003, J INVEST DERMATOL, V121, P918, DOI 10.1046/j.1523-1747.2003.12471.x; YONG K, 1990, BLOOD REV, V4, P211, DOI 10.1016/0268-960X(90)90001-9; Yoshizumi M, 2003, J PHARMACOL SCI, V91, P172; Zamboni P, 2005, J VASC SURG, V42, P309, DOI 10.1016/j.jvs.2005.04.003; Zhao YH, 2001, BIOPHYS J, V80, P1124, DOI 10.1016/S0006-3495(01)76090-0	100	617	674	1	42	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 3	2006	355	5					488	498		10.1056/NEJMra055289	http://dx.doi.org/10.1056/NEJMra055289			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	069FT	16885552				2022-12-28	WOS:000239432500008
J	Wexler, ID; Branski, D; Kerem, E				Wexler, Isaiah D.; Branski, David; Kerem, Eitan			War and children	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HEALTH; TERRORISM; CONFLICT; MORTALITY; TRAUMA; SUDAN		Hebrew Univ Jerusalem, Sch Med, Hadassah Hebrew Univ Hosp, Dept Pediat, IL-91240 Jerusalem, Israel	Hebrew University of Jerusalem; Hadassah University Medical Center	Wexler, ID (corresponding author), Hebrew Univ Jerusalem, Sch Med, Hadassah Hebrew Univ Hosp, Dept Pediat, Mt Scopus Campus, IL-91240 Jerusalem, Israel.	shwexler@hadassah.org.il						Allwood MA, 2002, J AM ACAD CHILD PSY, V41, P450, DOI 10.1097/00004583-200204000-00018; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; Bandura A, 1999, Pers Soc Psychol Rev, V3, P193, DOI 10.1207/s15327957pspr0303_3; Bellamy C., 2004, STATE WORLDS CHILDRE; *COAL STOP US CHIL, 2001, GLOB REP 2001; Fiske ST, 2004, SCIENCE, V306, P1482, DOI 10.1126/science.1103788; Fremont WP, 2005, CHILD ADOL PSYCH CL, V14, P429, DOI 10.1016/j.chc.2005.02.001; Geltman PL, 2005, ARCH PEDIAT ADOL MED, V159, P585, DOI 10.1001/archpedi.159.6.585; Ghobarah HA, 2004, SOC SCI MED, V59, P869, DOI 10.1016/j.socscimed.2003.11.043; Grandesso F, 2005, JAMA-J AM MED ASSOC, V293, P1490, DOI 10.1001/jama.293.12.1490; Guha-Sapir D, 2004, DISASTERS, V28, P418, DOI 10.1111/j.0361-3666.2004.00267.x; Herman J.L., 1997, TRAUMA RECOVERY; Iacopino V, 1999, JAMA-J AM MED ASSOC, V282, P479, DOI 10.1001/jama.282.5.479; Lautze S, 2004, LANCET, V364, P2134, DOI 10.1016/S0140-6736(04)17555-7; Lonigan CJ, 2003, CHILD ADOL PSYCH CL, V12, P171, DOI 10.1016/S1056-4993(02)00105-0; Machel G., 1996, IMPACT ARMED CONFLIC; Markenson D, 2004, BIOSECUR BIOTERROR, V2, P301, DOI 10.1089/bsp.2004.2.301; Meddings D R, 2001, Med Confl Surviv, V17, P6, DOI 10.1080/13623690108409551; *OFF UN HIGH COMM, UNHCR GLOB REP 2005; Olness K, 2005, AMBUL PEDIATR, V5, P244, DOI 10.1367/A04-122R2.1; Pine DS, 2005, NEUROPSYCHOPHARMACOL, V30, P1781, DOI 10.1038/sj.npp.1300814; SWISS S, 1993, JAMA-J AM MED ASSOC, V270, P612, DOI 10.1001/jama.270.5.612; *UN CHILDR FUND, STAT WORLDS CHILDR 1; *UN HUM SEC NETW, 2003, CHILDR ARM CONFL INT; Wexler ID, 2005, LANCET, V365, P1278, DOI 10.1016/S0140-6736(05)74818-2	25	14	15	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 2	2006	296	5					579	581		10.1001/jama.296.5.579	http://dx.doi.org/10.1001/jama.296.5.579			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	069YW	16882966				2022-12-28	WOS:000239486900024
J	Demoly, P; Bousquet, J				Demoly, Pascal; Bousquet, Jean			The relation between asthma and allergic rhinitis	LANCET			English	Editorial Material							DIAGNOSIS; INFLAMMATION; THERAPY; NASAL; CARE		Univ Hosp Montpellier, Hop Arnaud de Villeneuve, INSERM, U454, F-34295 Montpellier 5, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier	Demoly, P (corresponding author), Univ Hosp Montpellier, Hop Arnaud de Villeneuve, INSERM, U454, F-34295 Montpellier 5, France.	demoly@montp.inserm.fr	Demoly, Pascal/Y-9938-2019	Demoly, Pascal/0000-0001-7827-7964				Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Braunstahl GJ, 2000, AM J RESP CRIT CARE, V161, P2051, DOI 10.1164/ajrccm.161.6.9906121; Celedon JC, 2001, AM J RESP CRIT CARE, V163, P1108, DOI 10.1164/ajrccm.163.5.2005086; Chanez P, 1999, AM J RESP CRIT CARE, V159, P588, DOI 10.1164/ajrccm.159.2.9801022; Corren J, 2004, J ALLERGY CLIN IMMUN, V113, P415, DOI 10.1016/j.jaci.2003.11.034; Dahl R, 2005, ALLERGY, V60, P875, DOI 10.1111/j.1398-9995.2005.00819.x; Demoly P, 2006, ALLERGY, V61, P699, DOI 10.1111/j.1398-9995.2006.01112.x; Demoly P, 2005, ALLERGY, V60, P1089, DOI 10.1111/j.1398-9995.2005.00843.x; Leynaert B, 2000, AM J RESP CRIT CARE, V162, P1391, DOI 10.1164/ajrccm.162.4.9912033; Malo JL, 1997, EUR RESPIR J, V10, P1513, DOI 10.1183/09031936.97.10071513; Philip G, 2004, CURR MED RES OPIN, V20, P1549, DOI 10.1185/030079904X3348; Price D, 2005, CLIN EXP ALLERGY, V35, P282, DOI 10.1111/j.1365-2222.2005.02182.x; TARAMARCAZ P, 2003, COCHRANE DB SYST REV, V4; ten Brinke A, 2002, J ALLERGY CLIN IMMUN, V109, P621, DOI 10.1067/mai.2002.122458; Vignola AM, 2004, ALLERGY, V59, P709, DOI 10.1111/j.1398-9995.2004.00550.x	15	36	39	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG-SEP	2006	368	9537					711	713		10.1016/S0140-6736(06)69263-5	http://dx.doi.org/10.1016/S0140-6736(06)69263-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	080ID	16935669				2022-12-28	WOS:000240240200007
J	Pincock, S				Pincock, Stephen			Ellis Samols - Obituary	LANCET			English	Biographical-Item												stephenpincock@gmail.com		Pincock, Stephen/0000-0003-1655-2902				ELLIS S, PUBLICATION LIST	1	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL-AUG	2006	368	9533					360	360		10.1016/S0140-6736(06)69095-8	http://dx.doi.org/10.1016/S0140-6736(06)69095-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	069JJ	16903004				2022-12-28	WOS:000239441900014
J	Walker, SP; Chang, SM; Powell, CA; Simonoff, E; Grantham-McGregor, SM				Walker, Susan P.; Chang, Susan M.; Powell, Christine A.; Simonoff, Emily; Grantham-McGregor, Sally M.			Effects of psychosocial stimulation and dietary supplementation in early childhood on psychosocial functioning in late adolescence: follow-up of randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							NUTRITIONAL SUPPLEMENTATION; JAMAICAN CHILDREN; BEHAVIOR; GROWTH; SCHOOL; HOME; DEPRESSION; COGNITION; LIFE	Objective To determine whether dietary supplementation or psychosocial stimulation given to growth retarded (stunted) children age 9-24 months has long term benefits for their psychosocial functioning in late adolescence. Design Sixteen year follow-up study of a randomised controlled trial. Setting Poor neighbourhoods in Kingston,Jamaica. Participants Of 129 stunted children identified at age 9-24 months, 103 adolescents aged 17-18 were followed up. Intervention Supplementation with 1 kg milk based formula each week or psychosocial stimulation (weekly play sessions with mother and child), or both, for two years. Main outcome measures Anxiety, depression, self esteem, and antisocial behaviour assessed by questionnaires administered by interviewers; attention deficit, hyperactivity, and oppositional behaviour assessed by interviews with parents. Results Primary analysis indicated that participants who received stimulation had significantly different overall scores from those who did not (F = 2.047, P = 0.049). Supplementation had no significant effect (F = 1.505, P = 0.17). Participants who received stimulation reported less anxiety (mean difference - 2.81, 95% confidence interval - 5.02 to - 0.61), less depression (- 0.43, - 0.78 to - 0.07), and higher self esteem (1.55, 0.08 to 3.02) and parents reported fewer attention problems (- 3.34, - 6.48 to - 0.19). These differences are equivalent to effect sizes of 0.40-0.49 standard deviations. Conclusions Stimulation in early childhood has sustained benefits to stunted children's emotional outcomes and attention.	Univ W Indies, Res Inst Trop Med, Epidemiol Res Unit, Kingston 7, Jamaica; Inst Psychiat, London SE5 8AF, England; Inst Child Hlth, London WC1N 1EH, England	University West Indies Mona Jamaica; University of London; King's College London; University of London; University College London	Walker, SP (corresponding author), Univ W Indies, Res Inst Trop Med, Epidemiol Res Unit, Kingston 7, Jamaica.	susan.walker@uwirnona.edu.jm	Simonoff, Emily A/B-7593-2011	Simonoff, Emily/0000-0002-5450-0823	Wellcome Trust [066088] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Baker-Henningham H, 2005, ARCH DIS CHILD, V90, P1230, DOI 10.1136/adc.2005.073015; Chang SM, 2002, J CHILD PSYCHOL PSYC, V43, P775, DOI 10.1111/1469-7610.00088; Conners CK, 1998, J ABNORM CHILD PSYCH, V26, P257, DOI 10.1023/A:1022602400621; COSTELLO EJ, 1988, J AM ACAD CHILD PSY, V27, P726, DOI 10.1097/00004583-198811000-00011; FARRAN DC, 2000, HDB EARLY CHILDHOOD, P501; GALLER JR, 1989, J AM ACAD CHILD PSY, V28, P254, DOI 10.1097/00004583-198903000-00018; Gardner JMM, 1999, J CHILD PSYCHOL PSYC, V40, P819, DOI 10.1111/1469-7610.00497; HAMIL PVV, 1977, VITAL HLTH STAT SERI, V11; Olds D, 1998, JAMA-J AM MED ASSOC, V280, P1238, DOI 10.1001/jama.280.14.1238; Olweus D, 1989, CROSS NATL RES SELF; REYNOLDS CR, 1978, J ABNORM CHILD PSYCH, V6, P271, DOI 10.1007/BF00919131; RICHARDSON SA, 1975, J BIOSOC SCI, V7, P255, DOI 10.1017/S0021932000010142; RICHARDSON SA, 1972, J HEALTH SOC BEHAV, V13, P276, DOI 10.2307/2136764; WALKER SP, 1991, AM J CLIN NUTR, V54, P642, DOI 10.1093/ajcn/54.4.642; Walker SP, 2005, LANCET, V366, P1804, DOI 10.1016/S0140-6736(05)67574-5; Walker SP, 2000, J PEDIATR-US, V137, P36, DOI 10.1067/mpd.2000.106227; WARR P, 1983, TRAV HUMAIN, V46, P355; Yoshikawa H, 1995, FUTURE CHILD, V5, P51, DOI 10.2307/1602367	18	64	67	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 2	2006	333	7566					472	474		10.1136/bmj.38897.555208.2F	http://dx.doi.org/10.1136/bmj.38897.555208.2F			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	085QP	16877454	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000240618900019
J	Yao, J; Munson, KM; Webb, WW; Lis, JT				Yao, Jie; Munson, Katherine M.; Webb, Watt W.; Lis, John T.			Dynamics of heat shock factor association with native gene loci in living cells	NATURE			English	Article							GLUCOCORTICOID-RECEPTOR; TRANSCRIPTION; ARCHITECTURE; PROMOTER; OLIGOMERIZATION; CHROMOSOMES; EXPRESSION; ACTIVATOR; TURNOVER; EXCHANGE	Direct observation of transcription factor action in the living cell nucleus can provide important insights into gene regulatory mechanisms(1,2). Live-cell imaging techniques have enabled the visualization of a variety of intranuclear activities, from chromosome dynamics(3) to gene expression(4). However, progress in studying transcription regulation of specific native genes has been limited, primarily as a result of difficulties in resolving individual gene loci and in detecting the small number of protein molecules functioning within active transcription units. Here we report that multiphoton microscopy imaging(5) of polytene nuclei in living Drosophila salivary glands allows real-time analysis of transcription factor recruitment and exchange on specific native genes. After heat shock, we have visualized the recruitment of RNA polymerase II (Pol II) to native hsp70 gene loci 87A and 87C in real time. We show that heat shock factor (HSF), the transcription activator of hsp70, is localized to the nucleus before heat shock and translocates from nucleoplasm to chromosomal loci after heat shock. Assays based on fluorescence recovery after photobleaching(6) show a rapid exchange of HSF at chromosomal loci under non-heat-shock conditions but a very slow exchange after heat shock. However, this is not a consequence of a change of HSF diffusibility, as shown here directly by fluorescence correlation spectroscopy(7). Our results provide strong evidence that activated HSF is stably bound to DNA in vivo and that turnover or disassembly of transcription activator is not required for rounds of hsp70 transcription. This and previous studies(8,9) indicate that transcription activators display diverse dynamic behaviours in their associations with targeted loci in living cells. Our method can be applied to study the dynamics of many factors involved in transcription and RNA processing, and in their regulation at native heat shock genes in vivo.	Cornell Univ, Field Biochem Mol & Cell Biol, Ithaca, NY 14853 USA; Cornell Univ, Sch Appl & Engn Phys, Ithaca, NY 14853 USA; Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA	Cornell University; Cornell University; Cornell University	Lis, JT (corresponding author), Cornell Univ, Field Biochem Mol & Cell Biol, Ithaca, NY 14853 USA.	www2@cornell.edu; jtl10@cornell.edu	Munson, Katherine M/P-2462-2015; Webb, Watt W./B-5905-2011; Yao, Jie/E-2229-2017	Munson, Katherine M/0000-0001-8413-6498; Yao, Jie/0000-0002-7640-4840				AGARD DA, 1983, NATURE, V302, P676, DOI 10.1038/302676a0; AXELROD D, 1976, BIOPHYS J, V16, P1055, DOI 10.1016/S0006-3495(76)85755-4; Belmont AS, 2001, TRENDS CELL BIOL, V11, P250, DOI 10.1016/S0962-8924(01)02000-1; Bosisio D, 2006, EMBO J, V25, P798, DOI 10.1038/sj.emboj.7600977; Bridges CB, 1935, J HERED, V26, P60, DOI 10.1093/oxfordjournals.jhered.a104022; Cramer P, 2002, CURR OPIN STRUC BIOL, V12, P89, DOI 10.1016/S0959-440X(02)00294-4; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; Freeman BC, 2002, SCIENCE, V296, P2232, DOI 10.1126/science.1073051; Green MR, 2005, MOL CELL, V18, P399, DOI 10.1016/j.molcel.2005.04.017; Janicki SM, 2004, CELL, V116, P683, DOI 10.1016/S0092-8674(04)00171-0; Larson DR, 2003, J CELL BIOL, V162, P1233, DOI 10.1083/jcb.200303200; Lipford JR, 2005, NATURE, V438, P113, DOI 10.1038/nature04098; Lis J, 1998, COLD SPRING HARB SYM, V63, P347, DOI 10.1101/sqb.1998.63.347; MAGDE D, 1972, PHYS REV LETT, V29, P705, DOI 10.1103/PhysRevLett.29.705; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; Misteli T, 2001, SCIENCE, V291, P843, DOI 10.1126/science.291.5505.843; Muratani M, 2005, CELL, V120, P887, DOI 10.1016/j.cell.2004.12.025; Nalley K, 2006, NATURE, V442, P1054, DOI 10.1038/nature05067; OBRIEN T, 1993, MOL CELL BIOL, V13, P3456, DOI 10.1128/MCB.13.6.3456; Reeves WM, 2005, MOL CELL BIOL, V25, P9092, DOI 10.1128/MCB.25.20.9092-9102.2005; Schwartz BE, 2004, METHOD ENZYMOL, V376, P393; Shav-Tal Y, 2004, NAT REV MOL CELL BIO, V5, P855, DOI 10.1038/nrm1494; Spector DL, 2003, ANNU REV BIOCHEM, V72, P573, DOI 10.1146/annurev.biochem.72.121801.161724; Stavreva DA, 2004, MOL CELL BIOL, V24, P2682, DOI 10.1128/MCB.24.7.2682-2697.2004; WEEKS JR, 1993, GENE DEV, V7, P2329, DOI 10.1101/gad.7.12a.2329; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Zandi E, 1997, GENE DEV, V11, P1299, DOI 10.1101/gad.11.10.1299; Zhang J, 2002, NAT REV MOL CELL BIO, V3, P906, DOI 10.1038/nrm976; Zipfel WR, 2003, NAT BIOTECHNOL, V21, P1368, DOI 10.1038/nbt899	30	160	163	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 31	2006	442	7106					1050	1053		10.1038/nature05025	http://dx.doi.org/10.1038/nature05025			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	078YF	16929308				2022-12-28	WOS:000240142000052
J	Bookout, AL; Jeong, Y; Downes, M; Yu, RT; Evans, RM; Mangelsdorf, DJ				Bookout, Angie L.; Jeong, Yangsik; Downes, Michael; Yu, Ruth T.; Evans, Ronald M.; Mangelsdorf, David J.			Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network	CELL			English	Article							VITAMIN-D-RECEPTOR; THYROID-HORMONE; MOLECULAR DETERMINANTS; ALPHA; GENE; MOUSE; BETA; IDENTIFICATION; DEGENERATION; METABOLISM	In multicellular organisms, the ability to regulate reproduction, development, and nutrient utilization coincided with the evolution of nuclear receptors (NRs), transcription factors that utilize lipophilic ligands to mediate their function. Studying the expression profile of NRs offers a simple, powerful way to obtain highly relational information about their physiologic functions as individual proteins and as a superfamily. We surveyed the expression of all 49 mouse NR mRNAs in 39 tissues, representing diverse anatomical systems. The resulting data set uncovers several NR clades whose patterns of expression indicate their ability to coordinate the transcriptional programs necessary to affect distinct physiologic pathways. Remarkably, this regulatory network divides along the following two physiologic paradigms: (1) reproduction, development, and growth and (2) nutrient uptake, metabolism, and excretion. These data reveal a hierarchical transcriptional circuitry that extends beyond individual tissues to form a meganetwork governing physiology on an organismal scale.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Pharmacol, Dallas, TX 75390 USA; Salk Inst Biol Studies, Howard Hughes Med Inst, Gene Express Lab, La Jolla, CA 92037 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; Salk Institute	Mangelsdorf, DJ (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Pharmacol, 6001 Forest Pk Rd, Dallas, TX 75390 USA.	davo.mango@utsouthwestern.edu	Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965; Yu, Ruth/0000-0002-9527-9627; Mangelsdorf, David/0000-0002-4355-0796	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U19DK062434] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NIDDK NIH HHS [U19DK62434, U19 DK062434] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akhmedov NB, 2000, P NATL ACAD SCI USA, V97, P5551, DOI 10.1073/pnas.97.10.5551; Barish GD, 2005, MOL ENDOCRINOL, V19, P2466, DOI 10.1210/me.2004-0529; Beland M, 2005, J BIOL CHEM, V280, P13858, DOI 10.1074/jbc.M412981200; Beuschlein F, 2002, ENDOCR RES, V28, P597, DOI 10.1081/ERC-120016972; BOOKOUT AL, 2005, CURRENT PROTOCOLS MO; BOOKOUT AL, 2003, NUCL RECEPT SIGNAL, V1, DOI DOI 10.1621/NRS.01012; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; Chen YT, 2005, MOL CELL BIOL, V25, P2722, DOI 10.1128/MCB.25.7.2722-2732.2005; Chung SSW, 2004, DEV DYNAM, V230, P754, DOI 10.1002/dvdy.20083; Cooney AJ, 2001, TRENDS ENDOCRIN MET, V12, P247, DOI 10.1016/S1043-2760(01)00424-6; Cupp AS, 1999, ENDOCRINOLOGY, V140, P2343, DOI 10.1210/en.140.5.2343; Dixit SG, 2005, CURR DRUG METAB, V6, P385, DOI 10.2174/1389200054633907; Duran-Sandoval D, 2005, J BIOL CHEM, V280, P29971, DOI 10.1074/jbc.M501931200; Edwards PA, 2002, J LIPID RES, V43, P2; Evans RM, 2004, NAT MED, V10, P355, DOI 10.1038/nm1025; Forrest D, 2000, THYROID, V10, P41, DOI 10.1089/thy.2000.10.41; Fu MG, 2005, MOL ENDOCRINOL, V19, P2437, DOI 10.1210/me.2004-0539; GomezSanchez EP, 1996, STEROIDS, V61, P184, DOI 10.1016/0039-128X(96)00010-4; Gronemeyer H, 2004, NAT REV DRUG DISCOV, V3, P950, DOI 10.1038/nrd1551; Gullberg H, 2000, MOL ENDOCRINOL, V14, P1739, DOI 10.1210/me.14.11.1739; Haider NB, 2000, NAT GENET, V24, P127, DOI 10.1038/72777; Haussler MR, 1997, J ENDOCRINOL, V154, pS57; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; He YW, 2000, IMMUNOL RES, V22, P71, DOI 10.1385/IR:22:2-3:71; Inagaki T, 2006, P NATL ACAD SCI USA, V103, P3920, DOI 10.1073/pnas.0509592103; Iwaki T, 2001, COLOR ATLAS SECTIONA; Kalaany NY, 2005, CELL METAB, V1, P231, DOI 10.1016/j.cmet.2005.03.001; Kallay E, 2001, CARCINOGENESIS, V22, P1429, DOI 10.1093/carcin/22.9.1429; Kato S, 2000, J BIOCHEM, V127, P717, DOI 10.1093/oxfordjournals.jbchem.a022662; Kobayashi M, 1999, P NATL ACAD SCI USA, V96, P4814, DOI 10.1073/pnas.96.9.4814; Le Menuet D, 2004, MOL CELL ENDOCRINOL, V217, P127, DOI 10.1016/j.mce.2003.10.045; Lee M, 2002, J COMMUN NETW-S KOR, V4, P81, DOI 10.1109/JCN.2002.6596898; Lu TT, 2001, J BIOL CHEM, V276, P37735, DOI 10.1074/jbc.R100035200; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; Luo JM, 2003, MOL CELL BIOL, V23, P7947, DOI 10.1128/MCB.23.22.7947-7956.2003; Makishima M, 2002, SCIENCE, V296, P1313, DOI 10.1126/science.1070477; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Marrif H, 2005, ENDOCRINOLOGY, V146, P2872, DOI 10.1210/en.2004-1544; *MGD, 2003, MOUS GEN INF WEBS; Ogawa S, 2005, CELL, V122, P707, DOI 10.1016/j.cell.2005.06.029; Opherk C, 2004, MOL ENDOCRINOL, V18, P1346, DOI 10.1210/me.2003-0283; Otte K, 2003, MOL CELL BIOL, V23, P864, DOI 10.1128/MCB.23.3.864-872.2003; Park Joo-In, 2003, Keio Journal of Medicine, V52, P174; Parker KL, 2002, ANN MED, V34, P171, DOI 10.1080/713782137; Paxinos G., 2001, MOUSE BRAIN STEREOTA; Perlmann T, 2004, CELL TISSUE RES, V318, P45, DOI 10.1007/s00441-004-0974-7; Ponnio T, 2004, MOL CELL BIOL, V24, P9070, DOI 10.1128/MCB.24.20.9070-9078.2004; Qiu Y, 1996, J STEROID BIOCHEM, V56, P81, DOI 10.1016/0960-0760(95)00225-1; Schreiber SN, 2004, P NATL ACAD SCI USA, V101, P6472, DOI 10.1073/pnas.0308686101; Shi YH, 2004, NATURE, V427, P78, DOI 10.1038/nature02211; Shih David Q, 2002, Curr Diab Rep, V2, P125, DOI 10.1007/s11892-002-0071-9; Shulman AI, 2005, NEW ENGL J MED, V353, P604, DOI 10.1056/NEJMra043590; STEKEL D, 2003, MICROARRY BIOINFORMA; Szakacs G, 2004, CANCER CELL, V6, P129, DOI 10.1016/j.ccr.2004.06.026; Tontonoz P, 2003, MOL ENDOCRINOL, V17, P985, DOI 10.1210/me.2003-0061; Warnecke M, 2005, GENE DEV, V19, P614, DOI 10.1101/gad.317905; Watanabe M, 2004, J CLIN INVEST, V113, P1408, DOI 10.1172/JCI200421025; Weiss RE, 1998, ENDOCRINOLOGY, V139, P4945, DOI 10.1210/en.139.12.4945; Willson TM, 2002, NAT REV DRUG DISCOV, V1, P259, DOI 10.1038/nrd753; Willy PJ, 2004, P NATL ACAD SCI USA, V101, P8912, DOI 10.1073/pnas.0401420101; WILSON JD, 1992, WILLIAMS TXB ENDOCRI; Winoto A, 2002, CELL, V109, pS57, DOI 10.1016/S0092-8674(02)00710-9; Wintermantel TM, 2004, HORM METAB RES, V36, P387, DOI 10.1055/s-2004-814567; Zhang YQ, 2004, GENE DEV, V18, P157, DOI 10.1101/gad.1138104	66	770	789	0	51	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 25	2006	126	4					789	799		10.1016/j.cell.2006.06.049	http://dx.doi.org/10.1016/j.cell.2006.06.049			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	080VN	16923397	Bronze, Green Accepted			2022-12-28	WOS:000240276700026
J	Carlsson, F; Stalhammar-Carlemalm, M; Flardh, K; Sandin, C; Carlemalm, E; Lindahl, G				Carlsson, Fredric; Stalhammar-Carlemalm, Margaretha; Flaerdh, Klas; Sandin, Charlotta; Carlemalm, Eric; Lindahl, Gunnar			Signal sequence directs localized secretion of bacterial surface proteins	NATURE			English	Article							GRAM-POSITIVE BACTERIA; PYOGENES M-PROTEIN; STREPTOCOCCUS-PYOGENES; CELL-WALL; STAPHYLOCOCCUS-AUREUS; PATHWAY; TRANSLOCATION; ENVELOPE; SORTASE; PEPTIDE	All living cells require specific mechanisms that target proteins to the cell surface. In eukaryotes, the first part of this process involves recognition in the endoplasmic reticulum of amino-terminal signal sequences and translocation through Sec translocons, whereas subsequent targeting to different surface locations is promoted by internal sorting signals(1). In bacteria, N-terminal signal sequences promote translocation across the cytoplasmic membrane, which surrounds the entire cell, but some proteins are nevertheless secreted in one part of the cell by poorly understood mechanisms(2,3). Here we analyse localized secretion in the Gram-positive pathogen Streptococcus pyogenes, and show that the signal sequences of two surface proteins, M protein and protein F ( PrtF), direct secretion to different subcellular regions. The signal sequence of M protein promotes secretion at the division septum, whereas that of PrtF preferentially promotes secretion at the old pole. Our work therefore shows that a signal sequence may contain information that directs the secretion of a protein to one subcellular region, in addition to its classical role in promoting secretion. This finding identifies a new level of complexity in protein translocation and emphasizes the potential of bacterial systems for the analysis of fundamental cell-biological problems(4).	Lund Univ, Dept Lab Med, SE-22362 Lund, Sweden; Lund Univ, Dept Cell & Organism Biol, SE-22362 Lund, Sweden; Lund Univ, Dept Clin Sci, SE-22362 Lund, Sweden	Lund University; Lund University; Lund University	Lindahl, G (corresponding author), Lund Univ, Dept Lab Med, SE-22362 Lund, Sweden.	gunnar.lindahl@med.lu.se	Flärdh, Klas/H-6584-2019	Flärdh, Klas/0000-0002-7131-9743; Carlsson, Fredric/0000-0003-0875-4395				Bae T, 2003, J BACTERIOL, V185, P2910, DOI 10.1128/JB.185.9.2910-2919.2003; Barnett TC, 2002, J BACTERIOL, V184, P2181, DOI 10.1128/JB.184.8.2181-2191.2002; Brandon LD, 2003, MOL MICROBIOL, V50, P45, DOI 10.1046/j.1365-2958.2003.03674.x; Campo N, 2004, MOL MICROBIOL, V53, P1583, DOI 10.1111/j.1365-2958.2004.04278.x; Carapetis JR, 2005, LANCET INFECT DIS, V5, P685, DOI 10.1016/S1473-3099(05)70267-X; Carlsson F, 2005, MOL MICROBIOL, V56, P28, DOI 10.1111/j.1365-2958.2005.04527.x; Carlsson F, 2003, J EXP MED, V198, P1057, DOI 10.1084/jem.20030543; COLE RM, 1962, SCIENCE, V135, P722, DOI 10.1126/science.135.3505.722; Dilks K, 2003, J BACTERIOL, V185, P1478, DOI 10.1128/JB.185.4.1478-1483.2003; Gitai Z, 2005, CELL, V120, P577, DOI 10.1016/j.cell.2005.02.026; HAANESFRITZ E, 1988, NUCLEIC ACIDS RES, V16, P4667, DOI 10.1093/nar/16.10.4667; HOLLINGSHEAD SK, 1986, J BIOL CHEM, V261, P1677; Janakiraman A, 2004, TRENDS MICROBIOL, V12, P518, DOI 10.1016/j.tim.2004.09.003; Mazmanian SK, 1999, SCIENCE, V285, P760, DOI 10.1126/science.285.5428.760; Muth TR, 2003, ANNU REV CELL DEV BI, V19, P333, DOI 10.1146/annurev.cellbio.19.110701.161425; Navarre WW, 1999, MICROBIOL MOL BIOL R, V63, P174, DOI 10.1128/MMBR.63.1.174-229.1999; OTOOLE P, 1992, P NATL ACAD SCI USA, V89, P8661, DOI 10.1073/pnas.89.18.8661; Ozeri V, 2001, MOL MICROBIOL, V41, P561, DOI 10.1046/j.1365-2958.2001.02535.x; Palmer T, 2005, TRENDS MICROBIOL, V13, P175, DOI 10.1016/j.tim.2005.02.002; Rafelski SM, 2006, MOL MICROBIOL, V59, P1262, DOI 10.1111/j.1365-2958.2006.05025.x; Rosch J, 2004, SCIENCE, V304, P1513, DOI 10.1126/science.1097404; Rosch JW, 2005, MOL MICROBIOL, V58, P959, DOI 10.1111/j.1365-2958.2005.04887.x; Rosenstein R, 2000, BIOCHIMIE, V82, P1005, DOI 10.1016/S0300-9084(00)01180-9; Rudner DZ, 2002, P NATL ACAD SCI USA, V99, P8701, DOI 10.1073/pnas.132235899; SCHNEEWIND O, 1995, SCIENCE, V268, P103, DOI 10.1126/science.7701329; SELA S, 1993, MOL MICROBIOL, V10, P1049, DOI 10.1111/j.1365-2958.1993.tb00975.x; SWANSON J, 1969, J EXP MED, V130, P1063, DOI 10.1084/jem.130.5.1063; van Wely KHM, 2001, FEMS MICROBIOL REV, V25, P437, DOI 10.1016/S0168-6445(01)00062-6	28	91	93	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 24	2006	442	7105					943	946		10.1038/nature05021	http://dx.doi.org/10.1038/nature05021			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	076LT	16929299				2022-12-28	WOS:000239960500043
J	Rejec, T; Meir, Y				Rejec, Tomaz; Meir, Yigal			Magnetic impurity formation in quantum point contacts	NATURE			English	Article							DIMENSIONAL ELECTRON-GAS; CONDUCTANCE; DOTS	A quantum point contact (QPC) is a narrow constriction between two wider electron reservoirs, and is the standard building block of sub-micrometre devices such as quantum dots and qubits ( the proposed basic elements of quantum computers). The conductance through a QPC changes as a function of its width in integer steps of G(0) = 2e(2)/h ( where e is the charge on an electron, and h is Planck's constant), signalling the quantization of its transverse modes(1,2). But measurements of these conductance steps also reveal an additional shoulder at a value around 0.7 G(0) (refs 1 - 4), an observation that has remained a puzzle for more than a decade. It has recently been suggested(5,6) that this phenomenon can be explained by the existence of a magnetic 'impurity' in the QPC at low electron densities. Here we present extensive numerical density-functional calculations that reveal the formation of an electronic state with a spin-1/2 magnetic moment in the channel under very general conditions. In addition, we show that such an impurity will also form at large magnetic fields, for a specific value of the field, and sometimes even at the opening of the second transverse mode in the QPC. Beyond explaining the source of the '0.7 anomaly', these results may have far-reaching implications for spin-filling of electronic states in quantum dots and for the dephasing of quantum information stored in semiconductor qubits.	Ben Gurion Univ Negev, Dept Phys, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Ilse Katz Ctr Meso & Nano Scale Sci & Technol, IL-84105 Beer Sheva, Israel	Ben Gurion University; Ben Gurion University	Rejec, T (corresponding author), Ben Gurion Univ Negev, Dept Phys, IL-84105 Beer Sheva, Israel.	tomaz.rejec@ijs.si	MEIR, YIGAL/F-1888-2012	Meir, Yigal/0000-0003-1606-8969				Aguado R, 2000, PHYS REV LETT, V85, P1946, DOI 10.1103/PhysRevLett.85.1946; Berggren KF, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.085323; Cronenwett SM, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.226805; DiCarlo L, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.036810; Georges A, 1999, PHYS REV LETT, V82, P3508, DOI 10.1103/PhysRevLett.82.3508; Graham AC, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.136404; Hirose K, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.026804; HOHENBERG P, 1964, PHYS REV B, V136, pB864, DOI 10.1103/PhysRevB.7.1912; JACKSON JD, 1975, CLASSICAL ELECTRODYN, P147; KOHN W, 1965, PHYS REV, V140, P1133, DOI 10.1103/PhysRev.140.A1133; Kristensen A, 2000, PHYS REV B, V62, P10950, DOI 10.1103/PhysRevB.62.10950; Matveev KA, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.106801; Meir Y, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.196802; Reilly DJ, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.033309; Starikov AA, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.235319; Thomas KJ, 1998, PHYS REV B, V58, P4846, DOI 10.1103/PhysRevB.58.4846; Thomas KJ, 1996, PHYS REV LETT, V77, P135, DOI 10.1103/PhysRevLett.77.135; VANWEES BJ, 1988, PHYS REV LETT, V60, P848, DOI 10.1103/PhysRevLett.60.848; [No title captured]	20	136	137	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 24	2006	442	7105					900	903		10.1038/nature05054	http://dx.doi.org/10.1038/nature05054			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	076LT	16929294	Green Submitted			2022-12-28	WOS:000239960500033
J	Stead, LG; Judson, KA				Stead, Latha G.; Judson, Kurtis A.			Ocular bleeding due to anticoagulation	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Mayo Clin, Rochester, MN 55905 USA	Mayo Clinic	Stead, LG (corresponding author), Mayo Clin, Rochester, MN 55905 USA.		Ganti, Latha/AAF-6268-2020	Ganti, Latha/0000-0001-7717-3864					0	2	2	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 24	2006	355	8					E7	E7		10.1056/NEJMicm050635	http://dx.doi.org/10.1056/NEJMicm050635			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	076KA	16928990				2022-12-28	WOS:000239955200012
J	Smith, CH; Barker, JNWN				Smith, Catherine H.; Barker, J. N. W. N.			Psoriasis and its management	BMJ-BRITISH MEDICAL JOURNAL			English	Review							POPULATION-BASED COHORT; MONITORING PATIENTS; METHOTREXATE; MORTALITY; CANCER; RISK; SKIN		St Thomas Hosp, Univ London Kings Coll, St Johns Inst Dermatol, Skin Therapy Res Unit, London SE1 7EH, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Smith, CH (corresponding author), St Thomas Hosp, Univ London Kings Coll, St Johns Inst Dermatol, Skin Therapy Res Unit, London SE1 7EH, England.	catherine.smith@kcl.ac.uk	Smith, Catherine H./G-5268-2012	Smith, Catherine H./0000-0001-9918-1144; Barker, Jonathan/0000-0002-9030-183X				Ashcroft DM, 2000, BMJ-BRIT MED J, V320, P963, DOI 10.1136/bmj.320.7240.963; Boffetta P, 2001, J INVEST DERMATOL, V117, P1531, DOI 10.1046/j.0022-202x.2001.01520.x; Bowcock AM, 2005, NAT REV IMMUNOL, V5, P699, DOI 10.1038/nri1689; Boyman O, 2004, J EXP MED, V199, P731, DOI 10.1084/jem.20031482; Chalmers RJ, 2000, COCHRANE DB SYST REV; Chalmers RJG, 2005, BRIT J DERMATOL, V152, P444, DOI 10.1111/J.1365-2133.2005.06422.X; DEKORTE J, 2005, J INVEST DERMATOL, V9, P140; Fortune DG, 2005, DERMATOL CLIN, V23, P681, DOI 10.1016/j.det.2005.05.022; Gelfand JM, 2003, ARCH DERMATOL, V139, P1425, DOI 10.1001/archderm.139.11.1425; Griffiths C E, 2000, Health Technol Assess, V4, P1; Hannuksela-Svahn A, 2000, J INVEST DERMATOL, V114, P587, DOI 10.1046/j.1523-1747.2000.00898.x; Harlow D, 2000, BRIT J DERMATOL, V143, P979, DOI 10.1046/j.1365-2133.2000.03830.x; HEYANDAEL VM, 2003, NEW ENGL J MED, V349, P658; LEBOWOHL M, 2006, JAMA-J AM MED ASSOC, V295, P208; Mallbris L, 2004, EUR J EPIDEMIOL, V19, P225, DOI 10.1023/B:EJEP.0000020447.59150.f9; Mason J, 2002, BRIT J DERMATOL, V146, P351, DOI 10.1046/j.1365-2133.2000.04713.x; Maurice PDL, 2005, BRIT J DERMATOL, V152, P451, DOI 10.1111/J.1365-2133.2005.06459.X; Nickoloff BJ, 2004, J CLIN INVEST, V113, P1664, DOI 10.1172/JCI200422147; Owen CM, 2000, COCHRANE DB SYST REV; Poikolainen K, 1999, ARCH DERMATOL, V135, P1490, DOI 10.1001/archderm.135.12.1490; Rapp SR, 1999, J AM ACAD DERMATOL, V41, P401, DOI 10.1016/S0190-9622(99)70112-X; Reich K, 2005, LANCET, V366, P1367, DOI 10.1016/S0140-6736(05)67566-6; Salisbury C, 2005, BMJ-BRIT MED J, V331, P1441, DOI 10.1136/bmj.38670.494734.7C; Smith CH, 2005, BRIT J DERMATOL, V153, P486, DOI 10.1111/j.1365-2133.2005.06893.x; Stern RS, 2004, J INVEST DERM SYMP P, V9, P136, DOI 10.1046/j.1087-0024.2003.09102.x	25	76	79	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 19	2006	333	7564					380	384		10.1136/bmj.333.7564.380	http://dx.doi.org/10.1136/bmj.333.7564.380			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	078OD	16916825	Green Published			2022-12-28	WOS:000240112200018
J	Ohta, T; Bostwick, A; Seyller, T; Horn, K; Rotenberg, E				Ohta, Taisuke; Bostwick, Aaron; Seyller, Thomas; Horn, Karsten; Rotenberg, Eli			Controlling the electronic structure of bilayer graphene	SCIENCE			English	Article							BAND-STRUCTURE; BERRYS PHASE; GRAPHITE; SUPERCONDUCTIVITY; TRANSPORT	We describe the synthesis of bilayer graphene thin films deposited on insulating silicon carbide and report the characterization of their electronic band structure using angle-resolved photoemission. By selectively adjusting the carrier concentration in each layer, changes in the Coulomb potential led to control of the gap between valence and conduction bands. This control over the band structure suggests the potential application of bilayer graphene to switching functions in atomic-scale electronic devices.	Univ Calif Berkeley, Lawrence Berkeley Lab, Adv Light Source, Berkeley, CA 94720 USA; Max Planck Gesell, Fritz Haber Inst, Dept Mol Phys, D-14195 Berlin, Germany; Univ Erlangen Nurnberg, Inst Phys Kondensierten Mat, D-91058 Erlangen, Germany	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Max Planck Society; Fritz Haber Institute of the Max Planck Society; University of Erlangen Nuremberg	Rotenberg, E (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Adv Light Source, 1 Cyclotron Rd, Berkeley, CA 94720 USA.		Bostwick, Aaron/E-8549-2010; Rotenberg, Eli/B-3700-2009; Seyller, Thomas K/F-8410-2011	Rotenberg, Eli/0000-0002-3979-8844; Seyller, Thomas K/0000-0002-4953-2142; Bostwick, Aaron/0000-0002-9008-2980				BLASE X, 1995, PHYS REV B, V51, P6868, DOI 10.1103/PhysRevB.51.6868; Crain JN, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.205302; DIVINCENZO DP, 1984, PHYS REV B, V29, P1685, DOI 10.1103/PhysRevB.29.1685; Forbeaux I, 1998, PHYS REV B, V58, P16396, DOI 10.1103/PhysRevB.58.16396; HANNAY NB, 1965, PHYS REV LETT, V14, P225, DOI 10.1103/PhysRevLett.14.225; HOCK KM, 1993, SURF SCI, V284, P349, DOI 10.1016/0039-6028(93)90505-E; McCann E, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.086805; MCCLURE JW, 1957, PHYS REV, V108, P612, DOI 10.1103/PhysRev.108.612; Morozov SV, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.201401; Novoselov KS, 2005, NATURE, V438, P197, DOI 10.1038/nature04233; Novoselov KS, 2006, NAT PHYS, V2, P177, DOI 10.1038/nphys245; Novoselov KS, 2004, SCIENCE, V306, P666, DOI 10.1126/science.1102896; Reich S, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.035412; Rotenberg E, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.246404; Seyller T, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2213928; SLONCZEWSKI JC, 1958, PHYS REV, V109, P272, DOI 10.1103/PhysRev.109.272; Tang ZK, 2001, SCIENCE, V292, P2462, DOI 10.1126/science.1060470; WALLACE PR, 1947, PHYS REV, V71, P622, DOI 10.1103/PhysRev.71.622; Weller TE, 2005, NAT PHYS, V1, P39, DOI 10.1038/nphys0010; Yao Z, 2000, PHYS REV LETT, V84, P2941, DOI 10.1103/PhysRevLett.84.2941; Zhang YB, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1862334; Zhang YB, 2005, NATURE, V438, P201, DOI 10.1038/nature04235	22	2701	2757	28	1427	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 18	2006	313	5789					951	954		10.1126/science.1130681	http://dx.doi.org/10.1126/science.1130681			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	074MR	16917057	Green Submitted			2022-12-28	WOS:000239817000038
J	Amarenco, P; Bogousslavsky, J; Callahan, A; Goldstein, LB; Hennerici, M; Rudolph, AE; Sillesen, H; Simunovic, L; Szarek, M; Welch, KMA; Zivin, JA				Amarenco, Pierre; Bogousslavsky, Julien; Callahan, Alfred, III; Goldstein, Larry B.; Hennerici, Michael; Rudolph, Amy E.; Sillesen, Henrik; Simunovic, Lisa; Szarek, Michael; Welch, K. M. A.; Zivin, Justin A.		SPARCL Investigators	High-dose atorvastatin after stroke or transient ischemic attack	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYOCARDIAL-INFARCTION; SERUM-CHOLESTEROL; PREVENTION; EVENTS; RISK; INTERVENTION; REDUCTION; CORONARY; STATINS; DISEASE	BACKGROUND: Statins reduce the incidence of strokes among patients at increased risk for cardiovascular disease; whether they reduce the risk of stroke after a recent stroke or transient ischemic attack (TIA) remains to be established. METHODS: We randomly assigned 4731 patients who had had a stroke or TIA within one to six months before study entry, had low-density lipoprotein (LDL) cholesterol levels of 100 to 190 mg per deciliter (2.6 to 4.9 mmol per liter), and had no known coronary heart disease to double-blind treatment with 80 mg of atorvastatin per day or placebo. The primary end point was a first nonfatal or fatal stroke. RESULTS: The mean LDL cholesterol level during the trial was 73 mg per deciliter (1.9 mmol per liter) among patients receiving atorvastatin and 129 mg per deciliter (3.3 mmol per liter) among patients receiving placebo. During a median follow-up of 4.9 years, 265 patients (11.2 percent) receiving atorvastatin and 311 patients (13.1 percent) receiving placebo had a fatal or nonfatal stroke (5-year absolute reduction in risk, 2.2 percent; adjusted hazard ratio, 0.84; 95 percent confidence interval, 0.71 to 0.99; P=0.03; unadjusted P=0.05). The atorvastatin group had 218 ischemic strokes and 55 hemorrhagic strokes, whereas the placebo group had 274 ischemic strokes and 33 hemorrhagic strokes. The five-year absolute reduction in the risk of major cardiovascular events was 3.5 percent (hazard ratio, 0.80; 95 percent confidence interval, 0.69 to 0.92; P=0.002). The overall mortality rate was similar, with 216 deaths in the atorvastatin group and 211 deaths in the placebo group (P=0.98), as were the rates of serious adverse events. Elevated liver enzyme values were more common in patients taking atorvastatin. CONCLUSIONS: In patients with recent stroke or TIA and without known coronary heart disease, 80 mg of atorvastatin per day reduced the overall incidence of strokes and of cardiovascular events, despite a small increase in the incidence of hemorrhagic stroke.	Rosalind Franklin Univ Med & Sci, N Chicago, IL 60064 USA; Denis Diderot Univ, Paris, France; Univ Lausanne, Lausanne, Switzerland; Neurol Consultants, Nashville, TN USA; Duke Univ, Med Ctr, Durham, NC USA; Heidelberg Univ, D-6800 Mannheim, Germany; Pfizer, New York, NY USA; Univ Copenhagen, Copenhagen, Denmark; Univ Calif San Francisco, San Francisco, CA 94143 USA	Rosalind Franklin University Medical & Science; UDICE-French Research Universities; Universite Paris Cite; University of Lausanne; Duke University; Ruprecht Karls University Heidelberg; Pfizer; University of Copenhagen; University of California System; University of California San Francisco	Welch, KMA (corresponding author), Rosalind Franklin Univ Med & Sci, 3333 Green Bay Rd, N Chicago, IL 60064 USA.	michael.welch@rosalindfranklin.edu	Sillesen, Henrik/ABB-5668-2020; Szarek, Michael/ABE-1965-2021	Szarek, Michael/0000-0002-0046-0264; Kaste, Markku/0000-0001-6557-6412				Amarenco P, 2004, STROKE, V35, P2902, DOI 10.1161/01.STR.0000147965.52712.fa; Amarenco P, 2004, CEREBROVASC DIS, V17, P81, DOI 10.1159/000074799; Amarenco P, 2004, LANCET NEUROL, V3, P271, DOI 10.1016/S1474-4422(04)00734-3; Amarenco P, 2003, CEREBROVASC DIS, V16, P33, DOI 10.1159/000070275; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Colhoun HM, 2004, LANCET, V364, P685, DOI 10.1016/S0140-6736(04)16895-5; Collins R, 2004, LANCET, V363, P757; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Goldstein LB, 2004, CEREBROVASC DIS, V18, P1, DOI 10.1159/000078600; Hardie K, 2004, STROKE, V35, P731, DOI 10.1161/01.STR.0000116183.50167.D9; ISO H, 1989, NEW ENGL J MED, V320, P904, DOI 10.1056/NEJM198904063201405; Lee SH, 2002, STROKE, V33, P2845, DOI 10.1161/01.STR.0000036092.23649.2E; PEDERSEN TR, 1994, LANCET, V344, P1383; Plehn JF, 1999, CIRCULATION, V99, P216, DOI 10.1161/01.CIR.99.2.216; RANKIN J, 1957, Scott Med J, V2, P200; Sacco RL, 2006, STROKE, V37, P577, DOI 10.1161/01.STR.0000199147.30016.74; Sever PS, 2003, LANCET, V361, P1149, DOI 10.1016/S0140-6736(03)12948-0; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; Vickrey BG, 2002, STROKE, V33, P901, DOI 10.1161/hs0402.105246; Waters DD, 2002, CIRCULATION, V106, P1690, DOI 10.1161/01.CIR.0000031568.40630.1C; WATERS DD, 2005, CIRCULATION S1, V112, P2020; Wiviott SD, 2006, J AM COLL CARDIOL, V47, P472, DOI 10.1016/j.jacc.2005.12.002; Wiviott SD, 2005, J AM COLL CARDIOL, V46, P1411, DOI 10.1016/j.jacc.2005.04.064; YANO K, 1989, STROKE, V20, P1460, DOI 10.1161/01.STR.20.11.1460	24	1952	2139	2	84	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 10	2006	355	6					549	559						11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	071QM	16899775				2022-12-28	WOS:000239616700005
J	Goldbach-Mansky, R; Dailey, NJ; Canna, SW; Gelabert, A; Jones, J; Rubin, BI; Kim, HJ; Brewer, C; Zalewski, C; Wiggs, E; Hill, S; Turner, ML; Karp, BI; Aksentijevich, I; Pucino, F; Penzak, SR; Haverkamp, MH; Stein, L; Adams, BS; Moore, TL; Fuhlbrigge, RC; Shaham, B; Jarvis, JN; O'Neil, K; Vehe, RK; Beitz, LO; Gardner, G; Hannan, WP; Warren, RW; Horn, W; Cole, JL; Paul, SM; Hawkins, PN; Pham, TH; Snyder, C; Wesley, RA; Hoffmann, SC; Holland, SM; Butman, JA; Kastner, DL				Goldbach-Mansky, Raphaela; Dailey, Natalie J.; Canna, Scott W.; Gelabert, Ana; Jones, Janet; Rubin, Benjamin I.; Kim, H. Jeffrey; Brewer, Carmen; Zalewski, Christopher; Wiggs, Edythe; Hill, Suvimol; Turner, Maria L.; Karp, Barbara I.; Aksentijevich, Ivona; Pucino, Frank; Penzak, Scott R.; Haverkamp, Margje H.; Stein, Leonard; Adams, Barbara S.; Moore, Terry L.; Fuhlbrigge, Robert C.; Shaham, Bracha; Jarvis, James N.; O'Neil, Kathleen; Vehe, Richard K.; Beitz, Laurie O.; Gardner, Gregory; Hannan, William P.; Warren, Robert W.; Horn, William; Cole, Joe L.; Paul, Scott M.; Hawkins, Philip N.; Pham, Tuyet Hang; Snyder, Christopher; Wesley, Robert A.; Hoffmann, Steven C.; Holland, Steven M.; Butman, John A.; Kastner, Daniel L.			Neonatal-onset multisystem inflammatory disease responsive to interleukin-1 beta inhibition	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NF-KAPPA-B; MUCKLE-WELLS-SYNDROME; AUTOINFLAMMATORY DISEASES; ACTIVATE CASPASE-1; FEBRILE RESPONSE; ANAKINRA; MUTATIONS; CYTOKINES; GENE; ASC	BACKGROUND: Neonatal-onset multisystem inflammatory disease is characterized by fever, urticarial rash, aseptic meningitis, deforming arthropathy, hearing loss, and mental retardation. Many patients have mutations in the cold-induced autoinflammatory syndrome 1 (CIAS1) gene, encoding cryopyrin, a protein that regulates inflammation. METHODS: We selected 18 patients with neonatal-onset multisystem inflammatory disease (12 with identifiable CIAS1 mutations) to receive anakinra, an interleukin-1-receptor antagonist (1 to 2 mg per kilogram of body weight per day subcutaneously). In 11 patients, anakinra was withdrawn at three months until a flare occurred. The primary end points included changes in scores in a daily diary of symptoms, serum levels of amyloid A and C-reactive protein, and the erythrocyte sedimentation rate from baseline to month 3 and from month 3 until a disease flare. RESULTS: All 18 patients had a rapid response to anakinra, with disappearance of rash. Diary scores improved (P<0.001) and serum amyloid A (from a median of 174 mg to 8 mg per liter), C-reactive protein (from a median of 5.29 mg to 0.34 mg per deciliter), and the erythrocyte sedimentation rate decreased at month 3 (all P<0.001), and remained low at month 6. Magnetic resonance imaging showed improvement in cochlear and leptomeningeal lesions as compared with baseline. Withdrawal of anakinra uniformly resulted in relapse within days; retreatment led to rapid improvement. There were no drug-related serious adverse events. CONCLUSIONS: Daily injections of anakinra markedly improved clinical and laboratory manifestations in patients with neonatal-onset multisystem inflammatory disease, with or without CIAS1 mutations.	NIAMSD, NIH, Bethesda, MD 20892 USA; NEI, NIH, Bethesda, MD 20892 USA; NIDCD, NIH, Bethesda, MD 20892 USA; NINDS, Ctr Clin, NIH, Bethesda, MD 20892 USA; NCI, NIH, Bethesda, MD 20892 USA; NIAID, NIH, Bethesda, MD 20892 USA; NIDDKD, NIH, Bethesda, MD 20892 USA; Univ N Carolina, Chapel Hill, NC USA; Univ Michigan, Ann Arbor, MI 48109 USA; St Louis Univ, St Louis, MO 63103 USA; Childrens Hosp, Boston, MA 02115 USA; Childrens Hosp, Los Angeles, CA 90027 USA; Univ Oklahoma Coll, Oklahoma City, OK USA; Univ Minnesota, Minneapolis, MN USA; Childrens Hosp & Reg Med Ctr, Seattle, WA USA; Univ Washington, Ctr Bone & Joint, Seattle, WA 98195 USA; SUNY Hosp, Syracuse, NY USA; Texas Childrens Hosp, Baylor Coll Med, Houston, TX 77030 USA; Watauga Med Ctr, Boone, NC USA; Adult & Pediat Rheumatol, San Antonio, TX USA; UCL Royal Free Univ Coll Med Sch, London, England	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of North Carolina; University of North Carolina Chapel Hill; University of Michigan System; University of Michigan; Saint Louis University; Harvard University; Boston Children's Hospital; Children's Hospital Los Angeles; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Minnesota System; University of Minnesota Twin Cities; Seattle Children's Hospital; University of Washington; University of Washington Seattle; State University of New York (SUNY) System; Baylor College of Medicine; University of London; University College London; UCL Medical School	Goldbach-Mansky, R (corresponding author), NIAMS, Bldg 10,Rm 9S-205,10 Ctr Dr, Bethesda, MD 20892 USA.	goldbacr@mail.nih.gov	Goldbach-Mansky, Raphaela/N-5917-2017; Butman, John/J-2780-2013; Aksentijevich, Ivona/AAF-1335-2019; Butman, John A/A-2694-2008; Hawkins, Philip N/C-5573-2008	Butman, John/0000-0002-1547-9195; Vehe, Richard/0000-0003-4679-8305; Paul, Scott/0000-0003-1274-6670; Canna, Scott/0000-0003-3837-5337; Dailey Garnes, Natalie/0000-0002-4016-4929	MRC [G7900510] Funding Source: UKRI; Intramural NIH HHS [ZIA AR041138-11] Funding Source: Medline; Medical Research Council [G7900510] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010688] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000647, Z01AI000646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041138, Z01AR041123] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [Z01DC000064] Funding Source: NIH RePORTER	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Aganna E, 2002, ARTHRITIS RHEUM-US, V46, P2445, DOI 10.1002/art.10509; AGANNA E, 2002, ARTHRITIS RHEUM, V46, P3398; Agostini L, 2004, IMMUNITY, V20, P319, DOI 10.1016/S1074-7613(04)00046-9; Aksentijevich I, 2002, ARTHRITIS RHEUM-US, V46, P3340, DOI 10.1002/art.10688; Anderson JP, 2004, GENE, V338, P25, DOI 10.1016/j.gene.2004.05.002; BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1, DOI 10.1152/ajpcell.1992.263.1.C1; BREDER CD, 1988, SCIENCE, V240, P321, DOI 10.1126/science.3258444; Brekenfeld C, 2001, INVEST RADIOL, V36, P266, DOI 10.1097/00004424-200105000-00004; Dinarello C A, 1998, Int Rev Immunol, V16, P457, DOI 10.3109/08830189809043005; Dinarello CA, 2005, J EXP MED, V201, P1355, DOI 10.1084/jem.20050640; Dowds TA, 2004, J BIOL CHEM, V279, P21924, DOI 10.1074/jbc.M401178200; Feldmann J, 2002, AM J HUM GENET, V71, P198, DOI 10.1086/341357; Frenkel J, 2004, ARTHRITIS RHEUM-US, V50, P3738, DOI 10.1002/art.20497; Frosch M., 2005, ROBBINS COTRAN PATHO, V7th, P1347; Granel B, 2005, RHEUMATOLOGY, V44, P689, DOI 10.1093/rheumatology/keh547; Grenier JM, 2002, FEBS LETT, V530, P73, DOI 10.1016/S0014-5793(02)03416-6; GRIPSHOVER NM, 2000, MANDELL DOUGLAS BENN, P998; Hawkins PN, 2004, ARTHRITIS RHEUM-US, V50, P607, DOI 10.1002/art.20033; Hawkins PN, 2003, NEW ENGL J MED, V348, P2583, DOI 10.1056/NEJM200306193482523; Hoffman HM, 2001, NAT GENET, V29, P301, DOI 10.1038/ng756; Hoffmann SC, 2002, TRANSPLANTATION, V74, P916, DOI 10.1097/00007890-200210150-00003; Kagiwada K, 2004, ENDOCRINOLOGY, V145, P5044, DOI 10.1210/en.2004-0054; Kanneganti TD, 2006, NATURE, V440, P233, DOI 10.1038/nature04517; Li S, 2001, BRAIN RES, V910, P163, DOI 10.1016/S0006-8993(01)02707-X; Lovell DJ, 2005, ARTHRITIS RHEUM-US, V52, P1283, DOI 10.1002/art.20953; Luheshi GN, 1998, ANN NY ACAD SCI, V856, P83, DOI 10.1111/j.1749-6632.1998.tb08316.x; Manji GA, 2002, J BIOL CHEM, V277, P11570, DOI 10.1074/jbc.M112208200; *NAT CTR BIOT INF, 2006, OMIM ONL MEND HER MA; O'Connor W, 2003, J IMMUNOL, V171, P6329, DOI 10.4049/jimmunol.171.12.6329; Prieur A M, 1987, Scand J Rheumatol Suppl, V66, P57; PRIEUR AM, 1981, J PEDIATR-US, V99, P79, DOI 10.1016/S0022-3476(81)80961-4; RUSSELL EJ, 1987, RADIOLOGY, V165, P609, DOI 10.1148/radiology.165.3.3317495; Stojanov S, 2005, CURR OPIN RHEUMATOL, V17, P586, DOI 10.1097/bor.0000174210.78449.6b; Vitkovic L, 2000, J NEUROCHEM, V74, P457, DOI 10.1046/j.1471-4159.2000.740457.x; Wang E, 2001, EXPERT OPIN BIOL TH, V1, P277, DOI 10.1517/14712598.1.2.277; WILKINS J, 1994, CLIN CHEM, V40, P1284; Yu JW, 2006, CELL DEATH DIFFER, V13, P236, DOI 10.1038/sj.cdd.4401734	37	656	693	0	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 10	2006	355	6					581	592		10.1056/NEJMoa055137	http://dx.doi.org/10.1056/NEJMoa055137			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	071QM	16899778	Green Published, Green Accepted			2022-12-28	WOS:000239616700008
J	Joseph, E; Yeni, P; Gathe, J; Estrada, V; DeJesus, E; Staszewski, S; Lackey, P; Katlama, C; Young, B; You, L; Sutherland-Phillips, D; Wannamaker, P; Vavro, C; Patel, L; Yeo, J; Shaefer, M				Eron, Joseph, Jr.; Yeni, Patrick; Gathe, Joseph, Jr.; Estrada, Vicente; DeJesus, Edwin; Staszewski, Schlamo; Lackey, Philip; Katlama, Christine; Young, Benjamin; You, Linda; Sutherland-Phillips, Denise; Wannamaker, Paul; Vavro, Cindy; Patel, Lisa; Yeo, Jane; Shaefer, Mark		KLEAN study team	The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial	LANCET			English	Article							SOCIETY-USA PANEL; NAIVE PATIENTS; TENOFOVIR DF; THERAPY; NELFINAVIR; RESISTANCE; AIDS; LOPINAVIR/RITONAVIR; RECOMMENDATIONS; EFAVIRENZ	Background Lopinavir-ritonavir is a preferred protease inhibitor co-formulation for initial HIV-1 treatment. Fosamprenavir-ritonavir has shown similar efficacy and safety to lopinavir-ritonavir when each is combined with two nucleoside reverse transcriptase inhibitors. We compared the two treatments directly in antiretroviral-naive patients. Methods This open-label, non-inferiority study included 878 antiretroviral-naive, HIV-1-infected patients randomised to receive either fosamprenavir-ritonavir 700 mg/100 mg twice daily or lopinavir-ritonavir 400 mg/100 mg twice daily, each with the co-formulation of abacavir-lamivudine 600 mg/300 mg once daily. Primary endpoints were proportion of patients achieving HIV-1 RNA less than 400 copies per mL at week 48 and treatment discontinuations because of an adverse event. The intent-to-treat analysis included all patients exposed to at least one dose of randomised study medication. This study is registered with ClinicalTrials.gov, number NCT00085943. Findings At week 48, non-inferiority of fosamprenavir-ritonavir to lopinavir-ritonavir (95% CI around the treatment difference -4.84 to 7.05) was shown, with 315 of 434 (73%) patients in the fosamprenavir-ritonavir group and 317 of 444 (71%) in the lopinavir-ritonavir group achieving HIV-1 RNA less than 400 copies per mL. Treatment discontinuations due to an adverse event were few and occurred with similar frequency in the two treatment groups (fosamprenavir-ritonavir 5 3, 12%; lopinavir-ritonavir 43, 10%). Diarrhoea, nausea, and abacavir hypersensitivity were the most frequent drug-related grade 2-4 adverse events. Treatment-emergent drug resistance was rare; no patient had virus that developed reduced susceptibility to fosamprenavir-ritonavir or lopinavir-ritonavir. Interpretation Fosamprenavir-ritonavir twice daily in treatment-naive patients provides similar antiviral efficacy, safety, tolerability, and emergence of resistance as lopinavir-ritonavir, each in combination with abacavir-lamivudine.	Univ N Carolina, Dept Med, Div Infect Dis, Chapel Hill, NC 27599 USA; Hop Bichat, F-75877 Paris, France; Therapeut Concepts PA, Houston, TX USA; Hosp Clin San Carlos, Madrid, Spain; Orlando Immunol Ctr, Orlando, FL USA; Hosp JW Goethe Univ, Frankfurt, Germany; ID Consultants PA, Charlotte, NC USA; Hop La Pitie Salpetriere, Paris, France; Rose Med Ctr, Denver, CO USA; GlaxoSmithKline Inc, Res Triangle Pk, NC USA; GlaxoSmithKline Inc, Greenford, Middx, England	University of North Carolina; University of North Carolina Chapel Hill; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Hospital Clinico San Carlos; Orlando Immunology Center; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; GlaxoSmithKline; GlaxoSmithKline	Joseph, E (corresponding author), Univ N Carolina, Dept Med, Div Infect Dis, Chapel Hill, NC 27599 USA.	joseph_eron@med.unc.edu	Estrada, Vicente/G-7518-2015	Estrada, Vicente/0000-0002-7795-5986; Shaefer, Mark/0000-0002-0545-7304				Bartlett JA, 2006, JAIDS-J ACQ IMM DEF, V41, P323; Crum NF, 2006, JAIDS-J ACQ IMM DEF, V41, P194, DOI 10.1097/01.qai.0000179459.31562.16; *DEP HLTH HUM SERV, 2006, GUID US ANT AG HIV 1; *DIV AIDS NIAID, 1992, DIV AIDS TABL GRAD S; Gallant JE, 2006, NEW ENGL J MED, V354, P251, DOI 10.1056/NEJMoa051871; Gallant JE, 2004, JAMA-J AM MED ASSOC, V292, P191, DOI 10.1001/jama.292.2.191; Gathe JC, 2004, AIDS, V18, P1529, DOI 10.1097/01.aids.0000131332.30548.92; Gunthard H, 2006, ANTIVIR THER, V11, pS82; Gulick RM, 2004, NEW ENGL J MED, V350, P1850, DOI 10.1056/NEJMoa031772; Hetherington S, 2001, CLIN THER, V23, P1603, DOI 10.1016/S0149-2918(01)80132-6; Hirsch MS, 2003, CLIN INFECT DIS, V37, P113, DOI 10.1086/375597; Johnson Victoria A, 2005, Top HIV Med, V13, P125; Kempf DJ, 2004, J INFECT DIS, V189, P51, DOI 10.1086/380509; King MS, 2004, J INFECT DIS, V190, P280, DOI 10.1086/422037; MacManus S, 2004, AIDS, V18, P651, DOI 10.1097/00002030-200403050-00009; Mocroft A, 2003, LANCET, V362, P22, DOI 10.1016/S0140-6736(03)13802-0; Walmsley S, 2002, NEW ENGL J MED, V346, P2039, DOI 10.1056/NEJMoa012354; Yeni PG, 2004, JAMA-J AM MED ASSOC, V292, P251, DOI 10.1001/jama.292.2.251	18	240	250	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 5	2006	368	9534					476	482						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	071AL	16890834				2022-12-28	WOS:000239569000030
J	Horton, R				Horton, Richard			A prescription for AIDS 2006-10	LANCET			English	Editorial Material							HIV/AIDS		The Lancet, London NW1 7BY, England		Horton, R (corresponding author), The Lancet, London NW1 7BY, England.							Gruber J, 2005, SOC SCI MED, V60, P1209, DOI 10.1016/j.socscimed.2004.06.053; Horton R, 2006, LANCET, V367, P3, DOI 10.1016/S0140-6736(06)67899-9; Manandhar DS, 2004, LANCET, V364, P970, DOI 10.1016/S0140-6736(04)17021-9; Morrow OI, 2004, AIDS BEHAV, V8, P365, DOI 10.1007/s10461-004-7321-6; Muturi NW, 2005, J HEALTH COMMUN, V10, P77, DOI 10.1080/10810730590904607; PICARD A, 2001, GLOBE MAIL      0815, pA1; PICARD A, 2006, GLOBE MAIL      0818, pA7; *UNICEF UNAIDS PEP, 2006, AFR ORPH VULN GEN; 2006, GLOBE MAIL      0817, pA14	9	8	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG-SEP	2006	368	9537					716	718		10.1016/S0140-6736(06)69266-0	http://dx.doi.org/10.1016/S0140-6736(06)69266-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	080ID	16935672				2022-12-28	WOS:000240240200010
J	Roumie, CL; Elasy, TA; Greevy, R; Griffin, MR; Liu, XL; Stone, WJ; Wallston, KA; Dittus, RS; Alvarez, V; Cobb, J; Speroff, T				Roumie, Christianne L.; Elasy, Tom A.; Greevy, Robert; Griffin, Marie R.; Liu, Xulei; Stone, William J.; Wallston, Kenneth A.; Dittus, Robert S.; Alvarez, Vincent; Cobb, Janice; Speroff, Theodore			Improving blood pressure control through provider education, provider alerts, and patient education - A cluster randomized trial	ANNALS OF INTERNAL MEDICINE			English	Article							CLINICAL-PRACTICE GUIDELINES; PRIMARY-CARE; CHRONIC ILLNESS; HYPERTENSIVE PATIENTS; PHARMACY RECORDS; UNITED-STATES; RISK; MANAGEMENT; PHYSICIANS; TRANSLATION	Background: Inadequate blood pressure control is a persistent gap in quality care. Objective: To evaluate provider and patient interventions to improve blood pressure control. Design: Cluster randomized, controlled trial. Setting: 2 hospital-based and 8 community-based clinics in the Veterans Affairs Tennessee Valley Healthcare System. Patients: 1341 veterans with essential hypertension cared for by 182 providers. Eligible patients had 2 or more blood pressure measurements greater than 140/90 mm Hg in a 6-month period and were taking a single antihypertensive agent. Intervention: Providers who cared for eligible patients were randomly assigned to receive an e-mail with a Web-based link to the Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7) guidelines (provider education); provider education and a patient-specific hypertension computerized alert (provider education and alert); or provider education, hypertension alert, and patient education, in which patients were sent a letter advocating drug adherence, lifestyle modification, and conversations with providers (patient education). Measurements: Proportion of patients with a systolic blood pressure less than 140 mm Hg at 6 months; intensification of antihypertensive medication. Results: Mean baseline blood pressure was 157/83 mm Hg with no differences between groups (P = 0.105). Six-month follow-up data were available for 975 patients (73%). Patients of providers who were randomly assigned to the patient education group had better blood pressure control (138/75 mm Hg) than those in the provider education and alert or provider education alone groups (146/76 mm Hg and 145/78 mm Hg, respectively). More patients in the patient education group had a systolic blood pressure of 140 mm Hg or less compared with those in the provider education or provider education and alert groups (adjusted relative risk for the patient education group compared with the provider education alone group, 1.31 [95% Cl, 1.06 to 1.62]; P = 0.012). Limitations: Follow-up blood pressure measurements were missing for 27% of study patients. The study could not detect a mechanism by which patient education improved blood pressure control. Conclusions: A multifactorial intervention including patient education improved blood pressure control compared with provider education alone.	Vanderbilt Univ, Tennessee Valley Healthcare Syst, Nashville, TN 37212 USA; Vet Adm Med Ctr, Nashville, TN 37203 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Roumie, CL (corresponding author), Vanderbilt Univ, Tennessee Valley Healthcare Syst, 1310 24th Ave S,GRECC 4A120, Nashville, TN 37212 USA.	christianne.roumie@vanderbilt.edu						American Heart Association, FACTS HIGH BLOOD PRE; Appel LJ, 2002, JAMA-J AM MED ASSOC, V288, P3039, DOI 10.1001/jama.288.23.3039; Austin PC, 2004, JAMA-J AM MED ASSOC, V291, P44, DOI 10.1001/jama.291.1.44-b; Benetos A, 2002, ARCH INTERN MED, V162, P577, DOI 10.1001/archinte.162.5.577; Benetos A, 2001, J AM COLL CARDIOL, V37, P163, DOI 10.1016/S0735-1097(00)01092-5; Berlowitz DR, 1998, NEW ENGL J MED, V339, P1957, DOI 10.1056/NEJM199812313392701; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1909, DOI 10.1001/jama.288.15.1909; Bodenheimer Thomas, 2003, Dis Manag, V6, P63, DOI 10.1089/109350703321908441; Bosworth HB, 2005, CONTEMP CLIN TRIALS, V26, P155, DOI 10.1016/j.cct.2004.12.006; Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; Carter Barry L, 2003, J Clin Hypertens (Greenwich), V5, P31, DOI 10.1111/j.1524-6175.2003.01460.x; Carter Barry L., 2000, J Clin Hypertens (Greenwich), V2, P172; Carter BL, 2003, ANN PHARMACOTHER, V37, P1335, DOI 10.1345/aph.1D094; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Cushman William C, 2002, J Clin Hypertens (Greenwich), V4, P393; Davis D, 2000, CAN MED ASSOC J, V163, P1278; Davis D, 2003, BMJ-BRIT MED J, V327, P33, DOI 10.1136/bmj.327.7405.33; Davis D, 1998, INT J PSYCHIAT MED, V28, P21, DOI 10.2190/UA3R-JX9W-MHR5-RC81; Davis D, 1996, J GEN INTERN MED, V11, P705, DOI 10.1007/BF02600164; Effects of treatment on morbidity in hypertension, 1970, JAMA-J AM MED ASSOC, V213, P1143, DOI DOI 10.1001/JAMA.213.7.1143; Godfrey Marjorie M, 2003, Jt Comm J Qual Saf, V29, P159; Goldstein MK, 2005, AM J MANAG CARE, V11, P677; Grimshaw Jeremy M, 2002, J Contin Educ Health Prof, V22, P237, DOI 10.1002/chp.1340220408; Hajjar I, 2003, JAMA-J AM MED ASSOC, V290, P199, DOI 10.1001/jama.290.2.199; Hibbard JH, 2003, MED CARE, V41, pI61; Hunt JS, 2004, J GEN INTERN MED, V19, P925, DOI 10.1111/j.1525-1497.2004.40046.x; Hyman David J., 2000, J Clin Hypertens (Greenwich), V2, P324; Hyman DJ, 2002, CLEV CLIN J MED, V69, P793, DOI 10.3949/ccjm.69.10.793; Hyman DJ, 2000, ARCH INTERN MED, V160, P2281, DOI 10.1001/archinte.160.15.2281; Institute of Medicine, 2001, CROSS QUAL CHASM, DOI [10.17226/10027, DOI 10.17226/10027]; Kannel WB, 1999, AM HEART J, V138, pS205, DOI 10.1016/S0002-8703(99)70311-X; KASSIRER JP, 1993, NEW ENGL J MED, V329, P1263, DOI 10.1056/NEJM199310213291710; LAHER M, 1981, BRIT MED J, V282, P1360, DOI 10.1136/bmj.282.6273.1360-a; Lloyd-Jones DM, 2000, HYPERTENSION, V36, P594, DOI 10.1161/01.HYP.36.4.594; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; MURRAY DM, 1988, AM J PREV MED, V4, P331, DOI 10.1016/S0749-3797(18)31142-5; Neal B, 2000, LANCET, V356, P1955; O'Connor P J, 1999, Jt Comm J Qual Improv, V25, P68; O'Connor PJ, 2003, ARCH INTERN MED, V163, P2677, DOI 10.1001/archinte.163.22.2677; Ogden LG, 2000, HYPERTENSION, V35, P539, DOI 10.1161/01.HYP.35.2.539; Onat A, 2003, CLIN CARDIOL, V26, P91, DOI 10.1002/clc.4960260209; Pastor-Barriuso R, 2003, ANN INTERN MED, V139, P731, DOI 10.7326/0003-4819-139-9-200311040-00007; Phillips LS, 2001, ANN INTERN MED, V135, P825, DOI 10.7326/0003-4819-135-9-200111060-00012; Renders CM, 2001, DIABETES CARE, V24, P1821, DOI 10.2337/diacare.24.10.1821; Rolnick SJ, 2002, AM J MANAG CARE, V8, P441; Rothman AA, 2003, ANN INTERN MED, V138, P256, DOI 10.7326/0003-4819-138-3-200302040-00034; Sennett C, 2000, Manag Care, V9, P2; SHAPIRO D, 1995, PSYCHOPHYSIOLOGY, V32, P425, DOI 10.1111/j.1469-8986.1995.tb02093.x; STAMLER J, 1993, ARCH INTERN MED, V153, P598, DOI 10.1001/archinte.153.5.598; STEINER JF, 1993, J GEN INTERN MED, V8, P306, DOI 10.1007/BF02600143; STEINER JF, 1988, MED CARE, V26, P814, DOI 10.1097/00005650-198808000-00007; Steiner JF, 1997, J CLIN EPIDEMIOL, V50, P105, DOI 10.1016/S0895-4356(96)00268-5; STGEORGE IM, 1983, J ROY COLL GEN PRACT, V33, P508; The AO, 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI DOI 10.1001/JAMA.288.23.2981; Wagner EH, 2001, HEALTH AFFAIR, V20, P64, DOI 10.1377/hlthaff.20.6.64; Wagner TH, 2001, J HEALTH ECON, V20, P1059, DOI 10.1016/S0167-6296(01)00107-2; WATKINS CJ, 1987, J ROY COLL GEN PRACT, V37, P548; Zillich Alan J, 2003, J Am Pharm Assoc (2003), V43, P561, DOI 10.1331/154434503322452184; 2004, AHRQ PUBLICATION	59	159	164	0	16	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	2006	145	3					165	175		10.7326/0003-4819-145-3-200608010-00004	http://dx.doi.org/10.7326/0003-4819-145-3-200608010-00004			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	070MN	16880458				2022-12-28	WOS:000239526800002
J	Diggle, L; Deeks, JJ; Pollard, AJ				Diggle, Linda; Deeks, Jonathan J.; Pollard, Andrew J.			Effect of needle size on immunogenicity and reactogenicity of vaccines in infants: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INJECTION; LENGTH; VACCINATION; MUSCLE	Objectives To assess the immunogenicity of vaccines for infants mid to investigate whether the incidence of reactogenicity is reduced after each immunisation dose using needles of varying lengths and gauges. Design Randomised controlled trial. Setting 18 general practices within two UK primary care trusts. Participants 696 healthy infants vaccinated at 2, 3, and 4 months of age, with follow-up to 5 months of age. Interventions Combined diphtheria, tetanus, whole cell pertussis, and Haemophilus influenzae type b vaccine and a serogroup C meningococcal glycoconjugate vaccine administered using either a wide, long needle (23 gauge/0.6 turn diameter, 25 mm), a narrow, short needle (25 gauge/0.5 mm diameter, 16 mm), or a narrow, long needle (25 gauge, 25 mm). Main outcome measures Local mid general reactions recorded by parents for three days after each dose; and diphtheria, tetanus, mid H influenzae type b antibody concentrations and functional antibody against serogroup C Neisseria meningitidis 28-42 days after the third dose. Results Local reactions to diphtheria, tetanus, whole cell pertussis, H influenzae type b vaccinations decreased significantly with wide, long needles compared with narrow, short needles. At all three doses one less infant experienced local reactions at days 1, 2, or 3 for every six to eight vaccinated. Significantly fewer infants vaccinated with the long needle experienced severe local reactions. Non-inferiority of the immune I response was shown using a wide, long needle rather than a narrow, short needle for serogroup C meningococcal glycoconjugate vaccine and for diphtheria but not for H influenzae type b or tetanus, although no evidence was found of a decrease. Little difference was found between needles of the same length but different gauges in local reaction or immune response. Conclusions Long (25 mm) needles for infant immunisations can significantly reduce vaccine reactogenicity at each dose while achieving comparable immunogenicity to that of short (16 mm) needles.	Univ Oxford, Churchill Hosp, Dept Paediat, Ctr Clin Vaccinol & Trop Med,Oxford Vaccine Grp, Oxford OX3 7LJ, England; Univ Birmingham, Dept Epidemiol & Publ Hlth, Birmingham B15 2TT, W Midlands, England	University of Oxford; University of Birmingham	Diggle, L (corresponding author), Univ Oxford, Churchill Hosp, Dept Paediat, Ctr Clin Vaccinol & Trop Med,Oxford Vaccine Grp, S Parks Rd, Oxford OX3 7LJ, England.	lindla.diggle@paediatrics.ox.ac.uk	Deeks, Jon/AAV-5745-2020	Deeks, Jon/0000-0002-8850-1971				BERNIER RH, 1981, AM J DIS CHILD, V135, P826, DOI 10.1001/archpedi.1981.02130330036011; *CHIEF MED OFF CHI, 2006, IMP CHANG CHILDH IMM; Davenport JM, 2004, J ADV NURS, V46, P66, DOI 10.1111/j.1365-2648.2003.02966.x; Diggle L, 2000, BRIT MED J, V321, P931, DOI 10.1136/bmj.321.7266.931; *GEN REG OFF SCOTL, 2004, EST POP BIRTHS STILL; *GOV STAT SERV, 2004, STAT B, V16, P1; Groswasser J, 1997, PEDIATRICS, V100, P400, DOI 10.1542/peds.100.3.400; HICK JF, 1989, PEDIATRICS, V84, P136; HMSO, 1996, IMM INF DIS; IPP MM, 1987, PEDIATR INFECT DIS J, V6, P721, DOI 10.1097/00006454-198708000-00005; Madore DV, 1999, CURR MED RES OPIN, V15, P105, DOI 10.1185/03007999909113370; Mark A, 1999, VACCINE, V17, P2067, DOI 10.1016/S0264-410X(98)00410-1; MAYONWHITE RT, 1997, IMMUNIZING CHILDREN; *N IRE STAT RES AG, 2004, BIRTHS DEATHS NO IR; *OFF NAT STAT, BIRTHS 2004 PROV SEL; Poirer MK, 1996, VACCINE, V14, P25, DOI 10.1016/0264-410X(95)00170-6; Ruben FL, 2001, CLIN INFECT DIS, V32, P170, DOI 10.1086/317553; SANDEN FLR, 1991, ARCH INTERN MED, V151, P821; Shakespeare TP, 2001, LANCET, V357, P1349, DOI 10.1016/S0140-6736(00)04522-0; SHAW FE, 1989, VACCINE, V7, P425, DOI 10.1016/0264-410X(89)90157-6; Watson M, 2001, BRIT MED J, V322, P492; Weir DM, 1997, IMMUNOLOGY, V8th; *WHO, WHOIVB0406; Zuckerman JN, 2000, BRIT MED J, V321, P1237, DOI 10.1136/bmj.321.7271.1237	24	54	58	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 16	2006	333	7568					571	574A		10.1136/bmj.38906.704549.7C	http://dx.doi.org/10.1136/bmj.38906.704549.7C			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	089KB	16891328	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000240878200013
J	Pellegrini, M; Celeste, A; Difilippantonio, S; Guo, R; Wang, WD; Feigenbaum, L; Nussenzweig, A				Pellegrini, Manuela; Celeste, Arkady; Difilippantonio, Simone; Guo, Rong; Wang, Weidong; Feigenbaum, Lionel; Nussenzweig, Andre			Autophosphorylation at serine 1987 is dispensable for murine Atm activation in vivo	NATURE			English	Article							TELANGIECTASIA MUTATED ATM; DOUBLE-STRAND BREAKS; DNA-DAMAGE; MRE11-RAD50-NBS1 COMPLEX; CHECKPOINT; KINASE; SITES; CELLS; NBS1; PHOSPHORYLATION	The ATM ( ataxia telangiectasia mutated) protein kinase is activated under physiological and pathological conditions that induce DNA double-strand breaks (DSBs). Loss of ATM or failure of its activation in humans and mice lead to defective cellular responses to DSBs, such as cell cycle checkpoints, radiation sensitivity, immune dysfunction, infertility and cancer predisposition. A widely used biological marker to identify the active form of ATM is the autophosphorylation of ATM at a single, conserved serine residue (Ser 1981 in humans; Ser 1987 in mouse)(1). Here we show that Atm-dependent responses are functional at the organismal and cellular level in mice that express a mutant form of Atm ( mutation of Ser to Ala at position 1987) as their sole Atm species. Moreover, the mutant protein does not exhibit dominant-negative interfering activity when expressed physiologically or overexpressed in the context of Atm heterozygous mice. These results suggest an alternative mode for stimulation of Atm by DSBs in which Atm autophosphorylation at Ser 1987, like transphosphorylation of downstream substrates, is a consequence rather than a cause of Atm activation.	NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA; NIA, Genet Lab, NIH, Baltimore, MD 21224 USA; NCI, SAIC Frederick, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Nussenzweig, A (corresponding author), NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA.	andre_nussenzweig@nih.gov	Wang, Weidong/AAV-2446-2021; Pellegrini, manuela/AAC-1423-2022	Wang, Weidong/0000-0002-0658-7928; pellegrini, manuela/0000-0001-6387-5187	Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010283, Z01BC009255, ZICBC009255, ZIABC010283] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [ZIAAG000688, Z01AG000688, Z01AG000657, ZIAAG000657] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ali A, 2004, GENE DEV, V18, P249, DOI 10.1101/gad.1176004; Andegeko Y, 2001, J BIOL CHEM, V276, P38224; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Bartkova J, 2005, CELL CYCLE, V4, P838, DOI 10.4161/cc.4.6.1742; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; Cerosaletti K, 2004, J BIOL CHEM, V279, P38813, DOI 10.1074/jbc.M404294200; Cerosaletti K, 2006, MOL CELL BIOL, V26, P1691, DOI 10.1128/MCB.26.5.1691-1699.2006; Costanzo V, 2004, PLOS BIOL, V2, P600, DOI 10.1371/journal.pbio.0020110; Difilippantonio S, 2005, NAT CELL BIOL, V7, P675, DOI 10.1038/ncb1270; Dupre A, 2006, NAT STRUCT MOL BIOL, V13, P451, DOI 10.1038/nsmb1090; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Goldstine JV, 2006, DNA REPAIR, V5, P432, DOI 10.1016/j.dnarep.2005.12.002; Goodarzi AA, 2004, DNA REPAIR, V3, P753, DOI 10.1016/j.dnarep.2004.03.041; Gupta A, 2005, MOL CELL BIOL, V25, P5292, DOI 10.1128/MCB.25.12.5292-5305.2005; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Horejsi Z, 2004, ONCOGENE, V23, P3122, DOI 10.1038/sj.onc.1207447; Kitagawa R, 2004, GENE DEV, V18, P1423, DOI 10.1101/gad.1200304; Kozlov S, 2003, J BIOL CHEM, V278, P9309, DOI 10.1074/jbc.M300003200; Kruhlak MJ, 2006, J CELL BIOL, V172, P823, DOI 10.1083/jcb.200510015; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Liu QH, 2000, GENE DEV, V14, P1448; Mochan TA, 2003, CANCER RES, V63, P8586; Ramiro AR, 2006, NATURE, V440, P105, DOI 10.1038/nature04495; Sun YL, 2005, P NATL ACAD SCI USA, V102, P13182, DOI 10.1073/pnas.0504211102; Takai H, 2000, GENE DEV, V14, P1439; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Yang YP, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng080; You ZS, 2005, MOL CELL BIOL, V25, P5363, DOI 10.1128/MCB.25.13.5363-5379.2005; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060	30	152	153	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 14	2006	443	7108					222	225		10.1038/nature05112	http://dx.doi.org/10.1038/nature05112			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	083OB	16906133				2022-12-28	WOS:000240467000049
J	Schwarzenbach, RP; Escher, BI; Fenner, K; Hofstetter, TB; Johnson, CA; von Gunten, U; Wehrli, B				Schwarzenbach, Rene P.; Escher, Beate I.; Fenner, Kathrin; Hofstetter, Thomas B.; Johnson, C. Annette; von Gunten, Urs; Wehrli, Bernhard			The challenge of micropollutants in aquatic systems	SCIENCE			English	Review							SURFACE WATERS; WASTE-WATER; RISK-ASSESSMENT; HUMAN HEALTH; ENVIRONMENT; ECOTOXICOLOGY; CONTAMINANTS; PHARMACEUTICALS; TRANSFORMATION; OXIDATION	The increasing worldwide contamination of freshwater systems with thousands of industrial and natural chemical compounds is one of the key environmental problems facing humanity. Although most of these compounds are present at low concentrations, many of them raise considerable toxicological concerns, particularly when present as components of complex mixtures. Here we review three scientific challenges in addressing water-quality problems caused by such micropollutants. First, tools to assess the impact of these pollutants on aquatic life and human health must be further developed and refined. Second, cost-effective and appropriate remediation and water-treatment technologies must be explored and implemented. Third, usage and disposal strategies, coupled with the search for environmentally more benign products and processes, should aim to minimize introduction of critical pollutants into the aquatic environment.	Swiss Fed Aquat Sci & Technol, Eawag, CH-8600 Dubendorf, Switzerland; ETH, Inst Biogeochem & Pollutant Dynam, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; Swiss Federal Institute of Aquatic Science & Technology (EAWAG); Swiss Federal Institutes of Technology Domain; ETH Zurich	Schwarzenbach, RP (corresponding author), Swiss Fed Aquat Sci & Technol, Eawag, CH-8600 Dubendorf, Switzerland.	rene.schwarzenbach@env.ethz.ch	von Gunten, Urs/O-1637-2013; Escher, Beate Isabella/ABE-8070-2020; Wehrli, Bernhard/A-4406-2013; Wehrli, Bernhard/B-4420-2008; Escher, Beate I/C-7992-2009; Wehrli, Bernhard/M-3847-2019; Hofstetter, Thomas/A-6262-2008	von Gunten, Urs/0000-0001-6852-8977; Escher, Beate Isabella/0000-0002-5304-706X; Wehrli, Bernhard/0000-0001-7029-1972; Wehrli, Bernhard/0000-0001-7029-1972; Escher, Beate I/0000-0002-5304-706X; Wehrli, Bernhard/0000-0001-7029-1972; Hofstetter, Thomas/0000-0003-1906-367X				AHEL M, 1994, WATER RES, V28, P1131, DOI 10.1016/0043-1354(94)90200-3; Altenburger R, 2004, ENVIRON SCI TECHNOL, V38, P6353, DOI 10.1021/es049528k; Aronson D, 2006, CHEMOSPHERE, V63, P1953, DOI 10.1016/j.chemosphere.2005.09.044; Berg M, 2001, ENVIRON SCI TECHNOL, V35, P2621, DOI 10.1021/es010027y; Bignert A, 1998, ENVIRON POLLUT, V99, P177, DOI 10.1016/S0269-7491(97)00191-7; Boxall ABA, 2004, ENVIRON SCI TECHNOL, V38, p368A, DOI 10.1021/es040624v; Brian JV, 2005, ENVIRON HEALTH PERSP, V113, P721, DOI 10.1289/ehp.7598; Chevre N, 2006, ENVIRON SCI TECHNOL, V40, P426, DOI 10.1021/es050239l; Daughton CG, 1999, ENVIRON HEALTH PERSP, V107, P907, DOI 10.2307/3434573; *ECETOC, 1999, 990317 ECETOC; Eggen RIL, 2003, PURE APPL CHEM, V75, P2445, DOI 10.1351/pac200375112445; Elsner M, 2005, ENVIRON SCI TECHNOL, V39, P6896, DOI 10.1021/es0504587; Eriksson P, 2001, ENVIRON HEALTH PERSP, V109, P903, DOI 10.2307/3454990; Escher BI, 2004, ENVIRON SCI TECHNOL, V38, p455A, DOI 10.1021/es0406740; Escher BI, 2002, ENVIRON SCI TECHNOL, V36, P4201, DOI 10.1021/es015848h; Fenner K, 2005, ENVIRON SCI TECHNOL, V39, P1932, DOI 10.1021/es048917b; Geyer H, 2000, HDB ENV CHEM, V2-J, P1; Goss KU, 2004, CRIT REV ENV SCI TEC, V34, P339, DOI 10.1080/10643380490443263; Hermens JLM, 2004, ENVIRON SCI TECHNOL, V38, p446A, DOI 10.1021/es040672f; Heugens EHW, 2001, CRIT REV TOXICOL, V31, P247, DOI 10.1080/20014091111695; Hladik ML, 2005, ENVIRON SCI TECHNOL, V39, P6561, DOI 10.1021/es050268w; Huber MM, 2005, ENVIRON SCI TECHNOL, V39, P4290, DOI 10.1021/es048396s; Hug SJ, 2001, ENVIRON SCI TECHNOL, V35, P2114, DOI 10.1021/es001551s; IWATA H, 1994, ENVIRON POLLUT, V85, P15, DOI 10.1016/0269-7491(94)90234-8; Jackson RB, 2001, ECOL APPL, V11, P1027, DOI 10.1890/1051-0761(2001)011[1027:WIACW]2.0.CO;2; Jobling S, 1998, ENVIRON SCI TECHNOL, V32, P2498, DOI 10.1021/es9710870; Joss A, 2005, WATER RES, V39, P4585, DOI 10.1016/j.watres.2005.09.011; Kester MHA, 2000, ENDOCRINOLOGY, V141, P1897, DOI 10.1210/en.141.5.1897; Kolpin DW, 2002, ENVIRON SCI TECHNOL, V36, P1202, DOI 10.1021/es011055j; Lettieri T, 2006, ENVIRON HEALTH PERSP, V114, P4, DOI 10.1289/ehp.8194; Leu C, 2004, ENVIRON SCI TECHNOL, V38, P3835, DOI 10.1021/es0499593; Lindstrom A, 2002, ENVIRON SCI TECHNOL, V36, P2322, DOI 10.1021/es0114254; MacDonald RW, 2000, SCI TOTAL ENVIRON, V254, P93, DOI 10.1016/S0048-9697(00)00434-4; Major DW, 2002, ENVIRON SCI TECHNOL, V36, P5106, DOI 10.1021/es0255711; Martin JW, 2004, ENVIRON SCI TECHNOL, V38, P5379, DOI 10.1021/es049331s; MCCARTY LS, 1993, ENVIRON SCI TECHNOL, V27, P1719, DOI 10.1021/es00046a001; McDonough W, 2003, ENVIRON SCI TECHNOL, V37, p434A, DOI 10.1021/es0326322; MCGINN AP, 2002, STATE WORLD 2002; Mengis M, 1997, LIMNOL OCEANOGR, V42, P1530, DOI 10.4319/lo.1997.42.7.1530; Miracle AL, 2005, REPROD TOXICOL, V19, P321, DOI 10.1016/j.reprotox.2004.06.007; Nghiem LD, 2005, ENVIRON SCI TECHNOL, V39, P7698, DOI 10.1021/es0507665; NRIAGU JO, 1988, NATURE, V333, P134, DOI 10.1038/333134a0; O'Hannesin SF, 1998, GROUND WATER, V36, P164, DOI 10.1111/j.1745-6584.1998.tb01077.x; Ohe T, 2004, MUTAT RES-REV MUTAT, V567, P109, DOI 10.1016/j.mrrev.2004.08.003; Pombo SA, 2005, FEMS MICROBIOL ECOL, V51, P197, DOI 10.1016/j.femsec.2004.08.010; Rand G.M., 1995, FUNDAMENTALS AQUATIC; Richardson SD, 2002, ENVIRON SCI TECHNOL, V36, p198A, DOI 10.1021/es022308r; Rieger PG, 2002, J BIOTECHNOL, V94, P101, DOI 10.1016/S0168-1656(01)00422-9; Schwarzenbach R.P., 2016, ENV ORGANIC CHEM, DOI 10.1002/0471649643; Smedley PL, 2002, APPL GEOCHEM, V17, P517, DOI 10.1016/S0883-2927(02)00018-5; Solomon KR, 1996, ENVIRON TOXICOL CHEM, V15, P31, DOI [10.1897/1551-5028(1996)015&lt;0031:ERAOAI&gt;2.3.CO;2, 10.1002/etc.5620150105]; Su CM, 2001, ENVIRON SCI TECHNOL, V35, P1487, DOI 10.1021/es001607i; Svrcek C, 2004, J ENVIRON ENG SCI, V3, P155, DOI 10.1139/S04-010; Tanabe S, 1999, MAR POLLUT BULL, V39, P62, DOI 10.1016/S0025-326X(99)00064-8; Turner RE, 2003, BIOGEOCHEMISTRY, V64, P297, DOI 10.1023/A:1024960007569; *UN ED SCI CULT OR, 2003, WAT PEOPL WAT LIF; Van Straalen N, 2003, ENVIRON SCI TECHNOL, V37, p324A; von Gunten U, 2003, WATER RES, V37, P1443, DOI 10.1016/S0043-1354(02)00457-8; Waichman AV, 2002, ENVIRON SCI POLLUT R, V9, P423, DOI 10.1007/BF02987596; WHO, 2004, WHO GUIDELINES DRINK, V3th; Wiesner MR, 2006, ENVIRON SCI TECHNOL, V40, P4336, DOI 10.1021/es062726m	61	2335	2415	88	1983	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 25	2006	313	5790					1072	1077		10.1126/science.1127291	http://dx.doi.org/10.1126/science.1127291			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	076ZT	16931750				2022-12-28	WOS:000239998200032
J	Shin, K; Margolis, B				Shin, Kunyoo; Margolis, Ben			ZOning out tight junctions	CELL			English	Editorial Material									Univ Michigan, Sch Med, Dept Internal Med & Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Margolis, B (corresponding author), Univ Michigan, Sch Med, Dept Internal Med & Biol Chem, Ann Arbor, MI 48109 USA.	bmargoli@umich.edu		Shin, Kunyoo/0000-0002-1519-9839				Furuse M, 1998, J CELL BIOL, V143, P391, DOI 10.1083/jcb.143.2.391; Knust E, 2002, SCIENCE, V298, P1955, DOI 10.1126/science.1072161; Macara IG, 2004, NAT REV MOL CELL BIO, V5, P220, DOI 10.1038/nrm1332; McNeil E, 2006, MOL BIOL CELL, V17, P1922, DOI 10.1091/mbc.E05-07-0650; O'Brien LE, 2002, NAT REV MOL CELL BIO, V3, P531, DOI 10.1038/nrm859; Schneeberger EE, 2004, AM J PHYSIOL-CELL PH, V286, pC1213, DOI 10.1152/ajpcell.00558.2003; Shin K, 2006, ANNU REV CELL DEV BI, V22, P207, DOI 10.1146/annurev.cellbio.22.010305.104219; Stevenson BR, 1998, ANNU REV CELL DEV BI, V14, P89, DOI 10.1146/annurev.cellbio.14.1.89; Umeda K, 2004, J BIOL CHEM, V279, P44785, DOI 10.1074/jbc.M406563200; UMEDA K, 2006, CELL	10	26	27	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 25	2006	126	4					647	649		10.1016/j.cell.2006.08.005	http://dx.doi.org/10.1016/j.cell.2006.08.005			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	080VN	16923383	Bronze			2022-12-28	WOS:000240276700011
J	Takahashi, K; Yamanaka, S				Takahashi, Kazutoshi; Yamanaka, Shinya			Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors	CELL			English	Article							TRANSCRIPTION FACTOR KLF4; SELF-RENEWAL; C-MYC; SOMATIC-CELLS; ES CELLS; TUMOR-SUPPRESSOR; BETA-CATENIN; DIFFERENTIATION; EXPRESSION; NANOG	Differentiated cells can be reprogrammed to an embryonic-like state by transfer of nuclear contents into oocytes or by fusion with embryonic stem (ES) cells. Little is known about factors that induce this reprogramming. Here, we demonstrate induction of pluripotent stem cells from mouse embryonic or adult fibroblasts by introducing four factors, Oct3/4, Sox2, c-Myc, and Klf4, under ES cell culture conditions. Unexpectedly, Nanog was dispensable. These cells, which we designated iPS (induced pluripotent stem) cells, exhibit the morphology and growth properties of ES cells and express ES cell marker genes. Subcutaneous transplantation of iPS cells into nude mice resulted in tumors containing a variety of tissues from all three germ layers. Following injection into blastocysts, iPS cells contributed to mouse embryonic development. These data demonstrate that pluripotent stem cells can be directly generated from fibroblast cultures by the addition of only a few defined factors.	Kyoto Univ, Dept Stem Cell Biol, Inst Frontier Med Sci, Kyoto 6068507, Japan; Japan Sci & Technol Agcy, CREST, Kawaguchi 3320012, Japan	Kyoto University; Japan Science & Technology Agency (JST)	Yamanaka, S (corresponding author), Kyoto Univ, Dept Stem Cell Biol, Inst Frontier Med Sci, Kyoto 6068507, Japan.	yamanaka@frontier.kyoto-u.ac.jp	Wilson, Matthew H/K-3193-2013; Takahashi, Kazutoshi/ABE-5504-2020; Jeong, Wonjun/AAM-5937-2020	Takahashi, Kazutoshi/0000-0002-5329-8395; 				Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Baudino TA, 2002, GENE DEV, V16, P2530, DOI 10.1101/gad.1024602; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Burdon T, 1999, DEV BIOL, V210, P30, DOI 10.1006/dbio.1999.9265; Cartwright P, 2005, DEVELOPMENT, V132, P885, DOI 10.1242/dev.01670; Cawley S, 2004, CELL, V116, P499, DOI 10.1016/S0092-8674(04)00127-8; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Chang DW, 2000, MOL CELL BIOL, V20, P4309, DOI 10.1128/MCB.20.12.4309-4319.2000; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; Cowan CA, 2005, SCIENCE, V309, P1369, DOI 10.1126/science.1116447; Do JT, 2004, STEM CELLS, V22, P941, DOI 10.1634/stemcells.22-6-941; Domashenko AD, 1997, MOL REPROD DEV, V47, P57, DOI 10.1002/(SICI)1098-2795(199705)47:1&lt;57::AID-MRD8&gt;3.0.CO;2-P; Dyce PW, 2004, BIOCHEM BIOPH RES CO, V316, P651, DOI 10.1016/j.bbrc.2004.02.093; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Katz JP, 2002, DEVELOPMENT, V129, P2619; Kielman MF, 2002, NAT GENET, V32, P594, DOI 10.1038/ng1045; Li Y, 2005, BLOOD, V105, P635, DOI 10.1182/blood-2004-07-2681; Lin TX, 2005, NAT CELL BIOL, V7, P165, DOI 10.1038/ncb1211; Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; Maruyama M, 2005, J BIOL CHEM, V280, P24371, DOI 10.1074/jbc.M501423200; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Meiner VL, 1996, P NATL ACAD SCI USA, V93, P14041, DOI 10.1073/pnas.93.24.14041; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Miyamoto Y, 2004, J BIOL CHEM, V279, P34336, DOI 10.1074/jbc.M402767200; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Rowland BD, 2005, NAT CELL BIOL, V7, P1074, DOI 10.1038/ncb1314; Sadot E, 2002, J CELL SCI, V115, P2771; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Tada M, 2001, CURR BIOL, V11, P1553, DOI 10.1016/S0960-9822(01)00459-6; Takahashi K, 2003, NATURE, V423, P541, DOI 10.1038/nature01646; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Tokuzawa Y, 2003, MOL CELL BIOL, V23, P2699, DOI 10.1128/MCB.23.8.2699-2708.2003; Toma JG, 2001, NAT CELL BIOL, V3, P778, DOI 10.1038/ncb0901-778; Toma JG, 2005, STEM CELLS, V23, P727, DOI 10.1634/stemcells.2004-0134; Vervoorts J, 2003, EMBO REP, V4, P484, DOI 10.1038/sj.embor.embor821; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Yao SY, 2004, MOL THER, V10, P27, DOI 10.1016/j.ymthe.2004.04.007; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	50	16978	18833	336	8630	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	AUG 25	2006	126	4					663	676		10.1016/j.cell.2006.07.024	http://dx.doi.org/10.1016/j.cell.2006.07.024			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	080VN	16904174	Bronze, Green Published			2022-12-28	WOS:000240276700016
J	Yang, XY; Downes, M; Yu, RT; Bookout, AL; He, WM; Straume, M; Mangelsdorf, DJ; Evans, RM				Yang, Xiaoyong; Downes, Michael; Yu, Ruth T.; Bookout, Angie L.; He, Weimin; Straume, Marty; Mangelsdorf, David J.; Evans, Ronald M.			Nuclear receptor expression links the circadian clock to metabolism	CELL			English	Article							REV-ERB-ALPHA; GENE-EXPRESSION; ROR-ALPHA; MICE LACKING; RESPONSE ELEMENT; LIPID-METABOLISM; PPAR-ALPHA; FAT MASS; TRANSCRIPTION; MOUSE	As sensors for fat-soluble hormones and dietary lipids, oscillations in nuclear receptor (NR) expression in key metabolic tissues may contribute to circadian entrainment of nutrient and energy metabolism. Surveying the diurnal expression profiles of all 49 mouse nuclear receptors in white and brown adipose tissue, liver, and skeletal muscle revealed that of the 45 NRs expressed, 25 are in a rhythmic cycle and 3 exhibit a single transient pulse of expression 4 hr into the light cycle. While thyroid hormones are generally constant, we find that TR alpha and beta dramatically cycle, suggesting that fundamental concepts such as "basal metabolism" may require reexamination. The dynamic but coordinated changes in nuclear receptor expression, along with their key target genes, offers a logical explanation for known cyclic behavior of lipid and glucose metabolism and suggests novel roles for endocrine and orphan receptors in coupling the peripheral circadian clock to divergent metabolic outputs.	Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Pharmacol, Dallas, TX 75390 USA; Texas A&M Univ, System Hlth Sci Ctr, Inst Biosci & Technol, Houston, TX 77030 USA; Univ Virginia, Ctr Biomath Technol, Charlottesville, VA 22904 USA	Salk Institute; Howard Hughes Medical Institute; Salk Institute; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Texas A&M University System; University of Virginia	Evans, RM (corresponding author), Salk Inst Biol Studies, Gene Express Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	evans@salk.edu	Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965; Mangelsdorf, David/0000-0002-4355-0796; Yu, Ruth/0000-0002-9527-9627	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U19DK062434] Funding Source: NIH RePORTER; NIDDK NIH HHS [U19DK62434-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akashi M, 2005, NAT STRUCT MOL BIOL, V12, P441, DOI 10.1038/nsmb925; Boethel CD, 2002, CURR OPIN PULM MED, V8, P502, DOI 10.1097/00063198-200211000-00003; Bois-Joyeux B, 2000, DNA CELL BIOL, V19, P589, DOI 10.1089/104454900750019344; CALNAN BJ, 1995, IMMUNITY, V3, P273; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Delerive P, 2002, J BIOL CHEM, V277, P35013, DOI 10.1074/jbc.M202979200; DeYoung RA, 2003, J BIOL CHEM, V278, P47104, DOI 10.1074/jbc.M307496200; DUMAS B, 1994, MOL ENDOCRINOL, V8, P996, DOI 10.1210/me.8.8.996; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Dussault I, 1997, MOL CELL BIOL, V17, P1860, DOI 10.1128/MCB.17.4.1860; Evans RM, 2004, NAT MED, V10, P355, DOI 10.1038/nm1025; FORMAN BM, 1994, MOL ENDOCRINOL, V8, P1253, DOI 10.1210/me.8.9.1253; Giguere V, 2002, TRENDS ENDOCRIN MET, V13, P220, DOI 10.1016/S1043-2760(02)00592-1; He WM, 2003, P NATL ACAD SCI USA, V100, P15712, DOI 10.1073/pnas.2536828100; Hong H, 1999, J BIOL CHEM, V274, P22618, DOI 10.1074/jbc.274.32.22618; Horard B, 2004, J MOL ENDOCRINOL, V33, P87, DOI 10.1677/jme.0.0330087; Horard B, 2003, J MOL ENDOCRINOL, V31, P349, DOI 10.1677/jme.0.0310349; Inoue I, 2005, J ATHEROSCLER THROMB, V12, P169, DOI 10.5551/jat.12.169; Kamei Y, 2003, P NATL ACAD SCI USA, V100, P12378, DOI 10.1073/pnas.2135217100; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; King DP, 2000, ANNU REV NEUROSCI, V23, P713, DOI 10.1146/annurev.neuro.23.1.713; Lee CH, 2003, ENDOCRINOLOGY, V144, P2201, DOI 10.1210/en.2003-0288; LEE SL, 1995, SCIENCE, V269, P532, DOI 10.1126/science.7624775; Lemberger T, 1996, J BIOL CHEM, V271, P1764, DOI 10.1074/jbc.271.3.1764; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; Luo JM, 2003, MOL CELL BIOL, V23, P7947, DOI 10.1128/MCB.23.22.7947-7956.2003; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Mootha VK, 2004, P NATL ACAD SCI USA, V101, P6570, DOI 10.1073/pnas.0401401101; Oishi K, 2005, BIOCHEM J, V386, P575, DOI 10.1042/BJ20041150; Okamura H, 1999, SCIENCE, V286, P2531, DOI 10.1126/science.286.5449.2531; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; Picard F, 2002, CELL, V111, P931, DOI 10.1016/S0092-8674(02)01169-8; Preitner N, 2002, CELL, V110, P251, DOI 10.1016/S0092-8674(02)00825-5; Raspe E, 2002, J BIOL CHEM, V277, P49275, DOI 10.1074/jbc.M206215200; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; RETNAKARAN R, 1994, MOL ENDOCRINOL, V8, P1234, DOI 10.1210/me.8.9.1234; Sato TK, 2004, NEURON, V43, P527, DOI 10.1016/j.neuron.2004.07.018; Schibler U, 2002, CELL, V111, P919, DOI 10.1016/S0092-8674(02)01225-4; Seo JB, 2004, J BIOL CHEM, V279, P22108, DOI 10.1074/jbc.M400238200; Storch KF, 2002, NATURE, V417, P78, DOI 10.1038/nature744; Straume M, 2004, METHOD ENZYMOL, V383, P149; Tiraby C, 2003, TRENDS ENDOCRIN MET, V14, P439, DOI 10.1016/j.tem.2003.10.001; Triqueneaux G, 2004, J MOL ENDOCRINOL, V33, P585, DOI 10.1677/jme.1.01554; Turek FW, 2005, SCIENCE, V308, P1043, DOI 10.1126/science.1108750; Ueda HR, 2002, NATURE, V418, P534, DOI 10.1038/nature00906; Xie W, 1999, MOL ENDOCRINOL, V13, P2151, DOI 10.1210/me.13.12.2151; Zambon AC, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r61; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248	49	730	753	6	84	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 25	2006	126	4					801	810		10.1016/j.cell.2006.06.050	http://dx.doi.org/10.1016/j.cell.2006.06.050			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	080VN	16923398	Bronze			2022-12-28	WOS:000240276700027
J	Margolis, TP; Whitcher, JP				Margolis, Todd P.; Whitcher, John P.			Fusarium - A new culprit in the contact lens case	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CORNEAL ULCERATION; ETIOLOGIC DIAGNOSIS; SOUTH FLORIDA; KERATITIS; WEAR; SPECTRUM; OUTBREAK; NEPAL		Univ Calif San Francisco, Francis I Proctor Fdn, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Margolis, TP (corresponding author), Univ Calif San Francisco, Francis I Proctor Fdn, Med Sci Bldg,S-310,513 Parnassus Ave,Box 0412, San Francisco, CA 94143 USA.	todd.margolis@ucsf.edu			NATIONAL EYE INSTITUTE [R01EY010008, P30EY002162] Funding Source: NIH RePORTER; NEI NIH HHS [EY10008, EY02162] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALFONSO E, 1986, AM J OPHTHALMOL, V101, P429, DOI 10.1016/0002-9394(86)90641-0; Alfonso EC, 2006, ARCH OPHTHALMOL-CHIC, V124, P941, DOI 10.1001/archopht.124.7.ecs60039; Bernal MD, 2006, ARCH OPHTHALMOL-CHIC, V124, P1051, DOI 10.1001/archopht.124.7.ecr60006; Chang DC, 2006, JAMA-J AM MED ASSOC, V296, P953, DOI 10.1001/jama.296.8.953; ERIE JC, 1993, ARCH OPHTHALMOL-CHIC, V111, P1665, DOI 10.1001/archopht.1993.01090120087027; Gonzales C A, 1996, Ophthalmic Epidemiol, V3, P159, DOI 10.3109/09286589609080122; HAGAN M, 1995, BRIT J OPHTHALMOL, V79, P1024, DOI 10.1136/bjo.79.11.1024; Khor WB, 2006, JAMA-J AM MED ASSOC, V295, P2867, DOI 10.1001/jama.295.24.2867; LIESEGANG TJ, 1980, AM J OPHTHALMOL, V90, P38, DOI 10.1016/S0002-9394(14)75075-5; RAPUANAO CJ, 2005, BACTERIAL KERATITIS, P11; *REG OFF SE AS, 2004, GUID MAN CORN ULC PR, P1; ROSA RH, 1994, OPHTHALMOLOGY, V101, P1005; *SING HLTH MIN HLT, 2006, INCR INC CONT LENS R; Srinivasan M, 1997, BRIT J OPHTHALMOL, V81, P965, DOI 10.1136/bjo.81.11.965; Upadhyay MP, 2001, BRIT J OPHTHALMOL, V85, P388, DOI 10.1136/bjo.85.4.388; UPADHYAY MP, 1991, AM J OPHTHALMOL, V111, P92, DOI 10.1016/S0002-9394(14)76903-X; Whitcher JP, 1997, BRIT J OPHTHALMOL, V81, P622, DOI 10.1136/bjo.81.8.622; 2006, MMWR MORB MORTAL WKL, V55, P400; 2006, FUSARIUM KERATITIS U	19	16	16	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 23	2006	296	8					985	987		10.1001/jama.296.8.985	http://dx.doi.org/10.1001/jama.296.8.985			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	076AL	16929565				2022-12-28	WOS:000239929300028
J	Barcelo, A				Barcelo, Alberto			Cardiovascular diseases in Latin America and the Caribbean	LANCET			English	Editorial Material									Pan Amer Hlth Org, Unit Non Communicable Dis, Washington, DC 20037 USA	Pan American Health Organization	Barcelo, A (corresponding author), Pan Amer Hlth Org, Unit Non Communicable Dis, Washington, DC 20037 USA.	barceloa@paho.org		BARCELO, ALBERTO/0000-0002-5258-6299				[Anonymous], 1996, GLOBAL BURDEN DIS CO; Arredondo A, 2005, PUBLIC HEALTH, V119, P711, DOI 10.1016/j.puhe.2005.01.009; Hennis A, 2002, J HYPERTENS, V20, P2363, DOI 10.1097/00004872-200212000-00014; Menendez J, 2005, REV PANAM SALUD PUBL, V17, P353; PERALTA MR, 2005, ARCH CARDIOL MEX, V75, P96; *SECR SAL MEX, 1996, ENC NAC ENF CRON; VELAZQUEZMONROY O, 2003, ARCH CARDIOL MEX, V73, P62; World Health Organization, 2004, GLOB STRAT DIET PHYS; Yach D, 2004, JAMA-J AM MED ASSOC, V291, P2616, DOI 10.1001/jama.291.21.2616	9	29	30	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 19	2006	368	9536					625	626		10.1016/S0140-6736(06)69223-4	http://dx.doi.org/10.1016/S0140-6736(06)69223-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	074YT	16920450				2022-12-28	WOS:000239849200007
J	Swindells, S; DiRienzo, AG; Wilkin, T; Fletcher, CV; Margolis, DM; Thal, GD; Godfrey, C; Bastow, B; Ray, MG; Wang, HY; Coombs, RW; McKinnon, J; Mellors, JW				Swindells, Susan; DiRienzo, A. Gregory; Wilkin, Timothy; Fletcher, Courtney V.; Margolis, David M.; Thal, Gary D.; Godfrey, Catherine; Bastow, Barbara; Ray, M. Graham; Wang, Hongying; Coombs, Robert W.; McKinnon, John; Mellors, John W.		AIDS Clinical Trials Grp	Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIV-INFECTION; INDUCTION THERAPY; RANDOMIZED-TRIAL; CLINICAL-TRIALS; DRUG THERAPY; RNA; LOPINAVIR/RITONAVIR; SECRETIONS; ADHERENCE; INDINAVIR	Context The long-term adverse effects, expense, and difficulty of adherence to antiretroviral regimens have led to studies of simpler maintenance therapies. Maintenance therapy with ritonavir-boosted atazanavir alone is a possible option because of low pill burden, once-daily dosing, safety, and unique resistance profile. Objective To assess whether simplified maintenance therapy with atazanavir-ritonavir alone after virologic suppression increases the risk of virologic failure ( 2 consecutive human immunodeficiency virus type 1 [HIV-1] RNA measurements of >= 200 copies/mL). Design, Setting, and Participants Single-group, open-label, multicenter, 24-week pilot study of 36 HIV-infected adults with virologic suppression for 48 weeks or longer receiving their first protease inhibitor (PI)-based regimen. The study was conducted between September 1, 2004, and April 18, 2006, at 12 participating AIDS clinical trial units in the United States. Intervention Participants switched PIs to atazanavir-ritonavir at entry and discontinued nucleoside analog reverse transcriptase inhibitors (NRTIs) after 6 weeks. Main Outcome Measures Virologic failure within 24 weeks of discontinuing NRTIs. Other measures included HIV-1 drug resistance, plasma atazanavir concentrations, adverse events, CD4 cell counts, plasma lipid levels, and HIV-1 RNA levels in seminal plasma. Results Thirty-six participants enrolled and 2 discontinued before simplification to atazanavir-ritonavir alone. Thirty-four patients were included in the analysis of the primary end point after 24 weeks: 1 withdrew voluntarily, and 33 continued the regimen. Virologic success ( absence of failure) through 24 weeks of simplified therapy occurred in 91% ( 31 of 34 patients; lower 90% confidence interval limit = 85%). Three participants experienced virologic failure 12, 14, and 20 weeks after simplification, with plasma HIV-1 RNA levels of 4730, 1285, and 28 397 copies/mL, respectively. Resistance testing at failure did not identify PI resistance mutations. Plasma atazanavir concentrations at failure were low or below detection in 2 of 3 participants experiencing failure. There were no treatment discontinuations for adverse events after simplification; no significant changes in CD4 cell counts or plasma lipid levels; and no detectable HIV-1 RNA in seminal plasma from all 8 participants tested. Conclusions These preliminary data suggest that simplified maintenance therapy with atazanavir-ritonavir alone may be efficacious for maintaining virologic suppression in carefully selected patients with HIV infection. These findings require confirmation in larger, randomized trials of this strategy.	Univ Nebraska, Med Ctr, Dept Internal Med, Omaha, NE 68198 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Cornell Univ, Weill Med Coll, Dept Med, New York, NY USA; Univ Colorado, Hlth Sci Ctr, Sch Pharm, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Internal Med, Denver, CO USA; Univ N Carolina, Dept Med, Chapel Hill, NC USA; Bristol Myers Squibb Co, Plainsboro, NJ USA; NIAID, HIV Res Branch, Div AIDS, Bethesda, MD 20892 USA; AIDS Clin Trials Grp Operat Ctr, Silver Spring, MD USA; Univ Washington, Dept Lab Med, Seattle, WA 98195 USA; Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA USA	University of Nebraska System; University of Nebraska Medical Center; Harvard University; Harvard T.H. Chan School of Public Health; Cornell University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of North Carolina; University of North Carolina Chapel Hill; Bristol-Myers Squibb; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Washington; University of Washington Seattle; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Swindells, S (corresponding author), Univ Nebraska, Med Ctr, Dept Internal Med, 985400 Nebraska Med Ctr, Omaha, NE 68198 USA.	sswindells@unmc.edu	Margolis, David M./Y-2468-2019	Margolis, David M./0000-0001-5714-0002	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR000146] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI034832, U01AI038858, U01AI027666, U01AI046386, U01AI025868, U01AI038855, U01AI034853, U01AI032770, U01AI025897, U01AI027661, U01AI039156, U01AI046376, U01AI046383] Funding Source: NIH RePORTER; NCATS NIH HHS [KL2 TR000146] Funding Source: Medline; NIAID NIH HHS [AI27661, U01 AI38858, AI46386, AI46383, AI38858, AI39156, AI46376, AI25868, AI27666, AI34853, AI32770, AI34832, AI38855, AI25897] Funding Source: Medline	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ananworanich J, 2003, AIDS, V17, pF33, DOI 10.1097/00002030-200310170-00001; Arribas JR, 2005, JAIDS-J ACQ IMM DEF, V40, P280, DOI 10.1097/01.qai.0000180077.59159.f4; BEST B, 2006, 13 C RETR OPP INF FE; *BRIST MYERS SQUIB, 2004, REYAT PACK INS; Busti AJ, 2004, PHARMACOTHERAPY, V24, P1732, DOI 10.1592/phco.24.17.1732.52347; Chesney MA, 2000, AIDS CARE, V12, P255, DOI 10.1080/09540120050042891; Cox D. R., 1984, ANAL SURVIVAL DATA; Dybul M, 2001, P NATL ACAD SCI USA, V98, P15161, DOI 10.1073/pnas.261568398; Fletcher CV, 2005, JAIDS-J ACQ IMM DEF, V40, P301, DOI 10.1097/01.qai.0000180078.53321.6a; GATELL J, 2005, 10 EUR AIDS C NOV 18; Gunthard HF, 2001, J INFECT DIS, V183, P1318, DOI 10.1086/319864; Havlir DV, 1998, NEW ENGL J MED, V339, P1261, DOI 10.1056/NEJM199810293391801; Johnson M, 2006, AIDS, V20, P711, DOI 10.1097/01.aids.0000216371.76689.63; Kahlert C, 2004, AIDS, V18, P955, DOI 10.1097/00002030-200404090-00017; LEITNER T, 2005, SEQUENCE COMPENDIUM; MALAN N, 2006, 13 C RETR OPP INF FE; Murphy R, 2002, ANTIVIR THER, V7, pL10; MURPHY R, 2005, 12 C RETR OPP INF FE; Nolan D, 2004, ANTIVIR THER, V9, P849; Pialoux G, 1998, NEW ENGL J MED, V339, P1269, DOI 10.1056/NEJM199810293391802; *REG COMPL CTR, TOX TABL; Reijers MHE, 1998, LANCET, V352, P185, DOI 10.1016/S0140-6736(98)06193-5; VERNAZZA P, 2005, 3 INT AIDS SOC C HIV; Vernazza PL, 2000, AIDS, V14, P117, DOI 10.1097/00002030-200001280-00006; Wafaa E, 2006, 13 C RETR OPP INF FE; Zuckerman RA, 2004, J INFECT DIS, V190, P156, DOI 10.1086/421246	27	73	74	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 16	2006	296	7					806	814		10.1001/jama.296.7.806	http://dx.doi.org/10.1001/jama.296.7.806			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	073SR	16905786	Bronze			2022-12-28	WOS:000239763400021
J	Krantz, MJ; Mehler, PS				Krantz, Mori J.; Mehler, Philip S.			QTc prolongation: methadone's efficacy-safety paradox	LANCET			English	Editorial Material							TORSADE-DE-POINTES; CARDIAC REPOLARIZATION; OPIOID DEPENDENCE; USERS; BUPRENORPHINE		Denver Hlth Med Ctr, Denver, CO 80204 USA	Denver Health Medical Center	Mehler, PS (corresponding author), Denver Hlth Med Ctr, Denver, CO 80204 USA.	PMehler@dhha.org						Ehret GB, 2006, ARCH INTERN MED, V166, P1280, DOI 10.1001/archinte.166.12.1280; HAYS H, 1999, PAIN RES MANAG, V4, P23; Huber A, 2001, DRUG ALCOHOL DEPEN, V63, pS70; Johnson RE, 2000, NEW ENGL J MED, V343, P1290, DOI 10.1056/NEJM200011023431802; Krantz MJ, 2005, PHARMACOTHERAPY, V25, P611, DOI 10.1592/phco.25.4.611.61020; Krantz MJ, 2003, PHARMACOTHERAPY, V23, P802, DOI 10.1592/phco.23.6.802.32186; Krantz MJ, 2002, ANN INTERN MED, V137, P501, DOI 10.7326/0003-4819-137-6-200209170-00010; Krantz MJ, 2004, ARCH INTERN MED, V164, P277, DOI 10.1001/archinte.164.3.277; LIPSKI J, 1973, AM HEART J, V86, P663, DOI 10.1016/0002-8703(73)90344-X; Martell BA, 2005, AM J CARDIOL, V95, P915, DOI 10.1016/j.amjcard.2004.11.055; Pearson EC, 2005, PHARMACOEPIDEM DR S, V14, P747, DOI 10.1002/pds.1112	11	25	25	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 12	2006	368	9535					556	557		10.1016/S0140-6736(06)69173-3	http://dx.doi.org/10.1016/S0140-6736(06)69173-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	074OF	16905001				2022-12-28	WOS:000239821000005
J	Freeman, AS; Byers, JE				Freeman, Aaren S.; Byers, James E.			Divergent induced responses to an invasive predator in marine mussel populations	SCIENCE			English	Article							BLUE MUSSEL; TRADE-OFFS; RECOGNITION; DEFENSES; HISTORY	Invasive species may precipitate evolutionary change in invaded communities. In southern New England ( USA) the invasive Asian shore crab, Hemigrapsus sanguineus, preys on mussels (Mytlius edulis), but the crab has not yet invaded northern New England. We show that southern New England mussels express inducible shell thickening when exposed to waterborne cues from Hemigrapsus, whereas naive northern mussel populations do not respond. Yet, both populations thicken their shells in response to a long-established crab, Carcinus maenas. Our findings are consistent with the rapid evolution of an inducible morphological response to Hemigrapsus within 15 years of its introduction.	Univ New Hampshire, Dept Zool, Durham, NH 03824 USA	University System Of New Hampshire; University of New Hampshire	Freeman, AS (corresponding author), Univ New Hampshire, Dept Zool, Rudman Hall, Durham, NH 03824 USA.	afreeman@cisunix.unh.edu	Byers, James/AFJ-8413-2022	Byers, James/0000-0001-9240-0287				Barbosa GE., 2005, ECOLOGY PREDATOR PRE; BERTNESS MD, 1981, EVOLUTION, V35, P995, DOI 10.1111/j.1558-5646.1981.tb04965.x; Byers JE, 2006, MAR ECOL PROG SER, V313, P27, DOI 10.3354/meps313027; Carlton JT, 2003, J BIOGEOGR, V30, P1809, DOI 10.1111/j.1365-2699.2003.00962.x; Cox GW, 2004, ALIEN SPECIES EVOLUT; DETHIER MN, 1988, MAR ECOL PROG SER, V50, P97, DOI 10.3354/meps050097; Kiesecker JM, 1997, ECOLOGY, V78, P1752; Leonard GH, 1999, ECOLOGY, V80, P1; Lohrer AM, 2002, MAR ECOL PROG SER, V227, P135, DOI 10.3354/meps227135; MALONEY RF, 1995, ANIM BEHAV, V50, P1193, DOI 10.1016/0003-3472(95)80036-0; McDermott JJ, 1998, ICES J MAR SCI, V55, P289, DOI 10.1006/jmsc.1997.0273; Padilla DK, 1996, EVOL ECOL, V10, P105, DOI 10.1007/BF01239351; Payne CM, 2004, ANN ZOOL FENN, V41, P843; Phillips BL, 2004, P NATL ACAD SCI USA, V101, P17150, DOI 10.1073/pnas.0406440101; Raimondi PT, 2000, OIKOS, V91, P353, DOI 10.1034/j.1600-0706.2000.910215.x; Reimer O, 2001, MAR BIOL, V139, P959; REZNICK D, 1982, EVOLUTION, V36, P160, DOI 10.1111/j.1558-5646.1982.tb05021.x; Riginos C, 2004, EVOLUTION, V58, P2438; Sanford E, 2003, SCIENCE, V300, P1135, DOI 10.1126/science.1083437; Schlichting CD, 1998, PHENOTYPIC EVOLUTION; SEELEY R, COMMUNICATION; SIH A, 2004, PHENOTYPIC PLASTICIT, V1, P112; Smith LD, 2000, MAR BIOL, V136, P461, DOI 10.1007/s002270050705; Strauss SY, 2006, ECOL LETT, V9, P354, DOI 10.1111/j.1461-0248.2005.00874.x; Tollrian R., 1998, ECOLOGY EVOLUTION IN; Trussell GC, 2000, EVOLUTION, V54, P151, DOI 10.1111/j.0014-3820.2000.tb00016.x; Trussell GC, 2000, P NATL ACAD SCI USA, V97, P2123, DOI 10.1073/pnas.040423397; Trussell GC, 2002, ECOLOGY, V83, P1635, DOI 10.2307/3071984; Trussell GC, 2002, ECOL LETT, V5, P241, DOI 10.1046/j.1461-0248.2002.00304.x	29	199	203	2	128	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 11	2006	313	5788					831	833		10.1126/science.1125485	http://dx.doi.org/10.1126/science.1125485			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	072KC	16902136				2022-12-28	WOS:000239671300058
J	Monaghan, AJ; Bromwich, DH; Fogt, RL; Wang, SH; Mayewski, PA; Dixon, DA; Ekaykin, A; Frezzotti, M; Goodwin, I; Isaksson, E; Kaspari, SD; Morgan, VI; Oerter, H; Van Ommen, TD; Van der Veen, CJ; Wen, JH				Monaghan, Andrew J.; Bromwich, David H.; Fogt, Ryan L.; Wang, Sheng-Hung; Mayewski, Paul A.; Dixon, Daniel A.; Ekaykin, Alexey; Frezzotti, Massimo; Goodwin, Ian; Isaksson, Elisabeth; Kaspari, Susan D.; Morgan, Vin I.; Oerter, Hans; Van Ommen, Tas D.; Van der Veen, Cornelius J.; Wen, Jiahong			Insignificant change in Antarctic snowfall since the International Geophysical Year	SCIENCE			English	Article							SEA-LEVEL RISE; SURFACE MASS-BALANCE; ICE SHEETS; GREENLAND; TRENDS; 20TH-CENTURY; ERA-40	Antarctic snowfall exhibits substantial variability over a range of time scales, with consequent impacts on global sea level and the mass balance of the ice sheets. To assess how snowfall has affected the thickness of the ice sheets in Antarctica and to provide an extended perspective, we derived a 50-year time series of snowfall accumulation over the continent by combining model simulations and observations primarily from ice cores. There has been no statistically significant change in snowfall since the 1950s, indicating that Antarctic precipitation is not mitigating global sea level rise as expected, despite recent winter warming of the overlying atmosphere.	Ohio State Univ, Byrd Polar Res Ctr, Polar Meteorol Grp, Columbus, OH 43210 USA; Ohio State Univ, Dept Geol Sci, Columbus, OH 43210 USA; Univ Maine, Climate Change Inst, Orono, ME 04469 USA; Arctic & Antarctic Res Ctr, St Petersburg 199397, Russia; Natl Agcy New Technol Energy & Environm, I-00060 Rome, Italy; Univ Newcastle, Sch Environm & Life Sci, Callaghan, NSW 2308, Australia; Norwegian Polar Res Inst, N-9296 Tromso, Norway; Australian Antarctic Div, Dept Environm & Heritage, Hobart, Tas 7001, Australia; Antarctic Climate & Ecosyst Cooperat Res Ctr, Hobart, Tas 7001, Australia; Alfred Wegener Inst Polar & Marine Res, D-27515 Bremerhaven, Germany; Shanghai Normal Univ, Dept Geog, Shanghai 200234, Peoples R China	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Maine System; University of Maine Orono; University of Newcastle; Norwegian Polar Institute; Australian Antarctic Division; Antarctic Climate & Ecosystems Cooperative Research Centre (ACE CRC); Helmholtz Association; Alfred Wegener Institute, Helmholtz Centre for Polar & Marine Research; Shanghai Normal University	Monaghan, AJ (corresponding author), Ohio State Univ, Byrd Polar Res Ctr, Polar Meteorol Grp, Columbus, OH 43210 USA.	monaghan.11@osu.edu	Fogt, Ryan L/B-6989-2008; Bromwich, David/C-9225-2016; Ekaykin, Alexey/K-9894-2015; FREZZOTTI, Massimo/AAK-7275-2020; van Ommen, Tas D/B-5020-2012; Lipenkov, Vladimir/Q-8262-2016	Fogt, Ryan L/0000-0002-5398-3990; Ekaykin, Alexey/0000-0001-9819-2802; FREZZOTTI, Massimo/0000-0002-2461-2883; van Ommen, Tas D/0000-0002-2463-1718; Lipenkov, Vladimir/0000-0003-4221-5440; Goodwin, Ian/0000-0001-8682-6409; Monaghan, Andrew/0000-0002-8170-2359				Bromwich DH, 2004, J CLIMATE, V17, P4603, DOI 10.1175/3241.1; Bromwich DH, 2004, J CLIMATE, V17, P427, DOI 10.1175/1520-0442(2004)017<0427:MAPPIS>2.0.CO;2; BROMWICH DH, 1988, REV GEOPHYS, V26, P149, DOI 10.1029/RG026i001p00149; Church JA, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2005GL024826; Comiso JC, 2000, J CLIMATE, V13, P1674, DOI 10.1175/1520-0442(2000)013<1674:VATIAS>2.0.CO;2; Davis CH, 2005, SCIENCE, V308, P1898, DOI 10.1126/science.1110662; Huybrechts P, 2004, GLOBAL PLANET CHANGE, V42, P83, DOI 10.1016/j.gloplacha.2003.11.011; Intergovernmental Panel on Climate Change, 2001, IPCC 3 ASS REP CLIM; Leuliette EW, 2004, MAR GEOD, V27, P79, DOI 10.1080/01490410490465193; MAYEWSKI PA, 1997, PAGES WORKSH REPORT, V971; Monaghan AJ, 2006, PHILOS T R SOC A, V364, P1683, DOI 10.1098/rsta.2006.1795; MORGAN VI, 1991, NATURE, V354, P58, DOI 10.1038/354058a0; MOSLEYTHOMPSON E, 1995, ANN GLACIOL, V21, P131, DOI DOI 10.3189/S0260305500015718; Ohmura A, 1996, J CLIMATE, V9, P2124, DOI 10.1175/1520-0442(1996)009<2124:APCIMB>2.0.CO;2; Rignot E, 2002, SCIENCE, V296, P2020, DOI 10.1126/science.1070942; Rignot E, 2002, SCIENCE, V297, P1502, DOI 10.1126/science.1073888; Thomas R, 2004, SCIENCE, V306, P255, DOI 10.1126/science.1099650; Turner J, 2005, INT J CLIMATOL, V25, P279, DOI 10.1002/joc.1130; Turner J, 2006, SCIENCE, V311, P1914, DOI 10.1126/science.1121652; Uppala SM, 2005, Q J ROY METEOR SOC, V131, P2961, DOI 10.1256/qj.04.176; van de Berg WJ, 2006, J GEOPHYS RES-ATMOS, V111, DOI 10.1029/2005JD006495; Van de Berg WJ, 2005, ANN GLACIOL-SER, V41, P97, DOI 10.3189/172756405781813302; van den Broeke M, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2005GL025239; Vaughan DG, 1999, J CLIMATE, V12, P933, DOI 10.1175/1520-0442(1999)012<0933:RONSMB>2.0.CO;2; Vaughan DG, 2005, SCIENCE, V308, P1877, DOI 10.1126/science.1114670; Velicogna I, 2006, SCIENCE, V311, P1754, DOI 10.1126/science.1123785; Zwally HJ, 2005, J GLACIOL, V51, P509, DOI 10.3189/172756505781829007; 2005, B AM METEOROL SOC S, V86	28	177	187	5	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 11	2006	313	5788					827	831		10.1126/science.1128243	http://dx.doi.org/10.1126/science.1128243			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	072KC	16902135	Green Submitted			2022-12-28	WOS:000239671300057
J	Simon, R; Stahl, Y				Simon, Ruediger; Stahl, Yvonne			Plant cells CLEave their way to differentiation	SCIENCE			English	Editorial Material							ARABIDOPSIS; GENES; CLV3; CLAVATA3; LOOP		Univ Dusseldorf, Inst Genet, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Simon, R (corresponding author), Univ Dusseldorf, Inst Genet, D-40225 Dusseldorf, Germany.	ruediger.simon@uni-duesseldorf.de	Stahl, Yvonne/A-9240-2014	Stahl, Yvonne/0000-0002-7543-5186				Brand U, 2000, SCIENCE, V289, P617, DOI 10.1126/science.289.5479.617; Cock JM, 2001, PLANT PHYSIOL, V126, P939, DOI 10.1104/pp.126.3.939; Fiers M, 2006, PLANT PHYSIOL, V141, P1284, DOI 10.1104/pp.106.080671; Fletcher LC, 1999, SCIENCE, V283, P1911, DOI 10.1126/science.283.5409.1911; Hobe M, 2003, DEV GENES EVOL, V213, P371, DOI 10.1007/s00427-003-0329-5; Ito Y, 2006, SCIENCE, V313, P842, DOI 10.1126/science.1128436; Kondo T, 2006, SCIENCE, V313, P845, DOI 10.1126/science.1128439; Motose H, 2004, NATURE, V429, P873, DOI 10.1038/nature02613; Ni J, 2006, PLANT PHYSIOL, V140, P726, DOI 10.1104/pp.105.072678; Rojo E, 2002, PLANT CELL, V14, P969, DOI 10.1105/tpc.002196; Schoof H, 2000, CELL, V100, P635, DOI 10.1016/S0092-8674(00)80700-X; Sharma VK, 2003, PLANT MOL BIOL, V51, P415, DOI 10.1023/A:1022038932376	12	7	9	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 11	2006	313	5788					773	774		10.1126/science.1131833	http://dx.doi.org/10.1126/science.1131833			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	072KC	16902118				2022-12-28	WOS:000239671300036
J	Pronovost, PJ; Miller, MR; Wachter, RM				Pronovost, Peter J.; Miller, Marlene R.; Wachter, Robert M.			Tracking progress in patient safety - An elusive target	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							INTENSIVE-CARE-UNIT; PHYSICIAN ORDER ENTRY; MEDICAL-CARE; QUALITY; INFECTIONS; EVENTS		Johns Hopkins Univ, Dept Anesthesiol & Crit Care, Baltimore, MD 21231 USA; Johns Hopkins Univ, Dept Pediat, Baltimore, MD 21231 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA USA	Johns Hopkins University; Johns Hopkins University; University of California System; University of California San Francisco	Pronovost, PJ (corresponding author), Johns Hopkins Univ, Dept Anesthesiol & Crit Care, 1909 Thames St,2nd Floor, Baltimore, MD 21231 USA.	ppronovo@jhmi.edu			AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [UC1HS014246] Funding Source: NIH RePORTER; AHRQ HHS [1UC1HS14246] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Bates DW, 1999, J AM MED INFORM ASSN, V6, P313, DOI 10.1136/jamia.1999.00660313; Berenholtz SM, 2004, CRIT CARE MED, V32, P2014, DOI 10.1097/01.CCM.0000142399.70913.2F; Brennan TA, 2005, NEW ENGL J MED, V353, P1405, DOI 10.1056/NEJMsb051157; CAPLAN RA, 1991, JAMA-J AM MED ASSOC, V265, P1957, DOI 10.1001/jama.265.15.1957; DONABEDIAN A, 1966, MILBANK FUND Q, V44, P166, DOI 10.2307/3348969; Gerberding JL, 2002, ANN INTERN MED, V137, P665, DOI 10.7326/0003-4819-137-8-200210150-00011; *I MED, 2004, PAT SAF ACH NEW STAN; Kohn LTCJ., BUILDING SAFER HLTH; Koppel R, 2005, JAMA-J AM MED ASSOC, V293, P1197, DOI 10.1001/jama.293.10.1197; Leape LL, 2005, JAMA-J AM MED ASSOC, V293, P2384, DOI 10.1001/jama.293.19.2384; Leape LL, 1999, JAMA-J AM MED ASSOC, V282, P267, DOI 10.1001/jama.282.3.267; Lilford R, 2004, LANCET, V363, P1147, DOI 10.1016/S0140-6736(04)15901-1; Makary MA, 2006, JT COMM J QUAL PATIE, V32, P351, DOI 10.1016/S1553-7250(06)32045-4; Needham DM, 2005, CRIT CARE MED, V33, P1701, DOI 10.1097/01.CCM.0000171205.73728.81; Needleman J, 2002, NEW ENGL J MED, V346, P1715, DOI 10.1056/NEJMsa012247; Pronovost P, 2006, CRIT CARE MED, V34, P1988, DOI 10.1097/01.CCM.0000226412.12612.B6; Pronovost Peter, 2005, Healthc Exec, V20, P14; Pronovost PJ, 2006, JT COMM J QUAL PATIE, V32, P102, DOI 10.1016/S1553-7250(06)32014-4; Pronovost PJ, 2004, LANCET, V363, P1061, DOI 10.1016/S0140-6736(04)15843-1; PRONOVOST PJ, 2005, J PATIENT SAF, V1, P33; Rozich JD, 2003, QUAL SAF HEALTH CARE, V12, P194, DOI 10.1136/qhc.12.3.194; Sexton JB, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-44; Thomas EJ, 2006, J PERINATOL, V26, P163, DOI 10.1038/sj.jp.7211451; Vincent C, 2003, NEW ENGL J MED, V348, P1051, DOI 10.1056/NEJMhpr020760; Wachter R.M., 2004, HEALTH AFFAIR	25	130	131	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 9	2006	296	6					696	699		10.1001/jama.296.6.696	http://dx.doi.org/10.1001/jama.296.6.696			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	071LN	16896113				2022-12-28	WOS:000239603800032
J	Mosam, A; Moodley, V; Ramdial, PK				Mosam, Anisa; Moodley, Vinesh; Ramdial, Pratistadevi K.			Persistent pyrexia and plaques: a perplexing puzzle	LANCET			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; DISSEMINATED HISTOPLASMOSIS		Univ Kwazulu Natal, Nelson R Mandela Sch Med, Dept Dermatol, ZA-4013 Congella, South Africa; Univ Kwazulu Natal, Nelson R Mandela Sch Med, Dept Paediat, ZA-4013 Congella, South Africa; Univ Kwazulu Natal, Nelson R Mandela Sch Med, Dept Anat Pathol, ZA-4013 Congella, South Africa	University of Kwazulu Natal; University of Kwazulu Natal; University of Kwazulu Natal	Mosam, A (corresponding author), Univ Kwazulu Natal, Nelson R Mandela Sch Med, Dept Dermatol, ZA-4013 Congella, South Africa.	mosama@ukzn.ac.za						HAJJEH RA, 1995, CLIN INFECT DIS, V21, pS108, DOI 10.1093/clinids/21.Supplement_1.S108; Pillay T, 1997, PEDIATR INFECT DIS J, V16, P417, DOI 10.1097/00006454-199704000-00019; Ramdial PK, 2002, J CUTAN PATHOL, V29, P215, DOI 10.1034/j.1600-0560.2002.290404.x	3	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 5	2006	368	9534					551	551		10.1016/S0140-6736(06)69166-6	http://dx.doi.org/10.1016/S0140-6736(06)69166-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	071AL	16890845				2022-12-28	WOS:000239569000041
J	Breon, FM				Breon, Francois-Marie			Climate - How do aerosols affect cloudiness and climate?	SCIENCE			English	Editorial Material								Anthropogenic aerosol emissions may increase cloud cover by up to 5%, resulting in a substantial net cooling of Earth's atmosphere.	Lab Sci Climat & Environm, F-91191 Gif Sur Yvette, France	UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS)	Breon, FM (corresponding author), Lab Sci Climat & Environm, F-91191 Gif Sur Yvette, France.	francois-marie.breon@cea.fr	Breon, Francois-Marie A/M-4639-2016	Breon, Francois-Marie A/0000-0003-2128-739X				Ackerman AS, 2000, SCIENCE, V288, P1042, DOI 10.1126/science.288.5468.1042; Anderson TL, 2005, B AM METEOROL SOC, V86, P1795, DOI 10.1175/BAMS-86-12-1795; Andreae MO, 2005, NATURE, V435, P1187, DOI 10.1038/nature03671; Breon FM, 2002, SCIENCE, V295, P834, DOI 10.1126/science.1066434; Kaufman YJ, 2006, SCIENCE, V313, P655, DOI 10.1126/science.1126232; Koren I, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL023187; Koren I, 2004, SCIENCE, V303, P1342, DOI 10.1126/science.1089424; Penner JE, 2004, NATURE, V427, P231, DOI 10.1038/nature02234; Rosenfeld D, 2000, SCIENCE, V287, P1793, DOI 10.1126/science.287.5459.1793; Yu H, 2006, ATMOS CHEM PHYS, V6, P613, DOI 10.5194/acp-6-613-2006	10	28	31	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 4	2006	313	5787					623	624		10.1126/science.1131668	http://dx.doi.org/10.1126/science.1131668			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	072IQ	16888128				2022-12-28	WOS:000239667500028
J	Pobbati, AV; Stein, A; Fasshauer, D				Pobbati, Ajaybabu V.; Stein, Alexander; Fasshauer, Dirk			N- to C-terminal SNARE complex assembly promotes rapid membrane fusion	SCIENCE			English	Article							T-SNARE; SYNAPTIC EXOCYTOSIS; PROTEINS; VESICLES; DOMAIN; CORE	Assembly of the soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) syntaxin 1, SNAP-25, and synaptobrevin 2 is thought to be the driving force for the exocytosis of synaptic vesicles. However, whereas exocytosis is triggered at a millisecond time scale, the SNARE-mediated fusion of liposomes requires hours for completion, which challenges the idea of a key role for SNAREs in the final steps of exocytosis. We found that liposome fusion was dramatically accelerated when a stabilized syntaxin/SNAP-25 acceptor complex was used. Thus, SNARES do have the capacity to execute fusion at a speed required for neuronal secretion, demonstrating that the maintenance of acceptor complexes is a critical step in biological fusion reactions.	Max Planck Inst Biophys Chem, Dept Neurobiol, D-37077 Gottingen, Germany	Max Planck Society	Fasshauer, D (corresponding author), Max Planck Inst Biophys Chem, Dept Neurobiol, Fassberg 11, D-37077 Gottingen, Germany.	dfassha@gwdg.de	Fasshauer, Dirk/B-1563-2013; Stein, Alexander/I-4950-2012	Fasshauer, Dirk/0000-0002-1040-4282; Stein, Alexander/0000-0002-2696-0611	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM072694] Funding Source: NIH RePORTER; NIGMS NIH HHS [P01 GM072694] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bowen ME, 2004, BIOPHYS J, V87, P3569, DOI 10.1529/biophysj.104.048637; Chen XC, 2002, NEURON, V33, P397, DOI 10.1016/S0896-6273(02)00583-4; Dieter B, 2002, PFLUG ARCH EUR J PHY, V443, P333, DOI 10.1007/s00424-001-0742-4; Fasshauer D, 2004, J BIOL CHEM, V279, P7613, DOI 10.1074/jbc.M312064200; Fasshauer D, 2002, NAT STRUCT BIOL, V9, P144, DOI 10.1038/nsb750; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; Fiebig KM, 1999, NAT STRUCT BIOL, V6, P117; Fix M, 2004, P NATL ACAD SCI USA, V101, P7311, DOI 10.1073/pnas.0401779101; Hanson PI, 1997, CURR OPIN NEUROBIOL, V7, P310, DOI 10.1016/S0959-4388(97)80057-8; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; Liu TT, 2005, BIOPHYS J, V89, P2458, DOI 10.1529/biophysj.105.062539; Margittai M, 2001, J BIOL CHEM, V276, P13169, DOI 10.1074/jbc.M010653200; Melia TJ, 2002, J CELL BIOL, V158, P929, DOI 10.1083/jcb.200112081; Nicholson KL, 1998, NAT STRUCT BIOL, V5, P793, DOI 10.1038/1834; Parlati F, 1999, P NATL ACAD SCI USA, V96, P12565, DOI 10.1073/pnas.96.22.12565; Pelham HRB, 1995, COLD SPRING HARB SYM, V60, P105, DOI 10.1101/SQB.1995.060.01.013; Rettig J, 2002, SCIENCE, V298, P781, DOI 10.1126/science.1075375; Sabatini BL, 1996, NATURE, V384, P170, DOI 10.1038/384170a0; Sorensen JB, 2006, EMBO J, V25, P955, DOI 10.1038/sj.emboj.7601003; Sudhof TC, 2004, ANNU REV NEUROSCI, V27, P509, DOI 10.1146/annurev.neuro.26.041002.131412; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Ungar D, 2003, ANNU REV CELL DEV BI, V19, P493, DOI 10.1146/annurev.cellbio.19.110701.155609; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Xiao WZ, 2001, NAT STRUCT BIOL, V8, P308, DOI 10.1038/86174	24	268	274	1	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 4	2006	313	5787					673	676		10.1126/science.1129486	http://dx.doi.org/10.1126/science.1129486			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	072IQ	16888141	Green Published			2022-12-28	WOS:000239667500045
J	Dong, L; Agarwal, AK; Beebe, DJ; Jiang, HR				Dong, Liang; Agarwal, Abhishek K.; Beebe, David J.; Jiang, Hongrui			Adaptive liquid microlenses activated by stimuli-responsive hydrogels	NATURE			English	Article							MICROFLUIDIC CHANNELS; POLYMER GELS; LENS; ARRAYS; FABRICATION; LIGHT	Despite its compactness, the human eye can easily focus on different distances by adjusting the shape of its lens with the help of ciliary muscles(1). In contrast, traditional man-made optical systems achieve focusing by physical displacement of the lenses used. But in recent years, advances in miniaturization technology have led to optical systems that no longer require complicated mechanical systems to tune and adjust optical performance. These systems have found wide use in photonics, displays and biomedical systems. They are either based on arrays of microlenses with fixed focal lengths(2-5), or use external control to adjust the microlens focal length(6-12). An intriguing example is the tunable liquid lens, where electrowetting or external pressure manipulates the shape of a liquid droplet and thereby adjusts its optical properties. Here we demonstrate a liquid lens system that allows for autonomous focusing. The central component is a stimuli-responsive hydrogel(13) integrated into a microfluidic system and serving as the container for a liquid droplet, with the hydrogel simultaneously sensing the presence of stimuli and actuating adjustments to the shape - and hence focal length - of the droplet. By working at the micrometre scale where ionic diffusion and surface tension scale favourably(14), we can use pinned liquid - liquid interfaces to obtain stable devices and realize response times of ten to a few tens of seconds. The microlenses, which can have a focal length ranging from -infinity to +infinity ( divergent and convergent), are also readily integrated into arrays that may find use in applications such as sensing, medical diagnostics and lab-on-a-chip technologies(15-19).	Univ Wisconsin, Dept Elect & Comp Engn, Madison, WI 53706 USA; Univ Wisconsin, Dept Biomed Engn, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Jiang, HR (corresponding author), Univ Wisconsin, Dept Elect & Comp Engn, 1415 Johnson Dr, Madison, WI 53706 USA.	hongrui@engr.wisc.edu						Agarwal AK, 2005, J MICROELECTROMECH S, V14, P1409, DOI 10.1109/JMEMS.2005.859101; Atencia J, 2005, NATURE, V437, P648, DOI 10.1038/nature04163; Bassetti MJ, 2005, J MICROELECTROMECH S, V14, P1198, DOI 10.1109/JMEMS.2005.845407; Beebe DJ, 2000, NATURE, V404, P588, DOI 10.1038/35007047; Burns MA, 1998, SCIENCE, V282, P484, DOI 10.1126/science.282.5388.484; Camou S, 2003, LAB CHIP, V3, P40, DOI 10.1039/b211280a; Carlson K, 2005, APPL OPTICS, V44, P1792, DOI 10.1364/AO.44.001792; Cayre OJ, 2004, J MATER CHEM, V14, P3300, DOI 10.1039/b413361g; Choi HW, 2004, APPL PHYS LETT, V84, P2253, DOI 10.1063/1.1690876; Chronis N, 2003, OPT EXPRESS, V11, P2370, DOI 10.1364/OE.11.002370; Hayes RA, 2003, NATURE, V425, P383, DOI 10.1038/nature01988; Jacobs HO, 2002, SCIENCE, V296, P323, DOI 10.1126/science.1069153; Kuiper S, 2004, APPL PHYS LETT, V85, P1128, DOI 10.1063/1.1779954; Land MF, 1997, ANNU REV ENTOMOL, V42, P147, DOI 10.1146/annurev.ento.42.1.147; Lele AK, 1997, MACROMOLECULES, V30, P157, DOI 10.1021/ma950894l; Lopez CA, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.2058209; Miyata T, 1999, NATURE, V399, P766, DOI 10.1038/21619; Osada Y, 2004, J MACROMOL SCI-POL R, VC44, P87, DOI 10.1081/MC-120027935; PARK TG, 1992, J APPL POLYM SCI, V46, P659, DOI 10.1002/app.1992.070460413; POPOVIC ZD, 1988, APPL OPTICS, V27, P1281, DOI 10.1364/AO.27.001281; Ren H, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1935749; Ren HW, 2004, OPT LETT, V29, P1608, DOI 10.1364/OL.29.001608; Saitoh A, 2003, APPL PHYS LETT, V83, P1725, DOI 10.1063/1.1598650; Sershen SR, 2005, ADV MATER, V17, P1366, DOI 10.1002/adma.200401239; SUZUKI A, 1990, NATURE, V346, P345, DOI 10.1038/346345a0; TANAKA T, 1982, SCIENCE, V218, P467, DOI 10.1126/science.218.4571.467; TOATES FM, 1972, PHYSIOL REV, V52, P828, DOI 10.1152/physrev.1972.52.4.828; Yang R, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1901829; Yang S, 2005, ADV MATER, V17, P435, DOI 10.1002/adma.200401002; Zhang DY, 2003, APPL PHYS LETT, V82, P3171, DOI 10.1063/1.1573337	30	817	837	27	745	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 3	2006	442	7102					551	554		10.1038/nature05024	http://dx.doi.org/10.1038/nature05024			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	069NQ	16885981				2022-12-28	WOS:000239455900040
J	Jin, HC; Sperka, T; Herrlich, P; Morrison, H				Jin, Hongchuan; Sperka, Tobias; Herrlich, Peter; Morrison, Helen			Tumorigenic transformation by CPI-17 through inhibition of a merlin phosphatase	NATURE			English	Article							NF2 TUMOR-SUPPRESSOR; MYOSIN-BINDING SUBUNIT; RHO-ASSOCIATED KINASE; NEUROFIBROMATOSIS TYPE-2; PROTEIN PHOSPHATASE; SMOOTH-MUSCLE; GENE-PRODUCT; PHOSPHORYLATION; ASSOCIATION; CANCER	The tumour suppressor protein merlin ( encoded by the neurofibromatosis type 2 gene NF2) is an important regulator of proliferation in many cell and tissue types(1-4). Merlin is activated by dephosphorylation at serine 518 (S518), which occurs on serum withdrawal or on cell - cell or cell - matrix contact(5,6). However, the relevant phosphatase that activates merlin's tumour suppressor function is unknown. Here we identify this enzyme as the myosin phosphatase (MYPT-1-PP1 delta). The cellular MYPT-1-PP1 delta - specific inhibitor CPI-17 causes a loss of merlin function characterized by merlin phosphorylation, Ras activation and transformation. Constitutively active merlin (S518A) reverses CPI-17-induced transformation, showing that merlin is the decisive substrate of MYPT-1-PP1 delta in tumour suppression. In addition we show that CPI-17 levels are raised in several human tumour cell lines and that the downregulation of CPI-17 induces merlin dephosphorylation, inhibits Ras activation and abolishes the transformed phenotype. MYPT-1-PP1 delta and its substrate merlin are part of a previously undescribed tumour suppressor cascade that can be hindered in two ways, by mutation of the NF2 gene and by upregulation of the oncoprotein CPI-17.	Fritz Lipmann Inst, Liebniz Inst Age Res, D-07745 Jena, Germany; Forschungszentrum Karlsruhe, Inst Toxicol & Genet, D-76021 Karlsruhe, Germany	Leibniz Institut fur Alternsforschung - Fritz-Lipmann-Institut (FLI); Helmholtz Association; Karlsruhe Institute of Technology	Morrison, H (corresponding author), Fritz Lipmann Inst, Liebniz Inst Age Res, Beutenbergstr 11, D-07745 Jena, Germany.	helen@fli-leibniz.de	Morrison, Helen/F-9748-2014; Jin, Hongchuan/C-3686-2009; Morrison, Helen/B-3984-2017; Sperka, Tobias/E-2659-2017	Morrison, Helen/0000-0003-4938-1409; Morrison, Helen/0000-0003-4938-1409; Jin, Hongchuan/0000-0002-6697-3097				Baser ME, 2004, AM J HUM GENET, V75, P231, DOI 10.1086/422700; Baser ME, 1996, NEUROLOGY, V47, P1269, DOI 10.1212/WNL.47.5.1269; BEULLENS M, 1992, J BIOL CHEM, V267, P16538; Colbran RJ, 1997, J NEUROCHEM, V69, P920; DeVitis LR, 1996, HUM GENET, V97, P632; Dounay AB, 2002, CURR MED CHEM, V9, P1939, DOI 10.2174/0929867023368791; Eto M, 1999, BIOCHEMISTRY-US, V38, P16952, DOI 10.1021/bi992030o; Eto M, 1997, FEBS LETT, V410, P356, DOI 10.1016/S0014-5793(97)00657-1; Evans DGR, 2000, J MED GENET, V37, P897, DOI 10.1136/jmg.37.12.897; Feng JH, 1999, J BIOL CHEM, V274, P37385, DOI 10.1074/jbc.274.52.37385; Fukata Y, 1998, J CELL BIOL, V141, P409, DOI 10.1083/jcb.141.2.409; GUTMANN DH, 1994, CURR OPIN NEUROL, V7, P166, DOI 10.1097/00019052-199404000-00014; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Hartshorne DJ, 1999, MOL CELL BIOCHEM, V190, P79, DOI 10.1023/A:1006917032557; Ito M, 2004, MOL CELL BIOCHEM, V259, P197, DOI 10.1023/B:MCBI.0000021373.14288.00; Liu QR, 2002, J BIOL CHEM, V277, P13312, DOI 10.1074/jbc.M107558200; McClatchey AI, 1997, GENE DEV, V11, P1253, DOI 10.1101/gad.11.10.1253; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; McClatchey AI, 2003, NAT REV CANCER, V3, P877, DOI 10.1038/nrc1213; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Shimizu T, 2002, J BIOL CHEM, V277, P10332, DOI 10.1074/jbc.M109979200; Surks HK, 2003, J BIOL CHEM, V278, P51484, DOI 10.1074/jbc.M305622200; Surks HK, 2003, CELL SIGNAL, V15, P937, DOI 10.1016/S0898-6568(03)00057-3; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; Uppal S, 2003, INT J CLIN PRACT, V57, P698; Xiao GH, 2003, GENE CHROMOSOME CANC, V38, P389, DOI 10.1002/gcc.10282	28	144	153	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 3	2006	442	7102					576	579		10.1038/nature04856	http://dx.doi.org/10.1038/nature04856			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	069NQ	16885985	Bronze			2022-12-28	WOS:000239455900046
J	Gibson, MC; Patel, AB; Nagpal, R; Perrimon, N				Gibson, Matthew C.; Patel, Ankit B.; Nagpal, Radhika; Perrimon, Norbert			The emergence of geometric order in proliferating metazoan epithelia	NATURE			English	Article							PATTERNED CELL-PROLIFERATION; DROSOPHILA-MELANOGASTER; WING DISK; DIVISION; POLARITY; PROTEIN; GROWTH; SHAPE; SIZE	The predominantly hexagonal cell pattern of simple epithelia was noted in the earliest microscopic analyses of animal tissues(1), a topology commonly thought to reflect cell sorting into optimally packed honeycomb arrays(2). Here we use a discrete Markov model validated by time-lapse microscopy and clonal analysis to demonstrate that the distribution of polygonal cell types in epithelia is not a result of cell packing, but rather a direct mathematical consequence of cell proliferation. On the basis of in vivo analysis of mitotic cell junction dynamics in Drosophila imaginal discs, we mathematically predict the convergence of epithelial topology to a fixed equilibrium distribution of cellular polygons. This distribution is empirically confirmed in tissue samples from vertebrate, arthropod and cnidarian organisms, suggesting that a similar proliferation-dependent cell pattern underlies pattern formation and morphogenesis throughout the metazoa.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University	Gibson, MC (corresponding author), Stowers Inst Med Res, 1000 E 50th St, Kansas City, MO 64110 USA.	mgx@stowers-institute.org; rad@eecs.harvard.edu		Gibson, Matthew/0000-0001-5588-8842; Perrimon, Norbert/0000-0001-7542-472X				ABBOTT LA, 1981, J THEOR BIOL, V90, P495, DOI 10.1016/0022-5193(81)90302-7; Amonlirdviman K, 2005, SCIENCE, V307, P423, DOI 10.1126/science.1105471; Bertet C, 2004, NATURE, V429, P667, DOI 10.1038/nature02590; BRYANT PJ, 1985, DEV BIOL, V107, P355, DOI 10.1016/0012-1606(85)90317-3; BRYANT PJ, 1970, DEV BIOL, V22, P389, DOI 10.1016/0012-1606(70)90160-0; Classen AK, 2005, DEV CELL, V9, P805, DOI 10.1016/j.devcel.2005.10.016; COWAN R, 1988, J THEOR BIOL, V131, P33, DOI 10.1016/S0022-5193(88)80118-8; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; GARCIABELLIDO A, 1971, DEV BIOL, V24, P61, DOI 10.1016/0012-1606(71)90047-9; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; Graustein WC., 1931, ANN MATH, V32, P149, DOI [10.2307/1968421, DOI 10.2307/1968421]; Halanych KM, 2001, AM ZOOL, V41, P629, DOI 10.1668/0003-1569(2001)041[0629:ABROMP]2.0.CO;2; Hayashi T, 2004, NATURE, V431, P647, DOI 10.1038/nature02952; Kelso RJ, 2004, NUCLEIC ACIDS RES, V32, pD418, DOI 10.1093/nar/gkh014; Lewis FT, 1926, ANAT REC, V33, P331, DOI 10.1002/ar.1090330502; Lewis FT, 1928, ANAT REC, V38, P341, DOI 10.1002/ar.1090380305; Milan M, 1996, P NATL ACAD SCI USA, V93, P640, DOI 10.1073/pnas.93.2.640; Morin X, 2001, P NATL ACAD SCI USA, V98, P15050, DOI 10.1073/pnas.261408198; Resino J, 2002, P NATL ACAD SCI USA, V99, P7502, DOI 10.1073/pnas.072208199; Schwann, 1847, MICROSCOPICAL RES AC; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TAYLOR H., 1998, INTRO STOCHASTIC MOD; Tepass U, 2001, ANNU REV GENET, V35, P747, DOI 10.1146/annurev.genet.35.102401.091415; Thompson D. W., 1917, GROWTH FORM; WEAIRE D, 1984, CONTEMP PHYS, V25, P59, DOI 10.1080/00107518408210979; Zallen JA, 2004, J PHYS-CONDENS MAT, V16, pS5073, DOI 10.1088/0953-8984/16/44/005	26	294	297	3	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 31	2006	442	7106					1038	1041		10.1038/nature05014	http://dx.doi.org/10.1038/nature05014			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	078YF	16900102				2022-12-28	WOS:000240142000049
J	Haber, JE				Haber, James E.			Comment on "Cell type regulates selective segregation of mouse chromosome 7 DNA strands in mitosis"	SCIENCE			English	Editorial Material								Armakolas and Klar ( Reports, 24 February 2006, p. 1146) suggested that segregation of mouse chromosome 7, after induction of a site-specific crossover between homologous chromosomes, is driven by a preferential inheritance of the old Watson and the old Crick DNA strands. However, this interpretation only considered half of the possible outcomes. The conjecture fails when all possible outcomes are examined.	Brandeis Univ, Rosenstiel Ctr, Waltham, MA 02454 USA; Brandeis Univ, Dept Biol, Waltham, MA 02454 USA	Brandeis University; Brandeis University	Haber, JE (corresponding author), Brandeis Univ, Rosenstiel Ctr, Waltham, MA 02454 USA.	haber@brandeis.edu		Haber, James/0000-0002-1878-0610				Armakolas A, 2006, SCIENCE, V311, P1146, DOI 10.1126/science.1120519; Bailey SM, 2004, CYTOGENET GENOME RES, V107, P14, DOI 10.1159/000079565; Liu PT, 2002, NAT GENET, V30, P66, DOI 10.1038/ng788	3	6	6	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 25	2006	313	5790								10.1126/science.1127836	http://dx.doi.org/10.1126/science.1127836			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	076ZT	16931739				2022-12-28	WOS:000239998200053
J	Patolsky, F; Timko, BP; Yu, GH; Fang, Y; Greytak, AB; Zheng, GF; Lieber, CM				Patolsky, Fernando; Timko, Brian P.; Yu, Guihua; Fang, Ying; Greytak, Andrew B.; Zheng, Gengfeng; Lieber, Charles M.			Detection, stimulation, and inhibition of neuronal signals with high-density nanowire transistor arrays	SCIENCE			English	Article							ELECTRICAL DETECTION; PYRAMIDAL NEURONS; NETWORKS; PROPAGATION; RECORDINGS; DENDRITES; CELL	We report electrical properties of hybrid structures consisting of arrays of nanowire field-effect transistors integrated with the individual axons and dendrites of live mammalian neurons, where each nanoscale junction can be used for spatially resolved, highly sensitive detection, stimulation, and/or inhibition of neuronal signal propagation. Arrays of nanowire-neuron junctions enable simultaneous measurement of the rate, amplitude, and shape of signals propagating along individual axons and dendrites. The configuration of nanowire-axon junctions in arrays, as both inputs and outputs, makes possible controlled studies of partial to complete inhibition of signal propagation by both local electrical and chemical stimuli. In addition, nanowire-axon junction arrays were integrated and tested at a level of at least 50 "artificial synapses'' per neuron.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA	Harvard University; Harvard University	Lieber, CM (corresponding author), Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA.	cml@cmliris.harvard.edu	patolsky, Fernando/AAD-1188-2021; Timko, Brian/AAH-8466-2019; Chu, Yung-Ming/C-6318-2009; Zheng, Gengfeng/G-7023-2011	patolsky, Fernando/0000-0002-1382-5357; Timko, Brian/0000-0002-7958-8980; Zheng, Gengfeng/0000-0002-1803-6955; Greytak, Andrew/0000-0001-8978-6457				Antic S, 1999, J NEUROPHYSIOL, V82, P1615, DOI 10.1152/jn.1999.82.3.1615; Bi GQ, 1999, NATURE, V401, P792, DOI 10.1038/44573; Cui Y, 2001, SCIENCE, V293, P1289, DOI 10.1126/science.1062711; Cui Y, 2003, NANO LETT, V3, P149, DOI 10.1021/nl025875l; Frick A, 2004, NAT NEUROSCI, V7, P126, DOI 10.1038/nn1178; Froemke RC, 2005, NATURE, V434, P221, DOI 10.1038/nature03366; Fromherz P, 2002, CHEMPHYSCHEM, V3, P276, DOI 10.1002/1439-7641(20020315)3:3<276::AID-CPHC276>3.0.CO;2-A; Gulledge AT, 2003, J NEUROSCI, V23, P11363; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; Huang Y, 2004, PURE APPL CHEM, V76, P2051, DOI 10.1351/pac200476122051; James CD, 2000, IEEE T BIO-MED ENG, V47, P17, DOI 10.1109/10.817614; James CD, 2004, IEEE T BIO-MED ENG, V51, P1640, DOI 10.1109/TBME.2004.827252; Jimbo Y, 2003, IEEE T BIO-MED ENG, V50, P241, DOI 10.1109/TBME.2002.805470; Jin S, 2004, NANO LETT, V4, P915, DOI 10.1021/nl049659j; Kawaguchi H, 1998, EXP BRAIN RES, V122, P378, DOI 10.1007/s002210050526; Lambacher A, 2004, APPL PHYS A-MATER, V79, P1607, DOI 10.1007/s00339-004-2991-5; Larkum ME, 2002, J NEUROSCI, V22, P6991; LARRY R, 2003, FUNDAMENTAL NEUROSCI, P115; Marom S, 2002, Q REV BIOPHYS, V35, P63, DOI 10.1017/S0033583501003742; Martin AR, 2001, NEURON BRAIN CELLULA; Merz M, 2005, ADV FUNCT MATER, V15, P739, DOI 10.1002/adfm.200400316; Nowak LG, 1998, EXP BRAIN RES, V118, P477, DOI 10.1007/s002210050304; Offenhausser A, 1997, BIOSENS BIOELECTRON, V12, P819, DOI 10.1016/S0956-5663(97)00047-X; Oviedo H, 2005, J NEUROSCI, V25, P4985, DOI 10.1523/JNEUROSCI.0562-05.2005; Patolsky F, 2004, P NATL ACAD SCI USA, V101, P14017, DOI 10.1073/pnas.0406159101; Patolsky F, 2006, ANAL CHEM, V78, P4260, DOI 10.1021/ac069419j; RIJKHOFF NJM, 1994, IEEE T BIO-MED ENG, V41, P413, DOI 10.1109/10.293215; Rutten WLC, 2002, ANNU REV BIOMED ENG, V4, P407, DOI 10.1146/annurev.bioeng.4.020702.153427; Stuart GJ, 2001, NAT NEUROSCI, V4, P63, DOI 10.1038/82910; Sze S. M., 1981, PHYS SEMICONDUCTOR D, P431; Tarek M, 2005, BIOPHYS J, V88, P4045, DOI 10.1529/biophysj.104.050617; Voelker M, 2005, SMALL, V1, P206, DOI 10.1002/smll.200400077; Vuckovic A, 2005, MED BIOL ENG COMPUT, V43, P365, DOI 10.1007/BF02345814; Windhorst U, 1999, MODERN TECHNIQUES NE; Wyart C, 2002, J NEUROSCI METH, V117, P123, DOI 10.1016/S0165-0270(02)00077-8; Yuste R, 1997, CEREB CORTEX, V7, P546, DOI 10.1093/cercor/7.6.546; Zheng GF, 2005, NAT BIOTECHNOL, V23, P1294, DOI 10.1038/nbt1138; Zheng GF, 2004, ADV MATER, V16, P1890, DOI 10.1002/adma.200400472	38	703	746	5	341	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 25	2006	313	5790					1100	1104		10.1126/science.1128640	http://dx.doi.org/10.1126/science.1128640			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	076ZT	16931757				2022-12-28	WOS:000239998200040
J	Kearon, C; Ginsberg, JS; Julian, JA; Douketis, J; Solymoss, S; Ockelford, P; Jackson, S; Turpie, AG; MacKinnon, B; Hirsh, J; Gent, M				Kearon, Clive; Ginsberg, Jeffrey S.; Julian, Jim A.; Douketis, James; Solymoss, Susan; Ockelford, Paul; Jackson, Sharon; Turpie, Alexander G.; MacKinnon, Betsy; Hirsh, Jack; Gent, Michael		FIDO Investigators	Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEEP-VEIN THROMBOSIS; PARTIAL THROMBOPLASTIN TIME; CONTINUOUS INTRAVENOUS HEPARIN; INITIAL TREATMENT; ANTITHROMBOTIC THERAPY; SUBCUTANEOUS HEPARIN; PULMONARY-EMBOLISM; RANDOMIZED-TRIAL; WARFARIN; FONDAPARINUX	Context When unfractionated heparin is used to treat acute venous thromboembolism, it is usually administered by intravenous infusion with coagulation monitoring, which requires hospitalization. However, subcutaneous administration of fixed-dose, weight-adjusted, unfractionated heparin may be suitable for inpatient and outpatient treatment of venous thromboembolism. Objective To determine if fixed-dose, weight-adjusted, subcutaneous unfractionated heparin is as effective and safe as low-molecular-weight heparin for treatment of venous thromboembolism. Design, Setting, and Patients Randomized, open-label, adjudicator-blinded, non-inferiority trial of 708 patients aged 18 years or older with acute venous thromboembolism from 6 university-affiliated clinical centers in Canada and New Zealand conducted from September 1998 through February 2004. Of the randomized patients, 11 were subsequently excluded from the analysis of efficacy and 8 from the analysis of safety. Interventions Unfractionated heparin was administered subcutaneously as an initial dose of 333 U/kg, followed by a fixed dose of 250 U/kg every 12 hours (n = 345). Low-molecular-weight heparin (dalteparin or enoxaparin) was administered subcutaneously at a dose of 100 IU/kg every 12 hours (n = 352). Both treatments could be administered out of hospital and both were overlapped with 3 months of warfarin therapy. Main Outcome Measures Recurrent venous thromboembolism within 3 months and major bleeding within 10 days of randomization. Results Recurrent venous thromboembolism occurred in 13 patients in the unfractionated heparin group (3.8%) compared with 12 patients in the low-molecular-weight heparin group (3.4%; absolute difference, 0.4%; 95% confidence interval, -2.6% to 3.3%). Major bleeding during the first 10 days of treatment occurred in 4 patients in the unfractionated heparin group (1.1%) compared with 5 patients in the low-molecular-weight heparin group (1.4%; absolute difference, -0.3%; 95% confidence interval, -2.3% to 1.7%). Treatment was administered entirely out of hospital in 72% of the unfractionated heparin group and 68% of the low-molecular-weight heparin group. Conclusion Fixed-dose subcutaneous unfractionated heparin is as effective and safe as low-molecular-weight heparin in patients with acute venous thromboembolism and is suitable for outpatient treatment.	McMaster Univ, Hamilton, ON, Canada; Henderson Res Ctr, Hamilton, ON, Canada; McGill Univ, Montreal, PQ, Canada; Univ Auckland, Auckland 1, New Zealand	McMaster University; McGill University; University of Auckland	Kearon, C (corresponding author), Hamilton Hlth Sci, Henderson Div, 711 Concess St, Hamilton, ON L8V 1C3, Canada.	kearonc@mcmaster.ca	Douketis, James/AAO-5659-2021; ginsberg, jeffrey s/ABC-1065-2020					Anand S, 1996, ARCH INTERN MED, V156, P1677, DOI 10.1001/archinte.156.15.1677; Anand SS, 1999, ARCH INTERN MED, V159, P2029, DOI 10.1001/archinte.159.17.2029; BASU D, 1972, NEW ENGL J MED, V287, P324, DOI 10.1056/NEJM197208172870703; Bates SM, 2001, ARCH INTERN MED, V161, P385, DOI 10.1001/archinte.161.3.385; Buller HR, 2004, CHEST, V126, p401S, DOI 10.1378/chest.126.3_suppl.401S; Buller HR, 2004, ANN INTERN MED, V140, P867, DOI 10.7326/0003-4819-140-11-200406010-00007; Buller HR, 2003, NEW ENGL J MED, V349, P1695; Couturaud F, 2001, THROMB HAEMOSTASIS, V86, P980; FARRINGTON CP, 1990, STAT MED, V9, P1447, DOI 10.1002/sim.4780091208; Fedullo PF, 2003, NEW ENGL J MED, V349, P1247, DOI 10.1056/NEJMcp035442; Fiessinger JN, 2005, JAMA-J AM MED ASSOC, V293, P681, DOI 10.1001/jama.293.6.681; FLEMING T, 2006, RED BOOK 2006; Girolami A, 2004, ARCH INTERN MED, V164, P1077; Gould MK, 1999, ANN INTERN MED, V130, P789, DOI 10.7326/0003-4819-130-10-199905180-00002; Hirsh J, 2004, CHEST, V126, p188S, DOI 10.1378/chest.126.3_suppl.188S; HOMMES DW, 1992, ANN INTERN MED, V116, P279, DOI 10.7326/0003-4819-116-4-279; Hull RD, 1997, ARCH INTERN MED, V157, P2317, DOI 10.1001/archinte.157.20.2317; HULL RD, 1990, NEW ENGL J MED, V322, P1260, DOI 10.1056/NEJM199005033221802; Hull RD, 1997, ARCH INTERN MED, V157, P2562, DOI 10.1001/archinte.157.22.2562; HULL RD, 1986, NEW ENGL J MED, V315, P1109, DOI 10.1056/NEJM198610303151801; Kearon C, 1998, ARCH INTERN MED, V158, P1140, DOI 10.1001/archinte.158.10.1140; Kearon C, 2003, NEW ENGL J MED, V349, P631, DOI 10.1056/NEJMoa035422; Kearon C, 1998, ANN INTERN MED, V128, P663, DOI 10.7326/0003-4819-128-8-199804150-00011; Kearon C, 2000, THROMB RES, V97, P395, DOI 10.1016/S0049-3848(99)00189-9; Koopman MMW, 1996, NEW ENGL J MED, V334, P682, DOI 10.1056/NEJM199603143341102; Lee AYY, 2003, NEW ENGL J MED, V349, P146, DOI 10.1056/NEJMoa025313; Levine M, 1996, NEW ENGL J MED, V334, P677, DOI 10.1056/NEJM199603143341101; Levine MN, 2004, CHEST, V126, p287S, DOI 10.1378/chest.126.3_suppl.287S; O'Brien B, 1999, ARCH INTERN MED, V159, P2298, DOI 10.1001/archinte.159.19.2298; RASCHKE RA, 1993, ANN INTERN MED, V119, P874, DOI 10.7326/0003-4819-119-9-199311010-00002; Schulz KF, 2002, LANCET, V359, P614, DOI 10.1016/S0140-6736(02)07750-4; tenCate JW, 1997, NEW ENGL J MED, V337, P657	32	168	177	1	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 23	2006	296	8					935	942		10.1001/jama.296.8.935	http://dx.doi.org/10.1001/jama.296.8.935			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	076AL	16926353				2022-12-28	WOS:000239929300023
J	Xu, FJ; Sternberg, MR; Kottiri, BJ; McQuillan, GM; Lee, FK; Nahmias, AJ; Berman, SM; Markowitz, LE				Xu, Fujie; Sternberg, Maya R.; Kottiri, Benny J.; McQuillan, Geraldine M.; Lee, Francis K.; Nahmias, Andre J.; Berman, Stuart M.; Markowitz, Lauri E.			Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GENITAL HERPES; CHANGING EPIDEMIOLOGY; RISK FACTOR; INFECTION; TRANSMISSION; ACQUISITION; GLYCOPROTEIN; MEN; PREVALENCE; ANTIBODIES	Context Herpes simplex virus type 1 (HSV-1) and type 2 are common infections worldwide. Herpes simplex virus type 2 (HSV-2) is the cause of most genital herpes and is almost always sexually transmitted. In contrast, HSV-1 is usually transmitted during childhood via nonsexual contacts. Preexisting HSV-1 antibodies can alleviate clinical manifestations of subsequently acquired HSV-2. Furthermore, HSV-1 has become an important cause of genital herpes in some developed countries. Objective To examine trends in HSV-1 and HSV-2 seroprevalence in the United States in 1999-2004 compared with 1988-1994. Design, Settings, and Participants Cross-sectional, nationally representative surveys (US National Health and Nutrition Examination Surveys [ NHANES]), were used to compare national seroprevalence estimates from 1999-2004 with those from 19881994, and changes in HSV-1 and HSV-2 seroprevalence since 1976-1980 were reviewed. Persons aged 14 to 49 years were included in these analyses. Main Outcome Measures Seroprevalence of HSV-1 and HSV-2 antibodies based on results from type-specific immunodot assays; diagnosis of genital herpes. Results The overall age-adjusted HSV-2 seroprevalence was 17.0% (95% confidence interval [CI], 15.8%-18.3%) in 1999-2004 and 21.0% (95% CI, 19.1%-23.1%) in 1988-1994, a relative decrease of 19.0% between the 2 surveys (95% CI, -28.6% to -9.5%; P < .001). Decreases in HSV-2 seroprevalence were especially concentrated in persons aged 14 to 19 years between 1988 and 2004. In adolescents aged 17 to 19 years and young adults, the decreases in HSV-2 seroprevalence were significant even after adjusting for changes in sexual behaviors. Among those infected with HSV-2, the percentage who reported having been diagnosed with genital herpes was statistically different (14.3% in 1999-2004 and 9.9% in 1988-1994; P =.02). Seroprevalence of HSV-1 decreased from 62.0% (95% CI, 59.6%-64.6%) in 1988-1994 to 57.7% (95% CI, 55.9%-59.5%) in 1999-2004, a relative decrease of 6.9% between the 2 surveys (95% CI, -11.6% to -2.3%; P =. 006). Among persons infected with HSV-1 but not with HSV-2, a higher percentage reported having been diagnosed with genital herpes in 1999-2004 compared with 1988-1994 (1.8% vs 0.4%, respectively; P < .001). Conclusions These data show declines in HSV-2 seroprevalence, suggesting that the trajectory of increasing HSV-2 seroprevalence in the United States has been reversed. Seroprevalence of HSV-1 decreased but the incidence of genital herpes caused by HSV-1 may be increasing.	Ctr Dis Control & Prevent, Atlanta, GA 30333 USA; Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA	Centers for Disease Control & Prevention - USA; Emory University	Xu, FJ (corresponding author), Ctr Dis Control & Prevent, Mailstop E-02,160 Clifton Rd, Atlanta, GA 30333 USA.	fax1@cdc.gov						ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; Brown ZA, 2003, JAMA-J AM MED ASSOC, V289, P203, DOI 10.1001/jama.289.2.203; Celum CL, 2005, J INFECT DIS, V191, pS107, DOI 10.1086/425272; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P856; Corey L, 2004, NEW ENGL J MED, V350, P11, DOI 10.1056/NEJMoa035144; Corey L, 1999, SEX TRANSM DIS, V3rd, P285; Cowan FM, 2001, INT J EPIDEMIOL, V30, P588, DOI 10.1093/ije/30.3.588; ELANDTJOHNSON RC, 1980, SURVIVAL MODELS DATA, P69; Engelberg R, 2003, SEX TRANSM DIS, V30, P174, DOI 10.1097/00007435-200302000-00015; Fleming DT, 1997, NEW ENGL J MED, V337, P1105, DOI 10.1056/NEJM199710163371601; Freeman EE, 2006, AIDS, V20, P73, DOI 10.1097/01.aids.0000198081.09337.a7; Halpern-Felsher BL, 2005, PEDIATRICS, V115, P845, DOI 10.1542/peds.2004-2108; Hashido M, 1999, MICROBIOL IMMUNOL, V43, P177, DOI 10.1111/j.1348-0421.1999.tb02390.x; HOLMBERG SD, 1988, JAMA-J AM MED ASSOC, V259, P1048, DOI 10.1001/jama.259.7.1048; Kimberlin DW, 2004, NEW ENGL J MED, V350, P1970, DOI 10.1056/NEJMcp023065; Korn EL., 1999, ANAL HLTH SURVEYS; Lafferty WE, 2000, J INFECT DIS, V181, P1454, DOI 10.1086/315395; LAFFERTY WE, 1987, NEW ENGL J MED, V316, P1444, DOI 10.1056/NEJM198706043162304; Langenberg AGM, 1999, NEW ENGL J MED, V341, P1432, DOI 10.1056/NEJM199911043411904; LEE FK, 1986, J VIROL METHODS, V14, P111, DOI 10.1016/0166-0934(86)90041-8; LEE FK, 1985, J CLIN MICROBIOL, V22, P641, DOI 10.1128/JCM.22.4.641-644.1985; Lowhagen GB, 2000, SEX TRANSM INFECT, V76, P179, DOI 10.1136/sti.76.3.179; McClelland RS, 2002, AIDS, V16, P2425, DOI 10.1097/00002030-200212060-00007; MODADJER L, 1996, NATL HLTH NUTR EXAMI, V3; Mosher WD, 2005, ADV DATA, P10; NAHMIAS AJ, 1990, SCAND J INFECT DIS, P19; Nahmias AJ, 2006, HERPES SIMPLEX VIRUS, P55; National Center for Health Statistics/Centers for Disease Control and Prevention, 2004, NHANES AN GUID; Nilsen A, 2000, ACTA OBSTET GYN SCAN, V79, P693, DOI 10.1034/j.1600-0412.2000.079008693.x; Pebody RG, 2004, SEX TRANSM INFECT, V80, P185, DOI 10.1136/sti.2003.005850; Renzi C, 2003, J INFECT DIS, V187, P19, DOI 10.1086/345867; Reynolds SJ, 2003, J INFECT DIS, V187, P1513, DOI 10.1086/368357; Ribes JA, 2001, J CLIN MICROBIOL, V39, P3321, DOI 10.1128/JCM.39.9.3321-3325.2001; Roberts CM, 2003, SEX TRANSM DIS, V30, P797, DOI 10.1097/01.OLQ.0000092387.58746.C7; Santelli JS, 2004, J ADOLESCENT HEALTH, V35, P80, DOI 10.1016/j.jadohealth.2004.05.001; Schacker T, 2002, J INFECT DIS, V186, P1718, DOI 10.1086/345771; Schacker T, 1998, JAMA-J AM MED ASSOC, V280, P61, DOI 10.1001/jama.280.1.61; Schenker N, 2001, AM STAT, V55, P182, DOI 10.1198/000313001317097960; Schillinger JA, 2004, SEX TRANSM DIS, V31, P753, DOI 10.1097/01.olq.0000145852.43262.c3; SCHMIDLEY D, 2001, PROFILE FOREIGN BORN; Scoular A, 2002, BRIT MED J, V324, P1366, DOI 10.1136/bmj.324.7350.1366; Serwadda D, 2003, J INFECT DIS, V188, P1492, DOI 10.1086/379333; Smith JS, 2002, J INFECT DIS, V186, pS3, DOI 10.1086/343739; Stanberry L.R., 1997, VIRAL INFECT HUMANS, P419; Stanberry LR, 2002, NEW ENGL J MED, V347, P1652, DOI 10.1056/NEJMoa011915; Tran T, 2004, SEX TRANSM INFECT, V80, P277, DOI 10.1136/sti.2004.009753; Turner CF, 1998, SCIENCE, V280, P867, DOI 10.1126/science.280.5365.867; Vyse AJ, 2000, SEX TRANSM INFECT, V76, P183, DOI 10.1136/sti.76.3.183; Wald A, 2005, ANN INTERN MED, V143, P707, DOI 10.7326/0003-4819-143-10-200511150-00007; Wald A, 2002, CLIN INFECT DIS, V35, pS173, DOI 10.1086/342104; Wald A, 2002, J INFECT DIS, V185, P45, DOI 10.1086/338231; Wald A, 2001, JAMA-J AM MED ASSOC, V285, P3100, DOI 10.1001/jama.285.24.3100; Xu FJ, 2002, J INFECT DIS, V185, P1019, DOI 10.1086/340041; 1994, VITAL HLTH STAT, V1, P20	54	657	689	0	24	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 23	2006	296	8					964	973		10.1001/jama.296.8.964	http://dx.doi.org/10.1001/jama.296.8.964			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	076AL	16926356	Bronze			2022-12-28	WOS:000239929300026
J	Arjamaa, O				Arjamaa, Olli			Gene silencing in wet age-related macular degeneration	LANCET			English	Editorial Material							RNA INTERFERENCE		Univ Turku, Dept Biol, Turku 20014, Finland	University of Turku	Arjamaa, O (corresponding author), Univ Turku, Dept Biol, Turku 20014, Finland.	olli.arjamaa@utu.fi						*ACQ PHARM, 2006, ACQ PHARM REP POS IN; Campochiaro PA, 2006, GENE THER, V13, P559, DOI 10.1038/sj.gt.3302653; Caplen NJ, 2004, GENE THER, V11, P1241, DOI 10.1038/sj.gt.3302324; Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564; Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760; Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042; Stevenson M, 2004, NEW ENGL J MED, V351, P1772, DOI 10.1056/NEJMra045004	7	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 19	2006	368	9536					630	631		10.1016/S0140-6736(06)69226-X	http://dx.doi.org/10.1016/S0140-6736(06)69226-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	074YT	16920453				2022-12-28	WOS:000239849200010
J	Franzosi, MG				Franzosi, Maria Grazia			Should we continue to use BMI as a cardiovascular risk factor?	LANCET			English	Editorial Material							BODY-MASS INDEX; MYOCARDIAL-INFARCTION; 52 COUNTRIES; MORTALITY; OBESITY		Mario Negri Inst Pharmacol Res, Dept Cardiovasc Res, I-20157 Milan, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Franzosi, MG (corresponding author), Mario Negri Inst Pharmacol Res, Dept Cardiovasc Res, Via Eritrea 62, I-20157 Milan, Italy.	franzosi@marionegri.it						Dyer AR, 2004, ANN EPIDEMIOL, V14, P101, DOI 10.1016/S1047-2797(03)00121-2; Flegal KM, 2005, JAMA-J AM MED ASSOC, V293, P1861, DOI 10.1001/jama.293.15.1861; Gurm HS, 2002, AM J CARDIOL, V90, P42, DOI 10.1016/S0002-9149(02)02384-6; Haslam DW, 2005, LANCET, V366, P1197, DOI 10.1016/S0140-6736(05)67483-1; LI TY, 2006, CIRCULATION, V113, P1524; Mcgee DL, 2005, ANN EPIDEMIOL, V15, P87, DOI 10.1016/j.annepidem.2004.05.012; McTigue K, 2006, JAMA-J AM MED ASSOC, V296, P79, DOI 10.1001/jama.296.1.79; Romero-Corral A, 2006, LANCET, V368, P666, DOI 10.1016/S0140-6736(06)69251-9; Yan LJL, 2006, JAMA-J AM MED ASSOC, V295, P190, DOI 10.1001/jama.295.2.190; Yusuf S, 2005, LANCET, V366, P1640, DOI 10.1016/S0140-6736(05)67663-5; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9; 2006, LANCET, V367, P1549	12	80	85	1	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 19	2006	368	9536					624	625		10.1016/S0140-6736(06)69222-2	http://dx.doi.org/10.1016/S0140-6736(06)69222-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	074YT	16920449				2022-12-28	WOS:000239849200006
J	Barkana, R				Barkana, Rennan			The first stars in the universe and cosmic reionization	SCIENCE			English	Review							21 CENTIMETER TOMOGRAPHY; INTERGALACTIC MEDIUM; HIGH-REDSHIFT; HYDROGEN; FLUCTUATIONS; GALAXIES; ORIGIN	The earliest generation of stars, far from being a mere novelty, transformed the universe from darkness to light. The first atoms to form after the Big Bang filled the universe with atomic hydrogen and a few light elements. As gravity pulled gas clouds together, the first stars ignited and their radiation turned the surrounding atoms into ions. By looking at gas between us and distant galaxies, we know that this ionization eventually pervaded all space, so that few hydrogen atoms remain today between galaxies. Knowing exactly when and how it did so is a primary goal of cosmologists, because this would tell us when the early stars formed and in what kinds of galaxies. Although this ionization is beginning to be understood by using theoretical models and computer simulations, a new generation of telescopes is being built that will map atomic hydrogen throughout the universe.	Tel Aviv Univ, Raymond & Beverly Sackler Fac Exact Sci, Sch Phys & Astron, IL-69978 Tel Aviv, Israel	Tel Aviv University	Barkana, R (corresponding author), Tel Aviv Univ, Raymond & Beverly Sackler Fac Exact Sci, Sch Phys & Astron, IL-69978 Tel Aviv, Israel.	barkana@wise.tau.ac.il						ARONS J, 1972, ASTROPHYS J, V177, P1, DOI 10.1086/151682; Barkana R, 2005, ASTROPHYS J, V626, P1, DOI 10.1086/429954; Barkana R, 2005, ASTROPHYS J, V624, pL65, DOI 10.1086/430599; Barkana R, 2004, ASTROPHYS J, V609, P474, DOI 10.1086/421079; Barkana R, 2001, PHYS REP, V349, P126, DOI 10.1016/s0370-1573(01)00019-9; Bharadwaj S, 2004, MON NOT R ASTRON SOC, V352, P142, DOI 10.1111/j.1365-2966.2004.07907.x; Bowman JD, 2006, ASTROPHYS J, V638, P20, DOI 10.1086/498703; Bromm V, 1999, ASTROPHYS J, V527, pL5, DOI 10.1086/312385; Ciardi B, 2003, MON NOT R ASTRON SOC, V344, pL7, DOI 10.1046/j.1365-8711.2003.06976.x; Di Matteo T, 2002, ASTROPHYS J, V564, P576, DOI 10.1086/324293; FUKUGITA M, 1994, MON NOT R ASTRON SOC, V269, P563, DOI 10.1093/mnras/269.3.563; Furlanetto SR, 2004, ASTROPHYS J, V613, P1, DOI 10.1086/423025; GUNN JE, 1965, ASTROPHYS J, V142, P1633, DOI 10.1086/148444; Haiman Z, 1997, ASTROPHYS J, V483, P21, DOI 10.1086/304238; HOGAN CJ, 1979, MON NOT R ASTRON SOC, V188, P791, DOI 10.1093/mnras/188.4.791; Hu EM, 2002, ASTROPHYS J, V568, pL75, DOI 10.1086/340424; KAISER N, 1987, MON NOT R ASTRON SOC, V227, P1; KAISER N, 1984, ASTROPHYS J, V284, pL9, DOI 10.1086/184341; KAMIONKOWSKI M, 1994, ASTROPHYS J, V426, pL57, DOI 10.1086/187339; Lidz A, 2006, ASTROPHYS J, V639, pL47, DOI 10.1086/502678; Loeb A, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.211301; Madau P, 1997, ASTROPHYS J, V475, P429, DOI 10.1086/303549; MCQUINN M, IN PRESS ASTROPHYS J; MELLEMA G, IN PRESS MON NOT R A; NAOZ S, IN PRESS MON NOT R A; SCOTT D, 1990, MON NOT R ASTRON SOC, V247, P510; SHAPIRO PR, 1987, APJ, V321, P107; TEGMARK M, 1994, ASTROPHYS J, V420, P484, DOI 10.1086/173579; Tegmark M, 1997, ASTROPHYS J, V474, P1, DOI 10.1086/303434; White RL, 2003, ASTRON J, V126, P1, DOI 10.1086/375547; Wyithe JSB, 2004, NATURE, V427, P815, DOI 10.1038/nature02336; YOSHIDA N, IN PRESS ASTROPHYS J; ZAHN O, IN PRESS ASTROPHYS J; [No title captured]	36	20	20	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 18	2006	313	5789					931	934		10.1126/science.1125644	http://dx.doi.org/10.1126/science.1125644			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	074MR	16917052	Green Submitted			2022-12-28	WOS:000239817000032
J	Bayer, R; Fairchild, AL				Bayer, Ronald; Fairchild, Amy L.			Changing the paradigm for HIV testing - The end of exceptionalism	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Columbia Univ, Mailman Sch Publ Hlth, Dept Sociomed Sci, Ctr Hist & Eth Publ Hlth, New York, NY 10027 USA	Columbia University	Bayer, R (corresponding author), Columbia Univ, Mailman Sch Publ Hlth, Dept Sociomed Sci, Ctr Hist & Eth Publ Hlth, New York, NY 10027 USA.		Fairchild, Amy/F-1811-2018	Fairchild, Amy/0000-0002-1292-7212				BAYER R, 1991, NEW ENGL J MED, V324, P1500, DOI 10.1056/NEJM199105233242111; U.S. Public Health Service, 2001, MMWR Recomm Rep, V50, P1; HENN M, 2006, CITY HLTH INFORM, V25, P9; STOTO MA, 1999, REDUCING ODDS PREVEN; 2001, MMWR RECOMM REP, V50, P63	5	122	126	1	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 17	2006	355	7					647	649		10.1056/NEJMp068153	http://dx.doi.org/10.1056/NEJMp068153			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	074AN	16914699	Bronze, Green Published			2022-12-28	WOS:000239784500002
J	Bernardi, R; Guernah, I; Jin, D; Grisendi, S; Alimonti, A; Teruya-Feldstein, J; Cordon-Cardo, C; Simon, MC; Rafii, S; Pandolfi, PP				Bernardi, Rosa; Guernah, Ilhem; Jin, David; Grisendi, Silvia; Alimonti, Andrea; Teruya-Feldstein, Julie; Cordon-Cardo, Carlos; Simon, M. Celeste; Rafii, Shahin; Pandolfi, Pier Paolo			PML inhibits HIF-1 alpha translation and neoangiogenesis through repression of mTOR	NATURE			English	Article							MAMMALIAN TARGET; TUMOR ANGIOGENESIS; SUPPRESSOR PML; RAR-ALPHA; RAPAMYCIN; PROTEIN; HYPOXIA; GROWTH; CANCER; EXPRESSION	Loss of the promyelocytic leukaemia (PML) tumour suppressor has been observed in several human cancers. The tumour-suppressive function of PML has been attributed to its ability to induce growth arrest, cellular senescence and apoptosis. Here we identify PML as a critical inhibitor of neoangiogenesis ( the formation of new blood vessels) in vivo, in both ischaemic and neoplastic conditions, through the control of protein translation. We demonstrate that in hypoxic conditions PML acts as a negative regulator of the synthesis rate of hypoxia-inducible factor 1 alpha (HIF-1 alpha) by repressing mammalian target of rapamycin ( mTOR). PML physically interacts with mTOR and negatively regulates its association with the small GTPase Rheb by favouring mTOR nuclear accumulation. Notably, Pml(-/-) cells and tumours display higher sensitivity both in vitro and in vivo to growth inhibition by rapamycin, and lack of PML inversely correlates with phosphorylation of ribosomal protein S6 and tumour angiogenesis in mouse and human tumours. Thus, our findings identify PML as a novel suppressor of mTOR and neoangiogenesis.	Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Canc Biol & Genet Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Dept Pathol, New York, NY 10021 USA; Weill Cornell Med Coll, Howard Hughes Med Inst, Dept Med Genet, Div Hematol Oncol, New York, NY 10021 USA; Univ Penn, Ctr Canc, Howard Hughes Med Inst, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; Univ Penn, Ctr Canc, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University; Howard Hughes Medical Institute; Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Pandolfi, PP (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Canc Biol & Genet Program, 1275 York Ave, New York, NY 10021 USA.	p-pandolfi@ski.mskcc.org	Simon, Celeste/AAG-3941-2021; bernardi, rosa/B-1650-2013	bernardi, rosa/0000-0002-3607-6336; Alimonti, Andrea/0000-0002-9362-2313				Amano K, 2004, J MOL CELL CARDIOL, V36, P469, DOI 10.1016/j.yjmcc.2004.01.006; Arsham AM, 2003, J BIOL CHEM, V278, P29655, DOI 10.1074/jbc.M212770200; Bernardi R, 2004, NAT CELL BIOL, V6, P665, DOI 10.1038/ncb1147; Brahimi-Horn C, 2005, CRIT REV ONCOL HEMAT, V53, P115, DOI 10.1016/j.critrevonc.2004.09.003; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; Corada M, 2002, BLOOD, V100, P905, DOI 10.1182/blood.V100.3.905; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; Gambacorta M, 1996, AM J PATHOL, V149, P2023; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; Gurrieri C, 2004, JNCI-J NATL CANCER I, V96, P269, DOI 10.1093/jnci/djh043; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Harrington LS, 2005, TRENDS BIOCHEM SCI, V30, P35, DOI 10.1016/j.tibs.2004.11.003; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Kaelin WG, 2002, GENE DEV, V16, P1441, DOI 10.1101/gad.1003602; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kim JE, 2000, P NATL ACAD SCI USA, V97, P14340, DOI 10.1073/pnas.011511898; KOKEN MHM, 1995, ONCOGENE, V10, P1315; LAVAU C, 1995, ONCOGENE, V11, P871; Liao F, 2002, CANCER RES, V62, P2567; Lin HK, 2004, NATURE, V431, P205, DOI 10.1038/nature02783; Liu LP, 2006, MOL CELL, V21, P521, DOI 10.1016/j.molcel.2006.01.010; Long XM, 2005, J BIOL CHEM, V280, P23433, DOI 10.1074/jbc.C500169200; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Marti Hugo H., 1999, Thrombosis and Haemostasis, V82, P44; Martin DE, 2005, CURR OPIN CELL BIOL, V17, P158, DOI 10.1016/j.ceb.2005.02.008; Paglin S, 2005, CANCER RES, V65, P11061, DOI 10.1158/0008-5472.CAN-05-1083; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; Park IH, 2002, J BIOL CHEM, V277, P31423, DOI 10.1074/jbc.M204080200; Rabbany SY, 2003, TRENDS MOL MED, V9, P109, DOI 10.1016/S1471-4914(03)00021-2; Rafii S, 2003, NAT MED, V9, P702, DOI 10.1038/nm0603-702; Rego EM, 2001, J EXP MED, V193, P521, DOI 10.1084/jem.193.4.521; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Sawyers CL, 2003, CANCER CELL, V4, P343, DOI 10.1016/S1535-6108(03)00275-7; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Takahashi Y, 2004, ONCOGENE, V23, P2819, DOI 10.1038/sj.onc.1207533; Trotman LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809; Vignot S, 2005, ANN ONCOL, V16, P525, DOI 10.1093/annonc/mdi113; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; Zhang P, 2000, INT J CANCER, V85, P599, DOI 10.1002/(SICI)1097-0215(20000301)85:5<599::AID-IJC1>3.0.CO;2-#; Zhu J, 2001, ONCOGENE, V20, P7257, DOI 10.1038/sj.onc.1204852	47	312	327	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 17	2006	442	7104					779	785		10.1038/nature05029	http://dx.doi.org/10.1038/nature05029			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	074DK	16915281				2022-12-28	WOS:000239792700038
J	Lowry, AR				Lowry, Anthony R.			Resonant slow fault slip in subduction zones forced by climatic load stress	NATURE			English	Article							EPISODIC TREMOR; SILENT SLIP; EARTHQUAKES; MODEL; DEFORMATION; EVENTS	Global Positioning System (GPS) measurements at subduction plate boundaries often record fault movements similar to earthquakes but much slower, occurring over timescales of similar to 1 week to similar to 1 year. These 'slow slip events' have been observed in Japan(1,2), Cascadia(3-7), Mexico(8,9), Alaska(10) and New Zealand(11). The phenomenon is poorly understood, but several observations hint at the processes underlying slow slip. Although slip itself is silent, seismic instruments often record coincident low-amplitude tremor in a narrow ( 1 - 5 cycles per second) frequency range(12). Also, modelling of GPS data(3,7,9) and estimates of tremor location(13) indicate that slip focuses near the transition from unstable('stick-slip') to stable friction at the deep limit of the earthquake-producing seismogenic zone. Perhaps most intriguingly, slow slip is periodic at several locations, with recurrence varying from 6 to 18 months depending on which subduction zone ( or even segment) is examined(4-6,9). Here I show that such periodic slow fault slip may be a resonant response to climate-driven stress perturbations. Fault slip resonance helps to explain why slip events are periodic, why periods differ from place to place, and why slip focuses near the base of the seismogenic zone. Resonant slip should initiate within the rupture zone of future great earthquakes, suggesting that slow slip may illuminate fault properties that control earthquake slip.	Univ Colorado, Dept Phys, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Lowry, AR (corresponding author), Utah State Univ, Dept Geol, Logan, UT 84322 USA.	arlowry@himalaya.colorado.edu	Lowry, Anthony R/F-8158-2012	Lowry, Anthony R/0000-0001-6023-3090				ANDERSON JG, 1986, SCIENCE, V233, P1043, DOI 10.1126/science.233.4768.1043; BLANPIED ML, 1995, J GEOPHYS RES-SOL EA, V100, P13045, DOI 10.1029/95JB00862; CHOUET B, 1988, J GEOPHYS RES-SOLID, V93, P4375, DOI 10.1029/JB093iB05p04375; Cohen SC, 2004, ADV GEOPHYS, V47, P1, DOI 10.1016/S0065-2687(04)47001-0; DIETERICH JH, 1979, J GEOPHYS RES, V84, P2161, DOI 10.1029/JB084iB05p02161; Douglas A, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL023607; Dragert H, 2004, EARTH PLANETS SPACE, V56, P1143, DOI 10.1186/BF03353333; Dragert H, 2001, SCIENCE, V292, P1525, DOI 10.1126/science.1060152; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; FAN Y, 2004, J GEOPHYS RES, V109, DOI DOI 10.1029/2004JD004345; Fluck P, 1997, J GEOPHYS RES-SOL EA, V102, P20539, DOI 10.1029/97JB01642; Hirose H, 1999, GEOPHYS RES LETT, V26, P3237, DOI 10.1029/1999GL010999; Kao H, 2005, NATURE, V436, P841, DOI 10.1038/nature03903; Liu YJ, 2005, J GEOPHYS RES-SOL EA, V110, DOI 10.1029/2004JB003424; Lowry AR, 2001, GEOPHYS RES LETT, V28, P3753, DOI 10.1029/2001GL013238; LOWRY AR, UNPUB GEOPHYS J INT; MALONE S, 2004, EOS, V85; Melbourne TI, 2003, SCIENCE, V300, P1886, DOI 10.1126/science.1086163; Miller MM, 2002, SCIENCE, V295, P2423, DOI 10.1126/science.1071193; Obara K, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020848; OKADA Y, 1992, B SEISMOL SOC AM, V82, P1018; Perfettini H, 2001, J GEOPHYS RES-SOL EA, V106, P13455, DOI 10.1029/2000JB900366; Perfettini H, 2001, GEOPHYS RES LETT, V28, P435, DOI 10.1029/2000GL011686; Rogers G, 2003, SCIENCE, V300, P1942, DOI 10.1126/science.1084783; Shen ZK, 2005, B SEISMOL SOC AM, V95, P2009, DOI 10.1785/0120050020; Shibazaki B, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017047; Szeliga W, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020824; Wahr J, 1998, J GEOPHYS RES-SOL EA, V103, P30205, DOI 10.1029/98JB02844; Wahr J. M., 1983, GEODESY GLOBAL GEODY, P327; Williams CA, 2001, GEOPHYS RES LETT, V28, P2125, DOI 10.1029/2000GL012623	30	60	62	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 17	2006	442	7104					802	805		10.1038/nature05055	http://dx.doi.org/10.1038/nature05055			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	074DK	16915286				2022-12-28	WOS:000239792700043
J	Bunnell, R; Mermin, J; De Cock, KM				Bunnell, Rebecca; Mermin, Jonathan; De Cock, Kevin M.			HIV prevention for a threatened continent - Implementing positive prevention in Africa	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							SEXUALLY-TRANSMITTED-DISEASES; ANTIRETROVIRAL THERAPY; DISCORDANT COUPLES; TRANSMISSION; INTERVENTIONS; RISK; BEHAVIOR; WOMEN		Ctr Dis Control & Prevent Uganda, Global AIDS Program, Natl Ctr HIV STD & TB Prevent, Entebbe, Uganda; World Hlth Org, Dept HIV AIDS, Geneva, Switzerland	World Health Organization	Bunnell, R (corresponding author), Uganda Virus Res Inst, POB 49, Entebbe, Uganda.	rrb7@cdc.gov	Mermin, Jonathan/J-9847-2012					ALLEN S, 1992, BRIT MED J, V304, P1605, DOI 10.1136/bmj.304.6842.1605; Auvert B, 2005, PLOS MED, V2, P1112, DOI 10.1371/journal.pmed.0020298; Bunnell R, 2006, AIDS, V20, P85, DOI 10.1097/01.aids.0000196566.40702.28; Bunnell RE, 2005, AIDS CARE, V17, P999, DOI 10.1080/09540120500100718; Castilla J, 2005, JAIDS-J ACQ IMM DEF, V40, P96, DOI 10.1097/01.qai.0000157389.78374.45; Centers for Disease Control and Prevention (CDC), 2003, MMWR Recomm Rep, V52, P1; Cohen MS, 1998, LANCET, V351, P5, DOI 10.1016/S0140-6736(98)90002-2; Crepaz N, 2006, AIDS, V20, P143, DOI 10.1097/01.aids.0000196166.48518.a0; Farquhar C, 2004, JAIDS-J ACQ IMM DEF, V37, P1620, DOI 10.1097/00126334-200412150-00016; Gichangi P, 2000, INT J STD AIDS, V11, P257, DOI 10.1258/0956462001915660; Gordon CM, 2005, AIDS EDUC PREV, V17, P6, DOI 10.1521/aeap.17.2.6.58697; Heyns AD, 2006, JAMA-J AM MED ASSOC, V295, P519, DOI 10.1001/jama.295.5.519; KORENROMP EL, 1995, J INFECT DIS S1, V191, pS168; Leonard L, 2000, AIDS EDUC PREV, V12, P21; Marks G, 2005, JAIDS-J ACQ IMM DEF, V39, P446, DOI 10.1097/01.qai.0000151079.33935.79; Medley A, 2004, B WORLD HEALTH ORGAN, V82, P299; Mermin J, 2005, TROP MED INT HEALTH, V10, P961, DOI 10.1111/j.1365-3156.2005.01488.x; NAKAYIWA S, 2006, AIDS BEHAV      0520; Sweat MD, 2004, AIDS, V18, P1661, DOI 10.1097/01.aids.0000131353.06784.8f; *TACAIDS NBS ORC M, 2005, TANZ HIV AIDS IND SU; *UNAIDS, AIDS EP UPD DEC 2005; *UNAIDS, INT HIV PREV UNAIDS; *US DEP HHS, ACH HIV FREE GEN REC; Wawer MJ, 1999, LANCET, V353, P525, DOI 10.1016/S0140-6736(98)06439-3	24	108	108	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 16	2006	296	7					855	858		10.1001/jama.296.7.855	http://dx.doi.org/10.1001/jama.296.7.855			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	073SR	16905790	Green Published			2022-12-28	WOS:000239763400025
J	Porta, M				Porta, Miquel			Persistent organic pollutants and the burden of diabetes	LANCET			English	Editorial Material									Univ Autonoma Barcelona, Inst Municipal Invest Med, E-08003 Barcelona, Spain; Univ N Carolina, Chapel Hill, NC USA	Autonomous University of Barcelona; University of North Carolina; University of North Carolina Chapel Hill	Porta, M (corresponding author), Univ Autonoma Barcelona, Inst Municipal Invest Med, E-08003 Barcelona, Spain.	mporta@imim.es	Porta, Miquel/B-5787-2008; Porta, Miquel/AAD-5371-2020	Porta, Miquel/0000-0003-1684-7428; Porta, Miquel/0000-0003-1684-7428				Alonso-Magdalena P, 2006, ENVIRON HEALTH PERSP, V114, P106, DOI [10.1289/ehp.8451, 10.1289/ehp.8062]; Daneman D, 2006, LANCET, V367, P847, DOI 10.1016/S0140-6736(06)68341-4; Hansen LG, 1998, ENVIRON HEALTH PERSP, V106, P171, DOI 10.2307/3433919; Lee DH, 2006, DIABETES CARE, V29, P1638, DOI 10.2337/dc06-0543; Longnecker MP, 2001, ENVIRON HEALTH PERSP, V109, P871, DOI 10.2307/3454649; Luch A, 2005, NAT REV CANCER, V5, P113, DOI 10.1038/nrc1546; NHANES III, 2005, 3 CDCP DEP HLTH HUM; Porta M, 2002, OCCUP ENVIRON MED, V59, P651, DOI 10.1136/oem.59.10.651; Remillard RBJ, 2002, ENVIRON HEALTH PERSP, V110, P853, DOI 10.1289/ehp.02110853; Rewers M, 2004, LANCET, V364, P1645, DOI 10.1016/S0140-6736(04)17368-6; Schafer KS, 2002, J EPIDEMIOL COMMUN H, V56, P813, DOI 10.1136/jech.56.11.813; Vasiliu O, 2006, EPIDEMIOLOGY, V17, P352, DOI 10.1097/01.ede.0000220553.84350.c5	12	76	80	1	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 12	2006	368	9535					558	559		10.1016/S0140-6736(06)69174-5	http://dx.doi.org/10.1016/S0140-6736(06)69174-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	074OF	16905002				2022-12-28	WOS:000239821000006
J	Dale, C; Moran, NA				Dale, Colin; Moran, Nancy A.			Molecular interactions between bacterial symbionts and their hosts	CELL			English	Review							III SECRETION SYSTEMS; IN-VITRO CULTIVATION; BUCHNERA-APHIDICOLA; GENOME SEQUENCE; SECONDARY ENDOSYMBIONT; SODALIS-GLOSSINIDIUS; WOLBACHIA-PIPIENTIS; BACTERIOPHAGE-WO; BLOCHMANNIA-FLORIDANUS; OBLIGATE SYMBIONT	Symbiotic bacteria are important in animal hosts, but have been largely overlooked as they have proved difficult to culture in the laboratory Approaches such as comparative genomics and real-time PCR have provided insights into the molecular mechanisms that underpin symbiont-host interactions. Studies on the heritable symbionts of insects have yielded valuable information about how bacteria infect host cells, avoid immune responses, and manipulate host physiology. Furthermore, some symbionts use many of the same mechanisms as pathogens to infect hosts and evade immune responses. Here we discuss what is currently known about the interactions between bacterial symbionts and their hosts.	Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Univ Arizona, Dept Ecol & Evolutionary Biol, Tucson, AZ 85721 USA	Utah System of Higher Education; University of Utah; University of Arizona	Dale, C (corresponding author), Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA.	dale@biology.utah.edu; nmoran@u.arizona.edu	Moran, Nancy A/G-1591-2010					Akman L, 2002, NAT GENET, V32, P402, DOI 10.1038/ng986; Aksoy S., 1995, Insect Molecular Biology, V4, P23, DOI 10.1111/j.1365-2583.1995.tb00004.x; Backhed F, 2004, P NATL ACAD SCI USA, V101, P15718, DOI 10.1073/pnas.0407076101; Backhed F, 2005, SCIENCE, V307, P1915, DOI 10.1126/science.1104816; Baldo L, 2006, MOL BIOL EVOL, V23, P437, DOI 10.1093/molbev/msj049; Baldo L, 2005, J BACTERIOL, V187, P5406, DOI 10.1128/JB.187.15.5406-5418.2005; Bandi C, 2001, TRENDS PARASITOL, V17, P88, DOI 10.1016/S1471-4922(00)01812-2; BAUMANN L, 1994, APPL ENVIRON MICROB, V60, P3440, DOI 10.1128/AEM.60.9.3440-3443.1994; Baumann P, 1996, CURR MICROBIOL, V32, P279, DOI 10.1007/s002849900050; Baumann P, 2005, ANNU REV MICROBIOL, V59, P155, DOI 10.1146/annurev.micro.59.030804.121041; Bordenstein SR, 2005, NAT REV MICROBIOL, V3, P688, DOI 10.1038/nrmicro1233; Bordenstein SR, 2004, MOL BIOL EVOL, V21, P1981, DOI 10.1093/molbev/msh211; Bordenstein SR, 2000, HEREDITY, V84, P54, DOI 10.1046/j.1365-2540.2000.00637.x; Boyd EF, 1997, J BACTERIOL, V179, P1985, DOI 10.1128/jb.179.6.1985-1991.1997; Braendle C, 2003, PLOS BIOL, V1, P70, DOI 10.1371/journal.pbio.0000021; Bresolin G, 2006, MOL MICROBIOL, V59, P503, DOI 10.1111/j.1365-2958.2005.04916.x; Brownlie JC, 2005, CURR BIOL, V15, pR507, DOI 10.1016/j.cub.2005.06.029; Brussow H, 2004, MICROBIOL MOL BIOL R, V68, P560, DOI 10.1128/MMBR.68.3.560-602.2004; Buchner P., 1965, ENDOSYMBIOSIS ANIMAL; Christie PJ, 2004, BBA-MOL CELL RES, V1694, P219, DOI 10.1016/j.bbamcr.2004.02.013; Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; Dale C, 2006, APPL ENVIRON MICROB, V72, P2997, DOI 10.1128/AEM.72.4.2997-3004.2006; Dale C, 2005, MOL BIOL EVOL, V22, P758, DOI 10.1093/molbev/msi061; Dale C, 1999, INT J SYST BACTERIOL, V49, P267, DOI 10.1016/S0020-7519(01)00151-5; Dale C, 2002, P NATL ACAD SCI USA, V99, P12397, DOI 10.1073/pnas.182213299; Dale C, 2001, P NATL ACAD SCI USA, V98, P1883, DOI 10.1073/pnas.021450998; Darby AC, 2005, APPL ENVIRON MICROB, V71, P4833, DOI 10.1128/AEM.71.8.4833-4839.2005; Degnan PH, 2005, GENOME RES, V15, P1023, DOI 10.1101/gr.3771305; Dobson SL, 2002, APPL ENVIRON MICROB, V68, P656, DOI 10.1128/AEM.68.2.656-660.2002; Fares MA, 2002, NATURE, V417, P398, DOI 10.1038/417398a; Ferree PM, 2005, PLOS PATHOG, V1, P111, DOI 10.1371/journal.ppat.0010014; Foster J, 2005, PLOS BIOL, V3, P599, DOI 10.1371/journal.pbio.0030121; Foultier B, 2002, J MOL EVOL, V55, P37, DOI 10.1007/s00239-001-0089-7; Fujii Y, 2004, BIOCHEM BIOPH RES CO, V317, P1183, DOI 10.1016/j.bbrc.2004.03.164; Gil R, 2004, MICROBIOL MOL BIOL R, V68, P518, DOI 10.1128/MMBR.68.3.518-537.2004; Gil R, 2003, P NATL ACAD SCI USA, V100, P9388, DOI 10.1073/pnas.1533499100; Gomez-Valero L, 2004, J BACTERIOL, V186, P6626, DOI 10.1128/JB.186.19.6626-6633.2004; Goodson MS, 2005, APPL ENVIRON MICROB, V71, P6934, DOI 10.1128/AEM.71.11.6934-6946.2005; Groisman EA, 1996, CELL, V87, P791, DOI 10.1016/S0092-8674(00)81985-6; Herold S, 2004, INT J MED MICROBIOL, V294, P115, DOI 10.1016/j.ijmm.2004.06.023; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; Hurst GDD, 2000, EMERG INFECT DIS, V6, P329, DOI 10.3201/eid0604.000402; Hurst GDD, 2001, NAT REV GENET, V2, P597, DOI 10.1038/35084545; Iturbe-Ormaetxe I, 2005, J BACTERIOL, V187, P5136, DOI 10.1128/JB.187.15.5136-5145.2005; KAKEDA K, 1991, J BIOCHEM, V110, P583, DOI 10.1093/oxfordjournals.jbchem.a123623; Koga R, 2003, P ROY SOC B-BIOL SCI, V270, P2543, DOI 10.1098/rspb.2003.2537; Koropatnick TA, 2004, SCIENCE, V306, P1186, DOI 10.1126/science.1102218; LAI CY, 1994, P NATL ACAD SCI USA, V91, P3819, DOI 10.1073/pnas.91.9.3819; Latorre A, 2005, HEREDITY, V95, P339, DOI 10.1038/sj.hdy.6800716; Lefevre C, 2004, MOL BIOL EVOL, V21, P965, DOI 10.1093/molbev/msh063; LI J, 1995, P NATL ACAD SCI USA, V92, P7252, DOI 10.1073/pnas.92.16.7252; Lo N, 2003, MOL BIOL EVOL, V20, P907, DOI 10.1093/molbev/msg097; MacDonald TT, 2005, SCIENCE, V307, P1920, DOI 10.1126/science.1106442; MAHILLON J, 1998, J BACTERIOL, V180, P5306; Masui S, 2000, J MOL EVOL, V51, P491, DOI 10.1007/s002390010112; Masui S, 2001, BIOCHEM BIOPH RES CO, V283, P1099, DOI 10.1006/bbrc.2001.4906; Mavingui P, 2005, APPL ENVIRON MICROB, V71, P6910, DOI 10.1128/AEM.71.11.6910-6917.2005; McFall-Ngai MJ, 2002, DEV BIOL, V242, P1, DOI 10.1006/dbio.2001.0522; McGraw EA, 2004, CURR OPIN MICROBIOL, V7, P67, DOI 10.1016/j.mib.2003.12.003; Moran NA, 2005, P NATL ACAD SCI USA, V102, P16919, DOI 10.1073/pnas.0507029102; Moran NA, 2005, APPL ENVIRON MICROB, V71, P3302, DOI 10.1128/AEM.71.6.3302-3310.2005; Moran NA, 2004, CURR OPIN GENET DEV, V14, P627, DOI 10.1016/j.gde.2004.09.003; Moran NA, 2003, P NATL ACAD SCI USA, V100, P14543, DOI 10.1073/pnas.2135345100; Moran NA, 1996, P NATL ACAD SCI USA, V93, P2873, DOI 10.1073/pnas.93.7.2873; Moran NA, 2005, J BACTERIOL, V187, P4229, DOI 10.1128/JB.187.12.4229-4237.2005; Mosavi LK, 2004, PROTEIN SCI, V13, P1435, DOI 10.1110/ps.03554604; Mota LJ, 2005, FEMS MICROBIOL LETT, V252, P1, DOI 10.1016/j.femsle.2005.08.036; MUNSON MA, 1991, J BACTERIOL, V173, P6321, DOI 10.1128/jb.173.20.6321-6324.1991; Nakabachi A, 2005, P NATL ACAD SCI USA, V102, P5477, DOI 10.1073/pnas.0409034102; Oliver KM, 2006, P ROY SOC B-BIOL SCI, V273, P1273, DOI 10.1098/rspb.2005.3436; Oliver KM, 2005, P NATL ACAD SCI USA, V102, P12795, DOI 10.1073/pnas.0506131102; Oliver KM, 2003, P NATL ACAD SCI USA, V100, P1803, DOI 10.1073/pnas.0335320100; ONeill SL, 1997, INSECT MOL BIOL, V6, P33, DOI 10.1046/j.1365-2583.1997.00157.x; Piel J, 2002, P NATL ACAD SCI USA, V99, P14002, DOI 10.1073/pnas.222481399; Pugsley AP, 2004, MOL MICROBIOL, V52, P3, DOI 10.1111/j.1365-2958.2003.03966.x; Russell JA, 2005, APPL ENVIRON MICROB, V71, P7987, DOI 10.1128/AEM.71.12.7987-7994.2005; Sanogo YO, 2006, INSECT BIOCHEM MOLEC, V36, P80, DOI 10.1016/j.ibmb.2005.11.001; Scarborough CL, 2005, SCIENCE, V310, P1781, DOI 10.1126/science.1120180; Sexton JA, 2002, TRAFFIC, V3, P178, DOI 10.1034/j.1600-0854.2002.030303.x; Shigenobu S, 2000, NATURE, V407, P81, DOI 10.1038/35024074; Sinkins SP, 2005, NATURE, V436, P257, DOI 10.1038/nature03629; Stouthamer R, 1999, ANNU REV MICROBIOL, V53, P71, DOI 10.1146/annurev.micro.53.1.71; Tamas I, 2002, SCIENCE, V296, P2376, DOI 10.1126/science.1071278; Thelestam M, 2004, Rev Physiol Biochem Pharmacol, V152, P111; Toh H, 2006, GENOME RES, V16, P149, DOI 10.1101/gr.4106106; Tram U, 2003, MICROBES INFECT, V5, P999, DOI 10.1016/S1286-4579(03)00192-8; van der Wilk F, 1999, VIROLOGY, V262, P104, DOI 10.1006/viro.1999.9902; van Ham RCHJ, 2003, P NATL ACAD SCI USA, V100, P581, DOI 10.1073/pnas.0235981100; Veneti Z, 2005, SCIENCE, V307, P1461, DOI 10.1126/science.1107182; Veneti Z, 2004, APPL ENVIRON MICROB, V70, P5366, DOI 10.1128/AEM.70.9.5366-5372.2004; Wagner PL, 2002, MOL MICROBIOL, V44, P957, DOI 10.1046/j.1365-2958.2002.02950.x; WELBURN SC, 1987, ANN TROP MED PARASIT, V81, P331, DOI 10.1080/00034983.1987.11812127; Wernegreen JJ, 2001, J BACTERIOL, V183, P785, DOI 10.1128/JB.183.2.785-790.2001; Wernegreen JJ, 1999, MOL BIOL EVOL, V16, P83, DOI 10.1093/oxfordjournals.molbev.a026040; WERREN JH, 1995, P ROY SOC B-BIOL SCI, V261, P55, DOI 10.1098/rspb.1995.0117; Wilcox JL, 2003, MOL MICROBIOL, V48, P1491, DOI 10.1046/j.1365-2958.2003.03522.x; Wolschin F, 2004, APPL ENVIRON MICROB, V70, P4096, DOI 10.1128/AEM.70.7.4096-4102.2004; Wommack KE, 2000, MICROBIOL MOL BIOL R, V64, P69, DOI 10.1128/MMBR.64.1.69-114.2000; Wu D, 2006, PLOS BIOL, V4, P1079, DOI 10.1371/journal.pbio.0040188; Wu M, 2004, PLOS BIOL, V2, P327, DOI 10.1371/journal.pbio.0020069; Zientz E, 2004, MICROBIOL MOL BIOL R, V68, P745, DOI 10.1128/MMBR.68.4.745-770.2004	101	380	412	4	174	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 11	2006	126	3					453	465		10.1016/j.cell.2006.07.014	http://dx.doi.org/10.1016/j.cell.2006.07.014			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	075KI	16901780	Bronze			2022-12-28	WOS:000239883400007
J	Campbell, B				Campbell, Bruce			Varicose veins and their management	BMJ-BRITISH MEDICAL JOURNAL			English	Review							ENDOVENOUS LASER TREATMENT; CONSERVATIVE TREATMENT; SURGERY; OBLITERATION; SCLEROTHERAPY; SYMPTOMS; LIGATION; DOPPLER; CLOSURE; REFLUX		Royal Devon & Exeter Hosp, Exeter EX2 5DW, Devon, England; Peninsula Med Sch, Exeter EX2 5DW, Devon, England	University of Exeter; University of Exeter	Campbell, B (corresponding author), Royal Devon & Exeter Hosp, Exeter EX2 5DW, Devon, England.	bruce.campbell@nice.org.uk						Bountouroglou DG, 2006, EUR J VASC ENDOVASC, V31, P93, DOI 10.1016/j.ejvs.2005.08.024; Bradbury A, 1999, BRIT MED J, V318, P353, DOI 10.1136/bmj.318.7180.353; Cabrera J, 2000, PHLEBOLOGY, V15, P19, DOI 10.1007/s005230070032; Caggiati A, 2002, J VASC SURG, V36, P416, DOI 10.1067/mva.2002.125847; Campbell WB, 2005, EUR J VASC ENDOVASC, V30, P664, DOI 10.1016/j.ejvs.2005.05.037; Campbell WB, 2003, ANN ROY COLL SURG, V85, P52, DOI 10.1308/003588403321001462; Campbell WB, 2006, EUR J VASC ENDOVASC, V31, P332, DOI 10.1016/j.ejvs.2005.08.009; CHANT ADB, 1985, BRIT MED J, V290, P204, DOI 10.1136/bmj.290.6463.204; Chengelis DL, 1996, J VASC SURG, V24, P745, DOI 10.1016/S0741-5214(96)70007-1; Darke SG, 1997, EUR J VASC ENDOVASC, V14, P457, DOI 10.1016/S1078-5884(97)80124-4; Dwerryhouse S, 1999, J VASC SURG, V29, P589, DOI 10.1016/S0741-5214(99)70302-2; Forlee MV, 2006, J VASC SURG, V43, P162, DOI 10.1016/j.jvs.2005.09.032; Goodwin H, 2000, BRIT J SURG, V87, P977, DOI 10.1046/j.1365-2168.2000.01562.x; HOBBS JT, 1974, ARCH SURG-CHICAGO, V109, P793; Lee AJ, 2003, J CLIN EPIDEMIOL, V56, P171, DOI 10.1016/S0895-4356(02)00518-8; Lurie F, 2005, EUR J VASC ENDOVASC, V29, P67, DOI 10.1016/j.ejvs.2004.09.019; Mercer KG, 1998, BRIT J SURG, V85, P1495; Merchant RF, 2002, J VASC SURG, V35, P1190, DOI 10.1067/mva.2002.124231; Michaels JA, 2006, BRIT J SURG, V93, P175, DOI 10.1002/bjs.5264; Min RJ, 2003, J VASC INTERV RADIOL, V14, P991, DOI 10.1091/01.RVI.0000082864.05622.E4; Mundy L, 2005, BRIT J SURG, V92, P1189, DOI 10.1002/bjs.5142; *NAT I CLIN EXC, 2001, REF ADV VAR VEINS; Nicolini P, 2005, EUR J VASC ENDOVASC, V29, P433, DOI 10.1016/j.ejvs.2004.12.022; Ratcliffe J, 2006, BRIT J SURG, V93, P182, DOI 10.1002/bjs.5263; Rautio T, 2002, J VASC SURG, V35, P958, DOI 10.1067/mva.2002.123096	25	63	69	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 5	2006	333	7562					287	292		10.1136/bmj.333.7562.287	http://dx.doi.org/10.1136/bmj.333.7562.287			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	073MV	16888305	Green Published			2022-12-28	WOS:000239748200017
J	Lie, RK; Emanuel, EJ; Grady, C				Lie, Reidar K.; Emanuel, Ezekiel J.; Grady, Christine			Circumcision and HIV prevention research: an ethical analysis	LANCET			English	Article									NIH, Ctr Clin, Dept Clin Bioeth, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	Lie, RK (corresponding author), NIH, Ctr Clin, Dept Clin Bioeth, 9000 Rockville Pike, Bethesda, MD 20892 USA.	riie@cc.nih.gov			Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		[Anonymous], 2001, IMP VOL COUNS TEST G; Auvert B, 2005, PLOS MED, V2, P1112, DOI 10.1371/journal.pmed.0020298; Belsky L, 2004, BRIT MED J, V328, P1494, DOI 10.1136/bmj.328.7454.1494; Cleaton-Jones P, 2005, PLOS MED, V2, P1073, DOI 10.1371/journal.pmed.0020287; Macklin R., 2004, DOUBLE STANDARDS MED; National Institute of Allergy and Infectious Diseases (NIAID), 2001, WORKSH SUMM SCI EV C; Siegfried N, 2005, PLOS MED, V2, P1071, DOI 10.1371/journal.pmed.0020393; Slack C, 2005, SOC SCI MED, V60, P1197, DOI 10.1016/j.socscimed.2004.06.049; UNAIDS and WHO, 2000, ETH CONS HIV PREV VA; *VOL HIV 1 COUNS T, LANCET, V356, P103; Winstock AR, 2000, EUR J CLIN MICROBIOL, V19, P823, DOI 10.1007/s100960000377; 2005, PLOS MED, V2, P293	12	17	18	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 5	2006	368	9534					522	525		10.1016/S0140-6736(06)69160-5	http://dx.doi.org/10.1016/S0140-6736(06)69160-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	071AL	16890839				2022-12-28	WOS:000239569000035
J	De Martino, B; Kumaran, D; Seymour, B; Dolan, RJ				De Martino, Benedetto; Kumaran, Dharshan; Seymour, Ben; Dolan, Raymond J.			Frames, biases, and rational decision-making in the human brain	SCIENCE			English	Article							ORBITOFRONTAL CORTEX; BASOLATERAL AMYGDALA; PREFRONTAL CORTEX; CHOICE; RISK; PSYCHOLOGY; DAMAGE	Human choices are remarkably susceptible to the manner in which options are presented. This so-called "framing effect" represents a striking violation of standard economic accounts of human rationality, although its underlying neurobiology is not understood. We found that the framing effect was specifically associated with amygdala activity, suggesting a key role for an emotional system in mediating decision biases. Moreover, across individuals, orbital and medial prefrontal cortex activity predicted a reduced susceptibility to the framing effect. This finding highlights the importance of incorporating emotional processes within models of human choice and suggests how the brain may modulate the effect of these biasing influences to approximate rationality.	UCL, Inst Neurol, Wellcome Dept Imaging Neurosci, London WC1 3AR, England	University of London; University College London	De Martino, B (corresponding author), UCL, Inst Neurol, Wellcome Dept Imaging Neurosci, 12 Queen Sq, London WC1 3AR, England.	b.martino@fil.ion.ucl.ac.uk	Holman, B.J./E-8868-2010	De Martino, Benedetto/0000-0002-3555-2732; Seymour, Ben/0000-0003-1724-5832; Dolan, Ray/0000-0001-9356-761X	Wellcome Trust [078865] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Adolphs R, 2006, BRAIN RES, V1079, P25, DOI 10.1016/j.brainres.2005.12.127; AMARAL D G, 1992, P1; ARROW KJ, 1982, ECON INQ, V20, P1, DOI 10.1111/j.1465-7295.1982.tb01138.x; Balleine BW, 2006, TRENDS NEUROSCI, V29, P272, DOI 10.1016/j.tins.2006.03.002; Baxter MG, 2002, NAT REV NEUROSCI, V3, P563, DOI 10.1038/nrn875; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Botvinick MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624; Corbit LH, 2005, J NEUROSCI, V25, P962, DOI 10.1523/JNEUROSCI.4507-04.2005; DAMASIO H, 1994, SCIENCE, V264, P1102, DOI 10.1126/science.8178168; GABAIX X, 2003, PSYCHOL EC DECISIONS, V1, P169; Gilovich T., 2002, HEURISTICS BIASES PS, DOI [DOI 10.1017/CBO9780511808098.004, DOI 10.1017/CBO9780511808098]; Greene J, 2002, TRENDS COGN SCI, V6, P517, DOI 10.1016/S1364-6613(02)02011-9; Hsu M, 2005, SCIENCE, V310, P1680, DOI 10.1126/science.1115327; KAHNEMAN D, 1979, ECONOMETRICA, V47, P263, DOI 10.2307/1914185; Kahneman D, 2000, CHOICES VALUES FRAME; Kim H, 2004, J COGNITIVE NEUROSCI, V16, P1730, DOI 10.1162/0898929042947865; LeDoux J. E., 1996, EMOTIONAL BRAIN; Loewenstein GF, 2001, PSYCHOL BULL, V127, P267, DOI 10.1037//0033-2909.127.2.267; MCNEIL BJ, 1982, NEW ENGL J MED, V306, P1259, DOI 10.1056/NEJM198205273062103; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Paton JJ, 2006, NATURE, V439, P865, DOI 10.1038/nature04490; ROLLS ET, 1994, J NEUROL NEUROSUR PS, V57, P1518, DOI 10.1136/jnnp.57.12.1518; Schoenbaum G, 2006, TRENDS NEUROSCI, V29, P116, DOI 10.1016/j.tins.2005.12.006; Schoenbaum G, 2003, NEURON, V39, P855, DOI 10.1016/S0896-6273(03)00474-4; Slovic P, 2002, HEURISTICS BIASES PS, P397, DOI [DOI 10.1017/CBO9780511808098.025, 10.1017/CBO9780511808098.025]; Stanovich K. E., 2002, HEURISTICS BIASES PS, P421, DOI DOI 10.1017/CBO9780511808098.026; Torrance G W, 1989, Int J Technol Assess Health Care, V5, P559; TVERSKY A, 1981, SCIENCE, V211, P453, DOI 10.1126/science.7455683; TVERSKY A, 1986, J BUS, V59, pS251, DOI 10.1086/296365; Winstanley CA, 2004, J NEUROSCI, V24, P4718, DOI 10.1523/JNEUROSCI.5606-03.2004	30	869	876	17	337	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 4	2006	313	5787					684	687		10.1126/science.1128356	http://dx.doi.org/10.1126/science.1128356			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	072IQ	16888142	Green Accepted, Green Submitted			2022-12-28	WOS:000239667500048
J	Hoyt, MA				Hoyt, M. Andrew			Cell biology - Extinguishing a cell cycle checkpoint	SCIENCE			English	Editorial Material							SPINDLE CHECKPOINT; STABILITY	The steps in cell division are precisely orchestrated. A key checkpoint is inactivated after it has performed its function so that the next steps can take place.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA	Johns Hopkins University	Hoyt, MA (corresponding author), Johns Hopkins Univ, Dept Biol, 3400 N Charles St, Baltimore, MD 21218 USA.	hoyt@jhu.edu						Draviam VM, 2004, CURR OPIN GENET DEV, V14, P120, DOI 10.1016/j.gde.2004.02.007; Hardwick KG, 1996, SCIENCE, V273, P953, DOI 10.1126/science.273.5277.953; Lew DJ, 2003, ANNU REV GENET, V37, P251, DOI 10.1146/annurev.genet.37.042203.120656; Palframan WJ, 2006, SCIENCE, V313, P680, DOI 10.1126/science.1127205; Pan J, 2004, GENE DEV, V18, P1439, DOI 10.1101/gad.1184204; Pinsky BA, 2005, TRENDS CELL BIOL, V15, P486, DOI 10.1016/j.tcb.2005.07.005	6	0	0	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 4	2006	313	5787					624	625		10.1126/science.1131625	http://dx.doi.org/10.1126/science.1131625			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	072IQ	16888129				2022-12-28	WOS:000239667500029
J	Calabrese, F; Barrile, D; Frison, G; Nalesso, A; Zuin, R; Saetta, M				Calabrese, Fiorella; Barrile, Domenico; Frison, Giampietro; Nalesso, Alessandro; Zuin, Ranzo; Saetta, Marina			An asthmatic patient with progressive lung dysfunction: a case of misdiagnosis	LANCET			English	Editorial Material									Univ Padua, Padova Hosp, Dept Pathol, I-35121 Padua, Italy; Univ Padua, Padova Hosp, Dept Cardiothorac & Vasc Sci, I-35121 Padua, Italy; Univ Padua, Padova Hosp, Dept Forens Toxicol & Antidoping, I-35121 Padua, Italy	University of Padua; Azienda Ospedaliera - Universita di Padova; University of Padua; Azienda Ospedaliera - Universita di Padova; University of Padua; Azienda Ospedaliera - Universita di Padova	Calabrese, F (corresponding author), Univ Padua, Padova Hosp, Dept Pathol, I-35121 Padua, Italy.	fiorella.calabrese@unipd.it	Saetta, Marina/D-1924-2009	SAETTA, MARINA/0000-0002-1547-2102				BAILEY ME, 1994, HUM PATHOL, V25, P203, DOI 10.1016/0046-8177(94)90279-8; MURRAY RJ, 1988, CHEST, V93, P427, DOI 10.1378/chest.93.2.427; Rome LA, 2000, CHEST, V117, P1324, DOI 10.1378/chest.117.5.1324; RUBIN RB, 1990, AM J MED, V88, P438, DOI 10.1016/0002-9343(90)90506-9; Tashkin D P, 2001, Curr Opin Pulm Med, V7, P43	5	2	2	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG-SEP	2006	368	9537					814	814		10.1016/S0140-6736(06)69291-X	http://dx.doi.org/10.1016/S0140-6736(06)69291-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	080ID	16935692				2022-12-28	WOS:000240240200033
J	Zhu, JL; Basso, O; Obel, C; Bille, C; Olsen, J				Zhu, Jin Liang; Basso, Olga; Obel, Carsten; Bille, Camilla; Olsen, Jorn			Infertility, infertility treatment, and congenital malformations: Danish national birth cohort	BMJ-BRITISH MEDICAL JOURNAL			English	Article							IN-VITRO FERTILIZATION; RISK; REGISTRY; CHILDREN; SWEDEN; IVF	Objectives To examine whether infertile couples (with a time to pregnancy of >12 months), who conceive naturally or after treatment, give birth to children with an increased prevalence of congenital malformations. Design Longitudinal study. Setting Danish national birth cohort. Participants Three groups of liveborn children and their mothers: 50 897 singletons and 1366 twins born to fertile couples (time to pregnancy : 12 months), 5764 singletons and 100 twins born to infertile couples who conceived naturally (time to pregnancy >12 months), and 4588 singletons and 1690 twins born after infertility treatment. Main outcome measures Prevalence of congenital malformations determined from hospital discharge diagnoses. Results Compared with singletons born to fertile couples, singletons born to infertile couples who conceived naturally or after treatment had a higher prevalence of congenital malformations-hazard ratios 1.20 (95% confidence interval 1.07 to 1.35) and 1.39 (1.23 to 1.57). The overall prevalence of congenital malformations increased with increasing time to pregnancy. When the analysis was restricted to singletons born to infertile couples, babies born after treatment had an increased prevalence of genital organ malformations (hazard ratio 2.32, 1.24 to 4.35) compared with babies conceived naturally. No significant differences existed in the overall prevalence of congenital malformations among twins. Conclusions Hormonal treatment for infertility may be related to the occurrence of malformations of genital organs, but our results suggest that the reported increased prevalence of congenital malformations seen in singletons born after assisted reproductive technology is partly the result of the underlying infertility or its determinants. The association between untreated infertility and congenital malformations warrants further examination.	Aarhus Univ, Danish Epidemiol Sci Ctr, Dept Epidemiol, Inst Publ Hlth, DK-8000 Aarhus C, Denmark; NIEHS, Epidemiol Branch, NIH, US Dept HHS, Res Triangle Pk, NC USA; Aarhus Univ Hosp, Dept Obstet & Gynaecol, Perinatal Epidemiol Res Unit, DK-8200 Aarhus N, Denmark; Univ So Denmark, Ctr Prevent Congenital Malformat, Inst Publ Hlth, DK-5000 Odense C, Denmark; Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90095 USA	Aarhus University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Aarhus University; University of Southern Denmark; University of California System; University of California Los Angeles	Zhu, JL (corresponding author), Aarhus Univ, Danish Epidemiol Sci Ctr, Dept Epidemiol, Inst Publ Hlth, DK-8000 Aarhus C, Denmark.	zjl@soci.au.dk	Olsen, Jørn/F-8801-2015; Basso, Olga/E-5384-2010; Obel, Carsten/H-9605-2016	Olsen, Jørn/0000-0001-7462-5140; Basso, Olga/0000-0001-9298-4921; Obel, Carsten/0000-0001-5004-1933	Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Andersen AN, 2005, HUM REPROD, V20, P1158, DOI 10.1093/humrep/deh755; Andersen TF, 1999, DAN MED BULL, V46, P263; BILLE C, 2005, THESIS U SO DENMARK; Hansen D, 2000, LANCET, V356, P875, DOI 10.1016/S0140-6736(00)02676-3; Hansen M, 2005, HUM REPROD, V20, P328, DOI 10.1093/humrep/deh593; Juul S, 1999, HUM REPROD, V14, P1250, DOI 10.1093/humrep/14.5.1250; Kallen B, 2005, BIRTH DEFECTS RES A, V73, P162, DOI 10.1002/bdra.20107; Klemetti R, 2005, FERTIL STERIL, V84, P1300, DOI 10.1016/j.fertnstert.2005.03.085; Knudsen LB, 1998, DAN MED BULL, V45, P320; Larsen H, 2003, SCAND J PUBLIC HEALT, V31, P12, DOI 10.1080/14034940210134194; McDonald S, 2005, AM J OBSTET GYNECOL, V193, P141, DOI 10.1016/j.ajog.2004.11.064; McDonald SD, 2005, J OBSTET GYNAECOL CA, V27, P449, DOI 10.1016/S1701-2163(16)30527-8; Olsen J, 2001, SCAND J PUBLIC HEALT, V29, P300, DOI 10.1177/14034948010290040201; Rimm AA, 2004, J ASSIST REPROD GEN, V21, P437, DOI 10.1007/s10815-004-8760-8; RINUM AA, 2004, J ASSIST REPROD GEN, V21, P437; Schmidt L, 2006, LANCET, V367, P379, DOI 10.1016/S0140-6736(06)68117-8; Silver RI, 1999, J UROLOGY, V161, P1954, DOI 10.1016/S0022-5347(05)68863-5; Westergaard HB, 1999, HUM REPROD, V14, P1896, DOI 10.1093/humrep/14.7.1896; Wright Victoria Clay, 2005, Morbidity and Mortality Weekly Report, V54, P1	19	235	237	0	21	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 30	2006	333	7570					679	+		10.1136/bmj.38919.495718.AE	http://dx.doi.org/10.1136/bmj.38919.495718.AE			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	092AA	16893903	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000241068200017
J	Maffei, A; Nataraj, K; Nelson, SB; Turrigiano, GG				Maffei, Arianna; Nataraj, Kiran; Nelson, Sacha B.; Turrigiano, Gina G.			Potentiation of cortical inhibition by visual deprivation	NATURE			English	Article							MONOCULAR DEPRIVATION; NEOCORTICAL SYNAPSES; OCULAR DOMINANCE; CORTEX; PLASTICITY; EXPERIENCE; NEURONS; ORIENTATION; AMBLYOPIA; CIRCUITS	The fine-tuning of circuits in sensory cortex requires sensory experience during an early critical period. Visual deprivation during the critical period has catastrophic effects on visual function, including loss of visual responsiveness to the deprived eye(1-3), reduced visual acuity(4), and loss of tuning to many stimulus characteristics(2,5). These changes occur faster than the remodelling of thalamocortical axons(6), but the intracortical plasticity mechanisms that underlie them are incompletely understood. Longterm depression of excitatory intracortical synapses has been proposed as a general candidate mechanism for the loss of cortical responsiveness after visual deprivation(7,8). Alternatively (or in addition), the decreased ability of the deprived eye to activate cortical neurons could be due to enhanced intracortical inhibition(9,10). Here we show that visual deprivation leaves excitatory connections in layer 4 (the primary input layer to cortex) unaffected, but markedly potentiates inhibitory feedback between fast-spiking basket cells (FS cells) and star pyramidal neurons (star pyramids). Further, a previously undescribed form of long-term potentiation of inhibition (LTPi) could be induced at synapses from FS cells to star pyramids, and was occluded by previous visual deprivation. These data suggest that potentiation of inhibition is a major cellular mechanism underlying the deprivation-induced degradation of visual function, and that this form of LTPi is important in fine-tuning cortical circuitry in response to visual experience.	Brandeis Univ, Dept Biol, Waltham, MA 02454 USA; Brandeis Univ, Ctr Behav Genom, Waltham, MA 02454 USA	Brandeis University; Brandeis University	Turrigiano, GG (corresponding author), Brandeis Univ, Dept Biol, Waltham, MA 02454 USA.	turrigiano@brandeis.edu		Maffei, Arianna/0000-0001-6755-8904; Nelson, Sacha/0000-0002-0108-8599				Antonini A, 1996, J COMP NEUROL, V369, P64; BARLOW HB, 1965, J PHYSIOL-LONDON, V178, P477, DOI 10.1113/jphysiol.1965.sp007638; Barrett BT, 2004, NEUROSCIENTIST, V10, P106, DOI 10.1177/1073858403262153; Buzas P, 2001, J COMP NEUROL, V437, P259, DOI 10.1002/cne.1282; Contreras D, 2003, J NEUROSCI, V23, P6936; Desai NS, 2002, NAT NEUROSCI, V5, P783, DOI 10.1038/nn878; DUFFY FH, 1976, NATURE, V260, P256, DOI 10.1038/260256a0; Egger V, 1999, NAT NEUROSCI, V2, P1098, DOI 10.1038/16026; FAGIOLINI M, 1994, VISION RES, V34, P709, DOI 10.1016/0042-6989(94)90210-0; Frenkel MY, 2004, NEURON, V44, P917, DOI 10.1016/j.neuron.2004.12.003; Gaiarsa JL, 2002, TRENDS NEUROSCI, V25, P564, DOI 10.1016/S0166-2236(02)02269-5; Gibson JR, 1999, NATURE, V402, P75, DOI 10.1038/47035; Hensch TK, 2005, NAT REV NEUROSCI, V6, P877, DOI 10.1038/nrn1787; Hirsch JA, 2003, NAT NEUROSCI, V6, P1300, DOI 10.1038/nn1152; Holmgren CD, 2001, J NEUROSCI, V21, P8270; Jin XM, 2005, J NEUROPHYSIOL, V93, P2117, DOI 10.1152/jn.00728.2004; Kayser AS, 2002, NEURON, V33, P131, DOI 10.1016/S0896-6273(01)00570-0; Kilman V, 2002, J NEUROSCI, V22, P1328, DOI 10.1523/JNEUROSCI.22-04-01328.2002; Kirkwood A, 1996, NATURE, V381, P526, DOI 10.1038/381526a0; Maffei A, 2004, NAT NEUROSCI, V7, P1353, DOI 10.1038/nn1351; Prusky GT, 2000, BEHAV BRAIN RES, V116, P135, DOI 10.1016/S0166-4328(00)00267-9; Rauschecker JP, 2002, PROG BRAIN RES, V138, P73, DOI 10.1016/S0079-6123(02)38072-5; Rittenhouse CD, 1999, NATURE, V397, P347, DOI 10.1038/16922; Schoppa NE, 2003, TRENDS NEUROSCI, V26, P501, DOI 10.1016/S0166-2236(03)00228-5; SILLITO AM, 1981, NATURE, V291, P318, DOI 10.1038/291318a0; SIMONS DJ, 1978, J NEUROPHYSIOL, V41, P798, DOI 10.1152/jn.1978.41.3.798; Thomson AM, 2002, PHILOS T R SOC B, V357, P1781, DOI 10.1098/rstb.2002.1163; White LE, 2001, NATURE, V411, P1049, DOI 10.1038/35082568; WIESEL TN, 1963, J NEUROPHYSIOL, V26, P1003, DOI 10.1152/jn.1963.26.6.1003; Woodin MA, 2003, NEURON, V39, P807, DOI 10.1016/S0896-6273(03)00507-5	30	282	285	2	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 7	2006	443	7107					81	84		10.1038/nature05079	http://dx.doi.org/10.1038/nature05079			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	081JM	16929304				2022-12-28	WOS:000240313900043
J	Elwyn, G; O'Connor, A; Stacey, D; Volk, R; Edwards, A; Coulter, A; Thomson, R; Barrat, A; Butow, P; Barry, M; Mulley, AG; Sepucha, K; Bernstein, S; Clarke, A; Entwistle, V; Feldman-Stewart, D; Holmes-Rovner, M; Llewellyn-Thomas, H; Moumjid, N; Ruland, C; Sykes, A; Whelan, T				Elwyn, Glyn; O'Connor, Annette; Stacey, Dawn; Volk, Robert; Edwards, Adrian; Coulter, Angela; Thomson, Richard; Barrat, Alexandra; Butow, Phyllis; Barry, Michael; Mulley, Albert G.; Sepucha, Karen; Bernstein, Steven; Clarke, Aileen; Entwistle, Vikki; Feldman-Stewart, Deb; Holmes-Rovner, Margaret; Llewellyn-Thomas, Hilary; Moumjid, Nora; Ruland, Cornelia; Sykes, Alan; Whelan, Tim		IPDAS Collaboration	Developing a quality criteria framework for patient decision aids: online international Delphi consensus process	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED-TRIALS; GENERAL-PRACTICE; HEALTH INFORMATION; INDICATORS; INSTRUMENT; KNOWLEDGE; CHOICES	Objective To develop a set of quality criteria for patient decision support technologies (decision aids). Design and setting Two stage web, based Delphi process using online rating process to enable international collaboration. Participants Individuals from four stakeholder groups (researchers, practitioners, patients, policy makers) representing 14 countries reviewed evidence summaries and rated the importance of 80 criteria in 12 quality domains on a I to 9 scale. Second round participants received feedback from the first round and repeated their assessment of the 80 criteria plus three new ones. Main outcome measure Aggregate ratings for each criterion calculated using medians weighted to compensate for different numbers in stakeholder groups; criteria rated between 7 and 9 were retained. Results 212 nominated people were invited to participate. Of those invited, 122 participated in the first round (77 researchers, 21 patients, 10 practitioners, 14 policy makers); 104/122 (85%) participated in the second round. 74 of 83 criteria were retained in the following domains: systematic development process (9/9 criteria); providing information about options (13/13); presenting probabilities (11/13); clarifying and expressing values (3/3); using patient stories (2/5); guiding/coaching (3/5); disclosing conflicts of interest (5/5); providing internet access (6/6); balanced presentation of options (3/3); using plain language (4/6); basing information on tip to date evidence (7/7); and establishing effectiveness (8/8). Conclusions Criteria were given the highest ratings where evidence existed, and these were retained. Gaps in research were highlighted. Developers, users, and purchasers of patient decision aids now have a checklist for appraising quality. An instrument for measuring quality of decision aids is being developed.	[Elwyn, Glyn; Edwards, Adrian] Cardiff Univ, Ctr Hlth Sci Res, Dept Gen Practice, Cardiff CF14 4YS, Wales; [O'Connor, Annette; Stacey, Dawn] Univ Ottawa, Ottawa, ON K1Y 4E9, Canada; [O'Connor, Annette] Ottawa Hlth Res Inst, Clin Epidemiol Program, Ottawa, ON K1Y 4E9, Canada; Univ Ottawa, Sch Nursing, Ottawa, ON K1H 8M5, Canada; [Volk, Robert] Baylor Coll Med, Dept Family & Community Med, Houston, TX 77098 USA; [Coulter, Angela] Picker Inst Europe, Oxford OX1 1RX, England; Med Sch Newcastle Upon Tyne, Sch Populat & Hlth Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; [Thomson, Richard; Barrat, Alexandra] Univ Sydney, Sch Publ Hlth, Screening & Testing Program, Sydney, NSW 2006, Australia; [Butow, Phyllis] Univ Sydney, Sch Psychol, Med Psychol Res Unit, Sydney, NSW 2006, Australia; [Barry, Michael; Mulley, Albert G.; Sepucha, Karen] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA 02114 USA; [Bernstein, Steven] VA Ann Arbor Healthcare Syst, HS R&D Ctr Excellence, Ann Arbor, MI USA; [Clarke, Aileen] Publ Hlth Resource Unit, Oxford OX4 2GX, England; [Entwistle, Vikki] Univ Dundee, Social Dimens Hlth Inst, Dundee DD1 4HJ, Scotland; [Feldman-Stewart, Deb] Queens Univ, Div Canc Care & Epidemiol, Canc Res Inst, Kingstown, ON, Canada; [Holmes-Rovner, Margaret] Michigan State Univ, Ctr Eth, E Lansing, MI 48824 USA; [Llewellyn-Thomas, Hilary] Dartmouth Med Sch, Dept Community & Family Med, Ctr Evaluat Clin Sci, Hanover, NH USA; [Moumjid, Nora] GRESAC, Ctr Leon Berard, F-69008 Lyon, France; [Ruland, Cornelia] Rikshosp Radiumhosp, Oslo, Norway; [Sykes, Alan] Acadvent Ltd, Swansea, Wales; [Whelan, Tim] McMaster Univ, Dept Med, Hamilton, ON, Canada; Juravinski Canc Ctr, Hamilton, ON, Canada	Cardiff University; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Baylor College of Medicine; Newcastle University - UK; University of Sydney; University of Sydney; Harvard University; Harvard Medical School; Massachusetts General Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; University of Oxford; University of Dundee; Queens University - Canada; Michigan State University; Dartmouth College; UNICANCER; Centre Leon Berard; University of Oslo; McMaster University; McMaster University	Elwyn, G (corresponding author), Cardiff Univ, Ctr Hlth Sci Res, Dept Gen Practice, Cardiff CF14 4YS, Wales.	elwyng@cardiff.ac.uk	Elwyn, G./L-4292-2015; Entwistle, Vikki Ann/I-9266-2019; Whelan, Timothy/D-3185-2017; Barratt, Alexandra/A-7349-2011; Elwyn, Glyn/B-4798-2009; Young, Alexander/A-1523-2009; Evans, Diane/F-9258-2017; Coulter, Angela/N-6998-2019; Clarke, Aileen/I-5679-2012	Entwistle, Vikki Ann/0000-0002-0856-4025; Whelan, Timothy/0000-0001-9844-2023; Barratt, Alexandra/0000-0002-2561-3319; Elwyn, Glyn/0000-0002-0917-6286; Young, Alexander/0000-0002-9367-9213; Coulter, Angela/0000-0002-6308-8375; Volk, Robert/0000-0001-8811-5854; Clarke, Aileen/0000-0001-8299-3146; Bernstein, Steven/0000-0003-3359-7168				Altman DG, 1996, BRIT MED J, V313, P570; Barratt A, 2004, BMJ-BRIT MED J, V329, P507, DOI 10.1136/bmj.329.7464.507; BROOK RH, 1994, BRIT MED J, V308, P218, DOI 10.1136/bmj.308.6923.218; Campbell SM, 2000, BRIT MED J, V321, P425, DOI 10.1136/bmj.321.7258.425; Charles C, 2005, HEALTH EXPECT, V8, P114, DOI 10.1111/j.1369-7625.2005.00325.x; Charnock D, 1999, J EPIDEMIOL COMMUN H, V53, P105, DOI 10.1136/jech.53.2.105; Cluzeau F, 2003, QUAL SAF HEALTH CARE, V12, P18; CONOVER W. J, 1980, PRACTICAL NONPARAMET; COULTER A, 1998, INFORMING PATIENTS A; Engels Y, 2005, FAM PRACT, V22, P215, DOI 10.1093/fampra/cmi002; Entwistle V, 2001, Health Expect, V4, P109, DOI 10.1046/j.1369-6513.2001.00141.x; Estabrooks C, 2001, J Health Serv Res Policy, V6, P170, DOI 10.1258/1355819011927431; Evans Rhodri, 2004, Inform Prim Care, V12, P109; Fitch K, 2000, EUR J CARDIO-THORAC, V18, P380, DOI 10.1016/S1010-7940(00)00530-3; Gagliardi A, 2002, BMJ-BRIT MED J, V324, P569, DOI 10.1136/bmj.324.7337.569; Heaney DJ, 2002, FAM PRACT, V19, P77, DOI 10.1093/fampra/19.1.77; *IPDAS COLL, BACKGR EV REP EXP PA; JONES J, 1995, BRIT MED J, V311, P376, DOI 10.1136/bmj.311.7001.376; Jones J, 1999, QUALITATIVE RES HLTH; Kahneman Daniel, 2000, CHOICES VALUES FRAME, P673, DOI DOI 10.1017/CBO9780511803475.038; Kennedy ADM, 2002, JAMA-J AM MED ASSOC, V288, P2701, DOI 10.1001/jama.288.21.2701; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; Molenaar S, 2000, MED DECIS MAKING, V20, P112, DOI 10.1177/0272989X0002000114; Murphy E., 1998, HEALTH TECHNOL ASSES, V2, pI, DOI [DOI 10.3310/HTA2030, 10.3310/hta2030]; O'Connor A M, 1999, J Natl Cancer Inst Monogr, P67; OConnor AM, 2003, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001431, DOI 10.1002/14651858.CD001431]; OCONNOR AM, 2004, HLTH AFF MILLWOOD; Schunemann HJ, 2003, CAN MED ASSOC J, V169, P677; SEPUCHA KR, 2004, HLTH AFF MILLWOOD; Sepucha KR, 2004, HLTH AFF MILLWOOD S; Ubel PA, 1997, SOC SCI MED, V44, P647, DOI 10.1016/S0277-9536(96)00217-1; Whelan T, 2004, JAMA-J AM MED ASSOC, V292, P435, DOI 10.1001/jama.292.4.435; Woolf SH, 2005, ANN INTERN MED, V143, P293, DOI 10.7326/0003-4819-143-4-200508160-00010	33	1116	1133	4	69	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 26	2006	333	7565					417	419		10.1136/bmj.38926.629329.AE	http://dx.doi.org/10.1136/bmj.38926.629329.AE			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	081AO	16908462	Green Published, Bronze, Green Submitted, Green Accepted			2022-12-28	WOS:000240289800019
J	Oki, T; Kanae, S				Oki, Taikan; Kanae, Shinjiro			Global hydrological cycles and world water resources	SCIENCE			English	Review							CLIMATE-CHANGE; AVAILABILITY	Water is a naturally circulating resource that is constantly recharged. Therefore, even though the stocks of water in natural and artificial reservoirs are helpful to increase the available water resources for human society, the flow of water should be the main focus in water resources assessments. The climate system puts an upper limit on the circulation rate of available renewable freshwater resources (RFWR). Although current global withdrawals are well below the upper limit, more than two billion people live in highly water-stressed areas because of the uneven distribution of RFWR in time and space. Climate change is expected to accelerate water cycles and thereby increase the available RFWR. This would slow down the increase of people living under water stress; however, changes in seasonal patterns and increasing probability of extreme events may offset this effect. Reducing current vulnerability will be the first step to prepare for such anticipated changes.	Univ Tokyo, Inst Ind Sci, Meguro Ku, Komaba 461, Tokyo 1538505, Japan; Japan Sci & Technol Agcy, Kawaguchi, Saitama 3320012, Japan; Japan Agcy Marine Earth Sci & Technol, Frontier Res Ctr Global Change, Kanazawa Ku, Yokohama, Kanagawa 2360001, Japan; Res Inst Humanity & Nat, Kita Ku, Kyoto 6038047, Japan	University of Tokyo; Japan Science & Technology Agency (JST); Japan Agency for Marine-Earth Science & Technology (JAMSTEC); Research Institute for Humanity & Nature (RIHN)	Oki, T (corresponding author), Univ Tokyo, Inst Ind Sci, Meguro Ku, Komaba 461, Tokyo 1538505, Japan.	taikan@iis.u-tokyo.ac.jp	Quinn, Patrick/B-5489-2010; Oki, Taikan/E-5778-2010; Kanae, Shinjiro/E-5606-2010	Oki, Taikan/0000-0003-4067-4678; Kanae, Shinjiro/0000-0002-3176-4957				Alcamo J, 2003, HYDROLOG SCI J, V48, P339, DOI 10.1623/hysj.48.3.339.45278; ALCAMO J, COMMUNICATION; ALLAN JA, 1998, YALE U FOR ENV STUDI, V103, P141; Arnell NW, 2004, GLOBAL ENVIRON CHANG, V14, P31, DOI 10.1016/j.gloenvcha.2003.10.006; Chapagain A, 2003, VALUE WATER RES REPO, V13; Church TM, 1996, NATURE, V380, P579, DOI 10.1038/380579a0; Crutzen PJ, 2002, NATURE, V415, P23, DOI 10.1038/415023a; DIRMEYER PA, IN PRESS B AM METEOR; Falkenmark M., 2004, EARTHSCAN; Gedney N, 2006, NATURE, V439, P835, DOI 10.1038/nature04504; Gleick PH, 2003, SCIENCE, V302, P1524, DOI 10.1126/science.1089967; Hanasaki N, 2006, J HYDROL, V327, P22, DOI 10.1016/j.jhydrol.2005.11.011; HIRABAYASHI Y, UNPUB; Intergovernmental Panel on Climate Change, 2001, CLIM CHANG 2001 SCI; International Commission on Large Dams, 1998, WORLD REG DAMS; Korzun V. I., 1978, STUDIES REPORTS HYDR, V25; Lvovitch M, 1973, T AM GEOPHYS UNION, V54, P28, DOI DOI 10.1029/EO054I001P00028; Milly PCD, 2005, NATURE, V438, P347, DOI 10.1038/nature04312; Nilsson C, 2005, SCIENCE, V308, P405, DOI 10.1126/science.1107887; NOHARA D, IN PRESS J HYDROMET; Oki T, 2001, HYDROLOG SCI J, V46, P983, DOI 10.1080/02626660109492890; OKI T, 2005, IAHS PUBLICATION, V300; Oki T., 2005, ENCY HYDROLOGICAL SC, DOI [10.1002/0470848944.hsa001, DOI 10.1002/0470848944.HSA001]; Old T., 2003, VALUE WATER RES REPO, V12, P221; Postel SL, 1996, SCIENCE, V271, P785, DOI 10.1126/science.271.5250.785; Rosegrant MW, 2003, ENVIRONMENT, V45, P24, DOI 10.1080/00139150309604555; Shiklomanov IA, 1997, ASSESSMENT WATER RES; UN, MILL DEV GOALS; UTSUMI N, 2006, THESIS U TOKYO; Vorosmarty CJ, 2000, SCIENCE, V289, P284, DOI 10.1126/science.289.5477.284; Yang H, 2003, ENVIRON SCI TECHNOL, V37, P3048, DOI 10.1021/es0263689; [No title captured]	32	2221	2364	102	1441	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 25	2006	313	5790					1068	1072		10.1126/science.1128845	http://dx.doi.org/10.1126/science.1128845			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	076ZT	16931749				2022-12-28	WOS:000239998200031
J	Hurst, LD; Feil, EJ; Rocha, EPC				Hurst, Laurence D.; Feil, Edward J.; Rocha, Eduardo P. C.			Causes of trends in amino-acid gain and loss	NATURE			English	Letter							PROTEIN EVOLUTION; TIME; CODE		Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England; Univ Paris 06, F-75005 Paris, France; Inst Pasteur, Unite GGB, F-75015 Paris, France	University of Bath; UDICE-French Research Universities; Sorbonne Universite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Hurst, LD (corresponding author), Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England.	l.d.hurst@bath.ac.uk	Rocha, Eduardo/A-4727-2008; Rocha, Eduardo/B-7009-2009; Hurst, Laurence/F-9215-2010	Rocha, Eduardo/0000-0001-7704-822X; Hurst, Laurence/0000-0002-1002-1054	Medical Research Council [G0300415] Funding Source: Medline; MRC [G0300415] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Akashi H, 2002, P NATL ACAD SCI USA, V99, P3695, DOI 10.1073/pnas.062526999; Brooks DJ, 2002, MOL BIOL EVOL, V19, P1645, DOI 10.1093/oxfordjournals.molbev.a003988; Ho SYW, 2005, MOL BIOL EVOL, V22, P1561, DOI 10.1093/molbev/msi145; Jordan IK, 2005, NATURE, V433, P633, DOI 10.1038/nature03306; Keightley PD, 2005, PLOS BIOL, V3, P282, DOI 10.1371/journal.pbio.0030042; McDonald JH, 2006, MOL BIOL EVOL, V23, P240, DOI 10.1093/molbev/msj026; Penny D, 2005, NATURE, V436, P183, DOI 10.1038/436183a; Rocha EPC, 2006, J THEOR BIOL, V239, P226, DOI 10.1016/j.jtbi.2005.08.037; Sharp PM, 2001, PHILOS T R SOC B, V356, P867, DOI 10.1098/rstb.2001.0863; Trifonov EN, 2004, J BIOMOL STRUCT DYN, V22, P1	10	31	31	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 24	2006	442	7105					E11	E12		10.1038/nature05137	http://dx.doi.org/10.1038/nature05137			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	076LT	16929253				2022-12-28	WOS:000239960500027
J	Venkataraman, L; Klare, JE; Nuckolls, C; Hybertsen, MS; Steigerwald, ML				Venkataraman, Latha; Klare, Jennifer E.; Nuckolls, Colin; Hybertsen, Mark S.; Steigerwald, Michael L.			Dependence of single-molecule junction conductance on molecular conformation	NATURE			English	Article							MICROSCOPY; TRANSPORT	Since it was first suggested(1) that a single molecule might function as an active electronic component, a number of techniques have been developed to measure the charge transport properties of single molecules(2-12). Although scanning tunnelling microscopy observations under high vacuum conditions can allow stable measurements of electron transport, most measurements of a single molecule bonded in a metal - molecule - metal junction exhibit relatively large variations in conductance. As a result, even simple predictions about how molecules behave in such junctions have still not been rigorously tested. For instance, it is well known(13,14) that the tunnelling current passing through a molecule depends on its conformation; but although some experiments have verified this effect(15-18), a comprehensive mapping of how junction conductance changes with molecular conformation is not yet available. In the simple case of a biphenyl - a molecule with two phenyl rings linked by a single C - C bond - conductance is expected to change with the relative twist angle between the two rings, with the planar conformation having the highest conductance. Here we use amine link groups to form single-molecule junctions with more reproducible current - voltage characteristics(19). This allows us to extract average conductance values from thousands of individual measurements on a series of seven biphenyl molecules with different ring substitutions that alter the twist angle of the molecules. We find that the conductance for the series decreases with increasing twist angle, consistent with a cosine-squared relation predicted for transport through pi-conjugated biphenyl systems(13).	Columbia Univ, Dept Phys, New York, NY 10027 USA; Columbia Univ, Dept Chem, New York, NY 10027 USA; Columbia Univ, Dept Appl Phys & Appl Math, New York, NY 10027 USA; Columbia Univ, Ctr Electron Transport Mol Nanostruct, New York, NY 10027 USA	Columbia University; Columbia University; Columbia University; Columbia University	Venkataraman, L (corresponding author), Columbia Univ, Dept Phys, 538 W 120th St, New York, NY 10027 USA.	latha@phys.columbia.edu; msh2102@columbia.edu	Hybertsen, Mark S./AAX-3175-2021; Venkataraman, Latha/G-9786-2011	Hybertsen, Mark S./0000-0003-3596-9754; Venkataraman, Latha/0000-0002-6957-6089				ALMENNINGEN A, 1985, J MOL STRUCT, V128, P59, DOI 10.1016/0022-2860(85)85041-9; AVIRAM A, 1974, CHEM PHYS LETT, V29, P277, DOI 10.1016/0009-2614(74)85031-1; Cui XD, 2001, SCIENCE, V294, P571, DOI 10.1126/science.1064354; Dadosh T, 2005, NATURE, V436, P677, DOI 10.1038/nature03898; Dulic D, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.207402; Guisinger NP, 2005, P NATL ACAD SCI USA, V102, P8838, DOI 10.1073/pnas.0501214102; HAY PJ, 1985, J CHEM PHYS, V82, P299, DOI [10.1063/1.448800, 10.1063/1.448799]; Launay JP, 2001, CHEM SOC REV, V30, P386, DOI 10.1039/b101377g; Liang WJ, 2002, NATURE, V417, P725, DOI 10.1038/nature00790; Moresco F, 2001, PHYS REV LETT, V86, P672, DOI 10.1103/PhysRevLett.86.672; Mujica V, 1999, ADV CHEM PHYS, V107, P403, DOI 10.1002/9780470141663.ch7; Nazin GV, 2003, SCIENCE, V302, P77, DOI 10.1126/science.1088971; Nitzan A, 2001, ANNU REV PHYS CHEM, V52, P681, DOI 10.1146/annurev.physchem.52.1.681; OLIVER AM, 1988, CHEM PHYS LETT, V150, P366, DOI 10.1016/0009-2614(88)80421-4; Perdew JP, 1996, PHYS REV LETT, V77, P3865, DOI 10.1103/PhysRevLett.77.3865; Piva PG, 2005, NATURE, V435, P658, DOI 10.1038/nature03563; Porath D, 2000, NATURE, V403, P635, DOI 10.1038/35001029; Ratner MA, 1998, ANN NY ACAD SCI, V852, P22, DOI 10.1111/j.1749-6632.1998.tb09862.x; Reed MA, 1997, SCIENCE, V278, P252, DOI 10.1126/science.278.5336.252; Reichert J, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.176804; *SCHRODINGER, 2002, JAG VERS 5 REL; TORNFOHR JK, 2002, PHYS REV B, V65; Venkataraman L, 2006, NANO LETT, V6, P458, DOI 10.1021/nl052373+; WOITELLIER S, 1989, CHEM PHYS, V131, P481, DOI 10.1016/0301-0104(89)80193-4; Wold DJ, 2002, J PHYS CHEM B, V106, P2813, DOI 10.1021/jp013476t; Xu BQ, 2003, SCIENCE, V301, P1221, DOI 10.1126/science.1087481; Yasuda S, 2003, J AM CHEM SOC, V125, P16430, DOI 10.1021/ja038233o	27	1127	1133	19	412	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 24	2006	442	7105					904	907		10.1038/nature05037	http://dx.doi.org/10.1038/nature05037			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	076LT	16929295	Green Submitted			2022-12-28	WOS:000239960500034
J	Pearson, SD; Miller, FG; Emanuel, EJ				Pearson, Steven D.; Miller, Franklin G.; Emanuel, Ezekiel J.			Medicare's requirement for research participation as a condition of coverage - Is it ethical?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							QUALITY IMPROVEMENT; CLINICAL-RESEARCH; TRIALS; CRITERIA		NIH, Dept Clin Bioeth, Bethesda, MD 20892 USA; Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA USA; Harvard Pilgrim Hlth Care, Boston, MA USA	National Institutes of Health (NIH) - USA; Harvard University; Harvard Medical School; Harvard Pilgrim Health Care	Pearson, SD (corresponding author), NIH, Dept Clin Bioeth, Bldg 10,Room 1C118 6th Floor, Bethesda, MD 20892 USA.	spearson99@yahoo.com						Casarett D, 2000, JAMA-J AM MED ASSOC, V283, P2275, DOI 10.1001/jama.283.17.2275; Cassell J, 2002, J MED ETHICS, V28, P315; *CTR MED MED SERV, NAT COV DET DAT COLL; *CTR MED MED SERV, PROP DEC MEM; Fernandopulle R, 2003, HEALTH AFFAIR, V22, P178, DOI 10.1377/hlthaff.22.2.178; Garber AM, 2001, HEALTH AFFAIR, V20, P62, DOI 10.1377/hlthaff.20.5.62; Hawkins JS, 2005, HASTINGS CENT REP, V35, P16, DOI 10.1353/hcr.2005.0075; Lindenauer PK, 2002, AM J MED, V113, P575, DOI 10.1016/S0002-9343(02)01250-0; McClellan MB, 2005, NEW ENGL J MED, V352, P222, DOI 10.1056/NEJMp048354; Melchart D, 2003, FORSCH KOMP KLAS NAT, V10, P179, DOI 10.1159/000073473; Mello MM, 2001, HEALTH AFFAIR, V20, P101, DOI 10.1377/hlthaff.20.5.101; Orentlicher D, 2005, HASTINGS CENT REP, V35, P20, DOI 10.2307/3528330; Pace C, 2003, CRIT CARE MED, V31, pS121, DOI 10.1097/01.CCM.0000054907.33928.48; ROPER WL, 2005, HLTH AFF MILLWOOD W, V5, P331; Tunis SR, 2003, JAMA-J AM MED ASSOC, V290, P1624, DOI 10.1001/jama.290.12.1624; Tunis SR, 2005, HEALTH AFFAIR, V24, P180, DOI 10.1377/hlthaff.24.1.180; Tunis SR, 2004, NEW ENGL J MED, V350, P2196, DOI 10.1056/NEJMe048091; Wadman M, 2005, NATURE, V433, P341, DOI 10.1038/433341a; Wertheimer Alan, 1987, COERCION	19	36	36	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 23	2006	296	8					988	991		10.1001/jama.296.8.988	http://dx.doi.org/10.1001/jama.296.8.988			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	076AL	16926358				2022-12-28	WOS:000239929300029
J	van Maldegem, BT; Duran, M; Wanders, RJA; Niezen-Koning, KE; Hogeveen, M; Ijlst, L; Waterham, HR; Wijburg, FA				van Maldegem, Bianca T.; Duran, Marinus; Wanders, Ronald J. A.; Niezen-Koning, Klary E.; Hogeveen, Marije; Ijlst, Lodewijk; Waterham, Hans R.; Wijburg, Frits A.			Clinical, biochemical, and genetic heterogeneity in short-chain acyl-coenzyme A dehydrogenase deficiency	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TANDEM MASS-SPECTROMETRY; COA DEHYDROGENASE; INBORN-ERRORS; ETHYLMALONIC ACIDURIA; SCAD GENE; VARIANT; METABOLISM; DISORDERS; MUTATIONS; PATIENT	Context Short-chain acyl-coenzyme A (CoA) dehydrogenase (SCAD) deficiency (SCADD) is an autosomal recessive, clinically heterogeneous disorder with only 22 case reports published so far. Screening for SCADD is included in expanded newborn screening programs in most US and Australian states. Objectives To describe the genetic, biochemical, and clinical characteristics of SCADD patients in the Netherlands and their SCADD relatives and to explore the genotype to phenotype relation. Design, Setting, and Participants Retrospective study involving 31 Dutch SCADD patients diagnosed between January 1987 and January 2006 and 8 SCADD relatives. SCADD was defined by the presence of (1) increased butyrylcarnitine (C4-C) levels in plasma and/or increased ethylmalonic acid (EMA) levels in urine under nonstressed conditions on at least 2 occasions, in combination with (2) a mutation and/or the c.511C> T or c. 625G>A susceptibility variants on each SCAD-encoding (ACADS) allele. Patients were included only if the SCAD-encoding (ACADS) was fully sequenced and if current clinical information could be obtained. Relatives were included when they carried the same ACADS genotype as the proband, and had increased C4-C and/or EMA. Main Outcome Measures Prevalence, genotype (mutation/mutation, mutation/variant, variant/variant), C4-C and EMA levels, clinical signs and symptoms, and clinical course. Results A birth-prevalence of at least 1: 50 000 was calculated. Most patients presented before the age of 3 years, with nonspecific, generally uncomplicated, and often transient symptoms. Developmental delay, epilepsy, behavioral disturbances, and hypoglycemia were the most frequently reported symptoms. The ACADS genotype showed a statistically significant association with EMA and C4-C levels, but not with clinical characteristics. Seven out of 8 SCADD relatives were free of symptoms. Conclusions SCADD is far more common than assumed previously, and clinical symptoms in SCADD are nonspecific, generally uncomplicated, often transient, and not correlated with specific ACADS genotypes. Because SCADD does not meet major newborn screening criteria, including a lack of clinical significance in many patients and that it is not possible to differentiate diseased and nondiseased individuals, it is not suited for inclusion in newborn screening programs at the present time.	Univ Amsterdam, Acad Med Ctr, Dept Pediat, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Lab Genet Metab Dis, NL-1105 AZ Amsterdam, Netherlands; Univ Groningen, Univ Med Ctr, Dept Pediat, Res Lab, Groningen, Netherlands; Univ Med Ctr Nijmegen, Dept Metab Dis, Nijmegen, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Groningen; Radboud University Nijmegen	van Maldegem, BT (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Pediat, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	b.t.vanmaldegem@amc.uva.nl	Hogeveen, M./L-4381-2015	Wijburg, Frits/0000-0002-0950-1368; Niezen-Koning, Klary E/0000-0002-9384-4354				AMENDT BA, 1987, J CLIN INVEST, V79, P1303, DOI 10.1172/JCI112953; BHALA A, 1995, J PEDIATR-US, V126, P910, DOI 10.1016/S0022-3476(95)70207-5; Birkebaek NH, 2002, ACTA PAEDIATR, V91, P480, DOI 10.1080/080352502317371751; Bok LA, 2003, PEDIATRICS, V112, P1152, DOI 10.1542/peds.112.5.1152; Corydon MJ, 1997, MAMM GENOME, V8, P922, DOI 10.1007/s003359900612; Corydon MJ, 2001, PEDIATR RES, V49, P18; Corydon MJ, 1996, PEDIATR RES, V39, P1059, DOI 10.1203/00006450-199606000-00021; DAWSON DB, 1995, J PEDIATR-US, V126, P69, DOI 10.1016/S0022-3476(95)70505-8; FRANKENB.WK, 1974, PEDIATRICS, V54, P612; Gregersen N, 1998, HUM MOL GENET, V7, P619, DOI 10.1093/hmg/7.4.619; Gregersen N, 2001, J INHERIT METAB DIS, V24, P189, DOI 10.1023/A:1010319001722; Gregersen N, 2001, HUM MUTAT, V18, P169, DOI 10.1002/humu.1174.abs; Gregersen N, 2000, EUR J PEDIATR, V159, pS213, DOI 10.1007/PL00014406; Holtzman NA, 2003, JAMA-J AM MED ASSOC, V290, P2606, DOI 10.1001/jama.290.19.2606; HOWELL R, 2005, NEWBORN SCREENING UN; KMOCH S, 1995, J INHERIT METAB DIS, V18, P227, DOI 10.1007/BF00711774; Koeberl DD, 2003, PEDIATR RES, V54, P219, DOI 10.1203/01.PDR.0000074972.36356.89; KRISTENSEN MJ, 1994, HUM MOL GENET, V3, P1711, DOI 10.1093/hmg/3.9.1711-a; Kurian MA, 2004, NEUROPEDIATRICS, V35, P312, DOI 10.1055/s-2004-830371; Leipnitz G, 2003, NEUROCHEM RES, V28, P771, DOI 10.1023/A:1022874103630; Mann MY, 2006, PEDIATRICS, V117, pS296, DOI 10.1542/peds.2005-26331; Matern D, 2001, J PEDIATR-US, V138, P585, DOI 10.1067/mpd.2001.111814; Nagan N, 2003, MOL GENET METAB, V78, P239, DOI 10.1016/S1096-7192(03)00034-9; NAITO E, 1990, J CLIN INVEST, V85, P1575, DOI 10.1172/JCI114607; *NAT PUBL HLTH PAR, 2002, OV PUBL HLTH SURV GE; NIEZENKONING KE, 1994, CLIN CHIM ACTA, V229, P99, DOI 10.1016/0009-8981(94)90232-1; Pollitt RJ, 2006, J INHERIT METAB DIS, V29, P390, DOI 10.1007/s10545-006-0259-2; Rhead W. J., 2002, Journal of Inherited Metabolic Disease, V25, P4; Schulze A, 2003, PEDIATRICS, V111, P1399, DOI 10.1542/peds.111.6.1399; Seidel J, 2003, J INHERIT METAB DIS, V26, P37, DOI 10.1023/A:1024019311933; SEWELL AC, 1993, EUR J PEDIATR, V152, P922, DOI 10.1007/BF01957531; THERELL BL, 2006, US NATL NEWBORN SCRE; Therrell BL, 2001, MOL GENET METAB, V74, P64, DOI 10.1006/mgme.2001.3238; van Maldegem BT, 2005, J INHERIT METAB DIS, V28, P557, DOI 10.1007/s10545-005-0557-0; Vreken P, 1999, J INHERIT METAB DIS, V22, P302, DOI 10.1023/A:1005587617745; Waisbren SE, 2003, JAMA-J AM MED ASSOC, V290, P2564, DOI 10.1001/jama.290.19.2564; Wilcken B, 2003, NEW ENGL J MED, V348, P2304, DOI 10.1056/NEJMoa025225; Wilson JM, 1968, PUBLIC HLTH PAPERS W, V34; Zytkovicz TH, 2001, CLIN CHEM, V47, P1945	39	91	94	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 23	2006	296	8					943	952		10.1001/jama.296.8.943	http://dx.doi.org/10.1001/jama.296.8.943			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	076AL	16926354				2022-12-28	WOS:000239929300024
J	Mathews, DJH; Donovan, P; Harris, J; Lovell-Badge, R; Savulescu, J; Faden, R				Mathews, Debra J. H.; Donovan, Peter; Harris, John; Lovell-Badge, Robin; Savulescu, Julian; Faden, Ruth			Science and law - Integrity in international stem cell research collaborations	SCIENCE			English	Editorial Material									Johns Hopkins Univ, Phoebe R Berman Bioeth Inst, Baltimore, MD 21205 USA; Univ Calif Irvine, Stem Cell Res Ctr, Irvine, CA 92697 USA; Univ Manchester, Inst Med Law & Bioeth, Manchester M13 9PL, Lancs, England; Natl Inst Med Res, MRC, Div Dev Genet, London NW7 1AA, England; Univ Oxford, Oxford Uehiro Ctr Practical Eth, Oxford OX1 1P, England	Johns Hopkins University; University of California System; University of California Irvine; University of Manchester; MRC National Institute for Medical Research; University of Oxford	Mathews, DJH (corresponding author), Johns Hopkins Univ, Phoebe R Berman Bioeth Inst, Baltimore, MD 21205 USA.	dmathews@jhmi.edu		Mathews, Debra/0000-0002-4897-7617; Lovell-Badge, Robin/0000-0001-9364-4179	Medical Research Council [MC_U117562207] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [MC_U117562207] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Hansen Bart, 2004, Med Law, V23, P19; *INT SOC STEM CELL, INT HESCR GUID; Wilmut I, 2005, SCIENCE, V310, P1903; INT STEM CELL FORUM	4	15	15	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 18	2006	313	5789					921	922		10.1126/science.1127990	http://dx.doi.org/10.1126/science.1127990			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	074MR	16917046	Green Submitted			2022-12-28	WOS:000239817000025
J	Crutcher, RM				Crutcher, Richard M.			Testing star formation theory	SCIENCE			English	Editorial Material									Univ Illinois, Dept Astron, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Crutcher, RM (corresponding author), Univ Illinois, Dept Astron, 1002 W Green St, Urbana, IL 61801 USA.	crutcher@uiuc.edu						Elmegreen BG, 2000, ASTROPHYS J, V530, P277, DOI 10.1086/308361; Girart JM, 2006, SCIENCE, V313, P812, DOI 10.1126/science.1129093; Mouschovias TC, 1999, NATO ADV SCI I C-MAT, V540, P305; Vallee JP, 2002, ASTRON J, V123, P382, DOI 10.1086/324634	4	1	1	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 11	2006	313	5788					771	772		10.1126/science.1131667	http://dx.doi.org/10.1126/science.1131667			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	072KC	16902116				2022-12-28	WOS:000239671300034
J	Zhang, D; Zaugg, K; Mak, TW; Elledge, SJ				Zhang, Dong; Zaugg, Kathrin; Mak, Tak W.; Elledge, Stephen J.			A role for the deubiquitinating enzyme USP28 in control of the DNA-damage response	CELL			English	Article							CLASS-SWITCH RECOMBINATION; CELL-CYCLE ARREST; TUMOR-SUPPRESSOR; P53-DEPENDENT APOPTOSIS; REGULATES APOPTOSIS; BETA-TRCP; P53; CHECKPOINT; PROTEIN; CANCER	The Chk2-p53-PUMA pathway is a major regulator of DNA-damage-induced apoptosis in response to double-strand breaks in vivo. Through analysis of 5313131 complexes we have discovered a new ubiquitin protease, USP28, which regulates this pathway. Using a human cell line that faithfully recapitulated the Chk2-p53-PUMA pathway, we show that USP28 is required to stabilize Chk2 and 5313131 in response to DNA damage. In this cell line, both USP28 and Chk2 are required for DNA-damage-induced apoptosis, and they accomplish this in part through regulation of the p53 induction of proapoptotic genes like PUMA. Our studies implicate DNA-damage-induced ubiquitination and deubiquitination as a major regulator of the DNA-damage response for Chk2, 5313131, and a number of other proteins in the DNA-damage checkpoint pathway, including several mediators, such as Mdc1, Claspin, and TopBP1.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet,Harvard Partners Ctr Genet & Genom, Boston, MA 02115 USA; Univ Hlth Network, Inst Breast Canc Res, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Med Biophys & Immunol, Toronto, ON M5G 2C1, Canada	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Elledge, SJ (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet,Harvard Partners Ctr Genet & Genom, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	selledge@genetics.med.harvard.edu	高, 雨莉/HGU-8187-2022	Zhang, Dong/0000-0002-4515-2070	NATIONAL CANCER INSTITUTE [T32CA090221] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI067751] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA90221] Funding Source: Medline; NIAID NIH HHS [U19 AI067751] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahn JW, 2003, J BIOL CHEM, V278, P20480, DOI 10.1074/jbc.M213185200; Alcasabas AA, 2001, NAT CELL BIOL, V3, P958, DOI 10.1038/ncb1101-958; Almog N, 2000, ONCOGENE, V19, P3395, DOI 10.1038/sj.onc.1203673; ARNERIK AY, 2004, BIOCHIM BIOPHYS ACTA, V1695, P189; Aurelio ON, 2000, MOL CELL BIOL, V20, P770, DOI 10.1128/MCB.20.3.770-778.2000; Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Busino L, 2003, NATURE, V426, P87, DOI 10.1038/nature02082; Chen DL, 2005, CELL, V121, P1071, DOI 10.1016/j.cell.2005.03.037; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Fei PW, 2002, CANCER RES, V62, P7316; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Jiang J, 2002, GENE DEV, V16, P2315, DOI 10.1101/gad.1027902; Jin JP, 2003, GENE DEV, V17, P3062, DOI 10.1101/gad.1157503; Kannouche PL, 2004, MOL CELL, V14, P491, DOI 10.1016/S1097-2765(04)00259-X; Lin SY, 2004, P NATL ACAD SCI USA, V101, P6484, DOI 10.1073/pnas.0401847101; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Manis JP, 2004, NAT IMMUNOL, V5, P481, DOI 10.1038/ni1067; McKinney K, 2004, MOL CELL, V16, P413, DOI 10.1016/j.molcel.2004.09.032; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Scacheri PC, 2004, P NATL ACAD SCI USA, V101, P1892, DOI 10.1073/pnas.0308698100; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Sweeney FD, 2005, CURR BIOL, V15, P1364, DOI 10.1016/j.cub.2005.06.063; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Tanaka K, 2001, NAT CELL BIOL, V3, P966, DOI 10.1038/ncb1101-966; VALERO R, 2001, GENOME BIOL, P2; Vialard JE, 1998, EMBO J, V17, P5679, DOI 10.1093/emboj/17.19.5679; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Wang S, 2000, P NATL ACAD SCI USA, V97, P1584, DOI 10.1073/pnas.97.4.1584; Ward IM, 2003, MOL CELL BIOL, V23, P2556, DOI 10.1128/MCB.23.7.2556-2563.2003; Ward IM, 2004, J CELL BIOL, V165, P459, DOI 10.1083/jcb.200403021; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	47	249	261	0	24	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 11	2006	126	3					529	542		10.1016/j.cell.2006.06.039	http://dx.doi.org/10.1016/j.cell.2006.06.039			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	075KI	16901786	Bronze			2022-12-28	WOS:000239883400013
J	Pagani, M; Pedentchouk, N; Huber, M; Sluijs, A; Schouten, S; Brinkhuis, H; Damste, JSS; Dickens, GR				Pagani, Mark; Pedentchouk, Nikolai; Huber, Matthew; Sluijs, Appy; Schouten, Stefan; Brinkhuis, Henk; Damste, Jaap S. Sinninghe; Dickens, Gerald R.		Expedit 302 Scientists	Arctic hydrology during global warming at the Palaeocene/Eocene thermal maximum	NATURE			English	Article							LIPID BIOMARKERS; D/H RATIOS; CARBON; SEDIMENTS; TEMPERATURES; DELTA; OCEAN; SEA	The Palaeocene/ Eocene thermal maximum represents a period of rapid, extreme global warming similar to 55 million years ago, superimposed on an already warm world(1-3). This warming is associated with a severe shoaling of the ocean calcite compensation depth(4) and a > 2.5 per mil negative carbon isotope excursion in marine and soil carbonates(1-4). Together these observations indicate a massive release of C-13- depleted carbon(4) and greenhouse- gas-induced warming. Recently, sediments were recovered from the central Arctic Ocean(5), providing the first opportunity to evaluate the environmental response at the North Pole at this time. Here we present stable hydrogen and carbon isotope measurements of terrestrial- plant- and aquatic- derived n- alkanes that record changes in hydrology, including surface water salinity and precipitation, and the global carbon cycle. Hydrogen isotope records are interpreted as documenting decreased rainout during moisture transport from lower latitudes and increased moisture delivery to the Arctic at the onset of the Palaeocene/ Eocene thermal maximum, consistent with predictions of poleward storm track migrations during global warming(6). The terrestrial- plant carbon isotope excursion ( about -4.5 to -6 per mil) is substantially larger than those of marine carbonates. Previously, this offset was explained by the physiological response of plants to increases in surface humidity(2). But this mechanism is not an effective explanation in this wet Arctic setting, leading us to hypothesize that the true magnitude of the excursion - and associated carbon input was greater than originally surmised. Greater carbon release and strong hydrological cycle feedbacks may help explain the maintenance of this unprecedented warmth.	Yale Univ, Dept Geol & Geophys, New Haven, CT 06520 USA; Purdue Univ, Dept Earth & Atmospher Sci, W Lafayette, IN 47906 USA; Purdue Univ, Purdue Climate Change Res Ctr, W Lafayette, IN 47906 USA; Univ Utrecht, Inst Environm Biol, Palaeobot & Palynol Lab, NL-3584 CD Utrecht, Netherlands; Royal Netherlands Inst Sea Res NIOZ, Dept Marine Biogeochem & Toxicol, NL-1790 AB Den Burg, Texel, Netherlands; Univ Utrecht, Dept Earth Sci, Fac Geosci, NL-3584 CD Utrecht, Netherlands; Rice Univ, Dept Earth Sci, Houston, TX 77005 USA	Yale University; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Utrecht University; Utrecht University; Royal Netherlands Institute for Sea Research (NIOZ); Utrecht University; Rice University	Pagani, M (corresponding author), Yale Univ, Dept Geol & Geophys, POB 208109, New Haven, CT 06520 USA.	mark.pagani@yale.edu	Dickens, Gerald R/G-1222-2011; Pagani, Mark/B-3233-2008; Pedentchouk, Nikolai/C-9935-2011; Damste, Jaap S Sinninghe/F-6128-2011; Kaminski, Michael/K-3334-2012; Huber, Matthew/A-7677-2008; Jakobsson, Martin/F-6214-2010; O'Regan, Matt/B-2157-2010; O'Regan, Matt/P-6277-2019; Brinkhuis, Henk/B-4223-2009; Gattacceca, Jerome/AAG-5651-2019; Palike, Heiko/A-6560-2008; Sluijs, Appy/B-3726-2009	Pedentchouk, Nikolai/0000-0002-2923-966X; Damste, Jaap S Sinninghe/0000-0002-8683-1854; Huber, Matthew/0000-0002-2771-9977; O'Regan, Matt/0000-0002-6046-1488; Gattacceca, Jerome/0000-0002-1639-7140; Palike, Heiko/0000-0003-3386-0923; Sluijs, Appy/0000-0003-2382-0215; Eynaud, Frederique/0000-0003-1283-7425; Takahashi, Kozo/0000-0001-8660-4371; Onodera, Jonaotaro/0000-0001-6942-2285; Jordan, Richard/0000-0002-8997-7349; Jakobsson, Martin/0000-0002-9033-3559; Kaminski, Michael A/0000-0002-7344-5874; Brinkhuis, Henk/0000-0003-0253-6610; Rea, Brice/0000-0002-9928-145X; Dickens, Gerald/0000-0003-2869-4860				[Anonymous], 1992, PLANT PHYSIOL; ARTHUR MA, 1985, NATURE, V315, P216, DOI 10.1038/315216a0; BACKMAN J, P IODP, V302; Bowen GJ, 2004, NATURE, V432, P495, DOI 10.1038/nature03115; Bowen GJ, 2003, WATER RESOUR RES, V39, DOI 10.1029/2003WR002086; Boyle EA, 1997, GEOPHYS RES LETT, V24, P273, DOI 10.1029/97GL00081; Bujak JP, 1998, LATE PALEOCENE-EARLY EOCENE CLIMATIC AND BIOTIC EVENTS IN THE MARINE AND TERRESTRIAL RECORDS, P277; Caballero R, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2004GL021581; Chikaraishi Y, 2003, PHYTOCHEMISTRY, V63, P361, DOI 10.1016/S0031-9422(02)00749-5; EGLINTON G, 1967, SCIENCE, V156, P1322, DOI 10.1126/science.156.3780.1322; Fricke HC, 1998, EARTH PLANET SC LETT, V160, P193, DOI 10.1016/S0012-821X(98)00088-0; GRIMALT J, 1987, GEOCHIM COSMOCHIM AC, V51, P1379, DOI 10.1016/0016-7037(87)90322-X; HAN J, 1969, P NATL ACAD SCI USA, V64, P436, DOI 10.1073/pnas.64.2.436; Koch PL., 2003, GEOLOGICAL SOC AM SP, V369, P49, DOI DOI 10.1130/0-8137-2369-8.49; Muri G, 2004, ORG GEOCHEM, V35, P1083, DOI 10.1016/j.orggeochem.2004.06.004; Pagani M, 2005, SCIENCE, V309, P600, DOI 10.1126/science.1110063; Pierrehumbert RT, 2002, NATURE, V419, P191, DOI 10.1038/nature01088; Pierrehumbert RT, 1998, GEOPHYS RES LETT, V25, P151, DOI 10.1029/97GL03563; Popp BN, 1998, GEOCHIM COSMOCHIM AC, V62, P69, DOI 10.1016/S0016-7037(97)00333-5; Railsback LB, 1989, PALEOCEANOGRAPHY, V4, P585, DOI 10.1029/PA004i005p00585; Sachse D, 2004, GEOCHIM COSMOCHIM AC, V68, P4877, DOI 10.1016/j.gca.2004.06.004; Sauer PE, 2001, GEOCHIM COSMOCHIM AC, V65, P213, DOI 10.1016/S0016-7037(00)00520-2; Sluijs A, 2006, NATURE, V441, P610, DOI 10.1038/nature04668; Spero HJ, 1997, NATURE, V390, P497, DOI 10.1038/37333; STERNBERG LDL, 1988, NATURE, V333, P59, DOI 10.1038/333059a0; Thomas DJ, 2002, GEOLOGY, V30, P1067, DOI 10.1130/0091-7613(2002)030<1067:WTFFTF>2.0.CO;2; Yakir D., 1998, STABLE ISOTOPES INTE, P147; YANG H, 2005, SALT LAK CIT ANN M O; Zachos JC, 2005, SCIENCE, V308, P1611, DOI 10.1126/science.1109004; Zachos JC, 2003, SCIENCE, V302, P1551, DOI 10.1126/science.1090110; Zegouagh Y, 1998, ORG GEOCHEM, V28, P571, DOI 10.1016/S0146-6380(98)00020-5	31	330	341	3	141	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 10	2006	442	7103					671	675		10.1038/nature05043	http://dx.doi.org/10.1038/nature05043			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	071UU	16906647	Green Published			2022-12-28	WOS:000239630200042
J	Rose, SH; Elliott, BA				Rose, Steven H.; Elliott, Beth A.			In only an instant	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												rose.steve@mayo.edu							0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 9	2006	296	6					631	632		10.1001/jama.296.6.631	http://dx.doi.org/10.1001/jama.296.6.631			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	071LN	16896094				2022-12-28	WOS:000239603800001
J	Boudville, N; Prasad, GVR; Knoll, G; Muirhead, N; Thiessen-Philbrook, H; Yang, RC; Rosas-Arellano, MP; Housawi, A; Garg, AX				Boudville, Neil; Prasad, G. V. Ramesh; Knoll, Greg; Muirhead, Norman; Thiessen-Philbrook, Heather; Yang, Robert C.; Rosas-Arellano, M. Patricia; Housawi, Abdulrahman; Garg, Amit X.		Donor Nephrectomy Outcomes Res	Meta-analysis: Risk for hypertension in living kidney donors	ANNALS OF INTERNAL MEDICINE			English	Review							TERM-FOLLOW-UP; LONG-TERM; RENAL-FUNCTION; BLOOD-PRESSURE; SINGLE-CENTER; CLINICAL-TRIALS; META-REGRESSION; NEPHRECTOMY; TRANSPLANTATION; DONATION	Background: The risk for hypertension after kidney donation remains uncertain. Purpose: To see whether normotensive adults who donate a kidney develop higher blood pressure and risk for hypertension compared with nondonor adults acting as control participants. Data Sources: MEDLINE, EMBASE, and Science Citation Index were searched from 1966 until November 2005 for articles published in any language. Reference lists of pertinent articles were also reviewed. Study Selection: The authors selected studies involving 10 or more healthy normotensive adults who donated a kidney and in whom blood pressure was assessed at least 1 year later. Data Extraction: Two reviewers independently abstracted data on study and donor characteristics, blood pressure measurements, outcomes, and prognostic features. Comparison data were abstracted from donor studies with control participants. Thirty primary authors provided additional data. Data Synthesis: Forty-eight studies from 28 countries followed a total of 5145 donors. Before surgery, the average age of donors was 41 years, the average systolic blood pressure was 121 mm Hg, and the average diastolic blood pressure was 77 mm Hg for all studies. In controlled studies in which the average follow-up was at least 5 years after donation (range, 6 to 13 years), blood pressure was 5 mm Hg higher in donors than in control participants (the weighted mean for systolic blood pressure using 4 studies involving 157 donors and 128 control participants was 6 mm Hg [95% Cl, 2 to 11 mm Hg], and the weighted mean for diastolic blood pressure using 5 studies involving 196 donors and 161 control participants was 4 mm Hg [Cl, 1 to 7 mm Hg]). There was statistical heterogeneity among the 6 controlled studies that assessed hypertension; an increase in risk was noted in 1 study (relative risk, 1.9 [Cl, 1.1 to 3.5]). Limitations: Most studies were retrospective and did not include control groups that were assembled and followed along with donors. Approximately one third of the donors had incomplete follow-up information. Conclusions: On the basis of the limited studies conducted to date, kidney donors may have a 5-mm Hg increase in blood pressure within 5 to 10 years after donation over that anticipated with normal aging. Future controlled, prospective studies with long periods of follow-up will better delineate safety and identify donors at lowest risk for long-term morbidity.	Univ Western Ontario, London, England; Univ Western Australia, Perth, WA 6009, Australia; Univ Toronto, Toronto, ON, Canada; Univ Ottawa, Ottawa, ON, Canada; McMaster Univ, Hamilton, ON, Canada	Western University (University of Western Ontario); University of Western Australia; University of Toronto; University of Ottawa; McMaster University	Garg, AX (corresponding author), London Hlth Sci Ctr, London Kidney Clin Res Unit, Div Nephrol, Room ELL-101,Westminster Tower,800 Commiss Rd E, London, ON N6A 4G5, Canada.	amit.garg@lhsc.on.ca	Garg, Amit X/G-3295-2011; Muirhead, Norman/G-3337-2011; Boudville, Neil/H-8864-2014	Thiessen Philbrook, Heather/0000-0003-2067-0514; Boudville, Neil/0000-0002-5884-640X; Knoll, Greg/0000-0001-5442-9310				ABOMELHA MS, 1993, ANN SAUDI MED, V13, P416, DOI 10.5144/0256-4947.1993.416; BASSERI A, 1995, TRANSPLANT P, V27, P2592; BEEKMAN GM, 1994, NEPHROL DIAL TRANSPL, V9, P163; Borchhardt KA, 1996, TRANSPLANTATION, V62, P47, DOI 10.1097/00007890-199607150-00010; Cappelleri JC, 1996, JAMA-J AM MED ASSOC, V276, P1332, DOI 10.1001/jama.276.16.1332; CHEN HW, 1992, TRANSPLANT P, V24, P1440; CLARKE KS, 2006, NEPHROL DIAL TRANSPL; DAlmeida P, 1996, TRANSPLANT P, V28, P93; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DUNN JF, 1986, ANN SURG, V203, P637, DOI 10.1097/00000658-198606000-00008; Eberhard OK, 1997, CLIN TRANSPLANT, V11, P415; ENGER E, 1973, SCAND J UROL NEPHROL, V7, P200, DOI 10.3109/00365597309133703; Fehrman-Ekholm I, 2001, TRANSPLANTATION, V72, P444, DOI 10.1097/00007890-200108150-00015; FOLLMANN D, 1992, J CLIN EPIDEMIOL, V45, P769, DOI 10.1016/0895-4356(92)90054-Q; Fourcade J, 2002, NEPHROLOGIE, V23, P173; FRIEDLANDER MA, 1988, AM J KIDNEY DIS, V11, P393, DOI 10.1016/S0272-6386(88)80052-0; Ghahramani N, 1999, TRANSPLANT P, V31, P3139, DOI 10.1016/S0041-1345(99)00754-X; Goldfarb DA, 2001, J UROLOGY, V166, P2043, DOI 10.1016/S0022-5347(05)65502-4; GONZALEZ R, 1989, TRANSPLANT P, V21, P1946; Gracida C, 2003, TRANSPLANT P, V35, P946, DOI 10.1016/S0041-1345(03)00174-X; Haberal M, 1998, CLIN NEPHROL, V50, P232; HAKIM RM, 1984, KIDNEY INT, V25, P930, DOI 10.1038/ki.1984.112; HIDA M, 1982, Tokai Journal of Experimental and Clinical Medicine, V7, P511; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Horcickova M, 2002, PRAKT LEK, V82, P735; Horton NJ, 1999, AM STAT, V53, P160, DOI 10.2307/2685737; Iglesias-Marquez RA, 2001, TRANSPL P, V33, P2041, DOI 10.1016/S0041-1345(00)02781-0; Ioannidis JPA, 2001, JAMA-J AM MED ASSOC, V286, P821, DOI 10.1001/jama.286.7.821; Johnson EM, 1997, TRANSPLANTATION, V64, P1124, DOI 10.1097/00007890-199710270-00007; KASISKE BL, 1995, KIDNEY INT, V48, P814, DOI 10.1038/ki.1995.355; Kostakis A, 1997, Geriatr Nephrol Urol, V7, P127, DOI 10.1023/A:1008238228407; Laird N M, 1990, Int J Technol Assess Health Care, V6, P5; LASKOW DA, 1991, TRANSPLANT P, V23, P1328; Lennerling A, 2003, TRANSPLANTATION, V76, P1243, DOI 10.1097/01.TP.0000087832.27092.4F; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; LIOUNIS B, 1988, MED J AUSTRALIA, V148, P436, DOI 10.5694/j.1326-5377.1988.tb139566.x; LIOUNIS B, 1988, MED J AUSTRALIA, V148, P440; LIU PL, 1992, J UROLOGY, V147, P337, DOI 10.1016/S0022-5347(17)37230-0; Lumsdaine Jennifer A, 2003, Prog Transplant, V13, P138; Marekovic Z, 1992, Lijec Vjesn, V114, P110; Matas AJ, 2004, AM J TRANSPLANT, V4, P216, DOI 10.1046/j.1600-6143.2003.00290.x; Mathillas O, 1988, Scand J Urol Nephrol Suppl, V108, P49; MENDOZA A, 1987, TRANSPLANT P, V19, P1500; MILLER IJ, 1985, AM J MED, V79, P201, DOI 10.1016/0002-9343(85)90010-5; MIMRAN A, 1993, NEPHROL DIAL TRANSPL, V8, P448; Miranda B, 1998, ANN NY ACAD SCI, V862, P129, DOI 10.1111/j.1749-6632.1998.tb09126.x; NAJARIAN JS, 1992, LANCET, V340, P807, DOI 10.1016/0140-6736(92)92683-7; ODONNELL D, 1986, S AFR MED J, V69, P177; PRANDINI R, 1987, TRANSPL P, V19, P1498; Rizvi SAH, 2005, TRANSPLANTATION, V79, P1247, DOI 10.1097/01.TP.0000161666.05236.97; RODRIGUEZITURBE B, 1985, LANCET, V2, P461; Saran R, 1997, NEPHROL DIAL TRANSPL, V12, P1615, DOI 10.1093/ndt/12.8.1615; Schostak M, 2004, CLIN TRANSPLANT, V18, P301, DOI 10.1111/j.1399-0012.2004.00165.x; Siebels M, 2003, NEPHROL DIAL TRANSPL, V18, P2648, DOI 10.1093/ndt/gfg482; SOBH M, 1989, International Urology and Nephrology, V21, P547, DOI 10.1007/BF02549594; Spital A, 2001, TRANSPLANTATION, V71, P1061, DOI 10.1097/00007890-200104270-00009; TALSETH T, 1986, KIDNEY INT, V29, P1072, DOI 10.1038/ki.1986.109; TAPSON JS, 1987, INT J ARTIF ORGANS, V10, P341, DOI 10.1177/039139888701000602; TERWEE PM, 1994, J AM SOC NEPHROL, V4, P1798; THIEL G, 1998, TRANSPL INT S1, V11, P50; Thompson SG, 2002, STAT MED, V21, P1559, DOI 10.1002/sim.1187; Tondo S, 1998, Minerva Urol Nefrol, V50, P121; Toronyi E, 1998, Transpl Int, V11 Suppl 1, pS481, DOI 10.1007/s001470050524; TORRES VE, 1987, KIDNEY INT, V31, P1383, DOI 10.1038/ki.1987.153; Undurraga A, 1998, TRANSPLANT P, V30, P2283, DOI 10.1016/S0041-1345(98)00622-8; van Houwelingen HC, 2002, STAT MED, V21, P589, DOI 10.1002/sim.1040; Vasan RS, 2002, JAMA-J AM MED ASSOC, V287, P1003, DOI 10.1001/jama.287.8.1003; WATNICK TJ, 1988, TRANSPLANTATION, V45, P59; Wiesel M, 1997, TRANSPLANT P, V29, P2769, DOI 10.1016/S0041-1345(97)00670-2; Wilczynski NL, 2004, BMC MED, V2, DOI 10.1186/1741-7015-2-23; Wilczynski Nancy L, 2003, AMIA Annu Symp Proc, P719; WILLIAMS SL, 1986, ANN INTERN MED, V105, P1, DOI 10.7326/0003-4819-105-1-1; YASUMURA T, 1988, JPN J SURG, V18, P252, DOI 10.1007/BF02471441; ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734	74	294	298	1	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	2006	145	3					185	196		10.7326/0003-4819-145-3-200608010-00006	http://dx.doi.org/10.7326/0003-4819-145-3-200608010-00006			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	070MN	16880460				2022-12-28	WOS:000239526800004
J	Wjst, M				Wjst, Matthias			beta 2-adrenoreceptor polymorphisms and asthma	LANCET			English	Editorial Material							BETA-2-ADRENERGIC RECEPTOR; GENETIC ASSOCIATION; METAANALYSIS; FALSE; TRUE		GSF Forschungszentrum Umwelt & Gesundheit, D-85764 Neuherberg, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Wjst, M (corresponding author), GSF Forschungszentrum Umwelt & Gesundheit, D-85764 Neuherberg, Germany.	wjst@gsf.de						Contopoulos-Ioannidis DG, 2005, J ALLERGY CLIN IMMUN, V115, P963, DOI 10.1016/j.jaci.2004.12.1119; Cordell HJ, 2005, LANCET, V366, P1121, DOI 10.1016/S0140-6736(05)67424-7; Hall IP, 2006, LANCET, V368, P771, DOI 10.1016/S0140-6736(06)69287-8; Holloway JW, 2005, J ALLERGY CLIN IMMUN, V115, P960, DOI 10.1016/j.jaci.2005.02.005; Liggett SB, 2006, CIRCULATION, V113, P1818, DOI 10.1161/CIRCULATIONAHA.105.618967; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; *POLYPHEN, 2006, PRED FUNCT EFF HUM N; REIHSAUS E, 1993, AM J RESP CELL MOL, V8, P334, DOI 10.1165/ajrcmb/8.3.334; Thakkinstian A, 2005, AM J EPIDEMIOL, V162, P201, DOI 10.1093/aje/kwi184; Todd JA, 2006, NAT GENET, V38, P731, DOI 10.1038/ng0706-731; Vercelli D, 2006, J ALLERGY CLIN IMMUN, V117, P1303, DOI 10.1016/j.jaci.2006.03.030; 2003, LANCET, V361, P357; 2005, NAT GENET, V37, P1153	13	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG-SEP	2006	368	9537					710	711		10.1016/S0140-6736(06)69262-3	http://dx.doi.org/10.1016/S0140-6736(06)69262-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	080ID	16935668				2022-12-28	WOS:000240240200006
J	Hammer, SM; Saag, MS; Schechter, M; Montaner, JSG; Schooley, RT; Jacobsen, DM; Thompson, MA; Carpenter, CCJ; Fischl, MA; Gazzard, BG; Gatell, JM; Hirsch, MS; Katzenstein, DA; Richman, DD; Vella, S; Yeni, PG; Volberding, PA				Hammer, Scott M.; Saag, Michael S.; Schechter, Mauro; Montaner, Julio S. G.; Schooley, Robert T.; Jacobsen, Donna M.; Thompson, Melanie A.; Carpenter, Charles C. J.; Fischl, Margaret A.; Gazzard, Brian G.; Gatell, Jose M.; Hirsch, Martin S.; Katzenstein, David A.; Richman, Douglas D.; Vella, Stefano; Yeni, Patrick G.; Volberding, Paul A.			Treatment for adult HIV infection - 2006 recommendations of the International AIDS Society-USA panel	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; TENOFOVIR DISOPROXIL FUMARATE; ACTIVE ANTIRETROVIRAL THERAPY; EARLY VIROLOGICAL FAILURE; HEPATITIS-C VIRUS; DRUG-RESISTANCE; HIV-1-INFECTED PATIENTS; COMBINATION THERAPY; DISEASE PROGRESSION; INITIAL TREATMENT	Context Guidelines for antiretroviral therapy are important for clinicians worldwide given the complexity of the field and the varied clinical situations in which these agents are used. The International AIDS Society - USA panel has updated its recommendations as warranted by new developments in the field. Objective To provide physicians and other human immunodeficiency virus (HIV) clinicians with current recommendations for the use of antiretroviral therapy in HIV-infected adults in circumstances for which there is relatively unrestricted access to drugs and monitoring tools. The recommendations are centered on 4 key issues: when to start antiretroviral therapy; what to start; when to change; and what to change. Antiretroviral therapy in special circumstances is also described. Data Sources and Study Selection A 16-member noncompensated panel was appointed, based on expertise in HIV research and patient care internationally. Data published or presented at selected scientific conferences from mid 2004 through May 2006 were identified and reviewed by all members of the panel. Data Extraction and Synthesis Data that might change previous guidelines were identified and reviewed. New guidelines were drafted by a writing committee and reviewed by the entire panel. Conclusions Antiretroviral therapy in adults continues to evolve rapidly, making delivery of state-of-the-art care challenging. Initiation of therapy continues to be recommended in all symptomatic persons and in asymptomatic persons after the CD4 cell count falls below 350/mu L and before it declines to 200/mu L. A nonnucleoside reverse transcriptase inhibitor or a protease inhibitor boosted with low-dose ritonavir each combined with 2 nucleoside ( or nucleotide) reverse transcriptase inhibitors is recommended with choice being based on the individual patient profile. Therapy should be changed when toxicity or intolerance mandate it or when treatment failure is documented. The virologic target for patients with treatment failure is now a plasma HIV-1 RNA level below 50 copies/mL. Adherence to antiretroviral therapy in the short-term and the long-term is crucial for treatment success and must be continually reinforced.	Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; Univ Fed Rio de Janeiro, Dept Prevent Med, BR-21941 Rio De Janeiro, Brazil; Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA; Int AIDS Soc USA, San Francisco, CA USA; AIDS Res Consortium, Atlanta, GA USA; Brown Univ, Sch Med, Dept Biomed, Providence, RI 02912 USA; Univ Miami, Sch Med, Dept Med, Coral Gables, FL 33124 USA; Chelsea & Westminster Hosp, Dept HIV Med, London, England; Univ Barcelona, Hosp Clin, IDIBAPS, Dept Med, Barcelona, Spain; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Stanford Univ, Med Ctr, Dept Med, Stanford, CA 94305 USA; Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA; San Diego Vet Affairs Healthcare Syst, San Diego, CA USA; Ist Super Sanita, Dept Drug Discovery & Evaluat, I-00161 Rome, Italy; Hop Bichat Claude Bernard, X Bichat Med Sch, Dept Infect Dis, F-75877 Paris 18, France; Univ Calif San Francisco, Dept Med, San Francisco, CA USA; San Francisco VA Med Ctr, San Francisco, CA USA	Columbia University; University of Alabama System; University of Alabama Birmingham; Universidade Federal do Rio de Janeiro; University of British Columbia; University of California System; University of California San Diego; Brown University; University of Miami; Imperial College London; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Harvard University; Harvard Medical School; Stanford University; University of California System; University of California San Diego; Istituto Superiore di Sanita (ISS); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center	Hammer, SM (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, 630 W 168th St,Box 82, New York, NY 10032 USA.	smh48@columbia.edu	Gatell, Jose M/ABC-3607-2020; Schechter, Mauro/AAG-7445-2020; VALLET, Yannick/F-9979-2011; VELLA, STEFANO/ABI-3368-2020; VELLA, STEFANO/V-8440-2019; Montaner, Julio/K-7621-2012; Vella, Stefano/GZM-0519-2022	VELLA, STEFANO/0000-0003-2347-5984; katzenstein, david/0000-0002-8593-4560				Aberg JA, 2004, CLIN INFECT DIS, V39, P609, DOI 10.1086/423390; ANANWORANICH J, 2004, 15 INT AIDS C JUL 11; ANANWORANICH J, 2006, 13 C RETR OPP INF FE; Anastos K, 2005, JAIDS-J ACQ IMM DEF, V39, P537; Arribas JR, 2005, JAIDS-J ACQ IMM DEF, V40, P280, DOI 10.1097/01.qai.0000180077.59159.f4; Bani- Sadr F, 2005, CLIN INFECT DIS, V41, P1806, DOI 10.1086/498312; Bani-Sadr F, 2004, CLIN INFECT DIS, V39, P1062, DOI 10.1086/424012; BAYLOR MS, 2004, J ACQ IMMUN DEF SYND, V35, pS21; Benhamou Y, 2006, HEPATOLOGY, V43, P548, DOI 10.1002/hep.21055; Bessesen M, 1999, CLIN INFECT DIS, V28, P1032, DOI 10.1086/514750; Bonacini M, 2002, GASTROENTEROLOGY, V122, P244, DOI 10.1053/gast.2002.30901; BONNET F, 2006, ANTIVIR CHEM CHEMOTH, V16, P63; Breen RAM, 2004, THORAX, V59, P704, DOI 10.1136/thx.2003.019224; Brenchley JM, 2006, NAT IMMUNOL, V7, P235, DOI 10.1038/ni1316; Brenchley JM, 2004, J EXP MED, V200, P749, DOI 10.1084/jem.20040874; *BRIST MYERS SQUIB, EF CAPS PACK INS; Burger D, 2006, BRIT J CLIN PHARMACO, V61, P148, DOI 10.1111/j.1365-2125.2005.02536.x; Burger DM, 2002, J ACQ IMMUN DEF SYND, V29, P101; Cahn P, 2004, 7 INT C DRUG THER HI; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; *CDCP, 1981, MMWR-MORBID MORTAL W, V30, P305; *CDCP, UPD GUID US RIF TREA; CHENG A, 2003, 9 EUR AIDS C OCT 25; Clark R, 2005, DRUG SAFETY, V28, P1075, DOI 10.2165/00002018-200528120-00003; Clark Rebecca A, 2005, Expert Rev Anti Infect Ther, V3, P213, DOI 10.1586/14787210.3.2.213; CRANE H, 2006, 13 C RETR OPP INF FE; Currier JS, 2000, J ACQ IMMUN DEF SYND, V24, P316; DANEL C, 2006, 13 C RETR OPP INF FE; De Santis M, 2002, ARCH INTERN MED, V162, P355, DOI 10.1001/archinte.162.3.355; Deeks SG, 2005, J INFECT DIS, V192, P1537, DOI 10.1086/496892; DEJESUS E, 2006, 13 C RETR OPP INF FE; Delaugerre C, 2002, ANTIMICROB AGENTS CH, V46, P1586, DOI 10.1128/AAC.46.5.1586-1588.2002; DEMEYER S, 13 C RETR OPP INF FE; Descamps D, 2000, JAMA-J AM MED ASSOC, V283, P205, DOI 10.1001/jama.283.2.205; Dore GJ, 2004, J INFECT DIS, V189, P1185, DOI 10.1086/380398; Dragsted UB, 2005, ANTIVIR THER, V10, P735; Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4; ELSADR W, 2006, 13 C RETR OPP INF FE; EMINI EA, 1996, 3 C RETR OPP INF JAN; ERON JJ, 1995, NEW ENGL J MED, V333, P1662, DOI 10.1056/NEJM199512213332502; Fenton K. A., 2006, Morbidity and Mortality Weekly Report, V55, P585; Fundaro C, 2002, AIDS, V16, P299, DOI 10.1097/00002030-200201250-00025; Gallant JE, 2006, NEW ENGL J MED, V354, P251, DOI 10.1056/NEJMoa051871; Gallant JE, 2005, CLIN INFECT DIS, V40, P1194, DOI 10.1086/428840; Gallant JE, 2004, JAMA-J AM MED ASSOC, V292, P191, DOI 10.1001/jama.292.2.191; Gandhi M, 2004, ANNU REV PHARMACOL, V44, P499, DOI [10.1146/annurev.pharmtox.44.101802.121453, 10.2165/00003088-200948030-00001]; GATELL JM, 2005, 10 EUR AIDS C NOV 17; GATELL JM, 2005, 3 IAS C HIV PATH TRE; Grabar S, 2005, JAIDS-J ACQ IMM DEF, V39, P284, DOI 10.1097/01.qai.0000160925.33935.72; GRINSZTEJN B, 2006, 13 C RETR OPP INF FE; GUEST J, 2006, 13 C RETR OPP INF FE; Gulick RM, 2004, NEW ENGL J MED, V350, P1850, DOI 10.1056/NEJMoa031772; GULICK RM, 2003, 2 INT AIDS SOC C HIV; Gulick RM, 2006, JAMA-J AM MED ASSOC, V296, P769, DOI 10.1001/jama.296.7.769; Gupta SK, 2005, CLIN INFECT DIS, V40, P1559, DOI 10.1086/430257; Haas DW, 2004, AIDS, V18, P2391; Hammer SM, 2005, NEW ENGL J MED, V353, P1702, DOI 10.1056/NEJMcp051203; Haubrich RH, 2001, CLIN INFECT DIS, V33, P1060, DOI 10.1086/322636; Havlir DV, 2000, JAMA-J AM MED ASSOC, V283, P229, DOI 10.1001/jama.283.2.229; HEFFELFINGER J, 2006, 13 C RETR OPP INF FE; Hicks C, 2004, 44 INT C ANT AG CHEM; Hirsch MS, 1998, JAMA-J AM MED ASSOC, V279, P1984, DOI 10.1001/jama.279.24.1984; Hirsch MS, 2003, CLIN INFECT DIS, V37, P113, DOI 10.1086/375597; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; *INT AIDS SOC US R, UPD DRUG RES MUT HIV; JACOBSON J, 2005, 3 IAS C HIV PATH TRE; Johnson M, 2005, AIDS, V19, P685, DOI 10.1097/01.aids.0000166091.39317.99; Kaleebu P, 2006, AIDS, V20, P1391, DOI 10.1097/01.aids.0000233572.59522.45; KATLAMA C, 2006, 13 C RETR OPP INF FE; KATLAMA C, 2005, 3 IAS C HIV PATH TRE; KITCHEN C, 2006, 13 C RETR OPP INF FE; Kumar PN, 2006, HIV MED, V7, P85, DOI 10.1111/j.1468-1293.2006.00346.x; Leon A, 2005, AIDS, V19, P213, DOI 10.1097/00002030-200501280-00017; Lichtenstein K, 2006, 13 C RETR OPP INF FE; Linfante A, 2004, CIRCULATION, V110, P664; Lo JC, 2005, CLIN INFECT DIS, V41, P1335, DOI 10.1086/496981; Macias J, 2005, J INFECTION, V51, P195, DOI 10.1016/j.jinf.2004.11.010; MALAN N, 2006, 13 C RETR OPP INF FE; MARCHOU B, 2006, 13 C RETR OPP INF FE; Martin AM, 2004, P NATL ACAD SCI USA, V101, P4180, DOI 10.1073/pnas.0307067101; Martinez E, 2004, LANCET, V364, P65, DOI 10.1016/S0140-6736(04)16591-4; Mattapallil JJ, 2005, NATURE, V434, P1093, DOI 10.1038/nature03501; Mehandru S, 2004, J EXP MED, V200, P761, DOI 10.1084/jem.20041196; MEYER S, 2006, 13 C RETR OPP INF FE; Moore DM, 2006, AIDS, V20, P371, DOI 10.1097/01.aids.0000196180.11293.9a; Moyle G, 2006, ANTIVIR THER, V11, P73; Negredo E, 2005, CLIN INFECT DIS, V41, P901, DOI 10.1086/432879; Nelson M, 2005, JAIDS-J ACQ IMM DEF, V40, P404, DOI 10.1097/01.qai.0000185314.56556.c3; NELSON M, 2006, 13 C RETR OPP INF FE; Nettles RE, 2005, JAMA-J AM MED ASSOC, V293, P817, DOI 10.1001/jama.293.7.817; Nicastri E, 2005, J MED VIROL, V76, P153, DOI 10.1002/jmv.20352; *NIH, 7 JOINT NAT COMM PRE; Novoa SR, 2006, CLIN INFECT DIS, V42, P291, DOI 10.1086/499056; Pai MP, 2004, PHARMACOTHERAPY, V24, P592, DOI 10.1592/phco.24.6.592.34744; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PALMISANO L, 2006, 13 C RETR OPP INF FE; PARKIN NT, 2006, 13 C RETR OPP INF FE; Persico M, 2001, HEPATOLOGY, V33, P627, DOI 10.1053/jhep.2001.22499; PHANUPHAK N, 2006, 13 C RETR OPP INF FE; Podzomczer D, 2005, ANTIVIR THER, V10, P171; POZNIAK A, 2006, 12 ANN C BRIT HIV AS; Raboud JM, 1999, J INFECT DIS, V180, P1347, DOI 10.1086/314998; Raboud JM, 1998, AIDS, V12, P1619, DOI 10.1097/00002030-199813000-00008; Rauch A, 2006, CLIN INFECT DIS, V43, P99, DOI 10.1086/504874; Ribaudo HJ, 2006, CLIN INFECT DIS, V42, P401, DOI 10.1086/499364; Rizzardi GP, 2000, J CLIN INVEST, V105, P777, DOI 10.1172/JCI9079; Robbins GK, 2003, NEW ENGL J MED, V349, P2293, DOI 10.1056/NEJMoa030264; Rockstroh JK, 2005, J INFECT DIS, V192, P992, DOI 10.1086/432762; Rotger M, 2005, J INFECT DIS, V192, P1381, DOI 10.1086/466531; Saag MS, 2004, JAMA-J AM MED ASSOC, V292, P180, DOI 10.1001/jama.292.2.180; Saag MS, 1996, NAT MED, V2, P625, DOI 10.1038/nm0696-625; Sanne I, 2005, J INFECT DIS, V191, P825, DOI 10.1086/428093; Santos J, 2005, INT J STD AIDS, V16, P677, DOI 10.1258/095646205774357398; Schluger NW, 2002, CHEST, V122, P597, DOI 10.1378/chest.122.2.597; SENSION M, 2005, 12 C RETR OPP INF FE; Sheran M, 2005, HIV CLIN TRIALS, V6, P158, DOI 10.1310/4KC0-56TM-VLBF-78BN; SKIEST D, 2006, 13 C RETR OPP INF FE; SMITH P, 2006, 13 C RETR OPP INF FE; Sterling TR, 1999, J INFECT DIS, V180, P666, DOI 10.1086/314967; Strader DB, 2004, HEPATOLOGY, V39, P1147, DOI 10.1002/hep.20119; Swindells S, 2006, JAMA-J AM MED ASSOC, V296, P806, DOI 10.1001/jama.296.7.806; Tavassoli N, 2006, PHARMACOTHERAPY, V26, P154, DOI 10.1592/phco.26.2.154; THOMPSON M, 2006, 13 C RETR OPP INF FE; *UNAIDS WHO, AIDS EP UPD DEC 2005; *US DEP HHS, US REC US ANT DRUGS; van Leth F, 2004, PLOS MED, V1, P64, DOI 10.1371/journal.pmed.0010019; Walmsley S, 2002, NEW ENGL J MED, V346, P2039, DOI 10.1056/NEJMoa012354; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Wensing AMJ, 2005, J INFECT DIS, V192, P958, DOI 10.1086/432916; WILKIN T, 2005, 45 INT C ANT AG CHEM; Wolters LMM, 2002, J CLIN VIROL, V24, P173, DOI 10.1016/S1386-6532(01)00245-1; World Health Organization, 2006, ANT THER HIV INF AD; Yeni PG, 2004, JAMA-J AM MED ASSOC, V292, P251, DOI 10.1001/jama.292.2.251	133	655	691	0	32	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 16	2006	296	7					827	843		10.1001/jama.296.7.827	http://dx.doi.org/10.1001/jama.296.7.827			17	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	073SR	17016878				2022-12-28	WOS:000239763400023
